<SEC-DOCUMENT>0000950170-25-043925.txt : 20250324
<SEC-HEADER>0000950170-25-043925.hdr.sgml : 20250324
<ACCEPTANCE-DATETIME>20250324165145
ACCESSION NUMBER:		0000950170-25-043925
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250324
DATE AS OF CHANGE:		20250324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Larimar Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001374690
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				203857670
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36510
		FILM NUMBER:		25764836

	BUSINESS ADDRESS:	
		STREET 1:		THREE BALA PLAZA EAST. SUITE 506
		CITY:			BALA CYNWYD
		STATE:			PA
		ZIP:			19004
		BUSINESS PHONE:		844-511-9056

	MAIL ADDRESS:	
		STREET 1:		THREE BALA PLAZA EAST. SUITE 506
		CITY:			BALA CYNWYD
		STATE:			PA
		ZIP:			19004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAFGEN, INC.
		DATE OF NAME CHANGE:	20100301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAFGEN INC
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lrmr-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-24T16:08:26.6125+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:lrmr="http://www.larimartx.com/20241231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_71c8a0af-ec2c-48d9-8f27-c3dbcbf31221" name="dei:AmendmentFlag" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_bd259818-bdf7-4a47-943a-9b295cab8d72" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd">FY</ix:nonNumeric><ix:nonNumeric id="F_e23d758f-b0a2-4652-a1a1-981d6741ce69" name="dei:EntityCentralIndexKey" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd">0001374690</ix:nonNumeric><ix:nonFraction id="F_bbd44322-5ac7-4240-84a9-fa6345eb0ea1" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_271b7562-2770-4053-8b6a-b815a279d5b4" name="us-gaap:CommitmentsAndContingencies" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8b10b1a7-f362-40fe-8916-abb51d917633" name="us-gaap:PreferredStockValue" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_f1c56ae0-d4be-4ff1-8d60-2cb57f25fa2a" name="us-gaap:PreferredStockValue" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_e67f9759-bc4c-4465-933e-6db26d968aa7" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_a5da52b3-1c55-4f2f-830b-7fe2b20e9c74">P5Y</ix:nonNumeric><ix:nonNumeric id="F_d10ed809-200f-4b30-80d3-8c8fcced056e" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</ix:nonNumeric><ix:nonNumeric id="F_8e858e57-0756-416b-b74d-b48de20c666a" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member</ix:nonNumeric><ix:nonNumeric id="F_a5f65a1c-dbe3-418f-9eaf-369ca80d6c94" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" contextRef="C_396ac9d3-7432-4c48-bc3e-b130ad436bcd">http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember</ix:nonNumeric><ix:nonFraction id="F_921994da-5811-4028-8f53-85e77eb89620" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_bf68a9db-6f62-4ef9-b2b4-384b78706dbf" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">6,284</ix:nonFraction><ix:nonNumeric id="F_87fbb33e-f754-46a6-98ea-b08d228c7b45" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_ec704a28-ca88-417d-afd5-2b5e09e3a38e">P3Y</ix:nonNumeric><ix:nonNumeric id="F_d09b5249-139c-4022-bd74-7a580647cdf5" name="us-gaap:LeaseExpirationDate1" contextRef="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373">2023-08-31</ix:nonNumeric><ix:nonNumeric id="F_f3be3bdd-793f-4d1a-9a7e-f230d03efd1b" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_7dab3a33-605b-4d11-95ef-1864d775ec57">P2Y</ix:nonNumeric><ix:nonNumeric id="F_3544ef17-f3b5-4927-ba28-69fcaa25789b" name="us-gaap:OpenTaxYear" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd">2020 2021 2022 2023 2024</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lrmr-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="C_8057ddb3-0a97-4d84-a521-6c651151f255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82b36523-042a-479d-8709-14a5821a01e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84970a30-febb-4823-a176-2eef9f5b17ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84d96472-3ce3-4f5b-8844-308604770292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:SixthSubleaseYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86c1a03b-7f05-4056-8a4b-a412c8acdc0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-09</xbrli:startDate><xbrli:endDate>2021-08-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89155b9d-f3b6-4453-9d28-eeacaa55b7e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8940587e-a90e-40f9-958f-9b1b19869429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b7bbdf5-c433-4df2-8d61-5681d6000126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lrmr:NoExpirationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ee26ea1-7981-475b-8275-d3cd88ccd7f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:DomesticAndStateLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8fc81d4f-669b-4cb9-9f96-bcb205c5ce02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-22</xbrli:startDate><xbrli:endDate>2025-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9310a56d-595a-456c-875c-d9c91b4958c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_937c9270-0745-4d6a-8ddd-353d3408b686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lrmr:EndOfStudyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lrmr:SkinCellsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_937d6158-f010-48b2-b04e-91b91f550795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9450bf35-e5d7-4e90-b946-f5ecc5c1b78f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:CommercialExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9458ab78-dd2a-4327-a9fc-7944f851ac55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_980a36da-7606-4c17-93a9-29aef7c80f1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9835f758-39d0-41f7-805e-a62b5ba91b72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:SecondMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-22</xbrli:startDate><xbrli:endDate>2025-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_990b03ea-4e3f-428b-9463-5722c03fe7ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99e2e692-a200-4366-9fac-4c228a2bb15b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lrmr:ZafgenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9be6fbc0-da98-4a6c-9580-1b53447c931e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lrmr:ZafgenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d2671b4-535d-41fb-ba97-cf95d740ca0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lrmr:MTSHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ea41f95-519b-41f4-8b6c-cb288ac9b104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a04137e2-f395-4ec2-a749-7530c63c5c1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1d529ba-7ef3-4346-82a1-30f1da0afd55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3be7c9e-9f11-490a-8fdf-1cfea83b9a27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4b86fbb-6763-470f-9324-890bb9b86ef7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5da52b3-1c55-4f2f-830b-7fe2b20e9c74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lrmr:EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6372807-b669-4c9a-bca6-c7c693a758c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:NomlabofuspSupportExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a95a6572-ed88-48df-9e64-6ef309bf3fc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a9758b43-c974-4811-91f8-dd665c753866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aae3cd8b-68ec-413d-a96c-c3611488b3a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:LabSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab791d56-0959-4081-945b-058f0d6c6f82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:TechnicalOperationsExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad1539c6-fc3e-4f7a-a9a5-26892c4889b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lrmr:NoExpirationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad4e109b-2beb-4b4b-8ec0-7ff1c78ca2a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af3f57a9-5b04-4e27-9565-2e843bcf12e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afb7c02e-1d17-4fbb-ad2f-056d597aacc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b039d28f-1551-4683-aa18-2d31487cc476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b144c1ed-8a46-4360-ac5f-f8187e2445a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1b8129e-de19-4748-9c09-33dfd9514f6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b23e5525-f6f6-400b-a668-fca905202d1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-22</xbrli:startDate><xbrli:endDate>2025-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b632cd5c-05ae-4251-a104-e7cf0498b02b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b79ab662-a9df-4027-a87d-1c4f950bae65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7ccda8d-34e0-4891-abca-16e72fec5b80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b89973be-3872-4363-9f3c-168e09a8a5a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be61e1b5-4f33-432f-86bc-37fe2c3476b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf68a9db-6f62-4ef9-b2b4-384b78706dbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf6d1d52-1fbd-434c-aff5-8c53c22ca6a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-22</xbrli:startDate><xbrli:endDate>2025-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfbc57ff-0284-43eb-9410-6bcf4e5de594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:DevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c18bcdd4-7898-4e7b-aeaa-04861be8d49c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c37bbde8-7943-40d4-8b87-262850af251a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3a77d44-ca39-48a6-af59-4ea835940adf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c441b869-7333-4da3-92e6-35ae34bd02de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c66d62d9-1b72-4c63-9f95-2f1a72677604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7bb7719-628e-435e-ba3a-d42b56b0336b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb7fc05a-bbd9-4909-a0df-1a1e3440df1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cde123be-1e24-4090-8fdb-2c9fe1cf13f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0f2886e-1b6f-49ac-a8ea-a868a6076338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d18029d6-d247-44b7-8d04-1bedb1e05fca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lrmr:FriedreichsAtaxiaResearchAlliancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lrmr:PatientAndCaregiverAwarenessEventsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d571d28c-42d3-4ede-a9a7-3e4acee72b97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:LabSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d699938b-88e6-4ed6-bb3e-ded55260a3c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:NomlabofuspSupportExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d69bdfda-1561-4df9-9031-4aaa6b8277e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lrmr:BeginningOfStudyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lrmr:SkinCellsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6ea5928-6ce4-4e0b-9b61-49f02098f481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d91923f9-f154-40c9-b314-889b9878641c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da30be71-5046-4b9b-aa5d-981a3c109ee3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd2a27c7-acca-4e22-922e-e6e22f9cea4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd95e4fc-82fa-4a33-961e-756339a32f40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e50d16e4-c0fa-4f34-9de4-4fa19f2af4a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e567f291-5928-46ca-9886-4b12d459c211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e624cc91-edd0-44c1-b110-f5bd07d78925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e75c96fd-9bc2-4e22-9c5a-481e9d15e507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec704a28-ca88-417d-afd5-2b5e09e3a38e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ec7837b7-c9c1-4c07-8288-455007933963"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-11</xbrli:startDate><xbrli:endDate>2023-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f10a217c-c7c4-4985-8b2d-21543f8fe157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1ad33a8-3ac6-4e46-a123-734c2ff51101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1f8400e-a7d9-400c-8bc4-a27496b8c9f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f552a753-5013-41ab-8a68-b985b7c0bac4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f56605f3-2e21-4b59-b70a-99e345371439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f62796d0-82ee-42f2-a018-74063dd58aa3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f69f438f-7f98-46a0-8c4d-079bbdf2a12a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-22</xbrli:startDate><xbrli:endDate>2025-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f87f0f4d-223e-43e5-99fb-70416e4efc02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc129cfd-3960-440f-aa81-c3cce8de7bad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fd07840a-58bc-4339-8331-bc488a2c40c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-27</xbrli:startDate><xbrli:endDate>2020-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe166586-acda-4afa-90ba-bbddb1cf7183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe3e5c5a-5d3a-4ea1-8f76-28fa8c02f25f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lrmr:PerformedInUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fef8b8b7-1ffd-45a1-bbb3-aeb02925b1c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00309e6d-c478-4991-a287-b2b26b553406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lrmr:FromPriorPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00c4f173-1035-4879-939f-3e16d63fb716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:IndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_013cfd75-8e64-4593-92c4-eddcb6f5a973"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0315db95-9995-4825-83b1-6bd13c7f5edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03512384-f164-4169-8f61-63c0a2fa35f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04060931-70f8-40a1-b038-ff2323e800fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06eb49df-ea1f-4795-b693-6ce41c4e020b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0788b521-b323-45f2-8f3d-8796f828638d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07cc377a-796d-498e-9d5b-1591bcb5477b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ca29918-24cb-4049-81da-b0b595cb7f08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:DevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d03b972-e68a-4737-840c-600693a1015c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FirstSubleaseYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1807f4b1-8435-4d6f-ad59-b534cb43cab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-05</xbrli:startDate><xbrli:endDate>2018-11-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19c7f11a-defa-4ab7-93a5-13259f5e0f82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ac20b4d-9dce-48ff-b9c6-72648d8b3bf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-22</xbrli:startDate><xbrli:endDate>2025-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b3789f9-d2e6-472a-a24f-4537eda96328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e6ff9a0-2992-49a2-9d8e-9424081411f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ecaa432-f3ba-4716-8bf2-ed620241e567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2164a742-c82f-4feb-86b4-11d2743876a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23a1dcc4-104b-43ca-95d3-232e06671bb5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_255549a6-f23b-4838-819a-a321c153cd07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:DomesticAndStateLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2778adb7-0fa7-4567-85f3-1f083a2430b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-28</xbrli:startDate><xbrli:endDate>2020-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_298722ae-af18-416d-b772-0febae7b0ff4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b1053b4-6091-48b6-907a-083f14aa104f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:TechnicalOperationsExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2da25a67-0650-40c0-a834-10e03326ad04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e43c4d6-c27e-4c64-957a-2c359c114241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30f69550-77db-454a-9913-83a4c6b940ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lrmr:FriedreichsAtaxiaResearchAlliancesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lrmr:TrackFAProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3122611a-d6b2-4e58-baae-c58bceaa1852"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lrmr:FromPriorPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35ab60ab-d305-4f2f-afea-0206294790a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_374ec650-46e4-4848-b593-f01df79d1e1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:IndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37be18e2-22dc-4e2a-9beb-0936213f0ff9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lrmr:EndOfStudyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lrmr:BuccalCellsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_391eac21-af51-488c-920c-35a738ee141e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_396ac9d3-7432-4c48-bc3e-b130ad436bcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3aec0197-d24a-4489-bac3-6d1692746976"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:LabSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-16</xbrli:startDate><xbrli:endDate>2023-10-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ddcccac-7c80-4352-b875-b59deec51ca1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e6edd92-c786-4088-97cc-096585e1d03d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41039f45-bcfe-4b0a-a6c8-f525353e3235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_410cee1a-9246-4e71-a46a-d8f61f308f49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FinalSubleaseYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41dc2a61-cb1b-4e3f-b8e4-3a5beacac631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_458d2390-7c95-42ed-9486-6626384ec15f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4652a096-8724-4cdf-a118-748dbb5359af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_476aa55d-daca-4a72-aade-622790de18ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47c2670a-5ab5-47d8-879f-4c1d86ad4d5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lrmr:PerformedOutsideUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49e828c3-8eec-482d-9de9-b54a375e1b3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a89193c-4cbe-4c85-bcc3-a83c9bc990b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b1f55d6-efd7-4b66-b757-9829759cb41d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FirstSubleaseYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c5e5e8c-5db3-4232-b8b8-f18e413251e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ccaf2c5-63d9-4610-8683-46ecfe234808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d107843-e44a-43f6-84f2-18bd5c829091"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d9b0d0f-39b2-4d7c-ad5a-792b1d5080d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e6a434c-62eb-44df-bb26-a28924999a6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f4d089e-ca07-4b47-be34-6ef0f252b0ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lrmr:EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55adc7a3-9555-42f6-8998-4ce928494a2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57646aae-7316-49d9-a9e1-466cd58a59b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bc874d9-7864-4d71-a931-3ccf2f2d90ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e95afea-eb7a-4026-b213-a7dc1020f814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fd8fb15-cf4d-4748-b06e-8e9b5decf68b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_651ed535-6eb6-4fb6-8481-d70f3753107b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68ab6f05-562c-4261-83f4-2fd2834ae9b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-22</xbrli:startDate><xbrli:endDate>2025-01-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6be3737e-d05f-4180-bd52-32638a31f43d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-11</xbrli:startDate><xbrli:endDate>2019-12-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_703f9a1d-ba57-4229-9130-75f431315872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:FromExerciseOfWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7578c18b-7d63-416f-a8a0-8914d0247733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_758e50cf-6269-441d-9861-9ff2dd1261da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_763a19f3-ed28-42b9-b147-b3bf06139429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7652464d-494e-4455-9127-a6517e3601ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-08</xbrli:startDate><xbrli:endDate>2019-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_778a5e08-2c19-4fa4-9229-8be5d4f04ff2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lrmr:BeginningOfStudyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lrmr:BuccalCellsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_791bdce5-955d-4624-ac03-8deed77c6490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d857bb0-3425-42ce-bed1-6edca2b32acc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7dab3a33-605b-4d11-95ef-1864d775ec57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ebc587a-1024-446d-8850-c2e50902fec2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f9933f3-6cd7-4632-83be-ff4608000844"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fd9fac5-2ec4-4412-abb9-5816a42accd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374690</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>lrmr:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:1.5pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form </span><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5a932fd-64df-49a7-873a-37ad37e025a2" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_9305b424-504f-4532-84a0-3a1478d3b4c7" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:DocumentAnnualReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_434d51a3-810d-4eb1-bd38-2f51d0e86748" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8843fc46-2c54-4006-bca1-00c019dbcb6e" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1f997dc-f40c-478b-9968-a40d2879e46c" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:96%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_18a28b17-e254-436d-a61e-ca6b1fe58fab" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the transition period from to</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5a862ad5-6f61-4168-8f3c-dab5e8a6fadf" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">001-36510</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:16pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e5405fa-599b-4351-9a14-865e49eff32a" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.04%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:49.5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_58c47b71-bece-41e6-aecf-9bde10bfacf0" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_3bf9237a-8d5d-4bf9-8196-a603a093ec54" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">20-3857670</span></ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Identification No.)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:7.2pt;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_3a236478-be7b-4e29-9024-ba3956ebac98" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Bala Plaza East</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_e5f92384-f5d8-4d46-8ade-9286aa75de50" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Suite 506</span></ix:nonNumeric></span></p><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_91ffa032-52b2-44de-8586-65e6e0ecb280" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Bala Cynwyd</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:8pt;"><ix:nonNumeric id="F_f239ea53-3dd9-416e-86a9-c24e19699e2d" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pennsylvania</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_7a6f48a8-0c74-47ca-b41c-a0abffdf72cd" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">19004</span></ix:nonNumeric></span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Zip Code)</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d7966022-37be-4f9a-90f6-252102321ed2" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">844</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9963f86d-46f2-4576-9e1a-62069157d493" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">511-9056</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:40%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.75pt solid #000000;padding-top:0in;border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:middle;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.75pt solid #000000;padding-top:0in;border-right:0.75pt solid #000000;vertical-align:middle;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.75pt solid #000000;padding-top:0in;border-right:0.75pt solid #000000;vertical-align:middle;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;border-right:0.75pt solid #000000;border-left:0.75pt solid #000000;vertical-align:middle;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_991402fb-5c2d-455d-bf1a-178c66018f17" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;border-right:0.75pt solid #000000;vertical-align:middle;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_afd9fc6a-b04f-4879-97bf-64821dbb76e5" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LRMR</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;border-right:0.75pt solid #000000;vertical-align:middle;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_b52ba00b-197b-4176-a261-32cd7cc26064" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_399a3e82-c6e8-4fe7-90a1-dec2389a8ac5" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes &#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4161032c-6f1c-40ee-887c-ff2231f50ca9" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_990095d4-c6ce-44db-b87d-a70f9dc134a0" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746; No &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7228c073-b839-4b94-a199-2aac8c026bb8" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746; No &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
    <td style="width:40%;box-sizing:content-box;"/>
    <td style="width:25%;box-sizing:content-box;"/>
    <td style="width:5%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_345a0002-a41a-4483-aa45-b943cfd4e52a" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_4554cdfd-710e-4d8c-8629-75835bf9f8d9" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:8pt;"><ix:nonNumeric id="F_a18f4584-a459-4433-8313-f21e53919281" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6b6758c-c65c-4303-86d3-50b42daaf3b9" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4cd3e50c-04a4-4b46-8b4d-b5fba08b3b6e" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;
</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/>
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;
</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94528d5f-e698-4c37-9f06-417aea3c582c" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On the last business day of the most recently completed second fiscal quarter, the aggregate market value (based on the closing sale price of its common stock on that date) of the registrant's Common stock held by non-affiliates of the registrant was $</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_086a3f71-828b-4a4f-bb31-23f553c123b5" contextRef="C_af3f57a9-5b04-4e27-9565-2e843bcf12e8" name="dei:EntityPublicFloat" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">313,608,353</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 20, 2025, the registrant had </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e973786-7bcb-42d4-a28e-2de7efaf6ef5" contextRef="C_391eac21-af51-488c-920c-35a738ee141e" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">64,027,892</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Common Stock, $0.001 par value per share, outstanding.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:2pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c691e078-8c18-441f-a0ee-2c3d2e1753d8" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#8217;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#8217;s fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.36pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1.5pt double;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13.3%;box-sizing:content-box;"/>
    <td style="width:78.52%;box-sizing:content-box;"/>
    <td style="width:8.18%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Item No.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page No.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.007in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#parti_291637"><span style="color:#0000ee;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART I</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1business_796317"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 1.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1business_796317"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">BUSINESS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1ariskfactors_798482"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 1A.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1ariskfactors_798482"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">RISK FACTORS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1bunresolvedstaffcomments_265117"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 1B.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1bunresolvedstaffcomments_265117"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">UNRESOLVED STAFF COMMENTS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1ccybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 1C.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item1ccybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CYBERSECURITY</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2properties_264380"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 2.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item2properties_264380"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PROPERTIES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3legalproceedings_49550"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 3.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item3legalproceedings_49550"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">LEGAL PROCEEDINGS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4minesafetydisclosures_57184"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 4.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item4minesafetydisclosures_57184"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">MINE SAFETY DISCLOSURES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#partii_672268"><span style="color:#0000ee;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART II</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item5marketforregistrantsscommonequity_9"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 5.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item5marketforregistrantsscommonequity_9"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item6selectedconsolidatedfinancialdata_6"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 6.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item6selectedconsolidatedfinancialdata_6"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[RESERVED]</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7managementsdiscussionandanalysis_41"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 7.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7managementsdiscussionandanalysis_41"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7aquantitativeandqualitativedisclosu"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 7A.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item7aquantitativeandqualitativedisclosu"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item8financialstatementsandsupplementary"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 8.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item8financialstatementsandsupplementary"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9changesinanddisagreementswithaccoun"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 9.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9changesinanddisagreementswithaccoun"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9acontrolsandprocedures_737107"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 9A.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9acontrolsandprocedures_737107"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CONTROLS AND PROCEDURES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9botherinformation_654168"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 9B.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9botherinformation_654168"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9cforeignjurisdictions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 9C</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item9cforeignjurisdictions"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#partiii_936646"><span style="color:#0000ee;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART III</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item10directorsexecutiveofficersandcorpo"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 10.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item10directorsexecutiveofficersandcorpo"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item11executivecompensation_214372"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 11.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item11executivecompensation_214372"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">EXECUTIVE COMPENSATION</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item12securityownershipofcertainbenefici"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 12.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item12securityownershipofcertainbenefici"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item13certainrelationshipsandrelatedtran"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 13.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item13certainrelationshipsandrelatedtran"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item14principalaccountingfeesandservices"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 14.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item14principalaccountingfeesandservices"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><a href="#partiv_994849"><span style="color:#0000ee;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">PART IV</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item15exhibitsfinancialstatementschedule"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 15.</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item15exhibitsfinancialstatementschedule"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">EXHIBIT AND FINANCIAL STATEMENT SCHEDULES</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ITEM 16.</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">FORM 10-K SUMMARY</span></a></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures_181481"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">SIGNATURES</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">105</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Statements made in this Annual Report on Form 10-K that are not statements of historical or current facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements discuss our business, operations and financial performance and conditions, as well as our plans, objectives and expectations for our business operations and financial performance and condition. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, statements that &#8220;we believe&#8221; or similar statements reflect our beliefs and opinions on the relevant subject only. These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uncertainties in obtaining successful non-clinical or clinical results that reliably and meaningfully demonstrate safety, tolerability and efficacy profiles that are satisfactory to the FDA, European Medicines Agency ("EMA") and/or other comparable regulatory authorities for marketing approval for nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601) or any other product candidates that we may develop in the future and unexpected costs that may result therefrom;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in patient recruitment for our clinical trials (including as a result of the impact of FDA approval of competitive products for the treatment of Friedreich's ataxia ("FA"), and/or the impact of other clinical trials of competitive products), delays as a result of clinical and non-clinical results and/or FDA's request for additional information or studies (whether clinical or non-clinical), changes in clinical protocols, adverse events, regulatory restrictions, including additional clinical holds, and milestones for nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to successfully execute our ongoing open label extension trial (&#8220;OLE&#8221;) and our pediatric PK run-in trial, including the timing of site initiations and the rate of patient enrollment;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to benefit from participating in the FDA&#8217;s Support for Clinical Trials Advancing Rare Disease Therapeutics (&#8220;START&#8221;) pilot program for the development of nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uncertainties associated with the clinical development and regulatory approval for nomlabofusp, including potential delays in the commencement, enrollment and completion of clinical trials, the timing of a potential Biologics License Application (&#8220;BLA&#8221;) submission for accelerated approval, including our ability to supply to the FDA all required data for the FDA to review and accept an accelerated application, or any other product candidates that we may develop in the future;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the difficulties and expenses associated with obtaining and maintaining regulatory approval for nomlabofusp or any other product candidate we may develop in the future, and the indication and labeling under any such approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">how long we can continue to fund our operations with our existing cash, cash equivalents and marketable securities and our estimates regarding future results of operations, financial position, research and development costs, capital requirements and our access and needs for additional financing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the use of proceeds from future financings, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability, and the ability of third-party manufacturers we engage, to optimize, scale and validate nomlabofusp or any other product candidate&#8217;s manufacturing process and to manufacture sufficient quantities of clinical supplies, and, if approved, commercial supplies of nomlabofusp or any other product candidates that we may develop in the future and our ability to maintain our relationships and contracts with our key vendors and to identify and contract with alternate or secondary key vendors;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to realize any value from nomlabofusp and/or any other product candidates we may develop in the future in light of inherent risks and difficulties involved in successfully bringing product candidates to market and the risk that the product candidates, if approved, will not achieve broad market acceptance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to comply with regulatory requirements applicable to our business and other regulatory developments in the United States and other countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and growth of the potential markets for nomlabofusp or any other product candidates that we may develop in the future, the rate and degree of market acceptance of nomlabofusp, if approved, or any other product candidate, that we may develop in the future and our ability to serve those markets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">given both approved and competing therapies and products for the treatment of FA, our ability to obtain and maintain designations or eligibility for expedited regulatory programs, and to commercialize current and future product candidates, if approved, (including the impact of potential barriers to entry if competitors are able to establish a strong market position before we are able to commercialize our products);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patent protection and defend our intellectual property rights against third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the performance and compliance with the rules and regulations of the FDA (and all other regulatory authorities) of third parties upon which we depend, including third-party contract research organizations ("CROs"), consultants and third-party suppliers, manufacturers, distributors, and logistics providers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit and retain key scientific, technical, commercial, and management personnel and to retain our executive officers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to maintain proper functionality and security of our internal computer and information systems and prevent or avoid cyber-attacks, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which geopolitical tensions including regional conflicts around the world, adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, banking instability, monetary policy changes, changes in trade policies, including tariffs (including tariffs that have been or may in the future be imposed by the U.S. or other countries), economic slowdowns or recessions, health epidemics, unforeseen emergencies and other outbreaks of communicable diseases could disrupt our operations, the operations of third parties on which we rely or the operations of regulatory agencies we interact with in the development of nomlabofusp and any other product candidates that we may develop; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential impact of regulatory developments in the U.S., including regulatory developments due to changes in the U.S. presidential administration healthcare reform in the United States, including the Inflation Reduction Act of 2022 ("IRA"), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the other risks and uncertainties included under the section titled &#8220;Risk Factors.&#8221;</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These forward-looking statements are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management&#8217;s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe the expectations reflected in the forward-looking statements are reasonable, the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements may not be achieved or occur at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this Annual Report on Form 10-K or to reflect the occurrence of any unanticipated events. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SUMMARY RISK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risk factors summarized and detailed below could materially harm our business, operating results and/or financial condition, and may impair our future prospects and/or cause the price of our common stock to decline. These are not all of the risks we face, and other factors not presently known to us or that we currently believe are immaterial may also affect our business if they occur. Material risks that may affect our business, operating results and financial condition include, but are not necessarily limited to, those relating to:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Position and Need for Capital</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have no commercial revenue and may never become profitable.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we have $183.5 million of cash, cash equivalents and marketable securities which we expect will fund operations into the second quarter of 2026. We may need to raise additional funding to complete the development and commercialization of nomlabofusp. This funding may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed would force us to delay, limit or terminate our product development efforts or other operations.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Product Development and Regulatory Approvals</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success is currently dependent upon the success of our lead product candidate, nomlabofusp. We cannot be certain that we will ultimately be successful with our clinical development or that we will ever be able to obtain regulatory approval for nomlabofusp.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failures or delays in the completion of our clinical trials could result in increased costs and could delay, prevent or limit our ability to generate revenue and continue our business.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may experience difficulties identifying and enrolling patients in our clinical trials given the limited number of patients who have the disease for which nomlabofusp is being studied or for any other product candidates we may study in the future. Difficulty in enrolling patients could delay or prevent clinical trials of nomlabofusp or any future product candidate. There is also a competing approved FA therapeutic, other competing studies and potentially other FA therapeutics that could be approved that may also limit the availability of prospective participants in nomlabofusp clinical trials.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp, including the effects of long-term daily patient dosing may cause adverse events or undesirable side effects in clinical trials that could delay or prevent its regulatory approval, limit the commercial profile of approved labeling, or result in significant negative consequences following regulatory approval, if any.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to pursue accelerated approval from the FDA for nomlabofusp for the treatment of Friedreich&#8217;s ataxia, however this may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that we will receive marketing approval. If we are unable to obtain approval under an accelerated pathway, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, reduce the likelihood of obtaining, and/or delay the timing of obtaining necessary marketing approvals. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities or unanticipated events during our non-clinical or clinical trials of nomlabofusp or future product candidates may result in changes to clinical trial protocols or additional non-clinical or clinical trial requirements, which could result in increased costs to us and could delay our development timeline.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain marketing approval for a product candidate, our product candidates will remain subject to regulatory oversight.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell nomlabofusp, if approved, we may not be able to generate any revenue.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive marketing approval for nomlabofusp, we may not achieve broad market acceptance, which would limit the revenue that we generate from our sales.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional competing technologies could emerge, adversely affecting our opportunity to generate revenue from the sale of nomlabofusp, if approved.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to manage expected growth in the scale and complexity of our operations, including attracting and hiring additional qualified management, our performance may suffer.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security laws, Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials. As a result, many important aspects of our drug development programs are outside of our direct control.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party supply and manufacturing partners for drug supplies, for our research and development, non-clinical activities and clinical activities and may do the same for commercial supply of our product candidates. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property Rights</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, in the United States and other countries, we are unable to adequately protect our proprietary technology or maintain issued patents which are sufficient to protect nomlabofusp or potential product candidates, third parties could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our key patent relating to nomlabofusp, which we license, will expire in 2040 and we will lose our ability to rely upon this patent to prevent competing products from entering the market, which may impair our ability to generate revenue.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our stock price could be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must maintain effective internal controls over financial reporting, and if we are unable to do so, the accuracy and timeliness of our financial reporting may be adversely affected, which could have a material adverse effect on our business and stock price.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ownership of our common stock is highly concentrated, and it may prevent other stockholders from influencing significant corporate decisions.</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="parti_291637"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1business_796317"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1. BUSINESS</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name ("INN") and the United States Adopted Name ("USAN") for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia (&#8220;FA&#8221;). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to increase FXN levels in patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, raising capital, and providing general and administrative support for such operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we had cash, cash equivalents and marketable securities of $183.5 million, which we anticipate will fund operations into the second quarter of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp Program Update</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed two Phase 1 clinical trials and a Phase 2 dose exploration trial and have an ongoing Phase 2 OLE trial in patients with FA and an ongoing pharmacokinetic (PK) run-in study in adolescent patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, we reported positive top-line data from our Phase 1 FA program after completing dosing of the single ascending dose ("SAD") trial in December 2020 and of the multiple ascending dose ("MAD") trial in March 2021. Data from these trials demonstrated proof-of-concept by showing that daily subcutaneous injections of nomlabofusp for up to 13 days resulted in dose-dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues (buccal cells, skin, and platelets). There were no serious adverse events associated with either the MAD or SAD trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we reported preliminary unblinded top-line data from the 25 mg cohort of our Phase 2 four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the FDA cleared initiation of a second cohort (50 mg) of our four-week, placebo-controlled, Phase 2 dose exploration trial of nomlabofusp in patients with FA and the initiation of our OLE trial with daily dosing of 25 mg.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we reported positive top-line data and successful completion of the Phase 2 dose exploration study. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. Patients who completed treatment in our Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we dosed the first patient in our OLE trial, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study ("FACOMS") database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 30, 2024, we announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we received access to the Medicines and Healthcare Regulatory Agency ("MHRA") Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) for the treatment of adults and children with FA. The ILAP is facilitating patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with UK regulatory authorities and other stakeholders. Along with the receipt of the ILAP designation, nomlabofusp has already been granted orphan drug designations in the U.S. and the European Union (the &#8220;EU&#8221;), and access to the PRIME scheme in the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we reported positive initial data from our ongoing OLE study. This data included safety, FXN levels, clinical, pharmacokinetic data and dose escalation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp was generally well tolerated for up to 260 days in subjects. The most common adverse events were injection site reactions, with most being mild, brief in duration, and self-limited. Two participants had serious adverse events (one seizure and one anaphylactic reaction) that resolved within 24 hours and withdrew from the study; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term 25 mg tissue FXN levels showed positive mean change from baseline of 1.32 pg/&#956;g in buccal cells and 9.28 pg/&#956;g in skin cells at Day 90 and that 25 mg of nomlabofusp increased and maintained tissue FXN levels over time, increasing from a mean level of 15% of healthy volunteers ("HV") at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tissue FXN levels appear to reach steady-state levels by Day 30 in buccal cells;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early clinical data showed trends toward improvement across a number of clinical outcomes for long-term 25 mg daily nomlabofusp including: (1) decreased values indicating early trends towards improvement in the Modified Friedreich Ataxia Rating Scale ("mFARS") and the FARS-Activities of Daily Living ("ADL"), Modified Fatigue Impact Scale and 9-hole peg test at 90 days relative to baseline;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key pharmacokinetic data showed rapid absorption after subcutaneous administration with exposure appearing to reach steady state in plasma by day 30 with no further accumulation, which is consistent with data from our Phase 1 and Phase 2 studies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also in December 2024, we announced that we were increasing the dose in the OLE to 50 mg of nomlabofusp daily for then currently enrolled and all future OLE study participants. In March 2025, we announced that our Safety Monitoring Team has deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp and therefore, we expect to see additional reactions. To reduce the risk of allergic reactions, including anaphylaxis, we amended the OLE protocol to administer premedication for the first month of dosing. The OLE study is ongoing with seven sites activated and participants continuing to enroll. All study participants are currently receiving the 50 mg dose of nomlabofusp. We plan to provide an update on OLE data on at least 30 to 40 study participants, some of whom have been receiving nomlabofusp for more than a year, in September 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we initiated dosing of adolescents (12-17 years old) in a PK run-in study for pediatric patients with FA. Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp at a weight-base dose expected to match the PK of adults receiving the 50 mg dose, or placebo, daily for seven days. Following assessment of safety and PK data, participants will be eligible to screen for the OLE study. The data from this cohort is expected to be presented during the nomlabofusp program update in September 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we announced that FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as a reasonably likely surrogate endpoint (&#8220;RLSE&#8221;) and the acceptability of FXN&#8217;s use as an RLSE would ultimately be a matter of review of the data in a future marketing application. FDA recommended focusing on assessments of skin FXN concentrations rather than buccal FXN concentrations due to more consistent sampling and less variability. FDA acknowledged that data we recently submitted appear to support a relationship between increased FXN</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">concentrations in skin cells and relevant tissues such as the heart, dorsal root ganglion and skeletal muscle. FDA also acknowledged that the nonclinical studies we submitted were performed at relevant human doses. FDA also suggested that we consider exploring the relationship between increases in FXN in skin and changes in pharmacodynamic (PD) markers such as lipid profiles and/or clinical measures to provide additional support for the use of FXN as an RLSE. We plan to continue discussions with FDA regarding the adequacy of the safety data set for a BLA submission seeking accelerated approval targeted for year-end 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have obtained feedback from both FDA and EMA on the global Phase 3 study protocol and we are on track to initiate the study by mid-2025 with potential sites in the U.S., E.U., U.K, Canada, and Australia.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our strategy is to become a leader in the treatment of rare diseases by leveraging our technology platform and applying our management team&#8217;s know-how and expertise to the development of nomlabofusp and other future pipeline programs. Key elements of our strategy include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Advance nomlabofusp through clinical development and regulatory approval in the United States the European Union and other foreign jurisdictions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We have completed two Phase 1 clinical trials and a Phase 2 dose exploration trial in patients with FA in the United States and have an ongoing OLE study in the U.S with patients age 18 or older with initial dosing of 25 mg of nomlabofusp daily, which, in November 2024, we began increasing to 50 mg daily. In January 2025, we started dosing adolescents (12-17 years old) in a nomlabofusp pediatric PK run-in study. Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp or placebo daily for seven days. Adolescents receive a weight-based dose expected to match the PK of adults receiving the 50 mg dose. Adolescents who complete participation in the PK run-in study will be eligible to screen in the ongoing OLE study following assessment of safety and PK data. We are continuing to develop and execute a clinical development plan for regulatory approval of nomlabofusp in the United States, the European Union, the United Kingdom ("UK"), Australia, Canada and potentially other countries. We have obtained feedback from both FDA and EMA on the global Phase 3 study protocol and we are on track to initiate the study by mid-2025 with potential sites in the U.S., E.U., U.K, Canada, and Australia. We are continuing discussions with FDA regarding the adequacy of the safety data set required to support BLA submission and we are targeting BLA submission by the end of 2025 to seek accelerated approval.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intend to pursue the use of tissue frataxin levels as a novel surrogate endpoint to support a potential Biologics License Application (&#8220;BLA&#8221;) submission for accelerated approval</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have had discussions with the FDA regarding the potential use of tissue FXN levels as a novel surrogate endpoint. The FDA acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. In March 2025, we announced that FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as an RLSE and the acceptability of FXN&#8217;s use as an RLSE would ultimately be a matter of review of the data in a future marketing application. We intend to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology information needed to support the novel surrogate endpoint approach. We are continuing to plan for a confirmatory study and have received feedback from FDA on the design of this study. We are targeting a BLA submission by the end of 2025. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If nomlabofusp receives regulatory approval(s), commercialize nomlabofusp in the United States, the European Union, and other relevant countries independently or with third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We intend to evaluate commercialization options in the United States, the European Union, the United Kingdom and in other foreign jurisdictions throughout the world where FA patients can benefit, if we are successful in obtaining regulatory approval. We may build our own internal sales force; partner with a contract sales organization, and/or enter into a joint marketing partnership with another pharmaceutical or biotechnology company, whereby we may jointly sell and market nomlabofusp, if approved; or we may seek to out-license nomlabofusp, whereby other pharmaceutical or biotechnology companies sell and market nomlabofusp and pay us milestone and/or royalty payments on sales. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expand our product candidate pipeline to treat a variety of rare diseases. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to expand our pipeline to treat additional rare diseases. A key component of this strategy is to utilize our novel protein replacement therapy platform technology to deliver FXN or other molecules to intracellular targets. We employ a rational approach to selecting disease targets, and take into account many scientific, business, and indication specific factors before choosing each indication. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continue to improve our novel protein replacement therapy platform. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to improve the scientific understanding of our platform, including how our technology allows enhanced delivery of cargo proteins, thereby impacting the biological processes associated with the diseases we seek to treat. In addition, with our expertise in the use of a CPP to effectively deliver proteins to intracellular targets, we believe that our scientists are well positioned to design and develop additional therapies that will address unmet medical needs associated with other rare diseases and develop other therapeutics with potentially disease modifying therapeutic action. We also plan to continue to build our intellectual property portfolio to expand our protein replacement therapy platform. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opportunistically evaluate enabling, adjacent or potential competing technologies, and where advantageous, seek licenses or collaborations regarding those technologies, to advance our platform.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We will continue to evaluate technologies that may enable or enhance our product candidates or our rare disease focus. To facilitate the advancement of our CPP platform, we periodically engage in partnering and licensing discussions with a range of biotechnology or pharmaceutical companies and academic institutions and maintain awareness of complementary technologies, synergistic opportunities and "tuck-in" options. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Continue to strengthen key relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We partner with experts in every aspect of development. We believe this expertise, along with our technology platform, will provide us with the ability to develop and commercialize the drug and biologic candidates we have under development and to maximize the value of our platform. In addition to partnering with experts in drug and biologic development, we collaborate with key opinion leaders, academic institutions, experts in the field of rare diseases and with patient advocacy groups associated with the diseases that are being targeted. We have established a scientific advisory board and we regularly seek advice and input from these experienced thought leaders on matters related to our research and development programs. The members of our scientific advisory board consist of distinguished research scientists, professors and industry experts recognized as key opinion leaders in the fields of rare disease, pediatrics and mitochondrial disease. We build these relationships to enhance our knowledge of the patient&#8217;s needs and utilize that knowledge to design development programs intended to address unmet medical needs and add value for potential patients. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Platform Technology for Treatment of Rare Genetic Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are estimated to be over 9,500 rare genetic diseases, which, collectively affect hundreds of millions of people worldwide. Of the hundreds of millions of individuals suffering from these rare genetic diseases, only approximately 5% have therapeutic options available to manage their disease. Many of these diseases result from a deficiency in the amount or the function of a particular target molecule, often a protein. Particularly challenging to treat are those diseases that result from the deficiency of a molecule that is active within a cell or within a cell-based organelle. The challenge to providing treatment of these diseases is the need to improve the amount or function of the therapeutic target by transporting a therapeutic element across the cell membrane and potentially the membrane of the organelle where the target is active in the diseased patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ability to transport therapeutic proteins across biological membranes has, to date, not been reproducibly achieved. The collective population of people with rare diseases stands to benefit from the emergence of a scalable treatment platform that can transport therapeutic proteins across cell membranes to deliver them to the intracellular site of activity. In addition, traditionally, medical treatment for each rare genetic disorder has been approached on a disease-by-disease basis. This approach is inefficient, as there are thousands of diseases, each with a distinct patient population, that cannot be addressed by traditional therapeutic approaches and are in need of treatment options. Our understanding of our therapeutics derived from proprietary gene expression data across several disease models supports the concept that product candidates based on our platform technology could significantly impact common pathological mechanisms in various diseases with comparable etiologies. We are utilizing this approach to identify therapeutic opportunities where our molecules and technology are more likely to be impactful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp For the Treatment of Friedreich&#8217;s ataxia</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Friedreich&#8217;s ataxia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Friedreich&#8217;s ataxia is a rare genetic disease that is the most commonly inherited ataxia in humans, with approximately 20,000 individuals living with Friedreich&#8217;s ataxia globally, and of these individuals, approximately 5,000 are in the United States and the majority of the remaining individuals are primarily in Europe. Friedreich&#8217;s ataxia results from a deficiency of the mitochondrial protein, FXN. FXN is an essential and phylogenetically conserved protein that is found in cells throughout the body, with the highest levels found in the heart, spinal cord, liver, pancreas, and skeletal muscle. FXN is encoded in the nucleus of the cell, expressed in the cytoplasm and transported into the mitochondria, where it is processed to the mature form. As part of this process the mitochondrial targeting sequence is cleaved off in the mitochondria by a naturally occurring enzyme.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Friedreich&#8217;s ataxia is a progressive multi-symptom disease typically presenting in mid-childhood that affects the functioning of multiple organs and systems. It is a debilitating neurodegenerative disease that results in poor coordination of legs and arms, progressive loss of the ability to walk, generalized weakness, loss of sensation, scoliosis, diabetes and cardiomyopathy as well as impaired vision, hearing and speech. Patients suffer from progressive neurologic and cardiac dysfunction. Key among these is a primary neurodegeneration of the dorsal root ganglia and the dentate nucleus of the cerebellum, which leads to the hallmark clinical findings of progressive limb ataxia and dysarthria. A hypertrophic cardiomyopathy is common and associated with early mortality, typically between 30 and 50 years of age. Omaveloxolone, the first drug approved for the treatment of FA, was approved by the FDA and the European Commission in February 2023 and February 2024, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nomlabofusp</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp, an investigational biologic fusion protein that is administered subcutaneously, consists of a CPP genetically fused to human FXN, and includes a mitochondrial targeting sequence. Using our proprietary peptide delivery technology, nomlabofusp is designed to carry the molecule from the intravascular space across the cell membrane and into the mitochondria where the CPP and the mitochondrial targeting sequence are cleaved off to yield mature FXN. See Figure 1.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 1.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_0.jpg" alt="img132800289_0.jpg" style="width:504px;height:188px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed two Phase 1 nomlabofusp clinical trials, and a Phase 2 dose exploration trial and have an ongoing OLE study in the U.S with patients with initial dosing of 25 mg of nomlabofusp daily, which in November 2024 we increased to 50 mg daily. In January 2025, we started dosing of adolescents (12-17 years old) in a nomlabofusp pediatric PK run-in study. Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp or placebo daily for seven days. Adolescents receive a weight-based dose equivalent to the 50 mg adult dose. Adolescents who complete participation in the PK run-in study will be eligible to screen in the ongoing OLE study. Following assessment of safety and PK data of each successive cohort, participants will be eligible to screen for the OLE study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the results of our non-clinical development program as well as results from our Phase 2 clinical trials, we believe that administering nomlabofusp may increase FXN levels in the mitochondria of patients with Friedreich&#8217;s ataxia and patients could potentially experience:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">improved cellular function; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a positive impact on Friedreich&#8217;s ataxia symptoms; and </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a slowing of progression of the disease, potentially prolonging life. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our Phase 1 clinical trials, nomlabofusp appeared to increase FXN levels in the peripheral tissues that were tested (buccal cells, skin biopsies and platelets) and data from our Phase 2 dose exploration study demonstrated dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Based on this, we believe that our technology may allow us to address other rare genetic diseases that either require the replacement of molecules that need to target specific intracellular organelles, or that share similar clinical symptoms that overlap with Friedreich&#8217;s ataxia. Finally, the use of nomlabofusp to improve mitochondrial function in other rare diseases that demonstrate evidence of mitochondrial dysfunction is also being explored.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Development of Nomlabofusp</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Knock-Out Mice and Other Non-clinical Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp has been demonstrated to prolong the life of knock-out ("KO") mice whose heart and skeletal muscles were deficient in FXN. These mice, when untreated, develop a severe hypertrophic cardiomyopathy similar to patients with Friedreich&#8217;s ataxia and, like many Friedreich&#8217;s ataxia patients, die early in life. In non-clinical studies of nomlabofusp, the median survival in animals treated with vehicle of 98 days was extended to a median survival of 166 days in animals treated with nomlabofusp subcutaneously three times per week (p=0.0001). Furthermore, 87.5% of mice treated with nomlabofusp survived beyond the mean age of death in the vehicle treated group (107.5 days) whereas only 33% of vehicle treated animals survived. Results are reflected in Figure 2.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 2.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_1.jpg" alt="img132800289_1.jpg" style="width:290px;height:202px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In a separate study conducted at an independent laboratory, a similar mouse model was studied. In this study doses of 2 mg/kg, 10 mg/kg, 30 mg/kg, 60 mg/kg and 100 mg/kg administered subcutaneously every other day were compared to vehicle. After 2 weeks of dosing, mitochondrial extracts from cardiac tissue were analyzed for the presence of human FXN. In addition, activity of succinate dehydrogenase ("SDH") an enzyme whose activity is dependent on the presence of FXN, was also analyzed. Human FXN was found in the mitochondria of the cardiomyocytes and increased with increasing dose. SDH activity which was suppressed to near zero in vehicle treated animals was also suppressed to near zero in the 2 mg/kg dose group. In the 10 mg/kg dose group activity was increased and in the 30 mg/kg dose group the activity was returned to that of wild type animals. There was no further increase in activity when the animals were dosed with 60 mg/kg or 100 mg/kg but the effect was maintained at levels equivalent to that of wild type animals. See Figures 3 and 4.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 3.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_2.jpg" alt="img132800289_2.jpg" style="width:280px;height:183px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 4.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_3.jpg" alt="img132800289_3.jpg" style="width:262px;height:170px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Another study, also performed at an independent laboratory, demonstrated the maintenance of cardiac function when the same KO mouse model was studied. These mice were treated with nomlabofusp at doses of 10 mg/kg every other day for 6 weeks. Echocardiograms were performed prior to initiating dosing and after 4 weeks of dosing. When compared to vehicle, mice treated with nomlabofusp maintained their left ventricular volume and ejection fraction while vehicle treated mice deteriorated over the same 4-week period. See Figures 5 and 6.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 5.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_4.jpg" alt="img132800289_4.jpg" style="width:510px;height:193px;"/></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 6.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_5.jpg" alt="img132800289_5.jpg" style="width:495px;height:198px;"/></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Using a neurologic mouse model, treatment with nomlabofusp prevented the development of ataxia in mice whose nervous system was deficient in FXN compared to those treated with placebo.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In multiple non-clinical studies in rodents and non-human primates ("NHPs"), human FXN was found to be distributed into all tissues tested following nomlabofusp dosing. See Figure 7.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 7.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:84.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.321%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:29.012%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.321%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:37.015%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:3.321%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:19.008%;box-sizing:content-box;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="11" style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Observed hFXN across all tissue and cell types tested:</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Brain</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Spinal Cord</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Skin</span></p></td>
   </tr>
   <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Heart</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cardiac Mitochondria</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Buccal Cells</span></p></td>
   </tr>
   <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Liver</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">CSF (Cerebrospinal Fluid)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Platelets</span></p></td>
   </tr>
   <tr style="height:3.6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dorsal Root Ganglia</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#10003;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Skeletal Muscle</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Human Primate and Rat Toxicology Studies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We previously conducted 28-day and 13-week GLP toxicology studies of nomlabofusp in two species, rat and NHP. In the rat studies, some injection sites showed edema and erythema with associated histologic changes localized to the injection site. The rat studies showed no significant clinical observations and no significant systemic histopathological findings. In the NHP studies, some injection sites were raised and firm with dose dependent histologic changes localized to the injection sites. The NHP 28-day study showed no systemic toxicity. The NHP 13-week study showed no systemic toxicity in the low and mid-dose groups, and minimal to mild histopathological findings in the high dose group. There were also several episodes of occasional transient muscle rigidity in some animals observed immediately after dosing in the two highest dose groups at very high exposures. These clinical observations resolved with no intervention and all of the NHPs who experienced these clinical observations received all doses and completed the in-life portion of the study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To support extended dosing of patients with nomlabofusp, we conducted a 26-week NHP toxicology study in 2021. In May 2021, we notified the FDA of certain mortalities which occurred at the two highest dose levels in the then-ongoing study. On May 25, 2021, the FDA placed a clinical hold on the nomlabofusp clinical program. In the clinical hold letter, the FDA stated that it needed to review a full study report from the then-ongoing NHP study and that we could not initiate additional interventional clinical trials until we submitted such report and received notification from the FDA that additional clinical trials could commence. At the time of the FDA clinical hold, we had no interventional clinical trials with patients enrolled or enrolling.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, we completed dosing in the 26-week NHP toxicology study. The study included four dose groups in addition to vehicle. Data from the study were collected throughout the second half of 2021 and included in the complete response to the clinical hold submitted to the FDA in January 2022. After additional interactions and submission of additional information requested by FDA, in September 2022, the FDA lifted its full clinical hold on the nomlabofusp clinical development program and imposed a partial clinical hold. Following additional interactions</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and submission of clinical data, in May 2024, the FDA removed the partial clinical hold on the development of nomlabofusp.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Interventional Study</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2021, we conducted a non-interventional study that enrolled 60 healthy adults to examine the range of tissue FXN concentrations in individuals who are homozygous for the normal FXN gene. Tissue samples in these studies were collected using the same sampling techniques and proprietary assay used in the interventional studies. Enrollment in this study was completed in 2022 and data has been used for comparison purposes in the Phase 2 clinical study described below. See Figure 8.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 8.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_6.jpg" alt="img132800289_6.jpg" style="width:624px;height:303px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FXN concentrations were measured in skin and buccal cells from 60 homozygous healthy volunteers utilizing the same sampling technique and assay as clinical trials of nomlabofusp; FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations normalized to total cellular protein content in each sample. 1. E.C. Deutsch et al. Molecular Genetics and Metabolism 101 (2010) 238&#8211;245. 2. Friedreich&#8217;s Ataxia Research Alliance</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Trials</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Completed Phase 1 Clinical Studies in Adults with Friedreich&#8217;s Ataxia</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We submitted our Investigational New Drug application ("IND") application for nomlabofusp and began Phase 1 clinical trials in 2019 in patients with FA. We completed two clinical studies of nomlabofusp in adult subjects with FA, a SAD study (completed in 2020) and a MAD study (completed in 2021). The primary objective for the SAD and MAD studies was to assess the tolerability of nomlabofusp at doses ranging from 25 mg to 100 mg administered via subcutaneous injection ("SC"). The secondary objectives were to establish the PK of nomlabofusp administration in humans and to explore the PD of nomlabofusp administration by measuring tissue FXN concentrations in accessible tissues, namely buccal and skin cells, and in platelets. Administration of nomlabofusp via SC injection appeared to be well tolerated up to doses of 100 mg administered daily for up to 13 days. No SAEs were reported in either study. The most common treatment emergent adverse events ("TEAEs") were injection site reactions ("ISRs") that were generally mild, self-limited, and usually resolved within approximately 1 hour. Patients in the 25 mg cohort were dosed once a day for the first 4 days followed by 1 dose every third day through day 13 for a total of 7 doses, while the patients in the 50 mg cohort were dosed once a day for the first 7 days followed by 1 dose every other day through day 13 for a total of 10 doses, and patients in the 100 mg cohort were dosed once a day for 13 days consecutively for a total of 13 doses (see Figures 9 and 10). The study was designed in this fashion to ensure that the PK of nomlabofusp in patients with FA were characterized at the lower doses before the dose was escalated. This is typical of first in human studies such as multiple-ascending dose trials that evaluate a study drug&#8217;s clinical safety profile.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There was rapid uptake of nomlabofusp into the circulation following subcutaneous injection, and exposure appeared to be proportional to dose.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 9.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_7.jpg" alt="img132800289_7.jpg" style="width:624px;height:301px;"/></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 10.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_8.jpg" alt="img132800289_8.jpg" style="width:624px;height:310px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample; Data represent median and 25th and 75th percentiles; FXN levels from day 4, &amp; day 13 measurements are shown for data derived from the 25 mg cohort; FXN levels from day 7 &amp; day 13 measurements are shown for data derived from the 50 &amp; 100 mg cohorts.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Completed Phase 2 Dose Exploration Study</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Phase 2 randomized, double-blind, placebo-controlled dose exploration study evaluated the safety, tolerability, PK and PD of two doses of nomlabofusp. Cohort 1 evaluated 25 mg and Cohort 2 evaluated 50 mg. Participants in either the 25 mg or 50 mg cohorts were randomized 2:1 to receive daily subcutaneous injections of either nomlabofusp or placebo for 14 days, and then every other day for an additional 14 days for a total 28-day dosing period.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we reported preliminary unblinded top-line data from the 25 mg cohort of the dose exploration study. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14. In July 2023, the FDA cleared initiation of the second cohort (50 mg) of the study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we reported positive top-line data and successful completion of the dose exploration study. Nomlabofusp was generally well tolerated and demonstrated dose response in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With regard to safety in the Phase 2 dose exploration trial, there were a total of 28 participants (19 received nomlabofusp and 9 received placebo). There were no serious adverse events reported. There was one allergic reaction which was considered to be a severe adverse event in the 25 mg cohort that resolved with standard treatment. This participant withdrew from the trial. The most common adverse events reported were mild and moderate injection site reactions which resolved without any intervention and there were no study discontinuations due to injection site reactions. Consistent with findings in our Phase 1 study, nomlabofusp demonstrated quick absorption after subcutaneous administration and had dose proportional increases in exposure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participants treated with 50 mg for 14 days daily had frataxin levels in skin cells increase from less than 17% at baseline relative to healthy volunteers, to 33% to 59% of healthy volunteers after 14 days of treatment. Patients treated with placebo showed no increase in their frataxin levels during this period. Additionally, the majority of treated patients in both cohorts with quantifiable levels of frataxin at baseline and day 14 achieve at least a 100% increase in tissue frataxin in skin cells, and at least a 30% increase in tissue frataxin levels in buccal cells. Figures 11 and 14 show a clear dose response and increase from baseline in skin tissue and buccal tissue frataxin levels, respectively.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The graph on the left in both Figures 12 and 15 shows a dose dependent increase in frataxin levels after 14 days of treatment. With both skin and buccal cells, when dosing is switched to every other day the magnitude of the increase in frataxin levels declines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The waterfall plots on the right in both Figures 12 and 15 depict the individual changes in frataxin levels from baseline in skin cells and buccal cells at day 14 respectively. Each bar represents an individual patient, with placebo treated participants in gray, the 25 mg cohort in aqua, and the 50 mg cohort in blue. The majority of patients treated with nomlabofusp had significant increases in frataxin levels while placebo patients were basically unchanged. Importantly, there also appears to be a dose response as frataxin levels are notably increased in most of the 50 mg cohort over the 25 mg cohort.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 11.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_9.jpg" alt="img132800289_9.jpg" style="width:624px;height:307px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only participants with quantifiable levels at baseline and day 14 and day 28 are included in the tables.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 12.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_10.jpg" alt="img132800289_10.jpg" style="width:624px;height:314px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample. Data represent median and 25th and 75th percentiles. Only participants with quantifiable levels at both baseline and day 14 are included in the figures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">**Median baseline FXN levels in patients were 3.5 pg/&#181;g for the placebo, 3.7 pg/&#181;g for the 25 mg cohort and 2.1 pg/&#181;g for the 50 mg cohort.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figures 13 and 16 depict how many people had a shift in frataxin levels in skin cells and buccal cells as a percentage of average healthy volunteers after 14 days of treatment. On the left is the 25 mg cohort and on the right is the 50 mg cohort. On the far left of each figure are categories of the percentage of average healthy volunteers. Figures in black to the left of the black vertical line represent patients at baseline. Figures to the right of the black</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">vertical line represent day 14 frataxin levels as a percentage of average healthy volunteers. In blue are individuals that increase by 25% to 50% and in green are individuals that exceeded 50% of average healthy volunteers.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 13.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_11.jpg" alt="img132800289_11.jpg" style="width:624px;height:324px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only participants with quantifiable levels at baseline and day 14 are included in the figures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*% of healthy volunteer FXN level is calculated by dividing each participant's FXN level by the average FXN level (16.34 pg/&#181;g) from the noninterventional healthy volunteer study (N=60).</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 14.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_12.jpg" alt="img132800289_12.jpg" style="width:624px;height:321px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only participants with quantifiable levels at baseline and day 14 and day 28 are included in the tables.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 15.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_13.jpg" alt="img132800289_13.jpg" style="width:624px;height:302px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*FXN levels measured via detection of peptide derived from mature FXN; FXN concentrations are normalized to total cellular protein content in each sample. Data represent median and 25th and 75th percentiles. Only participants with quantifiable levels at both baseline and Day 14 are included in the figures.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">**Median baseline FXN level in patients were 2.1 pg/&#181;g for the placebo, 1.8 pg/&#181;g for the 25 mg cohort and 1.6 pg/&#181;g for the 50 mg cohort.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Figure 16.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img132800289_14.jpg" alt="img132800289_14.jpg" style="width:624px;height:333px;"/></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Only participants with quantifiable levels at baseline and day 14 are included in the figures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*% of healthy volunteer FXN level is calculated by dividing each participant's FXN level by the average FXN level (8.24 pg/&#181;g) from the noninterventional healthy volunteer study (N=60).</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Open Label Extension</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, we initiated the OLE trial evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver, with the first patient dosed in March 2024. Participants who completed treatment in the Phase 2 dose exploration study, or who previously completed a prior clinical trial of nomlabofusp, are potentially eligible to screen for the OLE study. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study ("FACOMS") database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we reported positive initial data from our ongoing OLE study. This data included safety, FXN levels, clinical, pharmacokinetic data and dose escalation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp was generally well tolerated for up to 260 days in subjects. The most common adverse events were injection site reactions, with most being mild, brief in duration, and self-limited. Two participants had serious adverse events (one seizure and one anaphylactic reaction) that resolved within 24 hours who withdrew from the study;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term 25 mg tissue FXN levels showed positive mean change from baseline of 1.32 pg/&#956;g in buccal cells and 9.28 pg/&#956;g in skin cells at Day 90 and that 25 mg of nomlabofusp increased and maintained tissue FXN levels over time, increasing from a mean level of 15% of HV at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tissue FXN levels appear to reach steady-state levels by Day 30 in buccal cells;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early clinical data showed trends toward improvement across a number of clinical outcomes for long-term 25 mg daily nomlabofusp including: (1) decreased values indicating early trends towards improvement in the Modified Friedreich Ataxia Rating Scale (mFARS) and the FARS-Activities of Daily Living ("ADL"), Modified Fatigue Impact Scale and 9 hole peg test at 90 days relative to baseline;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key pharmacokinetic data showed rapid absorption after subcutaneous administration with exposure appearing to reach steady state in plasma by day 30 with no further accumulation, which is consistent with data from our Phase 1 and Phase 2 studies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also in December 2024, we announced that we were increasing the dose in the OLE to 50 mg of nomlabofusp daily for then currently enrolled and all future OLE study participants. In March 2025, we announced that our Safety Monitoring Team has deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp and therefore, we expect to see additional reactions. To reduce the risk of allergic reactions, including anaphylaxis, we amended the OLE protocol to administer premedication for the first month of dosing. The OLE study is ongoing with seven sites activated and participants continuing to enroll, and all study participants are currently receiving the 50 mg dose of nomlabofusp. We plan to provide an update on OLE data on at least 30 to 40 study participants, some of whom have been receiving nomlabofusp for more than a year, in September 2025.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part upon our ability to obtain and maintain proprietary protection for our current and future products and technologies, and to operate without infringing the proprietary rights of others. Our policy is to protect our proprietary position by, among other methods, filing for patent applications on inventions that are important to the development and conduct of our business with the U.S. Patent and Trademark Office and its foreign counterparts. We also intend to rely on regulatory exclusivity (also called data exclusivity), which is separate and distinct from the protection afforded by patents, to protect our products. We further protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement. Agreements with our employees also prevent them from bringing the proprietary rights of third parties to us. In addition, we require confidentiality or service agreements from third parties that receive our confidential information or materials.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 17, 2025, our intellectual property portfolio was composed of numerous international Patent Cooperation Treaty ("PCT"), foreign, United States non-provisional patent applications,   issued United States patents and United States provisional patent applications that we own or co-own, and five issued United States patents and additional non-provisional patent applications in the United States and in certain foreign jurisdictions that we license from academic institutions. The issued patents in the United States licensed by us, which include issued patents covering the composition of matter for nomlabofusp and methods for treating FA, have expiration dates between 2025 and 2040 without taking potential patent term extension into consideration. The international and the United States non-provisional patent applications licensed by us relate to composition of matter and methods of use for nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The additional patent applications we own or co-own, which include PCT, foreign and United States non-provisional patent applications, United States patents, and United States provisional patent applications are related to the development of nomlabofusp, including methods of use of nomlabofusp, and to our peptide-delivery platform technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A provisional patent application allows for an effective filing date to be established with regard to an invention, but once a provisional patent application is filed, either a corresponding non-provisional patent application or a petition to convert the provisional patent application into a non-provisional patent application must be filed within 12 months or such effective filing date will be lost. If we or our licensor timely files non-provisional patent applications in the United States and in countries outside of the United States with regard to our provisional patent applications and these non-provisional patent applications result in issued patents, such patents are expected to expire in 2045, without taking potential patent term adjustment or patent term extension into consideration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp is covered by licensed issued patents (composition of matter and methods of use) in the United States which, if properly maintained, will expire in 2025 and 2040, excluding any patent term extensions that might be available following the grant of marketing authorizations. We also possess an exclusive license to non-provisional applications in the United States and certain countries outside the United States for nomlabofusp (composition of matter and methods of use). If these patent applications in the United States and other countries result in issued patents, those patents would be expected to expire in 2040. This estimated expiration excludes any patent term adjustment that might be available following the grant of the patent and any patent term extensions that might be available following the grant of marketing authorizations. We cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also use other forms of protection besides patent protection and regulatory exclusivity, such as trademark, copyright, and trade secret protection, to enhance our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable. We aim to take advantage of all of the intellectual property rights that are available to us and believe that this comprehensive approach will provide us with proprietary exclusive positions for our product candidates, such as nomlabofusp, where available.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In-License Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to a License Agreement dated November 30, 2016 with Wake Forest University Health Sciences ("WFUHS") and a License Agreement dated November 30, 2016, as amended, with Indiana University ("IU"). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by us with respect to the development of nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In partial consideration for the right and license granted under these agreements, we will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, we are obligated to pay each of WFUHS and IU certain milestone payments of up to $2.6 million in the aggregate upon the achievement of certain developmental milestones, commencing on the enrollment of the first patient in a Phase 1 clinical trial. We will also pay each of WFUHS and IU sublicensing fees ranging up to a low double-digit percentage of sublicense consideration depending on our achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. We are also obligated to reimburse WFUHS and IU for patent-related expenses. In the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">event that we dispute the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. We are also obligated to pay to IU a minimum annual royalty of less than $0.1 million per annum starting in the 2020 calendar year for the term of the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that we are required to pay IU consideration, then we may deduct 20% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that we are required to pay WFUHS consideration, then we may deduct 60% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies. Any product candidates that we successfully develop into products and commercialize may compete with existing therapies and new therapies that may become available in the future. While we believe that our platform technology, product candidates and scientific expertise in the field of rare diseases provide competitive advantages, we face competition from various sources, including larger and better-funded pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies, as well as from academic institutions, governmental agencies and public and private research institutions. We expect to compete with Biogen&#8217;s SKYCLARYS</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TM</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (omaveloxolone), which was approved for the treatment of FA in adults and adolescents aged 16 and older by the FDA and the European Commission in February 2023 and February 2024, respectively. Other competitors currently developing therapeutics to treat FA include, but are not limited to Design Therapeutics, Lexeo Therapeutics, Neurocrine Biosciences/Voyager Therapeutics and PTC Therapeutics ("PTC"). The FDA has accepted for filing PTC&#8217;s NDA for vatiquinone for the treatment of children and adults living with FA with a target action date of August 19, 2025. Many of our competitors have significantly greater name recognition, longer operating histories and financial, technical manufacturing, marketing and human resources than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated amongst a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer or less costly than our product candidates or obtain regulatory approval for their products more rapidly than we may obtain approval for our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing and Supply</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp is a biologic fusion protein that is produced in E. coli. We have worked with contract manufacturers and research organizations to develop, in accordance with current Good Manufacturing Practices (&#8220;cGMP&#8221;) a manufacturing process and analytical methods for drug substance and drug product to support clinical trials. We also use third party manufacturers for the clinical packaging, storage and distribution of nomlabofusp. We rely on third parties to store the nomlabofusp master cell bank and working cell bank, each stored at a different location. We continue to advance the manufacturing of nomlabofusp, obtain stability data, and produce drug product for future clinical trials. We are continually trying to optimize our manufacturing process to increase yields, decrease costs and increase reliability in supply chains. The final process will need to be successfully scaled up to support commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for us by KBI Biopharma, Inc. ("KBI"). We are party to a Master Services Agreement, as amended, with KBI, pursuant to which KBI provides biological development and clinical manufacturing services with respect to nomlabofusp. We are no longer producing the frozen liquid form of drug product. We are producing a lyophilized version of the drug product from the same KBI drug substance at Bora Pharmaceutical Services, Inc. (&#8220;Bora&#8221;). We are party to a Master Services Agreement with Bora, pursuant to which Bora provides biological development and clinical manufacturing services with respect to nomlabofusp. In February 2025, FDA accepted the data supporting the comparability of the lyophilized drug product to the frozen solution and agreed with our plans to introduce the lyophilized product into our clinical development program in mid-2025. The frozen solution is the dosage form currently being used in the OLE. The lyophilized drug product is the formulation that we intend to commercialize.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To supply nomlabofusp drug substance commercially, we intend to scale up the manufacturing process. We have selected Lonza to support this scale-up effort. We are currently tech transferring the process to Lonza and are making adaptations to the process that enable facility fit. We are party to a Master Services Agreement with Lonza, pursuant to which Lonza provides biological development and clinical manufacturing services with respect to nomlabofusp. We intend to demonstrate the comparability of the drug substance manufactured by Lonza and submit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this data to the FDA for their review in 2026. Acceptance of this comparability will allow for the use of drug substance manufactured by Lonza in the clinical development of nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received concurrence from the FDA that our proposed matrixed potency control strategy appears reasonable, pending review of the BLA. We are in the process of implementing this assay at a third-party testing lab and intend to provide a comprehensive data package that supports our ongoing clinical and commercial development. As development of this assay is scientific in nature, efforts may prove to be unsuccessful and will require further discussions with FDA on an appropriate strategy.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employees and Compensation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to achieve the goals and expectations of our Company, it is crucial that we continue to attract and retain top talent. To facilitate talent attraction and retention, we strive to make our company a safe and rewarding workplace, with opportunities for our employees to grow and develop in their careers, supported by strong compensation, benefits, paid time-off and health and wellness programs, including programs that build connections between our employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, we employed 65 full-time employees in the United States, of which 48 are directly engaged in research and development with the rest providing administrative, business, commercial and operations support. None of our employees are represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be good.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Scientific Advisors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established a scientific advisory board and we regularly seek advice and input from these experienced thought leaders on matters related to our research and development programs. The members of our scientific advisory board consist of distinguished research scientists, professors and industry experts recognized as key opinion leaders in the fields of rare disease, pediatrics and mitochondrial disease. Their scientific perspectives will be invaluable to determine our strategic scientific pathway and support the development of other potential treatments for complex rare diseases to help fill unmet medical needs in this space. We intend to continue to leverage the broad expertise of our advisors by seeking their counsel on important topics relating to our product development and clinical development programs. Our scientific advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, our scientific advisors may have arrangements with other companies to assist those companies in developing products or technologies that may compete with ours. All of our scientific advisors are affiliated with other entities and devote only a small portion of their time to us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our scientific advisors are set forth in the table below:</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25.64%;box-sizing:content-box;"/>
    <td style="width:1.98%;box-sizing:content-box;"/>
    <td style="width:71.38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marni Joy Falk, MD</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Director, Mitochondrial Medicine Frontier Program at Children&#8217;s Hospital of Philadelphia; Professor, Department of Human Genetics and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Giovanni Manfredi, MD, PhD</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finbar and Marianne Kenny Professor of Clinical and Research Neurology, Weill Cornell Medicine; Professor of Neuroscience, Weil Cornell Medicine</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jill Ostrem, MD</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Medical director and division chief of University of California San Francisco (UCSF) Movement Disorders and Neuromodulation Center. Carlin and Ellen Wiegner Endowed Professor of Neurology.</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;vertical-align:top;padding-bottom:0in;"><p style="text-indent:-10pt;padding-left:10pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark Payne, MD</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Professor of Pediatrics, Indiana University School of Medicine</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Facilities</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We lease office and laboratory space, which consists of approximately 8,000 square feet and 4,000 square feet located in Bala Cynwyd, PA and King of Prussia, PA, respectively. The office lease currently expires on August 31, 2026 and the lab lease expires on May 9, 2028.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of the Merger (as defined below) with Zafgen, Inc ("Zafgen"), we acquired a non-cancellable operating lease for approximately 17,705 square feet of office space at 3 Center Plaza, Boston, Massachusetts (the "Boston Lease"). The Boston Lease expires on October 30, 2029. On October 27, 2020, we entered into a sublease agreement whereby we subleased all 17,705 square feet of office space leased under the Boston Lease until October 30, 2029.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on us.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Corporate Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We were founded in 2005 as a Delaware corporation under the name Zafgen, Inc. ("Zafgen"). On May 28, 2020, Zafgen completed a reverse merger with Chondrial Therapeutics, Inc. ("Chondrial") in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated December 17, 2019, by and among Zafgen, Zordich Merger Sub, Inc., Chondrial and Chondrial Therapeutics Holdings, LLC, pursuant to which Zordich Merger Sub, Inc. merged with and into Chondrial, with Chondrial surviving as our wholly owned subsidiary. Following completion of the merger, Zafgen, Inc. changed its name to Larimar Therapeutics, Inc.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our principal executive offices are located at Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004, and our telephone number is (844) 511-9056. Our website address is www.larimartx.com. The information on, or that can be accessed through, our website is not part of this Annual Report on Form 10-K and is not incorporated by reference herein. We have included our website address as an inactive textual reference only.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission ("the SEC") under the Securities Exchange Act of 1934, as amended ("the Exchange Act"). The SEC maintains an internet website, www.sec.gov, that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Copies of each of our filings with the SEC on Form 10-K, Form 10-Q and Form 8-K and all amendments to those reports, can be viewed and downloaded free of charge at our website, www.larimartx.com as soon as reasonably practicable after the reports and amendments are electronically filed with or furnished to the SEC.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our code of ethics, other corporate policies and procedures, and the charters of our Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee are available through our website at </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.larimartx.com</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We intend to post information regarding any amendments to, or waivers from, our code of ethics on our website.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S. Government Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, drug and biologic products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, record keeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or condition of a human being are subject to regulation under the FDCA, with the exception that the section of the FDCA that governs the approval of drugs via new drug applications (&#8220;NDAs&#8221;), does not apply to the approval of biologics. In contrast, biologics are approved for marketing under provisions of the Public Health Service Act (&#8220;PHS Act&#8221;), via a Biologics License Application (&#8220;BLA&#8221;). However, the application process and requirements for approval of BLAs are very similar to those for NDAs. FDA approval or licensure also must be obtained before the marketing of drug and biological products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Development Process</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug or biologic product may be marketed in the United States generally involves the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of non-clinical laboratory tests and animal studies according to Good Laboratory Practices ("GLPs"), and applicable requirements for the humane use of laboratory animals or other applicable regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation of clinical trial material in accordance with cGMPs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an institutional review board ("IRB") reviewing each clinical site before each clinical trial may be initiated; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials according to Good Clinical Practices ("GCPs") and any additional requirements for the protection of human research subjects and their health information, to establish the safety, purity, potency, and efficacy, of the proposed drug or biological product for its intended use; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an NDA or BLA for marketing approval that includes evidence of safety, purity, potency, and efficacy from results of non-clinical testing and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of an FDA inspection prior to NDA or BLA approval of the manufacturing facility or facilities where the drug or biological product is produced to assess compliance with cGMPs, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential FDA audit of the non-clinical and clinical study sites that generated the data in support of the NDA or BLA; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential FDA Advisory Committee meeting to elicit expert input on critical issues and including a vote by external committee members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval, or licensure, of the NDA or BLA, and payment of associated user fees, when applicable; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with any post approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategies ("REMS") and the potential requirement to conduct post approval studies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before testing any drug or biological product candidate in humans, the product candidate enters the non-clinical testing stage. Non-clinical tests include laboratory evaluations of product chemistry, pharmacology, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the non-clinical tests must comply with federal regulations and requirements including GLPs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The clinical study sponsor must submit the results of the non-clinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some non-clinical testing typically continues after the IND is submitted. An IND is an exemption from the FDCA that allows an unapproved product to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer an investigational product to humans. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor must resolve any deficiencies to the satisfaction of the FDA, and the FDA must lift the clinical hold before the clinical trial can begin. The FDA may also impose clinical holds on a drug or biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not re-commence without FDA authorization and then only under terms authorized by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical trials may involve the administration of the drug or biological product candidate to healthy volunteers or subjects under the supervision of qualified investigators, generally physicians not employed by or under the study sponsor&#8217;s control. Clinical trials involving some products for certain diseases, including some rare diseases may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">begin with testing in patients with the disease. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND application. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research subjects or his or her legal representative provide informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data monitoring committee. The data monitoring committee may review safety data and/or efficacy data.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The drug or biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for rare diseases, the initial human testing is often conducted in patients. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The drug or biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the safety and efficacy of the drug or biologic. In rare instances, a single Phase 3 trial may be sufficient when either (1) the trial is a large, multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible, or (2) the single trial is supported by confirmatory evidence. In drugs and biologics for rare diseases where patient populations are small, Phase 3 trials might not be required if substantial evidence of effectiveness and an acceptable risk/benefit profile can be demonstrated from Phase 2 trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">An OLE study may also be conducted. An OLE study typically enrolls participants from previous clinical trials and is designed to gather the long-term safety and tolerability data on a potential new medicine beyond the time period of the original studies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication in real-world scenarios. They provide additional information regarding risks, benefits and best use, including longer term safety data. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reactions over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biological product has been associated with unexpected serious harm to patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the drug or biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug or biological product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are also various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with the research. In each of these areas, the FDA and other regulatory authorities have broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its clinicaltrials.gov website. Sponsors or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and responding to requests for expanded access requests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Review and Approval Processes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After the completion of clinical trials of a drug or biological product, FDA approval of an NDA, or BLA, must be obtained before commercial marketing of the product. The NDA or BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Prescription Drug User Fee Act, as amended ("PDUFA"), each NDA or BLA may be accompanied by a significant application fee. The applicant for an approved application is also subject to an annual program fee. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for product candidates designated as orphan drugs, unless the product candidate also includes a non-orphan indication.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Within 60 days following submission of the application, the FDA reviews an NDA or BLA submitted to determine if it is substantially complete before the agency files it. The FDA may refuse to file any NDA or BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the NDA or BLA must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA files it. Once the submission is filed, the FDA begins an in-depth substantive review of the NDA or BLA. The FDA reviews the NDA or BLA to determine, among other things, whether the proposed product is safe and effective (for drugs) or safe, potent, and effective (for biologics), for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMPs to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. One of the performance goals agreed to by the FDA under the PDUFA is to review standard NDAs or BLAs in ten months from filing and priority NDAs or BLAs in six months from filing, whereupon a review decision is to be made. The review process may be extended by three months if the FDA classifies a response to an FDA request for additional information or clarification as a major amendment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the review, the FDA will also determine whether a REMS is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if required.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA or BLA, the FDA may inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical trial sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the NDA or BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than the sponsor interprets the same data. If the agency decides not to approve the NDA or BLA in its present form, the FDA will issue a complete response letter that usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a drug or biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. As a condition for approval, the FDA may also require additional non-clinical testing as a Phase 4 commitment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-Approval Requirements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of drug and biological products continues after approval, particularly with respect to cGMP. We will rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following approval, the manufacturing facilities are subject to periodic inspections by the FDA and such inspections may result in an issuance of FDA Form 483 deficiency observations, untitled letter, or a warning letter, which can lead to plant shutdown and other more serious penalties and fines. Prior to the institution of any manufacturing changes, a determination needs to be made whether FDA approval is required in advance. If not done in accordance with FDA expectations, the FDA may restrict supply and may take further action. Annual product reports are required to be submitted annually. Other post-approval requirements applicable to drug and biological products, include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, product tracing requirements, registration and listing, record-keeping requirements, reporting of adverse events, reporting updated safety and efficacy information, and complying with electronic record and signature requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">After an NDA or BLA is approved, the product may also be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, before releasing the lots for distribution by the manufacturer. In addition, the FDA may conduct laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of drug and biological products. Systems need to be put in place to record and evaluate adverse events reported by health care providers and patients and to assess product complaints. An increase in severity or new adverse events can result in labeling changes or product recall. Defects in manufacturing of commercial products can result in product recalls.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturers must also comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval or license revocation, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug and biologic product manufacturers and other entities involved in the manufacture and distribution of approved drug and biological products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA or BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Orphan Drug Designation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation ("ODD") to a drug or biologic product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biologic product available in the United States for this type of disease or condition will be recovered from sales of the product. ODD must be requested before submitting an NDA or BLA. After the FDA grants ODD, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. ODD does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a product that has ODD receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same disease or condition for seven years, except in limited circumstances, such as showing clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same disease or condition or the same product for a different disease or condition but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of a product for seven years if a competitor obtains approval first for the same product as defined by the FDA for the same disease or condition, or if the second product is determined to be encompassed within the competitor&#8217;s scope of product for the same disease. If a company pursues marketing approval for an indication broader than the orphan drug designation it has received, it may not be entitled to orphan drug exclusivity.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Review and Approval Programs</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has various programs, including fast track designation, priority review, accelerated approval, and breakthrough therapy designation, that are intended to expedite or simplify the process for the development and FDA review of drug and biological products that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drug and biological products to patients earlier than under standard FDA review procedures. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a drug or biological product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. In addition to other benefits, such as the ability to have greater</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interactions with the FDA, the FDA may initiate review of sections of a fast track NDA or BLA before the application is complete, a process known as rolling review.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA may give a priority review designation to drug or biological products that treat a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Most products that are eligible for fast track designation may also be considered appropriate to receive a priority review.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, drug and biological products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug or biological product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug or biological product receiving accelerated approval to perform post-marketing studies with due diligence to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biological product may be subject to accelerated withdrawal procedures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Food and Drug Omnibus Reform Act (&#8220;FDORA&#8221;) was recently enacted, which included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study, which may include milestones such as a target date of study completion and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA not later than 180 days following approval and not less frequently than every 180 days thereafter until completion or termination of the study. FDORA also provides the FDA increased authority for expedited procedures to withdraw approval of a drug or biologic or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. FDORA also enables the FDA to initiate enforcement actions for the failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports. In addition, the FDA generally requires, unless otherwise informed by the agency, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug or biologic product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biologic product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast-track designation, priority review, accelerated approval and breakthrough therapy designation, do not change the standards for approval and may not ultimately expedite the development or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rare Pediatric Disease Vouchers</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Rare Pediatric Disease Voucher Program is intended to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Although there are existing incentive programs to encourage the development and study of drugs and biologics for rare diseases, pediatric populations, and unmet medical needs, this program provides an additional incentive for the development of drugs and biologics for rare pediatric diseases, which may be used alone or in combination with other incentive programs. A rare pediatric disease is defined as a disease that is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and is a rare disease or condition as defined in the FDCA, which includes diseases and conditions that affect fewer than 200,000 persons in the United States and diseases and conditions that affect a larger number of persons and for which there is no reasonable expectation that the costs of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing and making available the product in the United States can be recovered from sales of the product in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The sponsor of an application for a drug product that obtains rare pediatric disease designation may be eligible for a voucher that can be used or sold to obtain a priority review for a subsequent application submitted under section 505(b)(1) of the FDCA or section 351 of the PHS Act. A rare pediatric disease drug product must meet certain eligibility requirements for a priority voucher at the time the sponsor seeks approval. The rare pediatric disease priority review voucher program was most recently re-authorized by Congress through December 31, 2024, with the potential for priority review vouchers to be granted through September 30, 2026. Under the amended statutory sunset provisions, after December 20, 2024, the FDA may award a priority review voucher for an approved rare pediatric disease product application only if the sponsor has rare pediatric disease designation for the drug and if that designation was granted by December 20, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers unless the program is re-authorized by Congress.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Information and Pediatric Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), certain NDAs and BLAs and certain supplements to an NDA or BLA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (&#8220;PSP&#8221;) within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Best Pharmaceuticals for Children Act (&#8220;BPCA&#8221;), a drug or biologic product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and to patent terms for drugs; for biologic products, pediatric exclusivity adds six months only to exclusivity periods for all formulations, dosage forms, and indications. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of term of the patent or exclusivity remaining at the time of approval.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biosimilars</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009 ("BPCIA") created an abbreviated approval pathway for biological products that are demonstrated to be "biosimilar" or "interchangeable" with an FDA-licensed reference biological product. Biosimilarity requires that the proposed biological product be highly similar to the reference product not withstanding minor differences in clinically inactive components; that there be no differences in conditions of use, route of administration, dosage form, and strength; and that no clinically meaningful differences between the product and the reference product in terms of safety, purity, and potency as shown through analytical studies, animal studies and a clinical trial or trials. In order to meet the higher hurdle of interchangeability, a sponsor must demonstrate that the biosimilar product can be expected to produce the same clinical results as the reference product, and for a product that is administered more than once, that the safety and efficacy risk of switching between the reference product and biosimilar product is not greater than the risk of maintaining the patient on the reference product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation that are still being evaluated by the FDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the BPCIA, a reference biologic is granted 12 years of exclusivity from the time of first licensure or BLA approval, of the reference product during which FDA cannot approve an application for a biosimilar or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">interchangeable product relying on the reference product. Additionally, no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. During the 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing product that does not rely on the reference product; the BLA must be based on the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. Finally, the first biologic product submitted under the biosimilar abbreviated approval pathway that is determined to be interchangeable with the reference product may obtain exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i) one year after first commercial marketing of the first interchangeable biosimilar, (ii) 18 months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii) 18 months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv) 42 months after the first interchangeable biosimilar is approved if a patent lawsuit is ongoing within the 42-month period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation Outside of the United States</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing clinical studies, commercial sales, and distribution of our products. Most countries outside of the United States require that clinical trial applications be submitted to and approved by the local regulatory authority for each clinical study. In the European Union, for example, an application must be submitted to the national competent authority and an independent ethics committee in each country in which we intend to conduct clinical trials, much like the FDA and IRB, respectively. Under the Clinical Trials Regulation (EU) No 536/2014, which replaced the Clinical Trials Directive 2001/20/EC on January 31, 2022, a single application is now made through the Clinical Trials Information System (&#8220;CTIS&#8221;), for clinical trial authorization in up to 30 European Union/European Economic Area countries at the same time and with a single set of documentation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The assessment of applications for clinical trials is divided into two parts (Part I contains scientific and medicinal product documentation and Part II contains the national and patient-level documentation). Part I is assessed by a coordinated review by the competent authorities of all European Union Member States in which an application for authorization of a clinical trial has been submitted (Member States concerned) of a draft report prepared by a Reference Member State. Part II is assessed separately by each Member State concerned. The role of the relevant ethics committees in the assessment procedure is governed by the national law of the Member State concerned, however overall related timelines are defined by the Clinical Trials Regulation. The Clinical Trials Regulation also provides for simplified reporting procedures for clinical trial sponsors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of countries outside the U.S. before we can commence clinical studies or marketing of the product in those countries. The approval process and requirements vary from country to country, so the number and type of non-clinical, clinical, and manufacturing studies needed may differ, and the time may be longer or shorter than that required for FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To obtain regulatory approval of a product under the European Union's regulatory system, we are required to submit a marketing authorization application ("MAA"), to be assessed in either the centralized procedure or a national authorization procedure. The centralized procedure allows applicants to obtain a marketing authorization ("MA") that is valid throughout the European Union and the additional Member States of the European Area (Iceland, Liechtenstein and Norway) ("EEA"). It is compulsory for medicinal products manufactured using biotechnological processes, for orphan medicinal products, for advance therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and for human products containing a new active substance which are not authorized in the European Union and which are intended for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, auto-immune and other immune dysfunctions, viral diseases or diabetes. The centralized procedure is optional for any other products containing new active substances not authorized in the European Union or for products which constitute a significant therapeutic, scientific or technical innovation or for which a centralized authorization is in the interests of patients in the European Union. When a company wishes to place on the market a medicinal product that is eligible for the centralized procedure, it sends an application directly to the EMA, to be assessed by the Committee for Medicinal Products for Human Use ("CHMP"). The CHMP is responsible for conducting the assessment of whether a medicine meets the required quality, safety and efficacy requirements, and whether the product has a positive risk/benefit/risk profile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The time limit for the evaluation procedure is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP). The EMA then has</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fifteen days to forward its opinion to the European Commission which will make a binding decision on the grant of an MA within 67 days of the receipt of the CHMP.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are two other procedures in the European Union for the grant of an MA in multiple European Union Member States, where a product does not fall within the mandatory scope of the centralized procedure. If a product has already been authorized for marketing in a European Union Member State, this national MA can be recognized in another European Union Member State through the mutual recognition procedure. If the product has not received a national MA in any European Union Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation (EC) No. 141/2000, provides that a product may be designated as an orphan medicinal product if its sponsor can establish that it is intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating condition that affects not more than 5 in 10,000 persons in the European Union when the application is made. In addition, orphan designation can be granted if the product is intended for a life threatening, seriously debilitating, or serious and chronic condition in the European Union where without incentives derived from orphan designation.it is unlikely that sales of the product in the European Union would be sufficient to justify the necessary investment in its development. Orphan designation is only available if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed orphan product will be of significant benefit to patients over the existing options. We have obtained orphan designation in the European Union for nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Orphan designation provides opportunities for fee reductions, protocol assistance and access to the centralized procedure in the European Union. Fee reductions are not limited to the first year after an MA is granted, except for small and medium enterprises. In addition, if a product which has an orphan designation subsequently receives a centralized MA for the indication for which it has such designation, the product is entitled to orphan market exclusivity, which means the regulatory authorities in the European Union may not approve any other application to market a "similar medicinal product" for the same indication as the authorized orphan product for a period of 10 years. A &#8220;similar medicinal product&#8221; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The exclusivity period may be reduced to six years if, at the end of the fifth year, its is determined that the designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, an MA may be granted to a similar medicinal product for the same indication as an authorized orphan product if:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the second applicant can establish that its product, although similar to the authorized orphan product, is safer, more effective or otherwise clinically superior; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the MA holder of the authorized orphan product consents to a second orphan medicinal product application; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the MA holder of the authorized orphan product cannot supply enough orphan medicinal product.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The EMA offers a scheme to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and is intended to reinforce early dialogue with, and regulatory support from, the EMA in order to stimulate innovation, optimize development and enable accelerated assessment of such product candidates. It is intended to build upon the scientific advice scheme and accelerated assessment procedure offered by the EMA. The scheme is voluntary and eligibility criteria must be met for a medicine to qualify for PRIME.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PRIME scheme is open to medicines under development and for which the applicant intends to apply for an MA through the centralized procedure. Eligible products must target conditions for which there is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the European Union or, if there is, the new medicine will bring a major therapeutic advantage) and they must demonstrate the potential to address the unmet medical need by introducing new methods or therapy or improving existing ones. Applicants will typically be at the exploratory clinical trial phase of development and will have preliminary clinical evidence in patients to demonstrate the promising activity of the medicine and its potential to address to a significant extent an unmet medical need. In exceptional cases, applicants from the academic sector or SMEs (small and medium sized enterprises) may submit an eligibility request at an earlier stage of development if compelling non-clinical data in a</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">relevant model provide early evidence of promising activity to establish proof of principle, and first in man studies indicate adequate exposure for the desired pharmacotherapeutic effects and tolerability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a medicine is selected for the PRIME scheme, the EMA:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Appoints a rapporteur from the CHMP or from the Committee for Advanced Therapies ("CAT") to provide continuous support and to build up knowledge of the medicine in advance of the filing of an MAA; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issues guidance on the applicant&#8217;s overall development plan and regulatory strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Organizes a kick-off meeting with the rapporteur and experts from relevant EMA committees and working groups; Provides a dedicated EMA contact person; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:1.204%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.373618365115996%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provides scientific advice at key development milestones, involving additional stakeholders, such as health technology assessment bodies and patients, as needed.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For SMEs who enter the scheme based on data showing proof of principle, the appointment of the rapporteur occurs once they have generated data confirming eligibility at proof of concept stage. They are required to submit relevant data and justification as the product development reaches this stage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Medicines that are selected for the PRIME scheme are also expected to benefit from EMA&#8217;s accelerated assessment procedure at the time of application for marketing authorization. Where, during the course of development, a medicine no longer meets the eligibility criteria, support under the PRIME scheme may be withdrawn.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A Pediatric Investigation Plan ("PIP") in the European Union is aimed at ensuring that the necessary data are obtained to support the authorization of a medicine for children, through studies in children. All applications for marketing authorization for new medicines have to include the results of studies as described in an agreed PIP, unless the study results are deferred, or the medicine is exempt because of a waiver. This requirement also applies when a marketing-authorization holder wants to add a new indication, pharmaceutical form, or route of administration for a medicine that is already authorized. Several rewards and incentives for the development of pediatric medicines for children are available in the EU Medicines authorized across the EU with the results of studies from a PIP included in the product information are eligible for an extension of their supplementary protection certificate ("SPC")by six months(provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires). This is the case even when the studies&#8217; results are negative. For orphan medicines, the incentive is an additional two years of market exclusivity. Scientific advice and protocol assistance at the EMA are free of charge for questions relating to the development of pediatric medicines.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All of the aforementioned European Union rules are generally applicable in the EEA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The UK left the European Union on January 31, 2020. As a result of the Northern Ireland protocol following Brexit, the EMA remained responsible for approving novel medicines for supply in Northern Ireland, the European Union regulatory framework continues to apply in Northern Ireland under the EU centralized procedure, and as separate authorization was required to supply the same medicine in Great Britain (England, Wales and Scotland). On February 27, 2023, the UK government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the previous system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA is now responsible for approving all medicinal products destined for the UK market (Great Britain and Northern Ireland), and the EMA no longer has any role in approving medicinal products destined for Northern Ireland through the EU centralized procedure. A single UK-wide MA will be granted by the MHRA for all novel medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. In addition, the new arrangements require all medicines placed on the UK market to be labeled &#8220;UK only&#8221; indicating they are not for sale in the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The MHRA has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines that will benefit patients, an accelerated assessment procedure and new routes of evaluation for novel products and biotechnological products. On January 1, 2024, a new international recognition framework came</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">into effect in the UK under which the MHRA may have regard to decisions on the approval of MAs made by the EMA and certain other regulators when determining an application for a new UK MA.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is now no pre-marketing authorization orphan designation in the UK. Instead, the MHRA will review applications for orphan designation in parallel to the corresponding MA application. The criteria are essentially the same, but have been tailored for the UK market, i.e. the prevalence of the condition in the UK (rather than the EU) must not be more than 5 in 10,000. Should an orphan designation be granted, the period or market exclusivity will be set from the date of first approval of the product in the UK.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we received access to the UK&#8217;s Medicines and Healthcare Regulatory Agency ("MHRA") Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) which for the treatment of adults and children with FA. We may also apply for access to the UK&#8217;s Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) for the treatment of adults and children with FA. This Scheme aims to accelerate the time to market and facilitate patient access to certain types of medicinal products in development which target a life-threatening or seriously debilitating condition, or where there is a significant patient or public health need in the UK. To access the ILAP, an applicant applies for an Innovation Passport designation. Once an Innovation Passport designation is granted, the MHRA and its partner agencies (including The All Wales Therapeutics and Toxicology Centre, National Institute for Health and Care Excellence and the Scottish Medicines Consortium) will work with the Innovation Passport designee to define a Target Development Profile, (&#8220;TDP&#8221;). The TDP sets out a unique product-specific roadmap towards patient access in the UK and provides access to a toolkit to support all stages of the design, development and approvals process, including continuous benefit-risk assessment, increased support for novel development approaches and enhanced patient engagement. However, although the goal of the ILAP is to reduce the time to market and enable earlier patient access, access does not accelerate conduct of clinical trials or mean that the regulatory requirements are less stringent, nor does it ensure that a marketing authorization application will be approved or that any approval will be granted within a particular timeframe or at all.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare Laws and Regulations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is also significant uncertainty related to the insurance coverage and reimbursement of newly approved products and coverage may be more limited than the purposes for which the medicine is approved by the FDA or comparable foreign regulatory authorities. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Factors payors consider in determining reimbursement are based on whether the product is a covered benefit under its health plan; safe, effective and medically necessary; appropriate for the specific patient; cost-effective; and neither experimental nor investigational. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of the United States, the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular therapy to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. We cannot be sure that reimbursement will be available for any of our product candidates that we commercialize and, if reimbursement is available, the level of reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Healthcare Laws</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales of our product candidate, if approved, or any other future product candidate will be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we might conduct our business. The healthcare laws and regulations that may affect our ability to operate include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute prohibits, among other things knowingly and willfully, directly or indirectly, soliciting, receiving, offering, or paying any remuneration that is in exchange for or to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;), amended the intent element of the federal Anti-Kickback Statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to commit a violation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal false claims and false statement laws, including the federal civil False Claims Act, prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent. The ACA amended the federal Anti-Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal civil False Claims Act; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA") created additional federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors or making any false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH") and their implementing regulations, impose obligations on healthcare providers, health plans, and healthcare clearinghouses, known as covered entities as well as their business associates and their subcontractors that perform certain services involving the storage, use or disclosure of individually identifiable health information; including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. HITECH increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Physician Payments Sunshine Act enacted as part of the ACA, and its implementing regulations requires certain manufacturers of approved drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to collect and report annually to the Centers for Medicare and Medicaid Services, the agency that administers the Medicare and Medicaid programs ("CMS") information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. The reported data is made available in searchable form on a public website on an annual basis. Failure to submit required information may result in civil monetary penalties; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Foreign Corrupt Practices Act ("FCPA") prohibits U.S. businesses and their representatives from offering to pay, paying, promising to pay or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business. </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many states have similar laws and regulations, such as anti-kickback and false claims laws that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, we may be subject to state laws that require pharmaceutical companies to comply with the federal government&#8217;s and/or pharmaceutical industry&#8217;s voluntary compliance guidelines, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Certain states and local jurisdictions also require the registration of pharmaceutical sales representatives. Further, certain states require the posting of information relating to clinical studies and their outcomes. A growing number of states require the reporting of certain drug pricing information, including information pertaining to and justifying price increases and the price set for newly launched drugs, or to prohibit prescription drug price gouging. We may also be subject to state and foreign laws governing the privacy and security of health information, many of which differ from each other in significant ways and often are not preempted by HIPAA. In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations and new laws continue to be proposed. At the state level, numerous states have or are in the process of enacting or considering comprehensive state-level data privacy and security laws, rules and regulations while other states have focused on more narrow aspects of privacy. In the state of Washington, for example, the My Health My Data Act will require regulated entities to obtain consent to collect health information, grant consumers certain rights, including to request deletion of their information, and provide for robust enforcement mechanisms, including enforcement by the Washington state attorney-general and a private right of action for consumer claims. Other states have also enacted, proposed, or are considering proposing, data privacy laws, which could further complicate compliance efforts, increase our potential liability and adversely affect our business. Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare Reform</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices, and medical services, in addition to questioning safety and efficacy. CMS also has authority to revise reimbursement rates and to implement coverage restrictions for some drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products. While Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, although private payors have their own methods and approval process apart from Medicare determinations, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, included provisions that affected the pharmaceutical industry. Among other things, the Affordable Care Act expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program, expanded the 340B program, and increased the amount of Medicaid drug rebates manufacturers are required to pay to states. Since that time, there have been multiple healthcare reform measures, including the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) which, among other things, allows HHS to directly negotiate the selling price of a statutorily specified number of drugs and biologics each year that CMS reimburses under Medicare Part B and Part D. The negotiated price may not exceed a statutory ceiling price. Only high-expenditure single-source biologics that have been approved for at least 11 years (7 years for small molecule drugs) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D products in 2023, negotiations began in 2024, and the negotiated maximum fair price for each product has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, 20 Part B or Part D drugs will be selected. A drug or biological product that has an orphan drug designation for only one rare disease or condition will be excluded from the IRA&#8217;s price negotiation requirements, but will lose that exclusion if it receives designations for more than one rare disease or condition, or if is approved for an indication that is not within that single designated</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rare disease or condition, unless such additional designation or such disqualifying approvals are withdrawn by the time CMS evaluates the drug for selection for negotiation. The IRA also imposes rebates on Medicare Part B and Part D drugs whose prices have increased at a rate greater than the rate of inflation, and in November 2024, CMS finalized regulations for these inflation rebates. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including significant civil monetary penalties. These provisions have been and may continue to be subject to legal challenges. For example, the provisions related to the negotiation of selling prices of high-expenditure single-source drugs and biologics have been challenged in multiple lawsuits brought by pharmaceutical manufacturers. Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the biopharmaceutical industry and the pricing of prescription drug products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For example, the FDA released a final rule in September 2020 providing guidance for states to build and submit plans for importing drugs from Canada, and FDA authorized the first such plan in Florida in January 2024. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional federal, state and foreign healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for prescription drug products, once approved, or additional pricing pressures.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1ariskfactors_798482"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1A. RISK FACTORS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should consider carefully the following risks and uncertainties when reading this Annual Report on Form 10-K, as well as the other information contained herein, including our audited consolidated financial statements and the related notes and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operation.&#8221; If any of the following risks occur, our business, financial condition and results of operations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">could be materially and adversely affected. Although we believe that we have identified and discussed below the key risk factors affecting our business, there may be additional risks and uncertainties that are not presently known or that are not currently believed to be significant that may adversely affect our performance or financial condition. In that event, the trading price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Financial Position and Need for Capital</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred significant losses since our inception and anticipate that we will incur continued losses for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception we have devoted substantially all of our resources to the development of nomlabofusp. We have incurred significant losses in each year of operation since our inception in 2016. For the years ended December 31, 2024 and 2023, we had net losses of $80.6 million and $36.9 million, respectively, and, as of December 31, 2024, we had an accumulated deficit of $269.2 million and we expect to continue to incur significant expenses and net operating losses ("NOLs") for the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have devoted substantially all of our financial resources and efforts to research and development, including non-clinical studies, our clinical development program, the development of manufacturing processes as well as the manufacture of initial lots of clinical trial material. We expect to incur significant losses for the foreseeable future to further develop and commercialize our lead drug candidate, nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that our expenses will increase substantially if and as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue clinical development efforts for nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek regulatory and marketing approvals in the United States and in foreign jurisdictions for our product candidates that successfully complete clinical trials, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establish sales, marketing, distribution and other commercial infrastructure to commercialize various products for which we may obtain marketing approval, if any;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">contract for the manufacture of larger quantities of product candidates for clinical development and potentially commercialization;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our operational, financial and management systems and hire and retain additional personnel, such as clinical, manufacturing, quality control, regulatory and finance personnel; and; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">experience any delays or encounter issues with any of the above.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no sales, marketing or medical affairs infrastructure and have no experience in the sales, marketing, or distribution of pharmaceutical products. Assuming nomlabofusp ultimately is approved for marketing in the US and elsewhere, we will need to establish commercial capabilities as well as customer service and support, logistics, and other related functions, or make arrangements with third parties to perform these services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net losses and negative cash flows have had, and will continue to have, an adverse effect on our liquidity and potentially the ability for us to raise capital due to our unfavorable operating results.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have no commercial revenue and may never become profitable.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any commercial revenue. Our ability to generate revenue and become profitable depends upon our ability to obtain regulatory approval for, and to successfully commercialize, nomlabofusp or other product candidates that we may develop, in-license or acquire in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This will require success in a range of challenging activities, including completing numerous clinical trials of nomlabofusp or any future product candidates, obtaining marketing approval for nomlabofusp and any future product candidates, manufacturing, marketing and selling those products for which we, or any future collaborators</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">or partners, may obtain marketing approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance and/or government payors. Even if we are able to successfully achieve the above, we do not know what the reimbursement status of nomlabofusp or any other future product candidates will be or when any of these products will generate revenue for us, if at all. We have not generated, and do not expect to generate, any product revenue for the foreseeable future, and expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, non-clinical studies and clinical trials and the regulatory approval process for nomlabofusp and any future product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to generate revenue from nomlabofusp or any future product candidates also depends on a number of additional factors, including our ability to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully complete development activities, including the remaining non-clinical studies and planned clinical trials for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complete and submit BLAs to the FDA and MAAs to the EMA and obtain regulatory approval for indications for which there is a commercial market;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complete and submit applications to, and obtain regulatory approval from, other foreign regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacture or have manufactured any approved products in commercial quantities and on commercially reasonable terms;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">develop a commercial organization, or find suitable partners, to market, sell and distribute approved products in the markets in which we have retained commercialization rights;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">achieve acceptance among patients, clinicians and advocacy groups for any products we develop;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain coverage and adequate reimbursement from third parties, including government payors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">set a commercially viable price for any products for which we may receive approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of increased expenses, and if or when we might achieve or maintain profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never generate revenues that are large enough for us to achieve profitability. Even if we are able to complete the processes described above, we anticipate incurring significant costs associated with commercializing nomlabofusp or any of our future product candidates. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become and remain profitable could decrease the value of our business and could impair our ability to raise capital, maintain our discovery and clinical development efforts, expand our business or continue our operations and may require us to raise additional capital that may dilute the ownership interest of shareholders. A decline in the value of our business could also cause shareholders to lose all or part of their investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to raise additional funding to complete the development and commercialization of nomlabofusp. This funding may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed would force us to delay, limit or terminate our product development efforts or other operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, our existing cash, cash equivalents and marketable securities were $183.5 million, which we anticipate will fund our operations into the second quarter of 2026.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to continue to spend substantial and increasing amounts to conduct clinical trials of nomlabofusp and further research and development activities for nomlabofusp, and for any additional product candidates that we may develop, in-license or acquire in the future. In addition, raising funds in the current economic environment may present substantial challenges, for example, any sustained disruption in the capital markets from adverse macroeconomic conditions, such as the disruption and uncertainty caused by inflationary pressures, rising interest rates, banking instability, monetary policy changes, changes in trade policies, including tariffs (including tariffs that have been or may in the future be imposed by the U.S. or other countries), economic slowdowns or recessions, could negatively impact our ability to raise capital and we cannot predict the extent or duration of such macroeconomic disruptions. Additionally our expenses will increase as we expand, through development, in-license or acquisition, our pipeline of product candidates. If we obtain marketing approval for any of our product candidates, we will likely incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution to the extent that such sales, marketing, manufacturing and distribution are not the responsibility of a future</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborator. Accordingly, we will need to obtain additional funding in connection with our continuing operations. Our current cash, cash equivalents and marketable securities may not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of the development and commercialization of nomlabofusp. Accordingly, we may be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If additional capital is needed to complete the development and commercialization of nomlabofusp, there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms or at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or we do not have sufficient authorized shares, we may be required to delay, limit, or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our business, financial condition, and results of operations will be materially adversely affected. We could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results, financial condition and prospects. In addition, geopolitical tension including, for example, the broader impact of the ongoing conflict between Russia and Ukraine and the current conflict in Israel and Gaza (including any escalation or expansion), and the impact of a future pandemic, epidemic or outbreak of an infectious disease or liquidity constraints, failures and instability in U.S. and international financial banking systems on the global financial markets may reduce our ability to access capital, which could negatively affect our liquidity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If additional capital is needed to complete the development and commercialization of nomlabofusp, and if we are unable to obtain funding when needed and/or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion or pre commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies, nomlabofusp or other product candidates that we may develop, in-license or acquire in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may seek additional capital through a combination of private or public equity offerings, debt financings, collaborations and licensing arrangements or other sources. To the extent we raise additional capital through the sale of equity or convertible debt securities, existing ownership interests will be diluted and the terms of such financings may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt or equity financings may be coupled with an additional equity component, such as warrants to purchase shares, which could also result in dilution of our existing stockholders' ownership.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights, including future revenue streams, to nomlabofusp or other product candidates that we may develop, in-license or acquire in the future, or grant licenses on terms that are not favorable to us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our ability to use our NOLs and certain other tax attributes may be limited.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 we had NOL carryforwards that expire for U.S. federal income tax purposes of $ </span><span style="color:#333333;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$198.2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, a portion of which begin to expire in 2026. Our NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in taxable years beginning before January 1, 2018 are permitted to be carried forward for 20 taxable years under applicable U.S. federal income tax law. Under current U.S. federal income tax law, NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely. As of December 31, 2024, the Company</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">had federal net operating loss carryforwards that were generated after December 31, 2017 of $159.5 million that do not expire, however these carryforwards are limited to 80% of the taxable income in any one tax period.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, under Section 382 of the Internal Revenue Code (the "Code") if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as capitalized research and development costs and research tax credits) to offset its post-change income may be limited. We believe that as a result of our merger with Zafgen, our ability to utilize NOLs acquired in the transaction and our other NOLs is expected to be severely limited by Section 382 of the Code. Additionally, our July 2021, September 2022 and February 2024 equity transactions could also limit our ability to utilize NOLs in the future. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed and would adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could affect the tax treatment of any of our future domestic and foreign earnings. Any new taxes could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, under Section 174 of the code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. are capitalized and amortized, which may have an adverse effect on our cash flow. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. Generally, future changes in applicable U.S. tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial conditions and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Product Development and Regulatory Approvals</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success is currently dependent upon the success of our lead product candidate, nomlabofusp. We cannot be certain that we will ultimately be successful with our clinical development or that we will ever be able to obtain regulatory approval for nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have no drug products for sale and our business is currently wholly dependent on our successful clinical development, regulatory approval and commercialization of nomlabofusp, our lead product candidate and our only product candidate in clinical development, for which we have completed two Phase 1 studies and a four-week, placebo-controlled Phase 2 dose exploration study. We have an ongoing Phase 2 OLE trial in patients with FA and an ongoing PK run-in study in adolescent patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the regulatory and manufacturing hurdles faced by our product candidate, the administration of a protein such as nomlabofusp may cause an immune response, resulting in the creation of antibodies directed against the protein. These anti-drug antibodies can have no effect or can neutralize the effectiveness of the protein or require that higher doses be used to obtain a therapeutic effect. Neutralizing antibodies may be detected at a later date or upon longer exposure periods and there can be no assurance that neutralizing antibodies will not be detected in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, while nomlabofusp was selected by the FDA for participation in its Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program, it is unknown whether participation in the program will accelerate the development of nomlabofusp and whether the FDA will continue investing its resources in this program. If our efforts to develop and commercialize nomlabofusp for the treatment of FA are unsuccessful, or we experience significant delays in doing so, our business could also be substantially harmed. The success of nomlabofusp will depend on several factors, including the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining our IND with the FDA in order to continue to conduct clinical trials in the United States;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully submitting a BLA for accelerated approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully recruiting, enrolling and retaining patients in and completing any clinical trials, if allowed to continue, including trials in pediatric patients;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">demonstrating long-term chronic daily dosing safety, tolerability and efficacy profiles that are satisfactory to the FDA, EMA and other comparable regulatory authorities for marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully completing all necessary toxicology studies to support clinical development and regulatory approval for nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">receiving timely marketing approvals from applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">managing the extent and cost of any required post-marketing approval commitments to applicable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing and maintaining arrangements with third-party manufacturers for nomlabofusp, including developing, validating and maintaining a commercially viable manufacturing process that is compliant with cGMPs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developing, validating and implementing a potency control strategy acceptable to the FDA, EMA and other comparable regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining and growing an organization of scientists and business people who can develop our product candidates and technology;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining, maintaining and protecting our patents, trade secrets and regulatory exclusivity in the United States and other countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">successfully launching commercial sales following any marketing approval, including establishing a specialty sales organization, or successfully partnering with another organization, if applicable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtaining commercial acceptance of our product candidates, if approved, by patients, the medical community and third-party payors and obtaining and maintaining healthcare coverage and adequate reimbursement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintaining an acceptable safety profile following any marketing approval; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competing with other therapies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of these factors are outside of our control, including the clinical development and regulatory approval processes, results of non-clinical and toxicology studies and clinical trials, potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts, respectively. The process of obtaining regulatory approval is expensive and time consuming. The FDA and foreign regulatory authorities may never approve nomlabofusp for sale and marketing, and even if nomlabofusp is ultimately approved, regulatory approval may be delayed or limited in the United States or in other jurisdictions. Even if we are authorized to sell and market nomlabofusp in one or more markets, there is no assurance that we will be able to successfully market nomlabofusp or that nomlabofusp will achieve market acceptance sufficient to generate profits. If we are unable to successfully develop and commercialize nomlabofusp due to failure to obtain regulatory approval for nomlabofusp, to successfully market nomlabofusp, to generate profits from the sale of nomlabofusp, or due to other risk factors outlined in this report, it would have material adverse effects on our business, financial condition, and results of operations as nomlabofusp is currently our sole product candidate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical development is a lengthy and expensive process with an uncertain outcome, and the results of non-clinical studies, toxicology studies or clinical trials may not be predictive of future non-clinical studies, toxicology studies or clinical trial results.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. We cannot guarantee that any non-clinical studies, toxicology studies or clinical trials will be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the non-clinical study, toxicology study or clinical trial process. Despite promising non-clinical, toxicology or clinical results, any product candidate can unexpectedly fail at any stage of non-clinical, toxicology or clinical development. The historical failure rate for product candidates in our industry is high, especially for products in early stages of development.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results from non-clinical studies, toxicology studies or clinical trials of a product candidate may not predict the results of later non-clinical or clinical trials of the product candidate, or in clinical trials with different patient populations such as children and adolescents and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through non-clinical studies and initial clinical trials. It is not uncommon to observe results in clinical trials that are unexpected based on non-clinical studies and early clinical trials, and many product candidates fail in clinical trials despite very promising early results. Favorable safety and efficacy outcomes in adult clinical trials may not be seen in pediatric clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, current and future non-clinical and clinical data may be susceptible to varying interpretations and analyses. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies. Furthermore, we cannot provide assurance that we will be able to successfully progress any future non-clinical programs from candidate identification to Phase 1 clinical development. As is typical in candidate development, we have a program of toxicology studies in animals for nomlabofusp and cannot provide assurance that the findings from such studies or any ongoing or future clinical trials will not adversely affect the clinical development of nomlabofusp. For the foregoing reasons, we cannot be certain that our non-clinical studies and clinical trials will be successful. If non-clinical studies or clinical trials for nomlabofusp or any future product candidates or indications fail to demonstrate safety or efficacy to the satisfaction of the FDA or the equivalent regulatory authorities in other countries, the FDA or equivalent regulatory authority will not approve our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not know whether any ongoing or future clinical trials for nomlabofusp will be completed on schedule, if at all, as the commencement and completion of clinical trials can be delayed, prevented or terminated for a number of reasons, including as a result of safety concerns, or ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, other regulatory authorities, IRBs or ethics committees, an independent data monitoring committee, or safety review committee, overseeing the clinical trial at issue or other regulatory authorities due to a number of factors, including, among others:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inspection of the clinical trial operations or trial sites by the FDA, the EMA, or other applicable regulatory authorities that reveals deficiencies or violations that require us to undertake corrective action, including the imposition of a partial clinical hold or a full clinical hold;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unforeseen safety issues, including any that could be identified in our prior or future toxicology studies, adverse events or lack of effectiveness;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in government regulations or administrative actions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">problems with clinical supply materials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lack of adequate funding to continue the clinical trial;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges in recruiting and enrolling patients to participate in clinical trials, including the size and nature of the patient population, such as pediatric patients, the proximity of patients to clinical trial sites, eligibility criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the relevant disease and competition from FDA-approved therapeutics for FA and other clinical trial programs for similar indications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties in retaining or recruiting clinical investigators in our ongoing or future clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties retaining patients who have enrolled in a clinical trial but may be prone to withdraw due to rigors of the clinical trial, perceived lack of efficacy, side effects, screening and monitoring measures, personal issues or loss of interest;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">severe, serious or unexpected drug-related adverse events experienced by patients in clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unanticipated negative effects of chronic long-term daily patient dosing;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, the EMA, or other applicable regulatory authorities may disagree with our clinical trial designs, our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical sites and subjects may deviate from trial protocol or drop out of a trial; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reports from non-clinical studies or clinical testing of other therapies that raise safety or efficacy concerns.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failures or delays in the completion of our clinical trials could result in increased costs and could delay, prevent or limit our ability to generate revenue and continue our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For our lead product candidate nomlabofusp, we have completed two Phase 1 clinical trials in patients with FA and our four-week, placebo-controlled Phase 2 dose exploration study. We have an ongoing Phase 2 OLE trial in patients with FA and an ongoing run-in study in adolescent patients with FA. Our clinical trials may be delayed or terminated as a result of safety issues in non-clinical or clinical trials, ambiguous or negative interim results or events outside of our control.  If future clinical trials of nomlabofusp fail or further delays occur in the United States and or other countries, we may not be able to develop and commercialize nomlabofusp and could fail to realize the potential advantages of doing so, and it could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, disruptions caused by future pandemic, epidemic or outbreak of an infectious disease, may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. Further, FA is a rare disease and as a result, there are a limited number of patients in close proximity to clinical trial sites and clinical trial patients may need to travel from other countries to the clinical trial sites in order to participate. In addition, given the limited number of FA patients, the approval of a competing therapy for the treatment of FA may make patients less likely to enroll in our clinical trials or less likely to be eligible for our clinical trials. Any inability to successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue from product sales. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may seriously harm our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be successful in our efforts to identify, discover or acquire additional product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently only have one product candidate nomlabofusp in clinical development, although we have other product candidates in pre-clinical development. Therefore, the success of our business largely depends upon our ability to identify, develop, in-license or acquire and commercialize products targeting rare diseases. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. In addition, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have no marketed proprietary products and have not yet advanced a product candidate beyond Phase 2 clinical trials, which makes it difficult to assess our ability to develop nomlabofusp or any future product candidates and commercialize any resulting products independently.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have little experience in later stage clinical development, and related regulatory requirements or the commercialization of products. As a result, we have not yet demonstrated our ability to independently and repeatedly conduct clinical development after Phase 1, successfully conduct an international multi-center clinical trial, conduct a pivotal clinical trial, obtain regulatory approval, manufacture drug product on a commercial scale or arrange for a third party to do so on our behalf, and commercialize therapeutic products. We will need to develop such abilities if we are to execute on our business strategy to develop and independently commercialize product</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">candidates for orphan and niche indications. To execute on our business plan for the development of independent programs, we will need to successfully:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">execute our clinical development plans for product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain required regulatory approvals in each jurisdiction in which we will seek to commercialize products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">build and maintain appropriate sales, distribution and marketing capabilities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gain market acceptance, including reimbursement, for our future products, if any; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization activities.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unsuccessful in accomplishing these objectives, we will not be able to develop and commercialize any product candidates independently and could fail to realize the potential advantages of doing so, and it would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We cannot be certain that we will be able to successfully complete clinical trials for nomlabofusp or any other product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have advanced only one product candidate into clinical development, nomlabofusp. Our business currently depends primarily on nomlabofusp&#8217;s successful clinical development, regulatory approval and commercialization. We submitted our IND and it was accepted, permitting the conduct of clinical trials. We completed two Phase 1 and our four-week, placebo-controlled Phase 2 dose exploration study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In clinical development of any product candidate, the outcome of toxicology studies and early clinical trials may not be positive and may not be predictive of the success of later non-clinical studies or clinical trials. Adverse toxicology or safety results could lead to clinical holds or other developmental delays. Interim results of clinical trials do not necessarily predict success in those or future clinical trials. Success in adult clinical trials may not predict the outcome of pediatric clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Published clinical data or case reports from third parties or early clinical trial data of nomlabofusp or any future product candidates may not be predictive of the results of later-stage clinical trials. Interpretation of results from early, usually smaller, studies that suggest a clinically meaningful response in some patients, requires caution. Results from later stages of clinical trials enrolling more patients, or different patient populations, such as pediatric patients, may fail to show the desired safety or efficacy results or otherwise fail to be consistent with the results of earlier trials of the same product candidate. Later clinical trial results may not replicate earlier clinical trials for a variety of reasons, including differences in trial design, different trial endpoints (or lack of trial endpoints in exploratory studies), different patient population, number of patients, patient selection criteria, trial duration, drug dosage and formulation and lack of statistical power. These uncertainties are enhanced where the diseases under study lack established clinical endpoints, validated measures of efficacy, as is often the case with orphan diseases for which no drugs have been developed previously and where the product candidates target novel mechanisms. For example, to our knowledge, nomlabofusp is the only protein replacement therapy being developed for the treatment of FA and therefore non-clinical studies may not be adequate to predict efficacy in a clinical trial due to our novel protein replacement therapy platform.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, such as pediatric patients, variability of the disease being studied, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. If we fail to ultimately receive positive results in clinical trials of nomlabofusp, the development timeline and regulatory approval and commercialization prospects for nomlabofusp, and, correspondingly, our business, financial prospects and results of operation would be negatively impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, nomlabofusp or any future product candidates may not be approved even if they achieve their primary endpoint in clinical trials. The FDA, EMA or foreign regulatory authorities may disagree with our trial design and our interpretation of data from non-clinical studies and clinical trials. In addition, FDA, EMA or foreign regulatory authorities may disagree with the extent of population exposure to assess clinical safety. Any of these regulatory authorities may change its requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that, if successful, would potentially form the basis for</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an application for approval by the FDA, EMA or another regulatory authority. Furthermore, any of these regulatory authorities may also approve nomlabofusp or any future product candidates for a narrower indication than we may request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA and other comparable foreign authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be granted for any product candidate that we develop and may decide that our data are insufficient for approval or require additional non-clinical, clinical, or other data. The U.S. Supreme Court&#8217;s July 2024 decision to overturn prior established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may experience difficulties identifying and enrolling patients in our clinical trials given the limited number of patients who have the disease for which nomlabofusp is being studied or for any other product candidate we may study in the future. Difficulty in enrolling patients could delay or prevent clinical trials of nomlabofusp or any future product candidate. There are also competing FA therapeutics, other competing studies and potentially other FA therapeutics that could be approved</span><span style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">that may also limit the availability of prospective participants in nomlabofusp clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Identifying and qualifying patients to participate in clinical trials of nomlabofusp is critical to our success. The timing of our clinical trials depends in part on the speed at which we can recruit patients to participate in testing nomlabofusp, and we may experience delays in our clinical trials if we encounter difficulties in enrollment, such as difficulties with enrollment in pediatric clinical trials.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The conditions for which we are planning to evaluate nomlabofusp and any product candidates we may evaluate in the future, are rare genetic diseases. Accordingly, there are limited patient pools from which to draw for clinical trials. Arranging for investigative sites and recruiting patients for clinical trials in this disease may be very difficult. The recent FDA approval of a product for the treatment of FA may impact our ability to enroll patients in our clinical trials as patients using other FA treatments may be excluded from participation in our nomlabofusp studies or may be less likely to participate in our nomlabofusp clinical trials due to the availability of another FA therapy. If other companies are studying their investigational products in Friedreich&#8217;s ataxia and/or if other companies have their products approved for the treatment of FA, it may be more difficult to enroll eligible patients into our clinical trials. Competing priorities at sites and participation of subjects in other studies may limit our ability to execute clinical trials in a timely fashion, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the rarity of FA and other diseases that we are studying, the eligibility criteria of our clinical trials will further limit the pool of available study participants as it will require patients to have specific characteristics that we can measure to assure their disease is either severe enough or not too advanced to include them in a clinical trial. The process of finding and diagnosing patients may prove costly, especially since the diseases we are studying are rare. We also may not be able to identify, recruit, and enroll a sufficient number of appropriate patients to complete our clinical trials because of demographic criteria for prospective patients, the perceived risks and benefits of the product candidate under study, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. The availability and efficacy of approved and competing therapies and clinical trials can also adversely impact enrollment. Furthermore, our inability to enroll a sufficient number of patients for our clinical trials, including pediatric clinical trials, could result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for nomlabofusp or any future product candidates, and jeopardize our ability to achieve our clinical development timeline and goals, including the dates by which we will commence, complete and receive results from clinical trials. If patients are unwilling to participate in our trials for any reason, the timeline for recruiting patients, conducting trials, and obtaining regulatory approval of potential products may be delayed. Enrollment delays in our clinical trials may also jeopardize our ability to commence sales of and generate revenues from nomlabofusp, which could cause the value of our company to decline and limit our ability to obtain additional financing, if needed. Any of these occurrences may harm our business, financial condition, and prospects significantly.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">FA has no FDA-approved therapies that address frataxin deficiency, which is the underlying cause of the disease, and clinical endpoints required to obtain approval are not well defined.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are currently no FDA-approved products to treat FA that are designed to increase frataxin levels. We have concentrated our research and development efforts on developing a novel, FA therapy designed to address frataxin deficiency, which is the underlying cause of the disease, and our future success depends on the success of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">this therapeutic approach. The clinical trial requirements of the FDA and other comparable regulatory agencies and the criteria these regulators use to determine the safety and efficacy of any product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have had discussions with the FDA regarding the use of tissue FXN levels as a novel surrogate endpoint. The FDA acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology. In March 2025, we announced that FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as a reasonably likely surrogate endpoint ("RLSE") and the acceptability of FXN&#8217;s use as an RLSE would ultimately be a matter of review of the data in a future marketing application. We intend to pursue an accelerated approval using FXN levels, supportive PD and clinical information, and safety data from the OLE study, along with non-clinical pharmacology information needed to support the novel surrogate endpoint approach. We are beginning to plan for a confirmatory study and are targeting a BLA submission by the end of 2025. The FDA or other regulatory authorities may not agree with this approach.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory authorities in the United States, the United Kingdom and the European Union have not issued definitive guidance as to how to measure and achieve efficacy in treatments for FA. As a result, the design and conduct of clinical trials of nomlabofusp may take longer, be more costly or be less effective as part of the novelty of development in FA. The FDA may not accept that the supportive PD and clinical information, and safety data from the OLE study, along with additional non-clinical pharmacology data we ultimately submit in our BLA, adequately supports the use of FXN levels as a novel surrogate endpoint. Even if the FDA supports the use of FXN levels as a novel surrogate endpoint, the FDA may not agree with the adequacy of the design of clinical trials intended to assess this novel surrogate endpoint.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if applicable regulatory authorities do not object to our proposed endpoints in an earlier stage clinical trial, such regulatory authorities may require evaluation of additional or different clinical endpoints in later-stage clinical trials.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Nomlabofusp, including the effects of long-term daily patient dosing, may cause adverse events or undesirable side effects in clinical trials that could delay or prevent its regulatory approval, limit the commercial profile of approved labeling, or result in significant negative consequences following regulatory approval, if any.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any adverse events or undesirable side effects caused by, or other unexpected properties of, nomlabofusp in non-clinical or clinical studies could cause us, any future collaborators, an IRB or ethics committee or regulatory authorities to interrupt, delay or halt clinical trials of our product candidate and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. It is possible that as we progress nomlabofusp through clinical trials and toxicology studies, or as the use of nomlabofusp becomes more widespread if it receives regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, may be reported by patients. For example, recently our Safety Monitoring Team deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp. To reduce the risk of allergic reactions, including anaphylaxis, we amended the OLE protocol to administer premedication for the first month of dosing. If such side effects become known or their incidence increases later in development or after approval, such findings may harm our business, financial condition and prospects significantly. Further, if a serious safety issue is identified in connection with the use of nomlabofusp commercially or in third-party clinical trials elsewhere, such issues may adversely affect the development potential of nomlabofusp elsewhere or result in regulatory authorities restricting our ability to develop or commercialize nomlabofusp, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if nomlabofusp were to receive marketing approval and we or others identify undesirable side effects caused by the product (or any other product) after the approval, a number of potentially significant negative consequences could result, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may request that we recall or withdraw the product from the market or may limit the approval of the product through labeling or other means;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed&#8221; warning or a contraindication or a precaution, or labeling restrictions based on patient population;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of the product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may decide to recall or remove the product from the marketplace;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued or held liable for injury caused to individuals exposed to or taking our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be required to conduct expensive post-marketing studies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could lose our commercial market opportunity and our revenues could decrease substantially;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage to the public perception of the safety of nomlabofusp; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer and physicians or patients might be less likely to use our product or may refer patients to products produced by our competitors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates and significantly impact our ability to successfully commercialize our product candidates and generate revenues, all of which would materially adversely affect our business, financial condition and results of operations. In addition, the patient populations under investigation with nomlabofusp have many co-morbidities that may cause severe illness or death unrelated to our product candidate, which may be attributed to nomlabofusp in a manner that negatively affects the safety profile of our product candidate.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may publish interim, preliminary or &#8220;top-line&#8221; data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Material adverse changes between interim, preliminary or &#8220;top-line&#8221; data and final data could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our approach to discover and develop fusion proteins for delivering proteins is novel and may never lead to marketable products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have concentrated our efforts and research and development activities on delivering proteins (FXN or other) to intracellular targets. Our future success depends on the successful development and manufacturing of such therapeutics and the effectiveness of our platform. The scientific discoveries that form the basis for our research are relatively new.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp uses a novel and unproven approach and mechanism to treat FA and therefore its efficacy and safety are difficult to predict, and there is no guarantee that nomlabofusp will be approved by the FDA, the EMA, or any other regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If nomlabofusp proves to be ineffective, unsafe or commercially unviable, it is possible that our platform and pipeline would have little, if any, value, which would substantially harm our business, financial condition, results of operations and prospects. In addition, our approach may expose us to additional financial risks and make it more difficult to raise additional capital than other, more advanced proven technologies, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Protein replacement therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in the development or commercialization of our protein replacement therapy platform or product candidates or otherwise harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The manufacture of fusion proteins, such as nomlabofusp and any fusion protein candidates, is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for clinical trials and commercial products for nomlabofusp or any</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fusion protein product that may receive regulatory approval in the future. Additionally, because biologic products are complex, the manufacture of such products and product candidates is more difficult and costly. We may not be able to have such products reliably manufactured in accordance with the applicable regulatory requirements in sufficient quantities to support our development programs and, if ultimately approved, commercial supply.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are a limited number of contract manufacturers who specialize in the manufacture of biologic products and those that do may still be developing appropriate processes, controls and facilities for large-scale production. While we believe that there will be sufficient sources of supply that can satisfy our clinical and commercial requirements, we cannot be certain that we will be able to identify and establish additional relationships with such sources, if necessary, in a timely manner or at all, and what the terms and costs of such new arrangements would be, or that such suppliers would be able to supply our potential commercial needs. Furthermore, in the event our primary manufacturer cannot meet our needs, any switch to an alternative manufacturer, if available, would result in a significant delay, would require FDA approval, and cause material additional costs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As further described in these risk factors, the manufacturers of biologic products must comply with strictly enforced cGMP requirements, state and federal regulations, as well as foreign requirements when applicable. Any failure by us or our contract manufacturing organizations to adhere to or document compliance to such regulatory requirements could lead to a delay or interruption in the availability of our program materials for clinical trials or commercial use, among other consequences. If we or our manufacturers fail to comply with the FDA, EMA, or other regulatory authorities, it could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, clinical holds or termination of clinical trials, Form 483s, warning or untitled letters, regulatory communications warning the public about safety issues with a product, import or export refusals, license revocation, seizures, detentions, or recalls of product candidates or product, operating restrictions, criminal prosecutions or debarment, suits under the civil False Claims Act, corporate integrity agreements, or consent decrees any of which could significantly and adversely affect supplies of our product candidates and our business, financial conditions and results of operations could be materially adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current dependence upon others for the manufacture of our product candidates may also adversely affect our business, results of operations, financial condition, and our ability to commercialize any product candidates that receive regulatory approval on a timely and competitive basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fast track designation by the FDA or any future expedited program designations may not lead to a faster development, regulatory review or approval process and it does not increase the likelihood that any of our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have received fast track therapy designation for nomlabofusp for the treatment of FA. We may, in the future, apply for other expedited program designations from the FDA (such as breakthrough therapy) for nomlabofusp or future product candidates. Designation for these programs is within the discretion of the FDA. Accordingly, even if we believe nomlabofusp or a future product candidate meets the criteria for designation, the FDA may disagree. The receipt of a designation may not result in a faster development process, review or approval compared to products considered for approval without these expedited program designations and, in any event, does not assure ultimate approval by the FDA. In addition, even though nomlabofusp has obtained fast track designation, the FDA may later decide that it no longer meets the criteria for designation and revoke it. Approval of other therapies for the treatment Friedreich&#8217;s ataxia could negatively impact our continued fast track therapy designation for nomlabofusp for the treatment of FA. In addition, if we apply to the FDA for other designations for nomlabofusp or future product candidates, the FDA might not grant such designations. If we apply for any similar programs in foreign countries for nomlabofusp or future product candidates, those designations also might not be granted by the regulatory authorities of those countries. Any of the above could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We intend to pursue accelerated approval from FDA for nomlabofusp for the treatment of Friedreich&#8217;s ataxia, however this may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that we will receive marketing approval. If we are unable to obtain approval under an accelerated pathway, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, reduce the likelihood of obtaining, and/or delay the timing of obtaining, necessary marketing approvals.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We intend to pursue an accelerated approval from FDA for nomlabofusp for the treatment of FA using FXN concentrations as a surrogate endpoint, supportive pharmacodynamic and clinical information and safety data from the OLE study, along with non-clinical pharmacology information needed to support our surrogate biomarker</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approach. Under the FDA&#8217;s accelerated approval program, the FDA may approve a drug or biologic for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. The FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as an RLSE and the acceptability of FXN&#8217;s use as an RLSE would ultimately be a matter of review of the data. There can be no assurance that data we intend to generate will be successful in establishing that increases in FXN concentrations are reasonably likely to predict clinical benefit or that increases in FXN concentrations due to treatment with nomlabofusp meet the legal standards to support approval of a marketing application. In addition, non-clinical pharmacology and clinical studies may not provide adequate information or may fail to support the predictive value of increases in FXN and, therefore, its ability to serve as a surrogate endpoint, or may fail to support that increases in FXN are the result of treatment with nomlabofusp. Even if these evidentiary requirements are met, we may not be able to accrue adequate exposures to assess clinical safety or expedite the scale up of manufacturing or meet other CMC requirements in a timeframe commensurate with the expedited assessment of clinical efficacy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approval of other therapies for the treatment of FA, including the approval of omaveloxolone for the treatment of FA, could negatively impact our ability to utilize the accelerated approval pathway, and/or get approval for nomlabofusp. For drugs or biologics granted accelerated approval, post-marketing confirmatory trials are required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. These confirmatory trials must be completed with due diligence and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the FDA may withdraw approval of any product candidate approved under the accelerated approval pathway if, for example:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the trial or trials required to verify the predicted clinical benefit of the product candidate fail to verify such benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with such product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">other evidence demonstrates that the product candidate is not shown to be safe or effective under the conditions of use;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we fail to conduct any required post-approval trial of our product candidate with due diligence; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we disseminate false or misleading promotional materials relating to the relevant product candidate.</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA may terminate the accelerated approval program or change the standards under which accelerated approvals are considered and granted in response to public pressure or other concerns regarding the accelerated approval program. Changes to or termination of the accelerated approval program could prevent or limit our ability to obtain accelerated approval of any of our clinical development programs. Recently, the accelerated approval pathway has come under scrutiny within the FDA and by Congress. The FDA has put increased focus on ensuring that confirmatory studies are conducted with diligence and, ultimately, that such studies confirm the benefit. In addition, the Food and Drug Omnibus Reform Act (&#8220;FDORA&#8221;), included provisions related to the accelerated approval pathway. Pursuant to FDORA, the FDA is authorized to require, as appropriate, that a post-approval study to be underway prior to approval or within a specified time period following approval. FDORA also requires the FDA to specify conditions of any required post-approval study and requires sponsors to submit progress reports for required post-approval studies and any conditions required by the FDA. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to verify the drug or biologic&#8217;s predicted clinical benefit. FDORA enables the FDA to initiate enforcement action for a sponsor's failure to conduct with due diligence a required post-approval study, including a failure to meet any required conditions specified by the FDA or to submit timely reports.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain orphan drug designation or other regulatory exclusivity for nomlabofusp or obtain such exclusivity for any of our other product candidates in the future, our competitive position would be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We received orphan drug designation from the FDA for nomlabofusp for the treatment of FA in July 2017. In the United States, orphan drug designation entitles a party to financial incentives such as tax advantages and user-fee waivers. In addition, if a product candidate that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">means that the FDA may not approve any other applications, including an NDA or BLA, to market the same drug for the same disease or condition for seven years, except in limited circumstances, including if the FDA concludes that the later drug is clinically superior to the approved drug. A drug is clinically superior if it is safer, more effective, or makes a major contribution to patient care. In the case of a biological product, whether a drug is the same drug is based on the principal molecular structural features of the product. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we may lose orphan drug exclusivity if we are unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Moreover, orphan drug exclusivity may not effectively protect our product candidates from competition because different drugs can be approved for the same condition. Further, even after an orphan drug is approved, the FDA or comparable foreign regulatory authority can subsequently approve another drug for the same condition if such regulatory authority concludes that the later drug is clinically superior, which means that it is shown to be safer, more effective or makes a major contribution to patient care.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also received orphan designation for nomlabofusp in the European Union. In the European Union, the European Commission may grant orphan designation in respect of products that are intended for the diagnosis, prevention or treatment of a life threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug. In each case, orphan designation is only available if there is no other satisfactory method approved in the European Union of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed orphan product will be of significant benefit to patients over the existing options. In the European Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following the grant of marketing authorization.  This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable so that market exclusivity is no longer justified. Loss of orphan drug designation for nomlabofusp or the failure to obtain such designation in other countries or for any future product candidates could adversely affect our business, financial condition and results of operation.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If another product has received approval in the indications for which we have received orphan drug designation, we may still receive approval in that indication if we can demonstrate that our product candidate is clinically superior to the existing orphan product. This demonstration of clinical superiority may be done at the time of initial approval or in post-approval studies, depending on the type of marketing authorization granted. Having to comply with these additional requirements to obtain orphan drug exclusivity could adversely affect our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Although we have obtained rare pediatric disease designation for nomlabofusp, we may not be eligible to receive a priority review voucher in the event the FDA determines we no longer meet the criteria for designation, revokes the designation or FDA approval does not occur prior to September 30, 2026.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The sponsor of an application for a rare pediatric disease drug product may be eligible for a voucher that can be used or sold to obtain a priority review for a subsequent application submitted under section 505(b)(1) of the FDCA or section 351 of the PHS Act. The rare pediatric disease priority review voucher program began to sunset on December 20, 2024, due to failure to pass a continuing resolution package that included its reauthorization. Under the amended statutory sunset provisions, after December 20, 2024, the FDA may award a priority review voucher for an approved rare pediatric disease product application only if the sponsor has rare pediatric disease designation for the drug and if that designation was granted by December 20, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease priority review vouchers. Congress may vote to reauthorize this program, but its future remains unknown at this time. We received rare pediatric disease designation from the FDA for nomlabofusp in 2019. We may, in the future, apply for rare pediatric disease designation from the FDA for future product candidates that may qualify for designation if Congress reauthorizes the program. Vouchers for rare pediatric disease drugs are awarded for qualifying applications when the drug receives approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although nomlabofusp has received rare pediatric disease designation, nomlabofusp may not receive a priority review voucher for a number of reasons: nomlabofusp may not receive approval; nomlabofusp may receive approval in adults, but not pediatric patients; nomlabofusp may not meet the eligibility requirements for a priority voucher at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time we seek approval for nomlabofusp; or we may not meet the current deadline for receiving a priority review voucher (September 30, 2026), in which case we would not be able to obtain a voucher unless Congress further reauthorizes the program. Finally, a rare pediatric disease designation does not necessarily lead to faster development or regulatory review of the product or increase the likelihood that it will receive marketing approval. If the program is reauthorized and we apply for designation for future product candidates as drugs for rare pediatric diseases, the FDA may not grant the designation. The failure to maintain rare pediatric disease designation for nomlabofusp or if FDA approval does not occur prior to September 30, 2026 could result in the inability to receive a priority review voucher which could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain PRIME designation in the European Union for nomlabofusp, our competitive position could be harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PRIME scheme is open to medicines under development and for which the applicant intends to apply for an MA through the centralized procedure. Eligible products must target conditions for which where is an unmet medical need (there is no satisfactory method of diagnosis, prevention or treatment in the European Union or, if there is, the new medicine will bring a major therapeutic advantage in comparison to existing therapies) and they must demonstrate the potential to address the unmet medical need by introducing new methods or therapy or improving existing ones. Applicants will typically be at the exploratory clinical trial phase of development and will have preliminary clinical evidence in patients to demonstrate the promising activity of the medicine and its potential to address to a significant extent an unmet medical need. In exceptional cases, applicants from the academic sector or SMEs may submit an eligibility request at an earlier stage of development if compelling non-clinical data in a relevant model provide early evidence of promising activity to establish proof of principle, and first in man studies indicate adequate exposure for the desired pharmacotherapeutic effects and tolerability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a medicine is selected for the PRIME scheme, the EMA:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">appoints a rapporteur from the CHMP or from the CAT to provide continuous support and to build up knowledge of the medicine in advance of the filing of an MMA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issues guidance on the applicant&#8217;s overall development plan and regulatory strategy;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">organizes a kick-off meeting with the rapporteur and experts from relevant EMA committees and working groups;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provides a dedicated EMA contact person; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provides scientific advice at key development milestones, involving additional stakeholders, such as health technology assessment bodies and patients, as needed.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For SMEs who enter the scheme based on data showing proof of principle, the appointment of the rapporteur occurs once they have generated data confirming eligibility at proof of concept stage. They are required to submit relevant data and justification as the product development reaches this stage.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Medicines that are selected for the PRIME scheme are also expected to benefit from EMA&#8217;s accelerated assessment procedure at the time of application for marketing authorization. Where, during the course of development, a medicine no longer meets the eligibility criteria, or if a medicine granted early access to the PRIME scheme cannot later demonstrate proof of concept, support under the PRIME scheme may be withdrawn. Approval of other therapies for the treatment Friedreich&#8217;s ataxia, including the approval of omaveloxolone could negatively impact our continued access to this and similar programs. Loss of PRIME designation for nomlabofusp or the failure to obtain such designation for any future product candidates could adversely affect our business, financial condition and results of operation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in regulatory requirements, FDA guidance, guidance from other regulatory authorities or unanticipated events during our non-clinical or clinical trials of nomlabofusp or future product candidates may result in changes to clinical trial protocols or additional non-clinical or clinical trial requirements, which could result in increased costs to us and could delay our development timeline.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in regulatory requirements, FDA guidance or guidance from EMA or unanticipated events during our non-clinical or clinical trials may force us to terminate or adjust our clinical programs. The FDA, or other applicable regulatory authorities may impose additional clinical trial and/or non-clinical study requirements. Amendments to our clinical trial protocols would require resubmission to the FDA, or the applicable regulatory authorities as well as IRBs and ethics committees for review and approval, which may adversely impact the cost, timing or successful completion of a clinical trial. If we experience delays completing, or if we terminate, any of our clinical trials, or if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we are required to conduct additional clinical trials, or non-clinical studies and/or post-market studies, the commercial prospects for nomlabofusp or any other potential product candidates may be harmed and our ability to generate product revenue will be delayed or eliminated, and it would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to market any product outside of the United States, we must comply with numerous and varying regulatory requirements of other countries regarding drug development and commercialization. The approval processes varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. Even if we receive marketing approval for nomlabofusp in the United States, we may never receive regulatory approval to market nomlabofusp outside of the United States.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in the FDA, other government agencies or comparable regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed, approved or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current administration is focused on reducing costs of the federal government generally, including significantly reducing the number of government employees. Without appropriation of additional funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted. The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, and accept the payment of user fees, statutory, regulatory and policy changes. In addition, government funding of other government agencies or comparable foreign regulatory authorities on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disruptions at the FDA, other agencies or comparable foreign regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. Changes in FDA staffing could result in delays in the FDA&#8217;s responsiveness or in its ability to review submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in a timely fashion or at all. Similar consequences would also result in the event of another significant shutdown of the federal government. As an example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC have had to furlough critical employees and stop critical activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If a prolonged government shutdown occurs, including as a result of reaching the debt ceiling, if the FDA or SEC experiences significant decreases in funding or personnel it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business and our timelines. Further, government shutdowns could impact our ability to access the public markets and obtain additional capital in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Regulatory requirements governing biologic products have changed frequently and may continue to change in the future. Such requirements may lengthen the regulatory review process, require us to perform additional non-clinical studies or clinical trials, and increase our costs, or may force us to delay, limit or terminate certain of our programs.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory requirements governing biologic drug products are evolving and may continue to change in the future. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for nomlabofusp for the treatment of FA or any other future protein replacement therapy product candidates in any indication, if at all. Regulatory review agencies and the new requirements and guidelines they promulgate may lengthen the regulatory review process, require us to perform additional or larger studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval studies, limitations or restrictions. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delays, failure or unexpected costs in obtaining, the regulatory approval necessary to bring our product candidates to market could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of such product candidates. The regulatory approval process for novel product candidates such as ours can be more expensive and take longer than for other, better known or more extensively studied product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The clinical trials of nomlabofusp and any future product candidates are, and the manufacturing and marketing of nomlabofusp and any future product candidates, will be subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries, such as within the European Union, where we intend to seek regulatory approval of, and market, any product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through non-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval of or may result in the decision not to approve our product candidates. We have not obtained regulatory approval for nomlabofusp, and it is possible that this product candidate or any product candidates we may seek to develop in the future will never obtain regulatory approval. If marketing approval is obtained, it will likely include post-marketing studies, and other post-marketing requirements, and surveillance such as REMS which will require the expenditure of substantial resources beyond the proceeds we currently have on hand.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, we are not permitted to market nomlabofusp in the United States, or the European Union until we receive approval of a BLA from the FDA or the grant of an MA from the European Commission, or in any other foreign countries until we receive the requisite marketing approval from such countries. The development of drugs for FA or other rare diseases may require initial non-clinical studies, early and usually smaller, clinical trials and randomized, double-blind placebo controlled long-term safety and efficacy trials in order to test the safety and efficacy of the drug.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp requires substantial further clinical development before we can submit a BLA to the FDA. Development and/or regulatory programs for nomlabofusp in any countries other than the United States (such as a MAA to the EMA) are only in very preliminary stages and may require substantial further development in those countries prior to regulatory submissions seeking regulatory approval for marketing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even after successful completion of clinical trials, there is a risk that the FDA or other regulatory agencies may request further information from us, disagree with our findings or otherwise undertake a lengthy review of our submission.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and certain European regulatory authorities may delay, limit or deny testing or approval of nomlabofusp for many reasons, including, among others:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to demonstrate that nomlabofusp is safe and effective to the satisfaction of the FDA or the EMA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or the EMA for marketing approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA may disagree with the number, design, size, duration, conduct or implementation of our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA may require that we conduct additional non-clinical studies and/or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA may not approve the formulation, manufacturing, labeling or specifications of nomlabofusp;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the CROs that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA may find the data from non-clinical studies and clinical trials insufficient to demonstrate that nomlabofusp&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA may disagree with our interpretation of data from our non-clinical studies or clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA may not accept data generated at our clinical trial sites;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if and when our BLA is submitted, the FDA could require an FDA advisory committee assessment, or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional non-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA could require development of a REMS as a condition of approval or post-approval, or may not agree with our proposed REMS, or may impose additional requirements, including requirements that limit the promotion, advertising, distribution, or sales of nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA may find deficiencies with or not approve the manufacturing processes or facilities of third-party manufacturers with which we contract; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA or the EMA may change their approval policies or adopt new regulations rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these factors, many of which are beyond our control, could jeopardize our ability to obtain and/or maintain regulatory approval for and successfully market nomlabofusp. Any delay or failure in obtaining required approvals could have a material adverse effect on our business, financial condition and results of operations. This process can take many years and will likely require the expenditure of substantial resources. Of the large number of drugs in development in the United States, only a small percentage will successfully complete the FDA regulatory approval process and be commercialized. It is possible that the FDA or other regulatory agencies will not approve any application that we submit. It is possible that our product candidates may not obtain appropriate regulatory approvals necessary for us to commence clinical trials for our product candidates. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and clinical trials, we cannot ensure that nomlabofusp, or any other of our potential product candidates will be successfully developed or commercialized.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to healthcare laws and regulations, and health information privacy and security laws, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Healthcare providers, physicians and others will play a primary role in the recommendation and prescription of nomlabofusp or any potential product candidates, if approved. Our future arrangements with third-party payors will expose us broadly to applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute nomlabofusp or potential product candidates, if we obtain marketing approval. In addition, we may be subject to patient privacy regulation by both the federal government and the states or other countries in which we conduct our business. For more information, see the section of this report titled &#8220;Business &#8211; Healthcare Laws and Regulations &#8211; Other Healthcare Laws.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales team, were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines and exclusion from government funded healthcare programs, such as Medicare and Medicaid, any of which could substantially disrupt our operations and would materially adversely affect our business, financial condition and results of operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exclusions from government funded healthcare programs, which could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial potential for our approved products, if any, could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry. New laws, regulations or judicial decisions or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could adversely affect our business, operations and financial condition. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that may affect our ability to profitably sell our product and product candidates, if approved. The United States government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. Previously, in March 2010, the ACA was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Healthcare reform initiatives recently culminated in the enactment of the IRA, which, among other things, allow allows HHS to directly negotiate the ceiling price of a statutorily specified number of drugs and biologic each year that CMS reimburses under Medicare Part B and Part D, requires the payment of rebates on Medicare Part B and Part D drugs whose prices have increased at a rate faster than the rate of inflation, and redesign the Medicare Part D cost sharing structure, including revising manufacturer financial liability for covered products. For more information, see the section of this report titled &#8220;Business &#8211; Healthcare Laws and Regulations &#8211; Healthcare Reform.&#8221; Moreover, the Creating and Restoring Equal Access to Equivalent Samples Act ("CREATES" Act), was enacted in 2019 requiring sponsors of approved new drug applications and biologics license applications to provide sufficient quantities of product samples on commercially reasonable, market-based terms to entities developing generic drugs and biosimilar biological products. The law establishes a private right of action allowing developers to sue application holders that refuse to sell them product samples needed to support their applications. If we are required to provide product samples or allocate additional resources to respond to such requests or any legal challenges under this law, our business could be adversely impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional federal, state and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if approved, reimbursement policies could limit our ability to sell product candidates that we elect to sell on our own.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved by regulatory authorities, market acceptance and sales of product candidates that we elect to sell on our own will depend on reimbursement policies and may be affected by healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels for those medications. Cost containment is a primary concern in the U.S. healthcare industry and elsewhere. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that reimbursement will be available for nomlabofusp, if approved, or future product candidates that we elect to sell on our own and, if reimbursement is available, the level of such reimbursement. Reimbursement may impact the demand for, or the price of, product candidates that we elect to sell. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize product candidates that we elect to sell. For more information, see the section of this report titled &#8220;Business &#8211; Healthcare Laws and Regulations &#8211; Coverage and Reimbursement.&#8221;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some foreign countries, particularly in Canada and European countries, the pricing of prescription pharmaceuticals is subject to strict governmental control. In these countries, pricing negotiations with governmental authorities can take six to 12 months or longer after the receipt of regulatory approval and product launch. To obtain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">favorable reimbursement for the indications sought or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of product candidates that we elect to sell on our own with other available therapies. If reimbursement for product candidates that we elect to sell on our own is unavailable in any country in which we seek reimbursement, if it is limited in scope or amount, if it is conditioned upon our completion of additional clinical trials, or if pricing is set at unsatisfactory levels, our business, financial conditions and results of operations could be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain marketing approval for a product candidate, our product candidates will remain subject to regulatory oversight.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we receive marketing approval for nomlabofusp or a future product candidate, regulatory authorities may still impose significant restrictions on the indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. Nomlabofusp or future product candidates will also be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information. The FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate serious safety risks related to the use of a drug. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. Any regulatory approvals that we receive for nomlabofusp may also be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including post-approval clinical trials, and surveillance to monitor the quality, safety and efficacy of the product, all of which could lead to lower sales volume and revenue. For example, the holder of an approved BLA or NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA or NDA. The holder of an approved BLA or NDA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or NDA or foreign marketing application. If we, or a regulatory authority, discover(s) previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or our contractors fail to comply with applicable regulatory requirements following approval of nomlabofusp, a regulatory authority may:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issue a warning letter, or untitled letter asserting that we are in violation of the law;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for non-compliance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">request voluntary product recalls;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend or withdraw regulatory approval;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspend any ongoing clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to approve a pending BLA or NDA or comparable foreign marketing application (or any supplements thereto) submitted by us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrict the marketing or manufacturing of the product;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seize or detain the product or otherwise require the withdrawal of the product from the market;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to permit the import or export of product candidates; or</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refuse to allow us to enter into supply contracts, including government contracts.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize nomlabofusp, if approved, and adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the FDA&#8217;s policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of nomlabofusp. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive marketing approval for nomlabofusp in the United States, we may never receive regulatory approval to market nomlabofusp outside of the United States.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may pursue marketing approval for nomlabofusp in the United States, the European Union and in other jurisdictions worldwide. In order to market any product outside of the United States, we must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of other jurisdictions, including potential additional clinical trials and/or non-clinical studies. Approval procedures vary among jurisdictions and can involve additional testing and additional administrative review periods. The time required to obtain approvals in other jurisdictions might differ from that required to obtain FDA approval. The marketing approval processes in other jurisdictions may implicate all of the risks detailed above regarding FDA approval in the United States as well as other risks. In particular, in many countries outside of the United States, products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can result in substantial delays in bringing products to market in such countries. Marketing approval in one jurisdiction does not necessarily ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the regulatory process or commercial activities in others. Failure to obtain marketing approval in other countries or any delay or other setback in obtaining such approval would impair our ability to market a product candidate in such foreign markets. Any such impairment would reduce the size of our potential market, which could have a material adverse impact on our business, financial condition, results of operations and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The prevalence of FA is estimated to be approximately three times greater in the European Union than in the United States, and, therefore, represents our largest potential market for nomlabofusp. Our future profitability will depend, in part, on our ability to commercialize nomlabofusp and future product candidates in the European Union and other foreign markets for which we may rely on collaborations with third parties. If we commercialize a product candidate in foreign markets, we would be subject to additional risks and uncertainties, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our customers&#8217; ability to obtain reimbursement for a product candidate in foreign markets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with the FCPA;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to directly control commercial activities because we may need to rely on third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">different medical practices and customs in foreign countries affecting acceptance in the marketplace;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">import or export licensing requirements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">longer accounts receivable collection times;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">longer lead times for shipping;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">language barriers for technical training;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced protection of intellectual property rights in some foreign countries;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency exchange rate fluctuations; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sales in the European Union and other foreign markets of a product candidate could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell nomlabofusp, if approved, we may not be able to generate any revenue.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not currently have an established infrastructure for the sales, marketing and distribution of biologic or drug products in the United States or foreign countries. In order to market a product candidate, if approved by the FDA or any other regulatory authority, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, or if we are unable to do so on commercially reasonable terms, our business, results of operations, financial condition and prospects will be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we receive marketing approval for nomlabofusp, we may not achieve broad market acceptance, which would limit the revenue that we generate from our sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The commercial success of nomlabofusp, if developed and approved for marketing by the FDA or EMA or other applicable regulatory authorities, will depend upon the market size for, and the awareness and acceptance of nomlabofusp among the medical community, including physicians, patients, advocacy groups and healthcare payors. Market acceptance of nomlabofusp, if approved, will depend on a number of factors, including, among others:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if the actual number of patients with FA is lower than we believe;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the relative convenience and ease of subcutaneous injections as the necessary method of administration;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any adverse side effects associated with nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings contained in the labeling approved for nomlabofusp by the FDA, EMA, or other regulatory authorities, such as a &#8220;boxed&#8221; warning or if any approval that we obtain is based on a narrower definition of possible patient populations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">availability of alternative treatments, including any competitive FA therapies approved or in development that have been or could be approved or commercially launched prior to approval of nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength of marketing and distribution support and timing of market introduction of competitive products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">publicity concerning our products or competing products and treatments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pricing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">patient acceptance of the cost and inconvenience associated with refrigerated storage for nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payor acceptance;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased political pressure on pharmaceutical pricing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased pressure on orphan drug pricing for affected patient groups;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of any future changes in U.S. healthcare, including medical financial assistance or a transition to a single-payor system;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effectiveness of our sales and marketing strategies;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to increase awareness of nomlabofusp through marketing efforts;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain sufficient third-party coverage or reimbursement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness or ability of patients to pay out-of-pocket in the absence of third-party coverage; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the likelihood that the FDA may require development of a REMS, as a condition of approval or post-approval or may not agree with our proposed REMS or may impose additional requirements that limit the promotion, advertising, distribution or sales of our product candidates.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If nomlabofusp is approved but does not achieve an adequate level of acceptance by patients, advocacy groups, physicians and payors, we may not generate sufficient revenue from nomlabofusp to become or remain profitable and our business, financial condition and results of operations could be materially adversely affected. Our efforts to educate the medical community and third-party payors about the benefits of nomlabofusp may require significant resources and may never be successful.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. If we are found to have improperly promoted off-label uses, we may become subject to significant liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as nomlabofusp or any potential product candidates, if approved. If we receive marketing approval for nomlabofusp, or any potential product candidates, physicians may prescribe our product candidates to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion and required that they enter into corporate integrity agreements with the Office of Inspector General of the Department of Health and Human Services. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of nomlabofusp or any potential product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Additional competing technologies could emerge, adversely affecting our opportunity to generate revenue from the sale of nomlabofusp, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. For example, omaveloxolone, was approved for the treatment of FA in adults and adolescents aged 16 and older by the FDA and the European Commission in February 2023 and February 2024, respectively. We expect nomlabofusp, if approved, will compete with omaveloxolone and other new, future approved products and may need to demonstrate compelling advantages in efficacy, convenience, tolerability and safety to be commercially successful. Other competitive factors, including biosimilar and gene therapy competition, could force us to lower prices or could result in reduced sales. Many of our current or potential competitors, either alone or with strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, non-clinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. New products developed by others could emerge as competitors to nomlabofusp or any other potential product candidates, resulting in nomlabofusp or other product candidates being obsolete before we are able to recover expenses incurred in connection with their development or realize revenues from any commercialized product. The pricing of our current product candidate, if and when approved for marketing, will depend, in part, on the pricing strategies adopted by our competitors. If these or other companies enact pricing strategies that impact the price we can charge for our product candidate, if approved, we may reduce our prices and our revenue and results of operations could be affected. Any new product could also affect our ability to recruit and retain clinical trial patients, to obtain and maintain designations or eligibility for expedited regulatory pathways, and to commercialize current and future product candidates. Given that we are still in a relatively early phase of development for nomlabofusp, the recent approval and commercialization of omaveloxolone and the approval of any future competing technologies could provide competitors with a significant competitive advantage and may create an additional barrier to market acceptance of nomlabofusp. If we are not able to compete effectively against our current and future competitors, our business will not grow and our financial condition and results of operations will be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Our competitors also may obtain FDA, EMA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may face competition from biosimilars and may face increasing competition over time.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may face competition from biosimilars in both the United States and Europe, and over time we may face increasing biosimilar competition. To the extent that governments adopt more permissive approval frameworks and competitors are able to obtain broader or expedited marketing approval for biosimilars, the rate of increased competition for our biologic drug products could accelerate. Expiration or successful challenge of applicable patent rights could trigger such competition, and we could face more litigation regarding the validity and/or scope of our patents. Our products may also experience greater competition from lower cost biosimilars or generics that come to market when branded products that compete with our products lose their own patent protection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the European Union, the European Commission has granted marketing authorizations for biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals originally issued in 2005 and updated in 2014. In addition, in an effort to spur biosimilar utilization and/or increase potential healthcare savings, some countries in the European Union have adopted biosimilar uptake measures such as requiring physician prescribing quotas or promoting switching or pharmacy substitution of biosimilars for the corresponding reference products, and other countries may adopt similar measures. Some countries in the European Union may impose automatic price reductions upon market entry of the second or third biosimilar competitor.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the ACA authorized the FDA to license biosimilars via a separate, abbreviated pathway. A growing number of companies have announced that they are in varying stages of development of biosimilar versions of existing biotechnology products. Some companies pursuing development of biosimilars may challenge our patents well in advance of the expiration of our material patents. The U.S. pathway includes the option for biosimilar products meeting certain criteria to be approved as interchangeable with their reference products. Some companies developing biosimilars may seek to license their products as interchangeable biologics, which could make it easier for prescribers or pharmacists to substitute those biosimilars for our products. In addition, critics of the 12-year exclusivity period in the biosimilar pathway will likely continue to seek to shorten the data exclusivity period and/or to encourage the FDA to interpret narrowly the law&#8217;s provisions regarding which new products receive data exclusivity. While we are unable to predict the precise impact of biosimilars, we expect in the future for there to be greater competition in the United States as a result of biosimilars and downward pressure on product prices and sales. These biosimilars or generics may affect the tier designation by third party payors and may require prior authorization for use of nomlabofusp, thereby adding barriers to access. This additional competition could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Business</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to manage expected growth in the scale and complexity of our operations, including attracting and hiring additional qualified management, our performance may suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are an early-stage clinical biotechnology company with a small number of employees, and our management systems currently in place are not likely to be adequate to support our future growth plans. As a result, we are highly dependent on our management and scientific personnel. The loss of the services of any of our executive officers, other key employees or consultants and other scientific advisors in the foreseeable future, might impede the achievement of our research, development and commercialization objectives. Competition for qualified personnel in the biopharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to continue to hire additional personnel as we expand our clinical development and if we initiate commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on consultants and advisors, including scientific, non-clinical, manufacturing and clinical advisors, to assist us in formulating our development and commercialization strategy. These consultants and advisors may be employed by other employers and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. In addition, a possible future pandemic, epidemic or outbreak of an infectious disease may pose a risk to our ability to retain and rely on our executive officers and key employees, including the potential that one or more of such employees or members of their families may contract the virus, which could impact the ability of such employees to perform as expected, which in turn would adversely impact our current and planned operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recruiting and retaining qualified scientific, medical clinical, manufacturing, quality assurance, regulatory, legal, public company financial, business, sales, marketing and commercial personnel and implementing and improving our operational, financial and management systems will be critical to our ability to grow and succeed. These demands also will require the hiring of additional executive or management-level personnel or the development of additional expertise by our senior management personnel. Hiring a significant number of additional employees, particularly those at the executive or management level, would increase our expenses significantly. In addition, we may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical companies for similar personnel. We also experience competition for the hiring of scientific personnel from universities and research institutions. Moreover, delays or failures in clinical trials may also make it more challenging to recruit and retain qualified scientific personnel. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our business strategy will be limited and our business, financial condition and results of operations would be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, if we fail to expand and enhance our operational, financial, management and compliance systems in conjunction with potential future growth, such failure could have a material adverse effect on our business, financial condition and results of operations. We may be unable to successfully implement these tasks on a larger scale and, accordingly, may not achieve our research, development, business and growth goals.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions or alliances.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate such businesses with our existing operations and company culture.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delays or prevents us from realizing their expected benefits or enhancing our business. We cannot be certain that, following any such transaction, we will achieve the expected synergies to justify the transaction and it could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans or expand our internal efforts and growth.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For nomlabofusp, and any future product candidates, we may decide to collaborate with pharmaceutical and/or biotechnology companies for the development and potential commercialization of those product candidates in some or all markets.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration for nomlabofusp or other potential product candidates will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the applicable product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. The terms of any collaboration or other arrangement that we may establish may not be favorable to us.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be restricted under existing license agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable or unwilling to do so, we may have to curtail the development potential product candidates for which we are seeking to collaborate, reduce or delay our development program or one or more of our other development programs, delay potential commercialization in some or all markets or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense, including potentially increasing our infrastructure and investment outside the United States. If we elect to increase our expenditures to fund development or commercialization activities on our own, we will need to obtain additional capital, which may not be available to us on acceptable terms if at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. In addition, such efforts may require diversion of a disproportionate amount of our attention away from other day-to-day activities and require devotion of a substantial amount of our time to managing these activities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration could adversely affect our business, financial condition, results of operations and could harm our business reputation.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face risks related to health epidemics, and/or other outbreaks of communicable diseases, which could significantly disrupt our operations and may materially and adversely affect our business and financial conditions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business could be adversely impacted by the effects of a global pandemic, epidemic or outbreak of an infectious disease. Such global outbreaks of communicable diseases globally could materially and adversely impact our operations, including without limitation, our manufacturing and supply chain for nomlabofusp and our planned clinical trials, which could continue to face, enrollment difficulties as hospitals or clinical trials sites experience closures. Because FA is a rare disease, there are a limited number of patients in close proximity to clinical trial sites and clinical trial patients travel from throughout the United States to clinical trial sites to participate. Any travel advisories or infection risks could present increased risks to patients traveling to a clinical trial site for dosing if clinical trials are allowed to continue. These events could delay our clinical trials, increase the cost of completing our clinical trials and negatively impact the integrity, reliability or robustness of the data from our clinical trials. In addition, employee health and availability could be impacted, which may have a material and adverse effect on our business, financial condition and results of operations. Future pandemics could adversely affect global economies and financial markets resulting in an economic downturn that could have a material adverse effect on our business and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, sensitive third-party data, business plans, transactions, financial information and medical information collected by our patient access management team (collectively,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sensitive data). Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, HIPAA, as amended by HITECH, imposes specific requirements relating to the privacy, security, and transmission of individually identifiable health information. Additionally, in the past few years, numerous U.S. states&#8212;including California, Virginia, Colorado, Connecticut, and Utah&#8212;have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain data processing activities, such as targeted advertising, profiling, and automated decision-making. The exercise of these rights may impact our business and ability to provide our products and services. Certain states also impose stricter requirements for processing certain personal data, including sensitive information, such as conducting data privacy impact assessments. These state laws allow for statutory fines for noncompliance. For example, the California Consumer Privacy Act of 2018, as amended by the California Privacy Rights Act of 2020 (CPRA) (collectively, CCPA) requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for fines of up to $7,500 per intentional violation and allows private litigants affected by certain data breaches to recover significant statutory damages. Although some U.S. comprehensive privacy laws exempt some data processed in the context of clinical trials, these laws may increase compliance costs and potential liability with respect to other personal data we may maintain about California residents. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more jurisdictions to pass similar laws in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside the United States, an increasing number of laws, regulations, and industry standards may govern data privacy and security. For example, the European Union&#8217;s General Data Protection Regulation (EU GDPR), United Kingdom&#8217;s GDPR (UK GDPR) (collectively, the GDPR), Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or LGPD) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law (PIPL) impose strict requirements for processing personal data. For example, the GDPR includes obligations requiring disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, limiting retention periods for personal data, creating mandatory data breach notification requirements in certain circumstances, and requiring that certain measures (including contractual requirements) are put in place when engaging third-party processors Companies that fail to comply with the GDPR may face temporary or definitive bans on data processing and other corrective actions; fines of up to 20 million Euros under the EU GDPR / 17.5 million pounds sterling under the UK GDPR or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Swiss Federal Act on Data Protection, or the FADP, also applies to the collection and processing of personal data, including health-related information, by companies located in Switzerland, or in certain circumstances, by companies located outside of Switzerland. The FADP has been revised and adopted by the Swiss Parliament. Companies must comply with the revised version of the FADP and its revised ordinances from September 1, 2023, which may result in an increase of costs of compliance, risks of noncompliance and penalties for noncompliance.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (EEA) and the UK have significantly restricted the transfer of personal data to countries whose privacy laws it believes are inadequate, including the United States in certain circumstances, unless a derogation exists or adequate international transfer safeguards are put in place (for example, the European Commission approved Standard Contractual Clauses, and the UK International Data Transfer Agreement/Addendum) and transfer impact assessments carried out. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws.  If we are unable to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere, the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We are also bound by other contractual obligations related to data privacy and security, and our efforts to comply with such obligations may not be successful. We publish privacy policies, marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, under various privacy laws and other obligations, we may be required to obtain certain consents to process personal data. For example, some of our data processing practices may be challenged under wiretapping laws, if we obtain consumer information from third parties through various methods, including chatbot and session replay providers, or via third-party marketing pixels. These practices may be subject to increased challenges by class action plaintiffs. Our inability or failure to obtain consent for these practices could result in adverse consequences, including class action litigation and mass arbitration demands.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obligations related to data privacy and security (and consumers&#8217; data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our internal computer systems, as well as those of CROs, CMOs, vendors, contractors, and consultants, and potential collaborators may experience failures, unauthorized access, or security breaches, potentially causing a material disruption in our product development programs, operations, harm to our brand, significant liabilities, loss of revenue, and additional costs.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite implementing comprehensive security measures, both our internal computer systems and those of our contracted third-party service providers are susceptible to various threats, including cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. The extensive use of mobile devices accessing confidential information further heightens the risks, leading to potential device loss, security incidents, and data breaches that could result in the loss of confidential information and intellectual property. Any system failure, accident, or security breach causing interruptions in our operations may lead to a material disruption in our product development programs and business operations, potentially requiring substantial resources for recovery. For instance, the loss of clinical trial data from completed trials could lead to delays in regulatory approval efforts and significantly increase costs for data recovery or reproduction.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to risks stemming from misappropriation, misuse, leakage, falsification, or intentional or accidental release or loss of information maintained in our information systems and networks, including personal</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information of our employees. External parties may attempt to penetrate our systems or induce our employees or those of our vendors to disclose sensitive information. As with other companies, we face threats to our data and systems, including malicious codes, viruses, and cyber-attacks. The increasing number and complexity of these threats over time pose a challenge. A material breach in our security or that of our vendors, contractors, or consultants could harm the market perception of our security measures, resulting in business loss and damage to our reputation and credibility. This could significantly adversely affect our business, financial condition, and results of operations, necessitating substantial amounts of money and resources to repair or replace information systems or networks. Despite our continuous efforts, the possibility of such events occurring cannot be entirely eliminated.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In our endeavor to protect systems storing critical information, we have implemented security measures. However, given their size and complexity and the increasing amounts of information maintained, these systems, including our internal information technology systems and those of third-party entities like Contract Research Organizations, Contract Manufacturing Organizations, contractors, and consultants, remain potentially vulnerable to breakdowns, interruptions, and security breaches. Incidents such as service interruptions, system malfunctions, natural disasters, terrorism, war, telecommunication, and electrical failures, as well as security breaches from inadvertent or intentional actions by employees, contractors, consultants, and other third parties, including cyber-attacks by malicious entities, may compromise our system infrastructure. This could lead to the loss, destruction, alteration, or unauthorized access to our data, including trade secrets, confidential information, intellectual property, proprietary business information, and personal information, or data processed or maintained on our behalf. Such incidents could result in financial, legal, business, and reputational harm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rise in phishing and social engineering attacks and the increase in remote working further elevate security threats. Any disruption or security incident could lead to loss, damage, or unauthorized access to data, potentially exposing us to litigation and governmental investigations, delaying the development and commercialization of our product candidates, and subjecting us to fines or penalties for noncompliance with privacy and security laws. Notifications and actions following a security incident could impact our reputation and incur significant costs, including legal expenses and remediation. Significant efforts and costs are expected for detection and prevention. Our reliance on third parties for manufacturing introduces an additional layer of risk to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insurance policies, including a specific policy related to cybersecurity losses, may be insufficient, with potential availability issues in the future, high deductibles, and limitations in coverage, posing challenges in mitigating losses from disruptions, failures, or security breaches.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If our information technology systems or data, and/or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions, interruptions to operations or clinical trials, reputational harm, litigation, fines and penalties, disruptions of our business operations, and a loss of customers or sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of our business, we, or the third parties upon which we rely, process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cyberattacks, malicious internet-based activity, online and offline fraud and other similar activities threaten the confidentiality, integrity, and availability of our sensitive data and information technology systems, and those of the third parties upon which we rely. These threats are prevalent, continue to rise, and are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; hacktivists, threat actors, personnel misconduct or error (such as through theft or misuse), organized criminal threat actors, sophisticated nation-states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We and the third parties upon which we rely are subject to a variety of evolving threats, including but not limited to, social engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunction,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fire, flood, and other similar threats.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state-supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, disruption of clinical trials or otherwise affecting our ability to provide our products or product candidates, loss of sensitive data (including data related to clinical trials) and income, significant extra expenses to restore data or systems, reputational harm and the diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments (including, for example, if applicable laws or regulations prohibit such payments). Remote work has become more common and has increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections, computers and devices outside our premises, including at home, while in transit or in public locations. Future business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies. Furthermore, we may discover security issues that were not found during due diligence of such acquired or integrated entities, and it may be difficult to integrate companies into our information technology environment and security program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts, including, without limitation, cloud-based infrastructure, drug suppliers, data center facilities, encryption and authentication technology, employee email, content delivery to customers, and other functions. Our ability to monitor these third parties&#8217; information security practices and posture (including whether any unremediated vulnerabilities exist or have been exploited) is limited, and these third parties may not have adequate information security measures in place. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties&#8217; infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate vulnerabilities in our information security systems (such as our hardware and/or software, including that of third parties upon which we rely). We and the third parties upon which may rely may not, however, detect and remediate all such vulnerabilities including on a timely basis. For example, we have identified certain vulnerabilities in our information systems, and we have taken steps to mitigate the risks associated with known vulnerabilities. These steps include implementing compensating controls and other protective measures. Further, we and the third parties upon which we rely may experience delays in developing and deploying remedial measures and patches designed to address identified vulnerabilities. Vulnerabilities could be exploited and result in a security incident.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of the previously identified or similar threats could cause a security incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information or our information technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to provide our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may expend significant resources or fundamentally change our business activities and practices (including our clinical trials) to try to protect against security incidents. Certain data privacy and security obligations may require us to implement and maintain specific security measures or industry-standard or reasonable security measures to protect our information technology systems and sensitive data.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Applicable data privacy and security obligations may require us to notify relevant stakeholders, including affected individuals, customers, regulators, and investors, of security incidents. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; diversion of management attention; interruptions in our operations (including availability of data); financial loss; and other similar harms. Security incidents and attendant consequences may prevent or cause customers to stop using our products, deter new customers from using our products, and negatively impact our ability to grow and operate our business.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to experiencing a security incident, third parties may gather, collect, or infer sensitive data about us from public sources, data brokers or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or market position. Additionally, sensitive information of the Company could be leaked, disclosed, or revealed as a result of or in connection with the use of generative AI technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, our insurance coverage may not be adequate or sufficient in type or amount to protect us from or to mitigate liabilities arising out of our privacy and security practices. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face risks related to information technology regulatory and compliance requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to an evolving landscape of data privacy and security regulations, including the General Data Protection Regulation (GDPR), Health Insurance Portability and Accountability Act (HIPAA), California Consumer Privacy Act (CCPA), SEC cybersecurity disclosure requirements, among others. Failure to comply with these regulations may result in substantial fines, litigation, regulatory investigations, and reputational harm. The complexity of maintaining compliance across multiple jurisdictions increases our operational burden, requiring continuous updates to security policies, employee training, and IT infrastructure enhancements. Additionally, new or amended privacy laws may impose additional costs and operational challenges, impacting our ability to conduct business effectively. If we or one of our third-party service providers fail to adhere to regulatory requirements, we may be subject to enforcement actions, consent decrees, or restrictions on our ability to process sensitive data, potentially delaying our product development or commercialization efforts.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our critical IT systems and data storage rely on cloud service providers. While these providers implement security controls, misconfigurations, lack of visibility into shared responsibility models, or insider threats can lead to data exposure or service disruptions. Failure to comply with evolving global data privacy and security regulations, such as GDPR, HIPAA, CCPA, SEC cybersecurity rules, and industry-specific compliance requirements (e.g., FDA 21 CFR Part 11 for regulated data), could subject us to significant fines, legal liabilities, and reputational harm.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face the risk of shadow IT and unapproved software use by employees</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Employees or contractors may use unauthorized or unapproved software, cloud services, or personal devices to access, store, or transmit company data, a practice commonly referred to as "Shadow IT". The use of such unapproved technologies increases security risks, as these applications and services may not adhere to our established cybersecurity and compliance standards. Shadow IT may introduce vulnerabilities, expose sensitive data to unauthorized parties, or lead to misconfigurations that may increase the likelihood of cyberattacks or data breaches. Additionally, unvetted third-party applications may not comply with regulatory requirements, exposing us to compliance violations and potential legal liabilities. Despite our ongoing efforts to monitor and control the use of unauthorized software, we may not be able to eliminate all instances of Shadow IT, which could materially impact our security posture, regulatory compliance, and business operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face potential product liability exposure, and, if claims are brought against us, we may incur substantial liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The use of nomlabofusp and other potential product candidates in clinical trials, if any, and the sale of nomlabofusp and other potential product candidates, if developed and approved, exposes us to the risk of product liability claims. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with nomlabofusp or other potential product candidates. For example, we may be sued if any product we develop allegedly causes injury or death or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to stop development or, if approved, limit commercialization of our product candidates. Any such product liability claims</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability and a breach of warranties. Claims could also be asserted under consumer protection acts in other jurisdictions. If we become subject to product liability claims and cannot successfully defend ourselves against them, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other things:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of patients or clinical investigators from our clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay or termination of clinical trials;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards to patients or other claimants;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for nomlabofusp or our other potential product candidates following marketing approval, if obtained;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage to our reputation and exposure to adverse publicity;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased FDA warnings on product labels;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiation of investigations by regulators or ethics committees;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls, withdrawals, or labeling, marketing or promotional restrictions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">distraction of management&#8217;s attention from our primary business;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased product liability costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to successfully commercialize nomlabofusp or other potential product candidates, if approved.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain product liability insurance coverage for our clinical trials with a $5 million aggregate coverage limit. Nevertheless, our insurance coverage may be insufficient to reimburse us for any expenses or losses we may suffer. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses, including if insurance coverage becomes increasingly expensive. If we obtain marketing approval for nomlabofusp or other potential product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may not be able to obtain this product liability insurance on commercially reasonable terms. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be substantial, particularly in light of the size of our business and financial resources. A product liability claim or series of claims brought against us could cause our stock price to decline and, if we are unsuccessful in defending such a claim or claims and the resulting judgments exceed our insurance coverage, our financial condition, business, results of operations and prospects could be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have limited experience in conducting or supervising clinical trials and must outsource all clinical trials. As a result, many important aspects of our drug development programs are outside of our direct control.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited experience in conducting or supervising clinical trials that must be performed to obtain data to submit in concert with applications for approval by the FDA, the EMA or other comparable foreign regulatory authorities. As a result, we expect to continue to rely on CROs, clinical trial sites, clinical data management organizations and consultants to design, conduct, supervise and monitor our non-clinical studies and clinical trials. We, our CROs, and contractors are required to comply with various regulations, including the FDA&#8217;s regulations regarding current Good Clinical Practices ("cGCPs") which are enforced by regulatory agencies, including the FDA, and comparable foreign regulatory authorities to ensure the health, safety and rights of patients are protected in clinical development and clinical trials, and that trial data integrity is assured. Regulatory authorities ensure compliance with these requirements through periodic inspections of trial sponsors, principal investigators and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial sites. Our expected reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. If we or any of our CROs, contractors, or clinical trial sites fail to comply with applicable requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot ensure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with such requirements. In addition, our clinical trials must be conducted with products produced under cGMP requirements, which mandate, among other things, the methods, facilities and controls used in manufacturing, processing and packaging of a drug product to ensure its safety and identity. Failure to comply with these regulations may require us to repeat non-clinical studies and/or clinical trials, which would delay the regulatory approval process, and could also subject us to enforcement action, up to and including, civil and criminal penalties, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our CROs and contractors are not our employees, and except for remedies available to us under our agreements with such CROs and contractors, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and non-clinical programs. If our CROs and contractors do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed or reduced. In addition, operations of our CROs and contractors could be affected by earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions. If their facilities are unable to operate because of an accident or incident, even for a short period of time, some or all of our research and development programs may be harmed or delayed, and our operations and financial condition could suffer.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have less direct control over the conduct, timing and completion of these clinical trials and the management of data developed through the clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on CROs and contractors does not relieve us of our regulatory responsibilities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we must, at times, share confidential information with third parties. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting agreements, or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, such as trade secrets, intellectual property, data from clinical studies and future development plans. Despite the contractual provisions employed when working with third parties, the need to share confidential information increases the risk that such confidential information become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our confidential information, a competitor&#8217;s discovery of our confidential information or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. We currently have a small number of employees, which limits the internal resources we have available to engage new third-party providers, if necessary, and monitor existing third-party providers. To the extent we are unable to engage new third-party providers, if necessary, and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with CROs, and contractors there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, results of operation and prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third-party supply and manufacturing partners for drug supplies for our research and development, non-clinical activities, and clinical activities, and may do the same for any commercial supplies of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, non-clinical and clinical study drug substance and drug product. We have not yet manufactured or formulated nomlabofusp or any other product candidate on a commercial scale and may not be able to do so for any of our product candidates. We will work to develop and optimize our manufacturing process; however, we cannot be sure that the process will result in therapies that are safe, potent or effective. Given our reliance on third parties and the risk of manufacturing commercial scale quantities, our ability to adequately commercially launch and/or supply nomlabofusp could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own manufacturing facilities or supply sources for such components, non-clinical and clinical study drug substance, product and materials, including devices that may be required for administration, but may develop these capabilities in the future. There can be no assurance that our supply of research and development, non-clinical and clinical development of drugs and other materials will not be limited, interrupted, restricted in certain geographic regions or will be of satisfactory quality or continue to be available at acceptable prices. In particular, replacement of any product formulation manufacturer we may engage could require significant effort and expertise because there may be a limited number of qualified replacements. For example, we rely and expect to continue to rely on a small number of manufacturers to supply us with our requirements for drug substance and formulated drug product related to our nomlabofusp clinical program. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for us by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. We are undertaking a program with a third party manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, we intend to use in certain of our future planned clinical trials. Our research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs. In addition, because we rely on multiple manufacturers for our nomlabofusp clinical program, termination of our agreements with any of these manufacturers could significantly adversely impact our current and planned operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that any of our suppliers or manufacturers fails to perform their obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also rely on third parties to store master and working cell banks. We currently have one master cell bank and one working cell bank for nomlabofusp and believe we would have adequate backup should any cell bank be lost in a catastrophic event. However, it is possible that we could lose multiple cell banks and have our manufacturing severely impacted by the need to replace the cell banks, which could materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may rely on third party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">manufacturing requirements could adversely affect our business, financial condition and results of operations in a number of ways, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">an inability to initiate or continue clinical trials of product candidates under development;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of the cooperation of a collaborator, including termination or nonrenewal of the agreement at a time that is costly or inconvenient for us;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in manufacturing associated with having to change manufacturers;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">subjecting our product candidates to additional inspections by regulatory authorities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to cease distribution or to recall batches of our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We and our contract manufacturers are subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for nomlabofusp, are subject to extensive regulation. Some components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA or NDA on a timely basis and where required, must adhere to the FDA&#8217;s or other regulator&#8217;s GLPs and cGMP regulations enforced by the FDA or other regulators through facilities inspection programs. The facilities and quality systems of some or all of our third party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of nomlabofusp or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of nomlabofusp or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection, the FDA or other regulatory approval of the products will not be granted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our third party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or any of our third party manufacturers fail to maintain regulatory compliance, the FDA or other regulators can impose regulatory sanctions including, among other things, refusal to approve a pending application for a biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. The number of manufacturers with the necessary manufacturing capabilities is limited. In addition, an alternative manufacturer would need to be qualified through a BLA or NDA supplement or similar regulatory submission which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These factors could also cause the delay of manufacturing development, clinical trials, regulatory submissions, required approvals or commercialization of nomlabofusp or any other product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenues. Any of the above would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in methods of product candidate manufacturing may result in additional costs and/or delays.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As product candidates progress through clinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize yield, manufacturing batch size, change drug product dosage form, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates and generate revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could materially increase our costs and potential liability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#8217; exercise of rights under the agreement. With respect to our collaboration and contract service agreements, we typically indemnify our collaborators from any third party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consulting agreements, we typically indemnify consultants from claims arising from the good faith performance of their consulting services.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Should our obligation under an indemnification provision exceed applicable insurance coverage or should we be denied insurance coverage, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds their applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">To the extent we are able to enter into collaborative arrangements or strategic alliances, we may be exposed to risks related to those collaborations and alliances.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Biotechnology companies sometimes become dependent upon collaborative arrangements or strategic alliances to complete the development and commercialization of product candidates. In seeking collaborative arrangements and strategic partners, we face significant competition from other companies as well as public and private research institutions. There can be no assurance that we will be able to enter into or maintain strategic alliances on terms favorable to us, or at all. If we elect to enter into collaborative arrangements or strategic alliances, these arrangements may place the development of our product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us, which could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dependence on collaborative arrangements or strategic alliances would subject us to a number of risks, including the risk that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to control the amount and timing of resources that our collaborators may devote to the relevant product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our collaborators may experience financial difficulties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to relinquish important rights, such as marketing and distribution rights;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business combinations or significant changes in a collaborator&#8217;s business strategy may also adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborative arrangements are often terminated or allowed to expire, which would delay the development and may increase the cost of developing our drug candidates.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property Rights</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If, in the United States and other countries, we are unable to adequately protect our proprietary technology or maintain issued patents which are sufficient to protect nomlabofusp or potential product candidates, third parties could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success will depend in part on our success in obtaining and maintaining issued patents and other intellectual property rights in the United States and elsewhere and protecting our proprietary technology. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our patent portfolio, we in-license from WFUHS a certain issued U.S. patent that relates to the use of the TAT-FXN fusion protein for treating FA. We also in-license from IU United States patents and pending non-provisional applications in the United States and certain foreign countries that relate to the composition of nomlabofusp and methods of use, and certain U.S. patents relating to materials and methods of use relating to the development of nomlabofusp. We also own or co-own pending international PCT, foreign and United States non-provisional applications, United States Patents, and United States provisional applications relating to the development of nomlabofusp, including methods of use of nomlabofusp, biomarkers and to our peptide delivery platform technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In some cases, we have only filed provisional patent applications on certain aspects of our technologies and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a non-provisional patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to both in-licensed and owned intellectual property, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot provide any assurances that any of our pending patent applications that mature into issued patents will include claims with a scope sufficient to protect nomlabofusp, or other potential product candidates. Other parties have developed technologies that may be related or competitive to our approach and may have filed or may file patent applications and may have received or may receive patents that may overlap or conflict with our patent applications, either by claiming the same methods or formulations or by claiming subject matter that could dominate our patent position. The patent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, ex parte reexamination, or inter partes review proceedings, supplemental examination and challenges in district court. Patents may be subjected to opposition, post-grant review, or comparable proceedings lodged in various foreign, both national and regional, patent offices. These proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be costly. Thus, any patents that we may own or exclusively license may not provide any protection against competitors. Furthermore, an adverse decision in an interference proceeding can result in a third party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize nomlabofusp, and other potential product candidates.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. If these developments were to occur, they could have a material adverse effect on our potential future sales.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product. Any litigation to enforce or defend our patent rights, even if we were to prevail, could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering nomlabofusp are invalidated or found unenforceable, our financial position and results of operations would be materially and adversely impacted. In addition, if a court found that valid, enforceable patents held by third parties covered nomlabofusp, our financial position and results of operations would also be materially and adversely impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect nomlabofusp or any other products or product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of our pending patent applications will issue as patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will be able to successfully develop and, if approved, commercialize nomlabofusp before our relevant patents expire;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we were the first to make the inventions covered by each of our patents and pending patent applications;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we were the first to file patent applications for these inventions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">others will not develop similar or alternative technologies that do not infringe our patents;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any of our patents will be found to ultimately be valid and enforceable;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we will develop additional proprietary technologies or product candidates that are separately patentable; or</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">that our commercial activities or products will not infringe upon the patents of others.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely upon unpatented trade secrets, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, by confidentiality agreements with our employees and consultants. We also have agreements with our employees and selected consultants that obligate them to assign their inventions to us and have non-compete agreements with some, but not all, of our consultants. It is possible that technology relevant to our business will be independently developed by a person that is not a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through such breaches or violations. Further, our trade secrets could otherwise become known or be independently discovered by our competitors. If we are unable to adequately protect our proprietary technology or maintain issued patents which are sufficient to protect nomlabofusp or potential future product candidates, third parties could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and prospects.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our key patent relating to nomlabofusp, which we license, will expire in 2040 and we will lose our ability to rely upon this patent to prevent competing products from entering the market, which may impair our ability to generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#0000ff;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have in-licensed a certain patent relating to nomlabofusp from WFUHS. The U.S. patent relating to use of the TAT-FXN fusion protein for the treatment of FA expires in 2025. When these patents expire, we will be unable to use these patents to try to block others from marketing nomlabofusp in the United States We have also in-licensed an issued United States patent and pending non-provisional patent applications in the United States and certain foreign countries relating to the composition of nomlabofusp and methods of use from IU. This United States patent will expire in 2040 at the earliest. Pending applications if issued as patents, would also expire in 2040 at the earliest. We cannot predict whether these patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. When these various patents, if issued, expire, we will be unable to use the patents to try to block others from marketing nomlabofusp in the United States.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We own a certain United States provisional application and certain United States and foreign non-provisional applications and a United States patent relating to our platform technology. The United States Patent will expire in 2041 at the earliest, and the pending applications, if issued as patents, would be expected to expire in 2041-2044. The provisional application may not be timely converted into a non-provisional application, and we cannot predict whether these provisional applications and non-provisional patent applications will issue as patents in any particular jurisdiction, or whether the claims of any issued patents will provide sufficient protection from competitors or third parties for potential product candidates. When these various patents expire, we will be unable to use the patents to try to block others from marketing products pertaining to our platform technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once our patents expire, we will be subject to competition from third parties who will be able to use the intellectual property covered by these patents, which could impair our ability to generate revenue and could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or may increase the costs of commercializing nomlabofusp or other potential product candidates, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties. We cannot ensure that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third parties.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Third parties may allege that nomlabofusp or our other potential product candidates or the use of our technologies infringes patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. Any claim relating to intellectual property infringement that is successfully asserted against us may require us to pay substantial damages, including treble damages and attorneys&#8217; fees if we are found to be willfully infringing another party&#8217;s patents, for past use of the asserted intellectual property and royalties and other consideration going forward if we are forced to take a license. In addition, we may also be required to indemnify certain of our licensors, vendors or suppliers from any damages they incur related to any infringement of any third party intellectual property by our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, if any such claim were successfully asserted against us and we could not obtain such a license, we may be forced to stop or delay developing, manufacturing, selling or otherwise commercializing nomlabofusp.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our products. Patent litigation is costly and time</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, intellectual property litigation or claims could force us to do one or more of the following:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cease developing, selling or otherwise commercializing nomlabofusp;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cease preparations or development of our other potential product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pay substantial damages for past use of the asserted intellectual property;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain a license from the holder of the asserted intellectual property, which license may not be available on reasonable terms, if at all; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in the case of trademark claims, redesign or rename the trademarks or trade names of our product candidates to avoid infringing the intellectual property rights of third parties, which may not be possible and, even if possible, could be costly and time-consuming.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business, financial condition and results of operations. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have systems in place to remind us to pay periodic maintenance fees, renewal fees, annuity fees and various other patent and application fees, and we employ an outside law firm to pay these fees. The U.S. Patent and Trademark Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ an outside law firm and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs, our competitors may be able to enter the market, which would have a material adverse effect on our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may infringe on our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of our or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing which could materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business, financial condition and results of operations could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States, which could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering our product candidate, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, e.g. opposition proceedings. Such proceedings could result in revocation or amendment of our patents in such a way that they no longer cover our product candidates or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot ensure that there is no invalidating prior act, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection would have a material adverse impact on our business, financial condition, and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries and jurisdictions throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, an April 2020 report from the Office of the United States Trade Representative identified a number of countries, including India and China, where challenges to the procurement and enforcement of patent rights have been reported. Several countries, including India and China, have been listed in the report every year since 1989. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent on licensed intellectual property for nomlabofusp. If we were to lose our rights to licensed intellectual property, we may not be able to continue developing or commercializing nomlabofusp, if approved.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have an exclusive license with WFUHS, pursuant to which we exclusively license certain patent rights relating to use of the TAT-frataxin fusion protein, on a worldwide basis. We have an exclusive license with IU, pursuant to which we exclusively license certain patent rights relating to nomlabofusp and its use for the treatment of mitochondrial diseases, on a worldwide basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our license agreements with WFUHS and IU impose, and we expect our future license agreements will impose, various development, diligence, commercialization, and other obligations on us in order to maintain the licenses. In spite of our efforts, WFUHS, IU, or a future licensor might conclude that we have materially breached our obligations under such license agreements and seek to terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. If these licenses are terminated, or if the underlying patent rights licensed thereunder fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our product candidates or of nomlabofusp. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether and the extent to which inventors are able to contest the assignment of their rights to our licensors; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the priority of invention of patented technology.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize nomlabofusp, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Some intellectual property may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our in-licensed patent rights from WFUHS were funded in part by the U.S. government and are therefore subject to certain federal regulations. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States in certain circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have not yet registered trademarks for a commercial trade name for nomlabofusp or other potential product candidates and failure to secure such registrations could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In many jurisdictions, we have not yet registered trademarks for a commercial trade name for nomlabofusp or other potential product candidates. Any future trademark applications may be rejected during trademark registration proceedings. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, the USPTO and comparable agencies in many foreign jurisdictions give third parties an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Moreover, any name we propose to use with our product candidates in the United States must be approved by the FDA, and similarly in many foreign jurisdictions regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or a foreign regulatory authority objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA or other regulatory authorities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect to rely on trademarks as one means to distinguish any of our products that are approved for marketing from the products of our competitors. Once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our drugs, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation by extending the patent terms and obtaining data exclusivity for nomlabofusp, our business may be materially harmed.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of development and FDA marketing approval of nomlabofusp or our other potential product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, (the "Hatch-Waxman Amendments"). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain a patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our ability to generate revenues, business, financial condition and results of operations could be materially adversely affected.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our proprietary rights may not adequately protect our technologies, which may adversely affect our position in the market, business, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on unpatented trade secrets, know-how, and technology, which are difficult to protect, especially in the pharmaceutical industry, where much of the information about a product must be made public during the regulatory approval process. We seek to protect trade secrets, in part, by entering into confidentiality agreements with employees, consultants and others. These parties may breach or terminate these agreements or may refuse to enter into such agreements with us, and we may not have adequate remedies for such breaches. Furthermore, these agreements may not provide meaningful protection for our trade secrets or other proprietary information or result in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effective assignment to us of intellectual property and may not provide an adequate remedy in the event of unauthorized use or disclosure of confidential information or other breaches of the agreements. Despite our efforts to protect our trade secrets, we or our board members, employees, consultants, contractors or scientific and other advisors may unintentionally or willfully disclose our proprietary information to competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to maintain trade secret protection, our competitive position may be adversely affected. Competitors may also independently discover our trade secrets. Enforcement of claims that a third party has illegally obtained and is using trade secrets is expensive, time consuming and uncertain. If our competitors independently develop equivalent knowledge, methods and know-how, we would not be able to assert our trade secrets against them and our business, financial condition and results of operations could be harmed.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in patent law in the U.S. and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The Leahy Smith America Invents Act ("the Leahy Smith Act") enacted in September 2011, brought significant changes to the U.S. patent law system. These include provisions that affect the way patent applications are prosecuted and may affect patent litigation. The United States Patent Office continues to develop and implement new regulations and procedures to govern administration of the Leahy Smith Act, and many of the substantive changes to patent law associated with the Leahy Smith Act became effective on March 16, 2013. The Leahy Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations, financial condition and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the U.S. PTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our employees&#8217; former employers.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of our employees have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we are not aware of any claims currently pending against us, we may be subject to claims that we or our employees inadvertently or otherwise used or disclosed the trade secrets or other proprietary information of our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying monetary claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to develop and commercialize nomlabofusp or our other potential product candidates, which would materially adversely affect our business, financial condition and results of operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Common Stock</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our stock price could be highly volatile, and purchasers of our common stock could incur substantial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain regulatory approvals for product candidates, and delays or failures to obtain such approvals;</span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the results of, and delays in, current, and any future, non-clinical or clinical trials of nomlabofusp or any of our future product candidates, including any delays related to a future pandemic, epidemic or outbreak of an infectious disease;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">geopolitical tension, including the potential impact of ongoing conflict between Russia and Ukraine and the current conflict in Israel and Gaza (including any escalation or expansion);</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the entry into, or termination of, key agreements, including key licensing or collaboration agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the failure of nomlabofusp or any of our future product candidates, if approved for marketing and commercialization, to achieve commercial success;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">issues in manufacturing our approved products, if any, or product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the initiation of material developments in, or conclusion of, disputes or litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcements by us or our commercial partners or competitors of new commercial products, clinical progress (or the lack thereof), significant business developments, contracts, commercial relationships, or capital commitments;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse publicity relating to our markets, including with respect to other products and potential products in such markets;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the introduction of technological innovations or new therapies competing with our potential products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the loss of key employees;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general and industry-specific economic conditions potentially affecting our research and development expenditures;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, including a global pandemic, or macroeconomic factors such as geopolitical tensions, tariffs, or the outbreak or escalation of hostilities or war; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the structure of health care payment systems;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse regulatory decisions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in investor perceptions of us or our industry;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading volume of our common stock; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">period-to-period fluctuations in our financial results.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. Therefore, there is a risk that investors may lose all or part of their investment in our securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology sector. These broad market fluctuations may also adversely affect the trading price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management&#8217;s attention and resources, which could significantly impact our profitability and reputation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We must maintain effective internal controls over financial reporting, and if we are unable to do so, the accuracy and timeliness of our financial reporting may be adversely affected, which could have a material adverse effect on our business and stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We must maintain effective internal control over financial reporting in order to accurately and timely report our results of operations and financial condition. In addition, as a public company, the Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our disclosure controls and procedures quarterly and the effectiveness of our internal control over financial reporting at the end of each fiscal year.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The rules governing the standards that must be met for our management to assess our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act are complex and require significant documentation, testing and possible remediation. These stringent standards require that our audit committee be advised and regularly updated on management&#8217;s review of internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management may not be able to effectively and timely implement controls and procedures which respond to the increased regulatory compliance and reporting requirements that are applicable to us as a public company. If we fail to staff our accounting, finance and information technology functions adequately or maintain internal control over financial reporting adequate to meet the demands that are placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act, or to otherwise prevent material weaknesses in internal control over financial reporting, our business and reputation may be harmed and our stock price may decline. Furthermore, investor perceptions of us may be adversely affected, which could cause a decline in the market price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Ownership of our common stock is highly concentrated, and it may prevent other stockholders from influencing significant corporate decisions.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entities affiliated with Deerfield Management Company beneficially own or control approximately 33.3% of our outstanding common stock (assuming no exercise of outstanding options) as of December 31, 2024, on a fully-diluted basis. Accordingly, such entities have substantial influence over the outcome of a corporate action by us requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transaction. These stockholders also may exert influence in delaying or preventing a change in control of the combined company, even if such change in control would benefit our other stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are a smaller reporting company. We cannot be certain whether the reduced disclosure requirements applicable to smaller reporting companies will make our common shares less attractive to investors or otherwise limit our ability to raise additional funds.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently a &#8220;smaller reporting company&#8221; as defined in the Exchange Act of 1934 and have elected to take advantage of certain of the scaled disclosures available to smaller reporting companies, including simplified executive compensation disclosures in our filings, exemption from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that an independent registered accounting firm provide an attestation report on the effectiveness of internal control over financial reporting and certain other decreased disclosure obligations in our SEC filings, including, among other things, only being required to provide two years of audited financial statements in annual reports. Reduced disclosure in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict whether investors will find our common stock less attractive because of our reliance on any of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions in our certificate of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders, and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law ("DGCL") which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We do not anticipate that we will pay any cash dividends in the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The current expectation is that we will retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be stockholders&#8217; sole source of gain, if any, for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our failure to meet the continued listing requirements of The Nasdaq Stock Market LLC could result in a delisting of our Common Stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to satisfy the continued listing requirements of The Nasdaq Stock Market LLC ("Nasdaq") such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair a stockholders ability to sell or purchase shares of common stock when they wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow the common stock to become listed again, stabilize the market price or improve the liquidity of the common stock, prevent the common stock from dropping below the Nasdaq minimum bid price requirement or prevent future noncompliance with Nasdaq&#8217;s listing requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial reporting obligations of being a public company in the United States are expensive and time-consuming, and our management will be required to devote substantial time to new compliance matters.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The obligations of being a public company in the United States require significant expenditures and place significant demands on our management and other personnel, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended, and the rules and regulations regarding corporate governance practices, including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act") and the listing requirements of Nasdaq on which our securities are listed. These rules require the maintenance of effective disclosure and financial controls and procedures, internal control over financial reporting and strong corporate governance practices, among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation or being delisted, among other potential problems.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional, reckless or negligent failures to comply with the regulations of the FDA and applicable non-U.S. regulators, provide accurate information to the FDA and applicable non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. Employees may also unintentionally or willfully disclose our proprietary and/or confidential information to competitors. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. In addition, we are subject to the risk that a person or government could allege fraud or other misconduct, even if none occurred. If any such actions are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy, geopolitical events and general conditions in the global financial markets. A severe or prolonged economic downturn due to geopolitical tension resulting from ongoing conflict between Russia and Ukraine and the current conflict in Israel and Gaza (including any escalation or expansion) or other factors could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, in early 2023, several financial institutions closed and were taken into receivership by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our business, financial condition or results of operations.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1bunresolvedstaffcomments_265117"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1B. UNRESOLVED STAFF COMMENTS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item1ccybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C. CYBERSECURITY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_3919e60d-1333-4f10-a0e4-f191b61d1e14" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_3919e60d-1333-4f10-a0e4-f191b61d1e14_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cyber Risk Management and Strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to manage cybersecurity risks relating to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products (Information Systems and Data).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Director of Information Technology, assisted by our managed information technology service provider and other third party service providers, leads the Company&#8217;s cybersecurity risk management processes. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods in certain contexts, including, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing threat intelligence reports and feeds, conducting scans of certain environments, and other tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage risks from cybersecurity threats to our Information Systems and Data, as applicable depending on the environment, including incident detection and response, disaster recovery/business continuity policies, network security controls and data segmentation, access controls, physical security, asset management and tracking, systems monitoring, and employee training.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of risks from cybersecurity threats are part of the Company&#8217;s overall risk management processes. Our Director of Information Technology works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab61f33f-787c-4145-82da-0e82a501810d" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14e744d5-cece-42ef-977d-d5c2a35de90d" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party service providers</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to assist us to identify, assess, and manage risks from cybersecurity threats. These third-party service providers may include threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and dark web monitoring services.</span></ix:nonNumeric></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have established a process to conduct diligence on certain third parties before engaging with those third parties, such as those that support our GxP processes, which may include a security assessment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified any cybersecurity incidents or threats that have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f26ee33-a564-4304-a0b5-c19339b8e585" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition; however, like other companies in our industry, we and our third-party vendors may, from time to time, experience threats and security incidents relating to our and our third-party vendors&#8217; information systems and infrastructure. For more information, please see our risk factors under Part 1 Item 1A. Risk Factors.</span></p><div><ix:nonNumeric id="F_fbd75ab1-d570-4397-8a4b-70ed267323da" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true" continuedAt="F_fbd75ab1-d570-4397-8a4b-70ed267323da_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d4cc33b-c36b-4bfb-8eb8-57fadbdd81e4" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors holds oversight responsibility over the Company&#8217;s cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e582ce18-5833-4dfc-be5c-63267606dc3c" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of the board of directors is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of the Company&#8217;s processes for monitoring and controlling cybersecurity risks.</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_21fc6cbf-c0ec-49ee-8803-860c55dc65fa" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><div><ix:nonNumeric id="F_896bf020-3849-46ba-9431-a64f1a35abc8" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7da98fe-37ec-4da7-8bcc-16a01d5fc9ec" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who has over 10 years of information technology management experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of Information Technology, along with management, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and communicating key priorities to relevant personnel. Management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_3919e60d-1333-4f10-a0e4-f191b61d1e14_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fbd75ab1-d570-4397-8a4b-70ed267323da_1"><div><ix:nonNumeric id="F_bd75036f-b276-48f6-ab9c-86c2ff9de130" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have processes designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5ceded3-4130-49a6-9d12-137385593e3b" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vice President Legal and Compliance, Vice President Finance and Administration, Vice President - Controller, Chief Financial Officer and Director of Information Technology</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company&#8217;s incident response policy includes a process for reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35c4cb76-ac39-4da3-941c-010c468717b4" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives reports from members of the Company&#8217;s management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them, as applicable.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></ix:continuation></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item2properties_264380"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 2. PROPERTIES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to an operating lease for approximately 3,927 square feet of laboratory space in King of Prussia, PA. We believe the lab space is sufficient for our needs for the next several years.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to an operating lease for approximately 8,104 square feet of office space in Bala Cynwyd, Pennsylvania that serves as our corporate office. We expect to increase our office space at our Bala Cynwyd Pennsylvania office in the near term by approximately 7,107 square feet to 15,211 square feet. We believe that appropriate office space will be readily available on commercially reasonable terms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are party to an operating lease for approximately 17,705 square feet of office space in Boston, Massachusetts. This lease  expires in October 2029. On October 27, 2020, we entered into a sublease agreement whereby we subleased all 17,705 square feet of office space leased under the Boston Lease until October 2029.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item3legalproceedings_49550"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 3. LEGAL PROCEEDINGS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may be subject to other legal proceedings and claims in the ordinary course of business. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us due to diversion of management time and attention as well as the financial costs related to resolving such disputes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item4minesafetydisclosures_57184"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 4. MINE SAFETY DISCLOSURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:-15.385%;padding-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="partii_672268"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item5marketforregistrantsscommonequity_9"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock is publicly traded on the Nasdaq Global Market under the symbol &#8220;LRMR.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 24, 2025, we had approximately 62 record holders of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not declared or paid any dividends since our inception nor do we expect to pay dividends in the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our equity compensation plans is incorporated by reference herein to Part III, Item 12 of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no sales of unregistered securities other than as previously disclosed by us in our Current Reports on Form 8-K as filed with the SEC.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item6selectedconsolidatedfinancialdata_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 6. [Reserved.]</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item7managementsdiscussionandanalysis_41"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> RESULTS OF OPERATIONS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with the audited consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion contains forward-looking statements based upon our current plans, expectations and beliefs that involve risks, uncertainties and assumptions. Our actual results may differ materially from those described in or implied by these forward-looking statements as a result of many factors, including those set forth under the section titled &#8220;Risk Factors&#8221; and in other parts of this Annual Report on Form 10-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ("CPP") technology platform. Our lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich's ataxia (&#8220;FA&#8221;). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to systemically increase FXN levels in patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, raising capital, developing sales and marketing capacities, and providing general and administrative support for such operations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp Program Update</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have completed two Phase 1 clinical trials and a Phase 2 dose exploration trial, and have an ongoing Phase 2 OLE trial in patients with FA and an ongoing PK run-in study in adolescent patients with FA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, we reported positive top-line data from our Phase 1 FA program after completing dosing of the single ascending dose ("SAD") trial in December 2020 and of the multiple ascending dose ("MAD") trial in March 2021. Data from these trials demonstrated proof-of-concept by showing that daily subcutaneous injections of nomlabofusp for up to 13 days resulted in dose-dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues (buccal cells, skin, and platelets). There were no serious adverse events associated with either the MAD or SAD trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we reported preliminary unblinded top-line data from the 25 mg cohort of our Phase 2 four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the FDA cleared initiation of a second cohort (50 mg) of our four-week, placebo-controlled, Phase 2 dose exploration trial of nomlabofusp in patients with FA and the initiation of our OLE trial with daily dosing of 25 mg.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we reported positive top-line data and successful completion of the Phase 2 dose exploration study. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. Patients who completed treatment in our Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, we dosed the first patient in our OLE trial, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study ("FACOMS") database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 30, 2024, we announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we received access to the Medicines and Healthcare Regulatory Agency ("MHRA") Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) for the treatment of adults and children with FA. The ILAP is facilitating patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with UK regulatory authorities and other stakeholders. Along with the receipt of the ILAP designation, nomlabofusp has already been granted orphan drug designations in the U.S. and the European Union (the &#8220;EU&#8221;), and access to the PRIME scheme in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we reported positive initial data from our ongoing OLE study. This data included safety, FXN levels, clinical, pharmacokinetic data and dose escalation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp was generally well tolerated for up to 260 days in subjects. The most common adverse events were injection site reactions, with most being mild, brief in duration, and self-limited. Two participants had serious adverse events (one seizure and one anaphylactic reaction) that resolved within 24 hours and withdrew from the study; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term 25 mg tissue FXN levels showed positive mean change from baseline of 1.32 pg/&#956;g in buccal cells and 9.28 pg/&#956;g in skin cells at Day 90 and that 25 mg of nomlabofusp increased and maintained tissue FXN levels over time, increasing from a mean level of 15% of HV at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tissue FXN levels appear to reach steady-state levels by Day 30 in buccal cells;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early clinical data showed trends toward improvement across a number of clinical outcomes for long-term 25 mg daily nomlabofusp including: (1) decreased values indicating early trends towards improvement in the Modified Friedreich Ataxia Rating Scale (mFARS) and the FARS-Activities of Daily Living ("ADL"), Modified Fatigue Impact Scale and 9 hole peg test at 90 days relative to baseline;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key pharmacokinetic data showed rapid absorption after subcutaneous administration with exposure appearing to reach steady state in plasma by day 30 with no further accumulation, which is consistent with data from our Phase 1 and Phase 2 studies.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also in December 2024, we announced that we were increasing the dose in the OLE to 50 mg of nomlabofusp daily for then currently enrolled and all future OLE study participants. In March 2025, we announced that our Safety Monitoring Team has deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp and therefore, we expect to see additional reactions. To reduce the risk of allergic reactions, including anaphylaxis, we amended the OLE protocol to administer premedication for the first month of dosing. The OLE study is ongoing with seven sites activated and participants continuing to enroll. All study participants are currently receiving the 50 mg dose of nomlabofusp. We plan to provide an update on OLE data on at least 30 to 40 study participants, some of whom have been receiving nomlabofusp for more than a year, in September 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In January 2025, we initiated dosing of adolescents (12-17 years old) in a PK run-in study for pediatric patients with FA. Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp at a weight-base dose expected to match the PK of adults receiving the 50 mg dose, or placebo, daily for seven days. Following assessment of safety and PK data, participants will be eligible to screen for the OLE study. The data from this cohort is expected to be presented during the nomlabofusp program update in September 2025.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, we announced that FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as a reasonably likely surrogate endpoint (&#8220;RLSE&#8221;) and the acceptability of FXN&#8217;s use as an RLSE would ultimately be a matter of review of the data in a future marketing application. FDA recommended focusing on assessments of skin FXN concentrations rather than buccal FXN concentrations due to more consistent sampling and less variability. FDA acknowledged that data we recently submitted appear to support a relationship between increased FXN concentrations in skin cells and relevant tissues such as the heart, dorsal root ganglion and skeletal muscle. FDA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">also acknowledged that the nonclinical studies we submitted were performed at relevant human doses. FDA also suggested that we consider exploring the relationship between increases in FXN in skin and changes in pharmacodynamic (PD) markers such as lipid profiles and/or clinical measures to provide additional support for the use of FXN as an RLSE. We plan to continue discussions with FDA regarding the adequacy of the safety data set for a BLA submission seeking accelerated approval targeted for year-end 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have obtained feedback from both FDA and EMA on the global Phase 3 study protocol and we are on track to initiate the study by mid-2025 with potential sites in the U.S., E.U., U.K, Canada, and Australia.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing Activities, Including Recent Material Financings</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have funded our operations to date primarily with proceeds from sales of common stock, proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents, marketable securities and restricted cash upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we completed an underwritten public offering in which we issued and sold 19,736,842 shares of our common stock at a public offering price of $8.74 per share. We received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we entered into a Sales Agreement (the "ATM Agreement") with Guggenheim Securities, LLC in connection with the establishment of an &#8220;at-the-market&#8221; offering program providing for the sale of up to an aggregate of $100 million of shares of our common stock from time to time. To date, we have made no sales under the ATM agreement.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles ("GAAP"). The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amount of assets, liabilities, costs and expenses, and related disclosures. We believe that the estimates and assumptions involved in the accounting policies described below may have the greatest potential impact on our consolidated financial statements and, therefore, consider these to be our critical accounting policies. We evaluate these estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs for certain research and development activities, such as manufacturing, non-clinical studies and clinical trials are generally recognized based on the evaluation of the progress of completion of specific tasks using information and data provided by our vendors and collaborators, and accordingly, are considered an area of significant judgment and management&#8217;s review of manufacturing, non-clinical and clinical expenses. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. We work with vendors and suppliers to ensure that our estimates of our research and development expenses are reasonable. We expect to increase our investment in research and development in order to advance nomlabofusp through additional clinical trials. As a result, we expect that our research and development expenses will continue to increase in the foreseeable future as we pursue clinical development of nomlabofusp and/or any other product candidates we develop.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Compensation Expense</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of highly subjective assumptions which determine the fair value of stock-based awards. The assumptions used in our option-pricing model represent management&#8217;s best estimates. These estimates are complex, involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, and thus are inherently subjective. If factors change and different assumptions are used, our stock-based compensation expense could be materially different in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to May 28, 2020, we were a private company and lacked company-specific historical and implied volatility information for our common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies with comparable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">characteristics including enterprise value, risk profiles and position within the industry. Beginning on January 1, 2023, the Company began blending its historical data starting in June 2020 (following its merger with Zafgen in 2020) with its historical peer group. We regularly evaluate our peer group to assess changes in circumstances where identified companies may no longer be similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation. We expect to continue to do so until we have full historical data regarding the volatility of our own traded stock price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The expected term of our stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that we have never paid cash dividends on common stock and do not expect to pay any cash dividends in the foreseeable future.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. Typically, we issue awards with only service-based vesting conditions and record the expense for these awards using the straight-line method. We account for forfeitures as they occur.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We classify stock-based compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Operations Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not generated any revenue from product sales, and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts result in clinical success and regulatory approval or collaboration agreements with third parties for our product candidates, we may generate revenue from those product candidates or collaborations.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The majority of our operating expenses since inception have consisted primarily of research and development activities, and general and administrative costs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses, which consist primarily of costs associated with our product research and development efforts, are expensed as incurred. Research and development expenses consist primarily of:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party contract costs relating to research, formulation, manufacturing, non-clinical studies and clinical trial activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">employee related costs, including salaries, benefits and stock-based compensation expenses for employees engaged in scientific research and development functions;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">external costs of outside consultants and vendors;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">payments made under our third-party licensing agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sponsored research agreements;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">laboratory consumables; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocated facility-related costs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the clinical and commercial development of nomlabofusp, or any other product candidates we develop. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product candidates. The duration, costs, and timing of clinical trials and development of nomlabofusp or any other product candidates we develop will depend on a variety of factors, including:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, rate of progress and expense of clinical trials and other research and development activities;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trial results; </span></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">uncertainties in clinical trial enrollment rate or design;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant and changing government regulation;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing and receipt of any regulatory approvals;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the influence of the FDA or other regulatory authorities on our clinical trial design and timing;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing manufacturing capabilities or making arrangements with third-party manufacturers and risk involved with development of manufacturing processes, FDA pre-approval inspection practices and successful completion of manufacturing batches for clinical development and other regulatory purposes;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patent and trade secret protection and regulatory exclusivity for our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit and retain key research and development personnel.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A change in the outcome of one or more of these variables with respect to the development of a product candidate could significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct additional non-clinical or clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses consist primarily of personnel costs, consisting of salaries, related benefits and stock-based compensation, costs related to our executive, finance, information technology, and costs related to other administrative functions. General and administrative expenses also include insurance expenses and professional fees for auditing, tax, and legal services, including legal expenses to pursue patent protection for our intellectual property. We expect that our general and administrative expenses will increase in the foreseeable future as we hire additional employees to implement, improve and scale our operational, financial, commercial and management systems.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following commentary is a discussion and analysis of our financial condition as of December 31, 2024 and results of operations and cash flows for the year ended December 31, 2024 compared to the year ended December 31, 2023 and should be read in conjunction with the consolidated financial statements and accompanying notes.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comparison of the years ended December 31, 2024 and 2023</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2024 and 2023:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.552%;box-sizing:content-box;"/>
    <td style="width:1.26%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.842%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.862%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.28%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.922%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Decrease)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Statement of Operations Data:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,278</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27,670</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,608</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,612</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,088</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,524</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90,890</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,758</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49,132</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(90,890</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,758</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(49,132</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,286</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,809</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,477</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(80,604</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(36,949</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(43,655</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses for the twelve months ended December 31, 2024 increased $45.6 million compared to the twelve months ended December 31, 2023 due to continued and increased clinical development of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">nomlabofusp and related regulatory and bioanalysis. The increase in research and development expenses was primarily driven by an increase of $36.1 million in nomlabofusp manufacturing costs including production scale-up, costs and manufacturing costs related to producing drug product doses to be used in ongoing and planned clinical trials, an increase of $4.5 million in personnel expense due to increased clinical, regulatory, quality and manufacturing headcount, an increase of $1.3 million of professional fees related to regulatory, quality, medical, and clinical consulting costs, an increase of $1.2 million in clinical costs primarily associated with the OLE study which began dosing patients in the first quarter of 2024, an increase of $1.0 million in stock compensation costs associated with the incremental 2024 grants for existing and new employees, an increase of $0.9 million related to our participation in the Friedreich&#8217;s Ataxia Research Alliance's ("FARA's") TRACK-FA Neuroimaging Consortium conducting a natural history study designed to establish disease-specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials, an increase of $0.3 million in internal lab costs related primarily to gene expression and lipid studies and an increase of $0.2 million in facility costs associated with the new lab space.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">General and administrative expenses</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General and administrative expenses for the twelve months ended December 31, 2024 increased $3.5 million compared to the twelve months ended December 31, 2023. The increase in general and administrative expenses was primarily driven by an increase of $1.5 million in professional fees primarily related to consulting costs related to commercial activity and other public company related expenses, an increase of $1.4 million in personnel expense due to increased headcount, an increase of $0.4 million of other expense related to computer software, information technology services and recruiting and an increase of $0.2 million in stock compensation costs associated with 2024 grants to existing and new employee grants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other income, net</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other income, net was $10.3 million of income in the twelve months ended December 31, 2024 compared to $4.8 million in the twelve months ended December 31, 2023. The increase primarily relates to interest income on a higher investment base and higher investment yields on that base during the current period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have not generated any revenue from any sources, including from product sales, and have incurred significant operating losses and negative cash flows from our operations. We have devoted substantially all of our resources to developing nomlabofusp, building our intellectual property portfolio, developing third-party manufacturing capabilities, business planning, capital raising, and providing general and administrative support for such operations.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our sources and uses of cash for each of the periods presented below:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.033%;box-sizing:content-box;"/>
    <td style="width:1.5%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.963000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.52%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.983%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(70,760</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(33,459</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(85,387</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,353</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161,883</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,736</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(76</span></p></td>
    <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net cash used in operating activities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, net operating activities used $70.8 million of cash, resulting from our net loss of $80.6 million, adjusted for noncash expenses of $3.7 million, and changes in our operating assets and liabilities provided cash of $6.2 million. Our net loss was attributed to operating expenses of $90.9 million, offset by other income (net) of $10.3 million. The change in operating assets and liabilities was primarily due to an increase in accounts payable, an increase in accrued expenses and offset by an increase in prepaid assets, all associated with increasing expenditures and development activity.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, operating activities used $33.5 million of cash, resulting from our net loss of $36.9 million, adjusted for noncash expenses of $6.0 million, and changes in our operating assets and liabilities resulting in a use of cash of $2.5 million. Our net loss was attributed to operating expenses of $41.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, offset by other income (net) of $4.8 million. The change in operating assets and liabilities was primarily due to a decrease in accounts payable and accrued expenses and an increase in prepaid assets.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, investing activities used $85.4 million of net cash, resulting from purchases of $227.9 million in marketable securities, which was offset by $143.0 million of maturities and sales of marketable securities.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, investing activities provided $33.4 million of net cash, resulting from $134.8 million of maturities and sales of marketable securities, which was offset by purchases of $101.2 million in marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, financing activities provided $161.9 million of cash primarily from an offering of common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2023, financing activities provided less than $0.1 million of cash from the exercise of stock options and warrants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Capital Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not yet commercialized any products and do not expect to generate revenue from the commercial sale of any products for several years, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have to date incurred net losses. We incurred net losses of approximately $80.6 million and $36.9 million for the twelve months ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $269.2 million and a cash, cash equivalents and marketable securities balance of $183.5 million, excluding restricted cash of $0.6 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Losses have resulted principally from costs incurred in connection with research and development activities, and general and administrative costs associated with the development of nomlabofusp and our operations. We expect to incur significant expenses and operating losses for the foreseeable future as we expect to continue to incur expenses in connection with our ongoing activities, if and as we:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">continue to advance the development of nomlabofusp through additional clinical trials, including related manufacturing costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to identify and advance development of additional product candidates into clinical development and identify additional indications for our product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seek to obtain regulatory approvals for nomlabofusp and other potential product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">identify, acquire or in-license other product candidates and technologies;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">maintain, leverage and expand our intellectual property portfolio; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">expand our operational, financial, commercial and management systems and personnel, including personnel to support our clinical development and future commercialization efforts and our operations as a public company.</span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, we completed an underwritten public offering in which we issued and sold 19,736,842 shares of our common stock and received net proceeds of approximately $161.8 million after deducting underwriting discounts, commissions and other offering expenses. We anticipate that our current cash, cash equivalents and marketable securities will fund operations into the second quarter of 2026. If we encounter unexpected delays in our clinical trials or if there are other unanticipated changes to our operating plan from our current assumptions that negatively impact our operations, we may reduce expenditures in order to further extend our existing cash resources. Until we can generate substantial revenue, if ever, we expect to seek additional funding through a combination of public or private equity offerings, debt/royalty financings, collaborations, strategic alliances and licensing arrangements or other sources. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, minimum cash balances, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or we do not have sufficient authorized shares, we may be required to delay, limit, or eliminate the development of business opportunities and our ability to achieve our business objectives, our competitiveness, and our business, financial condition, and results of operations will be materially adversely affected. We could also be required to seek funds through arrangements with collaborative partners, strategic alliances or otherwise at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits, as well as the potential impact of health crises on the global financial markets may reduce our ability to access capital, which could negatively affect our liquidity and ability to continue as a going concern.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain sufficient funding when needed and/or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion and/or pre commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. Certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Please read Note 2 to our audited consolidated financial statements included in Part IV, Item 15, of this Annual Report for a description of recent accounting pronouncements applicable to our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other Company Information</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item7aquantitativeandqualitativedisclosu"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not
 required to provide the information required under this item.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item8financialstatementsandsupplementary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audited consolidated financial statements and the report of our independent registered public accounting firm are included in this Annual Report on Form 10-K on the pages indicated in Part IV, Item 15.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9changesinanddisagreementswithaccoun"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9acontrolsandprocedures_737107"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9A. CONTROLS AND PROCEDURES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain &#8220;disclosure controls and procedures,&#8221; as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and our principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to the year ended December 31, 2024, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of December 31, 2024 to provide reasonable assurance that the information required to be disclosed by us in this Annual Report was (a) reported within the time periods specified by SEC rules and regulations and (b) communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding any required disclosure.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under that framework, our management concluded that our internal control over financial reporting was effective as of December 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9botherinformation_654168"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9B. OTHER INFORMATION</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a) None.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b) During the fourth quarter of the fiscal year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7db3b5aa-1304-423e-86b0-c2ce1a0d4c73" contextRef="C_791bdce5-955d-4624-ac03-8deed77c6490" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_877d2a6f-1893-4b93-833a-b57981a77d8e" contextRef="C_791bdce5-955d-4624-ac03-8deed77c6490" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f5d6938d-567e-45a1-84e0-c2b5fb659d1c" contextRef="C_791bdce5-955d-4624-ac03-8deed77c6490" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_5af7aee8-c290-48ea-a8e8-5d291002aa62" contextRef="C_791bdce5-955d-4624-ac03-8deed77c6490" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">no</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> director or &#8220;officer&#8221; as defined in Rule 16a-1(f) under the Exchange Act adopted or terminated any Rule 10b5-1 trading plan or arrangements or any non-Rule 10b5-1 trading plan or arrangements, in both cases as defined in Item 408(a) of Regulation S-K.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item9cforeignjurisdictions"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="partiii_936646"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item10directorsexecutiveofficersandcorpo"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 10.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 10 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2025 annual meeting of stockholders.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96a22d8b-91ba-46ed-8d11-efdd9c1d0952" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> insider trading policies and procedures governing the purchase, sale, and other dispositions of our securities by directors, officers, and employees that we believe are reasonably designed to promote compliance with insider trading laws, rules and regulations, and applicable Nasdaq listing standards. Our insider trading policy states, among other things, that our directors, officers, and employees are prohibited from trading in such securities while in possession of material, nonpublic information. The foregoing summary of our insider trading policies and procedures does not purport to be complete and is qualified by reference to our Insider Trading Policy filed as an exhibit to this Annual Report on Form 10-K. In addition, with regard to trading in our own securities, it is our policy to comply with the federal securities laws and the applicable exchange listing requirements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item11executivecompensation_214372"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 11.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXECUTIVE COMPENSATION</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 11 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2025 annual meeting of stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item12securityownershipofcertainbenefici"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 12 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2025 annual meeting of stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item13certainrelationshipsandrelatedtran"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 13 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2025 annual meeting of stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item14principalaccountingfeesandservices"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent accounting firm is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0830f69-9d78-4f43-889f-799f00891c68" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a64bc75f-5ea5-4d9a-b3b7-bccaacc8766a" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Philadelphia, Pennsylvania, USA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, PCAOB Auditor ID: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_985b56aa-e227-4004-ab11-f2c32f8790ec" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:AuditorFirmId"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">238</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by Item 14 of Form 10-K is incorporated by reference to the information contained in our definitive proxy statement for the 2025 annual meeting of stockholders.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="partiv_994849"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item15exhibitsfinancialstatementschedule"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 15.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See Index to the Consolidated Financial Statements on page F-1 of this Annual Report.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Financial Statement Schedules</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None, as all information required in these schedules is included in the Notes to the Consolidated Financial Statements.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Exhibits</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reference is made to the Exhibit Index below for a list of exhibits required by Item 601 of Regulation S-K to be filed as part of this Annual Report.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following exhibits are being filed herewith:</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibit_index"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> INDEX</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">* Filed Herewith</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+ Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"># Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x5E; Certain schedules, annexes or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K, but will be furnished supplementally to the SEC upon request.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">** Furnished herewith. This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;text-indent:7.2pt;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:center;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312519316828/d845901dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger, dated as of December 17, 2019, by and among Zafgen, Inc., Chondrial Therapeutics, Inc., Chondrial Therapeutics Holdings, LLC, and Zordich Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 of the Company&#8217;s Current Report on Form 8-K filed on December 18, 2019).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520065288/d846972dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to Agreement and Plan of Merger, dated as of March 6, 2020, by and among Zafgen, Inc., Chondrial Therapeutics, Inc., Chondrial Therapeutics Holdings, LLC, and Zordich Merger Sub, Inc. (incorporated by reference to Exhibit 2.1 of the Company&#8217;s Current Report on Form 8-K filed on March 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312514247362/d747935dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Ninth Amend</span><span style="color:#0000cc;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">ed </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">and Restated Certificate of Incorporation of Larimar Therapeutics, Inc. (formerly known as Zafgen, Inc.) (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 24, 2014).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520157924/d936040dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Zafgen, Inc. related to the Reverse Stock Split, dated May 28, 2020 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520157924/d936040dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Zafgen, Inc. related to the Name Change, dated May 28, 2020 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000095017024093733/lrmr-ex3_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Larimar Therapeutics, Inc., dated May 31, 2024 (incorporated by reference to Exhibit 3.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 8, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312514247362/d747935dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated By-laws of Larimar Therapeutics, Inc. (formerly known as Zafgen, Inc.) (incorporated by reference to Exhibit 3.2 of the Company&#8217;s Current Report on Form 8-K filed on June 24, 2014).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459021011003/lrmr-ex42_407.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of the Company&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.2 of the Company&#8217;s Annual Report on Form 10-K filed March 4, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520257168/d887315dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Larimar Therapeutics, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on September 29, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520257168/d887315dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Larimar Therapeutics, Inc. Form of Stock Option Grant Notice and Award Agreement under its 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed on September 29, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000095017024031529/lrmr-ex10_3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Restricted Stock Award Agreement for Company Employees under the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K filed on March 14, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000095017024031529/lrmr-ex10_4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-Qualified Stock Option Grant Notice and Award Agreement (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Annual Report on Form 10-K filed on March 14, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000095017025009196/lrmr-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Performance-Based Restricted Stock Unit Award Agreement under the<br/>Larimar Therapeutics, Inc. 2020 Equity Incentive Plan (incorporated by reference to<br/>Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 27, 2025).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520157924/d936040dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated as of June 1, 2020, by and among the Company and certain Investors (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520181162/d926045dex103.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Registration Rights Agreement, dated as of June 8, 2020, by and among the Company and certain Investors (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Registration Statement on Form S-3 filed on June 26, 2020).</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520157924/d936040dex103.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Indemnification Agreement between the Company and its directors (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520211426/d82303dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated July 31, 2020, by and between the Company and Carole Ben-Maimon (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on August 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520157924/d936040dex104.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated June 1, 2020, by and between the Company and Michael Celano (incorporated by reference to Exhibit 10.4 of the Company&#8217;s Current Report on Form 8-K filed on June 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1374690/000119312523026958/d399840d8k.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement, dated February 7, 2023, by and between the Company and Gopi Shankar (incorporated by reference to Exhibit 10.10 of the Company&#8217;s Annual Report on Form 10-K filed on March 14, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000095017023041293/lrmr-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employment Agreement dated May 23, 2023, by and between the Company and Russell Clayton (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2023).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13#</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex106_306.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of November 30, 2016. (incorporated by reference to Exhibit 10.6 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14#</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex107_305.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment 1 to License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of November 28, 2017 (incorporated by reference to Exhibit 10.7 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15#</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex108_304.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment 2 to License Agreement, by and between the Company and Wake Forest University Health Sciences, effective as of March 29, 2019 (incorporated by reference to Exhibit 10.8 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16#</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex109_303.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">License Agreement, by and between the Company and Indiana University Research and Technology Corporation, effective as of November 30, 2016 (incorporated by reference to Exhibit 10.9 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17#</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459020040314/lrmr-ex1010_302.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to License Agreement, by and between the Company, the Trustee of Indiana University and Indiana University Research and Technology Corporation, effective as of August 16, 2019 (incorporated by reference to Exhibit 10.10 of the Company&#8217;s Quarterly Report on Form 10-Q filed on August 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000095017022016917/lrmr-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to License Agreement, by and between the Company and The Trustees of Indiana University, effective as of May 28, 2020 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000095017022016917/lrmr-ex10_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to License Agreement, by and between the Company and The Trustees of Indiana University, effective as of June 9, 2022 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 11, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000119312520181158/d913803dex45.htm"><span style="color:#0000ee;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notice of Substitute Option Grant between the Company and a certain Optionee (incorporated by reference to Exhibit 4.5 of the Company&#8217;s Registration Statement on Form S-8 filed on June 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000095017024031529/lrmr-ex10_20.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Lease, dated as of August 8, 2019, by and between Larimar Therapeutics, Inc. and Bala Plaza Property, Inc. (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Form 10-K filed on March 14, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000095017024031529/lrmr-ex10_21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Lease, dated as of March 9, 2023, by and between the Company and Bala Plaza Property, Inc. (incorporated by reference to Exhibit 10.21 to the Company&#8217;s Form 10-K filed on March 14, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">10.23</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000156459019018086/zfgn-ex104_74.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Commercial Lease by and between the Company and Shigo Center Plaza Owner, LLC dated as of February 12, 2019 (incorporated herein by reference to Exhibit 10.4 of the Registrant&#8217;s Form 10-Q filed on May 9, 2019)</span></a><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">10.24</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000119312520282731/d37391dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sublease, dated October 27, 2020 by and between the Company and Massachusetts Municipal Association, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on October 30, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">10.25</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000156459021026084/lrmr-ex101_148.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Master Services Agreement, dated as of September 20, 2017, by and between the Company and KBI Biopharma, Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">10.26</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000156459021026084/lrmr-ex102_147.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to Master Services Agreement, dated as of November 9, 2018, by and between the Company and KBI Biopharma, Inc. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">10.27</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">+</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1374690/000095017023007855/lrmr-ex10_23.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Master Services Agreement, dated as of September 20, 2022, by and between the Company and KBI Biopharma, Inc. (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Form 10-K filed on March 14, 2023)</span></a></p></td>
   </tr>
  </table>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:89%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000095017024056965/lrmr-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Sales Agreement, dated as of May 9, 2024, by and between the Company and Guggenheim Securities, LLC (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 9, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.1*&#x5E;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex19_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Insider Trading Policy.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Subsidiaries of Larimar Therapeutics, Inc.</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Rule 13a-14(a)/15d-14(a) certification of Principal Executive Officer.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2*</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="lrmr-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Rule 13a-14(a)/15d-14(a) certification of Principal Financial Officer.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.1**</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="lrmr-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Section 1350 certification of the Principal Executive Officer and Principal Financial Officer, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97.1</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001374690/000095017024031529/lrmr-ex97_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Larimar Therapeutics. Inc.&#8217;s Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the Company's Form 10-K filed on March 14, 2024.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_16_form_10k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 16. Form </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K Summary</span></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span><span id="signatures_181481"></span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"/>
    <td style="width:3.78%;box-sizing:content-box;"/>
    <td style="width:46.22%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:0;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:0;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:0;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Carole S. Ben-Maimon, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name: Carole S. Ben-Maimon, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title: President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:0.046%;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.14%;box-sizing:content-box;"/>
    <td style="width:2.7%;box-sizing:content-box;"/>
    <td style="width:40.48%;box-sizing:content-box;"/>
    <td style="width:2.7%;box-sizing:content-box;"/>
    <td style="width:20.98%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Carole S. Ben-Maimon, M.D.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President, Chief Executive Officer and Director (principal executive officer)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carole S. Ben-Maimon, M.D.</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Celano</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer<br/>(principal financial and accounting officer)</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Celano</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Joseph Truitt</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman, Board of Directors</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Joseph Truitt</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Thomas E. Hamilton</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thomas E. Hamilton</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jonathan Leff</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jonathan Leff</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Jeffrey W. Sherman, M.D., FACP</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jeffrey W. Sherman, M.D., FACP</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Frank E. Thomas</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td rowspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 24, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.007in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Frank E. Thomas</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.94%;box-sizing:content-box;"/>
    <td style="width:6.06%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID </span><span><ix:nonNumeric id="F_29bfa366-7d14-457b-9b90-3a343a24b305" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">238</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_change"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Changes in Stockholders Equity for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</span></a></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_condensed_consolidated_financia"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="report_independent_registered_public_acc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Board of Directors and Stockholders of Larimar Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11b81838-f2ec-4f39-a409-97c41bc3d814" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Larimar Therapeutics, Inc. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, of changes in stockholders&#8217; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Emphasis of Matter</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in Note 1 to the consolidated financial statements, the Company will require additional financing to fund future operations. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans to mitigate this matter are also described in Note 1.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matters</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accrued Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As described in Notes 2 and 6 to the consolidated financial statements, the Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers. Within accrued expenses, total accrued research and development expenses amounted to $17.1 million as of December 31, 2024. Management&#8217;s process involves reviewing open contracts and purchase orders, communicating with personnel and outside vendors to identify</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">services that have been performed, and estimating the level of service performed and the associated costs incurred for the services when invoices or other notification of actual costs have not been received.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The principal considerations for our determination that performing procedures relating to accrued research and development expenses is a critical audit matter are (i) the significant judgment by management in developing the estimates of accrued research and development expenses and (ii) a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating audit evidence for these accrued research and development expenses related to management&#8217;s estimates of the level of service performed and the associated costs incurred for the services when invoices or other notification of actual costs have not yet been received.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures also included, among others; (i) testing management&#8217;s process for estimating accrued research and development expenses; (ii) evaluating the appropriateness of the method used by management to develop the estimate; (iii) testing the completeness and accuracy of the data used by management to develop the estimates related to the level of service performed and the associated costs incurred for the services when invoices or other notification of actual costs have not yet been received; (iv) evaluating the reasonableness of the estimated costs incurred for the services which have not been invoiced or other notification of actual costs have not yet been received, on a sample basis, by tracing to underlying supporting documentation, such as underlying contracts, invoices and information received from certain third party service vendors, where applicable, and; (v) testing a selection of invoices received by the Company subsequent to December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ PricewaterhouseCoopers LLP</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Philadelphia, Pennsylvania</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 24, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2020.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDAT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ED BALANCE SHEETS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c301ca0-cabb-4b02-9e3f-f818d1e904d6" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,218</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47281a5f-7791-4a7d-9996-9a576aba5ea9" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,749</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a081653-2f00-424b-adf6-c573cfb77c6b" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,236</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c87ee92a-fe18-4fad-ae16-e1b12a9f55c9" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,041</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff6a9af7-cee7-424b-ad2f-56b37869b6fe" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,850</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d148ce1-793a-4bb4-a1a2-9b616fe8ecf8" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,385</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_965b21e9-fff2-4619-9303-122979313bd3" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">195,304</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00779eb0-05e0-46ad-9aef-30d5d1f7d6c3" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,175</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e8905bf-82e0-466e-b15b-e074caef0008" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">881</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_163c1827-0d69-49a2-9db2-9119ff014fff" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a033f9ee-0724-4833-ba91-9097ae5f74eb" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,838</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acdc26e3-773a-434c-b766-ad25439c96e8" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,078</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4d3463f-b347-4793-a74b-a7099f5c5518" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">606</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ec565f8-8781-4f52-a7a6-bb632f66a57a" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,339</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63624bf7-2a10-407e-a798-ea378dfc7e57" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">596</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_676186df-55ab-4faa-8a9b-be7058667e74" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">659</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91bd9daa-e3c7-436f-8c3d-30f5d884fe2f" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,225</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ead6db1d-fbf1-4239-be44-4dab558013a2" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,935</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aac5e54-e47c-4426-91d2-58e750b07c5a" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,424</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a73e1fb-2472-4ceb-849d-f0ef8cb0ac9f" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,283</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b6f7729-a562-446b-b103-fd670bef8c6d" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,872</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b67bba8d-023c-4250-8939-067801d70e17" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,386</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fb79ec3-d36f-4665-8873-8f5d1d709abb" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,060</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b998ae3b-af89-4def-a2e4-2a96e0ae984a" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">837</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f12d967-02bc-45e5-80ed-22a95fbfdb5c" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,356</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6775aef-15ee-4f0d-9520-42126f710177" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,506</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48b6969e-a2ab-4133-810f-338e83399ae1" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,057</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed18227a-d2b4-4658-acbb-4677d202a1d2" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,709</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a6cb1ab-3e60-43f2-9d58-748dbdcb59d1" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,413</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8af1a1c-25d5-4e6b-b2cb-938d78592c7e" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,215</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_bbd44322-5ac7-4240-84a9-fa6345eb0ea1;"><span style="-sec-ix-hidden:F_271b7562-2770-4053-8b6a-b815a279d5b4;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (See Note 8)</span></span></span></span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock; $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9349a457-b88b-4b6d-a25f-473c068db78b" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_90dc5f58-624d-4718-87c7-d4357005d966" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e54fdf24-29c1-477b-82e0-eab9e0bc010b" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b950f0da-6ce8-4ebd-9998-4af0b7958b3c" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized<br/>&#160;&#160;&#160;as of December 31, 2024 and December 31, 2023; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feb54f7a-d6b1-4f26-b932-d6c19b0dc355" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_689c44d2-c96b-40f9-98f1-5f12a15abd5c" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_42029bbf-5e92-4722-b876-c2b1e81afcd4" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2859acc8-2287-42e2-9808-6ce26b0e20e3" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and<br/>&#160;&#160;&#160;outstanding as of December 31, 2024 and December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_8b10b1a7-f362-40fe-8916-abb51d917633;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="-sec-ix-hidden:F_f1c56ae0-d4be-4ff1-8d60-2cb57f25fa2a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></span></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b11371a-940a-4e4d-9945-9c3b330b756c" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_311f4dcb-777f-4862-90d8-4560970aa1d6" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value per share; </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efc93f66-cda6-44fe-9bf9-e806a53d9b0a" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d48e582d-7dfb-4699-8999-5e09f605d6fe" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">115,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;authorized as of December 31, 2024 and December 31, 2023; <br/>&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2624b7a6-bca7-41a8-a406-1c1ffa42146a" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d3529f1b-27ab-448e-81de-0dde47671640" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,815,065</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2095d81d-021b-45f6-a8e2-15728a39c2b8" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3dcffadd-a46c-4c9e-9e7d-ac6eb7e3065d" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,909,069</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding as of <br/>&#160;&#160;&#160;December 31, 2024 and December 31, 2023, respectively</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c47aa97d-651e-44d2-917a-5ecb725e35d5" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7e1fe52-0c0c-4ae3-bf65-aa1927a4145b" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d4b7442-7a16-4a88-ba31-2ad1732b5439" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">440,758</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bdb536b-4900-4890-b997-3af885c64213" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,150</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f7b891a-d8cd-4b70-9ea5-bb9a695f90e0" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">269,158</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a4914f0-42c5-4e57-9282-4e0e87104d3d" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">188,554</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated other comprehensive gain</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c62e8a9-cea3-4fb7-90fe-1456b7e822d5" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_764653ac-f859-4be1-aae2-3de1b2c34e26" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77b49b3b-83de-4d12-a331-abbaf9c52603" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171,812</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a45b402f-2099-46af-9370-af2ad6b3077e" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,720</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e931512-c9ca-4665-a8fd-d40970e2d67e" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,225</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cb872b1-990b-4cf7-a130-ecb765132329" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,935</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_operat"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> OPERATIONS AND COMPREHENSIVE LOSS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.62%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:12.883000000000001%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2a09208-2e86-47e5-8cca-2fd65719864c" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,278</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b29d16fb-1e97-4f1f-941a-fc9d7668412e" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,670</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70581d76-6ef6-49d6-996a-d10de1d9a329" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,612</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5c7d88e-2ec5-4aff-aa85-a8273e6e1b5a" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_061fcbaf-5487-4c2d-b425-61af5ca445ad" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,890</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c91a24cf-2863-4f7d-a8cf-edb2813d097d" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,758</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9e4740f-4809-4f2c-8b07-239a0c13cb18" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">90,890</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3386eb88-9037-4a48-8270-f24688f29d59" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,758</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3a7c346-349b-4697-860e-1545be29238b" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,286</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_486fbadd-93c4-48ff-bac5-2786aa0135f3" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,809</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_545851e1-9907-41fd-be62-0602b606972b" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1aa49fe-4ec6-4cea-a25e-0e582a309c4e" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss per share, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3540d1fd-9f06-435c-844b-33455b985d3f" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_4e0485eb-cec3-4c0d-b5bf-fde588820442" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.32</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4b012bd-b96e-4cfc-8a27-a59ad00c0276" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_905ee4af-f837-480c-b6be-49e78de9d93d" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.84</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63d1d18c-bd61-47f4-bef6-51ba49f0f85f" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d76bf5cc-f2e9-40e7-ab1e-0226be141ac9" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">61,256,084</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bd96eb7-0fce-4756-a5d7-515ef6307968" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9490a0ff-8462-4852-8ce6-0b3d9155c2e7" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,901,241</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Comprehensive loss:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fca5a8f3-2262-4053-a802-a0a8b14d4344" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d3020a8-bdc1-42c7-857e-9aeb5dc3032d" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0a24fb8-5712-416d-a380-d7766af6a011" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cf6c1f1-72c8-4586-8155-8806a8bb2e1b" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other comprehensive gain</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e584dbe-ab49-4ce2-89e8-548fff912126" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_637502b5-fdb7-4b38-b8e1-3d6a6993e83b" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3449a0b9-ee2f-46a0-89bc-1bb427bc72a7" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,537</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0cf3a58-21c1-4a11-baac-258261996886" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,837</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_change"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS O</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F CHANGES IN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except share data)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.328%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.961%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Par Value</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eeb898e3-2c48-48cd-8e37-f386b6bc9ce9" contextRef="C_c3a77d44-ca39-48a6-af59-4ea835940adf" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,909,069</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d69095b7-07a5-47c7-b4c5-ec70a23bfd27" contextRef="C_c3a77d44-ca39-48a6-af59-4ea835940adf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f1c25ee-8171-4c87-ad43-49105ee06135" contextRef="C_f10a217c-c7c4-4985-8b2d-21543f8fe157" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,150</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_020a4247-e1d2-42d1-a2d0-6f61e2a031ad" contextRef="C_3ddcccac-7c80-4352-b875-b59deec51ca1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">188,554</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3b2862a-6581-45fa-b035-d66e4ce9844b" contextRef="C_b89973be-3872-4363-9f3c-168e09a8a5a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14129381-8c24-48c2-ba20-77d5e03b186b" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,720</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Issuance of common stock, net</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af44b008-868b-4f8f-8be7-cd97fb0d9e6c" contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,736,842</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65846680-6080-46da-8c48-26ed9aaf675e" contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f17a4ad-4677-4932-aa3c-5f1056a043b6" contextRef="C_41039f45-bcfe-4b0a-a6c8-f525353e3235" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_adf01f88-ad49-4cc7-af35-079fc0b1dcec" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,756</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5230e2e2-5c43-4760-b678-07cbf9d58bd2" contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">153,750</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77b99fcc-1ab3-4cbd-99a7-5450b117400c" contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0324be2e-e40e-4559-901b-8cc565bbefa2" contextRef="C_41039f45-bcfe-4b0a-a6c8-f525353e3235" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1afb878e-400d-4f77-a0d2-8b739fda880d" contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,404</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7bdda64-8c16-414d-8c80-52167bca648c" contextRef="C_41039f45-bcfe-4b0a-a6c8-f525353e3235" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9208759-2003-4db5-beac-f6d900646c78" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_566dbabd-459d-4e9d-a301-50c2cf43b68e" contextRef="C_41039f45-bcfe-4b0a-a6c8-f525353e3235" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,796</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b93aed6-398b-43ec-b029-186f7e56584d" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,796</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on marketable debt securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_093ea44e-04f2-4534-8aef-16d81c5841b9" contextRef="C_35ab60ab-d305-4f2f-afea-0206294790a2" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c512a226-9795-4a48-bcd6-e628bcb87ae0" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net Loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79e8ff57-4ce3-48ec-9b15-f1b9256e5569" contextRef="C_19c7f11a-defa-4ab7-93a5-13259f5e0f82" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a096d7bc-5f7c-4543-9c6c-594b63f2e265" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2024</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a57ad577-9c6b-49da-809c-e1204aa5015b" contextRef="C_2da25a67-0650-40c0-a834-10e03326ad04" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,815,065</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9be0c0cb-3a6b-4fa4-b19d-6a20deef7ecc" contextRef="C_2da25a67-0650-40c0-a834-10e03326ad04" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e91dcae6-1b3a-4a56-aa22-9cb8e287212e" contextRef="C_cb7fc05a-bbd9-4909-a0df-1a1e3440df1c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">440,758</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1ac7dd6-847f-410a-a43d-695f91c476a5" contextRef="C_e50d16e4-c0fa-4f34-9de4-4fa19f2af4a2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">269,158</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bec4289b-e535-4685-9206-fdac1c7ade17" contextRef="C_4ccaf2c5-63d9-4610-8683-46ecfe234808" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">148</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_339cb994-ebea-430b-b129-64216bce706c" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">171,812</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.828%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:7.441%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.941%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:6.961%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-in</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Comprehensive</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Par Value</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gain (Loss)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2022</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25c19937-ff98-4279-9c04-b214689c26ad" contextRef="C_fef8b8b7-1ffd-45a1-bbb3-aeb02925b1c1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,269,200</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ad25dc6-a7ad-42bc-bc0b-586d1703e6a6" contextRef="C_fef8b8b7-1ffd-45a1-bbb3-aeb02925b1c1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_085e6a78-a4de-4bf4-9827-ce891a9f785d" contextRef="C_651ed535-6eb6-4fb6-8481-d70f3753107b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">262,496</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2bd4d9e-fcd1-4989-9e8b-10588da28857" contextRef="C_84970a30-febb-4823-a176-2eef9f5b17ed" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151,605</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b46252e5-df05-480c-8d22-3623ddcbdf59" contextRef="C_9ea41f95-519b-41f4-8b6c-cb288ac9b104" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d10f769-e88a-48a6-8fc4-8b4e8d8042e2" contextRef="C_e567f291-5928-46ca-9886-4b12d459c211" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,903</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db4cadbf-e520-40f2-9e20-735da915663f" contextRef="C_d6ea5928-6ce4-4e0b-9b61-49f02098f481" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,615</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90fd5f90-b4de-4e85-b60a-bdc91624657b" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,615</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db4fa724-f2f2-4526-9d10-2fa20cbedce5" contextRef="C_dd2a27c7-acca-4e22-922e-e6e22f9cea4d" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,466</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfc7b489-c798-42dc-b3c6-f9cdcf3d7459" contextRef="C_d6ea5928-6ce4-4e0b-9b61-49f02098f481" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8829f24-3ab5-4a7c-9bd9-8e83e643963b" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc918255-a502-40c7-a08f-0b2a3b7e4f66" contextRef="C_dd2a27c7-acca-4e22-922e-e6e22f9cea4d" name="lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_012ca6c2-c24a-454b-9e22-0416536d1f86" contextRef="C_d6ea5928-6ce4-4e0b-9b61-49f02098f481" name="lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be32de8f-eb58-4682-95f6-2396175b151a" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gain on marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70daee25-24be-44df-96f2-2e1a78171bd3" contextRef="C_d0f2886e-1b6f-49ac-a8ea-a868a6076338" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47f21a3e-e1f3-4fd0-9a13-e391c6e0e700" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d9fb608-5e06-4136-bfd2-bd17aabb7d09" contextRef="C_57646aae-7316-49d9-a9e1-466cd58a59b6" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a611ff1-932a-465f-ae40-7b2c1323ae81" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balances as of December 31, 2023</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_440f7506-b91e-467c-8aec-f11dd0fd79bc" contextRef="C_c3a77d44-ca39-48a6-af59-4ea835940adf" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">43,909,069</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b53199d-0ff9-48b0-a4cf-1b0ba327865b" contextRef="C_c3a77d44-ca39-48a6-af59-4ea835940adf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5ffda59-74f3-463b-835c-d8acc3d38920" contextRef="C_f10a217c-c7c4-4985-8b2d-21543f8fe157" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270,150</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00ced02e-5ac7-4c46-90df-d653bb5d59fa" contextRef="C_3ddcccac-7c80-4352-b875-b59deec51ca1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">188,554</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8799b47-04af-4451-84d8-2337065e35fd" contextRef="C_b89973be-3872-4363-9f3c-168e09a8a5a6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c2ab780-644e-41ed-b83d-f8759d1998ec" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81,720</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED ST</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATEMENTS OF CASH FLOWS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.995%;box-sizing:content-box;"/>
    <td style="width:1.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:1.32%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:10.182%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">  </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25bcc1ed-8906-4121-9230-4f4d96744279" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,604</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e9e211c-25ed-4a12-a656-43bf0571f35f" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fcc625a-17e8-45a4-b7b9-91255bdfd6f2" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,796</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3976328-4c81-430b-a251-48b31e0394ad" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,615</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease expense</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bf0ade9-f78f-4b71-b099-0e56782a2de9" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:CashAndNonCashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">189</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b456c7c5-6402-4a7c-92e4-7dc973a8135b" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="lrmr:CashAndNonCashOperatingLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">82</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation expense</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee92bfe2-b1ad-4ea4-a795-217d760f2fc7" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">318</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b26f0aa0-2550-4de8-92e6-c141b4e50b7d" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net accretion of discount on marketable securities</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f65f1be5-ee4c-4f80-a503-d5bc176c1789" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,256</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6247cb9-f29c-4c07-8456-ef95468523d7" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,843</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td colspan="2" style="padding-top:0.01in;text-indent:10pt;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32869129-0822-48b9-be64-52fddbc71bd5" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,465</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e2057ba-ec5b-4c70-8e86-65ed110e4853" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,065</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26c1cc01-1e26-4063-8bb5-21299194611e" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,141</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba90cf90-4055-4103-96bf-502a11c67ba7" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">403</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f249beae-c9a0-403e-9a57-364eaf59df83" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,436</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c38b526-a526-42be-a603-413cac8c0498" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,022</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c166a39b-335f-484b-aaa4-0cd56580671b" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5174d865-6a12-4f76-b697-e0df517449b0" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash used in operating activities:</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f207342b-de63-4504-9eca-d8949f2ccf08" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">70,760</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce512d47-72f8-43fa-8145-9793fe799614" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,459</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of property and equipment</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97400da7-6eae-4ca6-801d-d05e5d3ba7f2" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">515</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b4187d4-6ed8-4705-b4f2-0dbbbbc42581" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">164</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchase of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f39daf72-a3cc-432d-a015-d1e8b2231d6d" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">227,872</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a74991b-6a18-45de-81e5-2ec84efab595" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,233</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Maturities and sales of marketable securities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddf88761-7dfa-461c-8f78-edfdeb041938" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,000</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a98de15b-9ddc-49ca-b8be-9bee8a338f4e" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">134,750</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72e4b8ac-932d-4c0b-a503-ce7e80b6555e" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">85,387</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98472223-76ee-42c1-8f37-56290f39cb3c" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,353</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">   </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from sale of common stock, net of issuance costs</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_461be0b4-d3c7-487e-8073-d104ad4aeba6" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,806</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options and warrants</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b8a57e2-5590-48a9-8a26-d43779d55b77" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:ProceedsFromStockOptionsAndWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1840d36c-278b-4568-8ee2-e49bf957b5c4" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="lrmr:ProceedsFromStockOptionsAndWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5ff26b6-2116-46fd-a4c9-50680a6f8b0c" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161,883</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9644f828-a9ed-47e7-bb4a-e3a12fddf7a3" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62ce7ec2-b0f8-4808-b462-95f828a2be27" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,736</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffc1a51d-2860-4e36-be37-965d03bddcdf" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a6a6b5d-ee14-4d04-9dc4-bfc0b5021e1d" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6050f6e8-9548-479e-be49-6cad0cc2972e" contextRef="C_e567f291-5928-46ca-9886-4b12d459c211" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,164</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of period</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a443991a-6327-490b-aae2-ff86383f622a" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,824</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b354956a-376b-400d-8bc9-ad22beab26a5" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,088</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental disclosure of non-cash investing and financing activities:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leased assets obtained in exchange for new operating lease liabilities</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dabeff0-1176-4cc7-ae0a-bf9f255043e7" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">465</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a44033af-a05a-478b-9387-927c1716c414" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">790</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Offering costs included in accounts payable and accrued expense</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1505305f-2d42-4fb5-b7cb-dafcbe79dd38" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:OfferingCostsIncludedInAccountsPayableAndAccruedExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of stock options included in other current assets</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1b2285b-141b-4342-ae13-4e407440aea7" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="lrmr:ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
    <td style="padding-top:0.01in;white-space:nowrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_condensed_consolidated_financia"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLID</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATED FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div><ix:nonNumeric id="F_e91d44fd-a721-4bf4-ab8f-288457a02f82" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true" continuedAt="F_e91d44fd-a721-4bf4-ab8f-288457a02f82_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business and Basis of Presentation </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Larimar Therapeutics, Inc., together with its subsidiary (the &#8220;Company&#8221; or &#8220;Larimar&#8221;), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich&#8217;s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Larimar has completed two Phase 1 clinical trials and a Phase 2 dose exploration trial, and has an ongoing Phase 2 OLE trial in patients with FA and an ongoing run-in study in adolescent patients with FA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the Company reported positive top-line data from its Phase 1 FA program after completing dosing of the single ascending dose ("SAD") trial in December 2020 and of the multiple ascending dose ("MAD") trial in March 2021. Data from these trials demonstrated proof-of-concept by showing that daily subcutaneous injections of nomlabofusp for up to 13 days resulted in dose-dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues (buccal cells, skin, and platelets). There were no serious adverse events associated with either the MAD or SAD trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, the Company reported preliminary unblinded top-line data from the 25 mg cohort of the Phase 2 four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the FDA cleared initiation of a second cohort (50 mg) of the four-week, placebo-controlled, Phase 2 dose exploration trial of nomlabofusp in patients with FA and the initiation of the OLE trial with daily dosing of 25 mg.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company reported positive top-line data and successful completion of the Phase 2 dose exploration study. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. Patients who completed treatment in the Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In March 2024, Larimar dosed the first patient in the OLE trial, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study ("FACOMS") database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 30, 2024, Larimar announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company received access to the Medicines and Healthcare Regulatory Agency ("MHRA&#8221;) Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) for the treatment of adults and children with FA. The ILAP is facilitating patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with UK regulatory authorities and other stakeholders. Along with the receipt of the ILAP designation, nomlabofusp has already been granted orphan drug designations in the U.S. and the European Union (the &#8220;EU&#8221;), and access to the PRIME scheme in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_e91d44fd-a721-4bf4-ab8f-288457a02f82_1" continuedAt="F_e91d44fd-a721-4bf4-ab8f-288457a02f82_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company reported positive initial data from the ongoing OLE study. This data included safety, FXN levels, clinical, pharmacokinetic data and dose escalation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp was generally well tolerated for up to 260 days in subjects. The most common adverse events were injection site reactions, with most being mild, brief in duration, and self-limited. Two participants had serious adverse events (one seizure and one anaphylactic reaction) that resolved within 24 hours and withdrew from the study; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term 25 mg tissue FXN levels showed positive mean change from baseline of 1.32 pg/&#956;g in buccal cells and 9.28 pg/&#956;g in skin cells at Day 90 and that 25 mg of nomlabofusp increased and maintained tissue FXN levels over time, increasing from a mean level of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_004f83f6-73db-4bbe-b2c5-79b985f13f8f" contextRef="C_778a5e08-2c19-4fa4-9229-8be5d4f04ff2" name="lrmr:MeanLevelHVAtBaselinePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of HV at baseline to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77be9fd8-71a2-4066-8f01-bf0a7c9c0d23" contextRef="C_37be18e2-22dc-4e2a-9beb-0936213f0ff9" name="lrmr:MeanLevelHVAtBaselinePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in buccal cells and from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45f17f02-c237-4ba3-8946-556e9644b1f3" contextRef="C_d69bdfda-1561-4df9-9031-4aaa6b8277e8" name="lrmr:MeanLevelHVAtBaselinePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_160f54e2-7b52-4f10-b661-4dcf2f3e77d2" contextRef="C_937c9270-0745-4d6a-8ddd-353d3408b686" name="lrmr:MeanLevelHVAtBaselinePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in skin cells at Day 90;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tissue FXN levels appear to reach steady-state levels by Day 30 in buccal cells;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early clinical data showed trends toward improvement across a number of clinical outcomes for long-term 25 mg daily nomlabofusp including: (1) decreased values indicating early trends towards improvement in the Modified Friedreich Ataxia Rating Scale (mFARS) and the FARS-Activities of Daily Living ("ADL"), Modified Fatigue Impact Scale and 9 hole peg test at 90 days relative to baseline;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key pharmacokinetic data showed rapid absorption after subcutaneous administration with exposure appearing to reach steady state in plasma by day 30 with no further accumulation, which is consistent with data from our Phase 1 and Phase 2 studies.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also in December 2024, Larimar announced that it was increasing the dose in the OLE to 50 mg of nomlabofusp daily for then currently enrolled and all future OLE study participants. In March 2025, the Company announced that its Safety Monitoring Team has deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp and therefore, Larimar expects to see additional reactions. To reduce the risk of allergic reactions, including anaphylaxis, Larimar amended the OLE protocol to administer premedication for the first month of dosing. The OLE study is ongoing with seven sites activated and participants continuing to enroll. All  study participants are currently receiving the 50 mg dose of nomlabofusp. The Company plans to provide an update on OLE data on at least 30 to 40 study participants, some of whom have been receiving nomlabofusp for more than a year, in September 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, Larimar initiated dosing of adolescents (12-17 years old) in a PK run-in study for pediatric patients with FA. Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp at a weight-base dose expected to match the PK of adults receiving the 50 mg dose, or placebo, daily for seven days. Following assessment of safety and PK data, participants will be eligible to screen for the OLE study. The data from this cohort is expected to be presented during the nomlabofusp program update in September 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, Larimar announced that FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as a reasonably likely surrogate endpoint (&#8220;RLSE&#8221;) and the acceptability of FXN&#8217;s use as an RLSE would ultimately be a matter of review of the data in a future marketing application. FDA recommended focusing on assessments of skin FXN concentrations rather than buccal FXN concentrations due to more consistent sampling and less variability. FDA acknowledged that data the Company recently submitted appear to support a relationship between increased FXN concentrations in skin cells and relevant tissues such as the heart, dorsal root ganglion and skeletal muscle. FDA also acknowledged that the nonclinical studies Larimar submitted were performed at relevant human doses. FDA also suggested that Larimar consider exploring the relationship between increases in FXN in skin and changes in pharmacodynamic (PD) markers such as lipid profiles and/or clinical measures to provide additional support for the use of FXN as an RLSE. Larimar plans to continue discussions with FDA regarding the adequacy of the safety data set for a BLA submission seeking accelerated approval targeted for year-end 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company has obtained feedback from both FDA and EMA on the global Phase 3 study protocol and is on track to initiate the study by mid-2025 with potential sites in the U.S., E.U., U.K, Canada, and Australia.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_e91d44fd-a721-4bf4-ab8f-288457a02f82_2" continuedAt="F_e91d44fd-a721-4bf4-ab8f-288457a02f82_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_37d8d48f-74b8-4361-a1e4-c9c870cba969" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with U. S. Generally Accepted Accounting Principles ("GAAP")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_558aa2df-8d8c-4175-9459-32539a0a55ab" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:GoingConcernPolicyTextBlock" escape="true" continuedAt="F_558aa2df-8d8c-4175-9459-32539a0a55ab_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b41891ee-19d7-4981-87e3-6ba47c017a21" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">80.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd503a94-1acb-4f4f-b3a4-ac20b02867d8" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">36.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024, and 2023, respectively, and cash flow used in operations of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4520e5f-10a5-4681-a199-9c86716b6298" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">70.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce77c4c9-a8f4-4b11-a7f5-8ed3dff16de3" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively. In addition, as of December 31, 2024, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cde0441-cf98-49de-b40c-f3cda5dfe906" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">269.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2024, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b03a925a-c8b8-4754-9baf-7dd24b6d9006" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">183.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e28576e5-8e48-4987-84e2-579b8c41f436" contextRef="C_1b3789f9-d2e6-472a-a24f-4537eda96328" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,736,842</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in an underwritten public offering at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6210a19e-4587-4977-9103-3300d1f9e0fc" contextRef="C_afb7c02e-1d17-4fbb-ad2f-056d597aacc2" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15501c02-1472-4e6d-a8e6-f47a6d031838" contextRef="C_1b3789f9-d2e6-472a-a24f-4537eda96328" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">161.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205, "Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into the second quarter of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_e91d44fd-a721-4bf4-ab8f-288457a02f82_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_558aa2df-8d8c-4175-9459-32539a0a55ab_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></ix:continuation></div>
  <div><ix:nonNumeric id="F_898c9d36-2362-441f-9f12-af94ab8f1a88" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_898c9d36-2362-441f-9f12-af94ab8f1a88_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2136b73a-2f60-46e8-8603-2e9acecec519" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0384acff-cbec-4bd8-a83e-ebcdaa6ab519" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_903c991d-c6b0-44a2-8da4-d6f76f5a9e3f" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_8cbb98ad-90be-46e7-b3b1-1d34f784b7b0" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:MarketableSecuritiesPolicy" escape="true" continuedAt="F_8cbb98ad-90be-46e7-b3b1-1d34f784b7b0_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_898c9d36-2362-441f-9f12-af94ab8f1a88_1" continuedAt="F_898c9d36-2362-441f-9f12-af94ab8f1a88_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8cbb98ad-90be-46e7-b3b1-1d34f784b7b0_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">income; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#8217; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value would be recorded in net income.</span></p></ix:continuation></div><div style="font-size:11pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3366c433-de0f-441c-8dff-1689becd10d4" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e67f9759-bc4c-4465-933e-6db26d968aa7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2769560-89b9-46ad-9155-f0153602274c" contextRef="C_4f4d089e-ca07-4b47-be34-6ef0f252b0ad" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a78ce45f-1d08-40a2-a8d5-a5815fef984f" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment, net&#184; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c91d1c2-d252-4e4b-8675-117040b6aacf" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs associated with internal research and development and external research and development services, including drug manufacturing and scale- up, other drug development and testing costs, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and to scale up the manufacturing process, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dbcc0fc4-1882-4179-9421-b37df38a7382" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_898c9d36-2362-441f-9f12-af94ab8f1a88_2" continuedAt="F_898c9d36-2362-441f-9f12-af94ab8f1a88_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5098410-ae5b-4d29-86db-1f447bea3531" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_f8fdd861-97a3-45bc-a894-afdcb6027d0c" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_f8fdd861-97a3-45bc-a894-afdcb6027d0c_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company is managed on a consolidated basis and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d28de841-8788-430c-80af-12a02621a9ee" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_baa13b8d-c08c-47cd-bdd5-09adfb77d853" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment related to the development of clinical and preclinical product candidates for the development of the Company&#8217;s proprietary new therapies, primarily nomlabofusp, the Company's life science segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company's </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d10ed809-200f-4b30-80d3-8c8fcced056e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("CEO").</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the Company and its reportable segment based on net loss, which is reported on the consolidated Statements of Operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. All long-lived assets are located in the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_982048d3-5cc3-4dce-9537-5cec34526103" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated financial information, including consolidated net loss, to evaluate performance, forecast future period financial results, allocate resources for the company by, among other things, comparing budgeted to actual results.</span></ix:nonNumeric></span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_898c9d36-2362-441f-9f12-af94ab8f1a88_3" continuedAt="F_898c9d36-2362-441f-9f12-af94ab8f1a88_4"><div><ix:continuation id="F_f8fdd861-97a3-45bc-a894-afdcb6027d0c_1"><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f9b44a9-63af-44bc-8fc0-67b9cdc6e514" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:1.62%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
          <td style="width:12.883000000000001%;box-sizing:content-box;"/>
          <td style="width:1%;box-sizing:content-box;"/>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Technical operations</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0d22609-becb-42e9-941f-ba06c85faee7" contextRef="C_ab791d56-0959-4081-945b-058f0d6c6f82" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,805</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c52f45c7-9769-4002-9d94-cba58fbf77a4" contextRef="C_2b1053b4-6091-48b6-907a-083f14aa104f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,781</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0264fd14-6013-494a-b75f-99de8fdcd0f6" contextRef="C_bfbc57ff-0284-43eb-9410-6bcf4e5de594" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,361</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_664460db-ba0d-48c9-ba71-3d1f65d7c242" contextRef="C_0ca29918-24cb-4049-81da-b0b595cb7f08" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,733</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nomlabofusp support</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc161b5b-2204-4b0c-b37f-14bea290c57e" contextRef="C_a6372807-b669-4c9a-bca6-c7c693a758c3" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,112</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4412534-117d-4916-9215-4e6ef8837d06" contextRef="C_d699938b-88e6-4ed6-bb3e-ded55260a3c7" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,156</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ae54e79-e77d-41da-bd1e-14ce7a3a45ca" contextRef="C_c18bcdd4-7898-4e7b-aeaa-04861be8d49c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,944</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f052631-7aa3-49ce-bffc-a8081876974d" contextRef="C_4d9b0d0f-39b2-4d7c-ad5a-792b1d5080d1" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,088</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_117b33ac-d373-48f7-ab42-89cd04306794" contextRef="C_9450bf35-e5d7-4e90-b946-f5ecc5c1b78f" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,668</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc99e24e-ed69-41f5-bbda-7fa44c9b5ed3" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90,890</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0af35313-32a7-496d-8862-c11d2d5189c4" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,758</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cc86cfe-f832-4b35-980e-09cee4d10526" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,286</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93c0d6b9-3db5-4bbf-b0ba-965a9ae78926" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,809</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42c138f5-a5ce-4161-9706-a933939fb8c6" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,604</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb294e7f-0467-4c9f-8857-e737858c8941" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d16c0d6-eba2-4e4a-961a-2e97f99eb735" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9a9ee81-b5fe-48be-8fee-8bd72a2e987e" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:LikelihoodPercentageMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc19524e-74fd-453f-a212-bdbd368d364c" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s only element of other comprehensive gain (loss) was unrealized gain (loss) on marketable securities.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_5ad2e8e5-902b-4c98-8783-f9adc7c739e7" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_5ad2e8e5-902b-4c98-8783-f9adc7c739e7_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#8217;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8b6df93-1666-44f7-8d3c-256b4ee80cfb" contextRef="C_ec7837b7-c9c1-4c07-8288-455007933963" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Accordingly, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67956c3e-f910-4082-af21-35556f8dfe21" contextRef="C_703f9a1d-ba57-4229-9130-75f431315872" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5a620aa9-23e4-4eff-bc8b-55ad45b3ac81" contextRef="C_703f9a1d-ba57-4229-9130-75f431315872" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_898c9d36-2362-441f-9f12-af94ab8f1a88_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_5ad2e8e5-902b-4c98-8783-f9adc7c739e7_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c2896b0-97d1-4240-920e-5934367998ce" contextRef="C_4652a096-8724-4cdf-a118-748dbb5359af" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,135,390</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c85b36c3-242e-4749-b50b-eb5e40b20444" contextRef="C_c7bb7719-628e-435e-ba3a-d42b56b0336b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,888,502</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options to purchase common stock, outstanding as of December 31, 2024 and 2023 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d58edcb6-0742-4b18-876a-b0e14c9a3abd" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires disclosure of incremental segment information on an annual and interim basis. The amendments also require companies with a single reportable segment to provide all disclosures required by this amendment and all existing segment disclosures in ASC 280, Segment Reporting. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c29843b-49ce-488c-a165-bc15442dd93f" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8e858e57-0756-416b-b74d-b48de20c666a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, effective December 31, 2024, in these consolidated financial statements. ASU 2023-07 only impacted the disclosures and did not impact the consolidated financial statements. See Note 2, Segment Information, for disclosures related to the adoption of ASU 2023-07.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, &#8220;Improvements to Income Tax Disclosures (Topic 740),&#8221; which requires entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes as well as additional information about reconciling items if certain quantitative thresholds are met. This ASU will require all entities to disclose income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. All entities are required to apply the guidance prospectively, with the option to apply it retrospectively. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it will adopt this ASU on January 1, 2025, the adoption of which is not expected to have a material impact on the Company&#8217;s consolidated results of operations or cash flows.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221;, which requires disaggregated disclosures in the notes of the financial statements of certain categories of expenses that are included in expense line items on the face of the income statement. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company will evaluate the impact adopting ASU 2024-03 will have on the Company's consolidated financial statements and disclosures.</span></p></ix:nonNumeric></div></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_1442177e-e6a1-4b1f-99f5-93eea897e005" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:FairValueDisclosuresTextBlock" escape="true" continuedAt="F_1442177e-e6a1-4b1f-99f5-93eea897e005_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Cash Equivalents/Marketable Securities</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and December 31, 2023 are measured in accordance with the standards of ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:11.54%;box-sizing:content-box;"/>
      <td style="width:88.46%;box-sizing:content-box;"/>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level &#8211; 1</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p></td>
     </tr>
     <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level &#8211; 2</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p></td>
     </tr>
     <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level &#8211; 3</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2024 and 2023 were considered representative of their fair values due to their short term to maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79925af4-90e1-4ec0-8281-bcc618fdb146" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s cash equivalents and marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets <br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds invested in government <br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cd26507-6022-46d8-b264-6c9a34c12f54" contextRef="C_990b03ea-4e3f-428b-9463-5722c03fe7ef" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,702</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ba52513-a379-4322-8173-7e68f8d40c09" contextRef="C_a4b86fbb-6763-470f-9324-890bb9b86ef7" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,702</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e9c6b13-9862-4af4-9fc4-6b3be1eab6f3" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,702</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_475e5493-c6fe-49a1-97a4-428fa3f5621d" contextRef="C_980a36da-7606-4c17-93a9-29aef7c80f1d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,702</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04c0b08e-8de2-4232-8040-941ab2333ed3" contextRef="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,947</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_858d13af-6162-4ab8-a70d-31e841e3d0ff" contextRef="C_937d6158-f010-48b2-b04e-91b91f550795" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,947</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb2cac64-35ce-4e43-876e-e44def27691b" contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a9360b9-04ea-4290-9590-45eadcc17dae" contextRef="C_1e6ff9a0-2992-49a2-9d8e-9424081411f5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebeaa54c-d9b2-431f-9c94-1d1576a7bb54" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,236</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be748b30-f025-41cc-aeef-9c49d9fc6a43" contextRef="C_980a36da-7606-4c17-93a9-29aef7c80f1d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,947</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_416d2a9b-aaa5-4c65-adc6-08f416cb2dd0" contextRef="C_06eb49df-ea1f-4795-b693-6ce41c4e020b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,289</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf8a30f3-45c5-4178-8d3d-f15bc3661be8" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,938</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c189753-41ad-44da-950b-8027b3038a46" contextRef="C_980a36da-7606-4c17-93a9-29aef7c80f1d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,649</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d526f8fc-c077-4285-b758-10fb36d55e32" contextRef="C_06eb49df-ea1f-4795-b693-6ce41c4e020b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds invested in government <br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2f7cb0b-4545-4c24-9d24-d56a593ef451" contextRef="C_03512384-f164-4169-8f61-63c0a2fa35f3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,701</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b284aee9-cf50-4ab7-b171-dca2e90b10bf" contextRef="C_b039d28f-1551-4683-aa18-2d31487cc476" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,701</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_499da8ed-d9c9-4adb-84cc-de94bd141539" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,701</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef1752c7-77c3-41ee-a8f1-ace1e3427655" contextRef="C_c66d62d9-1b72-4c63-9f95-2f1a72677604" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,701</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5319573d-e9bf-4226-a230-9b6c1e489f13" contextRef="C_f552a753-5013-41ab-8a68-b985b7c0bac4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,334</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2fcd62d-0bca-4800-a667-a9b9f27c5a38" contextRef="C_7f9933f3-6cd7-4632-83be-ff4608000844" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,334</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c58c606e-1317-4852-af8b-a93842b25577" contextRef="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,719</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36c7d8f4-b4a7-4725-9ec3-a8606180fc2c" contextRef="C_2e43c4d6-c27e-4c64-957a-2c359c114241" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,719</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ff89584-15f0-4fae-ad68-9405e0b80e43" contextRef="C_4e6a434c-62eb-44df-bb26-a28924999a6a" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,988</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ededc3c-8725-4bad-98d9-8e32f03a5ea9" contextRef="C_89155b9d-f3b6-4453-9d28-eeacaa55b7e1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,988</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f4b3a6f-1ece-43ab-aaf2-d83da5189d98" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,041</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dfff828-d1b4-4a57-8d0f-2b91081a3075" contextRef="C_c66d62d9-1b72-4c63-9f95-2f1a72677604" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,334</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6aa9e4c9-d417-4bd9-87d2-27170ee403bd" contextRef="C_b79ab662-a9df-4027-a87d-1c4f950bae65" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,707</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ed566b7-b01e-4a6b-9c41-d1b58d2b3870" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,742</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71f98989-d561-4ba9-99a3-4c5a336a2794" contextRef="C_c66d62d9-1b72-4c63-9f95-2f1a72677604" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,035</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05f61845-1145-4092-afc5-6df5d0096a27" contextRef="C_b79ab662-a9df-4027-a87d-1c4f950bae65" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,707</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_1442177e-e6a1-4b1f-99f5-93eea897e005_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accrued interest receivable related to the Company&#8217;s investments was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ee7f69c-8ff2-4c70-9117-b5d8ac7aaf82" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad051fe7-de83-4036-be26-1ba944b826fc" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively, and is included in prepaid expenses and other current assets on the consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the unrealized loss for available-for-sale investments were non-credit related, and the Company does not intend to sell the investments that were in an unrealized loss position, nor will it be required to sell those investments before recovery of their amortized cost basis, which may be maturity. As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9b2c16b-210d-4089-9a21-4841e49b6e18" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3c5d3fd1-8436-4c57-958f-32ac6682e68a" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowances for credit losses for the Company&#8217;s investments were recorded. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e32cba59-6780-40ef-8c54-17b4af8083e4" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4ecacdeb-5a82-4304-9aa3-59ca56a641b8" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment losses related to investments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company's cash equivalents and marketable securities consisted of a U.S. government money market fund, U.S. Treasury Bills and U.S. government and agency securities, all held in our name in a separate custody account with U.S. Bank. The U.S. government money market fund has same-day liquidity access and the U.S. government and agency securities all have maturities of 360 days or less.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9869da07-2113-4b11-95c7-8a0957e46729" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" escape="true" continuedAt="F_9869da07-2113-4b11-95c7-8a0957e46729_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.22%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.184000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized <br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71b00013-8b7e-4076-99c4-74df8883d86c" contextRef="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,945</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d2f5e9e-f558-4b07-a437-d1325eca89f4" contextRef="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c211a10-5cab-4105-9c16-c7433fe5ff91" contextRef="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,947</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bd2669b-309b-4715-ad28-1e52ec177f07" contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,143</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5df0051-1caa-4c74-b543-e1aac9c21c93" contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d21c26a-f490-427a-ae7c-d1f4ba1d05cc" contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a62b9018-ddc9-40c0-9bc1-d8b652bd07ce" contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,289</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92221ff6-07b8-431f-bda9-3140572bc072" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,088</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82a0b5e4-e5f3-49b3-a4c5-cbfce5a2bd86" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bd9d121-856a-4621-96b0-467dc9fd50c7" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4f75028-19c9-42b9-8b7f-16a81092ccbf" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,236</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e61a1c52-737b-4ba6-b6e4-4456be367094" contextRef="C_f552a753-5013-41ab-8a68-b985b7c0bac4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,330</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71ff369e-ad8f-4207-9251-3d1913f43839" contextRef="C_f552a753-5013-41ab-8a68-b985b7c0bac4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db3abb9e-f4fa-4ff8-aaac-35c0dc0a6bc3" contextRef="C_f552a753-5013-41ab-8a68-b985b7c0bac4" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,334</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ea60e42-2d26-4e34-8d64-002fe1e32e73" contextRef="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,653</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1966e177-66d7-4eed-9588-4e5536c1e07b" contextRef="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b16d513-22f6-4c7f-92ef-23e6602a42eb" contextRef="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,719</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ada9cb82-39f0-4cee-918d-9dc73dc6d3c8" contextRef="C_4e6a434c-62eb-44df-bb26-a28924999a6a" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,977</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37bc2fc2-d9ef-44cd-8f0f-4fd6bee147e3" contextRef="C_4e6a434c-62eb-44df-bb26-a28924999a6a" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d70d4c3b-e7ba-4591-b496-ce9ad87c77d2" contextRef="C_4e6a434c-62eb-44df-bb26-a28924999a6a" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,988</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc3cde69-7465-41a4-9794-60e54aee03ca" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,960</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb79e914-3df2-4dc3-bf82-4d311c45b74d" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">81</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bf93dc9-898e-4215-90d8-1be91034ac3e" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,041</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_9869da07-2113-4b11-95c7-8a0957e46729_1"></ix:continuation></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3475fc3-2b27-4aaa-b747-829bc71b86d8" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b497e4df-0748-4ad1-b493-b4d0f9090d36" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8c064bd-6ce1-4aa5-a4e6-907cf93571b2" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="lrmr:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,780</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ecb86e8-f910-47fb-bd82-3d90c02f37db" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="lrmr:PrepaidResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,994</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d03afd8d-6783-49af-ac1d-f107cdc91871" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,054</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9b757db-f5be-464c-ae13-7d1f03b61150" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">332</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ffb3323-86d2-4f0b-b37b-f3771c2d4cfc" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">499</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_746ad3d7-9f0c-4513-a775-a5c45dce36ca" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">682</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6d42783-48db-4c83-be56-fc9d75860ac8" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="lrmr:OtherPrepaidExpenseAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06b3d483-55da-4e19-956e-6f7f13a4c169" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="lrmr:OtherPrepaidExpenseAndOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">377</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec95783-cd76-44f6-918d-6f3a221a791d" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,850</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f59c6b83-190c-48e1-b063-ef5c54738264" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,385</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3130217-ea9e-47c0-b226-9d4e80da56ed" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fixed Assets</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed67ef58-4cbf-49c7-bae9-f6ff47043e06" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fixed assets, net consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:12.775%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.399%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:10.776%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1123c8ed-a6ae-45cf-9c82-25292ee04703" contextRef="C_7fd9fac5-2ec4-4412-abb9-5816a42accd8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04d72b60-d272-4296-928a-cd006e0f78c7" contextRef="C_7fd9fac5-2ec4-4412-abb9-5816a42accd8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cef92b41-2452-4b71-a093-c1fda25ee34e" contextRef="C_fe166586-acda-4afa-90ba-bbddb1cf7183" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e5b3f9bb-c2f0-4bef-a5ff-23594fe5e6fb" contextRef="C_1ecaa432-f3ba-4716-8bf2-ed620241e567" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71d464c2-47ba-42a9-a1a2-e18d911e6595" contextRef="C_1ecaa432-f3ba-4716-8bf2-ed620241e567" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,707</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03f689d6-107e-4b87-a055-8e73f28ce9ae" contextRef="C_55adc7a3-9555-42f6-8998-4ce928494a2a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_be996420-b383-497e-acdc-3af951adabec" contextRef="C_d91923f9-f154-40c9-b314-889b9878641c" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6d1b647-8dca-4f7d-9303-96acbb87edac" contextRef="C_d91923f9-f154-40c9-b314-889b9878641c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">555</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c99e0a2c-6458-492b-a69c-901330f0de68" contextRef="C_49e828c3-8eec-482d-9de9-b54a375e1b3c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">555</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_a5f65a1c-dbe3-418f-9eaf-369ca80d6c94;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">lease term</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9fabbda-59df-4f8f-a182-59a264d3f05f" contextRef="C_396ac9d3-7432-4c48-bc3e-b130ad436bcd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b23c02d-0f82-46ce-9731-bc7aef4439b8" contextRef="C_82b36523-042a-479d-8709-14a5821a01e3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57920912-e1a8-4a76-a118-794e67d12ba7" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,424</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66b2ab22-35eb-456b-a349-b34d9f36a6f9" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,909</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_288f1372-8f20-47b0-8a27-87775df88c0d" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc3fc17b-4a36-4be4-aca1-5484f75d8639" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,225</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Property, plant and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_237c511c-2c1c-4613-b5df-0abcc6c574ac" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">881</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0246b2c7-7384-4c9c-938a-2914669d8d86" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">684</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b0a0661-c26b-42c1-bf54-a49c2ddf3f57" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:DepreciationExpenseExcludingLeasedAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_147068ac-e88f-4872-ad81-84fc07371351" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="lrmr:DepreciationExpenseExcludingLeasedAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. In addition, for the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c87d94f-ae9c-4bb6-ae33-068da712fcc8" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="lrmr:DepreciationExpensesRelatedToSubletAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7f2e15e6-6b5b-43e4-aa6c-9666c97c12de" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:DepreciationExpensesRelatedToSubletAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of depreciation related to sublet assets recorded as other expense.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_ed20d6f4-b8bf-444c-bc79-525426ad3241" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4352fe3-4788-4846-8e11-8d505da47a5b" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true" continuedAt="F_c4352fe3-4788-4846-8e11-8d505da47a5b_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01207b7c-b6c5-4eeb-91ed-5ea6193b7758" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="lrmr:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,057</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96b542cb-5faf-48d3-80bc-340b2f5a2cde" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="lrmr:AccruedResearchAndDevelopmentExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,594</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_289a93be-9e47-4815-a8e6-76e15dcf8052" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,254</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a33d5ea6-4fd0-4a1b-85be-c82b382611b1" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,365</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf941a40-a608-41d6-9227-0716cc4a9f52" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">561</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20536ca5-3310-4a79-bcbe-5e76293e5c87" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">427</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5258bd18-baed-4237-8207-28fefdafc74a" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,872</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc8b51b7-7f6d-4d7a-ba16-e7621b62a752" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,386</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:continuation id="F_c4352fe3-4788-4846-8e11-8d505da47a5b_1"></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:nonNumeric id="F_c3895246-711a-482c-9488-7da5ac691e72" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_c3895246-711a-482c-9488-7da5ac691e72_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity and Stock Options</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock and Prefunded warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the &#8220;Purchasers&#8221;) for the sale by the Company in a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c84194b9-a986-4f0a-9477-6679c25acd22" contextRef="C_2778adb7-0fa7-4567-85f3-1f083a2430b1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,105,359</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock and prefunded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b50c33a1-9492-48a6-84a8-0298222d9558" contextRef="C_a3be7c9e-9f11-490a-8fdf-1cfea83b9a27" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, for a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4c16f9a-6064-4b7b-8316-34eced4f1ebc" contextRef="C_a3be7c9e-9f11-490a-8fdf-1cfea83b9a27" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">11.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of the common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d34ddd7-feab-4e67-a7dc-7dbb43888c7d" contextRef="C_2164a742-c82f-4feb-86b4-11d2743876a0" name="lrmr:WarrantsIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">11.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cef464ad-dd95-49d4-a1c3-d45161d556b4" contextRef="C_2164a742-c82f-4feb-86b4-11d2743876a0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.01</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and were exercisable indefinitely. In August 2023, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6fe126f-db20-47e8-b010-06b069e14830" contextRef="C_bf68a9db-6f62-4ef9-b2b4-384b78706dbf" name="lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of prefunded warrants were exercised and the Company received cash proceeds of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_921994da-5811-4028-8f53-85e77eb89620;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six thousand two hundred and eighty-four dollars</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and prefunded warrants were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eafc1521-d8ef-4f75-84af-c9b6cbacd2f3" contextRef="C_f1f8400e-a7d9-400c-8bc4-a27496b8c9f5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, transaction costs totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a527e7f9-3c2b-437b-aa6c-afe27a39cf4f" contextRef="C_f1f8400e-a7d9-400c-8bc4-a27496b8c9f5" name="lrmr:StockAndWarrantIssuanceTransactionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and resulted in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ffbb297-2d0e-424e-9042-607a6d4a5d6f" contextRef="C_f1f8400e-a7d9-400c-8bc4-a27496b8c9f5" name="lrmr:ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">75.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company&#8217;s Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45bdc95c-24cf-4e95-86a4-ce93e19d98ca" contextRef="C_2778adb7-0fa7-4567-85f3-1f083a2430b1" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,105,359</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock sold and the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19cbcd8b-445c-4726-86e6-093247a5d849" contextRef="C_a3be7c9e-9f11-490a-8fdf-1cfea83b9a27" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">628,403</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2ead07d-ad70-4195-a059-47696639dd57" contextRef="C_9d2671b4-535d-41fb-ba97-cf95d740ca0f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">35,260</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s Amended and Restated Certificate of Incorporation, authorized the Company to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f851ac56-92ca-4d72-8548-b249e91d796b" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">115,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7eed030-4a6c-4bec-a1a1-8e098c4cfe8a" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value common stock, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f147832-77ed-4aa8-bc3a-f6ecf4b7e186" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_79fb49a4-4b5e-47c0-be22-42322b3d7a0e" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">63,815,065</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued and outstanding, and up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88defbe5-280d-4fb3-8a29-6c6e141fb52d" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30260502-27ef-424b-a005-d678ad790bd4" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value undesignated preferred stock, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_366286cc-9dd8-43c3-b7d0-e0e003c3c111" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4dc4fa8f-1243-4479-a1ec-6e8809a0bdda" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7aef83da-0807-4f01-8951-3073233eb8bb" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:CommonStockVotingRights"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the &#8220;Board&#8221;), if any. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_891b2147-6d50-4dab-99ec-5a61ac1165d4" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DividendsPayableCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends have been declared or paid to date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9e0583d-e356-4973-a144-6348909c57fb" contextRef="C_b1b8129e-de19-4748-9c09-33dfd9514f6c" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,736,842</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in an underwritten public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edd943db-a437-4b7b-b3f5-35b063e2b74d" contextRef="C_cde123be-1e24-4090-8fdb-2c9fe1cf13f3" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4388ac5c-0ee0-42d5-b747-5b53aa7061d0" contextRef="C_b1b8129e-de19-4748-9c09-33dfd9514f6c" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">161.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 ATM Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, the Company entered into a sales agreement (the "2022 ATM Agreement") with a Guggenheim Securities, LLC in connection with the establishment of an &#8220;at-the-market&#8221; offering program under which the Company could sell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f42c4c2-e2fc-4dd2-bf01-e7175f82f627" contextRef="C_9458ab78-dd2a-4327-a9fc-7944f851ac55" name="lrmr:AggregateGrossSalesProceedsUnderSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of shares of common stock (the &#8220;ATM Shares&#8221;) from time to time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, in connection with the underwritten public offering described above, the Company terminated the 2022 ATM Agreement. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_962c65bd-9a41-4dee-93c5-06b1146946d4" contextRef="C_7ebc587a-1024-446d-8850-c2e50902fec2" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ATM Shares were ever sold pursuant to the 2022 ATM Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company entered into a sales agreement (the "ATM Agreement") with Guggenheim Securities, LLC in connection with the establishment of an &#8220;at-the-market&#8221; offering program under which the Company could sell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2424f102-64ad-4723-af9f-e18798c7ab88" contextRef="C_23a1dcc4-104b-43ca-95d3-232e06671bb5" name="lrmr:AggregateGrossSalesProceedsUnderSalesAgreement" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of shares of common stock (the &#8220;ATM Shares&#8221;) from time to time. To date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f3c64b9b-8c12-4d6e-a075-bc008a04254c" contextRef="C_7ebc587a-1024-446d-8850-c2e50902fec2" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sales of common stock have been made under this ATM Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the "Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2020 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;), nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based restricted stock units, and cash or other stock-based awards. ISOs may be granted only to the Company&#8217;s employees, including the Company&#8217;s officers, and the employees of the Company&#8217;s affiliates. All other awards may be granted to the Company&#8217;s employees, including the Company&#8217;s officers, the Company&#8217;s non-employee directors and consultants, and the employees and consultants of the Company&#8217;s affiliates.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c3895246-711a-482c-9488-7da5ac691e72_1" continuedAt="F_c3895246-711a-482c-9488-7da5ac691e72_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1110f9bb-6646-4ca8-8557-c5f68e6ad8b6" contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f65977c-3419-4316-8f76-693c563b8416" contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,700,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92a80cd5-489a-4375-b868-e9066d2d5d35" contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#8220;Plan Limit&#8221;).</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The maximum aggregate number of shares that may be issued under the 2020 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_782bd396-6d90-4f05-8fd1-bdf2f3f92823" contextRef="C_8057ddb3-0a97-4d84-a521-6c651151f255" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> over the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62ef3f82-65b7-4857-ad67-3678d80bda08" contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term of the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As permitted by the 2020 Plan, the Company added </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b2c296a-99a5-4d3f-a78c-166cf5a7f478" contextRef="C_b7ccda8d-34e0-4891-abca-16e72fec5b80" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,552,603</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfb5e2a0-fe00-4064-8ab3-d4918cd14c78" contextRef="C_476aa55d-daca-4a72-aade-622790de18ed" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,756,363</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for grant to the 2020 Plan on January 1, 2025 and January 1, 2024, respectively, increasing the maximum number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan as of January 1, 2025 to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9eb4fdf6-0a21-47a8-849c-e565696f16b9" contextRef="C_298722ae-af18-416d-b772-0febae7b0ff4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,179,529</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the twelve months ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b489d19d-d416-4f23-a4a3-5c637410fac6" contextRef="C_3122611a-d6b2-4e58-baae-c58bceaa1852" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,242</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_286571c1-54ad-443e-949d-827e32f3a040" contextRef="C_00309e6d-c478-4991-a287-b2b26b553406" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">224,437</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued under the Prior Plans were canceled and became available for grant under the 2020 Plan. In addition, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46afff41-b1e4-4486-9725-4d0ef4aca4c5" contextRef="C_5e95afea-eb7a-4026-b213-a7dc1020f814" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">626,926</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were available for grant under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Valuation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb074e22-97fc-459b-a752-3d22e1efa633" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.62%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:15.02%;box-sizing:content-box;"/>
        <td style="width:1.64%;box-sizing:content-box;"/>
        <td style="width:14.08%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f69359a-2ced-4d51-acfe-46a19e14a7b1" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f98dc8a3-14fc-405f-a5be-72355f374007" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f89b1b69-fb24-41d4-bd3e-ee8a7dc92257" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.22</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1ea0ee34-d666-4245-93cd-3abd8926877d" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.23</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24c33936-ef98-4272-a2e0-6fd60f3516b1" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">95</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c346944f-ffed-4e12-b3da-027b324dece0" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">94</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81236a9e-0eb7-4e63-b34a-0b86e1622ac2" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0b8974e-78de-46d0-8f16-4fdfbfcc8f07" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">0.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2810430e-0520-4561-8e33-d637a650473e" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 (amounts in millions, except for share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.39%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.502%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.062000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.602%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.042%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value (a)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a95bc63d-ce0b-4aaa-a7ae-353bfe532694" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">4,273,502</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f507a0b-45de-426d-9d78-ed9f32afe5cb" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.06</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3a618ce6-e0ee-457f-b121-9f290c037eed" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45085b7e-1c7b-4d87-b71d-975f7e67a47d" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,235,377</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5df27407-8da4-487c-bae1-77a2a733a174" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.35</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32cc7d5e-c4e7-413b-bd6e-6657284c85b0" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">15,404</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f77839e-6181-459e-a8fb-9e51cd76a517" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.00</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0e70eef-46da-475f-b3d5-cbcb00cec692" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">57,088</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6d7732c-e3d1-468b-9910-31459d6d0d7d" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.08</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02280e6c-8a2c-43ac-bde7-5a39fce68ab7" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,436,387</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7413e03-8618-4b07-92a6-75419e2bb4f4" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.78</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_3932a7db-94cf-490a-924a-058e79c90bfd" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8df5d249-b87f-4217-89c6-2eede8523974" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f6aad12-c898-4018-976f-d5cec7b0dec5" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,094,992</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcba4715-0313-43d5-a69e-25e96f8b4af1" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.45</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_66839798-9a69-4e16-80bc-6b7e90ec2399" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47c0ddf4-5bb5-46e7-b5b2-4813f6d81636" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e283898e-b0f9-4bf0-ba58-08f6585cbfa0" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,436,387</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd2c31d-a3a7-499f-916a-c547bfa5f42d" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.78</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2bb30d92-9e6c-402d-9766-b35d5129cc48" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5453b9f-e4d7-4b3a-8e00-1b2a4abde12b" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Option Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56b72155-047c-4d8e-88b5-991bbc1f895d" contextRef="C_8940587e-a90e-40f9-958f-9b1b19869429" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,235,377</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock to employees and directors under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date. Of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7ff3e42-aa18-4627-92cc-883a8dde0681" contextRef="C_8940587e-a90e-40f9-958f-9b1b19869429" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,235,377</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options granted, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55f2b4c8-12d7-4271-9aef-dc495a0bc4d0" contextRef="C_a95a6572-ed88-48df-9e64-6ef309bf3fc6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,140,377</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were granted to employees and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ee5f350-1340-41ed-bacb-1a2f6456d8dd" contextRef="C_a95a6572-ed88-48df-9e64-6ef309bf3fc6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_211628cf-3711-4965-b552-3cb905e6b077" contextRef="C_07cc377a-796d-498e-9d5b-1591bcb5477b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7921bfc-a461-4cad-b1bf-437ecdcb09ad" contextRef="C_e75c96fd-9bc2-4e22-9c5a-481e9d15e507" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">95,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options were annual grants to the Company's directors and vest </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f535e90f-3ae0-4d59-9d36-3886cb0a56dc" contextRef="C_e75c96fd-9bc2-4e22-9c5a-481e9d15e507" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date. The weighted-average grant date fair value of options granted under the 2020 Plan during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f2298bd-c463-4102-ae67-b18de591d027" contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c3895246-711a-482c-9488-7da5ac691e72_2" continuedAt="F_c3895246-711a-482c-9488-7da5ac691e72_3"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation expense related to unvested stock options granted under the 2020 Plan was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ca20bdc-1f8e-4dd9-a86d-2d0cec6afbcd" contextRef="C_fc129cfd-3960-440f-aa81-c3cce8de7bad" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e4d17c7-1cc5-496f-8c5e-715968aa4c81" contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.63</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inducement Stock Option Grant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edf52b06-02b1-4eb2-a97a-a0c356416b62" contextRef="C_41dc2a61-cb1b-4e3f-b8e4-3a5beacac631" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> inducement awards granted in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation expense related to unvested inducement options granted under the 2020 Plan was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cd8979b-bc1d-46d0-a1d6-b022adb9316c" contextRef="C_3e6edd92-c786-4088-97cc-096585e1d03d" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_150fd180-25b8-4d12-a842-d94fc3576b1a" contextRef="C_41dc2a61-cb1b-4e3f-b8e4-3a5beacac631" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.28</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs were granted under the 2020 Plan to the Company's employees in order to maintain retention of key employees. The value of an RSU award is based on the Company's stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56997e96-ca4e-473e-9fcd-b3ca58ac62cd" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activity with respect to the Company's RSUs during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 was as follows (in millions, except share, contractual term, and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.39%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.502%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:8.062000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.602%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:9.042%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value (a)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6134f825-cff2-4088-8608-27591338dd05" contextRef="C_b144c1ed-8a46-4360-ac5f-f8187e2445a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">615,000</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f70a90fe-95c1-4c69-9a51-53e7f32a923e" contextRef="C_b144c1ed-8a46-4360-ac5f-f8187e2445a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d4a14836-c6df-432c-a6cc-2151b8f1964a" contextRef="C_a04137e2-f395-4ec2-a749-7530c63c5c1c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e9cacd1-0c36-44a1-9235-8815531131a9" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">245,372</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bcee7d34-3139-42b4-8a7b-2769256eccde" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.21</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53c12ff4-41a8-4c66-98b7-35c847e44138" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">153,750</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e805475c-4088-4374-9751-b22a0a7f907a" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.94</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_355aeed6-e210-4175-a277-8a93337deaf1" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">7,619</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_584fb90e-b6a1-43fa-b7f5-8b7eaeeb4b7d" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.64</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7178190-6944-43df-88bb-900bf114705b" contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">699,003</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_431ec574-f93c-406d-8150-6a0e72a49aec" contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.69</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_02da442d-9eba-45af-b19d-0540357c5108" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5773a42-70b9-4337-9a9b-d9fe621e9e68" contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested and expected to vest as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4c1b448e-31ea-454b-932b-1383de7a6075" contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">699,003</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56a89e08-65ca-4dd1-ba94-849100949936" contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.69</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_c0afa914-2a1b-4b59-9164-b956dfb85e65" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></ix:nonNumeric></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3326af6-8d33-4671-abc9-82c2171480dc" contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02" name="lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28c2c299-3a74-4dbd-9a1a-2cd1d443d24b" contextRef="C_a9758b43-c974-4811-91f8-dd665c753866" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">245,372</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of RSUs to employees under the 2020 Plan. The RSUs vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01bfb9ce-c6d0-45ca-92a5-c306f0ed7636" contextRef="C_a9758b43-c974-4811-91f8-dd665c753866" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and have a weighted-average grant date fair value during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13bcd528-bed4-4a3e-82c2-a43ec0aab40a" contextRef="C_a9758b43-c974-4811-91f8-dd665c753866" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.21</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation expense for RSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38ac12a5-bb75-4fd2-8876-4335334fe9d5" contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03b02e60-fc3c-492a-bb74-01f08d308ebe" contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">January 2025 Option, Restricted Stock Unit Grants and Performance-Based Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 22, 2025, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e18581d-0b5a-4dcb-8371-c558358a0b5d" contextRef="C_f69f438f-7f98-46a0-8c4d-079bbdf2a12a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,084,162</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bad42637-c583-4007-b146-61b803514baa" contextRef="C_1ac20b4d-9dce-48ff-b9c6-72648d8b3bf5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">347,360</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of restricted stock units and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6dbdc709-4bec-4bdc-a770-de6a97889a2a" contextRef="C_b23e5525-f6f6-400b-a668-fca905202d1b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">200,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Performance-based restricted stock units to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18d398eb-11da-4cfa-9e3d-7766ecaa9276" contextRef="C_f69f438f-7f98-46a0-8c4d-079bbdf2a12a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5df335a4-2134-47ff-9ba9-365cf6be3666" contextRef="C_bf6d1d52-1fbd-434c-aff5-8c53c22ca6a0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The shares of restricted stock will vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06a43593-23d0-431a-a8c4-24b0610a76b5" contextRef="C_8fc81d4f-669b-4cb9-9f96-bcb205c5ce02" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The performance-based restricted stock units were granted to the Company's named executive officers. The grants included two performance milestones. The fist milestone, which relates to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2e7ac7a-f67d-4c51-b84c-578d39651558" contextRef="C_68ab6f05-562c-4261-83f4-2fd2834ae9b1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of each grant, will vest if the FDA accepts the filing of a biologic license application for accelerated approval of nomlabofusp by December 31, 2026. The second milestone, representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f114aaa1-edef-452a-86b8-56f01330e113" contextRef="C_9835f758-39d0-41f7-805e-a62b5ba91b72" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of each grant will vest if the FDA approves the Company nomlabofusp BLA within 12 months of the BLA acceptance (no later than December 31, 2027.) If the first milestone is not achieved by December 31, 2026, the full grant will be forfeited.</span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_c3895246-711a-482c-9488-7da5ac691e72_3"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92a276fe-8235-44a0-9255-e01e7e6b057d" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true" continuedAt="F_92a276fe-8235-44a0-9255-e01e7e6b057d_1"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.527%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.777000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:11.838000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7aa16ca-835d-40a9-90dd-5280e8b6ba4c" contextRef="C_f56605f3-2e21-4b59-b70a-99e345371439" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,053</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cb39aaf-627d-42e1-832f-37ad2c0bc44d" contextRef="C_04060931-70f8-40a1-b038-ff2323e800fc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,077</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d5f2de6-dfe7-4653-8104-351a6079ce43" contextRef="C_b632cd5c-05ae-4251-a104-e7cf0498b02b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,743</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_908dfc79-fc29-433a-9cb6-3f283d0f9591" contextRef="C_4c5e5e8c-5db3-4232-b8b8-f18e413251e5" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,538</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7859519-4ff9-437b-a9c7-512b72e7cc36" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,796</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e82b435-a01a-49c6-823b-9f79b31e7cfc" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,615</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <div><ix:continuation id="F_92a276fe-8235-44a0-9255-e01e7e6b057d_1"></ix:continuation></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_fd9b7802-7179-4332-acd7-4a803269f4fb" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_fd9b7802-7179-4332-acd7-4a803269f4fb_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Licenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is party to an exclusive License Agreement (the &#8220;WFUHS License&#8221;), dated November 30, 2016, as amended, with Wake Forest University Health Sciences (&#8220;WFUHS&#8221;) and an exclusive License Agreement (the &#8220;IU License&#8221;), dated November 30, 2016, as amended, with Indiana University (&#8220;IU&#8221;). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by the Company with respect to the development of nomlabofusp. Both agreements continue from their effective date through the last to date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In partial consideration for the right and license granted under these agreements, the Company will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, the Company is obligated to pay each of WFUHS and IU certain milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7af5f693-9c00-4648-948e-46c2821c2039" contextRef="C_c37bbde8-7943-40d4-8b87-262850af251a" name="lrmr:MilestonePaymentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_98fd4cfb-2e95-49f0-9dc1-0eccbd337542" contextRef="C_374ec650-46e4-4848-b593-f01df79d1e1f" name="lrmr:MilestonePaymentAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate upon the achievement of certain developmental milestones, which commenced with the enrollment of the first patient in a Phase 1 clinical trial. The Company enrolled the first patient in its SAD trial on December 11, 2019 and paid WFUHS and IU less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac167afc-43cb-4784-98a4-a46884160650" contextRef="C_6be3737e-d05f-4180-bd52-32638a31f43d" name="lrmr:PaymentForLicenseAgreements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company will also pay each of WFUHS and IU sublicensing fees ranging from a high-single digit to a low double-digit percentage of sublicense consideration depending on the Company&#8217;s achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. The Company is also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that the Company disputes the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. The Company is also obligated to pay to IU a minimum annual royalty of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0384cd11-b968-4dc9-aaf0-3d490cb33316" contextRef="C_374ec650-46e4-4848-b593-f01df79d1e1f" name="lrmr:MinimumAnnualRoyaltyObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per annum.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the Company is required to pay IU consideration, then the Company may deduct </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_269d407f-03a9-47b9-83d8-1d9b512e2541" contextRef="C_00c4f173-1035-4879-939f-3e16d63fb716" name="lrmr:LicenseAgreementConsiderationDeductionPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that the Company is required to pay WFUHS consideration, then the Company may deduct </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ab7b81d-4173-4fa7-9f9b-c8cd977d5418" contextRef="C_9310a56d-595a-456c-875c-d9c91b4958c9" name="lrmr:LicenseAgreementConsiderationDeductionPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">60</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, the Company initiated dosing of a Phase 2 study. Pursuant to the terms of both the WFUHS License and the IU License, the company recognized milestone expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f5f431e-15bd-4f30-aa33-2d7c46b2c6df" contextRef="C_0788b521-b323-45f2-8f3d-8796f828638d" name="lrmr:MilestoneExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million within research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both agreements continue from their effective date through the last date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bala Cynwyd Office Space</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 8, 2019, the Company entered into an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_641cbf68-dcb4-4578-b3bb-7d4ac98324c6" contextRef="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">4,642</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space in Bala Cynwyd, Pennsylvania, effective as of December 15, 2019, for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23ba6c66-aa03-41e8-a711-0dc6359e0073" contextRef="C_ec704a28-ca88-417d-afd5-2b5e09e3a38e" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years and six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with an option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_87fbb33e-f754-46a6-98ea-b08d228c7b45;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dfb67d46-7ca5-472b-80bd-8e567af2b22c" contextRef="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 15, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 9, 2023, the Company executed a lease extension agreement on its original </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88a46b2d-ebfc-41e6-9859-2b3c9f2a4253" contextRef="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">4,642</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square footage of office space in Bala Cynwyd, Pennsylvania (which was set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d09b5249-139c-4022-bd74-7a580647cdf5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and agreed to lease an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8aafb59-382e-4698-9bee-49649439d166" contextRef="C_5bc874d9-7864-4d71-a931-3ccf2f2d90ca" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">3,462</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space from the same landlord.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_fd9b7802-7179-4332-acd7-4a803269f4fb_1" continuedAt="F_fd9b7802-7179-4332-acd7-4a803269f4fb_2"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease extension on the original </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34230ea0-519b-4861-a783-fe0ca7c08995" contextRef="C_dd95e4fc-82fa-4a33-961e-756339a32f40" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">4,642</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square footage commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43ee9270-7bfd-44a1-ba2e-0418f6a8c36a" contextRef="C_dd95e4fc-82fa-4a33-961e-756339a32f40" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99b0c0f1-3215-4759-8257-cb3a8c9ea50b" contextRef="C_5fd8fb15-cf4d-4748-b06e-8e9b5decf68b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_df5d642c-55b4-4324-a11a-bacf9a07a10e" contextRef="C_5fd8fb15-cf4d-4748-b06e-8e9b5decf68b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The new lease on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1bcb953-8a88-475c-a995-c900a9f356ec" contextRef="C_5bc874d9-7864-4d71-a931-3ccf2f2d90ca" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">3,462</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional square footage commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d5a6e41-0896-44b8-abac-57321170ac99" contextRef="C_5bc874d9-7864-4d71-a931-3ccf2f2d90ca" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29a1da94-5c43-42ba-b7ca-ae8adc67f4d8" contextRef="C_7652464d-494e-4455-9127-a6517e3601ea" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ae4512c7-c113-4a8f-9ea8-cd902221999c" contextRef="C_7652464d-494e-4455-9127-a6517e3601ea" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The right of use assets and lease liabilities with these leases are reflected in the financial statements for the year ended December 31, 2024 as are the right of use asset and lease liability of the Company's Boston office space and lab space discussed below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Boston Office Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Company's 2020 merger with Zafgen described in footnote 1, on May 28, 2020, the Company acquired a non-cancellable operating lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d6e9b35-3e35-454f-bdc0-9141ed403327" contextRef="C_f62796d0-82ee-42f2-a018-74063dd58aa3" name="lrmr:AreaOfOfficeSpace" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">17,705</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space (the &#8220;Premises&#8221;). The lease expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ff57f01d-f30c-4b68-a0e0-cafafb149422" contextRef="C_f62796d0-82ee-42f2-a018-74063dd58aa3" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 30, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As part of the agreement, the Company was initially required to maintain a letter of credit, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95b974f3-e133-4f4e-a798-78ef7041ec7f" contextRef="C_c441b869-7333-4da3-92e6-35ae34bd02de" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In October of 2024, upon the agreement with the landlord that we had achieved certain clinical development milestones required in the lease, this letter of credit was reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0afb67fa-215c-4aab-a688-6adee118b5a9" contextRef="C_763a19f3-ed28-42b9-b147-b3bf06139429" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. During both periods presented, this cash deposit and is classified as restricted cash within the consolidated financial statements. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The right-of-use asset is being amortized to other income/(expense) over the remaining lease term as a result of the sublease described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Massachusetts Municipal Association, Inc. (the &#8220;Subtenant&#8221;), whereby the Company sublet the entire Premises to the Subtenant. The initial term of the Sublease commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_590c6407-2fa8-40ad-8f1b-9cd83951376f" contextRef="C_fd07840a-58bc-4339-8331-bc488a2c40c3" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 4, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and continues until </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abb980be-8531-4e08-b27d-9e42dd0c4852" contextRef="C_fd07840a-58bc-4339-8331-bc488a2c40c3" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 30, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the Sublease, the Company evaluated the need for impairment under ASC 360 "Impairment Testing: Long-Lived Assets Classified as Held and Used," and determined there was no impairment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sublease provided for an initial annual base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0dd824a2-7be4-428e-95b6-1ebb69c276be" contextRef="C_4b1f55d6-efd7-4b66-b757-9829759cb41d" name="lrmr:SubleaseAnnualBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which increases annually up to a maximum annual base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0887635b-6a1f-4c09-9d45-2246e46cbd04" contextRef="C_410cee1a-9246-4e71-a46a-d8f61f308f49" name="lrmr:SubleaseAnnualBaseRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Subtenant also is responsible for paying to the Company future increases in operating costs (commencing on January 1, 2022), future increases in annual tax costs (commencing July 1, 2021) and all utility costs (commencing March 1, 2021) attributable to the Premises during the term of the Sublease. As part of the Sublease, the subtenant deposited a letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cec55fda-549e-49ff-9650-fe665f2f8b98" contextRef="C_0d03b972-e68a-4737-840c-600693a1015c" name="us-gaap:SecurityDepositLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbab8d91-4fcc-448a-8011-b8fbb033b7aa" contextRef="C_84d96472-3ce3-4f5b-8844-308604770292" name="us-gaap:SecurityDepositLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lab Space</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_868bc3e6-541f-43a6-8dbe-283e5a07a3b0" contextRef="C_1807f4b1-8435-4d6f-ad59-b534cb43cab2" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2019</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_64741758-6cab-459c-b460-7f413210d734" contextRef="C_1807f4b1-8435-4d6f-ad59-b534cb43cab2" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2020</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with an option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f3be3bdd-793f-4d1a-9a7e-f230d03efd1b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36088e0d-0166-422a-9630-937394228e71" contextRef="C_ad4e109b-2beb-4b4b-8ec0-7ff1c78ca2a2" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2021</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e636a3ec-0b0a-4cb2-9de4-43075ef6505d" contextRef="C_86c1a03b-7f05-4056-8a4b-a412c8acdc0b" name="us-gaap:LeaseExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In September 2023, the Company extended this lease for an additional year with the option to terminate with four months' notice. On March 28, 2024, the Company gave the requisite notice and vacated the property in May 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 16, 2023, the Company entered into an operating lease for alternate lab space in King of Prussia, Pennsylvania for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e715c503-c07c-41ff-b0cc-14c4cd7d9c4a" contextRef="C_aae3cd8b-68ec-413d-a96c-c3611488b3a4" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property. The actual lease term commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1506bd6e-8d94-4ba4-85d7-72ff74ea7d10" contextRef="C_3aec0197-d24a-4489-bac3-6d1692746976" name="lrmr:LeaseTermCommencementDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 10, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon commencement of the lease term, the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c730f1d1-dba3-4a12-a258-9c1fc8d7da7a" contextRef="C_d571d28c-42d3-4ede-a9a7-3e4acee72b97" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1a9dd06e-5f3f-4452-9a6a-2135fcf3ddae" contextRef="C_d571d28c-42d3-4ede-a9a7-3e4acee72b97" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which are reflected in these consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lease Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expense arising from operating leases was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5cd38bf-655f-4dec-8d16-2039866c2cc5" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f30b871-98af-4826-b4ec-e8c75ca03918" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:OperatingLeaseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 and 2023, respectively. For operating leases, the weighted-average remaining lease term for leases at December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb4f0213-046a-4bd4-93dd-961aeeef61ca" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c05bdb22-4bd4-4fda-a7c0-90cf8737e2b7" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. For operating leases, the weighted average discount rate for leases at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c17d653-1c09-459d-80c4-234473d4dbee" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3cb2ae6f-60e0-40ff-bf6b-a8baceb3cf4b" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The Company has not entered into any financing leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fd9b7802-7179-4332-acd7-4a803269f4fb_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d87f61fb-cd92-482d-a1db-31865962ef3e" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of lease liabilities due under these lease agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.1%;box-sizing:content-box;"/>
        <td style="width:1.94%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:15.96%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leases</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_904cc617-2b1e-4f09-bbe8-f40c59a48bf0" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,543</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_018fdca9-3320-43c6-a851-419fea63de7b" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,473</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_137a7645-15ba-4714-8fbc-51d1e5cf5243" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,267</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45fc5294-4568-4996-bd8e-36f9443e61bc" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,189</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a35459f-5449-43ca-a797-93ef68ec5595" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">959</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2391f712-852e-47c5-817c-c2d75c8ce6a2" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e5d4f82-6b7d-497e-9be8-a83cd3dcc318" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,431</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb344c1f-b92a-45ab-be56-40cf1ce5ddb9" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,314</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dd775e3-3907-4ab9-9f7a-3241988fb400" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,117</ix:nonFraction></span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company&#8217;s business, operating results, financial condition or cash flows.</span></p></ix:continuation></div>
  <div><ix:nonNumeric id="F_8aa8f4be-6282-4c8c-a63c-d235bf987e15" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_8aa8f4be-6282-4c8c-a63c-d235bf987e15_1"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72fc1778-1964-4a25-ac10-22fc4f2be3ab" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a21b7094-43d0-4a42-a467-69cdc1a8a89e" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> income tax benefits for the net operating losses incurred in each year due to its uncertainty of realizing a benefit from those items.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2e0dd42-cee0-4603-ad77-9d552ea0f656" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The domestic and foreign components of loss before income taxes are as follows.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.987%;box-sizing:content-box;"/>
        <td style="width:2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.596%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.797%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_db1cd6c9-d452-4fe5-8600-81b54c0c763f" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,604</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc47eb51-8725-44c9-97bb-168999c1e525" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,948</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_328a72ab-91be-438a-b2a3-8d12d08feaa3" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8477ac70-26b8-4a49-a33a-67872fd5ecad" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80,604</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85521b31-a658-4360-8a9b-bff5d3bd2cd2" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">36,949</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d84a189d-ac8b-4270-a10e-eed06f2b7721" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.193%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.023%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.6%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:13.182%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92b7e310-1fde-48fe-896f-8eb584017d06" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c01d7eae-3b8e-43ca-aa26-c6259670a4d1" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_878fb1af-3a8a-4244-bee9-b4ccbf307cf1" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f59c22ce-bf09-48f2-9705-51fc6e6b9739" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8025b5d0-0323-472c-a021-98625686fac4" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c08fce39-204f-46f6-84bb-d638621ac64d" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research and development tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3588c994-7338-4b05-b12b-628c68bd0554" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">14.5</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbe00552-b9e7-4b1b-a83a-cde8a69ee1fc" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">8.2</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nondeductible permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca87d510-b935-4305-92b7-b93953ad3357" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_080a5876-58a7-4a5f-8388-36ddea385024" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation forfeitures - DTA Write Off</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bebe5ee1-3160-4410-85f7-25a5cba0a3d6" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="lrmr:EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2f23cfc-a9ed-4eab-a26e-ed3d346b627b" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">38.7</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02449dd8-2f0c-4ec5-8874-3d4084bcf2b5" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">29.6</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdaa7389-22aa-4a98-b987-f54249f89bc6" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a76996f2-b0c9-4ddc-81ea-b319294db60f" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div><ix:continuation id="F_8aa8f4be-6282-4c8c-a63c-d235bf987e15_1" continuedAt="F_8aa8f4be-6282-4c8c-a63c-d235bf987e15_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6cc877f4-8fa0-4b69-8b36-8e1b28f1f560" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65%;box-sizing:content-box;"/>
        <td style="width:2%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:14.54%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.84%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D - acquired in merger with Zafgen</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cf12f94-aeaf-402b-bab1-eda36baa97e4" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,678</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a912f6d-b708-40e7-8df9-ee5736df5c11" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,678</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D - Section 174 Costs post 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33f36dc2-1a06-4f62-9dc8-6c54718664cc" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,616</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31d6c62b-7b36-4d18-9004-cb076d058691" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,411</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f954465-ea16-4251-b5ea-f840c32629a6" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,879</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9983e0-32d6-4278-95f3-35c0c717137d" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,490</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72432283-b1ad-452b-8b47-6ac2d870d414" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,177</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ff8b0ca-5368-4680-8c04-a968d845e2e2" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,195</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c598b854-97e2-4168-bb0b-fd7b05b28d20" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,022</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e3d355f-942c-4d7f-ab12-770c23c19d06" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,319</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ff2bd06-c869-4d9c-ae5a-6130ff7f7bec" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8253081-458e-4071-ba21-8b0e2aeaa3aa" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals &amp; reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b468a85-a671-47c5-9f81-d9b79bd2078c" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a73f5378-a11f-48cf-867d-d240b6f1940a" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets &amp; intangibles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5004763d-1952-4e9e-8582-5d08cbc7ce78" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e2e5e21-a0d2-447e-a6de-47099b598877" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee365fc6-e966-477c-98e1-5ea046b92270" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="lrmr:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,196</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19405c41-f979-4d91-b5d8-f916fd06c032" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="lrmr:DeferredTaxAssetsOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,298</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14b82c90-7087-4d0a-bb4b-802303c5f3c8" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,736</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddd3873c-8ad3-4312-aedf-f5a3dccae245" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,538</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcc00162-0a47-425d-93b7-58a700ac5010" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">708</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b9504a9-c936-4c82-8d59-44d22672e9cd" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d649b855-6cc2-48c7-a17b-102785582cdd" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">708</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d66512a3-e0ee-47b2-a30b-97d7648db127" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">768</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b4ff837-cbff-4487-925c-2fb19c43e512" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,028</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8de57bb-4d6a-415e-a99b-62d9cdf9cb72" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,770</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in the valuation allowance for deferred tax assets during the year ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related primarily to the increase in net operating loss carryforwards and tax credit carryforwards and a decrease other deferred tax assets associated with a reduction in the Company&#8217;s effective state rate. </span><span><ix:nonNumeric id="F_d29713e7-b649-420d-a030-39beded0c5e1" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:SummaryOfValuationAllowanceTextBlock" escape="true" continuedAt="F_d29713e7-b649-420d-a030-39beded0c5e1_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes to the valuation allowance were as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d29713e7-b649-420d-a030-39beded0c5e1_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:1.62%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
        <td style="width:12.883000000000001%;box-sizing:content-box;"/>
        <td style="width:1%;box-sizing:content-box;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of the beginning of the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de4eaa9c-a0ce-4578-be3c-a8f9cf77dcf8" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,770</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da49e685-b5fc-4091-88e5-c0abd9414102" contextRef="C_e567f291-5928-46ca-9886-4b12d459c211" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,831</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increases recorded to income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_553fc9fb-9a0f-457f-843a-fcaacff73a03" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,258</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f05628b-5993-42b2-a449-7ec2f157b273" contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,939</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ca23c1b-1885-40fd-bfd6-d3db0d042007" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">173,028</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5be1e4d-708c-47f6-9c5f-f35db9208b78" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,770</ix:nonFraction></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had net operating loss carryforwards that expire for federal, foreign and state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1cbc8b4-f2d7-4ad9-bb91-7edc218f329b" contextRef="C_be61e1b5-4f33-432f-86bc-37fe2c3476b7" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">198.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8a378e3-c428-477d-a791-08978c683a7f" contextRef="C_a1d529ba-7ef3-4346-82a1-30f1da0afd55" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9c7c4c5-b77d-4d93-a7f8-cf96498e75a0" contextRef="C_4d107843-e44a-43f6-84f2-18bd5c829091" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">164.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal and state operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c2bb7e5-a698-4a9e-824f-5318ec77e1a3" contextRef="C_7d857bb0-3425-42ce-bed1-6edca2b32acc" name="lrmr:NetOperatingLossCarryForwardExpirationYearBegin"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_852bc970-dbe6-4996-b7c8-df62a54bddd8" contextRef="C_4a89193c-4cbe-4c85-bcc3-a83c9bc990b0" name="lrmr:NetOperatingLossCarryForwardExpirationYearBegin"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2030</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, while the foreign net loss carryforward can be carried forward indefinitely. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal net operating loss carryforwards that were generated after December 31, 2017 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47a41144-8f03-4eaa-b983-aeedc20cf3ac" contextRef="C_8b7bbdf5-c433-4df2-8d61-5681d6000126" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">159.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that do not expire, however these </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a43241a-e2c0-453d-945d-99277ec87af5" contextRef="C_ad1539c6-fc3e-4f7a-a9a5-26892c4889b7" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carryforwards are limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9354fcc9-3553-4010-a42c-120e84e5ebc3" contextRef="C_ad1539c6-fc3e-4f7a-a9a5-26892c4889b7" name="lrmr:OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">80</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the taxable income in any one tax period.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company also had available tax credit carryforwards for federal and state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2997382-cfa5-48b9-8c02-cc1c13d2167f" contextRef="C_8ee26ea1-7981-475b-8275-d3cd88ccd7f7" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3b18211-165c-47e9-b49c-60a024a54cf6" contextRef="C_255549a6-f23b-4838-819a-a321c153cd07" name="lrmr:TaxCreditCarryForwardExpirationYearStart"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Utilization of the pre-Merger net operating loss carryforwards attributable to Zafgen, of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae5e7a8c-53bf-4ed7-982f-67af6d97bd93" contextRef="C_99e2e692-a200-4366-9fac-4c228a2bb15b" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes occurred during the tax year associated with the Merger. In addition to the limitation of the pre-Merger NOL&#8217;s of Zafgen, the net capitalized R&amp;D deferred tax assets in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a1c7595-21cc-414c-a241-ff843cbf35bb" contextRef="C_99e2e692-a200-4366-9fac-4c228a2bb15b" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">66.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ec20827b-95a7-4931-8fdb-cc0097da5c3d" contextRef="C_9be6fbc0-da98-4a6c-9580-1b53447c931e" name="lrmr:NetCapitalizedRDDeferredTaxAssetsRealizationDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&amp;D is disposed within five years of the Merger, or May 28, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The ownership changes will limit the amount of pre-merger Zafgen carryforwards that can be utilized annually to offset future taxable income with an annual limitation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4d040bf-2c32-42fc-865b-cdf463af3ff2" contextRef="C_9be6fbc0-da98-4a6c-9580-1b53447c931e" name="lrmr:NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand per year. The Company has reduced their NOL and R&amp;D tax credit deferred tax assets associated with the pre-Merger Zafgen operations as a result of the 382 analysis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes that as a result of its merger with Zafgen, its ability to utilize NOLs acquired in the transaction and our other NOLs is expected to be severely limited by Section 382 of the Code. Additionally, the Company&#8217;s July 2021, September 2022 and February 2024 equity transactions could also limit its ability to utilize NOLs in the future. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company experienced a change of control, as defined by Section 382, at any time since inception, utilization of its net operating loss carryforwards or tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8aa8f4be-6282-4c8c-a63c-d235bf987e15_2"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Additionally, our July 2021, September 2022 and February 2024 equity transactions could also limit our ability to utilize NOLs in the future. Any limitation may result in expiration of a portion of the net operating loss carryforwards or tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, no amounts are being presented as an uncertain tax position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Tax Cuts and Jobs Act ("TCJA") requires taxpayers to capitalize and amortize research and experimental expenditures under IRC Section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during the year ended December 31, 2022 and resulted in the capitalization of research and development costs </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a7d62b1-8baa-45ee-acaf-28530285d893" contextRef="C_f1ad33a8-3ac6-4e46-a123-734c2ff51101" name="lrmr:CapitalizedResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">69.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7022a54d-7194-4347-b1c7-4286dfd438fe" contextRef="C_da30be71-5046-4b9b-aa5d-981a3c109ee3" name="lrmr:CapitalizedResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15730f7a-d93f-46d3-94c3-4b0d2fe61604" contextRef="C_458d2390-7c95-42ed-9486-6626384ec15f" name="lrmr:CapitalizedResearchAndDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">22.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2024, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company is amortizing these costs for tax purposes over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_670afaf1-a787-4bb1-b71f-9bd782082514" contextRef="C_fe3e5c5a-5d3a-4ea1-8f76-28fa8c02f25f" name="lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if the research and development was performed in the U.S. and over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57a7ff60-913c-426e-bcfe-213d6812f5af" contextRef="C_47c2670a-5ab5-47d8-879f-4c1d86ad4d5f" name="lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if the research and development was performed outside the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s net deferred tax asset balance before the valuation allowance was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2da44a4-e6bc-42e5-a64e-c7d822fb63c1" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">173.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bafb025-cbd1-41f5-a795-81665d863c35" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">141.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and was comprised principally of net operating loss carryforwards, capitalized research and development expenses and tax credit carryforwards. During the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, gross deferred tax assets increased due to deferred tax assets acquired as a result of additional net operating loss carryforwards and research and development tax credits generated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2024 and 2023. Management reevaluates the positive and negative evidence at each reporting period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de79c642-9907-4169-b6c7-61f3595660a8" contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_30398e9b-f160-48c8-9359-8b86e5e59a1c" contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any amounts for unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. The Company&#8217;s tax years are still open under statute from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3544ef17-f3b5-4927-ba28-69fcaa25789b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the present. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision.</span></p></ix:continuation></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a366905-834b-472b-8cdc-e9701dfd6fc1" contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Party</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company entered into an agreement with the Friedreich&#8217;s Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners. The consortium will conduct a natural history study designed to establish disease-specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials. As an industry partner, the Company will help fund the study and contribute to the study design, research activities, and analysis. The Company will have access to all study data for use in its regulatory filings, as appropriate. During the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6dc26ce-d3be-43e4-82cb-f89dc83276f2" contextRef="C_30f69550-77db-454a-9913-83a4c6b940ff" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of costs related to the Track-FA program and will fund future costs going forward. One of the Company&#8217;s Directors is also a director of FARA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, during the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sponsored patient and caregiver awareness events held by FARA for a cumulative $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_625dc98f-fa00-42a8-852a-bd45c8f67c65" contextRef="C_d18029d6-d247-44b7-8d04-1bedb1e05fca" name="us-gaap:OperatingCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>lrmr-ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GOODWIN PROCTER DRAFT:  2/15/2023</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESTRICTED STOCK UNIT AWARD AGREEMENT<br>FOR COMPANY EMPLOYEES<br>UNDER the larimar therapeutics, inc.<br>2020 equity INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name of Grantee:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No. of Restricted Stock Units:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant Date:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Larimar Therapeutics, Inc. 2020 Equity Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Larimar Therapeutics, Inc. (the &#x201c;Company&#x201d;) hereby grants an award of the number of Restricted Stock Units listed above (an &#x201c;Award&#x201d;) to the Grantee named above.  Each Restricted Stock Unit shall relate to one share of common stock, par value $0.001 per share (a &#x201c;Share&#x201d; or &#x201c;Shares&#x201d;) of the Company.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions on Transfer of Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any Shares issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) Shares have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting of Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates.  If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.</font></div></div>
  <table style="margin-left:6.667%;border-spacing:0;table-layout:auto;width:83.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:58.46%;box-sizing:content-box;"></td>
    <td style="width:41.54%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Incremental Number of<br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Restricted Stock Units Vested</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Vesting Date</font></p></td>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:0.6pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.107%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">_____________ (___%)</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">_______________</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:0.6pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.107%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">_____________ (___%)</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">_______________</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:0.6pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.107%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">_____________ (___%)</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">_______________</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;text-indent:0.6pt;vertical-align:top;padding-bottom:0in;"><p style="margin-left:0.107%;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">_____________ (___%)</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">_______________</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination of Employment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If the Grantee&#x2019;s employment with the Company and its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121521257.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Issuance of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of Shares equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incorporation of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Committee set forth in Section 2 of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.   The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event.  To the extent authorized by the Committee, the required tax withholding obligation may be satisfied, in whole or in part, by withholding from Shares to be issued to the Grantee a number of Shares with an aggregate Fair Market Value that would satisfy the withholding amount due. The Company has the right to deduct any such taxes from payment of any kind otherwise due to the Grantee.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Grantee acknowledges that the Company has not advised the Grantee regarding the Grantee&#x2019;s tax liability in connection with this Award. The Grantee acknowledges that the Grantee has reviewed with the Grantee&#x2019;s own tax advisors the tax treatment of this Award (including the issuance of any Shares in settlement of the Restricted Stock Units hereunder) and is relying solely on those advisors in that regard. The Grantee understands that the Grantee (and not the Company) will be responsible for the Grantee&#x2019;s own tax liabilities arising in connection with this Award.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 409A of the Code.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#x201c;short-term deferrals&#x201d; as described in Section 409A of the Code.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Continuation of Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement will not confer upon the Grantee any right to continue in the employment or service of the Company or any of its Affiliates, or limit in any respect the right of the Company or its Affiliates to discharge the Grantee at any time, for any reason.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement represents the entire agreement between the parties with respect to the subject matter hereof and supersedes any prior agreement, written or otherwise, relating to the subject matter hereof.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121521257.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Privacy Consent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;).  By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Grantee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Electronic Delivery of Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Grantee authorizes the Company to deliver electronically any prospectuses or other documentation related to this Award and any other compensation or benefit plan or arrangement in effect from time to time (including, without limitation, reports, proxy statements or other documents that are required to be delivered to participants in such arrangements pursuant to Federal or state laws, rules or regulations). For this purpose, electronic delivery will include, without limitation, delivery by means of e-mail or e-mail notification that such documentation is available on the Company&#x2019;s Intranet site. Upon written request, the Company will provide to the Grantee a paper copy of any document also delivered to the Grantee electronically. The authorization described in this Paragraph may be revoked by the Grantee at any time by written notice to the Company.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121521257.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Larimar Therapeutics, Inc.</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	Title:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:36pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dated:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grantee&#x2019;s Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grantee&#x2019;s name and address:</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="margin-left:43.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.8in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121521257.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>lrmr-ex10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html>
 <head>
  <title>EX-10.4</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">larimar therapeutics, inc.</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br>NON-QUALIFIED stock option grant notice</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and award agreement</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NON-PLAN INDUCEMENT AWARD</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Larimar Therapeutics, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), hereby grants to the individual listed below (&#x201c;Participant&#x201d;) an non-qualified stock option to purchase the number of Shares set forth below (the &#x201c;Option&#x201d;). The Option is subject to the terms and conditions set forth in this Non-Qualified Stock Option Grant Notice (the &#x201c;Grant Notice&#x201d;) and the Award Agreement attached hereto as Exhibit A (the &#x201c;Agreement&#x201d;), which is incorporated herein by reference. This Option has been granted as an employment inducement grant pursuant to Rule 5635(c)(4) of the Marketplace Rules of NASDAQ Stock Market, Inc., is not issued under the Company&#x2019;s 2020 Equity Incentive Plan, as amended through the date hereof (the &#x201c;Plan&#x201d;), and does not reduce the share reserve under the Plan. However, for purposes of interpreting the applicable provisions of this Option, the terms and conditions of the Plan (other than those applicable to the share reserve) shall govern and apply to this Option as if this Option had actually been issued under the Plan. This Option is not intended to be an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Grant Notice and the Agreement.</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.05pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Participant:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:5.85pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Grant Date:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:5.8pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price Per Share:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:5.8pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total Number of Shares Subject to Option:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:5.8pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expiration Date:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting Schedule:	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">]</font></p>
  <p style="margin-left:0.987%;text-indent:4.175%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;margin-right:1.611%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">By Participant&#x2019;s signature below, Participant agrees to be bound by the terms and conditions of the Agreement and the Grant Notice, and, for purposes of interpreting the provisions of the Option, the terms and conditions of the Plan (other than those applicable to the share reserve) shall govern and apply to this Option as if this Option had actually been issued under the Plan. Participant has reviewed the Agreement, the Plan and the Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing the Grant Notice and fully understands all provisions of the Grant Notice, the Agreement and the Plan. This document may be executed, including by electronic means, in multiple counterparts, each of which will be deemed an original, and all of which together will be deemed a single instrument.</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PARTICIPANT</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">_____________________________________	________________________________<br>Name:	Name:</font></p>
  <p style="margin-left:0.987%;font-size:10pt;margin-top:6.2pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title:	Title:</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">exhibit a<br>to NON-QUALIFIED stock option grant<br><br>Notice Award agreement</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Grant Notice to which this Agreement is attached, the Company has granted to Participant an Option under the Plan to purchase the number of Shares set forth in the Grant Notice.</font></p>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Award of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In consideration of Participant&#x2019;s employment with or service to the Company and for other good and valuable consideration, effective as of the Grant Date set forth in the Grant Notice, the Company has granted to Participant the Option to purchase part or all of the aggregate number of Shares set forth in the Grant Notice, subject to the terms and conditions set forth in the Grant Notice and this Agreement, and, as set forth above, for purposes of interpreting the provisions of the Option, the terms and conditions of the Plan (other than those applicable to the share reserve) shall govern and apply to this Option as if this Option had actually been issued under the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date of Grant; Term of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Option is granted on the Grant Date and may not be exercised later than the Expiration Date, subject to earlier termination in accordance with this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Option Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The exercise price per Share of the Option (the &#x201c;Exercise Price&#x201d;) is set forth in the Grant Notice.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting and Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vesting</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Subject to the continued service of the Participant with the Company through the relevant vesting dates, the Option shall become vested and exercisable in such amounts and at such times as set forth in the Grant Notice.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Service with Affiliates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Solely for purposes of this Agreement, service with the Company will be deemed to include service with an Affiliate of the Company (for only so long as such entity remains an Affiliate of the Company).</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Effect of Termination of Service on the Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Participant&#x2019;s service ceases for any reason, the termination or survival of the Option will be determined in accordance with Section 7 of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Method of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Participant may exercise the Option by delivering a payment of the Exercise Price, any required tax withholding and written notice of exercise to the Company in accordance with Section 5(d) of the Plan. To the extent permitted (and subject to procedures established) by the Committee in its discretion, the Participant may also pay the Exercise Price (i) by surrendering previously acquired Shares to the Company, which Shares have an aggregate Fair Market Value on the date of exercise equal to the aggregate </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price then due (or by means of attestation, whereby the Participant identifies specific previously acquired Shares having an aggregate Fair Market Value on the date of exercise equal to the aggregate Exercise Price then due and the number of Shares actually delivered upon exercise is reduced by the number of such identified Shares), or (ii) by means of a broker-assisted cashless exercise. The notice of exercise must also be accompanied by any further documents or instruments necessary or desirable to carry out the purposes or intent of this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Partial Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The minimum number of Shares with respect to which the Option may be exercised at any one time shall be the lesser of (i) 100 Shares, or (ii) the total number of Shares as to which the Option is then exercisable.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:13.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:4.8%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions on Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Option may not be exercised, and any purported exercise will be void, if the issuance of Shares upon such exercise would constitute a violation of any law, regulation or exchange listing requirement. The Committee may from time to time modify the terms of the Option or impose additional conditions on the exercise of the Option as it deems necessary or appropriate to facilitate compliance with any law, regulation or exchange listing requirement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investment Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Participant represents and warrants he or she is acquiring the Option (and upon exercise of the Option, will be acquiring the subject Shares) for investment for the Participant&#x2019;s own account, not as a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. As a further condition to the exercise of the Option, the Company may require the Participant to make any representation or warranty as may be required by or advisable under any applicable law or regulation.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-Transferability of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Except as may be permitted by the Committee in accordance with Section 14 of the Plan, the Option may not be sold, pledged, assigned, hypothecated, gifted, transferred or disposed of in any manner, either voluntarily or involuntarily, other than by will or by the laws of descent and distribution.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Exercise Price, as well as the number and kind of shares subject to the Option, are subject to adjustment at the discretion of the Committee, including, but not limited to, in accordance with Section 3(d) of the Plan.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Participant acknowledges that the Company has not advised the Participant regarding the Participant&#x2019;s tax liability in connection with the Option. The Participant acknowledges that the Participant has reviewed with the Participant&#x2019;s own tax advisors the tax treatment of the Option (including the purchase and sale of Shares subject hereto) and is relying solely on those advisors in that regard. The Participant understands that the Participant (and not the Company) will be responsible for the Participant&#x2019;s own tax liabilities arising in connection with the Option.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Continuation of Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement will not confer upon the Participant any right to continue in the employment or service of the Company or any of its Affiliates, or </font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limit in any respect the right of the Company or its Affiliates to discharge the Participant at any time, for any reason.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As set forth above, this Option is not granted pursuant to the Plan.  Instead, this Option is granted as an &#x201c;employment inducement award&#x201d; pursuant to the exemption provided by Rule 5635(c)(4) of the Marketplace Rules of NASDAQ Stock Market, Inc.  However, for purposes of interpreting the provisions of this Option, the terms and conditions of the Plan (other than those applicable to the share reserve, but, including the powers of the Administrator set forth in Section 2 of the Plan) shall govern and apply to this Option as if this Option had actually been issued under the Plan.  The Participant has received a copy of the Plan, has read the Plan and is familiar with its terms, and hereby accepts the Option subject to the terms and provisions of the Plan only for purposes of interpreting the provisions of this Agreement, including that the Committee is authorized to interpret this Option and the Plan and to adopt rules and regulations not inconsistent with the Plan as it deems appropriate. The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee with respect to questions arising under the Grant Notice or this Agreement, or any interpretations of the Plan or the Plan&#x2019;s governance and applicability to this Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entire A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">g</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Grant Notice and this Agreement represent the entire agreement between the parties with respect to the subject matter hereof and supersede any prior agreement, written or otherwise, relating to the subject matter hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement may only be amended by a writing signed by each of the parties hereto; provided that the Company may amend this Agreement without the Participant&#x2019;s consent, if the amendment does not materially impair the Participant&#x2019;s rights hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governin</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">g</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Agreement will be construed in accordance with the laws of the State of Delaware, without regard to the application of the principles of conflicts of laws.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headin</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">gs. The headings in this Agreement are for convenience only. They form no part of the Agreement and will not affect its interpretation.</font></div></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data Privacy Consent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	  In order to administer the Option and to implement or structure future equity grants, the Company, its affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Option (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Participant (a) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (b) waives any privacy rights the Participant may have with respect to the Relevant Information; (c) authorizes the Relevant Companies to store and transmit such information in electronic form; and (d) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Participant shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="text-indent:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.4%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Electronic Delivery of Documents</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Participant authorizes the Company to deliver electronically any prospectuses or other documentation related to the Option and any other compensation or benefit plan or arrangement in effect from time to time (including, without limitation, reports, proxy statements or other documents that are required to be delivered to participants in such arrangements pursuant to Federal or state laws, rules or regulations). For this purpose, electronic delivery will include, without limitation, delivery by means of e-mail or e-mail notification that such documentation is available on the Company&#x2019;s Intranet site. Upon written request, the Company will provide to the Participant a paper copy of any document also delivered to the Participant electronically. The authorization described in this paragraph may be revoked by the Participant at any time by written notice to the Company.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACTIVE/121518754.3</font><font style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>4
<FILENAME>lrmr-ex19_1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html>
 <head>
  <title>EX-19.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LARIMAR THERAPEUTICS, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INSIDER TRADING POLICY</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Updated October 28, 2024</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">I.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purpose</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Larimar Therapeutics, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) has adopted and updated this Insider Trading Policy (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to satisfy the Company&#x2019;s obligation to prevent insider trading and to help the Company&#x2019;s personnel and its external advisors avoid violating insider trading laws.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">II.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons Subject to the Policy</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to (i) all officers, directors and employees of the Company and any of its subsidiaries, (ii) immediate family members and any persons that reside in the same household as any of the foregoing persons and (iii) any other person whose transactions in Company Securities (as defined below) are controlled by the foregoing persons, and any trust, partnership, corporation or other entity over which such persons have investment control (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Individuals subject to this Policy are responsible for ensuring that members of their households also comply with this Policy and therefore should make them aware of the need to confer with you before they trade in Company Securities (as defined below) and should treat all such transactions for the purposes of this Policy and applicable securities laws as if the transactions were for your own account.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy does not, however, apply to personal securities transactions of your immediate family members (as defined below) where the purchase or sale decision is made by a third party not controlled by you or your immediate family members (as defined below).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Policy, &#x201c;i</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mmediate family member</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means any spouse, child, stepchild, grandchild, parent, stepparent, grandparent, sibling, mother or father-in-law, son or daughter-in-law, or brother or sister-in-law (as well as other adoptive relationships), whether or not sharing the same household as the persons described in item (i) above.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All consultants and outside advisors assisting the Company on sensitive matters are expected to abide by this Policy, although the Company assumes no responsibility with respect to the actions of persons who are not under its direct control.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons in possession of material non-public information related to, affecting or regarding the Company or its subsidiaries (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inside Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) when their employment or service terminates may not trade in Company Securities (as defined below) until that information has become public or is no longer material.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">III.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions Subject to the Policy</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This Policy applies to all transactions in securities of the Company (collectively referred to in this Policy as &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company Securities</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), including common stock, options to purchase common stock, preferred stock, convertible debt, restricted stock and warrants, or any other type</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of securities that the Company has or may issue, as well as derivative securities that are not issued by the Company, such as exchange-traded put or call options or swaps relating to the Company Securities.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">IV.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Policy</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Insider who is in possession of Inside Information may, either directly or indirectly, (i) purchase or sell Company Securities or, (ii) without the consent of the Company, provide Inside Information to any other person outside of the Company, including family and friends, provided that notwithstanding the foregoing (y) a director may provide Inside Information to their employer provided such employer otherwise complies with this paragraph or (z) an Insider may disclose Inside Information as required by law.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Insiders may not disclose, convey or &#x201c;tip&#x201d; Inside Information to any person by providing them with Inside Information other than to disclose on a &#x201c;need to know&#x201d; basis to directors, officers and employees of the Company or outside advisors in the course of performing their duties for the Company (it being understood that directors may disclose Inside Information to their employers; provided that such employer complies with the requirements of the first paragraph of this Section</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IV). When sharing Inside Information with other directors, officers and employees of the Company or outside advisors, or other persons involved in the business and affairs of the Company, such information should be confined to as small a group as possible. Unlawful tipping includes passing on Inside Information to friends, family members or acquaintances under circumstances that suggest that persons subject to this Policy were trying to help the recipients of such information to make a profit or avoid a loss by trading in Company Securities based on such information.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">V.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition of Inside Information</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Material Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information is considered &#x201c;material&#x201d; if a reasonable investor would consider that information important in making a decision to buy, hold or sell Company Securities or the securities of another public company. Any information that could be expected to affect the Company&#x2019;s stock price, whether it is positive or negative, should be considered material. Determining whether information is material is not always straightforward; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities with the benefit of hindsight. When doubt exists as to whether information would be considered &#x201c;material,&#x201d; the information should be presumed to be material. While it is not possible to identify in advance all information that will be deemed to be material, some examples of such information would include the following:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">merger, acquisition, joint venture, partnerships, strategic alliances, collaborations or investment proposals;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">annual or quarterly financial statements;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">earnings estimates;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes to operational or financial guidance;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant expansion or curtailment of operations;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material information regarding an existing or potential customer or supplier;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unusual borrowings;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public or private securities offerings;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation (pending or threatened);</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in senior management or members of the Board of Directors;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">information concerning clinical trials and their results, intellectual property, regulatory approvals or other developments (positive or negative), product or technological plans, developments or agreements;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">communications to or from regulatory agencies;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new product launches or the introduction of new business strategies;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the status of the Company&#x2019;s progress toward achieving significant Company goals;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">listing on or delisting from a stock exchange;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">new major contracts, customers, distributors or suppliers, or the loss of any of the foregoing;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">material changes in the Company&#x2019;s pricing or cost structure for its products;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a company restructuring;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant related party transactions; or</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">similar information concerning a significant subsidiary, business unit or investment.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Non-Public Information</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Information that has not been widely disseminated to the public is generally considered to be non-public information. Information generally becomes available to the public when it has been disclosed by the Company or third parties in a press release or other authorized public statement, including any filing with the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Once information is widely disseminated, it is still necessary to afford the investing public with sufficient time to absorb the information. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a general rule, information should not be considered fully absorbed by the marketplace until </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">after the second full trading day after the information is released</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If, for example, the Company were to make an announcement prior to the start of trading on a Monday, a person covered by this Policy should not trade in Company Securities until the start of trading on Wednesday. Depending on the particular circumstances, the Company may determine that a longer or shorter period should apply to the release of specific material non-public information.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are unsure whether you are in possession of Inside Information, you should consult with the Chief Financial Officer prior to engaging in, or entering into an agreement, understanding or arrangement to engage in, a purchase or sale transaction of any Company Securities.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">VI.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special and Prohibited Transactions</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to the other restrictions set forth in this Policy, the following transactions are strictly prohibited at all times:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">trading in call or put options involving Company Securities and other derivative securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">engaging in short sales of Company Securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">holding Company Securities in a margin account;</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">all forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">pledging Company Securities to secure margin or other loans.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If you are unsure whether a particular transaction is prohibited under this Policy, you should consult with the Chief Financial Officer prior to engaging in, or entering into, an agreement, understanding or arrangement to engage in, such transaction.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">VII.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transactions Not Subject to Trading Restrictions Under the Policy</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The trading restriction prohibitions in this Policy do not apply to:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the granting of options or other equity awards or the purchase or sale of Company Securities from or to the Company, as applicable;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">bona fide gifts of Company Securities;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">purchases or sales of Company Securities made pursuant to any binding contract, specific instruction or written plan entered into </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">outside of a blackout period</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and while the purchaser or seller, as applicable, was unaware of any material, non- public information and which contract, instruction or plan (i) meets all of the requirements of the affirmative defense provided by Rule 10b5-1 promulgated under the Securities Exchange Act of 1934, as amended (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10b5-1 trading plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended or modified in any respect after such initial pre-clearance without such amendment or modification being pre-cleared in advance pursuant to this Policy; or </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">transactions between Insiders and the Company with respect to grants under its equity incentive plan (or, to the extent applicable, granted outside such plan), including the exercise of stock options for cash; the vesting of restricted stock or restricted stock units (&#x201c;RSUs&#x201d;) or the exercise of a tax withholding right pursuant to which a person has elected to have the Company withhold shares subject to an option to satisfy tax withholding upon the exercise of stock options or the vesting of any restricted stock or RSUs.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequently, restrictions contained in this Policy would apply to the sale of Company Securities in the open market to pay the exercise price of an option and to the &#x201c;cashless exercise&#x201d; effected through a broker or &#x201c;same day sale&#x201d; of an option, which generally entail the sale of a portion of the underlying stock on the market to cover the costs of exercise or the resulting taxes. In addition, any sale of the underlying securities acquired upon the exercise of an option or RSU is subject to the Policy.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">VIII.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional Procedures</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Blackout Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All officers and directors of the Company, as well as certain key employees listed on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hereto (as may be amended from time to time by the Chief Financial Officer), as well as any family members or other persons that reside in the same household as those persons (all of the foregoing being &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Persons</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) are subject to additional restrictions on their ability to engage in purchase or sale transactions involving Company Securities. Restricted</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Persons are more likely to have access to Inside Information regarding the Company because of their positions or affiliations with the Company and, as a result, their trades in Company Securities are more likely to be subject to greater scrutiny. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, Restricted Persons are prohibited from trading in Company Securities during the period beginning on the last day of the last month of each fiscal quarter and ending on the beginning of the second trading day following public disclosure of the financial results for that quarter or the full year. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a list of the blackout periods for the current and next fiscal year, which shall be updated by the Chief Executive Officer or Chief Financial Officer from time to time. </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Quarterly Blackout Period Guidance included in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex B</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provides a guide to the blackout periods. These blackout dates are subject to change. If you are considering buying our selling LRMR securities, complete the Request for Clearance to Trade as set forth in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex C</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Special Blackout Periods</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, from time to time, the Company may impose special blackout periods on one or more directors, officers or other employees if, in the judgment of the Chief Executive Officer or Chief Financial Officer and internal and external legal counsel, it is likely that such person or persons have become aware of significant corporate developments that have not yet been disclosed to the public, even when trading otherwise may be permitted. If a director, officer or employee becomes subject to a special blackout period, such persons are prohibited from (i) trading in Company Securities and (ii) without the consent of the Company, disclosing to others the fact that they are subject to such special blackout period. These special blackout periods may vary in length and may or may not be broadly communicated to Insiders. Unless otherwise specified, the Company will re-open trading at the pre-market the third day following the date of public disclosure of such significant corporate developments. If, for example, the Company imposed a special blackout period on a Monday, the persons subject to such special blackout period should not trade in Company Securities until the pre-market on Thursday.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pre-Clearance Procedures</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All directors, officers and other employees must obtain prior clearance from the Chief Financial Officer, or such person&#x2019;s designee, by submitting (in writing or via email) the information contained in the Request for Clearance to Trade as set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">C</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto, before such person makes any purchases, sales or gifts of Company Securities, regardless of whether a blackout period is then in effect. In evaluating each proposed transaction, the Chief Financial Officer, or such person&#x2019;s designee, will consult as necessary with senior management and outside counsel before clearing any proposed trade. The Chief Financial Officer is under no obligation to approve a transaction submitted for pre-clearance, and may determine not to permit the transaction. If a person seeks pre-clearance and permission to engage in the transaction is denied, then he or she should refrain from initiating any transaction in Company Securities. Clearance of a transaction is valid for no more than the 5-business day period (or such shorter period as may be prescribed in the pre-clearance form) immediately following receipt by such person of such clearance. Pre-clearance is not required for trades pursuant to an approved 10b5-1 trading plan, but directors, officers and other employees must receive prior approval before implementing, terminating or amending such a plan by the Chief Financial Officer, or such person&#x2019;s designee.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">IX.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rule 10b5-1 Plans</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company permits all directors, officers and other employees to adopt a 10b5-1 trading</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">plan pursuant to the Company&#x2019;s procedure for adopting such a trading plan. All directors, officers and other employees must obtain pre-clearance prior to entering into, modifying or terminating a 10b5-1 plan. The restrictions on trading set forth in this Policy shall not apply to trades made pursuant to a 10b5-1 trading plan. More information concerning trading plans is available from the Chief Financial Officer.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">X.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consequences of Violations</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purchase or sale of Company Securities while aware of Inside Information, or the disclosure of Inside Information to others who then trade in Company Securities, is prohibited by federal and state securities laws. Insider trading violations are pursued vigorously by the SEC, U.S. Attorneys and state enforcement authorities, as well as the laws of foreign jurisdictions. Punishment for insider trading violations is severe and could include significant fines and imprisonment. While the regulatory authorities concentrate their efforts on the individuals who trade, or who tip inside information to others who trade, the federal securities laws also impose potential liability on companies and other &#x201c;controlling persons&#x201d; within the organization if they fail to take reasonable steps to prevent insider trading by company personnel.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, an individual&#x2019;s failure to comply with this Policy may subject the individual to Company-imposed sanctions, including dismissal for cause, whether or not the employee&#x2019;s failure to comply results in a violation of law. A violation of law, or even an SEC investigation that does not result in prosecution, can tarnish a person&#x2019;s reputation and irreparably damage a career.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">XI.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Administration of the Policy</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#x2019;s Chief Financial Officer, and in such person&#x2019;s absence, an employee designated by the Chief Financial Officer, in consultation with internal and external legal counsel, shall be responsible for administration of this Policy. All determinations and interpretations by the Chief Financial Officer (or his or her designees) shall be final and not subject to further review.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any person who has a question about this Policy or its application to any proposed transaction may obtain additional guidance from the Chief Financial Officer.</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.667%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">XII.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You must sign, date and return the Certification set forth on </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex D</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> attached hereto (or such other certification as the Chief Financial Officer may deem appropriate) stating that you have received, read, understand and agree to comply with this Policy. The Company may require you to sign such a Certification on an annual basis, which Certification may be in electronic format. Please note that you are bound by the Policy whether or not you sign the Certification.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex A</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Persons</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Carole Ben-Maimon</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">John Berman</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Michael Celano</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Russell Clayton</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adrienne Clements-Egan</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Frank Conway</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jenna Gartland</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Thomas Hamilton</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mohamed Hamdani</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jennifer Johansson</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jonathan Leff</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Keith Lynch</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Frank Nazzario</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Susan Ostrander</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mark Payne</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marion Petryk</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rochelle Rivera</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Noreen Scherer</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Gopi Shankar</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jeffrey Sherman</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Frank Thomas</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Joseph Truitt</font></div></div>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex B</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[***]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex C</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Request for Clearance to Trade</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;box-sizing:content-box;"></td>
    <td style="width:41%;box-sizing:content-box;"></td>
    <td style="width:6%;box-sizing:content-box;"></td>
    <td style="width:48%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">To:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Larimar Therapeutics, Inc.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Three Bala Plaza East, Suite 506</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Bala Cynwyd, PA 19004</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attention: Chief Financial Officer</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Phone Number:</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">E-mail:</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7%;box-sizing:content-box;"></td>
    <td style="width:39%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:6%;box-sizing:content-box;"></td>
    <td style="width:44%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I hereby request clearance for myself (or a member of my immediate family or household) to execute the following transaction relating to the securities of Larimar Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Type of Transaction:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15%;box-sizing:content-box;"></td>
    <td style="width:85%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I wish to purchase shares of common stock. Number of shares of common stock to be purchased:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">                                             </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I wish to sell shares of common stock. Number of shares of common stock to be</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">sold:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">                                             </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">I wish to gift shares of common stock. Number of shares of common stock to be</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">gifted:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">                                             </font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">                                             </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expiration Date for Transaction:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                                                                                    </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the request is for a member of my immediate family or household:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18%;box-sizing:content-box;"></td>
    <td style="width:28%;box-sizing:content-box;"></td>
    <td style="width:4%;box-sizing:content-box;"></td>
    <td style="width:14%;box-sizing:content-box;"></td>
    <td style="width:36%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name of Person:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Relationship:</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I hereby represent that I am not aware of any material, non-public information concerning Larimar Therapeutics, Inc. or its subsidiaries at the time of submitting this request and I agree that should I become aware of any material, non-public information concerning Larimar Therapeutics, Inc. or its subsidiaries prior to consummating the approved transaction, I will not consummate such transaction.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I understand that once approved, the authorization is valid on the date of approval and during the remaining term of the trading window in which it is approved. I further understand that the approval will lapse if, in the judgment of the Chief Financial Officer, I am likely to be aware of material, non-public information or at the expiration of the trading window in which approval is granted, whichever is the first to occur.</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34%;box-sizing:content-box;"></td>
    <td style="width:22%;box-sizing:content-box;"></td>
    <td style="width:44%;box-sizing:content-box;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Signature</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Approved by:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34%;box-sizing:content-box;"></td>
    <td style="width:22%;box-sizing:content-box;"></td>
    <td style="width:44%;box-sizing:content-box;"></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:12pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="z-index:-3;min-height:1in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid #000000;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annex D</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I hereby certify that:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I have read and understand Larimar Therapeutics, Inc.&#x2019;s (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) Insider Trading Policy (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). I understand that the Chief Financial Officer is available to answer any questions I have regarding the Policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since I have been affiliated with the Company, I have complied with the Policy.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:7.14323979728499%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I will continue to comply with the Policy for as long as I am subject to the Policy.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Print name:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                                                        </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Signature:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                                                         </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                                                                                </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>lrmr-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIST OF SUBSIDIARIES</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:73.333%;text-indent:25%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.32%;box-sizing:content-box;"></td>
    <td style="width:33.34%;box-sizing:content-box;"></td>
    <td style="width:33.34%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:14.4pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Subsidiary</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ownership Percentage</font></p></td>
    <td style="border-top:0.5pt solid;padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jurisdiction of Incorporation or Organization</font></p></td>
   </tr>
   <tr style="height:14.4pt;background-color:#bdd6ee;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0in;border-right:0.5pt solid;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Zafgen Australia Pty Ltd.</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    <td style="padding-top:0in;border-right:0.5pt solid;padding-left:0.075in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Australia</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>lrmr-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.39in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:24pt;font-family:Times New Roman;margin-bottom:24pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-239510, 333-268312, and 333-279275) and Form S-8 (Nos. 333-239509, 333-249287, 333-270535, 333-270536, 333-270945, and 333-277946) of Larimar Therapeutics, Inc. of our report dated March 24, 2025 relating to the financial statements, which appears in this Form 10-K.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">/s/ PricewaterhouseCoopers LLP</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">Philadelphia, Pennsylvania</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">March 24, 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.39in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:'Georgia',serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>lrmr-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Carole S. Ben-Maimon, M.D., certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Larimar Therapeutics, Inc.;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: March 24, 2025</font></p>
  <table style="border-spacing:0;table-layout:auto;width:44.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Carole S. Ben-Maimon, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Carole S. Ben-Maimon, M.D.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">President and Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.88in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>lrmr-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.88in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Michael Celano, certify that:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1. I have reviewed this Annual Report on Form 10-K of Larimar Therapeutics, Inc.;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:4pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: March 24, 2025</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:auto;width:44.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:9.35pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.75pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Celano</font></p></td>
   </tr>
   <tr style="height:2.9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Celano</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Principal Financial Officer and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.88in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>lrmr-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;">
  <div style="z-index:-3;min-height:0.88in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATION</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Larimar Therapeutics, Inc. (the &#x201c;Company&#x201d;), does hereby certify, to the best of such officer&#x2019;s knowledge, that:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	The Annual Report on Form 10-K for the period ended December 31, 2024 (the &#x201c;Report&#x201d;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.88%;box-sizing:content-box;"></td>
    <td style="width:1.12%;box-sizing:content-box;"></td>
    <td style="width:3.34%;box-sizing:content-box;"></td>
    <td style="width:1.12%;box-sizing:content-box;"></td>
    <td style="width:45.54%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 24, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Carole S. Ben-Maimon, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Carole S. Ben-Maimon, M.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(Principal Executive Officer)</font></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: March 24, 2025</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;/s/ Michael Celano</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Michael Celano</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-border-spacing"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.88in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img132800289_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_0.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %F:^5S0X0DE-! 0      &$< 5H  QLE1QP"   "Z:8< E  "')R,CDS
M.3DX' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@6F]R9&EC:" M(%!R
M96QI;6EN87)Y(%!R;WAY(%-T871E;65N=%]' #A"24T$)0      $+KC1,8D
M!!COD?'4<#WU46$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9G]9(         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              %@   #L          !
M      $              [    %@                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     ,X0DE-! P     "^8    !    H
M #P   '@  !P@   "\H &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( #P H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M]!<?U'KKL;/R:*\3 ]&JYU=9=0#('T9=O:W<DR8\4LA(CT%ZZ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MGG4/Y,X=T_DW?K'^>=WAX^'2G_H_^0?\[Q__ /J<?_D_V?14>TVXXPY_9VE
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M]#^-&<=?]7U[N_IZ*@?AW/A-^?\ 9\:ARWY8]H7( _XB_IX>.@XC%C;AG#?
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MK&^P??B\N^^_LQTV\S@/7OZ=._H=CW[T]I+QK\O[.<OY#^QFB]?,?V,#MO\
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MPUYW?]O]7HQG:K]^+RZQG[86G=_F4'?W=/TX&#['M)>-?J&<Y<?^3-&\^?\
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MU>)H)5CCF:-UBD>2-)"I"O)$(S(@; !9!)&6&Y42*6^<,^T1';D&WS!X\]_
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MZOK^K>FX>8]=O+^(.G,/Y3;:8[L=WLW[NG3QZ=U,]^>_V[=_7KX=>^G+?KS
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MZ:>/7QP-QTZ]??L<>BH\.8;!TZ<^G7J(AS#W]-_>#O\ CXV_3[W=\?&_Z/<
M0V'PV^C8-N74 ^K8>?NTQGU;C'OWV_7](IG'KZY]VV_ZOH--^O7<-M_'GX
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M#/\ N36W\)ENY_/^OO=X;:OGZ_D_AGYFNWJ[7I[\TY+[_NJ[W_UW_#]>:GV
MGP9_W)K;^$RW_P"?>/\ 5J>?+^3^&=_^:+W_ /6[N[NIR7_I5W_??\/=_C3V
M GP9_P!R:V_A,M_^??TVT\^7\G\,_-%_VO7MTWV'3#DO_2KO^^_X:>P$^#/^
MY-;0_P"<RW_QOAT\^7\G\,/KM%_0P-.2_P#2KL_]M^I13V GP9_/^Q-;>?\
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MQXM]A.TX@O"^%<-6Q3CEG%8\.MC%92+P[6B2SQR22O--<E2]W)+([3N[:CC
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MX96FE92#(Y(]8KBD*%</ PQJ\"!6WJ(T8R-#^CE-VRH>K#("R[DI_MBI]SV
M-]L ;@ Z-%$Z<IXT:,8 C9%9!I(*X1@5[) *C&%P,8P*+?7RW?GZWEVM]K,G
MGBW$PNN8P*L_G <3:RI(+:\D'!.*]K2)C&&_H,>R9[MFS+]:M4$/UFR*H5FU
M#NB%V;M"JK V0_\ 1( JJ"92]X;?051G  U8U8 &K  &< 9V &^V !TKE)/-
M+^%FEE[<DGRDCO\ *2D&63M$]N0JI=OG,5743@8Z/4$(+<K08F-]%*DT0(V]
M!:]P5&/7])8(E1[KNRI,G'ZNT3 H$;K"*J0$4^VU.7'@#0N %&-(QA!A!@C
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MAM;2[8!3@GY*[4XQD"-V.RG%(^:5[8:V%WJ7M*L1N)[;+$; <R C.<9=!G)
M-?4S?AI)%5PIE;'9&Z,.E85G!KC7P02@5I8L"C,J+"_[HD8K-F+$IOC'!N>1
M,5F505S 09D8SG;,0SW9G56A&>F9E=&B'6174ID,"9Z,')YA (.?D2PFP.IY
M11Q)C.@HP;!4XK%1R?CB_JND:-?*?<%F+1F_>HUJQ1,TJT92!W"3)VY3CG;@
MZ#=TJT=)(*JE*115LNF41.D<I;@Z0V#I) #8[)+*'4 ],LA##?=2&&V]3(R
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M2Q_ZOL\@XB:Z^^-T$#2<DFBZ;5TQBG'IW=/W+=RLB@LDV.H9-99),X 95,#
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MI%"!;QQ%S0R$FG,G!^S9N"(*&0(<0,*A]$"QB8(-//GY\AU$DMYI:6FC)/S
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M\38Z1@$8;>M,2RW2MAO.F9B2-X]?"7X2P3T&%Q+UQS47(( Q;U<^#^Q]7E)
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M".,\4.1LN#9);%93 LF%,MWQ"W9P0H4</X1<\19]]OE)(HT [HS)G?3C4D3
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M(M .S9&;Q<KRSU:-&CUMEG>,F B*5CEI8P;:!@C$A6B4J!DD]&.K4"  [:R
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M+8G7L#V$>V AIQ1"YK^LYEM+M1L31T:/DXQ%X4[A=3O$]Q,T>IACFF]FNU;
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MN\J>&01W#13*Y5DF4%(IF/R;F:1XM/+TC9W/'$XSPG*'B$J3*7%Y'XSN66[
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M8G1Q YSHN$LIH5(9>:EW)?1J&;'R:JW#;H.Y!VY052\A1+QIO$?/1_#1PUY
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M,8().9DL88Y1;I-4:-4TFR#.#CT4"0$65)-C659%:O-2I@U[(-X1:7E5HM(
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M/<MG*^><654169@+;B\%N-( QR5BO@8LE1HMB2ZJ^I=Q+/GG)C/"V%KU"T&
M;WG*UFJ-<?5^3G%YBOUH+'%S<@YEBS%;1=>M6*!8I%9F*0HIKH/4DUG""H&,
M&[C,<T4: D/%<2L'!#1F#A%WQ(Q=!E^=;+::R%5F;6%4%17.(ZHY7;!Y<T42
ME&&F19.)V]@)0>UI1HIO.,=ID "MG#&M1)_BXS[9:W!SL;46=-MJF,)O),"T
MCWLU)U42SV [%?86'N3!W HO9B1@)V#7;)I,7$4BH\<1_:3.8JR"NW0KYZT9
MR;9+F,!@K)(8[GR7D61!L4?S?C$L(D8XU6\[ :698NL2YNK2WET$2W=JKNNI
M=*N/*&!^UD@PM-PJWE*]>7<QY;*HTE^R'&MEBI.'\9+XO@K5-P$>O'/Z56WE
MC2O\LZC\3M<A.,GLXM2%=LV^+'\RJK4D%BG=/TWB8K)N'4D8:^GJ<(LLZH51
M!-<HKEM<=HL%X+16NRH+%9%(ND,89O-WA(60L[1\H5+);ZF+%X;5SL \[3P"
M9E@4Z5UPL3!('(7G12]I5Y8>DRO$IEV(R"QOD2ZHV2*DTQ17%+''426M+BG.
MW4UG*/IZB]7*X:+%/;&$7,[OG+T#)$;Q1FYB$3=B+&Q(.9/&RN5DFX' CD#6
M&N)?*&&1X-.5$1:"V,V2=XXP'PRO7.5P8(9D*B2./C4C1Y([,%OP.:*.;;:5
M3+<*AP-I&)52&6JG&<;>6K!,5ROP>.*6XE;G8(&.]'&3M2JF)#2\Q/Q2]5RR
MD6$1]'N[-"'"3*QC54FJO<R;-3T=LWCYB3\R,SI 0 >9&)7E!^2.K@G$N*M!
M%^,T]O-8):3A].3<HV$=>4W>0!&FSD"*=H1&V!,RKQ6PX<L[8RJPSQWKW,17
M7M;E=3JS-':$MQ?9/R<UQ>T91$3C%V\OG"W(2U>&7LQ+Q9XRZV6MREO>UM!"
M*0:N\>-$UGU/E32 D6<.&<V22,Q(BT;2/: K)/!(58Q:[@<IL:@I\G#Q&(SJ
M=(P;BY2",C2!<6YP2^8UKCEI=1MI9UMYPLOXC21\4GL<08R>9RK4SN""5BN$
MR ")&NU?BFRY&P-4RK,4]L@M9\,2UI9U1I,3):374GV3\9U)E.70YZZI+^DP
M#&QRUAFGD?W2;*OL7+1%FN?OI-/E'D2<IRJF2#@+R3O^!@?B7VQEF"GL[1)'
M#'(6(#2&,N8T!8:F18WD5-3I#<\>CC"[S3IPP6J1 D:E//8N\1 . S:=9VK)
MCSB(RI9.&GB-R#4FE)2OV*I*VP-.E8D)R=IMF-7JW6IM"Q,D';1H_=-GZDR\
M00:H^DM@5;)ID?/$P.X/J96$%C(H*-=3B.1).J(.,S\.)&!G$D$(E!(!&LD'
M !KG$5,MU&YU+#$61TVR[\-BNU!!."8YI3&0-R$P5U$K7LQ]Q.9 GLSQV*K'
M4ZLF92;G*E+L89[/&N4&>M4Q*R'R=*1CZ+3BV^-;9)B,)6E ?G> >1A%#O'C
MQT^C8WLJ1R&8HQ"*MY(O3,'FW$6L8K:XZCGW,:B[BT,P,3H-+(3*.3%HHX=8
MS(?,D;.!SS<V7G4DL &?D[:3]S2ASGFI*00%026%*9=R-B[B'S);;NLQ=XN#
M(6,L9QKIS,6MK%4:L26)W=T5G7$:HH>J)G>6ST:)=S -4WJS^82CU9 S=!DU
M)Y8)-%M<B3M2/Q#B1C)&-0L^#V-Q;PHS9($SN4"K@-.;C9FT5VG4F:'E E8[
M'A[.#I&#=\5O+:XF(4 MR4C5CK+:8E@("@N38\/QZYH/ DM4U@N.2CWGK2):
MPC-Y:$YUA-QN&L>Y75E)KOH%8&]>:JVZ6A7Z;9FXDD$H0[Q,JKGO8XGIY1W5
MW6)C',VMQF.$P\8M>%2<X@ZAI%P]R<  + P+$,62JH8%TU2(C0Y1,<V9)[.\
MNXS &PI9Q;0H@8DYN5RH*@/59/B&SA*9$B4$IBF6?''J_!,F@_P^>8#US.6O
M-]LI<ZBUFI5A)(/8,T)!D;SD2(IJ$623!"4;)N%7)<A2A+O&[:;B58T[G2/@
M_$;@AU( 827-L@A()P[1DZA@GD!S,(KA=5I+(\A!!5TN[$(%(SAA%<,& SE1
M)D [#NA.-W+=E?4Z"@\=T9[+WJ8J38[MM*6QW%8P4L\+D"4?4?(A1@VCD,@5
M8:8U"39-3,FRWK0R*R44";1T^FDXDTLKB*&67G("T-QHX>]Z/-SL3AD2%M1V
M%Q"YT/JA'4*-R=2$N$$+8$T>;^WLP\XP0B.DS3*1G!AD0<Q,3'?'"M_>Y4Q%
MC7),E"C7)"\TJN6E] "JJN,.\F8ML]<QO?+HMEE0:+JG1*=5NBH8I2B=,IA$
MH=)D$<A53E2L;J3C($D:R!6QMJ75I8C8D$X&<#SPNTB:F7!#2(? F.1DU#^J
MVG4/ '&_6LGZY5UII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*\SEDS>@D#QHV=@@L1P@#E!)<$5TQW362[TAN[5(/,BA-CE'H(:R6*]H;$'
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M*S=!5)<=UTE$DSIK#]J&ZI#%$J@[%+S. C]J7R#9@'J,TKB+9L0  K9
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H-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5__]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img132800289_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_1.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &K2^:#8X0DE-! 0      &$< 5H  QLE1QP"   "Z:8< E  "')R,CDS
M.3DX' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@6F]R9&EC:" M(%!R
M96QI;6EN87)Y(%!R;WAY(%-T871E;65N=%]' #A"24T$)0      $+KC1,8D
M!!COD?'4<#WU46$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9F            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              %Y   "'          !
M      $              AP   %Y                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     $#0    !    H
M '    '@  #2    $!@ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( '  H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M]GYON6)E?4=U]V1:,[8+GW!H]$.VTY+LVW,J=-OZ2[?U6_[/D;?T.RK]7O\
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MT_33
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( ,H!(@,!$0 "$0$#$0'_Q  >  $  00# 0$
M    "0$'" H"! 8% __$ %L0   & @$" P,$"0\'!PT   $" P0%!@ '$0@2
M"2$Q$Q1!%1DB45)9<9&2F+'1U!<R.E1687F!DY:AM]+5\ H6(T)8P=,8)"4F
M4VF()R@S-D178FATHL3A\?_$ !T! 0  !P$!               ! @,$!@<(
M!0G_Q !2$0 ! P,# 00%!@D("0 +   !  (#! 41!A(A,0<305$4(F&1T0@7
M4G&!\!4C,E62E:&QP1A"5%:3E-7A%B0E,S188M/Q)S4W0V5R=8+"TN+_V@ ,
M P$  A$#$0 _ -_C")A$PBXFYX'CD! !'R^X/'W?/X>6$4.D!U>;Q?>-I>^B
M5S88U30D%T3US=T?!!!1Z<PE?9&]_(+IX>P%3^4E61H\WLRQYU1;D.4%"E[A
M$<(IC<(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$5!]!^X.$4<FP?$IU!2^N73'05&05EMFU-J(V5U.3D>U59T
M_724'2W5V8,YN9=-1:2DY.1K<JJ,)%.#O&#%=!_(>Q371(H3[A6*I?C'ZQLE
M_D(RPZ<V-2=-RC/J.6U5O63DZI(P6T'O2E$24WN)BSJD7)N+-608QT'.N:XZ
MGFZ*-C2B'1VOL3?0*17;Z/\ Q)8/J?L\_2[EIVX=/%F0U=0M[TYEL&RTR7:7
M;26SG+UG3[JVDZW)NF<)(+.69&\Q59<Z4K$+R$>D<RYES F3V>/DH_:/*Q<G
M_E+VT9*-DH^0CS^&C46Q7S%XV=M#.4]IE.H@5PW441%8A! YD@/WE*(&$O @
M.2[V\^LW@X/(X. <'R.".OFI=S>1N:2#@@$$@]<$>'LSC*V+_?&G[:;A]U9,
M/RFQN:>CFG[1\4+FCJYH^LA/?6?[;;?RZ7]O(Y'F/>$WL^DW](?%/?6?[;;?
MRZ7]O&1YCWA-[/I-_2'Q3WUG^VVW\NE_;QD>8]X3>SZ3?TA\4]]9_MMM_+I?
MV\9'F/>$WL^DW](?%/?6?[;;?RZ7]O&1YCWA-[/I-_2'Q3WUG^VVW\NE_;QD
M>8]X3>SZ3?TA\4]]9_MMM_+I?V\9'F/>$WL^DW](?%/?6?[;;?RZ7]O&1YCW
MA-[/I-_2'Q07K,//WMM_$NF/] &YQN;YCWA-S3T<WWCXKC\H,>.??&W "8.1
M73 .2CP8.1-Y]H^1N/0?7 <#C!!W<MP>OU>?V)N:.2YN 2"<C@M.'#KU:>".
MH/5<O?6?[:;?RZ7]KSQD>8]X3>SZ3?TA\507S( $1=M@  Y$?;I>0!]?TL%S
M0"2X  9))& /,GP";V?2;^D/BJIO6:Q@*BZ05,)0. )JD./://!N"B/T1[1X
M-Z#QY#DK9(W'#7M<2 [#7 G:[H[ R=IP<'IQU400[.T@X )P0< ]#QX'P*[.
M3J*81<#J$3#DY@('(!W&'M+R8> #D?+D1'CUP@!)P 2?8">@R3]0'CT7PYVR
MP]=A92P2LBS91$*Q>R<J^<K=C=DPCFJKUZX6.4#B4K=JBJLH %,?L(/!1')0
M]AZ.:>=O#@?6\NO7V=4!!Z'.3@8\3Y?7[%;O2F_-2]1- A]J:8OE>V%KJP*2
M"4);:ZY57BI-2)?K1DD1N=R@V5Y92#==FMREQ[9,Q2F]!R+G-82'.:T@9()
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MDD@F94Q/ECJ8?]U-"]T3P?86$.''&0<Y&,\G$2GC"P4'&]&\TX;0\-'F)?\
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M^]]S($9\ ?//E[CGZN/K4#X<!W(Z]/KZ'^'UCJN@:.*<XF,DF #_ *I0(/F
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MT0!Y!#96M:0*=6U_2:TE(.)9*O5&MP:4J[9ECG<DG$P[1B1^Z8%31*R<.RH
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MJY.7"\9,(F$3")A$PB81?DHB53D1$2CVB'(>G ^H_ >?W^0XP1D$>?">&/\
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M2DCGJ)W;Y)(X(:1T;&.>7$-:,#/&!@*X"FH?$\,!_P#SQ=-=P$,)2$T8V#N
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M?07U!,8'4:&V=R0.L+.33S)K !8;5%669&/:NEJ<T$%#-YIRQ1% KQL3WM-
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?81,(F$3")A$PB81,(F$3")A%_]D!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img132800289_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1OZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &]Z^<30X0DE-! 0      &$< 5H  QLE1QP"   "Z:8< E  "')R,CDS
M.3DX' (% $!-:6-R;W-O9G0@5V]R9" M(%!R;VIE8W0@6F]R9&EC:" M(%!R
M96QI;6EN87)Y(%!R;WAY(%-T871E;65N=%]' #A"24T$)0      $+KC1,8D
M!!COD?'4<#WU46$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 9B            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              %1   "!0         !
M      $              @4   %1                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     4X0DE-! P     $5T    !    H
M &@   '@  ##    $4$ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( &@ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M +2>K>E/3I*CT.^[)Z-@9%X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P !  $"!P$               @)"@$" P0%!@<+_\0
M5Q    8! P("!@0'"P8+"0   0(#! 4&!P ($0DA$C$3%!5!47$*%F&Q%R(Y
M@9&AMQ@9,C8X4W-XDL'1(R0E)B?P,T)'2%)66&)WAI8H1F-F<M+6X?'_Q  >
M 0$  04! 0$!             0($!08' P@)"O_$ #D1  (! P($! ,&!P !
M!0     ! @,$$04A!A(Q00<34? B87$4@9&AL<$(%3)2T>'Q%B,S0F)R_]H
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M7'ER^HUPCV5MM-GKFV ^>9+(V*EK5D%O*7&E3D\G[)J=/B<>2\^_QTY#();
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M:-X^.C8YLBRCX]@S1(W:,F+-N1-LT:-6Z2:#=LW331013(DD0I"E* '(: :
M: : : : : : : : : : : : : : : : : : : : I/;\MON1<H[A]O-LJ<:[
ME*]+X WS;79EZ1B^?QM#L^XW&U%>T&]3WLY!TXB:U[2Q9)5.;G#ME46BUDAF
MYA*=Z4BP$!+]T'Q6QSCZL83GJWBNTI[#;YMSRS9E[;E"W-K=EB?<8$F(^191
MEED)EK'X[FI+%MN@[:RB48)4U:MOJZ4"_(3V>V#W[_XCRC.O1<WCY=PFUQI
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M: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
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M*HE$DP 'D 'X@ _I#GW\#^H- 8Z : : : : : : : : : : : : : : : :
M: : : : : : : : : : : : : MWMUUC<M^IY@FE8\IK:SE1LN&I6Z.U#YP6
M"HSMDR@PEI:Q6<D388Z&/'KTB&=HX_+7(F;J*5D&8-D<K:&B72;</?OW]2NM
MD#"^'<LN8!YE/$V-,EO*HNX<U9WD"B5:Y.:TY=J,U73B 7L<5)*PZ[E6/8*N
M%8X[9191BS.H8QFR(D ZZ^VT;<I1E88V3P%A:1CK=<&N0[6P?8NI#ME9[^QY
M]2O%A:N(-1":M[/D1:V22(YF6XB(I/2: CKGXA"[V>GT0I"E*"VZD *!0 H
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M@X\F:7%?6]:(9V((F D90A49U=.LR]<LJX-/^!A+57) PF1E6QC 2HT T T
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M:6Q;/U+*=9R')[BL=5R72Q4@C8HZ[REBH.+]LEER! P$I*1M2C([*]O1?6&
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MU(15-G9VNC+R:(WB=@YYDM.)09W;:'++NBM9IJS; !3-;;6NI!<XC'L6VO\
MEJ*<3\ON5K$19,@Y>R!1W.'L:8_:8LQKM3R/?(FCR5I4O.6I)I5[3G1Y3IP[
MB'NUGM<M!WFPPR9?$B!,W#^QC<0.(MX^*]S.<G^4BYZ&1;8WGCW"PV<E2?(R
M%REZWD1E SM5A0QW9HZ5EJ4_&L5^6ML Q=T"$7C'J)DE 5>^OO\ 8'@,ETWM
MZLFXH\JMN#@&$A<*_EJT;EXRL7:\5FI6'-.4Y*UOY-Q&0)J+/)Y(HSJK25(P
MRDE<%*C-5;'V/HN4@_')N2QK(#=QW3GWE56$KU?JF<HUW4Z8:-:Q%-DLS9KB
M5IRF$B=D:]MQDXR0WKTQ=J77;G9<(;AA/,5WVBYKD5E&%)$PQFKV7A((#DHK
MI^;UXS<+5\L16>(FG4:2R_C3(V2J+4LL92.\?(T_;]LNQ1+/9"9L=%FW>7)%
MXZV\Y/K'L[(2\:>=I]]:V"5L<?8Y&:AV0':-U#7)%EZE6&XN*+?;#1Z?!;>K
M,O$UE3.TI U*3?Y5R&VE;!88[#UGJM2@49&)8)(*2N8V%Q@'C!F]30(QA6]C
MC)("MGH!H"!FX'^6WT_?Z?=1^QIGH">1?(/D'W: QT T!H*K"F;CP\AX0'GG
M[3=AX[AY>?''?4-M=%GI]-WWWSMU&R67)+?&,[_7'^_V/,[=FC&-"GJ[5KG?
MJ95;);723&L05@LD5$2]A>N723%JVAHY\Z0=2"SAZX09IIM2+&%RL1$.5#%*
M-Q1L[VXA4K4;2M4H4,NXK0IRG3I12RI3E%.,5_\ IQV+RAI]Y<TJU>WMZM6E
M0CSU9QBW&G'O*3Z**P\OTW]"&O4)SO;L2T6!@ZNU@UF^1R6:M3JLLS>.54(U
M6)!!0\89K(L"MW?@>*<*+E=) (!XD#=QU\O_ ,1GB;K' >AV5OHU*WG5U:I5
MM;JI<TZDE""AS25)QE'^I))[XQV]>X^ ?AQI?B%Q!?4=3N*]"&E4*%]2C0<8
MRJ.-9?#-N,_AVWV37S[09S+G2W9LZ1/43-;6D&U/2=L.8*Q$>Q6KUKZ:,3Q1
M(+IJ/@>R,B95V4XF*95(R"9BB'*7B_&&\_AQ\0=5XZX8O/YM3MJ=71[I6=%6
MRG&,J/)&2<HSG+=.6S2Z=7N6GCSX?:?X?\54+/3KBXN*6HVLKV?VCE;ISG6F
MG&+C"&8[965GMVWLG/HP_P"6+V\^?\5,T<B'P'%EF ?S=^_V:^C3AI]64OE[
MP\QX'CD.1$>.W;MY: QT T!@8> $?@ C^@- ;0'90(!SBF4O'<PG I ^T3"(
MAQ^?\^J.>*2;E''JFN5?5Y[OI_K(VPWE87?.WYX*<O5;.FKL$S\H0 '_ $75
M_P 9,_(&$UXK1>1$HB!P[^0?9V[<ZW#@!+_RS1]\Q=:MV6,?9:[[+.?F;MX>
M//%.GJ+BFZ5XUG$MXVE:6W6*SA;-Y[=6BWSZ+Q1#?+""'!3?@HR.)OQ>>?"$
M  A^-Y<B(&Y'R$.W;RZ[XK-K@ZYPWE7UJXM=4U3N7G&'UQW3^ATKCAR?#UQ*
M6(N5:UYE%*.[K33>W79/"6SR>PY./_MQOIA$1\63K&("'_%#ZU.P$ Y#R$0
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M(0 *4H%  T!K^B2_FT_[!?\ #0&/HDOYM/\ L%]WE[O=H!Z-/^;)_8+_ (:
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6 : : : : : : __9              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img132800289_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_3.jpg
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M ?_$ !X  0 #  (# 0$            '" D%!@,$"@(!_\0 /1   @(" P
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M6;][^T_!6\LC%HHKSUJC0%VMTM3LCU%7 .5JS;&S##F(!1!LG98"9>4V*CB
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M]NM)["T-@L9/JO:==S &DZ&'+18AIO"Y \F CL9N9]&<N/W;FPS0 C J$ZT
M8ATGN/R_^Q_U4H_C#X@'Y>/'?ZRMU?V(<*-NY\A\T_&'Q /R\>._UE;J_L0X
M3;N?(?-/QA\0#\O'CO\ 65NK^Q#A-NY\A\T_&'Q /R\>._UE;J_L0X3;N?(?
M-3)J=OOYKB^[WIKS3U"S@R6?ACK4^Y+IMO%KC+TP^^>WV5PT3I/M!D%W&KZ6
M8K\;+TTZ+8=E9*.UXW3,AQX9_,8^)4P<*$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$5?+;Z6H-.W%7M'&UW<;BXV$>M%=N*IHW;5JUG7![<U:)T.=
MTVZCJ!FL:=(88F8_2+8;6 9!%&/),/A]XK>C"G&V?KRZ^*A?UQ\072/CAA(H
MV7]\SLX-2; W(1$"+)&%VAHX)DJZM#M)(I >[UL-DO:*J$F/E6J&4Z)[]ZV%
M,5&B"L! ">GU[?<H.VMZEUSN@OQ.*JBL"BSO/;12?%$77+(6OA/T?:]^Z8ON
M75Q&2=57$3"Z4)]V@P9,E3EVD[7M8T@_1?8\16 (U?V$^8!^*U"LD=BFKSV*
MH%I5]KE3LHZR?9%QSBO!/\PYL4Y;U2L:(V3-..P['E9+U[I0:8'A,.*S!GDP
M*B*BJC]P?$%_BQXW_3WNS^YOA3MV/F/DGW!\07^+'C?]/>[/[F^$V['S'R3[
M@^(+_%CQO^GO=G]S?";=CYCY)]P?$%_BQXW_ $][L_N;X3;L?,?)50V;X8]5
M;8O#F_VG;WE_%V\_#'1<:S1>V10H\:UC$-ET/A+Z"))CS?*QQ4SR?(O,F58-
M&,!.OZRERD*<^&^/[O/P^CUST4JZ;\\^UM&5AA4Z7MOR7(L96-I9B,V^@]Q$
ME=&LHQ!L1XY _1R^+$)>O7KUB^+N#*6((*#"6::3K*3(HV['S_T^O8I:^X/B
M"_Q8\;_I[W9_<WPFW8^8^2?<'Q!?XL>-_P!/>[/[F^$V['S'R5NEF++!:NP<
MS DN, 1,6Q"P8@);.RQ'CZ.F7!EEGE" RE=2YB#$G&D0#Y1Q3%D28939E"][
MA$X1.$3A$X1.$7$O@B62-TN"FQ&,/4L0A",LY(\8"2@YH()LI(L<I8\8I9,,
M^\XL<I,>L>\L,>\NNNN_*=CI(9HV'2]\4C&.)(#7.86M)(R1@D'(!(\-U>)S
M621O<,M:]CG  $EK7 D8. <@$8) /BLROAM^./2'E G<4V_]N)-HQWN"A1U3
M!1<;Y:^TF=;DN.3K(CJZHDV(/3'%ZJZB[6]D=D_(R=%]1=0#?:<X]'G"7$7"
M[KL;[=8;F*UM"*415E=5<DTYJS,7?;((0SF<^+'+U:M!UXTMSNO&/$-FOHMP
MM-!+0FE-49^934M/S1,*?E8^S2RZ]'*DSKTZ=0TYR[&I?.F+1TX1.$3A$X1.
M$3A$X1.$3A$X19';_P!S[7C]MH:-K^W[^I*R.H42HI556U!7[#IZ^WZRV*^@
M]N]A;2N%MM%44Z]JDS-!W;$M(UI4-SY&5MBK%V$;&6CJ^!6&,>!)R>IR /<-
MC[R1[/%0UN75 T'Q+//EHV0(VV'L:.&I,:A>UOCG7UG^2CPVI:FTE/%W[WHA
MZ=J>FZ]IUD-QA*.]"U.VE*Z]/\W7G]KNZUCL%GP^!_?H@/JD#8>(+CCH/#(W
MR-MC^BV'OFE-0;1/ 9[)UE1;X<L4NT(1%NK"BP90H[&)( ]3]XM!"8YEC0.:
M: P&?"0:7"67O[+K*3/+(JJM?INM(*A#X[KU83@(DH/LK6\@RU:/&,-A.?7]
MH,F)>>.'77<QK-D88S9G3Y2&,F1A; Z><PF>>0K-^]_:?@KDV2>Q"UYZ34%2
M5Y;!T[*>LI;(_.JM>;V"(.;-.L>V=76[DRKJ<YAB.*R>+ZC:35(<LQXM==3P
M8+B2JJH?CCX@_P"6'QM^NS=O_P"='"G;N?(?-/QQ\0?\L/C;]=F[?_SHX3;N
M?(?-/QQ\0?\ +#XV_79NW_\ .CA-NY\A\T_''Q!_RP^-OUV;M_\ SHX3;N?(
M?-5(VAI'XC&R;T^ND%5T?3876-+QCKE8^(9OT%.OZK!,>1G8\(_P^QH_K2PP
MXM*KEC##E3KL6XN$7;B9I(MB*00/_P C\_O>/0Y\-EICJIMNAPC/(W?0=8:\
MLD;62%6IU5MVU[D1F(^@Q,XF)]AMVD=$GK6N9^9XTB8>L-0XPQA#L7TLQLR]
M>5=O#]L?$J3^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$6+.S(-)Y_$5U.R7ZRU(FA%DKPIKVQ_#EWIL/8KC:\^Y]MA$L*UZ&6Z?J^N
MM&#SW8GNU!;<=[8LH5M8S,GG52S3ME5PL)7WT]3C?[X'@-L9W]H [97([6T!
M Y^*%0MAT[6E?+&KZC6-YVG9B\$ ]=&:-#[C7ZP]M'5DV CL1EY[CIO<.MHM
M442TABV18$?LHD7IDL('*,^J=_'&,GIX^SS_ "6RO"JJ;^OO]Y^1O^<C5G_U
M+9'"LW[W]I^"N1PJIPB<(G")PB<(G")PB]0\K,($TV((ME(((25&N Z'[./S
M'ASEP""Z+(#$[+*RPZ@&Z*+%'[FDPZF(@C^M+C9C0Y[6ES6!SFM+WZM# 2 7
M.TM<[2WJ[2USL X:3LK-:'.:TN:P.<&E[\Z6@D N=I#G:6]3I:XX!P"=E!7F
MST75?4.NI-GTFJ[ JM<ZLCRL"P[%1+ZZW8F5R? %P4$  [=_2O#;]&I)929A
MI\6REH+D-CT+]I)E;U9JBQ5HH:J>DGFY,4[C1ROFC8V=I?&USWQ1>NZ/1*
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M=%24;+D^[8HZ:"*.G<ZLDCCE>_ ,9$O,E/+$CY7ND..Z'AQL 30)92X(CA"
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M6PQP4\]9)'50WB)E6YKZ0AU(YM!%=*.65\T#7.DDM^LU%3'!)V[T#47&+_2
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MHI8\9<<)9,,9.L>L\<),\>LNNL\NN_2.66%VN&62)^"W5&]T;M)P2-32#@D
MD9QL.R\W-:\8>UKAG.' .&>^"",JM?BE*F6>4/-Q:U2L7E,=":BE8$@@"B$'
M2=45+)U(9-!%'(3G]I++G]>?+/+Z\DF7T_6SR[[V/C*::7BGB)DDLLC([[=Q
M&U\CGM8/MTPPQKB0T8 &&@; #P"^"TL8VVT!:QK2ZBI2XM: 7'DL.20,G<GK
MW5I>:PLBG")PBZO=[E7]=TZT7NUG8+:U3T+2QO#L_H[[@6J Y32NX\.\L>YB
M,XX>XQA\._M22,XAXNLI9,,>_GJZJ"AI:BLJ7B.GI89)YGG[L<32]V!MEQ P
MUHW<XAHW(6/NUTHK):[A>+E,(*"V4=175<QWT4]-$Z60M&1K>6M+8V#UI'EK
M&@N< LXUVW/-*.]7'W:2/*&J<^:]16*1_":R+?2$VNY7NFFU7M7BU[6D-8RZ
MM7:X:IBBR"#9UWLV+&.8<@W/0V7.P0UE5QBYI;'+8+74&</D?,75576TCZ;E
M\SEND#J>"!\0&ADD&L %KGKAT'$O =)=[GZ7WL=%35? G#5<ZM;+/)6%]QNE
MWM<MN-.*CD/J&2VZBH9:5K3#%44)E:&O8^8Z;K6(#A< V5ECL%C0(5BN/$EP
MG%- -@C)#+&FP[[PF')'ECFAEP[[PDCSQSQ[[Z[Z[YT&.1DK&2QN:^.1C9(W
MM(+7L> YKFD;%KFD$$;$$%=\@GAJ8(:FGD9-3U$4<\$T;@^.6&5@DBDC<,AS
M)&.:YKAL6D$;%<+;Z74=@(B*Q>*VEME=+E&G*26!<,T6$3!S8$BRS!EQRP29
MCD1X30Y98=]QRX8YX]]9===\^JGJ:BDE;/2SRT\S0X-EA>Z-X#@6N <T@@$$
M@[[@KZX*B>ED$U/-)!*T$"2)[F/ <,. <T@@$$@[[C9=1H.B]-:K/+:ZUU=1
M*&R.$F -.J=94HB2@B"XCYQ9YEXL&<L$QT,1DL>??>,A,>,V?7<G7UN?15W2
MY5[&QUM=553&.#F,J)Y)6M<UI8' /<0"&$M!'1IP-E[U-QKZUK65=94U+6N#
MFMGFDE#7!I:" ]Q (:2T'P&W12A/#@1#-!)W)U'/%)#GW%-*/+UA)AWAEW%/
M!G%/!)UCEW]2:&2.6/+Z,X\\,\<<NL;(QLL;XW:@V1CF.+'OB>&O:6G1)&YD
MD;L$Z7QO:]APYCFN (^6-[HWLD;I+HWM>T/8R1FIA#AKCD:^.1N1ZS)&N8\9
M:YI:2#7?7'E+26N*[)6X*>ON0^;IRYC/V*&NNK43)R;F7F $8Z"G["7#==X1
MQCBX0_,S8S,F&1C8TXXGF7#'H>X!X7M;K4RR4U]B-=75S:GB>"FOU9"ZNG,S
MJ>">NIY/L]-%ZK6Q0MCYKP^JJ3/63U%1+TOB?TP<>\3W-MTDO=38Y10T-"ZG
MX9GJ;%1S"A@$+:B>"AGCY]3+ZSG2S.?RF%E+3""C@IZ>+O"G1FGD-Q77]#K6
MG(K<H4F)%KA*C"4YAKSY>Y2\81%\0X&)<OUYH>F/RO;&,0HT*,K ,TJ";8*/
MT?<$6Z^4O$=NX6L=OO5%1ST%+6T%OIZ-T%-4OUS!D-,R*G$S\R1BJY/VIL,T
M\#9FP3S1OP-9Z0.-KC9*KARX\4WNX66MK(*^JHJ^X5%8V>HIFZ82^:I?+4&%
MI#)#2\[[*Z>&"H?"Z>"&1DJ\W!:>L]K?\+WQ]>?<M1^(?8:*Y)])TQ:N$6MH
MK2V@J9K1(BGK%?M+>J82?)'61!7I\%2LG[6(#"(-<62M)9+Q#82MJ.DMSL3G
MZ\EH3PJK-#XD'NZV^'DFJ&M4UNGV))L1K;5YL#=JS5XJL*X(A)@E@R6B%939
M%Y-Y,).I>L.L.H,>\.\N\LOHYSZ0N-ZK@N&URTUOAKS<)*N-XEEDB$0IVP.:
M6F-C\Z^<0<XQI&/%;IP=PM!Q-)7LGK):04;*=[3'&QY>9G2@@ZW#&GEC&,YS
MNJ73?%*/\]W"ET&72(MOGWY>FU^+;X[!FKF%7(OU](2SK(5F5+>YM8E>8^1,
M9$C%?F3UGT/G#!WAW/GJ'_B6^PU=)0NLS:MU]KI:Y\HKS3BE=75G)=&(C1SF
M41$:@XR1EV=) QJ.PC@AMVIZFK%S-.VU4K*5L9I!,9VTM*) \R"IB$9>#I(#
M'AN-0)S@?0!SNJY4G")PB<(G")PB<(G")PB<(G")PB<(NK7B[536M,MNQ+V\
M"K-)HM;=V^W6-EEG@O15JN+26[MN;E%A++\LO6B$E3=0Q2S981=XQ122=XX9
M$ R<#J=@J7^AM@4W9"WQY;Z2^%>UXSVM2E<1\49(F4;2JA;<JEF5F!,8!&"]
MI7[,D;H'*X\48U:W6F@&00DCR1XE8;:L_A/P6;'NKXD?F[S]Z4#UPM*]";3F
M#?39>BS=;>EMYTE7IR&0M2#@OK%76MPJ:[;#_>71):=4U2)@#(AZZ2P$=,9_
MNO\ 0/ _HZXBO_#C[C(VP6QKX .'67'ARR5LMX<&2R&2IJI(GU<,3N46LFEB
MFFD875+6/AC'-T.]7^@H;@*=KJZI(>?MYI[A60MI!EK=,<37")[QJR6-<QC2
M!&2'N]6OOE;XF_@U/IC5=5V5=/8E*O%4SH^L2D27<V[6*$D-:B6@2;!#"1;!
M!KZ:CQFCRP$58,>5XMA[A%5UQH#U]I'G^*/1IQS+>+I5VVCX1K:*J%;<VSS6
M>S1SM?)/)(*![IZ!\\U:6.#FU3W""4ZG2U$3]C\-MXALK:6FCJ)KK#+$8:<L
M;5UCHR&L:#. R<,9"' @Q@%[1@-C<.GTQ;.V95=1ZZO&T;<01C5M?59Y<+#D
MLAP/8])Z^OG9L.P0NI8NRBNAAY/L!^I(^Y9/JX?7Q^GZ>ORI75D-NHJJOJ-?
MV>CIY:F8L;K>(H6&1Y:W(U.TM.!D9[KM7"/#%TXUXHX>X0LC:=UXXFO%OL=K
M;53"GIG5]SJHZ2E$\Y:\0Q&:5@DDTNT-R=)QA8*4'_Q#>IRFEDAVIH*_U].,
M3#'4S]<O*_=S6XWS!N!1#T"TSZXC1YXBX+IA(0C'G<\I!D)&0F(D,I?)J3TP
MV]SYA7VBKAC:0*=]'+#5.D&7!QE9.:(1>J&%H:Z7)<X$MT@N_H]Q)_RR.-(:
M.U2<'^DCAJYUTL4CKS3<46^Y\/P44O*IW0QVZIL\?%3K@TS.JHYGSP6\1LB@
MDC$YF>R"^'E3XL?FSU]M(/4.MJSN%#;#DKM]%)?*W3U2C %##'.7U*<AOUFD
MZGEPEQ^6CP&SQSR^GJ7.'Z/I[VRP<?V7B.O;;J&"Y15#HI9@:J"F9'HA +LN
MAJYSD@^J-)SXD+\Y^F3_ (-/2GZ#^#Y^-^++OP-<++3W"WVUXX>NU[JZUU1<
M7O9 607+ARTL,;',=S7.F:6C!8V1:5FPJF0LP+&)>P"(QZP(#-P&*%GPZRQS
MZQF'GZDAEQZSQQSZQSPRZZRQQRZZ^GKKOK=GL9(TLD8U[';.8]H<TC.<%K@0
M=P#N.J_(\L,4\;H9XHYHGC#XI6-DC> 00',>'-< 0#@@[@'J%155J[7DWI.Q
M44OQ;I\'30%(4L*_MGO5NL>H3]BP&9LFP>.$87WA&LE6LAA RY5\4D+ZOL<L
M9I1V@LN&G1VRC-^GHW<)6QEJ91Q207/^&V_#Z\/,DK,!G,$9CD:UKBP$30/P
M2V1I'(J?ART/XZK;/)Z*.&X>%H;13347$G_3MAT37MDKIZF$ 0\]M.ZGJ(XX
MI'0-+:VBG(>YE1&X7I @4J@0UBN%<M6KQ8 EZ\",8,$$,6+&$80,0?J,<84>
M'#"* >&/"*&+#&./#'#'KKK<6,9&QD<;&QQL:UC&,:&L8QH :UC6@-:UH #6
M@    #"Z[###3PQ4]/%'!!!&R*&"&-L4,,4;0R.**-@:R.-C &L8QH:UH#6@
M  (?--F";@K-7#L\A"<5TY^&98,)V4.?0DIH@Y81!0D9'<>9(\!HDTT..<<1
M0^>6,N'HS0'M+PYS YNL,<&O+,C4&N+7AKB,AKBQP!P2UP&#[-TZFZPXLU#6
M&D-<6Y]8-<6N#7$9 ):X [EI&RKYY;M_H*X:QD?>G*S0J+L66VVI=!5Z+"Y&
M7 UU"UE1+C3)7S]_.:0])6GOEY@A, 4]<9(Y,!\9\B,\\O?8+-35PBL=1555
M$*>G>9ZIT1>Z:6,2O8T111!HB#V0O:YI<)F2C. %D[Q#:H*P16>>HJ:000O,
MU28R]TLC!(]K1''&&B(/;$]K@7"5DF^,!6.^8'_X\/\ U</^[F&6*3Y@?_CP
M_P#5P_[N$3Y@?_CP_P#5P_[N$3Y@?_CP_P#5P_[N$3Y@?_CP_P#5P_[N$3Y@
M?_CP_P#5P_[N$73MA?:E4>U1KK TKYT:,\L1Q7B5D3D.<&#(V/L"1HN< 823
M9#_+Y]D+"\?L9I.L(^I.\,\/DKVO=150CFFIWB%[VS0&,3,+ 7C098YHP3IT
MG5$\:2<#."/HI'-;4P%\4<S3(UKHY@\QN#CI.H1OC?@9R-+VG(&^,A8K_":W
M%:/2=HW<XV2NL2S&E%UVPBK+-+7FZZP/MEG7 M\VGD-H:=J.4 97!B@XE;6
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M=WF4JBYJ&5(0 U%KLRRU CBRYFU(QV'GF-&1D5"36_\ $X]>I/C^:D+]WAX
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ME<  9(!!QC??Q\QD8(\1XC(*U)T=KAAJ'4M#UFSM1%U+I5?#0?B,A4 D[,%
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E$3A$X1.$3A$X1.$3A$X1.$3A$X1.$7__V0$!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img132800289_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_4.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16$4&AO=&]S:&]P(#,N,  X0DE-! 0
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M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    * $$ 4 !. "
M+0 @ #0 ,P X       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      ,U    !@             "7   !CH          0
M           !              8Z   "7                      !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "7     !29VAT;&]N9P  !CH    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   EP     4F=H=&QO;F<   8Z     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    &.$))300,      KG     0
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$1  (1 0,1 ?_$ !X  0 " P # 0$            '" 4&"0$#! (*_\0
M5!   00#  $" P,&"@<#!1$ !0(#! 8  0<($1()$R$4%5@6%Q@B,34C.4%1
M87B6F+?7,G&1L<'5X8&A\"0E-T*"*#-(5FAU=G>&AXB2I[.UT?'_Q  < 0$!
M  (# 0$              0(% P0&!PC_Q ! $0 ! P,!!08$! 4"!04!
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M8579K==CRFT<HN-<BD93((]>J^5-5P*\[ACZ^F%7T/SROXHWG07'<EM5KI?
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MU*GWMIUMQ:MZU@%&/A^?N+RU_K^^7/\ B*O(GU7CXK[3N*O'R;\D+^Y2# &
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M & , 8 P!@# & 4"^'Y^XO+7^O[Y<_XBKR)]5^>A5X^3?DA?W*08 P!@# &
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M?5?=;)Q:\:-!:X6*"&96W$09Q$"(F2&-(<?@1G-[;U??OWXD7CY)\D.D6"#
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M/''_ +NN]D__ +R<U\$^;B_THG>OHB?<ZBY2# & , 8 P!@# & , 8 P!@#
M& , 8 P".NKV.W5"B'[13!-?-%*_ EFI(^R%2 > Z)%PI,XC\F6-%EW]S_DQ
M])B,+BH8=6K>G9#.M:WO6W>IK*.WU%50P4]1/3QOF6*JGDIXG11,?))B2*"H
M<DFZW$:+'NN<J(YS4U/3['VRS7K:&VVB^UERH*2Y5,%!%4VNCIJZH965D\5/
M2]I!55=%'^6WY<SR-E=(QJ?HBD5<)\/&;;;[[SNM72Y!J\!FVL4,L0T=7"Q
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MTOMU6/.Z2I26*6T6O#KFT^NMMIW4QQAE+F]Z]-(<=0K?JG>M>BD[WE/LSM+
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M'R;\DY\#I)E(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M <N^>_QPODK_ #?H*^.'^+G9<G-?!/FXR_I_N^G^3J)E,1@# & , 8 P!@#
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M%/S&(ZW-QGW&Y*%M)>OO_'Q'3O\ NJ?0EO\ 2$[;^"'O?[/_ (]^,O[?YO\
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M6O%P3\"V\[Y780I:-+AK=*A25(%.#YC[K33A"/\ *(2:%3"X\/>F4]2U>"#
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MY$-I$AM*),=3L5YAYP#7K9UGG%%MM HMOMPJO6OJ4LZ/Y^()K>8<M,^LAW;
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MF-%XYT^GKY(5+ _#T^(4<XW0*Q8>C]%#]+#^1?BM?9]HNW4:MU(=2"G,:AT
M1TWL_/A9DN8>=U..6 $0V(*EHY&UO0&""J>"D,R6Y+'>O+IU[L>?=YYN415T
MT5'>N%1%3XZ^6<$O7WQ0\^2-!\5IM2BWECJG..=0J=T6M3O)>PN<E.7@7TZ$
M4-]&LI,3T&I]004NH1B6?C7(79KU.'P)+5&G\U1%:<DO7'O*^/OX<!E-<_),
M\%3N[NG5,+Q_H$1I6D(TKT]VDITKTWO>O7TUZZUO?UWKU_9O?UWKZ[^N#$_6
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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E & , 8 P!@# & , 8 P!@# & , 8 P#_V0$!              $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img132800289_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_5.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15H4&AO=&]S:&]P(#,N,  X0DE-! 0
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M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    * $$ 4 !. "
M+0 @ #0 ,P X       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M  H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F
M9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M       !.$))30/X      !P  #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@  #A"24T$
M"       $     $   )    "0      X0DE-!!X       0     .$))300:
M      ,U    !@             ":@  !@L          0
M           !              8+   ":@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   ":@    !29VAT;&]N9P  !@L    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   FH     4F=H=&QO;F<   8+     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    *.$))300,      K,     0
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M\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^%! 6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0'_P  1" #& >\# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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M:_0%V=?RV&D,M^]SGED6XOV-I2GW+7O:UJ]/52M[4K>][WO"K>(\Q]5. +^
MPW]E#O\ *,X465PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:;O
MB6\VE6OL_C<5#<LNG1;06$] YU6EO\OX'V3D<>:69@VZ4..5?NUEKHJK7F9
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M2:>XCN&\ZODP,_I).5^-W?M-9UINZ<FBVN,VGU>L')[%#F:VG6]^YQRI6]P
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MG.#0RYT[Z>(N.,;M8-^A>"3AI;5'>[M=%L;=I+<QPCKQ56B7(!;=*:2FA!/
M"N ?;GZ\-RK=SX$*9!Y(<6B,D!4^$3@2$^^/-'RF)L1]&_U+9DQG'&74[_\
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M]IJJN&WTD%&?@[A6544L;!%77!WP(C8USZ=C9*N4]DS=.TH/UWE-A3[@/3*
M:3Z:WZB[A7I^O16M[U_[L0=_7K6]Z_GUK>_Y-YKTUJNE/_OVVOAXC^K1U$?#
MC_?&.&5JXDC/![#Y.:?H5[>,1'S$:<B3X4I&]>NEQI3#Z-ZW^K>E-.*UO6_7
M7ZM_RYXW1O8</8]A'$.:6GY@+FNYK>M_JWK?_P!OSS@B?K_7A%%MFXMS&V3%
M%2E1&QCWM4ENS ].UVS1U*7MSYC!\&Y *(<2[O;J5;DJ]'=:<]-K2G>L35V.
MU5CS++1Q,J""!5T^:6K;DYRVIIS',"'?J&7G]6#C*Q-78K36R=M-11-J>ZKI
M]ZEK&G.<MJJ<Q3@@G(._H=>*\OOFO3ZQKW4#L!*=%;WI2 '51;5UB+]-)3\E
MNR0GPEGB-^U/II<B475K_2VVM:E+WY/Y7=J3)MUZED8,$4UWA%<TD;H+15,=
M!5QM+0=7.FPXEV"25X_Y5=J0?^&WN61@R137B%M>P\FMJXW4]9&!PWGOJ-.+
M222OAKIO3ZWM2.A\<+.Q&U+TJP\P)LWF"M"-?D^X 6R*M,9*M?GMMD<1VW^>
MMN*TG:]P76[4IQ<K),6 D?$VF5M?&0,8<:8MAK& YS@12X_Y$ E07:[4F?YG
M8YBP9_U-HE%QC('_ '&F+8*UN>389<<]"JQ^(9OE5E\E_-4K1H0./._%G,%M
M):KR0!R+!E\W"H/LO0Y<""3AH?M4*4Z7CN--_-+H^JEH7(<;=7](NE]BNNR^
MQ#8JZ:=LEOO$_8S/F:\"FOE70ATD$VZYKZ=T;Z8;S Z-HW!ACFY[K3<:&X35
MLE)('$O8=Q\4D$S0T=E('Q3,CE:6S1O8\.:"'MP1PSL9S65G4PB81,(M&OE)
M>_(J;Y?:B'QYVC<@K(VA0:N#JOE1XJ\[*');W670P+JUG!=#JUHN#]?MA(J$
MKU9!*? 3A]BAOCQCLTN9]\&9\^6-..O7'S P2J,8\>>O#W[M<Z%7K\T.A'>5
M@0-U,^3PSQFY%'^Y0[.<&<GA]!Z&9/1A9.RQF 1FP2C%5K@>%7:Z=FE69G.[
M,1*)C_('SQ3^FM2*@&<\3UY9/%>L\.;A;>A\LW>BW9OTVU ^8,1Z-83G'9?%
M^E!6ZR<+U*V53I]=<((@2[77K8"*"Y<P?3Z$EIV*_#>KON81.E0=??3KEW:C
MUW]95L\JBUJ]/^&'R+I1KIYU71.KUZ;U(HLB5^C,B#30E):B=<YQ<8PANSAS
M.D:M%8[3<6]OR_JG0L](F4*VTQ!5#D.O+R5SX#VZZ\SG%^3W'>= O,3X;_5!
MH!3-_>[Y:^<O6%9<V\IVG"_#[R;FPA.Q+I)0%&VY<5A]4]D4V2<VC:%R]M+6
MVJ'[CZA3AZ_G/U6S[*B81,(F$3")A$PB\V!M]4L\NPPJW80QN94S2JY9XPJ?
M%FO@3R!HTPH05;CN+5"()%&1)'<5_2'=0R,.1[?ER&E*(O281,(H0M_$QY$[
M*OG/C<OF'2I&F]R[("C-20UHVQZ?*BW^I..1QEMA[3K36Y2G!UCC-:2@;8(.
MD^F\'66..2H?<+=.^U71V"^J@8'P59:,-9<J,N9%6QC !<715;6C=AJH0M_L
MFWM32V^'9W:6@@VMV5B+A#:KA*^*NM DSOS;-WEC9*NRSY)>(0RJM<CR755L
MJ"25AA':2=4(Q:KWD)#H!B3(;@A[W!?D2.47%]?[AC<"PRDIW42\YQ*MLU.V
MO1YWO_>!9$ZA.I2^B&]RTDK:3:"!ENF<X1P7"-SG6>N<<!O95+\?!3R$X;15
MI9*79;3RU36]H?;6["4MXI9;Q_#NX3;24443JBNV>J(XXMLK'$TY>*FV0DB]
M45.TCM+S98Y*<-_J5=+;G$Q-L/K>E:TI.]*2K6MI5K>MZWK>O76];U^6];U^
M>MZ_+>LV-?-"""0000<$'0@CB".XA?N%%!WDJ&*6/@_4ZZ$KUJM1<_4204:!
MI9.&'L$^<50F!&2Q/GF0$1J"P](1*--/%&-20K)"*EN6MY,-_(6B*GENML^*
MK&T%/#<*.KEJG25$;8VT51'5X+J6.2;^H8!%N-86R%X9(1&YY'DKH!4TD\#A
M,1(P#$$KH9"0X.#1(U["UKB )!O /C+F.!:XM/QXTB20#A_.P1FM7.HE0E?B
M"" &^EX1RQ1)@U/T4A:R \[9(C@R2ZPJ2%9;*N;C"78;#C$-QM45J76GIZ:Y
MW!M)7-N-/-6U57'5,EJIFO%9.^JW ^LCBG_I&7LBPL#&%FY&7,:TF4%.*6DB
M@;V^&!VE3,Z>5I<XN+3(Z20[@)Q&T/+61[K&AH:&B=,\"]B81,(F$3")A$PB
M81,(F$3")A$PB81:R_B%3O*0@YRBJ</J!V/1]7048Z!?JSV[AW);*<C31%QK
MNN7UF3V %9D0#4R<0 V#[E!!R_O@V+/JC;T#9"5.CE1IG0'3O4OC[A=.=^&]
M"/".5N]7+QZ("3/J]V[#R-(2!6EBWYLRSWSL \<.YK-IH,&PB:3/4ZLD6)(Q
M3"@M>F->_P!CYJ?+W_=19X@]"V3ZOT>M@/&[Q7IS;KR&NJ])\3^U4KH$8-=1
M49Q\54^P5U?-^276)8'XLR<X(GM!K'$1M<EB6_ <V]Z%3SUUYC&?F<^*V484
M3"* /+#^*SY*_P"P#LG_  ZL>%6\1YCZJ:@7\!AO[*'?Y1G"BRN$3")A$PB8
M1,(M=OECQ3E%_P#)'P[+W2A5VRSR]VN==+O%H6I2"X,'SRS6<0)*QU*^F)01
MYUALBQ&FLOMI=^8WM*F'GFE[SLU>+G0[/[74]'6S4\7P5',&Q.#2V6>NIJ2:
M1CL;['R4SC$YS'-=NXU!#2.)C8^:GF<,RTKG24[\G,3VAT@+,' P\!X!!&\-
M[&=5Z6U^!W((\Z6?Y?0N4BY,IUR40H-YYV M?-33SF_<]].RN$BQ4J9)WK2=
M$*N2T.CJ_?WZT17[D+^?"JVJMLKJG9W:J\4+W'>DMU7<KA56J<YR0V,U/Q%"
M]W 24DG8L)+WT<YT7T6FVML-YIXK;M]LU2WB*-G94^TEFBI+5M;0LUW3).(#
M;K]#'G)I[M3?%RM_ILNU,W!'AJ_QOQ'BFXM=Z=XZ@_'^_$W]1H+<8H5 TZS2
M5K3II%,Z%4B *O%I$A2O1@#+^S6A&M*TY7VV?8XY[Z7^*>TH?%0WNOK;76.=
MN11W-U-7T%4\G=:*&Y3POIJA\G%M/+V%:0"YU*T ./5<OX8!]+47C8FMIMMK
M#3Q]M536JGEH[[:HF@N>Z^;,NE?<J&*(-_7<*<5MG(QN7%QWF-GIWP\Y>WOW
M +7W6I>FM_)17._=:9BL>[>]^K, G:R@[6M;W^6EQ%H_+7JG>O7UV$;77,_[
M]+8ZO/\ <:FPVDO=_P"I\5+$\\>.\"OG'PD8.CIVXX8J)\#NX%Y'H1A<FO&0
MW$1I(;RC\H!>V];^0EZXT6PLMJ]-^WYB;/S<R_)1K?IO:'I*MJUKV^[6LG_4
MD#O][9G9F7/]Q%'74Y//'PMQA:T^(;XXRGP[LY%34CPWHW#_ />)RXM\7\B!
MRTJ ^7MDEI1K>M-7SD',K*VK6DZ2C2U5>)SY]?IZ>Y:MO^]Q>_7W)U^6[_.-
MGY/]_9.G9GOH;O<J8^./B7U[1X?IP!SXJF*8?VU3SR[2*)__ /#8B??U7V[4
M?,X=Z*&]OX#8_P!?JS8> 70'KT]VO3_K +NLS?N]NMZWO4;2?7?^A^KT-J]C
MY,B6RWZFY&GOU'/W'_MGLD>->'ZCPU)4#*L?_'@=IP-,\:^8J3]%]M$O-47K
M?U=1\9[CZ?EI0V]=,HCBOSW^ZVQ/HM[;1ZZ]->S4M?Y[WOYGIKTR.CV-D/Z*
MO:2D\):*V5P\MZ.NH3Z[@\N8FK &&4[SW_U)(_;^E)\UKF^'R[UQSS<\M'+Q
MPP5SUF1MUVTDQRC[[5:L*90)-=K\0X2G*BV2-;0'S+4N:J V^24A!Z"D8-EH
M';V;:_9G8ZU;*[(UECK'5%7##64U&YT@WZFBN-947.ZRRP!SC"YEV=AP<YYB
M>YU.7O<TO6!M%!#3W*LE90,IG@3-,C72N(^(F;/(S>>\MD$\G^H+BW.]DM+6
MNW3O SYDMG3")A$PBU>^5,KX>!"]USIG<+,HO:6[Q7^&G(5!O'090LH?IU@D
MVX)1>WT7FYQ(2PC*@?7+-Q@O2 A!F&]+?W%AOMRW&G)C\?YY_/BKGKKAZ*[G
M66.8VQRJ\TZ#0JWU?5AL@4JU2C<.D'TA6@<Q1&#T:?6K>2BO/!ZL;ACT:+!!
MY8J/+S!RHD)2MN.LU1>DYM.:E!2<:+S0URR$*M-H'0P)F)5(.BS:#<V0_<!4
M>H'3T!(FW39$H_$<GO0#LG<YR4:%0"#SS6$4A81,(J'>6W\8/X;?^]G?/^33
MRCR'AZM^H17QRHF$3")A$PB81?F]:5K:5:UO6];UO6_SUO6]>F];U_+K>ORW
MA%2[Q?\ !#B/B5=>LWKEK1C13KQ+9$Q%+HKZH%;:^[E2* 5*;% A;]<J<>'+
M#!H=4BOJ PX=6$2HT%LL^7($BI).,]W7[^:NEA1,(F$70*"AAL=,$&1\(J*(
MQW(D\:1C,S(,V*\G:'8\J+(0XR^RXG>TK;<0I"M;]-ZWG7+%%/%)#/&R:&5I
M9)%*QKXY&.&'->QP+7-(T(((*]%)5U5!4P5M#4ST=92RMFIJJEED@J()F'+)
M89HG-DCD:=6O8X.!X%5V_1M?^.M*D\/FHLM-C^]UWB=Q)NZC1F_76]Q^:7:6
MX]+J7IKWJ9KY]LY6%K]D:!NM,J7(UKG\LN%E;O6)XJJ)F2;%6RD,8W_A:JYY
M+Z+'%M-4BHH]!'%\&TEX^F_]4[.;;O$6W\#K7?)=UC-O;)2,[65^"!)M58(&
M,AO.3NA]RMKK?=FMS+4"ZO C,DT'KE2Z ]+$Q%SZ_<1*-*/T&U1-A;@$WO?M
MVZ^+>6I)$8M>MIC'PD@H F^F_HR;RDK2C)V^[T=P<^%ADIZV$#XFWU;.PK:<
MGO="XD2Q$Y#*FG?-2RD'LIGX.-6VCV,O.S<<%;,VGN5DK21;=H[/,*^R5XQO
M!D=9&T&FJPW#I;;7QTERIP09Z2,%I.9Z/:B='HUGMXBN+MDRMBWS&P#96($<
MG0X.TODE-DIS;T9A<,<B5.2AQM2I*HVHK6M.O(WKNN55+0T%560TQJY*:%TW
MPXE9 9&1_JDQ+("QI;&'O&1^HMW1JX%>'9>T4M_V@M-DK+FVSP72LCH1<74<
MU>VGGJ,QTH=2T[F2R-FJG0TY<UP$0E,S_P!$;@OGF]I,7:E +6<K"J?-/0D$
MD 5F81Y<:#*]7ASRR4!IF,ZJ9!6Q+4TEM*XVWMQW?5QM6\6RJGKJ&FJZBE-%
M)41B7X8SLJ"QC_U1DRQAK'%\9:\@#]!=NDD@E7:BT45AOURL]ONS;W3VZH=2
M.N+:&>W-EJ(?Z=4QM+4O?*QL%0V2$/+BV41]JS]#PO<9[E@$PB81,(F$3")A
M$PB81,(F$3")A$PBJ+Y;4'B'1J?#(=6Z+8><S^!D6>Z!+?STS";Z%0'XH:RU
M--H'U^0!N23$<J(,6:N1(4RF'TDI<EU@)%4>C0W8X]?;Y\%1GN[^[F%@PLGQ
M#Y9X.U\&_88<3Q'UR2)SJ#(LKUD7.L%*LPQRIZK;\%V)'NT^WV51"0%56H8E
MJW/'Y;H>$&CE$(@M.'DFN?'.>[WY?9=;PI%>'\:O6F3XI2)<C[:L13[ZFRN]
M(9Z%#FBWS=G&,W@5UIN)?HY,E)N9RR)*V" W*L3AV25U,G(=2ZE]D.3QZ[E=
M_"BT[^;7&.X='\K^7'N2T?R!A2*[2H\L1W:I=(!1.:TBWL+NP\'3U\ZE]&J;
MD4+9"5A&G>YW4A4.E3"5)K%=J-0K#165).AX1GGYC]CZZ@CN[UR!P#PU/#'S
M^W$<>Y0#0.0>8_+/!;RK& Z@.XC6R58N1,ASGR;MUF[I<$5J#XMU 'U$Q2K/
M3NJE60DNY]1%7X\+^^FBT)YV9H\]6ABBLB(Z&=<_;D/$XUSWIG+F^F2.>\>[
M UP1KC7O[EOQ!>GV0/Z?J^U#_3U_7Z?2,_KRKBLKA$PB81,(F$3"*EGD#QCK
MO0^T\1OE)N"0E:Y4468FCE6*NBW%SR\8H")O1(1/E-QDNR)H0BJ$XN4>;B28
M^EQ1X\03V@\CU07^[6R*HM]#8K#<:*YAL5RK+E776GKHXF.;+'%1Q49^&WH)
MF15372@ND(,+\1O#F[/9Z38R:VW.;:"][2V^\,819Z6T6>UUUMD< UW:7*HK
M+C2U(9/_ %:7LZ:*,T^658FGW74K[IYY5K"Q)P"$LXF<!L8@:>"$V%Q2(DO"
MCD1TZ.Y_ILRH<MMV.^VKTUZH<;5KUUK?IZZUO.F>G@JH9*>IABJ()FEDL,\;
M)8I&'BU\;PYCVGO#@0O9;[C7VFLI[C:ZVJMU?22-FI:VBJ):6JIY6_VR0SPN
M9+&\?\F.!QD<"5 2>6] Y4UIWAUDT6K4;]WOC_2",\F$;81I/_4J->'%2K)3
M5*TE26(9G\6UQCW:9ABA;/[XC7Q:;C: #8:KMJ5FO\ENDLLT#6 :1V^O)?54
M&O\ :R?XZE:,,B@@;@CZ.=KMF]L'[FW]J-'=9=/^MMEJ:GI+@^1V?]1M#8&B
M*UWT#(,D]%_)KI)N[\U95O):[U5-[C6;"69J-G@E.:=%4C7NHUV0S FSEZTG
M3BZL::<=K]SAZ4K]S(K9&<\VCT^NB07M+81ZZ&^TM3,VCJHYK7<R/_+Z\-CE
MD/>:29KG4U<P<=ZDEE<UI':LC<2T8>^; 7:V4;[U::BCVJV8#B!M#8'25-/3
MMUW6W>A>QERL4^!@QW2EIXW.TIYJAFZ]TTYFUHB81,(J'>-EJ<+>4OFQ 56+
M4*T]<>82M3BPUF+ 3H5RVN!],+?1,?4F02TG9,8CY?I(%;U)6II>_DYL5WK#
M-8-B(OA:N+>MVT#^TFB:R-A@VAJ:?<>X/<1),!V\ P0^G(>2TY:L/051FK:Z
M,TM7#E^]OS1-9&.R:R+=WA(X[TO^[$,$.B&\2T_I5\<UU9A,(F$3"+6=(^'T
M_>O(/H_<^M]!:DE'+H#L_#CG. XZEWNA00\V9)0#M)MD4J%>@VX;L(3]BM\.
MU#MKA/'HJAI0@XEB==:<L#FKGK\<N?[:+W?FSXM/>2L(&P<M/'N<\^J@<T3L
MG3+-S:+9NOTY32F9*R7-+^9L8<!S&/$'QY4HG89HTVZRXTT\F.RVTIY%ZZZ^
MJ XZT(Y'FK+\#Y1'X=R"C<JB7_H/4HU/%.06;[U.R[M][L;<F=+))E';#MB-
MHAMG4WZ,?[64-Q14:##;]S<=*U%%+^$4%&O)WQXKB+&Z?[/SD*W43L:LV59.
MTBX20QV6LBA@;-W(?;TV\I08SI:M>YEG[.6V\XWH9.VP10%Y:*2OR"^&RM"M
M*2KRRO2DJ3O2DJ2KPS\HMZ4G>O76];UO6];UO>MZWZZR'AZM^H17RRHF$3")
MA$PB81,(F$3")A$PB81,(HXZ%RJG=+CPOQ!"D1C(AWZFNVT'+="V^L3=;TI,
ML!886VY\%>]ZUJ1&^8Y!G,[7&GQ)49QQE>-N-JHKFUGQ$;FSP'?I:R![H*VD
MDX[]-4QD2Q$XP]H<8Y6Y9*Q["6G:-FML+YLK)/\ RRHCDH:UG972RW"%E=9+
MM 1@PW*V3[U/4- UCEW6U%.\-EIIH96M>*F^0G5>E^/7(;PGI@W?5:85!$ZL
M'Z)7DB@%E'S;)#D"1T>]UMUV,,D*TY*UZ'JOIF/)^6EN0"@O.?.<T_:6\W/9
MBR7&2[1&[T#Z>6FAN-*(:>KC?4L,$+;C2N<R%V7O ^*H]UCM ZEB/ZG?9/X:
M;'[*_P 2]M=GSLI5#8^^T=QI+O6[,W,UERM53!:YXJRIDV>NK&2U<8+8CFW7
M<ODB#B^.XU#&;C9F\2NO!NU<*IML!C"0F*.B(J#T4IN,J0J;5HL49)DMJBNN
MMJC25-Z>8]RDN:0KVN(2I._7-;&WNGV@V>H*^FBEAC;'\(63;N_VE(!!(X;C
MG M<YN6G.<'4 K1OXS;%5VP?\0K[9KA5TM9-53NO<<U'VHC$%XEFK(8G"9C'
MB6)KRR3 +"X;S7$'2R>;0OEB81,(F$3")A$PB81,(F$3")A$PB81:V_+?PJ/
M>57<N<3;&JGPN)"J)8Z_;RXO:0?9XTXDR<^7! 66)7I)"?7ILV37GI-;*V+5
M$F0X5DA6VD6[[R-<$.OKUW^7>KP\^[[_ "X>/>%*E^\/6KKPKA_&X'4S=-)\
M#NO-[[2^@5NB<TBRMG>7(GMUU4BB:K".=1HBDS4+E#Q=:@#D/1FW(,.'K>FT
M.NN"9USY]_/QU^_BNKXD<9Z14#_7^O=DN%QM'2^EFT4N4W; W-PWRZ5QVU7N
MO\]L,%CFM=K@M2+O72K-LVU/C2"0Z.4ABI$EQ<%6]NOWZ_9#UQ]M>7USJ5=K
M"B810!Y8?Q6?)7_8!V3_ (=6/'77!5O$>8^JFH%_ 8;^RAW^49PHLKA$PB81
M,(F$3"*H?0_"OD?2[-?K6>F6Z.2Z+.I!,V@84'QXT6=0'-.@Y AMX1)<@;D.
M:UHZVEUQD^QM4(JW)A+5'WQA:*<Q&, &*X_S,$@?KF,+X3&\<# ]K@Y[ &N>
MY@+G_JE$G-[S('!X#@^E^#.KQB+M&2M<-UP_JL<T]E+_ 'Q;Y[-S2V(QVZ0A
M+:$H3K6DH2E"=:_+6DIUK6M:UK^36M:UG,DDDDY)))/,G4E=8 : T# :  .0
M P![+ZR*IA%Y2XT:H]!#/ +G7QEB$O;TO48C&0ZJ.^G\VI<*1KVR8$UA7[N/
M-A/,2F%ZTMEY"M:WGDK:&CN,#J>MIHJF%VNY*P.W7#@]CO[HY&G5LC"U[3JU
MP*S%CV@O6S5<RY6*Y5=LK6 M[:EE+!+&?[H:B(YBJ:>0:24]0R6"1I+7QN&B
MA3\*=CY&W\SGYB1U^DQ4;_\ 9_?"R&;T,CH_T6*ET.2GV%T--ITVP+O")$AS
M?MU^*(Z=>S>#^$O5G&;=,Z]4+!_Y=<)@VX1,'!M'<W@B?= PV&XASWG&:Y@6
M^?SC8?;1Q;M)0Q;$WZ9P_P#:39VC<_9ZKE=_=)>MF8CO43GO)?+66!T4;,D_
MRB4G(D&A]CI5^DOA8<F8 N0]M*C5"M<-T#;Q"_52%[=%3-)^X0TN(4ALN&>)
M!Y/I[H\]S6_RR-OO5#<7.@8Z2GK8@#/;ZR-U/6P'@=Z&3':Q@@@3P.EIW\62
MN"UO:+8>_;.0QU\\4%RL52XB@VCL\[+C9*T8!;N5D&?AIRUS2ZBKF4M;$3B6
MG85*N99:>JF\9YIX[U/KG2+3S&\$CW2;5N<[?Q,GJ]@N"4NM3XC;DB76B1N?
M$@/B'&(HB _](VZ)'[T)B*8B+VQO(5.VAOU-3V,UEHG;:-&4]%3T$=73"/>B
M>V5U.QLX:Y[RZ9KR!).1(\&359>MV/O]DI(+S<K'>+?07,QBFKJZEJXJ.K=-
M$9X>PEG:(GE\+'21[A.8FN+?TA6RS'K$)A$PB81,(J,^;/D%1^55<;S'J'CS
MV'N- \@6I/(2,3G4*DRPQ6=?D/5M% +*L?1*07;G6<=+(+0Z+:>C11<:?.ED
MAZ(JG$OOUJ@\"!C77(]M,9]1KCFIP\:.VU3R(XI3>LTFN6BH5LZJR!H57ND4
M9!M &11[6<H9469A!S!Z!%E0RU:G,_(:*RG6VDMIE?)E:>CM$((T./0Y'O@*
M=L(M-_=_AX]M[L;Z];SEXYK$NUWLMM%50T_.M1$0"XO8>/\ 8^+ J,W6FJR,
M^R$*;!["=Z-(F13)M%XO4LE%(O@!CH^2/F.O#HE<LCAKC!SYZ'Z@#R&>)4G>
M2U+NX3RZ^&P6=Z;((\ZC=XL]8'\R<J(*.W#L@[P[\F_G77=R:5NPR7ID!A4%
M0![W"V?G*E(5MY",'N\Q]1]/\Y7%;0LJ)A$PB81,(F$3")A$PB81,(F$3")A
M%#'D-3:Q>N*]("6T/%."V:B>,M0Y?S=-ME @J83%34*9<:<2]"G1V9#6TKUK
M:D>U>E(4I*L)M'0TEQL=SIJV!E3 :.>7LY,[O:01.FA?^D@AT<C&O;@\1KD9
M"WK^&E\NVSVW>RU?9:Z:WUC[U;J%\\&YO.I*^LAI*R!PD:]ACGIY9(W@MR [
M+2UP#A]^/U&J?/N/T0'3 <0 )DUT0;?A0_G;;>+&AD.<3G.*?=>=4_,E.*=<
MWM?MU^2$)0A*4Z;.V^BMEEM]+04\=+ ::&8Q1YW3+/&R260[Q<2Z1[BYQ)XG
M3 T7'^)&T%YVEVVVBN%]N$]RK(KI76^.>?<#V4=!5ST])3M$;&-$<$+6L;AN
M3@N<7.))F3,VM'3")A$PB81,(F$3")A$PB81,(F$3")A%"OD'SZ]=+Y3::US
M+I=KY1T#8X@0IMKJ9 .,<U9XHH@D -L$HS5;BU^$IAAZ$JPMP0RBJX3&_H)#
M3NO:X5!P?SJJM^ U&\PZE"Z5,\K;+=RC91=$B48'T2_<VZ%91DP16OD] ,-%
M.6TVIUV)7+':9#DBMP):IQU@;$1LJT.<4B-D&>_KY#KEP0X[ON/J3^.61J=A
MV515C[%Y25+B?1*C0[75KH[!LU!ZET69>H R.NH@0_**M-MIP:_*=E-SBEBF
M"ATM^&)$0I>X[+3;Y.1"U-&HFN_W^W7HKC/ICSUZ^:K1+\KQWDGX<^8) IS>
MW<4LU.X[?Q!2E="*5&<5<AW7QZB]-IY>$1J)XZ&D,F*I<Q*WX&IR20HHR0&S
MHJ%QT.OE0,.;YCGSQWXY+8\"_@,-_90[_*,X7%97")A$PB81,(F$3")A$PB8
M1,(F$4?WWE](Z5#9C6P*U*EP?F+#'X3SXJT5V4M*DZG5VR#G(Q@-,;VKWI=@
MRVDK4G6GD.M^J-X^X6JAN;&MK( ]\>3!4,<Z&KIG$8[2EJHBR>G?_P#5%(W/
M!V1D+9-G-K;_ +*SR2V:O?##4;K:ZW3LCK+3<XFN#C3W.UU39:&NA=N[I940
MO+03V;F.PX16K7;N0M*4C4KOU#BZUI+.MP!/9 D-'O\ S]RU1*WT5++:4;6K
MW5<\YZ[2TP7D>FEXG_QVSC(WMHK>P:-'907N!@\S'1W/ QDYH:C&=UM0_ .W
MC_H';5X#C#_#C:&4G+\5%9L-7S.W>YHFNFS!>[(:,7>W-T+Y*&+);6?Q-\D>
M9=3\D?($+50%B%$[0\(L8]9@% %+8@4T$#J9V-/2U.?F0YLDTO<IJ(XSZN-)
M6[,W'EZVQFI;&[6VB];4;2TM%!513U!@JF&>F9!B*AIZ:AJ&R8D,C)#4'>:Q
M[ 2W)?NO&ZOJW\9?X6[5[(?PM_AK77>XVNLI+3'76NI%#<:BL;)47RX5]YMT
MM,7T\<,U/%0?T'S-D_0\M9 )8#VBV69]37Y63")A$PB811'V6N<MO-;&<][!
MS>!U2GWFRB 3M5-<_5T6MZ(HV^6&EK,,6*+#PH<9)&)>_$QAJ*-%D=P$JFL2
MI,72R+[XQ+H":6BL\QH1'FE+Y^6+T -4)?."O+A8UBK3G1JE52N$0X2._4I+
MC:WP)H+$6$,0UIG#I#[#R75$4LX1,(J'>6W\8/X;?^]G>_\ DT\H\A^X^H17
MQRHF$3")A$PB81,(F$3")A$PB81,(JH>9WE8$\-N(E^T'Z99;O"'D1P=D97F
M)*VT$BSBF!OWF6/'FR8T?.F::%QYD"OFW/NTX<Q(BQX;\@A$A..L_14#/MGV
M^715<NH>=W)K!T3@'C;9N3]G>B>6-1CG!KB(16M%80PO('OUV*^Y6YSB6F)T
M:-8Y]KU*M0%8T#7IR8\:S)G.P&O-6TD%?2RT=2)#!4-#)6Q334[W-R'%O:T[
MXY6M=NX>&O >PN8_+'.!RMCO-?L]=*.]VM]/'<+?*9J5]51TE?%'*8WQB4TM
M=#44LCXQ(7PNDA>8IFLFB+)8XWC <?\ B#<@$"/)ZGU[DG:@]6\/8ZY!9\XP
M<L)"4(:;%,F4291^3)F1GP-JDVP0V,"EKE%17:,5)PI;3R8U;1*&C@M]+%1T
MHE;!""V-LT\]2]K2XNW>UJ))97-;G=8USR&,#6, 8UH'*^WNX;172IO-U=2O
MKZYS7U#Z2AHK="][6-9VAI;?3TU*R20-WY9&PM?-*Y\LKGRO<XW+\3/(X5Y7
M<*I7;1%/LU&CVJ S]77K1&=8D03D6)$19((V1)C#YA02%L*R==9+S@X*7/E!
MICSH4?KVLYZUAU9#")A$PB81,(F$3")A$PB81,(F$3")A%X?IEC#5+G]QL)^
M_@N5BQU=*+?Z19902(#I+KT5R-#LI%ZR/Q@*F1,UZ/+U'+O(@2W&T19.]MO*
M3LB\!R*^5CK,R?T'F?D+3>S<X2,@UA0ZARJ-9*^,MPM.GBY5=JJDF9,06)-2
M&%2P$R6J' 9W'<AQ6/FJ<>)Z8\\@_-3OA%%M^XSS[IQZIV&[!MFY5.'7D0+A
MR)+OVF2+Z/6UU.W#RXS6_IBL0F"=<A[9E)6EK3BUMZTI6_4BI!U#PB\;N+^&
MODI6@E!;NK3?+NKWB*;[$1G=BM8^Q".-N5.O2Q=HZ*[83(MNL5:K5VO5M@?+
MC-AA0>''AZ;VE:UL?-4'+FY[B/#O\/-;' 7\"!O[*'_Y1G"BRN$3")A$PB81
M,(F$3")A$PB81,(F$3"+71XO\RX+6/)GR1)\_D!7;**("1XQF#;%%Y#(@Z%#
M%KI[('W*3\UMFXZW&F2%LK4+F;4+VXPK]XU\TV3L^S=%M5M3-;/AOC(Y88F"
M*M,\C8:B"GGKAV1F?H*\%KW%O]*0=B"W^U?IW^+6U?\ $2[?PH_A;2;21U[+
M764M94U;ZBS"BB?66^OKJ.PYJ/A8MQTECQ-!$Q[15P8JPV1N)%L7SZ6OS$F$
M3")A$PBU!?$O=2JV\P@M(9Y 2FUFP-C?+B.'\DS1WFLC18;O\("(OC<[7B/S
MRVO4PTU?;T#J,U^&W&V.,O[<CZAZX\1PX=>:HT^XTU]\Y]BK<^$-YC6?B82M
M-]1ZOWJ?S]I-?-]XZMS(]R^?T\K(?F$G2(<98 5;D%APF-)BB&S,$;('R6HS
M"-FC!1LI(2SQXZ?/R4/UY*XF5$PBH=Y;?QA/AM_[V=\_Y-/*/(>'JWZA%?'*
MB81,(F$3")A$PB81,(F$3")A$PBZ,\8.*LHCDX$(BPT^U);9G16);3<EC?N9
M?0V^AQ"7FE;VIMU.M+1O?JE6MX18[55K&GQ\G5<!:DB6($86_H3 T\-C"M2=
M#&(#OR/?$9':F2]06HZFT1-2I'R$M_.<]Q%\ZJ-4TB>UJLU_395E^,4;T''Z
M01CRITHG)8G(U']LMF02G39[[;^G$.S9DJ4XE3S[JUD64@#1XIA449 ACHRY
M$N8J/!C,Q&%2Y\EV;.E*:CH;;W(F3'WY<I[:?F2)+SK[JENN+5LB[N$3")A$
MPB81,(F$3")A$PB81,(F$3"+7K\2:JV*R\8YO.J[6IA>B^1/).CQA+M"B=3B
M&GJ9,+%80Z?S1WI/*R=YB:)H@SEU^L65^U/N0FI(((5F14M(AZ[U1]CX?0'\
M<U#/A1<;0_Y$]3/VL>6-F^Y ZCLG80WBUT'Q(YX"?Y2(,QD:56^X]%L=[Z#<
MST.P0(T\G5!LX:,%!QZ"DN*VPPE5ZZUZ^:'H9SW^ T]?3*VX843"* /+#^*S
MY*_[ .R?\.K'A5O$>8^JFH%_ 8;^RAW^49PHLKA$PB81,(F$3")A$PB81,(F
M$3")A%"/4&^^JM%&<Y)*H;52;38_T@1K9#G/EI#BP\ANK[!.Q9D=I+;)M<9\
MHT[\E:XC2M-2=[5ME74>VWJC=W-SX&84Y/$5^0^ OU_VB&=D\< )S)J8VM/8
MT1$1;Q>'"IC,N",&E_ME:W]+CV@W^U;@MR8@S(#SFLPT!\0>($L3FWO&F/<)
M%5"LA2<&OEHL55MBV9M5ED$UHD+??%G*TM;XU?R=*AEX[;,D>VWO<M[DV.-D
MG:-BC;NUM$7M:P--30MI6RUT9>"'PR2UK331NS(6Q/=5 AP;".Z2JJ)X6T\]
M75R1-IY&PB2H=(VGJ'/,5/*R)['1%M/3N+WM#6ASF-@8US7.>=@4?YWR&?J=
MH5(^2W\]32=H;V][$_-VVC:W=H1M?NVA.W'-I3Z:VM>]>[?:_=WG;F0S>.[D
MY.[D[N3@9.,9.!D]PX+QMWMUN_C>W1O8&!O8UP,G SG R<#O/%<N<5R3")A$
MPBK#V;Q3I?:;U7ND$+]VWGEOK=3*TB(4X_U2P\Y5-K9DN..S!Y=H*K39+7W,
M5!D,./ZVMG;7M1OVJ5K9/# /77AX+.<,\<*EP67>"8&X=6O)SH<P'-LM@ZUT
M0WT4X]NN#5B1$:&0-J4Y!A18;BT:BQ]);6XK;JM;7O>]E<Z : #DK!846MWX
MFE)[O>>/58=PL?T(P1CG+ZLP+YF>EU^R+*3^(=1#\J)N2H)D%)4* =F(<_-3
MU[G?1C_HV2Q%AV! D*;*CK/#U\%X7S&KGF84[KX)S^4U#CUE 4KL)(VLS;"'
M2_JP]OD>,/?:V>)=$=J=4*B05 >;,_;@IF+*>GRKD2 "GXC44@IU,.OU]0<C
M]T&,'.<]W+K\\%.WUWQ+?Z,>#/\ ?OOO[.L:\A[G\*)]=\2W^C'@S_?OOO[.
ML:\A[G\(GUWQ+?Z,>#/]^^^_LZQKR'N?PB\TY</B8-W&'4OT>^&"VY=:)6+=
MB1<>^[ QECR@L:D+(F?HZ]&R\Q)-4Z)&WKU=AP9KNM_O6\:\AGS^^/LB]+]=
M\2W^C'@S_?OOO[.L:\A[G\(GUWQ+?Z,>#/\ ?OOO[.L?JY#W/X1/KOB6_P!&
M/!G^_???V=8UY#W/X11K4^I?$TM%]ZK1W.1^(X!GF1*J#H]K-VKOL6LWQ-HJ
M8^T.3:7._1WO1.( <G* &W/1/TIN)*B^F_9ZXU\/?O\ ;RZXN7S\%)7UWQ+?
MZ,>#/]^^^_LZQKR'N?PB?7?$M_HQX,_W[[[^SK&O(>Y_")]=\2W^C'@S_?OO
MO[.L:\A[G\(H[Y=TSXF?2JJ[9Y')_$.BN-VN^5C0&Y6OOHPTXU2+O8*:R?1%
MWSK>]A;6R";L]:D[]/K:\7%S/1/S_33)[@,>9_"I]] I$^N^);_1CP9_OWWW
M]G6->0]S^%$^N^);_1CP9_OWWW]G6->0]S^$6(L-C^)>! '#B*/X3EUA@Y,L
M@2+NO?9!,HH="?F)'#F/T=:^=/F[9U&B->NOF2'6T>O[K&O(>_[(N4,>^)<7
M#BBRJ7X2#5%!L$BH<0N_?69\!4V*U)W"FL[YU^]2XNW=L26__ \VM/\ )C7D
M/?\ 9%DOKOB6_P!&/!G^_???V=8UY#W/X1/KOB6_T8\&?[]]]_9UC7D/<_A%
MX;H?4OB.\M P;@7Y+XLWX,U<: "-5SEUF[F:O"@MNO%>JA@P%'3:!&A/:K0T
MS*L9!<R0S%CC!4R0^XEMI6\:]X'OG[!!^?IU]EL?RHF$3")A$PB81,(F$3")
MA$PB810YV_@G+_(JI#J3U@'.. 0]H#702D78['5"@NTU[4K[,:&G:H5#&X,V
M!];)VPY%GM>BG/=O6]I3O1 <*+>9^$/CUR7H 3J%2!W:1=JV/.# ):X==ZOT
M!L1$LD>/$-I'CKQ<[ ,BND8T6.R_(9B(D;;90G3FM)UA7)QCN\@/?GZJVN%%
MX7J+USC\SZ)(YRRU(Z$Q1;<]0X[Z&'&7[FU7R"ZNR\B2I$9;3IQ,%#B)"TL*
M0K>G5);VK>B+1_1+=YCZ\'_*>-!Y[V7L84M6;:)A3O+*T$N9=; BYOB[47.H
MS0@LG0R!>W"8/8)=^A5H-]&*A..QGXE;*20*ASC4UUSP\N['7=S&NA7+0$<!
MPX:C.3X\N*OV(ZYY_-B1C;?ACR-:$#H2$+7Y9H;4I"8S6DJ6WOBOJA2DZUM2
M-[WM.][3O>_3&O,8\OOG[*:<S[?NLC^E_P"(!_4OY#_BV;_8KC7F/;]TTYGV
M'Y3]+_Q /ZE_(?\ 5_WMF_V*_P#\QKS'CI^_Y33F?8?E1WTORK\XN5B )FP^
M$?/9L6PWFE4"$V \HMEI+1F]V&%6Q,J8RSQ9*HP>+.GM/EB*M[;@04/25I5I
MOV[:\Q['\H #WX]/W4B?I?\ B ?U+^0_XMF_V*8UYCV/Y33F?8?E/TO_ ! /
MZE_(?\6S?[%<:\Q[?NFG,^P_*?I?^(!_4OY#_BV;_8IC7F/#0_E-.9]A^5'5
MR\K/.*CV?F%3+>$?/9)'K%J)5"NOBO*+<\?!)BZE8+E(D6&6WQ?2! UP97)L
M:/,>TM#I1^#"TG2I.EH'/,>N?;CRSY\AQ3 UU.GA^_U4B_I?^(#_ %+^0?Z_
M^]LW_P"7_P E,:\Q[?NFG,^W[I^E_P"(!_+X7\@_Q;-__O\ ^"G_ *?^N\:\
MQ[=WO\_DFG,^W[]>*?I?^(!_4OY#_BV;_8K_ #__ ,_UXUYCV_?E^?!-.9]A
M^5'+7E;YQ/=;F<:1X1\]U9X/.Q_2WB"O*%6JRH$2LA&KL0FC?Z%_D+.HGC'W
MWQ>D?,:@.,2]KVEW2=-?#V/YU]Q\TTYGV'YZ]%(WZ7_B ?U+^0_XMF_V*XUY
MCV_=-.9]A^4_2_\ $ _J7\A_Q;-_L5QKS'M^Z:<S[#\I^E_X@']2_D/^+9O]
MBF->8]C^4TYGV'Y49U#RS\W[K>^K<]%^$- C&N/E:L'LLLIY/[@AB$JW56#;
MASE;(KXNILS&CCI[,<D\REO4,BEV&O2EM[5MKS'L?KGYX]$TYGV_=29^E_X@
M']2_D/\ BV;_ &*8UYCV/YZ^C3F?8?E/TO\ Q /ZE_(?\6S?[%,:\Q['\IIS
M/L/RGZ7_ (@']2_D/^+9O]BF->8]CZ=Z:<S[#\J9?&7LUP[=0[!8+]S5/*;?
M5.E]!YF>J;-C<ML#4^@GWP3Q838G -;^Z"2RF=RQ\E IEM;"D[0MS6_=E0C'
M?E6)PHF$3")A$PBUF>0);R)C>;G$X5*>ZLWS5;'(=1XE8$GY/,"3,^Y=28\@
ME]'(#QDBM1Y B@1>=RZWJWDAS[!!]"Z@F44D3F=E>X\.B.'SZ*V9X43")A%0
MKEQ3H)OS@[?J.5ZT)Y)5*>T"D!>AP+BNK7[HY/=+)[.\ET2!CZE7J!S8 PL"
MF<%(SB/0;C=;BJ5\V'184M]S_?Y?LKW#A\M//OU\?3B<7UPHF$3"*A/B99?(
M<_WCS7;[95>C5>J1NH45SC,.V)"+J,6E.<^'17(-#G@SQN&3;=E0D';-*CK2
MVT?.28<KZ8G&G#![77Y?NJ<:8]>L#KYWVPHF$4*^24_HXKQW[P3X[&F3.M#N
M.=,G<PB#HK<XA)Z#$IAI^G,0(3J'6YDYVPMCT1(KC3J)$A3;*FG-+VA0\"J.
M(SS4;>%1BYFN%PGKP&Z((*P;E?A,%_IY6UE;/80(VU$HP6U)5>P=>N@\,?A)
M1.#"+*.V1&05MQ4S)\)$26Z0]</LK9X43"*C7Q#)O8(7CPXOBDB^0K2_?:3'
M)S^>0K,0-0:LX0=49?F1Z+#GWW[.M2(D6<[2XRC+#DB,[)4V 0:6D>OSZ*CT
M]>_K_&N%9;B4BVR^-<GE7ULPS>)'-Z2_<6K$U%8/MVAVMC5GD&F82&X;)5)1
M4K1!J,VVPB5IU+:$)UI.BBD_")A%JH\ZG_*,1TAF=Q^Q=@>HI+A\UHV#YU79
M\N)7)$/O_ (EL."YP 1/-S.B3>2&.F.@6(\A\Q%'"9K]2$;),3)3Y48[_KX'
MY$XR>Y6_\.9G39_C/R:7V+\3;Z$Z#(:,KND.3 MKT%NPF&JS(LL.;&ASV#<F
MJMA'R22,6,2W*<=618:G*D(U!P&>2'&3CAUX!68RJ)A$PB81,(F$3")A$PB8
M1,(F$3")A$PBHGY^=[N7 ><\Q*5+HE#XU&OO: G/;;VCIE;W:Z9RVL2Z/T"U
M[/E1#MBJ@];AD_4@-)@R2Q^!!C3;4PYK4F9])%>*@9_ XGKCZ*?_ !KZ):>N
M>/G%>HW<$BL7#H/,:7<++7VX\R(T)-'P$$D0A,Q"&M3HS+4F0YIF/+]9#+6T
M-NJ6M.U;(>)QS4VX43"+6K\2'R9Z%XWU?E\GF_9>%\HLUXL9<$#'=E@QIB+Y
M8HL8;)%A]$2]NI-<I% %PG#!CIG0BQIV8 @QP8VN"#)\] &R2H&3\].M?#Q6
MQ\>\Y(@09#KD5UU^'&>==@N;=A.N.LH6MR&[O\W8JU*VJ.YO\UM;0K?Y[PHN
MWA$PBUR=M\OKU1?-OQI\<0E4L ^AW^RR@EWMI'E/2"XNU3"_-K_:0@RF]!'@
M%\^$MU:=51C]M5-/2#7RRN_<,&APQ8JXSW==>"N!C.?3V^V?9;&\*)A$PBU1
M<>\SNJ7GXBO7_&>UN#@-(J+MQ$T^G1J=6IY>=!J5?HAJ+>C5KB=9=Z!7XUA7
M9IZACMCXH,H!N.F,(K5R('H4K<J=_ ^>F/KGY*D8 \<<_7NQIY^G+:[E43")
MA%J#^'SYH=I\CO(#R&YWTD]0RU=H+=@F5\?5ZZ.%E +HKKUTHD2!,>$W>V%Q
M\=VO@1DQ\3UL#S;H<LA(<+!JM,J:T%,F<_XZQQX'CW+D1@>WTU\]>\$CGX[?
M,JXIA%5?S=Z=TKBGB;WSK_)':LS>N8\RM=[$NW$?.*A$MU83*,SDK&#Y4)V;
M-=APWF!S+TR/#3-=9>F*=C-.1GX>!QR5&I YG"J%XS^8G6^I>9MXXS9;?SPQ
M6X$7M")?*@51E#.@<>B<N-\I$T*XW"RJL<]145VL;<S-C!LSJR B:B_0- )Q
M5H:1??=^.//G^-?3PSW"- >__/TT\B=?#;+E43")A$PB81,(F$3")A$PB81=
M$H2A!AA$N1?;BCQ4&62GRGEH:9C0X,=R3*?=<<VE#;;+#2W%K6I*4I3M2MZU
MK>\(M>7CW\2OCG9?'2W^1=R$E>3!J5=:]3RU4=>?Z-:)"^B#:58>0.AQ%&$S
M31LQTNN]&ID@75A 6:9@GB,^M.-R9H>6_N9TSUX<52"#CY]W?GVQKE297OB#
M^(UILO)*B$ZPS*.]O8?D\[C.56Z1&)[2+'8JE T;GS*\Q!ISUAL=2L@BJQK?
M(!R;--$2V C4U:$I5>OK]<=%,'!.-!U_GEWK WKXAWCQR$S=Q'8K'(I^ZIT.
MX46*^#K/1[[J3&H=2YO;K98;$FN4!;-2@ ('3 KY>5)DD:]!&:^Y.696]3X8
MPF"> ZX#W(P,<3ZJ,_,KXEM:\.[*1KIKE1N][WS*G=5J\L'9X8[=JKDZYF O
M3E1HT@-,W#5RJDB%]'FK6](_$ I3PZ,@:_&^J>==?N@&?<#WZ\_FI K_ ,1K
MQV7&IJ^@V)OG<[I_6NJ\TYD.>:-6A5D%<T[*3XA'Z";F@ #T"B52U7*##AC2
M5LD0 \>8:&#E&Y,EU>TS(3!Y<,9\,C/^?)>5/?%0\3()>MQJ]>&+0$G=0)\O
MM)UF#9A:@<]FFWFRUTO5!$VL[G]5%W@U1IE-IDNA:)C[,<D_)!$"<B/N$\R.
MO'A[]W-,'EU]L=^<8[U:WF_DER3K70NE<OHA@Z6MW(I[8B^MOTBZB00<RIN*
MZ^$8MQ8!"JA8T/U,C))B!!F<0'+<VF7':^6[M%4QP\5.V$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PBX),6-,97&F1V)4=ST^8Q)9;?97[5
M:4GWM.I6A7HK6E:]R=^BM:WK\]:PBY]:UK6M:UK6M:]-:U^6M:U^K6M?R:UA
M$PB81=&:+&$M-Z(CH,_3/O\ E:FQ(\K37O\ ;[_EZ?;<]GO]J??[?3W>U/KZ
M^FO0B[NM:UK6M:UK6M:UK6M>FM:U^6M:UK\M:UK]6L(OW"*IK?F%SI?E>4\2
MUA[-&LHBAOW"7T"4R*8YSHY#@A;!-YN@JX4T1_',.DV$3>WQZQB(B:Q)7.U,
MWN.^A$SKCPSUUW*XTS\N_P _)=X=YG^)%AJ%GZ*)[WRTW3: 3"#+':(%@A$1
MH0S:-/LUZ B3'T\I\D?90\L1%':DRB<)>I,1#T-]MURYRF#R/LN]?/+/BG.V
MZ"<L5VK#'.K_ $BZ]%A=0_%=833H-/I L.7GGE/.%DD2PJ1#-1G=$0$$I#'M
MZV^5>A,.,N+*+HF?,'B4?F%<[+4+-#Z7S4YU^D<9GVJC31Y(?5K'=[^)YHQ+
ML7U$J(]"@@[6>$13K.FUDHD:<S-;@O1E)<437D>&?,#710#X^_$_X#WP$JT)
M&6_EM=&<SL'4[@8ZBP%KT.CU\9TB3S>O1[$IHO,<02ODF*[8*A&A-R_N(1R)
MO:FY\Z)#>@.=?L>O54@@XXGPUZ_8J8[9YO>*56"?BB'UKG]F,E^<6+H=6!5T
M\&D6:\5VK0#I!^"#VZ^PVX1D.UL[!'BB,J')>(BBL=#&G1A#4:Y_/7LF#RZ[
M_;O7I0'F)XW6!GGZ6>LU&,5Z85DUVI!'B;3Q G9AGV-BP 8^X>I,61)K):QB
M*]8)L>0Z*%V.6D#)GME4KB)*>A]N:LUA$PBZ[,.)&<D.QXL=AV4O3LIUEAII
MR2XG7M2Y(6A*5/+UK>]:6YM2M:WZ:WZ81=C")A%QO,LR&G&)#3;[#R%-O,O-
MI=:=;7K:5MN-KTI"T+3O>E(4G:5:WO6];UA%QMQ(C3[LIJ-';DOH;;?D-LMH
M?>0UKT:0ZZE.G'$-:WO3:5JWI&OR3K6L(NQA$PB81,(F$3")A$PB81,(F$7A
MNG<_#=7YW=N96.6:@U^_5@S4C<NNDW0QQD2>@O#B&Q95E*W1\Q460ZAJ4VE2
MVMJ]R=;WK"*C/7/AS<TG<VZ?6_&QFO\ C_;>A2^$EF)8(40%TP+8N!73=LJM
ML& *$5I9,+=)#;[X^9;@QJ*5=^C".R-24"],/3'USY]=::*Y//N(]QCH>:PW
M%/A><8Y^[X\7N^32%U[APP \.D7@:[)& [9.D7>V]&961"G'[*6=B5ZU78\_
M79,FPNG]L.M[.%RS_O<VQP)X]=#UYE">/(G/EUP4V7CP1X/T&7U.;86;?M_L
M,'KP^X[A69V(A<?MU1YM2;O]L2F*OZ!:PG*JIH4I.W/MTM)&0G3OUNT-WOSY
M_/'X3/V(]"2/F?IR6<[%X5\#[Q<^97OI-<G&CW)J+T_G-5WHCMJ"Y5>NTF10
M+A",PE,.M%%NU^7)0.=>]NX$Q]R6VE2U;3A 2,^./EJ%$*?A>^);8;QG"L5B
MPLM>*06/6^9SOOVI)*: :/0+5(%W&5.@2M6!LA91S1R=+TW")+GOSG&9K")T
ME#DP/ECT3)UUX_X^FGEZ+S _X1WA>+@$A4*GV%D9,NI.^C(2#K*45<Y-KUOK
MPS=9D(%IG#V:FW=C)6GNO2I9  ;:&$(D_P!P]AO&!X\2>/CGZ\ON<MX^'#'#
MK.FG[@%6CH'BOS'G7<^@^1(B1;B73.E5T;5K!//6-XB,9##784E,<:+0Q&89
M<DRA\62](E*FO,J0M@>N%$>=C+8\]?%,Z8\<JR651,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%KSM7PW.&V/I9WN>W37
MZ<3?5+3T^5T:6J!LH0@V3EQCD2>3%UP84)]_E4*F$HHQ R&_"L2D"(#VK&F2
MA;JY@<AW]P[_ /*N\>'#0#3P.<^?BJC\0^$D=?X/TGC?E!TQ)U=BLG!B=$,<
M^EQS4RFPO'NHKJE/1[KS2DA24%4&3*&LUXW6#OTP5+22YZQG7)!QQCGQT^7#
M&??OUYJEW# TP<Y[R>/#]O;17 OOPY>,WOF/*.3KL%OKE7Y!RB_\BKS59CTP
M5J4"Z+  P3<^:/8JB0D:>QL S)@,!Q8P2R]+E)<'/,_);:8'RQZ*9USXY7M.
MD^#W,^G\-\DN"F;+=1U;\F.@&^E6,Z$EA85FIUH+2:D0AS*1+4%>AP%U\K2P
MQ4*^1@DY<><EQYV0]OY6FJIGAX=:^FF."B"?\*SQOFBO)L*S,N8P;Y/UGC-7
ML,,?*K[<2CQ.&0@2:>[18;]>D0HNY1NO#[/8(9N.;&EC"I7S8:(<IV*HKG@-
M-,_-1HCX,7C&R4J!B+8+G#FUCGY&C2OI*_R*/'.29DN\$8ER^F:YJAJKVD82
MZ =G,RJ2FN19K_TRRD2:M,A<B8Z]]#X#*I<2".X^?Y^N5*8SX8O(  KA]<K-
M_P"F5JL^/G4Y'2N;A@OX$CO X,TQ6+(1YN+L3M*?M=?YZ3L5<>($PU:.!W2$
M6P& LR4^'T,ACF- .'?I[^.BF3KG7//RQGS6R?*HF$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA%X=/3><KO*^9(O=15T5L?\ =5T9-A%;MB1WLV[]9L!J5]STQ\G6W]K^F_*/
MKZC>M,_N\]IMMP%%_,C0U8MYD[(5WP\OPO:9QN=ON]EO;QW<;W]WZ?[M%P[2
M/?[/M&=IC/9[S=_'/<SO8\<87N-_EK>_YL\2Y\%0VC?$;\;;X'XD?B$;-7Q'
M<A'6#X8A;A8P#"I83C4,C/MQ;I$QXXY#K YZ&*F2P,UM\E&,0FE$&740$.24
M <ZJX.HY>O70XZ*:+!Y9>.U5O#W/[)UJDA#L2M'+1/>)V(/"$CH==L 2L%(,
MXE(G-LQC;)BP#(R!"]?6.;?UK2/F*:;<*==>RZ=R\Q/&2D5PW9"G;>;SF@O-
M#G74AP-QKIFQFZ$ JINZ2SM:!Q":IIV/(K=<.$QRH*'&YT<7/=9<VU"EN,,_
MGV5P>7AU[K+S_*'APJRT:L%+^!&2.B<DM7<*R5(DAT&O2.;4[\,.&K#(-29C
M4./&:AVJ$39=VM4=P7!,3E/ML#G5*==>Z8.OAQ\%@KUYF>+?.Z8[>K%W3F.@
MBJQ8;:+:@76M32MC$U?[FV8_#8U!1,@Q,8FAB@I,.-K;RB\"8,WI,R+(::*8
MU Y_=226[AQROKHC-@ZA0@,GIZ8*N>1#5K"#)=ST2>'1H/X;C2YK3QC4J47%
M0V504OH<F$Q\1"E2)L9MTBBL#YG^.=MZ>ODM-Z74[?9XT8/,(O@+74) <?&,
M1NE2/W4Z188JR4P0KEEA9L @''*F0NI V9.'M#-DIPQG*N#WZ?GK5=V-YB>.
M,TG(8B=7I,JM1J<W<WNBQ[567N=(B.VU5*0'_%#1A4;\1*.Z0T@7\KW.-/L*
M;=6X\VTHIUCOZZ/<K%""XH^*&G01,>:"&(,4F(,"9D<B+*#9S"),(@.GQ''H
MLV%,C.MR(LJ,ZXQ(9<0ZTXM"DJV19#")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A%YVV50!>*Z4JEH@[)@#3"8I.#J7-@[DL)>;?TCZL=)B
M36?1UIM7NCR6E[]OMVK:5*3OT4M5/15$552R=E/"[>BDW&/W7$%N=R1KV.T)
M&'-(UX+B]K7M+'#+7#!&2,CS!!]BM?3/PM/&YGO#O:M*MRX+D-:=<X4>G:KJ
M"C@O8A9'1I,A-MVS]-OYZ1ZC6VTSO5S;ZH?I UOI_B=M$;&+-_I!('@_S'L&
M?$&(2"41]B6_"9WANF3L,EAQNA_]18\6JF%3\1_4SC_;WSNY+=TG/]_#NWL9
M\-%L'J]7!TNO"JK6H6QH$)$U"%P=RIL[<:,E:UI;^J(R)<U_T4XK>E2)+J_3
M?M]WMTG6M!JJF>LJ):JI?VD\[M^5X8QF\X@ G<C:QC= -&M [\960:QK6AC1
MAH& ,DX'F<D^I*U9UWX2/- 84\ D=<OY(::YS7N:L,[&U^,FOB1?CQ?>!&YH
M!'R9#4.?;E7R3T$YMYN4R]91<%A3;L+;F="YY.0>\'.?%2!+^'H5EQ#+_P#T
MC+G%M%IE6N=;;".J(,4@V[:;Q0;T[!;@B2,"4)"-2Z(V#EP!Y=J43KI>;#>)
M,S$((+==?3R3.N<#R[N&.'[KH#?AB4.'RZ!R^5TZUS(<.LS*HX=2# 13$@;*
MXGV[B*5[VE#L9N2P&[:3-IWIE<91<+%3],F+.E-)F,@@]^B;QR3Z_,'[8\E[
M?H'P_JMT48W$,],NC<XOR3H?+[]/4Y+,QK-)Z#)YX=E6@"(LYHY H'VJW\T
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M?J#6[L9WOU;W $+5JQY6>8*_*A?,5<80JB)L3X_0S066AW4) !<]*?TD[?\
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M[40EVX)3'G>$9>"T/QNEPQG*Z?B(.W-+VT7Q(B[<P;[>V$)?V8E,>=_LR_\
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M$8EAE;NR,)(#AD$#+2'#! .A&H714TT%9!)35,8F@F;NR1N+@'M!#L$M(=Q
M.A'!5):\&.0-])7T!4FPNP5H6Q^!5RHOX53#5"^E1$2I,71SY;4G_M-"]E]N
M?7_N]KVUO;6]/&P=G%S-QWZDQD%OP!>WX7<[/<#,[O;[K7?U1F4GM->&BTIO
M\/+&V[FZ[]46%IC_ ):7Q_ B/LPP,&(Q4X#QVP)J,]IW[N6JVH2N!*X"A5D,
M/9A A\14&(-UMQYAJ(KW^YC>Y"WG'$*^8O2OFK7M6E;TK>];S<:>GAI88Z>G
M8(X8F[L; 7$-;DG&7%SCJ2<DDY/%;M3T\-)!%34T8B@A:&11MR0QHX %Q)[^
M\DK7U2/AJ<QHM6X/61U_O$U7#+R7L\<P0C5EPC=ZY(W6=5J@6K;8=MI0*EM\
MWY R#FCD1"VVN8 D293GU4[:^['77I[+OS\_/CS\_P E8R?\-&IN5.;5 G9+
MZ!CG*Q&H]IE- J44=/4V/3>,U7[/["P66D3*<E<2KIA1D2J+/3LN<@MJ2G8F
M4+*$D_;YGCZ^/JH1[!X ERVRE,K=PC.@:#XF][K44A8"3D*3T*U=&B=8&<@&
MWROA:BX,CU[BJK[<2HNUP")$X0)&].[K#+L#4F9"-#C&OX_QS5SJ"2="#[8^
MN,'P4LEOA@4*\205LZ#T@_<KS]ZFE;26/4SG! &>#%J5QZB/U]BHZJT.N#'H
ME=XA2&HA]D:MY<YRQ2I(UR&7C"A53.F.N_\ *MGVWQAIG<+9RZVG2A41)YT2
M3HE!&,C7(5_IWWZL7%=!M.IL1]W[ N[T6DV;:Q[D:8ET"Z/2[J"6(-NE.OK^
M5!-1^'1RVFW2VW(982&Y5EZG5.G1MKK-127'.5WN8CO\JMS+0V*2>.!BEQ#Q
MX3>ILMM<$-IK2DSBT9DKIU]U<GZ_,8^0X+IA?AVUJKRZ>4JO7[V!,U(%.IWW
M)L!0S"2E*/R"CUL!R1UCKID8Q*-)FP=1#+$34L.X):VRW)C32,223/'.N3G&
MN,^ZY*A\.3F=/ZIR_JL>U%"Y3FT"!$1"/5>GE=DGPENZ-<0!" 4EBG257EPB
M/2"+,QT.]IR7'$B51'!<I1202F-<]==#B<B<Y&!@]PX=:>O?P&-B>51,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7_]D!
'          $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img132800289_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_6.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0+R17AI9@  34T *@    @ ! $[  (
M   -   !2H=I  0    !   !6)R=  $    :   "T.H<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M1G)A;FL@0V]N=V%Y    !9 #  (    4   "II $  (    4   "NI*1  (
M   #-3<  )*2  (    #-3<  .H<  <   $,   !F@     <Z@    $
M
M
M
M
M
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MH=**=F@CC:\DI*H[>K,;_A#?#'_0N:3_ . ,7_Q-'_"&^&/^A<TG_P  8O\
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MA<TG_P  8O\ XFC_ (0WPQ_T+FD_^ ,7_P 36S11[.'8/K>(_P"?DOO9C?\
M"&^&/^A<TG_P!B_^)H_X0WPQ_P!"YI/_ ( Q?_$ULUG:QK5OHL,<MTDKK(VT
M>6 3G'N135*,G91)GCJ\(\TJC2]65_\ A#?#'_0N:3_X Q?_ !-'_"&^&/\
MH7-)_P# &+_XFK>D:O!K-HUQ:I(B*Y0B0 '. >Q/K6=)XQT^/4FLFAN?,64Q
M$A5VYSC^]TJEA[MI1,WF52,5)U79[:LF_P"$-\,?]"YI/_@#%_\ $T?\(;X8
M_P"A<TG_ , 8O_B:V:*CV<.QM];Q'_/R7WLQO^$-\,?]"YI/_@#%_P#$T?\
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M;-%'LX=@^MXC_GY+[V8W_"&^&/\ H7-)_P# &+_XFC_A#?#'_0N:3_X Q?\
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M?\(;X8_Z%S2?_ &+_P")K9HH]G#L'UO$?\_)?>S&_P"$-\,?]"YI/_@#%_\
M$T?\(;X8_P"A<TG_ , 8O_B:V:*/9P[!];Q'_/R7WLQO^$-\,?\ 0N:3_P"
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M=4^SAV+^N8C_ )^/[V8W_"&^&/\ H7-)_P# &+_XFC_A#?#'_0N:3_X Q?\
MQ-;-%'LX=@^MXC_GY+[V?.WQITRPTKQG:0:796]E$VGHYCMXEC4MYD@SA0.<
M <^U%6?CQ_R/5G_V#4_]&RT5\UBDE6DD?M^12E++*,I.[L>S^#?^1%T'_L&V
M_P#Z*6MFL;P;_P B+H/_ &#;?_T4M;-?2T_@7H?B&+_WBIZO\SD?&^LR6\::
M=;-M,J[I6!YV] /QYJGX:\)P7UDM[J)8I(?W<2G&0#U)K.\9$GQ/.#V5 /\
MOD5W^D*JZ)9!!@?9TQC_ '17HR;IT8\O4^<IQ6)Q<W4U4=D<_K/@NT-G)+I2
MO',B[A%N+!\=N><TSP9!JMC-+!=VLT=JZ[@9!C:WT/K77T5A[:3ARO4[?J=.
M-558:6['#?$#_C\L_P#KFW\ZVO!7_(M1_P#71_YUB_$#_C\L_P#KFW\ZVO!7
M_(M1_P#71_YUM/\ W=')2_Y&$_3_ "-^LKQ/_P BS>_[@_F*U:RO$_\ R+-[
M_N#^8KEI_&CTJ_\ "EZ/\CD_ 7_(>F_Z]F_]"6CQ[_R'H?\ KV7_ -":CP%_
MR'IO^O9O_0EH\>_\AZ'_ *]E_P#0FKT/^8CY'@_\R_YD'A'6?[-U/R)FQ;W!
M"MG^%NQ_I77>+_\ D5;S_@'_ *&M<=KFC?9M-T_48%_=3V\8D _A?8.?Q_G6
MFVL_VGX"NXIFS<VXC5L]67>N#_2HG%2E&I'OJ:T:DJ=*>'J=FU]Q)\/?^8C_
M -LO_9Z[2N+^'O\ S$?^V7_L]=I7-B/XK/1R_P#W:/S_ #85RGB7Q5-I]U)I
M]C%B8 9E;G&1G@>O-=75;^S;/[<UZ;=#<MC,C#)&!@8ST_"HIRC%WDKF]>%2
M<.6G*W^1Y-=1W$5TZWBNLYPSB3[W(SS^=>NVG_'G#_US7^5>;>+_ /D:KS_@
M'_H"UZ3:?\></_7-?Y5TXE\T(L\S+H\E6K'M_FSS[QGJ+W>MM:JV8K;"A1W8
MCD_T_"MQ?!%H-%*,':^\O=YF_H^.F.F,UR6M.4\27K]2MPQP?]ZM">3Q1-;G
M4G>[2$_-E'V@#KG:#T]\5LXR4(J+L<D:D'5J2J1<G^2-GPIHNK:3?NUU&J6\
MJ89?,!Y'0X'X_G6=XZOGFU6.S!_=P("1ZL>_Y8K4\)^)9M0E-C?MOF"YCDQ]
MX#L??WKG/%__ "-5Y_P#_P! 6HIJ3K^_O8VKRA'!)4F[-]?O.AA\%V<F@+PY
MO7BWB3<1AB,XQTQ63X(OG@UO[+G]W<*01_M 9!_G7H8    P!T KRS021XIM
M,?\ /?%33DZD)J1IB*<,/5I.FK=/R.[\1:]_8=O$RP^;)-D)DX QCK^=>>ZE
M<7]](M]J&\B;(C8C"D#LOL,UZC=:?:7TD3W<"S&$DIOY S[=#TKD_B" JZ<%
M   D  [?<I8:<4U%+4O,*524)3E+W5:R^[<UO!7_ "+4?_71_P"=;]8'@K_D
M6H_^NC_SK?KGJ_Q&=^%_@0]$%<!XZOGFU6.S!_=P("1ZL>_Y8KOZ\Q\7_P#(
MU7G_  #_ - 6M<*DZARYI)QH675G0P^"[.30%X<WKQ;Q)N(PQ&<8Z8K)\$7S
MP:W]ES^[N%((_P!H#(/\Z]#    & .@%>6:"2/%-IC_GOBM*<G4A-2.?$4X8
M>K2=-6Z?D;WCZ^<26UBIPFWS7'KS@?R-2Z/X0L;K08Y;L/\ :+A-ZN&(V ],
M#H>,=:R?&_\ R,9_ZY+_ %KN]*XT:RQ_S[I_Z"*4Y.%&/*52A&OBZGM%>VAY
M_P"&+J33?$T<+'Y9',$@!ZGH/UK<\:V^HWLUO!:6TTL"+O8QJ2"Q..?H!^M<
M[.S)XSD9/O+J!(^OF5ZC55I<DXSMT(P=/VM&=%O1,Y/1?!]E)I,<FI0R&XE&
M2&8H8_;'K]:Y9@^B^)2ML[$V\^U3W89Z'\*[SQ#XAAT:V*J0]TX^2//3W/M_
M.N2\,Z3/K.L?;;G+0QR>9([?QOG./SZTZ4I<LISV(Q-*FIPHT5[RZ_YGH%W=
MPV-J]Q=/LBC^\V"<<XZ"JVGZWI^J2O'87'FN@W,-C+@?B!3]5L/[3TN:S\SR
MO- &_;NQ@@]/PK-T#PS_ &'=2S?:_/\ ,3;CRMN.<^IKD2AR-MZGK3E655**
M]WJ_Z9O5'<V\5W;/!<+OBD&UER1D?A4E%9;'0TFK,Q?^$0T/_GQ_\C/_ /%5
MY]HUO%=ZU:P7"[XI) K+DC(_"O6Z\I\/?\C%8_\ 79:[L/.3C*[/$QU*G"I2
M48I7?;T.]'A'1%8$67(Z?O7_ ,:L:GKUAI.!=S?O",B-!EC^';\:M7MR+.PG
MN6QB*-GP3UP.E>:Z392^)->*W,K?/F69QUQ[?F!65.+J)RF]$=6(J+#M4Z$5
MS2.MB\<Z3)(%9;B($_>>,8'Y$FN@@N(KJ!9K>19(W&593D&N:U3P9I_]FR-8
M*\4\:%E)<D/CL<_TK(\#ZE)#JQL2Q,5PI(7/1@,Y_(&FZ<)P<J?0F.(KTJL:
M=>WO;-'87^NZ=I=PL-]<>5(R[P-C-QDCL/8U6O\ Q5IFGA-\CS,ZAPD2Y(!&
M03G&*Y?Q[_R'H?\ KV7_ -":M+0?"5E<Z5%=:DKS2SKN WE0H/3IU..?QI^R
MIQ@IR$\3B)UI4J:6G4V=+\2Z=JTGE6[LDO:.48)^G8UK5Y;KFG-H&N>7;2,
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M+249.[.G"1Y\2ZM)6@/U/6K+2(PUY+AF^[&HRS?A67#XYTF60*PN(@3C<Z#
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M&;=C=G^[UKK[J)I[.:),!I(V4$],D8IUYQDXV88&E4IPFI*USSGP=_R-%O\
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M5-LFO"NZL,1&-[+5?UZD_CV^@D2VM(Y%>5'+.JG.WMS^M7O 7_(!F_Z^6_\
M05K/;P%,M@0ES&]V7'+9"*O.>Q)/2M_PSI$^BZ;);W3QN[3%P8R2,8 [@>E$
MY05'DB[CHTZTL7[6I&UT<%;L-*\3H;D$"WN?G^@/6O2+S5;2TTUKQIXVCVDH
M0P.\]@/6LKQ!X4CU>7[3;2"&YQAMP^5_KZ&L>T\ W)G7[==0K$#R(<DG\P,5
M4I4JJ4I.UB*4,3A92A"-T]F8WAG_ )&6R_ZZ?T->@^(-/_M/0[B!1F0+OC_W
MAS^O3\:Y_2_!]]8:W#=O+;&&.0MM5F+8Y]J[*HKU$YJ46:X'#RC1E3J*U_\
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M11169TA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW%8W&IZC=W,K2ZJJC:).2(S]Y@3WS@'_ .O2?$K3?[8^)VE:<7\LW-FD8?\
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M5VDDG!!8="3@@]Z],HH XVRLO%U[X0UF#Q&UO+=75K+';01!0P)1A@L/EY)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G_P"/'_(]6?\ V#4_
M]&RT4?'C_D>K/_L&I_Z-EHKY?%_QY'[MD'_(KH?X3V?P;_R(N@_]@VW_ /12
MULUC>#?^1%T'_L&V_P#Z*6MFOI:?P+T/Q+%_[Q4]7^844459S!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% 'S_ /'C_D>K/_L&I_Z-EHH^/'_(]6?_
M &#4_P#1LM%?+XO^/(_=L@_Y%=#_  GL_@W_ )$70?\ L&V__HI:V:QO!O\
MR(N@_P#8-M__ $4M;-?2T_@7H?B6+_WBIZO\PHHHJSF"BBB@ HHHH **** "
MBN&U#XLZ%INI75C/::BTMM,\+E(T*DJ2#C+].*K_ /"YO#W_ #YZG_WZC_\
MBZZ5A:[5U$YWBJ*=G(]!HKS[_A<WA[_GSU/_ +]1_P#Q='_"YO#W_/GJ?_?J
M/_XNCZI7_E8OK5#^8]!HKS[_ (7-X>_Y\]3_ ._4?_Q='_"YO#W_ #YZG_WZ
MC_\ BZ/JE?\ E8?6J'\QZ#17GW_"YO#W_/GJ?_?J/_XNC_A<WA[_ )\]3_[]
M1_\ Q='U2O\ RL/K5#^8]!HKS[_A<WA[_GSU/_OU'_\ %T?\+F\/?\^>I_\
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M_P +F\/?\^>I_P#?J/\ ^+H^J5_Y6'UJA_,>@T5Y]_PN;P]_SYZG_P!^H_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G
M_P"/'_(]6?\ V#4_]&RT4?'C_D>K/_L&I_Z-EHKY?%_QY'[MD'_(KH?X3V?P
M;_R(N@_]@VW_ /12ULUC>#?^1%T'_L&V_P#Z*6MFOI:?P+T/Q+%_[Q4]7^84
M4459S!1110 4444 %%%% 'S/XJ_Y'+6O^O\ G_\ 1C5DUK>*O^1RUK_K_G_]
M&-637U]/X%Z'R=3XV%%%%60%%%% !1110 4444 %%%% !1110 4444 %%%%
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M>60< ' !XX^N;_P^EN-)^*4=CX5\/>*-+\)WUFYGMM7LIHX;2X7)5HV<G:&
MQC/4_3 ![763XJUP>&?"6J:V8/M/]GVLEQY.[;YFU2<9P<9]<5Y!\-_ASHOC
M&#Q5=>*XYM0MU\17L5M9M<.D,/S LX52/G).,G. HQBLZWM$U/X(?$70]9>7
M4;?POJE]%ILES(S/$(E_=\YYQDXSZX["@#W'PMJTNO>#]&UBXC2*74+""Z=$
MSM5I(U8@9[ FM6O"YO"-U8_L\^'?^$&TRX8WHL+_ %JUL)V2:^B,*F8*V<AF
M.WA>V>.U5/!UU\/XO'^C#PO)J_@751(4N-'U&"55U$$8"'<Y4-GH<Y)[$XH
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MOQ=X;NG$&F:E'_PD%DQR%7/RW _ @''HM7?@U:RZAI>L>-KZ,I=^*+Y[E X
M9+9"4A3\%!/T(H ])HKR_P"/4$]UX.T6WM+@VMQ+X@LTBG49,3$L WX'FL/X
MB^ M,^''A"3QKX+DNK'6])EBEEN)+MY#?JTBJZS;B0V=V?TH ]LHKP_5-"L_
M''[1ZV>J"4Z9)X8CN[BT$K1B<"7"H^W!(!D!QQRHS5K4= M->^*ME\-U:XM/
M"6BZ-]MDT^"Y=/M3M)M"NV=S( P/7KWYH ]FHKQW4-$MOA3\2O";>$7GM-&U
MZZ:PO=*,[/#O(RDJ*Q.U@3R?;W-5_!7A/3/BO-KGBCQNL^HR?VI/::?;FXDC
M2QAC("[55AM?N2>>,]Z .^\(^*;W7_$GBO3[R*W2+1M06UMVB5@S*4#9;).3
MD]L5UE>">'M,?1?!/QFTZ2\GO?LRW4:W%P^Z1U%HVW<W<@8!/?%=[X+./V?=
M+S_T+X_]$T =]17@,%_?S?";X8>%-/O9M/3Q%(L-W<V[;9! GS.BMV+9'/M[
MUWEM\'M&T+6M,U3P5<7'A^XM9PUT(Y))DOHL'='(KOC)_O=1]<$ 'H5%?.2:
MKIGC;QCXEO?'7AOQ1XDM;+4I+#3[33+.::TM4CX)/EL!YC9R<Y(R/;';?""Z
MU6WU_7](&F^(+7PS$(IM).NVTL<D.1B2(,^=R@\@9X'UH ]7HK&\5Q^()O#\
MD/A&>VMM3ED1$N+E-Z0H6&]]O<A<X'<XKBL?%[PI.#G3?'UHXY7$>FW,9_\
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M:)[91117RQ],%%%% !5>=BMW;^A+ _E5BJEW_P ?5K_O'^5 %NBBB@ HHHH
M**** ,[7?$.D^&=+?4=?U""PM$.#+,V,GT ZD^PYK(\-_$GPCXNOC9:!K45Q
M=A=XMY(WAD9>N5615+#W -<CXUBAO_VA/ MEK"A]/2UNI[6*091[D#N#QD *
M1[XH^-\4-O/X,U.R55UV/Q#;0V;H/WCHV=Z>I4\9'3\Z .<\3>.=+\2_&4Z'
M<^,-<T?1;.S$2II*W$#RWIE*%694)*@=_N\#!ZY]X5=J!02<#&2<DUYS9?\
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MYQBNOB^(_@GPOI\>F7OB2XDDM+>!BUXDTUQ*LJ[HV/R;G8KR< D=\51\;?\
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M^QC\P>PQ6O\ $+2KS3_B1\-_#OA^+37M[*VF^PV^K,ZVSRQH "VP$E@ "/\
M:QZT >E^&OB3X2\77K6>@:S'<7:KO^SR120R,OJ%D52P]P#7/^%-5OY_CO\
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MZUN<31['CDC]-R. P'!YQ6?JWQ6\$:'K;Z1JGB""&]C(65%C=UA/H[JI5/\
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MN;>0QS6TG]Y''(/Z<#TK(T3X6Z1I6O6^MZAJ6L>(-2M%*VMQK-YYYM@>NP
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M\DUZ%10!X]X-^$.B:O\ #GP\T^J:[#I][IMM<76DP:BRVD\C1*SEDQD;F))
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M.Q%>7^-+WPI!\2;^;Q7<ZYX&U!42.#6=,N76/5H=O1B(V7*],'G@<\"O;J*
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M)YS,4D,8"G"Y+$# XZ]>]9D_Q3U[2;!-9\3^ +[2_#[%2]ZM]'-+ C$!7D@
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M'_$)_$.L:MHFN:)/H&LZ2B2W-M+,LR&-AD,DB\,/P[CWQQNI^+=7U[XE^(-
MNO'%KX)L-&,:Q1F*(37H9<F3?+P /]GL1GUK)^&-W92?''Q1-IVKZCXEMH]%
M4"]NF$CW1#KN$> H*YRH XX//>@#JT^+>N7VB2>)-%\ W=]X90.XOO[0B2:2
M-"0TBP8)(^4\9!K<UOXE6ECH>@W>BZ;<ZO>>(B%TVQ1EA9SLW'>S<(%'7K@U
MY7:6OA6T\.76O_#KXFWWA!(Q)(VCW\Z.D,BDY0V['()/3[V<\9Z5M:GKFB^+
MOAKX*NOBK'?:-?:G([6^K69\A+*4;@KM(3\F]0K $$<YX"Y !VVA?$#4KCQA
M#X9\6^%I] U"[@>>S=;M+J&X5.6 =0,,!V(_F,P7/Q'UC4-;U/3_  1X.FUY
M-*G-O=7<U_'9Q>: "40L"6(R.P'Z9Y#0M8UCPS\4- \.:-X[_P"$VTO41+]J
MMIMDTUDBKD2-,I/?^]C/IR"(]/\ %^I>+]2UV;7OB/;^#+;3;^6U7284ACF"
M(>)&>7YB3TX&,C\* .LA^+,EUX!\0ZY;^&[A-4\.2M%?Z3<7 0H5P7(D"L"
MNXYQSM/L:Z'5O'.G:9\,Y?&B_OK);%;N)-^WS"P&Q,\X)9@O3@FO-_@/]CU+
M5OB L5S=ZG8W%Y$JW&H,6ENHRCC>Q('WAST'!%<]HMO>W^KZ7\'+L226^B:Y
M-=W;L<A]/BQ+"&]G:0#VP* /H'1+VYU+0;&^OK/[#<W-NDLEKYF_R690=A;
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MJ6(_E_%'E%%>K_\ "D?^I@_\DO\ [91_PI'_ *F#_P DO_ME'U[#_P WX/\
MR#ZEB/Y?Q1Y117J__"D?^I@_\DO_ +91_P *1_ZF#_R2_P#ME'U[#_S?@_\
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M3Y';4445X![H4444 %5+O_CZMO\ >/\ *K=5;K_CZMOJW\J +5%%% !1110
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ME#!7$G'SC!(^;/!-/?2=.ET@:5+86KZ<(A"+-H5,/E@8";,8V@ #&,<5;HH
MJ7&DZ==Z4=,NK"UGT\H(S:20JT6T8PNPC&!@8&.U<?X@\*W>H?%3PIJ,.G12
MZ-I]E>6]UDILC\Q%5%V$Y(.,< @5T&E^*['5_%FO>'K:*X6[T+[/]I>15$;^
M<A==A!). .<@<^M;= %#2M"TC0HGCT32K+3HY#N=;.W2(,?4A0,TY-%TN)KU
MH]-LT;4/^/PK H-SQC]YQ\_!(YSP:NT4 4?[#TG[/90?V79>3I[*]G']G3;;
M,HPIC&,(0. 1C%27^EV&J+"NIV-M>+;S+/"+B%9!'(N=KKD'##)P1R,U:HH
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M /12ULU]+3^!>A^)8O\ WBIZO\PHHHJSF"BBB@ HHHH **** "BBB@ HHHH
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M+ 8'7J/0G<^#=A>:7\(- L]3M)[.ZBA<207$9C=#YC'E3@C@T <I-\7-5F^
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MGVD+<3$Q.CC^)6!YX(]CFM"[-CJEO!8^%/@?;V^L2R*LLFMZ#%#9VRY^9C(
M-_&<;?K[$ VO%GBCQ5=_%G0?#?A'58[&QUC2&N7GDM$E\C#%O- (R6VJ% )V
MY;)%1^)O%OB'P]JNB^!D\46"ZS>0R7=[XAU&WCB2W@#,$VQ9"%SC;UQQG'/&
MC>:/?+^T'X?O8M/E_L^WT"6![F&W801OO.$W=%XZ+GI6?\3/"5Q_PL+2/&B^
M&8?%=A!9G3]0TMH$FD";F=98T?AF!8\=?S)  S3?'&J^'/'>C:+JWB_3/%^F
MZW(UNES;1PQW%I-C*AEB.THQXS@?IS:@UGQA\0/&&OVOA?7X?#>C:!=FP,PL
M4NIKNX7[^0_"J#Z<GUYXJZ#!;:MXVTUO#'PJLM"TRU)EN]3U?14M9U8?=$"C
M#!L_Q'C\N32Y-7^%?BSQ)%+X;U;6M"UO4'U.TN-'M_/:&60?/&\8(*C( !Z<
M#\  ^$W]LCXL?$A?$S6[ZFC::DTELI6.0"&0(X!Z;E"DCL2:]<KROX6)KUU\
M2/'VM^(="N]'&I-8-;)<(<,BQ2* &^ZS!=FX G:QP:]4H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^?_CQ_R/5G_P!@U/\ T;+11\>/^1ZL_P#L&I_Z-EHKY?%_QY'[
MMD'_ "*Z'^$]G\&_\B+H/_8-M_\ T4M;-8W@W_D1=!_[!MO_ .BEK9KZ6G\"
M]#\2Q?\ O%3U?YA1115G,%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !145S<P6=M)<7<T<$,8W/)(P55'J2:
MX70?B;'XF^(S:)H\2/I<=J\GVIU8/*ZD#*\_=YQR,G% '?T5S?C/Q<OA6PMA
M;VC7^I7\OD65HAP9']2>P&1^8^M<[?\ C'QGX4:TO?&&E:6^DW$RQ2/IKR&2
MV+=-P8D-^''OR* /1J* <C(Y%<AXN\87VE:U8>'_  Y81W^M7R&54F?;'#&,
M_.V.W!_(_2@#KZ*\]?QGXH\,ZS86_CK3M-%CJ$H@COM,=]L4AZ!@_/\ +N><
M5Z%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5KC_C\MOJW\JL
MU7G_ ./RW_X%_*@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?/_QX_P"1ZL_^P:G_ *-E
MHH^/'_(]6?\ V#4_]&RT5\OB_P"/(_=L@_Y%=#_">S^#?^1%T'_L&V__ **6
MMFL;P;_R(N@_]@VW_P#12ULU]+3^!>A^)8O_ 'BIZO\ ,****LY@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M I:MH]AKM@;+5K9;JV+*YB<G!(.1G'O7 6]O#:?M#)!:PQPPQZ)M2.-0JJ-W
M0 <"O3*X#^S;[_A?G]H?8[C[%_9'E_:?*;R]V[[N[&,^U &+\1+W48?B_P"&
M(])MX;B[%M(+5;@GRUD<LI=L=E W<<\5<U[4?''@.WBUS5-8M]?TM9$6]MQ9
MK T(8XRA7D\D#)]N*T_B%X>U.XU/1O$WAVW6[U#1Y26M2V//B/4 ^HY_[Z/I
MBL7Q-J.O_$72X_#FF^&=4TF"YD0WUWJ4/E)&BL&PO]_D _AT[@ ]1@F2YMXY
MX3NCE0.I]01D5!)96"WG]I2VUN+F.,K]J:-=ZIW&_J!^-9&K:M=^'9]"T[3-
M$N=2M[J9;:6:(MBT0%5WOA3Q@D\D?=/-<3\4[_7=0UNVT*VT?6IM!55DOI=-
MM6=KC//EAL8P.,^YZ'% #M5O6^*7B^QTS159O#^CW0N;R^QA995R B'OP3S_
M +1/0#/JM><:)XU&EVMKI>F?#WQ%96J$(H^PL%7)Y8G]237H] !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5!-_Q^6__ OY5/4$O_'Y!]&_E0!/
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?/_P >/^1ZL_\ L&I_Z-EHH^/'_(]6?_8-3_T;
M+17R^+_CR/W;(/\ D5T/\)[/X-_Y$70?^P;;_P#HI:V:QO!O_(BZ#_V#;?\
M]%+6S7TM/X%Z'XEB_P#>*GJ_S"BBBK.8**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHKAM0\:ZC::E=6\<-J4AF=%+(V2
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M5BLFG.(8MK222?[J("Q'/4"I/#7B_0/%]F]SX;U.&^CC;;($RKQGT9& 9?Q
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M,+RS.L<:*6=W. H'4D]A7%0?&7X?W&I"QB\36WF,_EB1HY%A+>@F*B,_]]4
M=O16-KOB_0?#$UG'KVI1V)OO,\AI5;:VQ=SY8#"X7GDBL[P_\3?!_BG5CIFA
MZW%<7NTLL#Q21-(!R2F]1O& 3E<\<T =517+^)/B3X2\(WPLM?UF.WNRF\V\
M<4DTBKZLL:L5'N<5KZ)XATGQ'I":IH>H07MD^<31-P".H/H1Z'F@#1HKB!\9
M/A^VI?81XFM?,\SRO-V2>3N]/.V^7_X]6%\8/B(OA/4O"EG:ZG):?:=6MIK_
M ,J!GWV0?Y\,%.<X^ZOS$=L&@#T+5_$>A^'_ "?[>UG3],\_=Y7VVZ2'S-N,
M[=Q&<9&<>HK11UDC5XV#HP!5E.01ZBN-U+7?"NDV?_"810/>WNMVT5O:1HCM
M<7RC<T<,<3<KDN21@=<MTXN_#O0KWPWX TS2]4"+=0J[R11MN6'?(SB)3W"!
M@@QQA>.* .FHHHH **** "BBB@ HHHH **** "BBB@#Y_P#CQ_R/5G_V#4_]
M&RT4?'C_ )'JS_[!J?\ HV6BOE\7_'D?NV0?\BNA_A/9_!O_ "(N@_\ 8-M_
M_12ULUC>#?\ D1=!_P"P;;_^BEK9KZ6G\"]#\2Q?^\5/5_F%%%%6<P4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7DFL_\
M(>O_ /KYD_\ 0C7K=>2:S_R'K_\ Z^9/_0C7;A/B9XV;?!'U*5%%%>B?/A11
M10 4444 %%%% !1110 4444 >@^ O^0#-_U\M_Z"M=/7,> O^0#-_P!?+?\
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MH!TK4%Z!IU&;>3W;DI]* /2:*** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH **** "HV_X^$_W6_I4E1M_P ?$?\ NM_2@"2BBB@
MHHHH **** /+_B:OV;XI?#+49N+:/4KBU8GIYDT:B/\ '*FNB\>>.CX$;1[J
M\TXS:3>78MKZ_$A L0V-KLH4Y4G.3D8QWS5KQ]X5_P"$Q\(7&FPRB"]C9;FQ
MN"/]3<1G<C?GP?8FM/2VNM3\.VQ\0:<MM=3P 7=G(R2JKXPRY!*L,YQ[4 >5
M?&/7=)\9:1HOACPGJ-MJFMWVI036WV&5)C;*N2TS$$[0!W^O;->S5FZ5X;T/
M0I)'T31M/TYY?]8UG:I$7^NT#-:5 'D'A*:!/C5\4=+GO(;2\U#[$MK'+(%>
M3_1Y,E0>6QN!XSUI/@QXNT#PY\-HO#OB+4;/1=6T.6>&^M;R80N#YK-O 8C<
M"&'(S_*O49]!TBZU:'5+K2K&;4+<8AO)+9&FC'^RY&1U/0U#J7A?0-9NDN=8
MT/3;^XCQLENK2.5EQZ%@2* ."^#!;5-0\9>*+:*2+2M:U<R6&]"OFH@(,H![
M,3^8/I7J5(B+'&J1J$10 JJ, #T%+0!YAI/_ "<_K_\ V+\'_HQ:V];^(UOX
M:^(EEX?\0VT>GZ9?VC2VVKS3XC>8, 82" %.,G);NOK75)IEA'JDFI1V-LM_
M+&(I+I85$KH.0I?&2/;.*74--L=6LVM-5LK>]MG^]#<Q+(C?56!% 'E&M:C9
M>,_C]X/'A.YCOAH$5S/JE[:L'CC210J1EQP22&&WMN]CCV"J>F:/IFB6OV;1
MM.M-/@SGRK2!8ESZX4 5:E+K"YB4.X4E5)QD]AF@#YTU^*_T77_$/PHTX21Q
M^*=6@N;!T_Y8VLV6N2/]E?**X]":Z'XQZ-#I?B;P'J4MU?Z1X>TTS64]_IK!
M)+#>BK$=Q5@J\8)QT!'4BNF\+Z'XCU[XB-XS\;:-!HKV5D;+3=/2Z2Y9-S$R
M2M(HQDCY0/0GIW]"G@ANH'@N8DFBD&'CD4,K#T(/6@#PO6]+\%SZQH&F7'Q
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MQ4]7^844459S!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "HW_P"/F/\ W6_I4E1/_P ?47^ZW]* ):*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !7#_%WQKJ/@'X?S:YH\-K-=1SQQA+I&9,,<'A64Y_&NXKR7]I7_ )(S<_\
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M@_\ 8-M__12ULU]+3^!>A^)8O_>*GJ_S"BBBK.8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR36?^0]?_ /7S)_Z$:];K
MR36?^0]?_P#7S)_Z$:[<)\3/&S;X(^I2HHHKT3Y\**** "BBB@ HHHH ****
M "BBB@#T'P%_R 9O^OEO_05KIZYCP%_R 9O^OEO_ $%:Z>O'K?Q&?78/_=X>
M@5GZ_P#\BUJ?_7I+_P"@&M"L_7_^1:U/_KTE_P#0#44_C1T3^%GAU%%%?5GS
M 4444 %%%% !1110 4444 %%%% !7N.@?\BUIG_7I%_Z *\.KW'0/^1:TS_K
MTB_] %>7F/P1/2R_XY&A1117BGL!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %5Y_\ C\MOJW\JL56N/^/RV^K?RH LT444 %%%% !7#_%WP5J/
MC[X?S:'H\UK#=23QR![IV5,*<GE58Y_"NXHH *X/PWX'U+1YO'+W,]JP\0WL
MMQ:^6['8K(5 ?*C!R>V:[RB@#QW6O"$&B?#CP3HFJZ_;:/XDTRYC32K]4>2%
M[D9_=D[1\K#CG'0=>APOBA;>-[T>%K7Q?J6AI-+KELEKINCK*3</GYI7:3D!
M1V P-W)Z5[?KF@:5XETJ33=>L(;ZSD(+13+D9'0@]0?<<UB>'?ACX/\ "NHC
M4-#T6.&\5=B7$LTD[H.F%,C,5ZGICK0 EOX5OH?B_>>*FEMS8SZ/'8K&&;S1
M(LI<DC&-N#ZY]J@F\'W\GQM@\8K-;?V?'H9TXQ%F\WS/.9\XVXVX/7.<]J[.
MB@#R_3O _C;P-<W]K\/M0T6?1+R=KB*RUE90UD[<L$:,'<N>QQ^>2;5Q\/\
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M&93/9AXW$:[5.2-AX) Y'-='X]\)WOBA?# TV2WB&D>(+34YA,S+NBBW;E7
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MPN-2\$W7BC2=&TE4\1VGV9;:Z:>YW9R?FVA0G S[[:[;_FZ;_N3/_;V@#(\
M?%"TU?XL>)=%N-8N;FU9K6WT6*2VEZ)'(923L^4D\EGP6P,9P*[+7?BIX*\-
M:J^FZQKT,5Y'_K8HXI)C%_OE%(3J/O8KE_ ;2+\9/BNT S('L"@QU/DR8KE/
M@NOCV7X>_;?#<'A.=+ZZGDO)M1FN!<R3;R&\T(A&<8P,]"/4T >RW_C/P]IO
MA%O%%SJD)T155C>0AIEPSA!@("3\S <#CO46A^//#7B76KK2M"U1;V[M5+2B
M.)]F VTD2%=K8)Q\I->(>(M"OO#_ .S[\0;>^U'1;E9=5BF6TT:Y::*Q9KF+
M?%A@"F"/N]J^@-!LK?3O#NFV=I&L<%O:QQ1J!C:H4 #]* ,GQ_\ \)3)X9^S
M>!E1=2N;B.%KERG^BQ$_/* Q 8@=NO/'2O/O'FD:Q\+?"I\7Z/XUU[4+BQFB
M^TV6KW@G@O$>1590A'R'YLY7H ?K7K&N:YIWAS1;G5M:NDM;*U3?+*_;T '<
MD\ #DDUYEI6DZM\7M8L?$?BJV?3O"EE*+C2M'D_UEXW\,T_MW5?0^G+ $GQ8
MUAKG7O!F@?\ "0WGANUU*6>ZOKVUO?LK10QQ9P9#P,EL<Y&1]*U? _A72(=5
M75]$^(_B#Q/' &1H+C74O+<D@CYE4=1U'/45>UVP\!Z]\2-/TWQ%907WB*"R
M:XM(;J)V3R=Q!(!_=L<@\')&,\5R7BK2=.\)?&_P-<>$;2#3[S5I)[;4+6T4
M1I/ %!W,B\<9)SCDJ/3@ ]<O+N&PL9[RZ8K!;QM+(RH6(51DD  D\#H!FJ^B
M:UI_B+1;;5M%N5NK&Z3?#,JE=PSCH0".01@BKQ 92&&0>"#WKY\_MRY^'/A;
MQSX#L]WVV*\6/0(P>7CO3A G^X2Q^M 'L=KXZ\-7GA>7Q'#JT*Z/$[(UY,K1
M)E6VG&\#=SP,9R>F:I^'OBAX-\4ZDNGZ)KD4UVZ[HX98I(6D'J@D5=P^F:\P
M^(GAZY\.?\*J\):0NGRVUO<R IJ)9;6>Y14*&3:"?F9I#C'):M+QSH/C_6[?
M29/$-UX'T8V.HPS6E\E[<1R)(#PB,Z8);'W>^/:@#TKQ-XZ\->#S"OB/5H;.
M2<9BAVM)*X]0B L1[XI/#'COPUXS$_\ PC6K17KV_P#KHMK1R1\XY1P& SWQ
M7&ZOKZI\7+^W\%>#AK?B>SLXHM0U"YOOL\5K"^'1!NSG(P?E Z]\&L/PQ-KA
M_:@D;Q';Z7:7\WAL^;#ICNZ[?.&WS&8#+\#IQC;[T =W;_%WP-=W=G:VVNK+
M/>R^3#&EM,3OW^6 WR?)EA@;L9[4NL?%OP-H6JS:=J>OQ1W5NVR=8X995A;.
M,.R*54Y[$BN:_9WL;>W^'5Y<1Q@2W6K7+RMCDE6"C\ !_.LW2M&\;^%(M5/@
M4>'?&7AK4+VXN#;O,$G)<_/&7SL;'3DGZ#I0![%8WUKJ5C#>Z?<1W-K.@>*:
M)@RNIZ$$=:KZWKNE^'-+DU+7;Z&QLX^&FF; R>@'J3Z#FN7^$6JZ-JOP\MAX
M=TF71K:TFEMI-/EE:0V\JMEU#-RPRV<^_2L#XB117WQN^'=AK"A]*9KN9(Y%
MS')<+'E,YXR#MQ[GWH ZSPY\3?!_BO4/L.A:W%/=E=RP2QR0O(,9RJR*I88Y
MXS7F'B;QSI?B7XRG0[GQAKFCZ+9V8B5-)6X@>6],I0JS*A)4#O\ =X&#UST?
MQYBA@T7P[J=JJKKEMKELNG2*/WC,S'* ]2I R1TX%7[+_DYC5/\ L68?_2@T
M >C*NU H).!C).2:XS5OB_X$T34)K'4/$,(G@;9,((99UB;.,,T:L%.?4CH?
M2NONIX[:TFGN&*Q1(SNPSPH&2>/:O(?!FMZ[>>&L?#'P%I^G>';B25[>[U?4
MC^_)8[G:,!GQG(Y)XQCCH >I6GB'1[[P^-<M-2M9=*,9E^V"4>6%&=Q+=L8.
M<],&N6B^-/P^GCN'C\20[;>-I&+02KO5>I3*?O,>BYKQ+3YY&_9WCM)7C_LN
M;QBMO?FW)6);4N&.W/.S=MQGU%>M_'32]'/P0U5;FW@CBLHHVLMJ >2X=50)
MZ9!V\=B: .UU;Q5H>@Z"NM:SJ4%EI[JK)-,2N_<,@ =22.< 9]JH>&OB+X4\
M7W<EKX?UB.YNHUW-;O&\,FWU"2*I(]P*\L\6C6+SXH?#JTTM-+F>+1FN+.'5
MW=;=I]GS'Y 27"A2..,9K6UW0O'&I>./".I^);SP9I4UAJ2&*2UO)UN+F,G]
MY @=/GW+GY?Y<T =/?ZO=^%?BY8VUW=3SZ-XIC,4*2R%EL[N)<@+G[JR+_"/
MXAGN:[RO+OCI\FE^$)8<_:X_%-E]GQU+?/QGL/\  5ZC0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?/_QX_P"1ZL_^P:G_ *-EHH^/'_(]6?\
MV#4_]&RT5\OB_P"/(_=L@_Y%=#_">S^#?^1%T'_L&V__ **6MFL;P;_R(N@_
M]@VW_P#12ULU]+3^!>A^)8O_ 'BIZO\ ,****LY@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "O)-9_Y#U__P!?,G_H1KUN
MO)-9_P"0]?\ _7S)_P"A&NW"?$SQLV^"/J4J***]$^?"BBB@ HHHH **** "
MBBB@ HHHH ]!\!?\@&;_ *^6_P#05KIZYCP%_P @&;_KY;_T%:Z>O'K?Q&?7
M8/\ W>'H%9^O_P#(M:G_ ->DO_H!K0K/U_\ Y%K4_P#KTE_] -13^-'1/X6>
M'4445]6?,!1110 4444 %%%% !1110 4444 %>XZ!_R+6F?]>D7_ * *\.KW
M'0/^1:TS_KTB_P#0!7EYC\$3TLO^.1H4445XI[ 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !52Z_X^K;_>/\JMU4N_^/JV_P!X_P J +=%%% !
M1110 4444 </\5O#UWJ_ABVU/18C+J_A^\CU2RC'64QG+1_\"7/'<@5-JWAW
MP]\5?#FCZK]HNH=@%WIVH6,WDW%L6 SM;G!X ((ZKZBNRHH \[N/@MH-]+:W
M6J:MKVHZE:7$=Q!J%Y?"66/80P105V!20,@+DXZUU/\ PBEC_P )]_PEWFW'
M]H?V9_9GE;E\KRO-\W.,9W;N,YQCMWK;HH Y7_A7VG1>/I?%MCJ&IV-Y<[/M
MEM;7 %O>;%VJ9$*G. >Q'KUS6;??"/1YM6O-0T?5M=\//?N7NXM'OO(BG8]6
M*E2 3ZK@UWE% '%3_"CPU)\-[KP3:QW%EIEVZR3R02#SY'$BOO+L&R24 )(Z
M<#'&.RAB6"".)"2L:A03UP!BGT4 <KX_^'^G?$71[?3-8OM0M;>"<3@6,J(7
M8 @;MRMD#)K 'P:P,#XC?$ #_L.?_85Z310!S'BCP!H_BU;&34'O+?4-/_X]
M-2LYS%<PDC!PXZY]P14/AGX<Z3X;UB76&N]2UC5Y(_*_M#5KGSYDCSG8O "C
MZ 5UM% "$X4G!.!T%>,V)T/XK?'#2_$V@12W.E>'K,^=?O \23W.X^5& X!)
M3<SYQP<>V?9Z* ,;Q3X3TCQEHK:7K]MY\&\2(RL5>)QT=&'*D>OU'2N<L/A'
MHT&L66HZOJVN^(9-/</9Q:Q?>?' PZ,%"@$CU.3P*[RB@#C-?^&.EZWXF;Q!
M::IK&A:K+&L5Q<Z1=B$W"#@!P58'  [=AZ"FZ#\*M \-^+(O$6FS:@=1%L]O
M/)<7/G&[W$$O(S@L6X'((''2NUHH P?!WA"P\$Z"=)TJ:YF@,\D^ZY96;<YR
M1E5 Q^%<[/\ ![2!?7<^BZ[XBT"&]D,MQ9Z5J'DP2.?O':5.W/\ LD5Z!10!
ME^'/#FE^$]!@T?0K86UG #M3)8DDY+$GDDGN:K^*_!^C^--+2QUR!G$4@F@F
MB<QRP2#HZ..0:W** .(TCX5:/I^NVNL:IJ>M>(KZR_X\Y-:O?/%L?5%  S[D
M$]^H%;D7A6RA\<S^*EEN#?3V*V+1EE\H1J^\$#&=V3ZX]JVZ* &R1I-$\<JA
MT=2K*PR"#U%>>6WP5T*SC>SM=:\1PZ-([,=&CU-DM,,<E< !MIR>-W->BT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %5+S_CZMO\ >/\ *K=4[S_CYMO]X_RH N4444 %%%% !1110 4444 %%%%
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MB@ HKCXOB1IUWXUG\-:7I6L:C+:SK!=WMK:AK6U<C.'<L,8[X!KL* "BBB@
MHHHH **** "BBB@#Y_\ CQ_R/5G_ -@U/_1LM%'QX_Y'JS_[!J?^C9:*^7Q?
M\>1^[9!_R*Z'^$]G\&_\B+H/_8-M_P#T4M;-8W@W_D1=!_[!MO\ ^BEK9KZ6
MG\"]#\2Q?^\5/5_F%%%%6<P4444 %%%% !1110 4444 %%%% !1110 4444
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M'+=,*,=N0>/0/"&FWUM\9_B+?7-G<0VEY_9GV:XDB98Y]ENP;8Q&&P>#CH:
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M=V>,=<UQ;^%?$-GX,^&OB;2-*FN-6\+VH6ZTM_W4TD,D0610&Z. .A]3UZ4
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MYS<LZ;B"I)R2.1DGVQN^"_!=KX-L;M8[NXU"_P!0N#<WU_=$>9<2'N0.  .
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ME]'+%#+(F6$L:R$D] ,X'?'4UE:A:Z)INM:V?C-X8\03W<U[,]MX@A:62"*
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M1MX*@#D<8)_"@"3XK^);OPA\+=;UK33MN[>%4A? .QY)%C#8/'&_/X5S-O\
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MO#WC>Z\70ZYXTUVUA@M8FC@T?17E%L[-_'*7P7/H".#T[Y /,=-_Y(1\6?\
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M4-<USQ#/:3:SKMQ'+<"S5O*B2--D<:EN6P,_,0,YZ4 =;1110 4444 %%%%
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M_%CPO>_#*))#:^=_:]]8P-%;_9BGRQ2-@*[%L;5Y(QGBO8Z* ..\23Z=X_\
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M87>V<C'Y5U] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS ) [!B1VK:\1?#[3O$/B2PU]=0U/2M4L8O(6YTV<1F2+=N\MP58%<Y...M
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M?_T4M;-8W@W_ )$70?\ L&V__HI:V:^EI_ O0_$L7_O%3U?YA1115G,%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q_B/\
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M4\E<*VXDY ZY)/!K8^+NEZGM\.^*=%L9=1G\-ZB+J:TA&9)8&&)-@[M@#]:
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M_P#Z.6JWQ*T>R^']YH_C_P -6$&GKIMVD&KQV<0C6XLY#L8LJC#,I(P??V%
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M5/5_F%%%%6<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT<' SGYMQ_8$[_Z[6K]M_P TVQPNYQ]TK@?(!_='!P,Y^;=D?\7)_P"I5_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?/_QX_P"1ZL_^P:G_ *-EHH^/'_(]6?\ V#4_]&RT5\OB_P"/(_=L
M@_Y%=#_">S^#?^1%T'_L&V__ **6MFODF'Q7XBMH(X+?7]4BBC4(D:7DBJB@
M8  !X ':G_\ "9>)_P#H8]6_\#I?_BJ]F&)M%*Q^:8C).:M.7M-V^GGZGUG1
M7R9_PF7B?_H8]6_\#I?_ (JC_A,O$_\ T,>K?^!TO_Q57]:\C#^PO^GGX?\
M!/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9>)_^ACU;_P #I?\ XJCZUY!_87_3
MS\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A,O$__0QZM_X'2_\ Q5'UKR#^
MPO\ IY^'_!/K.BODS_A,O$__ $,>K?\ @=+_ /%4?\)EXG_Z&/5O_ Z7_P"*
MH^M>0?V%_P!//P_X)]9T5\F?\)EXG_Z&/5O_  .E_P#BJ/\ A,O$_P#T,>K?
M^!TO_P 51]:\@_L+_IY^'_!/K.BODS_A,O$__0QZM_X'2_\ Q5'_  F7B?\
MZ&/5O_ Z7_XJCZUY!_87_3S\/^"?6=%?)G_"9>)_^ACU;_P.E_\ BJ/^$R\3
M_P#0QZM_X'2__%4?6O(/["_Z>?A_P3ZSHKY,_P"$R\3_ /0QZM_X'2__ !5'
M_"9>)_\ H8]6_P# Z7_XJCZUY!_87_3S\/\ @GUG17R9_P )EXG_ .ACU;_P
M.E_^*H_X3+Q/_P!#'JW_ ('2_P#Q5'UKR#^PO^GGX?\ !/K.BODS_A,O$_\
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M6O(/["_Z>?A_P3ZSHKY,_P"$R\3_ /0QZM_X'2__ !5'_"9>)_\ H8]6_P#
MZ7_XJCZUY!_87_3S\/\ @GUG17R9_P )EXG_ .ACU;_P.E_^*H_X3+Q/_P!#
M'JW_ ('2_P#Q5'UKR#^PO^GGX?\ !/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9
M>)_^ACU;_P #I?\ XJCZUY!_87_3S\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_X
MJC_A,O$__0QZM_X'2_\ Q5'UKR#^PO\ IY^'_!/K.BODS_A,O$__ $,>K?\
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MR#^PO^GGX?\ !/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9>)_^ACU;_P #I?\
MXJCZUY!_87_3S\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A,O$__0QZM_X'
M2_\ Q5'UKR#^PO\ IY^'_!/K.BODS_A,O$__ $,>K?\ @=+_ /%4?\)EXG_Z
M&/5O_ Z7_P"*H^M>0?V%_P!//P_X)]9T5\F?\)EXG_Z&/5O_  .E_P#BJ/\
MA,O$_P#T,>K?^!TO_P 51]:\@_L+_IY^'_!/K.BODS_A,O$__0QZM_X'2_\
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M"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A,O$__0QZM_X'2_\ Q5'UKR#^PO\
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M?^!TO_Q5'_"9>)_^ACU;_P #I?\ XJCZUY!_87_3S\/^"?6=%?)G_"9>)_\
MH8]6_P# Z7_XJC_A,O$__0QZM_X'2_\ Q5'UKR#^PO\ IY^'_!/K.BODS_A,
MO$__ $,>K?\ @=+_ /%4?\)EXG_Z&/5O_ Z7_P"*H^M>0?V%_P!//P_X)]9T
M5\F?\)EXG_Z&/5O_  .E_P#BJ/\ A,O$_P#T,>K?^!TO_P 51]:\@_L+_IY^
M'_!/K.BODS_A,O$__0QZM_X'2_\ Q5'_  F7B?\ Z&/5O_ Z7_XJCZUY!_87
M_3S\/^"?6=%?)G_"9>)_^ACU;_P.E_\ BJ/^$R\3_P#0QZM_X'2__%4?6O(/
M["_Z>?A_P3ZSHKY,_P"$R\3_ /0QZM_X'2__ !5'_"9>)_\ H8]6_P# Z7_X
MJCZUY!_87_3S\/\ @GUG17R9_P )EXG_ .ACU;_P.E_^*H_X3+Q/_P!#'JW_
M ('2_P#Q5'UKR#^PO^GGX?\ !/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9>)_^
MACU;_P #I?\ XJCZUY!_87_3S\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A
M,O$__0QZM_X'2_\ Q5'UKR#^PO\ IY^'_!/K.BODS_A,O$__ $,>K?\ @=+_
M /%4?\)EXG_Z&/5O_ Z7_P"*H^M>0?V%_P!//P_X)]9T5\F?\)EXG_Z&/5O_
M  .E_P#BJ/\ A,O$_P#T,>K?^!TO_P 51]:\@_L+_IY^'_!/K.BODS_A,O$_
M_0QZM_X'2_\ Q5'_  F7B?\ Z&/5O_ Z7_XJCZUY!_87_3S\/^"?6=%?)G_"
M9>)_^ACU;_P.E_\ BJ/^$R\3_P#0QZM_X'2__%4?6O(/["_Z>?A_P3ZSHKY,
M_P"$R\3_ /0QZM_X'2__ !5'_"9>)_\ H8]6_P# Z7_XJCZUY!_87_3S\/\
M@GUG17R9_P )EXG_ .ACU;_P.E_^*H_X3+Q/_P!#'JW_ ('2_P#Q5'UKR#^P
MO^GGX?\ !/K.BODS_A,O$_\ T,>K?^!TO_Q5'_"9>)_^ACU;_P #I?\ XJCZ
MUY!_87_3S\/^"?6=%?)G_"9>)_\ H8]6_P# Z7_XJC_A,O$__0QZM_X'2_\
MQ5'UKR#^PO\ IY^'_!/K.BODS_A,O$__ $,>K?\ @=+_ /%4?\)EXG_Z&/5O
M_ Z7_P"*H^M>0?V%_P!//P_X)]9T5\F?\)EXG_Z&/5O_  .E_P#BJ/\ A,O$
M_P#T,>K?^!TO_P 51]:\@_L+_IY^'_!/K.BODS_A,O$__0QZM_X'2_\ Q5'_
M  F7B?\ Z&/5O_ Z7_XJCZUY!_87_3S\/^"?6=%?)G_"9>)_^ACU;_P.E_\
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MX'2__%4?6O(/["_Z>?A_P3ZSHKY,_P"$R\3_ /0QZM_X'2__ !5'_"9>)_\
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-GZSD]+V. I4[WLC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img132800289_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ) !*H# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P";VIH/^"F7QO653<^#OA5- #\\<&D>+K:5AVVS2>-;I$.>Y@?TP.M>?_\
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ME^+'B&[DL?#$?A^PU^,,FZ]NAJUM;S:5IEK!D>9J6H3W=M96\1*1B>8-/)#
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ML%^';3X@:)\6?AE\=]-O/#^C>-K?Q1X>L-*\+6OB&QBL;#6$U*W\/2>)-/\
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M5!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1J5J>7\;XC&XN4(N2H8;ZSQ-A%5J-)J$'B<5AZ/-*T?:5H1O>23_ '#\:_\
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MC*5.-&4_V=_X*+_\F[-_V/7AC_T3JU><?\$Q/^2=?$K_ +'6P_\ 3%;UZ/\
M\%%_^3=F_P"QZ\,?^B=6KSC_ ()B?\DZ^)7_ &.MA_Z8K>OEL-_R:S'_ /8Y
MA_Z?P1^GX_\ Y2>R7_LCJO\ ZA9L?",VDV>N_MR:AI&H1)/87_[46JP7UO*I
M>.ZLS\4;IKFUD"NC;+J%7MW8,"JR%@"1M/[1?M6HC_LY?&!757 \&:@X#*&
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M]JY[5Y(91'%5\R>:2Q%)8=X*="?)34G44M(35"2:48P3G=T4I/HQ7B%PCBO
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MSE2;G"NLOS"F\%1K1DDI4L/C52RVES6OA,5-1TLC]#:***_ C^\#^<3X$?\
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M^OZ(J/%?_DHL%_V)<-_ZG9B+Z+'_ ";[./+C+,+?^&3AX****_,3^E@HHHH
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M(T8)/*K==15_6\5^Z7UG$6HM.BO;5/W32LG2][]VTM$XVLM#+^RLKOB7_9N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ>O\_&BC_5#+?^?^._\ !N'_ /F8/]8L;_SZPO\ X!5_^7G^@=_P^[_X)?\
M_1SG_F%_VA/_ )T]'_#[O_@E_P#]'.?^87_:$_\ G3U_GXT4?ZH9;_S_ ,=_
MX-P__P S!_K%C?\ GUA?_ *O_P O/] [_A]W_P $O_\ HYS_ ,PO^T)_\Z>C
M_A]W_P $O_\ HYS_ ,PO^T)_\Z>O\_&BC_5#+?\ G_CO_!N'_P#F8/\ 6+&_
M\^L+_P" 5?\ Y>?Z!W_#[O\ X)?_ /1SG_F%_P!H3_YT]'_#[O\ X)?_ /1S
MG_F%_P!H3_YT]?Y^-%'^J&6_\_\ '?\ @W#_ /S,'^L6-_Y]87_P"K_\O/\
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M #ZPO_@%7_Y>?Z!W_#[O_@E__P!'.?\ F%_VA/\ YT]'_#[O_@E__P!'.?\
MF%_VA/\ YT]?Y^-%'^J&6_\ /_'?^#</_P#,P?ZQ8W_GUA?_  "K_P#+S_0.
M_P"'W?\ P2__ .CG/_,+_M"?_.GH_P"'W?\ P2__ .CG/_,+_M"?_.GK_/QH
MH_U0RW_G_CO_  ;A_P#YF#_6+&_\^L+_ . 5?_EY_H'?\/N_^"7_ /T<Y_YA
M?]H3_P"=/1_P^[_X)?\ _1SG_F%_VA/_ )T]?Y^-%'^J&6_\_P#'?^#</_\
M,P?ZQ8W_ )]87_P"K_\ +S_0._X?=_\ !+__ *.<_P#,+_M"?_.GH_X?=_\
M!+__ *.<_P#,+_M"?_.GK_/QHH_U0RW_ )_X[_P;A_\ YF#_ %BQO_/K"_\
M@%7_ .7G^@=_P^[_ ."7_P#T<Y_YA?\ :$_^=/1_P^[_ ."7_P#T<Y_YA?\
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MY_X[_P &X?\ ^9@_UBQO_/K"_P#@%7_Y>?Z!W_#[O_@E_P#]'.?^87_:$_\
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M9,>(,?.481HX5RE)1BE"K=RD[)+]_NV[']V/_#[O_@E__P!'.?\ F%_VA/\
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MV9I4SS,J4:<JF'PT%5BITVX55S1:34DO;WLTTTW:Z=T?Z!W_  ^[_P""7_\
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M6%_\ J__ "\_T#O^'W?_  2__P"CG/\ S"_[0G_SIZ/^'W?_  2__P"CG/\
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M , J_P#R\_T#O^'W?_!+_P#Z.<_\PO\ M"?_ #IZ/^'W?_!+_P#Z.<_\PO\
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M\Z>O\_&BC_5#+?\ G_CO_!N'_P#F8/\ 6+&_\^L+_P" 5?\ Y>?Z!W_#[O\
MX)?_ /1SG_F%_P!H3_YT]'_#[O\ X)?_ /1SG_F%_P!H3_YT]?Y^-%'^J&6_
M\_\ '?\ @W#_ /S,'^L6-_Y]87_P"K_\O/\ 0._X?=_\$O\ _HYS_P PO^T)
M_P#.GH_X?=_\$O\ _HYS_P PO^T)_P#.GK_/QHH_U0RW_G_CO_!N'_\ F8/]
M8L;_ ,^L+_X!5_\ EY_H'?\ #[O_ ()?_P#1SG_F%_VA/_G3T?\ #[O_ ()?
M_P#1SG_F%_VA/_G3U_GXT4?ZH9;_ ,_\=_X-P_\ \S!_K%C?^?6%_P# *O\
M\O/] [_A]W_P2_\ ^CG/_,+_ +0G_P Z>C_A]W_P2_\ ^CG/_,+_ +0G_P Z
M>O\ /QHH_P!4,M_Y_P"._P#!N'_^9@_UBQO_ #ZPO_@%7_Y>?Z!W_#[O_@E_
M_P!'.?\ F%_VA/\ YT]'_#[O_@E__P!'.?\ F%_VA/\ YT]?Y^-%'^J&6_\
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M#_\ S,'^L6-_Y]87_P  J_\ R\_T#O\ A]W_ ,$O_P#HYS_S"_[0G_SIZ/\
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M^(6A:])=QZY8ZZ]CX5\ S6EA?6%[)'#:!-0>PU2WT[7+:Z6]TZU"6LMS.G_
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MGW_@HY_P3-^+?P1_9Z^#/A"P_:\\#7FB>(O"<G@G3AX>\$ZC]H\ ^*++Q_\
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M/\=OV(_C8/V:]-\&C]CB\UB\'@S1OB@TVC^.AJUMX1@%CI5R_P .;9_ .FV
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M[U6T_)[XZ?\ !0+_ (73^PG^SG^Q3_PJ3_A&O^% >);'Q#_PLO\ X3W^V?\
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M1M UR;1;EA+?:5I/B2[T2WO/L.Z)OYIOVQ/VD/AS\>-<\/Z#\*_V=_@5\#/
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MP-_:"E^,EKX;\&:QKOQL\,Q>-O\ A#O ^K:KX!\/:K:^ =!U$2:'IGB>_O\
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MQCK26'G&C7J4:CH8:K*<7:G3FIS2E!2BYJE[LFFD[OE_7B[_ &:_@A'\?_\
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M9UK'X.+C&$H*#QU&=9.@^6I26'C3KU5!PDH*=1-\D;5&G\*3:/KW]F;]F?\
M9J_9D_9\_P""BW[9_P 4_@[H?[0M_P#LO_M%^-/V;_A7\+?B1'8Z_P"#+2XT
MGQEX'\)Z5K_B32;N)M.UV:XU3XC^'TU2[O+:Y:UT?0M5;0[>/4M1$J<G\;/!
M'[/O[9W_  2I\;?MV^%OV>?A=^S/\;OV=OBWI'PT\9:;\"_#MMX*^&_Q!M=:
MUGX6Z5<R0^$+1[B&SA2W^+&A:E8SWD]SK>GWVBZM8/JVH:;>PU\N? G_ (*I
M>)/A%XV_:KM_%?P5\+?&#]G7]K?X@>/?B#\0/V?/%_B*>VMM-U3QQKE]J4K:
M-XWM?#T\J7D.EW5MHFH7\OA<IJ7]D:1JEI9:-J%A Z<_^T__ ,%([?XN?L[>
M&_V1?V?/V>_"W[*7[-^DZU%XCU_P/H/C/5_B1KWC76[2[BO]/F\1>-M?T;1-
M3OK>WU&"WU6X-[:WNKZEJ=CID]_K4T&G6]H.Q83,7BX5)1JN;Q>&J_6OK25&
M&#A1IQKX1X=5;N<YJHKJE*$Y351U$XJ_,\1@_J\H1E!1^KUJ?U?V#=26)E4D
MZ6(59PLHJ+@]:BE%0<%!J1^OW_!6OXP?LR?L$?&OX>?#_P"$'[ _[#WBSQ'X
MU^$Z>,?%J_$+]G_0K[2-*TZ+Q7XFTCP'-H.BZ%%X=\/6<][K&E^+AXPNH89M
M>\1:18Z)I-UJ&E6^FZ-=)G?\'!WQB^Q?#;]E_P"''_"K/@W=_P#"S_A[=>)_
M^$]OO!'VCXD_#S_A'M0\#ZA_PCWPN\4?VHG_  B7A?7/M7V+Q#I/V'4/[2T^
MWM;;[1!Y.]OQ4_X*1?MU_P##P?XX^%?C-_PJS_A4?_",_"C0_AC_ ,(W_P )
MO_PGWVW^Q?%_CKQ5_;G]L?\ "(>"_LWVG_A-/L']F_V7<>3_ &;]J_M"7[9]
MGM?8?VP/^"FGA3]LWX ?#OX>?$K]ES1[7XY_#/P=H'@[PW^T'8?%C7C!86EK
M>^%KOQ?<V7PG@\+6/A^.7QG'X82VE-_KVJ7&@17URFD7<<#W%O=8X;*J]&62
MUJE"I4JT'7^O-XB,YPG4BE2FW*MRSA2EK)4G*7*DE">QI7Q]*HLSIPJPA3JJ
ME]52HRC&2A*\XI1I\T95(Z)U%&/,V^:.Y^3=%%%?4GA!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?U:?\&QG_ #>Y
M_P!VV?\ O?:_E+K^K3_@V,_YO<_[ML_][[7A\2?\B7&_]RW_ *ET#U,E_P"1
MGAO^XW_J/5/ZM****_*S[P*_'K]J;_@B9^RK^UU\>/'7[0WQ(\?_ +06B>-/
MB#_PC']LZ7X(\5?#G3?"]K_PB?@WP]X'T[^R[+7OA3XEU:'SM)\-6-Q>_:];
MO?,U&6[E@^S6TD-I!^PM%=&&Q6(P=1U<-6G1J2@Z;E!I-P;C)QU3T<HQ?JD8
MUJ%'$14*].-2"DIJ,ME))I/1K6TFOFS^?C_B&\_8=_Z*I^U;_P"%Q\(?_G&4
M?\0WG[#O_15/VK?_  N/A#_\XROZ!Z*[?[<S;_H/K_?'_P"1.;^R\O\ ^@6E
M]S_S/Y^/^(;S]AW_ **I^U;_ .%Q\(?_ )QE'_$-Y^P[_P!%4_:M_P#"X^$/
M_P XROZ!Z*/[<S;_ *#Z_P!\?_D0_LO+_P#H%I?<_P#,_GX_XAO/V'?^BJ?M
M6_\ A<?"'_YQE'_$-Y^P[_T53]JW_P +CX0__.,K^@>BC^W,V_Z#Z_WQ_P#D
M0_LO+_\ H%I?<_\ ,_GX_P"(;S]AW_HJG[5O_A<?"'_YQE'_ !#>?L._]%4_
M:M_\+CX0_P#SC*_H'HH_MS-O^@^O]\?_ )$/[+R__H%I?<_\S^?C_B&\_8=_
MZ*I^U;_X7'PA_P#G&4?\0WG[#O\ T53]JW_PN/A#_P#.,K^@>BC^W,V_Z#Z_
MWQ_^1#^R\O\ ^@6E]S_S/Y^/^(;S]AW_ **I^U;_ .%Q\(?_ )QE'_$-Y^P[
M_P!%4_:M_P#"X^$/_P XROZ!Z*/[<S;_ *#Z_P!\?_D0_LO+_P#H%I?<_P#,
M_GX_XAO/V'?^BJ?M6_\ A<?"'_YQE'_$-Y^P[_T53]JW_P +CX0__.,K^@>B
MC^W,V_Z#Z_WQ_P#D0_LO+_\ H%I?<_\ ,_GX_P"(;S]AW_HJG[5O_A<?"'_Y
MQE'_ !#>?L._]%4_:M_\+CX0_P#SC*_H'HH_MS-O^@^O]\?_ )$/[+R__H%I
M?<_\S^?C_B&\_8=_Z*I^U;_X7'PA_P#G&4?\0WG[#O\ T53]JW_PN/A#_P#.
M,K^@>BC^W,V_Z#Z_WQ_^1#^R\O\ ^@6E]S_S/Y^/^(;S]AW_ **I^U;_ .%Q
M\(?_ )QE'_$-Y^P[_P!%4_:M_P#"X^$/_P XROZ!Z*/[<S;_ *#Z_P!\?_D0
M_LO+_P#H%I?<_P#,_GX_XAO/V'?^BJ?M6_\ A<?"'_YQE'_$-Y^P[_T53]JW
M_P +CX0__.,K^@>BC^W,V_Z#Z_WQ_P#D0_LO+_\ H%I?<_\ ,_GX_P"(;S]A
MW_HJG[5O_A<?"'_YQE'_ !#>?L._]%4_:M_\+CX0_P#SC*_H'HH_MS-O^@^O
M]\?_ )$/[+R__H%I?<_\S^?C_B&\_8=_Z*I^U;_X7'PA_P#G&4?\0WG[#O\
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M_P#G&4?\0WG[#O\ T53]JW_PN/A#_P#.,K^@>BC^W,V_Z#Z_WQ_^1#^R\O\
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M'_YQE'_$-Y^P[_T53]JW_P +CX0__.,K^@>BC^W,V_Z#Z_WQ_P#D0_LO+_\
MH%I?<_\ ,_GX_P"(;S]AW_HJG[5O_A<?"'_YQE'_ !#>?L._]%4_:M_\+CX0
M_P#SC*_H'HH_MS-O^@^O]\?_ )$/[+R__H%I?<_\S^?C_B&\_8=_Z*I^U;_X
M7'PA_P#G&4?\0WG[#O\ T53]JW_PN/A#_P#.,K^@>BC^W,V_Z#Z_WQ_^1#^R
M\O\ ^@6E]S_S/Y^/^(;S]AW_ **I^U;_ .%Q\(?_ )QE'_$-Y^P[_P!%4_:M
M_P#"X^$/_P XROZ!Z*/[<S;_ *#Z_P!\?_D0_LO+_P#H%I?<_P#,_GX_XAO/
MV'?^BJ?M6_\ A<?"'_YQE'_$-Y^P[_T53]JW_P +CX0__.,K^@>BC^W,V_Z#
MZ_WQ_P#D0_LO+_\ H%I?<_\ ,_GX_P"(;S]AW_HJG[5O_A<?"'_YQE'_ !#>
M?L._]%4_:M_\+CX0_P#SC*_H'HH_MS-O^@^O]\?_ )$/[+R__H%I?<_\S^?C
M_B&\_8=_Z*I^U;_X7'PA_P#G&4?\0WG[#O\ T53]JW_PN/A#_P#.,K^@>BC^
MW,V_Z#Z_WQ_^1#^R\O\ ^@6E]S_S/Y^/^(;S]AW_ **I^U;_ .%Q\(?_ )QE
M'_$-Y^P[_P!%4_:M_P#"X^$/_P XROZ!Z*/[<S;_ *#Z_P!\?_D0_LO+_P#H
M%I?<_P#,_GX_XAO/V'?^BJ?M6_\ A<?"'_YQE'_$-Y^P[_T53]JW_P +CX0_
M_.,K^@>BC^W,V_Z#Z_WQ_P#D0_LO+_\ H%I?<_\ ,_GX_P"(;S]AW_HJG[5O
M_A<?"'_YQE'_ !#>?L._]%4_:M_\+CX0_P#SC*_H'HH_MS-O^@^O]\?_ )$/
M[+R__H%I?<_\S^?C_B&\_8=_Z*I^U;_X7'PA_P#G&4?\0WG[#O\ T53]JW_P
MN/A#_P#.,K^@>BC^W,V_Z#Z_WQ_^1#^R\O\ ^@6E]S_S/Y^/^(;S]AW_ **I
M^U;_ .%Q\(?_ )QE'_$-Y^P[_P!%4_:M_P#"X^$/_P XROZ!Z*/[<S;_ *#Z
M_P!\?_D0_LO+_P#H%I?<_P#,_GX_XAO/V'?^BJ?M6_\ A<?"'_YQE'_$-Y^P
M[_T53]JW_P +CX0__.,K^@>BC^W,V_Z#Z_WQ_P#D0_LO+_\ H%I?<_\ ,_GX
M_P"(;S]AW_HJG[5O_A<?"'_YQE'_ !#>?L._]%4_:M_\+CX0_P#SC*_H'HH_
MMS-O^@^O]\?_ )$/[+R__H%I?<_\S^?C_B&\_8=_Z*I^U;_X7'PA_P#G&4?\
M0WG[#O\ T53]JW_PN/A#_P#.,K^@>BC^W,V_Z#Z_WQ_^1#^R\O\ ^@6E]S_S
M/Y^/^(;S]AW_ **I^U;_ .%Q\(?_ )QE'_$-Y^P[_P!%4_:M_P#"X^$/_P X
MROZ!Z*/[<S;_ *#Z_P!\?_D0_LO+_P#H%I?<_P#,_GX_XAO/V'?^BJ?M6_\
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M-Y^P[_T53]JW_P +CX0__.,K^@>BC^W,V_Z#Z_WQ_P#D0_LO+_\ H%I?<_\
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MPUSP]-+<2S>'H+5';4DCBCN)9#%*RHH[BO/_ !E_R,?PF_[*!J7_ *JOXET
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M^.__ $*?PD_\$/C'_P";VC_B&7%/_/K!?^%D/_D0_P")E/##_H*SG_PT5O\
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M)/\ P0^,?_F]H_XAEQ3_ ,^L%_X60_\ D0_XF4\,/^@K.?\ PT5O_EA^P_\
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M?_(A_P 3*>&'_05G/_AHK?\ RP_8?^S?BI_T.7P__P##:>(__GLT?V;\5/\
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M]H_XAEQ3_P ^L%_X60_^1#_B93PP_P"@K.?_  T5O_EA^P_]F_%3_H<OA_\
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M'_05G/\ X:*W_P L/V'_ +-^*G_0Y?#_ /\ #:>(_P#Y[-']F_%3_H<OA_\
M^&T\1_\ SV:_'C_AYC\=_P#H4_A)_P""'QC_ /-[1_P\Q^.__0I_"3_P0^,?
M_F]H_P"(9<4_\^L%_P"%D/\ Y$/^)E/##_H*SG_PT5O_ )8?L/\ V;\5/^AR
M^'__ (;3Q'_\]FC^S?BI_P!#E\/_ /PVGB/_ .>S7X\?\/,?CO\ ]"G\)/\
MP0^,?_F]H_X>8_'?_H4_A)_X(?&/_P WM'_$,N*?^?6"_P#"R'_R(?\ $RGA
MA_T%9S_X:*W_ ,L/V'_LWXJ?]#E\/_\ PVGB/_Y[-']F_%3_ *'+X?\ _AM/
M$?\ \]FOQX_X>8_'?_H4_A)_X(?&/_S>T?\ #S'X[_\ 0I_"3_P0^,?_ )O:
M/^(9<4_\^L%_X60_^1#_ (F4\,/^@K.?_#16_P#EA^P_]F_%3_H<OA__ .&T
M\1__ #V:/[-^*G_0Y?#_ /\ #:>(_P#Y[-?CQ_P\Q^.__0I_"3_P0^,?_F]H
M_P"'F/QW_P"A3^$G_@A\8_\ S>T?\0RXI_Y]8+_PLA_\B'_$RGAA_P!!6<_^
M&BM_\L/V'_LWXJ?]#E\/_P#PVGB/_P">S1X9U3Q5_P )5XC\,^)K_P /ZI_9
M?A_PGKME>Z%H&H^'_P#D8-1\9:?<VMU;:AXG\3^?Y'_",6\T$\-Q:_\ 'U-'
M)"^Q'KF_V?OB?=_&;X0>#/B3J&EVVC7_ (CMM56]TZSFEGM(;O1=>U7P_<RV
MKSCSEMKN;2GO(()GFEMHKA;:2XN7B-Q+TFF_\E4\9?\ 9/\ X:?^I'\6:^%Q
M6&K8/$XC!XB*A7PM>MAJ\%)24:U"I*E4BI1;C)1G"24HMIVNFTS]ORS,<)F^
M6Y?FV J.K@<TP.$S'!590G3E4PF-H4\3AZCIU%&I3<Z-6$G"<8SBWRR2DFCT
M"BBBL#N"N'\::MK]A/X/TSPY<Z/97WB?Q1-HDM]K>E7NM6MI:6WA'Q7XE>2/
M3[#7/#TTMQ+-X>@M4=M22.*.XED,4K*BCN*\_P#&7_(Q_";_ +*!J7_JJ_B7
M0 ?V;\5/^AR^'_\ X;3Q'_\ /9H_LWXJ?]#E\/\ _P -IXC_ /GLU^0/_!4'
M_@J'\5_V*OBQX&^$OPH\!?#W7[_7OAU9?$36M?\ B';^)-5LUMM7\3>*?#5A
MI.EZ7X;\2^%)H9[>3PE>W=Y>W>HW4<R7UK##:Q-!-)+^8O\ P_\ ?VQ_^B:_
MLS_^$=\4O_GRU^JY%X,\<<0Y3@LZR_"X!8+,*3K89XC,*-*K.ESRA&<J:4W!
M3<7**DU+ELW%-V/SO-_%#A/)<QQ65XW$8SZW@ZBI5U1P56I3C4Y8R<5-N*DX
MJ23:3C>Z3:U/ZN/[-^*G_0Y?#_\ \-IXC_\ GLT?V;\5/^AR^'__ (;3Q'_\
M]FOY1_\ A_[^V/\ ]$U_9G_\([XI?_/EH_X?^_MC_P#1-?V9_P#PCOBE_P#/
MEKU_^( >(G_0-E/_ (=*7_R']6?E?SO^(R\$_P#/_,?_  WU/_DS^KC^S?BI
M_P!#E\/_ /PVGB/_ .>S1_9OQ4_Z'+X?_P#AM/$?_P ]FOY1_P#A_P"_MC_]
M$U_9G_\ ".^*7_SY:/\ A_[^V/\ ]$U_9G_\([XI?_/EH_X@!XB?] V4_P#A
MTI?_ "']6?E<_P"(R\$_\_\ ,?\ PWU/_DS^KC^S?BI_T.7P_P#_  VGB/\
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M (=*7_R']6?E<_XC+P3_ ,_\Q_\ #?4_^3/ZN/[-^*G_ $.7P_\ _#:>(_\
MY[-']F_%3_H<OA__ .&T\1__ #V:_E'_ .'_ +^V/_T37]F?_P ([XI?_/EH
M_P"'_O[8_P#T37]F?_PCOBE_\^6C_B 'B)_T#93_ .'2E_\ (?U9^5S_ (C+
MP3_S_P Q_P##?4_^3/ZN/[-^*G_0Y?#_ /\ #:>(_P#Y[-']F_%3_H<OA_\
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M!/\ S_S'_P -]3_Y,_JX_LWXJ?\ 0Y?#_P#\-IXC_P#GLT?V;\5/^AR^'_\
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M(G_0-E/_ (=*7_R']6?E<_XC+P3_ ,_\Q_\ #?4_^3/ZN/[-^*G_ $.7P_\
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M1J\P0L#V%>?_ !+_ .1<TW_LH'PF_P#5J>#: #^S?BI_T.7P_P#_  VGB/\
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M\>/^A?PS_P")'AO_ )2'_$IWB_\ ] >0_P#A\H?_ "H_MB_LWXJ?]#E\/_\
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M //9K^)W_B)O_;S_ .B2?LB_^$%\9?\ Y_E'_$3?^WG_ -$D_9%_\(+XR_\
MS_*/^)'O'C_H7\,_^)'AO_E(?\2G>+__ $!Y#_X?*'_RH_MB_LWXJ?\ 0Y?#
M_P#\-IXC_P#GLT?V;\5/^AR^'_\ X;3Q'_\ /9K^)W_B)O\ V\_^B2?LB_\
MA!?&7_Y_E'_$3?\ MY_]$D_9%_\ ""^,O_S_ "C_ (D>\>/^A?PS_P")'AO_
M )2'_$IWB_\ ] >0_P#A\H?_ "H_MB_LWXJ?]#E\/_\ PVGB/_Y[-']F_%3_
M *'+X?\ _AM/$?\ \]FOXG?^(F_]O/\ Z))^R+_X07QE_P#G^4?\1-_[>?\
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M;\5/^AR^'_\ X;3Q'_\ /9K^)W_B)O\ V\_^B2?LB_\ A!?&7_Y_E'_$3?\
MMY_]$D_9%_\ ""^,O_S_ "C_ (D>\>/^A?PS_P")'AO_ )2'_$IWB_\ ] >0
M_P#A\H?_ "H_MB_LWXJ?]#E\/_\ PVGB/_Y[-']F_%3_ *'+X?\ _AM/$?\
M\]FOXG?^(F_]O/\ Z))^R+_X07QE_P#G^4?\1-_[>?\ T23]D7_P@OC+_P#/
M\H_XD>\>/^A?PS_XD>&_^4A_Q*=XO_\ 0'D/_A\H?_*C^V+^S?BI_P!#E\/_
M /PVGB/_ .>S1_9OQ4_Z'+X?_P#AM/$?_P ]FOXG?^(F_P#;S_Z))^R+_P"$
M%\9?_G^4?\1-_P"WG_T23]D7_P (+XR__/\ */\ B1[QX_Z%_#/_ (D>&_\
ME(?\2G>+_P#T!Y#_ .'RA_\ *C^V+^S?BI_T.7P__P##:>(__GLT?V;\5/\
MH<OA_P#^&T\1_P#SV:_B=_XB;_V\_P#HDG[(O_A!?&7_ .?Y1_Q$W_MY_P#1
M)/V1?_""^,O_ ,_RC_B1[QX_Z%_#/_B1X;_Y2'_$IWB__P! >0_^'RA_\J/[
M8O[-^*G_ $.7P_\ _#:>(_\ Y[-']F_%3_H<OA__ .&T\1__ #V:_B=_XB;_
M -O/_HDG[(O_ (07QE_^?Y1_Q$W_ +>?_1)/V1?_  @OC+_\_P H_P")'O'C
M_H7\,_\ B1X;_P"4A_Q*=XO_ /0'D/\ X?*'_P J/[8O[-^*G_0Y?#__ ,-I
MXC_^>S1_9OQ4_P"AR^'_ /X;3Q'_ //9K^)W_B)O_;S_ .B2?LB_^$%\9?\
MY_E'_$3?^WG_ -$D_9%_\(+XR_\ S_*/^)'O'C_H7\,_^)'AO_E(?\2G>+__
M $!Y#_X?*'_RH_MB_LWXJ?\ 0Y?#_P#\-IXC_P#GLT?V;\5/^AR^'_\ X;3Q
M'_\ /9K^)W_B)O\ V\_^B2?LB_\ A!?&7_Y_E'_$3?\ MY_]$D_9%_\ ""^,
MO_S_ "C_ (D>\>/^A?PS_P")'AO_ )2'_$IWB_\ ] >0_P#A\H?_ "H_MB_L
MWXJ?]#E\/_\ PVGB/_Y[-']F_%3_ *'+X?\ _AM/$?\ \]FOXG?^(F_]O/\
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M\\>*%>?^,O\ D8_A-_V4#4O_ %5?Q+KT"O/_ !E_R,?PF_[*!J7_ *JOXET
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MM'27^TZY!!>W,MC_ &9'?OK,.R'3KQ_M,^GQ6;>3M6X+R1*_#5^M_CV_\)?
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MVI\L%%%% !1110 4444 %%%% ']R'_!'G_E'-^SM_P!U<_\ 5Z?$ZOO#3?\
MDJGC+_LG_P -/_4C^+-?!_\ P1Y_Y1S?L[?]U<_]7I\3J^\--_Y*IXR_[)_\
M-/\ U(_BS7^:7'G_ "7'&?\ V5?$7_JWQA_=W"'_ "27"_\ V3N2?^JS"GH%
M%%%?*'T05Y_\2_\ D7--_P"R@?";_P!6IX-KT"O/_B7_ ,BYIO\ V4#X3?\
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M3?';:)\1A%?>./&UU.^J^*=)MO%UTNB-J/B".]]MO/A3^S9\>OCQ_P %"?\
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MZMHVG>(+"&:_\/ZCJVDRRRZ3JUA<R1VU_.]J\[6EV(+R"XMXOZC-2^*WP?\
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M6_N_%WBW5=/U[Q+KD-U;BTU/1[_3[;4AXUI/[./[)_[7/[/VI:;JO[-/P'^
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M*\MGCN+2[M+B..>VN8)(YH)HTEB='16'Z#?\.SOCO_T-GPD_\'WC'_Y@J/\
MAV=\=_\ H;/A)_X/O&/_ ,P5)\9<*M-/.L"TTTTY3::>C33A9IK1I[E1\'O%
M&$HSAP;G<)PDI0G&%*,HRB[QE&2K)QE%I-----73N?.WC+]K']H7Q]X:N_"'
MBGXE:E?>']0B6WU"RL])\-Z'+?VPC:)[.^U#0=&TS4KRRN(W9+VRN;R6UOE.
M+R&? Q2\*_M0?'SP3X.?P%X8^)>MZ7X7-M=V=O9BWTB[OM-M;VV%K)!HFO7^
MG76OZ#'#&-^GC1=4L/[+N2UYIGV2\9IS]+?\.SOCO_T-GPD_\'WC'_Y@J/\
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M .AL^$G_ (/O&/\ \P5'_#L[X[_]#9\)/_!]XQ_^8*NK_7/A;_H=X+_P*?\
M\@>9_P 0<\3_ /HB\Y_\%4?_ )<?G=17Z(_\.SOCO_T-GPD_\'WC'_Y@J/\
MAV=\=_\ H;/A)_X/O&/_ ,P5'^N?"W_0[P7_ (%/_P"0#_B#GB?_ -$7G/\
MX*H__+C\[J*_1'_AV=\=_P#H;/A)_P"#[QC_ /,%1_P[.^.__0V?"3_P?>,?
M_F"H_P!<^%O^AW@O_ I__(!_Q!SQ/_Z(O.?_  51_P#EQ^=U%?HC_P .SOCO
M_P!#9\)/_!]XQ_\ F"H_X=G?'?\ Z&SX2?\ @^\8_P#S!4?ZY\+?]#O!?^!3
M_P#D _X@YXG_ /1%YS_X*H__ "X_.ZBOT1_X=G?'?_H;/A)_X/O&/_S!4?\
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M4K]F?_PL?BE_\YJC_AP%^V/_ -%*_9G_ /"Q^*7_ ,YJC_B*OAW_ -%;E/\
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M::=*S33LT]+7OU&O#WC=--<.YDFFFFH0336J::J733U36Q\1>,_^"F/[='Q
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M%M]$A73I5V:8+.$F,_IS_P . OVQ_P#HI7[,_P#X6/Q2_P#G-4?\. OVQ_\
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M/3M*\265G;6,T^GVT,-C/-;R>&_![XP_$;X!?$;P[\6OA+XB_P"$3^(/A/\
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M_9LNI?9+!K][E].L6M_T7_X<!?MC_P#12OV9_P#PL?BE_P#.:H_X<!?MC_\
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M^%[\9?\ YP='_$,A^WG_ -%;_9%_\+WXR_\ S@Z/^)EO ?\ Z.?PS_X/Q/\
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M@GG;O^$'_P"%B_\ "/\ _"S?^$-_L_\ XIG_ (1;_A,?[!_X0?\ XH#^S_\
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M=!T#2+-"YM='T'2]-TNWEFN)XK-)KFXDD_<[_B&0_;S_ .BM_LB_^%[\9?\
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M]D7_ ,+WXR__ #@Z/^)EO ?_ *.?PS_X/Q/_ ,S!_P 1W\(/^B^R'_P=7_\
ME!_.C17]%W_$,A^WG_T5O]D7_P +WXR__.#H_P"(9#]O/_HK?[(O_A>_&7_Y
MP='_ !,MX#_]'/X9_P#!^)_^9@_XCOX0?]%]D/\ X.K_ /R@_G1HK^B[_B&0
M_;S_ .BM_LB_^%[\9?\ YP='_$,A^WG_ -%;_9%_\+WXR_\ S@Z/^)EO ?\
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M *H#X55^6= '[Y?\1%G[;/\ T2[]EG_PB?BU_P#/OH_XB+/VV?\ HEW[+/\
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MJV/A6RUNZ\.6NLZ-J/B*+2M.U;3KNY /V-_XB+/VV?\ HEW[+/\ X1/Q:_\
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M2ZC;Z3X?\-^'].NM5UK6-2NFV066GZ?9QRW-S.YR=L<9V(KR.5C1V4 _<_\
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MO_90/A-_ZM3P;7H%>?\ Q+_Y%S3?^R@?";_U:G@V@#\5_P#@J_\ \%8?B_\
ML+?&#P#\'?@_\//AMXAU'Q#\-+'XEZYXB^)-KXGUBR6UUGQ5XL\+Z=H^DZ3X
M7\4^$)X+BVD\'7]Y>W]YJ5W',E_:006D36\TLOY4_P#$19^VS_T2[]EG_P (
MGXM?_/OH_P"#BS_D]GX7?]FL^"?_ %;7QOK\#: /WR_XB+/VV?\ HEW[+/\
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MW[+/_A$_%K_Y]]?CU\"/V=/C+^TQXGU_P;\$?!W_  FWB3POX,UCXA:[IO\
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MRQ71XY(O'EE'?>'_  [9PZ8+[L_&_P"SE^SA'^SS^W#\'?%/P&_8P\&_%/\
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M+]I/XL_L=_$W]GSX*?"CXN:_'<?$K6OB%8Z5\ OCK^P=^QM\4_ G@NQU:_\
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M:7?6,U\JK9:E)>6 %K5*T_X*)?MC6/Q?\)?'JU^,'E?%CP+\++;X*^%?%?\
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M#8QR10O& ?(%%%% !1110 4444 %%%% !1110!_?)_P15_Y1F?LT_P#=9/\
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MFVLHKKP_H4^G 'ZV_L\_LA_ ;]K3P7^PA\:M)^'WPS\,^$OV8_'WQ/\ A/\
MMI6NG^%M!L+3Q=I?P9T.3QGX!\7_ !/CTW2-/M/$TWBS2/#&CP^/=7URROGU
MV;XB2V=]?SK:/%<_ST_'KQ_X=^*?QH^)_P 0_!_@W0/AYX/\6>--=U;PAX&\
M,>'-#\)Z+X4\)R7LL?AG0[;0/#44.AV-QI^AQ6$&I-IZ-'>ZFMY?R37$]U+/
M)^@O@_\ ;K^$?P>_8>^.?P6^$VG?'&Z_:*_:TDL+/X]:UXRN? %A\$/"U@UY
MXHC\5WWP>T#PI':W]K<>,_#.KQ^&-6TG4_#FE)!;WXGM]=-IX/T+2=2_)^@#
M]T] LK/4?^"/'[*.GZA:6U_87_\ P5#T&ROK&]@BNK.]L[KP9\0X+FTN[:=)
M(;BVN(9'AG@F1XIHG>.1&1B#^EFI_#G]ESXM_P#!4KQ;^Q8W[)7[-'@GX6?L
M]>$M#^/NHZCX0^#>BZ9XX^)_C>Q^'_@W4M,\'ZU-X;6U&I_"JW3XG:1K^J?#
M#1M$M3XP\0>!T&OW.LZ%K.N:%JG\N]I^TS\;K'X0>$?@-:^-O*^$_@3XIVWQ
MJ\*>%/\ A&_"+_V5\3;.SU"PMO$O]NR:"_B2^\NTU6_B_L;4M8O/#[^?YDFE
M-+%"\>SK?[7?[1NO_M&1_M:WWQ1U:#]H>+4]#U=?B3HFF>'/#5Z;KP]X:T_P
M9812:'X<T;2O"LVF7'A+3+;PWKFB2Z$^C>)M%DU#3O$EAJUKJVJQ7H!^_OQ&
M^"?['G[4.K_L6>(_V?OA1\+?BQX^\3?M 7WA36)/A=^S/\?OV#?V7/BU\-/#
M'@OXH>/M>TC6?$/BCP?\4/",NL>$]1\#I'XCF\-:EXM^(/B#1$U[1[318K73
MH5T/Z,\1^$_V;X?AI\(OVB/"'P<_8VN_B5\)_P#@H#\.?A1?7/P2_9QU[X7_
M  Y\.W>L>)]&^'7B_P #7^J^*+?0+_XZS_#V\\3W/B'PW\9-*TGPGX.OO&FA
M^&]9T'P?HEUX<UO3]0_G ^(/_!1W]MKXI?$GX9?%OQK^T#XKU#QU\'-175_A
MOJ&F:7X3\+Z1X<U(O/\ :[W_ (1#PIX>T3P=J\^KVES<:-XA?7= U3_A)/#4
M\OA;7QJ7AQVTLZ/Q8_X*8?MQ_'#PSJ?A#XG_ !\UGQ%X?U37O"GBA[2W\*?#
MSPY<:7XB\$7UIJ?AC6?"^J>%O"&B:MX.U#3-1L;:^^T^$[[19+VZ1Y]0-W)-
M.T@!_1_\8?$GPM\6?'?_ (*W>)?B#^RQ^RU\0];_ &1O@M\+O$G@'5_&'P@T
MG6=:\7>(+[X8>(?&D6I?$S6[RXGU77I+>_L=(T)WT*Z\+7=UX,TBR\.R7B^3
M%?1<UX5T3]F+6?BO_P $U=.NOV&_V0TN?^"@7P,U?Q+\998/A-9C1O"LO@SX
M2-XXTR'X/>$Y;R;P]X O;SQ%XEO4UOQ$EEJOB36M#M-'T[4=5GOM%TO6+3^?
MWX@?\%3/V[_BEX>\:>%?'?QT&O:%\0_!%Q\./&-HWPP^#>FRZUX,NO[1\_19
M-0TCX>:?J5F'.K:BRZAI]W::I&UU(T5\C!"OFVG_ +=_[5FE:Y^SWXDL/BIY
M&M?LK>&-1\'? 6]_X0?X<2_\()X;U;P[;^%-0T[[/-X/DM/%'VC0+6"P^V>,
MX/$5_%Y?VJ"ZCO6>Y8 _H\^%7[-W["O[+OPA^%5OXX\-?!7Q)J7QJ_:.^-_A
M!M0^(_[('Q3_ &QO%7C;3O _Q=\3>!])^$'PSUKX?WMW/\*/'UAX6TB#2;66
M]L/$5SK?BFTU_5[7PCKMWX?UF&W^>?'_ (?_ &4_V0OV-OCC\8/AK^RU\(_C
M'J/A']O+7OA_\)'_ &H/@KXB?5_#?A_7_ .BZC<>%?'WAOQU9>"OBGK6B>#]
M,O\ Q7H7A_PQX[NH1!X@_L'QU>6=YK>EVE_)^0'PP_X*<?MT_!NQ\9Z9\.?V
M@=<T'3?'WB[Q)X[\1Z?<>%/AYX@LAXJ\8:A>:OXFU3P_:^)?"&L0>#1K&JW]
MYJ=W8>#H]!TPZC<27L=G'<XE'@^L_M._';Q%\']5^ WB#XAZEKOPOUWXHWWQ
MIUO1=9T[0=3U?6?BCJ=M+::EXQU7QM>Z5/XZU#4M0BGF>^BN_$LUA=W4TM[<
M6DEY(]P0#^O30]+^%/[.'[17[;^A_";X%_ [PUH?B3_@GOH?[2EUX6'@JU_L
MJ^UFQMO'/AO5/!,FBV-SI>FP_"G7(="TJ;Q5X,TBPT^PU/5+B74Y+BVO=4G,
MG\^W_!)7Q'_PF'_!5OX(>+O[!\-^%O\ A*?&'QO\1_\ ",>#M+_L3PCX<_MO
MX1_%74_[!\*Z+Y]U_9'AO2/M7]GZ'I?VFX_L_3+>UM//F\KS&\$L?^"E?[;>
MF_&&#X]V'QQN[3XK6_PTLO@^OB2'P+\,$M9OASIVJRZY8>'+WPN/!7_"(Z@+
M35II+ZWU6_T&YUN*9AMU((JJOA?@O]I;XV?#WX]R_M/>#_&BZ-\<9_%'C+QG
M)XV7PUX1O5/B3X@6^NVOB[45\,:EH%YX.C75K?Q+K<8L8_#RZ=IXO=VEVEDU
MM9M;@'Z\^.?VP/V&OV7;+]O'PE^S?X2_:S\5?&W]I'3_ (E_!WQJWQPU'X56
M_P '_#[:[J_B_2O$WB#P_IG@F[FO-8;3;C7=2N/#EKXL\.:K=S6:1Z:VJ:%:
MZIXA35OTV^*O[,O_  3B^'L&L_L8:_X0\$7%YIW[-\/B*-/AO^Q1\>/B/^UA
M:WS7*O9_M G]J+X;:=XMLKWPO#XE5?M^CW/@N3PW#?.OA'7M4'A S>"IOX\_
M$.OZMXKU_7/%&OW?V_7?$FL:GK^M7WD6UK]MU;6+V?4=1N_LUE#;6=M]IO+F
M:;R+2W@MH=_EP0Q1*B+]B:I_P4?_ &W=:^!<_P"S=JG[0OB^]^$%WX;/@Z\T
M&6P\+?V_>^$VFWS>&K[XB)H"_$F]T*ZM2VB7VE77BZ:RO_"TDOA&\AG\+RR:
M0P!^R'BO4O@O\'? 7_!(GX;Z'^R+^R7XGU#]K?P+\#+'XQ?$'Q[\#?"_B3QQ
M-;W6M_"739]0\.ZJ!8VMMXEUE/%7B@^)]?U_3O$=[KBW6F"9HVTQ6EZ[XI?!
M+]G_ /9XN/\ @I_^U=X:_9?^#GQ=\6?!7XQ_#[X7?#CX-^+_  #IVK?!'X:^
M%-<\%?"S4M=\97'PKT.UT[1W@N+OQ7?W-U>[+26Q_L.1M,U+0DO_ !#=W_\
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M)(O-UR*7RW W)YD4;[2-R*<@1_\ #4/@#_H$>,/_  7Z+_\ -!0/EEV?]?\
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M,91<H24HMKE>J3;C)+^2G_B'3_;9_P"BH_LL_P#A;?%K_P"<A1_Q#I_ML_\
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M@:E_ZJOXEUZ!7G_C+_D8_A-_V4#4O_55_$N@#\5/^"L'_!)[XR?MT?&3X?\
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ML_\ 14?V6?\ PMOBU_\ .0K]=O\ A_[^QQ_T37]IC_PCOA;_ //EK[%\%?\
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M?LR?\%=/V9?VJ_C'X<^!_@/PO\9O#?C'Q99Z_=:%<^.O#/@VPT*]E\-Z'?\
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MJ]UXM\?^"$CFU#5/#FMQ6UO8#4'5-/EDN3;B2#S?AS_B)O\ V#/^B2?M=?\
MA!?!K_Y_E?K>0^ _C!Q1E&!S_(/#_B#,\GS.DZ^ S##X>E[#%454G2]K2=2M
M3G*FYTYJ,N5*27-%N+3?Z1D_A!XF9_EN$SC)^#,YQ^68^FZV#QE&C3]CB*2G
M*G[2FYU82<'*$DI<J4K7C=--_G?_ ,0Z?[;/_14?V6?_  MOBU_\Y"C_ (AT
M_P!MG_HJ/[+/_A;?%K_YR%?HA_Q$W_L&?]$D_:Z_\(+X-?\ S_*_3?\ :/\
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M\Y"OT0_XB;_V#/\ HDG[77_A!?!K_P"?Y1_Q$W_L&?\ 1)/VNO\ P@O@U_\
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MMOBU_P#.0H_XAT_VV?\ HJ/[+/\ X6WQ:_\ G(5^B'_$3?\ L&?]$D_:Z_\
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M'8^)%\-_#K]I/X\W6G_ GPQXU\/Z!=V^F6,FL>'M1N_A-\)8=4@LT;Q9XO\
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M'7[?5)HOM-N;#5#F2WALO+9/LZ+MV-;L3M-S'=?-'B7_ ),X_;P_[-G^)_\
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MX(1?\I6/V5_^ZX?^LX?%^OU*_;T^&?[+7CC]CW]H'P?^P2O_  3O^)9_9?\
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M_DPS_@AO_P!FBWG_ *IK]D6OYT:_HN_X+0?\F&?\$-_^S1;S_P!4U^R+5O\
MX(K_  E^#7BGX _M%?$/QM\(?V5M:\<:%\:?@1X*TSXH?MW:#IVI?L\KX,\6
MZDP\4> / %WK#36J_'"2PMM0N=/MK.S\R2^\0_#NSU>Y_LO51:7'X3X<<<X;
MPZ^CU@N*<5E^)S2GA^,^-L!#!X6K1H5*E?-_&'B?+*$I5:S:A2IU<5&I5=.G
M7J\D7R49:N/Y#P/Q;0X(\%L)Q!B,%7S"%'BCBO!QPN'JTJ,YU<R\3<_P%*4J
ME5VC3IU,1&=1PIUJG+%\E*6K7\XU?T7?M)?\JVG_  3]_P"SNO&?_J5?MMU^
M6W_!2[P!X$^%O[>7[4'P_P#AG\.]7^%/@;PO\3]1T_P_X%UBSCT\Z3;M8:?=
M75[HEE#J&IP6_@OQ%J%Q=^)O $<%TD'_  @^L>'C#9:9$4TVT_4G]I+_ )5M
M/^"?O_9W7C/_ -2K]MNOH_$C.:'$6%^CAQ!AJ-7#X;/?%O@W.</0KNE*O1H9
MGP#QKC:5&LZ%2M0=6G3KQA4=&M5I.<9.G4G#ED_;XYS2EG>'\#LYH4ZE&AF_
MB/POFE&C6=-U:5+'\'<58NG3JNE.I2=2$*L8S=*I4IN2;A.4;2?\Z-%?K9_P
M2*_X97_X6M\9/^&@O^&;O^%C_P#"F/$/_#,?_#9&[_AEC_A:VR;S?^%M^=_Q
M*?LO]E?\@K^V/ES_ &A_PCW_ !6O_"+U?_X+*_!'X;_"'X[? KQ%\.-(^"/A
MX?&_]E3X6?%GQWI'[.#W,7P(N/B1>ZGXM\+>*O%/P3TNYA@%C\'?%K>%[+5O
MA_<VR_9M;L#=ZRC7#WDE]=_>_P#$2\)'Q-_XAI7R/-\-B*N62QV"SRO2C#+<
MPJT\'#,*U'!I^]6P]+#2JT98R,VEF.%Q6"E0C[)5I_8_Z^8:/'JX$K93F5"O
M5P$L7A,VJPC# XVI##1QE6EA4_>J4*=!U*<L4I66-P^(PDJ*Y%5E]9_LV_\
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MQ,\16I1AA:-2K!3=)5JTZDZ5*G1DZCE#\&:_HN_X(O\ _)AG_!<C_LT6S_\
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MO2HTJ:G4J5(P@V?B/7UU_P $_?\ D_/]B3_L[K]FW_U<O@ROU3>T_9]^$?\
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M&?AKXP_ F.ZUGXC_ +/.@6O@/]G7XU>/_#5QIB>-]3^#_P ,[RYL_'_@[1_
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MTJWFE6%W;I-!?Z==P2V\DBSH8U=HQ')$S_+/_"@?CO\ ]$4^+?\ X;?QC_\
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MM]'L=)TS3_U$^ __ "@?_;3_ .SF/"O_ *D7[)E?F?\ \,6?MC_]&F?M,?\
MAB/BE_\ ,K7[1_!+]F3]H;3_ /@B[^U?\*M3^"WQ+TOXG^+_ (XZ5XR\+_#K
M4_!VN:?XZUWP[HVL_LZ7=[?Z=X1NK*+Q!<'R?!GB9K6T73Q>WW]E2_8K><2V
MYF?&F.X<P64\)8++L?E%'"8/CC@QTZ&'QN$Y*&'H9U0JU:C4:K:A""G6KUIM
MOXZU6;;E)G"V$SS%9CQ)BL=@\RJXC%<)<4*=:OA<1S5:];*ZM.G!.5-)RG)Q
MITJ4;+X*=.*2C$_GU\#?$3X@?"_75\4_#3QUXQ^'GB9+2XL%\1>!O$^M^$M=
M6QO-GVNR75] OM/U!;2Z\J/[1;"X$,_EIYJ-L7'T-^T!^VU\>OVF/AS\(OAC
M\5/$<FK:#\(+*[BL;W^V/&=_K/CC5[F)+>'Q=\2+CQ'XKUZS\2^,--LS?6&F
M:_#I^F75G8ZQK-JH:+4)EK _X8L_;'_Z-,_:8_\ #$?%+_YE:/\ ABS]L?\
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M1%RD<5N=BA ]K(R!8B'W6]LT/)>)?^3./V\/^S9_B?\ ^JM^)M6/^%>>/_\
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MB>>FK)_9WAZP_LW2H?)\*ZM#N@L_-F\MY=GFSMYA\R9G? W8'FG_  KSQ_\
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M +RRVB11KD_,\CJBC)9@ 37\^'[9[OEIMMI_5U]Y^IM>?Z;_ ,E4\9?]D_\
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MXH_%O6M0TG5I/".C:P=*NDTSQ5H=Y;IJ MA>0W;M:&?[-="'\"O^'?O[>?\
MT9)^UU_XC;\9?_F,K_;_ ,!LXX%S'Z/? O#O$&=\-5<)C>$9Y5F^58_.,OI.
MKA\15QF'QF#Q=">*IU8*I3G.E5IR4)I-K1G^L'A!F?"..\%^$<DSK-<BJ8;%
M\-3R_,LNQF9X*FZE&M4Q-'$X7$4I8B%2*G"4J=2#Y9)-K1GR+7]='_!6W_E
MS_P3*_[LP_\ 6-OB37\Z2_\ !/O]O1V51^Q+^UR"S!06_9O^,:*"3@;G?P:J
M*N3RS,%4<L0 37]4/_!4/]F/]H7QU_P1<_8.^$?@?X-?$;QM\5/A.G[)[_$'
MX<>#?"FL>*_&WAS_ (1;]F7QGX"\2K<^&?#UKJ6KW#Z#XKUO3M*U465K<_8G
ME>XG*6D$\\?D^-W%?"^(\0_HZU:'$F05Z6$\2,76Q=2CG&75:>%HRR:I1C6Q
M$X8B4:-*56I3I*I4<8.I.$$^:23\[Q7XBX?K<:^"52CGN3U:>&XXQ-7$3IYG
M@JD*%*65SI1JUI0KM4J;J3A34ZCC%SG&-^:23_F-_8;_ &^_B/\ L#Z_\1_%
M'PO^%?P&^(>N_$SPQ9>#-6U'XT^#?$WBNXT?PK%<7MSK.@>'7\.>-_!AM-*\
M7RSZ>?%MC?G4[;6%\/Z"AB@6RE%SXM^TI\?_ /AI'XA6_P 0?^%)_L_? 3[/
MX;TWPW_PA'[-?PW_ .%6_#V?^S;S4[S^WKGPU_;.N^;XDO\ ^T_LNI:I]M7[
M59Z?ID'D1_9-TG<_\._?V\_^C)/VNO\ Q&WXR_\ S&4?\._?V\_^C)/VNO\
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MJ=&CAL)AH1I4Z5*/Y7?\% O^3\_VV_\ L[K]I+_U<OC.OH[P5_P5U_:A\!?
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MB#PO?6?B.WAT_38HKFZU"^M;5M.LKRPL[348?MC?MY_P5W_9#_:C\>?L3_\
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MTRQXO-*V&\3^'LTQ&(K1IXJ4YQHRQ6;YI74(QIPJXK,\PJQ57$XNO/B\6)\
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MN8;6&34/V??BKI-BDL\BQHUYJFJ^%;+3-/ME9@9KR_N[:TMXPTMQ/%$K./\
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MB<+BN(LHP^)P]>E)PJT:]"KC(5:-6G-.-2G4C&<))QE%--'UM17SYX _:H^
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M.I!5(QG"4H.7,HSBVK2391117GG8%%%% !1110 4444 %%%% !1110 4444
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MBH.IA<?E_#6=8W!XF"E*#G0Q6&P56A6@IQE%RISDE*,HWNFC]=**_,7X8_\
M!93_ ()L?&/XA^"_A5\//VEK/6?'GQ"\1Z5X1\':+??"WXW>&8=:\2ZY=1V&
MC:.FM^*OAKHF@6=YJM_-!I^GKJ.J6B7=_<6UE [W5S!%)^G5>'Q#PEQ5PCB,
M/A.*^&>(.&,5BJ+Q&%PW$.39CDN(Q.'C-TY5\/1S+#8:I6HJI&5-U:<904XN
M#ES)H\C.N'.(>&ZU'#\19#G.08C$4G6P]#.LKQV5UJ]%3=-UJ-+'4*$ZM)33
M@ZD(R@IIQ;NF@HHHKY\\8**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O/]2_Y*IX-_[)_P#$O_U(_A-7H%>?ZE_R53P;_P!D_P#B7_ZD?PFH ] H
MHHH *\_\9?\ (Q_";_LH&I?^JK^)=>@5Y_XR_P"1C^$W_90-2_\ 55_$N@#\
M'?VZ?^3J/BE_W)'_ *KGPA7R37UM^W3_ ,G4?%+_ +DC_P!5SX0KY)K^MN&_
M^2=R#_L2Y5_Z@T#_ "A\1?\ DX/'?_99<3_^KO''UM^PM_R=1\+?^YW_ /5<
M^+Z_9/XJ_MC_ +(GP)\4)X(^-_[5/[.'P;\:/IEIK:>$/BK\<?AC\//%#Z-?
MRW,-CJZ:!XN\4:1JS:9>S65Y%:7XM#:7,MI<QPRN\$H3\;/V%O\ DZCX6_\
M<[_^JY\7U]__ +5?P%_:[^(_Q13Q%\$/#W_!-S4O!8\,Z1I[W/[5?[.?Q.^*
M?Q1.LVMQJ+WR)XG\(_$SPCI*>&4AGLQI&F'2GN[2X_M&6:\F2YBCA_%_%?\
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M_A?-AXHLO B?%V?P^XLHM$MO@1?: ?%JKI$>LSPSBXB][_X*C?LY^-/VL_\
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M;VNIZGXGL_&'A+3=6\4>'M$TO2YYKO\ /3X9_M$?L_\ Q)_X(@W_ /P3_P#
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M^RM@#]0:\_TW_DJGC+_LG_PT_P#4C^+->@5Y_IO_ "53QE_V3_X:?^I'\6:
M/0**** "O/\ QE_R,?PF_P"R@:E_ZJOXEUZ!7G_C+_D8_A-_V4#4O_55_$N@
M#^4?_@O[_P GC_#7_LV?P;_ZM+XRU^&]?N1_P7]_Y/'^&O\ V;/X-_\ 5I?&
M6OPWK_1CPK_Y-WPE_P!BFE_Z<JG\1>(?_);<1_\ 8QG_ .FZ9^F'_!'G_E(S
M^SM_W5S_ -47\3J_L/\ B[^UG^RO^S]K>F>&OCS^TQ^S]\$O$>M:6-<T?0/B
M[\9?AS\-M;U;1#=W-@-8TS2O&7B31;Z_TLWUG=V0U"U@EM#=VMS;";SH)47^
M/#_@CS_RD9_9V_[JY_ZHOXG5_45^UW\$OVJ/B=XW\-:O\!M"_P""?.J>'+#P
MJFFZQ/\ M=_ 'XC?%OQNFMC5]3NC%X:UKP;\1/!MCIOA46-Q:.FEW5E=W8U=
M]3NS=>3<10Q_S1])#_DN,J_[)3 _^K?/3]W\#?\ DDLQ_P"RBQ?_ *K,H/J#
MX/?M&_L]?M#6VNWGP!^/'P9^.5GX6GL+;Q-=?![XH>"/B9;>';G58[J72[?7
M9_!>N:W%I$^I16-[)81:@UO)>1V=T]NLBV\Q3XH_X*@?MF_&G]E'X>_"[PW^
MRSX'\$_%']J?XY>,O%.D_"[X>>/-.\1:QH&H>%?A9\./%7Q9^+'B"\TSPGXD
M\*Z_.FC^&/#-MHME/::O';V?B+Q7X?GU.*331=8]N_8\^%/[0OPMT[QY!\?M
M(_8PTJ\UF]\/R^&1^QY\'/&_PATZ>VLH-635#X\MO&GC;QI+KE['+<V7_"/S
MZ?-81V$$FK1W$<[74+1_E/J*_MA_M>?\%2_CY\?OV1M=_9MTCP1^P7X1/[%'
MA35/VD?!_P 2_'OA75OBWXU.E_$7]HC7O!&G_"_Q_P"!K[3/&'A0P^#OAAXA
MOM6U6:S_ ++A>Q@T;[9+=WL7\_'[,?LG\'OVK/A#\7/V5/ 7[8:>)]&\(?![
MQE\)M+^+NJ:_XEUBSL]+\$Z)-HJZIXBL_$NKSFVLK6Y\'7<6HZ+KTC^4D&I:
M7>1!0RA:^+K7_@J5\+?BM^T]^Q/\%OV;/$^A^-?"_P"T'XV^,&D?$]O&WPV^
M+G@#QQIG@[PA^SM\3OBUX \9?#?3_B!IOP]FU+PSXJ\4^ 3IL?CF+PYXT\&Z
M_H\&K66@W\&I"/4;7\5%\ ?M$_#;]DK_ (*3_P#!*;QWI/A[QQ\3/@QXW^$7
M[</PQ\!?"#1-;M/#?Q9_9'\>_'WP-\8/C9\./@YX1U[4M9\52>&?!?B3P[X_
M\*V>@7]_J^I:MJ?B*V\$W=]J,&H_:9OOGXA?MF?LJ?M8_P#!3[_@D#!^SIXK
ML/BEJ/@KQ;^V'<^)O%WA_P .ZS;Z;\.K;Q#^QM\2DM?AKXGU;4])T]- \<:O
M/I#:G?\ P\NGB\1Z)!X5>YU[2=-$FG&Z /O^#_@K3_P3UGU71],_X:,TRVM]
M9\83?#T^*M1\ ?%K2_AQX=\>0:O>:&?!OC[XIZEX"M/AM\-?%$U]8R/9Z%\0
MO%?AC4K_ $VXTW6[*VN-%U?2M0O?1_AA^WO^S+\?;SXD^$_@E\3X]6^('P]^
M'EU\1[S0?&OPY^+OP_+^#I$GM])^(&EV7CCP1X5U+QW\-[K4TAM_^$N^'B>(
M]'O5ECAT[49KFZM%E_".Y\+^'+S_ (-[=:@O-"TJZA\1?MMSW.NQ7-C;3QZM
M<7/_  6A@\+W$U^DL;+<RS^&[:#0IGD#-)I,2V+DVV8S^DWQS51_P5>MG"J'
M;_@CO^U8K-@;BJ_M(_L_E5+=2JEW*@G +L1@L<@'J?@#_@IE^S]X:^!7[,/B
MW]I'XU?#M/BG^T'\";3XQ>'[7X)_#7]H/6/"GQ0MK.[\):1XBN?@GX,UKP#?
M_%O6%.L>--#DT+X?ZSH1^*MWHLNH:P?"\VF^'O$=]I70?$S]OKX:>(?V0O%O
M[3?[,7Q=^$MWIOACXL_"OX5:GXD^-'@WXX6WACPEXG\2_&[X7?#KQAX%\?\
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M3->NO"VD>$]%N=4T:UO=0^U$ ^T_@?\ \%8I?VB/A)HOCKPK)X%^&'B(?\%
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M> VVI0S2@'](=O\ &FU^&W[+'_#0WQW\3Z#+IO@OX*3_ !?^)OBOPGX%\8^
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MASX-^-6K^)/AM^U-\+_A9X<\!>+OV.]4\'>+IOVA]2^*G@;PS!X>NO!7P_\
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M'@U-:D^$_BG]K3P?JUU\0?B9H?[,\.K.=(?2M?\ "WAWP5HGC"#P:L/A._\
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M"7GP(U\?ML_&7X$O\5O&OCV^U)?#]C/^RS\+]?O-;\%^'-$.F+X9TWXE>)-
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MN\T^PGN[#Q+!K\EJCZTSN ?J[7G^F_\ )5/&7_9/_AI_ZD?Q9KT"O/\ 3?\
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M+>ZMX-?\.Z<;N!S+:F9(Y2GX!?L<_"GQ1\/=;_X($^%/BA\/=2\!>(-/O/\
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MY_J7_)5/!O\ V3_XE_\ J1_":O0*\_U+_DJG@W_LG_Q+_P#4C^$U 'H%%%%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RY^U!^S7_PTC_PSO\
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M_ B['B7P\E[X,T^.[^&?E_##7U_MG4I=)\4[[S1Q_P (9MN+UM/ /G?X=_\
M!1/]OT?LV?L;_MO?%OX?_LJ1_ +]HKQI^SCX"\;_  M\!Z=\5(/C'X9L_CMX
MFT+X>6_Q6\.^-]?\>WG@J:RN/%NL6_B#3_A+>^$+[4-'\+:I8:9J'Q5U?5K'
M4=1.9XP_;1OOV3I_^"G_ ,3? OPG^&7A_5M)_P""AGP'^$OBOXFZV?B_JW@3
MP]I_Q#^"OP*L]8_:'_:#T^V\7^*+Z+P[\/\ 1=0CTN]T_P"%.F?#S1KV&T\.
M0W-A;:K>:UXDO/I.Z_X)]_&6?_@FE^Q[^QJGB;X8CXG_ +/OB?\ 8WUKQGKK
M:SXJ'@/4[7]GGXI^!O''C2/PQJ@\%GQ#>W&J:3X9O[?PNFJ^%]%CO=1FLXM6
MET2VDFN[???]D']L/P)K/[;WCKX#_%GX+^#_ !K^T'^UQ\./CWX'TKQGH&I>
M-_!/C3X5^&?A'\-OAOXW^#7QGM[WPDNI^#8?',GA36?,\0_#9_$&N:5IXTB?
M3]6MKB^U*TM #Q#7OVF_VN?C3^Q9^WG>:%\2OV+OB/8>$_V;M?\ %WPD_:[_
M &7O$.L:[\+]?BN?#/BF\^)G@+6/A/9?'3Q-\4?AQ\6/"7A+1KW_ (1'Q5-\
M0[KPW'XDUW0==N-/NW\-:_X,N>0^$O[1G[?'@'X>?\$F?V9O UW^ROXD\<?M
M5?LO_$KQ7<?$KQA\/_BZGAOX<>#/@A\+?V;_ !%\/[W6/#&G_&8:[XV\2W.@
M>._$'AKQJEIXE\/6GB;Q=J/AKQ)H\O@K1-'UK1-:]-^%'_!-/XFW'CG]LOXL
M_$#P[^RQ^S7KW[4/[)NM?LM6OPG_ &0[3Q5JOPS>]UO_ (2R[N_CG\4=:\0^
M!OA'+XT^):W?B2+1]/\ [/\ A_HQT_PK;7-A=:UK%Y>O=IZ'\"?V./VH]%\>
M_P#!-;QO\9[KX!:?-^Q%\!?VBO@-XSM?AAXR^(GB*/Q?IWCSP5^S[X+^&7B?
MPPOBOX9^%&6]N8?A)KNH^.](U6XT^#P[+J&DVWA_4?%RRWD]D -^._[0O_!0
M#X>:GXU\[Q5_P3O_ &=?"GP\\'>##H?B_P#:>\1Z[]E_:1\:/X0MM3^(>M^!
M]/T3X]^"Y/@1\-++QG)=>#?"S_$BZ\=>*I?L4VLZI8BP:W:X^+O%_P"TQ^U%
M^UY\1?\ @A=^T#\%M;^$WP@L?V@6^.'BQ_ 'C[PQ\0_'VDZ;\1;#]EKXT2^.
MCXCN/"GQ/^'</BWP9%X3MM7T[X<69T[2-=T+Q;=6GBS6-4U/34NO"4_NWC#_
M ()R_M%I^TY^U1\6O#?A7]AKXLG]I#Q;I^O>!_VBOVE-!\>^-?VA_P!F#P_'
MX)T'PK'X#^'/@J3P=KWACQ#X4\'ZCI5UXE\%Z=I'Q9^$T3ZO>^?KZ7L-K86E
MB_X;_P#!/']JWX+_  "_X)8:1X'US]GOQ%\;_P#@GIX@^),7B;1/%?BWXCZ5
M\*OB'X5^)?PY^)7PEU*]T+QII'PSU'Q=I?B#3_#7C2R\16.EZA\/VTUM<2ZT
M:XUB2PLHM7U, XSP)^V'KOP;TWX^> ?@-\'?A8G[0?[1'_!83]HG]F_X7Z1J
MFN_$NV\!:CXEL_#VC^+_ !S^T!\7Y=7\4^--=EM_#_A70;O4O%/ACX9R>#M'
MUB^&A:3X1\,^%Q>ZEJ,?TI8_MB_M3_!?XL_$O]G#]J?P_P# G7_B-_PR5\4/
MVIO@+\6O@AH/Q%\,_#3QJOPGN5TKQM\./&WP[\;>+_&7B;PWXA\-7NL>$M97
M4M/^(E_HWB;PYJTHM[K0-;C&F+YUK/\ P34^-JZ5XY\>^"_'OPH\/?M#>#_^
M"F?Q;_;W_9NUC6(O%OB'X?WGACXC>'[;P?J'PF^,,-KI7A_7])M_&7A.ZUK3
M_%%WX,77+CP]J%OH.IZ'JNL+#>V4WH=E^QQ^U1\:/BW\2OVD/VI_$7P*\/\
MQ%'[)'Q2_97^ WPB^"&N_$/Q-\,O!B_%FZCU7QI\2?''Q%\;>#O!WBGQ'XC\
M17FB^%-%CTW3?A[I^B>&O#>F3F*S\0ZX\>J  \1^'W[>_P"WO:_#']@O]J/X
MR> /V7$^ /[:7Q,_9F^%]S\-_A_9?%"U^,GP_MOVHTT[2/AW\4#XY\1>-[_P
M3K.F76N:OHFMZU\.H/!"ZGX:T#6X]*M_'7BJ_P!+N]7N/W;K\JM:_8;^+.H_
ML5?\$VOV<(/$/P[3QQ^QW\1?^"=?B_XFZK+JWB5?"FNZ;^R->^ ;GXD0>!+Y
M/"4FKZG?:VGA74!X(B\0:'X8M]2>:R&O7/AH23M;_JK0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>?Z;_ ,E4\9?]D_\ AI_Z
MD?Q9KT"O/]-_Y*IXR_[)_P##3_U(_BS0!Z!1110 5Y_XR_Y&/X3?]E U+_U5
M?Q+KT"O/_&7_ ",?PF_[*!J7_JJ_B70!\/\ Q[_Y*SXK_P"X%_ZC6C5X_7L'
MQ[_Y*SXK_P"X%_ZC6C5X_0;QV7HOR/8/@)_R5GPI_P!QW_U&M9KZ-^-'Q%_:
M6\'>(-+L/@K^S5X;^-/AZYT9+S5/$.M?'O2/A1<:7K+7MY"^C1:)J'@'Q9+J
M,*6,-G??VJE[;1L]Z]H+4-:M++\Y? 3_ )*SX4_[CO\ ZC6LU]&_&C]C[]FG
M]HCQ!I?BKXU?"+PW\0O$.BZ,GA_2]4UJ75TN++1H[V\U)+")=/U*RB\E;[4+
MRXR\;2%YW!<J%50SGNO3]6;WP2\;_'?QG;^(I/C?\"="^"%QI\VF)X<M]$^,
M6F_%Q?$<-RE\=3FN)].\'>$1H3:6\%BD<4T=\=0%\[H]O]D=9?P*_P""C/@[
M]HC5?^"Q/PN^*?[*M]=W7QR_9E_X)I^)/V@_"OPSC8+I?Q\TGPU^U+H_@[Q[
M\"M<8'S$B^('P^\>>*8/#DL(\^W\=V/A&XBELWB%_:_OK\$OV9O@1^SA;^(K
M7X(?#;0OAU;^+9M,N/$<6B2:DZZK-HR7T>F27']HW]\0UFFI7RQ^28P1</O#
MX3;X/<_LP>/IO^"FVB?MH)J_@\?"[3?V$?%'[,$^@MJ&M#Q\_C[6_P!H'PA\
M5K75XM+'A\^'6\'Q^'= O+*XU!_%,>M)K4MM;Q^'Y;%Y=1A"#XIE_:1^%W[4
M7[;G_!'O]HOX9:TD_P /_'O[-_\ P4<\0+)J;1V-_P"&+NST/]EJV\3^&?%4
M,KJFD^(/!FM6>IZ!XFM)G\NQU/2[P+-+;+'<28=K_P %!_VZ_$W[*OB3_@I5
MX)^%?[.-_P#L<:'IGBSXH:7\!]1C^)L7[4'B;]G3P'KNL67B+XF#XHQ^)(OA
M?X=\6WGA/0=2^(>E?#J[^%VIV=OH:Q:5J7CB/5C($[OPG_P2V\4?#'_@J'IO
M[7'PY\9^$8/V4]6\-?'OQ+XI_9_U9]3AO_"OQ[_:"T3P3X>^)_BKX>Z):^&[
MOPQ<>%?B?;_#GP?KWC2SU37M)N;7Q):ZI<V5AJ5MJOE6G V7_!/C]O#PS^RK
MXG_X)K>#?BI^S;I_['&NZ?XM^%^D?':]D^)\O[4'A?\ 9P\=Z[J]WX@^&;?#
M!?#<GPO\2>,;;PGKNI_#_3/B+=?$[2;&70Y(=0U'P/<:M%)/. ?M+#\3/!3_
M  PB^,ESK46F?#IO 2?$RX\1:I%/9PZ?X*;P\/%,NM:C!)&;FTBM-"+7UW$\
M1G@2.1&C\Q"M?R__ +'/C#XC?!S]I?\ 9D_X*<_$N]U'2O 7_!9?XM?%KX5?
M$SP_K%P5MOA[:>*;N#5?^"<,+N9/L=S?R> /A_>^"(;A7MHX;'QT7)U*]N$C
MMOV]_;D_97^)_P <OV(M;_8[_9V\5>'/A[:^.-'^'OP;\4>+?&&M:W;WN@?L
M_6M_HNE_$^W\/2:7X8\4MKWC37OASINH^$=,T[6K;2]&U Z]>7&I:YIODHTG
MQW^T=_P08_85\8?L_?$+PA^S-\!_AK\!/V@T\,V][\$OC5IDOBBSUCP3\3O"
ME[I_B'P5K5_K=O>:OJ=OI]WKVC6.G^)]2LM,U/5(]$U#5;FQL;R^$,$@!]'>
M.?VEOVK?BC^UK\8/V9/V/]%_9_T:P_9>\&_##Q%\<OB#^T+9?$/Q!;^(_&?Q
MDTC5O%'@3X5> -$^'?B'PO=>'63PCI"Z]XI^).LW'BZWT4:UI=C9?#[69A(\
MGYA?LI_M4_M#? ?]B+]GN?X/?#'X=WWQ5_:B_P""O7[3G[/6O^"_BIK&N/H'
M@4?$?XD_M6^,M0U"3Q+X2FL[F2;P!XI\$:1=:Q>6^CZPNO\ A?3?$>E:1HMM
MK6LZ/JVD?H';?LU?MY_"KXR>)_VF/@?J/[*6N?%+]ICX*_!#PQ^UI\//BKXF
M^*VF_#S3/CK\%_#-]X6TKXN?![QGX-^'%UXAU[PW=:'K%QH>J?#WQ'X*\"RZ
MU::%H=]#XJ\.W4UQ!:^2_!#_ ()J_M)> ?@1^Q=\._B#\1_A'XO^(7[/W_!2
MWQS^VG\5?%VD7?B[3-'\9^"_%J?M(/,GA73I_!\EQ;>/+^_^,>@7UWX8U(V?
MAO3!!KMK;>-=26PTZ?5P#=\'_M(?\%2O'7Q[_:5_9(T+3?V'(_B?^SCX:^&'
MQ&O?C?J'@SXYP_"[Q;X=^,VB:_>?#OP#!\(X/BU/XOT#Q5=ZIX.\9PZ]XWF^
M*NK:+H^GZ'9W-IX+UB?6A!IN#\'/VK[/]J[XY?\ !&'XZ:U\(O!VD^*_V@OV
M6?VWO'#:M-J_CJZUSX7:GI6B_LWVOBW0O @TWQ=H_@_4O#WC'4I<:A-X_P#!
M?C#7+33-%T$>&]1\+WLGB&;6OO[X1_L[>-O /[:_[9?[2&L:IX6N? _[1'P]
M_9,\)^"M*TV]U:;Q7I>H_ ?3OC79^+Y_%-C=:)9Z1966HR_$?0V\-R:3KNMS
MWB6NJG4[;1V@LUOOC+]DW_@G9\:_@1_PZH_X2_Q1\+=1_P"&&?V>OVJ/A-\6
MO^$;UOQ9>?\ "0^(_CC_ ,*E_P"$3O?AU_:?@C1_[6T33_\ A ]7_P"$BN?$
MO_"(WUI]ITW^S=-U;SKK[& ?/7AG_@I)_P %"I/V+_#/_!1/Q7\-_P!DY?@!
MIWCC1M!\<?"#1+'XJP?&GQ1X'_X7K;_ OQ)\0O!?C34/']SX$\(:C;ZQ+<Z_
MHG@'Q!X;\7M>^&[#[9<^,[?6+^#PY#Z?\4?VJ;W]E[XJ_P#!:#XT^!_@AX7\
M2>-?@?X<_8@U6XO]-N/B7=:KX^/BKX;/I4/B+XFV2^)?%&DV7A'X0Z5JMWKV
MJ2?"[P/X2U)_ NBZ[<ZU'XCUV.UU.'N?^'=WQK_X=#_\,!_\)1\+?^%Q?]#+
M_;?BS_A6G_)SG_"Z?^0S_P (3_PE/_(K?Z!_R)O_ "'_ /1?^0=_Q-:]?U_]
MD[]J/2/BO_P43^+_ ,#/C)\/?A/X[_:=M?V6KOX"^++_ $"3Q\/#.K? ?P5)
MX?\ %VE?%+P?K_AI-'C\/^.&:X\/07GAG5-=UK3]"U>Z\06;:7K^FV-G* >%
M_!_]KC]JW]H/P5\<+'P-\7OV!?CSX2E_9^\2>,/ G[2G[-.I^(Y/#OPP^)%K
M=+:O\,/C!\!]6^/6O_%>>\U/PS/?Z]X<\9:)XK\(P6>HZ2=.UW0M-FNK7=\G
M_LB?M.?MU?#+]C#_ ()'_"KP9=_LZ_$3XA_MF6&O^&_"/BOQWX/^*T=MX&^'
MGA?]GQ/BI8>(_B.]M\7+K5OB)X_T2\T#QOKWC74M)O?".G>/[&31]#TK3O V
MIF_\3S?7?PA_X)[_ !EU;]K)_P!JCXQ^"?V/?V<M3T[X"_%3X*W7A[]C6#QC
MJUU\:-1^*K>'DN?&WQJ\1>*_AW\)!?6O@N'0/.\&>$5T3Q)?6NHW\MW>>.IX
M;:ULXZ/[,W[ W[4_PZL/^"7VA_%?5_V?VT__ ()V^+?C5X?N]3^'OB[XBZI>
M?$CX2^)_V6_%/P4^'7B.WTGQ)\--"@T7XBW'BWQ3+=^-?"$FL7'AK1O#MA'J
M.A^-?$6IW3:#; 'J_P 7?C/_ ,%!O ^K_P!A:CXQ_P""?'P"\-^$?ASX1O\
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M'618WOB*ZU+4O&>J265M$X!\1_#;_@I)_P %"[[]C#]G7_@HC\2OAQ^R9%\
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M"0Q^88XT1F(10,3_ (4)\)O^A4_\KOB7_P"7-=!_PAOB/_HK/Q _\%OPK_\
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M /.TH_X0WQ'_ -%9^('_ (+?A7_\[2@#T"BO/_\ A#?$?_16?B!_X+?A7_\
M.TH_X0WQ'_T5GX@?^"WX5_\ SM* /0**\_\ ^$-\1_\ 16?B!_X+?A7_ /.T
MH_X0WQ'_ -%9^('_ (+?A7_\[2@#T"BO/_\ A#?$?_16?B!_X+?A7_\ .TH_
MX0WQ'_T5GX@?^"WX5_\ SM* /0**\_\ ^$-\1_\ 16?B!_X+?A7_ /.TH_X0
MWQ'_ -%9^('_ (+?A7_\[2@#T"BO/_\ A#?$?_16?B!_X+?A7_\ .TH_X0WQ
M'_T5GX@?^"WX5_\ SM* /0**\_\ ^$-\1_\ 16?B!_X+?A7_ /.TH_X0WQ'_
M -%9^('_ (+?A7_\[2@#T"BO/_\ A#?$?_16?B!_X+?A7_\ .TH_X0WQ'_T5
MGX@?^"WX5_\ SM* /0**\_\ ^$-\1_\ 16?B!_X+?A7_ /.TH_X0WQ'_ -%9
M^('_ (+?A7_\[2@#T"BO/_\ A#?$?_16?B!_X+?A7_\ .TH_X0WQ'_T5GX@?
M^"WX5_\ SM* /0**\_\ ^$-\1_\ 16?B!_X+?A7_ /.TH_X0WQ'_ -%9^('_
M (+?A7_\[2@#T"BO/_\ A#?$?_16?B!_X+?A7_\ .TH_X0WQ'_T5GX@?^"WX
M5_\ SM* /0**\_\ ^$-\1_\ 16?B!_X+?A7_ /.TH_X0WQ'_ -%9^('_ (+?
MA7_\[2@#T"BO/_\ A#?$?_16?B!_X+?A7_\ .TH_X0WQ'_T5GX@?^"WX5_\
MSM* /0**\_\ ^$-\1_\ 16?B!_X+?A7_ /.TH_X0WQ'_ -%9^('_ (+?A7_\
M[2@#T"BO/_\ A#?$?_16?B!_X+?A7_\ .TH_X0WQ'_T5GX@?^"WX5_\ SM*
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M/Q _\%OPK_\ G:4?\(;XC_Z*S\0/_!;\*_\ YVE KM[NYZ!17G__  AOB/\
MZ*S\0/\ P6_"O_YVE'_"&^(_^BL_$#_P6_"O_P"=I0!Z!17G_P#PAOB/_HK/
MQ _\%OPK_P#G:4?\(;XC_P"BL_$#_P %OPK_ /G:4 >@45Y__P (;XC_ .BL
M_$#_ ,%OPK_^=I1_PAOB/_HK/Q _\%OPK_\ G:4 >@45Y_\ \(;XC_Z*S\0/
M_!;\*_\ YVE'_"&^(_\ HK/Q _\ !;\*_P#YVE 'H%%>?_\ "&^(_P#HK/Q
M_P#!;\*__G:4?\(;XC_Z*S\0/_!;\*__ )VE 'H%%>?_ /"&^(_^BL_$#_P6
M_"O_ .=I1_PAOB/_ **S\0/_  6_"O\ ^=I0!Z!17G__  AOB/\ Z*S\0/\
MP6_"O_YVE'_"&^(_^BL_$#_P6_"O_P"=I0!Z!17G_P#PAOB/_HK/Q _\%OPK
M_P#G:4?\(;XC_P"BL_$#_P %OPK_ /G:4 >@45Y__P (;XC_ .BL_$#_ ,%O
MPK_^=I1_PAOB/_HK/Q _\%OPK_\ G:4 >@45Y_\ \(;XC_Z*S\0/_!;\*_\
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M )VE 'H%%>?_ /"&^(_^BL_$#_P6_"O_ .=I1_PAOB/_ **S\0/_  6_"O\
M^=I0!Z!17G__  AOB/\ Z*S\0/\ P6_"O_YVE'_"&^(_^BL_$#_P6_"O_P"=
MI0!Z!17G_P#PAOB/_HK/Q _\%OPK_P#G:4?\(;XC_P"BL_$#_P %OPK_ /G:
M4 >@45Y__P (;XC_ .BL_$#_ ,%OPK_^=I1_PAOB/_HK/Q _\%OPK_\ G:4
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M_P (;XC_ .BL_$#_ ,%OPK_^=I1_PAOB/_HK/Q _\%OPK_\ G:4 >@45Y_\
M\(;XC_Z*S\0/_!;\*_\ YVE'_"&^(_\ HK/Q _\ !;\*_P#YVE 'H%%>?_\
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M'?\ HE?[5O\ X0_PA_\ GYUV_P!AYM_T 5_NC_\ )'-_:F7_ /052^]_Y']
M]%?S\?\ $2'^P[_T2O\ :M_\(?X0_P#S\Z/^(D/]AW_HE?[5O_A#_"'_ .?G
M1_8>;?\ 0!7^Z/\ \D']J9?_ -!5+[W_ )'] ]%?S\?\1(?[#O\ T2O]JW_P
MA_A#_P#/SH_XB0_V'?\ HE?[5O\ X0_PA_\ GYT?V'FW_0!7^Z/_ ,D']J9?
M_P!!5+[W_D?T#T5_/Q_Q$A_L._\ 1*_VK?\ PA_A#_\ /SH_XB0_V'?^B5_M
M6_\ A#_"'_Y^=']AYM_T 5_NC_\ )!_:F7_]!5+[W_D?T#T5_/Q_Q$A_L._]
M$K_:M_\ "'^$/_S\Z/\ B)#_ &'?^B5_M6_^$/\ "'_Y^=']AYM_T 5_NC_\
MD']J9?\ ]!5+[W_D?T#T5_/Q_P 1(?[#O_1*_P!JW_PA_A#_ //SH_XB0_V'
M?^B5_M6_^$/\(?\ Y^=']AYM_P! %?[H_P#R0?VIE_\ T%4OO?\ D?T#T5_/
MQ_Q$A_L._P#1*_VK?_"'^$/_ ,_.C_B)#_8=_P"B5_M6_P#A#_"'_P"?G1_8
M>;?] %?[H_\ R0?VIE__ $%4OO?^1_0/17\_'_$2'^P[_P!$K_:M_P#"'^$/
M_P _.C_B)#_8=_Z)7^U;_P"$/\(?_GYT?V'FW_0!7^Z/_P D']J9?_T%4OO?
M^1_0/17\_'_$2'^P[_T2O]JW_P (?X0__/SH_P"(D/\ 8=_Z)7^U;_X0_P (
M?_GYT?V'FW_0!7^Z/_R0?VIE_P#T%4OO?^1_0/17\_'_ !$A_L._]$K_ &K?
M_"'^$/\ \_.C_B)#_8=_Z)7^U;_X0_PA_P#GYT?V'FW_ $ 5_NC_ /)!_:F7
M_P#052^]_P"1_0/17\_'_$2'^P[_ -$K_:M_\(?X0_\ S\Z/^(D/]AW_ *)7
M^U;_ .$/\(?_ )^=']AYM_T 5_NC_P#)!_:F7_\ 052^]_Y'] ]%?S\?\1(?
M[#O_ $2O]JW_ ,(?X0__ #\Z/^(D/]AW_HE?[5O_ (0_PA_^?G1_8>;?] %?
M[H__ "0?VIE__052^]_Y'] ]%?S\?\1(?[#O_1*_VK?_  A_A#_\_.C_ (B0
M_P!AW_HE?[5O_A#_  A_^?G1_8>;?] %?[H__)!_:F7_ /052^]_Y'] ]%?S
M\?\ $2'^P[_T2O\ :M_\(?X0_P#S\Z/^(D/]AW_HE?[5O_A#_"'_ .?G1_8>
M;?\ 0!7^Z/\ \D']J9?_ -!5+[W_ )'] ]%?S\?\1(?[#O\ T2O]JW_PA_A#
M_P#/SH_XB0_V'?\ HE?[5O\ X0_PA_\ GYT?V'FW_0!7^Z/_ ,D']J9?_P!!
M5+[W_D?T#T5_/Q_Q$A_L._\ 1*_VK?\ PA_A#_\ /SH_XB0_V'?^B5_M6_\
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MW_HE?[5O_A#_  A_^?G1_8>;?] %?[H__)!_:F7_ /052^]_Y'] ]%?S\?\
M$2'^P[_T2O\ :M_\(?X0_P#S\Z/^(D/]AW_HE?[5O_A#_"'_ .?G1_8>;?\
M0!7^Z/\ \D']J9?_ -!5+[W_ )'] ]%?S\?\1(?[#O\ T2O]JW_PA_A#_P#/
MSH_XB0_V'?\ HE?[5O\ X0_PA_\ GYT?V'FW_0!7^Z/_ ,D']J9?_P!!5+[W
M_D?T#T5_/Q_Q$A_L._\ 1*_VK?\ PA_A#_\ /SH_XB0_V'?^B5_M6_\ A#_"
M'_Y^=']AYM_T 5_NC_\ )!_:F7_]!5+[W_D?T#T5_/Q_Q$A_L._]$K_:M_\
M"'^$/_S\Z/\ B)#_ &'?^B5_M6_^$/\ "'_Y^=']AYM_T 5_NC_\D']J9?\
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MFW_0!7^Z/_R0?VIE_P#T%4OO?^1_0/17\_'_ !$A_L._]$K_ &K?_"'^$/\
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M*_VK?_"'^$/_ ,_.C_B)#_8=_P"B5_M6_P#A#_"'_P"?G1_8>;?] %?[H_\
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M2O\ :M_\(?X0_P#S\Z/^(D/]AW_HE?[5O_A#_"'_ .?G1_8>;?\ 0!7^Z/\
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M?T#T5_/Q_P 1(?[#O_1*_P!JW_PA_A#_ //SH_XB0_V'?^B5_M6_^$/\(?\
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M  A_^?G1_8>;?] %?[H__)!_:F7_ /052^]_Y'] ]%?S\?\ $2'^P[_T2O\
M:M_\(?X0_P#S\Z/^(D/]AW_HE?[5O_A#_"'_ .?G1_8>;?\ 0!7^Z/\ \D']
MJ9?_ -!5+[W_ )'] ]%?S\?\1(?[#O\ T2O]JW_PA_A#_P#/SH_XB0_V'?\
MHE?[5O\ X0_PA_\ GYT?V'FW_0!7^Z/_ ,D']J9?_P!!5+[W_D?T#T5_/Q_Q
M$A_L._\ 1*_VK?\ PA_A#_\ /SH_XB0_V'?^B5_M6_\ A#_"'_Y^=']AYM_T
M 5_NC_\ )!_:F7_]!5+[W_D?T#T5_/Q_Q$A_L._]$K_:M_\ "'^$/_S\Z/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 9\"^(S%'=>'K'5-/'C;QNUU8^)K:/519:N+FSMK:_TMM-ND2YU'2_M?J?\
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M1HR6K<I0A&4EQX/!_6O:N56-&G1C!RD^2]ZDU"*7M*M&&[U<JD>BBI2DHO\
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M1QU[X1-X4TOQ+XX\/?!GP5K?B36_!WA[Q/K*>!+SP7\.+KQ/X.TB]UVPO9M
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MQ$U#5M9UG5M0^(GP^L/"FD^%+#X?7%]J.HWUQ>V;6=[-<W,VFPZ:[W7Z ?\
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MKL<./_P4@T/]I3XV_L9>//&'ASXY_L@_\%!O@3X!\7?\)#J_QT\*^"]&\/\
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MUIJVH17$]CH\-Y(9-1UJ\@M5:YGM='TR&\U.>"';)-%:M&KQEO,7^DOXI_M
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M_P (S\*-<^)W_"2?\(1_PGWVW^Q?%_@7PK_8?]C_ /"7^"_LWVG_ (33[?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?U:?\ !L9_S>Y_W;9_[WVOY2Z_JT_X-C/^;W/^[;/_ 'OM>'Q)_P B
M7&_]RW_J70/4R7_D9X;_ +C?^H]4_JTHHHK\K/O K_/Q_P""WG_*4#]IS_NB
M_P#ZSU\)Z_T#J_/SXW_\$LOV#_VCOBAXG^,_QF^!7_"9?$KQE_8O_"2>)/\
MA9WQC\/?VE_PCWA[2?"FC_\ $G\*?$+0] L_L>@:'I=A_H&EVOVC[+]JNO/O
M9[FYF]K(LRH97BZF(Q$*LX3PTZ*5&,)2YI5:,TVIU*:Y;4Y)M2;NUI:[7F9K
M@JN.P\*-&5.,HUHU&ZCDH\JA4BTG&$W>\UTM:^NR?^<U17^@=_PY$_X)?_\
M1L?_ )FC]H3_ .>Q1_PY$_X)?_\ 1L?_ )FC]H3_ .>Q7UG^M^6_\^,=_P""
ML/\ _-)X'^KN-_Y^X7_P.K_\H/\ /QHK_0._X<B?\$O_ /HV/_S-'[0G_P ]
MBC_AR)_P2_\ ^C8__,T?M"?_ #V*/];\M_Y\8[_P5A__ )I#_5W&_P#/W"_^
M!U?_ )0?Y^-%?Z!W_#D3_@E__P!&Q_\ F:/VA/\ Y[%'_#D3_@E__P!&Q_\
MF:/VA/\ Y[%'^M^6_P#/C'?^"L/_ /-(?ZNXW_G[A?\ P.K_ /*#_/QHK_0.
M_P"'(G_!+_\ Z-C_ /,T?M"?_/8H_P"'(G_!+_\ Z-C_ /,T?M"?_/8H_P!;
M\M_Y\8[_ ,%8?_YI#_5W&_\ /W"_^!U?_E!_GXT5_H'?\.1/^"7_ /T;'_YF
MC]H3_P">Q1_PY$_X)?\ _1L?_F:/VA/_ )[%'^M^6_\ /C'?^"L/_P#-(?ZN
MXW_G[A?_  .K_P#*#_/QHK_0._X<B?\ !+__ *-C_P#,T?M"?_/8H_X<B?\
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M_P#T;'_YFC]H3_Y[%'_#D3_@E_\ ]&Q_^9H_:$_^>Q1_K?EO_/C'?^"L/_\
M-(?ZNXW_ )^X7_P.K_\ *#_/QHK_ $#O^'(G_!+_ /Z-C_\ ,T?M"?\ SV*/
M^'(G_!+_ /Z-C_\ ,T?M"?\ SV*/];\M_P"?&._\%8?_ .:0_P!7<;_S]PO_
M ('5_P#E!_GXT5_H'?\ #D3_ ()?_P#1L?\ YFC]H3_Y[%'_  Y$_P""7_\
MT;'_ .9H_:$_^>Q1_K?EO_/C'?\ @K#_ /S2'^KN-_Y^X7_P.K_\H/\ /QHK
M_0._X<B?\$O_ /HV/_S-'[0G_P ]BC_AR)_P2_\ ^C8__,T?M"?_ #V*/];\
MM_Y\8[_P5A__ )I#_5W&_P#/W"_^!U?_ )0?Y^-%?Z!W_#D3_@E__P!&Q_\
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M4DMKKV%G:[LVKJ[MNS^0ZW_X*K?MB1?M9VG[9-WXRT'5/BA9>&[OP+;Z%?\
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M(KXZM#>>)+*X\1>((9%CUMY->>QT=-'TV\UUHM6U"SO+ZST^:T_KT_X<B?\
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MGMM>>X\2^(\6^HW5GITFL/I*Z7>ZQ!IT&F:G>7>CSZAIU[_6[_PY$_X)?_\
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MV\>L:/KESJP_MG6$N;R#7K;^UHM4NX=;CU.%HDB_LO\ ^'(G_!+_ /Z-C_\
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M+=^"KG1?%?A^PT[5C8?$C7)C/KNF>([,WEII,@L1#!>6]]_:7_PY$_X)?_\
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M_P#1L?\ YFC]H3_Y[%'_  Y$_P""7_\ T;'_ .9H_:$_^>Q1_K?EO_/C'?\
M@K#_ /S2'^KN-_Y^X7_P.K_\H/\ /QHK_0._X<B?\$O_ /HV/_S-'[0G_P ]
MBC_AR)_P2_\ ^C8__,T?M"?_ #V*/];\M_Y\8[_P5A__ )I#_5W&_P#/W"_^
M!U?_ )0?Y^-%?Z!W_#D3_@E__P!&Q_\ F:/VA/\ Y[%'_#D3_@E__P!&Q_\
MF:/VA/\ Y[%'^M^6_P#/C'?^"L/_ /-(?ZNXW_G[A?\ P.K_ /*#_/QHK_0.
M_P"'(G_!+_\ Z-C_ /,T?M"?_/8H_P"'(G_!+_\ Z-C_ /,T?M"?_/8H_P!;
M\M_Y\8[_ ,%8?_YI#_5W&_\ /W"_^!U?_E!_GXT5_H'?\.1/^"7_ /T;'_YF
MC]H3_P">Q1_PY$_X)?\ _1L?_F:/VA/_ )[%'^M^6_\ /C'?^"L/_P#-(?ZN
MXW_G[A?_  .K_P#*#_/QHK_0._X<B?\ !+__ *-C_P#,T?M"?_/8H_X<B?\
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M_P#T;'_YFC]H3_Y[%'_#D3_@E_\ ]&Q_^9H_:$_^>Q1_K?EO_/C'?^"L/_\
M-(?ZNXW_ )^X7_P.K_\ *#_/QHK_ $#O^'(G_!+_ /Z-C_\ ,T?M"?\ SV*/
M^'(G_!+_ /Z-C_\ ,T?M"?\ SV*/];\M_P"?&._\%8?_ .:0_P!7<;_S]PO_
M ('5_P#E!_GXT5_H'?\ #D3_ ()?_P#1L?\ YFC]H3_Y[%'_  Y$_P""7_\
MT;'_ .9H_:$_^>Q1_K?EO_/C'?\ @K#_ /S2'^KN-_Y^X7_P.K_\H/\ /QK^
MK3_@V,_YO<_[ML_][[7ZM?\ #D3_ ()?_P#1L?\ YFC]H3_Y[%?5O[,7[$/[
M+_[&W_";_P##-WPQ_P"%<?\ "Q_^$:_X3/\ XK3XA>+_ .V?^$0_M_\ X1W_
M )'SQ9XH_L[^SO\ A*-=_P"05]A^U_;O].^T_9K/[/YV;\1X''Y?B,)1I8N-
M2K[+EE5A1C!>SKTJKYG&O.2O&#2M%ZM7LKM=F7Y-BL)C*.(J5,/*%/VG,H3J
M.3YZ4X*RE2BMY)N\EI?=Z'U;1117Q1],%%%?!GQT_;GTGX'_ !(UCX=W_P .
MM1\03:5:Z1=KJMIXCMK&.XCU73+74 K6DVD3M \#3O 0+B99%C68,AD,,?9@
M<OQN9XA87 8>IBL0X2FJ5))S<(*\I6;2M%/74\C/,_R;AO 2S3/<PP^69?"K
M3HRQ6)E*-)5:S<:4&XQD^:;32TZ'WG17Y7?\/0O#G_1(-;_\*ZP_^4='_#T+
MPY_T2#6__"NL/_E'7M_ZF<4_]"3&_P#@,/\ Y,^+_P"(Q^&'_1:9-_X-K?\
MRD_5&BORN_X>A>'/^B0:W_X5UA_\HZ/^'H7AS_HD&M_^%=8?_*.C_4SBG_H2
M8W_P&'_R8?\ $8_##_HM,F_\&UO_ )2?JC17Y7?\/0O#G_1(-;_\*ZP_^4='
M_#T+PY_T2#6__"NL/_E'1_J9Q3_T),;_ . P_P#DP_XC'X8?]%IDW_@VM_\
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MO_!M;_Y2?JC17Y7?\/0O#G_1(-;_ /"NL/\ Y1T?\/0O#G_1(-;_ /"NL/\
MY1T?ZF<4_P#0DQO_ (##_P"3#_B,?AA_T6F3?^#:W_RD_5&BORN_X>A>'/\
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MT2#6_P#PKK#_ .4='_#T+PY_T2#6_P#PKK#_ .4='^IG%/\ T),;_P" P_\
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M"?\ HH\N_P# ZG_RL_H(HK^??_B(/^!G_1 _BQ_X.O!__P FT?\ $0?\#/\
MH@?Q8_\ !UX/_P#DVC_B%7B)_P!$EFW_ (+I?_+?/\^S#_B(?!/_ $4>7?\
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M_*S^@BBOY]_^(@_X&?\ 1 _BQ_X.O!__ ,FT?\1!_P #/^B!_%C_ ,'7@_\
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MQ8_\'7@__P"3:/\ B%7B)_T26;?^"Z7_ ,M\_P ^S#_B(?!/_11Y=_X'4_\
ME9_0117\^_\ Q$'_  ,_Z('\6/\ P=>#_P#Y-H_XB#_@9_T0/XL?^#KP?_\
M)M'_ !"KQ$_Z)+-O_!=+_P"6^?Y]F'_$0^"?^BCR[_P.I_\ *S^@BBOY]_\
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MB?\ 1)9M_P""Z7_RWS_/LP_XB'P3_P!%'EW_ ('4_P#E9_0117\^_P#Q$'_
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M8?$+_P"9FC_B(3_X)M_]%%\9_P#AL/B%_P#,S1_Q!/QE_P"C3>)7_B#\3?\
MSL\_S[,/^(4^*'_1N>.O_$3S[_Y@/W!HK\/O^(A/_@FW_P!%%\9_^&P^(7_S
M,T?\1"?_  3;_P"BB^,__#8?$+_YF:/^()^,O_1IO$K_ ,0?B;_YV>?Y]F'_
M !"GQ0_Z-SQU_P"(GGW_ ,P'[@T5^'W_ !$)_P#!-O\ Z*+XS_\ #8?$+_YF
M:/\ B(3_ .";?_11?&?_ (;#XA?_ #,T?\03\9?^C3>)7_B#\3?_ #L\_P ^
MS#_B%/BA_P!&YXZ_\1//O_F _<&BOP^_XB$_^";?_11?&?\ X;#XA?\ S,T?
M\1"?_!-O_HHOC/\ \-A\0O\ YF:/^()^,O\ T:;Q*_\ $'XF_P#G9Y_GV8?\
M0I\4/^C<\=?^(GGW_P P'[@T5^'W_$0G_P $V_\ HHOC/_PV'Q"_^9FC_B(3
M_P"";?\ T47QG_X;#XA?_,S1_P 03\9?^C3>)7_B#\3?_.SS_/LP_P"(4^*'
M_1N>.O\ Q$\^_P#F _<&BOP^_P"(A/\ X)M_]%%\9_\ AL/B%_\ ,S1_Q$)_
M\$V_^BB^,_\ PV'Q"_\ F9H_X@GXR_\ 1IO$K_Q!^)O_ )V>?Y]F'_$*?%#_
M *-SQU_XB>??_,!^X-%?A]_Q$)_\$V_^BB^,_P#PV'Q"_P#F9H_XB$_^";?_
M $47QG_X;#XA?_,S1_Q!/QE_Z--XE?\ B#\3?_.SS_/LP_XA3XH?]&YXZ_\
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M1_Q$)_\ !-O_ **+XS_\-A\0O_F9H_X@GXR_]&F\2O\ Q!^)O_G9Y_GV8?\
M$*?%#_HW/'7_ (B>??\ S ?N#17X??\ $0G_ ,$V_P#HHOC/_P -A\0O_F9H
M_P"(A/\ X)M_]%%\9_\ AL/B%_\ ,S1_Q!/QE_Z--XE?^(/Q-_\ .SS_ #[,
M/^(4^*'_ $;GCK_Q$\^_^8#]P:*_#[_B(3_X)M_]%%\9_P#AL/B%_P#,S7Z
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M.%)XBE1Q%6&'E2PN*<\'B9TL72JT8>+T445[!\B%%%% !1110 4444 %%%%
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MV7_"GP8_9 _X)O:U_P %!?B'^SY\+?VF/C)\7OV@3^SQ\$/"?QRT6/QY\&?
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M+]G_ /;/^"/[ G[8G@RQ^ '[ 5]^TW\1/&?P6_:-"WUKX%_9N\*ZQ\-=+\4
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MCDJ*ZW_A ?'?_0E>+?\ PG-8_P#D.C_A ?'?_0E>+?\ PG-8_P#D.CZSAO\
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M$VGC+6_&%WX*CMH[9K>WM?&NL1VFNZK<07L#WT.I74<%W#)*J1E1!&U9'_"
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M )A[.G_S[A_X#'_(_:G^WM._Z -I^<'_ ,B4?V]IW_0!M/S@_P#D2OPYN/\
M@NE^R!!^RQIW[2J?#[]J>\\8:I^T==?LA6G[&5A\$)[K]MO_ (:9TZ[,NK?!
MFY^"L?B/^R[+Q=I'A(?\)[J/VSQQ!I$.ARV?AQ-4E^)NIZ7X O>RT3_@L/\
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M6*^3\Z11,[1G%JO$@&TYR,'E6'!J_P!O:=_T ;3\X/\ Y$K'TW_677_8.O\
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M^1*/[>T[_H VGYP?_(E<M11SS_FE_P"!/_,/9T_^?</_  &/^1U/]O:=_P!
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M*"O*O%6HOIGQ*\$SI$LI?P-\28=K,5 #:_\ "M]V0"<@Q@8]_:O5:\8\>_\
M)0_ W_8F?$?_ -/GPOH Z[_A+I_^?*+_ +^O_P#$T?\ "73_ //E%_W]?_XF
MN0HH Z__ (2Z?_GRB_[^O_\ $T?\)=/_ ,^47_?U_P#XFN0K^9+_ (+U?M^?
M'#]C_P#:+_8 ^'/@S]OW_AW=\$OCCX?_ &H+_P"-/QP_X96\(_M;_8+_ .&^
MD?#.]^',7_"M-5\&^)O%MU_:6NZ]=^%O,\)WVD0V?_"3?VWKJ7UGHT:0@']3
MG_"73_\ /E%_W]?_ .)H_P"$NG_Y\HO^_K__ !-?QZ?L(?\ !:/XS:/^R5_P
M5>_:"\??M ^!_P#@J'\,?V$=7^#6O?!/XT:;X$\,_L6_$?XS:5\2O"T#^-/#
M7B_X*:3X7U37OA/X/\'>)[<Z9X \<^)_AA=2?$/5[3XB0:5K?B"U\-2V/A+]
M8_B+_P %;_ _P?\ VE/%GP6^)?PIU/2/A_X _P""3FH?\%4O&/Q3T3QA'KNM
MVOA[1_B<WP]U/X-:)\.)O"ND0ZSK+6T;ZOI/C"?QYI4&HZ@]MH,WA?3XIGUN
M$ _:C_A+I_\ GRB_[^O_ /$T?\)=/_SY1?\ ?U__ (FOP$_9[_X+!?&3Q#X$
M^*_Q@_;0_P"";?Q]_8S^"7A+]DFY_;4^%_Q<LO&>A_M"^"_B?\(M+TV?7M0\
M+^(]9\)^%_!^D?!CXZZEX=NO#VL>#_@MX]U1?%>LPW'B6+7_ /A#W\/:<?$_
M<?L8?\%+OVM?VDIO$J_&'_@E/^T#^SS9^(/V:[3]IW]F#7M-^*'@/XN^#OV@
M?#E_;27FD?#+Q%X__LCX<> /V=OCGXJM-2\)W7A/X9_&#Q3IE\UM?^)[OQK?
M>!;/PM:W'B0 _</_ (2Z?_GRB_[^O_\ $T?\)=/_ ,^47_?U_P#XFOY<O!__
M  7"^-7Q=B_X*/\ [-GCO]F'P[^QW^UW^RI^P'^T/^U-X/N/ 7[6G[/W[;NB
M>'M>^$UOKW@O5]#^(=U\,M"?PG\//B?X"^(MSX1NV^%7C>TU[6;[3I-0N?&/
MASP_I)T%/%_[(_\ !.?XL>/_ (\?L"_L8?&OXK:__P )5\3?BQ^S#\$OB'\0
M/$W]E:+H?]O^,?%_P\T#7?$6L?V-X;TW1_#^E?VAJM[=77]GZ+I6FZ7:>;Y%
MC96ULD<* 'WY_P )=/\ \^47_?U__B:/^$NG_P"?*+_OZ_\ \37(44 =?_PE
MT_\ SY1?]_7_ /B:LWGB:6UNI[=;2-Q#(4#&1@6 [D!<"N'K1U?_ )"=[_UW
M?^E &]_PET__ #Y1?]_7_P#B:/\ A+I_^?*+_OZ__P 37(44 =?_ ,)=/_SY
M1?\ ?U__ (FC_A+I_P#GRB_[^O\ _$UR%% '7_\ "73_ //E%_W]?_XFC_A+
MI_\ GRB_[^O_ /$UR%% '7_\)=/_ ,^47_?U_P#XFC_A+I_^?*+_ +^O_P#$
MUR%% '7_ /"73_\ /E%_W]?_ .)H_P"$NG_Y\HO^_K__ !-<A10!U_\ PET_
M_/E%_P!_7_\ B:/^$NG_ .?*+_OZ_P#\37(44 =?_P )=/\ \^47_?U__B:/
M^$NG_P"?*+_OZ_\ \37(44 =?_PET_\ SY1?]_7_ /B:/^$NG_Y\HO\ OZ__
M ,37(44 =?\ \)=/_P ^47_?U_\ XFC_ (2Z?_GRB_[^O_\ $UR%% '7_P#"
M73_\^47_ ']?_P")H_X2Z?\ Y\HO^_K_ /Q-<A10!U__  ET_P#SY1?]_7_^
M)H_X2Z?_ )\HO^_K_P#Q-<A10!U__"73_P#/E%_W]?\ ^)H_X2Z?_GRB_P"_
MK_\ Q-<A10!U_P#PET__ #Y1?]_7_P#B:/\ A+I_^?*+_OZ__P 37(44 =?_
M ,)=/_SY1?\ ?U__ (FC_A+I_P#GRB_[^O\ _$UR%% '7_\ "73_ //E%_W]
M?_XFC_A+I_\ GRB_[^O_ /$UR%% '7_\)=/_ ,^47_?U_P#XFLKX=7;7^K?%
M*[9!&TOQ LLHI+ >7\,?AO&,$@$Y"9Z=3BL6KWPK_P"/OXF_]E M?_5:_#J@
M#UJBBB@ KQ_XN:=H>K2_#73_ !)HFF>(]%N/B!<?;=&UFPL]3TV\\KX<?$.>
MV^TV-_#<6D_V>[C@NH?-A?RIX(IH]LL:,OL%>2_%3_C[^&7_ &4"Z_\ 5:_$
M6JA.=.<*E.<J=2G*,X3A)QG"<6I1G"46I1E&23C)---)IIHJ,I0E&<)2A.$E
M*$XMQE&46G&49)IQE%I-----)IW.8_X5W\#?^B)?#+_PA/"'_P IJ/\ A7?P
M-_Z(E\,O_"$\(?\ RFK9HKO_ +8S;_H:9C_X6XG_ .6G9_:>9?\ 0PQW_A77
M_P#EGDON,;_A7?P-_P"B)?#+_P (3PA_\IJ/^%=_ W_HB7PR_P#"$\(?_*:M
MFOR"_P""T7[=_P <?^"?W[.?P4^)/[/[?LZ67C?XM_M;_!_]G2\\2_M5GQ?;
M?!'P/X=^)NB>/KF^\<>-=9\%>,/!FK^&M%\+WWAK2]2U[Q-+?:E8Z)X8BUZ\
MFT._F2W: _MC-O\ H:9C_P"%N)_^6A_:>9?]##'?^%=?_P"6>2^X_63_ (5W
M\#?^B)?#+_PA/"'_ ,IJ/^%=_ W_ *(E\,O_  A/"'_RFK^=K]@C_@K+^U;\
M1_VG?C9\"OVG]7_X)X_M+_#[X<?LAZK^U2O[07_!*3Q_\0_BM\,OA_=^&/&&
MH^'KOX._%;6_B-XDU;1D^(_CC1K'4O$O@_1K?6/#%SI]AX?6::#Q)I_B2]U+
MP)^@GP[_ ."KW[.WQ,D_X)PQZ#X,^--HW_!3_1_BQK?P".K^'? T \(VGP=\
M$1^/?$T?Q?\ L?Q&OSH%Q?:/(MMH2>"Q\0([K4@8=0ETRUQ>$_MC-O\ H:9C
M_P"%N)_^6A_:>9?]##'?^%=?_P"6>2^X_2'_ (5W\#?^B)?#+_PA/"'_ ,IJ
M/^%=_ W_ *(E\,O_  A/"'_RFK\A?@3_ ,%R/V0?VA?VD_"G[/7@OP)^T_I'
MASXG^-?'_P -?@9^U7XT^"=SX=_9%_:!^(WPTBOIO$_@?X/_ !>;Q!=7?B#7
MHTT7Q&MBNK>$]!T^\N?#M[8)?KJ&H^&[773X$_\ !<C]D']H7]I/PI^SUX+\
M"?M/Z1X<^)_C7Q_\-?@9^U7XT^"=SX=_9%_:!^(WPTBOIO$_@?X/_%YO$%U=
M^(->C31?$:V*ZMX3T'3[RY\.WM@E^NH:CX;M==/[8S;_ *&F8_\ A;B?_EH?
MVGF7_0PQW_A77_\ EGDON/UZ_P"%=_ W_HB7PR_\(3PA_P#*:C_A7?P-_P"B
M)?#+_P (3PA_\IJ_*CX:_P#!8KX,^._VO_"?[&_BS]EW]OG]GKQ7\3O$WQ0\
M)_!+XK_M+_LN:Y\&O@G\=-5^%5E?ZUJW_"L?$7B+Q WC&]@USPKIT_BSP^WB
M;P'X7F71Y=/MO$D'ASQ#JFF:'=^F?\$J?VQ/B9^W+^RM=?'+XLZ%X$\/>+(/
MCG\?OADFG?#O3/$&D^'3H/PK^*/B'P3X>NVM/$OB?Q=J1U>\TK2;:XUFX&KB
MRN-0>>6QL-.MFCM(S^V,V_Z&F8_^%N)_^6A_:>9?]##'?^%=?_Y9Y+[C]"_^
M%=_ W_HB7PR_\(3PA_\ *:C_ (5W\#?^B)?#+_PA/"'_ ,IJV:*/[8S;_H:9
MC_X6XG_Y:']IYE_T,,=_X5U__EGDON,;_A7?P-_Z(E\,O_"$\(?_ "FJ[=?#
MOX+&VTTS_!OX;SQ+:RQV<4G@?PFZ6=N+Z[D>W@5](98HGNY;F[,<01#/<S2E
M3)+([7*T;O\ X\]*_P"O:X_]+[JD\WS5V;S/,&T[J^-Q.CLU=?O='9M771M;
M,7]I9CI_M^-T=U_M5?1VM=?O-';33IH<K_PKOX&_]$2^&7_A">$/_E-1_P *
M[^!O_1$OAE_X0GA#_P"4U;-%/^V,V_Z&F8_^%N)_^6C_ +3S+_H88[_PKK__
M "SR7W&-_P *[^!O_1$OAE_X0GA#_P"4U'_"N_@;_P!$2^&7_A">$/\ Y35L
MT4?VQFW_ $-,Q_\ "W$__+0_M/,O^AACO_"NO_\ +/)?<8W_  KOX&_]$2^&
M7_A">$/_ )34?\*[^!O_ $1+X9?^$)X0_P#E-6S11_;&;?\ 0TS'_P +<3_\
MM#^T\R_Z&&._\*Z__P L\E]QC?\ "N_@;_T1+X9?^$)X0_\ E-1_PKOX&_\
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M_1$OAE_X0GA#_P"4U'_"N_@;_P!$2^&7_A">$/\ Y35LT4?VQFW_ $-,Q_\
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MI\4_^QSTG_U67P\KZ!KY^@_Y'3XI_P#8YZ3_ .JR^'E &S1110 5_*5\<O\
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M/VY]<\/#X'_"F]_9U^*?QK_:[\=_LW>#/VB/BM\ _P!F_5_@E<P?"+PSK?\
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M_M-?#=?B+X(LO$_AZ73O$OBCP#X\\ >/-)M]!^(?PL^)_@35Y_#_ (]^&7Q
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MX'?L_>'-4\$>)=?\%#X>?$WPU\0_#7BC5+.;7_!_BSP9XCT.#1?%.@^*.O\
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M?6 U=_S$L_V??#_B;_@I_P##OX'? +XW?MI^'_ '[&?@OPU^T?\ M;W.N_\
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MY_P4ZUOXS?&C]LN:_P#AK_P40^)/P8^&]O\ #C]O/]M3X*^&/ 7PYTC]G?\
M9I\7:1X=\+_#_P"#OQ[\#?#JR@TWQ/X[\5:U!++X3N9I[G57@OGN["WM+.#]
M9/@+\6=<^,/AWQSKFN>$M*\)MX2^-/QE^%.G?V'XIU+Q?I/B33OA/\0M=\ #
MQ/;ZIJO@SP+=6E[?WV@WUIX@\/II%_9>&?$VGZUH&G>*/%VGZ=;>)-3_ #S^
M$OP3_P""A/[+_P 2OVW]0^$7PC_8T^+?@S]J#]KCQG^TWX+\1?$?]KCXW?"'
MQ/X6MO%/PA^#7PRMO"_BCP'X9_8:^,FE7D^FW?PH?6I[W2OB4L=_;:TNG1I8
MRV1OKD Y3X!?MI_M,Z!\&M?^%MW\.-8_:M_:&^%'[97[0W[(EQ\6?&.H#X)_
M!R?P!\#([GX@V'[0?[4GQB\"?#+XC>&/@I;S_!B_\-:+?OHGPRU>Z^('QKFM
M]$\+>#=)T?6M5U3PEG_!K_@LSX8^*FD>&]87X:_#C7-%TK]N_P $?L+_ !O^
M(WP)_:/T[X\? _P1JWQC\&1:Y\#OC'\+/BMIWPO\(6WQE^''C7QSXB^'/PC\
M3IJF@?"G7O 'CGQ??QW>GZWIOAM[O5N!\?\ _!)+Q\GA+]FF^FT[]FO]M;Q1
MX,_:1_:F_:;_ &KO@M^U;:ZS\._V<_VC_BO^U=X>\2I?_$/2+"T^&G[4-OX*
MUKX!Z[>:+X<^"&A>)/AG\0[>Q^%TNO:')XBT3Q&UCXBKQWXT?LP>(?V>OV2?
M^"M?BG]N?XH?LX?#^;]MSQ9X/^*O[/=O\(M>\2SW7A3]H3P'\#O"I^"GP9^'
MGA7QOX/\/:I\4/B3\.OB?\$O!<WPDD\$V4_BSX\7/AN7Q3:?"'X2WURO@#20
M#]LO@+^TNOQ[^*W[5_@?0O!4VF^"/V8_BYH'P.M?B5-K<MS#\2OB$GPU\)?$
M'XF6>E>'I- L!H^E?#6]\<:'X'GU,:]K;:[XIL?%,*VFDVNBVD^L?GI^W1XX
M_;7\(_M\_P#!.:+3_B?X)^'/['7C/]K?PS\+D^'7P\OO&-U\6OCIXCU7]G']
MHOQUXKUKXX^(KBV\,^'?"OPT\%WW@[0M%\#_  ;\-P?$"R\;:K<WOQ,\=^+]
M/U#1O!G@CPW]E?\ !-WX%^-OV?OV./A%X5^+2*?COXU@\2_'3]HV[W1O)>_M
M$?M ^+-:^,OQI>22$"%TL/B!XUUO1K%8!]G@TO2[&VMRT$$;&;]KK]FGQW\?
M?BA^P?XU\':MX2TW2OV7OVN+?X]^/[?Q+?ZQ9ZAJ_@^+X$_&WX8-IO@^+2]!
MUFVU#Q*=?^).A7BV>M7?A_2SH]IJUP=9%[!9Z??@'QK_ ,%-/!?BWX:>#?VB
M?VG]=_: _;6U#Q);_#N#2OV,_A9^RC_POGP=X&^ _P 2?!_@C6_$3>.?CA'\
M(_$,OP:^(GACQ/\ $"T@\1>/_B'^V_IEE^SEX&^'6BV7@?4["TLKCQ+J/C3]
M8O@YKVM>*OA#\*_%'B/6O"GB3Q#XD^&_@?7M>\1> ]1M-8\#Z]K6L>&-+U#5
M-:\&:OI\UQ8:IX4U2^N)[[P[J-E<3VE]I$]G<VTTL,J.WQQ\;_!W_!1Z'QW\
M<+7X$>*_V9OB5\(/C/X1T+2/A]IWQ^U?Q3\-];_9*\31>%)/"/B[5-"T7X8_
M!/Q^?VI_!WBB]-O\2E\&?$+Q_P#!O7]*\2C7/!]I\1AX.UW1CX)^D/V4_P!G
M_1/V4OV9_@)^S3X;US4?$^B? CX2^ _A5I_B75K>"SU/Q%%X)\.:?H+:]?65
ML\MM8W.L364FHR6-O+-!9-<_989I8X5D8 ]_HHHH **** "BBB@ HHHH *O?
M"O\ X^_B;_V4"U_]5K\.JHU>^%?_ !]_$W_LH%K_ .JU^'5 'K5%%% !7DOQ
M4_X^_AE_V4"Z_P#5:_$6O6J\E^*G_'W\,O\ LH%U_P"JU^(M %&BBB@ K\@O
M^"T7["'QQ_X* _LY_!3X;?L_K^SI>^-_A)^UO\'_ -HN\\-?M5CQ?<_!'QQX
M=^&6B>/K:^\#^-=&\%>#_&>K^)=%\47WB72]-U[PS+8Z;8ZWX8EUZSFURPF>
MW6?]?:* /YCOV0O^".'[4^C?M3ZW^T1^TEX0_P""7W[*6CV'[+OQD_9V\._#
M[_@E7\(/B+\-]!^(US\;H(K#5?%7QOT_QYHWA6UUG_A!;6TM[[PM:6,FH2:E
MJGV%KF;18]#1]5Y']C?_ ()&_P#!3[X4_'?_ ()::A^T5\7_ -B'Q%^SI_P3
M E_:&\+> -)^#L?QMT[XL>,/!'Q>^%NJ>"])\2^*[GQCX0F\,ZMXU&J2:);W
MWAW2KCP?X=\/Z!I]W>0ZUXQUF\VQ_K%^W3_P43\5_LR_%+X._LO_ +-?[+7C
M+]MG]LGXX^'O%OQ \(_ CPO\0_"/P<\.>'/A1X!:./Q7\2?BC\9/'=KJ/A?X
M>:%-=O)H/@UM4TRX@\7^+H/^$3AOM.UG4-%@U7F_V9/^"J_A'Q_^SC^T_P#'
M']LSX+^-?^"?>O?L2>//%'P]_:H\*?%?46\=^!_"&M:+;V6M:,_PO^,/A/P]
M8Z)\=!XH\-:_X/DTC1_ GA]_%NJ^*/%6@>'_  KX;\5:3XP^&'BOXA@'RE^P
M-_P3\_X*J?L6Z_\ !?\ 9:TW]JG]EW3/^":/[.OC[XC>)_"D_@GX=^(M4_;#
M^,W@3Q5XG\3^-=#^#?Q:/Q"\+ZY\*?!GARW\2^,+U]9\9_"_5K;Q_)INB6MI
MI^L12ZW+<:%7_81_X)[_ /!5O]C/5?A!^RIH?[67[+N@?\$V_P!GKQM\3/$?
M@O4O!/PUU_7/VP_BYX+\6^(_%/C/P[\)/BU!\1O"^M_"7PGX<L/%/C&[N-9\
M7?#/5[7QY<:;H5K8V6LQ/KLUQH7MOQR_X+D_LF:'_P $W/VA/^"C_P"R)K.B
M?MB^"OV?/$7P]\*>(/ ECK/B[X(ZS)K_ (\^*GP[^&ZV.N?\)_\ #.]\8^$%
ML[/Q_'XHTN\U'X<7=CXGMM+ELM*NA%-/J=AZ0/\ @K;\#_!'Q>_X*7^#_P!H
MRUTCX ?"'_@FWJ_[-NE^*/C=K/BO5?%T7Q%/[1?P^F\::8EC\/= \!IXAT?5
M])U,6GA;2O#GA^\^(6L^+[R\CN;"VT^4?V<X!^5W[,__  1E_P""CW@[]KC]
MBC]I']J#XT?L9?&;5_V0?C-\9;_7_C5I5C\;KS]KO]I?X4?%3PKXPT71-;^.
M7QG^(FD^*)]6\1?"B35=)T/X4_ O0ET3X8>"?!NH:]IMGX[O+C3M(:Z_8[_@
ME3^QW\3/V&OV5KKX&_%G7? GB'Q9/\<_C]\34U'X=ZGX@U;PZ-!^*GQ1\0^-
MO#UHUWXE\,>$=2&KV>E:M;6^LVXT@V5OJ"3Q6-_J-LL=W)[+^QM^WO\ LB_\
M% _ ?B#XE_L@_&G1?C'X2\*>(CX4\3SV>A>,?!^N>'M<-G#J%O;:UX/^(7AS
MPEXQTVVU"SF\_2-5N]!ATG6A;WZZ3?7LFFZ@MM]?T %%%% !6C=_\>>E?]>U
MQ_Z7W59U:-W_ ,>>E?\ 7M<?^E]U0!^37_!6G]H?QG^SE\)_V9];\+_M%?\
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MXYT[6_ G@"+P]IOPONOAUJFBMXMUA]<N?C#J6O?\2Z]3Y@_9[_X)M_&SP?\
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M(%KNH_"CQUX\\/:OX%UOQ?M>"?\ @IY\'?'&M> -4L_A3\>]'_9Z^+_QBC^
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M</\ G_T[_P "3_\ &Z ,ZBM'^SA_S_Z=_P"!)_\ C=']G#_G_P!._P# D_\
MQN@#.K)O]!T/5;_0]5U31=)U+4_#%]=:GX;U*_TZSO+_ ,/:E>Z5?Z%>ZAH=
MY<0R7&DWUWH>JZIHUU=V$EO<7&E:E?Z=+(]I>7$,G3_V</\ G_T[_P "3_\
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M2)TW]G#_ )_]._\  D__ !NC^SA_S_Z=_P"!)_\ C= &=16C_9P_Y_\ 3O\
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M]\;_  Y93R:9JVI>$=(U.*[T_6-3TW2?'.G6\,TFL_U!?8K;_H*67_?%[_\
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MH_8K;_H*67_?%[_\B4?8K;_H*67_ 'Q>_P#R)0!G45H_8K;_ *"EE_WQ>_\
MR)1]BMO^@I9?]\7O_P B4 9U%:/V*V_Z"EE_WQ>__(E'V*V_Z"EE_P!\7O\
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M\#[;_P".4?V;)_S]:=_X'VW_ ,<H _B"OO\ @D%^W?XU_P""8O\ P50TJ]^
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M"QN9[2[@FMYI(VZO^S9/^?K3O_ ^V_\ CE']FR?\_6G?^!]M_P#'* ."\"^
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MSJ^F2,UK?3>$_&?BC09)XW;3=;U"V,=PX!TM%%% !17RS^UK^U=X8_9%\$>
MO&'B'X=?$[XKZC\4/C5\,_@#X#\!_".+X=-XN\0?$CXMZM-H?@RP2Z^*OQ&^
M%7@;2]-NM4B6UO=6USQIIEK8>?%/.WV<3S0\3\//VW--U_XQ^#_@+\9OV=_V
MA/V3/B5\4=-U[4/@MIWQ[7X#ZWH/QGG\':5J/B'QUX>\"^-?V;OCO^T'X,M?
M&?@SPSILGBO5/!/CG7_!GBO5_"HO_$G@_1_$VC>&?&5[X< /MRBBB@ HK!\5
M>*O"_@7POXD\;^-_$F@^#O!?@[0=8\5>+_%_BK6-/\/>%_"OA?P]I]QJ^O\
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M3US2+&:[>*.ZU*SA9YX]SX>?$:Z^(8N[Z#X>^-O#'A>3P_X&\1^%?&/B:Y\
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M_90+K_U6OQ%KUJO)?BI_Q]_#+_LH%U_ZK7XBT 4:*** "BBB@ HHHH ****
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M>.[L=1TZ^M));6]L;VUEBN;2[MI9;>YMY8YH9'C=6(!>HHHH **** "BBB@
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M4/B-K/["'[&FK?$+5O$]WXVU7QYJ?[+_ ,$;_P 9ZGXSO]5DUV^\7:AXHNO
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MQGPDE\2VGQ._X)[>"]4\4?#/7O!OPM_:M_X+%_#/X/\ A_X0^._BS\5_A_\
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M<:]X?OYO%]GX!U<#5/!=MX@?48?"VH@7VAI87(\VK6K_ +-W[.WB _%]M>^
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M&?@M^V]^S[X$^'_['FNZ99^%_AK\;/VI/"_[3W_"E+GPSKWA8^ /!_[4K?M
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MCN'X8?#WX=ZUXGN++0-+E\5?$626.7P1IOB6^U&#P=_PE&G+=ZWHMQXA@OM
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MUP\TTH!^*MC\2[S2?&7[4?P=^'OB+]HD^"OV@/\ @MQ\:O#'@KX._LDKX/\
M!?QC^/MI\-?V5_!OQ4_:J\ ?#KX[>)OCU^S7I/[.WAJU^/\ X*^)GBGXP_$_
M1/B3IGCC5]8T?QMX)\,7%KXF\:>)-8M/,O#GQ?\ VU_ASX1_X*3?VUK_ ,5O
M >J_\$Q_CW^P?^U_I_P!T[]KWXQ?MBZOI?P@\2_!;2?B)^U5^SWXW_:%^*-G
MX.^)/QN\'Z]\(+[QMXSC\"^.E\2>%O!OQ*^P/X$U?6-*\.^#_$T?]#OB/]@C
M]DKQ'\&_A1\!$^$=OX+^&?P)UZU\5?!>Q^$7C'XA?!#Q7\+/%5M!K=O<>*?
M7Q-^#GBWP+\3O"_B778O$WB8>+O$&D>,+75_&K^)?$<OB^\UN77M6>\\@U3]
MACPE^SQ\.?VA[S]A+X+_  UD^.G[27AG2O"7Q*U3]H;X^?'N7PIX^FL-.\8:
M7:?$GXJ^(-3TGX_^*/B-X_TX>-M9O?$>L:EH]GX[^+\,D6B^-_BM91V.CZKI
M0!F?L#_%#Q'^TQ\5_P!MK]J.S^(FK^*O@#XA^->E_L^?LOZ#9^)=8U+X=KX
M_9HT ^%?B1\3?"VEKJ,WA";4OB7^T#KWQ8L;OQ=H>G1W^N^$_ O@?3=1U.^@
MT*PCM?F?_@JA^SI\&8/CY_P3L_:@D\%Q:C\=K_\ X*/_ +%WPLM_B!K>M^)?
M$%WX;^']EJ/Q,U>;POX$T;7-9U#PU\.M/UW5;@:CXP/@+1?#=SXXO;+2+GQE
M/KLVAZ,]C^FW['7[,?@W]C']ESX%?LL^ +RYU7PO\$/AUH/@>UUV]M8;&^\3
M:E8P&X\1>+=0L;>6>WLM0\6^)+K5O$M_9V\TMO:WFJSV\$CQ1HQ[WXK? _X7
M?&[_ (5M_P +/\,?\)/_ ,*B^+'@[XX?#S_B=>(M%_X1[XH^ ?[1_P"$2\3_
M /%/:MI/]K?V3_:VH?\ $EUS^T_#M_\ :/\ B9Z3>>5!Y8!\P?M._#F3XS^"
M_P!IGX8_LE?&+]FGX+?M)>+/#.C^%?VD?&NL_#30OBE\1++P1X@^&?C+3/ >
MF^-+7P]\0/!6L^!O%<FDZO'JOPL\?_%C1OBMX6\.>&+7Q UC\'O&MAJ>+'8_
MX)J?$7P7\5_^"??[&7CKX<^"];^'/@75/V;OA)8>%? ?B+Q);>--6\(Z-X:\
M':7X7M- G\:V=EI=OXUM].31?L^G>,TT?0V\6::EIXAET'0IM2DTBRV?CO\
ML#_LL_M(>+=2\=?%'P+XJ_X2OQ%X(E^&7CC6/AK\:?CG\"Y?BG\-I7N&7X>?
M&BV^!WQ)^'5E\:_ MJE]JMMI_A'XLVWC+P_IECKWB73].TZUL?$NOV^H_5?A
MOPWX=\&^'= \(>$- T7PIX2\*:+I7AOPOX7\-Z58Z%X=\-^'="L8-+T30- T
M32X+73-'T71],M;;3M*TK3K:VL=/L;:"TM((;>&.-0#:HHHH **** "BBB@
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MJ*T?[2?_ )]-._\  &#_ .)H_M)_^?33O_ &#_XF@#.HK1_M)_\ GTT[_P
M8/\ XFC^TG_Y]-._\ 8/_B: ,ZBM'^TG_P"?33O_  !@_P#B:/[2?_GTT[_P
M!@_^)H SJ*T?[2?_ )]-._\  &#_ .)H_M)_^?33O_ &#_XF@#.HK1_M)_\
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M']J77]VT_P# "Q_^1Z ,ZBM'^U+K^[:?^ %C_P#(]']J77]VT_\  "Q_^1Z
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M.HK1_M2Z_NVG_@!8_P#R/1_:EU_=M/\ P L?_D>@#.HK1_M2Z_NVG_@!8_\
MR/1_:EU_=M/_   L?_D>@#.HK1_M2Z_NVG_@!8__ "/1_:EU_=M/_ "Q_P#D
M>@#.HK1_M2Z_NVG_ ( 6/_R/1_:EU_=M/_ "Q_\ D>@#.HK1_M2Z_NVG_@!8
M_P#R/1_:EU_=M/\ P L?_D>@#.HK1_M2Z_NVG_@!8_\ R/1_:EU_=M/_   L
M?_D>@#.HK1_M2Z_NVG_@!8__ "/1_:EU_=M/_ "Q_P#D>@#.HK1_M2Z_NVG_
M ( 6/_R/1_:EU_=M/_ "Q_\ D>@#.HK1_M2Z_NVG_@!8_P#R/1_:EU_=M/\
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MM'^T%_Z!^G?]^)/_ (]1_:"_] _3O^_$G_QZ@#.HK1_M!?\ H'Z=_P!^)/\
MX]1_:"_] _3O^_$G_P >H SJ*T?[07_H'Z=_WXD_^/4?V@O_ $#]._[\2?\
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M4?V@O_0/T[_OQ)_\>H SJ*T?[07_ *!^G?\ ?B3_ ./4?V@O_0/T[_OQ)_\
M'J ,ZBM'^T%_Z!^G?]^)/_CU']H+_P! _3O^_$G_ ,>H SJ*T?[07_H'Z=_W
MXD_^/4?V@O\ T#]._P"_$G_QZ@#.HK1_M!?^@?IW_?B3_P"/4?V@O_0/T[_O
MQ)_\>H SJ*T?[07_ *!^G?\ ?B3_ ./4?V@O_0/T[_OQ)_\ 'J ,ZBM'^T%_
MZ!^G?]^)/_CU']H+_P! _3O^_$G_ ,>H SJ*T?[07_H'Z=_WXD_^/4?V@O\
MT#]._P"_$G_QZ@#.HK1_M!?^@?IW_?B3_P"/4?V@O_0/T[_OQ)_\>H SJ*T?
M[07_ *!^G?\ ?B3_ ./4?V@O_0/T[_OQ)_\ 'J ,ZBM'^T%_Z!^G?]^)/_CU
M']H+_P! _3O^_$G_ ,>H SJ7P%_R4/QS_P!B9\./_3Y\4*T/[07_ *!^G?\
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MPOY[?[2_9._:3B_:9^'WB;6]4\%77PQ^)OPL^)OC3X&_''X7W.NVOBR+X?\
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MW]W<0VWP\^%U_P",M0\+:1?64-B?&%U8W_CW6+7_ (2+Q5K$\P!^T5%?%?\
MP4F\5>*/ O\ P3J_;Y\;^"/$FO>#O&G@[]BO]J?Q5X0\7^%=8U#P]XH\*^*/
M#WP,\=:OH'B3PWK^D7%GJNAZ]H>JV=IJ>CZQIEW:ZAIFH6MO>V5Q!<P12K^;
M_P :OA'KG[+'_!.^/]O?X"?'+]K*'X[? #X >#OVH-<TOXM_ME_M5_M#_"GX
MSZ'X/\$Z;XW^+GPG^(?PH_:'^,7Q1^'EKX?^*?A-?$VBP>*?!OAOPU\0/AUK
MUWHOBOX?>)-'O-%_L[40#]]**_(3]K7_ (*>^-/V;_#_ ,6?B;IOP"^'6F_
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MXC_^GSX7U[/7C'CW_DH?@;_L3/B/_P"GSX7T )1110 45^:/_!83]LOXG_\
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M6/A_2_"^CWO@<Z_XM'B/QWH6@3>B_LJ_\%2/"'[4>O\ [(SZ?\*]8\"?#?\
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MBM^U?X'T+P5-IO@C]F/XN:!\#K7XE3:W+<P_$KXA)\-?"7Q!^)EGI7AZ30+
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M_!FO_P $U_CK\2/VB?V7K#XB?$;7D^($,'Q.^,G@KX9?&Y/#%KX*/[1WP5\
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M[+?QU^"OPU^*6@7D6@CQYX5NOB%XB\%:U+J_B"7P+?76CZ3X;A\7^)/Z^**
M/PF\2_\ !/#]L'PS^WG^W5\<_@U=?L.^*/V:/VX?V9OA7\,O&/P__:A\)_&'
MXJZ\GC[X%_";7OAOX$\.^)/A]I-YH/@OQ=\'?%R:J;/XFOK'CBYU[4=!O"MC
MH#7NF7?_  E/#_\ !'+_ ():_M4_L)?&O]H7XJ_&?5OV5?@_\.?BSX:L+'1?
MV2OV%?%/[4&N?LX2?$B]\3'7O$WQXU30/VFO$&L7G@;X@+HMCI/P\T?0?AQ%
M:>"5\%1P6-KI6@IHEG;7W]"-% !1110!HZ;_ *RZ_P"P=?\ _I-)6=6CIO\
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M\'WG[*FI7]Q\#O EYXT^%'B>?XI_ W4#;:D_PIU#P_H.CQ?TCT4 ?A9\//\
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MFW7ASPS;/K>I:I$W]2E% !7PA\-_V7_B/X/_ &U/V[?VCKCQ9X=TGPE^T_\
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MUB:RDU&2QMY9H+)KG[+#-+'"LC>_T4 %%%% !1110 4444 %%%% !5[X5_\
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M'X.W.DRZQX5U_P"%O[-/BW6]8\=6O@;WKX9?L8_&_3_C9\);/]G/]DCX[_\
M!-/P5>?$+XPZ[^VAHVD_M=> /B9^PA\3/!/CCP#XE\*:QH_[.7[.OA;XT>+/
M[.\=^)/'LW@7QO\ #WXAO^RI^R5=^'/"NB^*6\7Z7:>(=1TOP=7]%=% '\PW
M[/?_  3;^-G@_P"'G[(?[+GC?]F+XWZMKW[-OQ3^"$OQ _:(^*G_  4=_:2\
M<?L*>(?AU^SIXIL?$WASXD_ G]EWPG^W-8^,++XO:]_PB7@B]^'?PF\<?LP?
M#OX)_"+QI=ZU=7&K>)?"'@/P]H?Q#ZCX1_L!?M;^&/&/[.NJZY\)OL-AX$^(
MG_!=;7?%4_\ PGGPSN?[*TK]LGXC3:]^S==>59^,KB:^_P"%C:2ZW?D:;'>7
M/A#/D>/(?"]R#"/Z4:* /P6\.?L3?M(I^R=_P0G^$VJ> [[2/%?[(GBGX./^
MU!9Z;XW\!1W_ ,+="T+]B#XU_!7Q?>VFKP^);G2?%L^F^./&FB^'DC\!W/B^
M2\.H?VI:6M]H-M?WT'S'\!/^"9_QK\$?"S]F']D7QG^S-\</$^L? /XJ?!N/
MQG^TA\3?^"C/[2/B7]@GQ)\+?@3XXTOQOH?Q*^%7[*'@_P#;JTGQQ8?%_4+7
MPMX4?X?_  =\2?LT>"?@Q\,_BB;G4[CQ1K_@?P=I$'C7^H6B@#R7X4?%[2_B
MS+\4+?3_  SXI\+W/PI^+7BOX0ZU!XH/A64:SJGA>ST74T\3>'+KPAXI\66%
MSX6U_2?$.EZAI0U2[TCQ5I[R76C^+O"WACQ'INI:+:?F!\*X_P!I_P#9=_;!
M_P""COC-OV$_VC?CI\/?VEOCW\)_B9\+?'OP7^(7[$MKHM]X>\+?LO?!GX6Z
MW#J^C_'#]KSX*>-]&U2U\7^#=>M$MKGPD;>XM+>&^M[N6WN86?\ 8/1=!T+P
MW9S:?X=T72=!T^XU;7M>N+'1=.L]+LY]=\5:[J/BCQ1K4UM8PP0RZMXD\2ZQ
MJ_B+7M1=&O-8UW5-1U?4)KC4+ZYN)=:@#^>77OV-OVWO#O@O0/BQJNA_$[Q1
MX@_:&_;Z^(_[6?[<G[,/['_[3]U\#/BF?A;XK^!NH?!CX$_![X:_M(O\3?V9
M$\0R_ :S\(_!/7OBI':_$KX4:+\4O$.B>+%T6ZU'0[30+'4O%OA7_P $W]:\
M*?"K_@LSX;\2?LS>&/\ @GU^SA^T5\(?V?\ QI^S%8:%XW^$-Y;_  ;U+]G'
MX/\ B*#3/%WQ$E^&GC#6[#0_BSX&^)_@CPG\;_B)JMOJ/B3PG>:GKYDTSXR?
M$K6K+Q/XI/\ 4'7G/Q3^#OPC^.?A1_ ?QL^%GPY^,/@>34M-UF3P9\4_!'AG
MX@^%)-8T>?[5I&JOX=\6Z9J^D-J6E7/^D:;?-9FZL9_WUK+%)\U 'Y]_\$?O
M"_Q(G_8YT?\ :+^.6D1:)\?OVW_&OB;]L/XO:7'I]QIPT.\^+,>F0?#3PA#;
M7[S:O;V/@7X'^'?AAX/L[/5YGO[)=&D@FBM7#6L/>_$'X$?$SXC?\%._V;_C
M?KWA2.X_9^_9J_91_:#3P5XK;5_#>8/VF/CMXZ^%GA2[ME\/G57\5O-I?P0\
M&>++>#73H$6BVL'C&_TVTUX76H:KI<_Z&T4 >2:9\8-*U/XY>,/@,/#7BBTU
M_P '_#+P+\59O%-R_A*7PAK&A>/O$GCKPKI^G:8FG^*[[QG::UINI_#_ %EM
M0'B7P;X>T6]MYK=O#&M>(I[+Q!;Z)^>W[0'A7]H/X=_\%,_A)^UGX _99^+?
M[2/PJTK]A3XT_L[>($^#7C3]F;0/%'A_X@^.?C_\#/B5H+7^C_M$?M _ :"\
MT&3PY\-=?%UJ6A:CK$UMJ%QI=JUDR7%S/9_J=;Z#H=IK.J>([31=)M?$.MV.
MDZ9K6O6^G6<.LZOIN@2:I-H6GZIJD<*WU_8Z+-KFM2Z3:7<\MOITFKZI)9QP
MMJ%V9M:@#\&/CO\ LZ?M]?M$P?MJ?M:> /"OB#]F'X\>*?V3O"?[+?[(OP/U
M'XM^"-*^,EIX-\-?%C4?BS\;-<\9_%7X2^*O'OPP^$_Q9_: B>V^''PEUSP'
M\4/%UK\)]-T?PG\0-8\9^&?%.HZYIOA3S_\ 9\_8C\9:#_P4M^!?[2G@S_@G
M[X]_9U^!UI\"OVH?A?\ &[Q_^T+\>?A#\=?VH_B9\1OB1=?#'Q'H'BKXY^*[
M+]HG]I+QG\2_AVVE^'+KP!\,]4U;XW_%#QIHEZ/$OA[6OAW\+_AMIOA+7O%G
M]$]8OB3PWX=\9>'=?\(>+] T7Q7X2\5Z+JOAOQ1X7\2:58Z[X=\2>'==L9]+
MUO0-?T35(+K3-8T76-,NKG3M5TK4;:YL=0L;F>TNX)K>:2-@#\$/^"*7P"\7
M^$?'/[4WBSQAK4/BKP)^R]XHU[_@F3^Q[KT%[/J=I<_LS?LU?%KXD>,&U6/4
M+F\U!KKQ"=<^(7A[X,^.KNVN/*DUG]G*RTJ<RR:!'':?IY_P48^$_C_X\?L"
M_MG_  4^%.@?\)5\3?BQ^S#\;?AY\/\ PS_:NBZ'_;_C'Q?\/-?T+P[H_P#;
M/B34M'\/Z5_:&JWMK:_VAK6JZ;I=IYOGWU[;6R23)]0^!? 7@7X7>$/#_P /
MOAGX+\)_#KP#X3T^/2/"O@CP+X<T?PCX0\-:5"SO#IGA_P ->'[/3]%T;3XG
MDD:.RTZRMK9&=V6(%B3UE 'PCXQ\2_M>? [P]^RR_P +?@'IGQ]^&NB> I?!
MO[2/PN\(^)? OA[]H[1=>M/ V@0_#WQ1\'M<^*GQ7^%_P$\1^'M%\4:7K>@?
M%'PWXM\;:#K%QI&N:/XJ\!Z[JEQX=O\ PKXDP_\ @GK\#_BQ\*M&_:?^(OQ?
M\)V7PKU[]JO]K#X@?M*:-\"=.\2:5XJ7X*>&O%GA#X>^%+;PSXCU?PS>:GX)
MO/B7XMU?P3K7Q5^*T_@'5]<\&#Q]X_UNTT;Q)XL%G/XMU[]"J* "BBB@ HHH
MH **** "BBB@ I? 7_)0_'/_ &)GPX_]/GQ0I*7P%_R4/QS_ -B9\./_ $^?
M%"@#V>BBB@ KY^U#3_%^F>+_ !W=6O@3Q!KNGZ[X@TS5=.U'2M3\$Q6\MO%X
M)\(Z),CPZWXNT;4(IHM0T:]C99+)8V18Y8I)$D!'T#10!\_>?XT_Z);XS_\
M!M\,O_GAT>?XT_Z);XS_ /!M\,O_ )X=?0-% 'S]Y_C3_HEOC/\ \&WPR_\
MGAT>?XT_Z);XS_\ !M\,O_GAU] T4 ?/WG^-/^B6^,__  ;?#+_YX='G^-/^
MB6^,_P#P;?#+_P">'7T#10!\_>?XT_Z);XS_ /!M\,O_ )X='G^-/^B6^,__
M  ;?#+_YX=?0-% 'S]Y_C3_HEOC/_P &WPR_^>'1Y_C3_HEOC/\ \&WPR_\
MGAU] T4 ?/WG^-/^B6^,_P#P;?#+_P">'1Y_C3_HEOC/_P &WPR_^>'7T#10
M!X3:7WC&W:9G^%?C4B2TNH%VZK\,20\T+1H3GXB+\H9@6(R0,X!/%5//\:?]
M$M\9_P#@V^&7_P \.OH&B@#Y^\_QI_T2WQG_ .#;X9?_ #PZ//\ &G_1+?&?
M_@V^&7_SPZ^@:* /G[S_ !I_T2WQG_X-OAE_\\.CS_&G_1+?&?\ X-OAE_\
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M ^>O^$CT_P#Z!WC?_P -9\5?_F)H_P"$CT__ *!WC?\ \-9\5?\ YB:^A:*
M/GK_ (2/3_\ H'>-_P#PUGQ5_P#F)H_X2/3_ /H'>-__  UGQ5_^8FOH6B@#
MYZ_X2/3_ /H'>-__  UGQ5_^8FC_ (2/3_\ H'>-_P#PUGQ5_P#F)KZ%HH ^
M>O\ A(]/_P"@=XW_ /#6?%7_ .8FC_A(]/\ ^@=XW_\ #6?%7_YB:^A:* /G
MK_A(]/\ ^@=XW_\ #6?%7_YB:/\ A(]/_P"@=XW_ /#6?%7_ .8FOH6B@#YZ
M_P"$CT__ *!WC?\ \-9\5?\ YB:/^$CT_P#Z!WC?_P -9\5?_F)KZ%HH ^>O
M^$CT_P#Z!WC?_P -9\5?_F)H_P"$CT__ *!WC?\ \-9\5?\ YB:^A:* /GK_
M (2/3_\ H'>-_P#PUGQ5_P#F)H_X2/3_ /H'>-__  UGQ5_^8FOH6B@#YZ_X
M2/3_ /H'>-__  UGQ5_^8FC_ (2/3_\ H'>-_P#PUGQ5_P#F)KZ%HH ^>O\
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LO+#5?B'<7L%K%XETC2+BZ-K!J6GR3R6T,L,8O(%:7S&*+[510 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img132800289_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $V G # 2(  A$! Q$!_\0
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M*"4HM^$_\,M_LR_]&Z? G_PT7P__ /F>H_X9;_9E_P"C=/@3_P"&B^'_ /\
M,]7NU%<?]EY9_P!"[ ?^$F'_ /E?DON/5_UZXW_Z+'BK_P 2'-__ )L/"?\
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MCB%1J4^1QE%3M%M_X9;_ &9?^C=/@3_X:+X?_P#S/4?\,M_LR_\ 1NGP)_\
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M?_#1?#__ .9ZC_AEO]F7_HW3X$_^&B^'_P#\SU>[44?V7EG_ $+L!_X28?\
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M@>VTG19;Z=M%GT1<68DN+:PE\K;"+&VWQ6D]I=H)IVA^*7QI^-OQ,^"/[/\
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M7%Y1@\-4E4PZKT_K.7_VE@9JK*>"S.56@Y1_5AF559F8*J@LS,0%50,EF)P
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M\-B(8K"U<1E6!6)PE6,<1A95J>%I_J_KGQY.C?M(>"_V?O\ A%C<#Q=X,O\
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MEM99H;^<)&.;_9YM=6^'7[9>E>!_#_AOQY\+O"WB?P)J][=> ?&_BJ/Q1>W
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M-XZU6\@\2>-X?'$'BE]#TZ/4-(U""33]D%O8K<M;SI]GLYK4RR3(YAO9AM
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M9S^MXNKFF(Q=>O5P\5/VF'P,:%.-'$QA6]O.,*=&!1117S)^DA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>$_M2?\FR_M
M%_\ 9"?B[_ZK_P 0U[M7A/[4G_)LO[1?_9"?B[_ZK_Q#7#FG_(MS'_L!Q?\
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MLJE4P[Q>:\V,E/'TL12S:A0RC+89G6Q66JE27UBE1]DE652GV8O 47E>&QN
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M4Q%/"QFX.AC6XU&L#2Q%'VD9YO3Q&'^L8SZS@*%&6'GC*LL+[>EA*E.;5/\
M*O\ X;3_ &Q?^CK/VB/_  [_ (Y_^75'_#:?[8O_ $=9^T1_X=_QS_\ +JOF
M>BOT?^P<B_Z$N4?^&W!?_*/+\^[/B?[7S;_H:YG_ .%^+_\ EWDON/MOX/\
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M-W<V>HVKVB6S,UTYECA5C#(5^P?&G[0VBV'["'Q#\>1>'(_"?CCXH_$7XU?
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M4G551T(+X[J226:41B:>>80QB&!9II9E@A!R(8%D=E@A!)(BB"1@\[<UK_\
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M2\.^$O"WC?1_VI]2TSP5X@\/>+-$N+#X)>)_#VNS>*O";6LGACQ+XA\2>'O
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MQ\_\,Y\1?_F<H_X9B_:8_P"C<?CY_P"&<^(O_P SE']K95_T,\O_ /"W#?\
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M?\,Q?M,?]&X_'S_PSGQ%_P#F<H_M;*O^AGE__A;AO_EH?V;F'3 8S_PEK_\
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M+H^VV?\ S]VW_?\ B_\ BZ\9_P"&:_@'_P!$D\#?^"*U_P#B:/\ AFOX!_\
M1)/ W_@BM?\ XF@#V;[;9_\ /W;?]_XO_BZ/MMG_ ,_=M_W_ (O_ (NO&?\
MAFOX!_\ 1)/ W_@BM?\ XFC_ (9K^ ?_ $23P-_X(K7_ .)H ]F^VV?_ #]V
MW_?^+_XNC[;9_P#/W;?]_P"+_P"+KQG_ (9K^ ?_ $23P-_X(K7_ .)H_P"&
M:_@'_P!$D\#?^"*U_P#B: /9OMMG_P _=M_W_B_^+H^VV?\ S]VW_?\ B_\
MBZ\9_P"&:_@'_P!$D\#?^"*U_P#B:/\ AFOX!_\ 1)/ W_@BM?\ XF@#V;[;
M9_\ /W;?]_XO_BZ/MMG_ ,_=M_W_ (O_ (NO&?\ AFOX!_\ 1)/ W_@BM?\
MXFC_ (9K^ ?_ $23P-_X(K7_ .)H ]F^VV?_ #]VW_?^+_XNC[;9_P#/W;?]
M_P"+_P"+KQG_ (9K^ ?_ $23P-_X(K7_ .)H_P"&:_@'_P!$D\#?^"*U_P#B
M: /9OMMG_P _=M_W_B_^+IRW5J[!$N8'=CA56:-F8]<!0Q)..< 5XO\ \,U_
M /\ Z))X&_\ !%:__$UYQ\5?@=\(?"'A6Q\2>%_AWX6T#7])\?\ PFGTW6-*
MTR*RU"QED^*O@RVD>VN8-DL1DMYYH) K8DAEDBD#1R.I /K:BBB@ HHHH **
M** "BBB@ HHHH **** "BBN-^(L_C>U\ >-KGX:6.D:G\1(/"NOS>!=/U^=[
M;0[WQ;'I=TWAZUU>>-HVBTZ;51:I=L)8?W#.#/ "9D +'C?QMX7^'/A76O&_
MC35H]#\+^';47NL:I+;WEVMI;M-%;1E;33K>[O[J6:XGAMX+:SM;BYGFECBA
MB=W53YX?VA?AFI*L_CX,I((_X4Y\8."#@CCP(1P?0D5\K?'R[^/<G[',K>.=
M&\)VVOE-,A^([ZKKMRVM&WM_BMH<&BZSHEKX>TFXT)-0UO0$@UJ]T"6_AL_#
ME_=IH$.I:G%8R:A+^BU 'B/_  T-\,O[_C[_ ,,Y\8?_ )A*/^&AOAE_?\??
M^&<^,/\ \PE>W44 >(_\-#?#+^_X^_\ #.?&'_YA*/\ AH;X9?W_ !]_X9SX
MP_\ S"5[=10!XC_PT-\,O[_C[_PSGQA_^82C_AH;X9?W_'W_ (9SXP__ #"5
M[=10!XC_ ,-#?#+^_P"/O_#.?&'_ .82C_AH;X9?W_'W_AG/C#_\PE>W44 >
M(_\ #0WPR_O^/O\ PSGQA_\ F$H_X:&^&7]_Q]_X9SXP_P#S"5[=10!XC_PT
M-\,O[_C[_P ,Y\8?_F$H_P"&AOAE_?\ 'W_AG/C#_P#,)7MU% 'B/_#0WPR_
MO^/O_#.?&'_YA*/^&AOAE_?\??\ AG/C#_\ ,)7MU% 'B/\ PT-\,O[_ (^_
M\,Y\8?\ YA*/^&AOAE_?\??^&<^,/_S"5[=10!XC_P -#?#+^_X^_P##.?&'
M_P"82C_AH;X9?W_'W_AG/C#_ /,)7MU% 'B/_#0WPR_O^/O_  SGQA_^82O0
M/!GCKPS\0-*N-9\*WMU>65GJ=YHUZM_H^M:!?V6J:?Y7VNRO-)\0:=I>JVLT
M2S0R 7%E&LL,T4T+20R([==7D/PG)-]\7<DG_B[^OCGG@>'O"@ ^@  'H!B@
M#UZBBB@ HHHH **** "O"?VI/^39?VB_^R$_%W_U7_B&O=J\)_:D_P"39?VB
M_P#LA/Q=_P#5?^(:X<T_Y%N8_P#8#B__ %'J'U7 O_);\&_]E5P]_P"K?!A^
MRW_R;+^SI_V0GX1?^J_\/5[M7A/[+?\ R;+^SI_V0GX1?^J_\/5[M2RK_D5Y
M;_V 8/\ ]1Z8<=?\EOQE_P!E5Q#_ .K?&!1117>?*A1110 4444 %%%% &=:
M:1I-ADV.EZ=9%KF2]8VEE;6^Z\FC,,UV?)B3-S+"S123G]Z\;%&<J2*^=_%O
M_)WGP-_[(-^T=_ZFO[-]?3-?,WBW_D[SX&_]D&_:._\ 4U_9OH ^F:*** "B
MBB@ HHHH **** "BBB@ HHJ.83&&46[1I.8Y! \J-)$DQ4B-I8T>-WC5]I=%
MDC9E!574D,!:OMYO;Y@M7V\WM\R2BOBR[\5_M3VWQBT3X2+XP^!32:S\,O%/
MQ%&N-\,_'0^S-X<\4^%/#2Z2+ ?%$K*EX/% O6NS=HT)L3 MNXF$J_8VFIJ,
M>G6":O/:7.JI96J:G<Z?;RVEC<:@L""\GLK2>XNY[6TEN!(]O;S7=S+#$R1R
M7$SJ9&]#'9?+ PP\Y8K"8A8JE[:DL/*O)^Q<IP52?M:%%14ITYQ2NYWBVXJ+
MBWZ&-R^6"CAYRQ6%Q"Q5+VU)8>5:3]ESSIJI+VM"BHISISBE?FO%MQ47&3NT
M445YYYX4444 %%%% !7COQX_Y)VW_8]?"+_U;?@>O8J\=^/'_).V_P"QZ^$7
M_JV_ ] 'L5%%% !1110 4444 %%%% !1110 4444 %%%% 'S!^V9_P FU?$O
M_KEX5_\ 4X\,U]/U\P?MF?\ )M7Q+_ZY>%?_ %./#-?3] !1110 4444 %%9
M^K7EUI^EZC?6.F76M7EG8W5U::/92V<%YJEQ!"\L.GVL^H7%I80W%Y(JV\,M
M[=6UJDDBM//%$&=?FSPY^T5XL\1^-]:\!1?L[_%"QUCPNWA&3Q5->:_\*38:
M%8>,UO9=*U!YK;Q]<2:A%%;:;?W%]#IL-U=0+;B)89)YHHV[<+E^*QE.O5H*
MBZ>&@JE=U,7A,.Z<'.%-3<<17I3<'4JTZ:E&,HNI4A3OSSC%]N%R_%8RG7JT
M%1=/#14Z[JXO"8=TX.<*:FXXBO2G*#J5*=-2C&474J0IWYY1B_J.BBBN(X@H
MHHH **** "BBB@ HHHH **** "O(/A/_ ,?WQ=_[*_X@_P#4>\*5Z_7D'PG_
M ./[XN_]E?\ $'_J/>%* /7Z*** "BBB@ HHHH *\)_:D_Y-E_:+_P"R$_%W
M_P!5_P"(:]VKPG]J3_DV7]HO_LA/Q=_]5_XAKAS3_D6YC_V XO\ ]1ZA]5P+
M_P EOP;_ -E5P]_ZM\&'[+?_ ";+^SI_V0GX1?\ JO\ P]7NU>$_LM_\FR_L
MZ?\ 9"?A%_ZK_P /5[M2RK_D5Y;_ -@&#_\ 4>F''7_);\9?]E5Q#_ZM\8%%
M%%=Y\J%%%% !1110 4444 %?,WBW_D[SX&_]D&_:._\ 4U_9OKU,_%[X6#4=
M'T<?$/P=)JWB#QAKWP_T33(O$&FS:AJOC?PM'<S>)O"ME9Q7#W$^N>'8K2Y?
M7-/2,W&DK$?MZ097=Y;XM!_X:[^!C8.T_ ?]H\!L'!(\:_LW$@'H2 02.H!&
M>HH ^F**** "BBB@ HHHH **** "BBB@ HHHH ^8-5_Y/.\#_P#9LWQ/_P#5
MH_">OI^OF#5?^3SO _\ V;-\3_\ U:/PGKZ?KU\U_A9/_P!BBE_ZF8T];-/X
M.3_]BFG_ .IN."BBBO(/)"BBB@ HHHH *\=^/'_).V_['KX1?^K;\#U[%7CO
MQX_Y)VW_ &/7PB_]6WX'H ]BHHHH **** "BBB@ HHHH **** "BBDW+NV;A
MNQNVY&[;G&['7&>,XQGB@!:*** /F#]LS_DVKXE_]<O"O_J<>&:^GZ^7_P!L
ML@_LU?$L@@CRO"O(.1QXY\- \CT/!]Z^H* "BBB@ HHHH *^:OAS_P G+_M+
M_P#8N? /_P!,WCVOI6OFKX<_\G+_ +2__8N? /\ ],WCVO6R[_<\_P#^Q31_
M]7N2GK9=_N>?_P#8IH_^KW)3Z5HHHKR3R0HHHH **** "BBB@ HKA_$OQ.^&
MW@N^BTSQC\0O _A/4I[5;V'3_$OBS0="OIK-Y9(4NXK35-0M;B2U>:&6);A(
MS$TL4D8<NC :GAGQGX/\:VEQ?^#?%?AOQ;8VER;.[O?#.NZ7KUI:W8C28VMQ
M<:5=7<,-R(98I3!(ZR^7(DFW:ZD[O#8F-)5Y8>O&A*UJSI5%2=W96J./([O1
M6EJ]$;O#8F-)5Y8>O&A*UJSI5%2=W96J./([O16EJ]$=)1116!@%>0?"?_C^
M^+O_ &5_Q!_ZCWA2O7Z\@^$__']\7?\ LK_B#_U'O"E 'K]%%% !1110 444
M4 %>$_M2?\FR_M%_]D)^+O\ ZK_Q#7NU>$_M2?\ )LO[1?\ V0GXN_\ JO\
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M#'\L_P!NGQ5IOAG]H#]FW1]*TCPO<2?$WQ=IGAOQ[J^M^'?"?B))-'TWQ_\
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M!/JD&N?K10!^?-EX3_;C?Q[9W3>*].M/!5O\?/B#J0MM4U/P]=S/\(+WXK>
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M]/ZOEE&G.I4=#D<WG60U5&/LZ]2;YJ=:$TY0BDFU)J:<3ZIHHHKYPXPHHHH
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M0>()=*N+W3K6TFW/_P (UH]SI$=QX*\.W$MQ#X/?4-933[R:'46CB^NZ\?\
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M2ZC")?M&M7=CIVFSWF^:22,R6>DV]K80^3$R0#R($WK&'?,C,QV:* "BBB@
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M_P!SV/L;S]H>!C?]8_[:RSZA_9G]A>SG_:GUCVWU[VGO\OU?E]RUO9>S_O\
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M!]'T5\X?\+6^.O\ T:QXG_\ #K?"3_YHZ/\ A:WQU_Z-8\3_ /AUOA)_\T=
M'T?17SA_PM;XZ_\ 1K'B?_PZWPD_^:.C_A:WQU_Z-8\3_P#AUOA)_P#-'0!]
M'T5\E:U^T)\7=!USP=X>U#]ECQI_:/CK5-4T?0OLWQ+^$]Q;"\T?P[JOBB[_
M +1N%\2JMC =+T:]%O,RR"6\$%KA3,KCIO\ A:WQU_Z-8\3_ /AUOA)_\T=
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MFD.LP6,88P(&MZ?\%OA9JVK:GH&E_&3XQ:EKNB+$^LZ+I_[3?Q.O-6TA)R1
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MHKYY_P"&;/"G_10?V@/_ !(/XO?_ #6T?\,V>%/^B@_M ?\ B0?Q>_\ FMH
M^AJ\@^$__']\7?\ LK_B#]?#WA3%<Q_PS9X4_P"B@_M ?^)!_%[_ .:VO3O
M'P]\/_#;1KK1/#TVO7<-_K%_KVHZAXG\2:[XMUS4=6U(Q"ZN[[7/$5_J.J7+
M>7;V]O#')<F*VMH(8((XXXU6@#N**** "BBB@ HHHH *\)_:D_Y-E_:+_P"R
M$_%W_P!5_P"(:]VKPG]J3_DV7]HO_LA/Q=_]5_XAKAS3_D6YC_V XO\ ]1ZA
M]5P+_P EOP;_ -E5P]_ZM\&'[+?_ ";+^SI_V0GX1?\ JO\ P]7NU>$_LM_\
MFR_LZ?\ 9"?A%_ZK_P /5[M2RK_D5Y;_ -@&#_\ 4>F''7_);\9?]E5Q#_ZM
M\8%%%%=Y\J%%%% !1110 4444 %%%<SXP\9^%/A_X?O?%?C77],\,^'-/DL8
M+S6-7N4M+*"?4[^VTK3;=I7^]<:AJ=[9Z?96Z!IKJ]NH+:!'FE1& .FHK@/"
M/Q5^&WCY96\%^.O"_B;R+71[RX71]9LKV2V@\02ZI;Z,;F**4R6\NHW&AZS;
M6]O,L=PUSI6H6[1+-:3QIVOVZRR1]LM<BZ^PD?:(<B]V[_L9&_/VK80_V?\
MUVT[MF.: +5%<SX:\:>$?&.A6'B?PIXFT/Q#X=U23R=.UK2-3M+[3;V<SFU$
M%O=P2O#).;D& 0JQE,V(PFX@'FOB=\9/A?\ !G0;'Q/\4/&NB>#=#U37[;PK
MI=[JDTA_M/Q+=VVH7MOH.FVUI%<WE_JTMEI.J78L;2WFN%M=.OKAXUAM9G0
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M_P""0&H^#/!U[X.L?C+X O[35/ GB?X=13:K\"WN8/AWIFJ?#KP9X#T[Q?\
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MXIL_%-\^A-X=\;^++C4&OO&6LII.K2^([);RRN;?3Y+_ ,ZWY+X;2?MOZ%\
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MM_S#83^Y_P!./-A_Q!/PQ_Z)G_S,\0?_ #U#_A\7^S+_ -"+\=O_  F?A_\
M_//H_P"'Q?[,O_0B_';_ ,)GX?\ _P \^BBA<2YWI_MO;_F&PG]S_IQYL/\
MB"?AC_T3/_F9X@_^>H?\/B_V9?\ H1?CM_X3/P__ /GGT?\ #XO]F7_H1?CM
M_P"$S\/_ /YY]%%"XESO3_;>W_,-A/[G_3CS8?\ $$_#'_HF?_,SQ!_\]0_X
M?%_LR_\ 0B_';_PF?A__ ///H_X?%_LR_P#0B_';_P )GX?_ /SSZ**%Q+G>
MG^V]O^8;"?W/^G'FP_X@GX8_]$S_ .9GB#_YZA_P^+_9E_Z$7X[?^$S\/_\
MYY]'_#XO]F7_ *$7X[?^$S\/_P#YY]%%"XESO3_;>W_,-A/[G_3CS8?\03\,
M?^B9_P#,SQ!_\]0_X?%_LR_]"+\=O_"9^'__ ,\^C_A\7^S+_P!"+\=O_"9^
M'_\ \\^BBA<2YWI_MO;_ )AL)_<_Z<>;#_B"?AC_ -$S_P"9GB#_ .>H?\/B
M_P!F7_H1?CM_X3/P_P#_ )Y]'_#XO]F7_H1?CM_X3/P__P#GGT44+B7.]/\
M;>W_ ##83^Y_TX\V'_$$_#'_ *)G_P S/$'_ ,]0_P"'Q?[,O_0B_';_ ,)G
MX?\ _P \^C_A\7^S+_T(OQV_\)GX?_\ SSZ**%Q+G>G^V]O^8;"?W/\ IQYL
M/^()^&/_ $3/_F9X@_\ GJ'_  ^+_9E_Z$7X[?\ A,_#_P#^>?1_P^+_ &9?
M^A%^.W_A,_#_ /\ GGT44+B7.]/]M[?\PV$_N?\ 3CS8?\03\,?^B9_\S/$'
M_P ]0_X?%_LR_P#0B_';_P )GX?_ /SSZ/\ A\7^S+_T(OQV_P#"9^'_ /\
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ME_Z$7X[?^$S\/_\ YY]%%"XESO3_ &WM_P PV$_N?]./-A_Q!/PQ_P"B9_\
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M/$'_ ,]0_P"'Q?[,O_0B_';_ ,)GX?\ _P \^C_A\7^S+_T(OQV_\)GX?_\
MSSZ**%Q+G>G^V]O^8;"?W/\ IQYL/^()^&/_ $3/_F9X@_\ GJ'_  ^+_9E_
MZ$7X[?\ A,_#_P#^>?1_P^+_ &9?^A%^.W_A,_#_ /\ GGT44+B7.]/]M[?\
MPV$_N?\ 3CS8?\03\,?^B9_\S/$'_P ]0_X?%_LR_P#0B_';_P )GX?_ /SS
MZ/\ A\7^S+_T(OQV_P#"9^'_ /\ //HHH7$N=Z?[;V_YAL)_<_Z<>;#_ (@G
MX8_]$S_YF>(/_GJ'_#XO]F7_ *$7X[?^$S\/_P#YY]'_  ^+_9E_Z$7X[?\
MA,_#_P#^>?110N)<[T_VWM_S#83^Y_TX\V'_ !!/PQ_Z)G_S,\0?_/4/^'Q?
M[,O_ $(OQV_\)GX?_P#SSZ\G^/?_  5J_9Q\7? SXT>%-.\%_&V#4/$_PG^(
MOAZQGO?#?@2.SAO-:\'ZQIMK+=O!\2;B=+:.>Y1YWAMYY5B#F.&5P$8HKEQW
M$F=3P6,C+&WC+"UXR7U?"*ZE2LU=4$U=2>VNNG0^@X3\&/#6CQ3PU6I<-\M2
?EQ!DU6G+^V,_ERSIYCAI0E:6:N+M))VDFGLTUH?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img132800289_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_9.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $S G # 2(  A$! Q$!_\0
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M_7%@'7>&6,^K_7/:_5GB(N@JW+[/VL>3FYE8X+_AFW]G;_H@?P6_\-9X&_\
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MPV EQ)F$<77PN&G2IXC$4<.\8JM2C0G5HPJU(Q<*<JE-2:<HWP?^&;?V=O\
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MX9M_9V_Z('\%O_#6>!O_ )14?\,V_L[?]$#^"W_AK/ W_P HJ]IHH_L[+_\
MH P7_A+0_P#E?DON#_73C'_HK.)O_#]FG_S5Y+[CQ;_AFW]G;_H@?P6_\-9X
M&_\ E%1_PS;^SM_T0/X+?^&L\#?_ "BKVFBC^SLO_P"@#!?^$M#_ .5^2^X/
M]=.,?^BLXF_\/V:?_-7DON/%O^&;?V=O^B!_!;_PUG@;_P"45'_#-O[.W_1
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M-/M]R0W%QI4#*;*_FAAA>7[9J%S:P#=$K>/ZQ\,?VX_B%\,](_9T\4:!\/-
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MNSUT^ M/TC1K&^ETWQ-J-UKMC:ZC-=V"ZE)]IN+6X;=N^S/V;?\ DW;X!_\
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M?$_]G'Q#^R]XLU3QU?\ P\\4?#\?#?6-7NO&&I:O\0;O0OLD-F][<^-?$?\
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MO E^-0\(Z?\ $O2]#DCEUE="<?9K*\TV\T;4Q88LY+Z2!(U3[HHH ^ ?$?\
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MQ1\2?%<OQ/TC_A9!\'_\+F^'_@OXDZ_X5^%_QS'@)X?^$4'Q9\&:>PM/$O\
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M?POK]M<6_P#8X:7P:FFNS:=H(E2XM;K$S:I,O[NN.N_^"9WP _X1O1]'\/\
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MUUX.\9^)?':0Z/;:??\ VK0[B."PTS0K'P[I6F-96(L[*.&%H9/NBB@#X/\
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M0VX__P"B-XC_ /#3C/+_ *=>:#_7K@S_ **C(_\ PY8;R_Z>>:/U]HK\@O\
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M (?C?L"_]#3\3?\ PU'BK_XQ1_Q#;C__ *(WB/\ \-.,\O\ IUYH/]>N#/\
MHJ,C_P##EAO+_IYYH_7VBOR"_P"'XW[ O_0T_$W_ ,-1XJ_^,4?\/QOV!?\
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M#>7_ $\\T?K[17Y!?\/QOV!?^AI^)O\ X:CQ5_\ &*/^'XW[ O\ T-/Q-_\
M#4>*O_C%'_$-N/\ _HC>(_\ PTXSR_Z=>:#_ %ZX,_Z*C(__  Y8;R_Z>>:/
MU]HK\@O^'XW[ O\ T-/Q-_\ #4>*O_C%'_#\;]@7_H:?B;_X:CQ5_P#&*/\
MB&W'_P#T1O$?_AIQGE_TZ\T'^O7!G_149'_X<L-Y?]//-'Z^T5^07_#\;]@7
M_H:?B;_X:CQ5_P#&*/\ A^-^P+_T-/Q-_P##4>*O_C%'_$-N/_\ HC>(_P#P
MTXSR_P"G7F@_UZX,_P"BHR/_ ,.6&\O^GGFC]?:*_(+_ (?C?L"_]#3\3?\
MPU'BK_XQ1_P_&_8%_P"AI^)O_AJ/%7_QBC_B&W'_ /T1O$?_ (:<9Y?].O-!
M_KUP9_T5&1_^'+#>7_3SS1^OM%?D%_P_&_8%_P"AI^)O_AJ/%7_QBC_A^-^P
M+_T-/Q-_\-1XJ_\ C%'_ !#;C_\ Z(WB/_PTXSR_Z=>:#_7K@S_HJ,C_ /#E
MAO+_ *>>:/U]HK\@O^'XW[ O_0T_$W_PU'BK_P",4?\ #\;]@7_H:?B;_P"&
MH\5?_&*/^(;<?_\ 1&\1_P#AIQGE_P!.O-!_KUP9_P!%1D?_ (<L-Y?]//-'
MZ^T5^07_  _&_8%_Z&GXF_\ AJ/%7_QBC_A^-^P+_P!#3\3?_#4>*O\ XQ1_
MQ#;C_P#Z(WB/_P -.,\O^G7F@_UZX,_Z*C(__#EAO+_IYYH_7VBOR"_X?C?L
M"_\ 0T_$W_PU'BK_ .,4?\/QOV!?^AI^)O\ X:CQ5_\ &*/^(;<?_P#1&\1_
M^&G&>7_3KS0?Z]<&?]%1D?\ X<L-Y?\ 3SS1^OM%?D%_P_&_8%_Z&GXF_P#A
MJ/%7_P 8H_X?C?L"_P#0T_$W_P -1XJ_^,4?\0VX_P#^B-XC_P##3C/+_IUY
MH/\ 7K@S_HJ,C_\ #EAO+_IYYH_7VBOR"_X?C?L"_P#0T_$W_P -1XJ_^,4?
M\/QOV!?^AI^)O_AJ/%7_ ,8H_P"(;<?_ /1&\1_^&G&>7_3KS0?Z]<&?]%1D
M?_ARPWE_T\\T?K[17Y!?\/QOV!?^AI^)O_AJ/%7_ ,8H_P"'XW[ O_0T_$W_
M ,-1XJ_^,4?\0VX__P"B-XC_ /#3C/+_ *=>:#_7K@S_ **C(_\ PY8;R_Z>
M>:/U]HK\@O\ A^-^P+_T-/Q-_P##4>*O_C%'_#\;]@7_ *&GXF_^&H\5?_&*
M/^(;<?\ _1&\1_\ AIQGE_TZ\T'^O7!G_149'_X<L-Y?]//-'Z^UXI^TK_R;
MG\?O^R*?%3_U!=>KYB_9R_X*=_LI?M4?$^T^$/PCUSQM?^-+W0]:\0P6^N>
M]=\/Z>=-T!+9]1=]2U"-+9)D6[A\J$G?,2P0?*:^G?VE?^3<_C]_V13XJ?\
MJ"Z]7Q_$^39MD5#'8+.<NQF5XN66UZZPV.P]3#5G1J4:T8553JQC)PG*$U&5
MK-QDMTS]"\.<TRW-^*N$\7E>.PN889<59'2=?"5H5Z2JQS/!2E3<Z;E%3C&<
M&XWNE)-K4_.3]M__ )0R:U_V;O\ L]?^G7X65_&+7]G7[;__ "ADUK_LW?\
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M0K8JM5JTIX">)K4WE]*-/"RG656<</6M^!=%?O9XL_X)J?!+QC\;_CW^S?\
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M*-1.-2E4G2J1<91<9TY.$XN,XPG%J2:<9QC.+5I1BTTBBBBM2 HHHH ****
M"OM/_@G'_P GX?LI?]E=TC_TVZM7Q97VG_P3C_Y/P_92_P"RNZ1_Z;=6KP>*
MO^27XE_[)_.O_5;B3V.'?^2@R'_L=95_ZGX<_OMK\/?^"^__ "9IX&_[.&\$
M_P#J&_$6OW"K\/?^"^__ "9IX&_[.&\$_P#J&_$6OX%\*O\ DXG"/_8XH?\
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M+XS?LV3:S\6/#OA.U\#_  U^(OA*RT/PIXT\,/=7#:1KWAR_B\5WEWHD8O\
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MK_LW?]GK_P!.OPLK^,6O[A?C]X<^&WBW_@E99>'?B_\ $6[^$WPYU/\ 9_\
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M ."8O_227QA_XC#XP_\ CM'_  S7_P $Q?\ I)+XP_\ $8?&'_QVC_73*O\
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MXC#XP_\ CM'_  S7_P $Q?\ I)+XP_\ $8?&'_QVC_73*O\ H7\6?^(3Q?\
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MP:G)X174I]9C\.W,<%G'I][ID.K75UJ5O#>V5P]M>W$MQ;R12/FOJ+_AFO\
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M;L.+OPYJ-T(7O!I-T)'%U:VMQ;"Y! G:0)&$_2/Q/^R+_P $WO"&LS:!K_\
MP49\86&J6]EHU_+:G]FCQ1<[;77]$T[Q#I<OG6MS)"?M6E:K9700.7A$X@G"
MSQR*,#_AFO\ X)B_]))?&'_B,/C#_P".UK_K9P[B:<IO*.(:]+%PP\YREP'Q
M35AB:=)JKA93;R*4:T*3DJF'<G*--OGIV=V9KAW.J$XP699+1J8>5:,(KB_A
M^G*A.HE3Q$8)9NG2E47N5E'E<U[L[I-'Q5H'[2/Q]\+>'_"7A3P[\7O&VC^&
M_ 6E^+=#\$:-::A ;/PGHGCR%K?QIH^A>?:S3V&E^)H7:/5;"*86LHV-%%"\
M<3)R%U\4?B1??#70_@W>^-_$5W\*/#.NW'B?PY\/;B^,WAC0_$-VEY'=:MI=
MDZ%[2YG74=0WK',+???7<BP++/([?H)_PS7_ ,$Q?^DDOC#_ ,1A\8?_ !VC
M_AFO_@F+_P!))?&'_B,/C#_X[4QXCX:C/VD,AS^%1UUB>>/A]Q1&;Q//7FL0
MY+(%)UU/%XJ:K-^T4L3B9<UZU9R;R//)1Y)9QD\H>R]@H2XSR!Q]@XT(>PY7
MG'*J+AA\-%TK>SY:%"+C:C!1^4_AM^V1^U;\'?"5CX"^%?Q_^(_@+P5I<]_<
MZ=X8\/:E8P:38W&J7L^I:C+;0W&G7+QO>W]U<7EQ^](>>:1P!G S+#]K']IW
M2_!_BKX?Z9\?/BCI_@CQQJ'B75/%OA>S\3W5OI6N7_C*[N;_ ,6SW$<2K/;+
MXEO;R\N=;M=.GLK/4);R\:XMW%U<"3Z__P"&:_\ @F+_ -))?&'_ (C#XP_^
M.T?\,U_\$Q?^DDOC#_Q&'QA_\=K!YQP?*I5JRX7S:57$5X8FO5EX;\1NI7Q,
M)RJ4\16J/A[GJUX3J3G"M-RJ0G.<HR4I2;V66<2QA2IQS_+HTZ-)T*--<<9(
MJ=*A.,(2H4H+.E&G1G",(2I02IRC&,91:5E^>5Y\1O'VH_#[0_A-?>,-?NOA
MCX9U[4/%/A[P'-?,?#6C>)-6CGBU+6[#3PH$5_=QW5TLDA=E3[5<M"D3W$S/
MZEXA_:V_:B\6Z5X*T/Q1^T!\4_$&C_#C6] \3>!M-U;Q1<WEKX<\1>%&1_#&
MN6R2*3>ZKX?>-'T>]U=M1FL7!>!E9Y"_UW_PS7_P3%_Z22^,/_$8?&'_ ,=H
M_P"&:_\ @F+_ -))?&'_ (C#XP_^.UM4XBX8K2IRJ\/Y[5E2K5L12E5\/>)Z
MCIU\2[XFO3<\@;A6Q%_W]6-JE:\O:2E>1E#),]IJ<:><Y13C4IT:,XT^-,A@
MIT:'+["C-1SE*5*C[OL:;O"EIR1C8^3]._;$_:KTBS\16&E_M!_%"QM/%FN>
M)/$VOQV^OA7N_$7C$W#>+-;L[AK9KK0=2\2/=W3ZS<^')](:^>YN'FR\KL?F
M_P#,]R2222>268DEF)R69B68DDDDDU^H'_#-?_!,7_I)+XP_\1A\8?\ QVC_
M (9K_P""8O\ TDE\8?\ B,/C#_X[5X;B;AS!NK+!Y'Q!A)5W%UY87@#BG#NL
MX)J#JNCD,'4<%)J+G=Q3DE9-DU\BSO%*FL3FV38E4E)4EB.,N'ZRI*?*Y*FJ
MN<25-3:@YJ%N9I.5VKGY?T5^H'_#-?\ P3%_Z22^,/\ Q&'QA_\ ':/^&:_^
M"8O_ $DE\8?^(P^,/_CM=?\ KIE7_0OXL_\ $)XO_P#G)Y_GV9S_ .J^8?\
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MB]_R+7[._P#V0/3/_5I_%BO$Z]L^+W_(M?L[_P#9 ],_]6G\6*X,5_O>6?\
M837_ /4'%'70_P!VQ_\ UXH?^IN%/$ZW_"GA7Q%XZ\4>'/!/A#2+OQ!XL\7:
MYIGAOPUH5@J->ZQKNLW<5AIFFVHE>*(37=W-%$KS2Q01!C+/+%"CR+@5]7_L
M9?&#X8_L_P#QG;XT_$K1-=\57'P_\$>,[[X9>$-#:2P_X2+XIZQI+^'/#B:I
MXGA=IO!FFZ18:OK.M)XGMK'5;W3]5LM,>RL'N=DD9FF(Q6$R['8G X6>.QM'
M"UIX/!P5WB<7R-8:@VYTXPA4K.$:M6=2G"E3<ZM2<(0E)& HX?$X["4,7B(X
M3"U<12ABL5*]L/AG-.O6249N4X4E.5.$83E4J*-.$)RDHOS+4OV?/C5I&M_%
M[PW?_#GQ!%X@^ L>G2_%W1HA87FH^#(M7UJP\.Z7)<6ME>W,NKI?ZQJFGVUJ
MWAU=7$L5W%? _P!G[KI?)UL-0>TN;]-.U)]/LIUM;[4$T^\?3[&[<J$M+Z^6
M VMG=,SHJVUS-%.6=%$9+J#^R,O[<G[/GB;7OB7X[T7Q-\:OV9?'_P :?V9_
MA)\(?$WB#P;8ZI\4/$'@CQS\&_B9I-SI7B.P\9MKG@_7?&(\6?"G0-*TC7-=
MNO[,U9M0CGCOH[Z::7SK7Q!_X* ? 'X@_#;]I[PG>Z9XVTW2/B3XH^+_ (@^
M&OPX\/>%;WP5=7>J>.[_ ,*WFFZKX]\:^$_'T?@GQ/X=\37WA\Z]X]\->-_A
MOK.N:%*\VC>"->^R7*S1_%X?B?BM3I0Q7"&)DY5<#2Q'L5B*4L/*>'R^GCYP
MO2Q>#Q5*.85LQ^K5:681HPP.#57$U8NIA:N.^HK9!P\XU)X?B7#I*GBZM#VO
ML:BK1A7QD\)&:]IAL5AJKP5/!*O2J8.566,Q7LZ%-\F)IX/\E? OPQ^('Q+\
M1Z9X2\#^$]6UWQ#K6B^(/$FCZ<(X=,_M70?"NBWWB+Q#JVG7FLS:=87MEI6B
MZ;?7\\UO=2!T@,5N)KF2*&3*\->"O&?C+7=%\,>%/"/B;Q!XC\1ZAI.DZ'HF
MEZ%J=QJ.IZEKK!-$L[>W%L&\W5LE[ RF..YA22XC<V\4LJ?M-J'_  44_9\N
MO%(UNXO/BMK^E^(/&/Q*\;:%HFN^"M,M[;]F'P[XI_94\0?!'3_@A\,ELO$-
MS!K?AC5O&>KZ?J.JW>BVWASP[::%H.GZE+I%UXBDNK@XNA?\% ?@-X:N/!7C
MW3=8^*"^-+OQ=_P3YU7QYX0M/!@TRQ\.Z#^RIX9UCPA\3]/TGQ?%XJ=?%I\5
MZ=KM_<:19R:?I%I?V#)I>H;GN;Q8H?%7%K524>#<0G/ X6>%IREBY<N8U<94
MHXBAB*JPD'[##X;]_*I*CA8<V&FJ>(KT<PP%8M</\.<U-/BBA)0Q>(CB)*&'
MBY8*GAJ=6C6H0>)DG5K5W[)4X5<1/EKQYZ5*K@<92/QFU?P[X@\/W>JV.MZ'
MJ^EW&A:W>^&]8%[IUW#!IWB#3Y9(KS1;J[,7V--2@:*1C:"<S/$!<1J\#)(W
MJ.@?LZ?&WQ3J/PJTKP_\/-6U2]^-_AWQ)XM^%2V]YHBVWB_PYX.?54\6ZK;W
MTVJ16.EV_AIM$U,ZXFO7.E3Z;';"6YA2.YM6G_0_XV_MR_"WQE^S5XO^#_A7
MQ%K>N:SK-IXR\.ZE%XO^%7B.[N/B)>^(/C)>?$?3?BW<>*M1^+YT/P;XDMM$
MN[*PN)=0\ ^+/'EKJ^@PZ9IWB)?"=\MO:>-?!?\ ;#\%_#S]C[XC_"#Q#H>M
MZG\:=*'Q#\+_ +//BFRC LO"'P^_:'MO#.D_'JQFU261H]*U!M+T'4+CPRXL
M[EAJ7B*[92D/VM)>Z.>\45\M>)H<._5\9'-WEKPN)6)DY86M0G1PN<<E2. G
M'"4LPJX3$8VG&=;DRN.,Y:\<72<:7(\IX?HXY4*V=^VPKRQ8_P"L8?V$5'$T
MZL*N(RQSA+&1EB9X*GB:&%FXTU/,987FI/#5%*I\2>$/AGX_\>ZRN@>$_"FK
MZKJ\OA?Q-XUM[5X8]+6\\)>#M$NO$GB;Q!I]UK,FGV>H:=I>A65SJ3S65Q<&
MYAC5+);F>:"*7D3I^I*N]]+U6-?-M8"9=,OXMMQ?QK-86KB2W4I=W\+I-8VK
MA;B\B99;:.5&#']QOB1_P4&_9I\1:;X/L-!U/XH7]IX2T+]I?0M!@\2>"-2E
MUKP]X=^,_P"S&?A/X2\+WOB75?'?BJ[\27>B^-[>.7Q)J]H^A:#)IUW;W6@>
M';'3])BM39TG_@H5^RQH/B.S\?O!\1?%FL>,/C'^SY\2_%GA#5_AU:P6?PV7
MX6_LOZI\!-1O]$UEO%DD'CG7?#OB>XL/'.@"!/#0OK:U@M+2]L=3MTO8^"/%
MW%3@ZLN",P?/@YU:.%4L1&NL93Q]2BL+6K3P?LH*O@%#&1JSIT:5"I3E0=7$
MO$X>4>R7#?#_ #JDN+,$G'%0IU<0XT94GAJF"IU?K%*E'%<\O8XURPLJ<)U:
MM:$U6]E0]A6B_P -1H^LM-J%LNBZTUSI,;S:O;+I&I-<Z1#&,R3:M;K:F;3(
M47YGEODMXT7YF8#FMWPUX#\8^,=)\9:[X8\/W^M:/\/=#L?$GC34;00_9] T
M?5-=T[PQI5Q<F6:)[BXU7Q!JVGZ3I>FV"76IZA=7!%G9S1P7+P_LSX+_ ."B
MWPBL?'OC^X\=^+?$FJ^"]=\*?"_0KS5? OP;\:_#SQIX^?P+X2\5Z#)<V7BZ
MQ_:'U?Q[I/B'38_$8T'3+SXL:O\ $'PSXGT=1J'B?2K;4-.MEO?F#]A_QMX,
MTGX??&/PUJ.LZ/X7U1?VA?V)/BW')KVI16DNH_#?X;?'62+Q9I\&Q%GU>Y\-
MMXHT+7[VPTFWN+Z>VCN]2AL/LFG7$UOV5.*<YHY?F.-Q7#U7 _49</2IRK2Q
M,J.)HYIB<-2S&SJX3!UH5,MIU*CJ6I3C2DZ3K\LHUJ,.>EP[EV(Q^7X+"9Q'
M'3QSSBFZ="G15>E7P-&K++X\M+$XNG4CF%54X4OWD)54IQH<RE2JR_.E]'UJ
M.\M=.ET36HM2OU5[#39='U*/4;^-C(%DL+![5;N]C)AF >UAE0F&49S&X7HK
M+X<^/-1\,^)O&5GX2UV;PUX.U+PUI'B;4C8R1'2=2\80:M=>&K66PG\O4YSJ
MMGH.LWT4MG97$$%AIUQ?7DMO:!)F_>S6OVE?A1XO^+GB7X<Z#\?O%/B[QOK,
MW[<]IX<^/NL6#:7\0/V?_P#A=KZ%-X,\+?#(:EK=G_;>D> +;PIJZ?:=!\5^
M$MMKXKO4\(VEO>6FHP#8U/\ :-^!OB#]J[2O ^E_%"\NXM3\%?$'4/C9\1M9
ML].M8H;CP3^P/?\ P:\+:8UU<:E;:;KOC&'Q#JWQ%U2YT33=8GTN?5]7T_3[
M#6+FYU#=!\K0\5:^,E['"9+">)CD^.SN=*.(QM62PF7UW*7-3>6T*E&./PE.
MM'!SJJ.(AC'14L#7H5*4ZWU^/\)\=E-'ZWF=?&83!/-<%E$<17P5'#T_K684
MDJ:526-JTZL\+B9P>(A2;HU,,JCAC*5:G5C2_G8AT?6;F3R;71-:NIC:17X@
MM='U*YF.GSLJ6^H"&"UDD-A<.Z+;WNW[+<,Z+#*Y90=SQ+X$\7^#]-\&ZQXF
MT"]T?2_B%X=F\5^"[ZY,#6_B#0;76M3\.7M[:-;S3&&73]>T?4])U'3[T6VI
MZ=>VC1WMG!YD!E_H$_9J^/OPM^(VO^#M)^$_Q2\6^!M ^#A_8 T_Q+\4-6/@
M;X:>)?'_ ()^ FE>*O#/C?P5XK\(^*_B;H.LV/PIU9K^W\7:K?Z1>>,;'23;
M3V6M:'?W*Z<E_P#F=^U]XR\+ZQ\(/V?/#VEZ]I/B76KGXG?MF?%R*[TR\M;Z
M31/AQ\5OCO<R?#W1KN2"22>R_ME/#>M^-+/3+P6]U%8:]:7T]I";^)I/I\MX
MOS',,ZI935R66!MB,/2Q7MIXF>(HTL3DN8YG3G4ISPN&AAIJK@Z-'DJ3J3<*
MS52G1K.G!_(X[AO!8/*:F8T\UCC&Z%:IA_90H1H5:E#-<!E\XTZD<37EB(>R
MQ56KSTXTX\]).$JM)3DO@"OM/_@G'_R?A^RE_P!E=TC_ --NK5\65]I_\$X_
M^3\/V4O^RNZ1_P"FW5J^@XJ_Y)?B7_LG\Z_]5N)/'X=_Y*#(?^QUE7_J?AS^
M^VOP]_X+[_\ )FG@;_LX;P3_ .H;\1:_<*OP]_X+[_\ )FG@;_LX;P3_ .H;
M\1:_@7PJ_P"3B<(_]CBA_P"DU#^Q?$/_ )(CB7_L65?_ $J!_(#1117^C!_$
M04444 %%%% !7MOQJ_X]?@3_ -FY?#S_ -/_ (ZKQ*O;?C5_QZ_ G_LW+X>?
M^G_QU7!B?]]R[_'BO_4:1UT/]VQO^"A_Z?@>)4445WG(%%%% !1110 4444
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ML0  6=BS$*H"J"Q)"J J]%   I*_1CXD*AN?^/>?_KC+_P"@-4U0W'_'O/\
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MKGQ'_P"_WA/_ .:6C_AVI^WK_P!&N?$?_O\ >$__ )I:[/\ 6SA7_HI^'?\
MP]Y9_P#-7FOO.;_5SB'_ *$&=_\ AIQ__P SGP]17W#_ ,.U/V]?^C7/B/\
M]_O"?_S2T?\ #M3]O7_HUSXC_P#?[PG_ /-+1_K9PK_T4_#O_A[RS_YJ\U]X
M?ZN<0_\ 0@SO_P -./\ _F<^'J*^X?\ AVI^WK_T:Y\1_P#O]X3_ /FEH_X=
MJ?MZ_P#1KGQ'_P"_WA/_ .:6C_6SA7_HI^'?_#WEG_S5YK[P_P!7.(?^A!G?
M_AIQ_P#\SGP]17W#_P .U/V]?^C7/B/_ -_O"?\ \TM'_#M3]O7_ *-<^(__
M '^\)_\ S2T?ZV<*_P#13\._^'O+/_FKS7WA_JYQ#_T(,[_\-./_ /F<^'J]
ML^+W_(M?L[_]D#TS_P!6G\6*]U_X=J?MZ_\ 1KGQ'_[_ 'A/_P":6O6/B9_P
M3N_;@U?0/@A;:9^S5\0;R?P]\&K#0-;BBE\+AM-UF+XA_$?5)-.N/,\1(#.F
MG:MIMV3$98O*O(L2%]ZKPXGBKA=XK+6N)>'VHXBLY-9UEK44\%B8IR:Q-DG*
M44F]W)+=HZJ'#O$"P^.3R'.DY4:*BGE6/3DUC,-)I+ZOJU%-M+9)O9,_,:O;
M/V:?$_A[P3^T=\ /&GB[5(M#\)^$?C3\,?$WB?6IHKF>'2/#^A^,=(U+6-3F
MALH;F\EBL=/MI[EX[2WGN76(K!#+(50^Z_\ #M3]O7_HUSXC_P#?[PG_ /-+
M1_P[4_;U_P"C7/B/_P!_O"?_ ,TM;8OB/A+&87$X2IQ1D$:>*P];#3E#.\K4
MXPKTY4I2@Y8B45)1G>+E&2O:\6M'GA\BXDPV(H8F'#^<RGAZ]*O",\IS!PE*
MC4C4C&:C0C)Q;BE)*46U>S3U/U/^(/[>/[''B[P;\5[/6=0L]8M_CQJ/@'X@
M_'7PM8Z1K4EWXY\0?#K]H+X2^&+?P]9+)I=A;N=6_9^^'VJ^,);*2]@M+S^V
M;FV>]AU:\^R1^&?$3]H;]F'7OBAX[N_!WB#]FOP9XRG^!OQ$\,_![XVP> ?$
MGC+P3HFM:M\7](U_P_8_$+0]8^!^@:;:>)8_A-;^)O"WA@Z-\._$B^%;37+;
MPMJ7BV^NK>WU8_$?_#M3]O7_ *-<^(__ '^\)_\ S2T?\.U/V]?^C7/B/_W^
M\)__ #2U^?X/ASPYP&F&XUPT8JI5J0A/B;)JM)*I0P.%A1G0FW1KX:EA<!AL
M(J&(IU:=7"TZ>'KJI3ITU'['%9UQQC'>OPK7;<*4)3AD&:TZC<*N)Q$JL*T+
M5:->IB,9B,3[:C.G.EB*DZU%TYSFY?I+XZ_:=_8[\8_%W4_%X^)W@.YO;7XL
M_M >-O">N:SX*U*/P]JD^K?LZ? WP=\,U\37NI_#CQGJ_A?PAJ/B?P[XXTRQ
MN=+\-:KX@\-7E@L>GPZ6M]#JI9=?M._L0V/Q1O=/T35?@G_PJ?XB?M)?%K7?
MB04^#JRV\_PC\3_LE>%-)TF.P.J>")]>\-:%J?QX@U/;I.@/9:I9>([)=0EB
MMM/:2\NOS=_X=J?MZ_\ 1KGQ'_[_ 'A/_P":6C_AVI^WK_T:Y\1_^_WA/_YI
M:F'#GA["G1I+CNBZ=#*ZV54XOB/($E2JN<J>(2C3BOK6%J5/;82JDE1JJ,HP
M=DBIYUQI.=2H^$:JJ5<PI9C4DLCSEN4Z:IQJ4&Y3;^K8F%-4\33;YJM-\KGN
MW\-HNQ%7DA?E!8ECM!(7+$DD[<9)))[\T^ON'_AVI^WK_P!&N?$?_O\ >$__
M )I:/^':G[>O_1KGQ'_[_>$__FEK]*_ULX5_Z*?AW_P]Y9_\U>:^\^&7#G$*
M27]@9WI_U*<?_P#,YX5X6_Y-\^-?_91O@+_Z1?&&O$Z_3GP]_P $[OVX+7X*
M?%;P_<?LU?$&+6M;\<_!S4M)TYI?"_GWUAH%K\3TUFZA*^(C$(].?6-,6X\R
M1'S>P^6L@W[/)_\ AVI^WK_T:Y\1_P#O]X3_ /FEK@P?%7"\:^:M\2\/I3S"
M$H-YUEJ4X_V5E<.:+^M6E'GC*#:NE.,H_%%I=6)X=X@=+ )9#G3<<'*,DLJQ
M[<9?7\=+EDEA]'RRC*SL^647:S3?P]7VK_P3]^.'AS]G+]I"'XO^)M7MM%@\
M,_"3XV1:#/=PWD\-]XVU+X>ZK:^"M#V65K=RK)KGB+[#IT4TT2V<#SB2[G@@
M5I!<_P"':G[>O_1KGQ'_ ._WA/\ ^:6C_AVI^WK_ -&N?$?_ +_>$_\ YI:6
M:YWP;G&6X_*L7Q/D'U7,<)7P6(]GGF5J;H8FG*E547+$2BFX3:3<9+75/8K+
M\IXHRW'8/,,-D&<_6,#B:.+H<^49BXJMAZD:M-R4:,6TIQ3:4D_,_5#Q%^V%
M^PC>#X7_  ^L]9\-ZC\+_AU\:?%GC7P=IFK:%K\NC:%XD^)_P%\<>([GXA>(
MDN/!NKEM \(_M >/[KPY+(/#OB&\T.33K77;+PWK6G:<CW'G7PR_: _8C7Q+
M\<-3\<:W\!]*;Q_?VGAOQ5H,'@GQ#K'@3Q)I"_ +4/#L/C3P#K5S\$M*\2ZY
MKVI_%6ZB3Q@UU:?"OPKIMQ#-\0-%\/ZK>WT!3\]/^':G[>O_ $:Y\1_^_P!X
M3_\ FEH_X=J?MZ_]&N?$?_O]X3_^:6OA(<-^'M.A6H4^/(Q>(PT</5K?ZTY-
M*K.;QJS&KBKR3A];Q&,:Q%:MR<TJJC-6U4OK9YWQK4K4JL^$)2]C7]O3I_ZO
M9JJ<8K"+!4\/HU/ZM1PR]C2I<]HTW*+<KIKW?XU?'3]GKQG^S+XT^&FE:E\.
M9_$'A[X)_L))\+;;1OAW9:)XD?XL^&=%U+2_VDYW\66GA2PU;4M6AMVL+#Q-
M=:[K4NG:M!;6C:0]](L\TOY3U]P_\.U/V]?^C7/B/_W^\)__ #2T?\.U/V]?
M^C7/B/\ ]_O"?_S2U]EDN9<&9'0Q&'PO%F35:>)Q,<5+ZQGN42<*JP6#P<_9
M^SJTDE6^J1Q5:Z<IXO$8BJW:HHQ^9S3 <49M6HUL1PYFM.=##O#Q]CD^914Z
M?UG$XF//STJC;I_670IV:4,/1H4DOW=W\/5]I_\ !./_ )/P_92_[*[I'_IM
MU:KW_#M3]O7_ *-<^(__ '^\)_\ S2U]6?L,?L$?ME_#G]L3]G+QWXY_9X\=
M^&?!_A7XF:9J_B/Q!J$OAHV.D:9#8:E'+>W0M=?N;DPI)+&K"&"63+C"'G$<
M3<4<,U>&^(:5+B/(*M6KD6<4Z5*GG.75*E2I/+L1&$*<(8ERG.<I1C",4Y2E
M)))MI%Y#P_G]//<DJ5,CSFG3IYQEE2I4GE>.A"$(8VA*<YRE048PC%.4I2:4
M4FVTD?V9U^'O_!??_DS3P-_V<-X)_P#4-^(M?N%7XS_\%R?!7B3QW^R/X+T?
MPO9V5[J$/QZ\'7\D5_K_ (=\.0BUA\)>/X9'6^\3:MHVGR2"2XB"VT=T]U(K
M,\<#QQ2LG\/^%U2G1\0>$ZE6I"E3AF]!SJ5)QITX+EGK*<VHQ7FVD?UAX@0G
M4X+XCITX3J5)9;5484XRG.3YH:1C%.4GY)-G\:]%>Y?\,W?&+_H7_#?_ (=/
MX1?_ #>4?\,W?&+_ *%_PW_X=/X1?_-Y7^AG]K95_P!#3+?_  NPO_RWS7WG
M\6?V;F/_ $+\?_X1XG_Y5YK[SPVBO<O^&;OC%_T+_AO_ ,.G\(O_ )O*/^&;
MOC%_T+_AO_PZ?PB_^;RC^ULJ_P"AIEO_ (787_Y;YK[P_LW,?^A?C_\ PCQ/
M_P J\U]YX;17N7_#-WQB_P"A?\-_^'3^$7_S>4?\,W?&+_H7_#?_ (=/X1?_
M #>4?VME7_0TRW_PNPO_ ,M\U]X?V;F/_0OQ_P#X1XG_ .5>:^\\-KVWXU?\
M>OP)_P"S<OAY_P"G_P =5+_PS=\8O^A?\-_^'3^$7_S>5]7^-OV$?VOOB/X>
M^"'B'X?_  (\4^-- M_@1X,T*37/#6K>#-6T<ZOI6O\ C/\ M*Q@U*U\3O9W
M<MD;F!9WM)IX%D?RQ*9$D5/+Q^>Y)A\3EU7$9SE-"E[7$1]I6S+!4J?-+#3Y
M8\\Z\8\TK.RO=V=D=^$RC-J]#&TZ.59E6G[.C)0I8#%U)N*KT[R4847)I75W
M:RNKO5'YO45]P_\ #M3]O7_HUSXC_P#?[PG_ /-+1_P[4_;U_P"C7/B/_P!_
MO"?_ ,TM:?ZV<*_]%/P[_P"'O+/_ )J\U]Y/^KG$/_0@SO\ \-./_P#F<^'J
M*^X?^':G[>O_ $:Y\1_^_P!X3_\ FEH_X=J?MZ_]&N?$?_O]X3_^:6C_ %LX
M5_Z*?AW_ ,/>6?\ S5YK[P_U<XA_Z$&=_P#AIQ__ ,SGP]17W#_P[4_;U_Z-
M<^(__?[PG_\ -+1_P[4_;U_Z-<^(_P#W^\)__-+1_K9PK_T4_#O_ (>\L_\
MFKS7WA_JYQ#_ -"#._\ PTX__P"9SX>HK[A_X=J?MZ_]&N?$?_O]X3_^:6C_
M (=J?MZ_]&N?$?\ [_>$_P#YI:/];.%?^BGX=_\ #WEG_P U>:^\/]7.(?\
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M+;1],T>\GT_5I+>[\JS@_&@9P,]<<_6ON+_AVI^WK_T:Y\1_^_WA/_YI:/\
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M>:O?W5_-C/VBFN52<>5W5E:[MRM7:UN^O1[I&D>3E]ZW-S*U^;X>JT5M?O\
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M,UC[OP^_Y*SA/_LJ<C_]6F#/SD_;?_Y0R:U_V;O^SU_Z=?A97\8M?V=?MO\
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M'4$&+(([@]*/[0O/^>__ )"@_P#C51W<RW%U<W"@JL]Q-,JMC<%DD9P&(X+
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M,%K+'/(CK^7W[&GP:_:7_9JD_:RTSXG_  W\(>,M8^,GQ+^'.KZ1X[^'6O\
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M%_<ZY<?$+PD88Q?7AM[6R73YO*AC7==.-B1_L9_PH#]L/_H\'X;?^(CZ9_\
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M/PV_\1'TS_Y]E'_"@/VP_P#H\'X;?^(CZ9_\^RONNBE_;V8_]2__ ,,^3_\
MS!Y+[A_V1@N^-_\ #IF?_P V'PP/@)^V*L;Q#]L'X:[)&C=O^,1],SF,.%Q_
MQ>SC_6-GC/N.<Q_\* _;#_Z/!^&W_B(^F?\ S[*^ZZ*7]NY@KZ9?KK_R)\G[
M)?\ 0!V2^Y!_9&#[XW3_ *FF9_\ S8?"G_"@/VP_^CP?AM_XB/IG_P ^RC_A
M0'[8?_1X/PV_\1'TS_Y]E?==%/\ M[,?^I?_ .&?)_\ Y@\E]P?V1@N^-_\
M#IF?_P V'PI_PH#]L/\ Z/!^&W_B(^F?_/LH_P"% ?MA_P#1X/PV_P#$1],_
M^?97V=IOBGPSK6JZ[H>C^(M"U;6_"\]I;>)M'TW5]/O]5\.W-_;_ &NQM]=T
M^UN);O2)[VU_TFTBU"&WDN;?]]"KQ_-5=?&?@][_ ,1Z4GBOPTVJ>#K2WO\
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MMB!2H_;"^&X5B"P'[)&F8)7.TD?\+LYV[FQGIN..II/^% ?MA_\ 1X/PV_\
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M5R>$.:HLSA)0<I0_M+,927+7EAY)6Q]GRU:=5<VD6J;=[R@I?K9_PH#]L/\
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MSY/_ /,'DON#^R,%WQO_ (=,S_\ FP^%?^% ?MA_]'@_#;_Q$?3/_GV4?\*
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MZA/=VE_:QS6-Q^,O@'X:_%F#_@F5^TM\!]+_ &:OC3J?QR_:VT?]JCXD^(_
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M(]'#4%AJ%*A%\RI04%*UG*WVFKO5O5ZO5L*^*_\ @H;_ ,FC_$K_ +#WP?\
M_5V_#FOM2OBO_@H;_P FC_$K_L/?!_\ ]7;\.:[,C_Y'63_]C3+_ /U+HG/F
MO_(KS+_L QG_ *CU#[4K\/?^"^__ "9IX&_[.&\$_P#J&_$6OW"K\/?^"^__
M "9IX&_[.&\$_P#J&_$6OK/"K_DXG"/_ &.*'_I-0^;\0_\ DB.)?^Q95_\
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M&RPNM0U[6;;Q-^P3X0\ :3J<WB/P WA:PU%_B_\ #F?2?A1=7%S;:;#;7/\
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MX0^+^FV>J^ +73/!\.J67BSXC;O$I_M:QM8+NYL)9&L[2Y:1+-$CRTGZ;?\
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MBE']_C]5=_\ "IF?\TE_T&=DCYO_ .%??M;?]'R:Y_XC;\%?\*/^%??M;?\
M1\FN?^(V_!7_  KZ0J2$,TL06,3,9$"PD$B5BP C(!4D.?E(#*<'@@\T_K<E
M_P PV5_^&;*/_F'^KORLOJ\?^?\ C_\ PZ9G_P#-A\W-\._VN557;]N'7U1\
ME&;]FOX+A7 X)5B,-@\'!..]'_"N_P!KD!6/[<.O[7)"-_PS7\%\.0<$*<88
M@\$#.#Q7P9^RY\9/@CK/[5'QI\?>!/VK-0UKX*_#G1?B;X0^,^L_&+]HRW\4
M77Q>^+MY\9=$M9?%_A#X3:CK:Z3\'O@]^S?+'J'P4\+>.-$\*^!-.^(6H>)K
M?P_8Z;X@TSP]!XPU_P"*?BI\;?BKH/A_XT:KX2^,?Q<C_:'U3P_^WQI'[67A
M+3O'GB^_L?@/I/AG]H_P1X%_90\1S^$YKRXTS]GSPCIG@;6+*#3_ (A> ](T
M37K_ .#NM?$'XFZ=+XMU;PY!J-G@\Q:2?U3+'=Z?\(^4:J\5=/ZAY^76W0V6
M!NVOK&/6V^:9GN];/_;-+?/=7MK;]R&^'G[7",4?]N+7D93AE;]FSX+*P/H0
M0"#]13?^%??M;?\ 1\FN?^(V_!7_  KPG_@FSXKUWQ+\$_B9I^M>*(?&=EX*
M_:6^+_A'P9XAT'XC^)OC7\-7\!1_\(WKWAC0_A!\<?&P3QG\8/ 'AB'7;G1#
MXN\4QIJEAXOM?%?@Z(R:7X7TZ5_T&K6&-<XQDL+EB4E>SR;*/TP.SMIY/ITS
MGA8PE*/M\>[.U_[4S/\ ^;#YO_X5]^UM_P!'R:Y_XC;\%?\ "N:\6?LX_'WX
MQ:1'\/?B5^V;XG\0>"-8USPMJ&OZ'9? 3X0Z!<ZM!X6\3Z/XMMM/76K!'O=-
MCN[_ $*TAGN[1&N([=Y?) D*L/K6M?0/^0UIO_7R/_0'JOKU:C^]I4<NIU:7
M[RG4IY1E,*E.I#WH5(3C@E*,X22E&2:<9*ZV5DL)2JM4ZE3&U*=1\E2$\SS*
M4)PG[LH3C+%M2C*+:E%IIIM-69[37XR_\%R]8\-:)^R-X,N_%/@FV\>Z<_QZ
M\&P1:-=>)M>\*QP7;^$O'[QZ@-1\.NE]*\,<<T(M)#]FE%R9)!OABK]FJ_#W
M_@OO_P F:>!O^SAO!/\ ZAOQ%KL\+J<:OB#PG3DYJ,\WH)NG5JT:B7+/X:M&
M=.K3?]Z$XR71G)X@S<."^(YQ46XY;5:4Z=.K!^]#XJ=6,Z<UWC.,D^Q_+=_P
ML+X-_P#1MFD?^'F^*/\ \?H_X6%\&_\ HVS2/_#S?%'_ ./UXE17^AG]FX;_
M )^YE_X><Y_^;_+\^[/XK^O5_P#GW@?_  UY7_\ ,?E^?=GMO_"PO@W_ -&V
M:1_X>;XH_P#Q^C_A87P;_P"C;-(_\/-\4?\ X_7B5%']FX;_ )^YE_X><Y_^
M;_+\^[#Z]7_Y]X'_ ,->5_\ S'Y?GW9[;_PL+X-_]&V:1_X>;XH__'Z/^%A?
M!O\ Z-LTC_P\WQ1_^/UXE11_9N&_Y^YE_P"'G.?_ )O\OS[L/KU?_GW@?_#7
ME?\ \Q^7Y]V>V_\ "PO@W_T;9I'_ (>;XH__ !^OZ6?^"</P7^+&C_LG>!O%
MGP3_ &D=;^"G@OXMZMXL^*!^%\/PJ\ ?$RR\(ZOK&O7>AWVGZ=XS\;9\4:Q9
M/'X<M;F.35F>>.2>6)2(EC5?Y.:_M:_X)G?\F%?LR_\ 8DZQ_P"IUXLK\3\=
M:<<#PMECHNI55;/\/3J4\?6K9K1E&.7YC45J&:5,90A-3A%JK"G&JES14U&<
MU+]5\(IO%\18Y55"#I9-7J4YX2E2RZJI/&X"F[ULOAA:TH.$FG3G4E3;M)P<
MXQDO5O\ A7W[6W_1\FN?^(V_!7_"C_A7W[6W_1\FN?\ B-OP5_PKZ0HK^5/K
M4O\ H&RO_P ,V4?_ ##_ %=^5OZ)^KQ_Y_X__P .F9__ #8?.:?#G]KN16:/
M]M_Q ZI]]D_9J^##*O&?F*J0O'/)''-1_P#"OOVMO^CY-<_\1M^"O^%?EE_P
M5!\8Z[HWQ_N]*L_BEX*^'G]F?\$__B?XY\!R?$/]K/XM?LQ6.F?%;3?BC=VN
MB>,/AQIWPT6>P^*_Q5TN"*SCTOPGXHM6L+B**PL)WET_4;NW>SJG_!3GXF:3
M\;?AK\,/#5[X0U:UUG0=,\*^)_!WQF^&]]\.?B!X/\82?L4W_P"T99>+OBAX
MCTKXF:AXO^TR^,;/2])\:0>!?V>;WX8VNF:IJ^B>'?']]XVTA]/KG68OGG!X
M3+5RR44_[&R>S;LO^@)/>^U]+[6TU6"3C%K$8YW3=O[4S16VZ_6VNMM;:^I^
MHG_"OOVMO^CY-<_\1M^"O^%./P\_:X"[C^W%KP4XPQ_9K^"X4YR!SC')5L>N
MTXZ&OQCOO^"M'[1%C\(_"^L):?"6\\23>-?BEH_C+XNQ>"_!C_!73+KP3\&_
M 'Q,\&_#70O$:?M90?";Q=J/Q"U7Q?K20^-/"_QLO?%&E>#O"5_87'P>C^)D
M6IZ#I]H_MI?'_P *>.OBOXST;1[&V\9>)?$.J:KX?\+_ !)UKXA^,/"/PNO?
M'[?\$M/!MQX*MM T+Q7X>T#5_"WABZ^/GC?5[:1-+AUB/5;6:[T'4]!@UOQ3
M:ZJ_[15],+EKV;?]C9197VVP.M[/;S^3^HO_ )_X[6Z7_"IF>K32ZXQ66N_X
M'[(?\*^_:V_Z/DUS_P 1M^"O^%'_  K[]K;_ */DUS_Q&WX*_P"%?DI\:?\
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M=?M=$.1^W#KY$?\ K"/V:_@N1'SCYSC"\\?-CGBOGWX7V_B7Q#^PW:?!V/\
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MMNOAJPM-,NKB]\1FXOH;FQ@_L&VCEU837MM=6<1LQ)=6UQ LD+_D+^PW\8/
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MM?\ 9N_[/7_IU^%E?QBU_9U^V_\ \H9-:_[-W_9Z_P#3K\+*_C%K^P/HN?\
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M[\NJ]S:^COK=[/6\J-TVHP=DVU>5U9KSMKOH[6OMH?J-Y%K_ -!!/_ 2Z_\
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MAUM[_P#0PR[LT?>/D6O_ $$$_P# 2Z_^)H\BU_Z""?\ @)=?_$U4HK^1K/\
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MAY2A&6&="*?MZ=6-6-*;=2.'J0=*52:K*5.I1C[7[(_9:_9&^$OQHU/X\_\
M"=>+?B38Z'\+OC7\&?A%X4?X>CPI->:XOQE^,>L_"G3=:UB\\1Z=?V@M](CM
MM.UYCI\2OJ,:W=K"@:ZMIK;U/Q%^P%\']%NI?$>G^-_C1K_@+PK\'_VIOB#X
MK\.V6B>#/^%K^+]>_9B^-5G\$KW3OAU9V]O>Z)8Z5XLU+4K;Q5*FK6OB#4/"
MNAV=W:W4^JW$R7=O^7WA[QKXR\(V]W:>$_%WB?PO:W]]H.J7UMX>U[5-%M[W
M5/"U_P#VKX8U*[ATZZMX[F_\-ZI_Q,M!O)E>XTC4/],L)+>X_>5Z[\*OVF/B
M9\+/&VG^.6O!\0[[2=(\<:3I&G_$/7O'5Y:Z"WQ%NCJ'B_6O#.I^&?%WA?Q1
MX6\1ZUJCS:GJ&M^'M?TV\U&^N[VXU)KR2[F8X9ED_%;Q6,QF X@J.@W!X?+/
M9T8<]&GE$<+/#QK5(J-"MB,RC+&K%<]Z*J65^2,37 YGP\L-A<-C,F@JR4E6
MQ_M*L^6K/,G7C7=*$KU:5' -85X?EM5<.9V<Y,V?VQ/@9X=_9O\ V@?%7PA\
M*ZOXHUS0M"\/_#W6K34/&EEI^G>*/,\:> _#_B^[LM8L-+BALK.ZTVZUF;3V
MMXD+Q"V"3/),KR-\QUZE\:_C#XR^/OQ/\4?%KQ])IS>)_%4FF+<P:/;3V>D:
M;I^AZ/8>']$TC2[>ZN[^\2QTO1]+LK.)[Z_OK^Y:*2[OKRYN[B:9_+:^HR>E
MCZ.4Y91S2M'$9G2R_!T\QKQ:<:V.AAZ<<543C"G%J==3DG&$$[W44G9>#F4\
M)5S''U,OINC@*F-Q4\%2DFI4\)*O.6'IM2E-IPHN$6G.335G*6[_ *@O^"4_
M[4?[-WPO_8S\,>"?B1\=?A=X%\8:=\1_BEJ%_P"&/$_BW3-+UNRLM9URUNM*
MNKK3II?M%O#J-JAN;*29$6Y@(EA+J&*_HS_PW%^QI_T='\$/_"[TK_XNOSY_
MX-W8HI/A%^U+YD4;_P#%[/"_WT5CQ\,/#N.2">,G'IDXZG/]$GV6V_Y]X/\
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M3G5I3K1488O S:4(5J#YFXI)NI9*_NMM-?2O_#<7[&G_ $='\$/_  N]*_\
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M?>#_ +\Q_P#Q-'V6V_Y]X/\ OS'_ /$T_P"ULL_Z%V8=/^9KAO*__,G]?O\
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MN!X2\9_#K54/AGQ#X7,D%P4GD+C]FZ_E$_X+3_M _%CX=_MCZWX2\+_M;O\
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M_8XH?^DU#YSQ#_Y(CB7_ +%E7_TJ!_(#1117^C!_$04444 %%%% !7]A7_!
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M@MY7/"FOY5_^'?G[<G_1IWQR_P#"*O/_ (Y7]S/[-O\ R;M\ _\ LBWPL_\
M4&T*O::_1_##Q<S;@#A>CE& RK+<=1Q52EF4JN,EBHU8U*N7X'"NG%4*U.'L
MU'"0DKQ<N:<KNUDOAO&/PVRWC'Q"XDS+&9CCL'5H9QG.!C3PL</*G*%/.\RK
MJ;=:E.7.Y8B479\MHQLKWO\ Y_O_  [\_;D_Z-.^.7_A%7G_ ,<H_P"'?G[<
MG_1IWQR_\(J\_P#CE?Z 5%?HG_$RO$G_ $3N1?\ @S,?_FD_+O\ B!.1_P#0
M[S?_ , P7_R@_P _W_AWY^W)_P!&G?'+_P (J\_^.4?\._/VY/\ HT[XY?\
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M_P##;B.N_P#S->I\46G_  4 _8OL+6VL;'XP:-965G!%;6EG:>#?'=M:VMM
MBQP6]M;P^$4B@@AC58XHHD6.-%5$4* *L?\ #PO]CG_HM6G?^$G\0/\ YDZ^
MSZ*7MLG>^!S-]_\ A6POS_YDOK_2U?LLS6V,P'_AMQ'_ ,]3XP_X>%_L<_\
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M $.\W_\  ,%_\H/\_P!_X=^?MR?]&G?'+_PBKS_XY7[W_P#!)'XZ_#+]DO\
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MX>%_L<_]%JT[_P )/X@?_,G1_P /"_V.?^BU:=_X2?Q _P#F3K[/HH]KD_\
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M+!_YC_X6_P#S$444?ZR<1?\ 0_SK_P .F._^7A_Q!;P<_P"C3>&?_B!\+?\
MSJ#_ (>)?MC?]%@_\Q_\+?\ YB*/^'B7[8W_ $6#_P Q_P#"W_YB***/]9.(
MO^A_G7_ATQW_ ,O#_B"W@Y_T:;PS_P#$#X6_^=0?\/$OVQO^BP?^8_\ A;_\
MQ%'_  \2_;&_Z+!_YC_X6_\ S$444?ZR<1?]#_.O_#ICO_EX?\06\'/^C3>&
M?_B!\+?_ #J#_AXE^V-_T6#_ ,Q_\+?_ )B*/^'B7[8W_18/_,?_  M_^8BB
MBC_63B+_ *'^=?\ ATQW_P O#_B"W@Y_T:;PS_\ $#X6_P#G4'_#Q+]L;_HL
M'_F/_A;_ /,11_P\2_;&_P"BP?\ F/\ X6__ #$444?ZR<1?]#_.O_#ICO\
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M'_PM_P#F(HHH_P!9.(O^A_G7_ATQW_R\/^(+>#G_ $:;PS_\0/A;_P"=0?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img132800289_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_10.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $Z G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^U#X'_ [X
M+W7P7^$ES<_"3X:3W%Q\-/ TT\\W@?PU+-/-+X9TQY9II9--9Y)97+222.Q9
MW9F))->H_P#"A_@A_P!$>^&'_A!^%_\ Y5T? ?\ Y(A\'O\ LF'@/_U%]+KU
M>O*P&!P3P.";P>%;>$PS;^KT=_8P_N>1]YQ1Q3Q/'B;B)1XCSY)9[FZ26;Y@
MDDLPQ"226(LDDDDEM9=CRC_A0_P0_P"B/?##_P (/PO_ /*NC_A0_P $/^B/
M?##_ ,(/PO\ _*NO5Z*ZOJ&!_P"@/"?^$]'_ .0\E]QX7^M7%'_129__ .'C
M,?\ YH\E]QY1_P *'^"'_1'OAA_X0?A?_P"5='_"A_@A_P!$>^&'_A!^%_\
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M  H?X(?]$>^&'_A!^%__ )5T?\*'^"'_ $1[X8?^$'X7_P#E77J]%'U# _\
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M4F?_ /AXS'_YH\E]QY1_PH?X(?\ 1'OAA_X0?A?_ .5='_"A_@A_T1[X8?\
MA!^%_P#Y5UZO11]0P/\ T!X3_P )Z/\ \AY+[@_UJXH_Z*3/_P#P\9C_ /-'
MDON/*/\ A0_P0_Z(]\,/_"#\+_\ RKH_X4/\$/\ HCWPP_\ "#\+_P#RKKU>
MBCZA@?\ H#PG_A/1_P#D/)?<'^M7%'_129__ .'C,?\ YH\E]QY1_P *'^"'
M_1'OAA_X0?A?_P"5='_"A_@A_P!$>^&'_A!^%_\ Y5UZO11]0P/_ $!X3_PG
MH_\ R'DON#_6KBC_ **3/_\ P\9C_P#-'DON/*/^%#_!#_HCWPP_\(/PO_\
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M@_UJXH_Z*3/_ /P\9C_\T>2^X\H_X4/\$/\ HCWPP_\ "#\+_P#RKH_X4/\
M!#_HCWPP_P#"#\+_ /RKKU>BCZA@?^@/"?\ A/1_^0\E]P?ZU<4?]%)G_P#X
M>,Q_^:/)?<>4?\*'^"'_ $1[X8?^$'X7_P#E71_PH?X(?]$>^&'_ (0?A?\
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M229P]Q,5?R;>.60(Y4*?E;PI^UK\4M&\7_#K3/CA\,- \'^%?BW-!;>$=?\
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M#%2QTL#PYEF,P&4\/X[VKJTZ^!RC#?VCCJ%.<Z_/F:QKQ.(BFZ2]I657Y&\
M?#CXH_'3X\>,OC7\0/ >H_"CP\/A[JO@+PSHNM3P3ZW<S:KI5SI#W,R0':\5
MM%>7MQ-.8XHVE:""!9%5W7YF\-_ [QOX$TF\^&_B?]DS6_B?XNBUNY@TSQC;
M^-+_ $OP'JVC37"".XOH;*_B2-(XTDE65EA95<?:8/,AVR?N'17)1XWQM"52
M%/!8:&#]A@:&&PE+$9AAUA89=&K'#\F)P^+I8NJI>WJO$1JUI*LY)^ZXQ:]7
M&>"V38VGAZM?.,QJYLL;G6.S'-L5E^09A/,ZV?U,)/,'5R[,,IQ658:4/J.%
MA@9X7!TY82%-Q7M%4FI?FS\6_A!XILOB#^QQ:>%/ MU#X?\ A[>:?#KD&@M<
MZIH_A2WBO+"22WDU*Z;[3+:6VV58[F;+RQQF0@9Q79^*? ?C"]_;W^'GCB'P
MWJTW@NR^&FL:7?\ B:.V)TFTO;C1?%4$=I-=;L).\MU;QJFTY>>,?Q5]YT5P
M+BG%^RA3E0I3E#*LVRIU)3JRG.&;UJU>O7E*4Y-UJ<ZTN2[:DDG/FDVW[LO#
M3*WB*U:&.Q=*%3BCA7BB%"G2PL*5&MPG@\'@L'@:<:=&$(X3$4L%3]LHP@X<
MTHT5""C%?E)X)T3]H#]G35?C1\,M ^"^K?$?2_B-KFKZMX.\7Z7J%G:Z/9)J
M\5W#'-K3SN&$=I;72-=VP\FY6Y@=8C+%*A'(>&OV9_BIXK_8TUCP)-X<O-(\
M>Z%\5;WQIIV@:L$L)-=@LXY+::WM9)76)!?17,LUA+*Z1R/"D9:/S=Z_L517
M<^-\;%JM1P&!HXR>,RW'8G%Q^LREB\3EM.5*E*K2G7E2A"I3DXU(4(TDW*4D
MU)IQ\./@OD\HO!XK/<[QF3T<IXAR/+LJJ_V="GE>7<18FCC,1##8JC@J>*K5
ML-B:,)X:MC:F*:A"E2E%PA+VGY/_  D^&,WB7XC>!%N/V0-6\$VGAVXL]2\1
M^,_&WCK6ITTG5-/:*0W/A:R6\E2Z:6>)GM[2XBE#,8Q-.L4;.WM7P%\">,]"
M_:\_:>\6ZSX:U;3?#'B:+2QX?UR[MC'IVL&*ZMWD%C/N(F**K,>!@ U][45R
MXWBO%8R..IO#0A2QN7++N2>+Q^+=&'UVACI583QN)Q$U.=2A&GRIQIJG;W'-
M<S]3)_"W+,IJ9+7CF-6MB,FS^>?JK2RK(<KCBZO]BXS)*6%KT<GRW 4I4:5#
M&5:ZJRC4Q$L0Y-U52DJ4?R\^!GP?^(B?#+]L#PUJGA35M'U3QUK'B9O"<&J1
M+9#6S<V&I"Q:UED?R_)N;AH8A*[*B^:I8A<D>[?L13^.M(^$UE\-_''PT\1^
M!+GX>QBQMM5UM[?[/XH?5=5UK5+J73[>(F6W73!/;6\OF-(EPTHEB<*-M?9M
M%99CQ+6S/#YCAZ^#PRCC\7@L;"<9UU/"U\'A(8+FI6J*-15</%QG&M&<8N<I
M02DH./3P[X;X/AK'Y!C\#F^82GDF4YQDM2E5I8*5+,\!FV:3SAPQ+>'=6A/"
MX^4*M*IA*M&4U2A3JN5.56-3X _:.\!>-/$7[5'[+_BC0O#.KZKX=\,S:B?$
M&LV5L9;#1Q)J4$B&^F##R=\:EUR#E1FK/[/G@3QEH'[4?[4?B?6O#6K:9X=\
M3ZC%)X>UF\MC%8:PBZC/(6L9BQ\X!&#D@#"G-?>U%0^),0\L65O#T/9+*O[*
M]I>I[3V7]J_VK[6W-R^T]K^ZM;EY-;<QI_Q#K+_]97Q-_:&-^LOBA<4_5N2A
M[#ZRN&EPS]5YN3VGU?ZLOK/-S>T]OIS>S]T_*'X8_L[^/O%OP>_:L\ ZUH6H
M^%M6\:>-O[6\(R:Y$;.VU273[V^U&QE63YR;*YFC@ADF ^19U<C -=9X*^(W
M[7UOX9^&_P (/#'P.N/"&O\ AF;3=#\4>/?%!L;[PB_A[3<6S75E#%<HZR/:
MA)&>*6ZDE=$2UB7SSY7Z945V5N+JN*EB?KF59=C*=;$PQE"CB%B)4\+BXX&C
M@)5(QA7@J\*E&A2E*CB%4I^TA&22M9^3@_"?#993RU91Q/Q!E%?"9;5R?'8O
M+WE]/$9IE<\ZQ6>PP\ZE;!UY8*M1Q6,Q%.GB\#*A6^KU:E.3;:E'X(\.>!/&
MMO\ M\^,_'E[X=U,>$;OX7:7I<'BG[(4T:[U6+1_#<,]M;SEVQ*)K>Y3R\97
MRW7)VDUX_P#'WX'^)-"_:)\1_%BY^$&O_&SP#X]T73XKG2_"6NRZ)KGA[7=-
ML+#359S!<02O#)%ID$BNZSVTD5S<(?)N(8R_ZKT5GAN+,;A<70Q4*%&U/),/
MD52E&IB*/ML+AU3Y:BK4*M*O0KN=*G4YZ-2"C*-DN5N+ZLQ\+,HS'*L;EM7'
M8M3Q/&>/XWPV*GALOQ?U3-,?*LJE"6#QV%Q6!QN"5'$5Z#I8NA4<XU%-R52$
M9K\O],^%7Q:L/V;_ (GWGPN^$:?!+XA^+=3L'@T+2/%.H:IXJUGPS8R.+EY;
MK4KF1=+URYMY3'#'!=I+/$LQS"\L4=?/4_PC\>:CJ'P8\4Z/^SCX[\)'PEXS
M\/MXY\2^(/$%WXM\6^*+F.YLKJ[OX[6YN9;JVT*Q-E=W"O,JR">\6 -,%#5^
MXM%=N%XYQN&EB9K X:<\3B:M=U)8G,744*V%A@W0JU)8N4L73IT::^KK&O$>
MPG*<Z:3<>7Q<Q\$\GS"GEU%YWF5&EE^783!1HT\OX?C0E6PF9U,VCCL-0IY3
M2I95B,3BZLECO['A@/KM&-.C7E*,9^T_+O\ :5\#Z[K_ ,4-;N?'?[*:?%3P
MM<6-K'X3\=?"_5Y=#\9_NA%LM_$MY+(^);7]_;A39D"/R);>X:)?LZ\KH7[,
M/QR\4_LC^-O OB/^T++Q!-XZM/&_PZ\&>(M7^WZAI>D:1&R)X?NK^:>>*UFO
MA)/-;QM.8EF6,2"W6=O+_6ZBL:7&F/P^"P.$P^%PM-X"O@<13J3J8S$1Y\!+
MFINEA\1BJE#"NLU_M3PL*/M4W%<D79=F*\',BQ^<9WFN89GF6)6=X+.L#7P]
M*AE& FJ.>04,0L3C\!EN'QV:+!I)Y;'-*V+6$FHSE[::YG^1WPN^%EYXC\:?
M#_3+W]CS5O"QT.ZL+GQ?XT\:>.=9.G:3>::UN[ZEX8LH[Z99Y9)H)98;&59A
M+*\,1DC@C>4_JOXEAEN?#FOV\$;33SZ+JL,,2#+RRRV,Z1QH.[.[*JCN2!6U
M17E9QGM?-\3AZ]2BJ,<,G[.E];QV+CS2J>UJ2Y\=B<3.'-))<E)TX*,8KE<E
MS/ZCA'@G!\)8#,,'0Q;QE3,9PE7Q7]EY+E<^2EAUAJ-/V62Y=E]*JZ<.>;JX
MB-:M.K5J2YXPDJ<?QCT[X.?%2/\ 89\3>"'\ ^)$\7W/Q3&J6_AUK C5)M.%
MRK?;4M]^3;[>=^X#%>[_ +5WPY\>>*_@G^SSHWASPGK>M:OX?U[PC<:YI]A:
MF:ZTN&TT&*"YEO(]P,2PSYCD.3AP1[U^DM%>K/C/&3QU#'/!X;GH9KC\UC34
MJO)*KC\-2PTZ3?-S>SIQI*4&GS.3?,VCY6EX.Y31R;&Y*LWS)T<=PMD?"LZS
MIX7VD,+D688G,:&*@O9\CQ%:IB94ZL9)TU",7"*E=LK\]OV*_AIXE\+ZW\?I
M_'/@R[TB/7/B-=:CH4NNZ9"/[0T][K4W%S8O*LA>W<21ME2 =RDC.#7Z$T5X
M&$S2K@\!FF IP@X9I'"1J5&Y*I26#Q'UB+I\K2?._=ES)^[MJ?>9KPSA<VSW
MAK/:]>K&MPS/-IX?#1C3E0Q7]KX*.!JK$<\7)*C"*J4O9N-Y_%=:'S=^TQXK
M\>^"_A9?Z;\(/"&K:]XT\1^9H>C+X?T\/#X=ANU87^NW'EA(8&M8I&%D#R]]
M-%,RM'#+7PCKO['GQ ^#/P^^%_Q:^%JZEK/QR\':G'KGC;3;2:2Y?7DUB6*6
MYT^VA9QYZ:2K-87R%Y/[0MY[ZXP[B+;^O]%>GE7$^*R?#TL-A,/A^26*GB,R
M]JI5/[5ISI2H+!XM-I?5(4JE5*G"S]I4=;F]HHM?-\3^&F5\6YCB<RS;'YA[
M>GEM# </K#2I45PQB*.*I8Z6;Y4U%O\ M2KB\-A7/$5>;_9\/'"**HRFI?G/
M\9]*\>?%/XA_L@^/M.\ >)[&'3?$$>I^,;&XL'6?PA,;O3S=P:OEOW4<,L4W
MES#<LT*K*IP2!X=^V5^RUXU3XFV?CKX4^'-7UWP]X]U?3]4\7Z%H4)ECTWQ3
MIEU&TFL7%HKJIM]2MIY[E)PI:&].H@E4N44_L3175E_&6-RNOE]3!X6A"C@,
M-C,(L-.=6=.OA\7C*N-C&JW+FYL-5G%T:D6I?NTY7YIJ7EY_X0Y-Q+@L\P^;
M9ECJN,SO,LHS>694J6&HXG!8_*\JPN45*N%C&FZ:IYAA</4CBZ$U*G_M,U!+
MDI.%:S5DM+5&!5EMH%93P598E!!'J""#[U^47P\U7XM? ?XZ_M#^*(_@!\1/
M'NE?$'Q1&=(N]"%G8VZ6NF:AJ]P+L2WBR"YBO%U*/R#%LV"%RX8.NW]9J*\G
M*<XCEM+,L/5P-''X?,Z%'#XBC6JXBBN6CB:>*@XSPU2G43]K2A>TU=*SNFT?
M5<4<(SXBQ'#V-PN=8S(\PX:QN*QN QF$PN!Q<G4Q>7U\MK1JT,PH8C#RB\-B
M*J5Z3<924E9Q37YZ_%:'XD_M:_ [QYX<B^$?BCX6^)_#.J^&];\.:9XTO+$I
MXODMWO)[RSLIK98TMVCMXG@#SL$-U<VRET0NP\4^%_PIN_$GC'X?Z1J'['FK
M^&CX?N],O/%OC7QKXZUG^SM+U+1WMYQJGANRAOI4GEEN[3SH;!DF61G6$R+;
MQEV_76BO4P_%U?!X/$8#!X&EAL+.I6K86G2QN:4W@ZF(P]*A7?/2QM.>*C)T
ME6A#%NK&G5E+E7LVZ9\UC_"K!YMFN SS-L[Q68YG1P^$PF:8C$Y-PS7CF^'P
M&/KX[!IT<3D]>EEE6$<1+!U:V5QPU2OAHP<VL1%5U^9'[:_P?^)\OCC1/B9\
M&-&U;5-7\8^%-8^&7CNWT6$22OI%]%'#!=7N70^1<6DALFDSM@%C$[8+"NR^
M./[+.L:C^RMX&^%W@"U@U#Q#\,YM$U^+2C+':KXFU*"VO$\1PQW#M&B7-_-J
MFHW5KYDD8>01P>;'E&7]!:*RI<79G0H9)1IQH)Y'7]O2J2C)RQ7)S1P]/%VE
M'GIX:A4K8>ERN$HT:LDI)I2.G%>%/#F,Q_&F-Q%3&R7&F"^I8G#PJ4X4\K55
M4:F.Q&67IR]G7S'&8;"8_%.JJM.IBL-3<J<H.<)?E)\'_AC)XE^)/@=KC]D3
M5O NG^'9+;4]?\:>-O'6M32:3K&GXE2?PO8K>RQW8GN8U\FTGB<[7)GG6.,E
M_0OAK\/_ (G:1^T+^UQXEL_!J>5XITRX3P5<^+;66/PEXHNVN)&2QN)HRS2V
M-VI,-PVPHL<A:1'CW*?T9HK3$\78K$2Q?^RTU3Q6!IX'V57%YABU3C#'4<?*
MHIXS%5ZEZE2A&G*$94Z:I62CSIS>&7>%.69?#*^7-,2\1EN=5\Y^LX7*\ARJ
M=>K6R;%9)3H2I93EF"PZA0P^+J5Z=6I2K5WB;N=1T6J*_"OQ'\%OB#XE:RLO
M!G[*WBSX1?&0:S!]H\<>$O%3Z9\/+.);]Y);VWL?MKND1MVC/FK>R(GE-)%"
MXD6%?V\\.VNI6/A_0K+6KL7^L6>CZ9:ZM?@DB]U*WLH(KZ[!(4D7-TDLP)52
M=^2 >*V**YL]XDQ&>T\)1K8:E0A@Y5YP<:V+Q-5RKJFIP]OC<1B*T,/#V2]C
MAXS5.FY3:3<KKTN"/#O+^",3FN+PF88K&ULVIX.C6C/"95EN%C3P+Q#I5?J6
M38'+\+5Q]5XB?UO,*M*6(Q"C3C)QC"S_ # \ _#/X@V.I_\ !0"6\\'Z[;1^
M/=+UZ+P6\UF57Q/)/8>.(X4T@[L7+2/>V:H/ER;F+^]Q GPR^(8_X)W#X?'P
M=KP\<!)1_P (L;,_VSSXSDO0!:[L\VI%P/F_U7S5^HU%=4^+\7.K2JO"8=.E
MF.39DDI5;.IDN!A@:--^]\%:$%.J_B4FU!I'E4?"7*J.&Q6&6:Y@XXKAWC#A
MR4W##*4,/QAGE3/,7B(I4[.MA*U1T,,G>G*DDZL93NWY;\$=+U'1?A#\.-(U
M:SGT[4].\(:+:7UC=)Y=Q:74-G&DL$T>3LDC8%67/!&*^4_'NN_M+?"[XP^+
M=4N? NK_ !^^"7BNWC?1O#>FG1Q/X4F+B3[(MI=0EBT+M-;&2YCNX;RT,,GF
M03(RC[^HKR<)FZP^,QN*K8#!XVGCU65;#XA54H>UK*OSX:O1J4\1AZU.<5R5
M:512Y>:,E*,FCZK-.%98_*,GRW!YYFV38C(WA'@\PR^>'<JWU7!RP3HYA@<5
M1Q&7YAA,11G)UL+BL/4IJHH5*;A."9^9?P$^$OQ!UWX_>-/CUJGPN'P1\)W/
MA;4M&TCP2KVB7NMWE_9"V-Q<V-BRP1 ,AO)Y?)MH7O%A2WM0-TB_./@K]E;X
MF6/P[\7_ !8T+PUXG\._&_P-\49/$'@_3[I7MY-<\-6L_G3VEG8A@D\ETT\D
MHD>5!/;+<6; B917[A45[U/CK,J56M4I8?#0A5IY9AO8<U>I36!RSVR6"JRJ
MU:E7$4L5"O4AB95ZDYS4O=<;)+X:MX(\.8G"X*ABLPS+$5L)7XDS%XQQP5"O
M+.N(_J<IYOAH83#8?#9?B,MK8'#ULNI8.A2H4IPO4A4;G*7YN?&#2OB%\5OB
M'^Q9\0;;X>^)K :3XJL]4\=6,U@ROX/GCUKPZ^H+JF6'E6L4EI>203_,LUK$
M)AP177_"OP+XRTK]M[X_>--1\-ZM9>$M?\,:-;:+XAGMBFEZG<0V7A9)8;2X
MW$2R1O:W"LNT8:"0?PU]Z45P2XFK?4IX"G@\/2H2RS&95!*=64J>'Q>:PS2Z
M<I>].E."H1<M)4_>DG/4]Z'AOA'G%'/,3F^.Q..AQ)E'$]:4J.%IT\1C\JX8
MJ<,<DH0IKDHXJC4EC*J@TX8CW*;C2]T^"?V._ OC+PCX]_:,O_%'AK5M!LO$
M7CZ2_P!"N=2MC!%JMF;F_87-DVYO-BVNAWX PZ^M>@?M?_ G7OC3X&T6Z\%3
MV\'C[P!KB>)?#"74@@AU$JJ"]THW)RMM+<F"UGMYG'E^?:)#(R),TB?6U%<]
M7B+&SSNEGM*%*ABZ2PRC32E.C*.'PM/".$XR=Y0KT8.-6/,KJ<E%QT:[\-P!
ME%/@O$<#XNMBL;E>*>8.I7E*%'%PGCLRKYK&K1G2CR4ZV#Q=:-3#3Y&E*C3E
M.,_>4OS4\8?%W]K[XF>$[;X;^%O@1XG^&OCG49+.S\0?$.YU:PM]$TM(9X6N
MM0T>99&>T65T!9C)>R)"[I;I*S*14_:;_9\^(NH77P,^()T?4?CE=_#O04\,
M_$70X+Y='U[Q-!*S7=UJ]E<6SVCAY+J:X!-L4E@\JVD>&:.2=4_3:BNVAQ7/
M!5\+5R[*<MR^G0GBYU*5!8J4\2\;0>'KQJ8NIB)XRE35)VP]/#UZ4:$[5(WF
MDUXV-\+Z6<8',\+Q%Q5Q#GV(QU+*J.'Q6,_LRG2RY9-C8YA@JE#*\/@*>4XC
M$3Q45+'5\=@\3/&TG*A/DI2<7^=_[-?PYD_X2[Q=XU7]F^Y^#ME:^'+[2O#^
ML^(_%FJ:UXRUB:^MTCN+&?3I[F>S%H-DK_:ML7ED6T$2RLTLB_..A_!SXJ0_
ML._$?P3-X!\2Q>+M1^)UOJ=CX=>P(U2[T];W39&O(+?>2\ 2*1B^X<(3BOV>
MHK:'&6,AB:F(6$I2Y\9DV+A"KB<;B'3_ +&G6G1I>VQ6(KUI1K2K3E5;GHW^
MZC!.QR5O!_**V78? 2S/%0=+*.+<JJU\+EV2Y>J[XOI8*CB\4\)EF P6"IU,
M)3P-&&%C"A[T%;$3K22D?FS\:_!7C:\\!?!73M5_9WTCXR>"](\&:59>)K&"
M>;3_ (F>&M673(X+B/2IS/%#;6Q(B8LJW6+B&2.>!08Y2W]B[X5_$;PA\1O'
MGB4^$?&'PN^#VH:+#I_ASX?^-/$!UO4CJWVBRE^WQ()72&.W6'4 ;CRK=MMW
M':!9UC,J_I116$N+,4\IQ64K"8>-/%JI&I4=;&SBHU<3]:<X82IB98*&)4_<
MCBH4(U53NK\S<WVTO"S+8<4Y;Q3+-<?/$97+#U,/AXX3)Z$Y3PV6QRR%&KFF
M'RZEG%;+I4H^VGEM;'5,,Z]G;V<8TT4445\H?J(4444 %%%% !7D_P >?^2'
M_&+_ +)?X]_]1?5*]8KR?X\_\D/^,7_9+_'O_J+ZI7+CO]RQG_8+B/\ TS,^
M@X2_Y*KAG_LH,F_]6.&%^ __ "1#X/?]DP\!_P#J+Z77J]>4? ?_ )(A\'O^
MR8> _P#U%]+KU>E@/]QP7_8)AO\ TS GBK_DI^(_^Q]G'_JPQ!^+O[?WQV^*
MW@O]K+X2?"KPS\8_C[\,_ GB/X ^-O&=]I_[//PJ\-?%?QCJOC72?%UMIFC7
M%UHFL^&->NH-'2QGGCN[I)K.P2X2R@N9(?M1N$YW4/\ @H%^TK^S=^S!\)?$
M7[0'@GX>ZI\9;?X1^)_B7\2?#/B[Q5=>%OB=KVCZ%XOETO1+?3/ASX+\->)5
MT/7=1\)O9ZMKOB#Q+/X>\#V&KB73/MT5Y*]K!^LVH_ _P!JOQO\ #7[0MW9Z
MFWQ+\)_#[7?ACH]_'J]]%I,?A/Q'K%GKNIVUQHB2#3[J\DU&PMI(;^:)KF"-
M6BC<(Q%>._'W]ASX#?M(^(]6\5?$.S\9VNL>)/AQ<?"/Q?-X,\<^(/!\7C3X
M<S:JVNQ>%/%<&C74,>L:99:R[ZE91RA7@N7<EWC8QUUG@GPE\8/^"@_[3&IZ
M-^V8/@A\(_ASI.@?LU?#SP[XD?XB^,?'-_)K2W'CGX=Z5XUTH6?@JV\/2V=]
MJVC0:E<R/'/JXT>>2SMXWN6:X:"H/^'@?Q5^%<NHR_$[P1)XE^(?_#-_[..O
MZ)X.T'Q[8CP-X@^)?QJ\6S>%=#!:\\%Z=>>'$N9);;5/$NMS:SJ-K#;+-8:;
MH44L,4]S^@^A_L7_  &T+2OCAHL.A:WJ&G?M$>'O#WACXI6^L>)M8U(:QI7A
M?P9;^ M(6R:>X+:3<P^'[6!);JQ,4L]]&+^5FN"6/ 67_!.3]EZ#PUX@\*ZI
MH'C#Q7IGB7X9^%_A/J,WB_Q_XH\0:K'X6\$Z[<>)?"$UAJUY?'4-/\0>'-9G
M6[TG7[6>/4;7[-:1+*8;=4H \E\:?M-?M%^$M0_9CTOXU?":U^%?B_Q_^U4O
MPJO]-^'GQ;TKQ'X2\0^%O^%<^)/%=KKT]U=>"+S5=0TFXN-/CM+GPU<P^$-6
M6ZB2]CUD6T?V>Y\V^#O_  4R^*_BF?X0:Y\5O@#X+\"?#K]H31/C-_PJ#Q1I
M/Q=M]0FNO%GP:L];U:_TWQM#K.@Z/9^$- U[2=#NIK/Q!=7<T>F2AAJ=O'&$
M,GU?X?\ ^"?OP \)Z3X0MM'@\>ZIK7@/XIS_ !N\/>)/&'Q)\8>+->O/B7_P
MBNI>$+/5?$FJZUJ5Y<ZUIMIHNISVD>C3E=/51')Y!EB1QX+^S)_P2M^#/PR^
M'^E6OQBT^Y^(OQ"?P?\ $?P7K32^+O%5_P##_3M.^)6KZK-XEO?!'A'4;M=-
M\*ZSKFC7=I8:MJVFVL-]*T,ACF17Q0!Y%_P]B\7V7PW_ &C?%,WPI^'_ (K\
M1?!/PK\$/&6@KX$\>>)+SP1XOL?C#XWMO!LNC)XEU_P7HMW+?^&YYW(US1=*
MU/PQKDT1?3=1:S9;@Y'Q=_;_ /VNUT'Q#X+\._"CX:_#GXU_#/\ :]^!'P0\
M>V4OCN?Q9X4U3PM\8?#R^+?#::+KO_".VTUO?ZCFWT/Q1<MI<W]B6\UQ>:6;
MV:,*GV5;_P#!,W]F1- \:>'+]?BGK]CX_P#!WPX\ ^))O$/Q5\6ZM?S^%/A)
MXBL?$OP\TFTO+F\,NGP^&;K3K.QLC:>4S:/%_9TYEB=RW=_$7]@_]GGXHGXQ
M2^*=)\6"\^.'CSX;_$SQGJ6C>-_$.B:G:>-OA/I-OHG@G7/"M]I]W#/X7N-.
MT^V2.9=*:*.\=I9;A7>1C0!X%\./V_\ QAXL_:HF_9V\8^ _A]\,Y[7QEK_@
MQ]"\:>-/$7ASXF:LFAZ%%J%MXT\#:9K?A"R\'?$/PKXBOQ<PZ7;>%_%-SKEM
MIL27]_91LS0)I?MB_M?_ !C^'WCKQQ\#?V>_A?I7C'Q?X0_9E\8?M">/?&&O
M>,[3PJ/!GA2"?5O#^C3>#["[TG4[;Q/XM@U/3KC5%T[5&L=(,$-O%/<2-)+#
M7NFG?L/_  /LOB+X6^)-Z_Q#\3:CX'\42^./!OA[Q?\ $7Q-XH\'^%_&T^CK
MH=QXLT30-8O+J.QUB:R#LYBG%D+N::[2S2>1GJQ^T/\ L1? +]I[Q#I7BOXG
M:1XIC\0Z=X4U7P'=:KX,\;^)?!%UXC\"ZS.UW?>#/%;^'+^R_P"$A\-/>237
ML>EZB)8(;J:6:/#.: /SN\,_\%*/C7HGP?T76]&^$UE\:;7X%_LT_"7XT?M6
M?$/Q'XUTWP/KDB>-]!;6KR'P!X;LM#EL-?U^WTBPU'6KQ)VT+1Y)##I]E()B
M5'N&E_\ !1_4=;_:8T3X.#P5X,\$>#_$/B#P3IOA74/BKXJ\0>!/&?Q)\->-
MO"MEXALO'?PO%]X5E\ >*[&.]U"'18_"J>,+?Q7=W4%TT-D"D<;^N^*/^"9W
M[)GBY?!,6K>$_%4=KX,\">%/AE<6.E^/_%>DZ?X^\!>")%E\,^&/BC9:?J5O
M;>/]-TUP^V/7X[AY4FFAGDDA?RQW_B#]B#X%^*?B#IGC[7[?QMJD6C^,_"WQ
M$TSX?7GCKQ!<_"RP\<^";.*R\)^)K#P)/<R:3IE_H,=O;RV,.F"ST\75O#<S
M64LR;R ? _@G_@L+;:_J7B_Q1K/P9NE^"]IX3^._BKPIXE\,:IK^M>+K*#X%
MVFKWUQ!\4-*N/"=CX8\&-X\M]"U)/!YM/%.L^;=K#:WHAF=D7T#]FS]J+]J+
MXL_MA^!O"_Q?\*:+\*O GC/]D@?&/P]\/_"WBO3?'&CZP->\6:=_87B/4=9E
MT#2]=TWQ%I^CW(TW4])67^R \RR6WVIT>>OJKPC^P9^SMX*\2^-==T;2?&<F
MB^.[#QMIFK_#/4OB)XQU'X0V=G\1GFD\:QZ'\,KC5F\)Z/\ V^]S=/=?9=/4
M1R75S+:B"2:1S7^ ?[ O[/?[-WCV/XE?#>U\?2>+8/!+_#FTOO&'Q'\6^-(;
M#P2NH0ZC8^'+"T\0:C>P6>FZ1-"L.D06ZH+"T9[:+]VP  /A3]KK]O+]H<#X
M]:-\!/!%AX6^'WP$^.'PD^"WC3XU3^*M+;QG#XR\0>(?!M]XAM-$^'VJ:#J6
MGW_A=M$\06VBW.IRWPU)YM4:>PM$-K)-#[?'_P %"-</[46C?L_7'A7X>ZGX
M?\5>)?B=X)T_7O!/Q U+Q+XL\-ZI\/?!MYXF@U#QAY'A5/ VG7'B!K&Y@7PS
MIGB?5O$GAS8DFN6$3.L!]B^*_P#P3B_9>^,GQ$U_XF^+= \96NO^*]6\*^(_
M%&G^%_B%XK\,>%?$7BGP7=6MQX=\5ZUX6TC4;?1=0\2626<-DVK7%J]Q<6.Z
MVN#(I!6_HW_!/G]G7P]\1='^)6C6OC^PU3PYX\\:_$KPWX?A^(GB;_A"?#WB
MWXCZ9<:5X\O](\)M=MI=K'XKM;@G5[<QO'-/%!-&(FCY /S#\._\%"OCYI.C
M_!+XOZ79ZKXT\&3_ +&OC'XV_$#X7^)O$6F:EJ%U!X<_:"E\%^(O&"^+]%\!
M:-J&K^(?#O@^&XNM-TVVT31=(NK>,VUW;B:#^TI/UI_9W_:4NOVBO%'QXF\+
M>'M*/PJ^&/C#2O G@3QU;:Q/=S?$77(_"NF:]XMN8[46*:?9:/HFHZO::):W
M5IJ&H/=7,-]YZ6[V_EGRG6?V#_ OPZ^&T5C^SKH&EI\0O!_P&\9?L^_#F/XK
M>*/%VM^"8O OC[Q->>)O$=GXIM;&Y:^U:X>_U34+BVOWWW<:^18^8MH"H]H_
M8U_9KT?]D?\ 9O\ AG\!M)O;?5I?!FCN->UVUMI+.'Q!XHU2YFU+Q!K,=M+)
M++#%>:C<S&WBED=XK5((V.4P #\NO@5^VU^U3+=ZIH]WX8MOB]\;_CW^TE\<
M/A_\'O GB'QSX?\ "7PH\ ^"_@.^K7GC%CJFC>#Y-?M(](T_[%:Q27T_B/4?
M%-R\%Q;)I\=K<K/[#X1_X*2_%OXK^/\ ]GKX5_"[X!^%'\=_%(_'#3?B79>,
M_B/=:9IGPT\0?L[>.M'\&_$NWTS4])\.:HGB[30-2:]\/W5NEG+J+-:P20PA
MKB2'ZJU__@GW^S;XA\#1>!;C1?%VG6]C\5/&/QFT+Q1H/COQ+H?CSPOX]\>W
M5S=>*M1\,^,=-O;?6M'LM6^USVT^DV]Q_9S6;BW-N4CCV]1\/?V)_P!GOX5^
M*_@YXS\"^%M2T/6O@7X*\?>!/ 9B\1:Q/:C2?B?J6GZQXXU#Q%;W-S,/$WB/
M7M5TV#4+OQ!K#7.I&Z>XD$X\YA0!X+_P4_\ BY^TU\&/V>]0\<_ &Z\,>%=-
MT*^\+7?Q!^(.I7$5[XGT;3]3\?\ @[PQ9Z%X(\-WFF:AIE[J6NRZ_*+_ %;6
M5^QZ7I-K=)!!)J%W;36WRO\ MR?\%&M:\ _M+?!+X#?"KXH>$_ VE>!_C%\(
M+']IS7-4OM!_MJ]L?'P%W:^!M+T_5K6\>WT2T\/2#Q!XW\2V\5L=..H>'M,L
M[Z&YN+@#]??C?\%_ G[0GPP\2_"'XEVFHW_@KQ8^AOK-KI6JWFB7\K>'?$>D
M>*M,,&IZ?)%=VWEZQHEA++Y3KY\"26\F8I7!X;XO?LE_ +XY7?A#4?B%\/=$
MU+5/!7COPS\1-+U>TL;+3]7O_$'A..6+2(O$.IV]J+WQ!HHCD"7NAZI/<:;?
MK#;"ZMY!;0; #SS]I_\ :<\<?"?Q7\"/A;\%OAMHWQ7^*?Q\UKQ%%X;LO$7B
M\>"_".E^&?!V@_\ "1^(M=U+7H]-U>>69[)X+?2+&TLY&NKF</-)#;HT@_-?
MX8_\%(_C;X#_ &2O#WQ,\?IX \=_$"[\2?M7Z[K^F^//&1T;Q3)H7P=^)OB/
M2].\#^"O#/PZ\&:Q=ZV;#2+$Z2GC35+#1_"FFQZ?:2^(-;:[OF8?KE\?_P!E
MOX1?M*:7X/L/B/INNV][\/\ 7#XA\$>)?!7B?6O _BWPOJ$ME)IE\NC>(O#E
MW8ZA:66J:9*^G:G8K(;:\M"(I(_E1E^=8/\ @ES^R;8>$M"\%Z)H_P 0_#ND
M:)X8^)W@:2;0/B?XOTW5O$'@3XO^)IO&'CSP3XHU:+4#?:]X8U;Q)/+J@TV\
ME86\SLD<GE,T9 /)KK_@I7XD%W=>$;3X1Z-%\3?&NK?LL2_ 'PAJ?C"[MU^)
M'@W]I33K/4+KQ%?W<.AS/IC?#G[/XHM_$"V,&HV<TFBPM'=1)>9BZ[X0_M_>
M(_B+^U+J_P"S_P")? _@?X;"S\9?$#PE9^&/&WB[Q!X7^,UY:>#MQT3QGHGA
M?7_"EAX5\<^&O&D,,VHV$?@KQ5JNIZ7I9ANM1M@?.2/9T#]A>>']KKX-_&G6
M'\'0_"S]EGX*)\(O@+HMJ=>U?XA:JMSH^F:2FJ_$G7-8FDL+T^$K:WU6'PNU
MC&UV)=3:^N)A<-.7]A3]B'X+P_$>R^*KOX[UWQ/X<U[QAXQ\!:9XM^(/BCQ%
MX1^'WC7QOIMUI>N>)?!NB:A>S-X?OKBTO+F"%;&Z%MIT5Q.=,MK21@X &_M^
M?%GXH? S]D;XT?%7X.IH7_">>#_#D5_IEUXA9C8Z9!/J5E8WVJ16_DS1WVH6
M-K=/-I]E.JV\]TL8G;RU*/\ FUXE_;M_;!^#?Q2^+NN>)_A_X5^('@;X;_!3
M]F+QI\1_"$?CJRT73? $WQ#O+C2?$.I>!+\^%1K?C#6]:-U9ZI)I^K/:Z;;+
M93V]M):LRB7]6M,_9QT'5OV9U_9J^+>N:W\4=!U7P7=>#O&>O:QJ>H1Z[XB@
MOI)IKB[.K?:9-3@N[>22/[!>FZ>\@-K;3-*TRECY@G_!/?\ 9S/A7Q_X0O;3
MQ]J^G?$WP+X!^'?C&]UKXB^)]3US4_#7PTU.?5O"<0UFZO'OH+ZTNKAUN=0B
ME%S>VZQ6]PS11JH /F:?_@J/<7'[3U]\(/#WPB?7_AGH/Q@\*? _Q%XGT_4?
M$=]\1[7Q-XJTO3[S_A,K;P5IGA*_T1?AOH%_J^GZ;KNK:EXJL=2M0TU]_9XM
M%5R_]GC_ (*-?%OXM?%CX)>%O&OP#\+^#_AM\??''[1'PY\">-M#^(\^OZVW
MB+]GM]>DUF]U+PU<>'=.%KHFJ1:%<6=O-]O:[340Q6"2R,<[_7L/[$WP.LOC
M2/COH\?C_P />+Y]7TKQ)K>C>'/B5XRT+P!XJ\4:+I,>AZ?XF\6> ],U6V\.
M>(-<33(;:VGO-0LI1>"UMVNXYGB#4_P-^Q+\!/AW=_!>]\,Z/XCM[CX!^,?C
M%X[^'+7?BS6;U;'Q#\=FUA_B'-JB7%PRZS:WK:[J']F6=^)(-'#Q"Q6(0QX
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M@[3/@[\<_BO\+=0TSQ#XEU.YDD^#%CJ>I0>&/C'.O@N#0? >H>-M-TV:_P!
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M:O\ P4^K:T^D1SZ?<>*]!T_3M7NQ;:==IIT>J)%$;IHB6\1_: _X)KZ?XO\
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M;2(K:,S:AIC13WTN^2Y+NQ- 'PCXG_:T^-DGQ@\(^#K/6M6\'3V?_!2+X1_
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M?\%>,_$?@?5[_P )^)5C&N>$==O?#E]92ZUX9U*2**>?2+XRV_VA!*@1F?<
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M]_\ AO?]M+_HYKXN?^%-)_\ &:/^&]_VTO\ HYKXN?\ A32?_&:/^):N(O\
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MB+_HH\D_\$X_R_Z<^;^[S#_B.V2?]"/-O_!N"_\ EQ_H$45_G[_\-[_MI?\
M1S7Q<_\ "FD_^,T?\-[_ +:7_1S7Q<_\*:3_ .,T?\2U<1?]%'DG_@G'^7_3
MGS?W>8?\1VR3_H1YM_X-P7_RX_T"**_S]_\ AO?]M+_HYKXN?^%-)_\ &:/^
M&]_VTO\ HYKXN?\ A32?_&:/^):N(O\ HH\D_P#!./\ +_ISYO[O,/\ B.V2
M?]"/-O\ P;@O_EQ_H$45_G[_ /#>_P"VE_T<U\7/_"FD_P#C-'_#>_[:7_1S
M7Q<_\*:3_P",T?\ $M7$7_11Y)_X)Q_E_P!.?-_=YA_Q';)/^A'FW_@W!?\
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M0;#5-62VE\*^$;V>&VM/$NH2-*8)]&N;BX@@AO=-FOHY)9 J\J^WRN']M/\
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ME\./CA^SY\4-*^.7B7Q5X/\ #?Q"\$>(]<O_  [H?B;PAHFIZ_JNE^*-.N=
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M%/&9A*C1I86$*U2=:K1P]&G)J52%./,X*%6I&G3HT*%.<;4Z5%19\V45]3?
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M9K^6VNI3)J9:1&F$K[S_ $'?\0^7[-/_ $6[X^?^!'PY_P#F$H_XA\OV:?\
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M@XZDW*6"PDI/=RS+"MNRLKMU&W9:>A_)C17]9W_$/E^S3_T6[X^?^!'PY_\
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M(O!VNZ ][8SV5R(T>\TS78I7B5Y5@FAV1$MWWAK]J[]GCX9>!OC/X$^!]O\
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M7,5A [EHK**YF EN([5"L"3R@22J@D<!F(K^LG_B'R_9I_Z+=\?/_ CX<_\
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M+PE<_$'P+X_O[W4/$=B=9/ABQMOAEX$O2?$/BW5M$\3A].\3WZB*Q?2+2_\
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M_$5ZVI:]\$_B9K.H-&D+7NI_ 'Q?>W311 B.,SW&@22%$!(1=V%!X KZKHH
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MB@#P+_AH?PW_ -"#\;__  S/C[_Y3T?\-#^&_P#H0?C?_P"&9\??_*>O?:*
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MMH/@_P#%*&W7SBMO%\ _%T<(-P9VN"(D\/B,>>US<F;"_O3<3E]QEDW?35%
M'S7:_&?X>V,=K#9?";XL6<5E)'-916OP'\8V\=I+##);Q2VJ0Z BV\D5O-+!
M&\01DAEDB4A'93K_ /#0_AO_ *$'XW_^&9\??_*>O?:* / O^&A_#?\ T(/Q
MO_\ #,^/O_E/1_PT/X;_ .A!^-__ (9GQ]_\IZ]]HH \"_X:'\-_]"#\;_\
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M**./QQXF2..*- J1QQH B1HJHB@*H"@"@#ZHHHHH **** "BBB@#@?&GPO\
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MKW5=5N)+[4+MHH$B@B:XNIY93'#''$A;;&BH HR&_P"/J#_KG/\ ^@BDL_\
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M\)^%_#WAA-8^%^@ZMJR:!H]AI(U35+@3^?J6H_88(3>WTV/WEW<F6=A@%]H
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M;/\ B3_[B?\ I,C[K[,?^W?S18JO:?\ 'I:_]>\/_HM:L57M/^/2U_Z]X?\
MT6M2O@E_BC^4Q]5Z/\XG[J?\$*O^2R?'+_L5?A'_ .K*GK^LSX\_\D/^,7_9
M+_'O_J+ZI7\F?_!"K_DLGQR_[%7X1_\ JRIZ_K,^//\ R0_XQ?\ 9+_'O_J+
MZI7_ #[?M!_^4C>/?^R<X3_]8[+#]P\*O^1EPE_V4N7?^KBB+\!_^2(?![_L
MF'@/_P!1?2Z]7KRCX#_\D0^#W_9,/ ?_ *B^EUZO7\9X#_<<%_V"8;_TS ]_
MBK_DI^(_^Q]G'_JPQ 4445UG@GX^?\%-OA2_Q0U7X;0:-X/^&OBR.PU*ZM_%
M%Q>>"/B#XN\8^&-3U"QMX]%U6_C^&MW+<7#RZ1]IM_!FD^+-*BTR74VN+Y=<
MTJ&U$R_7O[7.HCP5^S/JGBA9-7EF\*:?X3M[/P];Z_=>%;/Q)=ZMK7A[P[;Z
M/KUXFJZ8MM;W#W_D)/J>K1:9I5W-'J.I/<6]I(C_ #)^W7=?#CX(>,M*^)'B
M;X5_$;XRZC\=KF#P;)H7A0>*5L=#D\%>&Y4LH+B[\&:I::KID7B*&_FACO)M
M&US9>PR$SV$(1']K_;@\+:;J/[-]]XTU'Q)J/A'1?!OAG3GU3PS+X:^'_B[0
M_$6E:IK?@Z0Z#XFM/B)X+\4M*EC<:9:G3VBNM&LO[4\F\\0O<VUI&UH >E?L
M5>(=7\9?LZ>!O&>N076FZCXEE\37$GA^;Q3_ ,)E;>'(-*\6:[X?T_1[#Q F
MKZ[;W\5MI>D6(NIK#4Y=,GU,WUWIUKIMK<1Z=:_3&MSZM;:/JEQH-A;:IK<%
MA=RZ3IM[>G3;.^U%(7:SM+K4%M[MK*WGG$<<URMM<-#&S2"&0J%/RM^P9!:P
M?LF_"1;*RM-,M);?QA=6VFVFFZ-HXTZ&]^(/BR\CL+S2/#OAWPKH.DZO9K.+
M?7=,T;18=-L-:CO[2RO-7MX4UB_^O: /E;X0>*/VG;WX$Z1JWQ@^&GAF'XSS
MZOXLM/$?A>+QI8:-HUIH4&M:W%H&I6>L:7HOB"TF>XT6+27^RFVCE(G>>ZFB
MG22 M_8B:=_V7/A2]S"EO<O9^)GN+>.;[3'!.WC;Q*TT$=R(X1<)%(6C2<0Q
M><JB3RH]VP?4-]_QY7G_ %ZW'_HEZ^8_V*O^38_AA_UQ\6?^IUXGH ^IJ***
M "BBB@ HHKS3QA\5?#O@9=1FU_3/&,=AI444U[J]AX,\1:IH\4<QC5674K"P
MGM9,/*D;B.1BCG8P!&*TITJE:2A2A*I-[1@FY.[25DM6VVDDM6VD<F-Q^#RZ
MA+$X_$T<)AX7<Z^(G&E2@HQE.3G4DU&$8PA*4I2:2C%MM),P/BI^SM\%OC;>
MZ5J/Q3\!:9XQO=#M9[+2I[^[U>V:SM;F7SIX473=1LD=9)1O8RK(P/0@<5R/
MPO\ V./V8_@KKFC>(_A3\'O"_@35_#MK=V6A3: ^K6MMI5G>VDMC=6MCIK:E
M)ID$$MI/-#Y2681%D8QA&^:O;/#?B^S\327$=KH_BK3/LT44QD\1>%]:\/PS
M+,S*HM9=4M+9+F1=NZ2.$N\:LC. '4GK*^BI\8<8X/*I\.T>*>)<-D<Z-3#U
M,CI9YFE+*9X>NJWM:$\MABHX.5&LL17]I3=%PJ*O64HOVL^94'@,9&.,P\<-
M74FW#$0A3FW*$N5M5.7FO&4$KWNG%=D%%%%?,G8%%%% !1110 4444 %%%%
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M7\F?_!"K_DLGQR_[%7X1_P#JRIZ_K,^//_)#_C%_V2_Q[_ZB^J5_S[?M!_\
ME(WCW_LG.$__ %CLL/W#PJ_Y&7"7_92Y=_ZN*(OP'_Y(A\'O^R8> _\ U%]+
MKU>O*/@/_P D0^#W_9,/ ?\ ZB^EUZO7\9X#_<<%_P!@F&_],P/?XJ_Y*?B/
M_L?9Q_ZL,0%%%%=9X)^1'_!3^X\<69^%EOI.G:MKFD:E=^+[RW_X13P]X]\0
M>*]%N++1],M[\75I\/[JTU ^"&2>SNM<$PU%-1N)8M.O-.EL1D^V?MN:/\4_
M$WP4\,>&/"VA?#W5OA]JVBQ-\4IOB5=^!=)\,6LMC=^#[GP?;ZE;?$.^TO3U
MM+O51?RJB2":#5+'2K6Y@EAN7MI?FO\ X*Z:5KB1_ SQ)9:WX5L=+M9_B%IE
M['XVT.?4-)TZ6ZT2P(NM U73+_1-8TCQ5KJ.FB62VVKF6["QKI>G7&IQQFOJ
M7]ND>&[[]C/Q'X<U_P 5Z+X4EU?2_AC)876NV>AZQ;^;9>/OA^D4EYX=\9:E
MI>E:SI2ZG>:58ZM!X@U?1M,$>HQ1ZQX@T2.<ZE  >K?L5^&K#P?^S)\,/#6E
MZ7X8T;3M)@\5066G>#O$6@^+/#T%M)XY\37$+VGB#PO=WOA_4+FY287>JG2;
M@VEMJ\]_9I#;&W:VA^CM>M+N^T35[*Q2TDO+S3;RUMDOI[VULWFGMY(HUNKG
M3634+>!F8"6:Q=+N)27MV655(^7_ -A/1-+\._LH_"+1]&U;1M<T^VL/$TD>
MJ>'XO!MOH]S->^./$U]>BRM/A]?:KX-L$M[VYN+673M!U;5[73IX9;&35M4N
MK>>_N/JZ[N[6PM;F]O;B"TL[.":ZN[NYE2"VMK:WC:6>XGFD98X888D:2661
ME1$5F8A030!\R?"[X/?%7X:?!/3OAW<?&0ZEXCT77_&6H1^,M1\-R^*KB3PG
MJ^OZ]JWA_P +SQ>(];:\O[CP[I.H:;H[:W>7[W&HC2O.D@A%TR15_P!B))H_
MV7/A3'<3BZN([/Q,EQ<B%+87,Z>-O$JS7 MHV=+<32!I1 CND(;RU=E4,?H7
M2?$_AOQCX;;Q!X2U_1?$^A7MM?+9ZSX?U2RUG2KI[8SVMREO?Z?/<6LKV]S#
M+;SHDK-#/%)#(%D1E'S_ /L5?\FQ_##_ *X^+/\ U.O$] 'U-1110 4444 %
M?G)_P4%_:"\6_"?PUHW@G0/!R:CIWC^PO?[4\7:BMXVEZ2=.OK*2'3+?[,GD
MMJ=T1YV+N:-!:JS1+)(#M_1NOF_]HOQ#H%Y\.O&OA)K34-5UY]/LVM=-M_"V
MN:N))VO;.53;36^DW5D\RVYD8F*8O&N]25.17J9-.G3S/"5*N%^MTX58N5+F
MG!1NU&-9R@G949RC4:DN27+RRLG<^!\3L-C<;P-Q%@\NS]<-XW$9?65#,%1P
M^(G4C2@Z]? 4Z.(G!2GF.&I5L'S4I*O259U:-YP2=/\ 9,^-GB;X\_"FW\9>
M*O![^$=1@U.ZT=1$MTNEZW;V4</EZQI'VV..Y^RRES#("KQ+<PS+;RR1!2/I
MRN,\(^*O#>O0"PT W*?V;9VIEMY-!U;18((Y%*(D*W^G6,# ,C@Q6Q8Q@ E5
M4@GLZY,9*$L57G3PSP=.51RAAFYR]C!ZQAS32E+36[23OHDK(^@X7I8G#\/Y
M3AL;GD>),9AL%2H8O/(T\/1_M+$4ER5<0Z.%G4H4I.:<90A.;3C[\I3YFRBB
MBN8]X**** "BBB@ HHHH *\RU3XR?#;1;J2RU7Q*EA<Q7PTPI<:7K:*^H%G5
M+.";^S3#<W$A1Q%%;R2M-L8Q!PI(]-K\EOV[/VD_C#\.?B1X6\'>&?!=M;^&
M=$OO#/C71?%&HZ5?Z@GB3Q':-=,-.MI(F%HMO8NYM[BTC_T^61Q('2,HI]3*
M,NEFF+6$@ES.$IW=>%!*,+<VLZ=3G>JM&,>:UY6<8NWP'B3QM1X X;EQ#B9M
M4:>+PV#Y(Y5B\TE4JXJ34$XX7&8)86$8PJ2E7KU/9.2A15JM6G&?SE_P6_\
M^"??[.W_  40_92\6_&K7_%GC'P[X]_9(^''Q:\<>!?$/AJWDBM=06V\*KXF
MU+PCXBT+Q#9VT-[INK7?AS2=NIV3VU]IBM=-!+<&0P+]>_\ !*C_ ()O?!/_
M ()L_LZ_\*^^$.L^+/%=_P#$V]TCXB>/O&7C&XMO[2U[7;C0K.UL8[72M/5-
M,T33-,T_%O;6-H)I'FDN;FYO+AY4$7H,_P "7_;(^#ZZO\:O$?QS^&]K\6?
M%WX6\>?"GP=\1];\(>%KC0]5L;O1-4CCT=(6O;!/$>E3233B:9;X17F)6#C<
M?H7X3? RU^$EU--9?$[XQ>-;1M%MM#M='^(WCZ^\6Z3IMM:26[07.G6EW!&+
M>_2*W6U-V'9VMGEB(^<FOZ&S?QMXKJ_1XROP#GXI<1U>%LGXGS+/I<!SP'/D
M:C6GEV-P>5PS6#5:M0P'$/\ ;N=1P\G_ &7]<QE/&4:,L3R3H^MDM+#YC/!\
M2PPM*I4S/+,)7I8UX:O@*TJ6)I>UA4GE^)J5J^%JRPLZ%*I2K5)5X.$J<W'6
M)[G1117\RGU(4444 >(^(?\ DX?X6?\ 9*?C-_ZDOP8KVZO$?$/_ "</\+/^
MR4_&;_U)?@Q7MU !7YI_M%:UXMTS]NO]DK3H+][7PMKMEK<4JZ=J/BW2;N2:
MRNV>^M=5BLK6X\(>([&ZEN-'CMK/5KBPO]*C;4Y+9KHZE#&GZ65\!?M&W_A^
MS_:U_8]@O-86TU^_UCQ5;:9HEOXJ\+Z3>ZY8_8#-=S7.F:K<)XDN-(T:\BL+
MF>'PK:7LFO7T]CIFK_8],MY[I #F?A/X=N[+_@I!^T7KDRZ"MIJ/PB\*"SE1
MX1XIF;[=H4=S'>61\+0W]OH4#6T?]G:A<>,KW3M5N9+J/3- MI=,O[NOO#Q[
MXMG\$>'9?$$/AW5_$XM[W3K>?3-#%LVH+:WEY%;7-[%'<RPK/]BBD:9;2)C<
MWDJQVELC33ICXY^!GPM\?>$OVKOC5XQ\8?&WP#XV7Q/I-X;;X>^'=>\:6_B?
M0-+.LZ9-X=U/Q)X'U7QCK?A"QN;#2RNASZUH'AS0I[I6L"9/*O)K9OM#Q?X+
M\,^/=)CT/Q9I<>L:5'J.GZJMG+-<P)]OTNX6ZL)RUK-!(QM[A%E5"YC+*I96
MP* /"K+QAX;\2?M5VNDZ+JL%[JGACX+>*[3Q#IZ).EQI%U=^-?!4UO!=B6)(
M_,D2.0XADEVF-PY4[=WT]7@%U;P0?M.>&FA@AB:3X'^,S(\<:(\I7QSX(53*
MZJ'D*C@%RQ&3CJ<^_P! !1110 4444 %%%% !1110 445R]WXX\%V%S/97WB
M[PS9WEM(T-S:76O:7;W-O*OWHIX);I)8I%S\R.JL.XH ZBBO(_&7QV^$_@31
M_P"W->\;:(;$W4%H%TF]@UN[,UP2$Q9:6]U=&,;29)?*\N,8+L :\J_X;:_9
MT_Z'.[_\)W7/_D&@"_XI_:Z^%/A'Q)KGA;58O%)U/P_J5SI5^;70S/;&ZM6V
M2^1-]I3S8L_=?:NX=J^8/VD?VCOAU\6/ 5MX8\,Q:\-277;'43_:FD_8[806
MD<_F?O3-*#(?,&Q=HS@\BOE+XG>(](\8?$7QOXIT"Y:\T77_ !)J>J:7=-%+
M UQ97,VZ&4PSJDT18#.R1%<=P*X%_OQ?[S?^BVK]"P.28&E]4Q<%6]M&%&NK
MU4X\\J<9:QY-8IMZ7UV>A_%/&'BSQ;CWQ%PYB'E3RVMB\PRN:A@9PQ'U6&+J
M4(VK/$R2J\D(WFZ;3=WRJ]DOEQ_\\T_[Y7_"E0 *   !T X Y/:G4U/NC\?Y
MFO>N^Y^-V2:LDM'T\XGY^?\ !2/_ )(=X=_['^Q_]-E]7X=MT/T/\J_<3_@I
M'_R0[P[_ -C_ &/_ *;+ZOP[;H?H?Y5_M-]!?_DPV!_[*SB7_P!/X4_HKPS_
M .27A_V,,9^5$_IG_9X_Y()\&O\ LF_A7_TV0UZ\_P!^+_>;_P!%M7D/[/'_
M "03X-?]DW\*_P#ILAKUY_OQ?[S?^BVK_(/CO_DN.,_^RLXC_P#5SC3\ S+_
M '['?]A^(_\ 4N9,GWU_WE_F*_F"^-?_ "63XK_]E#\6_P#IYNJ_I]3[Z_[R
M_P Q7\P7QK_Y+)\5_P#LH?BW_P!/-U7]S_L\?^2O\1_^R:R?_P!6M4_3_"?_
M )&.;_\ 8#1_]2$>5R_Z^T_W[C_TG:IZ@E_U]I_OW'_I.U3U_JS+:'^%_P#I
M<C]O6\O7]$5[3_CV@_ZYK_*ED_U]I];G_P!$TEI_Q[0?]<U_E2R?Z^T^MS_Z
M)JG_ !)_]Q/_ $F0OLQ_[=_-$S=#]#_*OZA?A!_R2;X8_P#8@^$__3+9U_+T
MW0_0_P J_J%^$'_))OAC_P!B#X3_ /3+9U_G)^T0_P"28\,_^Q_G_P#ZK<$?
MDGBS_NV2_P#7_&_^F\.?"O\ P4Z_Y)I\*O\ LH&L?^HQ)7XRU^S7_!3K_DFG
MPJ_[*!K'_J,25^,M?LOT)O\ E'OAG_L<<5_^M#CSZ'PW_P"25PO_ &%8[_U)
MF5K/_CTMO^N$7_H"TK?\?4'_ %SG_P#0126?_'I;?]<(O_0%I6_X^H/^N<__
M *"*_K9_Q)_]Q/\ TF1]U]F/_;OYHL57M/\ CTM?^O>'_P!%K5BJ]I_QZ6O_
M %[P_P#HM:E?!+_%'\ICZKT?YQ/W4_X(5?\ )9/CE_V*OPC_ /5E3U_69\>?
M^2'_ !B_[)?X]_\ 47U2OY,_^"%7_)9/CE_V*OPC_P#5E3U_69\>?^2'_&+_
M +)?X]_]1?5*_P"?;]H/_P I&\>_]DYPG_ZQV6'[AX5?\C+A+_LI<N_]7%$7
MX#_\D0^#W_9,/ ?_ *B^EUZO7E'P'_Y(A\'O^R8> _\ U%]+KU>OXSP'^XX+
M_L$PW_IF![_%7_)3\1_]C[./_5AB HHHKK/!/RC_ ."IU]\18/#?P;T[P!JU
MMH2:WK_C"P\3ZM<>'+W7Y(-&72=*N([>VN(-0T^+P_->7T=O -;LY8O$]J2C
M>%[RQOUDG'T3^UOH_@B/]G<>._&?P\3XEZEX#L_"%[H>D1GQ0^JW5]J.N^&;
M*2ULKC0M0M]<F-U<&UN#'J.H'37N[.SO=>N$MK6:[BY'X]166D_%#68XO$VN
M:)=?$3_A"-)N]$'PSM_B-K.O7&DV]U;Z9JWPMBE\0&?0+G1/MDD>N^)I-"LM
M(\.7\T.JW.IO?16B-9_X*(:KX;M/V3?&7@S5/%&CZ;K?BR/P;IWAW2-?\:R^
M$=7\5O8^./!QU"RM;S3]3TS6;PF&:%-9%A<Q6QANS%JMU:V%U++0!VW[$?Q*
M\#^.O@GH6E^$=#TWP==>'/[8N=4\#:9J.MZQ%X<M=>\;^-6TJ675M=$EQ>7>
MLOI>IWNI);7NH:?8ZR-3T_2K^^TBVTZ^NOK+5K*74M+U'3X+^YTN>^L;JTAU
M.RCLY;W39KB!XHK^SCU"UO;![NS=UN;9;VRN[0SQ)]IM;B'?$_QC_P $Z-/>
MR_8_^$TUYI$.D:Q?+XVFUB)=>MO%EW+<Q?$;QA!"U]XLM[[5&\13Q6D<,*W\
M^IWTPB1+=IE,)C3[:FD\F&641R3&*-Y!%"H::78I;RXE+*&D?&U%+*"Q + '
M( /"O#GP"\&>$OAFOP]:]\2:UIUIJ_B7Q7<ZO/K,WA_7]7\1>);[5-9UO5]9
MU#P2GA@:C?:GJ6K7][?SW$+-?7=P]W>>?<[91QG[$4$=K^RY\*;6'>(;:R\3
M6\0DEDFD$4'C;Q+%&))IF>:9]B+OEE=Y9&R\CL[,Q]!\&?'CX8_$?X->"_C5
MI/B*WT;P%\3/"]EXB\*ZAXN>#PU<W%EK.G2WUE#<VVHSI]FOS;)(\EF9'E3R
MY,;@I-<!^Q)+%/\ LO?"N>"2.:">T\43P31.LD4T,WC?Q-)%+%(A*21R1LKQ
MNA*NC!E)!!H ^JJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP_
MXX(C6_PMW(CX^,W@3&Y5;&7U'.-P.,X&:]PKQ'XW?\>_PN_[+-X$_P#0]2KJ
MP7^]4?\ $_\ TF1\_P 5?\B#,/\ #A__ %+H'MU%%%<I] %%%% !1110!XCX
MA_Y.'^%G_9*?C-_ZDOP8KVZO$?$/_)P_PL_[)3\9O_4E^#%>W4 %?#?Q6\%7
MGCS]JGX(^.-*A\0II'P6U34O#WB^\.M>)/#'A;^T/&.CZ;K.B1:A96[1Z7\0
MY%+Z;;Z/;1![?PYK^I1-K,S1WL-HWW)7QIXCN?",G[6?AC39]$\1WOBE--35
M);?2OB3 G@^RTQ-':STGXA^.OA\)(XH-6&I37/@CP9+=O+J.K7227ECI\T&F
M?;]- /!_#%QXMN_^"EGQ,_X1K^QKVST_X<^&+/Q-J5Q8^*;5=,\,,]C<:AX<
MM[FY0^%+O6)M3DTW591H:Q:W-,=+EUB[FTJP:U7[[^+&H^*]*\&O?>"H-1NM
M?3Q-X$MTM]+TZ/5+J32;_P <^'+#Q*S6<D4P-K!X;NM6N;VX55>QM(9KY9$-
MON'YZ? +Q7X8\=?\%(OVB/$OA&ZUS4M-M?A+;^$-4O\ 6/#4OART'B'PKXMT
M/3=0LO#JZE\)O#>M:MIFGW4-_9WFN3_$SQ5IFIZA&?[&T*TL;5-2F_4NZN[2
MRB\^]N;>T@\R&'SKJ:.WB\ZXE2"WB\R5D3S)YY(X84SNEED2- SLJD ^:+/4
M?$]Y^UC':ZWX;M]&TG3_ (->+(O#>JQ:S;:C+XAM'\;^##<74]A#&DND-;NL
M2K#<-(TPE8JP\LBOI^O!K_\ Y.;\,?\ 9#O&G_J=>"*]YH **** "BBB@ HH
MHH *\ _:5\?>)/AO\,Y_$OA6Z@M-636M(LUFN+6*[C$%W.R3KY,P9"64 !L9
M7J.:]_KY-_;0_P"2*77_ &,GA_\ ]*GKNRV$*F88.G4BIPGB:491DKQE%S2:
M:>C3ZH^3X[Q6)P7!O$V+P=>KAL5ALFQU;#XBA.5.M1JPHRE"I3J0:E"<6DXR
MBTT]4SXG_P"&O_CA_P!![2__  1:?_\ &Z^,/&VOZGXL\7^)?$NM3)/JVM:Q
M=W^H311K;QR7,K#>R0QX2)<* $48&*[&O--2_P"0C?\ _7W/_P"AFOH^(\)A
M</A:$J&'HT9/$<KE3IQ@W'V<W9N*5U=+3R1^'>!?$>?YUG^<T,WSK,\SHT<F
M5:E2QV,KXFG3J_7L)3]I"%6<HQGR2E'F2O:4E>S9FN,20]?OOU)/_+)_4U+4
M4G^LA_WV_P#13U+7QQ_3IZ-H_P#R#++_ *XC^;5>?[\7^\W_ *+:J.C_ /(,
MLO\ KB/YM5Y_OQ?[S?\ HMJ_6<+_ +KA?^P;#_\ IF!_F[Q)_P C_/?^QYF7
M_JRK$E-3[H_'^9IU-3[H_'^9K<\CJO1_G$_/S_@I'_R0[P[_ -C_ &/_ *;+
MZOP[;H?H?Y5^XG_!2/\ Y(=X=_['^Q_]-E]7X=MT/T/\J_VF^@O_ ,F&P/\
MV5G$O_I_"G]$^&?_ "2\/^QAC/RHG],_[/'_ "03X-?]DW\*_P#ILAKUY_OQ
M?[S?^BVKR']GC_D@GP:_[)OX5_\ 39#7KS_?B_WF_P#1;5_D'QW_ ,EQQG_V
M5G$?_JYQI^ 9E_OV._[#\1_ZES)D^^O^\O\ ,5_,%\:_^2R?%?\ [*'XM_\
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M#\N'_:*_:(5H\_''QT%9B"3-I@X",0,FQXY _E3O^&BOVAO^BY>.?^_^E_\
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M_P!"W\7_ /P]?CG_ .3J_9NBOJ_^(^>.'_1W_$K3;_C-N(O_ )X'=_9>6_\
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M.R&VMH99I6P=J(QQQ5R+]K;X?S11S1> /VD9(IHTEBD7]E_X^%7CD4.CJ?\
MA7_(96!!]#0!]145\FC]LOX7-K$GA]?!G[19UJ/3DU=]-'[,/Q\^U+ILEQ]D
M6\,?_"OO]0;G,._/^L!7M4FK?MC?#'0M+U+6]8\$_M&:=I.CV%YJFJ:A=?LP
M_'R.VL=.L+>2ZO;N=_\ A7YV0VUM%)-*V#MC1FP<4 ?5U%?+L?[6OP_ECCEB
M^'_[23QRHDD;K^R_\?"KI(H=&!_X5_R&4@CZUGP?ME_"ZZU74-$M_!G[1<VK
M:5;V5UJ-@G[,/Q\-Q9V^I"8V,LZ?\*^^5;D03F+GYA$_I0!]945\GZO^V/\
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M\$_M&:=I6F6LM[J%]<_LP?'Q+>TM(%+S3S/_ ,*_.V.- 69L' !- 'UA17S
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MQ?4]9\%_M%Z=81S6MN]U=?LP_'Q(EFO;B*TM8RW_  K\_-/<S101CO)(B]Z
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MHKY.L_VR?A??WVK:;9>"_P!HNYO]!N+2UUBTB_9A^/C3:?<7UA;ZG:0W*_\
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M#?X)>*O /P:LOA_+\0KW2]9LM;\6^(KW7/"W]HWMHR^(]7UG6WT72;;QO?\
MB2_TW0=.EU46^DZ3_:,\6E65E9V%E*EI"J5YG^Q?\3OAIHW[,WPPTK5_B;X'
MAU/3K?Q39W\>I^+O#EEJ N[?QOXEBG:]M)-0B>WNGD4O/"T<9CD9EV*!B@#[
MGHKSG_A</PC_ .BI?#G_ ,+?PS_\LZ/^%P_"/_HJ7PY_\+?PS_\ +.@#T:BO
M.?\ A</PC_Z*E\.?_"W\,_\ RSH_X7#\(_\ HJ7PY_\ "W\,_P#RSH ]&HKS
MG_A</PC_ .BI?#G_ ,+?PS_\LZ/^%P_"/_HJ7PY_\+?PS_\ +.@#T:BO.?\
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M_M2NE0:?'X5TNU\9>)Y;-CI[>(K?4=4&K0^($U33M'N]/ .UN/BK^R[-\/\
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MC#J\LMIXAB\;W&NV]LNDO;2[7TM] A>[74Q=^1Y<[2V_V:,/-#)YZQBO5J*
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M0IITJ3221>P44 9NB_VK_8^D_P!N_91K?]FV/]LBQW?8O[5^RQ?VA]CWDO\
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M "VH_P"%W?&?_HKOQ/\ _"^\5_\ RVKI_P!9O^H+M_S$]^7_ *A_[WX'B?\
M$$/^JG[?\R7OR_\ 4V_O?@?TDT5_-M_PN[XS_P#17?B?_P"%]XK_ /EM1_PN
M[XS_ /17?B?_ .%]XK_^6U'^LW_4%V_YB>_+_P!0_P#>_ /^((?]5/V_YDO?
ME_ZFW][\#^DFBOYMO^%W?&?_ **[\3__  OO%?\ \MJ/^%W?&?\ Z*[\3_\
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MWX'])-%?S;?\+N^,_P#T5WXG_P#A?>*__EM1_P +N^,__17?B?\ ^%]XK_\
MEM1_K-_U!=O^8GOR_P#4/_>_ /\ B"'_ %4_;_F2]^7_ *FW][\#^DFBOYMO
M^%W?&?\ Z*[\3_\ POO%?_RVH_X7=\9_^BN_$_\ \+[Q7_\ +:C_ %F_Z@NW
M_,3WY?\ J'_O?@'_ !!#_JI^W_,E[\O_ %-O[WX'])-%?S;?\+N^,_\ T5WX
MG_\ A?>*_P#Y;4?\+N^,_P#T5WXG_P#A?>*__EM1_K-_U!=O^8GOR_\ 4/\
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M?]07;_F)[\O_ %#_ -[\ _X@A_U4_;_F2]^7_J;?WOP/Z2:*_FV_X7=\9_\
MHKOQ/_\ "^\5_P#RVH_X7=\9_P#HKOQ/_P#"^\5__+:C_6;_ *@NW_,3WY?^
MH?\ O?@'_$$/^JG[?\R7OR_]3;^]^!_2317\VW_"[OC/_P!%=^)__A?>*_\
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M=\9_^BN_$_\ \+[Q7_\ +:C_ (7=\9_^BN_$_P#\+[Q7_P#+:C_6;_J"[?\
M,3WY?^H?^]^ ?\00_P"JG[?\R7OR_P#4V_O?@?TDT5_-M_PN[XS_ /17?B?_
M .%]XK_^6U'_  N[XS_]%=^)_P#X7WBO_P"6U'^LW_4%V_YB>_+_ -0_][\
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M!=O^8GOR_P#4/_>_ /\ B"'_ %4_;_F2]^7_ *FW][\#^DFBOYMO^%W?&?\
MZ*[\3_\ POO%?_RVH_X7=\9_^BN_$_\ \+[Q7_\ +:C_ %F_Z@NW_,3WY?\
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+?^UG:][7L_0__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img132800289_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_11.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %$ G # 2(  A$! Q$!_\0
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M;%_OO9SAA/K-9TZ4_2?^% _ O_HC?PO_ /"$\,?_ "LH_P"% _ O_HC?PO\
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M%T^'P]HL%M=7%A>LUIIMO=74M\Q1[=;^:X'V&*W>1/-FD)\'_8N_:\\6^/\
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MTX0<Y148MKG/^% _ O\ Z(W\+_\ PA/#'_RLH_X4#\"_^B-_"_\ \(3PQ_\
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M^!?_ $1OX7_^$)X8_P#E91_PH'X%_P#1&_A?_P"$)X8_^5E=3XR^(?@KX?\
MA>;QGXO\1Z;HOAF%('&K7$WF07'VH!K2.R6 2RWTUT"#;0VD<TLZ_-&C*"1Y
MM\-?VGO@?\6];;PWX%\<6VIZZ();F/2KS3=8T6\NH( &F>RBUJPL&O!$A$D@
MMO-98R)"-G-<-/AZ5;#5<91R3VN$H.2KXFGEW/0HN*3DJE6-%TX.*DG+FDN5
M--V3/<Q'B=C,'F.%RC%^(.+PV:XZ,)8++:_%5>CC\7&I)QIRPV$J8Z->LIR@
MXP=.G)2E%J-VCH/^% _ O_HC?PO_ /"$\,?_ "LH_P"% _ O_HC?PO\ _"$\
M,?\ RLKYMT/XT>/#^VCX[^&FK^)]OPS\/> I_$$6BR:;I,<5C/;65C=37KZE
M'8KJKK&LD\ACDO7BVD_)A5 G^"O[9&@_%?XS>-/ MQ>Z#H^@PSVNE?#01SSW
M&H^-+N)[Z74=02X:..,*UI;I-%9)"H@B#,\\S9(]2KP17IT:F(AEN"Q%&CE6
M#S>M4H8>,E2PV.M[&$E*A&4J\4Y3JP@I1A3IU*CFZ<'(^7PWCQ*MB\/@*W%_
M$N QF+XHS?A/!T,;G.+I2Q.8Y*O]JK4Y0S&K"&"J3]G1PU6M*G5K5ZU"@J*K
M58P/HO\ X4#\"_\ HC?PO_\ "$\,?_*RC_A0/P+_ .B-_"__ ,(3PQ_\K*^+
M?A1^UVOA_P >?'J#XZ_$:"W\,^&/%J:-X*L)=&M3>Q0K=7B7$%E:>']*.KZF
MMO"EN;F:=+KR$9'DD0/D_:EG\=?A1??#[_A:EKXSTR7P$LH@G\0;;E;>RG,H
M@-OJ$#0"[L)TF98Y(;NWADC9TWJH=2<LQX-KY;5A3J912KTZKPL:.)PV7RJ8
M:M5Q>'I8BGAZ566&@JE=1JJ$J<4Y>TC*,>9*YU</>-[XBPE7$8;CO-<%6PZS
M&KBLNS#B>5#,L)A<KQU? 8C'8K"T\TK2H8)U,,ZM/$5'&'L)TYU'3<N5-_X4
M#\"_^B-_"_\ \(3PQ_\ *RC_ (4#\"_^B-_"_P#\(3PQ_P#*RNDU+XE>!-(\
M$)\2-2\3Z7:^!Y+&TU*+Q)),?[.ELK]HTLYXI%4O(MPTT8C5$+G=DJ K$='H
M6MZ7XET?3-?T2[2_TC6+*#4--O8E=8[JSND$MO<1K(J2!)8V5UW(IVD$@5Y,
M\HH0@ZL\LHPIJK*@ZDL%",%7@E*=%R=)156$6G*FWSQ33:2/JZ7'F>UJT</1
MXRS>KB)86GCHT*7$.-G6E@JTG"CBU3CC'-X:K.+C3KJ/LIRBU&3:LO./^% _
M O\ Z(W\+_\ PA/#'_RLH_X4#\"_^B-_"_\ \(3PQ_\ *RO7**Q^H8'_ * L
M)_X34?\ Y Z_];>*_P#HIN(?_#UF7_S3Y+[CR/\ X4#\"_\ HC?PO_\ "$\,
M?_*RC_A0/P+_ .B-_"__ ,(3PQ_\K*]<HH^H8'_H"PG_ (34?_D _P!;>*_^
MBFXA_P##UF7_ ,T^2^X\C_X4#\"_^B-_"_\ \(3PQ_\ *RO*OCI\"O@G9_!3
MXN7=K\(?AG;W-M\-?&\]O<0^!_#<4T$T7AO4GBFBECTY)(Y(G571T961U#*0
M0#7UC7DGQ^_Y(9\8_P#LF'CO_P!1G4ZY<=@,"L%C']3PBMA<0[_5J.G[F>ND
M+Z>6I[_"G%?%,N*>&HRXES^499_DT91EG.8N+3S'#)IIXFS36C3T:W#X!?\
M)#/@Y_V3#P)_ZC.F5Z#XDU9M!\/:YK:Z9>ZRVD:3J&I#2-.2)[_4_L5K+<_8
M;-)GCA>YNO+\F%99$1I'4,P!)KS[X _\D,^#G_9,/ G7K_R+.F=:];Z]:[,M
M:C@\!*4>>,<-A7*%W'F2I4VX\T;2CS+2ZU5[K4^;XRC.?$O%4*=3V52>>9Y&
M%51C-TIRQ^*4:BA/W9\DFI<LO=E:TM&S\<=)^''[)7QWTC6OBCX/\<:E^SOX
MMM;[4I]4T.7Q'IMLNC7,4C2C4UTB2>VN(;>\=Q*ITS4X[6&42VMO#$T00=U^
MS[\1_'?CO]E?]I'3O%^MWWBW3?!^B>*='\+>+]1,TUSK%A)X=U5IX&O+C]_=
MI9^1:SQM<O)=1)J*PS2$)&J_97B3]DK]G/Q;K-SX@U[X4^'KK5KR9KFZN;:;
M5]*CGG=M[S26FDZE8V322/\ /(WV?,C%F?<S$GU2S^''@;3O!=U\.].\,Z7I
MW@J]TZ\TF[\/Z?$]C9SV.H0M;WL4CVKQ7+274+LDUUY_VI\[C/O 8?IF.XKR
MVOA(X>*S;&-8W+\3AEFBPE:>44<+6C5K4<%CE4J8S%^VBO8)XF5&*I6<HN=Y
M'\RY)X6\18'-IYA4GPOE"EDV>Y?F,N&I9K@Z/%F+S/"2PV$Q><9+*A2RC*EA
M*LOKLEEU/%U'B;J$E2Y81_!GX/6NK>#;C]G_ .+7Q;TN/Q-\#HO%>J^&M"L[
MB8W-CX9U![@R_P!LW>FQCR=PU)Y-12*Z25M0CTIX;A?+2!3]V_MM30W'Q>_9
M)N+>2.>WG\974T$T3K)%-#+?^&WBEB=25>-T971U)5E(92017V<?@#\'S\-_
M^%1-X'TY_AR+@7:^&9+O5I+=+D70O1/%>OJ#:K%*+D>8'COE8 M&#Y3,ADU7
MX#_"?7$\!)J_A"#4!\,/+'@0W.JZ\\GA\0M;-"()?[4$EVL7V.U6-=1>\")
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MM96WV.UEM?LZ6<4,USF*(9?8$)]7_;>_Y-?^*G_8+TW_ -/FF_Y_PKWWP/\
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M]G2ZS<Q:;:S10-9W*K#+.T<0462F6! 0&AC8Q@A *>.RG+L=E&#H8+"U*5?
M\++.DZ%+"RK8W$UL?2PK]O5IX58JO%1]M-Q=1QA#V7LXP<:CJ+).*>(<FXKS
MC&9SF.'Q.#SKQ.EP<UC,5F=/"9/@,+D5;,X+!X;$9C++,%*4GA*2J0P\:M6J
M\6ZU2NJF&C0_030OC#\-?$FH^--+T?Q;I=U>_#SS#XTC,CPKX>6(W(E>_EG2
M.*../['<EY [(JPN20!7C-C^V]^S3J&NP:!#\0XX[BYO%L8-1N]%URST&2=W
M$:;=>N=/BTORG<@+,;H1G<#N"G-?$/[/VJ>"/%NO?MSZOK&LW5KX"\16PGN-
M?TVUGN[B#1K_ %'Q#''JEK:PQO-<K$62X\M4Q+$K;BJ%F'E+>(-0^$WPST36
M-$\:?L_?'GX26&IPKI/ACQ-X:LK'QK$HFD46\NGW-K8ZU#>A=QN7D?4MB.'<
M3QJBUI0X*RQXO&X.H\RGB*;RREAJ;FL+"5;&Y91QE6D\5++\1A98F%>KR4\)
M6J81NDN9UI.YSX[QEXCCE>3YOAH<.T<#B(\28K,*\:$\SJQP63\1XC*<+B(9
M;3S_  &90R^M@J'MJ^:8.AFT5BI*G'"0BXI_LGXS^-?PL^'FJZ5HOC7QIHWA
MW4-:TVXU?3(M1G:-+O3;5)Y)KN.=4:'R@MM-M)<%V4*@8LH/.?"[]I/X-?&/
M5;_0O 7B^'4]:TZ-YY=*O+'4-(OY[6)E22\LK;5+:TDOK2-GCWSVPD15DC8G
M:P-?GM^TSXF\&ZI\>/V2O%?CW2K?1_!>H>#]$U?6])U6%6L]*L[K4[F>"VU"
M#8(S8V%T]M]I5HQ$+6%_-C\K>E=)XQOO ^N_MU_ N7X,2Z#=26FB32>,;GP>
MEJ--6!8=::4ZC)IZ+9N_]CR6T3L=WRRV<;'S=@'GTN$\#++J-2HLSCB\1DN9
MYF\6I4'EN%KY95Q,98:M:BY3]O&C&%UB(.E*I3G'VRJ*,?<Q/BGGD.(,;0P\
M^&JN5X#C'AKAN.5N&-CQ%F>"XEPN6U*>8X3FQD:=-X.>,JU5"6!JK$4Z%>$_
MJTJ#G4_5JBBBOST_?@KR3X^_\D-^,7_9,/'?_J,ZG7K=>2?'W_DAOQB_[)AX
M[_\ 49U.N7'?[EC/^P7$>?\ RYF?0<)?\E5PS_V4&3?^K'#!\ O^2&?!S_LF
M'@3_ -1G3*];KR3X!?\ )#?@[_V3#P)_ZC.F5ZW2P'^XX+_L$PW_ *9@'%O_
M "57$W_909S_ .K'$GE7C;X'_"?XC^(-&\5>-_!&D>(_$'A](8]'U.^-X)[.
M.WNFO8(PEO=0PS1Q73-,D=S%,@=WXPS ^DZAIUAJUC=Z9JEE:ZCIU]!);7MC
M?0175I=V\JE9(+BWF5XIHG4D,DBLI'45<HKTIXK$U(4*=3$5ZD,*FL-"=:I*
M&'3DI-4(RDU13DE)JFHIR2;U5SY*CEN78>KC:]#+\%0KYE*,\QK4<+0I5<PG
M"#IPEC:D*<9XJ4:<I4XRKNHXP;@FHMH\.\*?LU? CP/XA3Q7X5^&'AG2/$,4
MC30ZG';W%Q+;3,2?.M8KVYN;>UF0DF*6WABDA/,3)@5V'B?X5?#WQEXI\)^-
M?$_A>QU?Q3X%N/M?A/6;B2\2YT2X^T177FVRP7,,#M]H@BEQ<0S+E ,;20?0
M:*VGF68U*RQ%3'XVIB%2E15>>*KSK*C.,H3HJK*HYJE.$I0E34N2492BTTVG
MR4>'>'\-A)8##Y'D]# SQ-/&3P5'+,%2PDL91JTZ]'%2PT*$:,L32K4J5:G7
M<'5IU:=.I&:G"+7D_P 1/@9\)/BS<V-[\1/ FB>*;S38VALKN_2XBNH8&8OY
M!N+*XM9IH Y9TAG>2*-F=D52[$S>$/@G\*? /B.^\6^#/!&C>&_$.I:7;Z+>
MZAI:7%N9]+M?),-H;7[0;*-%:WA=GBMDEDD4R2R.[NS>I44EF.8+#_5%CL8L
M*H2IK#+%5_JZISE&<X>QY_9\DIQC*4>7EE*,9--I,;X?R%X]YJ\DRAYHZM/$
M/,GEN">/=>C3G2I5GC'1^L.K2I5)TZ=1U.>%.<X1DHR:?G'@SX1?#?X>#Q4O
M@SPI8: /&]])J?BH6DM[)_;5],+E9+FY^U74^QW%Y<@BW\E/WS87A<.\$?"7
MX<_#C0-2\+>"O">FZ#X>UBXNKO5-)@-U<VE]<7L?DW;SI?W%TS">+Y)$W",K
MQLY->BT5-3'8VK[7VN,Q53V\J,J_M,15G[:6'CR8>57FF_:2H1]VBY\SI1T@
MXK0THY+DV&^JO#Y3EF'>!IXNE@G1P&%I?4Z6/FJN.I87V=*/U>GC*B53%PI<
MD<1-*=93EJ>3^ ?@7\(_A?/K=QX"\":+X;E\1P"UUS[&+J:/4K8,["VN(;VY
MN8?L^9'!A2-(BK%"I7Y:YS2OV7/V?=#\2Q>+]*^%/A6T\0P71OH+Y;:XDCAN
MMY=9H;":YDTZ)HW.^(1VBK"P#1*A (][HK7^U<TYZ]3^TL?[3$PC3Q-3ZYB.
M?$4X1Y(0KR]IS581A[L8U'*,8^ZDEH<O^J_#/L<'A_\ 5W(O89=6GB,OH?V1
ME_L<!7JU/:U*^#I_5^3"UJE5*I.I0C"<ZBYY2<M3B/'GPV\"?$_2%T'Q_P"%
MM)\4Z5',+B&UU2 N;><*5,MM<1/%=6KLAV.UO-&9$^5]R\5G?#OX0?#/X3VM
MW:?#KP9HWA2&_96O6TZ&5KBZV?ZM)KRZEN+MXHSRD)G\E&)94#$D^D45BL;C
M%AG@EB\2L'*7/+"*O56&<[I\[H*?LG*Z3YG"]TG>YV2R?*)YC'.)97ETLVA3
M]C#-)8'#/,84N5Q]E'&ND\3&GRMQY%54>5M6L['GO@CX4?#SX;W?B*_\#^%[
M'P]=^+-0.J^(I[.6\D?5=09I'-U.+JYN%60M+(2(1$F6/R],<[\0/V?/@O\
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MGB*,L?*C*49U6HJ%.$$DGRN;E)\6!PN'P><9IGD\MX6QF99CF']H4L5BN ^
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MJ[*I8,P!_C,^ _QV_:&_X*0_M@?\$3/B-\;_ (C:/IEIJG@C]MWQ#JOA30?
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MLY[BYM(;NVFNK/ROM=M%/%)<6OG*7A^TPHYD@\U 7B\U5\Q063(YJS7\3'[
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M0WXQ?]DP\=_^HSJ=>MUY)\?N?@9\8QZ_##QW_P"HSJ=<N._W'&=?]EQ&G?\
M<S/H.$O^2JX9_P"R@R;_ -6.&#X!?\D-^#O_ &3#P)_ZC.F5ZW7DGP!Y^!GP
M</K\,/ G_J,Z97)_$/\ :*TSP%XWN?A_8?"WXS?$O7].\.:'XIU@_#'P;8^(
M=/T33/$M_P"(-.T-=4O=0\0:(D5WJ-QX7UMH+:%;AA#9-)(R!T#+ ?[C@O\
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MVO@.R^,4NL>'[2\?XD6GPNN3>?#NW\6M(I.KQ>#;HFXT!;C<-/E.Z'!KB/\
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M^"?P?M/B'JUCXNTR/6]=M-.UKQ&WA_P!>:YKA>\LM,FMFD@TVPAN#&HZU/\
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MWX=O_#J_\*K^,7PU^,7CKPM\1/!MWHU_?:=J6KRW/PJFL+[PY>78O-%2:?\
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M/_HIWQ6_\1F_:)_^=G7[#?V9IO\ T#K'_P !+?\ ^-T?V9IO_0.L?_ 2W_\
MC= 'X\_\/[O^":?_ $4[XK?^(S?M$_\ SLZ/^']W_!-/_HIWQ6_\1F_:)_\
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M8ZIX^UB>/5-,^)G@;1O@MX:TR"ROM0@O/AL/#_A[03+IDUU!#-]$_#SX*_\
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M (0W5$U'PL\\VFPF_P!?TVZO+>,^'8;K5;7]0HY$E1)8G22.1%DCDC8.DB.
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MYL[@&&2&YM+^PN46XL-0LYX+RSG'FV\T;\U]2UYQX@_Y*-\/O^O3Q7_Z;HJ
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MR*TG_8R^,?\ U*M7_P ]_J>M>B5YY\+_ /D5I/\ L9?&/_J4ZO7H= !1110
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MAX7\0>,=,TOQ186,5GJ6G/IVI'0[B]N[?6I3>VVE1VLUW-872H$'S=:_M/\
MC76]-_; E\,_%3X<V\7@+5Y_"GP;USQYX>N_#D6B>-=%TOQ;JGC1?%]G!<73
MS^!-*BTJQLO#>O7D=C=ZU>:'XJU%HFTF?1GE_2RCKUKK/GSY[^#OQ:\2^/\
MX>_"[Q-+\/O&<X\8^'=?OM6UJ_C\+Z+%IEYX?GN;*PFO-.FU^.[EL?'DEJ=1
M\'7VCVNH:?<:/>6&HZC<:=;W*M7SY\1?VF_B3H7[,_Q"^*/BGP[>? SQ]I/C
M6T\(>%_"FH^'=0\57D&JZE?Z99>&]*US4-3M]!\+WD&MWE_'#K'C+P_J>I^
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M@"A\/_\ D0_!/_8H^&__ $S65==7(_#_ /Y$/P3_ -BCX;_],UE774 %%%%
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M/_!9W_E9O_98Y/\ R:I-[G_DG'[070<^A[>IK[,_X,K?^3'_ -KO_L[JX_\
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M%XI\3^&_%^K2^('.D#^W+636_"FD30V\@MQ#%'/"'(F8@ _>&O\ 'W^*Q/\
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MK[3/#WC'6-;\>>'/$^H7GB/5]/A^W2WNF/I%O':ZBVF);/:QEI?W<_X-B?\
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M.'G14,-B5*K355QQ-2DJR@FW;EA3J0NDM7)J3:LC_1-_9C_;0^!'[5'P4O\
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MWNIZUXD34_%4_B_4_ NO_$749I=;;3X_,L;WQ1&]S<6\EJSO;SSP&<%Q(/[
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M"&R"/L"OFG]FL'9\>LDG/[2WQ8//8>?H^!]!^M 'I'_"M'_Z*)\3O_"FM_\
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M\D-^#O\ V3#P)_ZC.F5Q_A/_ ).H^-O_ &1C]GS_ -2KX_UV'P"_Y(9\'/\
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M*<<?B:53$QE"E*C-4XX>"C&Q1117U1_5H4444 ?-?PW_ .3E/VF?^P'\!_\
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M_P#F,H_X53\5/^CD_'W_ (1OPJ_^8R@#WZBO ?\ A5/Q4_Z.3\??^$;\*O\
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M\5/^CD_'W_A&_"K_ .8RC_A5/Q4_Z.3\??\ A&_"K_YC* ,CX;_\G*_M,_\
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M_P (WX5?_,91_P *I^*G_1R?C[_PC?A5_P#,90![]17@/_"J?BI_T<GX^_\
M"-^%7_S&4?\ "J?BI_T<GX^_\(WX5?\ S&4 >_45X#_PJGXJ?]')^/O_  C?
MA5_\QE'_  JGXJ?]')^/O_"-^%7_ ,QE 'OU8'BO_D5O$O\ V -8_P#3=<UY
M!_PJGXJ?]')^/O\ PC?A5_\ ,94%U\(/B=>VUS9W/[2'CZ2VN[>>UN(_^$.^
M%:[X+B)X94##P:&4M&[ ,I#*2&4@@&@!OCP@?LG>,R3@#]GCQ$23T _X5M><
MFO\ /JT.>#_AC?X2$3PE?^&C[,9\Q ,_\**XYW8)(YQU S[U_H%Q?!#X@1:-
M%X>_X:&\<3:+%I<>B_V=<^"_A5<V\NEQV@L?L5PDO@QOM$,EHOD3"7=YR%O,
MW;CGR!/V"_ *:1:>'TUC0TT*PU0:W8Z.OP5^" TZTU@6XLQJEO:CP)Y<=]]D
M M?M &_[.!#G9Q7] >"GC?1\(J&/HU>&ZN??7>*N%^).:GFT,M5./#N5\69;
M+!M2R['.<L6^)HUHUTXJ@L%*G*E5]NITO*S++7F'):LJ7+1KTM8<]_;3P\U+
MXX_#["UNO->ZM9_6?PJY^%_PWQS_ ,4%X/\ _4>TZOX>OVL;_3T_;?\ ^"N<
M37]FLUK\,OCY/=0M=0"2VA$'P8(FN(S(&@C.0/,D55Y!SR*_M A^$?Q.MH8K
M>W_:-\=06\$4<,$$/@KX4QQ0PQ((XHHD7P8%2.-%5$10 JJ !@5@3?L[^(;F
MYO[VY^,%_<WNJQ20:M>W/PE^!T]YJL$VP30:I=2_#YY]0AF$40EBNY)DE\J+
M>K>6FWY+PI\39^&&.X@QL,GCG+SW)<#D[IRQSP*PRP?%/#O$OM^987%>U]H\
M@6$]G:GRK$NOSR=)4JF^.P2QL:474]G[*I*I?EYK\U&K2M;FC;^)>]^EK:W7
MP_\ \$,9X+K_ ()[>!+BVFBN()?'WQ0:*>"1)89%_P"$KNAN22,LCC((W*Q!
M(/-?E_\ \%DKRTA_X*B?L@VLUW;175U\-=$%M;23QI<7!'Q$U7(MX7<23$8.
M?*1L$8/-?T:Z=\%?B!H]I'8:-\?O%>C6$18Q6&D?#WX/Z98Q,[%I&CL['P-!
M;HTCDO(RQ@NY+,22352_^ OB_5;ZUU/5?C=KFJZI8KLL=3U/X8?!;4-2L4W&
M0)9W]WX"FNK5!(S2!8)8U#LS@;B2>O+?%:IEWB7QMXBK)(5I\8X;Q-PTLJ>/
M<(Y>O$?)\_RF<UC%@Y/$O*5GKKQB\-06->&5-O"JKSTYG@5/!8;!^T:6'>"?
MM.76?U.I1J?#S:>T]E;=\O-?6Q^$W_!N]>V=[K/[9YL[NVNU@\>:%#,UM/%.
M(IEO/$A,4IB=Q'(!R8WPX'45]F?\%W[NTL?V+/#%S>W5M96T?[17PJ\RYNYX
MK:WCW6?BT#S)IG2- 2<#<PR>!S7Z'Z5\"/&6@?:?[ ^..OZ!]ME\^]_L/X9_
M!C2/MDPSB:[_ +.\!VWVF4;FQ)/YCC<V#\QS-JGP1\>:Y:_8=<^/?BC7+'S$
MF^PZU\.O@[JMGYT>?*F^RW_@:X@\Z/<WERB/S$W-M8;CGY7Q>XOEXK\8<5\6
M5,!')'Q/#"0E@88AY@L%]5R7 9.FL1*C@WB.=8%8AIT:/*ZCI:\O/+YKBS@]
M<4<!<2\#O'O!1XAX?SC(7F2PZKO"+-L+B,,\4L*ZU)5G0^L<ZH^WIJIR\OM(
M7NOY5?V)]1TZ3_@HQ^Q#9IJ%D]Y+\#/V=+F*T6[MVNI+8_LO:\1<1VZR&9X"
M#_KE0QE2#N((S_6G^T;#+<?L]?'B""*6>:;X,_%"&&"&-Y9II9/!&N)'%%%&
MK22RR.P2..-6=W(55+$"N(M_V?/$UI?6VIVGQEU2TU2S@CM;/4[3X5?!&VU&
MSM883;PVMI?0_#]+JVMX;8FVA@@E2**W)@C58B5K>/PH^*; JW[2/CQE8$,K
M^"_A2ZLI&"K*W@PJRD<,K @@D$$&OSK+\ L!3Q,%5=7ZQBJF)NX<G)[2G2I\
MEN:7-;V=^:ZO>W*K:^=X?>'\. \OXFP$<TEF:XCXFS#B-U)8181X1X[+<KR]
MX116(Q"K*FLM]JJSE3YW6</91Y.:7\+NN>&_$3_LG0JGA[7W9_V@OBR(U70]
M49F:7]G3X'VL2*HM"S-)<P3VT:A2TD\,L" RQ.J_W_>#U9?"/A965E9?#FB*
MRL"K*PTRU!5E8 JP((((!!!! ->*_P#"E/'OEB'_ (7SXD\D.95A_P"%:_!C
MR5E( ,PB_P"$"\L3%553*%$A554L0H O_P#"J?BH.!^TEX^ [ >#/A4 /8 >
M#, >PK#*LHCE:FHUY5N?#X2A[T%"RPD*D%+24M:G/=K11MI>^GS_ (2^#N#\
M*5CUA<]Q.<_7\AX1R*3Q&!I8/V=/A+"YCA:.)7LL17YIXU9A*=2F[1HNE%1G
M44FX_P K_P"V;H6NW/\ P4%_;.EMM#UJXBD\'>)IHY;?2=0GCD@_X5IX>'GQ
MO%;.LD.[*^:A:,L"N[=Q7[0?\$1[.\LOV+$2\M+NS>3XJ_$"6-+RVGM7>)KJ
MR D1)XXV>,LK*)%!1BK '(('WLWP:^(CRR3R?M ^*Y)Y4,4UQ+\._@[)<31%
M=K133OX%::6)E 4QR.R%0%*E0!4L'PA^)=K&(;3]HGQI:0J25@L_ GPDM(%+
M'+%8;?P3%$I8\L0@+'DDFEA,HCA,=5QRKRFZCS!NFZ:BE]?Q6'Q+]Y2;?LGA
MU!:>\I.7NVLUPCX.8/A/CW-..J6>XK&U\TJ<>U)9=4P-*C1HOCOB3(N(\0HX
MB.(J3FLNJ9'3PM%NE'ZQ#$3JS5*5.,)?0=?#.@8_X90_:2Y_YFG]L;/J/^+E
M?$_/Y=J]H'PJ^*@.?^&DO'W'KX,^%6/Q_P"*,KF_%7PYMOA;^S!\8_"]OKFK
M>))KCPC\:?%6IZ[K:6$>HZEK?C4^*?%NM7,D&EVECI]O$=3UFZ6VMK2UAA@M
MEBA53LR>['_[CC?^P3$?^F9^GYH_H?A+_DJN&?\ LH,F_P#5CACT?X _\D,^
M#G_9+_ G_J,:97K=>2? '_DAGP<_[)AX$]O^99TSMVK\&_\ @OU_P7%^)'_!
M'&__ &6K/P!\#?!/QC3]H*T^,5SJLGC#Q!KNAGP\?AE-\-(K)-/&BY^T_P!J
M?\)Y<M<FX!$/]GPB/F5Z,!_N."_[!,-_Z9@'%O\ R57$W_909S_ZL<2?T?T5
M_G,?\1O'[1G_ $9#\%/_  O_ !U_\31_Q&\?M&?]&0_!3_PO_'7_ ,376?/G
M^C/17XK?\$8?^"GOCS_@J]^PI\0?VHO%GPRT#X2>)M ^+'Q,^%.G^&_!6K:M
MK-I+#X2\#^"/$FGZS#=ZMNO5U*XN?&,EL85'EJUC"\2YD85\4?LT?M!_M%?#
M/3--\2:G\7_BE\2E\4_L_P"B)XSN;-OBY\8/^%6?%#7?C/\ #SPQ%?\ Q#TG
MXT^)+KP9X)\6QZ'K7B!(M0T+4M)\*^'M.M];USQ/X#\1Z+I-HUB ?U 45^ W
M@G]OC]LG4+;X&ZQJ/AJU\17'B9?$WA[5/ &C?#K7HO&7B?6;/XH?$7P;H7B/
MQ!H^H^&_#T8\+W_AKPUX:US4?%WPZ\3V5MX*>_NM>U[P#K?AW7/#L$?G\_[4
M/[;OQ#^&/ACQ/XNU%(=12W\1:M-I_P %KSXE:?J-IJGB#]F[QAXEUOP%X\GM
M?AU\-;:PNOA_X[ATBU\*:9I<_B'Q5H6I(UIXTUIM>CLOM8!_1S17X.^,/VP/
MV[?"6C:?+!9^']:_X69K'BZ6?Q#JO@B[\(:+\ O"_AK]K:\^"T6HRZO!X9\8
MQW-K>?#*>P\32:UXS\->([&RU.SEUVZAC\-7+1Q>N_'#QA^T]\5/V2/V0=4B
MBNI/BS\0?V@/AMIGQ$T[X*_$[XL_!'0/$?A1=?\ %%K=K)\2+?P-I/Q!\.>&
M]:T;3]*U/6;N3P/8:;J%W/(NGV:Z'<:=,X!^PM%?AQ\7M;^.OPX^,WPB\(^#
M=?\ CMIOP0T+0_A9IW[=8L?B'X_^+MQ\,[#5/%[2?#2X^%_Q.\2VFG^-M=US
MQ!J,MQI_QUUKPO80ZC:?"7R]6N+>#7[>Q0\3^R!\4OVNM&\=?LD> /C#K_QD
M\<>%?C3\3_VH?B+IGQ$UJ'6IX]&TS0?$WQ*LI/@5\3+M8]B:)X=L+?P[XA^#
MNHZXD$&H:!%<:8E[>WUIIL8 /W]HK\%_%_[4/[:?@+X[^./ ?@U=(C\#S_'C
MXI:GI'B;XO\ _"=75EK]K!\1_AIX0TWX5>#X- ^&?Q#U.^TC3?!NL>(?%.B:
M%X8?PUJIU&*/4VU<^%[?6EBU/'?[9'[<]II/B.TTGPMX?\)?\(#\6M)_9[^(
M'Q#\6>'M2T7PE:^*%AU_QGJWQ+\.ZL/!'C2-_";Z$?"7@*+5KKPIJGA,^)+O
M4G^U6EW<Z>T(!^ZE%?S\W_[7O[97@S7;/Q)J=S:R)XG\9?"Z;Q-X1T/PI\0O
M$Z7D.J>'_#>GZEIWP:T+QSX.\/OKGAZ\DO;C6];\-+JGPS\>VD[W'B*P_M#2
M;"XTJY^H_P!L[]KOXV?!OX\^!?!7PKMM7O-.C'@&?Q!H%]\+KK6/#.OV/C3Q
M'>Z'JE\_B73GU/Q;JO\ PC=JMI>W-IX/TW0++0Y0%U_Q%>2ZE9:50!^L=%?E
M9^S;^U7\</$_P3_:O\6?%$3:UXI^"ZZC>^%]9\'_  XU#7?#^IBX\'W.NVMG
MX1@C@\ :GX^;1M1B2#4O#&IZ#X.\3>&KC=X9\2ZSJ5ZC:\U?]FKXJ?M$?M8_
M ?\ :&\+:KXMU+PCXN\,^-?#.D?#_P")KZ(?!.LZ]X8U#0_!WCW4[>YN/#=M
MI^E:?]NM[O6O Z>)O!?VX:):W9OK75M<U?2WO+@ _5NBOR3_ &+/C5\;[?XH
M^'?@_P#%[2/'GC Z[\-WD\-?$?6=9\1PV/\ PBW@.WL!IOBO4?"^MZ.\\][\
M1+K6KR74O%'B#Q#'XI@UG3CX8FTZ\L]/BNHOF#]I#]HG]K[XB^%O'GP]\*>,
M_'/@+5]=^(%MH?C*Q^&/@35?#WCC]G70O#W[67P2^&_AO2[#QW]@>?6I/B_\
M-O%OC/6-0U^*:Z6:S\.WFM^%Y=.\,7%Q&0#^@NBORC_;%_:C^-?P<^.?PU^&
M?PHGUVXM+B+X)VNKZ?>_#=-<T;7+/XG?%P_#3Q%K,_C&1]1U?4[[PAH,T7B6
M33M#TWP_IWA^[M8-0\8^)=1L->L]$C^;?'/[;/[>G]AVUUI/A+P?\.[;2O%/
MB_X1^+?&?CG0/$FF>%;7XK?!KP=I>I>*[G3KRQ^'_P 0=0U+PM\0_B%J>N^"
M_#/V/PP8O$>F> +MO!6O6NN>(M):X /WNHK\-_B?^UY^UUX/^$GB3QSJ&JWF
MC^--=^(7Q*\.^"?"GA#X-?VUX;T6V^&'AJXU:TM+CQ)XLTZTUVXB\=ZS=6MI
MI\5WX2U+Q7XDTZS72_"6B:3K2:GJ0\[\5?\ !0W]KVQ33=9T/3-!?XB>)=*^
M)GE_LU7OPS\31OX:\.^$]&\&W7ACXMIXSM=,U+7=2TW5=)U_5OB#J.AP6^LW
M-SIMK'X:T71WUG0/$%O<@']!E%?(O[%7Q(^+7Q0^#]SKWQAU/P/X@U^Q\9^)
M=#TGQ/X"FUVXTGQ'X<TZ>$:=J-W<ZOX!^'%C>:K'++=:?>7WA;PZOA:]-E'<
MZ9<R&2>.+ZZH **\D^/OQ(N_@Y\#OC!\6K#3;?6;[X9_#/QOX\L](NY9(+74
M[KPIX<U'7(+"YGA_>PP7<MBL$LD7[Q$=F3Y@*_F:3_@XJ^++*K?\,X_#\;E!
MQ_PE'B#C(SC[W:OW#PI^CKXK^-679KFOAYD6$S?!9+C:.7YC5Q.=91E<J.*Q
M%#ZS2A&GF.+PTZJ='WG.G&4(OW6U+0\W'9M@<NG3IXNI*$JL7."C3J5+Q4E%
MMN$96LWUZ:G]8%%?R@_\1%/Q9_Z-Q^'_ /X5'B#_ .*KZ[_83_X++?$']KK]
MI_P%\ M>^"_A#P?I?C#3/&M_<>(-)U[6+V_LG\*^$=6\201Q6UV3!(MW-IR6
MTI?E(Y6=/F K[OB3Z%GTA.$N'L]XISSA++L+DO#F49CGF;8FGQ1PYB9X?+<J
MPE7'8VM##T,RJ5Z\J6&H59QI483JU''DIQE)Q3Y:/$655ZM*C3KS=2M4A3II
MT*T4YU)1C%-N"2O*25VTEK?8^[/VJ_VO?''P9_:-^"WP&\)3_#?0;?XF?"KX
MF?$J^\4_$'P=\5_'/^D^ _'GPC\&6GAG2M*^%:M<Z=+J<7Q+N=1FUO7BFE6Y
MTF*V+J]Q7D_Q,_X*)?$KX?\ C[]HKX(6_P ,/!>K_%W]FWX3^,?C_P")[AO$
M\MKX+\2_"1=&C3X7MH2QW=UK]GXT\4>.+C_A&_%>BZA$]AX,T;3SXHNM2N/^
M$B\.Z/<_H5XC\/\ P;TSXQ>$_BCXIU3P]I'Q7L_AUXW^'/A.XUGQ5%I=S=>!
M-?UKPEXV\9V=AX?O-2@M-26/4? 'AS5+O54L+B\TJUTV95NK:SNKQ)OFOQ%^
MS#^PUXRTC01K5WX6OV^)_B_XC:_HGBZ+XO:A!XI^*>N_%6PN- \=:5;^,[7Q
M5'KGCO2]4T?[)H,?A>+4M3TK3--T'P]I^FZ?:1^']+2U_E0]PH_ K]N-OC7/
M/I\?@J/PQXB\,_ 37?'WQ,\(:G>3'Q!\/?BYX3U73-*\2?#358MJ++IZ+J5K
MK>A:WY4#Z]X7U30=>@AA@U188_._"7_!5GX*ZII&F1:OX.^)FI>*K7P9INK^
M,X/ /AK3_$>B:-XU/PVT#XFZ[X&LEF\1VOB.6]TW0/$6FS0ZK>Z);>&[E[J&
MV37GNEN(XO:M2T+]B+X5?%WQG\4]1\0^ _"OQ.^*WAW0OV=?B!KQ\:7"Q7MG
MX6T74]9T;PWXQC@U271/#&OVV@173#7=>CTC6+S3[6RM)M2G6WL85G\%_LM_
MLB^ ?'FGW'@V>UT?Q$?!/VN/P/:?%?7'T;6?#S>"(/AU+X_U+X?R>)9-,UO4
M[GP7:V6A7/Q O-*N;ZXM+*R:356FM895 .$U7_@I]^S;IWC2#P7:6OQ$\123
M:W=:=_PD/AOP]H^J^'I="M]7\*:!%X[TJ6/Q*FK>)_!]_KGBVWTRPN?">D:[
MK-Q-HWB*0Z(D&E^;//\  '_@H1X(^+GQ!\)?!?Q!X5U[PU\4_%,/CV_MS&V@
MP>#9]/\ "'CCXC>%[<Z)<:UXELO%OBB62Q\ 2SZU=^%_"VMZ/H6IZA:V>J:C
M8K<1LO'Z%\&_^"=GAKX?:7XN\%ZI%H_PV_8[T=O %UK'@;QS\0FT'3?#-KKM
MAX_'@CQ++X?U&X'Q3T!/$5[9ZG;Z+<_\)3:OJEPUC;H]RTMK7,^$9O\ @G7X
M=^(GPD\6^%+OXDZEXTA\1>-;;P%X(M="_:/\3KX9\6VGB?4;WQCK7BOX5_V#
MJ*^!=9TO7_BA*\WB'QWH&A?8XO$.FFWO!9+I[1 'I6O?\%'/ASX$\>?$3P1X
MS\%_$6^C^'WBKQM!XC\6>$?#6E7'A3P3X%\&^(OAWX/N_%/C.]U;QA9ZE*H\
M0_$+3PR>&M(U6[DTR&ZO1I,*6C^?U</[?G@*=_"\L7P?^/S:+XY\1^)-#\$>
M)F\)>$HM"\4:7X-35Y_%OC.QFD\>)>V7A;P_9Z'J6HWC:S8Z9KUQI\,=UIVA
M7J3Q!N)T/PI^P!\9O%7Q%M=!N3XF\3_%SQ)XQ\!>,[&&^^)5E+XCU74M=TGQ
MIXJCT^VN%LX%T6;5OA-:WR^)-&5/#QC\/:A:6.JF":\@GZ'2O@U^PK\+_C)J
M5A/X@T72_B=X \*:_P#$J3PSXS^*GB.\TWX;_#3X@ZGJFE:\VFZ#XG\0R^&?
M!WPY\0ZYJFJ//X?MH++0Y=4N9+Q+)9"LH .8L?\ @J=^SUJ?@CQ5X]T[PU\3
MY=%\,-H]U$]]:?#O08/$?A_75U)]-\2Z%KWB+XCZ3X36SN%TQQ'H>M^(-%\9
MS-=V(M_#$PFD,)<?\%6/V7K)/$]W?Q^/].TKPO\ #>P^)UQJ6HZ1X8T^75M"
MU*+0_LD7A[P_>>,(/%FLB:^\0Z=H\?B.ST!_ DFJ_:H4\7-;VSW1[8_\$^OV
M2[KPC;VT=AXN_P"$6M)I/$/A[4[;XS?$-;7PQH-SI%]9W&C>$=8C\5[/#_P^
MO-%U*[CN/#>E7$'AJ:Q='-KY<43IXE\1?V??^";GPY^'G@SQ[XRCUGQA\,_%
M>FVWP>^&%MX:\3?%_P"-VAWLOB6&*"!OAUX5\ W/C2X&NSCPM;3R>,?#^FFY
MT^XT:WO)]5M9H4E(!J_$+_@J1\/M+\ 7FN_#GX8?%#Q/XSTZXT]O$'AC5M"T
M6RL_ FDM\9_#OP:U+7?&&K6/BRXL[S2)-;U>].AW_@.Z\9Q:F-/>ZQ'8+)./
M1/C'^V[J_P (/VM?#WP!O?A)XN\1^#]:^'W@75;+Q'X5T_1]5U[Q%\0_B=XW
M\3^%?"WAG2(=2\9^';'2]%TNQ\%^(-5\1:QJUO,Q9([>T2-8C-<>'>+_ (=_
M\$V-?N;3X;>,_%'Q!&K>$-(G\1Z]J&K>,?VA-)U'Q;9:-K_A[XTW7@WXB^/)
M);.+XC:UHWB.+0/%-Q\)_$>MZQXET[59XK*7PO%>7<EE)]4^'M,_9-_:>^)?
M@_XT>')KGQCX_P!&\*> ?&&@ZM'_ ,)[X?\ [)T'PWXA\977@LZUHM_!I%EI
M6K6^M>)?%4TGAWQ#8VOB*:VN8Y]1TM].AL)% //M,_X*5?![6D\-_P!D_#7X
MZ7]W\0+SPU!\*=/B\)^$X[KXJV7BG6_$7AVQUGPA)<>.X;*#3;75O"^JQ:D/
M%5WX;U"UM5MK];":SN%E7HO W[>7@?XK?#'XF^._!/@/XB^'=0\%_ K5/CSX
M<TKXH:+H^@1>,O"$%KXM@TW4[!_#_B;Q+-;V,GB/P=J^B7\.I#3-3A:W^U6]
MI-:36]S)Q?BCX2?\$^_V5[?Q7\6O&OB/1O!ME\#KOPI\0M2.O?$[Q9XA7X-Z
M9;:YK-YX2TWPWX+_ +=U>\\%^#-1\1^,=5N=.\':%HEMH>M:IJ@>+3;J58?+
M]G\.?!W]E/P?X=\/^'+"71M TSXG_!:+X(^&-'\0>-M4TS5_%?PMO)O$GB<>
M'='T[Q#J]OK5U?[_ !KKM[/=6T'_  D-M%>K%/-$EG;QP 'B,O\ P4V^%_AO
MX57/Q!^(_P ,OBOX'US0=#\+ZYXI\$:Y%\,]#U>WTOQ-X!7X@6GB#1;[7_BA
MIWAO5M%O-.CN[/2[&'Q#_P )9>:G;2Z</#HGAG:.UJ?_  5+_9IT>7QRNH6O
MQ M(O ^D:%JSM>:7X5T^_P#$B^)=7\,Z%HD7ASPYJ/C*T\5RV6IZGXLTJ'3O
M%.K:%I'@C4HTO[G3_$]U;V3R-'KW[$?["*^#5L/$^MW2Z3!IAGD\7Z]^T3XT
M'B"3P9XG\.VWPOMM!N_'&H^.?[6G^'VI:%HMOX4TK0I]2?P\SV!M=.A%Y'+5
MCQ)^R)^P)IMWK+^-=6T.";1?"NF^'UMO%OQVUN./X<:1K>K^&=3TS4_#-MJ_
MC)!X!U76]>\#>&=1LO$.F+INH:AJNA6T]K=R3QR[@#@M:_X*C^!['6+?6(?!
MGBBU^&EKX-D\3Z])J.A>;\0+74?#G_#4K>//#MIHUEKYT&\DTZ+]FZZ/A[7-
M*UK6M"\0SZJJ6%[<6=U;ZA;=9XF_X*G_  "\%@V'B_P/\:?#WC&S?5KGQ!\/
M+WPSX2F\9^&_#^C^#?!7Q G\3WUII_CJ]TK4M/N?"'Q \,ZMINF>&M7UWQ3J
M#W-SIMMX??5+22R/=:K^R1^Q?J=[9>"/$=Q::SXHD\'2:9]A\0?&/Q#?^.=;
M\-ZG8?&*.XUC4WO/%;>(-:GU.S^,OQ4N)O$=T+BZNSJCW9O6;1-/DL>?^,'P
M._88C\'^*OVF_&5]<0>%]+6"^\4?$_X;>//'VH3ZAI,'AOP+\([KPL9?AGJF
MHZIXA\.ZQI'@7P7X<USP7IMK?V>M7^EQS7^FSZC+=S2 'KW[07[9GPJ_9LE^
M'Y\?6'B:>P^(;6!T[4]*D\&VL6FVVHZSH>B0W-YIOBKQAX8U_56AN-?M+J\T
M[PEH_B35[.PANKBXT^-A;177EVG?\%'OA+JM]8:/9_#/XYG7?%E_#IOPIT.?
MPIX4@U#XR77_  D7B?P[J/\ P@&_QU]D$.A_\(AKNNZM)XNNO"IC\.VHU"R6
M]GD6RK@_BXW[ '[0]_X,\8_&#4?&_A,S>&_$OAG0+OQO9?'G]G[2-=\.?"Q-
M-^*FJZ5JUMXGTOP+IVK1^&X67QAHT>JQO<WD.F^(+K0C?1Z#KRV&;8#_ ()N
M_$2S\2^']&\67]EK?[.UO\'=&UH:?K7Q@\$_$SX22?M"ZIH?COX0ZG8RR)HW
MC70M1\=7/C^P2R\1Z8OGVEIK>K>&]8OM/A@UG3K8 ^W_ -FKXP7WQZ^"_@[X
MK:CX=E\)7GBE=9DE\.7.?M>D_P!F:]J>D+:WR^=<".^5+!6NXDN)XXKAI$CE
MD158^[5YS\)?A3X+^"/P\\,_"[X>V-]IW@_PE9RV6C6NJ:SJWB'45BGN[B^G
MDOM;UV\U#5]3NI[NZGGFN[^\N+B5Y"7D/&/1J "BBB@ HKCOB'XGF\%> O&G
MC"VM8KZX\+>%M>\006<SM'#=RZ/IES?QV\KIATCF: 1NR_,JL2.17\V__#_/
MXG_]$!\"?^%'K_\ C7DYEG>793*C#'5I4I5U.5-1I5:MU!Q4FW3C)*SG'>U^
MFS/R#Q.\=?#7P?Q.483CW.<3E5?/*&+Q.6QH93F>9*M2P52A2Q$I2P&&Q$:3
MA/$4DHU7%S3;BGRNW]/-%?S#?\/\_B?_ -$"\"?^%'K_ /C7T1^RA_P6'\?_
M +17[0'PY^#6K?!SPCX=T[QOJD^GW.M:?KFL7-Y8K#8W%V)(8+D^3(Q,&PJ_
M&&SU%<%'BW(Z]:E0IXFHZE:I"E33PV(BG.I*,(1<G325Y22NVDM;O0^ R7Z8
M7@+Q!G&59#E?%6/KYGG68X+*LOH2X;S^C&KC<PQ-+"86G*M5R^%*E&=>M",J
ME2<805Y2DHJY]M_M4_M?>-_@U^T1\)?@5X4E^'.@6WQ ^%7CKXEWOBSX@>#O
MBMX[5KCPEX^^&G@FU\,:9H_PJ5KW39=03Q]-J,NO:[MTFW.G16K,)+C(\K^(
MO_!0OXG>!/B5^T!\!8/AEX)U?XO?L[_"GQ)\?O$E\WB6>S\#>(OA!)HZ0?#B
M;1D2[N_$-AXU\3^/FF\,^)M#U"%]/\':':P^*I=4U+^U]-T9_P!!/$GASX-:
M-\8_!OQ7\5ZGX?T3XK7?@W7_ (,^"+O7/%4>E3ZSX>\5^(_#'BW6/#.B:!>Z
ME;V6M:I>:YX0\/WD<EK876L0I:&WMY8[>ZN(I?G'7OV8OV'_ !AIWB]]7N/#
M&HW'AWQCX[\7?$?Q;%\6]1C\56&N_%"RG\.^,K/X@>,+7Q2FMQ:-K6D0Q>&U
M\,^(M031;32]&TS2K#3[>+1K2.W^E/Z>,G]G/]N9OC]J>BZ*/! \(^(K3]GW
M6OB+\3_".JW<C>(OAS\6/#'B#P]HFO\ PXU"%2(Y],\C7K;7=#UHI%)K/A^_
MT;58XK<7LEM!Y]X1_P""JWP<U.VM-,UKP9\1]2\66>CRS>+(_A]X>TWQ'H6B
M^)H-/N];N?",?VGQ)8^(Y-1M=$MTO[O4I="3PS:K*J3Z^AW!/>OAQX-_8W&L
MZM^UKX%O?"FFW?Q1\!6/P&U7XFWOB74M TWQ;X5^&WB+5O"MAHDL7B&^T^PN
MM3TO6]+U#1[;7ELQJ^J06D"PZA?:>+)SB>&?V=?V*OAKKFK_ !+T#6?#OAVR
M\%>;X9\:V\GQAOT^'5IKLFE7N@R7'Q$\-WGBEO"4WC<:5J\^G#5O$]F?$*P2
MV\8F!BM]@!R.O?\ !43]F?1?%EKX3M(/B)XHDN]0FC@UGPOX<TK4M&NO#L&J
M^"-";QOI1E\1VFJ^(O"[ZS\0?#EC"_AO2M7UN8OJ%S'HK6>FW<Z6O@%_P4*\
M#?%GQQX$^$'B+POKGAOXH^-=)\2:Y;-"VA0>"KBPTCQ5XYT.S30+O7/$EAXK
M\5S&R\%R2ZY<>%O"^NZ7X>U&\M[+6;_3S/$:Q?%/[.W_  3Y^"'@[X>W&JZC
MIOP^\._ ;P#/>>&TT'XH>+X-7/PBU3QU8>+)++7].\/Z_<^(O'GPQ_X3:[TO
M4DL]7M-:\.VDZV(016EO&J>B>%_V<?V-O#?BGX6?$;0=;TMY-(UN^LOA5:3_
M !EU;5/!%]XR?5?%&IW%SX=\-7?BJY\-:[XSM-2\2^)#'<6MG>:O9M/) H1;
M2%(0#D-5_P""BOP^\(>./'/@?Q3X'^(^K3>"O&WBO1]:U_P7X9TJZ\.^$O"?
MA_Q[X-^&EOXA\5W6K^,++4)C=^+/&5C (_#NEZG=R6*3WW]E6\5NQDZ1?^"@
M/P\GM-"UBR^$OQYOO"_C#QU+X%\"^+X/"?A2/PYXTDL-6UO2=>\2:/<77CJW
MOK/PYX<;PYK6H:O)X@T_1=:_LJR^V6&BWPGMXY9IO@M^Q=XJ^+/Q1^'T<FG:
MM\5?&7A_6?%_Q,\/:9XS\3SWUMHM]\2/"WBW5+S4S8:HVG>&KAO'?A_P[>)I
MXGT_4T@MVC@M!I,UT'V?AQ^R9^R9/J5E\5/AW:0^*K%=;U+5_"]_IOQ,\1>+
M_ ?AS?J^MWNMZ!X(TE?$>H^$O#WA:?Q#J^NW^K^%=#M;;19-:NKR:ZLOM(8*
M >3Z7_P5-_9\UOP5XE\=:7X8^*,FD^'7T6>$:A:?#OP_%X@T/7[C5[/3?$&D
M:]XC^)&D^$;>VFN]%N;==$U[Q%HOC"5I[*6W\-3VUPT\3KG_ (*J_LO64VK/
M?KX]T[2-(^%6D_%UM<U+2/#6G0:EX?UR/0TTRTT'1[WQ?!XJUZYGU;Q%IGAR
M36])T"[\$6FNR2VUYXMM[2(WQ\"TSPO_ ,$P]:^%DGBG3-3^,S?#S1_'B:'X
M1U*.']JZUO(M6*>)[2?PE\&K"32(]>UGP*\%KXD_M/2/AW8ZGX.2TA:YO/+M
MS:ROTEG\+?\ @ESKMZ/"R:M>^++'P?\ #/PAHFD>&;[Q-\8?$O@[3_#WC&31
M]*\,WG@^RN9+SP]?_$"*\CT:>]NO#CWGCKPIJ%M!JFNQZ/<6<ES" =OXR_X*
MD?#R'P7JFI?#GX7_ !4\1^.-$ETB?Q-X5UC0="LK;P)H&H?%W2?A(OBCQ;JU
MCXON;"]T'4]:N-770+OP)>^,9;M]'N);ZVL;4>:W?_&/]M[6OA%^UI8? *X^
M$7B[Q5X/;X0^!?&AU_PAI^D:QXD\1>._BG\2O$?P]\%>$="M=3\9>&[#3=.M
MF\(ZS?:UJNK1SB5Y8(8#916KW-YH>/\ ]A[]D*W\-Z%!\2;_ ,3Z5I\>MZ98
M7'B;Q/\ 'GX@:'K/CV[G\<6/CW0/"'CKQ;>^,K+4_B%I4?CC3K?6M!\(>)+_
M %6PAU$W T_3P+JYCEZ73X/V/OC_ /&GXF?$72==T[Q5\4/V=-0\'?#/XG:]
M::WXGTK1_ 6K_#36-?\ B3X?T#5+F273O"DU]X=U'QCK.JZM+:2WC0QWJ66M
MSB*V@MH@#B(O^"DGPANCX2&G?#7XY:H?B=>:9:_!C[!X5\)R)\98=1UC4-$D
MU'P+-)X[BA2QTN[T]I]4;Q7)X9N8=-N['4+>UNH+@[.S^$?[<7@/XX^&/&&L
M^#_!'Q(\*ZCH/P9MOCCH.G?$S1=$T0>*? ^JR^+=,T;6=.;P_P")_$K16LWB
M#P7KFE75OJ!T[4(_LR7<-M+:7-O</0\%_LT_L86&LZ/\2O"FHZ+JZZ-JVB>-
M? =VOQ?U7Q!X0\!P/XGU@Z3!\--*E\4WGAOP7X.U?Q9K&J6AT'PQ;6'AW6-6
M9=/>TN)[2"WBZ_P;\+_V3/AOIEX?#&M^#M+TO3? .C?LMZC<7'Q,%W;6'AW3
M-:\2ZKI'PYO;F_\ $,Z6OB<:OXWUTQQSR)XHN6U"&V:21(+2.( \ T__ (*?
M?#?2?A-9^/\ XF_"SXK> ?$L7A3PEXRU?P/K4?PVT/4)O#'B_P /ZOKFE^+?
M#NH^)/B=I7A[4_#]_+X?UK1M.LI=>M_%]WK-C-9IX::-'NEU+_\ X*G_ +,N
MFR>-OMMOX_MK;P5H'ASQ \UYI7A?3KSQ'!XMU[P9X8\.Q>'?#NI>,;/Q7-::
MQK_CS0=-T_Q/JF@Z5X(NW&H7,'BA[*R>Y>@?V*/V 9_"%_;3^)&OM'\%:@W@
M_5O%U]^TCXQO]9\+V=_H</A%?A7JWC2[\>3:EI/A:;2[B*PMOAY?ZC!I:7%U
MYUMIBWER9'ZBW_8D_8=\1:K9:&JP^*-4U#X>VR>#_#L_QG\4:]<:%X-BUCPA
MK%KXQ^'>CR>+;J;0)1XC\#^$-8A\;^'(()QK>CV=Y%J0N2YD /-+[_@J-X$B
M\107Z>$/$NF_#6U\*Q^(-?NM8T0-XXL+_1+3]K6[\<Z+%I=CKTFA7":9#^S%
M-+H&NZ9J^LZ+X@_MC;9W,MK=6NHVW7>*O^"H_P "? RS6/C#P#\;O#WC*TU#
MQ%;W_P .K_POX1/C2STGPKX ^&GQ-UKQ&MK:^/+G1]2TZ#PE\7O %Q!INC:U
MJ/BB\U#6CI=IX?FN[*\6'SO7?!?_  3LO?%WCOX3:WI/Q>\9^+?AKH^M^$/B
M/J4/AC]J'QPED$\!?%_Q/K-EX@^)6E:!JNA:UXFN_!_[07Q(O&9?$=]KM_>^
M*].L;;SM;L] M+>3XEZC_P $P_%WB;PUKWB?XE6EEXC^+?C?X9>&O#WCOPAX
MV^)NB1>(/%'QW^$^@^%_ WPZ/COPG/#I.EV_Q,^&'P2\+3ZMX&O]7T^UOK?P
M_P"&M;\2:=;WNN:-=ZH ?JYIFH6NKZ;I^JV3.]EJ=E::A:/)%)!(]K>P1W-N
MSPRJDL+M%*A:*5%DC8E'56! \Q^/W_)#/C'_ -DO\=_^HQJ==3X*\8^#_%UE
MK$7@S4XM2L_!WB36O .K+#;WMNNE^(O"%T=)UG1R+VWMVF;3;F$VYN+?S[2;
M;OM[B9#O/+?'[_DAGQC_ .R8>._?_F6=3[=ZY,?_ +CC?^P3$_\ IF9]!PE_
MR57#/_909-_ZL<,'P!_Y(9\'/^R7^!/_ %&-,K^(K_@];^$_Q3^)NL?\$Z&^
M&WPU\?\ Q!71M-_:E75V\$>#O$/BM=*:_NO@ ;%=2.A:=?\ V%KT6=V;07/E
M?:!:7)BW^1)M_MU^ /\ R0SX.?\ 9,/ G3I_R+.F=*]6DAAFQYL,4NW.WS(T
M?;G&<;@<9P,XZX&>E& _W'!?]@F&_P#3, XM_P"2JXF_[*#.?_5CB3_")_X9
M2_:C_P"C;?CW_P"&?^(7_P SU'_#*7[4?_1MOQ[_ /#/_$+_ .9ZO]W+[%9_
M\^EM_P!^(O\ XBC[%9_\^EM_WXB_^(KK/GS^5C_@T4\'^.OA7_P2;^)%AX^\
M$^*O!>O6W[6OQGUR'0?&7A_5O"^J7-BOPQ^#(M[M;#6K2RO#97-Q97-M'="'
MR7EM[A$<M#(%_2+X4_MZ?%/QA^SA\3?VEKC1/@QJWASX>^'/^$_\6_#?2/"/
MQ+\ ZU:>$-$\1WG_  F=E'X\^(-[:^!O%/B-/!FE:M)X>ETS&CWWB46=M=W$
M5E<@-^P<]C:7%I<V$D""TNX9K>XAC'E+)%<1M%,N8MC*7C8J74AQU# @$>)3
M?LT?!BX^%_@OX,3>$GE^&7@'6?#>N>'_  D^N:^^G27?A36AX@T6UUXMJ9N/
M%.CQ:NJ7=YH7B.;5-'U0QQPZG97<"", 'YNVG_!475K?Q=\ ]>U[X3:!IOP#
M^/'P1^,GQLTGXD+K;/JWPD\,:%XY^&_@+X-3?$NSA-U::;;?$74_&)M_&Y@D
ML&^&.H7NDZ7XI-I)H^O2)[]\0OV\= ^#GP?_ &7?C3\1_#-CI7@_XV^#/$/C
M?QXNEA[J_P##+:9\$]8^*BV/ANWGFM8-3U#4]7T^'0D;5+JVA,5R]S<W<&QI
ME]K;]AW]EV2Y\>2W'PLT^]LOB5X1^+'@+Q;X?OM7\0WOA2[\'?'#7/#GB?XI
M>'M/\*7.K2^'M"TWQ9XF\+:7XBNX-#T[3Q::W)JNJ:<;.\UK5I;S6\0_L=_L
M[>+/AC\,?@[XE^'Z:W\//@[X/G\"?#W0M1U_Q+<G0_#EQX#G^&KV\FI2:P=4
MU6^3PA<26,&KZO>WVK6]YLUB"\CU>..^4 \!TS_@I;\ -3TB_N]0\)?$_1KN
M$W^G0:!J?AWPS>77B#6K'Q?X<\':IX;\-7^B^+=7\->);Z"^\6:1J#RZ1K=Y
MH]WI;:A-::C<W>F7UG#2^'7_  4>^&_QJ\5_#OPY\*_"GB-K+Q;XY\.Z&-5\
M6VNCV]AJ7@WQ-HNL:KHGC+PG>>&/$/B*T*W*:;;%M#\1/H?B2QMM1M9+W0K<
MF40?0MA^QM^SY9R_#.YO?!VI>)]0^$?BKQ9XV\%ZKXU\9^-/&NK1>)_&_AVX
M\*^(]5U[4_%&OZK>>+9+O0[C[+;P^*)M7MM.EM[*\TZ&UO;&TN(6^ ?V-?V?
M_AI=Z/>>%/"VN1/X;\0:?XC\+0:OX^\>>([+PG=:3::A8Z7IGA:PU_Q'J-GX
M>\,Z=::I=067A72H+7P];Q_9UBTU?LEKY0!X%XD_X*+_  _\!>-/B5X/\6?#
MSXCZVGP_\5^-K;Q+XA\$^'_#MSH?A3P/X-\0_#GP;-XG\4OKGC73=3U R^(O
MB)IT"6OAG2]6U*73X;FZ71H4M29^V^*W[:>E?!+XY:Q\./&WPY\63?#30?!W
M@GQ-K?Q9\,VNCW^A>!)/&&N:IHRR^-;*\\0:=K::5#]A-P)/">@>)=16-W>6
MRV'*^F:U^QQ^SOXAU#XAZIJW@-[J^^*MOKUKXZF'B7Q5#_;,'B;Q%X4\5:T@
MC@UJ./3_ +9KO@CPU>AM-2T: :>;>W,5M=7D,_:^-OV>OA#\1=4\0ZQXS\(Q
MZ[>>*K#POI?B$7.IZQ'::IIW@[4YM8T"RN;&VU"&S-O;7UQ.US$L"KJ,$KVN
MHBZMCY5 'QMIW_!47]G_ %SP1XL\?Z?X-^(LVE^$;SP_<6W]HO\ "C0X-?TC
MQ0^I6^E>*-&\3>(/B?IO@S3H)OL$D;Z-XG\2^'?&FV\M%B\-RK+,8?#?'_\
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ML?"OC#P3;>+O%=KX8^+MIX+6VN$\*:SX]AL[&T>>&UABN@EF]E%;V.KZ9;@
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M_;G$/"?"TN(,]E+AKA^4I9UFC;EDV7-MO'U+MMX:[;N[M[W?</\ AXW\=/\
MH7?A?_X(?$__ ,V5'_#QOXZ?]"[\+_\ P0^)_P#YLJ**Z/K^._Z#<7_X4UO_
M ),\=<)<*:?\8SP]T_YDN6_W/^H;S?WL/^'C?QT_Z%WX7_\ @A\3_P#S94?\
M/&_CI_T+OPO_ /!#XG_^;*BBCZ_CO^@W%_\ A36_^3!<)<*:?\8SP]T_YDN6
M_P!S_J&\W][#_AXW\=/^A=^%_P#X(?$__P V5'_#QOXZ?]"[\+__  0^)_\
MYLJ**/K^._Z#<7_X4UO_ ),%PEPII_QC/#W3_F2Y;_<_ZAO-_>P_X>-_'3_H
M7?A?_P""'Q/_ /-E1_P\;^.G_0N_"_\ \$/B?_YLJ**/K^._Z#<7_P"%-;_Y
M,%PEPII_QC/#W3_F2Y;_ '/^H;S?WL/^'C?QT_Z%WX7_ /@A\3__ #94?\/&
M_CI_T+OPO_\ !#XG_P#FRHHH^OX[_H-Q?_A36_\ DP7"7"FG_&,\/=/^9+EO
M]S_J&\W][#_AXW\=/^A=^%__ ((?$_\ \V5'_#QOXZ?]"[\+_P#P0^)__FRH
MHH^OX[_H-Q?_ (4UO_DP7"7"FG_&,\/=/^9+EO\ <_ZAO-_>P_X>-_'3_H7?
MA?\ ^"'Q/_\ -E1_P\;^.G_0N_"__P $/B?_ .;*BBCZ_CO^@W%_^%-;_P"3
M!<)<*:?\8SP]T_YDN6_W/^H;S?WL/^'C?QT_Z%WX7_\ @A\3_P#S94?\/&_C
MI_T+OPO_ /!#XG_^;*BBCZ_CO^@W%_\ A36_^3!<)<*:?\8SP]T_YDN6_P!S
M_J&\W][#_AXW\=/^A=^%_P#X(?$__P V5'_#QOXZ?]"[\+__  0^)_\ YLJ*
M*/K^._Z#<7_X4UO_ ),%PEPII_QC/#W3_F2Y;_<_ZAO-_>P_X>-_'3_H7?A?
M_P""'Q/_ /-E1_P\;^.G_0N_"_\ \$/B?_YLJ**/K^._Z#<7_P"%-;_Y,%PE
MPII_QC/#W3_F2Y;_ '/^H;S?WL/^'C?QT_Z%WX7_ /@A\3__ #94?\/&_CI_
MT+OPO_\ !#XG_P#FRHHH^OX[_H-Q?_A36_\ DP7"7"FG_&,\/=/^9+EO]S_J
M&\W][#_AXW\=/^A=^%__ ((?$_\ \V5'_#QOXZ?]"[\+_P#P0^)__FRHHH^O
MX[_H-Q?_ (4UO_DP7"7"FG_&,\/=/^9+EO\ <_ZAO-_>P_X>-_'3_H7?A?\
M^"'Q/_\ -E1_P\;^.G_0N_"__P $/B?_ .;*BBCZ_CO^@W%_^%-;_P"3!<)<
M*:?\8SP]T_YDN6_W/^H;S?WL/^'C?QT_Z%WX7_\ @A\3_P#S94?\/&_CI_T+
MOPO_ /!#XG_^;*BBCZ_CO^@W%_\ A36_^3!<)<*:?\8SP]T_YDN6_P!S_J&\
MW][&M_P48^.+AE?PW\+75E*,&T#Q,P9&&&1@?&1!5AP5.01U%*/^"C7QR&,>
M'/A<-HVKC0/$PPO' _XK+@<#@<<#T%%%'U_'?]!N+_\ "FM_\F"X2X4T_P",
M9X>Z?\R7+?[G_4-YO[V(G_!1CXX1@*GAKX6(JYVJGA_Q*H&X[FP!XR &6Y..
MIY/-'_#QGXXCIX;^%HY!_P"0!XFZC)!_Y'+J"20>V3111]?QW_0;B_\ PIK?
M_)@N$N%-/^,9X>Z?\R7+?[G_ %#>;^]B_P##QKXY9S_PCGPNSG.?[ \39SC&
M<_\ "9=<<9].*C'_  45^-H"*/#'PJ"Q,6C \/>),1L<Y9!_PF.$8[FR5P3N
M.3R:**/K^._Z#<7_ .%-;_Y,%PEPII_QC/#W3_F2Y;_<_P"H;S?WL=_P\8^.
M&0?^$:^%F5&%/_"/^)<J,@X!_P"$RR!D X'< ]:XZS_;5\?Z?X[U?XHVWP_^
M$@\?>(/#^F^$]1\32Z'XMGU$^&='NY[^RT*S:?QO)%IVF?VA=S:A=6EA';17
MU]Y=W>K//##(A136/QUI?[;B]O\ H)K=U_?)_P!4N%+Q_P",9X>W7_,ERWM'
M_J&\W]YV9_X*,_')@RMX<^%K*X(8'0/$Q# C!# ^,L$$<$'((XZ4T_\ !1?X
MWE=A\-?"PH JA#X?\2E0J$%%V_\ "8XPI *C&%(!&***7U_'?]!N+_\ "FM_
M\F4N$N%-/^,9X>Z?\R7+?[G_ %#>;^]B_P##QGXY?]"W\+>N?^0!XFZXQG_D
M<NN.,^G%(/\ @HO\;U.Y?#/PL5BBQEAX?\2@F-<[4R/&.=BY.U?NC)P!DT44
M?7\=_P!!N+_\*:W_ ,F"X2X4T_XQGA[I_P R7+?[G_4-YO[V"_\ !1?XX*@C
M7PU\+%0+L"+X?\2A F,; H\8X"XXVXQCM2K_ ,%&?CDBJB>&_A:B* JJN@>)
ME55 P%51XR   X    X%%%'U_'?]!N+_ /"FM_\ )@N$N%-/^,9X>Z?\R7+?
M[G_4-YO[V._X>-_'3_H7?A?_ ."'Q/\ _-E1_P /&_CI_P!"[\+_ /P0^)__
M )LJ**/K^._Z#<7_ .%-;_Y,%PEPII_QC/#W3_F2Y;_<_P"H;S?WL/\ AXW\
M=/\ H7?A?_X(?$__ ,V5'_#QOXZ?]"[\+_\ P0^)_P#YLJ**/K^._P"@W%_^
M%-;_ .3!<)<*:?\ &,\/=/\ F2Y;_<_ZAO-_>P_X>-_'3_H7?A?_ ."'Q/\
M_-E1_P /&_CI_P!"[\+_ /P0^)__ )LJ**/K^._Z#<7_ .%-;_Y,%PEPII_Q
MC/#W3_F2Y;_<_P"H;S?WL/\ AXW\=/\ H7?A?_X(?$__ ,V5'_#QOXZ?]"[\
M+_\ P0^)_P#YLJ**/K^._P"@W%_^%-;_ .3!<)<*:?\ &,\/=/\ F2Y;_<_Z
MAO-_>P_X>-_'3_H7?A?_ ."'Q/\ _-E1_P /&_CI_P!"[\+_ /P0^)__ )LJ
M**/K^._Z#<7_ .%-;_Y,%PEPII_QC/#W3_F2Y;_<_P"H;S?WL/\ AXW\=/\
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M?^1RZX)&?0T@_P""B_QO4[E\-?"Q6"",,/#_ (E!\M22L>1XQSL!)(7[H))
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>D,H\-</QE'.<J:DLFRY--8["M--8:Z:>J:U3/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img132800289_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_12.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %! G # 2(  A$! Q$!_\0
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M?^&L\#?_ "BH_P"&;?V=O^B!_!;_ ,-9X&_^45>TT4?V=E__ $ 8+_PEH?\
MROR7W!_KIQC_ -%9Q-_X?LT_^:O)?<>+?\,V_L[?]$#^"W_AK/ W_P HJ/\
MAFW]G;_H@?P6_P##6>!O_E%7M-%']G9?_P! &"_\):'_ ,K\E]P?ZZ<8_P#1
M6<3?^'[-/_FKR7W'BW_#-O[.W_1 _@M_X:SP-_\ **C_ (9M_9V_Z('\%O\
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M (9M_9V_Z('\%O\ PUG@;_Y15[311_9V7_\ 0!@O_"6A_P#*_)?<'^NG&/\
MT5G$W_A^S3_YJ\E]QXM_PS;^SM_T0/X+?^&L\#?_ "BH_P"&;?V=O^B!_!;_
M ,-9X&_^45>TT4?V=E__ $ 8+_PEH?\ ROR7W!_KIQC_ -%9Q-_X?LT_^:O)
M?<>+?\,V_L[?]$#^"W_AK/ W_P HJ/\ AFW]G;_H@?P6_P##6>!O_E%7M-%'
M]G9?_P! &"_\):'_ ,K\E]P?ZZ<8_P#16<3?^'[-/_FKR7W'BW_#-O[.W_1
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M):'_ ,K\E]P?ZZ<8_P#16<3?^'[-/_FKR7W'BW_#-O[.W_1 _@M_X:SP-_\
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M_L[?]$#^"W_AK/ W_P HJ/\ AFW]G;_H@?P6_P##6>!O_E%7M-%']G9?_P!
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M8\/:U"D=W:M))!-%+#(D]K>V5U"R3V=]97$<=Q:W4#K)'*@!W1L\;_,'@/\
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MI452QM-Q=2*<5:/-&7M^@74M]H6B7L[%I[S2--NIF/):6XLX99&)  )+N2<
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M>7^[7/"LMAJZ?9W$]V\MJBWEFT%U=PWEM<-J3ZN\DOG.UH8/T>^"G[.OPV^
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M\<^)+#09=:MM*DM8M2FTY+R1#<QV4M]9I<-'D1M<Q!N7%:G[-O\ R;M\ _\
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M>%?$FLV=AXM\77%]K6JZ9+X@OKVYC634+N"TFEEBC9',N[\D_@GIR_!O58O
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M)/@Y\0/B)^TE\"O&GB3QIX:^(FMV=QX[^&GQF^&ND7>AZW^T?#8:78>#M/\
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MHEXITKQ+\8O&GPM^*ME^UMX'M/A'X.UK4?VDM2\(^)OV6FT_1+B7PAI?PO\
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MQ4_]077JXLR_Y%V/_P"P+%?^F*A]-P5_R67"7_939#_ZM<(._9M_Y-V^ ?\
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M?M\_]![X1?\ AKT_^:*C_A^)^WS_ -![X1?^&O3_ .:*C_B7?C[_ )_\/?\
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MN/\ A^)^WS_T'OA%_P"&O3_YHJ/^'XG[?/\ T'OA%_X:]/\ YHJ/^)=^/O\
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M^$7_ (:]/_FBH_X?B?M\_P#0>^$7_AKT_P#FBH_XEWX^_P"?_#W_ (<<5_\
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MBO\ YW!_Q&S@[_GSG?\ X18;_P";OZL_*_\ :/17\7'_  _$_;Y_Z#WPB_\
M#7I_\T5'_#\3]OG_ *#WPB_\->G_ ,T5'_$N_'W_ #_X>_\ #CBO_G<'_$;.
M#O\ GSG?_A%AO_F[^K/RO_:/17\7'_#\3]OG_H/?"+_PUZ?_ #14?\/Q/V^?
M^@]\(O\ PUZ?_-%1_P 2[\??\_\ A[_PXXK_ .=P?\1LX._Y\YW_ .$6&_\
MF[^K/RO_ &CT5_%Q_P /Q/V^?^@]\(O_  UZ?_-%1_P_$_;Y_P"@]\(O_#7I
M_P#-%1_Q+OQ]_P _^'O_  XXK_YW!_Q&S@[_ )\YW_X18;_YN_JS\K_VCT5_
M%Q_P_$_;Y_Z#WPB_\->G_P T5'_#\3]OG_H/?"+_ ,->G_S14?\ $N_'W_/_
M (>_\..*_P#G<'_$;.#O^?.=_P#A%AO_ )N_JS\K_P!H]%?Q<?\ #\3]OG_H
M/?"+_P ->G_S14?\/Q/V^?\ H/?"+_PUZ?\ S14?\2[\??\ /_A[_P ..*_^
M=P?\1LX._P"?.=_^$6&_^;OZL_*_]H]%?Q<?\/Q/V^?^@]\(O_#7I_\ -%1_
MP_$_;Y_Z#WPB_P##7I_\T5'_ !+OQ]_S_P"'O_#CBO\ YW!_Q&S@[_GSG?\
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M53R_$YA'"PSO"UX5*4W*CDT\3#$QQD8J%6E'$4+3^JXK%X?](Q_#'#TJ^/\
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M'P]%\0[G1-!UF+4(-7MV\R2YTBP?18(;FT\F*3U/]J_XZ?LJ?'#]E_4/V3_
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MOXO,,-3P>.QF$I8BGBJ6'Q%6C2Q-&<:E*O3A-QA5A.#<91G%*2<7;4****]
MXPHHHH **** *M]_QY7G_7K<?^B7K_00\3_\F&>(?^S1=6_]4U<5_GWWW_'E
M>?\ 7K<?^B7K_00\3_\ )AGB'_LT75O_ %35Q7\I_2L_Y)WA_P#[N3_U!P!_
M4GT4?^2_P_\ V/.#?_5U,]1_9M_Y-V^ ?_9%OA9_Z@VA5_$K_P %1;FV3_@H
M+^U(KW$"LOCO1PRM+&K _P#"!^$>""P(/L17]M7[-O\ R;M\ _\ LBWPL_\
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MK]KM/^?FW_[_ $?_ ,51]KM/^?FW_P"_T?\ \57ZE?\ #U3XD?\ 1K/[#?\
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M )^;?_O]'_\ %5^I7_#U3XD?]&L_L-_^(]V'_P NZ/\ AZI\2/\ HUG]AO\
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MET[M=+/L?QC5R[ASVM2_$M9/VD[K^P,0[/FUU^O:VN]?+[ORU^UVG_/S;_\
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MO:.M_J7@U5<(TW5_UFP?M'3C)RC3<_[,YG",IRDH-\JDYM*[;=_4>'^14_\
M6C$^S4W45/\ L+%<BG)0C*?+]>Y>=Q2BY6NU!)NR5ORU^UVG_/S;_P#?Z/\
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M'_R[H_X>J?$C_HUG]AO_ ,1[L/\ Y=UK_:W%W_1'X;_Q*,+Y?]2WS_!]C/\
ML[AS_HIJ_3_F08GR_P"H[S?W,_+7[7:?\_-O_P!_H_\ XJC[7:?\_-O_ -_H
M_P#XJOU*_P"'JGQ(_P"C6?V&_P#Q'NP_^7='_#U3XD?]&L_L-_\ B/=A_P#+
MNC^UN+O^B/PW_B487R_ZEOG^#[!_9W#G_135^G_,@Q/E_P!1WF_N9^6OVNT_
MY^;?_O\ 1_\ Q5'VNT_Y^;?_ +_1_P#Q5?J5_P /5/B1_P!&L_L-_P#B/=A_
M\NZ/^'JGQ(_Z-9_8;_\ $>[#_P"7=']K<7?]$?AO_$HPOE_U+?/\'V#^SN'/
M^BFK]/\ F08GR_ZCO-_<S\M?M=I_S\V__?Z/_P"*H^UVG_/S;_\ ?Z/_ .*K
M]2O^'JGQ(_Z-9_8;_P#$>[#_ .7='_#U3XD?]&L_L-_^(]V'_P NZ/[6XN_Z
M(_#?^)1A?+_J6^?X/L']G<.?]%-7Z?\ ,@Q/E_U'>;^YGY:_:[3_ )^;?_O]
M'_\ %4?:[3_GYM_^_P!'_P#%5^I7_#U3XD?]&L_L-_\ B/=A_P#+NC_AZI\2
M/^C6?V&__$>[#_Y=T?VMQ=_T1^&_\2C"^7_4M\_P?8/[.X<_Z*:OT_YD&)\O
M^H[S?W,_+7[7:?\ /S;_ /?Z/_XJC[7:?\_-O_W^C_\ BJ_4K_AZI\2/^C6?
MV&__ !'NP_\ EW1_P]4^)'_1K/[#?_B/=A_\NZ/[6XN_Z(_#?^)1A?+_ *EO
MG^#[!_9W#G_135^G_,@Q/E_U'>;^YGY:_:[3_GYM_P#O]'_\51]KM/\ GYM_
M^_T?_P 57ZE?\/5/B1_T:S^PW_XCW8?_ "[H_P"'JGQ(_P"C6?V&_P#Q'NP_
M^7=']K<7?]$?AO\ Q*,+Y?\ 4M\_P?8/[.X<_P"BFK]/^9!B?+_J.\W]S/RU
M^UVG_/S;_P#?Z/\ ^*H^UVG_ #\V_P#W^C_^*K]2O^'JGQ(_Z-9_8;_\1[L/
M_EW1_P /5/B1_P!&L_L-_P#B/=A_\NZ/[6XN_P"B/PW_ (E&%\O^I;Y_@^P?
MV=PY_P!%-7Z?\R#$^7_4=YO[F?E7?7EH+*\)NK<#[+<?\MXO^>+_ .U7^@OX
MF(/[!?B @@@_LB:L00<@@_!JXP01P0>QK^36Z_X*K_$F.UN9!^RQ^PRQ2"9P
MK_L]6#(Q6-F =?[;&Y3C##(R,C(K^N#XB:M+K_[$_CG79[2PL)M:_9:\3:M-
M8Z5;"STNREU'X2WUY)::;:!F%K86SS&&SM@S""W2.(,0N3_-'TE\9G&*X?R5
M9IDM+*8PCQ"Z,J>:TLR=>4L#@N>+C2PN']C[-*+O)SYW-I)<K;_I3Z,&&RS#
M\>X)Y?FE3,92SWA!58SRZI@?9)9RW%IU,16]ISMR5DH\O)=M\R2[S]FW_DW;
MX!_]D6^%G_J#:%7\3G_!4/\ Y2!_M1_]CUH__J!^$:_MC_9M_P"3=O@'_P!D
M6^%G_J#:%7\3G_!4/_E('^U'_P!CUH__ *@?A&O'^BU_R/L;_P!D;2_]3LG/
M2^E1_OF:_P#9PLY_].9T?!=%%=7X1\!^._B!?7.F> ?!'C+QWJ5E;+>7FG>"
MO"VO>*[^SLVE$*W=W9:!8:A<VUJTS+"MQ-$D+2L(PY<A3_;-2I3HPE4JU(4J
M<%>=2I*,(15TKRG)J,5=I7;6K2ZG\<PA.I.,*<)5)R=HPA%SG)[VC&*;;MT2
M.4HJ[J^FZEX>U*^T;Q!INH:!K.EW<FGZGH^N6-UI&JZ;?PG$MCJ&FZC%;7ME
M>1GB2VN8(IT_B09%9_F)O,>]/, R8]PW@>I7.X#D<D8YJHM2BI1:E&24HRB[
MQE%I-236C33333LTTUN2TXMQDN647RN+T:DM&FGJFGI9ZCZ*:CI(-R.KKDC<
MC!AD=1D$C([CM3J8'N?[-7_);?!__8,^(W_JJO'->"VO_'M;_P#7"'_T6M>]
M?LU?\EM\'_\ 8,^(W_JJO'->"VO_ ![6_P#UPA_]%K7!3_Y&F-_[%V5?^I6=
M'9/_ )%V$_[#LQ_]1\I)Z***[SC"B@ D@ $EB%4#DEF("J!U))(  Y)( YKM
M8?AK\2+C7=5\+V_P[\>W'B?0DLY-<\-P>#?$DWB'1(]0GLK;3Y-8T2/3&U/2
MX]0N=2TVVL'OK6!;VXU&PAMC+)>6RRYSJTJ6M2I3IKE<O?G&'NQE"$I>\U[J
ME4IQ;V4IP3=Y13N%.I/X(3GJH^Y&4O>:E)1T3U<83DENU"3VB[<515V'3-2N
M=93PY;Z=J%QXBDU%='C\/P65S-KDFL/="P328](CB;4'U1KXBR73EMC>->$6
MHA,Y\NG7VE:II;F/5-+U+3'6\U+3BFHV%W8L-1T6Y6SUG3]MU#$3?:/>.EGJ
MUH!]HTV[9;:]C@G81FN>%U'GCS22E&/,KRBTVI)7NTTFTUHTF^C)Y96<K.R?
M*W9V4M-&]D]5H]=5W*%%%%4(*]L^#W_(!_:%_P"S?=>_]6+\,:\3KVSX/?\
M(!_:%_[-]U[_ -6+\,:X,R_W3_N9P/\ ZG88Z\#_ +PO^O6)_P#4:L>)T=.M
M%-=%D1D895U9&&2,JP((R,$9!/((([5WG(?I!XJ_8,N/#O["W@S]J19_'K^/
M+]_!OCGQGX<N?#TT'@'2_@K\2?&/B3P/X-UG1_$#Z3''=^,(+_1]$UOQ%I8U
MJZ:Q\.^+='OY=,M8I8YI>\^(W_!,AQ\;_$WP_P#@I\</!/B7P?H'QIUCX+:Y
M<^+H];L/%_P[\5V?PUG^*&A^'/$%NNA:3IWQ \2>+M"T_4['P[:_#R.>&_\
M$=L= 4)-%+=#Y-U7]M?]IK6Y_%"ZK\3;^]T'QA\,K?X/:OX FL[5OA=;^ ;/
M0](\/Z?IN@_#5E/@[P[J6F6.@Z7/IWB+1M)L]=M=4@DU1+\W=S</)M^-?V\/
MVD/B%K%EK7BS6?AWJ4L'BO4O'.KZ8/@Y\,H?#OC?Q=JOAF+P9<>(?B-H"^&V
MTWQUJUOX3ABT#2M0U^&YOM&LE$FEW-I>XNQ^<1R[Q&C4E-9QE2]I4SJM%.4J
MM'#K,(Y=4R[!NC5RSFQ5/*:M',*>'KJOA)SAB,/*O"O3A7P]3[:6-X)E",'E
MN9>Y#*J4FE&G5KO!/&0QV)56&8<N'GF5*K@YUZ+HXB,9T*RH2HU)T:]/T'3/
M^">'Q!O/&/B+PCK'Q+\$^#&MOBUX4^ O@'4/&?A;XF^'I_B;\9?&G@]O&VA^
M"++PUJ'A.#Q+X-6+2O(MM;\2>+-/MO#^FZG>V,-I>ZM9W*WXW_%__!/K4K7P
M7\.O%?AOQC%HUUJ?@C]EY_B'H?C6.2ZO-.^)'[27Q9\9?"A+/PY-H.G16R>%
MO!VJ>%EO-3BU*:YU:XMY)OL-S=NT<:>.6G[>7[4-GXD\0^*D\<Z'<:IX@O/"
M>JV\&H?#_P %:GH_@O7O 7AJ?P=X&\3?#/1=0T6YT_X>^)O"/A>ZN-%T'7?#
M<-I?6MI,QEDN)UCF2KX4_;C_ &DO!S:1_9?BSPWJ$&A>"_AWX$TZR\4_#[P;
MXNL$TKX2^+=4\=?#G5Y[+Q#I-_;W7C+PKXLUO5=9T_QC<))KAN+V3S[F4)#Y
M6L\'XC.5*I',LE4J2RV4J2E)4J\H4Z<<TA-K*KP5>U3V,Y0K<M9^UI0PE+EP
M\<X8K@E*I!X#->6H\<E4:C*=*,ISEE\HIYE[SI7A[6*E3O3BZ=2>*FY5I?4*
M_P#!+_5M7T7P1:^$_C)H^L>-KJ__ &E9OB;!)X+\6'0/"OAO]G?X@67PSU'4
M/"\5G93:SXJU+4O%MW8Z9;Z2$MKO59O$&G3Z9&FGZ1JUX_@_@#]D2WO?VF_B
MA^RA\0/$\?\ PL32? WQ$_X5/K?P_P!6TO5/"GC+XJ>'O!Z^// NCSW%Y:33
MWGA_QSHEM>:<MC:?V;XAL-=N[.QDVWMM/8W')6/[;O[0]E;RV<FO>#M7L+K7
M/B[K>HZ=XC^&O@KQ%IVLP_'?56U[XL>%=<L=6TFZM]7\">+?$'V?Q#/X.OHY
M=(L=<T_2]2T^.VN--M&B\8L?B]X\TKXN:=\<]'U'3=#^)&C^--/\?Z1J6@>'
M=!T'1M)\1Z5=P7FGMIGA31M/L?#>GZ3;/;Q6ZZ'9Z;#ICV0>TEMY(YIO,Z,#
MEW'/L\TI9CG6 G[7!Y@LKJT:,%6H9C4QU6OEM6M.G@\/%X7#X5TL-B*/LZOM
M(145SR52K6QQ6-X3=3+ZF"RK&P]GBL$\PA5JR=*M@:>$I4<=3I0GBJ[6(K8B
M-2O1J\]/DE)MI)PITOT&L/\ @F9K/C2^TSP9X)\?P>'OB1X6^$?PZ\1?%S2?
MB'H^O_V);_&/XC^!]?\ BI:_"_P]K>A:!_8_AUM \#V.AV.I1^)=8U#7[KQ1
MJTHM=*_LNVDFBXG4OV [O7+/X&ZE\/\ QU:V-I\5-*_8ST'5H?&L4US<Z;\2
M/VLM#\6:I'<Z>VA6$,7_  A/A>;PK/$]M.+K7I8[A-EQ=L"U>4^%_P!O?]J+
MPCXF\=>,--\;Z#?Z_P#$3XDW?Q=U^Z\2^ /!OB>*Q^(FHZ#>^$]3\1^$K?6]
M)O$\&W&J>#]0NO!VH1>'3813>%FCT9!%;PQE8/!O[=G[2G@.;2)M \3>$)4\
M/Z#\)?#^@6>O_#3P/XET_0XO@7%JL'PKUK2;/6M'O([#Q9X4MM;U6UM_%%L8
M]8NK>\D2ZN)66)TX5E_B33E5E#-LGJ\E'!O#0JRDHO%5%"6:JK+^RIR^K>T=
M1Y>IJO4HT[4VXQLX];QG TU3C++LTI\U7$JO.$8N4</"ZR]TU_:,5[?D4?KK
M@Z4*L_?2DW)/URZ_X)F?&6R\":'XYO\ QW\+M'BU[Q#HEA;:?XEU6_\ #-E;
M>%?$7Q0N?A5I?CB[\5ZM;0^'5MQJD$?B;5/#$-Q+X@TGP3=0:[<QM(LUC'XS
M\;?V/O'?P4^-_P /O@3?ZY:^(/$?Q*O_  ]IGA_4_P#A$/&O@^U6[\1>+3X0
MMF>R\8Z3IDFIZ>+HPZG;:SX=O-:T?4=)NK::&_BNGDM(^:U;]K'XV:]X?TCP
M]K6I^"M73P_JT>J:)X@U?X6_#O6O&NEVL/C34OB'!X4M/&&L^'-1UM/ <'C'
M5]1U:/P4UR^@M'=S:5-:S:-(^GME^.?VF/BY\1/%OPO\9>(=3\/6E[\%Y[.?
MX8Z)X3\):%X)\(^$C:>+?^$XE72_#7A>TTZPM_[3\3;M1U65%\ZY8K"CQ00P
MQ1^G@,-QW3Q7/F&99/B,*Y9I^ZH8=TI1C.E'^RO>>'<JCHUHVK0YZ5Z52<IU
M:\J5.-3S\77X2GAU#!8'-*%=1R_][6KJJI2A4?\ :2LJZC#VM)WI3]G4M4A!
M0ITHU*DH?67B;_@GI!?^(?%MM\-?C+X8AM9/BC^TA\+?@[X+\>Z=XA/CGXG:
MM^RWHYU7X@S/K?AW06\&>'EUFUM+_4/#S:O-8VR>?IFC7,TMY-)=+1\,_P#!
M.?Q1J-WX;M]6^*_@F;68/&'[,>@_%7X>:#I_B8>+_AWIG[3,<&O^'[E]=U;2
M;?P?JUUHG@07OB+69M.O+VQT^ZMWTR5I9H6,UKQ?_P %'O%$NB^*M#^&/PW\
M,^#;;Q5\5/CW\2AJ&OVMEXD\4^%_^&A;:&#QI9^#?&")::MX9U5X+KQ#H,>M
M:!%HTI\+:G!92I<7T4UW(NJ_\%(_'5K\([/P%X#\,6'A_P 976A^!="\2_$+
M6=-\-ZMJTD/@+PGKO@K1;W2]6M].M?$FMZIIWAG6Y/#N@:EX^U'Q%=^'=%C@
M2QD?4K*UU"OCHXWQ7_<X:&3XQ0J8B&%CC,1B.%'&C2CC?9RQV,E3QT\5]2>5
MI3G3H8:MFLL>I8BG5]FXY=+[EY/X9.A4QL^*\D56.#GC)972PG':Q52L\"JJ
MRW#\W#JR[^T?[1O1A5JYA3RB.&Y:4Y_%F"YP?\$^O&_BO7;VV^%_C7POKNGZ
MQX-^ 'Q+^'^FZN=1M=9U?PC^T_\ %C4OAE\,=(U74H[&+2;?Q#H8M;;6O&>I
M10QZ++:2RMH:32!;<:MA^P;HC1[++XX^&/B7_P )O\-OVJ]8^$NL?#W2/$>B
M:;-\3/V2GTJ^\;>%/%]GXYT33[Z31]?TI?$MOH.HZ.\ :XLM-U=KN2PNOLDF
M/JW_  4(^(T?A7X*_#WP3H]IX,\"_#;X9_L\^!/&)TVR\+6WQ)\;ZA\ /%3>
M+]'U72OBS#X<F\5^&=,_MI8;[PWHLKZM9^'KU]0F>VU"'4KNVE]#^)G_  45
MT3Q3>07'@KX2:CX9?P[\+?VG/!O@:]U"_P#A_8W>C>,/VJ-3TJ/QKXNU'2OA
M[X#\&>&;B'0O"]KK-CI;6.E6VO:]XC\0WOB#Q%JDP06K^K/_ (B5[2E3<:+H
M5*F*5.5*KEO/0HTLLE3P4LQE.A3G*I7SB&'Q,Z>"J25/!5,52KU,4IPAA/GH
M?ZB\E2=ZJJPIX9SC5ACN6M5J8^$\7' J%6<80HY9*O0A/%P3GBH4*E*&'Y)3
MQ/Y:QNLL:2(<I(BNIZ95U#*<'GH13Z:BJBJBC"HJJH'0*H  _  "G5^H^A\!
MZG]T7_!(_P#Y1X?LV?\ 8O\ BO\ ]6'XNK]'J_.'_@D?_P H\/V;/^Q?\5_^
MK#\75^CU?YG\;_\ ):<7?]E-GO\ ZM,4?WAPE_R2O#/_ &3^3?\ JNPQ_FU>
M/O\ DH/Q#_[*#XZ_]2S6*Y2NK\??\E!^(?\ V4'QU_ZEFL5RE?Z58?\ W>A_
MUYI?^D1/X3K?Q:O_ %\G_P"E,**[O0/A;\4?%FA7WBGPI\,_B+XI\,:6;P:G
MXE\->!O%.O\ A_3CI\*W&H+?ZUI.DWFF6;6-NZ3WJW%U&UK Z2SB.-E8\")(
MRRJ)$+,N]5W+N9?[P7.2ON!BJA6I595(4ZM.I.C+EJQA.,Y4I?RU(Q;<):/2
M23T%*G4A&$ITYPC57-3E.$HQJ1T]ZFY)*<;M*\6U=I7N/HJ,30E6<2QE$.'8
M2*50CJ&;.%/(X)!YIX((!!!! ((.00>001P01T-:6:W1G==T+7MF@_\ )N?Q
M3_[+!\%/_47^,=>)U[9H/_)N?Q3_ .RP?!3_ -1?XQUP9C_!H?\ 8QRK_P!6
M>$.S!?QI_P#8)C__ %!Q)XG1117><@445JZ)H6N^)M4M=#\-:)K'B/6[[S_L
M6BZ!I=_K6KWOV6VFO+G['IFF6]U?77V:SM[B[N/(@D\FU@FN)-L,4CJI2C",
MISE&$(Q<I2DU&,8Q5Y2E)V2BDFVVTDE=Z#C&4I*,4Y2DU&,8IN4I-V226K;>
MB2U;T1E45TUAX*\::KHESXFTOP=XLU/PW9C5&O/$6G>&]:OM!M%T."VNM;:Z
MUFUL9=-MQHMK>V=SJYFN4&EV]Y:S7Q@CN86?'TO2]4UTZ@-#TS4=:.DZ7?ZW
MJHTBQNM3.EZ)I4:S:KK6I"QBG-AI&EPLLVI:G=^38V$3+)=SPHP8PJM)J;52
MFU2?+4:G%JG*]N6;O[COI:5G<;IS7)>$U[17A>+]]6O>&GO*VMU=6U*-%6+J
MTN[&8VU]:7=C<B*VG-M>VT]I<""\MHKRSF,%Q''*(;NSG@N[64H$N+6>&XA9
MX98W:O5III----)IIW33U336C36S)::;35FM&GNGV84444P/:]%_Y-P^)'_9
M;?A!_P"H1\7:\4KVO1?^3</B1_V6WX0?^H1\7:\4KS\%_'S3_L8+_P!5^ .O
M$_PL#_V"/_U,Q88D;"0Q27$[LL<%O$I:6XGD8)#!$B@L\LTK)%$B@L[NJJ"2
M!7[+>-_^"76B^ _BG^QAX)U?7?B@-#^-GCS3O@U\=]0OM"@T"Y\(_%F3P/H7
MCV^@^&E]JF@II^L>$)]/UF_TG2M;EB\16<VK^$_$$ U"YEA>WM_R(\)^)M4\
M%>*O#/C+0UT]M;\(^(-'\3Z*-6TRSUK2QJ^@ZA;ZIICZAH^H1S6&J6D5[:P2
MS6%[#+:72H8;B*2)W1OIW2/V\?VL=)U?4M=G^+VM>)]0U'XF^'_C%$?'<-OX
MYM/#_P 0O#%YKEYI&L>#K'Q*-0M?!UG'_P )'J]E=:'X<CT_1;W2IX=,N;%[
M6UMTC\/B3!\58NKA9</8[!X*C1PF90Q-/$3J0GBL5C</]5P=13AA:[HQRQRJ
M8^#3;Q&(C1I3C&G&4GZ^18KA[#4\0LZP>*Q56IB,#*A.A&$HX?#X6NL1BH.$
ML10]I+'J,<'.^E&@ZE2,I5)1BO:O!O\ P37\8?$C6M.;P!\:/AWXG\!^)/!V
MO^,_!_C'2/#7Q"U/6_$J^%_B9<?"_P 4^'-(^&%OH*?$#5M4\&ZQ#_:OBC4-
M+T>YT^T\+O;^(((Y8;R&U7R_2OV'/'^H^"IO$DOCGP+I_BZ[\*_&7XC>#OA1
M=V_BV#QAXZ^&7P \32^%_B?XRT^]N?#]MHWAN2QO;'6I] \+^+Y=(\2Z[;:'
MJ1.G6%U$EH_/?\-N_'\^*]"\7/>?#.6Y\+:,FB>%O#TOP9^&;>"/"Z)XNG\>
MOJ_AKP@OAQ-)\/>)[OQE=77B+4?$FC1V6JZI?W$J:C/<V6RT3)G_ &S/VD+S
MPKXJ\):C\0DU6U\8R_$'^U?$.J^&/"]]X\L]/^+6O1>)_BEX>\.>.YM)/B;P
MSX7^(>OP_P!I>+/#NBW]IIFI2S748@@@N[B*3SZ>%\0E-\^99-*DZ]"45.*]
MI3PT/KBG3J3IY5".(JU'+ 2QDZ=/"1J0I8J&!^HSK4ZM+LEB.#'!<N S2%14
M:JERR?).O+ZHXSIJ>8SE0ITU'&QP\9RQ4H2JT)XM8R-*=.I]._%/_@F_JFB?
M%S4?"'P]^(NE#P;J7Q2^.GPX\'7'C:WOKCQ)"/@)\%;+XS>(=1\23:#IMOIL
MXU[3YKC2=%72K.,P7A@DOXD@6:0=-/\ \$L]8\3W^C)\*_C3X<U70S\(O@7X
MR\1>(?&/A?Q1HMK:^.OCIX=U+Q3X:\/QQV.G7*Z1X2DT2PDU*^\6:M,\'A6R
M6(^(5-]=_8[;YJMO^"@'[4=MJ/C#5CXO\)WFH^-O$_B[QCJEYJ?PS\"ZE<Z5
MX@\?^![3X<^-KKP?<7FC2S^#H?%/@^PL]*UFT\/RV4%T;=+G:D\EPTV%8?ML
M?M 66CZ5X?N-3^'WB'1M'\&> ? MKI_C'X1_#GQE:SZ7\*K>YLOAEK&IVWB3
MP_J5MJOC/P%I][>Z9X9\7W\$VLV6F7ES82S7-M*R5P++O$Q4<+".=9/&KA\'
MAZ$ZCC&M#$XGV[EB,57C/*HSE*&$4*%*,*D(U,2I8FI&*DX+L^N\".KB)2RK
M,Y4ZV*K580C)TGAZ'L8JAAZ4HYC**C/$N=:K*4)RIT''#TV^53>G\!?V6IOC
MUX9^/?A/PW+KDG[1OPJU;P!<^%/!.GR:?J/ASQ9X4U/XB6_PT^)3R?9[:6^F
MU+P5JFL:!K\.HZ?J2:7-H#:A-/$T2)>1>]?$;_@GG806/QE^)'PF^)L6K?"/
MX1^+M5\/P6OB_2]9M_&7C?0_ GCOPO\ "SXA^+?#7B*U\/Z?X'U&%?&VKZG<
M:#I>E2:K'::!;:>FN:M%JMY%;3_#WP3^.WQ3_9V^(=O\5/A#XF/A;QS;:7K^
MC1ZN=/L=1B;3O$UHUIJ\$FG7L,EA)YBLES:,8/\ 0+^VL[RT$4UK"5[WP]^U
M]\>/#/PO/P?T_P 0>&KOP7_PC^N^$HWUOP'X2UKQ9;^%/$?BVW\?:MX9M_&]
M_I<GBF'09?'%K#XMATU-3%O#KRF]"L=J+ZN8Y?QF\SEB,KS; PP$L1@:BPV)
M4DU0J4Z%/-\.HO"8C2,L!1K9;-5E5C/-LTC4JTXT,*I^=@<9PO\ 4(T<QRW%
MO&*AC(.OAVG>O"=2>65>98JA=R6,K4L?%TG3E#+< X4YNMB''Z5^*_\ P3IU
MKPU\3?&'AWP-X_TJ;PE9:K^U\?"B>*8+VY\5MHG[(6G:'JGB6+7I]*T^QTBX
MUCQ=!K<47A^73;>WLK>6"5M3BM5**UK4_P#@E=\:]$\2?#CPMK/Q"^%^F:KX
MYU#4="U:TNKG68=2\*^)=/\ A]_PL6/0--TBXM+>_P#B3<:O8I=>&=$N_!4=
MS9ZCXXL;OPXDB,L=W+XE+^W[^T_<6?CJSO/%?A&^/Q$O_BMJ&O:C??#/P-=Z
MWI\GQPTNTT?XK6GA'7)]'?5?!^F>,[2PL9-2T_0KJT@%[9VUY"(Y8AGC-:_:
MY^-/B76_"_B7Q')\,]?\0>&8I(Y]9UGX,?"W4M3\<M+X5L/!+W/Q2O[OPM->
M_$:^'A?3+'3(;_Q)<7-W:/;IJ=G-;ZP!J X*&"\2HTZ%*IF^115+!8JE4K.C
M/$UJ^+<*ZP5>7-@L/&,:2G0C73<W4K4%5DITZM:E/KJXK@9SK5(9;F\G5Q6&
MJ4Z7M8X>E1PZE0^N45RXNNY2J.%>5)I15.G6=.+C.G2J1[WP)^R#=W_[8UM^
MR[XY\1WUIIFAR:[KOCOQ3I7ASQ!X7UBW\#^$/ >H?$;Q'<Z9X;\?Z)I>LZ5K
MSZ+IDVEV<&LZ/-9PZO,EQ$^JZ6D=Q<[-O^P9XS\0>"_#7B/P1\2? 7B;QKXO
M^%7PG^.6G?!@6OBG3_&&E_##XS^/K'X;^%=2U/Q1>Z-%X)N=3TOQ1JVEV6N:
M?::BEP]E--K%E ;9$@DX#P-^US\0-(_:>\.?M,_$%(_'6LV5LWAGQ-H&G1:=
MX2L=5^'-WX'O/AK>^"="MM-L3I7AZQM?!=])I^AHFGW-K97-O:7-U;WA682^
M@^(OV]?'UY\/?A[\+_"WA/POX:\->!_AE\,/AE-K5G:2:7\1=7T7X4^)'\5>
M'; _$+2+E/$T&@G7H=.\2W&AB_737\56L>I+8Q6MM%92YYM5\0<+B<K_ +/P
MKS!2P&2QS.6%J9.L+'&T:F82SF;IYE6RZM4AB8RP:HK"_5'*T.2IA.2LI]V2
M8+@C,*69+,LWP>2>SQ>9SR]YG1XBG7K86M#!1RR%.6199G<*=3#2CBIUGC%5
M@E*7N8N4H<G9O^P%IWA=K_Q+XF^-7AGQY\./#O\ PTUH7C'5?AGIGB31=1\.
M>.OV<_#-BNH:)/-X[T"VMKFPU7XC>(_"GA:SO[2TF35]/OGU'39(_M5L8<>Y
M_P""<OQ)T_Q'XNT'4?B=\.+2R^'GQ:^+OPN\>^)Y++Q2=)\.6'P0^#^D_&?Q
MW\1&L[?3[K5-0T"+P]JT.FZ7H5C!-XAO-83RS#':2+="Y^T)_P %#_&'QB\%
MR_#CPMX3TGP1X0U_7/$GB#QW/_87A*Q\2>)[OQ=XE\(>+/$UFMQX0TO1=(MX
M/$FO^"M'UWQ-K,VFR^(M>U4W:WE^NF74UDW4^+?^"F?C/QQ^T%)\1=;\)1Z7
M\&8_'7Q \:V7PK\&Z?\ #KP[XHN9OB+\/O\ A7.OCQMXONO FMZ/\3IM1\/K
M!I^O6WCCP[JECX@TFUL]/N6MI+.TNX/.P%;Q1KX2GBJ^%A@L14PF<JK@\=6R
M6IB*<\+4A+)I+^SX5\"\;C?K->G)0G#"PHX.E5Q=JC6'J]6:87P[P6-GA,+F
M5+-L-3KY3.GF&54<^I82K'%4Y+-:;CG%#+\R6'P3H497GAI5I5<35IX24Z=Z
M]/ROQW^QI:>!?A3\5_%T'Q%L/'/B/X?_  ^_9K^/6B:AX7LM0T[P;XE^!G[0
ME_KGAZ*[DL/$NFZ?XFL/%WA[78_"UW-%-Y-J^FZQ=V<EC]OM?-3X3K[[^.G[
M;=G\5_#/Q7\->&_AW=>#T^(_@[]F[X46^H7.JZ \FG_"C]G>/6]4ATBZTGPS
MX;\.:#;:UXP\8ZEIFJW,/AO3M(\+Z%H>@V6A:9I!)-TOP)7V_#/]O/!XF?$"
ME'%5,1AYT(2EA92A0>4Y8J\&\&HT=,R6872C'5MPC&BZ27QV>_V0L30CDS4L
M/"A6C5G&.(C&=59CCW1DEB7*KK@'@M7*6B2DW551NK??\>5Y_P!>MQ_Z)>O]
M!#Q/_P F&>(?^S1=6_\ 5-7%?Y]]]_QY7G_7K<?^B7K_ $$/$_\ R89XA_[-
M%U;_ -4U<5_.WTK/^2=X?_[N3_U!P!_1/T4?^2_P_P#V/.#?_5U,]1_9M_Y-
MV^ ?_9%OA9_Z@VA5_$Y_P5#_ .4@?[4?_8]:/_Z@?A&O[8_V;?\ DW;X!_\
M9%OA9_Z@VA5_$Y_P5#_Y2!_M1_\ 8]:/_P"H'X1KX_Z+7_(^QO\ V1M+_P!3
MLG/I/I4?[YFO_9PLY_\ 3F='P77Z ?L+^/= \*>'_P!K3PM>_'[0_P!FWQ?\
M4O@EX=\)?#CXEZ]K?C'PW;6'B2Q^)7A_Q!?10ZYX#T_4O$NG2OH-AJ$+3:?
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MU*%6E7HSE3K4*M.M1J1TE3JTIJI3J1?24)QC*+Z-)G[8?%+X^_LDV7BSQ_\
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MQ$HX#)8>R<L-B\7%R56A"7*Z& Q,N=)PYX1HN7MJ]&G5_.;_ (61\+/^C;/
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M);F:.W0K$DMQ+)/(J!Y9'D+,?\^B^_X\KS_KUN/_ $2]?Z"'B?\ Y,,\0_\
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M^9.NS_B.' '_ $&YC_X:L7Y?W?/\'V.?_B$_&7_0+@?_  XX;R_O>?X>MOR
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M/^BP_'K_ +^?#W_YDZ/^'%?[,G_18?CU_P!_/A[_ /,G1_Q&_@#_ *#,Q_\
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M:.(+V3P&;<V_BGP?KOA>]E/D>%XI/.M[+6;BXM?G\O[5%#YR20[XV[,P\:N
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M@>G_ #,L-Y?WO/\ #UM_+#??\>5Y_P!>MQ_Z)>O]!#Q/_P F&>(?^S1=6_\
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M_P#U _"-?VQ_LV_\F[? /_LBWPL_]0;0J_B<_P""H?\ RD#_ &H_^QZT?_U
M_"-5]%K_ )'V-_[(VE_ZG9.1]*C_ 'S-?^SA9S_Z<SH^"Z***_MP_C<****
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M=4O=,L_"^EWNN78U#7;[3--M-.O=<U!5*"_UN\LM-@N=7O@C,HO-1EN;D*S
M2X9@=#[*G_/]8?\ ?V?_ .1JT@I*-IRYG=ZVMIT6WG^:Z$37-*\8J*LM+KLE
M??K^OF5*N6G^KO\ _KQD_P#1T%)]E3_G^L/^_L__ ,C5;M;91'??Z;8G-DXR
M)9L+F:#YFS;C"CN1DY(X]')Z=?BAT?\ -'^O^&8HQ?,MNO5=O7S7WF315O[*
MG_/]8?\ ?V?_ .1J/LJ?\_UA_P!_9_\ Y&JK^OW/^NOY]F3ROR^]?Y^:^\J5
M\5:O>?$/PW^WSX2.M_&K7[OX0>,/V5/C=XAL?@W<6'AWP_\ #_P+J?PT\<_
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MDS]YIJ*2LE:\?TLK:Z:7UU;N5**M_94_Y_K#_O[/_P#(U'V5/^?ZP_[^S_\
MR-6E_7[G_77\^S(Y7Y?>O\_-?>>K>%_^0%8?[DO_ */DK?K#\-H$T6Q021R@
M)(-\19HV_?2?=+*A([<J.<UN5\Y7UK5O^OM3_P!+9[=+^%3_ .O</_24?YM7
MC[_DH/Q#_P"R@^.O_4LUBN4KJ_'W_)0?B'_V4'QU_P"I9K%<I7^IN'_W>A_U
MYI?^D1/\]ZW\6K_U\G_Z4PHHHK8S"BBB@ K^AK_@@=_Q^_M7?]@WX-_^EWQ
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M(TVV_L+7(1<:AJ5_-;V=G 998HA+<31QF62.,-O=0?[(O^%^_ ,=?CO\%/\
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MMT;X4:=XE.J:9/XM\6S3^'=8\-6VH>%]!U'PLFOC2M.UW7?#UUJT4$5[XO\
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M?[/5O\49/$8>[M7HVOI^]AM_X$>LU<M/]7?_ /7C)_Z.@KQK_A?WP#_Z+O\
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MICZ*_8G3?@E^ROI>A_LR:Y\7OV?_ !O\/M8\6ZO>^/;CX2> M<^(OQ?^+OQ
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M^&LHPXVR24Y1C%/,+RDU%*^58Y*[=DKMI+S=C^E.BO)O^%_? /\ Z+O\%/\
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MAK6;K5]%GFM)/M67]H+X#32232?'GX*/)*[R2,?BOX !9W8L[$#Q  "6)/
MYX %52P>/7-[3#UW?EM^ZJ-_#&^G);=V;3U>MG=-S4Q.$?+R5J*WO^\A^?-Z
MV[)VZ6/5J*\F_P"%_? /_HN_P4_\.QX!_P#F@H_X7]\ _P#HN_P4_P##L> ?
M_F@K?ZKBO^@;$?\ @FI_\CYK[S/ZQA_^?]'_ ,&P_P#DCV5?^0?-_P!?EK_Z
M(NZIUYBOQ_\ @#]AF7_A?'P3W&[MV _X6QX!R0(;H$_\C!T!8 _454_X7]\
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MB%X*U#PMX8.AZSJ::5!K\>H?#S5OB9X$T62YOO _B3QAI?CC2&TJ^]#T>_\
MV=+3XG_#OXP>)?VKO OC[QS\,OAY\4?AOX>OO$_Q4^"]O8RZ7\6O&?A+Q;XA
MUB^TKPVFA6'_  D%E9>!_#O@G2[ZQ@LHCX0MKJVU.VU'5+^[U.7S;X"?#7]D
M#]GOQ7#XG\,?M3>&?$]KX:\ :Q\(_A'X4\9?&CX.W/ASX)_"?Q#XWB^(6M^
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MX?\ !7C0&]U+PK96FC:YX9\7>*="\-:MX4U^;2O%5KK5ZVGOHOVFSOX[6_\
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MA'P:_P##8>"/_E'1_P ,Y_L]_P#1"/@U_P"&P\$?_*.O9:*^?^NXS_H+Q/\
MX/J__)GM?5<+_P! V'_\$T__ )'R7W'C7_#.?[/?_1"/@U_X;#P1_P#*.C_A
MG/\ 9[_Z(1\&O_#8>"/_ )1U[+11]=QG_07B?_!]7_Y,/JN%_P"@;#_^":?_
M ,CY+[CQK_AG/]GO_HA'P:_\-AX(_P#E'1_PSG^SW_T0CX-?^&P\$?\ RCKV
M6OSPC_X*!:-)^U?_ ,,\GX6ZRO@)OC3<_LQ0_&\^*=)^SR_M&V?P+@_:)N?
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M  3D^,6L_M/^)?VC_#^G?!BR\>7_ .VE\!_C%H?Q$;[;;^)-+^#/@7]BBZ^
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M$2^+'_A >)__ )6T?\,]?'W_ *(E\6/_  @/$_\ \K:/[3RW_H8X'_PKP_\
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MLK_2[R^T][JWC6YM+74K&>XC+1174+L)%?\ \-O_ +&G_1UO[.W_ (>3X?\
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MK6]YQ]I+H?A7_P %._ _Q>_:WU']F7PC\(OB5?\ AVS\0:[X$'QEL]*UB_\
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MI'$FF'MOV./V(O"O['EOXPDTOXD>/OBKKWBOPW\)?AY%XC\?1>%;2]T7X4_
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MWGAR:Q\2W/AO0-)3QQI,6E-_PG/@W29O$-EX;&IZ%/8>*_$5IJ@N8.#L9O\
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MVFY.4N=MOFG45HK](**^7/\ AM_]C3_HZW]G;_P\GP__ /E_1_PV_P#L:?\
M1UO[.W_AY/A__P#+^O%_LK-/^A;C_P#PCQ'_ ,K/5_M'+_\ H.P?_A30_P#D
MSZCHKY<_X;?_ &-/^CK?V=O_  \GP_\ _E_1_P -O_L:?]'6_L[?^'D^'_\
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MW_A+_@E]K.A3>(-:U7Q#\(M2\:2^._V>O%?@GQK%X4U%_$W@:R^$/[;OQO\
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M[[O[V7/[1U+_ *">I?\ @PO/_C]']HZE_P!!/4O_  87G_Q^J=%'LX?R0_\
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ME3_U79<7/MTG_/"Q_P# *'_"C[=)_P \+'_P"A_PJG17X+9=E]R/V#FEW?\
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M0"?.@X88Y'L>,X)Z5D5<M/\ 5W__ %XR?^CH*4DK+1?%#HOYD.,GS+5_TO\
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M_P#24?YM7C[_ )*#\0_^R@^.O_4LUBN4KJ_'W_)0?B'_ -E!\=?^I9K%<F2
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MM9K6V]N^ZV[G-9]GIOY$%?T/?\$"I6BOOVKV5(G)TSX-C$T2RKC[=\0.BOD
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M7_D'S?\ 7Y:_^B+NJ=3%*\]%\2Z+^2)3D[0U^S_[=+_+^KLN?;I/^>%C_P"
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M@:YXG\0_"S5)+'1=#O?$7BM_#WAZS^(.N>'WUB_T"_\ #>G:'J<>BZU"M_\
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M]6*27Z)?MM?M+_"/XT:9HNA?"FZ\4ZU;:K^T/\=/VEO$NJ>+/"X\+W7AJ_\
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MK^U8^#O^"@.3B?\ 8H(R<$Z=\?P2.Q('B-@"1U&XXZ9/6OX<OA=_R5OX-?\
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MM&^//C'P5X5^$?@[Q-\)--^'/Q^O- \:'7_$VGZO:?%KX#_LJ:7^T_J_@OQ
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M@I?9O_"'?\% O^>W[$__ (+_ (__ /S14?\ "'?\% O^>W[$_P#X+_C_ /\
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MDAY?WO+\7W%_9%#_ *"<=_X4O_Y'^KORM\ _\(=_P4"_Y[?L3_\ @O\ C_\
M_-%3O^$0_P""@N-OVC]BG;Z?8/V@,=<]/^$BQUY^M??E%']N8G_H&R__ ,)(
M>7][R_%]P_LBA_T$X[_PI?\ \C_5WY6^ O\ A#O^"@?/[_\ 8GYZ_P#$O^/_
M #]?^*BYI/\ A#O^"@?_ #W_ &)^.G_$O^/_ /\ -%7W]11_;F)_Z!LO_P#"
M2'E_>\OQ?</[(H?]!.._\*7_ /(_U=^5O@'_ (0[_@H%_P ]OV)__!?\?_\
MYHJ/^$._X*!?\]OV)_\ P7_'_P#^:*OOZBC^W,3_ - V7_\ A)#R_O>7XON'
M]D4/^@G'?^%+_P#D?ZN_*WP&GA#_ (*!HZ.L_P"Q/E'1Q_Q+_C_U1@P_YF+U
M'O\ 2A_"'_!0-W=VG_8GR[NY_P")?\?^KL6/_,Q>I]OI7WY11_;F(_Z!<OZ?
M\PD?+^]UMKW'_9%&UOK.-M>_^\O_ .1/@'_A#O\ @H%_SV_8G_\ !?\ '_\
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M?\]OV)__  7_ !__ /FBK[^HH_MS$_\ 0-E__A)#R_O>7XON']D4/^@G'?\
MA2__ )'^KORM\I_LF_$[XD_$/0/BWH?Q7TOP#IWC'X._&WQ+\)+J?X:OXE/A
M76;72/"O@CQ5:ZO;0^+)[G6;2YF'C%[2[MIKB>%9++S+>0QR #ZLKXP_9!_Y
M&7]M/_L\_P =?^JE^"=?9]<^;1A''UO9PC3C.&'JN$$U!3K8:C5J<J;;2=2<
MFE>RO9:)'1ELI2P5+GG*<HRK4^:;3DXTJ]6G#F:2NU"$4W;6UWJ?YM7C[_DH
M/Q#_ .R@^.O_ %+-8KD)D\R&6/:K[XW38S,BMN4KM9ERRJV<%E!8 Y'(%=?X
M^_Y*#\0_^R@^.O\ U+-8KE*_U PW\"A_UYI?^D1/X!K?Q:O_ %\J?^E,_9W0
MOVX_@-I^C^$]+\:^./B=\7-4UC1]>\##QWXB^#W@OPMXV_9G^&?BO]F+7O@E
MK?A3P]?^$3I:?%*T7QAJ^D>(H+.Q:P@?0/"L5V96\4:E<B?Q[PO^UQ\)O#O[
M<_PA^.$=UXEC^%WP9^"?ACX-Z=XGM_"K1>)_$EUX%_9\U3X7Z;XR'A'[=<7&
MFQZUXLN8+FST^[OIKW2="2UDO_W]O+;K^8=%?(TN \CI+'*+QELPRG&Y-7@J
MF%I4HX3'*<:TL/AZ&$I8?#U8TZDJ<'2I1HRO*O7HU\74K8FI])4XNS:H\&VL
M,G@LQPF:49<F(G4EB<'[-TE6K5L35K5J;G3C.7M*CJQLJ-&K2PT*5"G^YL/_
M  4!^%'Q%TGX8>$/'%[XM^*FKZ;+_P $\;G_ (1OX@:;IEEX;UCXG?!KQ?K;
M_M :SJOBGQ=J$?A[3;OQ-H^HZ/IS^-?$<T5IXKLK>*SUF\M=*TX&+R+_ (*<
M:K/!X*_9R\$>(_BYJOQ<^(&B>./VJ_%FMZKXFF\/-XJT_P )^.OB+H%[X#MM
M1@\.>*O&=M!HT6G:?>:5X8FN]=::^T_1Y9]-L;/P^FD(?R.(!!! (((((R"#
MP00>"".HJ.*"&!2D$,4*$[BL4:1J6Z9*H%!. !G&>*QP/ 6697FV79EEU>I0
MI8#$8G%O!U*%"K[6O7RJIE,?98B*I?4Z$*%6=:K1H4;XO$2C4Q%22HT(TM<7
MQAF&89;C<!C:5.K4Q=&AAEBH5:M/V=&EF-/,I>THMU/K56=6E&E3JU:J6&H*
M4*%.+J595):_8[_@C%XV^.$?QI^+?P@^!]A\'VU7QO\ #;3O'>MZQ\7AXZFL
M+.Q^'GB.'1[;3=&M? ]Y97#W>IS^/FN;F?4)A!!!I:K"&DF*-^.-?M)_P03_
M .3YO%O_ &;7XU_]6#\-JY?%B2AX><3U'3A4]EA,/6C"JG*FYTL?A*E-RBFN
M91G&,N5NS:5TU='1X=)RXUR""G.'M,55I2E!\LU"KA,13FHRL[.4)2C>UTG=
M6=F?T/?\(=_P4"_Y[?L3_P#@O^/_ /\ -%1_PAW_  4"_P">W[$__@O^/_\
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M _\ LBWPL_\ 4&T*OXG/^"H?_*0/]J/_ +'K1_\ U _"-?VQ_LV_\F[? /\
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MJ*C-/V=&$&E[.;Y5I.4'&1^^GB+X"?!#Q=\0_!OQ;\4_"+X;>(OBE\/(&M?
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M75^/O^2@_$/_ +*#XZ_]2S6*Y2O]/\/_ +O0_P"O-+_TB)_ 5;^+5_Z^3_\
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MX8^)_$_@'Q;XPU07_P#;?C+X<Z_X5UZ\75[^[DN6U8VVI6WT!KF@?L=?L_\
MQ5'Q3USPU\%OAI\;/B=X;\5Q?\)]+X;\/Z9\3/'7AKX8>$$\4^,X_P#A(H+
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M3MHN9V6EV%%%%<YN%%%% !7\_?[8NN_%FU_X**:#8Z;K'Q3L_'\7C#]@*/\
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M_P#1:_CI_P!_O ?_ ,R%'_$/I^S7_P!%K^.G_?[P'_\ ,A7[Y44?\1;\1_\
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M_P! V6?^&O ?_,_]7?E;U/[/I?\ /_'?^%^,\O\ I]Y?B^Y\;_\ "(_M[?\
M1<?V7_\ Q'KXC_\ S_J/^$1_;V_Z+C^R_P#^(]?$?_Y_U?9%%']J5O\ H&RS
M_P -> _^9_ZN_*Q_9]+_ )_X[_POQGE_T^\OQ?<^-_\ A$?V]O\ HN/[+_\
MXCU\1_\ Y_U'_"(_M[?]%Q_9?_\ $>OB/_\ /^K[(HH_M2M_T#99_P"&O ?_
M #/_ %=^5C^SZ7_/_'?^%^,\O^GWE^+[GQO_ ,(C^WM_T7']E_\ \1Z^(_\
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MGWE^+[GQO_PB/[>W_1<?V7__ !'KXC__ #_J/^$1_;V_Z+C^R_\ ^(]?$?\
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M[/I?\_\ '?\ A?C/+_I]Y?B^Y\;_ /"(_M[?]%Q_9?\ _$>OB/\ _/\ J/\
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M._\ "_&>7_3[R_%]SXW_ .$1_;V_Z+C^R_\ ^(]?$?\ ^?\ 4?\ "(_M[?\
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M_AKP'_S/_5WY6/[/I?\ /_'?^%^,\O\ I]Y?B^Y\;_\ "(_M[?\ 1<?V7_\
MQ'KXC_\ S_J/^$1_;V_Z+C^R_P#^(]?$?_Y_U?9%%']J5O\ H&RS_P -> _^
M9_ZN_*Q_9]+_ )_X[_POQGE_T^\OQ?<^-_\ A$?V]O\ HN/[+_\ XCU\1_\
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M_P"D1/\ I,S7_D:9E_V'XS_U(J!1116QP!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)^/?^1%\:?]BG
EXC_],]Y1165?^!6_Z]5/_2)'H93_ ,C7+/\ L88+_P!2:1__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img132800289_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_13.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $N G # 2(  A$! Q$!_\0
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MP]23;2C3KO&*E.3<6DHR;;B[+0P?^%#? _\ Z([\+_\ P@O"_P#\JZ/^%#?
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MX'^)W@"\%GXK\+-.]Q"B/+)!'>V4DJ1S^3YT3PS13)OBDV,KR12HY]R/Q'\
M#7_^$5/C3PP/$GFB#^Q/[;T[^TOM!.!;?9?M'F_:2?E%OM\[=\NS) KGQ?#C
MP.+KX*OE5!8C#1C.K&EAJ-:*I3A"I"M&I1A.$Z,Z<H3A5C)TY1E%J6QWY3XI
M8W.LKP6<8#C7.7@<PJ3H8:>)SK,L%5EBJ56="M@YX?%XBC7I8RC7I5*-7"SI
MQK0J4Y1<-#F_^%#? _\ Z([\+_\ P@O"_P#\JZ/^%#? _P#Z([\+_P#P@O"_
M_P JZ]$O=<T73;B"TU'6-+L+NYCEEMK6]U"TM;BXB@!::2"&>:.26.%06E>-
M66, ER *S/#OC;P?XN-VOA;Q1H/B%K!_+O4T?5;+4'M6SM!F2VFD:-&;*I(P
M$;D$(Q(-<BRK#N#JK+J+IQ47*HL'#DBI/EBW/V?*DVK1N]6K+5'JOC?/XUH8
M9\7YNL1-RC"@\_QJK3E3C&<XPI/%\\G"$H3DE%N,91D[)IG'?\*&^!__ $1W
MX7_^$%X7_P#E71_PH;X'_P#1'?A?_P"$%X7_ /E773:Q\1? 7A[58-"UWQEX
M9TC6;CR_)TS4=:T^TO6\W'E%K>>=)(Q+D>69 @?(*DBNAOM8TC3$MI-2U73=
M/2]F2WLWOKZUM$NYY<>7!;-<2QB>:3(V1Q%W?(VJ<BAY50BJ;>6T8JJN:DW@
MX)5(JSO3;IVFDK:QNEH*/'.>S=>,.,,VG+"R4,3&/$&,D\/.5E&%=+%MT9-V
M2C4Y6]+(\X_X4-\#_P#HCOPO_P#""\+_ /RKH_X4-\#_ /HCOPO_ /""\+__
M "KKJ],\?>"-9UFY\.Z1XN\.:GKUH'-SI%CK-A=:A%Y0S+NM89WE)A /G!5)
MBP?,"X-2:_XY\&>%KJQL?$OBKP_H-YJ3JEA:ZOJUC83W1=_+4PQ7,T;M&7!3
MS<"/>"I?<,57]D4?:*E_9=/VLHJ<:?U*/M'"UU-0]ES.-E=22M97O9$_Z^9U
M["6)_P!<\T^K4ZGL9XC_ %BQ?L(5E*,/92J_7/9QJ*;C#D<E)2<8VNTCD/\
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MMBHSJ25?#U%!04G."C.*Y6CFO^%#? __ *([\+__  @O"_\ \JZ/^%#? _\
MZ([\+_\ P@O"_P#\JZ[^^\1^'M,N6L]2U[1M/NTM7OGM;[5+&TN4LHE=I+QH
M)YXY5M8UCD9[@J(45'+. K8S=$\=^"O$EA?:GH'BOP]K&GZ9O.HWFGZO87-M
M8! S,U[-'.4M4"JS>9.T:%59@Q4$CC654'#VBRVBZ:Y5SK!PY$YNT%S>SY?>
M:M'7WFK*]CUGQSGL:JP\N,,VC7:J-47Q!C%5:HI2JM4WB^=JE%QE4M'W$TY6
M5CDO^%#? _\ Z([\+_\ P@O"_P#\JZ/^%#? _P#Z([\+_P#P@O"__P JZXKX
M&_M'>%_CGJOCZRT.W72X/"/B)M!TM-0U"S_M;Q%#:VY>_P!9MM,CD:6/34GQ
M%!*AF#QD22-&75*SOVM?C9XB^ ?PLM_'/AC3=+U74I?%NBZ"UKJYN!:BUU*W
MU.::4?9F63SD:RC"<[<,V><5Z,.%JDLUH9-+*\+2S"O4HTH4:U'#PM.O"%2F
MISY7&/NRCS7?N-.,K2BTO J^+V(APQC.,*7&>?XK(,%0Q>(K8S"9IFM5RI8&
MM.A7=*C[>-2;52E+D2BO:0Y*D.:$H2?HW_"AO@?_ -$=^%__ (07A?\ ^5='
M_"AO@?\ ]$=^%_\ X07A?_Y5UU&D^,-'FTG0+G6=7T;2]4U?P]9Z\]A<ZE:6
MLPMY+ 7EW<PV]S.D[65N$G9[C:8XXX9&D<"-R+/AOQKX0\8+=/X5\3Z%XB6R
MD\J\_L?4[/4&MGS@"=;:61HPQ!".X"/@[&;!QP2RBA%3D\MH\E-I3J+"4W3C
M>3C&\U3Y4I2BU%WM)K2]CW:7'F>594(0XOSCVN(AST:#S_&QKS2IPJR4:+Q?
MM'*%.<)SBHMPC*+E9-,X[_A0WP/_ .B._"__ ,(+PO\ _*NC_A0WP/\ ^B._
M"_\ \(+PO_\ *NNCUKXD?#_PYJD6BZ]XT\+Z/J\QC$>G:EK>GV=YF7'E;X)[
MA'B$FX%#*$#*0P)7FN@OM=T33!9'4M9TK3QJ3B/3C?:A:6@OY"JL$LO/FC^U
M.5=&"P>8VUU.,,,IY302IMY922JIRI-X."52,4FY4VZ=II*S;C=)694>.L\G
M*O&'&.;2EA9QIXF,>(<9*6'G)I1A72QC=&<FDHQJ<K;LDKGGG_"AO@?_ -$=
M^%__ (07A?\ ^5='_"AO@?\ ]$=^%_\ X07A?_Y5UUECX\\$ZEI6IZ[I_BWP
M[>:+HT\MMJVJV^L6,FGZ;<0[?-AO;M9S!;2+O3Y974MO7;G<,S>&_&?A+QC!
M-<>%/$NB>(H;=@EP^CZE:7_V=CD*)UMY9'BW8.PR*H?!*D@42RBC&,YRRRE&
M-*2A4E+!04:<VDXQFW22A)JS49--JS2V)AQWG=2=&E3XRS2I4Q-.57#TX<18
MN4Z]*#:E4HPCC'*K3BXM2G!2BG%IM-'&_P#"AO@?_P!$=^%__A!>%_\ Y5T?
M\*&^!_\ T1WX7_\ A!>%_P#Y5UNZS\4/AQX>U3^Q-=\=>%-(U?**VG:AKNG6
MMW$TF/+6>&6X5X"X(91,(R5(?&T@GHM5\1^']"TLZYK6MZ5I6C!8W_M34+^U
MM+!EF7="4NYI4A<S+S"$=C*/]6&IO**,?97RNFO;V]A?!17MKVM[*]+]Y>\;
M<E^GD$>/,ZD\2H<9YI)X*_UQ1XBQ;>$Y;W^LVQC]A;E=_:\EN5WV=N _X4-\
M#_\ HCOPO_\ ""\+_P#RKH_X4-\#_P#HCOPO_P#""\+_ /RKKK_#7CCP=XR2
M>3PGXHT'Q$ML0+D:/JEG?O;Y. 9X[>5Y(E8G"O(BJQR%)(.*VK?$7P%H.L0^
M']:\9>&=*UN?R_*TK4-:T^TOF\[F'=;SSI(AE!!B$@4R J4R&&3^R*7M)45E
M=/VT$Y3I?4H^TA%)-N4/9<T4E9MM))6\A/CW.5AZ>+?&F9K"U91A2Q+XCQ2P
M]2<GRQA3K?7/9SE*2M&,9-MJR5T<S_PH;X'_ /1'?A?_ .$%X7_^5='_  H;
MX'_]$=^%_P#X07A?_P"5=>K@A@&4AE8 JP((((R""."".01P17B,_BKXG)\<
M+;PI%:> C\,GT 7DUW)XEA7Q]_:OV=G*1>&M_GMIPE 'VK85,9+9XIX?*,)B
M'64,+E\/84*F(E[6GAZ7-"ER\T*?-%<]5W7)3C[TFM-B,?Q[Q)ERP;J\0<55
MEC<?ALOI?5<QS7$.G5Q3:IU:_L\0_8X6#A^^Q$[4Z2Y7)I-&O_PH;X'_ /1'
M?A?_ .$%X7_^5='_  H;X'_]$=^%_P#X07A?_P"5==+J?Q%\ :-9R7^J>-?"
MMC9171L9;FXU[3$B2]4!FLV;[2<7*J0SP?ZU%(9E"\UT^GZC8:M96VI:7>VN
MHZ?>1+/:7UC<175I<PMG;+!<0,\4J$@C<C$9!'4$5$LJP]."J3RVC"$I.,9R
MP<(P<DDW%2=-)R2LVD[I6=C>EQQGU:K*A1XOS>M6A"-2=&EQ!C*E6%.3Y8U)
M4X8MSC"4E:,VE%M63NCS/_A0WP/_ .B._"__ ,(+PO\ _*NC_A0WP/\ ^B._
M"_\ \(+PO_\ *NO ?VG_ -H/XD_"?QY\*? ?PX\/^&=<U3XE?VE:P+XCN;FS
MB34;>\L+6SB%S"PB@@D^U2&:68$)M4CC-=#\/O$'[8]YXQT.V^(_P^^%FC^"
M99YUU[4M"\5SZAJ]K;BSN&MWLK-HE6=VO1;1R*6&(GD8'*U["X1@LOH9E4IY
M'0H8FA6Q&'IXBO@:.)KT\/4J4I^RP\TJDY.I1E"$8IN<E%1U:/DGXSYH\^QO
M#N'S7Q!QV-RW&X++\PQ& IY_B\MP6(QU##8JA]9S"C5EAZ-..'Q5&M5J3E&-
M*FI2E90N>N_\*&^!_P#T1WX7_P#A!>%__E71_P *&^!__1'?A?\ ^$%X7_\
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M^9KG:M&[1RG_  H;X'_]$=^%_P#X07A?_P"5='_"AO@?_P!$=^%__A!>%_\
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M;9EC:E>E1@YM86G0Q,WB*DE"U.%+F<Y6C'4@_P"%#? __HCOPO\ _""\+_\
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M*5*?+"6K1S/_  H;X'_]$=^%_P#X07A?_P"5='_"AO@?_P!$=^%__A!>%_\
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MGQ1IOBRWM=&O-6LI7TL:CIES<PHEA,HV0,X*F>1U15?:.O\ B[\,]2\=Z/\
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M5+&Z^V6$3B.6^M/(GD^T6<4A"27,.^%'(5G#<5_-WX=_9_\ BUHFI?M4:_\
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ME]9:=:3W^H7EK8V-M&9KF\O+B*UM+>(8S+/<3ND,48R,O(ZJ,C)K^:/XS?L
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M_!WA77QI/Q&\,>&[CQ#=3Z-';7BG<R1*W'_M$?\ !/3XG>%?'GPX\"Z%\/\
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MQ%I_C&\A4K<?V9X#\(Z)9>#? FD65XZ+</ILMKI=_P"((HGP@EUN22-=KJ:
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M'0M0AUC1]53XO:]%X]N[VTU*V>XL;V]\'>#+BQ\#7;6\[2:?+OM"4^=*PO\
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MRS#5,;F&*H8+"4G!5<3B:L:-&FZM2-*FIU)M1CSU)PA&[UE)):L^PZ*_(O\
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M>_\ 1(<0_P#AKQ?E_P!._-!_KQP=_P!%-DG_ (<,-_\ +//\^S/UTHK\B_\
MA]U^P7_T-_CS_P -YKG^%'_#[K]@O_H;_'G_ (;S7/\ "C_B'/'O_1(<0_\
MAKQ?E_T[\T'^O'!W_139)_X<,-_\L\_S[,_43QM\/? OQ)TJUT/X@^$/#GC7
M1;'5K#7K32?%&CV.MZ=;ZUI;2/IVJ16>H0SP+>V32RFWG\OS(_,D"D!V!ZY5
M5%5$541%"HB@*JJH 554 !54        8K\C?^'W7[!?_0W^//\ PWFN?X4?
M\/NOV"_^AO\ 'G_AO-<_PH_XASQ[_P!$AQ#_ .&O%^7_ $[\T'^O'!W_ $4V
M2?\ APPW_P L\_S[,_72BOR+_P"'W7[!?_0W^//_  WFN?X4?\/NOV"_^AO\
M>?\ AO-<_P */^(<\>_]$AQ#_P"&O%^7_3OS0?Z\<'?]%-DG_APPW_RSS_/L
MS]=**_(O_A]U^P7_ -#?X\_\-YKG^%'_  ^Z_8+_ .AO\>?^&\US_"C_ (AS
MQ[_T2'$/_AKQ?E_T[\T'^O'!W_139)_X<,-_\L\_S[,_72BOR+_X?=?L%_\
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MV"_^AO\ 'G_AO-<_PH_XASQ[_P!$AQ#_ .&O%^7_ $[\T'^O'!W_ $4V2?\
MAPPW_P L\_S[,_72BOR+_P"'W7[!?_0W^//_  WFN?X4?\/NOV"_^AO\>?\
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M^ O_ "7O!W_8-BO_ %18P^2^D!_R*_$'_L?8G_UI*9_,A1117^AY_"84444
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MYA.HZ?J0E&LVUH@$5I)5\"?L&?"W]H#]D+QU^T+\#W\<Z?X\T7XX>*[#P?\
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M*L+".!/*B@]FTCQ-\*_CYXQ\#:!!^P=X'^'&C^%/VNOA;X$OOB-\,K/6]/\
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MPW?_  BUY='U'1D\1^$[=O!'BBSU.-_,C&DB"6RO(YK"74)6B>0?$VB_M?\
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M$OC#79/%/PVTKQ9?0>)_&-HUCXGUKP]J'B+POJ-[X6OM9M7,=Y)X>FT[?A'
M61$<<SR?Q*=!07$^51JNEEBJ5/;2<W5P^!C1QKI2_LIT:=.MC?\ ;(\V%G4K
M*$J5>;I5U2P_0LSX$55R>0Y@Z:J8]PA[.*BJ5;%NKA%5C_:/M9U*>$OA9..(
MC"DY1J48*I2]K6^XK#]F3X6Z]\&O >I6?ASPIH.MV7_!.CXS_%WQ#KMAX0\.
M:[<>,?&GA/XIV7AZPUR>YUVVOO[/U1]/N-EAXJT8VVN6%JD<=E=1Q7$V_/\
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M_P!"YXC_ /"?UC_Y"K^_/:4_^?D/_ H_YG\<<D_Y9?\ @+_R,JBM7^P/$/\
MT+GB/_PG]8_^0J/[ \0_]"YXC_\ "?UC_P"0J/:4_P#GY#_P*/\ F')/^67_
M ("_\C*HK5_L#Q#_ -"YXC_\)_6/_D*C^P/$/_0N>(__  G]8_\ D*CVE/\
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M(HL(+=0%KUGQ#^W1^VSXIUOP/XAUCQAX@DU3X>^*QXZ\/26/POT32K:?QJ+
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MP?PZLMI;@679?U_PR^X_:;RX_P#GFG_?*_X4>7'_ ,\T_P"^5_PK\E-1O_\
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M_P#GLT?V7^TW_P!#O\"__#8^/?\ Y[->\44 >#_V7^TW_P!#O\"__#8^/?\
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MO\"__#8^/?\ Y[->\44 >#_V7^TW_P!#O\"__#8^/?\ Y[-']E_M-_\ 0[_
MO_PV/CW_ .>S7O%% '@_]E_M-_\ 0[_ O_PV/CW_ .>S1_9?[3?_ $._P+_\
M-CX]_P#GLU[Q10!X/_9?[3?_ $._P+_\-CX]_P#GLT?V7^TW_P!#O\"__#8^
M/?\ Y[->\44 >#_V7^TW_P!#O\"__#8^/?\ Y[-']E_M-_\ 0[_ O_PV/CW_
M .>S7O%% 'RM\0]8_:;\!^ O&?C;_A*O@3J/_")>&-;\1_V>WPW\?VPOO[&T
M^XU VAN%^*LS0&Y%N81,(9/+9PY1@"*^I87,D,4A !DC1R!T!90Q SDXR>,D
MUX_^T3_R07XS?]DQ\;_^H[J%>NVO_'M;_P#7"'_T6M $]%%% !1110!EZY?7
M6F:/JFH6-G#J%Y96%U=6MC<7\6EVUU/#"\D4-SJ<T4\6GVSNH%Q>O!.+6'S)
MQ!.4$3^!ZO\ M/\ P_\ "^F_#N+Q;;ZUIOCKXD'3;?0_AKI-DWB/Q9+?7]OJ
M=PPMX+ 1PW.EQ1Z/J$Z:N[6L,MFEO<R0V[720#Z!U72].US3;[1]7LX-0TO4
M[6:RU"QN4$EO=VEPACGMYXSP\4L;,CJ>&4D'@U\W_&30=&\.2_LRZ-H6F66D
MZ7I/Q\\):=IEC8V\<%O8V$'@7XB)%:6R(!Y4$:@*L:D* ,8H ZC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KW>B@#PC_ (7UI_\
MT3'XT_\ AO+S_P"3*/\ A?6G_P#1,?C3_P"&\O/_ ),KN_%'Q3^&G@B_BTOQ
ME\0/!GA74I[9;R&P\0^)='T>\EM'DDB2ZCMM0N[>9[=Y898UF5#&SQNH8E&
MYK_AH7X#?]%G^%W_ (7?AG_Y95ZU#(<]Q-*G7PV2YMB*%6/-2K4,NQE6E4C=
MKFIU*=&4)QNFKQDU=/4S=6E%M.I336C3G%-/31INZW7WH3P[\:=$\0>)=*\+
M2^$_B)X;O]:AU&73;GQ5X1NM&TRY?2X8I[JV%\\\T:7)AF$D,3A?."2!&)0B
MK/Q[Q_PH[XQ9)'_%K_'G(Z_\BOJE<W<^.O!GCOQI\-+SP5XL\.^+;*PUGQ+:
M7]UX;UG3]:MK.[?P_%/';74VG7%Q'#<- XE2*1E<Q,'"E6!KI?CU_P D/^,7
M_9+_ !Y_ZB^J5XN:X?$82AC\/BJ%;#8BEAJZJT,12G1K4VZ$I)5*52,9P;C*
M,DI13<6FM&F?1\(M2XIX9<6I)\09-9III_\ "CAMFM&)\!<_\*.^#N>O_"K_
M  '_ .HOI=>LUY-\!/\ DAWP=Z?\DO\  ?3I_P BOI=>LUA@/]QP7_8)AO\
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M;_\ 7"'_ -%K7D7[1/\ R07XS?\ 9,?&_P#ZCNH5Z[:_\>UO_P!<(?\ T6M
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MP]*G5IT:E.K3BL31I2G*G2J5:LVDU&5+V3M.:/[H****_C\^\"BBB@ HHHH
M**** "N2\37WC"R:W;PSHVD:I#Y,[WKZGJDNG/"Z;3"L*QVTXD5U\PNS%=A"
M\$$D=;4%U_Q[7'_7";_T6U5!I23<8S5_AES<KOIKRRB]/5&&)I2K4)PA7K8:
M32:K8=TE5CRM2M%UJ5:G:5N65Z<O=;M9V:\7\ _$SQ+XLT/0_%NM:)X;\,>%
M]8^U@W5WXE0W=O);7EW8)%MFMX+:1YI[1W55F!\MA@%E(KU!?%?A=VC1/$F@
M,\Q58476-.9I6=@B"-1<DR%G(50H)9B%&3Q7@/PS^'7@?XG? +P5X<^('AC2
MO%FA)<:EJ*Z7K$!N+07MIXDUO[-<B,,G[V'S'V'/&X\'-?&?[('[-_P,U#XO
M_MI&_P#AAX9N_P#A#/VH4M?"9N8;RY&@6MGX#\&:E:VVE)<7DL=C;P:A++>Q
MP6Z1Q"YGDDV?, /T?)N&>%\UR;B_-<PS7.LMQ/"E&ABIX'+LDP688;%X?&9Y
M@,DPL88O%\08&M3K1JX]5J_-A9P5*BU!SG.\?GN'\5CZF39%B,17ECJ^:9=@
M<76KXF=.G.-:OE]+$UE"GAL)3IQI.:FX1U<7.U^5)'ZTT4    < # 'H!17Y
ML?4!1110!XW^T3_R07XS?]DQ\;_^H[J%>NVO_'M;_P#7"'_T6M>1?M$_\D%^
M,W_9,?&__J.ZA7KMK_Q[6_\ UPA_]%K0!/1110!\,?M@_$+XJ_"F^\ >*/"'
MB&2S\(^(_$'AWP+KNB:7\%I?B9>RWFK:Q.K:KXBUZ/6++_A%_"D5O<6U@9FT
M^^$5[=2W.,,RU-\0'LH_VI? EN_PX\4:C!J%O:3:AKUI\;;;PSI-_JFF0/-I
M^IM\$GU**\\=6^A0)MFUB!(+=1'=07%CJHTLB'B?VX-*\%^+/&'P)TFZ\4^!
MM%\;^#_'/A[Q4-+\:?$70/ <>L>"=7UC[%J<%O;>(FEA\3VQU3P_:27VF:+9
M+XF)M;6WT;5M,>^F^TX/QIO=2U#_ (*(?LJ06]O<3Z'H'A[QZEU);^&=0:"+
M7KKP_>Q>=J6N7/PVU:Q\J#2M4BCT:6T^(OA:..6^U:V^R:U=L]M" ?IK7SM\
M?O\ D+_LZ_\ 9Q/A?_U!_B+7T37SM\?O^0O^SK_V<3X7_P#4'^(M 'T31110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17X _M ?\%W/#OP'
M^-GQ.^#5S^S=XC\23_#?Q9J'A:77[;X@Z1IUOJSV!0&\BL9M N)K5)-_$,DT
MK+CESGCR#_B(T\+?]&I^*?\ PYVA_P#S-U_3N6?0V^DCG&6Y?F^6^&M?$Y=F
MN!PF98#$KB3@ZFL1@L?AZ>*PE=4ZW$-.K356A5IU.2K3A5AS<M2$)IQ7C3XA
MRBG.=.>,2G"4H27L<0[2B^62NJ33LTUHVM';I?\ I=HK\&?"7[;'Q1^-_AS2
MOBUX;USQ/X"T'QW;_P!MZ7X-.KVNI'P[:R,8ET\WT-E!%=;#&6,J0QJ2^ HQ
M71?\-"_&S_HI7B;_ ,"H?_C%?B^9<"9UD^8X_*,T>'P>997C<5EV8X2=3VLL
M+CL%7GAL7AI5<.JU"I*AB*=2DZE"K4I3<'*G4G!QD_R#&^/W#F"QF+P;R;.J
MSPF*Q&%=6G]15.J\/6G1=2FIXJ,U";AS1YXQERM<T4[H_<2BOPK;X[?&6>26
M63XF>+BS2-]W4FC4  * JH@4  =@.<TG_"\?C%_T4OQ?_P"#63_XFN/_ %5Q
M7_05AONJ^7]SS_!G%_Q,1P^]N'\[MT;J9>G;36WUAVT;TN]O,_83Q#\:_A5X
M4U>ZT#Q'XXT32-8LA$;O3[N2=;B 31B6+>$@=1OC8.N&/!K%_P"&C?@?_P!%
M*\.?]_KG_P"1J_%35]<UGQ)J5UK.OZG>:QJMVX^TZA?RF:ZG$0\N(22$ L(T
M 1>.%  XK-KOCPKA5&/M,17<^6//R.FH<S2<N7FI\W+>]KZVM?5._P ?B/I#
M9^Z]9X/),G6$=6H\*L2L:\2L.YMT57=+&*DZRI\OM732@YI\J46K:_[7W_!;
M[4OV=?CWXN^$O@7X0>$OB9X;\.VN@S6?C"3QEJNF/J$NJZ/:ZC=0M9PZ-/''
M]CGN&M@RRL) @?.20/F;_B(M^(/_ $;'X/\ _#@ZS_\ *"OQW_;M&/VG/'P_
MZ8>&_P#U']/KY!K_ &J\)?HA_1WX@\+O#O/<[\.,)F&<9QP5PSF>:8^IGG%%
M&IC,?CLGPF)Q>)G2PN>4,-3E7KU)U)0H4:5*+DU3IPBE%?J&5\7YWFF78',I
MXB.'GCL+0Q<J%"E2=&C*O3A4=.E[6%2HZ<&^6//.<^7XI-NY]3?MF_M3ZG^V
M7\?_ !%\==7\'V/@6^U;0?"OAQ_#VG:I<:S:Q)X:TS[%'=K?7-M:2L]VK;WB
M\A5BP &<Y8_+-5X/]9=_]=H__1*U8K^S\@R#*.%<CRCAG(,''+LCR'+<#E.4
MX"%6O7C@\OP.%I4,+AHUL55KXFK&E2A&"G7K5:LDKSG)W9S3JU*\YUJLN>K5
MG*I4FTDY3DVY2:BDE=]$DO(K0?ZR[_Z[K_Z(AJS5:#_677_7=?\ T1#5FO9G
MNO\ ##_TB/\ 7YZF</A7S_-G[B?\$W/^2%Z__P!C]J7_ *16U?H)7Y]_\$W/
M^2%Z_P#]C]J7_I%;5^@E?X"?24_Y/UXJ_P#96XS_ -,X<_EKBW_DIL\_[&-?
M\T?B%_P4H_Y+EX:_[)KHW'_<:U__  _3WK\]*_0O_@I0/^+Y>&CZ_#71L?0:
MUK_]<U^>E?[!_1C_ .3!^%O_ &2^'_\ 4C$G[_P5_P DKDG_ &!K_P!.5#^G
M[_@@+_R(?CW_ ++U+VSG_BTVD<D]O3W^E?T,_'O_ )(=\8N<?\6O\><_]ROJ
ME?SS?\$!O^1"\>_]EYE_]5-I/OP./3KCOS7]#/Q[_P"2'?&+G'_%K_'G/_<K
MZI7^'GTU?^4C/&7_ +#\#_ZR.2']0>&?_(RX,_['F4_^K>D'P$_Y(=\'?^R7
M^ ^^?^97TOOD_P Z]9KR;X"X_P"%'?!W'3_A5_@/T_Z%?2_3BO6:_F7 ?[C@
MO^P3#?\ IF!Z_%?_ "5/$O\ V/\ ./\ U8XD^#_^"A^C03?L_:SXEM?#?BW5
MO$V@7%I:Z!K_ (*T[P=K^O>"EUW4=.M=4\06?A3Q[XE\-^&?$]S):0#2;#2[
MEM3O6O\ 4K=]/TV>;<*O?L;:'XMC_8\\(:9>W<T'BB\MO$\]Q+XST'PU)JEJ
M;[Q+J=S);^)?#7AC5I?#%KK\-E(T-YI5M=PZ?8ZF/*N[&)(9[*M/]L:TUZVT
M/PUXMO?B'X5^'?P:\+V7BT?&;4_&?ART\8Z#-IFMIH-AX6-YX7O]9T6SU(6V
MNK^YE,EU>VEY<6C:?:M/(TB/^$E]J>H?LK:->_L[^)_AW\3)XY[P^%=1E\.W
MWP<\!:CIEMXKF35M&DT30M'\6:GHD6G::NH:>&M]-O;W5+VV666:"2\>YBZS
MP#R/_@G[\5]"^)\_Q9MO"6NRZWIW@W6;"R\2S:EX+\ ^&KE/$VMK=7#6.C7_
M (#T+PC#JND:5_9E[#-?WV@ZE::F]S93:1XENY;75K2W_2BOR&_X)2:1:Z)9
M_'32[36%U$:5=?#72;O3[;Q;\0/%UCX<OK?3/%%V^@^=XZ\+>&FT34;6TU"R
MDN]!TW^T/LEK-IUQ=S(EW9F7]>: "ODCX&#_ (R/_;<..OQ$^#//K_QCU\.Z
M^MZ^1_@9_P G(?MN?]E$^#'_ *SU\.Z /KBBBB@ HHHH *\]^*7PP\(_&+P3
MJ_@#QO92WV@:RL#3+;SO:W=M<VDR7-E>V=PF3#=6EQ&DT+E73<N'1T)4^A45
M=.I.E4A5I3E3J4Y1G3G!N,H3BU*,HM:III--;,Y<;@L)F6#Q67X_#4<9@<;A
MZN%Q>$Q-.-6AB<-7A*G6H5J4TXU*=2G*4)QDFG%M,^!OV-_V8OAK\,&U[X@Z
M.-8U/Q6VM>*O"-MJ.L7D4PT_1=.UB2T\FSM[:WMH4FO([6$WEQ(LDDA0*GEI
ME3)\ O\ D^']OK_?_9H_]4_;5]"_ #_D3-9_[*!X\_\ 4BO*^>O@%_R?#^WU
M_O\ [-'_ *I^VK]2X<Q%?%97XR5,15G6FO#S P4IN[4(^*7AIRQ7115W9))7
M;>[9\5P/DN4Y#PKPO@LFR_"Y;A)N.+G0PM)4X5,3B<#B9U\14>LJE:K)+GJ5
M)2FU&,;\L8I?>M%%%?E1]^%%%% !1110 4444 %077_'M<?]<)O_ $6U3U!=
M?\>UQ_UPE_\ 1;4X[KU7YDS^"7^&7Y,^$?&?@WXV_$+]@#Q_X(_9N\;6WPY^
M.WBCX:>/-'^%WC>ZD:"+P[XLN]9UI+"]%TL,[6,[#S+>UU)89&TVYGAOU7-N
M"/Y4_P#@A)^PW_P5Q^$__!0GQSXY^+OCOQ'X4^$7P\\9>*_#?[5&G^*?BO;>
M.K;XK>,+WPF9]*TRWTFTUO6QKFN)=ZGX>\0P^-+F.$6%A:/:)?\ G74ED?[.
M/V>/^2.>#/\ KEK7_J1ZQ7S5^QE_R6#]OK_LZB;_ -5OX*K^PO!WQ]XG\./!
M7Z3'ASE/#7 &:Y3QUD^#_M+-.(^%J&;<08'^T\[R[A>LLLS*6(I1IPPN#S"K
MC\KIXNAC*>59W3I9M@(T,2ZSK?"Y/E5#&97P+C*E;%4ZF%R;*N2%&NX4I<F6
M4JRYX6=[R@HS<7%U*;=.=XVM]_4445_'A]X%%%% 'C?[1/\ R07XS?\ 9,?&
M_P#ZCNH5Z[:_\>UO_P!<(?\ T6M>1?M$_P#)!?C-_P!DQ\;_ /J.ZA7KMK_Q
M[6__ %PA_P#1:T 3T444 ?!_[87BWP7\(]:^&WQ#\0^"-$\>ZAXZ\2>'_A!!
MIGBNW\-S:%8027&N>(8+VSN-;F@O+#7)));R.W.CQZE<7PAAC;39&MHWKA_B
M3X4\':)_P4#^ NJ:/I'AJ+Q5XWTCQ7XE\77U];^()_$#VVA^$[O0-,O]+N8=
M.NM.2/SH=&TE[9M7T6QM%>:ZN;/4;B]CC>Y^W_XIT[2Y_@)H-Y/X4AU;4/BQ
MX=UKPI#XCN-0%UJ%WH]RUMK,7AZ&'PAXHLK7Q5"NJ:';>&M4=M/U"SGU;4+B
MQO+06L\QXOQSX\\-^*/^"D7PC\/2:O+IFL_"[3?$.AQV%O\ &+4K<ZZWB+P.
MFH36=U\'+&,:-J,Y?Q/I6HKKNOS37UMI>A:A<:<EK(L'V@ _5"OG;X_?\A?]
MG7_LXGPO_P"H/\1:]4^(M]XDTWP5X@OO"-JUYXA@M(SI\*1B:4![JWBO+B"%
M@5FN;2P>ZN[:)E=9)X(T:.56,;?%'QD^('Q5TW0_V8M5U_X97NL/9_%32_$>
MO:RNO>'M!D%UI/@_XIO#I;Z'J%S%?)J>H:+;6VHO,D,>GQW,\EN?)P$4 _0R
MBOR_7_@I?I;*&'P)\:@, 0#XM\$Y (SS_P 3&AO^"E^EJI8_ GQL0HR0/%O@
MG)Q_W$: /U HK\P!_P %+M,(!_X45XUY_P"IL\$__+&C_AY=IG_1"?&O_A6>
M"?\ Y8T)7=EN]$*4E&+E)VC%.3;V22NV_1'Z?T5^<(_X*%0D CX'>+AD X/B
M_P % \C//_$P-!_X*$P@$_\ "CO%O )X\8>"L\?]Q"O3_L?-/^@*O_X"O\_-
M?>?#?\1-X!_Z*K*O_!E7R_Z=>:_$_1ZBOSA7_@H5"RJP^!WBT!@",^,/!6>1
MGG_B84'_ (*%0@,?^%'>+CA2<#Q?X*). 3C_ )"'?%']C9I_T!5_N7^?FOO%
M_P 1.X M?_6K*K;_ ,2KY?\ 3KS1^CU%?SMW/_!Q1\$+6ZNK5_V:_C69+2ZN
M;20KKOPYVF2UGDMY"N?$.2I>-BI(!*D$@'@0_P#$1?\  [_HVKXV<D#_ )#O
MPY[G'_0PU^WQ^BG](N45./A%Q<XRBI1DL-A;.+2::_VO9II_\,SZ59[E#2:Q
M]!II-.\M4]4_A/Z*J*_+#2?^"G^BZSI.EZQ;? CQREMJVFV&IVZ2^*_! E2#
M4+6*[A24+J1 D6.95< D!@<$CFM#_AY?I0Y;X%>-@HY8CQ9X))"CDD#^TAD@
M9P,C)[BOP&M2J8>K5H5H2IUJ-2=*K3DO>A4IR<)PDM?>C*+BUW1ZJ::33NFD
MT^Z>J9^G]%?D['\1_P#@KAXC0:_X0^$/[(Z>%-:_XFGAM-;\=>+!K*:'>_Z1
MI:ZL+(R68U);.2$7HM7:!;CS%C.T4X^+?^"R>#CX1_L:9P<9\=>-<9[?PU^A
MT_#EU*=.I_KWX;P]I"$^2IQ3&,X<\8RY:D?J3Y9QYK35WRM25W8Y'B[-KZKC
M'9VNJ.C]/>V/L/6/VPO@)H.KZKH6I^*[R#4M%U*]TG4(%\/ZU*L-]I]S):74
M2RQV31R".>)U$D;,C@;E8@@UF_\ #:_[._\ T.%[_P"$YKW_ ,@U^<-_^QW^
MUYXGU"_\2^)?!_PZM_$7B&^N];UV#1_&T?\ 9,.KZI/)>ZA%IGVFW-Q]@CNI
MY5M//_?>0$\SYLU4_P"&'_VH/^A4\%_^%O:__(U?GE6G[*K5I<].K[*I.G[2
MC+GI5.23CSTIV7/3G;FA*RYHM.RO8ZT[I.S5TG9Z-7Z-=&NIVWC#]I#XEZCX
ML\2W_A+XC>(H_"UYK5]<>'DCFDMHTTB24FS5+>6-98%$8P(I%5TZ$9KGX_V@
M_C69$!^)'B4@NH(-WP1D<'Y:U;']CW]IBVL[:WD\'^$"\,2QL5\;66TD9Y'[
MCISW ^G<W$_9%_:55E8^#O"7RL#_ ,CM9=CG_GA7WE+&9&J%)2E@N=4::DG1
MA?G5."E?]WOS;^:\C^+\UX7\7:F:9G4PV'XJ>&J9AC9X=T\VK1INA/%3E1=.
M*Q\5&#IN#BDHJ,5:RM8_DN_:HU;4M=_:.^-&L:Q>3:AJFH^/=:N;Z]N&WSW,
M[R(&EE; RQ  .?2O :_=_P"+/_!$?]N/Q]\2_&_C33(_A%9Z?XF\0WVKV=K=
M^-IOM4$%TX9([CRM.>/S5 PWELRYZ$UY[_PX9_;Q_P">OP:_\+:Z_P#E97^Z
MG!'TJ_H[99P7PAEN,\5.',+C,NX6X>P.+PTZ>:<V&Q.$RC!X>O0ER9=*'-1J
MTYTY<LI1O%\K:LS]KR[(,^CE^!CB<#B7B8X/"QQ#JSA.HZZHTU5=2;J-RG[3
MFYY-MN2DVV]3Z=_9#_Y-I^#_ /V*L/\ Z43&OHZNN^!G[!'[5'PP^$G@7P!K
M/ACP-?:GX7T6/3;R\L/&UM]CN)EED<O;^=;1S>60P \Q%;.>,8QZO_PR)^TK
M_P!"=X2_\+:R_P#C%?XT^(?%'#^:\?\ '.:9=FF&Q>7YEQAQ-F&!Q5/VBIXG
M!XW.L;B<-B*?/",N2M1JPJ1YHQERR]Z*::7\\9GX9\>5LSS&M2X9S"=*KF&,
MJTYQ>&Y9TZF)J3A-7KIVE&2DKI.U[K0^=H_X_P#KHU25]!K^R%^TLN[/@[PE
MRS-_R.UET/\ VPIW_#(G[2O_ $)WA+_PMK+_ .,5\?\ VSEG_0;2[;R\EUBM
M.WEZ,X%X7>(%DO\ 5;,=DM\-Y?\ 41Y_@^Q\[Q]&_P"NC]\_Q'_..W2GU]!I
M^R'^TLH;/@[PCR[,,>-K+H22/^6'6G?\,B?M*_\ 0G>$O_"VLO\ XQ0\YRM_
M\QE+9+[2V276(+PN\0$DO]5\QT26^&\O^HCS_!]C^7#]NW_DYSQ]_P!>_AOO
MG_F7]/[]_K7R#7]"'[2'_!&G]MGXR?%_Q-\0M!M?A1INEZU%I*6]GJ7C:3[;
M$;#3+:RE,OV?3Y(</) S)L<_(1G!R*\,_P"'#/[>/_/7X-?^%M=?_*RO]J_"
M3Z4?T?\ (?"WPZR3-_%'A[ 9KE/!/#&79E@JT,T=7"8[!Y/@\/BL-5=/+YP=
M2C6ISISY)RCS1=I-:G]%\/\ #>>X7(\HPV(RS$4J]#+L)1K4Y.ES4ZE.C3C.
M$K5&KQE=.S:T=FT?BU!_K+O_ *[1_P#HE:L5^S$7_!!;]O-'G8R_!G$LB,N/
M&UUD!8PAR/[+QR1D8/3KUXE_X<,_MX_\]?@U_P"%M=?_ "LK]#?TN?HVW?\
MQMSAK:'_ "[S;I"*?_,M[IH]6.0YPDE]0K??3[_X_/\ !GXLP?ZV[_Z[K_Z(
MAJS7[+Q_\$%OV\T>=C+\&<22!UQXVNLX$:(<_P#$KXY7M]:F_P"'#/[>/_/7
MX-?^%M=?_*RG/Z77T;6U_P ;<X:^&"_AYMTA%?\ 0M\M?,(Y#G"27U"M]]/O
M_C\_P9T__!-S_DA>O_\ 8_:E_P"D5M7Z"5C?LG?\$U_VM_@+\.=3\'>)M!^'
MNK7][XFN]:CN=(\;1?9EMY[>*)8G^U6D4GFAHR3A"N",,37T]_PR)^TK_P!"
M=X2_\+:R_P#C%?XT^._&O"O$WC%XB<09#G>#S/)LVXDQ6,R[,,/[54<7AITJ
M$85J:JTJ=11DXNW/"+T=TC^>^)/#?CG%Y_F^*PW#>/K8>OCJU2C5@\/RSA)Q
MM)7KIV?FELS^;W_@I1_R7+PU_P!DUT;\_P"VM?\ _K?YZ?GI7]'_ .UI_P $
MB?VS_CY\1M)\8>&-/^%^DV%AX2L- EM]8\;'[4]U::AJ5V\J?9;"6/R&2]C5
M=S!]ROE0,$_+O_#AG]O'_GK\&O\ PMKK_P"5E?Z;> ?TFO ;A;P<\/>'N(/$
MS(,KSK*>'Z&%S'+\1#,W6PF(C7KRE2J.E@*E-R491;Y)R6NY^S<*<,9_@N'L
MJPF+RO$4,10PRIU:4W2YH2]I)V=JC6TD]&]+GW#_ ,$!?^1"\>_]EZD[X_YI
M-I/;^+USV_&OZ&?CW_R0[XQ?]DO\>=\?\ROJG?(_G7Y#_P#!+[]C;X\?L4&?
MP+\:-/\ "<K^//B3JWC#2=8\)>(TU6VMH-.^'^G:(=.O+6:"VNA<7%Q!+,DT
M2/!'$JB1E=@#^O'QZQ_PH[XQ9Z?\*O\ 'GI_T*^J>O%?Y)_2NXHR#C3QN\5.
M*.%LTP^=9!F^*PM?+<TPJJK#XRE1X8RK"59TE6ITJJC#$8>M1?/3@^>G*R:L
MW_0_AS1JX?-^#J->$J=6&>Y0IPE;FBWFU%I.S:U33T;W#X"8_P"%'?!W&<?\
M*O\  ?7K_P BOI=>LUY/\!>/@?\ !W_LE_@/U_Z%?2_4G^=>L5^!X#_<<%_V
M"8;_ -,P/2XK_P"2IXE_['^<?^K'$GQ'_P %!-?TC3?V9_'VC:\ES'9>)[72
M]+TVYMM5U;16N?$D7B#2-1T72&UC0M'US5=!CNY;&2YGUZ"Q(TZVLIO+<74M
MNK<A^SK\6?#OPR_8:\/_ !-\41FWTNP_M"VOO+U\ZK#<:OX@\=R^&;21/%/B
MS^P)M0L;W6]4M2=<\01Z;=RVLK75W;K/^Z?I_P#@HWK-WHO[(_Q(FMO#VJ^(
MHKF[\'6NH1:9ITNKI9:;_P )CH=S>7&J:58^*/!^N:AI5[%;G0[BU\.:W!KD
MLFK0BTCD3S@$_8CM=+\2?L=^"K;4_"<5MI<\?BIU\+>*[#Q#=?95LO%>K7-A
M!J^F?$?4O$>LP7%I/;V\_P!EU75=3CL)H8OLEVT$,#KUG@'SY_P2N*C1OC,8
M_$>@ZU;ZCJ?@WQ!I]MI$L+:A;6.MCQ=</J/B.TMM<UZ'1M3U358M5@L=$FO9
M=0L?#^E:0;IDAFM+2T_6BORQ_P""8GQ$^+/Q(T#XI:O\4],U+2YX9?!$6GPZ
MK\,OAA\-9'OFB\4C76TJ/X<)"?$_AM9HK%=%\1:O%Y5['Y\FD3SPR73+^IU
M'R%\(OC]\5/'?C_Q]X9\4_!;5_#.B>%M&UO4[/48Q=_:8M7T[QOJWAO3/!5_
M-?QV^F:GKNM^&;"P\=VU_H5Q/H\>E:W:V<DXNX9E7+_9NU6YUGX_?MKWUWHN
MI:!/)\1O@VK:=JH@%X@7]GOX=@.PMI9X@K<A<2$G:<@=*^T:^2?@:1_PT?\
MMMCN/B)\&<_C^SU\.Z /K:BBB@ HHHH \C^)FM_%'PW8ZSX@\(VO@"[T'0]
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MX)&/]O6?"QS(['@$Y"J<8'6OU'^TLO\ ^@W"_P#@ZG_\EYK[S_/I\!<:M_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \L\:?\C]\*/\
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MH^G_ "!8_P#(_&HOCU_R0[XQ=?\ DE_CSIU_Y%?5*E\:?\C_ /"C_L(>*/\
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M !1110 4444 %%%% 'C?[1/_ "07XS?]DQ\;_P#J.ZA7KMK_ ,>UO_UPA_\
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MZ]^WCXGT&TUN;3/V7- ENI]3A;2M4M/C M[;C3M5O=-264?:8_DO4LUOK<[
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M.T:V@\3>&&TA?$&C2,RL+S2FU[2==T<72!2JG4-'U"WVNVZW8[2N_10!\U>
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MO'-YK\]A<O-#X-T7PB(;FSMFLGN9QI,]S)J5Q/81:;8":\F=[>STJT@B.Q<
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M]E9$6]]I5]H^DVFF3).-*L]$M[>"ZFB(V@'ME?$/[-?A3QIX6^-7[06F^(M
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MI'U%KI9)G@4 ]OKR;X]_\D.^,7_9+_'G?'_,KZIWKUFO)OCW_P D.^,7./\
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M:+IME/?37%VU[J[V-]XP\6W8DCBU;QIXBUW6%@B:[(/DG_#QKX+?]"G\4/\
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MB#2]2NO$?@+Q9H/B'Q'J]WXLN/#>L?"S45U/X>6]E;:C(D$NB^&+@W*VVGW
MDENX[RX74;N\)C:/@/\ AXU\%O\ H4_BA_X*/"G_ ,V5'_#QKX+?]"G\4/\
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MA3_YLJ/^'C7P6_Z%/XH?^"CPI_\ -E1_;>6?]!7_ )1Q'E_TZ\T'_$+N.O\
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M\*?_ #94?VWEG_05_P"4<1Y?].O-!_Q"[CK_ *$?_F3R?R_ZF'FC] **_/\
M_P"'C7P6_P"A3^*'_@H\*?\ S94?\/&O@M_T*?Q0_P#!1X4_^;*C^V\L_P"@
MK_RCB/+_ *=>:#_B%W'7_0C_ /,GD_E_U,/-'Z 45^?_ /P\:^"W_0I_%#_P
M4>%/_FRH_P"'C7P6_P"A3^*'_@H\*?\ S94?VWEG_05_Y1Q'E_TZ\T'_ !"[
MCK_H1_\ F3R?R_ZF'FC] **_/_\ X>-?!;_H4_BA_P""CPI_\V5'_#QKX+?]
M"G\4/_!1X4_^;*C^V\L_Z"O_ "CB/+_IUYH/^(7<=?\ 0C_\R>3^7_4P\T?H
M!7XR?'S]J#]K?X<#]H'PIX)\%^-/'M]>Q?$2/X7^.]'^&WC%]/T+5H?&=IHG
MA'P_I.G66@S.^J^'-#U34KG6KZ^:^\/>*-/\&Z7XGT34TF\67FFVGTW_ ,/&
MO@M_T*?Q0_\ !1X4_P#FRH_X>-?!;_H4_BA_X*/"G_S94?VWEG_05_Y1Q'E_
MTZ\T'_$+N.O^A'_YD\G\O^IAYH\?\,?MX?%A]=\3:%KGP*U[2KK2?B)<>%M:
MU;^S/B-XOT>RM$T'X>,?%FG6?ACPIJEWI?ARUN/%-IJ.H^%-1N+?Q9:Z=K$&
MHVNGWIL]>^Q_>?[.GC;QQ\1?@[X4\8?$C1E\/^--5G\41ZUHZ:/JVA+9?V7X
MOU_2--1=,UR.+4X1)I%A83^=.@CO?-^W6N;2Y@)^5-%_;Z_9Z\.6]U::!\//
MB!H]M>ZEJ.LWD.G>'O!UHEWJVK73WNIZE<B'Q@OGWU_=2//=7,NZ:9SEW("@
M;'_#QKX+?]"G\4/_  4>%/\ YLJ/[;RS_H*_\HXCR_Z=>:#_ (A=QU_T(_\
MS)Y/Y?\ 4P\T?H!17Y__ /#QKX+?]"G\4/\ P4>%/_FRH_X>-?!;_H4_BA_X
M*/"G_P V5']MY9_T%?\ E'$>7_3KS0?\0NXZ_P"A'_YD\G\O^IAYH_0"BOS_
M /\ AXU\%O\ H4_BA_X*/"G_ ,V5'_#QKX+?]"G\4/\ P4>%/_FRH_MO+/\
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M .;*C^V\L_Z"O_*.(\O^G7F@_P"(7<=?]"/_ ,R>3^7_ %,/-'Z 5Y-\>_\
MDAWQB_[)?X\_]1?5/<?SKY8_X>-?!;_H4_BA_P""CPI_\V5>;_&3_@H1\'-9
M^$7Q1TFW\*_$M)]3^'OC*P@>?2O"R0I->>'M0MXFE:/Q?*ZQJ\BLY2-V"@E4
M8X!Y<;G>6/!8NV)WPM>W[G$=:4K?\NO-?>>]PMX8\<4^)^'*D\CM"&?9/.3_
3 +2RAVC',,-)NRS!MV6MDFS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img132800289_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img132800289_14.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %- G # 2(  A$! Q$!_\0
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M6_\ #6>!O_E%1_PS;^SM_P!$#^"W_AK/ W_RBKVFBOF_[.R__H P7_A+0_\
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MBY\W+Q?Q&^1M3MG^9OD:2;4K8OW6E9M.S2LSQG_AFW]G;_H@?P6_\-9X&_\
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MX+?^&L\#?_**C_AFW]G;_H@?P6_\-9X&_P#E%7M!(4%F("@$DD@  #)))X
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MJTH0QDJJP=6O3HX_!UJF&I5YUZ=.K&<Z<8QDXZ'_  S;^SM_T0/X+?\ AK/
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M>O\ F P:M_U"T-+?]P_)?<?3KC7C!I-<6\2M-)IK/LT::TLT_K>VUOD>+?\
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M4_V^O!=C\,==T?PSXYG\#:>-"US7[$ZEI-BZ:3XKDO#=V0MKOSQ/8+=6\/\
MH\GESRQ2'8%+K^NEM"+>W@MPV\00Q0AB,%A$BIN(R<9VYQDXSC)KYIUW]FVV
MUO\ :2\,_M$MXPNK:Y\-Z*FCKX2718);:\5-.UG3_M#:P=02>%B-7:7RUL)
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M2Q]>4Y8BFH-4J-!TU-U6ZD[13CX&!XLS?A[(:N9YDN,\^S#-,YR+(,CRKBO
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M56KYAD.6U<PE0S##X7 U\+E4<:Z-2A2IU,QQ&98624L=EN';<%^MM!( ))
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M6MPBF>*?VS1?#OA_PW;R6GAW0M&T"TED\V6UT72[+2K>27:%\R2&Q@@C>3:
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MC*S27P]9>%Y+.Y@UNXU"/3[B)H)Y,>OT4 ?Q0?"W1O$7[:'PT_;Q^-_[0W[
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M%\"?$6[_ &8?BU^TCXW'_!LG^SU\"?&G@?Q'K'Q6\$ZQXM^+-U^U5X0D\?\
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MRX\2W'@J'P/X!T7P]I^M?#?4-$O=9U'1[6)X_$-[_?O7@GP9_9;_ &=_V>O
M/@WX8?!KX/>!O O@;X?+.O@S1-.T:*];P^;C5K_799++5=8.HZT9SJ^J7]\E
MQ/J,T\,MRXAD2-8T3WNMJ7MK/VRI)W7+[)S:M;6_/&+O?:W0\W'++5*G_9L\
M=.'*_:_7J>'IR4KKE5-4*M52C:[;DXM.R2:5V4445J<(4444 %%%% !1110
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M9SYI*HL=1PU."A;W7!T*]5N3?Q1E%)+52E>RGHHHK8\X**** "BBB@ HHHH
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M>2S, ?H7_P -._#[_H4?VAO_ !%/]IC_ .=/1_PT[\/O^A1_:&_\13_:8_\
MG3U\Z7G_  58_8:T[Q+^T1X<O_B]=VD/[+&B:_K7QH\72> /B#)X \.OX5B\
M(2^(?#]CXWM_#,WA[7O%VGGQ_P""8+;PIHU]>:[K]WXEL+3PQ9:W<1WT=GX=
MXU_X+(_ :UM%U+X7:%?>-]'LO@3^W1\5_&NH^,;GQ#\+;_X3>,?V&O#'PO\
M%'C'X5?%+P9JW@?6O'GAO6/$%A\4]&OAJ-OX;U*?2M%CM]9T[0_$]MJU@C '
MWY_PT[\/O^A1_:&_\13_ &F/_G3T?\-._#[_ *%']H;_ ,13_:8_^=/7S)IO
M_!5[]BUOB))\)_$WQ(U3PEXSTIO$6E>*]7U?X>?$ZS^$GAWQGX,^!.G?M*>+
M?!,OQJU3P5I?PZNO$>E_!2]N/B';Z6NM0ZG?^&M+U*Z33X;NW:QKT#X)?\%'
MOV.OCW\,OBU\7_!WQ>L= \!_ G3-'\0_%_5OBCHOB#X2R?#WP?XF\*1>._"/
MCOQ-8_$/3/#MWIO@?QAX)GC\5>&O%4\2Z1J>D"X=+E+JQU"UM0#UO_AIWX??
M]"C^T-_XBG^TQ_\ .GH_X:=^'W_0H_M#?^(I_M,?_.GKY9_X?,_\$F/^DC_[
M%_\ XD/\,_\ YH:/^'S/_!)C_I(_^Q?_ .)#_#+_ .:&@#ZF_P"&G?A]_P!"
MC^T-_P"(I_M,?_.GH_X:=^'W_0H_M#?^(I_M,?\ SIZ^6?\ A\S_ ,$F/^DC
M_P"Q?_XD/\,O_FAH_P"'S/\ P28_Z2/_ +%__B0_PR_^:&@#ZF_X:=^'W_0H
M_M#?^(I_M,?_ #IZ/^&G?A]_T*/[0W_B*?[3'_SIZ^6?^'S/_!)C_I(_^Q?_
M .)#_#+_ .:&C_A\S_P28_Z2/_L7_P#B0_PR_P#FAH ^IO\ AIWX??\ 0H_M
M#?\ B*?[3'_SIZ/^&G?A]_T*/[0W_B*?[3'_ ,Z>OEG_ (?,_P#!)C_I(_\
ML7_^)#_#+_YH:/\ A\S_ ,$F/^DC_P"Q?_XD/\,O_FAH ^IO^&G?A]_T*/[0
MW_B*?[3'_P Z>C_AIWX??]"C^T-_XBG^TQ_\Z>OEG_A\S_P28_Z2/_L7_P#B
M0_PR_P#FAKRCXC_\%]O^"0?PRUWX<Z+J_P"W;\!O$<?Q)\17GAJUUSX<^-='
M^)6A^#[RUT\W\%_\1KGP1=ZW=^"/#NHOMT^S\3:Q8Q:#'J#B/4=0L($EN8P#
M[]_X:=^'W_0H_M#?^(I_M,?_ #IZ/^&G?A]_T*/[0W_B*?[3'_SIZ_-3X\_\
M%AK_ .%7Q(_:#_X5M^S!-^T1^S+^RC\$O@+^T9\=_P!HCX:_'OP&M_:?!CX[
MZ9XX\06/COX5?#._T-K3XM:3X3\+_#_Q%XGUIM*^(^D2:AI%O$="74;ZXM;*
M?Z0\>?\ !6;]A_X9>+_&G@WQO\1O%N@WG@7P?K?CO5-:N?A#\5F\)ZIX<\)Z
M+X)\4>.+SPEXHB\'OI'C#_A O"7Q#\*>+O&1\-W.I0Z)X;O;_5)IGAT#Q -+
M /IO_AIWX??]"C^T-_XBG^TQ_P#.GH_X:=^'W_0H_M#?^(I_M,?_ #IZ\<^+
MG[??PP\!? 7]IGXZ?#7P3\4OVBXOV6O&?B[X:>._!7PB\*2S:Y=_$+P1H>D:
MYXJTO3=4\4S>'O#DOAKPE:ZW:-XT\=P:I=^&_#:V>NP-<7VK:)>:37BGBC_@
MJ[\+= D_X)WZ1I_PW\9^)O%_[?Z? 76XO#VC7EA/;? #P)\?_#@U3PCXQ^*N
MOI!)I\,>H^(3/X1\)Z1;I;7OCK4-#\87FA.+/PEJYC /L[_AIWX??]"C^T-_
MXBG^TQ_\Z>C_ (:=^'W_ $*/[0W_ (BG^TQ_\Z>OHBB@#YW_ .&G?A]_T*/[
M0W_B*?[3'_SIZ/\ AIWX??\ 0H_M#?\ B*?[3'_SIZ^B** /F;6/VM?A/X>T
MG5-?\0:+\=M#T'0].OM8UO6]6_9=_:3L=+T?2-,MI;W4M4U*]G^%*P6>GZ?9
M037=Y=3,L5O;0R2R,$0D?2L4L<\44\+K)#-&DL4B'*R1R*'1U/=64AE/<$&O
M!OVKO^37/VD_^R!?&+_U7?B.O9] _P"0%HO_ &"=._\ 2.&@#6HHHH ****
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M5?#C:MI,4U]& 1?\-._#[_H4?VAO_$4_VF/_ )T]'_#3OP^_Z%']H;_Q%/\
M:8_^=/72_&G]H/X+?L[_  [\;?%?XT?$7P[X#\ _#F#1;CQKKVI3SWAT >)=
M3L]%\-V]QI.D6^HZW/?^(M7U"QTS0-,LM-N=1UJ_NH+73;6ZFD5#H^&OC9\*
M_%_CWQ-\+O#WC72;_P"(?@[0?!/B?Q+X087=EK>E:%\1;#6]3\&:A-::A;6C
M3)K5AX<UNY2&U,]S91Z=,-2ALV:)9 #B?^&G?A]_T*/[0W_B*?[3'_SIZ/\
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M/[,-GX;&A0>!-?\ %/AWQ=\/?$_@/43J.D:]IEJ+WQ!<#PMKD_@W^S]0UF$
M^\?^&G?A]_T*/[0W_B*?[3'_ ,Z>C_AIWX??]"C^T-_XBG^TQ_\ .GKY&T[_
M (+'?\$_M0M/B)J,GQ<\1Z/I7PV\)>)O&FH:OXD^$'Q=\-Z5XMT?P;\9(/V>
M_%4/PNU#6_!-C:_%35M#^-E_HOPUO-(\ RZ_?-XH\0Z%96\4ZZC'(ON&A?\
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M\/O^A1_:&_\ $4_VF/\ YT]'_#3OP^_Z%']H;_Q%/]IC_P"=/7RS_P /F?\
M@DQ_TD?_ &+_ /Q(?X9?_-#1_P /F?\ @DQ_TD?_ &+_ /Q(?X9?_-#0!]3?
M\-._#[_H4?VAO_$4_P!IC_YT]'_#3OP^_P"A1_:&_P#$4_VF/_G3U\L_\/F?
M^"3'_21_]B__ ,2'^&7_ ,T-'_#YG_@DQ_TD?_8O_P#$A_AE_P#-#0!]3?\
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MQC>/::)>>*-.LM(:YBGU[0#J8!]'_P##3OP^_P"A1_:&_P#$4_VF/_G3T?\
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ML^"M;EU'1&74FT>S\4:=I3^(M-@$L>N>'O[4T2[M[FSU"XMY>T^:/R\_:O\
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M'_#(/[)G_1KW[.W_ (9/X:__ #,U]$T4 ?.W_#(/[)G_ $:]^SM_X9/X:_\
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M HHHH *^8_VJ/^17^$W_ &<Y^S7_ .KA\*U].5\Q_M4?\BO\)O\ LYS]FO\
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M9KZ)HH ^=O\ AD']DS_HU[]G;_PR?PU_^9FO,)O^";_[!L_QN\+?M%R_LE?
M@_%_P-X:3PIX,\4I\.O#L,'A;35U6_UG[9H?AN&RC\+V'B0WVHW&WQ=%HO\
MPE,%KLL+;6(;%3;G[8HH _+31_\ @D?^SII_QQUKXRZQ\1/VB_&6@ZO^U%X@
M_;0A_9\\3_$S3#^SUI'[3&N^5);_ !1L_!F@>#] \1ZEJ?A>^@M=7\'Z9XG\
M9^(-!\/Z[9V.N6NE-JME:W</QO\ %7_@@E\.M-_9[^-GPE_9G^*7BW3?'7Q[
M\%?!_P"#6M?$KX[:U!X@O/AM\-?A5\9-<^,OA_QQX%D^%_A'P!XE\2_'?P9X
MF\07FI>&/'WQ"\2ZSKWB34K?3I?'GBG5A;RR7/\ 0G10!\E_%3]B[X+?%O\
M93T/]C;6H/$?A_X+^&],^">C:'9^#M5M=&US3=+^ /B_P)XU\ 6-KJ5QINI6
MZ6T>J?#OP]:ZLC:>[7VEF^M8VMI;E+F'R;3/^"6O[&7A_P#:_P##'[<7A3X>
M:UX2^//AS6/C/XIN[WP_XX\66_A#Q=XU^.]OH%GX\\;>*_!MWJE[H]YXDGM=
M C@LY],CTC3W6^N)-6T[5IK#P]+HGZ&T4 %%%% !1110 5\MM_R>M#_V:W=?
M^K9M*^I*^6V_Y/6A_P"S6[K_ -6S:4 ?4E>*?M*_\FY_'[_LBGQ4_P#4%UZO
M:Z\4_:5_Y-S^/W_9%/BI_P"H+KU<69?\B['_ /8%BO\ TQ4/IN"O^2RX2_[*
M;(?_ %:X0=^S;_R;M\ _^R+?"S_U!M"KA?VSO^3<_&W_ &&_AC_ZM?P/7=?L
MV_\ )NWP#_[(M\+/_4&T*N%_;._Y-S\;?]AOX8_^K7\#T9;_ ,B[ ?\ 8%A?
M_3%,7&?_ "6'%G_92Y[_ .K3%'U'7Q1_P4=TGXVZ]^PM^U#HG[-\OCBW^.NK
M_"?7]-^%]S\-=0U/2O'=MXKO6M[>QN?#&HZ+J6CZQ9ZE;+)+.D^E:MIFHI%'
M*;+4+.Y\NXC^UZ*[3YH_G!^,_P "/VZ?@9XT_8L\$_#OQ'^UC\8O!/P\UP>+
MOV\?%/PC^)_QN_X1;XF?!CQ!\??!-SX-\$_#:W^/7QD^//Q:UCXK>$M6TX^*
M/B+IGAKXGZ?JUS^S7IOQ8\$6VL1Q_$CP=X3MNP_X)_:%_P %-_#G[5OPDT']
MIR3XS>(_V?V^&O[>?Q#A\:>+];OG31O$_P 0_P!ICX;6GPT^"7Q3TN74+DZQ
MJ'P^\*>$/$_C3]GWQ3J2S36_PE^*5]X+L191^$[F!_Z#J* /Y@_V?_B[_P %
MS] UK1?A#>?"&ZA\&>&OV1-?\9:'X\^-/AG7O&_BGQK\7]'&N^+;+2_%7CMM
M3-G9>//$OBVSA^#L?@?Q#KVGMIW@+5-.^(&FV=Y<VD-W+U'Q?^/_ /P6W\5Z
MOX1\(Z3^S[-X2^'7QK_8R^.?Q(\177A3PSK$/Q#^%?Q+\?\ @W]H#Q!\/_@X
MOC?P[=W]OX-^.7P*L[?X >$=)OKV^T;2_B%XZU'QC=6,UQ<MI@\._P!*E% '
MEWP.B\50?!7X/P>.O[7'C:'X7?#^+QC_ ,)!-)<:]_PE4?A/24\0_P!MSRR2
MRSZO_:XO/[2FEEEDDO/.=Y'9BQ]1HHH Q=$UZPU^/4I+#S]NE:UJF@W7GQ>4
M?M^D7)M;ORAN;?!YH/E2\>8OS;5Z5M5YE\,/^/7QM_V4WQW_ .GF2O3: "BB
MB@ HHHH **** "BBB@ HHHH **** "LC0-;LO$FAZ1X@TWSO[/UK3K35++[1
M'Y,_V6]@2XA\Z+<_ER>7(N]-S;6R-QQFM>O._A%_R2WX>?\ 8F^'?_37;4 >
MB4444 %%%% !1110 4444 >!?M7?\FN?M)_]D"^,7_JN_$=>SZ!_R M%_P"P
M3IW_ *1PUXQ^U=_R:Y^TG_V0+XQ?^J[\1U[/H'_("T7_ +!.G?\ I'#0!K44
M44 %%%% !7S'^U1_R*_PF_[.<_9K_P#5P^%:^G*^8_VJ/^17^$W_ &<Y^S7_
M .KA\*T ?3E?FS_P5+^'O[1_Q6_9]^'GP[_9@\1>//!_CGQ;^U%^SEH_BKQ9
MX"UKQ]H-QX:^$]S\1+ ?$O6O%6H?"WQ[\+_B&O@*Q\-BXE\80>$?B#X1UJ?2
MO,CM-:LV)>OTFHH _FU^*7PR_;W^&W[4W@?0?A\?VQ?'7[-OP_\ V>],^&_Q
M*U;PM\3OB)=>%O&_[:%S\!?BZOPL^+O@W2/B'XX^(7QEU?X#>&VU33?#GQED
MU'XI:K97GQKUGX*>(O$,'BRY^%?C7Q*UW]ESP_\ \%2M'^#/[:/@/X]M\>M=
M\:>"_P#@E]\&_!W[-GQ.E\07XU_XK?&C4_AI^T!XJNM<M;*+5FET+]J3P5KG
MB?P+\)_BIK*31:IXI\2^ O"?C<ZK,NNVS6_]'M% '\W7P]_:4_X+;^'9OVF)
M?$7[,Z>(/#7[/.@_!37OA/\ #ZZ\+:C>>.?C_P"'])?P]I/C+P=X4^)NHWL&
M@>)O'7Q#\%:AK'CKQ)K-QK%]JW@3XD>'8_"5QH]E::O<VD.5\7_B5_P6XUWX
MC_&_X%ZW\.)$^'/A;X1?LYWGA?XN? [PUXA\+:QXY^(D'BK]FO6/B7XF^'_C
M33KV:P@CU'7-2^.GA7Q9\-[_ %JUO].^&GA^QU.VL9(WOK[Q%_2U10 4444
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M_L!6_P#Z')7IM>9?!G_DEO@?_L!6_P#Z')7IM !1110 4444 %%%% !1110
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M1A=?,C8RK=U(/>F_\+/3_H0/B?\ ^$?/_P#)==I\T>GT5YA_PL]/^A ^)_\
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M3PR-:W]K#?65P$D56,-W97%O=6T@&R:WFBFC+(ZL0#_:]_X)"^+_ -GS4?\
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M\9==_P"">EN1=NVI+X5_MZ7XRZM$81,9AI\?P&U"#P4Y<?9DM]3M8$0(\:*
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M!?M7?\FN?M)_]D"^,7_JN_$=>SZ!_P @+1?^P3IW_I'#7C'[5W_)KG[2?_9
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M$$;S32-@G;'%&K.YP"<*I. 3T% '^_BS*BL[L%5069F(5551DLQ.   "220
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M?$]U/H-U.%U>WE_.7_@T"_;FE_9]U/\ X*%_!GXC^(M2C^'OAG]FB_\ VQ=
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MG_9Q\7^#OCW\%O$'@CP]\*X/AY/\ /$7[0?PF\!>,_AAX\O?%FOZWJ7Q OO
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M;?\ )ZT/_9K=U_ZMFTH ^I*\4_:5_P"3<_C]_P!D4^*G_J"Z]7M=>*?M*_\
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M;0IM*^)OAM-+OTU&XEO+R+5();2V2TCEN/\ 9._:L_Y,(_X*%?\ 9%_VR?\
MU6WC:O\ *&OO^42G[#G_ &D[_:N_]4W^QC0!_2=^T]_P:K?\%$_%/Q)_;9LO
MV9_C?^SSH?[,?[3'[17@3XL^'OA_XG\0>,-(UO5O#B>(/'WB;3)?$L-CX,U'
M3]"NO@U-\1M<L+/3+*\U=/%MG<R7=A)I\]K;V,W\]G_!2O\ 8?UNZ_X*5?\
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M&OC3]FNRFT_XJZ[\/Y]0O?!\GQ@\>I8^+O&.DZ-J>J6.EWVK?\(?HT_@_P
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ME]JNDV-]>^&M:BB>!-5T"[N8)+C2-0^SR2VKW>GR6\TMI+-:R.]O-)&W244
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M+X<VFEZ/+*EWJR/?Z;]AN4TV*5=,MXDGN1' 5:O]O"O\@?QW_P DI_X./?\
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MA?VSO^3<_&W_ &&_AC_ZM?P/1EO_ "+L!_V!87_TQ3%QG_R6'%G_ &4N>_\
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MMZ?XQL)M,T30E^)L&M2RZIH=M;7FI6<.@6-Y<W%X[V?WU_P;]?\ !/OX/?L
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MQ^U=_P FN?M)_P#9 OC%_P"J[\1U[/H'_("T7_L$Z=_Z1PT :U%%% !1110
M5\L?M;7$]IX*^%]S;6%SJ=Q#^TQ^S6\6GV<EI%=7;_\ "X_":^5#)?W-I9H^
M"7+7-U!'M1AOW%0?J>OF/]JC_D5_A-_V<Y^S7_ZN'PK0!ZK_ ,)KXH_Z)-XW
M_P#!I\.__FWH_P"$U\4?]$F\;_\ @T^'?_S;UZ/10!YQ_P )KXH_Z)-XW_\
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M^H+KU<69?\B['_\ 8%BO_3%0^FX*_P"2RX2_[*;(?_5KA!W[-O\ R;M\ _\
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MX:8&M1110 4444 %?,?[5'_(K_";_LYS]FO_ -7#X5KZ<KYC_:H_Y%?X3?\
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M:[I30:AI=[$;&66"6*YAB=HA!-O27RG_ *,/^"H_[?7B/QO_ ,$V?V')=/\
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M@/\ L"PO_IBF+C/_ )+#BS_LI<]_]6F*/J.BO,Y/%/Q&6214^%;R(KNJ2?\
M";>'T\Q%8A)-C1;DWJ VUN5SM/(IG_"5_$C_ *)0_P#X7'A[_P"-5VGS1Z?1
M7F'_  E?Q(_Z)0__ (7'A[_XU1_PE?Q(_P"B4/\ ^%QX>_\ C5 'I]%>8?\
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M2R2\U*\N;N2*"/SII&!8^ET44 %%%% !1110 4444 %%%% !1110!YM\8O\
MDEGC_P#[%;5__25Z_&O_ (.&?^3(_ '_ &<W\//_ %!OBG7[*?&+_DEGC_\
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M?_\ /;H_X:.\0_\ 1K?[3O\ X37PO_\ GMU].T4 ?,7_  T=XA_Z-;_:=_\
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MQR!6'# .I 8<$<]ZT** "BBB@ HHHH *^;OVH]'\4:GX!\)ZAX3\):[XXO\
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M:^%__P ]NOIVB@#YB_X:.\0_]&M_M._^$U\+_P#Y[='_  T=XA_Z-;_:=_\
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MUO\ :=_\)KX7_P#SVZ/^&CO$/_1K?[3O_A-?"_\ ^>W7T[10!\Q?\-'>(?\
MHUO]IW_PFOA?_P#/;KF?AW?>,OB!^TQ?_$N^^$?Q*^&WA/2O@4O@9;WXC6W@
M_3IM4\17GC]-?6UTFR\-^,O%-W/%;:;;22WMU=PV5O$\MM%#+<2RR)#]AT4
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M':9\1K?QEX@M/BQ#J.NV7AS3]-^$/A[PSH,?B7P/XM'COQ)I\FH>'INIM_\
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MPI\&_&GACP'H>F:!>7_C35](^+_C3PIX!\>Z/I5I/)8^)-6MSJB26-O=W]L
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M%]%N(M4\06"Z?HLW[0&MM\1/!^MV$VEV?@U+#Q/J?Z ?$#_@H#^QAX"UW5/
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M?A]XMUO4K3PAH7Q)TR[UCPMXO\+0:GJ5SXK\'ZOX;\4>'-9GT759-5M;VP2
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MC3;>.=:\)>!-2U;2?#NH6WA?7-;U;X;W=KX.T^YU?'C?5[O0CH\*76HZ2EZ
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M'@[Q-\=+#Q7XYU_Q+9?"KX;^/8?A/XR^$^CZ1X1\)R?$OXNZ!-X-\9:QX?\
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M/_XLZ/\ B('"/_0W_P#+#,__ )B#_B3_ .D7_P!&[_\ -MX&_P#HF/JOQO\
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M#J'AW4_'":A!#HMK)/;6=QX9T\>&XHI[=].BEO%NY=2:9'B\Y\??\$\?@/\
M$?0]*T/Q#?>/63P_XC^+WC/PW>Q:QH-Q<:%XQ^,/Q^\&?M*:GXDM[35/"^HZ
M-J%SX5^)G@/0G\)Z9KNEZMX>_P"$<;4O#_BK1_%-IJ$[5\D?\/??^K>?_,L_
M_BSH_P"'OO\ U;S_ .99_P#Q9T?\1 X1_P"AO_Y89G_\Q!_Q)_\ 2+_Z-W_Y
MMO W_P!$Q[SKG_!+GX)>)]>\$^)O$?Q"^+VL:QX*O/ >K6T\\GPGAM[C6?AS
M\9[GXY^'K_2M/M/A/!I_PXM[KQ;=?V3XFT?X06WP\T;Q7X,T[0/#.O6-]:>'
M]*DMN[\#?\$]/@S\/O$7AS7]"\4_%*2'POHFB:1I>@ZCX@\.W.D&ZT3X)^*?
MV?H]>N6C\)0:M+JU]\.?%+6U_%'J<.CMK.BZ/K%KI-K.-435/DO_ (>^_P#5
MO/\ YEG_ /%G1_P]]_ZMY_\ ,L__ (LZ/^(@<(_]#?\ \L,S_P#F(/\ B3_Z
M1?\ T;O_ ,VW@;_Z)CZE^ '[%&F_!C]I+Q)\9($LK?PYX;_9M^"G[+WPCL4\
M2:CX@US5?#7PVL"OB3XE_$"UN/#?A_1='^(?B:UT_P ">!)W\-MJD>H^%/AI
MH=[?ZA U[#H&B:VN?\$^?@IJ7CGXK_$_1-=^)'@OXC_%'XK?#;XU6WB[PUX@
MT9KKX9_$'X8:!JOA_3=0^&NE:]X;UOP_I>D^*(?$OC74/'WAW7])\2Z-XMU?
MQYXQO[ZTCEU9/LOR)_P]]_ZMY_\ ,L__ (LZ/^'OO_5O/_F6?_Q9T?\ $0.$
M?^AO_P"6&9__ #$'_$G_ -(O_HW?_FV\#?\ T3'T++_P3%^"MO9Q?\(U\2?C
MSX/\3!I9;OQYHGC/PU<^,=2O=:\-_%_PSX]U6_O?$'@C6]-DUCXC6WQQ\?:K
MXDU"'2H)-,\0SZ-JG@E?"8T6UMCU,W_!.?X"S_#1OA3+JWQ,;PNUQK=R9/\
MA*-,75C)KO[)]K^QQ=C[<OAP*!%\*[2'5;4BW#Q^.=^N2/-IS'0Z^4?^'OO_
M %;S_P"99_\ Q9T?\/??^K>?_,L__BSH_P"(@<(_]#?_ ,L,S_\ F(/^)/\
MZ1?_ $;O_P VW@;_ .B8^AM0_P""87P&UN+XF6'B#Q7\3]8T3XLG7]:\6Z*]
MS\.]-BE^)'BF]\.:YKWQ4MM8T?X<Z?XI;Q+-XQ\,VOCK3/#FHZ_J/PPT#Q3J
M>O3:-X L])U,:1;^@Z)^PE\/-%LM9*?$;XLR>)=>^&?Q!^%M[XPM+OX=^'=2
MM]#^(_BSPUXPU:ZTCP_X5^'&A> =)N-+OO"FDZ9HFE6G@]?"BZ#]OTS7/#NN
M_P!IW\]Q\<?\/??^K>?_ #+/_P"+.C_A[[_U;S_YEG_\6='_ !$#A'_H;_\
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M %;S_P"99_\ Q9T?\/??^K>?_,L__BSH_P"(@<(_]#?_ ,L,S_\ F(/^)/\
MZ1?_ $;O_P VW@;_ .B8_:2N=U?P?X2\07*7FO>%O#FMWD4*VT5UJ^B:9J5S
M';J[R+ D]Y:S2I"LDDDBQ*X0/([!=S,3^/O_  ]]_P"K>?\ S+/_ .+.C_A[
M[_U;S_YEG_\ %G6M'Q'X7P\U5P^>5:%1)I5*.$S:E-)Z-*<,)&236C5[/J)_
M0^^D4U9^'::[/BW@5K\>)C];?^%9_#?_ *)]X(_\)30?_D"C_A6?PW_Z)]X(
M_P#"4T'_ .0*_)+_ (>^_P#5O/\ YEG_ /%G1_P]]_ZMY_\ ,L__ (LZZO\
MB*V2_P#14YA_X!GG_P S>2^X7_$G?TA_^C<0_P#$KX$_^B;R7W'[*:7I&E:)
M9II^BZ9I^D6$;R21V.EV5MI]G&\SF25TMK2*&%'ED9I)&5 7=BS$L2:\R\-?
M 3X.^#/B/XH^+?@_X?>'_"GQ!\;Z+%H/C+7_  W!-H:^*[*WOCJ,%QXBTC2Y
M[70M9UN"Z+"'Q-J&F7'B.*UDEL$U5;"62V;\N/\ A[[_ -6\_P#F6?\ \6='
M_#WW_JWG_P RS_\ BSKBGXA\*5)RJ5,YE4J3DY3G/!9I*<Y2=Y2E*6#<I2;;
M;;;;>K92^A]](I*R\.[):)+BW@6R7;_DICZ@7_@G5\-&OH/$M]\7?V@-<^(_
MA@>"K/X1_%;Q+XS\,^)/B#\&/#_@#7O$_B'P]X8\'ZMK?@F^L_$FES3^,-?T
MKQ'??%;3?B)XD\6^'[BSTKQ'KVI#2].N+;O]1_8=^"^I?"?P+\%YKCQJ/!'P
MZ\&^+O#7AJV;7K6[O!XC\:+'_:WQ5U:;4=)O(-:^)L4T_B*YLM7U*UGT.*;Q
MKXP6?P[<P:NL-K\0?\/??^K>?_,L_P#XLZ/^'OO_ %;S_P"99_\ Q9U/_$0.
M$?\ H;_^6&9__,0?\2?_ $B_^C=_^;;P-_\ 1,?<]]^QGX _X5M\&_ ?AKQG
M\1_ VN? 3Q1K'C3X:?%3PQ?>$F^(&C^)_%6F^,-'\;:A/#K_ (.UWP'>V?C/
M2_'WBVRUGP_-X(_X1VT@U6$>'=*T-]'T1]-J?"[]AOX-?!WP!\8/AMX%U/XD
M:9X>^-?@7PQ\/_$UU_PFMTOB72-+\*_"BT^$-EJ_A3Q3:VEKKVD>*KO0[4Z_
MJ'B.:_OM1?QC=7.N6DEF##9P_$?_  ]]_P"K>?\ S+/_ .+.C_A[[_U;S_YE
MG_\ %G1_Q$#A'_H;_P#EAF?_ ,Q!_P 2?_2+_P"C=_\ FV\#?_1,>V>%?^"4
M'[-?AK0!X>EUKXE:Q:/\</@W\?+H->^ ?"UK>^+?@MX1L/ >DZ%<:'\/_AYX
M0\-CP-XT\):='H_Q-\-Q:-'_ ,)K'=:E=7][%>ZA<7+>AZ)_P3O^"WA_7M<U
M/3/$?Q!M="U3XDQ?%;3?!=M)X!LM$\.^+W^/7A[]I#5I[;6K'P!;>//$=AJ_
MQ)\.QLNG^/?&/BZ'PYX:U;6_#?@S_A&M/O(5M/E#_A[[_P!6\_\ F6?_ ,6=
M'_#WW_JWG_S+/_XLZ/\ B('"/_0W_P#+#,__ )B#_B3_ .D7_P!&[_\ -MX&
M_P#HF/1?BG_P2U^'FH>)?'WQH^'GB#Q?JWQPU;6?&_BWP6?&GB_0O#NC^'_%
M?CSXQ?#/XUW>JQ>/O#WPLUWXB3:EX)\7_"_P]/\ ""Z\;S?$S0?AYI=G;^"8
M_"6J_#R2\\+3N^"?_!,O3]!72/B)\6_B7XPNOCIJ/C/Q]XJ^(6O^%+_P5KEM
MXKT+Q5\?_&?Q\\->!=5\1>*?A1:ZA$OA#5/&>K:#)XN^&&@?!G4]9T/6->T$
M6&G^'Y=(T[2?./\ A[[_ -6\_P#F6?\ \6='_#WW_JWG_P RS_\ BSH_XB!P
MC_T-_P#RPS/_ .8@_P")/_I%_P#1N_\ S;>!O_HF/TWF_9^^'%Y\>-3_ &B=
M2TZ35O'^H_"[P=\)4BU6'2=0T+2_#O@?QEXU\<Z/J&C6ESI3ZAIWB&76O'>K
M+J&HQ:J8+BSM-(CCLH)[%KF?Y1\0_P#!,#]GOQ+8>(C?^(?BO%XO^(6C_%K0
M/C-\2[/Q-H$7CWXXZ-\8-5L-=U33OBCJ,OA*?2M:M/ ^K:+X>F^$4.GZ-I*?
M"S3="MO#/@]=.\+:EXAT76?G;_A[[_U;S_YEG_\ %G1_P]]_ZMY_\RS_ /BS
MH_XB!PC_ -#?_P L,S_^8@_XD_\ I%_]&[_\VW@;_P"B8^^_!W['7P>\ _&'
M]IGXU>$QXITGQ'^UAX>\%:'\4]!AUR-O!-O>^#++QE8'Q;X.\./8-%X8\5^+
MXO&MW<>/+^VN)K+Q1JNE:3KMWIL>MOK6HZSY1\,_^";_ ,!?A3K=S=^'-2\:
MW?A35?#\VC>)OAYKB^ -0\.^+[V_^$&C_!#6]<\3:\G@&V^(U\^O>"=$M9M2
M\+6_CFS^'P\47&H^*++P=9ZK>&5/EO\ X>^_]6\_^99__%G1_P /??\ JWG_
M ,RS_P#BSH_XB!PC_P!#?_RPS/\ ^8@_XD_^D7_T;O\ \VW@;_Z)CZ(T#_@F
M'\ _">F?!:Q\,^*_BQINH?!OP%%\,W\57VM>#?%/C#XE^$O^$^E^*%^/B%K_
M (Q\">(+A/$VL^.K[7M9UCQUX#C\#>-+I/%GBJPCUV"TU5([3U7Q-^P[\'O%
M?P3\+? 34M4\>Q>"O"'B7XI>*M*N[+7=+@\0OJ7Q<\,_&3PIXGCN]0DT":TE
ML[;3/CCXQDT6&/3H9+.\M= FN)KV.PNH=0^(O^'OO_5O/_F6?_Q9T?\ #WW_
M *MY_P#,L_\ XLZ/^(@<(_\ 0W_\L,S_ /F(/^)/_I%_]&[_ /-MX&_^B8^_
M-:_9 ^%NN^#OVA/!%[J7C5-(_:6TOPUI'Q FM]:T^/4;&U\*_#3PO\*M-;PM
M</HLD>ESOX;\(Z9<W;WL&JK+K,M[>1I#!-'9P^9_$/\ X)X_!GX@_$/7OBLW
MB7XA>&/'OB?Q!XRU76]>T5_A]JTLVC>/O#OPD\.^)_".FVOCKX?>,++0-,GC
M^"O@O5=(\1Z#;:;\1/#.L'7+CP[XUTRUUFZLJ^3_ /A[[_U;S_YEG_\ %G1_
MP]]_ZMY_\RS_ /BSH_XB!PC_ -#?_P L,S_^8@_XD_\ I%_]&[_\VW@;_P"B
M8^@-'_X)=? #2/BE>_%K_A*_BSJ'B*[\1ZMXC6&_UGP7(OF:Q\=_AG^T3-8:
MKX@A\!0>.?%UG8>//A1X7TKP_+XU\6^(]0\-?#\77@C0;W3M*6P-CW/@K]@'
MX2_#_2-,L-)\2_$S7G\.>(?@5XE\/#Q!XC\/I]G/[->L^(]9^$OAN6XTOP;:
M;]!L$\12:'K5Q<6U[KFL:38:?+=:D^JQW=_>_(W_  ]]_P"K>?\ S+/_ .+.
MC_A[[_U;S_YEG_\ %G1_Q$#A'_H;_P#EAF?_ ,Q!_P 2?_2+_P"C=_\ FV\#
M?_1,?9'[('[(FC_ 3]GKQA\)?&FD^'-0NOB]XW^+OCOXF^&-&U75O$W@G3K3
MXK:UJ26?PM\-:MX@TO0]:U3P#\.OANWAKX5>&&U+2-*DD\->%[()I>EP/'86
MWGNB?\$P?@1X;\&>!_ .A>./CA8>&_#WPXT_X2?$&)_'.E7VI_M > -.^(>K
M?%1=(^-&M7_A:YU75;^^\;>(_%E]K'B/P;=>"?$6KZ;XR\5Z%?ZG-I.JK;6O
MSS_P]]_ZMY_\RS_^+.C_ (>^_P#5O/\ YEG_ /%G1_Q$#A'_ *&__EAF?_S$
M'_$G_P!(O_HW?_FV\#?_ $3'T#-_P3 ^"#7OA]K/XB_'32O#^CZAX6US4_!N
MF^+?"D/AWQAXC\$?\+)B\*:YXG\WP)/K4LVDV7Q3U^R;3-'UC1] U%=+\*WF
MIZ1=ZIH:WUSU?B'_ ()S? ;Q-IMKHVJZO\2)M)3P_P##[PAJFG'Q#HQMO$/@
M_P  _ 3XJ?LUGPUK!/AK[0++Q;\+/C)XULO$]YI5QIFL+KDNE:]X;U+P[=Z8
MBR_*?_#WW_JWG_S+/_XLZ/\ A[[_ -6\_P#F6?\ \6='_$0.$?\ H;_^6&9_
M_,0?\2?_ $B_^C=_^;;P-_\ 1,?0$_\ P3$^#USI'AJ";XD_%I_%7@ZY\0Q>
M&/'_ -A^!ZZ]HWAGQ5X2\.^#-?\ "=IX?7X+#X;_ &;4;'PGX?U^3Q1+X%E^
M(,7C?38_%L'B^*_FN4FZ?XD_\$Y_@M\3?AAKOP@U;Q7\3;#P1XI^(?C;XC^)
M=,@OO NN)K&J^/=)M]'U:W:'QKX \4V>F3Z-#;1ZCX'\7Z':Z7\1O GB '7?
M"_C33KZ29Y?EC_A[[_U;S_YEG_\ %G1_P]]_ZMY_\RS_ /BSH_XB!PC_ -#?
M_P L,S_^8@_XD_\ I%_]&[_\VW@;_P"B8_932=,MM%TK3-&LC<M9Z3I]EIEH
MUY=W-_=M;6%M':P&ZOKV6>\O;DQ1(9[N[GFN;F7=-/+)*[N="OQ;_P"'OO\
MU;S_ .99_P#Q9T?\/??^K>?_ #+/_P"+.C_B('"/_0W_ /+#,_\ YB#_ (D_
M^D7_ -&[_P#-MX&_^B8_:2BOQ;_X>^_]6\_^99__ !9T?\/??^K>?_,L_P#X
MLZ/^(@<(_P#0W_\ +#,__F(/^)/_ *1?_1N__-MX&_\ HF/VDHK\6_\ A[[_
M -6\_P#F6?\ \6='_#WW_JWG_P RS_\ BSH_XB!PC_T-_P#RPS/_ .8@_P")
M/_I%_P#1N_\ S;>!O_HF/VDHK\6_^'OO_5O/_F6?_P 6='_#WW_JWG_S+/\
M^+.C_B('"/\ T-__ "PS/_YB#_B3_P"D7_T;O_S;>!O_ *)C]I**_%O_ (>^
M_P#5O/\ YEG_ /%G1_P]]_ZMY_\ ,L__ (LZ/^(@<(_]#?\ \L,S_P#F(/\
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HP^Y*&&X@R:O6G_K9P/+DI4<RPU2I+EAQ+*<N6$6^6,92=K13;2/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>lrmr-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-03-24T16:08:28.2862+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.larimartx.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:lrmr="http://www.larimartx.com/20241231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" namespace="http://xbrl.sec.gov/stpr/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" namespace="http://xbrl.sec.gov/cyd/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2" id="DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
        <link:definition>100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>100080 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" id="DisclosureDescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>995457 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995467 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1">
        <link:definition>995477 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995487 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssets" id="Role_DisclosureFixedAssets">
        <link:definition>995497 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>995507 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions" id="Role_DisclosureStockholdersEquityAndStockOptions">
        <link:definition>995517 - Disclosure - Stockholders&#8217; Equity and Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995527 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>995537 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedParty1" id="DisclosureRelatedParty1">
        <link:definition>995547 - Disclosure - Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995557 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995567 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables">
        <link:definition>995577 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>995587 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsTables" id="Role_DisclosureFixedAssetsTables">
        <link:definition>995597 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>995607 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables" id="Role_DisclosureStockholdersEquityAndStockOptionsTables">
        <link:definition>995617 - Disclosure - Stockholders&#8217; Equity and Stock Options (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995627 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>995637 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" id="DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>995647 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995657 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail">
        <link:definition>995667 - Disclosure - Summary of Significant Accounting Policies - Summary of Significant Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail">
        <link:definition>995677 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail">
        <link:definition>995687 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail" id="DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail">
        <link:definition>995697 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>995707 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail" id="Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail">
        <link:definition>995717 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail" id="Role_DisclosureFixedAssetsAdditionalInformationDetail">
        <link:definition>995727 - Disclosure - Fixed Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
        <link:definition>995737 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail">
        <link:definition>995747 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail" id="DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail">
        <link:definition>995757 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail" id="DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail">
        <link:definition>995767 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails" id="DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails">
        <link:definition>995777 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail" id="DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail">
        <link:definition>995787 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>995797 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail" id="DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail">
        <link:definition>995807 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>995817 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail">
        <link:definition>995827 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" id="Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail">
        <link:definition>995837 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail">
        <link:definition>995847 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail">
        <link:definition>995857 - Disclosure - Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" id="DisclosureRelatedPartyAdditionalInformationDetails">
        <link:definition>995867 - Disclosure - Related Party - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="lrmr-20241231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2" xlink:href="lrmr-20241231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:href="lrmr-20241231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="lrmr-20241231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="lrmr-20241231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail" xlink:href="lrmr-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" xlink:href="lrmr-20241231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail" xlink:href="lrmr-20241231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail" xlink:href="lrmr-20241231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="lrmr-20241231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="lrmr-20241231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="lrmr-20241231.xsd#DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails" xlink:href="lrmr-20241231.xsd#DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail" xlink:href="lrmr-20241231.xsd#DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="lrmr-20241231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" xlink:href="lrmr-20241231.xsd#DisclosureRelatedPartyAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd#eedm1" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="lrmr-20241231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="lrmr-20241231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:href="lrmr-20241231.xsd#DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="lrmr-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1" xlink:href="lrmr-20241231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="lrmr-20241231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssets" xlink:href="lrmr-20241231.xsd#Role_DisclosureFixedAssets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="lrmr-20241231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions" xlink:href="lrmr-20241231.xsd#Role_DisclosureStockholdersEquityAndStockOptions" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="lrmr-20241231.xsd#DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="lrmr-20241231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedParty1" xlink:href="lrmr-20241231.xsd#DisclosureRelatedParty1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="lrmr-20241231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="lrmr-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables" xlink:href="lrmr-20241231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="lrmr-20241231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsTables" xlink:href="lrmr-20241231.xsd#Role_DisclosureFixedAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="lrmr-20241231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables" xlink:href="lrmr-20241231.xsd#Role_DisclosureStockholdersEquityAndStockOptionsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="lrmr-20241231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="lrmr-20241231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail" xlink:href="lrmr-20241231.xsd#DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail" xlink:href="lrmr-20241231.xsd#Role_DisclosureFixedAssetsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail" xlink:href="lrmr-20241231.xsd#DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail" xlink:href="lrmr-20241231.xsd#DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LabSpaceMember" xlink:label="lrmr_LabSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestonePaymentAmount" xlink:label="lrmr_MilestonePaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LeaseTermCommencementDate" xlink:label="lrmr_LeaseTermCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EmployeesAndDirectorsMember" xlink:label="lrmr_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_BeginningOfStudyMember" xlink:label="lrmr_BeginningOfStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PrepaidResearchAndDevelopmentExpenses" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstMilestoneMember" xlink:label="lrmr_FirstMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AreaOfOfficeSpace" xlink:label="lrmr_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstAnniversaryMember" xlink:label="lrmr_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TechnicalOperationsExpenseMember" xlink:label="lrmr_TechnicalOperationsExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PerformedOutsideUsMember" xlink:label="lrmr_PerformedOutsideUsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SecondMilestoneMember" xlink:label="lrmr_SecondMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PerformedInUsMember" xlink:label="lrmr_PerformedInUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WarrantsIssuedPricePerShare" xlink:label="lrmr_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SubleaseAnnualBaseRent" xlink:label="lrmr_SubleaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_Ircsection174Member" xlink:label="lrmr_Ircsection174Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SkinCellsMember" xlink:label="lrmr_SkinCellsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AdditionalOfficeMember" xlink:label="lrmr_AdditionalOfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense" xlink:label="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NoExpirationMember" xlink:label="lrmr_NoExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MTSHealthPartnersMember" xlink:label="lrmr_MTSHealthPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestoneLiability" xlink:label="lrmr_MilestoneLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NomlabofuspSupportExpenseMember" xlink:label="lrmr_NomlabofuspSupportExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LicenseAgreementConsiderationDeductionPercentage" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SixthSubleaseYearMember" xlink:label="lrmr_SixthSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ZafgenMember" xlink:label="lrmr_ZafgenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_BuccalCellsMember" xlink:label="lrmr_BuccalCellsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DomesticAndStateLocalJurisdictionMember" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CapitalizedResearchAndDevelopment" xlink:label="lrmr_CapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstSubleaseYearMember" xlink:label="lrmr_FirstSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FromExerciseOfWarrantsMember" xlink:label="lrmr_FromExerciseOfWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MinimumAnnualRoyaltyObligation" xlink:label="lrmr_MinimumAnnualRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WakeForestUniversityHealthSciencesMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AtTheMarketEquityOfferingProgramMember" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DevelopmentExpenseMember" xlink:label="lrmr_DevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CommercialExpenseMember" xlink:label="lrmr_CommercialExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DepreciationExpenseExcludingLeasedAssets" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MeanLevelHVAtBaselinePercentage" xlink:label="lrmr_MeanLevelHVAtBaselinePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PaymentForLicenseAgreements" xlink:label="lrmr_PaymentForLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LikelihoodPercentageMinimum" xlink:label="lrmr_LikelihoodPercentageMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_GoingConcernPolicyTextBlock" xlink:label="lrmr_GoingConcernPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ProceedsFromStockOptionsAndWarrantExercises" xlink:label="lrmr_ProceedsFromStockOptionsAndWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EmployeesMember" xlink:label="lrmr_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CashAndNonCashOperatingLeaseExpense" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FromPriorPlansMember" xlink:label="lrmr_FromPriorPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeMember" xlink:label="lrmr_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TrackFAProgramMember" xlink:label="lrmr_TrackFAProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeAndLabMember" xlink:label="lrmr_OfficeAndLabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestoneExpenses" xlink:label="lrmr_MilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_InducementStockMember" xlink:label="lrmr_InducementStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FinalSubleaseYearMember" xlink:label="lrmr_FinalSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DepreciationExpensesRelatedToSubletAssets" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TaxCreditCarryForwardExpirationYearStart" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetOperatingLossCarryForwardExpirationYearBegin" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FriedreichsAtaxiaResearchAlliancesMember" xlink:label="lrmr_FriedreichsAtaxiaResearchAlliancesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockAndWarrantIssuanceTransactionCosts" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeSubleaseMember" xlink:label="lrmr_OfficeSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_PA" xlink:label="stpr_PA"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PatientAndCaregiverAwarenessEventsMember" xlink:label="lrmr_PatientAndCaregiverAwarenessEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EndOfStudyMember" xlink:label="lrmr_EndOfStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities and sales of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LabSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LabSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lab Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Valuation Allowance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Valuation Allowance for Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestonePaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of payment due upon reaching milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestonePaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestonePaymentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LeaseTermCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease term commencement date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LeaseTermCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Term Commencement Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LeaseTermCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term commencement date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs (Level 2) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees and Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesAndDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_BeginningOfStudyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beginning of Study [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_BeginningOfStudyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beginning of study.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease security deposits letters of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option vesting percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Award vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity and Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for costs related to research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Research And Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D - Section 174 Costs post 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Capitalized Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Per share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Unvested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Opinion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of office space.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Office Space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AreaOfOfficeSpace_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of office space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals &amp; reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, exercisable as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Anniversary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TechnicalOperationsExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Technical Operations Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TechnicalOperationsExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Technical operations expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TechnicalOperationsExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technical Operations [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Gain (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PerformedOutsideUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performed outside US.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PerformedOutsideUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performed outside US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SecondMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SecondMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SecondMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases recorded to income tax provision</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PerformedInUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performed in US.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PerformedInUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performed in US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Per unit amount of prefunded warrant issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WarrantsIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flow used in operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash flow used in operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Restricted stock units forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated other comprehensive gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Outstanding as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other temporary differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SubleaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease annual base rent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SubleaseAnnualBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual base rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_Ircsection174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IRC Section 174 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_Ircsection174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">IRCSection174.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_Ircsection174Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IRCSection174 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SkinCellsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Skin Cells [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SkinCellsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Skin cells.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SkinCellsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Skin Cells [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase shares of stock granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AdditionalOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AdditionalOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional office.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AdditionalOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity of Counterparty, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity of Counterparty, Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal and state research and development tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Costs and Expenses, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost related to FARA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen equity and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Equity And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Equity and Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Exercisable as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units, net of employee tax obligations, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Net Of Employee Tax Obligations, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value restricted stock award net of employee tax obligations, shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain on marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undesignated preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Included In Accounts Payable And Accrued Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of offering costs that were incurred, but not yet paid, during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs included in accounts payable and accrued expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NoExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No expiration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NoExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">No Expiration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NoExpirationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">No Expiration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2020 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum level of maximum number of shares allowed to be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Threshold Number Of Shares Allowed To Issue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MTSHealthPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MTS Health Partners.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MTSHealthPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M T S Health Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MTSHealthPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MTS Health Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undesignated preferred stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, In-Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net capitalized R&amp;D deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized R&amp;D - acquired in merger with Zafgen</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expense Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Bond Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateBondSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Bonds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of issued as a result of the exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercise of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of payment due for milestones that have been achieved</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash Equivalents and Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Stock Option and Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen stock option and incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Stock Option And Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2014 Stock Option and Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity Type of Counterparty [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Restricted stock units vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_USGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. Government securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_USGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U.S. Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_USGovernmentSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents and marketable debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Lease Liabilities Due Under Lease Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Expense [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, Restricted stock units granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense recognized period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Tax Authority [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Total deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Restricted stock units vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, change in ownership, annual utilization limit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryforwards Annual Utilization Limit Change In Ownership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The annual limitation amount of net operating loss carryforwards that can be utilized to offset taxable income due to changes in ownership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued and Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Gain (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Restricted stock units forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Restricted stock units forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NomlabofuspSupportExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nomlabofusp Support Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NomlabofuspSupportExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nomlabofusp support expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NomlabofuspSupportExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nomlabofusp Support [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount that may be deducted from consideration due to Licensor 2 as a percentage of consideration paid to Licensor 1, whereby Licensor 1 is the identified party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Consideration Deduction Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement consideration deduction percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum level of maximum number of shares allowed to be issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares that may be issued under stock option incentive plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited/Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets / (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WFUHS and IU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wake Forest University Health Sciences And Indiana University Research And Technology Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wake forest university health sciences and indiana university research and technology corporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SixthSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sixth Sublease Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SixthSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sixth Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SixthSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sixth sublease year member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Unvested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units, net of employee tax obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Net Of Employee Tax Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value restricted stock award net of employee tax obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase shares of common stock granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MASSACHUSETTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_MA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions used to Determine Fair Value of Stock Options Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ZafgenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zafgen.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ZafgenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zafgen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ZafgenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Zafgen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_BuccalCellsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Buccal Cells [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_BuccalCellsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Buccal cells.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_BuccalCellsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buccal Cells [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Statutory Income Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and State [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic And State Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Domestic and state local jurisdiction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of research and development costs capitalized during the period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalization of research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of limitation on operating loss carryforwards as a percentage of taxable income in any one tax period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Minimum Percentage Of Taxable Income In Tax Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, minimum percentage of taxable income in tax period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total potentially dilutive shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued as a result of the exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Exercise of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First sublease year member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FirstSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromExerciseOfWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">From exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromExerciseOfWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">From Exercise of Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MinimumAnnualRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum annual royalty payment that is required under a contractual arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MinimumAnnualRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Royalty Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MinimumAnnualRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual royalty pay obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WFUHS [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wake Forest University Health Sciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wake Forest University Health Sciences (WFUHS) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Percentage Of Outstanding Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of outstanding shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating right of use asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Prepaid Expenses and Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Credit Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of the limitation that a capitalized research and development deferred tax asset may be subject to.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Capitalized R D Deferred Tax Assets Realization Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net capitalized R&amp;D deferred tax assets realization description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Cash Equivalents/Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Prepaid Expense And Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other prepaid expenses and other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Voting Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nondeductible permanent differences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in deferred tax asset valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period of stock option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market equity offering program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Equity Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Offering Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CommercialExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CommercialExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CommercialExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Expense Excluding Leased Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate intrinsic value, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate intrinsic value, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, outstanding as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options included in other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from exercise of stock options included in other current assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Exercise Of Stock Options Included In Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MeanLevelHVAtBaselinePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mean Level HV at Baseline Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MeanLevelHVAtBaselinePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of HV at baseline, as a percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MeanLevelHVAtBaselinePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increasing from mean level</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation forfeitures - DTA Write Off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Stock Compensation Forfeitures, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax asset write-offs from stock compensation forfeitures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Real Estate, Type of Property [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets, useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of common stock, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets, (Level 1) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Vested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">2014 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fixed Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Vested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PaymentForLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for license agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PaymentForLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For License Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PaymentForLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LikelihoodPercentageMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum likelihood percentage threshold used to determine the amount of tax benefit to be recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LikelihoodPercentageMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Likelihood Percentage Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_LikelihoodPercentageMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of likelihood to be realized upon ultimate settlement, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undesignated preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liquidity and Capital Resources</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for the assessment of the ability to continue as a going concern.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Going Concern Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_GoingConcernPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Going Concern Assessment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromStockOptionsAndWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromStockOptionsAndWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options And Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromStockOptionsAndWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow from the exercise of options under share-based payment arrangements and from holders exercising their stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of lease expense, both cash and non-cash, related to operating leases.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Non Cash Operating Lease Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Remaining Contractual Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Unvested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term, Exercisable as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited/Expired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromPriorPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">From Prior Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromPriorPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">From Prior Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FromPriorPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">From Prior Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The term of the plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Duration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TrackFAProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Track F A Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TrackFAProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Track-FA program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TrackFAProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Track-FA program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Undesignated preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeAndLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Lab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeAndLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Lab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeAndLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and Lab.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash proceeds from exercises of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Domestic and Foreign Components of Loss Before Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Outstanding Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Unvested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Net Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of expense recognized during the period related to milestones. Such amount may include, but is not limited to, amounts due for attainment of milestones as well as deductions granted as part of a license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_MilestoneExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IU [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indiana University Research And Technology Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indiana University Research and Technology Corporation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Significant Suppliers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization period for capitalized research and development costs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Research and Development Amortization Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Vested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average grant date fair value, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average grant date fair value, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_InducementStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_InducementStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate sale of shares of our common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company&#39;s common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Gross Sales Proceeds Under Sales Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate sale of shares of our common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Limitations on Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FinalSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Final sublease year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FinalSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Final Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FinalSubleaseYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final Sublease Year [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance-Based Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interim Period, Costs Not Allocable [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equipment, furniture and fixtures and office equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment Furniture And Fixtures And Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment, Furniture and Fixtures and Office Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expenses related to sublet assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Expenses Related to Sublet Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for credit loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The first year in which a tax credit carryforward begins to expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carry Forward Expiration Year Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carry forwards, beginning of expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 63,815,065 and 43,909,069 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The first year in which a net operating loss carryforward begins to expire.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carry Forward Expiration Year Begin</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards, beginning of expiration period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on disposal of fixed asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (See Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Common Stock And Warrants Net Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance common stock and warrants net offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FriedreichsAtaxiaResearchAlliancesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Friedreich's Ataxia Research Alliances [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_FriedreichsAtaxiaResearchAlliancesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Friedreich's Ataxia Research Alliances.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs incurred during the period related to the issuance of stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock And Warrant Issuance Transaction Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease extension period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Vested and expected to vest as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Sublease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_OfficeSubleaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office Sublease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change in State Tax Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in state tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to a change in the state tax rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation arrangement by share-based payment award, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Bills [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net accretion of discount on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net accretion of discount on marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_PA_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PENNSYLVANIA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_PA_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pennsylvania [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PatientAndCaregiverAwarenessEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patient and Caregiver Awareness Events [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PatientAndCaregiverAwarenessEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Patient and caregiver awareness events.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_PatientAndCaregiverAwarenessEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patient and Caregiver Awareness Events [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible fixed assets and intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fixed Assets And Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets &amp; intangibles</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leased assets obtained in exchange for new operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EndOfStudyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">End of Study [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_EndOfStudyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">End of study.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Valuation allowance as of the beginning of the year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Valuation allowance at end of year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding as of December 31, 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total other comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs (Level 3) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term in years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount, after allocation of deferred tax liability but before allocation of valuation allowances, of deferred tax asset attributable to deductible differences and carryforwards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net Of Liabilities Before Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net deferred tax assets before the valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LabSpaceMember" xlink:to="lrmr_LabSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MilestonePaymentAmount" xlink:to="lrmr_MilestonePaymentAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LeaseTermCommencementDate" xlink:to="lrmr_LeaseTermCommencementDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EmployeesAndDirectorsMember" xlink:to="lrmr_EmployeesAndDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="lrmr_IncomeTaxesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_BeginningOfStudyMember" xlink:to="lrmr_BeginningOfStudyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PrepaidResearchAndDevelopmentExpenses" xlink:to="lrmr_PrepaidResearchAndDevelopmentExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:to="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FirstMilestoneMember" xlink:to="lrmr_FirstMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AreaOfOfficeSpace" xlink:to="lrmr_AreaOfOfficeSpace_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FirstAnniversaryMember" xlink:to="lrmr_FirstAnniversaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TechnicalOperationsExpenseMember" xlink:to="lrmr_TechnicalOperationsExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PerformedOutsideUsMember" xlink:to="lrmr_PerformedOutsideUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SecondMilestoneMember" xlink:to="lrmr_SecondMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PerformedInUsMember" xlink:to="lrmr_PerformedInUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_WarrantsIssuedPricePerShare" xlink:to="lrmr_WarrantsIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SubleaseAnnualBaseRent" xlink:to="lrmr_SubleaseAnnualBaseRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_Ircsection174Member" xlink:to="lrmr_Ircsection174Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SkinCellsMember" xlink:to="lrmr_SkinCellsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AdditionalOfficeMember" xlink:to="lrmr_AdditionalOfficeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" xlink:to="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares" xlink:to="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense" xlink:to="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NoExpirationMember" xlink:to="lrmr_NoExpirationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="lrmr_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MTSHealthPartnersMember" xlink:to="lrmr_MTSHealthPartnersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lrmr_AccruedResearchAndDevelopmentExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateBondSecuritiesMember" xlink:to="us-gaap_CorporateBondSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MilestoneLiability" xlink:to="lrmr_MilestoneLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" xlink:to="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_USGovernmentSecuritiesMember" xlink:to="lrmr_USGovernmentSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" xlink:to="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NomlabofuspSupportExpenseMember" xlink:to="lrmr_NomlabofuspSupportExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LicenseAgreementConsiderationDeductionPercentage" xlink:to="lrmr_LicenseAgreementConsiderationDeductionPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" xlink:to="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SixthSubleaseYearMember" xlink:to="lrmr_SixthSubleaseYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_IncomeTaxesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations" xlink:to="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ZafgenMember" xlink:to="lrmr_ZafgenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_BuccalCellsMember" xlink:to="lrmr_BuccalCellsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DomesticAndStateLocalJurisdictionMember" xlink:to="lrmr_DomesticAndStateLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_CapitalizedResearchAndDevelopment" xlink:to="lrmr_CapitalizedResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" xlink:to="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FirstSubleaseYearMember" xlink:to="lrmr_FirstSubleaseYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FromExerciseOfWarrantsMember" xlink:to="lrmr_FromExerciseOfWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MinimumAnnualRoyaltyObligation" xlink:to="lrmr_MinimumAnnualRoyaltyObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_WakeForestUniversityHealthSciencesMember" xlink:to="lrmr_WakeForestUniversityHealthSciencesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" xlink:to="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" xlink:to="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AtTheMarketEquityOfferingProgramMember" xlink:to="lrmr_AtTheMarketEquityOfferingProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DevelopmentExpenseMember" xlink:to="lrmr_DevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_CommercialExpenseMember" xlink:to="lrmr_CommercialExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DepreciationExpenseExcludingLeasedAssets" xlink:to="lrmr_DepreciationExpenseExcludingLeasedAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" xlink:to="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MeanLevelHVAtBaselinePercentage" xlink:to="lrmr_MeanLevelHVAtBaselinePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lrmr_TwoThousandFourteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PaymentForLicenseAgreements" xlink:to="lrmr_PaymentForLicenseAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_LikelihoodPercentageMinimum" xlink:to="lrmr_LikelihoodPercentageMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_GoingConcernPolicyTextBlock" xlink:to="lrmr_GoingConcernPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ProceedsFromStockOptionsAndWarrantExercises" xlink:to="lrmr_ProceedsFromStockOptionsAndWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EmployeesMember" xlink:to="lrmr_EmployeesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_CashAndNonCashOperatingLeaseExpense" xlink:to="lrmr_CashAndNonCashOperatingLeaseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FromPriorPlansMember" xlink:to="lrmr_FromPriorPlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OfficeMember" xlink:to="lrmr_OfficeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TrackFAProgramMember" xlink:to="lrmr_TrackFAProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OfficeAndLabMember" xlink:to="lrmr_OfficeAndLabMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_MilestoneExpenses" xlink:to="lrmr_MilestoneExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" xlink:to="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" xlink:to="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_InducementStockMember" xlink:to="lrmr_InducementStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" xlink:to="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FinalSubleaseYearMember" xlink:to="lrmr_FinalSubleaseYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" xlink:to="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DepreciationExpensesRelatedToSubletAssets" xlink:to="lrmr_DepreciationExpensesRelatedToSubletAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_TaxCreditCarryForwardExpirationYearStart" xlink:to="lrmr_TaxCreditCarryForwardExpirationYearStart_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_NetOperatingLossCarryForwardExpirationYearBegin" xlink:to="lrmr_NetOperatingLossCarryForwardExpirationYearBegin_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" xlink:to="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_FriedreichsAtaxiaResearchAlliancesMember" xlink:to="lrmr_FriedreichsAtaxiaResearchAlliancesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_StockAndWarrantIssuanceTransactionCosts" xlink:to="lrmr_StockAndWarrantIssuanceTransactionCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_OfficeSubleaseMember" xlink:to="lrmr_OfficeSubleaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_PA" xlink:to="stpr_PA_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_PatientAndCaregiverAwarenessEventsMember" xlink:to="lrmr_PatientAndCaregiverAwarenessEventsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:to="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_EndOfStudyMember" xlink:to="lrmr_EndOfStudyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:to="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="88.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_15"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_16"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_15" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense" xlink:label="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ProceedsFromStockOptionsAndWarrantExercises" xlink:label="lrmr_ProceedsFromStockOptionsAndWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" xlink:label="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CashAndNonCashOperatingLeaseExpense" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lrmr_ProceedsFromStockOptionsAndWarrantExercises" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lrmr_CashAndNonCashOperatingLeaseExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedParty1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_GoingConcernPolicyTextBlock" xlink:label="lrmr_GoingConcernPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lrmr_GoingConcernPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MeanLevelHVAtBaselinePercentage" xlink:label="lrmr_MeanLevelHVAtBaselinePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_BuccalCellsMember" xlink:label="lrmr_BuccalCellsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_BeginningOfStudyMember" xlink:label="lrmr_BeginningOfStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SkinCellsMember" xlink:label="lrmr_SkinCellsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EndOfStudyMember" xlink:label="lrmr_EndOfStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_MeanLevelHVAtBaselinePercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lrmr_BuccalCellsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lrmr_BeginningOfStudyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lrmr_SkinCellsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lrmr_EndOfStudyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FromExerciseOfWarrantsMember" xlink:label="lrmr_FromExerciseOfWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LikelihoodPercentageMinimum" xlink:label="lrmr_LikelihoodPercentageMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="lrmr_FromExerciseOfWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lrmr_LikelihoodPercentageMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TechnicalOperationsExpenseMember" xlink:label="lrmr_TechnicalOperationsExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DevelopmentExpenseMember" xlink:label="lrmr_DevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NomlabofuspSupportExpenseMember" xlink:label="lrmr_NomlabofuspSupportExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CommercialExpenseMember" xlink:label="lrmr_CommercialExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lrmr_TechnicalOperationsExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lrmr_DevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lrmr_NomlabofuspSupportExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lrmr_CommercialExpenseMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InterestReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AssetImpairmentCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lrmr_USGovernmentSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lrmr_USGovernmentSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PrepaidResearchAndDevelopmentExpenses" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_PrepaidResearchAndDevelopmentExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidInsurance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DepreciationExpenseExcludingLeasedAssets" xlink:label="lrmr_DepreciationExpenseExcludingLeasedAssets"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DepreciationExpensesRelatedToSubletAssets" xlink:label="lrmr_DepreciationExpensesRelatedToSubletAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="lrmr_DepreciationExpenseExcludingLeasedAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="lrmr_DepreciationExpensesRelatedToSubletAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lrmr_AccruedResearchAndDevelopmentExpenseCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MTSHealthPartnersMember" xlink:label="lrmr_MTSHealthPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstAnniversaryMember" xlink:label="lrmr_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EmployeesAndDirectorsMember" xlink:label="lrmr_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AtTheMarketEquityOfferingProgramMember" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_InducementStockMember" xlink:label="lrmr_InducementStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstMilestoneMember" xlink:label="lrmr_FirstMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EmployeesMember" xlink:label="lrmr_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SecondMilestoneMember" xlink:label="lrmr_SecondMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FromPriorPlansMember" xlink:label="lrmr_FromPriorPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WarrantsIssuedPricePerShare" xlink:label="lrmr_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockAndWarrantIssuanceTransactionCosts" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lrmr_MTSHealthPartnersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_FirstAnniversaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lrmr_EmployeesAndDirectorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandFourteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_AtTheMarketEquityOfferingProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="lrmr_InducementStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_FirstMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lrmr_EmployeesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_SecondMilestoneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lrmr_FromPriorPlansMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_WarrantsIssuedPricePerShare" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockAndWarrantIssuanceTransactionCosts" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestonePaymentAmount" xlink:label="lrmr_MilestonePaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeMember" xlink:label="lrmr_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WakeForestUniversityHealthSciencesMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstSubleaseYearMember" xlink:label="lrmr_FirstSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_PA" xlink:label="stpr_PA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PaymentForLicenseAgreements" xlink:label="lrmr_PaymentForLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeSubleaseMember" xlink:label="lrmr_OfficeSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FinalSubleaseYearMember" xlink:label="lrmr_FinalSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MinimumAnnualRoyaltyObligation" xlink:label="lrmr_MinimumAnnualRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeAndLabMember" xlink:label="lrmr_OfficeAndLabMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SixthSubleaseYearMember" xlink:label="lrmr_SixthSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LicenseAgreementConsiderationDeductionPercentage" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AdditionalOfficeMember" xlink:label="lrmr_AdditionalOfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestoneExpenses" xlink:label="lrmr_MilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LabSpaceMember" xlink:label="lrmr_LabSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestoneLiability" xlink:label="lrmr_MilestoneLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LeaseTermCommencementDate" xlink:label="lrmr_LeaseTermCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AreaOfOfficeSpace" xlink:label="lrmr_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SubleaseAnnualBaseRent" xlink:label="lrmr_SubleaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestonePaymentAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_WakeForestUniversityHealthSciencesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_FirstSubleaseYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_PA" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_PaymentForLicenseAgreements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeSubleaseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_FinalSubleaseYearMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MinimumAnnualRoyaltyObligation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeAndLabMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_SixthSubleaseYearMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_LicenseAgreementConsiderationDeductionPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_AdditionalOfficeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestoneExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_LabSpaceMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestoneLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_LeaseTermCommencementDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RestrictedCash" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_AreaOfOfficeSpace" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_SubleaseAnnualBaseRent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SecurityDepositLiability" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NoExpirationMember" xlink:label="lrmr_NoExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ZafgenMember" xlink:label="lrmr_ZafgenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PerformedInUsMember" xlink:label="lrmr_PerformedInUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PerformedOutsideUsMember" xlink:label="lrmr_PerformedOutsideUsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetOperatingLossCarryForwardExpirationYearBegin" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DomesticAndStateLocalJurisdictionMember" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_Ircsection174Member" xlink:label="lrmr_Ircsection174Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TaxCreditCarryForwardExpirationYearStart" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CapitalizedResearchAndDevelopment" xlink:label="lrmr_CapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="lrmr_NoExpirationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lrmr_ZafgenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lrmr_IncomeTaxesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lrmr_PerformedInUsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxPeriodAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lrmr_PerformedOutsideUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetOperatingLossCarryForwardExpirationYearBegin" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lrmr_DomesticAndStateLocalJurisdictionMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="lrmr_IncomeTaxesDisclosureLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lrmr_Ircsection174Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_TaxCreditCarryForwardExpirationYearStart" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_CapitalizedResearchAndDevelopment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="lrmr_IncomeTaxesDisclosureLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lrmr_IncomeTaxesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TrackFAProgramMember" xlink:label="lrmr_TrackFAProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FriedreichsAtaxiaResearchAlliancesMember" xlink:label="lrmr_FriedreichsAtaxiaResearchAlliancesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PatientAndCaregiverAwarenessEventsMember" xlink:label="lrmr_PatientAndCaregiverAwarenessEventsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lrmr_TrackFAProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="lrmr_FriedreichsAtaxiaResearchAlliancesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lrmr_PatientAndCaregiverAwarenessEventsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares" xlink:label="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MeanLevelHVAtBaselinePercentage" xlink:label="lrmr_MeanLevelHVAtBaselinePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_BuccalCellsMember" xlink:label="lrmr_BuccalCellsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_BeginningOfStudyMember" xlink:label="lrmr_BeginningOfStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SkinCellsMember" xlink:label="lrmr_SkinCellsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EndOfStudyMember" xlink:label="lrmr_EndOfStudyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_MeanLevelHVAtBaselinePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lrmr_BuccalCellsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lrmr_BeginningOfStudyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="lrmr_SkinCellsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lrmr_EndOfStudyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:label="lrmr_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FromExerciseOfWarrantsMember" xlink:label="lrmr_FromExerciseOfWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" xlink:label="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LikelihoodPercentageMinimum" xlink:label="lrmr_LikelihoodPercentageMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lrmr_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="lrmr_FromExerciseOfWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lrmr_LikelihoodPercentageMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TechnicalOperationsExpenseMember" xlink:label="lrmr_TechnicalOperationsExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DevelopmentExpenseMember" xlink:label="lrmr_DevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NomlabofuspSupportExpenseMember" xlink:label="lrmr_NomlabofuspSupportExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CommercialExpenseMember" xlink:label="lrmr_CommercialExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_NatureOfExpenseAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lrmr_TechnicalOperationsExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lrmr_DevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lrmr_NomlabofuspSupportExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lrmr_CommercialExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lrmr_USGovernmentSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_USGovernmentSecuritiesMember" xlink:label="lrmr_USGovernmentSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="us-gaap_CorporateBondSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lrmr_USGovernmentSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateBondSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FromPriorPlansMember" xlink:label="lrmr_FromPriorPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MTSHealthPartnersMember" xlink:label="lrmr_MTSHealthPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstAnniversaryMember" xlink:label="lrmr_FirstAnniversaryMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EmployeesAndDirectorsMember" xlink:label="lrmr_EmployeesAndDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AtTheMarketEquityOfferingProgramMember" xlink:label="lrmr_AtTheMarketEquityOfferingProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_InducementStockMember" xlink:label="lrmr_InducementStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstMilestoneMember" xlink:label="lrmr_FirstMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EmployeesMember" xlink:label="lrmr_EmployeesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" xlink:label="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SecondMilestoneMember" xlink:label="lrmr_SecondMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" xlink:label="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WarrantsIssuedPricePerShare" xlink:label="lrmr_WarrantsIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_StockAndWarrantIssuanceTransactionCosts" xlink:label="lrmr_StockAndWarrantIssuanceTransactionCosts"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" xlink:label="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" xlink:label="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lrmr_FromPriorPlansMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lrmr_MTSHealthPartnersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_FirstAnniversaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lrmr_EmployeesAndDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandFourteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lrmr_AtTheMarketEquityOfferingProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="lrmr_InducementStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_FirstMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lrmr_EmployeesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="lrmr_SecondMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_WarrantsIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_StockAndWarrantIssuanceTransactionCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" xlink:label="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestonePaymentAmount" xlink:label="lrmr_MilestonePaymentAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeMember" xlink:label="lrmr_OfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WakeForestUniversityHealthSciencesMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:label="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:label="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FirstSubleaseYearMember" xlink:label="lrmr_FirstSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_PA" xlink:label="stpr_PA"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PaymentForLicenseAgreements" xlink:label="lrmr_PaymentForLicenseAgreements"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeSubleaseMember" xlink:label="lrmr_OfficeSubleaseMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FinalSubleaseYearMember" xlink:label="lrmr_FinalSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd#stpr_MA" xlink:label="stpr_MA"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MinimumAnnualRoyaltyObligation" xlink:label="lrmr_MinimumAnnualRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OfficeAndLabMember" xlink:label="lrmr_OfficeAndLabMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" xlink:label="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SixthSubleaseYearMember" xlink:label="lrmr_SixthSubleaseYearMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LicenseAgreementConsiderationDeductionPercentage" xlink:label="lrmr_LicenseAgreementConsiderationDeductionPercentage"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AdditionalOfficeMember" xlink:label="lrmr_AdditionalOfficeMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestoneExpenses" xlink:label="lrmr_MilestoneExpenses"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LabSpaceMember" xlink:label="lrmr_LabSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_MilestoneLiability" xlink:label="lrmr_MilestoneLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_LeaseTermCommencementDate" xlink:label="lrmr_LeaseTermCommencementDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AreaOfOfficeSpace" xlink:label="lrmr_AreaOfOfficeSpace"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_SubleaseAnnualBaseRent" xlink:label="lrmr_SubleaseAnnualBaseRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestonePaymentAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_WakeForestUniversityHealthSciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" xlink:to="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_FirstSubleaseYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_PA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_PaymentForLicenseAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeSubleaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_FinalSubleaseYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_MA" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MinimumAnnualRoyaltyObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_OfficeAndLabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="lrmr_SixthSubleaseYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_LicenseAgreementConsiderationDeductionPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_AdditionalOfficeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestoneExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_MortgageLoansOnRealEstateNamePropertyTypeDomain" xlink:to="lrmr_LabSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_MilestoneLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_LeaseTermCommencementDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_AreaOfOfficeSpace" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="lrmr_SubleaseAnnualBaseRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SecurityDepositLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NoExpirationMember" xlink:label="lrmr_NoExpirationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ZafgenMember" xlink:label="lrmr_ZafgenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PerformedInUsMember" xlink:label="lrmr_PerformedInUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PerformedOutsideUsMember" xlink:label="lrmr_PerformedOutsideUsMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetOperatingLossCarryForwardExpirationYearBegin" xlink:label="lrmr_NetOperatingLossCarryForwardExpirationYearBegin"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" xlink:label="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DomesticAndStateLocalJurisdictionMember" xlink:label="lrmr_DomesticAndStateLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_Ircsection174Member" xlink:label="lrmr_Ircsection174Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TaxCreditCarryForwardExpirationYearStart" xlink:label="lrmr_TaxCreditCarryForwardExpirationYearStart"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" xlink:label="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CapitalizedResearchAndDevelopment" xlink:label="lrmr_CapitalizedResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" xlink:label="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" xlink:label="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" xlink:label="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_IncomeTaxesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="lrmr_NoExpirationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lrmr_ZafgenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lrmr_PerformedInUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_TaxPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lrmr_PerformedOutsideUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetOperatingLossCarryForwardExpirationYearBegin" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lrmr_IncomeTaxesDisclosureTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lrmr_DomesticAndStateLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="lrmr_Ircsection174Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_TaxCreditCarryForwardExpirationYearStart" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_CapitalizedResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OpenTaxYear" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail">
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureLineItems" xlink:label="lrmr_IncomeTaxesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_IncomeTaxesDisclosureTable" xlink:label="lrmr_IncomeTaxesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="lrmr_IncomeTaxesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lrmr_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_TrackFAProgramMember" xlink:label="lrmr_TrackFAProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_FriedreichsAtaxiaResearchAlliancesMember" xlink:label="lrmr_FriedreichsAtaxiaResearchAlliancesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PatientAndCaregiverAwarenessEventsMember" xlink:label="lrmr_PatientAndCaregiverAwarenessEventsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingCostsAndExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lrmr_TrackFAProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="lrmr_FriedreichsAtaxiaResearchAlliancesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="lrmr_PatientAndCaregiverAwarenessEventsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/srt/role/srt-eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202307Member" xlink:label="us-gaap_AccountingStandardsUpdate202307Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeTermOfLeaseMember" xlink:label="us-gaap_UsefulLifeTermOfLeaseMember"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lrmr_ProceedsFromStockOptionsAndWarrantExercises" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lrmr_CashAndNonCashOperatingLeaseExpense" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="16" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_ProceedsFromStockOptionsAndWarrantExercises" xlink:label="lrmr_ProceedsFromStockOptionsAndWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_CashAndNonCashOperatingLeaseExpense" xlink:label="lrmr_CashAndNonCashOperatingLeaseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lrmr_PrepaidResearchAndDevelopmentExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_PrepaidResearchAndDevelopmentExpenses" xlink:label="lrmr_PrepaidResearchAndDevelopmentExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" xlink:label="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="lrmr_AccruedResearchAndDevelopmentExpenseCurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:label="lrmr_AccruedResearchAndDevelopmentExpenseCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" xlink:label="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" xlink:label="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" xlink:label="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="lrmr-20241231.xsd#lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lrmr_FirstMilestoneMember" name="FirstMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_MilestoneExpenses" name="MilestoneExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_OfficeSubleaseMember" name="OfficeSubleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_DepreciationExpensesRelatedToSubletAssets" name="DepreciationExpensesRelatedToSubletAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_MilestoneLiability" name="MilestoneLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" name="EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_USGovernmentSecuritiesMember" name="USGovernmentSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_CashAndNonCashOperatingLeaseExpense" name="CashAndNonCashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_AreaOfOfficeSpace" name="AreaOfOfficeSpace" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_PrepaidResearchAndDevelopmentExpenses" name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_ProceedsFromStockOptionsAndWarrantExercises" name="ProceedsFromStockOptionsAndWarrantExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_LicenseAgreementConsiderationDeductionPercentage" name="LicenseAgreementConsiderationDeductionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets" name="DeferredTaxAssetsFixedAssetsAndIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_DomesticAndStateLocalJurisdictionMember" name="DomesticAndStateLocalJurisdictionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_NomlabofuspSupportExpenseMember" name="NomlabofuspSupportExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_IncomeTaxesDisclosureTable" name="IncomeTaxesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_Ircsection174Member" name="Ircsection174Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_FirstSubleaseYearMember" name="FirstSubleaseYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_FirstAnniversaryMember" name="FirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_AggregateGrossSalesProceedsUnderSalesAgreement" name="AggregateGrossSalesProceedsUnderSalesAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod" name="CapitalizedResearchAndDevelopmentAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_DeferredTaxAssetsOperatingLeaseLiabilities" name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_FromExerciseOfWarrantsMember" name="FromExerciseOfWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_NetOperatingLossCarryForwardExpirationYearBegin" name="NetOperatingLossCarryForwardExpirationYearBegin" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_LeaseTermCommencementDate" name="LeaseTermCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" name="ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_SixthSubleaseYearMember" name="SixthSubleaseYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_InducementStockMember" name="InducementStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_PerformedOutsideUsMember" name="PerformedOutsideUsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_LabSpaceMember" name="LabSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember" name="TwoThousandFourteenStockOptionAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_BuccalCellsMember" name="BuccalCellsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_AccruedResearchAndDevelopmentExpenseCurrent" name="AccruedResearchAndDevelopmentExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_MilestonePaymentAmount" name="MilestonePaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_TwoThousandSixteenEquityAndIncentivePlanMember" name="TwoThousandSixteenEquityAndIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_EndOfStudyMember" name="EndOfStudyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_TrackFAProgramMember" name="TrackFAProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense" name="OfferingCostsIncludedInAccountsPayableAndAccruedExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" name="OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_PatientAndCaregiverAwarenessEventsMember" name="PatientAndCaregiverAwarenessEventsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_NoExpirationMember" name="NoExpirationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_WarrantsIssuedPricePerShare" name="WarrantsIssuedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_IncomeTaxesDisclosureLineItems" name="IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_SecondMilestoneMember" name="SecondMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_AtTheMarketEquityOfferingProgramMember" name="AtTheMarketEquityOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_TechnicalOperationsExpenseMember" name="TechnicalOperationsExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_DepreciationExpenseExcludingLeasedAssets" name="DepreciationExpenseExcludingLeasedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares" name="StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_CommercialExpenseMember" name="CommercialExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_EmployeesMember" name="EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_OfficeAndLabMember" name="OfficeAndLabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" name="EquipmentFurnitureAndFixturesAndOfficeEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations" name="StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_SkinCellsMember" name="SkinCellsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_FromPriorPlansMember" name="FromPriorPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" name="ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_PerformedInUsMember" name="PerformedInUsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" name="NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_FinalSubleaseYearMember" name="FinalSubleaseYearMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_DevelopmentExpenseMember" name="DevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_AdditionalOfficeMember" name="AdditionalOfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_FriedreichsAtaxiaResearchAlliancesMember" name="FriedreichsAtaxiaResearchAlliancesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_MinimumAnnualRoyaltyObligation" name="MinimumAnnualRoyaltyObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" name="WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_MeanLevelHVAtBaselinePercentage" name="MeanLevelHVAtBaselinePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_BeginningOfStudyMember" name="BeginningOfStudyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" name="EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_TaxCreditCarryForwardExpirationYearStart" name="TaxCreditCarryForwardExpirationYearStart" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_WakeForestUniversityHealthSciencesMember" name="WakeForestUniversityHealthSciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription" name="NetCapitalizedRDDeferredTaxAssetsRealizationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_StockAndWarrantIssuanceTransactionCosts" name="StockAndWarrantIssuanceTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" name="DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_LikelihoodPercentageMinimum" name="LikelihoodPercentageMinimum" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_ZafgenMember" name="ZafgenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_CapitalizedResearchAndDevelopment" name="CapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="lrmr_OtherPrepaidExpenseAndOtherCurrentAssets" name="OtherPrepaidExpenseAndOtherCurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_OfficeMember" name="OfficeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_MTSHealthPartnersMember" name="MTSHealthPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="lrmr_SubleaseAnnualBaseRent" name="SubleaseAnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="lrmr_PaymentForLicenseAgreements" name="PaymentForLicenseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="lrmr_IndianaUniversityResearchAndTechnologyCorporationMember" name="IndianaUniversityResearchAndTechnologyCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 20, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LRMR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LARIMAR THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001374690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,027,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3857670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Three Bala Plaza East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bala Cynwyd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">511-9056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313,608,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#8217;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#8217;s fiscal year ended </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania, USA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Larimar Therapeutics, Inc. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, of changes in stockholders&#8217; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,218<span></span>
</td>
<td class="nump">$ 26,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">150,236<span></span>
</td>
<td class="nump">60,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,850<span></span>
</td>
<td class="nump">3,385<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">195,304<span></span>
</td>
<td class="nump">90,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,838<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">606<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">596<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">200,225<span></span>
</td>
<td class="nump">95,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,424<span></span>
</td>
<td class="nump">1,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">20,872<span></span>
</td>
<td class="nump">7,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">1,060<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,356<span></span>
</td>
<td class="nump">9,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,057<span></span>
</td>
<td class="nump">4,709<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">28,413<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 63,815,065 and 43,909,069 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">440,758<span></span>
</td>
<td class="nump">270,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(269,158)<span></span>
</td>
<td class="num">(188,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">171,812<span></span>
</td>
<td class="nump">81,720<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 200,225<span></span>
</td>
<td class="nump">$ 95,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">63,815,065<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">63,815,065<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 73,278<span></span>
</td>
<td class="nump">$ 27,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">17,612<span></span>
</td>
<td class="nump">14,088<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">90,890<span></span>
</td>
<td class="nump">41,758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(90,890)<span></span>
</td>
<td class="num">(41,758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">10,286<span></span>
</td>
<td class="nump">4,809<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80,604)<span></span>
</td>
<td class="num">$ (36,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic</a></td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (1.32)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">61,256,084<span></span>
</td>
<td class="nump">43,901,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">61,256,084<span></span>
</td>
<td class="nump">43,901,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80,604)<span></span>
</td>
<td class="num">$ (36,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable securities</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive gain</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (80,537)<span></span>
</td>
<td class="num">$ (36,837)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss) [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">$ 110,903<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 262,496<span></span>
</td>
<td class="num">$ (151,605)<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,269,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">7,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable debt securities</a></td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">81,720<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">270,150<span></span>
</td>
<td class="num">(188,554)<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="nump">161,756<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">161,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,736,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Vesting of restricted stock units, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">15,404<span></span>
</td>
<td class="nump">15,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 8,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on marketable debt securities</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="nump">$ 171,812<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 440,758<span></span>
</td>
<td class="num">$ (269,158)<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,815,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (80,604)<span></span>
</td>
<td class="num">$ (36,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">8,796<span></span>
</td>
<td class="nump">7,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_CashAndNonCashOperatingLeaseExpense', window );">Lease expense</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of discount on marketable securities</a></td>
<td class="num">(5,256)<span></span>
</td>
<td class="num">(1,843)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(8,465)<span></span>
</td>
<td class="num">(1,065)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">13,436<span></span>
</td>
<td class="num">(1,022)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">63<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities:</a></td>
<td class="num">(70,760)<span></span>
</td>
<td class="num">(33,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(515)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(227,872)<span></span>
</td>
<td class="num">(101,233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities and sales of marketable securities</a></td>
<td class="nump">143,000<span></span>
</td>
<td class="nump">134,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(85,387)<span></span>
</td>
<td class="nump">33,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of issuance costs</a></td>
<td class="nump">161,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ProceedsFromStockOptionsAndWarrantExercises', window );">Proceeds from exercise of stock options and warrants</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">161,883<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">5,736<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">28,088<span></span>
</td>
<td class="nump">28,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">33,824<span></span>
</td>
<td class="nump">28,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense', window );">Offering costs included in accounts payable and accrued expense</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets', window );">Proceeds from exercise of stock options included in other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_CashAndNonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease expense, both cash and non-cash, related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_CashAndNonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of offering costs that were incurred, but not yet paid, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of stock options included in other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ProceedsFromStockOptionsAndWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options under share-based payment arrangements and from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ProceedsFromStockOptionsAndWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cyber Risk Management and Strategy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have implemented and maintain various information security processes designed to manage cybersecurity risks relating to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products (Information Systems and Data).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Director of Information Technology, assisted by our managed information technology service provider and other third party service providers, leads the Company&#8217;s cybersecurity risk management processes. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#8217;s risk profile using various methods in certain contexts, including, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing threat intelligence reports and feeds, conducting scans of certain environments, and other tests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage risks from cybersecurity threats to our Information Systems and Data, as applicable depending on the environment, including incident detection and response, disaster recovery/business continuity policies, network security controls and data segmentation, access controls, physical security, asset management and tracking, systems monitoring, and employee training.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our assessment and management of risks from cybersecurity threats are part of the Company&#8217;s overall risk management processes. Our Director of Information Technology works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party service providers</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to assist us to identify, assess, and manage risks from cybersecurity threats. These third-party service providers may include threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and dark web monitoring services.</span></span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also have established a process to conduct diligence on certain third parties before engaging with those third parties, such as those that support our GxP processes, which may include a security assessment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not identified any cybersecurity incidents or threats that have </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">materially affected</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition; however, like other companies in our industry, we and our third-party vendors may, from time to time, experience threats and security incidents relating to our and our third-party vendors&#8217; information systems and infrastructure. For more information, please see our risk factors under Part 1 Item 1A. Risk Factors.</span></p><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors holds oversight responsibility over the Company&#8217;s cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of the board of directors is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of the Company&#8217;s processes for monitoring and controlling cybersecurity risks.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who has over 10 years of information technology management experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of Information Technology, along with management, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and communicating key priorities to relevant personnel. Management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have processes designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vice President Legal and Compliance, Vice President Finance and Administration, Vice President - Controller, Chief Financial Officer and Director of Information Technology</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company&#8217;s incident response policy includes a process for reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives reports from members of the Company&#8217;s management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them, as applicable.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Governance</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors holds oversight responsibility over the Company&#8217;s cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of the board of directors is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of the Company&#8217;s processes for monitoring and controlling cybersecurity risks.</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who has over 10 years of information technology management experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of Information Technology, along with management, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and communicating key priorities to relevant personnel. Management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have processes designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vice President Legal and Compliance, Vice President Finance and Administration, Vice President - Controller, Chief Financial Officer and Director of Information Technology</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company&#8217;s incident response policy includes a process for reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee receives reports from members of the Company&#8217;s management concerning the Company&#8217;s significant cybersecurity threats and risk and the processes the Company has implemented to address them, as applicable.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of the board of directors is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of the Company&#8217;s processes for monitoring and controlling cybersecurity risks.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors holds oversight responsibility over the Company&#8217;s cybersecurity risk management as part of its general oversight function. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The audit committee of the board of directors is responsible for overseeing the Company&#8217;s cybersecurity risk management processes, including oversight of the Company&#8217;s processes for monitoring and controlling cybersecurity risks.</span></span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who has over 10 years of information technology management experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Director of Information Technology, along with management, is responsible for helping to integrate cybersecurity risk considerations into the Company&#8217;s overall risk management strategy and communicating key priorities to relevant personnel. Management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security-related reports.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, who has over 10 years of information technology management experience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have processes designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Vice President Legal and Compliance, Vice President Finance and Administration, Vice President - Controller, Chief Financial Officer and Director of Information Technology</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, the Company&#8217;s incident response policy includes a process for reporting to the audit committee of the board of directors for certain cybersecurity incidents.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (80,604)<span></span>
</td>
<td class="num">$ (36,949)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Description of Business and Basis of Presentation </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Larimar Therapeutics, Inc., together with its subsidiary (the &#8220;Company&#8221; or &#8220;Larimar&#8221;), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich&#8217;s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Larimar has completed two Phase 1 clinical trials and a Phase 2 dose exploration trial, and has an ongoing Phase 2 OLE trial in patients with FA and an ongoing run-in study in adolescent patients with FA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2021, the Company reported positive top-line data from its Phase 1 FA program after completing dosing of the single ascending dose ("SAD") trial in December 2020 and of the multiple ascending dose ("MAD") trial in March 2021. Data from these trials demonstrated proof-of-concept by showing that daily subcutaneous injections of nomlabofusp for up to 13 days resulted in dose-dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues (buccal cells, skin, and platelets). There were no serious adverse events associated with either the MAD or SAD trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, the Company reported preliminary unblinded top-line data from the 25 mg cohort of the Phase 2 four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2023, the FDA cleared initiation of a second cohort (50 mg) of the four-week, placebo-controlled, Phase 2 dose exploration trial of nomlabofusp in patients with FA and the initiation of the OLE trial with daily dosing of 25 mg.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company reported positive top-line data and successful completion of the Phase 2 dose exploration study. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. Patients who completed treatment in the Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In March 2024, Larimar dosed the first patient in the OLE trial, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreich&#8217;s Ataxia Clinical Outcome Measures Study ("FACOMS") database.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 30, 2024, Larimar announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company received access to the Medicines and Healthcare Regulatory Agency ("MHRA&#8221;) Innovative Licensing and Access Pathway (&#8220;ILAP&#8221;) for the treatment of adults and children with FA. The ILAP is facilitating patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with UK regulatory authorities and other stakeholders. Along with the receipt of the ILAP designation, nomlabofusp has already been granted orphan drug designations in the U.S. and the European Union (the &#8220;EU&#8221;), and access to the PRIME scheme in the EU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, the Company reported positive initial data from the ongoing OLE study. This data included safety, FXN levels, clinical, pharmacokinetic data and dose escalation:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nomlabofusp was generally well tolerated for up to 260 days in subjects. The most common adverse events were injection site reactions, with most being mild, brief in duration, and self-limited. Two participants had serious adverse events (one seizure and one anaphylactic reaction) that resolved within 24 hours and withdrew from the study; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-term 25 mg tissue FXN levels showed positive mean change from baseline of 1.32 pg/&#956;g in buccal cells and 9.28 pg/&#956;g in skin cells at Day 90 and that 25 mg of nomlabofusp increased and maintained tissue FXN levels over time, increasing from a mean level of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of HV at baseline to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in buccal cells and from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in skin cells at Day 90;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tissue FXN levels appear to reach steady-state levels by Day 30 in buccal cells;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Early clinical data showed trends toward improvement across a number of clinical outcomes for long-term 25 mg daily nomlabofusp including: (1) decreased values indicating early trends towards improvement in the Modified Friedreich Ataxia Rating Scale (mFARS) and the FARS-Activities of Daily Living ("ADL"), Modified Fatigue Impact Scale and 9 hole peg test at 90 days relative to baseline;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key pharmacokinetic data showed rapid absorption after subcutaneous administration with exposure appearing to reach steady state in plasma by day 30 with no further accumulation, which is consistent with data from our Phase 1 and Phase 2 studies.</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Also in December 2024, Larimar announced that it was increasing the dose in the OLE to 50 mg of nomlabofusp daily for then currently enrolled and all future OLE study participants. In March 2025, the Company announced that its Safety Monitoring Team has deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp and therefore, Larimar expects to see additional reactions. To reduce the risk of allergic reactions, including anaphylaxis, Larimar amended the OLE protocol to administer premedication for the first month of dosing. The OLE study is ongoing with seven sites activated and participants continuing to enroll. All  study participants are currently receiving the 50 mg dose of nomlabofusp. The Company plans to provide an update on OLE data on at least 30 to 40 study participants, some of whom have been receiving nomlabofusp for more than a year, in September 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, Larimar initiated dosing of adolescents (12-17 years old) in a PK run-in study for pediatric patients with FA. Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp at a weight-base dose expected to match the PK of adults receiving the 50 mg dose, or placebo, daily for seven days. Following assessment of safety and PK data, participants will be eligible to screen for the OLE study. The data from this cohort is expected to be presented during the nomlabofusp program update in September 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2025, Larimar announced that FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as a reasonably likely surrogate endpoint (&#8220;RLSE&#8221;) and the acceptability of FXN&#8217;s use as an RLSE would ultimately be a matter of review of the data in a future marketing application. FDA recommended focusing on assessments of skin FXN concentrations rather than buccal FXN concentrations due to more consistent sampling and less variability. FDA acknowledged that data the Company recently submitted appear to support a relationship between increased FXN concentrations in skin cells and relevant tissues such as the heart, dorsal root ganglion and skeletal muscle. FDA also acknowledged that the nonclinical studies Larimar submitted were performed at relevant human doses. FDA also suggested that Larimar consider exploring the relationship between increases in FXN in skin and changes in pharmacodynamic (PD) markers such as lipid profiles and/or clinical measures to provide additional support for the use of FXN as an RLSE. Larimar plans to continue discussions with FDA regarding the adequacy of the safety data set for a BLA submission seeking accelerated approval targeted for year-end 2025.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the Company has obtained feedback from both FDA and EMA on the global Phase 3 study protocol and is on track to initiate the study by mid-2025 with potential sites in the U.S., E.U., U.K, Canada, and Australia.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with U. S. Generally Accepted Accounting Principles ("GAAP")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024, and 2023, respectively, and cash flow used in operations of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively. In addition, as of December 31, 2024, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2024, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,736,842</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in an underwritten public offering at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205, "Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into the second quarter of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">income; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#8217; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value would be recorded in net income.</span></p></div><div style="font-size:11pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e67f9759-bc4c-4465-933e-6db26d968aa7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment, net&#184; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs associated with internal research and development and external research and development services, including drug manufacturing and scale- up, other drug development and testing costs, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and to scale up the manufacturing process, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company is managed on a consolidated basis and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment related to the development of clinical and preclinical product candidates for the development of the Company&#8217;s proprietary new therapies, primarily nomlabofusp, the Company's life science segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company's </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d10ed809-200f-4b30-80d3-8c8fcced056e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("CEO").</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the Company and its reportable segment based on net loss, which is reported on the consolidated Statements of Operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. All long-lived assets are located in the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated financial information, including consolidated net loss, to evaluate performance, forecast future period financial results, allocate resources for the company by, among other things, comparing budgeted to actual results.</span></span></p></div><div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Technical operations</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,805</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,781</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,361</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,733</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nomlabofusp support</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,112</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,156</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,944</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,088</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,668</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90,890</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,758</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,286</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,809</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,604</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,949</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s only element of other comprehensive gain (loss) was unrealized gain (loss) on marketable securities.</span></p></div><div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#8217;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Accordingly, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,135,390</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,888,502</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options to purchase common stock, outstanding as of December 31, 2024 and 2023 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires disclosure of incremental segment information on an annual and interim basis. The amendments also require companies with a single reportable segment to provide all disclosures required by this amendment and all existing segment disclosures in ASC 280, Segment Reporting. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8e858e57-0756-416b-b74d-b48de20c666a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, effective December 31, 2024, in these consolidated financial statements. ASU 2023-07 only impacted the disclosures and did not impact the consolidated financial statements. See Note 2, Segment Information, for disclosures related to the adoption of ASU 2023-07.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, &#8220;Improvements to Income Tax Disclosures (Topic 740),&#8221; which requires entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes as well as additional information about reconciling items if certain quantitative thresholds are met. This ASU will require all entities to disclose income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. All entities are required to apply the guidance prospectively, with the option to apply it retrospectively. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it will adopt this ASU on January 1, 2025, the adoption of which is not expected to have a material impact on the Company&#8217;s consolidated results of operations or cash flows.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221;, which requires disaggregated disclosures in the notes of the financial statements of certain categories of expenses that are included in expense line items on the face of the income statement. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company will evaluate the impact adopting ASU 2024-03 will have on the Company's consolidated financial statements and disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Cash Equivalents/Marketable Securities</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Cash Equivalents/Marketable Securities</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and December 31, 2023 are measured in accordance with the standards of ASC 820, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements and Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:11.54%;box-sizing:content-box;"></td>
      <td style="width:88.46%;box-sizing:content-box;"></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level &#8211; 1</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></p></td>
     </tr>
     <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level &#8211; 2</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.</span></p></td>
     </tr>
     <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
      <td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     </tr>
     <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Level &#8211; 3</span></p></td>
      <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></p></td>
     </tr>
    </table><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2024 and 2023 were considered representative of their fair values due to their short term to maturity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s cash equivalents and marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets <br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds invested in government <br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,702</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,702</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,702</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,702</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,947</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,947</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,236</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,947</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds invested in government <br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,701</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,701</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,701</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,701</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,719</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,719</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,988</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,988</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,707</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,035</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,707</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accrued interest receivable related to the Company&#8217;s investments was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively, and is included in prepaid expenses and other current assets on the consolidated balance sheet.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024, the unrealized loss for available-for-sale investments were non-credit related, and the Company does not intend to sell the investments that were in an unrealized loss position, nor will it be required to sell those investments before recovery of their amortized cost basis, which may be maturity. As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> allowances for credit losses for the Company&#8217;s investments were recorded. During the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognize any impairment losses related to investments.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023, the Company's cash equivalents and marketable securities consisted of a U.S. government money market fund, U.S. Treasury Bills and U.S. government and agency securities, all held in our name in a separate custody account with U.S. Bank. The U.S. government money market fund has same-day liquidity access and the U.S. government and agency securities all have maturities of 360 days or less.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable Securities</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized <br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,945</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,947</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,088</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,236</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,653</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,719</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,977</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,988</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid Expenses and Other Current Assets</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,994</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,054</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">499</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,850</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,385</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fixed Assets</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fixed assets, net consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,707</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_a5f65a1c-dbe3-418f-9eaf-369ca80d6c94;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">lease term</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,424</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,909</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,543</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Property, plant and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">881</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depreciation expense was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, respectively. In addition, for the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, there was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of depreciation related to sublet assets recorded as other expense.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued Expenses</span></div></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,057</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,594</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,254</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,365</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">561</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">427</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,386</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity and Stock Options</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity and Stock Options</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Common Stock and Prefunded warrants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the &#8220;Purchasers&#8221;) for the sale by the Company in a private placement of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,105,359</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock and prefunded warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the Company&#8217;s common stock, for a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share of the common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.01</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and were exercisable indefinitely. In August 2023, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of prefunded warrants were exercised and the Company received cash proceeds of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_921994da-5811-4028-8f53-85e77eb89620;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six thousand two hundred and eighty-four dollars</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and prefunded warrants were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, transaction costs totaled $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and resulted in net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company&#8217;s Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,105,359</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock sold and the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,260</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s Amended and Restated Certificate of Incorporation, authorized the Company to issue up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value common stock, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,815,065</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued and outstanding, and up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> par value undesignated preferred stock, of which </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the &#8220;Board&#8221;), if any. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> cash dividends have been declared or paid to date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,736,842</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in an underwritten public offering price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2022 ATM Agreement</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, the Company entered into a sales agreement (the "2022 ATM Agreement") with a Guggenheim Securities, LLC in connection with the establishment of an &#8220;at-the-market&#8221; offering program under which the Company could sell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of shares of common stock (the &#8220;ATM Shares&#8221;) from time to time.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, in connection with the underwritten public offering described above, the Company terminated the 2022 ATM Agreement. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ATM Shares were ever sold pursuant to the 2022 ATM Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company entered into a sales agreement (the "ATM Agreement") with Guggenheim Securities, LLC in connection with the establishment of an &#8220;at-the-market&#8221; offering program under which the Company could sell up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of shares of common stock (the &#8220;ATM Shares&#8221;) from time to time. To date, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sales of common stock have been made under this ATM Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2020 Equity Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the "Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2020 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;), nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based restricted stock units, and cash or other stock-based awards. ISOs may be granted only to the Company&#8217;s employees, including the Company&#8217;s officers, and the employees of the Company&#8217;s affiliates. All other awards may be granted to the Company&#8217;s employees, including the Company&#8217;s officers, the Company&#8217;s non-employee directors and consultants, and the employees and consultants of the Company&#8217;s affiliates.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,700,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#8220;Plan Limit&#8221;).</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The maximum aggregate number of shares that may be issued under the 2020 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> over the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> term of the 2020 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As permitted by the 2020 Plan, the Company added </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,552,603</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,756,363</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares available for grant to the 2020 Plan on January 1, 2025 and January 1, 2024, respectively, increasing the maximum number of shares of the Company&#8217;s common stock that may be issued under the 2020 Plan as of January 1, 2025 to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,179,529</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the twelve months ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,242</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">224,437</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares issued under the Prior Plans were canceled and became available for grant under the 2020 Plan. In addition, as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">626,926</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock were available for grant under the 2020 Plan.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Valuation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.62%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:15.02%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:14.08%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.22</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.23</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock Options</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 (amounts in millions, except for share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.39%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.062000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.602%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.042%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value (a)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,273,502</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,235,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.35</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.08</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,436,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,094,992</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,436,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2024 Option Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,235,377</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock to employees and directors under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date. Of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,235,377</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options granted, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,140,377</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were granted to employees and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options were annual grants to the Company's directors and vest </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the grant date. The weighted-average grant date fair value of options granted under the 2020 Plan during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation expense related to unvested stock options granted under the 2020 Plan was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.63</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inducement Stock Option Grant</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> inducement awards granted in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation expense related to unvested inducement options granted under the 2020 Plan was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.28</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs were granted under the 2020 Plan to the Company's employees in order to maintain retention of key employees. The value of an RSU award is based on the Company's stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activity with respect to the Company's RSUs during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 was as follows (in millions, except share, contractual term, and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.39%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.062000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.602%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.042%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value (a)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">615,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,750</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.64</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">699,003</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.69</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested and expected to vest as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">699,003</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.69</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Grants</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company granted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,372</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of RSUs to employees under the 2020 Plan. The RSUs vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and have a weighted-average grant date fair value during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total unrecognized compensation expense for RSUs was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.4</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">January 2025 Option, Restricted Stock Unit Grants and Performance-Based Restricted Stock Units</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 22, 2025, the Company granted options to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,084,162</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common stock, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">347,360</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of restricted stock units and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">200,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Performance-based restricted stock units to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The shares of restricted stock will vest annually over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The performance-based restricted stock units were granted to the Company's named executive officers. The grants included two performance milestones. The fist milestone, which relates to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of each grant, will vest if the FDA accepts the filing of a biologic license application for accelerated approval of nomlabofusp by December 31, 2026. The second milestone, representing </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of each grant will vest if the FDA approves the Company nomlabofusp BLA within 12 months of the BLA acceptance (no later than December 31, 2027.) If the first milestone is not achieved by December 31, 2026, the full grant will be forfeited.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.527%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.777000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.838000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,053</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,077</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,538</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,796</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,615</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Intellectual Property Licenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is party to an exclusive License Agreement (the &#8220;WFUHS License&#8221;), dated November 30, 2016, as amended, with Wake Forest University Health Sciences (&#8220;WFUHS&#8221;) and an exclusive License Agreement (the &#8220;IU License&#8221;), dated November 30, 2016, as amended, with Indiana University (&#8220;IU&#8221;). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by the Company with respect to the development of nomlabofusp. Both agreements continue from their effective date through the last to date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In partial consideration for the right and license granted under these agreements, the Company will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, the Company is obligated to pay each of WFUHS and IU certain milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in the aggregate upon the achievement of certain developmental milestones, which commenced with the enrollment of the first patient in a Phase 1 clinical trial. The Company enrolled the first patient in its SAD trial on December 11, 2019 and paid WFUHS and IU less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Company will also pay each of WFUHS and IU sublicensing fees ranging from a high-single digit to a low double-digit percentage of sublicense consideration depending on the Company&#8217;s achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. The Company is also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that the Company disputes the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. The Company is also obligated to pay to IU a minimum annual royalty of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million per annum.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the event that the Company is required to pay IU consideration, then the Company may deduct </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that the Company is required to pay WFUHS consideration, then the Company may deduct </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2022, the Company initiated dosing of a Phase 2 study. Pursuant to the terms of both the WFUHS License and the IU License, the company recognized milestone expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million within research and development expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both agreements continue from their effective date through the last date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bala Cynwyd Office Space</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 8, 2019, the Company entered into an operating lease for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,642</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space in Bala Cynwyd, Pennsylvania, effective as of December 15, 2019, for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three years and six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with an option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_87fbb33e-f754-46a6-98ea-b08d228c7b45;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 15, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 9, 2023, the Company executed a lease extension agreement on its original </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,642</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square footage of office space in Bala Cynwyd, Pennsylvania (which was set to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d09b5249-139c-4022-bd74-7a580647cdf5;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">August 2023</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) and agreed to lease an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,462</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space from the same landlord.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The lease extension on the original </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,642</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square footage commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The new lease on </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,462</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional square footage commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of that date.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The right of use assets and lease liabilities with these leases are reflected in the financial statements for the year ended December 31, 2024 as are the right of use asset and lease liability of the Company's Boston office space and lab space discussed below.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Boston Office Lease</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the Company's 2020 merger with Zafgen described in footnote 1, on May 28, 2020, the Company acquired a non-cancellable operating lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,705</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space (the &#8220;Premises&#8221;). The lease expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 30, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As part of the agreement, the Company was initially required to maintain a letter of credit, of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. In October of 2024, upon the agreement with the landlord that we had achieved certain clinical development milestones required in the lease, this letter of credit was reduced to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. During both periods presented, this cash deposit and is classified as restricted cash within the consolidated financial statements. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#8217; right-of-use assets or lease liabilities. The right-of-use asset is being amortized to other income/(expense) over the remaining lease term as a result of the sublease described below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 27, 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Massachusetts Municipal Association, Inc. (the &#8220;Subtenant&#8221;), whereby the Company sublet the entire Premises to the Subtenant. The initial term of the Sublease commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 4, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and continues until </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 30, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In connection with the Sublease, the Company evaluated the need for impairment under ASC 360 "Impairment Testing: Long-Lived Assets Classified as Held and Used," and determined there was no impairment.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sublease provided for an initial annual base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which increases annually up to a maximum annual base rent of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Subtenant also is responsible for paying to the Company future increases in operating costs (commencing on January 1, 2022), future increases in annual tax costs (commencing July 1, 2021) and all utility costs (commencing March 1, 2021) attributable to the Premises during the term of the Sublease. As part of the Sublease, the subtenant deposited a letter of credit in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lab Space</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2019</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2020</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with an option to extend the lease for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f3be3bdd-793f-4d1a-9a7e-f230d03efd1b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2021</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In September 2023, the Company extended this lease for an additional year with the option to terminate with four months' notice. On March 28, 2024, the Company gave the requisite notice and vacated the property in May 2024.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 16, 2023, the Company entered into an operating lease for alternate lab space in King of Prussia, Pennsylvania for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">four years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property. The actual lease term commenced on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">May 10, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Upon commencement of the lease term, the Company recorded a right of use asset and lease liability of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which are reflected in these consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lease Expense</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expense arising from operating leases was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 and 2023, respectively. For operating leases, the weighted-average remaining lease term for leases at December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years, respectively. For operating leases, the weighted average discount rate for leases at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The Company has not entered into any financing leases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of lease liabilities due under these lease agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.1%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leases</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,543</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,473</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,267</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,189</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">959</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,431</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,314</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,117</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company&#8217;s business, operating results, financial condition or cash flows.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income Taxes</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the years ended December 31, 2024, and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company recorded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> income tax benefits for the net operating losses incurred in each year due to its uncertainty of realizing a benefit from those items.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The domestic and foreign components of loss before income taxes are as follows.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.987%;box-sizing:content-box;"></td>
        <td style="width:2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.596%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.797%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,604</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,604</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,949</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.193%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.023%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research and development tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nondeductible permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation forfeitures - DTA Write Off</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65%;box-sizing:content-box;"></td>
        <td style="width:2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.54%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D - acquired in merger with Zafgen</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,678</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,678</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D - Section 174 Costs post 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,616</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,411</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,879</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,490</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,177</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,195</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,022</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,319</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals &amp; reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets &amp; intangibles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,196</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,298</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,538</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,770</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in the valuation allowance for deferred tax assets during the year ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> related primarily to the increase in net operating loss carryforwards and tax credit carryforwards and a decrease other deferred tax assets associated with a reduction in the Company&#8217;s effective state rate. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes to the valuation allowance were as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of the beginning of the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,770</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increases recorded to income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,939</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,770</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had net operating loss carryforwards that expire for federal, foreign and state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">164.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The federal and state operating losses begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2030</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, while the foreign net loss carryforward can be carried forward indefinitely. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company had federal net operating loss carryforwards that were generated after December 31, 2017 of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">159.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that do not expire, however these </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">carryforwards are limited to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the taxable income in any one tax period.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company also had available tax credit carryforwards for federal and state income tax purposes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million which begin to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2039</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Utilization of the pre-Merger net operating loss carryforwards attributable to Zafgen, of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes occurred during the tax year associated with the Merger. In addition to the limitation of the pre-Merger NOL&#8217;s of Zafgen, the net capitalized R&amp;D deferred tax assets in the amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&amp;D is disposed within five years of the Merger, or May 28, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The ownership changes will limit the amount of pre-merger Zafgen carryforwards that can be utilized annually to offset future taxable income with an annual limitation of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> thousand per year. The Company has reduced their NOL and R&amp;D tax credit deferred tax assets associated with the pre-Merger Zafgen operations as a result of the 382 analysis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company believes that as a result of its merger with Zafgen, its ability to utilize NOLs acquired in the transaction and our other NOLs is expected to be severely limited by Section 382 of the Code. Additionally, the Company&#8217;s July 2021, September 2022 and February 2024 equity transactions could also limit its ability to utilize NOLs in the future. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company experienced a change of control, as defined by Section 382, at any time since inception, utilization of its net operating loss carryforwards or tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Additionally, our July 2021, September 2022 and February 2024 equity transactions could also limit our ability to utilize NOLs in the future. Any limitation may result in expiration of a portion of the net operating loss carryforwards or tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, no amounts are being presented as an uncertain tax position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Tax Cuts and Jobs Act ("TCJA") requires taxpayers to capitalize and amortize research and experimental expenditures under IRC Section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during the year ended December 31, 2022 and resulted in the capitalization of research and development costs </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in 2024, 2023 and 2022, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company is amortizing these costs for tax purposes over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if the research and development was performed in the U.S. and over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> if the research and development was performed outside the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s net deferred tax asset balance before the valuation allowance was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and was comprised principally of net operating loss carryforwards, capitalized research and development expenses and tax credit carryforwards. During the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023, gross deferred tax assets increased due to deferred tax assets acquired as a result of additional net operating loss carryforwards and research and development tax credits generated.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2024 and 2023. Management reevaluates the positive and negative evidence at each reporting period.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recorded any amounts for unrecognized tax benefits as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. The Company&#8217;s tax years are still open under statute from </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_3544ef17-f3b5-4927-ba28-69fcaa25789b;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2020</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to the present. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party</a></td>
<td class="text"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Related Party</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, the Company entered into an agreement with the Friedreich&#8217;s Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners. The consortium will conduct a natural history study designed to establish disease-specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials. As an industry partner, the Company will help fund the study and contribute to the study design, research activities, and analysis. The Company will have access to all study data for use in its regulatory filings, as appropriate. During the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of costs related to the Track-FA program and will fund future costs going forward. One of the Company&#8217;s Directors is also a director of FARA.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, during the twelve months ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company sponsored patient and caregiver awareness events held by FARA for a cumulative $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Presentation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with U. S. Generally Accepted Accounting Principles ("GAAP")</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_GoingConcernPolicyTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024, and 2023, respectively, and cash flow used in operations of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2024 and 2023, respectively. In addition, as of December 31, 2024, the Company had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">269.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2024, the Company had approximately </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">183.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2024, the Company sold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,736,842</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of its common stock in an underwritten public offering at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and received net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">161.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 205, "Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into the second quarter of 2026.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Significant Suppliers</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and Significant Suppliers</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#8217;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marketable securities</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Marketable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">income; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#8217; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value would be recorded in net income.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e67f9759-bc4c-4465-933e-6db26d968aa7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or</span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seven-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment of Long-Lived Assets</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Long-lived assets consist of property and equipment, net&#184; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Costs associated with internal research and development and external research and development services, including drug manufacturing and scale- up, other drug development and testing costs, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and to scale up the manufacturing process, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent Costs</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Costs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock-Based Compensation</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#8217;s stock options has been determined utilizing the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company is managed on a consolidated basis and has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> operating and reportable segment related to the development of clinical and preclinical product candidates for the development of the Company&#8217;s proprietary new therapies, primarily nomlabofusp, the Company's life science segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is the Company's </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d10ed809-200f-4b30-80d3-8c8fcced056e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">chief executive officer</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ("CEO").</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the Company and its reportable segment based on net loss, which is reported on the consolidated Statements of Operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. All long-lived assets are located in the U.S.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and regulatory approval.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The CODM uses consolidated financial information, including consolidated net loss, to evaluate performance, forecast future period financial results, allocate resources for the company by, among other things, comparing budgeted to actual results.</span></span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Technical operations</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,805</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,781</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,361</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,733</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nomlabofusp support</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,112</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,156</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,944</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,088</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,668</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90,890</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,758</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,286</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,809</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,604</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,949</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Gain (Loss)</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Comprehensive Gain (Loss)</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company&#8217;s only element of other comprehensive gain (loss) was unrealized gain (loss) on marketable securities.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Loss Per Share</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#8217;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Accordingly, the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">628,403</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company excluded </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,135,390</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,888,502</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options to purchase common stock, outstanding as of December 31, 2024 and 2023 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued and Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires disclosure of incremental segment information on an annual and interim basis. The amendments also require companies with a single reportable segment to provide all disclosures required by this amendment and all existing segment disclosures in ASC 280, Segment Reporting. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8e858e57-0756-416b-b74d-b48de20c666a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASU 2023-07</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, effective December 31, 2024, in these consolidated financial statements. ASU 2023-07 only impacted the disclosures and did not impact the consolidated financial statements. See Note 2, Segment Information, for disclosures related to the adoption of ASU 2023-07.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09, &#8220;Improvements to Income Tax Disclosures (Topic 740),&#8221; which requires entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes as well as additional information about reconciling items if certain quantitative thresholds are met. This ASU will require all entities to disclose income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. All entities are required to apply the guidance prospectively, with the option to apply it retrospectively. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it will adopt this ASU on January 1, 2025, the adoption of which is not expected to have a material impact on the Company&#8217;s consolidated results of operations or cash flows.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, &#8220;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#8221;, which requires disaggregated disclosures in the notes of the financial statements of certain categories of expenses that are included in expense line items on the face of the income statement. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company will evaluate the impact adopting ASU 2024-03 will have on the Company's consolidated financial statements and disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the assessment of the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478609/920-350-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary of Significant Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below summarizes the significant expense categories regularly reviewed by the CODM for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.993%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:1.62%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
          <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
          <td style="width:1%;box-sizing:content-box;"></td>
         </tr>
         <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
          <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Technical operations</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,805</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,781</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Development</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,361</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,733</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nomlabofusp support</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,112</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,156</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,944</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,088</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,668</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90,890</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,758</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
          <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other income, net</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,286</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,809</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
         <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,604</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
          <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,949</span></p></td>
          <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         </tr>
        </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Cash Equivalents and Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s cash equivalents and marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted<br/>Prices in<br/>Active<br/>Markets <br/>(Level 1)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs <br/>(Level 2)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs <br/>(Level 3)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds invested in government <br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,702</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,702</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,702</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,702</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,947</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,947</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,236</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,947</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,938</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,649</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash equivalents:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds invested in government <br/>&#160;&#160;&#160;securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,701</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,701</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,701</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,701</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,719</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,719</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,988</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,988</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,707</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total cash equivalents and marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,742</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,035</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,707</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Marketable Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following tables summarize the Company&#8217;s marketable securities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.22%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.184000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross<br/>Unrealized <br/>Losses</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,945</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,947</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,143</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147,289</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total marketable securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,088</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,236</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Treasury Bills</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,330</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,334</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. Government securities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,653</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,719</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Corporate bonds</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,977</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,988</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,960</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">81</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,041</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prepaid expenses and other current assets consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,780</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,994</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest receivable</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,054</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">332</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid insurance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">499</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">682</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other prepaid expenses and other assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total prepaid expenses and other assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,850</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,385</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Fixed Assets, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fixed assets, net consisted of the following:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.477%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:12.775%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.399%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:10.776%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">117</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5 years</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,707</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">555</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="-sec-ix-hidden:F_a5f65a1c-dbe3-418f-9eaf-369ca80d6c94;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">lease term</span></span></span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total property, plant and equipment</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,424</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,909</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Accumulated depreciation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,543</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,225</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Property, plant and equipment, net</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">881</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">684</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accrued expenses consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued research and development expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,057</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,594</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued payroll and related expenses</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,254</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,365</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued other</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">561</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">427</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;Total accrued expenses and other current liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,872</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,386</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity and Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions used to Determine Fair Value of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.62%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:15.02%;box-sizing:content-box;"></td>
        <td style="width:1.64%;box-sizing:content-box;"></td>
        <td style="width:14.08%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.12</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.72</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.22</span></span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.23</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.00</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes the Company&#8217;s stock option activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 (amounts in millions, except for share and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.39%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.062000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.602%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.042%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercise</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value (a)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Price</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,273,502</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.06</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.8</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,235,377</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.35</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,404</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited/Expired</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,088</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.08</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,436,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exercisable as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,094,992</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.45</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested and expected to vest as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,436,387</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.78</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(a)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Activity with respect to the Company's RSUs during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">twelve months ended December 31, 2024 was as follows (in millions, except share, contractual term, and per share data):</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.39%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.502%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:8.062000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.602%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:9.042%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Aggregate</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Remaining</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Intrinsic</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Grant Date</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Contractual</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Value (a)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Term (in years)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in millions)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2023</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">615,000</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">245,372</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153,750</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.94</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,619</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.64</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">699,003</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.69</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unvested and expected to vest as of December 31, 2024</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">699,003</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.69</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span></span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense was classified in the consolidated statements of operations as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.527%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.777000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:11.838000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,053</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,077</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,743</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,538</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,796</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,615</span></p></td>
        <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Lease Liabilities Due Under Lease Agreements</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maturities of lease liabilities due under these lease agreements as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 are as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.1%;box-sizing:content-box;"></td>
        <td style="width:1.94%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:15.96%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Year Ending December 31,</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(in thousands)</span></p></td>
        <td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Leases</span></p></td>
        <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,543</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,473</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,267</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,189</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">959</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,431</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,314</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Present value of lease liabilities</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,117</span></p></td>
        <td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Loss Before Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The domestic and foreign components of loss before income taxes are as follows.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.987%;box-sizing:content-box;"></td>
        <td style="width:2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.596%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.797%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,604</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,948</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,604</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,949</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.193%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.023%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.6%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:13.182%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal statutory income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in state tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research and development tax credit</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.5</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.2</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nondeductible permanent differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock compensation forfeitures - DTA Write Off</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in deferred tax asset valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.7</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29.6</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net deferred tax assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2024 and 2023 consisted of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65%;box-sizing:content-box;"></td>
        <td style="width:2%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:14.54%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.84%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D - acquired in merger with Zafgen</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,678</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,678</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized R&amp;D - Section 174 Costs post 2021</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,616</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,411</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock based compensation</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,879</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,490</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,177</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,195</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credit carryforwards</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,022</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,319</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other temporary differences</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals &amp; reserves</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Fixed assets &amp; intangibles</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease liability</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,196</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,298</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,736</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">142,538</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating right of use asset</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">768</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: Valuation allowance</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,770</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets / (liabilities)</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Changes in Valuation Allowance for Deferred Tax Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes to the valuation allowance were as follows:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.993%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:1.62%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
        <td style="width:12.883000000000001%;box-sizing:content-box;"></td>
        <td style="width:1%;box-sizing:content-box;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Years ended December 31,</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
        <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance as of the beginning of the year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,770</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130,831</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Increases recorded to income tax provision</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,258</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,939</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance at end of year</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">173,028</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
        <td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,770</span></p></td>
        <td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,604<span></span>
</td>
<td class="nump">$ 36,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flow used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,760<span></span>
</td>
<td class="nump">33,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(269,158)<span></span>
</td>
<td class="num">$ (188,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">19,736,842<span></span>
</td>
<td class="nump">19,736,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds net of issuance costs</a></td>
<td class="nump">$ 161,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lrmr_BuccalCellsMember', window );">Buccal Cells [Member] | Beginning of Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MeanLevelHVAtBaselinePercentage', window );">Percentage of increasing from mean level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lrmr_BuccalCellsMember', window );">Buccal Cells [Member] | End of Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MeanLevelHVAtBaselinePercentage', window );">Percentage of increasing from mean level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lrmr_SkinCellsMember', window );">Skin Cells [Member] | Beginning of Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MeanLevelHVAtBaselinePercentage', window );">Percentage of increasing from mean level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lrmr_SkinCellsMember', window );">Skin Cells [Member] | End of Study [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MeanLevelHVAtBaselinePercentage', window );">Percentage of increasing from mean level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_MeanLevelHVAtBaselinePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of HV at baseline, as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_MeanLevelHVAtBaselinePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lrmr_BuccalCellsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lrmr_BuccalCellsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lrmr_BeginningOfStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lrmr_BeginningOfStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lrmr_EndOfStudyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=lrmr_EndOfStudyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lrmr_SkinCellsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lrmr_SkinCellsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 11, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LikelihoodPercentageMinimum', window );">Percentage of likelihood to be realized upon ultimate settlement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,815,065<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,815,065<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">srt:ChiefExecutiveOfficerMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The CODM uses consolidated financial information, including consolidated net loss, to evaluate performance, forecast future period financial results, allocate resources for the company by, among other things, comparing budgeted to actual results.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate202307Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lrmr_FromExerciseOfWarrantsMember', window );">From Exercise of Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potentially dilutive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,135,390<span></span>
</td>
<td class="nump">4,888,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercises of warrants | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember', window );">Equipment, Furniture and Fixtures and Office Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember', window );">Equipment, Furniture and Fixtures and Office Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_LikelihoodPercentageMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum likelihood percentage threshold used to determine the amount of tax benefit to be recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_LikelihoodPercentageMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 80: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lrmr_FromExerciseOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lrmr_FromExerciseOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Significant Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 90,890<span></span>
</td>
<td class="nump">$ 41,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(10,286)<span></span>
</td>
<td class="num">(4,809)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">80,604<span></span>
</td>
<td class="nump">36,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lrmr_TechnicalOperationsExpenseMember', window );">Technical Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">44,805<span></span>
</td>
<td class="nump">6,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lrmr_DevelopmentExpenseMember', window );">Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">24,361<span></span>
</td>
<td class="nump">15,733<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lrmr_NomlabofuspSupportExpenseMember', window );">Nomlabofusp Support [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">4,112<span></span>
</td>
<td class="nump">5,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">15,944<span></span>
</td>
<td class="nump">$ 14,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=lrmr_CommercialExpenseMember', window );">Commercial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 1,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lrmr_TechnicalOperationsExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lrmr_TechnicalOperationsExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lrmr_DevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lrmr_DevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lrmr_NomlabofuspSupportExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lrmr_NomlabofuspSupportExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=lrmr_CommercialExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=lrmr_CommercialExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment losses on investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 26,702<span></span>
</td>
<td class="nump">$ 24,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">150,236<span></span>
</td>
<td class="nump">60,041<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">176,938<span></span>
</td>
<td class="nump">84,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">17,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">147,289<span></span>
</td>
<td class="nump">35,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">26,702<span></span>
</td>
<td class="nump">24,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">26,702<span></span>
</td>
<td class="nump">24,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">17,334<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">29,649<span></span>
</td>
<td class="nump">42,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, (Level 1) [Member] | U.S. Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">17,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets, (Level 1) [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">26,702<span></span>
</td>
<td class="nump">24,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">147,289<span></span>
</td>
<td class="nump">42,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">147,289<span></span>
</td>
<td class="nump">42,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member] | U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 147,289<span></span>
</td>
<td class="nump">35,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member] | Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 150,088<span></span>
</td>
<td class="nump">$ 59,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">150,236<span></span>
</td>
<td class="nump">60,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,945<span></span>
</td>
<td class="nump">17,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">2,947<span></span>
</td>
<td class="nump">17,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember', window );">U.S. Government Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">147,143<span></span>
</td>
<td class="nump">35,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 147,289<span></span>
</td>
<td class="nump">35,719<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lrmr_USGovernmentSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 9,780<span></span>
</td>
<td class="nump">$ 1,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">499<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_OtherPrepaidExpenseAndOtherCurrentAssets', window );">Other prepaid expenses and other assets</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other assets</a></td>
<td class="nump">$ 11,850<span></span>
</td>
<td class="nump">$ 3,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_OtherPrepaidExpenseAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_OtherPrepaidExpenseAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs related to research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets - Schedule of Fixed Assets, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 2,424<span></span>
</td>
<td class="nump">$ 1,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(1,543)<span></span>
</td>
<td class="num">(1,225)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 1,707<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 555<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">us-gaap:UsefulLifeTermOfLeaseMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DepreciationExpenseExcludingLeasedAssets', window );">Depreciation expense</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DepreciationExpensesRelatedToSubletAssets', window );">Depreciation expenses related to sublet assets</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DepreciationExpenseExcludingLeasedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DepreciationExpenseExcludingLeasedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DepreciationExpensesRelatedToSubletAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DepreciationExpensesRelatedToSubletAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 17,057<span></span>
</td>
<td class="nump">$ 4,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related expenses</a></td>
<td class="nump">3,254<span></span>
</td>
<td class="nump">2,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 20,872<span></span>
</td>
<td class="nump">$ 7,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 22, 2025</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>May 28, 2020</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,815,065<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,815,065<span></span>
</td>
<td class="nump">43,909,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividend paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,235,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options to purchase shares of stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,736,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,736,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=lrmr_InducementStockMember', window );">Inducement Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Share-based compensation arrangement by share-based payment award, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#8220;Plan Limit&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue', window );">Minimum level of maximum number of shares allowed to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock', window );">Percentage of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration', window );">Term of plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | From Prior Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">224,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Employees [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options to purchase shares of stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,756,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Common Stock [Member] | Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,235,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Common Stock [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,140,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Common Stock [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Common Stock [Member] | First Anniversary [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Employees [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Employees [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options to purchase shares of stock granted</a></td>
<td class="nump">347,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Executive Officer [Member] | Performance-Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Options to purchase shares of stock granted</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | First Milestone [Member] | Executive Officer [Member] | Performance-Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Second Milestone [Member] | Executive Officer [Member] | Performance-Based Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,552,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares that may be issued under stock option incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,179,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Common Stock [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options to purchase shares of common stock granted</a></td>
<td class="nump">2,084,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock option</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan [Member] | Subsequent Event [Member] | Common Stock [Member] | First Anniversary [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock option vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercises of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares that may be issued under stock option incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_WarrantsIssuedPricePerShare', window );">Warrants price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockAndWarrantIssuanceTransactionCosts', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts', window );">Proceeds from issuance common stock and warrants net offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,105,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">628,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercises of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | MTS Health Partners [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember', window );">ATM Offering Program [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember', window );">ATM Offering Program [Member] | Maximum [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AggregateGrossSalesProceedsUnderSalesAgreement', window );">Aggregate sale of shares of our common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwritten Public Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,736,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_AggregateGrossSalesProceedsUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_AggregateGrossSalesProceedsUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term of the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_StockAndWarrantIssuanceTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period related to the issuance of stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_StockAndWarrantIssuanceTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_WarrantsIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per unit amount of prefunded warrant issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_WarrantsIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478790/946-405-45-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=lrmr_InducementStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=lrmr_InducementStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lrmr_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lrmr_FromPriorPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lrmr_FromPriorPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lrmr_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lrmr_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lrmr_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lrmr_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lrmr_FirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lrmr_FirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lrmr_FirstMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lrmr_FirstMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lrmr_SecondMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lrmr_SecondMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=lrmr_MTSHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=lrmr_MTSHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lrmr_AtTheMarketEquityOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.12%<span></span>
</td>
<td class="nump">3.72%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 19 days<span></span>
</td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">4,273,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">2,235,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(15,404)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, Forfeited/Expired</a></td>
<td class="num">(57,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">6,436,387<span></span>
</td>
<td class="nump">4,273,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable as of December 31, 2024</a></td>
<td class="nump">3,094,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Vested and expected to vest as of December 31, 2024</a></td>
<td class="nump">6,436,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, balance</a></td>
<td class="nump">$ 9.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">5.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/Expired</a></td>
<td class="nump">10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, balance</a></td>
<td class="nump">7.78<span></span>
</td>
<td class="nump">$ 9.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable as of December 31, 2024</a></td>
<td class="nump">10.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Vested and expected to vest as of December 31, 2024</a></td>
<td class="nump">$ 7.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Exercisable as of December 31, 2024</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, Vested and expected to vest as of December 31, 2024</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding as of December 31, 2024</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable as of December 31, 2024</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest as of December 31, 2024</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details) - Restricted Stock Units (RSUs) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, Restricted stock units granted</a></td>
<td class="nump">245,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, Restricted stock units vested</a></td>
<td class="num">(153,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Restricted stock units forfeited</a></td>
<td class="num">(7,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding</a></td>
<td class="nump">699,003<span></span>
</td>
<td class="nump">615,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Unvested and expected to vest as of December 31, 2024</a></td>
<td class="nump">699,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, balance</a></td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Restricted stock units granted</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Restricted stock units vested</a></td>
<td class="nump">4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Restricted stock units forfeited</a></td>
<td class="nump">4.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, balance</a></td>
<td class="nump">4.69<span></span>
</td>
<td class="nump">$ 4.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Unvested and expected to vest as of December 31, 2024</a></td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term, Outstanding as of December 31, 2024</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual term, Unvested and expected to vest as of December 31, 2024</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Outstanding as of December 31, 2024</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue', window );">Aggregate intrinsic value, Unvested and expected to vest as of December 31, 2024</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,796<span></span>
</td>
<td class="nump">$ 7,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,053<span></span>
</td>
<td class="nump">3,077<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,743<span></span>
</td>
<td class="nump">$ 4,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 16, 2023</div></th>
<th class="th">
<div>Mar. 09, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Aug. 09, 2021</div></th>
<th class="th">
<div>Oct. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 04, 2020</div></th>
<th class="th">
<div>May 28, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 11, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th"><div>Nov. 05, 2018</div></th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,838<span></span>
</td>
<td class="nump">$ 3,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,057<span></span>
</td>
<td class="nump">$ 4,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | Office and Lab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | Additional Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania [Member] | Lab Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">May 10,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts [Member] | Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts [Member] | Office Sublease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LeaseTermCommencementDate', window );">Lease term commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  04,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease term expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 30,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts [Member] | Letter of Credit [Member] | Office [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts [Member] | First Sublease Year [Member] | Office Sublease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SubleaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts [Member] | First Sublease Year [Member] | Letter of Credit [Member] | Office Sublease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Lease security deposits letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts [Member] | Final Sublease Year [Member] | Office Sublease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_SubleaseAnnualBaseRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts [Member] | Sixth Sublease Year [Member] | Letter of Credit [Member] | Office Sublease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Lease security deposits letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesMember', window );">WFUHS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LicenseAgreementConsiderationDeductionPercentage', window );">License agreement consideration deduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesMember', window );">WFUHS [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MilestonePaymentAmount', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_IndianaUniversityResearchAndTechnologyCorporationMember', window );">IU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_LicenseAgreementConsiderationDeductionPercentage', window );">License agreement consideration deduction percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_IndianaUniversityResearchAndTechnologyCorporationMember', window );">IU [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MilestonePaymentAmount', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MinimumAnnualRoyaltyObligation', window );">Annual royalty pay obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember', window );">WFUHS and IU [Member] | Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_MilestoneExpenses', window );">Milestone expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember', window );">WFUHS and IU [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_PaymentForLicenseAgreements', window );">Payment for license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_LeaseTermCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease term commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_LeaseTermCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_LicenseAgreementConsiderationDeductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that may be deducted from consideration due to Licensor 2 as a percentage of consideration paid to Licensor 1, whereby Licensor 1 is the identified party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_LicenseAgreementConsiderationDeductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_MilestoneExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized during the period related to milestones. Such amount may include, but is not limited to, amounts due for attainment of milestones as well as deductions granted as part of a license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_MilestoneExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_MilestonePaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment due upon reaching milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_MilestonePaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_MinimumAnnualRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum annual royalty payment that is required under a contractual arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_MinimumAnnualRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_PaymentForLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_PaymentForLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_SubleaseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease annual base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_SubleaseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeAndLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeAndLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_AdditionalOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_AdditionalOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_LabSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_LabSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeSubleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=lrmr_OfficeSubleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lrmr_FirstSubleaseYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lrmr_FirstSubleaseYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lrmr_FinalSubleaseYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lrmr_FinalSubleaseYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=lrmr_SixthSubleaseYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=lrmr_SixthSubleaseYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_IndianaUniversityResearchAndTechnologyCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_IndianaUniversityResearchAndTechnologyCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">6,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,314)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 5,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Net capitalized R&amp;D deferred tax assets</a></td>
<td class="nump">66,678,000<span></span>
</td>
<td class="nump">66,678,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance', window );">Net deferred tax assets before the valuation allowance</a></td>
<td class="nump">173,000,000<span></span>
</td>
<td class="nump">141,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">2020 2021 2022 2023 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lrmr_ZafgenMember', window );">Zafgen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 33,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Net capitalized R&amp;D deferred tax assets</a></td>
<td class="nump">$ 66,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription', window );">Net capitalized R&amp;D deferred tax assets realization description</a></td>
<td class="text">is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&D is disposed within five years of the Merger, or May 28, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership', window );">Net operating loss carryforwards, change in ownership, annual utilization limit</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 198,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_NetOperatingLossCarryForwardExpirationYearBegin', window );">Net operating loss carryforwards, beginning of expiration period</a></td>
<td class="text">2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | No Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 159,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod', window );">Operating loss carryforwards, minimum percentage of taxable income in tax period</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Operating loss carryforwards, description</a></td>
<td class="text">carryforwards are limited to 80% of the taxable income in any one tax period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 164,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_NetOperatingLossCarryForwardExpirationYearBegin', window );">Net operating loss carryforwards, beginning of expiration period</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_DomesticAndStateLocalJurisdictionMember', window );">Federal and State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_TaxCreditCarryForwardExpirationYearStart', window );">Research and development tax credit carry forwards, beginning of expiration period</a></td>
<td class="text">2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member', window );">IRC Section 174 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_CapitalizedResearchAndDevelopment', window );">Capitalization of research and development costs</a></td>
<td class="nump">$ 69,200,000<span></span>
</td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member', window );">IRC Section 174 [Member] | Performed in US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod', window );">Capitalized research and development amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member', window );">IRC Section 174 [Member] | Performed outside US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod', window );">Capitalized research and development amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_CapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development costs capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_CapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period for capitalized research and development costs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of deferred tax liability but before allocation of valuation allowances, of deferred tax asset attributable to deductible differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation that a capitalized research and development deferred tax asset may be subject to.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_NetOperatingLossCarryForwardExpirationYearBegin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The first year in which a net operating loss carryforward begins to expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_NetOperatingLossCarryForwardExpirationYearBegin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The annual limitation amount of net operating loss carryforwards that can be utilized to offset taxable income due to changes in ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of limitation on operating loss carryforwards as a percentage of taxable income in any one tax period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_TaxCreditCarryForwardExpirationYearStart">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The first year in which a tax credit carryforward begins to expire.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_TaxCreditCarryForwardExpirationYearStart</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lrmr_ZafgenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lrmr_ZafgenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=lrmr_NoExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=lrmr_NoExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_DomesticAndStateLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=lrmr_DomesticAndStateLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=lrmr_Ircsection174Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=lrmr_PerformedInUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=lrmr_PerformedInUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=lrmr_PerformedOutsideUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=lrmr_PerformedOutsideUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (80,604)<span></span>
</td>
<td class="num">$ (36,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (80,604)<span></span>
</td>
<td class="num">$ (36,949)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate', window );">Change in state tax rate</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development tax credit</a></td>
<td class="nump">14.50%<span></span>
</td>
<td class="nump">8.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible permanent differences</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent', window );">Stock compensation forfeitures - DTA Write Off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in deferred tax asset valuation allowance</a></td>
<td class="num">(38.70%)<span></span>
</td>
<td class="num">(29.60%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to a change in the state tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax asset write-offs from stock compensation forfeitures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized R&amp;D - acquired in merger with Zafgen</a></td>
<td class="nump">$ 66,678<span></span>
</td>
<td class="nump">$ 66,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts', window );">Capitalized R&amp;D - Section 174 Costs post 2021</a></td>
<td class="nump">22,616<span></span>
</td>
<td class="nump">9,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">4,879<span></span>
</td>
<td class="nump">3,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">50,177<span></span>
</td>
<td class="nump">45,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">28,022<span></span>
</td>
<td class="nump">16,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals &amp; reserves</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets', window );">Fixed assets &amp; intangibles</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liability</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">173,736<span></span>
</td>
<td class="nump">142,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating right of use asset</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">$ (173,028)<span></span>
</td>
<td class="num">$ (141,770)<span></span>
</td>
<td class="num">$ (130,831)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible fixed assets and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lrmr_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance as of the beginning of the year</a></td>
<td class="nump">$ 141,770<span></span>
</td>
<td class="nump">$ 130,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increases recorded to income tax provision</a></td>
<td class="nump">31,258<span></span>
</td>
<td class="nump">10,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at end of year</a></td>
<td class="nump">$ 173,028<span></span>
</td>
<td class="nump">$ 141,770<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lrmr_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lrmr_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lrmr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party - Additional Information (Details) - Friedreich's Ataxia Research Alliances [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lrmr_FriedreichsAtaxiaResearchAlliancesMember', window );">Track-FA program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost related to FARA</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lrmr_FriedreichsAtaxiaResearchAlliancesMember', window );">Patient and Caregiver Awareness Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Cost related to FARA</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lrmr_FriedreichsAtaxiaResearchAlliancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lrmr_FriedreichsAtaxiaResearchAlliancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=lrmr_TrackFAProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=lrmr_TrackFAProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=lrmr_PatientAndCaregiverAwarenessEventsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=lrmr_PatientAndCaregiverAwarenessEventsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( '*&>%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( '*&>%J0N5:R\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( '*&>%I%56=.$ H  "(Z   8
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MD%A]D:S0K^@],2E9KC\F!!(W5SO [PL& [W^H@ZP>2WT^G]02P,$%     @
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MK$X854>+HMRD%T*;+;]L9N94!M(&F.=+(?13Q^[[S3DO_@M02P,$%     @
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MVQQ8!D(;X.\+SM7N07^@_U?#[#M02P,$%     @ <H9X6B*V#J<@!@  KB<
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M90<>"'<>"'W:9W_IXE-PZ3P<]<K8KC05YFDV3H,XT'%[VH?O$,/Q-)SNQ Z
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M7.DFM=M"CU$0)D"?;SA7>\,DZ =S^AM02P,$%     @ <H9X6BQU:+Y# @
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MPR"D&HE3X%YM0#01RYVYXS^5-\@..1=E,X0WO?16@R8$CYS*P<5Q7"Y03UM
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M!V5W4@-_BZAK>^P+HE'P0=Q&$N74<XQZ#FN/PH;2TGDR=1X9H?)FU362^Y!
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MBOOI0^MK^0LJ"]^VOI1?@0F0G0_@_LH#.^('3M#_29U7_P=02P,$%     @
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M;Y;1E- 9X4HC^:T3.02.V#\U*J7H1+YQ)HYDQI$/"QZR#C,U[ KOD/&XZ9;
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MDU#/8I0/VZ#8U'+"GG-RQ(1VZ"1-QUD+Y[R7$A)?!P5J:;F34&ULHB5EC^O
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M/CKDE&*^!:EA9O\^[56J4= 3W0"N9)C:A)C]6%-HSI-[[:9-I^$1A]9'W_*
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M2NMJ:M(^P0$IAL8C2L(ZO6W(J4#>)=HY=+]F#@TC)@9X-8B3\"L6IL\'"W:
MQTBE_G7LNO*[3KR"Z!(<_B)%%@2$Y"%/$YP&10?]:$^* _6.->W4MY*YPB<M
M_D&/P2<] 'Y/*_H !];^ZC@@X,EL<9G 0$0TUMC5+#/EXP26'SJ35P!)O%\G
M(</A1^!Q.RQ[\0,N%K,KN *3T726@[W]PL[#S4&!;*PL$[/(OE;;IPZ)XV6K
MI.UCZ(F5Q)@BS./X4*'EYEG!C=BSG%Q*K^]QNPPP#H1YHK>?$N>GQTTQ1-Q&
MCV;Z&U*?7I9,T)O3;O-81U@C8MF=SRLB+'-ICTS 9#3+_%C"_WZR!6#RXUG9
M]<Z/_8C:X^S'[[@[$C_QQS\BT?3R.WCQV_@K@C?RXWEIN/P$X4^Z6^,5]]JL
M:.IB_NS)F;QN&3Z0*/-/Z2W;OF^W_.?&: )J#*#GJY8$SW_ !O&W%5_\+U!+
M P04    " !RAGA:.][,WO<(  !^&@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6RU65MOV[@2?L^O(+S!GA90;$MV;"=- B3IWH!3H+O9R\/!>:"E
M<<2-)*HD%=?]]6=F*,GR)7:ZQ7FQ)8H<SGQS^RA=+;5YLBF $Y_SK+#7O=2Y
M\G(PL'$*N;1]74*!3Q;:Y-+AK7D<V-* 3'A1G@VBX7 RR*4J>C=7//;1W%SI
MRF6J@(]&V"K/I5G=0::7U[VPUPS\IAY31P.#FZM2/L(#N#_*CP;O!JV41.50
M6*4+86!QW;L-+^_&-)\G_*E@:3O7@BR9:_U$-[\DU[TA*009Q(XD2/Q[AGO(
M,A*$:GRJ9?;:+6EA][J1_B/;CK;,I85[G?VE$I=>]V8]D<!"5IG[32]_AMJ>
M<Y(7Z\SRKUCZN9-I3\25=3JO%Z,&N2K\O_Q<X]!9,!N^L""J%T2LM]^(M7PO
MG;RY,GHI#,U&:73!IO)J5$X5Y)0'9_"IPG7NYD>IC/A39A6(#R!M90 1=U;(
M(A'WTJ;BAT^5>I89#0X^2/,$3LXS$ \05T8Y!?9JX% /DC:(ZSWO_)[1"WN&
MD?B@"Y=:\4.10+(I8( &M%9$C15WT4&)[R'NBU$8B&@8C0_(&[6HC%C>Z#@J
M[Y6-,TW 6/&?V[EU!@/IO_N,]B+'^T52<EW:4L9PW</LL6">H7?S_7?A9/CN
M@,+C5N'Q(>G_)S<>W'._1:.^^'9=7A3Q>PKB7N>E+%;??S>+PND[%&LMU-(S
M)><J\R)<*IV0!D3N!20"[Q<D]YGE4D7 JH);&E4\4F8KDB7T0F T03X'TT84
M"]\>'6U*5U1A8FT26<2 2>Q25 &$=;A6FH0%WS[<BUDT# Y"U VX0"Q3%:<"
M+$&D,,UQ#LHU &<9/$/&QDBN;ZD"(TV<K@26ZEHOLJQC,XF'SX@>JK-0!6JJ
M9$8J.MY?))VMY1Q+>'=QWE&TSY[8MS>"2$4R(7RK$G\(!,R9 B/%0!&O" =5
ME!5:ZS0_78O!1[+P#A5H0^/.5>T7FMS10B2HM]>$$1&,B&6W8%W&:$UHX4)G
MV'GLY<F_&3".F_"=",4O+VB1@TMUHC/]N&)9GRKM4%1I5(RXO*D*F?R-A1F2
MMXRT2E 7%2.0=21V-*= 5$WKP;)-L6[[6YI$K])$%7%6)=O:D )6Y2J3YJ5$
MV-D_X"F-#YHTT7/*8$Y$$DJ*[#HB$("!C3F0*$P=EZWHJ2J:N\#K4\TIZAW&
M%DX@08LJRX0#DS=>7 >?*K"B5N3.;5A&KW905724)]NL>BS4 GV"05*OWA_(
M_;T599]V5L0:F8AUA#P"J3*.Y)CJ&6W)%[ N;$&--NMDV\H6<)&H2%XI5ZW"
M.&@JV/ ;UE'$\K6S S8REL:L*.=E[E=YN.U^P ^7.ZYP2T!XV? $J,@9X$I?
M8,6@@/+B$=@UNE8D"+$''<=LJHWSKL<Q)%&$P\K#[A.3U&64;$T,U1=@8[:]
MLHTP:[D7Y*-V79[\KAUB\:O/I8=.N'2N3]XH*E^ZLE0PWY[LR#NYWU+I\@1Y
M#:QJK3#LJ="JXAFH6E B/NIG, 47KU,138+I,.I>L*W1N_55K>>.Z?6*^J]9
MUBSZL ^4RY,_^@\(O.'H7XD[E6&MC(*+\;3^W1;#\W]::]P!.!Q/@VAVT2[9
MNJ_5WN^<\'P81*-)O>G^E5_AZU,13B?!Q6A&0%X$D_$%#=52UT#N=.]O==X8
MH0^[%Z]WGE]1_WV#\\)I,!J-F[^O<-_H/)B&:^]MWI[<:U-J@[U5S#5A@.C.
M9NWDC;N#CIX,@^$X;-0;1VCN]%O\/$/ QI0F*&HX.O<7)'.-/965ICJJ LL.
M.H]('BC?' QDDKQ9-X7M$N.][6OC4G)L]4,\=649'R!1MU,Q[(_6(T?J3( ;
MVA*X^U)WY+YKFU;.087UM)2*:1F>=,$CH+G'$C4EQS6TPG,IJL8Z4PG;,9<9
MTTT^_VTT,Q%GN XK&3$ 7)WOQC;MQ$'BFK":4U@UG),Z*Y?T9,WH:O)1BZDY
MR [!\.RWT)V6[2D3(1L0:K[3AXUI-%\5VWVZ)94'#>OZ#&6P09U,Y7[YR,2S
MVX7C-L9CG>=@N#66L@3CO11OYD @%%'354?YZ*N4[S;(MBEW52>T\0:I!?L5
M>9-\HM:(4:S;#NRQ;%%%47,GF><NC,8.FRJ3G"'/1L9,OJ'UQ(O(2UZ-[5%1
M.2007TB5!/V#(="<5[IT2R= 8>'#E@]+&*!TJW,XZZ3LF8\3699&RS@EG(D/
MUN&$%+#+RVK^N4D]C_)+!*-!J8,I&\> LLR&*F-J(?N@=#<R\<"3LG.CG\ ,
M$L":8WQ(M]EE90ZBPZF[,:.LK2@MD0@I+*?^'5@@YAA<*0&P,9GS>D6^'=3O
MB'!(_^W?177.2"E22FWX^( I+3OIW^&TWJZ^N-U?;SSYJPI4B)R)Q%!;?S20
MSQ+-0!%G>'=F9;89=$SO"EV<U3;5Y=&G0*= BD0C1(5V7%0+KI\6B-.GFP+Y
M-,%2J2@4.SJ5VBH"($!A&!A8;C"'$4'<&9N @:YDO94A<T ;:&9,V;U:DT\D
MN\;Q'K'&<L\G^::(Y7)%XM?$\P4(UY275*-@U4NJK![&&AXRH1XYVCV@5M5@
MG>^+]_XHSF?A)614*OT+,* 78(?5V? #=@I4CWN:QESZ0@<"/!OB4V6XWM4Z
M=AI=1ZWCYF]L]Z^O(MWU^8C"&O-LIQ#O-*! [.,T;5,Z7L.IHJ20<1O5E1$%
MY2[%'<["(LC%G5Z@)JOF&.4;$XN_D\63KXE'%14I%GTJ#&<)1E.F$(V$7TK$
M&!^VS957:>V5EL]M2"I?ET:3(>;_RK\\0*E]L?_%V#\X-_W3(])MFU8_&<I=
M_[M^<W7\>'3+#?+E@\>Y6)]=^#1P[,@1CD<BG$S$&Y0OWC8L_R )/>7SQG!&
MQX-P0K_UXM/F(++G:'!(<::S0['FVY[?'J';D_.10,4W&?<^ICW%(U&X2;9/
M3L7Y17"!$8(<>/.D45/L?2^0!YUO DAP'OG+!V4IYH'_/-".MA]7;OTWA?5T
M_V4&0_%18=/*8(%+A_WI>4\8_[7#WSA=\A<&Y 5.YWR98G,$0Q/P^4)CCZUO
M:(/VD]/-_P!02P,$%     @ <H9X6G79B7NM @  8@8  !D   !X;"]W;W)K
M<VAE971S+W-H965T,30N>&ULI57+CMHP%-WS%5=I5;42(D^&1P$)9EIU%J.B
MF3X651<FN1!K$CNU'9C^?:^=D%*)02-U0_PXY]QS<'PS.TCUJ'-$ T]E(?3<
MRXVIIKZOTQQ+I@>R0D$[6ZE*9FBJ=KZN%++,D<K"CX+@RB\9%]YBYM;6:C&3
MM2FXP+4"79<E4[]76,C#W N]X\(]W^7&+OB+6<5V^(#F:[56-/,[E8R7*#27
M A1NY]XRG*X2BW> ;QP/^F0,-LE&RD<[N<WF7F -88&IL0J,'GN\QJ*P0F3C
M5ZOI=24M\71\5/_HLE.6#=-X+8OO/#/YW!M[D.&6U86YEX=/V.896KU4%MK]
MPJ'!)HD'::V-+%LR.2BY:)[LJ?T?3@CCX!E"U!(BY[LIY%S>,,,6,R4/H"R:
MU.S 175L,L>%/90'HVB7$\\LU@HKQC/X\$3'K%$#$QE\-CDJN*Z50F%@J34:
M/?,-E;,D/VVE5XUT](QT&,&=%";7\$%DF/TKX)//SFQT-+N*+BK>8#J ..Q#
M%$3)!;VX"Q\[O?AEX4^R-YGAQW*CC:(WY^>Y^(UX<E[<WJ:IKEB*<X^NBT:U
M1V_QYE5X%;R_8#WIK">7U/_OW"Y*GS>>#.#%)3LDGB*E0Z8MDC7(5-+UU@9I
M>PL$@*TLJ$]PL9OVZ+2QW!#'GOCII&>/W[X#<>\M%T23M:8*^EWO6-C:9BK-
M7>$,]]1[JM*6[1R]ADE_- [H&?8GDZ1W*PP2RQ U1;YGFP)I)Q@F$,=1I\N%
MKA43*4(RF<#5..HU^:OG [=!A^$(XM&H]T4:5KP 3[["_GAH#<;]>#R$<^^,
M?W+O2U0[U]WLGUH+T[2 ;K5KH,NF;_R%-]WWCJD=I8,"MT0-!J.A!ZKI:,W$
MR,IUD8TTU)/<,*>/ "H+H/VME.8XL06ZS\KB#U!+ P04    " !RAGA:^"E5
MV3P#   O!P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R556UKVS 0
M_NY?<7ACK&#BE]A-FB6!M%M9H8.RUP]C'Q3['(O)EB?)3?KO=Y(3-X4V8Y#(
MTNGNT7-WNM-\*]5O72$:V-6BT0N_,J:=A:'.*ZR9'LD6&]HII:J9H:7:A+I5
MR IG5(LPB:+SL&:\\9=S)[M3R[GLC. -WBG075TS]7")0FX7?NP?!)_YIC)6
M$"[G+=O@%S3?VCM%JW! *7B-C>:R 87EPE_%L\O4ZCN%[QRW^F@.UI.UE+_M
MXJ98^)$EA )S8Q$8?>[Q"H6P0$3CSQ[3'XZTAL?S _JU\YU\63.-5U+\X(6I
M%O[4AP)+U@GS66X_XMZ?S.+E4F@WPK;7C4DY[[21]=Z8&-2\Z;]LMX_#D<$T
M>L$@V1LDCG=_D&/YGAFVG"NY!66U"<U.G*O.FLCQQB;EBU&TR\G.+*_Y#@M8
M:8U&ST-#B%8>YGOKR]XZ><$Z3N"3;$REX4-38/$4("0J Y_DP.<R.8GX'O,1
MC., DBA)3^"-!__&#F_\ E[O&?Q<K;51= 5^/>=D#Y$^#V'+8J9;EN/"IWNO
M4=VCOWSS*CZ/WIT@F X$TU/H_TS :>ML!,< ^P5SBP :*NI<4@%I0U)9@JD0
M2BFH$GFSF7D4;*S7J%S CQ?>-XUE)^"6E^@R88>Q]Y8W!"$[S9I"GWE7LFX[
M0Q;XI^,M5:J!#!Z0*0VO(8XG_>C=LO4S&G$PB28TQA>)=]VIAIM.(1 PE'QG
MYQHF>]4LR^S?NT4JOTJ* GC=*GF/%E"#L&(@'C6D&?V\K](P :31HC(/ ;2"
MT<$6^I%&$J3D51Q<1!>$J_4,5GG>U9U@-E0%4J9SSESC>$MJ63J&,S=+D@S.
MO+M3X'W@7\-T&M-X/DTIMD=XN*..2HRWS,8I&HVIKH5P+8I0K"09)-1U7=+Z
M0* MLB>)ZI-C[6R" FJ3ND77Z,3#"&X(LBBX/37X3R@(K+)Z9!D/G.@>/8F/
MPCYH1E)K7PMRO;]_M)%+5;C["-*B'5P?/5<WX5$3JU%M7*O6='^[QO3];) .
MK\&J;X*/ZOU3\HFI#6_LS2C)-!I-,A]4WY[[A9&M:XEK::C!NFE%+QHJJT#[
MI93FL+ '#&_D\B]02P,$%     @ <H9X6K#JZC2= @  X 4  !D   !X;"]W
M;W)K<VAE971S+W-H965T,38N>&ULC53;;MLP#'W/5PC>,&Q $%]S69882-H.
MVT.!H-WE8=B#;-.Q4%GR)#EI_WZ4G+A9D09[B4F*Y^A0#+G82_6@*P!#'FLN
M]-*KC&GFOJ_S"FJJ1[(!@2>E5#4UZ*JMKQL%M'"@FOM1$$S\FC+AI0L7VZAT
M(5O#F8"-(KJM:ZJ>UL#E?NF%WC%PQ[:5L0$_731T"_=@OC<;A9[?LQ2L!J&9
M%$1!N?16X7R=V'R7\(/!7I_8Q%:22?E@G:_%T@NL(."0&\M \;.#*^#<$J&,
M/P=.K[_2 D_M(_MG5SO6DE$-5Y+_9(6IEM[,(P64M.7F3NZ_P*&>L>7+)=?N
ME^R[W#CV2-YJ(^L#&!743'1?^GAXAQ/ +'@%$!T D=/=7>147E-#TX62>Z)L
M-K)9PY7JT"B."=N4>Z/PE"'.I*L\5RT4Y.81VZQ!+WR#K/;,SP\,ZXXA>H4A
MC,BM%*;2Y$844/Q+X*.<7E-TU+2.+C)>0SXB<3@D41 E%_CBOL;8\<6O\&WH
M$\TX:$)%05S!E&OR:Y5IH_!?\?M<S1UC<I[13LI<-S2'I8>CH$'MP$O?O0DG
MP:<+>I->;W*)_;]Z<I'AO+[)B+QD[@-P#.02YTT;#,F2F I(*3D.+A/;^0#[
M G4&RO7FU!G81MENQ8/W3"!,MAK?6G\8'/FM"*KRRK6@@!TN@P9'VSQ?_):$
MTV$PGJ*1#,<?DQ[:T">%&AQ2 :?F5&X\C,9X\S">C'N 1-F*C"<A2:+IX)LT
M%,$OZ[1L76+>*F65<$8SQIEA3DP4#&?3"(WI,)Y-R+FN^B=35X/:NMUB7[ 5
MIAO /MJOKU4WM<_IW>Z[I6K+A"8<2H0&H^G8(ZK;)YUC9.-F.),&-X(S*US!
MH&P"GI=2FJ-C+^B7>OH74$L#!!0    ( '*&>%K<PU,VDA   )DS   9
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M8J]/_1]YNN4O7\S3/$\W_.M:22 2#<#[99KF_@]:H/PVSJM_ U!+ P04
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M$/*D9WXI,_6R!U?QRMVIWL7WWPQ/CY[O$&%<BS#>1?W+;;:;W/E [%;*NR+
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M5ZBR'"W >QK!55_H@/IWC!?_!5!+ P04    " !RAGA:^GNS6DH-  !K)0
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MF!$Y=PJ#]%""VT O9Q!V^[[-$\WLL =*<,?A#Z('79S.&"&^XJ-?*3"(TJ7
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M<F5.LY 9\J\W@V>M ,I,55Z,9G')[(<,2,BP^ LLFA6DX*6BAW"P2=FGY#L
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M F_&]OCH@.."^, LQ-I;9NS?_W9]-GOQG?M2[J(\P8,@3R@A<Y*T;EUT(!3
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M7-<'W!SC+X<^%UX A$5$P1BUW>+2Z7>FJ*:?BQ+@=H51$*$8S\84P<$R +,
M.'.&32.))DP"L7&>HK[&(%_$PZ-9E+U(=I <:K1[A[W6'PVX&N8MFI4ZD3(
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M=8(OHS;[ =,7Y01A+0 '8+XZ9XN(ZE%"\*K$8W@&'VULZW7L(" '25ZUA1(
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M="F)80J@:)I)4MT^+&*M6=:$ZB1S]ZA$F83QX+DQ!=DRL>1VR35HFGK1(CE
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M%:WB802FL$<%^"G$<B8/AIEA*RC>G[W%C97]I-8&(/4?&$Z0)?4OTUO8F,R
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M!E7K29A@1-<@]3O<I"B[Y.L7BZH% 6%$CM^4F&2-N@,61=O2\8,4+0A9F(=
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M"$%E'OD0&1N(DJH.]81@S@N= ?$+MMWXNA"8/33E65>XCT[0:M7PH6!\1O+
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M99^;!X7$-$_@XVY*(0&X-'&O!6A4E _%QSX)G!!U$_D()RYY%O KNRWZJGJ
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MCPHZ-_T*K?\L+I+ .D:&2,S%'A%Z'<RA#-;>%:)\?R$*O"]<Y *#,#[B>NL
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MW9H*/&IG0.N54O9EX#;8?3*6?P%02P,$%     @ <H9X6JF!ZF6J @  X04
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MZH86,/=P)C2H+7C9IP_#4?CEC-ZDUYN<8\\>< 3+E@.1:_*V4:>TGF4[K?5
M"X?^%Q('3AL\PJ2F K*6'">7B<UT@/V .@?E>G+L#&R#;)?BP043").MQC?6
MEX,#OTU(55&YIR]AB]N@P=DVKXD_DN'8#],Q&HF??DYZ:$-?%&IP2 6<FF.Y
ML1^EF-F/1VD/D"A;D70T)$DT'CQ*0Q'\MD[+U@46K5)6"6<T9YP9YL1$H3\9
M1VB,_7@R(J>Z&1R-70UJXY:+?<%6F&X"^]-^?RVZL7T-[Y;?'54;)C3AL$9H
M>#5./:*ZA=(Y1C9NB'-I<"4XL\(=#,H&X/U:2G-P;()^JV?_ %!+ P04
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M-#LCUL-(=E5ZO\5=E:ZI6_R--:(*O)=YR8M-PQOZT<+7?$MK@#N'E39KR%:
MU;0\ ,0#B-8$\AFHKI/9 <]EA6 B9.0BRZB&+H/[!$IC3>DE5V#)J83V"T'
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M20"_9T+H_0L9:&^)L_\ 4$L#!!0    ( '*&>%J5(>]ANP0  +$7   9
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;+U:VV[;.!#]%<);+%K
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MX9:\I2;/' JM:D&K:+XMM#JOE7)T)Z\6"JV*2:MHOBVT.LN5]'3-^NP;5Y!
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M=V_E[:;LU3)E[#--!8C)1$WS3R)5?'SYMM;R0+)9_L+3D$G)DOSCE. QX=D
M]?V$J>U4<9"]0U6^,]?_'U!+ P04    " !RAGA:MO!EJ#0$  "%%   &0
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;+58VV[;.!#]%4);+%K
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MD"8 ]Y="Z-W$M-#^QLS^ 5!+ P04    " !RAGA:>A_SF#H8  !M;0$ &0
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MRB3V>'H881L.7!G@_HPQ^311!U2-O?\/4$L#!!0    ( '.&>%KX?19J>A4
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MW(/99+[];_:]>B)V!IC](P.ZU8#N_H"K(P-ZU8#>_H#!D0']:D!_;T"W>V3
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M-H#[*\[5TXG>Y^@VPN;_ U!+ P04    " !SAGA:LOA(,><"  !Y!P  &0
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MM?PIJFDR3IC;FN>_C)4_C?9<+4MKE)HF:5=Q+ZR7Y;OB98"\XRO7EGB^NN4
M,DW.QM#@6EKGVS/:]CDP/@DXN3MJO+F2R@L[YU[\:4VSDWH3FH&[&*';:.-P
M^.R">&[_3QC->BU+,3=E4POMNSA:H0*@=ENY<PG3O!;3Y' *X[IB7[6'(+%K
MW34%YX8[A4M?5]U=>\!%,;3G$BKL==6"QX.<P;%1LH*K5^R2*ZY+P=K@.@28
M$8#98(#L9,$19$Y YD>$7 :(\ /'S)K=[(1%D 4!60P&.=MR_#Q.",C)<)#<
M;1'D&0%Y%AEROQ+6B;*Q84S?2O?(OG/--RWK[PQ!?B @/\2%7/ ]>W)L(6S[
M\S!LYM*5RKC&"H3XD4#\&!?Q6CM9"<ON+*\@2[,+:[GNHHBSSR>"\--Q"1?P
M;)92N#:G+_# 3L=4$A_'Q9P+5UJY"^5AI%PV3FKA.LI+CF.9DJZ)+)ME4]?<
M[@/B4FZTA)]Q\.-%69H&_(@Q*>.DD95SQ:5E]UPU@GT7/ R7+@>%:,[ZT:2<
MDT:6SL**'9<PM7B!1MR_S^2-W\+C.FML[]FDK)-&ULZ5?(%4?N%<?TJ14I))
M(UL&GCC;B-?082[**VEDL2R]*1^W1D'*<0_LZ]]-\$OHUK8"BR6ES))&5LO,
MU+7T:%# U!ZRH] A-6)(RBUI=+F4IA;LCK_TF2B;I)%U<AL*X;E;<.OW>'Y-
MR2.++ \R*S]D&).21S:D/!YRC$DN5X:41S^:E#RR(>71QZ3DD1U1'NP$%OE*
MN-\P'&61[,@6^24@I9-L2)WT.YG223:D3M@)QJ2$DAU1*+_L:LHL662SD"N
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( '*&>%J0N5:R\@   "L"   1
M          "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( '*&
M>%J97)PC$ 8  )PG   3              "  >0!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ <H9X6D559TX0"@  (CH  !@
M ("!)0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( '*&
M>%K^T]PDI@4  )$7   8              " @6L2  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !RAGA:()DW;.4"  #S"0  &
M        @(%'&   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ <H9X6B](TP%-!   =A   !@              ("!8AL  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( '*&>%HBM@ZG( 8  *XG   8
M              " @>4?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !RAGA:-_LG/V4&  "S&P  &               @($[)@  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ <H9X6@./?I8""@
M93$  !@              ("!UBP  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( '*&>%IT^Q_I3@(  *0%   8              " @0XW
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !RAGA:+'5H
MOD,"  "*!@  &               @(&2.0  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ <H9X6CRE,S@1 @  W00  !D
M ("!"SP  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !R
MAGA:;U\Y$EX:  !>1P  &0              @(%3/@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( '*&>%KG<TDZEQL  &=1   9
M          " @>A8  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#
M%     @ <H9X6CO>S-[W"   ?AH  !D              ("!MG0  'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !RAGA:==F)>ZT"  !B
M!@  &0              @('D?0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;%!+ 0(4 Q0    ( '*&>%KX*579/ ,  "\'   9              " @<B
M  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ <H9X6K#J
MZC2= @  X 4  !D              ("!.X0  'AL+W=O<FMS:&5E=',O<VAE
M970Q-BYX;6Q02P$"% ,4    " !RAGA:W,-3-I(0  "9,P  &0
M    @($/AP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M '*&>%H.8?"F] T  -,H   9              " @=B7  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ <H9X6OI[LUI*#0  :R4  !D
M             ("! Z8  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !RAGA:Q.@MJR\$  #W"   &0              @(&$LP  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( '*&>%I<*G?8$"0
M .ER   9              " @>JW  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ <H9X6JA-C\@M P  G08  !D              ("!
M,=P  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !RAGA:
MPC276 ,$   <#   &0              @(&5WP  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( '*&>%HPCR2MN0(  $H&   9
M      " @<_C  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ <H9X6D9<$8OH @  /@8  !D              ("!O^8  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !RAGA:J8'J9:H"  #A!0
M&0              @('>Z0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( '*&>%I,HLST_P4  $(/   9              " @;_L  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ <H9X6NOST'?J
M @  5@8  !D              ("!]?(  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !RAGA:Q<@9(Z<%   Q#@  &0
M@($6]@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '*&
M>%J5(>]ANP0  +$7   9              " @?3[  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ <H9X6OWG6Y3H!@  /R<  !D
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M=#,U+GAM;%!+ 0(4 Q0    ( '*&>%I.N98_Q0(  ! (   9
M  " @8,9 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M<H9X6E/#&DS8 P  'Q   !D              ("!?QP! 'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !RAGA:9NL8'7P"  !B!@  &0
M            @(&.( $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( '*&>%H[H+^\K0(  #T'   9              " @4$C 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ <H9X6GH?\Y@Z&
M;6T! !D              ("!)28! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !RAGA:^95H/^H"   A"   &0              @(&6
M/@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( '*&>%I&
M[ZT/R@0   H8   9              " @;=! 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ <H9X6MU MI0Y!   S!,  !D
M     ("!N$8! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '.&>%I",6+$L0(  $,'   9              "
M@5]O 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ <X9X
M6H4XJK63 P  ;@L  !D              ("!1W(! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " !SAGA:TD-M,6H$   4$P  &0
M        @($1=@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( '.&>%JR^$@QYP(  'D'   9              " @;)Z 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ <X9X6B$62^BW @  C@<
M !D              ("!T'T! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " !SAGA:$K$@4$4#  #*%   #0              @ &^@ $
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( '.&>%J7BKL<P    !,"   +
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4!08     /  \ %L0  ":C0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>162</ContextCount>
  <ElementCount>332</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995457 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995467 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995477 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995487 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995497 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995507 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995517 - Disclosure - Stockholders??? Equity and Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions</Role>
      <ShortName>Stockholders??? Equity and Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995527 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995537 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995547 - Disclosure - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedParty1</Role>
      <ShortName>Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995557 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995567 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995577 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995587 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995597 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995607 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Stockholders??? Equity and Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables</Role>
      <ShortName>Stockholders??? Equity and Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Description of Business and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995667 - Disclosure - Summary of Significant Accounting Policies - Summary of Significant Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Significant Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995677 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995687 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995697 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail</Role>
      <ShortName>Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995707 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995717 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail</Role>
      <ShortName>Fixed Assets - Schedule of Fixed Assets, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995727 - Disclosure - Fixed Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail</Role>
      <ShortName>Fixed Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995737 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995747 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail</Role>
      <ShortName>Stockholders Equity and Stock Options - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995757 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail</Role>
      <ShortName>Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995767 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995777 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995787 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail</Role>
      <ShortName>Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995797 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995807 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995817 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995827 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995837 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995847 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995857 - Disclosure - Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lrmr-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995867 - Disclosure - Related Party - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails</Role>
      <ShortName>Related Party - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lrmr-20241231.htm">lrmr-20241231.htm</File>
    <File>lrmr-20241231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img132800289_0.jpg</File>
    <File>img132800289_1.jpg</File>
    <File>img132800289_10.jpg</File>
    <File>img132800289_11.jpg</File>
    <File>img132800289_12.jpg</File>
    <File>img132800289_13.jpg</File>
    <File>img132800289_14.jpg</File>
    <File>img132800289_2.jpg</File>
    <File>img132800289_3.jpg</File>
    <File>img132800289_4.jpg</File>
    <File>img132800289_5.jpg</File>
    <File>img132800289_6.jpg</File>
    <File>img132800289_7.jpg</File>
    <File>img132800289_8.jpg</File>
    <File>img132800289_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="539">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>86
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lrmr-20241231.htm": {
   "nsprefix": "lrmr",
   "nsuri": "http://www.larimartx.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "lrmr-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "lrmr-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 284,
   "keyCustom": 48,
   "axisStandard": 28,
   "axisCustom": 0,
   "memberStandard": 32,
   "memberCustom": 41,
   "hidden": {
    "total": 16,
    "http://fasb.org/us-gaap/2024": 13,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 162,
   "entityCount": 1,
   "segmentCount": 74,
   "elementCount": 629,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 539,
    "http://xbrl.sec.gov/dei/2024": 41,
    "http://xbrl.sec.gov/cyd/2024": 13,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "100060 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_e567f291-5928-46ca-9886-4b12d459c211",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e567f291-5928-46ca-9886-4b12d459c211",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "100080 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_791bdce5-955d-4624-ac03-8deed77c6490",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_791bdce5-955d-4624-ac03-8deed77c6490",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation",
     "longName": "995457 - Disclosure - Description of Business and Basis of Presentation",
     "shortName": "Description of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995467 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1",
     "longName": "995477 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "995487 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssets",
     "longName": "995497 - Disclosure - Fixed Assets",
     "shortName": "Fixed Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "longName": "995507 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions",
     "longName": "995517 - Disclosure - Stockholders\u2019 Equity and Stock Options",
     "shortName": "Stockholders\u2019 Equity and Stock Options",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "longName": "995527 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "longName": "995537 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedParty1",
     "longName": "995547 - Disclosure - Related Party",
     "shortName": "Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995557 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995567 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables",
     "longName": "995577 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "995587 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsTables",
     "longName": "995597 - Disclosure - Fixed Assets (Tables)",
     "shortName": "Fixed Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "longName": "995607 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables",
     "longName": "995617 - Disclosure - Stockholders\u2019 Equity and Stock Options (Tables)",
     "shortName": "Stockholders\u2019 Equity and Stock Options (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "995627 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "longName": "995637 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
     "longName": "995647 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail)",
     "shortName": "Description of Business and Basis of Presentation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "lrmr:GoingConcernPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995657 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "lrmr:LikelihoodPercentageMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "lrmr:LikelihoodPercentageMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail",
     "longName": "995667 - Disclosure - Summary of Significant Accounting Policies - Summary of Significant Expense (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Summary of Significant Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ab791d56-0959-4081-945b-058f0d6c6f82",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail",
     "longName": "995677 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:InterestReceivable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
     "longName": "995687 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Cash Equivalents and Marketable Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail",
     "longName": "995697 - Disclosure - Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)",
     "shortName": "Fair Value Measurements and Cash Equivalents/Marketable Securities - Summary of Marketable Securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
     "longName": "995707 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "lrmr:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "lrmr:PrepaidResearchAndDevelopmentExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
     "longName": "995717 - Disclosure - Fixed Assets - Schedule of Fixed Assets, Net (Detail)",
     "shortName": "Fixed Assets - Schedule of Fixed Assets, Net (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail",
     "longName": "995727 - Disclosure - Fixed Assets - Additional Information (Detail)",
     "shortName": "Fixed Assets - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "lrmr:DepreciationExpenseExcludingLeasedAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "lrmr:DepreciationExpenseExcludingLeasedAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
     "longName": "995737 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "lrmr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "lrmr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
     "longName": "995747 - Disclosure - Stockholders Equity and Stock Options - Additional Information (Detail)",
     "shortName": "Stockholders Equity and Stock Options - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail",
     "longName": "995757 - Disclosure - Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)",
     "shortName": "Stockholders Equity and Stock Options - Assumptions used to Determine Fair Value of Stock Options Granted (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail",
     "longName": "995767 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)",
     "shortName": "Stockholders Equity and Stock Options - Summary of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
     "longName": "995777 - Disclosure - Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)",
     "shortName": "Stockholders Equity and Stock Options - Summary of Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_b144c1ed-8a46-4360-ac5f-f8187e2445a1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail",
     "longName": "995787 - Disclosure - Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)",
     "shortName": "Stockholders Equity and Stock Options - Summary of Stock-Based Compensation Expense (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "longName": "995797 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail",
     "longName": "995807 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)",
     "shortName": "Commitments and Contingencies - Schedule of Maturities of Lease Liabilities Due Under Lease Agreements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
     "longName": "995817 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail",
     "longName": "995827 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)",
     "shortName": "Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail",
     "longName": "995837 - Disclosure - Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)",
     "shortName": "Income Taxes - Reconciliation of Federal Statutory Income Tax Rate (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail",
     "longName": "995847 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets (Detail)",
     "shortName": "Income Taxes - Schedule of Net Deferred Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e624cc91-edd0-44c1-b110-f5bd07d78925",
      "name": "lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail",
     "longName": "995857 - Disclosure - Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)",
     "shortName": "Income Taxes - Summary of Changes in the Valuation Allowance for Deferred Tax Assets (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0315db95-9995-4825-83b1-6bd13c7f5edd",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
     "longName": "995867 - Disclosure - Related Party - Additional Information (Details)",
     "shortName": "Related Party - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_30f69550-77db-454a-9913-83a4c6b940ff",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_30f69550-77db-454a-9913-83a4c6b940ff",
      "name": "us-gaap:OperatingCostsAndExpenses",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lrmr-20241231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r150",
      "r151",
      "r152",
      "r192",
      "r193",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r256",
      "r257",
      "r260",
      "r381",
      "r382",
      "r383",
      "r384",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r417",
      "r418",
      "r419",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r459",
      "r460",
      "r469",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r944"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type",
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r62"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r774"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion of discount on marketable securities",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "lrmr_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for expenses related to research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r119",
      "r578"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive gain",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r63",
      "r122",
      "r573",
      "r607",
      "r611"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss) [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r14",
      "r421",
      "r424",
      "r484",
      "r602",
      "r603",
      "r931",
      "r932",
      "r933",
      "r941",
      "r942",
      "r943",
      "r946"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "lrmr_AdditionalOfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "AdditionalOfficeMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Office [Member]",
        "documentation": "Additional office.",
        "label": "Additional Office [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r941",
      "r942",
      "r943",
      "r946",
      "r1011",
      "r1072"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r308"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_AggregateGrossSalesProceedsUnderSalesAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "AggregateGrossSalesProceedsUnderSalesAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate sale of shares of our common stock",
        "documentation": "The potential aggregate gross sales proceeds available under a sales agreement to sell shares of the Company's common stock.",
        "label": "Aggregate Gross Sales Proceeds Under Sales Agreement",
        "verboseLabel": "Aggregate sale of shares of our common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r834",
      "r844",
      "r877"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r826",
      "r837",
      "r847",
      "r880"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r848",
      "r872",
      "r881",
      "r885",
      "r893"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r345"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag",
        "terseLabel": "Amendment",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Net accretion of discount on marketable securities",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r68",
      "r278",
      "r1021"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total potentially dilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "lrmr_AreaOfOfficeSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "AreaOfOfficeSpace",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office space.",
        "label": "Area Of Office Space",
        "terseLabel": "Area of office space"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses on investment",
        "label": "Asset Impairment Charges",
        "totalLabel": "Asset Impairment Charges, Total",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r28"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r94",
      "r121",
      "r143",
      "r174",
      "r177",
      "r186",
      "r187",
      "r227",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r410",
      "r414",
      "r461",
      "r568",
      "r654",
      "r737",
      "r738",
      "r774",
      "r801",
      "r972",
      "r973",
      "r1027"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r123",
      "r143",
      "r227",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r410",
      "r414",
      "r461",
      "r774",
      "r972",
      "r973",
      "r1027"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash equivalents and marketable securities",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Cash equivalents and marketable debt securities",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r763"
     ]
    },
    "lrmr_AtTheMarketEquityOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "AtTheMarketEquityOfferingProgramMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market equity offering program.",
        "label": "At The Market Equity Offering Program [Member]",
        "terseLabel": "ATM Offering Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r830"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r830"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r830"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]",
        "terseLabel": "Auditor Opinion"
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r245",
      "r567"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "terseLabel": "Marketable securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r245",
      "r440",
      "r562",
      "r763",
      "r766",
      "r954",
      "r1015",
      "r1016",
      "r1017"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total",
        "label": "Debt Securities, Available-for-Sale, Current",
        "verboseLabel": "Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r245"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r886"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_BeginningOfStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "BeginningOfStudyMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beginning of Study [Member]",
        "documentation": "Beginning of study."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_BuccalCellsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "BuccalCellsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Buccal Cells [Member]",
        "documentation": "Buccal cells.",
        "terseLabel": "Buccal Cells [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r400",
      "r754",
      "r755"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r400",
      "r754",
      "r755"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Presentation",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r73",
      "r74"
     ]
    },
    "lrmr_CapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "CapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Research and Development",
        "documentation": "The amount of research and development costs capitalized during the period.",
        "terseLabel": "Capitalization of research and development costs"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_CapitalizedResearchAndDevelopmentAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "CapitalizedResearchAndDevelopmentAmortizationPeriod",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period for capitalized research and development costs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Research and Development Amortization Period",
        "terseLabel": "Capitalized research and development amortization period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r117",
      "r726"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1013",
      "r1014"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "lrmr_CashAndNonCashOperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "CashAndNonCashOperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of lease expense, both cash and non-cash, related to operating leases.",
        "label": "Cash and Non Cash Operating Lease Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r70",
      "r140"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r70"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r113",
      "r149",
      "r192",
      "r228",
      "r229",
      "r230",
      "r236",
      "r237",
      "r256",
      "r260",
      "r382",
      "r391",
      "r392",
      "r401",
      "r402",
      "r404",
      "r417",
      "r418",
      "r428",
      "r429",
      "r459",
      "r460",
      "r469",
      "r479",
      "r480",
      "r529",
      "r530",
      "r600",
      "r601"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r113",
      "r192",
      "r228",
      "r229",
      "r230",
      "r236",
      "r237",
      "r238",
      "r256",
      "r260",
      "r382",
      "r391",
      "r392",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r416",
      "r417",
      "r418",
      "r419",
      "r428",
      "r429",
      "r430",
      "r433",
      "r459",
      "r460",
      "r469",
      "r479",
      "r480",
      "r529",
      "r530",
      "r600",
      "r601",
      "r918"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r162",
      "r233"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant exercise price",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant issued",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Issuance of warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "lrmr_CommercialExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "CommercialExpenseMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial [Member]",
        "label": "Commercial Expense [Member]",
        "documentation": "Commercial Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (See Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r89",
      "r570",
      "r641"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r262",
      "r263",
      "r711",
      "r964",
      "r969"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r792",
      "r794",
      "r795",
      "r796",
      "r797",
      "r941",
      "r942",
      "r946",
      "r1011",
      "r1070",
      "r1072"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share",
        "verboseLabel": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r642"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55",
      "r642",
      "r660",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 115,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 63,815,065 and 43,909,069 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r572",
      "r774"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Voting Rights",
        "terseLabel": "Common stock voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r126",
      "r128",
      "r133",
      "r563",
      "r585",
      "r586"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Gain (Loss)",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Significant Suppliers",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r99"
     ]
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate Bonds [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r904"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r904"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r906"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r906"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r908"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r906"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r899"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r900"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r900"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r898"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r898"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r898"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r901"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r903"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r903"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r904"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r907"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r905"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r902"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total",
        "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance",
        "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r245",
      "r249",
      "r250"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Total deferred tax liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r87",
      "r372"
     ]
    },
    "lrmr_DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D - Section 174 Costs post 2021",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research and Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_DeferredTaxAssetsFixedAssetsAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible fixed assets and intangible assets.",
        "label": "Deferred Tax Assets Fixed Assets And Intangible Assets",
        "terseLabel": "Fixed assets &amp; intangibles"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "verboseLabel": "Net capitalized R&amp;D deferred tax assets",
        "terseLabel": "Capitalized R&amp;D - acquired in merger with Zafgen",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets / (liabilities)",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "lrmr_DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of deferred tax liability but before allocation of valuation allowances, of deferred tax asset attributable to deductible differences and carryforwards.",
        "label": "Deferred Tax Assets Net Of Liabilities Before Valuation Allowance",
        "terseLabel": "Net deferred tax assets before the valuation allowance"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other temporary differences",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Tax Credit Carryforwards, Total",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Accruals &amp; reserves",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "periodStartLabel": "Valuation allowance as of the beginning of the year",
        "negatedLabel": "Less: Valuation allowance",
        "periodEndLabel": "Valuation allowance at end of year",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r374"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfNetDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating right of use asset",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r29"
     ]
    },
    "lrmr_DepreciationExpenseExcludingLeasedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "DepreciationExpenseExcludingLeasedAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of depreciation expenses recognized in the period, excluding depreciation for leased assets as part of a sublease agreement.",
        "label": "Depreciation Expense Excluding Leased Assets",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_DepreciationExpensesRelatedToSubletAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "DepreciationExpensesRelatedToSubletAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expenses related to sublet assets",
        "label": "Depreciation Expenses Related to Sublet Assets",
        "documentation": "The amount of depreciation expense recognized in the period related to leased assets as part of a sublease agreement."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_DevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "DevelopmentExpenseMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Expense [Member]",
        "documentation": "Development expense.",
        "terseLabel": "Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1071"
     ]
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends Payable",
        "terseLabel": "Dividend paid",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r88",
      "r798",
      "r1038"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r830"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "terseLabel": "Document Financial Statement Error Correction",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r830",
      "r873"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "lrmr_DomesticAndStateLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "DomesticAndStateLocalJurisdictionMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and State [Member]",
        "label": "Domestic And State Local Jurisdiction [Member]",
        "documentation": "Domestic and state local jurisdiction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Domestic Tax Authority [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r164",
      "r166",
      "r168",
      "r169",
      "r170",
      "r173",
      "r398",
      "r408",
      "r437",
      "r438",
      "r564",
      "r587",
      "r730"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r166",
      "r168",
      "r169",
      "r170",
      "r173",
      "r398",
      "r408",
      "r437",
      "r438",
      "r564",
      "r587",
      "r730"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r172"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r760"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r357",
      "r385",
      "r760"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in deferred tax asset valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r760",
      "r940",
      "r1004"
     ]
    },
    "lrmr_EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Change in State Tax Rate",
        "terseLabel": "Change in state tax rate",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to a change in the state tax rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Nondeductible permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r940",
      "r1004"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r760",
      "r940",
      "r1004"
     ]
    },
    "lrmr_EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation forfeitures - DTA Write Off",
        "label": "Effective Income Tax Rate Reconciliation, Stock Compensation Forfeitures, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax asset write-offs from stock compensation forfeitures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfFederalStatutoryIncomeTaxRateDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state research and development tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Federal and state research and development tax credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r940",
      "r1004",
      "r1005"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognized period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Options to Purchase Common Stock [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_EmployeesAndDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "EmployeesAndDirectorsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and directors.",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_EndOfStudyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "EndOfStudyMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "End of Study [Member]",
        "documentation": "End of study."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r913"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "lrmr_EquipmentFurnitureAndFixturesAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "EquipmentFurnitureAndFixturesAndOfficeEquipmentMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment, furniture and fixtures and office equipment.",
        "label": "Equipment Furniture And Fixtures And Office Equipment [Member]",
        "terseLabel": "Equipment, Furniture and Fixtures and Office Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r110",
      "r130",
      "r131",
      "r132",
      "r146",
      "r147",
      "r148",
      "r151",
      "r157",
      "r159",
      "r161",
      "r175",
      "r232",
      "r239",
      "r257",
      "r295",
      "r380",
      "r381",
      "r394",
      "r395",
      "r396",
      "r399",
      "r407",
      "r408",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r436",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r484",
      "r583",
      "r602",
      "r603",
      "r604",
      "r622",
      "r684"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r823",
      "r834",
      "r844",
      "r877"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r831",
      "r841",
      "r874"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r451",
      "r763"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r451",
      "r763"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash Equivalents and Marketable Securities",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r450",
      "r451",
      "r453",
      "r495",
      "r496",
      "r497",
      "r746",
      "r747",
      "r751",
      "r752",
      "r753",
      "r763",
      "r766"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecurities1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements and Cash Equivalents/Marketable Securities",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r448",
      "r449",
      "r450",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r561",
      "r763",
      "r767"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets, (Level 1) [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r297",
      "r302",
      "r441",
      "r451",
      "r495",
      "r751",
      "r752",
      "r753",
      "r763"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r297",
      "r302",
      "r441",
      "r442",
      "r451",
      "r496",
      "r746",
      "r747",
      "r751",
      "r752",
      "r753",
      "r763"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r441",
      "r442",
      "r443",
      "r444",
      "r451",
      "r497",
      "r746",
      "r747",
      "r751",
      "r752",
      "r753",
      "r763",
      "r766"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r439",
      "r441",
      "r442",
      "r443",
      "r444",
      "r450",
      "r451",
      "r453",
      "r495",
      "r496",
      "r497",
      "r746",
      "r747",
      "r751",
      "r752",
      "r753",
      "r763",
      "r766"
     ]
    },
    "lrmr_FinalSubleaseYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "FinalSubleaseYearMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final sublease year",
        "label": "Final Sublease Year [Member]",
        "terseLabel": "Final Sublease Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r247",
      "r248",
      "r279",
      "r292",
      "r426",
      "r458",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r584",
      "r744",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r775",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r956",
      "r957",
      "r958",
      "r959",
      "r1012",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019"
     ]
    },
    "lrmr_FirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "FirstAnniversaryMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First anniversary.",
        "label": "First Anniversary [Member]",
        "terseLabel": "First Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_FirstMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "FirstMilestoneMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First milestone [Member]",
        "documentation": "First milestone [Member]",
        "terseLabel": "First Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_FirstSubleaseYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "FirstSubleaseYearMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sublease year member.",
        "label": "First Sublease Year [Member]",
        "terseLabel": "First Sublease Year [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "terseLabel": "Foreign Tax Authority [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r358"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r848",
      "r881"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r848",
      "r881"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r848",
      "r881"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r848",
      "r881"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r848",
      "r881"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "lrmr_FriedreichsAtaxiaResearchAlliancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "FriedreichsAtaxiaResearchAlliancesMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Friedreich's Ataxia Research Alliances [Member]",
        "documentation": "Friedreich's Ataxia Research Alliances."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_FromExerciseOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "FromExerciseOfWarrantsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "From exercise of warrants.",
        "label": "From Exercise of Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_FromPriorPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "FromPriorPlansMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "From Prior Plans [Member]",
        "label": "From Prior Plans [Member]",
        "terseLabel": "From Prior Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on disposal of fixed asset",
        "label": "Gain (Loss) on Disposition of Assets",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r936"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r664"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "lrmr_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liquidity and Capital Resources",
        "documentation": "Disclosure of accounting policy for the assessment of the ability to continue as a going concern.",
        "label": "Going Concern Policy [Text Block]",
        "terseLabel": "Going Concern Assessment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r830"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r78"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r356"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r91",
      "r93",
      "r565",
      "r580",
      "r732",
      "r737",
      "r947",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfLossBeforeIncomeTaxesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r356"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "terseLabel": "Income Statement Location",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r261",
      "r445",
      "r447",
      "r452",
      "r597",
      "r599",
      "r669",
      "r723",
      "r765",
      "r1041"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r261",
      "r445",
      "r447",
      "r452",
      "r597",
      "r599",
      "r669",
      "r723",
      "r765",
      "r1041"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "terseLabel": "Income Tax Authority",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r357",
      "r358",
      "r367",
      "r377",
      "r760",
      "r1009"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r357",
      "r358",
      "r367",
      "r377",
      "r760",
      "r1009"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r351",
      "r357",
      "r364",
      "r365",
      "r366",
      "r369",
      "r376",
      "r386",
      "r388",
      "r389",
      "r390",
      "r617",
      "r760"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r107",
      "r160",
      "r161",
      "r174",
      "r178",
      "r187",
      "r355",
      "r357",
      "r387",
      "r588",
      "r760"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r353",
      "r354",
      "r369",
      "r370",
      "r375",
      "r379",
      "r614"
     ]
    },
    "lrmr_IncomeTaxesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "IncomeTaxesDisclosureLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Disclosure [Line Items]",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_IncomeTaxesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "IncomeTaxesDisclosureTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes Disclosure [Table]",
        "label": "Income Taxes Disclosure [Table]",
        "terseLabel": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r935"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "lrmr_IndianaUniversityResearchAndTechnologyCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "IndianaUniversityResearchAndTechnologyCorporationMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IU [Member]",
        "label": "Indiana University Research And Technology Corporation [Member]",
        "documentation": "Indiana University Research and Technology Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r848",
      "r872",
      "r881",
      "r885",
      "r893"
     ]
    },
    "lrmr_InducementStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "InducementStockMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Stock.",
        "label": "Inducement Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r897"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r897"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r897"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r528",
      "r728",
      "r962"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest receivable",
        "label": "Interest Receivable",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1074"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest receivable",
        "label": "Interest Receivable, Current",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r626",
      "r627",
      "r629",
      "r631",
      "r692",
      "r694",
      "r696",
      "r699",
      "r700",
      "r701",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r792"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r624",
      "r626",
      "r627",
      "r629",
      "r631",
      "r692",
      "r694",
      "r696",
      "r699",
      "r700",
      "r701",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r792"
     ]
    },
    "lrmr_Ircsection174Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "Ircsection174Member",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IRC Section 174 [Member]",
        "documentation": "IRCSection174.",
        "label": "IRCSection174 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_LabSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "LabSpaceMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lab space.",
        "label": "Lab Space [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r919"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r919"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "terseLabel": "Lease term expiration date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_LeaseTermCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "LeaseTermCommencementDate",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease term commencement date.",
        "label": "Lease Term Commencement Date",
        "terseLabel": "Lease term commencement date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r477"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity Type of Counterparty [Domain]",
        "documentation": "Nature of the other party participating in a financial transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Lease Liabilities Due Under Lease Agreements",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension period",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r53",
      "r143",
      "r227",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r411",
      "r414",
      "r415",
      "r461",
      "r640",
      "r731",
      "r801",
      "r972",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r90",
      "r575",
      "r774",
      "r938",
      "r960",
      "r1020"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r116",
      "r143",
      "r227",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r411",
      "r414",
      "r415",
      "r461",
      "r774",
      "r972",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_LicenseAgreementConsiderationDeductionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "LicenseAgreementConsiderationDeductionPercentage",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that may be deducted from consideration due to Licensor 2 as a percentage of consideration paid to Licensor 1, whereby Licensor 1 is the identified party.",
        "label": "License Agreement Consideration Deduction Percentage",
        "terseLabel": "License agreement consideration deduction percentage"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_LikelihoodPercentageMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "LikelihoodPercentageMinimum",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum likelihood percentage threshold used to determine the amount of tax benefit to be recognized.",
        "label": "Likelihood Percentage Minimum",
        "terseLabel": "Percentage of likelihood to be realized upon ultimate settlement, description"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "MA",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MTSHealthPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "MTSHealthPartnersMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MTS Health Partners.",
        "label": "M T S Health Partners [Member]",
        "terseLabel": "MTS Health Partners [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r304",
      "r346",
      "r444",
      "r523",
      "r596",
      "r598",
      "r612",
      "r632",
      "r633",
      "r693",
      "r695",
      "r697",
      "r698",
      "r702",
      "r721",
      "r722",
      "r743",
      "r748",
      "r756",
      "r766",
      "r767",
      "r771",
      "r772",
      "r785",
      "r974",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034"
     ]
    },
    "lrmr_MeanLevelHVAtBaselinePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "MeanLevelHVAtBaselinePercentage",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mean Level HV at Baseline Percentage",
        "documentation": "The amount of HV at baseline, as a percentage.",
        "terseLabel": "Percentage of increasing from mean level"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "lrmr_MilestoneExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "MilestoneExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized during the period related to milestones. Such amount may include, but is not limited to, amounts due for attainment of milestones as well as deductions granted as part of a license agreement.",
        "label": "Milestone Expenses",
        "terseLabel": "Milestone expenses"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MilestoneLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "MilestoneLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment due for milestones that have been achieved",
        "label": "Milestone Liability",
        "terseLabel": "Milestone payments due"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MilestonePaymentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "MilestonePaymentAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment due upon reaching milestone.",
        "label": "Milestone Payment Amount",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_MinimumAnnualRoyaltyObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "MinimumAnnualRoyaltyObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum annual royalty payment that is required under a contractual arrangement.",
        "label": "Minimum Annual Royalty Obligation",
        "terseLabel": "Annual royalty pay obligation"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r304",
      "r346",
      "r444",
      "r523",
      "r596",
      "r598",
      "r612",
      "r632",
      "r633",
      "r693",
      "r695",
      "r697",
      "r698",
      "r702",
      "r721",
      "r722",
      "r743",
      "r748",
      "r756",
      "r766",
      "r767",
      "r771",
      "r785",
      "r974",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate, Type of Property [Axis]"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Real Estate [Domain]"
       }
      }
     },
     "auth_ref": [
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_NatureOfExpenseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfExpenseAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Expense [Axis]",
        "documentation": "Information by type of cost or expense."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "lrmr_NetCapitalizedRDDeferredTaxAssetsRealizationDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "NetCapitalizedRDDeferredTaxAssetsRealizationDescription",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the limitation that a capitalized research and development deferred tax asset may be subject to.",
        "label": "Net Capitalized R D Deferred Tax Assets Realization Description",
        "terseLabel": "Net capitalized R&amp;D deferred tax assets realization description"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities:",
        "terseLabel": "Cash flow used in operations",
        "negatedLabel": "Cash flow used in operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "negatedLabel": "Net loss",
        "verboseLabel": "Net loss",
        "negatedTotalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r72",
      "r92",
      "r114",
      "r124",
      "r127",
      "r132",
      "r143",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r167",
      "r227",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r398",
      "r408",
      "r438",
      "r461",
      "r582",
      "r662",
      "r682",
      "r683",
      "r799",
      "r972"
     ]
    },
    "lrmr_NetOperatingLossCarryForwardExpirationYearBegin": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "NetOperatingLossCarryForwardExpirationYearBegin",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first year in which a net operating loss carryforward begins to expire.",
        "label": "Net Operating Loss Carry Forward Expiration Year Begin",
        "terseLabel": "Net operating loss carryforwards, beginning of expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards, change in ownership, annual utilization limit",
        "label": "Net Operating Loss Carryforwards Annual Utilization Limit Change In Ownership",
        "documentation": "The annual limitation amount of net operating loss carryforwards that can be utilized to offset taxable income due to changes in ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued and Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_NoExpirationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "NoExpirationMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No expiration.",
        "label": "No Expiration [Member]",
        "terseLabel": "No Expiration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_NomlabofuspSupportExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "NomlabofuspSupportExpenseMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nomlabofusp Support Expense [Member]",
        "documentation": "Nomlabofusp support expense.",
        "terseLabel": "Nomlabofusp Support [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r827",
      "r838",
      "r848",
      "r872",
      "r881"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Nonoperating Income (Expense), Total",
        "label": "Nonoperating Income (Expense)",
        "verboseLabel": "Other income, net",
        "negatedLabel": "Other income, net",
        "terseLabel": "Other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r738",
      "r948"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segment",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r733",
      "r741",
      "r948"
     ]
    },
    "lrmr_OfferingCostsIncludedInAccountsPayableAndAccruedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "OfferingCostsIncludedInAccountsPayableAndAccruedExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Costs Included In Accounts Payable And Accrued Expense",
        "documentation": "The amount of offering costs that were incurred, but not yet paid, during the period.",
        "terseLabel": "Offering costs included in accounts payable and accrued expense"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_OfficeAndLabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "OfficeAndLabMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and Lab [Member]",
        "label": "Office And Lab [Member]",
        "documentation": "Office and Lab."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_OfficeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "OfficeMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office.",
        "label": "Office [Member]",
        "terseLabel": "Office [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_OfficeSubleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "OfficeSubleaseMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Sublease [Member]",
        "label": "Office Sublease [Member]",
        "documentation": "Office Sublease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OpenTaxYear": {
     "xbrltype": "gYearListItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OpenTaxYear",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Open Tax Year",
        "terseLabel": "Open tax year",
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format."
       }
      }
     },
     "auth_ref": [
      "r367"
     ]
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses",
        "totalLabel": "Operating Costs and Expenses, Total",
        "terseLabel": "Cost related to FARA",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "terseLabel": "Operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r732",
      "r947",
      "r949",
      "r950",
      "r951",
      "r952"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Lease expenses",
        "verboseLabel": "Lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfLeaseLiabilitiesDueUnderLeaseAgreementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Lease, Liability, Total",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r773"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term in years",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r773"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Operating loss carryforwards, description",
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of limitation on operating loss carryforwards as a percentage of taxable income in any one tax period.",
        "label": "Operating Loss Carryforwards Minimum Percentage Of Taxable Income In Tax Period",
        "terseLabel": "Operating loss carryforwards, minimum percentage of taxable income in tax period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent, Total",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Unrealized gain on marketable debt securities",
        "terseLabel": "Unrealized gain on marketable securities",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r8",
      "r85"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive gain",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r8",
      "r85",
      "r125",
      "r128",
      "r157"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "lrmr_OtherPrepaidExpenseAndOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "OtherPrepaidExpenseAndOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, not separately disclosed.",
        "label": "Other Prepaid Expense And Other Current Assets",
        "terseLabel": "Other prepaid expenses and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r825",
      "r836",
      "r846",
      "r879"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r839",
      "r849",
      "r882"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r828",
      "r839",
      "r849",
      "r882"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwritten Public Offering [Member]",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_PA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2024",
     "localname": "PA",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_PatientAndCaregiverAwarenessEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "PatientAndCaregiverAwarenessEventsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patient and Caregiver Awareness Events [Member]",
        "documentation": "Patient and caregiver awareness events.",
        "terseLabel": "Patient and Caregiver Awareness Events [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_PaymentForLicenseAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "PaymentForLicenseAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for license agreements",
        "label": "Payment For License Agreements",
        "documentation": "Payment for license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r135",
      "r195"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_PerformedInUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "PerformedInUsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performed in US.",
        "label": "Performed in US [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_PerformedOutsideUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "PerformedOutsideUsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performed outside US.",
        "label": "Performed outside US [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share",
        "verboseLabel": "Undesignated preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r281"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Undesignated preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r642"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Undesignated preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r281"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Undesignated preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r642",
      "r660",
      "r1072",
      "r1073"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock; $0.001 par value per share; 5,000,000 shares authorized as of December 31, 2024 and December 31, 2023; no shares issued and outstanding as of December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r571",
      "r774"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total prepaid expenses and other assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "lrmr_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r745",
      "r961"
     ]
    },
    "lrmr_PrepaidResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "PrepaidResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs related to research and development.",
        "label": "Prepaid Research And Development Expenses",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options included in other current assets",
        "documentation": "Proceeds from exercise of stock options included in other current assets.",
        "label": "Proceeds From Exercise Of Stock Options Included In Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "documentation": "Proceeds from issuance of common stock and prefunded warrants to purchase common stock, net of offering costs.",
        "label": "Proceeds From Issuance Common Stock And Warrants Net Offering Costs",
        "verboseLabel": "Proceeds from issuance common stock and warrants net offering costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Gross proceeds",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities and sales of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r955"
     ]
    },
    "lrmr_ProceedsFromStockOptionsAndWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ProceedsFromStockOptionsAndWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options and warrants",
        "label": "Proceeds From Stock Options And Warrant Exercises",
        "documentation": "The cash inflow from the exercise of options under share-based payment arrangements and from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Cash proceeds from exercises of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r527",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r724",
      "r749",
      "r784",
      "r785",
      "r786",
      "r788",
      "r789",
      "r970",
      "r971",
      "r975",
      "r1040",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r527",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r724",
      "r749",
      "r784",
      "r785",
      "r786",
      "r788",
      "r789",
      "r970",
      "r971",
      "r975",
      "r1040",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r124",
      "r127",
      "r137",
      "r143",
      "r150",
      "r157",
      "r160",
      "r161",
      "r227",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r398",
      "r408",
      "r409",
      "r412",
      "r413",
      "r438",
      "r461",
      "r565",
      "r581",
      "r621",
      "r662",
      "r682",
      "r683",
      "r761",
      "r762",
      "r800",
      "r933",
      "r972"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r477"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r100",
      "r103",
      "r104"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property, plant and equipment",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Gross, Total",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r118",
      "r579"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, plant and equipment, net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r477",
      "r566",
      "r579",
      "r774"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r100",
      "r103",
      "r577"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Fixed Assets, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r477"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Fixed assets, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r296",
      "r304",
      "r335",
      "r336",
      "r337",
      "r346",
      "r444",
      "r498",
      "r507",
      "r523",
      "r596",
      "r598",
      "r612",
      "r632",
      "r633",
      "r693",
      "r695",
      "r697",
      "r698",
      "r702",
      "r721",
      "r722",
      "r743",
      "r748",
      "r756",
      "r766",
      "r767",
      "r771",
      "r772",
      "r785",
      "r792",
      "r968",
      "r974",
      "r1016",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r296",
      "r304",
      "r335",
      "r336",
      "r337",
      "r346",
      "r444",
      "r498",
      "r507",
      "r523",
      "r596",
      "r598",
      "r612",
      "r632",
      "r633",
      "r693",
      "r695",
      "r697",
      "r698",
      "r702",
      "r721",
      "r722",
      "r743",
      "r748",
      "r756",
      "r766",
      "r767",
      "r771",
      "r772",
      "r785",
      "r792",
      "r968",
      "r974",
      "r1016",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r820",
      "r831",
      "r841",
      "r874"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r303",
      "r488",
      "r489",
      "r569",
      "r576",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r659",
      "r661",
      "r691"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r489",
      "r1026"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r665",
      "r666",
      "r669"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r303",
      "r488",
      "r489",
      "r569",
      "r576",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r659",
      "r661",
      "r691",
      "r1026"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedParty1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r489",
      "r490",
      "r618",
      "r619",
      "r620",
      "r667",
      "r668",
      "r669",
      "r688",
      "r690"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r1003"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r1003"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r723",
      "r737",
      "r1035"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development Expenses [Member]",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r821",
      "r832",
      "r842",
      "r875"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r822",
      "r833",
      "r843",
      "r876"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r829",
      "r840",
      "r850",
      "r883"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "terseLabel": "Letter of credit",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r937",
      "r1036",
      "r1039"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r928",
      "r937"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units, shares",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "Vesting of restricted stock units",
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r81",
      "r574",
      "r606",
      "r611",
      "r616",
      "r643",
      "r774"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r146",
      "r147",
      "r148",
      "r151",
      "r157",
      "r159",
      "r161",
      "r232",
      "r239",
      "r257",
      "r380",
      "r381",
      "r394",
      "r395",
      "r396",
      "r399",
      "r407",
      "r408",
      "r420",
      "r422",
      "r423",
      "r425",
      "r436",
      "r469",
      "r470",
      "r602",
      "r604",
      "r622",
      "r1072"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r773"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds net of issuance costs",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r163",
      "r305",
      "r916",
      "r945"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Marketable Securities",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Net Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r760",
      "r1004"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Domestic and Foreign Components of Loss Before Income Taxes",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "lrmr_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r665",
      "r666",
      "r669"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Expense",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions used to Determine Fair Value of Stock Options Granted",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Stock Units",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_SecondMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "SecondMilestoneMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second milestone [Member]",
        "documentation": "Second milestone [Member]",
        "terseLabel": "Second Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_SecurityDepositLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDepositLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease security deposits letters of credit",
        "label": "Security Deposit Liability",
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r625",
      "r628",
      "r630",
      "r694",
      "r696",
      "r700",
      "r703",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r725",
      "r750",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r787",
      "r792",
      "r975",
      "r1040",
      "r1042",
      "r1043",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r736",
      "r742"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r735",
      "r740"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r188",
      "r190",
      "r734",
      "r735",
      "r739"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares that may be added annually to the threshold number of shares issued under the Plan, as a percentage of the shares issued and outstanding on the last day of the immediately preceding fiscal year.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional Shares Percentage Of Outstanding Stock",
        "verboseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period of stock option",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Duration",
        "terseLabel": "Term of plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Number of shares, Restricted stock units forfeited",
        "negatedLabel": "Number of shares, Restricted stock units forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Restricted stock units forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase shares of stock granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Number of shares, Restricted stock units granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value, Restricted stock units granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Number of shares, Outstanding",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted average grant date fair value, balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted average grant date fair value, balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual term, Outstanding as of December 31, 2024",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Unvested and expected to vest as of December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that are unvested and expected to vest as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Outstanding Number",
        "terseLabel": "Number of shares, Unvested and expected to vest as of December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of awards that are unvested and expected to vest under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Unvested and expected to vest as of December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options that are unvested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options Unvested And Expected To Vest, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual term, Unvested and expected to vest as of December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of shares, Restricted stock units vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Restricted stock units vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockbasedCompensationExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "verboseLabel": "Increase in shares reserved for future issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Minimum level of maximum number of shares allowed to be issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum number of shares that may be issued under stock option incentive plan",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Shares available for grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of shares, Exercisable as of December 31, 2024",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable as of December 31, 2024",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of shares, Forfeited/Expired",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited/Expired",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Number of shares, Granted",
        "terseLabel": "Options to purchase shares of common stock granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, outstanding",
        "periodStartLabel": "Aggregate intrinsic value, outstanding",
        "terseLabel": "Aggregate intrinsic value, outstanding as of December 31, 2024",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of shares, Outstanding",
        "periodStartLabel": "Number of shares, Outstanding",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, balance",
        "periodStartLabel": "Weighted average exercise price, balance",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Vested and expected to vest as of December 31, 2024",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of shares, Vested and expected to vest as of December 31, 2024",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Vested and expected to vest as of December 31, 2024",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, description",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "lrmr_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum level of maximum number of shares allowed to be issued",
        "documentation": "The minimum threshold number of shares used to determine the maximum number of shares that may be issued under the Plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Number Of Shares Allowed To Issue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r313",
      "r332",
      "r333",
      "r334",
      "r335",
      "r338",
      "r341",
      "r342",
      "r343",
      "r344"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Stock option vesting percentage",
        "verboseLabel": "Award vesting",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value, Outstanding as of December 31, 2024",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsAssumptionsUsedToDetermineFairValueOfStockOptionsGrantedDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable as of December 31, 2024",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Exercisable as of December 31, 2024",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, Vested and expected to vest as of December 31, 2024",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r965",
      "r966",
      "r967"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r141"
     ]
    },
    "lrmr_SixthSubleaseYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "SixthSubleaseYearMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sixth Sublease Year",
        "label": "Sixth Sublease Year [Member]",
        "documentation": "Sixth sublease year member"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_SkinCellsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "SkinCellsMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Skin Cells [Member]",
        "documentation": "Skin cells.",
        "terseLabel": "Skin Cells [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55",
      "r59",
      "r60",
      "r110",
      "r130",
      "r131",
      "r132",
      "r146",
      "r147",
      "r148",
      "r151",
      "r157",
      "r159",
      "r161",
      "r175",
      "r232",
      "r239",
      "r257",
      "r295",
      "r380",
      "r381",
      "r394",
      "r395",
      "r396",
      "r399",
      "r407",
      "r408",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r436",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r484",
      "r583",
      "r602",
      "r603",
      "r604",
      "r622",
      "r684"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r625",
      "r628",
      "r630",
      "r694",
      "r696",
      "r700",
      "r703",
      "r710",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r725",
      "r750",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r787",
      "r792",
      "r975",
      "r1040",
      "r1042",
      "r1043",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r175",
      "r470",
      "r527",
      "r613",
      "r623",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r661",
      "r663",
      "r664",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r793"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r163",
      "r305",
      "r916",
      "r917",
      "r945"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfRestrictedStockUnitsDetails",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureFixedAssetsScheduleOfFixedAssetsNetDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r175",
      "r194",
      "r470",
      "r527",
      "r613",
      "r623",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r642",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r661",
      "r663",
      "r664",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r793"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r824",
      "r835",
      "r845",
      "r878"
     ]
    },
    "lrmr_StockAndWarrantIssuanceTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "StockAndWarrantIssuanceTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred during the period related to the issuance of stock and warrants.",
        "label": "Stock And Warrant Issuance Transaction Costs",
        "terseLabel": "Transaction cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Exercise of Warrants",
        "terseLabel": "Exercise of warrants, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock",
        "terseLabel": "Issuance of common stock, net, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r55",
      "r81",
      "r615",
      "r684",
      "r708"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureStockholdersEquityAndStockOptionsSummaryOfStockOptionActivityDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options, shares",
        "verboseLabel": "Number of shares, Exercised",
        "negatedLabel": "Number of shares, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r55",
      "r81",
      "r319"
     ]
    },
    "lrmr_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Exercise of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r54",
      "r55",
      "r81",
      "r622",
      "r684",
      "r708",
      "r800"
     ]
    },
    "lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations",
        "label": "Stock Issued During Period Value Restricted Stock Award Net Of Employee Tax Obligations",
        "documentation": "Stock issued during period value restricted stock award net of employee tax obligations."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfEmployeeTaxObligationsShares",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units, net of employee tax obligations, shares",
        "label": "Stock Issued During Period Value Restricted Stock Award Net Of Employee Tax Obligations, Shares",
        "documentation": "Stock issued during period value restricted stock award net of employee tax obligations, shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r55",
      "r59",
      "r60",
      "r81"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.larimartx.com/20241231/taxonomy/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r59",
      "r60",
      "r75",
      "r644",
      "r660",
      "r685",
      "r686",
      "r774",
      "r801",
      "r938",
      "r960",
      "r1020",
      "r1072"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' Equity and Stock Options",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r142",
      "r280",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r295",
      "r427",
      "r687",
      "r689",
      "r709"
     ]
    },
    "lrmr_SubleaseAnnualBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "SubleaseAnnualBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease annual base rent.",
        "label": "Annual base rent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r491"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r491"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Summary of Changes in Valuation Allowance for Deferred Tax Assets",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "lrmr_TaxCreditCarryForwardExpirationYearStart": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "TaxCreditCarryForwardExpirationYearStart",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first year in which a tax credit carryforward begins to expire.",
        "label": "Tax Credit Carry Forward Expiration Year Start",
        "terseLabel": "Research and development tax credit carry forwards, beginning of expiration period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "lrmr_TechnicalOperationsExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "TechnicalOperationsExpenseMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantExpenseDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technical Operations Expense [Member]",
        "documentation": "Technical operations expense.",
        "terseLabel": "Technical Operations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1025"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r863"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "lrmr_TrackFAProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "TrackFAProgramMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureRelatedPartyAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Track F A Program [Member]",
        "documentation": "Track-FA program.",
        "terseLabel": "Track-FA program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r891"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r279",
      "r292",
      "r426",
      "r458",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r584",
      "r763",
      "r764",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r775",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r956",
      "r957",
      "r958",
      "r959",
      "r1012",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r894"
     ]
    },
    "lrmr_TwoThousandFourteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen equity incentive plan.",
        "label": "2014 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_TwoThousandFourteenStockOptionAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "TwoThousandFourteenStockOptionAndIncentivePlanMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Stock Option and Incentive Plan [Member]",
        "documentation": "Two thousand fourteen stock option and incentive plan.",
        "label": "Two Thousand Fourteen Stock Option And Incentive Plan [Member]",
        "verboseLabel": "2014 Stock Option and Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_TwoThousandSixteenEquityAndIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "TwoThousandSixteenEquityAndIncentivePlanMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen equity and incentive plan.",
        "label": "Two Thousand Sixteen Equity And Incentive Plan [Member]",
        "terseLabel": "2016 Equity and Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_TwoThousandTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan [Member]",
        "verboseLabel": "2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_USGovernmentSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "USGovernmentSecuritiesMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Government securities.",
        "label": "U.S. Government Securities [Member]",
        "terseLabel": "U.S. Government Securities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfCashEquivalentsAndMarketableSecuritiesDetail",
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureFairValueMeasurementsAndCashEquivalentsmarketableSecuritiesSummaryOfMarketableSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Bills [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r751",
      "r753",
      "r763",
      "r1037"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r368",
      "r759"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r97",
      "r98",
      "r101",
      "r102"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesSummaryOfChangesInValuationAllowanceForDeferredTaxAssetsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increases recorded to income tax provision",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "lrmr_WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WFUHS and IU [Member]",
        "label": "Wake Forest University Health Sciences And Indiana University Research And Technology Corporation [Member]",
        "documentation": "Wake forest university health sciences and indiana university research and technology corporation."
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_WakeForestUniversityHealthSciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "WakeForestUniversityHealthSciencesMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WFUHS [Member]",
        "label": "Wake Forest University Health Sciences [Member]",
        "documentation": "Wake Forest University Health Sciences (WFUHS) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lrmr_WarrantsIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "WarrantsIssuedPricePerShare",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureStockholdersEquityAndStockOptionsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per unit amount of prefunded warrant issued.",
        "label": "Warrants Issued Price Per Share",
        "terseLabel": "Warrants price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r170"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "lrmr_ZafgenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.larimartx.com/20241231",
     "localname": "ZafgenMember",
     "presentation": [
      "http://www.larimartx.com/20241231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zafgen.",
        "label": "Zafgen [Member]",
        "terseLabel": "Zafgen [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478790/946-405-45-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>87
<FILENAME>0000950170-25-043925-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-043925-xbrl.zip
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M.P'BC/P[\V;X3?)W<E.0QS>Y$1QTVOJGF :_';PM72#XX.+CY>H%_>$Q*L*
M"9Z3!@R)A'EZP+R@WU4H?XP0*/PB/_I#;N(*=?EU@.+' )[;3S$A<XAGOW$@
MKL?) (@ 1#_>][/JY/X8U1\K4 O_ID5R=+]+V/$!^WV6GWWV?:O+^_W#/_2
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MDYIHZ:@>P2_XQZ<4?Y?7__EV '( <@!R '( <@!R '( <@!R '( <@!R '(
M<@!R '( <@!R '( <@!R '( <@!R '( <@!R '( <@!R '( <@!R '( <@!R
M '( <@!R '( <@!R '( <@!R /(?!CGRQ__]0[S *MS^W&JJ>T, 30#PWVP$
M(_^N#>"WGV>K!6X0 VE__#Q;$X =  0 28B!O_Q,(Y#PPVM$Q"2'C^#'W6D
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M&?G)Q'&FW\"<9B6*09!>T._BC:'*5W?,$T5> :X=.7_H=>V3XP)'2!)'AJ\
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MM3C>@==I@;>KK=NO?N.(CZI&]+9PY?R6?$89BL$.[\!8 66 QNZ^[U,=%_<
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MO;?#O&]V\[.FJ9R/S/V[<K)_I3)(4G8EF/$*\-(K\&MD&ART9A;9G08U;D^
M13U3G:P[6"=))8/>#B<#Z8^@M&O*:>B#T^E9(;-!U>7V2&&G-0"R@Y[GX.K*
MUWCW7,_[X'9S]YP T_CM[1)X/^CAS>M\"?'4)[0XGR<EA6_))&8_/^,[3&*]
MM3N'.02[W'G)-^XV%+9"3F[BIB%K:QXO$UY5:!WC)\<Q&^^1U)L"-C6P-O^
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M^X51>D2H@PKM'H]$KO3\/('=TX6"Z:[!05]NK]96T5X!41&=BNTKY^>=>[<
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M7[;FUGI,.I\>==SOO6C.)D;G!U^2:F?U<(>\]C6\UKQZ%?5INC,;[Z@;W=_
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M1#$-B:]4@1(PJ<YZ;%5;Z[XQ(;9W%Y?]4CXO4&MKEA[_JB%>'Z :!0P&<
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M>B1SW]Y6 ]=%E:U+MH^:>"3* 8D/BHD)?]M3D\N-%LQ0QU,_&R\#-ORP432
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M>(O9PVMU3O(DB*$2SSTC/S%,/T4CN30U,>-AV(/L32PIH,W-2=71Z)NE6[X
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MB8-(7SL?H=7Q._2PWCP6F7:CQR*%*C@VQ]Z;&M1\H*P)IZSF\ 4\7(PB^N4
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M &&GW1.ZP2;*7^SP_\@40TQ-%^B6T[TK%HX6@PH(^CM"AC5?I..7IV:;G.1
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M\_>(_<6*$^:X)%?T -VG72ZWI.,:_-</WH2G.YJG:;0 ((8PQUK!I!% +J&
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MN$![*HE#1OC$>?U(&M_J\VU+@IVEX1=V(@_ZMB$W7 _6VN/S>^:*=\?NBV)
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MM[0GK4Z,A?+1(L8D./),&92;1"$4I7A^6K3V*''(AB8/TIN/4C-C5) ^%IH
MTFM KAY;N3:)O8]$U6.8"EI-\_+"D2IB05_+%;YA0O).BX5&CQ!8YI3!N,)
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MUBE[I[WF[QO?FY2',HUR2X-S!4RCM<A#Z5:U%JN60HIJ/:7/[>SW^&0&(V2
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M[WB3JA0SJNQ7ZG.'SJVQ)BG95\.#Z)@M([O_](5'-XGB%$J[-U1G]L@+QZ3
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MAGI(:P RT.3KD+#;!E"[$_Q8+Z1@S_)026"X?0+_EA@E6Y%E_5L'[QI)'B?
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MV3KB\>!5DFIDNC>P,"K/;[M[!01V6]U-#*KHEF!,3R,Q%0T#4%($SF=M45\
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M[=8#E.CLPIK5>_I_EAGARS&N9+(RK/)<K\E'V9JT)Z6%Q62T0U4EP"K26\K
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ME0A+$"FV6,A\X1(21%3RI<= I +&%ED?+O#=FZWMQKMYQ#^^E\S?!/Z45V?
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MUOLZY\3\XM6/(W\#;_\U]FX$70_B@-OK>/TR%O#RD)#M2)7$2%$WX<M5TZQ
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M[X"&A@.:&W?QCC6I=S=?NJQ-//MJ=6KA?2#6:N%2Z0*=BD57NDFXL7F3/^Z
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M7*BCH>_.E@,?/LH=OE)=_;)GSO?G=KO>*W+,Y)J5HLGAU.CA),(5!$R:FE[
M$IGQ! -SPJ5U#"\,8[;@7.M@LK3^_TU&!C@  %!+ P04    " !SAGA:;I#J
MD0QL   %OP  $@   &EM9S$S,C@P,#(X.5\Q+FIP9^R\!UA3V_(WG-![[S52
M!:7WWIM([P(J)*&3A"3T*MBH4@2D*R(=E"I%%"Q4*=*[=*1*1U#@ SQZ/.=X
M_^]]WWN_]_F^YV$TR9Z9-?.;-6OV6FOO'7(T>#0!(+NDKJ4.  (Q@-Y ;P#@
M:(6A2]\!CH:C'. (D B_($!264L'"PMP3 SE+QW$_V0!-DS *P!,1DX-)@P
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MTY/?4X0?CK07$)*2DCIQ(RS,=]R"#^4-0]MX\<%0[-^=_/"C"D6!D8ZG3XI
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M=^_I.S@G.;F,)T2^('K"97=)W  ?GW=,C/"F4N8R(E\R*B8BR6XOF!M]EZN
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M8/"X(FWG!X%80J%56\X[ K5.>H8-]4+QH+KW"-$ZX'835_L_QK#5.$'X1ZR
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MKK1A*"H[LKFF*5J('F'W* _9+N"0/(U+U 0[(+EN0U$J_716"]+1:$.F2AK
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M7F03GT&^@ZR6+2(M$48R&A3>F#(7&:2-RF2V8SODDD^0SH3O/E4)2N,V=O1
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M. -T7V#]M[:\+OR7.RS^ U!+ P04    " !SAGA:G)F=3@Y, 0!U=@$ $P
M &EM9S$S,C@P,#(X.5\Q,"YJ<&?LNE=44UT;-1I?1;I([_ BO?<>X!4%! 2$
M4$(-15KH(AHD$$5Z57I'Q$@-/30IDD"0)M*K0(*@-$E ,-)R^,XYX__'.-]W
M\9_SWYR+;V?D9N^59\VYGKF?-9^,19FGK %NFA@:&P*N_'4%X'KY 5"6 '<
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M2D@_D52^G!KHI7<V\:UG_?]-4M,K71$_F&@OI_R%^,,D^IOZ9&9 \)>5-P5
MAHTB_I0/10YF_8?L_0>P+O4&@@\^4@!?!%@I -K+'!U<9H_IJ"9)[\>[<0J
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M]2KY%[3@>T+=T9C),>U;5K#9^VTAF?'\T,=S$:-+Y5+671#Z=2)WH+9@<HE
M5@-W*E]G'>?2EVQ[$Y2@?S4VI^9[NDR5AGZ1MU96A56G)5+_7=:&KMA#^_V;
MWSHX;$P%DRI*@H^E$Q0Z2J=#6AH:XG@Y&M+IG2WH>NJME"N28Y^U)TZ4Q_=/
MED4_*I'FU2\\Y=EWFGA\NB.K1 '83<F@^>^]KIAW7EU<6EEE%P+;+XY)F3VR
M20!]*U][Q22&ECXT/;YTFIFX\U<G%$#]]&D1XI/M:N4/OY;N\QI=67(\ 3&
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M9\?4AM=K6^UYH>P-].L"27:K,$,Q=8"G(T_8GPUB/2$W1D6/(VK1Y6]B/29
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M'(^MS3FP[O3U3BQ9F21(WE%,,=,:X-6.L/L(^0LVKG]>K^>[S[&CRS/3LLH
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M265/S296QH-EZ8.Z?L5G7Y45?.C4EWLG]??A+:>7CA&719#8AS$CM*:(KYU
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MDQD4'5^VFL%!OH'RK&+^&W6=QLR-RTE665U5'"F"XLS,N;"AJ=\>]0I?L;-
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M3:<9J\;[>O[(_J?OK" *^M4!,.OG7 372OLX(@@41XW&V'$UVTK%+L0CO=D
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M'*W]PMS7K(6_,0=2CK++@,U/7E^H)T>"R7H4R\I/7X979@]$;<,&WS@\EKT
MG:!E$'?$J F':- 69")&85US$J]7Y1.PF5K^^N=";O62V8=']_([+&C/5LS"
M)C8ST^J7E)/S/>]474.8NN=(#[_<^? 777AP?.L4H:LQCA4YC ^<>(1W&Z::
M.G"2P"1VNX76,DP!CU1I'4'X5/*M<BX3Y-"!2IZ1POZ'QUYM&7EB-W7O'FE2
M@H WYOQ6M[;.X6ZP;Y%8M+19N5%^*%#82VCSZR-.<2S!)T+XZ&V\RUPI*UA[
MHYL!2UQG[EA"'VAUP'05*X\:F9__X!-T>6Q72Y3YY_U;7D=/$-^('8S'FBQ(
MIQ/W\6_1?M.=[/J+#P/SN5@6FE2!R^EF%" P4.PE):$22,/-2C8/4^3KP=;.
M?/<A$:3A)T9N^I>L]_0E]K)YRZ9464P7LVDA#9ZHT31,N?0=9\-+XL)7K<I:
MQ)S0_R)&']=FWS[\<\".[W"W2P2Q>M5(>7F.M?+7IC?V\*-K,P.AGE"^?!/O
M#C"1PX73'UC1NE\B#G+/=L4<!RS*YZ[&Z.*^K;P1[@<FT['3+I/K:Q#0>?%J
MOA7@W_$ZHD"EN?#BP@L9[A1%]NQA2--SX=CL68#VU8^-80QRVNCFRETY2S#H
MFL7Q)2:4(LUNQWN$A[.B,O;T>P"SA=%UF"5/JSIR\D^M^HD/PM,E1,=1J;*,
M\..VN1:RP.3JVRT7L7@Y2-5<1JKB#8$?K(F')3&]ZI(@G85*:",J&NT7JMK6
M@7WL4P&>?BD_:2G*L\HMD\TS=N;ZK/4Z#\O8Z<O*SE-]L*3FU?/?EXYA/YX1
MRH*_;;%T\-#QYN,MM,0<G(K% 30NXDI!$/@3*JF?V2$5,+EQBL:XH^I@?,'9
MQRAV[NT6]\B[[5FI8410 _DUH?P*[OD[!WFV19M!&N(P:W '.I"J =9QL/N"
M/&^ES-'D/'%-G39T1C&IVMO;/W]69N)V\ (P/Y]FO1EF-W2$<N?-GS@FG0QJ
M*U75>B^9BJ69!0P\^SL8718S(F;^IU0XWG&8XL0^QYJ!.L&D7=C0/Q$W2@*H
MQX&*AV3;9V"%VTM \-GB<.,PN7FK.W;A^+?#[2FHD0+8:@CG+//CV1YFJV,;
M,'AIZ*>#*8O8C4P5N^%H@V0#M+1+%U7=)U $Z435!*'*;"R((>S7$JC1EJC&
M8))/19%ZY:,+=PJ.>'43_*&@)I7(%AN'8@OP($!P;6X2)YT_.96J(G83J](<
M<AI5@TO,0H2UF6T#OGOCFE@_QR83I; 'EAEW_NRPFOGP["VIV11U]X@<5F(]
MP@WTFO,)986O==9AZ+P(FHPQ;*<MP-NBZU;HJ/ U]+,$<9HYK?)J5I*CR.&Q
M[G^&TT\I_K$;PG\/$L5(;,#UH*^JL?-J@H$XRXEC8.26$GZ?H";X]F"Z0=W-
MB19"&EJG#9A?C%7Y\/ (X\J2EN' C7HASVLE?M^G -ZCM4=X/PZ,KV#*:VD%
M;+II4OY$23%"&8'CP#1'XFM/R;(=(MPT'7&F$F\A>%;1.(8P:RU( Q^\G\:E
MKB,>Z%-VYLY0LWPC0P@W]&;&3A[:DJ>+*]<>-65*+U8'<UBOH@W8[N4WN!A6
M6Y*%'*YK$2/.!8<(5Z(8P;G2M!2*:<E21V9YE;=W@*P_(Z'9Z4IK\=#^V]NO
M;OO\:ONR.D(03_#+2A8/V<KL9L!3/K\$1X.  F:O<@<AO45P:I.!C76?X!%E
M?B+WSER=L3%(_!E\1,?_/2/QR3 J6O^7OOTK^=]ANT$BKQF<@O="=X-F@Y[C
ME(/F1+Y"&@OV!J.^U+#R )X6YN#7*3P,6D6PLV1!C*4I57+$H-D :E\;Z84<
M:=&[8ZL7,ZG>'JS8?Z5G?6,5NW65[P5&<)6%"C9O#!(8J$Q*&/,W/H';U$,]
MPE5.?P9$)\7A#[)F-LTS>A\>V'2LIA[F.O22X0S=]97'+2,C.N<-[HQ^<",[
MCHH@UV!36XX31AG11FO[?59437L'=\<,W=],+.5D[<-\^H1' 3;Q-K%&YIC+
MV>PEQN;@UF[%,:/^6-Z#A!7CG^_,Z4IU@PQEWDE0><MA)4:%:]H]8- -@#E=
M#(MV5HT>H1-MR(4]_!DE-FU@[@W5Q?CP::8,YJI]'<[/.?LXB7B1>FI:4+*C
M4O;O#4C,-3!"N">""V>AOO9L&>(6>R=B=H*D^B 19)O%7OP%\.^0&K WV) ]
MF/)-O%O9@W35S-)RG$ZG$/H:6$M<;5YKM:DL\NLU%2H,M;SM9F"3)B)+KL<T
M#A&P1*4@@A(?N84TZ)J1@64H8UJ@J4)97$X7J<=#Z)X!H,2Z-(LM"<[OJ"NI
MZ^DV(R48K-]O&(8GSDJ&!TWI]I8Y'SZZ[MG&EYOF.8PC#'WGOJP3DSO@B=?
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M4<<_9Z'^G*[]=D=M;]I^O_WT+VL%8UWT@Z@T\%;%'E*3*_?Q8DJQ7&F-LT)
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MQ1):M98RU/",4)_:$1@N[7Z%/:,WU\S_A&O0)PO%,V-YHL!S@8Y:TS]/D9H
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M&OIXYF4HE7A:7FQ2+C13%X%YXW&I\B+>NR<TSB GC_U5W@]1<-PF3J@# VA
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M&[S88F5DEI,AH<AR5VY_^T"E68-&7SO#-]'II7613*QDM=%)5^D!NG5DKO5
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MCVWXKSK_3X?#^=R<3JRH2T/6V(IR_W[A H%+]E@V$E-2:+K<N!AM-6[_3^@
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M[V=>SG?^TGJ@V/2745[SU03KQF0MIZ7D :\DGBN2DG]^^Q#_3O'CAV/V?W(
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MCB79NT:_WL<K[9I4R?^[COB/C00ZRP3T=M"46;IB1\IF FRA40*;X_]8J?H
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M0CG/R;@$8CT%+MM'V1S@I6=O!9+K,+L&ATV@?(8]_0KM/!.09DGL872"V)F
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M);$$Q*9*N/OGH?+->YYU([7[EII71[7ZP8+D"9UG_A+^JH&!"%6)6SR/N9B
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M]^'Y#K^%!X[=N5*-Q,2\NKP8K:D]:YYY2I'6V+A,PTBK])=<8/4HGQG,4(X
M2FX%L4O%<SL%V+E1I-K2YK!-R17!:1Y.J[O&Q1$X2P 1S>6&K-]F<#B3-!D\
MF W8C"$8/QBC3+,L=7.B%(\'#W)I_I@-D#C7T-AH@H>TW(5;6>K:O_2#"39H
M]4 RG9JS+:I@]M1M0G<!H46I#1.Q^$%;K"+"P'(1$MPPLK>R#RG58B73<Y0'
M'9WE$P],+^I4(0/7'1I;/ML[?JJ-@?U*Y6[%'ZX2.;LBA4FL5)! ?D%2>QY8
MUP^QK*- $'AN6R; B3C6>JY6X@(1D\ :IC>KB6MK4':L;D7 M$]>"#<]9[D1
MW#DHX)^5FR_"Z!ZJ4(;;V6;OJZYMC7Q3,R(OSX\ -811ZZ4%#0D#GU^=;TCX
M_BK5H/=WVJ4[-[8RG'FUN#8^_FGD5S.&L@ZC.O7 *BB!"]=&6)@=Y:&<T/&X
MW*6_OD#M!1S4S>#2%;+[82(**=1N+K>HFM5*NO@JOFKG*Z9DO0W#\A3+-'46
M3>AWYQWE("5;EO_7C0=$X+1CS[PT!4$<0/-2'-8X+9VU*R3[?3[7Q6^IGYS=
M2,>D7_22>0D0$_$HR#HX.M0EL_)LF@++E7G*L?+37NEZ\_]@[\VCDHS:_E^:
M,S/+<C:IU-04;7 H!ZC,.:6T)#4E,U-$-#,3%:7)>4I-+4LI9W-6T'* %(?,
MS!2'Q '!!F<A%>\4X=#SO.=WWO4^SWG7>\Y_O[5^:\F2!8M]7WM?U[[VYWOO
MX88\.79;QB#P2*$("V5V.:710UHG$S5%FTE*G6QT4-W6W&@3USQ4$MGF5NT3
MZ ,]\N2'+4FN,E?]?+[!4^]+KYQL3\;9&-M#A20120&8 M"Y>6UA[G'""T#R
M%?%&F(J9<$T./@9G778Q=88^6!6$+[(Y@/93R#A9.=ZY&VN1L0MD*B-3WMY(
M$SKD:8( M!$F'%G?9*Y!E5K<[@!.$F^B<LW@^S[]L'UU8S3LU=C+6 3"&JX<
M?G "N>_7GT'\JZ_=2Z4]IW+-CUXMMNMPUV"A:"4K<RHPU,ZKKW)E?UM=_FG%
M?98V-YPY*6$RM$BQ@_.J\?9V_7;XTJ@-K@#4"[<;Z@#3"G.]!*#?NZL%H'*E
M/R17/$5ZO5L RJ$73?W;CRF.+0)0/1,_)R_^]_ J_,M&2P%(B;?*[WB1P2\M
MD?@/T S4A4[Q\"_*>I3>+N-?P7MZ_E]Y,IR%;[80^CH*&\3O6 =OZ"$1S)%[
M,!->R4;!FA!..B,_"$##CJV4-?PN_ 7 4TB/C; YMWA>$8$&^V]@\B/>,^G/
M(<)VRMQ+ "$ V3P=JH QXC9^"BN.07X''Q26[-^.YSKX@_GE_H43LAGK7$,^
ME0->RSAYZ[]#26@A [F:\2>6?X.L*RSC%B ,5 _Q-LI:<'W% GYX4@@U^&@!
MB&MS2TALI+?A!":,%Q^ 7]^4*P 5[_S]'C]$QU/\!:"\>?M^"0&H0HA,X<(?
M6=(+*U9N.YOPA"%DG;P>,NY*R=&@_PM8IM#XQG_OQ*-YQ<+RD:B5]\+ZZ,*!
M5 'H'6'M8@17V+:^?*\7_]_78 E 9V#_L@J+E]I&6/7)X%,F\<OC"@#BWTXE
MW*;\FUD'Y!M]7BYC]]\5$+%"NGO303!A4G@I[Y#KNSKP,Q<_#>(YTQ@A8AX1
M#@Q2:93)&?&U7S#^(W5- 6BR;X3_SE3(F! -?$<_>.4+?F,K8J6&KRP +:CR
M4Y46_HG44L>:"GDA3D(6;H2M0;S_"WQ: 2I\-;X]^*HPC$\3Z@G_H_55O!="
MGMY%^5Z-NRL 52&88'YI\>S:9V!)6&G8I/2&$+P5_\X,O$7PUL._XO]8C!L+
MA], (:ZO)':)CQH)*3PY0P0_;)V!GV%%4S8)PSH:)_Q%M=L$;,-TN7XEY'?2
M V&WN@ 5QP\?%\)GSII+2!->=@(V>@?)%8D4@&C'C?E_)T((PA":"WN%GZ'N
M/7#9-#!;Y(_Z^OFQZ13^5X+,LGIC&#N*&;$8S1-GNH@%(O=1W8IX-IR+ZA--
MZ,M-O;PS+.1>+WL /L&/XCI8.X]YM@ZZZE<.YF?ET^:)Q@[?SJS53%*HB_MG
MZLU;*& >C V+: R=U(ZDVY9YY YC4TV%O)Y@6IO%ZM:X4#W@V4N<1[2&;ZHB
M]Q=&6=9%!,KCY0'??5ZKFE]GCH]"B'@S-'@/5!&(Y"[9#_%$)L8"+O<?BAP4
M@"X-&IW(\4;4U0[V-NIQ5X.":D_! [;N[52^1-5)4O#_R,F)N+VC,E:-F7C:
M+>%(I+)%3JSRM<G8T_W'S.74=D7';LY1V_46! )M P7O^)"@W6J@2DV0M^2
MHXZRFP9*,Y]PINO<J>E#G1O%16.STC<GS=A/,K+EV+SC#,;H"*H>FE8ZRZ%/
MWW&4S[JYL+(@$\*K,M>Y:W),Y$B:HOJ^R*N3R5;UQQ>$G!,B%W:'<,#(+8R]
MSJ0D\@(+L&A[3GKNA  D@N8K5[$+XC<-&)D&YJ(R]-E>7%E$6QOO*:31I^K3
M)^1=4XU-\B Y;2IC,Z#Q@>[Y@*?.%-\S!15EUS[C*BJP:[/R',^]GDJ_9*J?
MBBZ8?K0?C=KJZO/H=$["9<GA*]N4$3'\MEW%Z\=Y6A>N7K#&2QX[HG;!%*D
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MXE?U8\.%$$]@,_T U6(!Z(4?2P#B*U*$7>-W8!A<J+J;SU \-W98]"U#M*\
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MM36ZH>'SV_BO7=%'ZNNR!P,98I]/-I_\GM![,4$A+OG1R7BS<Q^_F.).E0E
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M;9A3ZRMB<&#69LT%W]N]@:&+NZ921FM?!.1[NT%<=Y)D)MZ]2SPK+E6YD2,
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MF1MIC-W$I+U>BEO8@U&L:.)SW3*PK<M)+/%,N:\.L:XJQ1ICC/%LO%+_3,S
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M!"0!_SAJ0@.!2FE.T(M-PT&&45_.3Y-+(8Y79!)K]Z&*,.=S+L95JK>NG<&
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MYM+IPWE2;(U=YXRHK7%7<%%K\%;B]?D>\\,L-UNG0A]U\B^/GI'XM*\=E%P
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M.\3"Z;+W:O-UC,L2HG^LTD+8\HC/UM A(3$.\-5P2 T%7H=5FV)\R*ZH7]@
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M#)L_1XU]R4KJ*L9T&97 )>AN_A%_0#>4%2QKP*X!W6"O$1X0T& \[>;JPZ\
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M$?A[IV<*1.,2D(SM@X$-QQ9\S4+5KU*1^S&>WH>5#  7T>+Q9]UQ_.TAA:W
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MXX,3]1SS3C5)*LYY2T%(BW"D#O?^V4=BMDS^1JXV6F$X9!3R1_;]XDM-CZR
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M7VA*6W;_$-4(&[G[^U2W*&IKV&_Y-GVL\ELU:@A<"-__$>&%2#H!H2RG "+
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M[+(>Z_?9-#DA85"G%U7!<$E,\<F@F;L7D/RA"68KS3?=#6!4?ZG.:/;5M&)
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M;6_&HA=;K19_G:S>.$&JW$4-SP@%S-;VCW>UBN3[EP3CQ/^(*POL?,%1>%(
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M/SR"7T_L L/5Y<H>KY^!WY,^Z!Z]F7J=J6<?NFI?;J^_;%=I7:^R?M3YV8)
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M<C_-("9A^/:_PB@?+YRWK,11Q8'[Q32AB]-_1MN,;#HT1]Q,,E\.9XMJ,^O
MGZR_0"Z$(Z _KYW"A<#:A%A7??&UE'5^:@9/VPATJ&'. "\>4MW$>CMD&T&_
MBI7PG8<SH/_/:\,;#>WF3F(&;X_G18>7F54+G3\K$Z$W5%L#V>U^58-R0BJ/
MG71W'M1/>1U>8Q8LGNG4JK5M66;NW70?66A_]1'QXQZYR1^J@!A'H)CES[X
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M^+J*_D&;"2&'2ZVY'W;4HRVMP/"P"@I9ON>41OA]!]T9Z^>7#]9>_-"_HIW
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M:=4>"PA*^E6^N#\G@@:M-T];!SD4A2&M9#GT^Z+1).=H40#?)TLM(2\;/:6
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M *C-5<#2NF0/BI4AQK%= 5MBI8!!PS"2LW+M_1NE'_O/8H(]Y?#W.4W^UYR
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MV\\RUSVJND?_>1 ='@%O'I.Z$6);T@!SX07#G/WI/CAR70';G"?Q  :Z),'
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M"2%$2$K@6Z&:^K/?0M6X8Q;,7R:S28FX,'['0ZR'UW*ZEW&Y?2?ZI=')SON
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MH($V\2.ZB]S2J*G1B,1J(X.TZ2D[],HKXCM0Q(Q'O/O^&]]PVW '-6LL9&>
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M&3:\ ?%5/L-^704IZ0E.J3)_O]V-HA#66>XZ,S%MXOF2L[DTD/&FUD>?>>E
M@><(0PP2/>['^WL"D3?/8UA6 (7SVW9X;S47W(&2F?DY/:X.V(0R8:JCUHK
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M%1A<AF=_+3S95WZX1;TLN,E&L+?)M71H[FI$:C3R\5S.S,&0M+=)>_$FY\Z
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M9J>!<)*P_UI,L(#[]A3[R4?",K&AE%@#8[R?^"/FY_1%4>^,./"Z1L8B5\X
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MHSVAO'776'1R[D<D.Y&ZN'L6QWF"7 6I8 \ A Y3)?=(+I##9IFFJOVT:&Y
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M8'B& XE,L7T351GSNYE]Z;"M@AA.KL\([(K4,:\S ]@]:*0SI_-Y69!_FWE
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M:&1O@E%+B$\E@+XZA#,K=WVOXV(P'UG]D!"&J9H_@#JSBB'(YI&W0>@+Z)#
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MEG#JG=?-EPLM'3KC(HE4J$-'\U"FC\7BP05B8W%Y\(_-BUZ+OYVVDM:531'
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MND%T#/  O*:0KO70\,V;^*_<'$3BLB%)!$OH0+'O\9 #!!]*(D2"Y\98MKW
MSB0GRRH3NB(;!9BY0&U7,4SC:6Q(LK/O/1^N;CU6CKT$/%IU(-0C/;_.+^_;
MNU(DP^--\>F4!I<8HW'X ?]PXU>:2;Q;[&:,%-;*@EU"TY<J^F9:DL S*5E
MAK=7B73#Q-F;B_DJK8^X+/<1GF%S"16N,G;YE\J1E_R^@3MZAA6DTFW0G=6Q
M599/.X4($V*[=+0$>*U=3L7N(4CXRDV)5-<311>Y,$..\DI".0J>%#H[Q',O
M_V."_!NR&XWSP8.A(KKB5^10')EOS9E9F6<@E:$NWWV6QC>=>']QX.WP,4HG
M2?K\&#T9+U)=&,6(]FG?!HD;B853-YXTL:,_MZ!]&/*J,6\52<1<RZ$;%XWT
M1?TCP3&M=HR*M$D%CEYMF5<A^A.*ZP^4;9['C\!W;(-\,2+^;;I#K:K,55%
M@.%6 DV=1'X.V;UH^BO>2 S</FD^M+P2"#4)*)E'$L:K5M;)NTJ26N6XC.?(
MB=Q%3W>/X9^-K4V@+??G%+5MT(W>-)32,O\H$"YP))W+JMWYQTU7J>$95)3D
M>IX/[:\O@L'J3IM%[2@&R/;LML;"UK5)WOGF$;+Z4*L]$RS1S7QBE'<*N!%@
M^J,7D;R@_P3N!Q[3Y+8!*0R,"LZ<79+*"YG617D"]P,*@ _=#.)](Q08R^*&
M];6:;[KA#@ 8QAL]:C?A6L1Z&4R?9\S!I*ZG6:"2T44YO=3&G*FX[X.M)X*"
M%$#\!W/D#_!Q.6XA0&>'L$A45#Q!6),>J*MW!-!$5\S_HH@->O37]\"3IN3
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M"O<I6$"FL=#&IK??!)50E4?R"KQ></8P0^'"^+<0A58GCBS][&N8!@?>V7L
MV_W6RZ F?I/I]+A-=3A,-]R:4Y)<.+A<+?M9J/_V<)L4<DH_R? 6 BS/,R]%
MNBX4[R<?(A4,M(GA.R@B_)/^SE) S(4!OB9V5T>.P+B400U8\.1\U=9!O!+/
M$(@I6\AQ;AT+C&$2)'H8I+VXTQSQU^7^1'C"\C^O^KX/Z]ULM57_N_*?74]J
M!!-1@N]%DAY G5@39E24U/=^W/$Q\R%$M!][]6P,#0^ANSA$F]":9=\P]1,W
M$+$CGQFAW9)SD5.)ABB%C_2[1Z:H4OM?',^&L)V(HY'OH8AP H3X<UF[8QLD
MM@33]/!'IC]DI,$\W<\-/>_COY=+:(5'L/9!W2J3R*T6);X<(+WW#&&G=?E6
MN30GQ'W<O'^9R)-:Y-HVL]/>U-U5T=L&Q2('_* 6C.7+XRP3FE$]NRLFY 7*
M[:OOI.2(J@#XP#Q8:W^8=M,*U*3(XRRCK-+SX-COH//S3)0DP6<*T)BEDA+R
M13FKJ84CN.OLWL[(@,;VU7C9247.GWC(M#'EI3;U^*.', E>,FRQWC2]/2VG
MV/5U/[#=U V_UX,KANBH]^ON;@76%_>0:?J EA5U6?^M7,XJE10/D88B6.:F
M+ 1& NOMW%?GK@W?Z:?+(5$I>^IUP[L4ZXDI>CJKADE&;[Q^SH7S=S5SGB&?
M#$XN2G[1R2">![HW Q<$JQ".1H%Q.]X(),ZJ) !' M'3GLX]-+S,X,]H%R^.
M' V>-&G"@<?A=!EY1Y1MN_#*-0,_/?6ZV_&'AG$7*OU'UD[<3)_L5W5-I:LH
M"_Q& H%MEX:?&60TIO+L.;O])R4&-#DJ;TK])T]L%1CF674V((TIC-4T$R\Q
M((7U7KTVA6E<7XA-U]W5:0+9S[.J6E11'ZQW8[[*[N!X>;Z_I3D,4QF$WYP:
MBV*B8OB&V& T21X06'IVR3W<]7\6^@4"-TK <4MY>ZGXPYQ,^H//]<^GVE^X
M^2'KV^J9*!D[S02<A3>:>:RJVIMD/S!U.;[C FAM64".3NPH)$)L&W239P3,
M$\(Y.]>H5W#'!IEL4BRK&:BXQ<S#T+R4:T9PA]6[TQFO8NSJAUOURSO+P#*>
M .9*?;T[>OUESF?&+:^4MU.-V??YVK@30"Z+LAL ,_43PL!"/.%A&!0(L0$*
MGL]M[/8ZR8Z5;=.-L1M:@E#Y&AR=$>Y)++%]K"V)(/["\--EV<9-IS<O1C+<
MO[[O! H9FCRI5:Y+(P?5258$B);L@.RWBQ1AW+FA]#<<L\[\PZB8R%L-KRLG
ML;9V[*D'VZ#&L*A>(<# G@-)#7//,VL?DTT**%A$%I>JZ!HO."7T< GB..6M
MQSP(8PH,!'=X*IT9A&GR9%.FB?&&! GL^-5!(X(,3[<UEY:OJ:+<_W-58H&[
M,3S,WP8I+C;63KB?W0;M%ZMSJ9!>.Y]UE_-V!_.D0 /8M<D)#(!3+PV2*% 7
M D$'\>@+A8LLYA]C6[Z6HYJ#71H'>';3,L!]/Z:8[*8 /$NP&.=^C.'<RM+/
M%GF<A>"FMV9* O2>04TUX^^FCY0(E+'M5DYH!"ZX.8Y,$[G8"G[ABZRMG\EF
M>,($.)/"]$113663Y!*@ITN!#X.=P:/^D:04P]+05>F%,=F'TVDVAI37@SQ$
M&.;F#\/(7TM6F_O(,<Y4VL;$P/QQO_@(*(J,[X<9JAS*:,_79"\W=FP&[%GM
M5B2F$^I+@.@R7Z0N)<ZP2CC:F@?MO180.G?A6_ P\0#^'>FE1FYX)24M+$!\
M?QU*>+X-XHZ1Y=T=81$970^K%O@*0S\_(:C&8Y34O[%[G4;65W=A?>Q?<<2?
M- <6E/HWR]1Q&X,1!UONG=)%\X6)TU'*-Z9<$]KSC]8#?NCI42B";%TZYX6A
MB7A:44GLH2I6K_B8[PCR=Q]&;?#Y5FXU,:'^DS9RI$Y?HK>\W-7KJ]N$^X+L
MA$\29;I,P+6MLF()*3PPIX0Z>:(V&CE+@X#U<0:,8ZT^# IXCB_&=J'MYPD
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M6F,_W@F>TMY<<7#EXC;(9>$NS06,G9""-HK4MVVX=4$#FZ$(:0M$4'H!DE,
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M^ZR3L_K92N!:.KJNQBP_;_Q\CX15YMMP=@JJ;60!3NPD]!:@'I \5,)N]=[
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M7]B%/C+>H3J122BYY;>$^'*3IU@#WZ7# A?UD/>U4,I:V'V0LN@A938RH_'
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MU8ZA%O]@ANN\8 JL*LI*"%L27=G0$:2)RT#ZE4/>0LO<%&\!(Y"EQZ=[Y3Q
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MZV8\"N.4DALM>[BK=4Q,KA2A4= 1-[A:Y<K.I=]N>Y.ZX[7--3)8\QL>=:Z
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M<'JQ/X1KT9:@>1#$!K4.=S[I-V^!B. Z 70<I1'")]X6!(T_?R](4,$V45+
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M$G.6O>I Q]T*@A'>8(U;AW,5EEL*'_LF=J\#]F*CM7>_X/@ IX5&4Y!F7&4
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M;8,8"P+%V?#.1^2ZT/6G VDM08OF.HUGVM9(9^$\^EMSR8]GI*R@XA[Z)D]
M\&6P>S1L;1-4*$)JRG\;I'B &B)384_PKY>G_L9LA8(F!49H-,5-:_-;-"(Y
MG[3EFORCH1V\UDPRA>IFO!T,!H3=2 %]ZFH;6"A!<(@G%-4.!%TB5I?$LHTM
MUV42X^*P9TA_"%+(NS]QPI"#D0&OZ?>)SGW9<;SF>FOSK:55>3$/%,W2#XI[
M["B4.I;-!"Y!BXR5.*5W7**$BG%CKU4P*0W I<L=)%BX/ 2H+@2^=8\LH?)'
MI7=!3+/>?E!OJ7MHQK]\4RE^:/')6:;5C@;[ZK5Y-NP;7KE[6$FMA /EAN0'
M;?H]!D!"'<ODU>\)$<6#W-./\7NWWX@=Y/A\X'Y\W&%KJ>M?6I_Z[$$DWOBO
MJN)3E]?>A&N[VO)&RK?:[QK:';3GOKU_2O&IVEX3-"8F^UA>AO.%'K^/ZDP\
MZV9L_[[V5!/-K\KHP!U^N KFB-%5\EB.$!.@*Q'Y#$-L%"V=K?,>RJ$!#;W^
MD 0\)-]WV9?73J77$ =C@DXR?ANJM\TO":LQZ-G8$5@6MV T=77/2OI'FA$V
M"I>/7(XF2A@K*+\!&=\3A3HU@)QJ-2IW,>C+[C"()(G'-SJ@-&.10-&TM/XN
M)U*<9_)WU)M7\E8G_(/3K<%^3U.CS146BD*J$V3'4<$>SK.[R_9)^N9J@$8Q
MLWC>4TS*;@ORF/<"Q+/BL+3XJ10&C!SE\6CHHJD%Q43\>(?#S<6GGN9I/FW.
MEX%'S4-Q15_?'LU0Y(G9_,8Q2TG]C_D?P.L^:0[P@_.41$<0'C'RSF*LR8T'
MH3]H4W $5"?RM ;]*$;5%@W-XC@GKYW[3Y6O!=Z]X4?MZ%<PO'?%U'[RJ!.S
MK+JCQF[L</?+YKZ'* E!NDLLWYNO&Y"KF]_EH3+M!/U=+QR&SL]1(Z\6H.V;
M%G=YK;+:%F[E4V?U\7'*+SWO(>.6"\9[S@ZTZI7YUWT,I,2,]'34./)P6G,S
MXLKM>D5.&G]T?1,;ZFQ,S/,YWS-4Z^T*FO6)<%QOCY[D_UJ4D:&"Z3G $=.&
M\;'.;>ES% WQT[X-,4&7>WQ"@H4S5&3;P);A[S*3;,O,E)2GO7OB/F5&5^5Z
M7#T8X>&J5IT:/0!Q%&,$P*]2/.-$/I9R"R<S)$#+7KR'WO4^YPBGY_AT2=Q0
MLLG!7_]^T5X99'_*RBM#MQ5+PUA11X0K69LIGHJ&B[@T%:S5\9IL+\00:W )
M8Z5B9!H[9EM<!U&'+A'"*'NA"%'?.G*E:*ZD.NMNV27>MP.C-HT)V1=-W07:
MUH2.P(NE3TX/?!HZ34 #;?-.4RX174&)66A3%6R5R1!U&30H6IAW (O%V)Z%
M_.1B3BC-0VV58Y':9.'1 @I6(H/#R)=XL[^-,CL=?HE;+7RFW$%,(6S9?__O
MN ;](]G37E?WY%8;EB7?0N&U_*LVM29L&^V.M_ ,Q[3=" <7Z\28&@[$/)XU
M:NVUO<9#8X=[N*N^@2\B+?_7G$SC[;]7>ZX[^)F3;77*JKL!L[[.0__:@3W%
MF2]CIZ:/5RP^^+1N>GBIWN'FT8;M]CO]'GY]SSE5917^@0#JC#_#8#J!@H4>
M+?@R:%(%>Y9,]#*KD.0AUT"9W[I&=A_P.W-U@>NX=+%$N[GG2\[VOGON$9=.
M%!(WX4E@WA3A*F;U#%*G1;C)\W9G'Q>94;X:XHC2*F)]9W:ATI2_=KGPLT;]
M8N;.!O4&!LS?5?8_++ -;]VW#E^\350GC9J*FE\ELX50TN1A-#91YA[CS&L4
M"]_*I.E07.VT"J;?X0T>%7+;45S<IMB@LB^E4XRU\LV#%Y]C=""L2 7+M@B0
MNZ*ROU2/H#TNUT^,!517ZIS34EZ@CJO/E2\#L6&*(A1ZE;AL7X]4J:$HH$7A
MLL)01<]"E]TF2[J60A7LG XGFK24K#EDGW0ZY]PK-H,DXWZM^?.+UO2'$%S9
MF23Y0X/=1_Q7V%9DOZSU,LCNDOS29/]Y_P.+0T<[C7VJJX[?\'@YD%#I?\MO
M^U&GVD\?]^KX77E>M+L\+HLGJ3OV[$2F\55+;:<#"54:.>D5AZL\<45E 9\;
MYVY96AZ/]4^CVE.[,;L@V-*7,A EO:*X;B]$0&=(.MP&N>-#:-"Q K0\2N]I
M"SKH7WP><J&8Z]P9:74^QXP3>_M)X!9MF;<[AL,S/X0?BJQ1G[Y"<5L)ARY(
ML/G*S?NG&#J0Y51]8^H7$CH*F[NEE(/5/PVE19A5BO;!4Y?^<O9"]5@KW$<"
MWI>;D+]_;GGW<"BJ5?=%OT)7/9BU%77V; %6F@/V<4A9D]N@98F '3?H1[<L
M#BGQHJ  ::E8Z]"#[W M[>" 4:4U$NX&ZGPZ^";A;^8:AY1+W[8\&=B!=$LU
M*<5MM7+!21NA:=EVRN^*XD7X&/89P3#A,EK),\:F+;"C&K/#[$8<GE!<9#Y>
M1%',=WIVB=/;L!&_ 8=2XLV/=%'S3*R-).U%\^"'P8LI=2TXY*IRL&7G.PO?
MG1PG_![R6?<4X[WNF]NDF-#LI ,%,=L>V#]\RZC']YR,G;)V-2)H9O7@7VU_
M?7'WV2/6R7\_J,FPR!8?)J,/G/C*S:XL;']R8RU!\/>,UJZ/-0BK4^8$^&*R
M??Q?X%^?,BJSZ]V+"-X'&J+V#T+C7"QP5"C =;$-1)"+6!O;-4(U[X0LQ#CZ
MDOM#M%L2*IW9!R-[X)1O0+T8YX'/J42U3\][-/+)O1AWQ2/>X0']4BO^TNAU
M^31 FV(48/8$4'R'.O26C(,I9I!GHSP6I$F_5#J66D,H3J)S7/6=$F?72$J;
M8*S8OT5F6[9OC./\\_8D;R97!7LC;50'"*'X6QX.FDO3 5I!1XJH'L<Q,X)6
MQ*M@ZYK!R%^&BP;&>ZA[(>U*2$/,[]YPP[Z+O'F$XA-5,UNTBQ"\/WJILZ@Z
MZ$.8H L)_E!J3DO@F9.&)$%A-W:#6HMXB#80$.S3R$V4S4!;+OIB0@;PG;H;
MW,J>^M'4PH[3\!IQ6)6[CV@R.R;0L@J>DQ8FA;]_>_7K.4O))G>W$HD=I;P:
MOO/92>@\<XUO;]/YFKRD&S$C_.&*_5:CM6C'Y=5FY2C-C>V/-UW>X;?7:O#$
MNZ*8/P'N)HEM]X<G56A_#:/</BO_6^#;Z-YU#^VG![I]ZP,?]]<8O_T'7VZB
M:[6=W&%ZQ.6@Q,D!F4.Q$Q$V0*/^6;\!A RYI\0T66S4</*-W/+VS.26D3.M
MK<=^..E.!]F4+<JZSN77HWO/G4K??=-HOU$Y817T6HL8_%QN*GYK@Z)X8-,>
M--0 (VW:3&&^36A$.U#PX&O  [R956OBP<? W)&EESMF'@5:16HL2J18$/^,
M-.8_+LV$B/>H0^R5BPN&E+-0RI038,EC+R>72FK2T.8BJPZ$Q*M.7?(H&-"R
M!Z5!OL A;$";WB/?YWWD^S\JY:Q_53W3%&-Y=+AA[3^M>+.Q*>PX0YH"(OET
M@?,GR4(N!7Z?;-[-<E;KY1.4]2,4C1KRH"> I].B4:EA.F9Z*2Y:7F!"O91M
M6 ]N?7718@C%9#1W-<Q@3-J'6>^$<;F)"WRP.L'#Z";?5A3"V=G[<"/%@>)H
MX<,/!XW^(J+;;[%J#[2N1?QE+0$W?#I\SJ&6LYWK_[YV;=V,_&\,XL6,Z/S/
M"'+>JE1^A/5H95A:77J]Q_+I'6<'>_RK<AE/G0,.[\XXY'ZB!LV'>[Z^-<V.
M@P(P1G*O: K^=X8.YI=.]I6/UX5\O.840[_#3/-Q#OIYO3Q\=XP[=EV(*W)A
M:UH(43.<_NF:P=Y&#Q ^]PJD'0#4M6=A_1ATCF1$%R"Z2OKH5--H+/S!(GLC
M5$V ?S:^/>!@Y5"@X=E_]^FCQYG3:7,MROXVPT\OKW]T7+U+IB_;I9PDZ,Q3
M862$#XCDJF!9#!V6 QDG;IS7 *TEMG^ >#_HDQD=S/.#VA)K9PV3>\F^(I__
M@[TW#VHR6[^%T\<!$!!E'H2T(O,0$9!!2([:@( 0F66,B @!$1&0*#%I90@S
MW8P*0D0,80I1F61*A 1H14 (@PP"241DDD0&7R$D-_W[ZE;=<[NKOE/?/?75
MK;J7/T@E!<G>S[.>]:R5=^]W6TIU;[YJ&.E-FJ51H.ME'/;$Y$?DH5\,2('M
MG_C*F-%941/J3_R! (5Z()US<D8\<F(/"]NUE@Z6PFA.\]PX64FF,QW<&[W=
MVW&TTS"AMCYHTC=XB*<S9FCRQ97MQ!5K'(MIT2?M*_FT_]MI>Q:;'H63I\FD
M$-3DR:)SQKJ 0Q,A@P17M2T5MX@BXTB;H8Q,Y8<9!T44DDFKUID.EY;,+SCY
MJ?+;#(NLC&DORVR?O4K+(&2\'J(S.BX8Z,PM#<KEZ[B0':<&GE5W91DKX<B.
MN9.,FL2JE#()#TJ-%*TD_-P8S[1ZYDO \:'8[(/+1=<IMN5/P[?]^>FUR/75
M@T<IPYNGXWV7+1Q.OLIBS9AIOYV3N^SL?R]_YRZJC6F710T5\JD ),+#LM92
MH6H43MR#IV/M9UB#\LM\:%9?=]-=^$0C7@(XUZNFSVC(E@7J.]54,O4W^L6]
MQQNF3K?ERDVDP5Z*H]'AB+)Y\[<MR=Z_]GK1/#J]NIG:7J1$LMAP#:[&]7&P
M:Z9#K/3C8.>(GF&OEY0V:OJ[$R,<U,HUZ8)CI;H%X,.>F?I.2CT$W0VFF:)'
MXMQTL%*WCI9"Q-DT;?(_V?_]'G"ZL]C>_(7=N]/8+X7DC4-<&.]A2 IV92@V
M<M?-2XY_[_LL=_Z. !30#-[66-[=:P47@#256. =$W]? <A]M!NKLZL'^U0B
M5!8[+;!-$1#6]9XL]M.?NY<_K"=@-V.-1[#_\Z83KIZ0D&U:FN" -F3U/#GJ
M'R^!-3L)DG[8:P&H2X2I)JHO"J5[;8W^W5J71[-3S?P#1]GD1'SC]][LY.V0
ME<V=XZB7M*X /4;,#D(:M3Y'PJ?P@FKL8(D\Z\KB3*Q?KN?]3;U7GSKB4<30
M(!VD9(/*^?0HWO<O4ZGOGD]0-.]<\X:;D@RERY7>5SUTZ\NWA"OE-7MX5)T[
MK-2HH1AOJMCF-%CT'KE;.'PM>3\EZ+$=.+L481_%C];V2#Z &K<LG3(/Z&<0
M?=(?S-_"G\X-6(- .F*!?5MM\!\_F@4@ZI  Q'6_5\?@8R($H+4-+,\#0\#2
M1J''L4.U?!H6R+X-YK65\]6JN.K\S) M%0&('O]< )K_B+TL (5'Q>T>!B)Y
M#B<HB$V#=1XXZ =DYS0.]J6"S.!?5<1#MK/6L=$P \PX4@"""0/V?1O&U\UN
MG,0.]E-W^=D"4!IYA S<)=*SMTWQ'R(%H,-?A;DIC/GK"'9\TZE?LFE8EDO2
M-P&H*A(_MR.R%7<0.^2$(/+^,((B-E4_\S]C?';_QZF PX5&!5^,W=D%"T!R
MB"H$9Q.>"MX(ASV?Y:M_Q E AE^$M%*-/B\ E7OO)@M#H;8"^Q%GM]6L@!T"
M"Y_3R\7G!2#765CGEM3*UR,"T-,B*OS';U?0U*73_;OO>(T[P43>KA!KLP 5
MJ(;^RS2IP9B# E"G/2^<34[A@SD5]3N&?#IGL;6D,)W8DD.;VU^\;[(I=0XK
M@TI^;Z-?U/!'C<;7W C5UZ'X=XUWV/Y9R\?NH,$<#VSJR7,2F3OZ?-J94NV/
M#_B#GD?/7-T[IWK]MY.H-U:>+H/F=1Y+@>,BS%V"KHG>  ^>-/^)#C_L7(+?
MND$NEO1Z="\O=^PS68<Y;UL20A]MT?6H<8!Q[J=2K14#%UR7ER<UCCB=AI*+
MP\&%B'^)%SS]8K+8E5+Q+\Q2X8/8TY9+\\FHJ]Z!14J'1UD%2B['TWX)1GWR
MB+G\5G37[F_CR+-V8]GM*@^NF FE_7>AR^]K'1<F,H"GFCQ.E0V\.X4%G-;'
MAQ[5MOV)F;HF >C1?JT^?GFK_^YLW.?9#.C/ )$EWQ'+(H,!-EW-DFNS<?-<
M/ NN"!2Z<$]UQ$E6W_%\/ATVV;^ZRGL^99?W0.MQKW3!X>JOU]=A_]]2[P(_
MR:J^F*3KIY1 ='X<=""&2?]@?O90FL.)1/4"[1XC3P<C^^.U^;\MW&=NY^8M
M1=EJ1C]^3+3X=*EJP#77V36/D'TKKSBBY=04LFDM^MOXZFW\^KH0UMAR 8A5
MN>-/Y/&$3F96^-% ]:[#OQLSZNH-0R'T8)("4*JM0A^?0,$FK,#_=T#_OTP(
M.O$G_#V%\.=#A/!WI3*7\-*P+V/80"K/KDV*[S]>CMK#/^#!CI1!8N763*4F
MXK8TLQ#[>#JCZ)!GZ8@) <@I4V.49.4[UR^M34Y8&E:J=2JEWOUV3BG9ML1@
M^H*\F?U)4FF4OVB\PV,PSF6!(&F./S!KZO,;01)6CRU]YK:2>T]2)]C/VC/L
M,,MG>L"XH&7_4:1S<17D1]9LOKW&:,U=C-E_(D0^?T=]L'\G1/_*$'\-D9".
MI=R!WP4@V_H=8;I9UA^PW[YF_UW^P1/3%@*0C2D&O_XS_0=V)*YXY]&/\/]U
M7@=/3OL+0+]@A*](9T *=QW10K'P 5;_*IJ?%K8+^WPF5<B_E6MFWXW_4_"&
M-;YJXZ?PS/@:B@C(=L$/OM1S;,C-A5W9T6WLNP09(01=9B*_ALR3)U=A"Y]G
M^0*0D&VZ7?YEJA[;^7\;N;_K+7])W67^ '-P6Z=FX[_S3_OL]& ?XG]L4^7_
M,M6:3;V_B]Q?P<,?8ZUMJW-F@;Q (2)\%P!HYVX)#;_AYK4H )V4@!?NVMVA
MMN +J/^"0[M_F:C7DM??!>TOR-DE=<]NV#&I7.TN(1R:!SGW$OY/ZL7\0NK<
M[W7":>S]NEOT4<E?A<;7.YJ?H /F/.?YG524EK*Z&;[Q@*(O #U H2^.8(SY
M/<*_Y6N&S2ARX FQ4K)?MG?[!Y,I1[Z(,;'[%B-"V&"AZ9?'/>FU?HOD]*OF
M^$T?>\>/6!DW$]GO6KYJ*0!9 UT>(=WM+I8;!6KM ,XR/^QP=4U/IO<U\T+7
M'))BEZF'1?,^E[.ZR&CM9RO4AE=73)@TM/4!4]4PES^^/1RN76QU)IG/G5B2
M4]72:;WQS#6W8D%K_P\_0CAU_0IW\R.9IP].P2Z>XJ'/<-_#*-F5W&LO?O_>
MYJ7S/P&?P9H%=.WH_F;=?"-&T&ZA '3E=,K&H"*JQBF+M;:%?5'Z[;,UC*Z<
M6>0WXQS[)*3]U?F]X]'Y;M:T-SH7$7OV_)VV>Q)C?,-@2]:5*6$<\+8$OSV8
MY.7W>WWSUHU"Y]68^A6LXFC?J^C)$:KT&'S2>7EGSZ&5'XWCRY.3:PA(VW^*
M%L;_!F9* M#_?LQ0@%_?_'.V+.%[=W3_#<V2[1BP.4* 63M@Q\:J..Y ,'2:
MI] >TZ5P4.6725 0LJO+"=9MJ?7G5WB.#P_67<WYJL,S)I(>5YD@)5P_UO[^
M-OB<FD?]@%Z9X@ :C&M8OOB41 <\?W#EJMX3A1IJ*'HT+?)IVQ<D7)>Y]#(J
M6WJLE>A90SF3$K"J[$J"";M?CK1];$ZS/TR%\K]<_B3L7_CZ!?YORA^)"NFY
MN_"@<=6L&RK)O5;#A,A\85CW9+-@$LO-=^4["'[V>YN&X15+V_ZCI-V,85^X
M:=N;B"B5=AE'&9DC6428VWB=*<GQXE@LZ<:]H$NC9$-352_/T5@+4U4WMQ'#
M>63=6J/JV6]WZM8B#:]=*V!]_HR\5F0+4:\_,KZX]N\PYHA^7UI'.8E/F!OU
M$F7$8L>N@QMBV%K:C&C^N\\W,X@ZVF9OGWT>;HN8'4%A?W<3@'R,H/U.(^X"
MT/,7?FFW+F80^S:_!L3)/IT/;]Q;_-+S/]/LR7\#^\/_IS4-TM\WC9?*<3S9
MFIYQA&@[@IT*"Y[]\#!<&4S/!@&N [*[^(VAR]LAJ6@S]D=/OF.*L[",OITF
M2WXPJ*TQB>J6*#S/=1A6[UV _:7Q+.O>69#SR ^E)7"^EWFX5&&TNFJ<ALM]
MX8#3Z"W/Y(X?A>?LY_VL18?S7A4TUKAM_=9T)@6SUE"BA=U:!9M:?-D^OKWX
MGY!>X7_-1H8 ]'^5U_]57O];*Z__OTV.U[T[H?IDL=;F/2O-X&\SD!_"QKOJ
MM2T./$S8V0?\^D 4]E*S]HS(SPF<,/;>PYTB+\B?QI;Y!\A<S=.^CT167NQ(
MO#BO>9.\8WWII-&EB5]C^5,J>6R)D\(?O>TY(+7&D<RG\RW&0QJ>/R_VV2UH
M=ZIQ"B+XBEL;OO6W8QIL?BHHBGAR3;Y)?M H>>"#L:C!L'G"H198/]@>?2TJ
MC<G+O_;(0+_B1/:AUI/$HN%W)7<<]SQ82,_4-P1_V#%YNJ8%C3N5XT>B+L++
M]ZOHT[A?Q>9_$"[TN ZBSGAD?%MZ"+Y:<&O:)]9(KH-X^I:G@U5[8<3Z\;;!
MB6:^T]0<>/?WR"3\=D*H!\\9VWE1B/V?L8W@W6P?&/\)YC!Y-?NOIUU@9? <
M=]B/\^!5(:2#QH1HJP0GAO=N&V#_V!%6T-4(R*[SFT''11?^CR(!:*)K +OQ
M.0:M8",W"MB]QIP&[M^+KD")=*J=Y,X0@J\W%Q;%/6@W(*/J^ /]A$.DCQ\+
M[@=6^DWY-+Q[3J(/'3?0$Z45'H5O]3OD?>GRT!U)TKWI5>*0DW%4+H:L\Z:R
MVY]P>XQD2.2^.VJ9FZ'3Y:&E%=IU./IQZ5;&E>(;'Z4M''2_DBN6 M1&R V1
MAY"MR?=K%^-N(;=+L^LN?40JUQ5CQ>A-ELG%E=T1\<%WE%B.X0^/E<!2]]N$
M_$AM[^VP>GTR:-KL_I+7Z5\_W;*UJ$YW3<OSR;N:5Z[=UN."-#T^EFG"<#IM
MPO#-8:1'Y<SG(?32AZH,E)%+17>]EZ!I89;GS=1KZLY/9RA>C57:FY'%;K1\
MJ+:P8XI]$\'![B9 U;%+U=Q^E &9%^\K (V+8C=\QCLP_8AOOFAA:5T>3)G=
MKFZ/#A /%X#4Q@2@S2[PKGQC)YQO^W!V1R$8L9U?HIK[YVDE,GQ:/7C7[JW]
MEZ=I:^9=::#CO_ZDD>*Q)\<[Y<"3V.,YH#TYY_<4K08"X=QC;/]1-"22L];;
MK*;U/F? *9IV$V5&ST7A?LF^6/IV"IY[:4B=H>(VS!XQC#4X-=FY1KKL.Y5I
MVZ42I%]8T&<87>-0T*CK5M'BU_&C1VTE6-0A8#U@*=\A*C)8I]/LCLWI),M<
MX*C%4OE76]?O17EY,7 O16?[&R/'M]*;Y6S\<1=&ZF+S./.4DDH_5)J330R*
M!]N7_V[R4Q'MH_C>X:!A]=1&D5%E(%V#4?!AQI0I_U3&XMOB^*1G%:$EVWUX
MT\!H;-V5D19V2N&VOJFJ_/SUS1)8Q(B1S+WR&4OOI;%?[Y4[M04W=62)?; -
M+U5P6<@VR<D+>D?6;IC,\6ISTF3XF!1_>3.?_[AV!:]W^[8KPW8+[E$^[C%=
M9B/K(:HW!97"_B&RE21LDO?&J9M7>$9D&?)UP%H ^AD\J<#O_QX@ (VF<WI>
M&4.^PW<>O1: EFXK+@L?VB';FZD"T$A8;^H0@R0[;O.[DF*PO[?BU8R:?XC^
MT:FT]YNH>F/<8]RB2!KU<E_V07[7C,1NE3Q6C9H-F>VD6'#Q.$.TM8G:3\/\
M SQ[;G:JE=3<QQ [[IY%H]XXMBADXYZ,+U>^P+2FX@5G+3TF_D=,WR5"%C)>
MB!#.!1Q8A><DE/]SQ%ZIO4!AY[9(3TG07%-+-.O+9IN4 N\TUQ]/\^9KAV*.
M</>U?O%Q+N'NH9<:OF_8=>ZE-5&EU$N%=7MX2O6GLTZRS><^??3:&M^M:&SA
M76PETZ=V/HKT@"5(?*DP/JAH8)2BX OL'SPW; 4C+K9*T3S=YM8.+OD$9R40
M!HFH=-OAZYM3_JYBIK]0S>+,I#1G,[&14I/G6/(O@DFH>F\@KLI1)&T3<F1I
M^S)@P7D+/@C,=D^2DZ]P@GM3,.JAXLPF!CJVQA=P5FR0U+LXSFRA#-7FV1.F
M)P-8*YBH(VWTT)&\L:A\"-+-DB0[K]MP<_E$EK^;86>KZ:V!ZQY6%:0C7:5J
MK>3$Q\P4VMMV/482VAK>5&#V(%BT<[ZEL$6B.J_(A>C9UFEUU>A#OJ<2SE#M
M3K[N*XOQIU]8ZDKO:RL=,NV'R/#W,8. %HZN,J@(I'=9]M*I>P$C$L4 Y38'
M^3562@GP947BB$ QM["G5"I2)10C^I(S5L8TMW*<&TUW^&;02)5&U<.;./SB
MJID/-&1\C?<T"9CE8GDRRZZ-' 2-+ =$]AB%COO@'\""%P!<&3!F84@V64L%
M-Q1VXY70VHZP@TY/%H=\M9+:5:M1WI&FYHTZ=;'AZ7<T=R3[IQJBB%D^F!E$
MHR0^U>H<ZQEW !=5C7JPWG67U*Z,$_;Y?6%W80\VUWY"A6%%4"KT68D-_W,V
M+0R^&E#<!55H?344HQI'NSF)\)F\T.-MJ'7ILP-%=O>5 (2$B)SZ?;>0-2BY
M="@T0!R(FW.R[.N&2;6KL);W#E.D@69W[CBM)" ><FC1;.M[P$D..=VTP\N;
MP0NZF1.>S-J"0S]?_.V'SZ (RSA?]_=W+SUT'0WRJG3L7<G:;L0CPS+ANNUR
M\>Y;QGEZM\8P8WDG\EIN<@<4Z\0<GJGM,9VOY+YQ#SM9HOTVN@"A37P4/Y#/
M7+U"<-Y@+8Z4ZM[P(&P>$( Z(9L1"!N.#3F1?S)TNS>SCBP<MC=%LU/K >]2
MC-0!('(K#K@?S!ET&;&"R)7D30ZF-1HX=C??M@RFY$A/KGD4TY5CMJ\BB8O*
MC6P ]BOLJF/\[&0D"[=2)BP)K@#411]&2W)E^'+09F%!>0YOP@^@^EA$7+L:
MQ8ICF&W=/?^,,8/"]EIJ-'Y^W'0*/T$Y^GS\QLK*U:GX".O,7HV@G1O\]UN>
MWR;>D%&GO9ZWCD,-E^]FE;!@R90#7/F26AIWUB,BGM6;%-NGZFO?VCS*$V/-
M'KJ'IQL#EML6,>FJT7 AQT%/AV>>&GK*30>GSU@-4PR1LT<V[MDYO><?#^6;
M,'C89V$^(K@851';8;0=P;_S#K'I$=-)!?Z",X-_-F7=[KE<-K'X?#'[JMJP
M[QWUHDCC\CV%48/U_3K7+,;^@1D7>:A?1U(^X5%YS=1H-'R^,=RY5$I*(8G&
M]-<_=2R[OF;UJ)S<H(8KZ7K4I1F9V)/;#_5K5*1"TCJMNN3"W@R3[A,3"7:J
MSGE::75CQYJ.F>H-U0S"<UPCGCW6&=[=+Y3/#ZZ%0TTH#"NE.3RXD[F6JB8/
MV'&6Z0@%$WS*72AU-S62*_3L]S>%,K6 *LZS)GWQ$=F"X7S_R;'.P@55V;'\
M@RZ.?VUWJ7$PB"&OM"$UTU-'J)=/=]P:G+M!$&:EUU,8>#D3\H?!,Z-EW%HW
MO^E%JC0LW$"JN^A9G&5\J.>A;@%(%)[TF5/+M6Y@+0<4G$Z<B+K]NO$.7$CL
MD=C)]"ZH)G<\PV16Y8O9ME"-PE/-L JQ.V1I8$\G12NMEZ59_F0&@+MQP8FD
MS0Y-KI6*L,!@%ULYM\L4<$Z);BCO\J'?;"(E@B]S(E<G=AQ0!R..1>RASQS*
MMX(]X6EP^/=#R#P3#BPU9O<@Y'Y4V'.TWEA#L76X77L6K;M4MFELT]<7*^NK
MN)E>$_]&>HGE>:G$W!/!<K+PR#.^7DK6.*)".UO[["G70U:CJ/HE_^UC"FE5
MU:ZPJGI3F]%XBJUBOMD>LL?)+>/ERC#>U,^!;&YKZ$+K6H;$C&]E>#5_<ME>
M3B <J/\^G'L+/FY(G7N$5[K>+E8&?!:&#BO>@&I<._2E0'X2FQHKU!P2$[XH
M+SI"UA CA\28MW$#2!%2.,_IL-_L6!%NM$/3CBQ)K4ZSB^'-1@WIIAD88V[S
M%I0[VPG/%$INRM[9Y0+*SUPPO4;X#%D*'A& F(>XY(15SS5Z@ 'T4%/(2VY6
M;H5]U2+K"ZUJ*ARJVC[6<,_.OK6I2 6H*W4\_X/DN_4"F""CL.<Y6XU5@)X7
M7&II:*E(*\44FT0]N$E67KS]'&"X CB1) .KP%H@VF6,\?HFJM=K)#:4)SL.
M>=(0%XUT\^DO/[\='PPL;#T$6K@RW4)4!;-4X;2Q0NJ^A7H\,RN5"1,+#1#C
M9"=F$M.Q3//\&*HD*H#A_+R9S^">6K7SR%<8:+GRO+Q[[XEN,/%76M1'*R]H
MX*.K0(9> 7*G6C'.P25CT6Y';P85IYN5&3K98+$8D&__-C;\;;[YR#HW%G!
MQ4K(BYB4^=M!=E?#EJKSRER$S*2GNW1BJZ%D$3XQTGC^S-D2[9$J[7O!K$A
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MWVFGGV1QU?M:W('8$\-9NK&E1AX/7 M;TO/*WDQ05_814?YDGB,K,C- B;M
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M.EAJ9!\Q9[)[]P9QY",\^/["]EN<V5: -P9Q=;Z/OQ#NC[CQ?7J%^A?(N@A
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M_7LL$X:;T>)>PRLBT>&Z=V3"E#5JS<+KXR?M+6VY?[PYQBL)8.Y88M]X- I
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M@=S:=\QH,:5OVPT/9MS/4&EX'\^6OS3_[$GF#05* .;3EU11\9^;%D%@I$I
MT7%5!ZE*GY]DL$279BA_U?_)OQQ56=$.T1A=J4D&I^889RY-!;)4%5$;<>&
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MH6ZV( "8D;9Q8G .+Y9J#3Q]O+M\E[^I91!'V^Y<74QVN6NI+E[+=HRH5)=
M"TLNG4-W-_<_9=OF/ZC6,5S9WTL^F17M>3+[Z(GK)U!>5 $39R3AC&R@3_06
M>9.P=+"G#).*7'#%:XIAPS;@LJAXI(W@@%<1PVXC\%V>B&3:\4HOG \T8_@^
MB:,"]Z(F7C==\\D^O&BZ-B^;9JR*2G!VW'N^POD8K<[&M.1&!B51%M03;)/B
MH8<$=AQ[_ QGLN-T*'5^&[K^<[_1 E9J%O@XHU0Q7APF0\]G!^3^GHK.S4 <
M'G?4<HG5O_2 P#$ $$.#^V;N)U6OYA<19FEN*V.!S%"O8<OIN9!.21*[M2-<
M(T3EMR=76PKH-5<'/_.\Z^B&E.A:H4\]X8#!G75:+CVWI%2N6FG_N!#F[^!E
M)1/*V/T#A%_]&UN0_@+9!3>!7,&.25XBX%O EMEWNA>/J,V>*.(CQ3#_#S[G
ML-D5W^1XD=VA-7!IBYA_0#E;VCB!&M1&\+=:_G$4:BKG2%!Z<4L50T^KF-!\
MTMPH2 ] .=G#7YLDI39)^6 /XPPY<[ZL=L^$+Q42.0$SKVS:";RO8Y?B+IE*
M[5;@*=7Q?):3%Y&;@U3U^RLB*F1C2=M4+.SJ: @JZL^PX"11ZI+D<'2\@U!E
M]CHF=8AAD28KQ1VB+61WNW5.MG2]VGMOP!>1SD6F2%WWBKD]!PP#-F=-=FW.
MLWWB;Q+Q&1$N/ -:EH5A7QK:BM[8&;88VM37S(2[T)L-W;<]"%!VD+$YZ71G
MVE*D@ZT3;98"7=IR6+^:;X#\'D^!7PD;<,>" HJ]H,'OL_6.KU%IJY1VPGHK
MC,"2JQ+NWJ]72;-\YCW5I#$0Z7.2[S184[R]L56)ECGMC".!7IR#5)# (;3J
MI8K4J'U7<!:@=KOO'K#]E7^19;CLW: R*-.9Y-I4U\NFO:(UI+9H?5/1]7O5
M4%^P=[/:0_<-Q,6*O^3$/_.QSPHA%2_O'QYY9.E.2W]6P"[71(^,\'MESU^4
M,K6^VSJ@-R4X7PNA7U",)>-- Y(>[KV\[<YABG1RO+?Z3L?#S4_;F@>O?KZS
M8[L3]IF%C5HN-2?EO/4*NI!>ZOCWD'N)_B<]043^1=@)927):"V&O35%7F;R
M%04>8E@YO&U@U0QECG_+6H\SY!\5K(.N UXM2DT-%&SXZT&EXIS[Y=BLJ4EO
M&M%IB.H3[$$W\:G(3OHM5RFKNX,7>R[W]PS=YB?C78LJA*V@@U&B?^M'B]\N
M^&M=>+'R)>0.XVW8U0=/+X8MS3A?BV_\:M/WP+MP*:T^IFB5D?2<^OS81NO;
MK?L[ML6]/?)1-W*75IL[8^)I3UF1^I-"\B9U]2<YY59_N10SA=PMD:O53\$A
MXH8.B8A.)UXUC>:>N H(W "=JXVO0?,R3:P?(7[!]"SM\<C^A^=]C[XMZM36
MNON*.$<<IHM2YCO@@N.JZ\2P21O4U$&$LM>'LV)8_#L&9$ 5PR[4-<-7,WZD
M+N1<JT2BEHO&XD5JJW[(^V)8OZ9$+(,FVJ/(6N1EB8O1I.]& K-8N!A6H(X8
M1503A'*L# 0492H9]O?W:O\DX0.6@@F+*G'\%R1!QXS0S-0AE<?\4Y.L>1VS
M+(E=6^8FB52($CSY_J1H9H#^]?QOA,_$'VML(OCS&W\R%I0KW81/'T5:$O3]
M%9+\/J6WF_Q%*_$/"<T2P>BO-\SE]0/1'92D$L=TE*P!:S.:]1/./QS?= A
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M]QJ@><C6D8-BS!]SH(C3[%R'53\.@H'Y4,X)F.V:H SK>PJ+</J/<>J 0P%
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M<I=\DL\UQ_!I!>XPX\+[S,MCXXWT<2C,/<?1F!>Q)?L#9^<58;!\6CY^[''
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M.0$.<-1X6ATW+08QSU0!$GOD*)T:2,@>M*,D8>6'3!BJI-@.W*9!_FH*V8H
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MSJ<R?I,< X;+<*/*-^_1RN9P"O<<K'$)(Q+-+%L.64=!?FYM/-AT!* _8_U
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M<ZN</ 0(<BIXE1USF%=I!I&,4Z;99WQ@O=J>1M=6L7H6+?L?C\4!G!>\A@C
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M03'ZS</5:.;N"?:4Q;C8K*M)D(]/EDD2:4>(<P@A)<&GNVJ1U_[S;G*1<:^
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M4:(Q%>-^CNT43M"8)U<LIX?SSC.54)?8J#;HP4G<+$,N0J"""WF;#1O!=K;
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M&HAOP>Q*X=P&9_W8TLRI)TP2Z=&Q,B9Q',HRC5O'[FQ [>5AF,2#/?Z%O--
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M)T,T<".PS!V9>5=Q6&<P"_!KWYP0]"E\*&*2Y7SW@B&6]>PSI/RYS0!PM"W
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M =?.1V()]#O5_"2!%$ZMK=,1H$<T[0,#6F 5!X602L<*5H^M$-+:M.L-FYJ
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M#47QK[3"_!F=O#3>.2'D>J\08K,(^_@%1VHGC>5P@D!V$8C"@!. %D.NO2>
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M5G=*?7M>XJPM>W%3*LBE(P.C2P8,L%,29T3$!1D@GS>&6%A1^!A4/X'DSM6
M*5[=,<0K#OCEPD#1]YTXP2 R0,;!J;FW;<OA6,04>6=0XITFM9R7$(/XX%]A
MZ0=7<0O]!29?[%@M5?"B07X-X )N*7C,4VR9AMC0!G(CC#IA6D@$MD;(7 T2
MW&HN(0RI.DA+W.#(%RR)"0?WC29Z-?]<2K.#03Y3P-PQ)@/LY;VK?R]*,7\)
M4I>_8_2_/$;':4.9G,&$>M0D3JW"<B_$:M(Z+$QK28RKWP,Q2J?<-PLJ\CES
M*!=3!I?V/>3!QC_K800J0Q52JW)ZU.X<O_2E]*Z%2^U.VN<!J8&56EMLLU/+
M^QSM2FK)N;3,I"U%:W/7-^H93[8>B/)<WZIWD&)CH-SS4[2%"<:AH"!7:23C
M5LG^,9TC1\X$G$LNU#7]F.E?*0 1W.XK1+S3&&643Z>A=\"'K6Y6^-UKK;FY
MT8BDWO&0?Z&_@G&$2P:CTB6/"FM)O-&OL&O%RM5.339$[EN6+T0Y*.R#90 )
M22;IBM+YO'J1I0$I?GOK05[9&VM=:_TASJ+-!>Q*0"Q:4V+&"3'3:?I@.N+/
M]*$,5-^5 :-':9',O^8M5?!?<R]A+D45<;F!'$HK]\N(U0)0TH7]UU0FV;1*
M3LV'=R]*,V3 %X;DM@Q@CB(A-?X3,ZPX']9F(\@N.HVC(:P\A2+)=LM()')A
M-O*)TT60 <;HU<Q3FZ0I@)RD6M9,N- 7%8=^06_[0WN0@?H.HC9H8?KJ+4AK
M+,(+/_K<:ZWD9M_JG3NNM4Z(:K(K-Q4-3S>-Z_\>>K.DZ>8_&LMN-K0C[.!3
M7'$Q,/;CG?3+?IP@K5W-GL]<'H5:6*NHD=\X-0U&]]?XGDO5Z+5UB$OMMM5]
MDF%^($NA\?#&TYI7E?;E1[5P)V8Q'AA"2U^I[5V_#!47ZA/>1Z)UIKWUO\<-
M:O/L5<9<N/K?5/LWU?X74NW?,?J?':.:J T1HT,[(*X8R[>0+Q@HP2-"ABQZ
M5FZ)\@4!D),#'X2.E4&4SI8,9B3H3:2(KA;QCAVURSS9MQ0J3E2"*L^]>O6B
MUQ#+.+(X[9PC?:]T@:$TI!VKYC[NW$FKT6\!?0ZX+=^&1$\W> H(O$? =S8Z
M#;5?@#4=>P7 YXR%RJPVY9B.!4WCW.@B:Y=[C#%-2]0F<E I7BFVR-8Q1?%L
M5K)G3%GRQ:Q T]G;Y4L62O?S\?&0=6VJ]IT]S1<,,&_K][_VTKAC=+W^CJJG
M<P$OJ_"GS%MVF9]>^)C2A-,<[#?E,'49X$$CXQ99WI>\5 G""+1TE"P-04 K
M.(D<78.P=7J:E,S'+6D_=K!2>]X@GT;Y3SK4.J 5^"11 _Q0A*A1HU$'*R\B
MI,:<'K"7:N-SDV5 ^R!"&\\?*LD 1Q^T;.A_ 5!+ P04    " !SAGA:"XKJ
MC2X[ 0 (9 $ $P   &EM9S$S,C@P,#(X.5\Q,RYJ<&>D^F=44^L;!8C'BE*E
M=U#IO?<0KG(!(=)"#55$2NB=( &N= A%J=(O0HATZ540$D"ITH)T$D2D20*(
M00(,OYG_FO^'N1]<,R??SGGSKG>?_3Q[/SLK%U\NU@!W#'3U=0%7KEX!/+G\
M "X6 =J *_\?K_]M\O]UCRL7'P",MZY(7_6[=N4^X"KCE6N,5RZP 'X X,J-
M_VL!X/]W7;EZ[?J-FU2W;E/37"YHN0.X>N7:M:O7K]VX<?WZY=.(R^> ZXPW
MF.[)/;C);.I$==^?1?[%J]); @\;^E@ADT1!A:<!T;>IV=@Y.+F$A$5$Q<05
ME9155-74M?_6T=5[I&]@9FYA:64-M7%^YN+JY@[S" P*#@F%ASV/B8V+3TA,
M2L[(S,K.R7V=E_^FK!Q5@7Y;6=78U-S2VM;>T=F/P0X,#GW\-#PU/3.+F_LR
MOX GK'_=^+;Y?6N;='!X]//X%_GD]_]P70%<^[^A_R<NQDM<5Z]?OW:=ZG^X
MKEP-_=\"QNLW[LG=9'I@2N7DSWQ?_L4MEH>O2AOZ;@LH0(BL3P,FJ=D$%?%"
MI/]!^S^1_1FPZ/]7R/YO8/]_7 L VFM7+LF[Q@C0 IQ/1]ZDT)&E@HE6>-[9
MN7ZM^%QV%7XZ((,F]I#,C8&,*4[#/0TSH*@<0Z6O&=!GKF&\RWG+2#G!_)]:
M9)/5:Q> [VD4F0M /TW_!8!274Z^G4XV7:7RGSYGC?KG O"3?6H'&^6IM4 U
M> &XMHJOS7UQ9$\%G4&$$6X?,;*]EQJ5U?/K7]#@S?QK^#Y4VL?4->,OBSO[
M@RPX'LV79F,XVQ?]3][)8^?Z(7['S=_-$GZ\JVI>JC("-ABP;$BT3?+K$-R2
MH+W4SN1>C3'5@B38!IGG B";ZECU3:WB?M7OP4!)H5L0S!0V<&RXQ</$-'I2
M8U%[\0* UT8P7 #>:!![+P"W9&@N  =UZ?^!IOYEM^$I^'RJ][K(9/!J>M0M
MH!@[9EG/O'7JIV;4AY6[!98=D\7?WZ59)7W6/6#5%P2'Q3JZ6SNHNC)ET?WJ
M@J,Q#=_9SL7:<<V+6@SV4%L/V1WVMI?0+]P:[1GA8:ECF"&F).=@4<X8N7M_
M20T\MSYGAR)D9SV>'"SIT#I7TBJ+7"7"%U@]('X6HE6O@Q6KM8L+@LK+- SD
M]2OR#L+8D1WQ469R&!."@_0(:?ZQJ,5HP.X^8_&S+Q1I?F;.$3ID,3\_!)G#
MU%AFJLUL.)ZK)#8(22ESCKL Q-$1M<X3]_^'\6[W)=SA3JW_>"-=_'3PQ;YS
M^618MQ@A@@9KNJB\&%.V'1*ZYZ/_X3!C!<IW=R@.QFJ1>$^_KV;,C9" 26?P
M*/F2OY_6+5;N<?K*UFA&:5D=]T,X\X?DYQ&_^FNR]_YYK1N2'=7YH9@UTRS8
M1<?%)/C?>G7P-7;+V[90,_..-]GKU?K>7\,SUG<)',_A':0Z%UHAJ.C4 #B1
M9(J9R?06G:XC)6=]7;(QD/=N[Y*BY?\/TLK.650^7 !^"_1>HB!&_P^0^,[D
MCY\1XAC#3.C[F5TIQ43O@:5.U-A&MSHBI.::%&9%__YB#2VGP?"S+WVY,(WX
M (32NN,M^##G)A&=U*S%J..!E[;5F]F3&>M2#DG"72+G)6O0)I<>M_;[^></
M$\>9JAJWZ0NY4K8EA51NZ2],9LV"K-M0F; ]9[?!>8HG! -&-B42)/IF2A]L
MDF=M6E0I9BA]PLGV0V6<"3*YM5X[[4])>?_PP+6MN;/=A.:!-W"8X>'DW^-7
MAE2%_@+-GN01AXZSSNI!\C"NU<1(/H02V;%J2YV^-KC<'KE_9WDK="+8J\<W
M^T;-1DK%H^3=B.^U]\3+7WK.C,!M.%$\EO?C^45+M6]( N58&YKZUK8>6N="
M%.^CH;I28U,9!K\5N\J^M2,'=N?B_?,<'%,F5%>YT\;%UJO6_/*4'A\J8<U1
M.36*#9E!?MEHU<$4?\5GBZGY78ZW?_%31'U?7 ".]"+9+_ON!C[JW&+R D#-
MO19UQKAZ68OD!W#'"T!V\#>M)M\]?I'!,L($#;D:([,6E;0"Z&:+E" V&?VZ
M\P;8^(!W+RNC// $%&1,._FX@)#I+/&)Y>WF4CHV"D 7=<YHMFY,R\ 4]H9A
MUWCOO<8I>._ZFFU$[AZ?[X+^B4[/JD;H2),@]>8 <?T#86>M>L.<38".8[P&
MYO06EXQ2?5@NH8OB,&(N4P^(Q5O*!VUPZE1ZA6Z Q)P#:^IO%#Y1G5.#\_27
M?W=")XTW2;)"GU9:%%%_4<.3X,E*6\ZB<RA(JIWDUF"SN%F6G:):[Q^7I4SP
M&+MA>_2T*4ZQBZ;K]4;. NZ727-+>WLRP 9V-SZL+,,:;V)CE0IU!N3>I1XE
M[J=V\Q/60WK82+HQ!+9W4=(_%2,L1TS"+<<_NX)AY>Z3!>(9LHP=UP68Z (D
MJ^G7MFLZD6A6=G$D%?VCRLN:U'(;SO28[)JMEC+=[E&96+?A<!LXZ<0:#LO^
M>TCQJ%4S2W%3[<\<./S4SQ3[-<LVQ8530SAO**H_GLQ_ ?@[])*].PZ7/&[8
M\Q-+>Z@N ).\Y$OV8MDOB3RQLE=N(+%_<.";??*Y9943[O8(YP/L%7D\$UP+
MFOK9O12F4[M9))@"?K61=Y7JH_BCNOA3ZRE%;&LF9#9H65/&%1RNTM/3T@SN
MV!C*O=%D!^8HALDKZS&&(E*K D3#+&Y5>6\T/ZVJ\S!<6\M^5*TQ[5-4D=':
MT&E##0PL'IM+4<4H%[YK-,$. A^D9&+&+4WC@AJ\)S-##)34;*<^'OZ7OO\G
M)]73P(BU5#=H!_''*\(^O<?SG_\&!I9;[RBSV\0ZF(QVU3H5;0C?82ADU4=2
MC=+$0#S/U8AN<74U7@@PH9[ANTI^9I6US?;OEM387SJK(V:T5@JZ>YQ^9F,?
MTN'BCGX#5L<Z_.Z542[3QXW)A; S ]!D_YR9R;'=N+(5Q !G]?Z5ULZWX%VA
MI N W:%QM5GEKEOB!<"Z(;*?-:N,P46\U^[8_VW%.KV>D) (Q\*>P,L_%8[N
M].,0\@G!$7FN2I[ UWH:3GH=70 2'(3.AR9]FM'%^C*[8V-+IDOVP#1B%]!/
MH/H#HG4)J@^1^,[-D+AR95:I Z%209[&L"]0I$F?RA8\GP?]_B='(>F^K?L/
M+JL<>88\%H\I8=Q*F:=S-3<&>26I.JX^!U]DP^)N5;WK=U3]L$A2APN>'%"(
M-WQ;[P:A:W-A1QT!NTL&@!C@"+&CF"8E\(N3?WN-*\WMG]V;LOT6]4F7C?JD
M>@IET"JN4"GDR&#ZX('^.+5"\H;[M]X_-/"Z\U-L)-^TM,T$9*[9&[0GY7"R
MY]L"Y@9G-2;9EW>[BQ2K6>*4TG3#H]^PF >,7VU5"#+F)4M@<]@7BE\0>AD\
MN2+SNK=5\B/KG0*]G]Q14' 8X]F0,A%O"LML=K> QK!>3U/*-O$[1DJ]V:JS
M&'_G]]7(Y[/=RD3NBL?DW(K'\+&FVY#:KD<-L!VCG!I2I:1#NBEGX9$,J9I5
M06YZ9-FY0"9_,1M96JK)_&EU)I.Y3_7@CNO%U>L[4O3+0>U  8+PYZ#F&24:
MK3U?1FU/'X<+ +1U6N 5*MU0G\3"5/H:^$Q?0-<>TM3KZ9A:?)],16Q<'0)Q
M3 >]MX+D#G1*1^,Z.]K9WLQ!VF:^Y9L>NT*!7SU%^P/;:.<W6;]CXJK 2J69
M8(G^J5&)F3(#%D]33/]T_2WS"C3(BN.T,5UIM7TZI5:TN9NZ1^;I/0S'N"QJ
M,.Q<XFZ?R0!!PEDVK\+38CCG9O-WJZ"WI_"9 @LQ\"O1>AB]P<MOL:4BWU?_
M0T7T_I^&,6=:3L;H%>A_E@XN<M2=^FGHB,$]/_QBMVV9TT03)GEC8WE4^9="
M^9Z+#U-(>&J%ZGJ\[JL/J1^;\+U<9.U!FJ!S5A(HCB#4F#G<?3XTL_OS9BMB
M[39N <HEB[V3MB:PMNO:-W2],9G1+'/$_< ,9O2FWRQH/4QU\-#\!)+U9L9^
M3[CY?7I(+I];MLO#.P3*^@+AWH1NS 2IH5ZQLK\FR[W;L3D@3JT_,!GIE_)F
MX]FTZOZ?TEF&ZQ%$:!&_5;(AZ^'3_;]!]7(I>F@/FY42M[ \_PW?Z/!8>&S!
M"VW1OX:UKUKE?Y=I669^S*8'P075 CV,!*93CTMA[C)?Q6N81B;RM5K4K'1I
MJ%XOVAO)8L0V%)DJ5J#ZXI7#F7!5(8B<?H?9_Q2SR4=%'YK-ISXA(DY*X/@V
ME</FCTY*@2=PBCEM"F<YV4LZ![D)9Z1X!+3N9G1LEOPA05#G]8GKVS:6Z+JM
M<RGBWC=DF;%4:VW5X@Z;/.RW-U8#\<77!Q=XHQGY'@2U!_O:=RPIJ,13W/ R
M''U*0W% \!MX,G?(;;_?(!0LZCA$C5K$-NP9O.W)KKQX0I_X(Q:P:!G'>,"(
MF*YB>2D$TO= MW#!2*X@*",VO\DTT[!:L568)[1HIHC+G#RB6&G&;&3A=X3'
M6G<8O1=51D%2!%("JHVDI0S\(,G^L.;)RR3R9WYFVSDQP)# QS>KU:"TR@LW
M>S1[D+P04EJWA6OS5WQ]@(.[M%O]TWXOZ[& T".$]]UBI 6)/^%(2G(G']>&
M@MG(6J^>FIGTMC2_<\D+?0CY 8.P*\C(QH;(I_]TJNQ^DQ*1?=#IN;CXQ?$&
MZUZ]9[C$U-G&/G> (_JE7KI")= @@?-;!ESBS%\OL<$;K^8;5;/(<1;787]6
M+]1A?QRR]E\:_Y\2V(MQ4"6&IF2$ 44(J518L-=?'5R@2K?(XQ/5F_"]C;#[
MEB+4!_>K>>($8Y(7VK".5]S5L2!^7+<+ODC"MF3DH+E6VV9Z3Z9@_!LO[G \
MXU[6G:=,-^2OHN0YGIU_1.T)Z;@$G34S9VU%&("F&/65-QA<QEBR"[P%L[MC
MR;_4K)_#VP;S\OMGLYS 3.1TEG<_141&.,QJ?TZXJ1D83*8\6_3X9,\S\8=#
MXO9:_)6L>$M ]=5;=U.B;ZU%JUWWTX&GG(N3"TMXI+K%6-'_I&-$/M_X.A<
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M<JYL689P*NX]7#5I/O7)12T[:ON&X (^?D[BNT&?VJC-S/8@FBZL?K>)%.-
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MU!9RCGLJI9(B\M74 :66/G*HW6V=0S5+]A>'*7,IY'A51)L4VEAR/>W.J,C
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MS!9[]I/(6!9[MF>0S56K*JH>9?GON^V?HN-5CXF]!&9_9GS*7 (JTR\5:'Y
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MJ(LA4?9DQ]D7+3 FYME10\EJ3A:!U+(N#N:R'0#&CC7.^Z.:1G;R!YM7^'#
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M2"T4.ZS\USAUWM=@':N%RQI&]M+^E.']?@%HQ%7_NT)1(T4V_4M1FUHSCG8
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M3\W&QY</%L0?NGSB6KGM;<43:#VC.7/;U;U O3\T.(>YO6Y:7Q=F90YAGGZ
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MRHM7&_B9ML7[LE2*A+"57%#E#%0&KIT#!E>H'"42SI$7P]\"39;Q44,-45H
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M)FDX9%6(D]=7[V>M&?S?KR->GL'KW&K-2)\+,!6BTSD'_#7]OUU(]G"MU;M
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M1O^GP./5PJB25 PUN4T=*$]&!,1R?:ZAY.:+Q2@ 4G!D?%>?X'1$-+F97N1
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MWH[FIV<9'Y)9<Z>]5RKEG>O'4.:%=)K?0I616@Z19GJC_>B$MMI2N&1KZ4;
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MEFT!_PO^3?G_8_P+C-Y!LC1FG-<+1P!^#1@C>8QJ8H[/>(:+4XQW>WTXOUE
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M^H>/>>'=$A-;[SM^_6HT#X^)%2RH/B5YXT0Q1U4)!ZA/@:V8Y?VVBYB@D?/
M&$O];&PR0<D*_V"?TK=?;WF/_G?A_R[\?V/A%HI)+S0J^R@NWHR2UL-[!&EG
ME3WM?[J2PAL;%":YX6B2="5IV<#WXN\YCX:0VZE:;Z[W#8L5W[%\_!-'S UG
M0X]X ,ZL\Q*BT'MN+G5<T88]HT5P[J2?7^,$78>NUG&UB-BF7/E6X8TX._)*
M7JP0*Z(5M*V!\#*N7;8V]QS+M(:9B_JM('9SP0:4HK\H[+%!6$XS(C0F6PPW
MF3ON-N:'LB&*E8M=:PI3%2YJKA<:!H\4#$3=ECFO"]>5>2+\ZDP9[5$_36$]
MP5X&W8NE+$IC:7'[!8'!$'VRQW.:%WETL]-%F;P>?Z],*X</#_^&]+<?VR[U
M,6@@TZS[?1':60$!XCK<;+%69T6<>CJ[4F[Y% #;+%T$_9LN0B^KO;>+3R=2
MA*\*TR"*D?>TSZ2*-I=>.G$UR,?:[UE^RE4;:9'.QD'UJY;FO86U7CDF72IF
M<4BWWA+Y'A&M="]6=7/H^J:/Q)*%H.2\=IY%+$V1"3K !"VK%4R5326C_C:6
M6D1C7>W UA(3=*8]S:7FYBWH['WXSK$H)FCL'(\2JTQ1+'H5G8E>[N=C.6Y$
M]C\OGST@Q7:>">*6HOIN#=.481%Z"SE[.MCH,!AZ">XXQ3K*NE 4AEX_[$KA
MG_\,I4BV2_Q\#&EX%Z< ^G^QL?4Q09XY>Z=P(KC5UP"!";+\=K'MX13#L)P)
M6GD&W5?Q^8#[3X]['@Q5>/>80XDT/*.TT)_(X/""<HMUZ+A(1NWV$$[4JO$"
MKU=.OB2X."(?V=9-2HK4MCR*GU%R#0@,*3#W<XIORCOJ8F!K\S(:L0#%\ZUW
MXD10:N2^Q2Y]_E^A$Y%MDWDD7S-2<*2FE( CO?[W#*Q^'&Q [F-H5  -W2>G
M=E/K0]=CUK3$C@8Y1B?I*?]^*'WUP-80:HU"95QD@FJP]$Q8)!.TS0[$P_^:
M^DR0PGU7H^JSQ&P/ &>"KJ-C:@]LF;/TZN'_'YO4*50@O6B]G1<8Y.6805Z>
M<GKN*S=CK9/LG33=7+MQ)4KMK(K[(=5/483D[)0%*'DNO8'.G\%+DQIF@CX(
M+N;4#]-25J!4P:!UNE0 7&IJ[L<TQ-&1+;+4CJO(JD#8X@%"2=5+,^-AHK'@
MKR3X(^AS)*'GM]X@LB7FP2P.4A+=>:M&?_Q<[4E.E>(2JZ<1"0++\T56ICYE
MBV<-6NK#KS-!G6X095-*QDX:V2Y6M58LC,=,*F)?\I7*NQ8?HF)1;*OU0W?U
MUG,I'YV%NPYWG(CZ?'/J>_1+WC^Y@N]VOZ)I GE0<FNK%LMZ.:8NLTQV$L<(
M0W/9+1:@OZ2-A&8JA$G1% M,=:VC.6^/NP[)NVUGFM5]G_G6-@-9CZX1=P],
M^C%=Z.:X<G/53\*VAR1KD:)C6P3.^T2\*K#4_RW!)O=HN9I//6%KCPDZQ);(
MWP&!XN.:@-W3>Y>A/Y.6I#-Y8'ZA'(PHAJ$'0R"X3QG!\D?PA6&Z\?951@AN
M_G$>0P$JF;./M=KM@]$4?:4;P@WU[;8T*.N,*\%]JCD;9K20J:(_;@,=S029
MP_>N#(ODV&$Z6(9\@NMEN,E63E2HNY.(_[ZD&W2_(5^MP_]?7E[+^?>7UV;,
MRT&))BB)?AA@PV#;_4-99KM:*UJTCX^9H(!.]%<Y,2;H6L<V@&5<S99E@JH8
M+(8K%;]BZ7*;DD%:CV <0FFR'#%&"E(J]0QUVM\UL,STG9=0\^_"JF7]\JAX
M;]_:-GT]O]^!Z!*'LB%1P88G^4VO\\]]6+E$].A;/XAR!%S=*,'=4S5?D:I;
MRS_46HUX=ZY5&K];UG%P^SYU?_:<CQO5/+_EI%6U^JM!]EMUDTAVK*6+&WEE
M0:<+%Q^P_ "E32%$M]YM-OSHX.UJW,8_X':_B%M\1+]? 7^%:SE16/EMO7/@
M4NT_N1SH]^]0W\\PVBM8A/A#*0H&SK-O5_I+2AS,6P'$+\A'<_?.)0>0-:Q'
MM@CB!.\O!?49H"FPC@^I5&S&X%4J'#),55P3]9(X@RRP2\R;YY^'U[ GM*HL
M##\GU#?$H"0JO!AG1N2!9'+HT3I#=6NMLF0C*@1E8)IGSU'A(-=QZP";=.9W
M$&^#Y[LXD,+?MPHU$GL,V(:(YO06'8X LY6@S"G<I1>4:1+Y*W-BY(F=0ID4
M*_?XFQ2_O )/VRZ\^MBYEO:8#\56IT:/%Y&PW.'3!!&:(X67!.^B"^W( ADZ
M\>%\.4?5$M8*@4[RD;G1+P#A(NS$KS.#.W"IHUJ\.F8!LL/3 R='?XI 4&S;
M3;R'%FEF3SYI*!=1>6Y>>Y_6\*G@-07.<3>E$ND1US'O&H^-_+Q9UB+()4Z9
MSF9CAXFL0DJMA>(*HHIL;3*>=E7(I8A<%#3$:G[+';C89G/6P>J'58%%P,\?
MSPH^AOO=^%9>LL]O?,E?IGJF4YFL539Z22#9$?QR<&>C6<F4S8P3;*6I>LU7
MQF*DR>K#IWQ^+52&N79618;%D*FS@9="P\D63;S/#;P.A\*[%_^1BY+4H?[%
M! T<!H:8H+O]+(^__WQ9<*4>1UGS9X*<6 8_XN-B_+\L<H%_Q%C@P!Z%&@KW
ML53KD%"Z.@(VNY_>W[LFJM=J1FS)< *\;TH>98R4X\WR5C2\]C6;W7Y7C@%?
M'#EA[*^O[:IW:N=ZKGU@C#(.CX>?#I_$'7#%$,UW>]0.(H,O3>8"R66_I#QJ
MIU"Z#2^&H=$HNH5_(H2W,4S?\>>SV6ZAKF'A^'+51;O:>,<QXZ'QT[@&:"_O
M83S*CI[5SH<L)05W^T>^G 4*/_9O+...HR#96LF.C^PF5H.XV8S(<<MX@?*
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MWJX\/>P6[!O"2SNS'[I7GW;"Z;(P3$_110C!=8#=Z]1\1(+HWIEVT)^'TH;
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M7CMR 01B!W$=^'58<*]J^X^"8D_\3[/]4R_#_]># :CSU%NTBT IN9#:(:E
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M%G G &NB4/>P"!+;C:Z[G$/*B=N9TZ\'RA<X"<?>;)6K$TQK)[>K*GQB@TN
M1SWG@-&?NL:1D7EX628H"R'[DO$9ZH'9D\[F8H(J'*88^:&]J FJ"'K@%JO:
M5Y=9VF;"?_X]HXL<W#\G3U[HA.?W1^O!N.\?\7E%F81%,$:'=#&1Q>ZS1D\8
M8Y\W?@N557\:O!EG6<2ERGNN%#.X1/KE>O:'_3=]^_J#FN=5:\K)31";2R(I
M9%7U@GLV^J^=,A2_1XK^%B@82+4J:R)Z/!KDT @(0)QML A.+-_=%K"$]T?/
M_>_.XI/1:Y$DPF&:]&2[&.H2A?>I)DQR65*?(A_-.&Y4B*P@= =ZVAXW#:A
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M61M&]=/Y!1_59TG0']$.__XB N!%)?2FB-G=]M%IV<E3K:J4 S*X"53_7ZF
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MYS.-X)3B77(P:KX;Y6-F!IN,HU6QE/<=U%] #47Z E!02K,>TU)11;J1_W)
MZ6.[U:*DN.\^^AG?*^WLJPB-/G:, HV:]"RS,Z:<Q JE/)+*D7L))@\$?=S/
MNB!U&G4&H%.L^\.AE-THE#79T8[\.9;H*^8XOKHMW$O WYG86A=;GA,; PNB
MM6@/]]V+*E;"12HK*=_J&)$!$(QD2CE^>D"W)<K-"3?=8M,T&0X-Q^].A:H6
MO(7)]_A'>.,?OC\E%".T\PAXR%99GXI\VG ZX+2\UP<)I371/?EY+RDRRQ_4
M?_T-.8,2&5Z@&J(,WO*6%_]M4'0#&IM.Z)7B_KH".45.Q#Y6W9+@O= Z47&+
M(LXX$VV7O0![^G/YI[#8M2@SS:@K=Q)/A1P+4(*^/GBXD*8VU:Z ++KZ!6Q.
MFH$=L/\%.4.>3*O .R(?HH\/E<Z8E7[%+Y_<V>4NN221W,]E=T0O6[HI_[KE
MQ?1?[6=?0$11%V0>0XG<%#G34RPFXXMOSY^W@47R=_)V82)_>KV+@7:O'WZF
M?B6&Y>6[= KO%[P^ GY^)/2+W*B=KTR#[W38Z@8L>@1@P)^U*\"B[%SX:RBQ
M0,2"_RHK%CEZ-X1+&$O*-U--9FZ-N#>,.[T./HIZ<^/8P[3![W9/ 8UYZ%K.
M/#8>)\(X=Q/8W/%KG6C7EHHN<ASYW:I"$=2D"]# Y%H7P6I]YQX''+Z(,5:7
M6+%^<N6@6.HQT'D%; G4@]IB/4]W/CS1% (YA5R_<XRDND<1G!:[H>UXZNDY
M'J-#]XT?]89]MN\+2>.V'GXP>Q+^@G1N[YO\TT\_TN\V@KO:E=C$P^W3+[$K
M C%7"\!@#>4<M;Z+FIGRHN.BBSL(Q;&<C^1>CIO/)3ZX+]]H4\9Q*E#U*Q0U
M=GAT:IV;,A6OJM)EZT:]Q0)TGQX(NN/SDNL.\2W7:8U5N&Z7>-H)$1WA[J3.
M<\+)Z>EQ2L29%K\!YX:[92G[LB,/3<8C!2RO_/VMR[PG@1R*=8\4U]8P'Y"$
MCA;-;B)".9?\2PD^J9*G1U1^I$YR(K+7/XQ6O/'#FSU4.3DI/:3@S#.JQ/(7
M7FIBC#%N<KQ]"P CKUN2"3&DYDJ?TH_F\$L4R7K-8^#A-9$@ T[?3O]<^L<!
MS;AU[N)&Y)VDZV\?":T9,D%RNQ1T,1,4)^2XU,D$80)=)GOB#QJ=BE<W.O3T
M:/2IB/$3*U-:(Y%EE4"ZX#=%FPG%RHP\!_#X^P>U>_*256%H@4E,/XFK(F3.
M)/V'P*9XN"6XGPW.R36L]+[875C(ED?IQ+.RL1U$[NC5ST/%@WS>EK0Q5H\.
M6L'5JI;D <^G2.;U+-7 Y7LO%WW(VV'[E79ZQ(JZ=["\3>U8%I_([Z#:;^":
MMAZ3P38YW7Q%>Q/$O^:_/)B@B8#Y]]MJ;(ZTFZWT[%9!J<YO'AVB\O'AT\7@
M-!P?"DJ2XD>BELQ(YOYKE14Y1"P?$FXIM,&K[#"KG3]))M)FO*I;4)?FUU=W
MJ6XH.4I#;XY@+\5QQV=BK5T+=:,!2".M" 'F%'5\F'*6O,D7_RT,]RPFGN^,
M<KI[4I*#TW(E05.G6BA%+N*\U-2&Z7>@+**G>$$W/JI:W"_LR4?UV1K%GE:\
MX(K=8&.>[">?B9SQC4SWDZ]\B.=NQHV46)_@]7%0CTAPTPU$!4?KJ4I' QK/
MU)=^BO2A?OT8KTK^%*@_OD*Z$<BE676\J^M!<6'E5VB9"7=D_NPW92W]^XM)
M43EY059<\WZ=NB+2CRWT.K:&KSK0;M%E_K@3"@XOS[BBUN=/E8/H,$'CP=>Q
MSBQ=@O%![Q-Y&?$.&VK_^7%0]A^S'%(#% @Q*#4O?ZH!,M"IEB)75+R,$ZGU
MA9N,T306,"+ D8VS06=]!99'O25%1^I4Y)WC/J]855>E=<W)-595C]^:\&AY
M4N +L99ZB[H&%)'4>,*G<0<9@DNIDB(UY.%$&K0<B>FQ"Y84JLYQGD#X&)A1
MS2ZQQ_B=\O+]41T-JTT0.RO=O''3Z/X:YTQ?9C]-P*P+1L+QT X<;4B2D%Y8
MC$0<7;M7WGH>#<E],*F?4E?^% \4B'[^:JK9M>P<>L1TB]/1(..+O:GU +!+
M\NC.<F1PZ) ?=:X'>X/#YG.X?/0/?C4MH>G'.]M0Y*-_U]6HI&:4+B^0. "_
M_:&%U)\K7:%*,\O!Z2H]HI_J\8BGL/L']I_ Y1A3NDS0LV"B^Q5AH%(_$SVD
M!)0P O:G)FTV/-8>:!"'(S,]&*H=T&LH):!HV')LY8)4Y CZ/8;15,1X"LGY
M8*FV7\0$!8WV,RJ@NT),D)$ "XK>HW?-08:AO&\9-VHGI-E>?@F63)&YXIZJ
MX'IJ0+.JZ_&+ R'.KA=,YP]^.F#8/&%BRF*F3S@-Q:7!2,_\F:#W,JGE#<=D
MDI9G1B3?XQ#061@=%+II]I2@(**R\62VYCYH5^8Q^P.?I4;T76CBF-&ADG=>
MAV6B1 2R'G[BPXI6?CAU_'Z(\/SWP,DBS,X%8#ZI8_'2*,AT_B5F9SN'4_S#
M*O+0=\7,6PCL.+J6I:?WN;M8>F,934M+IPYO+I&%1!O^C-*A2[_]0+9CT435
ME76P.V\DE/_N4R$8"*@:(26.I%UN41S\('+S^.M33X]"HK)9>H2A< B%@E"\
M#*38J"?7DVY@?MO]_IW%E;H?%MG:<>QM=5W4=9YYF;BC(QW^)+%7FX1R)^QK
ME(VSX;E7RMDYK26L<-I!"U.AKD*>[UTJ.@)@-!,RS^"18(D%><&@B7U#B,FF
MFQ!-K&%>P@9:YX?VPL5H!^N70DH"6)K\J%#DA]H<RX=MZ>-"[3S&K<FUIQIY
M+KH]OG,AA F*"(1(O.Q?,Z4<DCPJW0$17& W7"_=O_H.%XP9,UO2.MIWG&(B
M)FRDT 5=WCVJ)=PK*[S2/52;9.;8,+D;3.\2UTF^>#QZ?$'URF7PYXK3>@_R
M*T9+[W[#NKW[A:J;9X*^$G;09-PSE!(Q QN]+]D42!SF_N5PN*\!(?BC;;)*
M.[$ OS3JG7;=D7#T=..XY-=OPP+PEN>F]OP_#C9+4\\RA@\=#Q=$WG]Z[C)"
MU8@):MC?YXECW.FQ*XWKL>NU2S-$F7O7K<!2SRV6.CPHL7)ZD7!;TFN@_>;E
M\XEKPOE)ACVOK.)L+4UEIV7OUDWY_9#0,*\:V:*J*%VK?SYL,59^N[JJ-CXX
MS=?'7[3WT/EU=]^7?>]+FU[/<R5Y;PO82G/\>:KJO[B!:_IR-J H!2:H$A,'
MW1I,X>UO17<]!WHS%QB":(P^@@EZ";]1TLIJ#^G=+@SU*)#'!%TKL42%+LZC
M^]2HL@SP-A.4"[^Q);TWI6I _RC"!-UJQ- U-'[IFC&N5K"^5D?\&0=Y+@Q[
M'"'%ULZS!:7XT-C'&+UAJFWNK1GS\BQRB<"QR(6="2IN3UN%IH0._8?K!,@/
MX!IDBR*Q:+?AN)-SVKZ"*.4O@*WY+2#>,OK:R"%MAC;Y6P]O\4?]RM;G2E_+
M"Z.-+T?!CCN;''G6H-UMZ37V@86 /91\:.7N,TSG"B\GKV"O3JQ\Y6AK -JC
M$.F];=>WGY\^D8#/>;):=Q-E*$C'X*?,&LU@)V8]D\SNI==X;\[,#LF7,:8J
MD3Y]D .PI]D:8?(FY*+>%5]K\XE6.,DT*(\8=H)V'H(AB:FHW:P:[]0IZAF;
M88(\'+5RGY.Z![,9(JY-#0W>T_14E$$>$K830IZ*IAFJI@3F>;$BN!AG&]N%
MZ(OD[2WHC&@>O:8;[].P?SGZP:=1K^#=,E4M'VN)M26^V2L^963>+%8'SYP[
M2(E^##Z_T ;MA9P"C$B:K0WDP]\J<LDU??I"B?*-+?JVU6I^-//W7FA>U(%'
M/YWQ62I;F#5AA.?/)WX_JELQ.E=8*)\"1+,@N-#_)!#? ^5K-2H$,#9UY+H<
MFO0#9(L9Y0[ #Z?8Q2%4K* 2[2FRD[CYTI:,,!VJJI=T2JU]>+<_\>MJLLGH
MUH/TPI+W9M20"X=1&+(&P^+2SBRK_6/)KDR0_0KQ6U@ 7 ;%)45YR1+9T_\T
MZ72+GMTN045;7Y!R'#$6^//TXH$]5F4=E@0N46I(_5W.*N%\R-BRVG7.;][X
MJ><HY?0:SP?(#)/GG2['#J^_X=(QRQ=6=?=57?8D-E.OI.@,^XMJ\]+X-W="
M@42B6D3P<5IXAAG%_25)K$VH!\?=JE0ZVTO" )=J'=M.9WN=:6P4.KEC7FZ"
M\#@_MB:+J'5\D!3RP* @;(EBQC#%8IB@57.*&B-==5GJ&7KC:K@P$S1M2(8S
M\D)]=0>O>ULF)Z2.QGM5I&NYUW[Y7">J&_<@SR5%?ZLP*4OQ2^+50-,2607S
MJ^I73;6"5D<?Y=N/,81I^J/^*G7<:AT,P3%LV4^J<<&W5):8AOD'#*_GIHH%
M>?[8>W[72OA[4DC%SSC%(BN$Q+)%H,]?B_)RJ3NM&8_>$"N1U\3=N.2$>".?
M%0PIW"ZVRA4QE14\>_G5G<PF*SNO%IEZ(V.!&Q+_=F89^R"A'M8#90.DYN5[
ME-2$D*5_D>F[<2B5LB5)\>KQ]=R&ULEM^2<7:L=41%JI W:A(H?.5_>5%5Y\
MFT#-B: %L-QA3/CQ!HK)DU;3/ #;W5!?8^);YAE<"9\V53YQ+YU?F:=+C^B?
MZBDSK7SM8O/97I0$JP6%Z"F:L,2YPU("^93+><3UXR@9\F0+PM<[=0E=L!)Z
M+U'B>[U&ITR55N*';)41PLS>\U]=(GEN5Z8-77<> FI_?/ 4\0%-/\*) DM0
MI9F4>(?+C]>]WN(<(&58-M?5U"++RS2)B",9O@+G'/NY'EQS;PJ0^=QM<*8Y
MX-6B<)>JE;^QP,R8W;O5E.GAN)[K75]*X/RV61SG;5.N5E]_YH1/L$ZN=AKU
M5FKQDARB@M$#XF0/^H-)W+;,I!+>9Q$ZS03U3$Z&'R)'1[":JR?4KX7+ 9?C
M7_Q+-"7SNHA6EM7.>:WQ2D[DI]0QXS/NL(Q0[)PN-D\I3T+$1"3V0?Q5Q(J%
M2NE9XXFL LGG:GD.D.C8+JTE6V)FE.;[RP^ZO^^Y2+;>65?46G(#W*P2KZQS
MO)JI)<H4".69LJ##*7HD\G_WHU<$5I,<SW#QYT)QC]8:JF_>, ]>P$36KOE)
MJ.))C[YN72$UC7ND629)"2#=.6'L\1_%!"B(OO>(,(&; X<<"E,"?:7/KH2?
MH]V/)N+6H&37SK3Z;% #>3A>4\+L.B4XIBY+?0)LDMOO(;&=^GA'M*E9:$QK
MLERE-<#1WJM!N]DOV1_KC6_[G7/;_Z=DWLZ3454MN!@@UV\+H!?68QVTB_$R
M+AQC-&C!36])=K)_C[.42^/X< +CS-P)?W3>TCDO[&V.61<7\UR"@Z.WOH]7
M\G(@WDSJ,Z[6Y:4/"3Y#W;$B+\9HSOCZ=Z>U\U+>-%6B>6?-[C1,IC:GEHAZ
M[_\B0[#>QAUC)Q?,1ED0$9F/&%N?6=4?:MT]_IAWW&%/;:>9%><"B7!ZRLL9
MZ.95QMD=; '8FN2LT25ZI)0DX6!CYJQF,:Y&>R)S%H'"AR4.46]^-=%\&1^_
M$N/KYN@3Y+NAVR%\").,\X3S>T+T60#ED<A[;4)Y#3$L3C/YHN4K;=*>KKNM
ML,7J!TK "Y6*W_=&LHVXF]H2G#5O/U5OM)7A>APN]R]J4[ @OU=\OSZ9J[C:
M6+NTL%?9CTWFI=FC@Z9B9XDI(W'5V4=E)+G#*G/(,%S"^Y@B)[*MS0UQ%V_A
M#R#)^C>TY9TLZD'4G=KQVI4FK>'#K]>T.,5*#GXC_(_VWCP>RO;M'Y]2J221
M*$*)5+862S&H9$M,J2QCF20Q)B8A@V%$]I@0[G2C&FN,R3IA$&,)6;(,1I89
MI8QM1HPK,V9^T^=^/L_W\SSWY_LLO]?]^OV>/YX_KG^XYKR.ZSB/Y?T^K_,\
MCO138\XF^E';!K;&FUZ,;*.?:06%I6/(1EQQ/NBUW1223*Z]K_ T1NC[\0ZF
MR%2N3XI*<Z]0<5OG]R[: OAT[4EW=\6#T;:;'AV,V'1PN/33>=%+]I_<3+;'
MOHE]<_+-&]#-JV=!()#02TG&'Y3Y_^TEILHJX&(G=QK-'Z9C-TZW7T.'' #D
M6 DO?YUZF>YI9*LRTC03C;Y@@&N_.G%(8F;3]1+^80'T%XPHFL>D/9AN_%R6
MPQ:)Y8,&SAA&/F[\\H:6PSEV&KEA3XN<TOP%.^HQ7S( ,<+?*Q8APW.6C1MV
M,\VXT/^S\KA"<,C[-Z=UG?ZT0>RG+/L-2S=^!442>PU<\S_FP1)GV;%+RZ:[
M89;]8=(HI%F_VDI=7>\>5(=VZ GV@%W] 'IDLIEJ/#DK[N0%,6@=_#%*=3+]
M+17MR@K-F7_E-\T'Q:S'1)-"Z%FJ-I7,1$)LPZ&W_6 %^N8&PW*F*9Z>90O9
MU8H;G0V33>JG+SDD.6NUYE'AZ1V*$Y:>^;2I#4*#%+!$WTU@1MHS[9HFMW"]
M4IOL&D[59Y Q$F GL,%4J"$?9%O9=V\^(-'-0B\L%VP1(/I$K[L!NSW>:'YL
M#%O9<3P"?CMUE+MCJIBPAZM8Q\1@T4<*@?US@2Z'H_F@YK? =Z#!2J;GFV/M
MNW+L)9955?1OB@,2XDC#Q *R*U(^\<ZM@2W*Z@T^%>\-]?F@"#_TGA=3CQME
MM!($M%^49<(KF11=1*Z*A>N%X?(!HP6IX, X_"A272/ P+:SW?[IA[OIS=2O
MA"-5*53V1JXEYYSL"IT$H>F^7Q"A[:F5,8M%0XI;3W?MJTHJ#H+O3BYHU4KN
M4$JG&J:Z%\![BRXK)JDFWF6()-K0)>WOU)X2C>DG0<%0M&Z)V&8+VG>2R[U)
MSF;(OJ;"SX O<DV#7-R4ZS3*L('>FZR_M^CZXN'GLP>V"+TFI!AN\^#)"%#,
M'!:PS]EV:I8/.KK*7#I;6D!KBV-1V]L4*K?V)E05']"R\G-@9@TW-15>H3:D
MXI1<M@_@P?8)>8Z?J5ZVP4H-I^/7E[NL<ZY)(SU.$*EN#X^2!MAW8EJOHH,W
MJJ99Z:]>,H*G@&2F?W< K?X$'V3:3]W+,>#J+]OJRUG>I/BDW+R*'M;M26J1
M-&_O!!F._KT"PT>T+[-AH#W%*=&XS6B/5HC(N/I*PK@"V459SS0U$'[Z8\:V
MD)L569DAOQ6@/-+<;5A;SF_[G/J^4:2$!/)6'$##IA<<K0=6BD-ER*8LE;C=
M^-Q1!ZB):/U+8A7B[ 'WZHCMM'C;M-],MWNWS-3K_<.YZG^XF%@JAF>U-"TL
M\$9)#>( @1N2G>.2MJC#!S$.\4&EIS#?16!:80/RQZOJ 6>6,8WW H?JLF.9
M%M-$YD1U>DV91@FK"/VN[HN?[E1%B+I!/A7TRXWHQ6UO:)'8EG0[1?48&[8=
M6+K$<K/TR*,"Z1,(57OWW^>R!00OFG:BU6ULRSHOM<#8[Q"R?A\IY<,;D;01
MW:O"OO\(@/Z*DQ!R'&L@XT9?@S( 96E'THRV PACYK<X-+Q$!5N*5BY&E<,
M2VU+V%:N'G/H=ZHW+\=/JJ+4.%#ER23$@FOV9A:)0_E05!W5K6=80?5^-&(2
MVH-S%Q5"7XHG"> S29I):,,P([C:3+7,@+2V\FX"6B/&?EB[2_\%HG#)N\KR
M1;T7KV=A$;]X%";V_J/4I+5EJD$OU7:-#(4L"#$Y-UF02$-55 V=&9J6\5B;
ML 5EW,93&PC;-Q>XGO,D]2KKZQ,]E\02E,Y8J[2+2R2MZ_EJ55ECY/F&S&\+
MGV;[NB0G1DO#>BS?\/ID=-OQNJTL3R*[5KDAIMB^?0J[PP6(X(.LPB./9A0
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MV5.$[RP;PU?:@13,VCD7N;N>&Y-9B/=[32TW*1FJ].<]25-V,&Y_\,%A_[X
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MF_3>;2CR=99I%4O3GO58;R+QS2@C\V&Q6[ZI^]!15L!BV2M8:XB;AX?1*-B
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M3-/!JM/J(NT3\D-<.;I $I$Y*B2.>U9S[Y7ZJB'_&8?'B'T;GW6E>N1%?O-
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MP)F VU\4A_]'8R"[OPS[_,\-ST;GCQ$$6 % #3<AUR5YQS!3N.8<[NBU?_J
MZN7>]9U\4.=9K.9ZP$PD[W"@'*8/RP>=#C+*V+@"_K2^R20,(V ]?S:$/XV_
M04S']-GQKK4$808(6@HLD7=SO,>8GZD=W$:&ZPRV;Z?J#S[H?XWL_S<C"SN-
M1F\4&B$P,4+L1\R""+3T-$1^TJ65)6$4Q=/_Q)-%M:YLB-C&M#W,5'F,-LJ=
MI4!W]:P38K0,KMO44 B$3 YYXM@ 5S8/R+DTV(^4<H%7YUC])::AP&Q?H+%<
M5R?W>D*_O<>'7*[M#U-T0CE"AQHK#(^@&LW**ZV$:=,*4G!*V'YF?E%@'O"
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M&-C')/_Q=<DU?:8]5TLDQ:*HX6^\#^]+6OT<(SE+.N=1&B/N0BVDG[B7EHB
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M7&HWV!;2,-N@='_'1%<:#G/W=H(\3%@N+%D8\+?].N91:VDQ8B^C+M0"@=_
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M]_&-H)XL*4'MZPT:/U O,ADW6AK,?;Y^C)XL?M_[!JQ7:)S'JX(4=#(6C_?
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MI5T8OFJ1>A#3]@_EPIW&ULK6Q))@>NP<V6$59X3M-'=M2TUS2H#;)_8WSL+
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MAU7V%-WNHOI74_\9)\K$-H'OG$GB:XX?\3QOI$B__3#^J&DDX/MFLC!YE[@
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MEVV*+3"/CKLUF0J6&X1% M$9) 7;0N?W>Z(TJ<F'H/X[!QZYTG"SVO1>,:>
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M#SHI#2>(V9KC!"]X..GA.6L/Q&X=%?X@'P7SU6U3&)E1\YKJ+&P-]I8Q//R
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M(SG-HU&W##VQ02R.!"/62G]^)YQL/[E]R \.C1D7_L]%0JDDUQ(-O5MXR/M
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M-IST\P5!0B:YM,"M(G60,7RJF[Y(7_'3G0P9HMW)81J<FCPVH:A]T4+W=Z8
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M^0MOMLK6=#8+]*=4"]S2)%0GWBT]\0EF/:%\,_MSW,CY<%$'$\:Z,HE61ZD
M!HRIA?XF8Y?U[H)"T=B,NSH'!L(0N./)Q9!4^=XRQ;O2X[XT'>UH.1S"146T
M,M$]E'TA;:I<)G!3PX]YJ,_9Y4Y+)5\,)PGNLK&4\LTN\6Q(--4_>M8U_C;.
M-&#8:$TUIHC9G\PH>7#JR^5[>W,=4Y"W!C2[OP/DR(;J#8F3[V\+2AVX*;Q?
MON7EIQI/_7<YKZ62KJK9C183<'9]\1&4 8H4?X!L,U,Q<FAACEMZ[[M%)DJU
M/6W91^2/&R';1WPY=_OQATV!B34W>Q7S'[?A)E^E*8\-L8\Q\\5*1@""C@"L
MT#+(D.T-#V"-BI6?\9P),O8M?"M<I0 ]%!PFM_JK=HY\YJ;\V_<C"_69]D5K
MG"_-EX\^UGA(K-Z,WP'MPR5!FS)3H=3#(QCJL2/JTSN@NC]\@"^N.OC@ZC(Q
MD!TFO._@@X7Y\WO\O\O6G+ZM7'&_[T=+^RT-&CV+6N7X:?%*A;6P[*6:2SF*
MIG96R17&0'#K)K=:P>5&67%E)?SICUZ>DN/PW=O'/MV-:=$L0_D_OU9G:I?1
M1V6^*+TT\>XY"J(D5;]\:/#4GU/1&;+7[D!=J@8T-17EKA;)1_ZLLGS"K][O
M<:I#]_IN#K3QZG!2H["&R8Q_EU>-[WDCSZ&?/W9'D3<]UK5WG36YX9@%JN)W
MBNFA'= AR&'D=*?CLFW)1]JZZ'*,4$AF""*W"R]\[[Z/P?,6O-$QK=E'QWX>
M OJ?=\ )Q>UR_KJG^]J[)A#23 ?9Y<8W<T<G67.C?9<<\];-5FST6<$U8BU)
MCGGC'^E/K$5S70[@ \2[^YP?>J#N5.U]JS[^[*2YIC$KY,ZS0'#::2<;7 %*
M@7TV*-]Z=0'!-@6:G3)[C:^,1H8>7W=/=C#V;V]-JHFKF@EQO8>(B@G5B2AH
M*XA-MS9RHBU_/FM#[M/]@1'< =V4(P;R!2+XD*G<V]+A?F%PJ@R+U9J;6AJ\
M#4M4DP_]_%0[W=A!NYGF&#0B<<PF,DID5<8PS,1[ULO;C#"^92 UZPSY'.*W
M<?AT_V2Y@WZ?)DEF=6G$";DXY3)U/#WBS;M-LVK_XV_?6G@_>51,WZ?ZG7I&
M.>'43)[HS_ /IYY_^JK[;.#(@#JM3B[^S6\;JJ]0]$VC+_03D_U^<](NZA?<
M\_$:SJS)\DO5)UVKU-'GL#-0VC="3C1CPVH:;>:.DIC [VW'4CG36&'/M;6?
M+5Y/_8Y7F\8T/;72;PBN]UVX;)A^9[OTQU1A;'BQ] 071BOOQ!U$TL\#,M3,
MO1P-)O$ARH1AZYGL-+:J?9N@%)*US!K@2WT5&;?=-)'7#>UMN9_'XNRWS[?[
M1;]=B1*1++^@7H'.'CT/9*=6NI%HJMCK9K7RI2$37^_(:9WY3% 6T]2Z97^L
MT+3V5._UD"LO*]HO'#,(>3/[:#RT4/*,6/<J1 Q\OYS:=(DQDW- 24)<OMV2
MMO=8J:DT[''IBVN_.2(H:]E)7.Z//V$3ZM>E!74J^(;\3EJANM4)W(/V.,8.
MJ)]WAON*(,VYFTXE9OQ9)!P.#@\FD9R]4<:Y=M>&M>LT)0S+($>*EUKD?Q5I
M*QM&%=EDNI"@K&OL6S%NI.$4><2:&<V!K(4^C)Q#HLRI*2@3F81\.G50PK,Q
MQC6YK#_:$+<#$A:Z>HUDA\]WE^Z4M9ODH&\EVXA@MM:D^@^/FV2HF@?*YMB?
M]?%^8;W\PHV37G4=@G=*-F)A#'[ **QIU@K51=)L_$N152=>UZEOX/Y=MU2L
MA%]+MPNT"?D-EG+GN>R/1MVOZ6F3!K+SM+?MQY(GRG9 T::FE>SUWUM\S]J0
MEQJQ+L(;(4@R9>ZCC\'EW?H+8\PB;,N]489C.NTZ!H2Z*GA^L&L+DU<B6J)5
M\ZN\7'_NABOC0V[S2'O %?VBP$K>!XJ\J<V\,.8?H,0'&*@-)BBR)=&[QFJA
M5 ]K*D;$_#;O:I9O$)VF-Q>29UMFJ_HXW\LQR>R(C>:=_4?,#V#K)MQ>VZ:=
M*<[PF$J*@Y&O]ESI/6NK_6'Y[O530,R9BR[%E0%WKZIJ&@A=/=EZ4HG\TCMD
MH^(2;Z\:B2A4APR1O<13^*$C9KD[8T!9"&5+4Q6#/^BG,\_6H S51^C&" 7[
MLX_UQ#-(FEXUFZ965L["J][JO]'^J$! A"E!-THCR""Q5QC$'HSP5Y0IXYGG
M@2TE!2QUPA@_A8,?FR/#MU57.%:S;\QJRP]$.7K:2,TVAM6T?E,>;"C%)E)V
MHU4 ?]I+L"Q/8Q$KC=8%IB_4QT%),O*EZR1%P^'SS4&WM>;FO7"9VE.T7PK!
M>,FZM"\>GJJ]P[/RZHA(V85&[JGB]SN@9B#U&J:AI' Z2<IOQ4]9]MII]\DD
M!7&GR##)8)I_KJ:=<>2"T9J_4!WKB6.Y1K=XVJ\=D#/**'IZNPLJ=CKM1<'@
MJ1?5RRXT)6A%8LWS^5-_[GPY'(!J15W[O;S)N/K6G*KF)6R47+GL5CK@66,S
M\'NCC]BPU=,')-,<4C$"JVA=CO14>\BX#=T,>G$"(@>7MR\-TWN!^[5Z5 DR
M/C<'3T_!"W^@/RUWF5":6W#@XVU6$R&>T4\5+6>44*,RVP5+.&K BTID,LW^
M1:T70.S/)^ 94QM.$Y%:;K8=XW;DF5XZ,GXFN"S.]V=?_YIOY&9/T]A76/0V
M>\!O6\#*[M9Z"IP:?&UYH>7]E=)-V-^$3\JNE5WZC">]U_WS-"]H%RGV&E]E
M&H1TBQPOB91NZF)@D\\<&)8HH*+.?@BFZVKH>BYXASOO3\B]DS\4\N-]I+UF
M$2QG>E BJ]=MX%V+)]Y?_8+SCY<31--V$49R3Y$B-W\=$PB61)T"DG'!>:SM
M/S)SRF,(GD+PM".DO&:HUCRJW,.!7C41_*?@[6W/"=NSF8Y9PS;:3<R5,C/H
M0CIE1HQ^ 3<OSMCH\5SO,W,CQ<CDS@DQ>)0D(B-C469_5.NO7^OV.Z#$IZS"
M .H[NWNS%YIL9S5B8U/_#*1 AJ7?A:X2 T[4O./8]'SQ;,G_$TY>+M,!:WYN
M+,_[GN/4_Y$-Y.M6Y7P^$Y.C_.OJ=FM9J<-6Z-W8<FGH ]-3@XSW]\3DJ)\=
M-2$N3RV3WCTIZ4$?H=[X;<R7UT099^$^_9";DD'VNC76*V,]EW*/:IY7J=(.
MWX#3H%U0)6#\ N "B:<2'V'$>$=1JHR^5&JA1N^<TC1/:;@<-KO8&N$:;A?V
MRJA'.(@<;E:+,\2&B0R&VR+"_/VC6>EQP=!Z"@,S/]R#^(=S^3WPD:E#HDBC
MM5 7Y2^W*A564F <G;%J_4*(>T;'K#E<\'%@[$?>D%)I\/7=9++UGA%CS]1-
MDG;AMI65/_=]#]BYZCYOMB?.%V\\$<@C97/]EX&T6CQ*7Q<S0_0J3ZIR?.\@
M9M\8K/\U^JS/8\JF PG_TJ^AE_K+;I.CK2SXZ VQN65S'M*11Z4F=-V4NHO;
M)+*U"7Y)I/$$=?^J:\O7B^GR1=-DJ\N<O=R7*'&F<O\(RG>"=PB.D6F7J^ZE
MF]2(]3@CH]N%E7(BW\ ,2V(BOEGT\2'?&/5[Q=")V[S:6EMXK_BK_AWSXT-V
MM[7X$X<)R$P*9@1V-R!%9SN+=$?S:=$<\UJ@O]<S.;X6UN/YO9O\V7V*0HKA
MU9@56QY05RJ\Q90]U/>M/)>YKJVR0<@:;3>B4D33\0S>@^)%6PR4C$O**'5?
M>LA:V!-7O.IA#GJ//4 :*D ]]]^X"P]I:_A\;"@\!K_4/B##+72M$1K>[R;V
MS*(FV&^QK] @O?=:_:#JK?/J V3[1ZJ02]XK.;[J13*"=XSV,VK%A%VQ^[Y?
M!=+%$OO]CA;,-T#.U"1WD< 9N<<[+E=I#"/;SG3.PZ^KG]2ORRFQ<-'5/A2>
MI_G>T5>=?6D']/$]![T#JE=G.N^ KOC$=-2V.[-R=D#9X0!W!W3#F5;.>]6Z
MB2H*^/>4- SWP77BGU[+3;30#BAK((&X6O8!LPE/^+\Y;TT.P4E_!V8)).Z
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M_>2COX__1KW@?.&\0(]]R.5=+6BR825G&23[@PT*I8RDKYP[7ESR.*CLP,C
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M'W/L_)EBEQEK<P7S&%GD<23'A8J3<CBT)%_T1%M1VVFY_PH>#]K\#W'K!Q9
M#7,.^?.RH&Q^I6F6'+T=T,^DS/_]ZNE_K]Z'E/W'[4W@XVTRWXEV'8<N*>^
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M[ZO7[+@GV&<_'"=3&9U)(V%VP=':Y>6(W++KU7Y/.]='_YX^3/\.XC8B)D_
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M*W)4>R'\[:CGO7NB$#M9ZEW;P_.1E8Y-"0.(A,?CZ8[%8]UOPS,9XNJ)K)0
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M_9><6WY[N>3M?!38Y!+WG>8&TLOE?/RXA,-0&Q/D6,3*KXA01N,6:1+XBZE
M4W2YU^B#@F:Y@=^,Q +6*KN>0NVEPQ,ZU"J:K71/ZD+.ZUS9A.^>M#F'ZD7C
M2+=^;I)4X2<'5#_3]L,I$%:[8K7*Y0T\T((WX#!OXE?BEGVT=H1R4MR:8WU$
M(8Y@#<]S]]?% 8TY"\&^\4!$9MH:".)HCN'7BJFMQWM=D@HS]G:U_W95S)[?
M3 N#BT"N5"#$F-%\X [(K8FEQ[>$8WSJ,D2LU;10.=FAR=TT8:IB/8GZZ=V
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M.:)JN<(,\1_*9\V:W/.R4OV'F><Y-S/@*;@+(K3J4%;T3>H=\##D$=!/VZ<
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M1>QB58O6_UZIXF__Z[(H_]=[A9S_9:J@H8P],SB&UH98;;F64 BQ$,IH-W,
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M]\M.TIN/<D4L)0(XT:V2 [NA(J!;C$SC;'U"^ZCZ#&8[);XCYF<*9T]A1X&
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M91?[V+V*Q<BQE5X;&MA=7_2O]0.45_J%D@ME)<$Y]RXWEGBOO^?@7/Z@_$P
M[T*HTU8_[L5%-USG)"ER2V6A51:.G^6>^,'SP%%Z14E7G:!M>2#G6<_^.Y)U
M!,<D3M_G9=P4.)4KRN76#-Z3JRSCBB>*ZE)S\&M-,50@,GCXU!VP"1R(BBWQ
M.=,3B15H''P-=+1TNAJ/^\3F5+R 0B5KIIT6+1\VOXD_5AD;A]G]C%]"FA'#
MD2^J!_ABKMSR>YC@KQZK"@XP3[.(W1EI) \@B#KI^H$4$MDIN(H2N7<X,"C
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MTXJ3T)]O26 TD[MTG5S-$-<N_Y[-20RT$R-\BA1+=Z_"+MX#<*LP9TL-Z)A
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M9YY+K:<-4;=K7S[^6DI*17A"$HL]&?[X.]1UZ"!: E<-M8]0W-)01Q78"R^
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M@3AM"U$N,3R</^<VPW>GU,R/&/#1<R,"!:]OOMK-J[#;]B@E'*.J^+8I8DC
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M+!">R-UDC-+YA$-90KD\ZF8"F5?/K-#AB6H'R@+")RP9<A"%O9(QEN4/4AV
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MYB?!S[Z6%GM*']L4X<:U-Q20/DHNR6*2MY(&Q;L;0;58TKY 7UDH11 )<1R
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M% ZU1M :0&% 6BY:31C4'F2%H#4^+=I9V9YS0& [1SN(!<S]3.KF3JN#L$"
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M"*@C& JQ^4,%]X?DS(5?^'@_^-IV-K:_"B[_$)SZ]I-]-G+0MK[[@/;BFQ
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M3A<+X+GW[DX_DCK.]\IGG#.)LJ,-[?^%]J,A8>#?EH;SX/_.48?;_+Y\8%J
M$;H6-K_QKEB!3O5 ;@AEN)*NNMJ/!'7I!_NWRMBV4)C'+;"=S8](X7]OO-(/
M]EET@2!K"^1YAL)V <$0_U!=_P?[]^J7+6UDH6 H[)?@$GY7D%'\*3AS0P,*
M.?O%1D"=3I<A..C7P.& 3P/Y-RZNY7FJ^QO_,NPLH?V%?3Z#6+_KG0WGFQ\
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MOCJDMPCZ6/F@>1BYM*O $I<=4!7?,K*\EU/=.KJRKV_M$IB06],V]O9 1-'
MQC4H,:^V?7SUD!" BGKJ+?JY3UB8&$+G+M#Q$:&?>N!,3XS![Q=-<N;!*^W!
M#P*,E@NP^S&R.J16<,$=)LPS!["8A5X/G3J1=14HKR>, "W^=.%?>\#RIPLG
M4P!<M'-,0L!-P+YNC#*31/B\05.-  /SID:FY(W'T2"]9ZM!O+,^A5V%Y7O
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M7@TR,#(QLWP0D%%4TM8WM'0-3&!5L+*&#8TM[)P:ID'Y\;K-G\C?W\2)=NK
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M<F^B'&AV5.0MGK8=R5C4S%-8</G3<^,,OX?ZUCA--[CN5>TCIWP=5'-8N>\
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MMP7L*1S(> ]<$$O.[!$GY6\$!KDU[NTO6AX&ZEZ>G6V%@BR*+UJCMBT;A5%
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M(;T#U%-PSN+*UW7D47]T]D]':7#7Q#WW?GKJ?KX#I-<*MN;C=&X(DI(\PMP
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MN4YS3WB<U_*./#H+MHS"N$=<SF][!S[2K@S-R'"#_,SMM'X\J:.@N'WIN8K
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M1!I*UN/^.%GK'>00D%$0S&=>,ZDTU$MZ\<I1F GJED,[4:%XH0BTER[%F7M
M7T(P\\)M32*Q-]H=1U"388CI#,NS;$',$UL4FLZOKF6*6NY'G>\T15P#/7FX
M4L- A:J4"&O:10I]'7K'#!D&6BS9O!#<E*GE[0+QC*&),MT@&A1Q^@NH%&RK
M,K-9ASFH@D2Q6#6C<IDY0CA.L>U60%T&6&P0.]H=#'LT'.4PB/+@<#[FLUD
M82.RI'I\NIR6$WB\5DI W[3:U(Q,3^S$H-B[6G_M 7V5/0N7(;B58JR33RV8
M;3"PTS#>&]'":NN) 9>3,3$GR7Z/ </I-,JG\#[URR[;FZ= E'),-5R(26;Z
M^6&;Q17IAL.I/8@DD.E#$&Z2*41GYL8F!SY(;":5?N&4(B.QV\UUVAS26WNN
ML5JDK,B6!&9;4)>$@%L.EJ,9,2)YRMF)>P"#F.4@[)0W"V)4Z%Q54=H2Z6$!
MVV3[=,_/-N'4M(GEP<'J\X"38+-8"K699P6S4?!J,9G,:7HTW,F2OY\/"7FT
MEM&AOI)TPY75T8XA0'B]RX8J4L'<5MMN<]J9S,_N8P\ZBRY#;;O7^?F@4Y.,
M\P.@V.0(YFRQQ10=]C+,Z5-1J R\>=4N*H#A$H2!UK:NPP6^*#-;Z9=S=\SN
M#NFM;SK3Q6HQ:$8V9U4+0IDYV&  .XC-('*931MO ^>9HZ@E@S+K0&!V*AUO
M.;)<JPLW!0>YX^PGB5UVT[P_(-@6AI$.NT3FFF.+ ;/+&FQ;Q@-]+>L#8R46
MHF0%@E.,[)[1<@P1DB,N!+@V7V]"=E':82TDQ-PW)BYY6'JR,!RMYR8YB<:4
MJMV5O]I/L8Q;86G3LPK"V!?DSH;!=5$3HRKH,1)4:$YGY8?$)ZCL.&W*B+1=
MQ=>WN%WOTV;:$%D4A%CGAZV>:YE%(9;F=@FUNN*)\")9%Q%@S\6A:-@<,=B-
MB&!E[HQCAE;G+*L!\<TM;6V66&$N^S92)O*V&-2**+>"/.:XQMD,*+%C>A8?
M:BY#Q:R-Q5)OG5E#MP5-F<_\HJ4QS)>Z8,9X0S.E&6@852&_7;*FP/4'H1_L
MB'I'#SFL+['[S@F;!\..4VDX98-6]2-D9UL<!:%-A4_%I3U2O#Y>C],1-5E*
M9#>AVTV5EX!:LOUYM _'LXC=#[R9*S$.5455YX2.&88^6-+](._G'7(V)UJX
M:EQ.5.+]N->D6V!FH8B'Y&.O:HU-2-:P[H1+,-?$/:39YGR[S-1QOC,9'E7W
M\B'JJ33FY!WFSY3 [AN^MHF0:(>)ZG@/XUGA!3409-B2)VH9]R@MB1-_YDL9
M-3= :S(?Q\9B8_=,D=V1R@&*:)9*4ZY!Q@F%8$%)5M2R$OL=+(' G EB(*NF
M:+466 >N4F=<8[;2P5L_9-H6B(C4Q@* D8%L 4G;X("^6%(PLGFVW:PI?".,
MF#:UTB%F6*F6JOF<KMC"!AA'P(FM%X)L*Z">HTX4E*=H<01NM72U&LD]<NIP
M9G#8%?&U*8@U*E>CVZ:7^3,88/BF11)PR:P)J(?V\F()"@4 M^UF%9L!7B6J
MSQ:@/=\P@P9"(VHN;VC+M@NQ.M@A@_FV9DFYS@N5N9"8IHL/-EWL@UT!6_-!
M/E^#^LJ8K3L,KV_Y3E;-88"0P"==;CCED8#HDRTS0O<]]1"D9@.N8C8DN<)S
MWYL+F358]T:RWUN4'< I%&S07_J87/%+)YR) *KI<9R9@M[.&%*EM(8CM-+M
M)?@JQ-D#:$^!B;$S.$%>5\[2"<JZE$PX0CP4-AMZ8:P;U-%I7W-+/LU"N4WX
M">_QV*+V+7G(%O):X#(H#(+8CNN#@[4+,P0S=1CWY22E^SV/FB[8I3:*9L5N
M04;4H%W@D5YX$K%.01.K*V:>&E8';3JQLR(-H[KI<LL9'B7.8<]!V->M"[,>
M121Y"7>0>C%<R5MEE'5+&5^6IK.6TKC@VS&T T!2G2=!9HJ#>D[V_2Z0^F"]
M0L=#6[ -63ED ;[<KV5&0D(0MV;+C$,&V'["F52GE:+64 T$V8V3C@=(N0QS
M?[,UX$!RAU-KCG4ZEA,D GN8&Q@PAAO#8X84,UV:MC%2^EW4(4O-U(H&$( D
M&F3!A)!=I$>M$DM9T;&"86VUZ:V[J*NN*GY>B$>;W/S&J,Q^ >E=9GYXR.46
MY##AUQ0($;2OLFI?[=')(!HHG9<<KJH&!*LNJ9=DI@/2U#""1I@'DSNK[[E%
M6)CV6!&7_(Z8SI'![F"'C=6GCO9=T D$.I&^2(5BV"6#PDS:D!0AKOIT[<1@
M@F<HFC(]G"+&>M2%#",KB;7:TV$D,")$ACPI.^QC2YT2;!%;%;S68JU%[IP=
MKH\48:3%0,$6'"2WC>J5:9?*.EUF"0+^TI&M15"$U0 QPP$NK[E<B<"^QI^%
MQ+I'E5W^RN!1M9/#SC/8LD6"Z ":*N30F(!Q(_&D&T7=^.;K"4AII6]D*VO%
M!E[=A(;+T)/56%]507BP0RSM&04E*>:D$6*J93V[FJ2-;$&&QD%CA)OMJ#%G
M3/>-8DZ9!;/CN9D^6>74ONLU\=;]#<63U;K.\"0Y/%]>2B :KL< ;CI9(%&)
M-0=W"I+IJW&:0L*\DJDN \/YOJXR'D!S&]F41([V:()9$M)BC[,N)]0XXVNH
M>4 .N1W#BWVZD5<</D54T("[S-OM%T.;4'=%9OC&EH;'F<T)14ZX5H 'Z3)<
M1?Y,T TL5-CQINR%C,$3"']P7\I0$AS0FDMI@%MU&#.IFS6%CVQ*M0\"ECU
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M"ZH]-$2!!=WSJN5TPI'4!,B0X4;NH4#=9FDC-1"R B.1F2D-:IFK<+FJYB0
M;T<X6S.K\N!MP$%=@MIHT;=*I#50?K19+V<XPK-1-(37:-ME"#W2VB_(Z3#R
M>F5/P%< HJA9/^F9/-/O5F$*[W)$I\RS@9[9B-F4,,=:W_,] ,R@E9R(Q;@_
MU(.2KDT!8"MDTE, 4@E4, JVQG #%_"FCW=>PZBX.<AWZ2#/J2:8'!CV)EEN
M]?#-NHMF.&%,TV!+40Q-BW"EA=INL,\()LXH<@J/+5\.\3T_G;FX/ZHX,4(4
MHW;Z7! 7X723.8<\A=N,@U!,.59U+ ]B$\3A'4[1!XD_X>TEWI8+:C9KAE%L
M1SW1H<NH#6T0[-/+]4YH>*K*13L/EH(Y9*,#PRG<:JM:<,VI*X92N^*CK($,
M6/55=<A(Q=*U\0!,T6(XGR^Y5;U1P'1%AOMDU>0$MA2:>AO,8S2+^XEQ2,VF
MJ8PC)!3:O:(+%!TB5IAPNXM$Q!OXTG"CQY#9:R>II"IN3V1*V[ 'F-O3%G[)
M9XMLV.Q4#L$U7 L$^[!2'+=7MF"_MPCA>=C!,! (X&XF(4-:<QJ6H9"=;$2U
MR[O#(NP T&Y99(LYQ>.L!;,&ZLQK)%^U011/A/J OO1Q.HL"8-TYTX*%%HV)
M["IS#N&KNE9)V_3UU7[3Y#C82K,NI)!* LWI9-/;V>(BYR00!T@XI#)&T:?<
MP0[E4HUHL2EHOQ4))XOV95M3C6[,MJ.%:1*F(&>F+9L*#"WA'>;W-&&:<>/4
M*%"OEZ>MV';(K^R3<N>B#D]O\Q2<;MQYRG4H6BMH+*B=9+3J"9SCNI"X-.:]
M#DZ3_K1NL9[A$F8NQ#P,[E0W'A!]&NS"?DJZ6RP55O A\5D[OJG*!,00_&8Y
M,Z&%ORWA:M!G(RB+,*ZEP4CMW,"46,=5QJYLM0-X7K((5&460KS @UU*(!3R
M:%<,#IL8E%^ 0>B7">SSRP&G]GLCNEH,C$ ><MO#)KD7A0PPHFY+$4;$2!JD
M.Z==;,&E(VH@5*V&E<(<GMZ."JOAC,YL![/1=%:JP58;!]1B#Z5TKZ\K/KMC
MP&8F-3"0&]B6,%T0Q@H5D^&DZ>T2MN<KH$P40\,BM;.O=I#CL:=,1'E5 D6@
M&-QB@PG PFY<JY2IHHLSQ\.D>'81V$P',(AV,UL)9M(%VFC-@8QL*=PF;@;V
M85,W5!<MNM&7#@./28 RU5[<+S"-ZS(G2S/[F[&ZW2TH99,O>C2?&D,OWR0@
MWHSC*(+'=3'7I7'LRR0^[B4'?YC32U\DAZ$,K<==M)C4(UC;K<;54 _'_=&\
MG0$M0Q2VK28%8X"E60X"8Z)0)",.HM%$2A4^%832C;;S_D&'HPXXZ!VP$CN!
M38QPY3S,F3[<H5II1=&^)<:*/5=@QP3<4M?@!)^O14\P7'IM:5 EX63AEPS2
M^&:9'W*]0&;FF</DXRKD4DN>3A=NU)0A(!F*;:C3:23GMJ1P A\FV=[0-T62
M*>F>HDD5\7>EQHM1WQO@'&!R&G? -CPV8C%GS&P'!K* RV89[GKJ8+GD%[7:
M+DH)6!7J,NV/RM84^SNDW+D!,<7&R=HF 4_E@H23!EW*L&.MLV^S9(6:5.-H
MCZV" A0]K!DP2ZD14JQ (0@7"],P!J7&D#%%#0:#/K**H)F_3@<H--<9C^>/
MDO=%)%54OSA@; D9-@U8#G9YG!6#-BGC8FROF&4:P]F^)$E;"I1)X-)NP,HV
M.$BQ/K8'@@*QP3[L @)KKE0[4>DNCSZ[?[A$M^*NK"G 2,*R0<69@-HZMS0]
M:.9VR;?A! DRJ2IZK<34T=.DQJQC=^=.IQZJ:?.* 90&%E!MD.5GG^M5:[WV
MT]+C-NUB?@\>,>\GZPA+':RV(& _7LUZ=#QM=:2/)8?78VR5TXL9I, &8K>E
M%KA39Z:R$DWTK$V#S:-FLY'4-4N)!+% &03$TG:O<-$T]:?PVA4$:C+OD:4\
M&GCP(:WPV3 *)Y+2""3KM0M]>?3$+.&0N"KL?$C3DI"1< YGI Z-56,VS\ I
M.U',(1E/!X@4!N04=.$%Q'9XZK")L5_,S%Y-X4O(4<D.LV7B0F1B)8!LF"V&
M/+.H)X(DLIH[77M:(5=!P++^=K6<@:+BSA7-'Y&A1\*]7;@\O(SG1<=/\3)=
MTW1_(,:Y*X\'Y6B?)NETU1LW;.RN8K>_UN=4/@_ZHM8UKT=D;.TW\GIH=T#2
M(%=]3%S5C'I@N)C'LK"&N!$])63I"&5V2'@ -J@OJ9PF)!*9Y!IE(G.+DM9U
M55O5=M%;6SGH[P+7D1G8+,'QCK1]Y^"^V@C+2&"I%4S?;*DEM/=KE]O1^B#;
MB3&"]9A5/D#!=@FNFK7$#\S^H$P&S&+21BQ4WV%;\ICA[<I\)W+4K%TY# >G
M133)\7H$TFFVS5U7L<@HV- R/Z%4IBBY71?^<G&+M2B0S7B_5:F#/V2L7NOR
M*.Y,^LH"A+A6%ZE:@O2U,UQO^7J:[&27C[R6Z9G6T#*"3;_T83M"B?&8-YI^
MGFO=6F&C8:.WAZ<5IE<UJF[7*%)@,XN?DP-O4YJ>Q#;6-EH$?%OT3)+;Z3 0
MI"*2#Q47AL!<\WS?U5=:NVATTFV\?7\)G?78*FT)[GZM"T%IK_15P/NKAF\M
M),=@T9AN:F.*6-!\T35 #4FJZQF9;=,V0=EAT2J%S-'VTC#7X6J'VH<]V+)L
M2(TR7-X+<PWNJ5U(MDVE"C,,PQF#;NW), Q+>Y.S:SRG$F6R60&+@0@0M@AA
M=*]G]%D,<Q"X*8:'7(]*[#I/*G>W@,6!8G>0;;E =MQX$[4\XE1Z/]T6DK$7
MA/EVC&!0Z._0X3H9(I$AVJ*,.? :J_KP%K27ZT,FE20;=8D/AZG>Q5ZRJJI>
MHD&=CQM,0&!(;SI/DDP1 6M4O#)AN#=H%4Z2AXT3(MM" Z10;G)0RRPN7XP/
MSB$C/-;,^Z#&"MMI9WU<@@-NKP>@@2<#^^F6D8 \::"J4X>V+ $58+S$1H7,
M#E>UM"J9/F<::9",%ZO=(4B%G;>3/*P-2H;:SSL@OO 'DDEJ/-?ECM/%E$!4
M:"O4]&Q%F&M0%E9FB% \B"A6?TQW>77M. XNUFG7^6$/EDB _GI K/8 .R^3
MA31&;,A$>SE92F/4RE10V<2+#-<2/!&7)1U' ('C -1%-@ ;&PX>+.D2V(]4
M& 8.CX-SHP)&[-FJE-@A/0,HUN50:H8I!E64NB-GQ6I:4VO<W%JUFU:=?L^I
M&CAHI)81N&><?;LO-.5A)E'%$LS6UK+++A)\70NA8JRW=<H+@9_A/F"T8\@.
M(Y]D1<2.VD[;-=O+ 8[ Q\9^'S5U"FF@+!U>2Q#!9#W9)4 RUW-AE=3ZO&E$
M,#(&A9;T=W[1]]>L1I6D+U;#+JEIH$4N[5;IA1XH'O8/SRNKX=9$.FS54^-)
MF#0316AG?N#O/$,"AX$W]\K<(V-/#V@LY.BA)4G$NE?H0WM0Q/K0.GALO*+=
M:H+B$V_2.1O!36-Q1$?:E% H@^GIO.\IA1[EIKG.F*/],$#.2'ZS<@TK[/OX
MA(U"&<EJO%D&] '!IGE1RW276X61R#-SKT&3U$_K?;KR12*0$UWIU;.=EE:4
M-P@CS\V<H&JGG2F432\W.+MO#<H6)O,D1J!#7!97&W?!ZCU04M.1Y*9F)[JD
M\NT4"U 'V7I8B69.?\-F%%KT(82?$@L"-"@%7[M9:4&+0MVG:1/2"GT 2Q05
MJXI("RMLX\[8C-ZG\RX:;3U"+MHN1<S,!N9J,I>K20<-FM*@4YK.:WX[=K.Y
M0W<]VE+%@D,N@?!#D"J<7/5V1<U/H#XVTQ&&U" ^I3W''&'+8KH>RX%")P*2
M8B J(!IHJS*W#I0E(<[<59X6# WW29\A9(0][(K,0&PCFUAA:P[3+Y1)@S*=
M7N"YFZ&-PH(;5%@.D(W"ZGW.P%>L+)F$PJI\!#=1YTS<O!@;.N,.2]6?'59*
M.N<&?K3U<2IN;)6!9)^?I:F?K3>I7,M^[YN_<^DM(KCUDBJ SSZCYS=MTVR;
M8"@OBD4!J*YO<.G2;7."(:%EG2C9U)VZV:0#;"Z*(X,R4UL.V5GK(K,@UUTQ
MS()$"C0Y^[ 50HI13NSKA!TM$+;:E_* $#-H/QJMY_OY6/5XI.A9E@0M$:E)
M$(O%K#ZE:\->&Q1ZC# 9""KRK.AOZ/RP$211+>O&>RVE4SLBTU9J.&0*MN(@
MDY3,DYQ4#2=V4\09VOFE3)W8-%D7M#XBY.$.-'<,/<;D98DPXS5^@'.MK9O3
M9IA4J% -AKNAV<%"K5]TH#U/?&[44K.,)18;H.Y<"H'H.< Z$:PR4\72BSH-
M/8+*^'7<=T"+/[QOPX&!Q_3W$PSAW;&B3 1;;%)OMV?I2N.9*AA*/-/S.[B>
M-"Q)RNNY*+A8[M&Q"E'J<EBN8IAOYOO1GJX/S@&#''[?X6F9T_NY'R0IU$[1
M(''$/M8J!DT1BAIM2*^N2[)/+>BX0^O62%9X( AZJE 5K%M57"\0J90[//%Q
M)+%;Y#6C*(@;[)2EH,="L^X #3+G?=E>S5<C$IK(=CD[?JXY[C)&K-]-]AX*
M%P+/S"R8&YNI4G*+LSOM19>;2W7+S88YMO<&==)X S%U8--G!^1X$*A9%'38
M(EYN80*Q^T089);AD7KF<G.FKCDR[64+$YI@9/_P7<!2'ZTW(<QK(SJ<ET9M
M&ES"M:G5+CC&[+N=RAB#0A Q1C$-'&O@L#>G*\(B'07@(\2M+-C*>F%%:WYY
M@,1'WPGTH<I4:D^C?7#=66J3Y[G)S1J(P19R,.%6*1Y@%3I.U  6!M8R)V@%
M*K?35BQ:W^\"$>N#.UAW#WL.;L*;9CQB)SD-<%.LZ<)AY[@R'=6P';3,NU6M
M :MP&^Q&#D0F(-(K"=J954G64O$:P11UDG+8UA9-M#D\_@BQO0%1+21B4H3*
MNKCO$N[=,((4NZCG7B^01^E.6$V"49HML<G=+^Q#&%4PJ&<5+!C#1, 6Z,P3
M6<-+93=G(Y0748::\G26JXFL<+*[8<1L$M*)G'3YBJSIB5:Q\Z0QJBFQR0Z3
M@IJ;G9,68,8MT#6J3O?!^N@]]9V&"8V1S3:5NT_;DJ8G_:U(4[-=,5A/A#H>
MI:3K;D>C>#0:;^7M,K4MZS!"J(<XPDZCTBA(;;0HEA"-[DH'3GF+63 C,,CV
M"QJ,<&&-KT03ZA:!A<E2U9B(6'+S EHFZJ2;+),8.H>X#'N=2Y[4"T(C>9=B
M@K7D*V:L: Q&P;+D*-8&A(5,0B&G1&L?E$DM,5W9'2G\A![KU#Q. Z\#[R-_
MJ!UF&=MC>UNV+*S#(!P#>1*^WI45 \$3L!<9T7B6*)"[3GJH1D",G>#\,JL;
MJAX$DPQRVX*QVT++%%C=C2?QV4U=4:QCG@@IW1OX83+LW.%"K;AY "A')I3/
MLX5D&94R(Q++W@[KC%DM04-:>@J<]0),K+N0M<)$SDT/Z O&TJI!H$J"*B9J
M%]9D*!I:GO-Q9=H%-V4:<6BS^20;ECM^9J>[WC)& S65H>.0*,)<2^;K&1T@
M^ORP14#(,B%*6QE9]'0<RJK(WA>9U*R):F JMCA5S,G0#;;^KEQI"6.BM:DN
M(%O08$$G$,(J5[H=46(&2DV$G'TMH4,5X\5&"G&(TM;;HRV.VA#(QNF@(I$&
M:W)5.NZ&7JJK]22!.#I?2TT^D;UUOE\383Q6=6'M]_:U/+#.@O8J6K00,BQP
M.3?KH2H.N?Z,'2:S'/+V<0?*.,6+W))$9':3;R)*)S@C<')"+:Q= @4)7N%J
M/MA-I\TAT.^WJ2#WF44J%=5J&H]S;MNM:QOKJTIH),P"T7<0*HF%&O%I[<+B
M4F/3F0<.=[J&D)6T&1)S.NA%A9ON#B); !-V>87)K"U%-P&54>;+B8)(T>((
M:;ERD7AFWJ;4VIMXP3J,T7"[I//]!9?S88?SMK*1@7=*WQB\M3<X2^@K22/D
MC(B$'IL;?)^A)QT<UJ'8#NEJV>'JJJ+FI3IPH46;: I>'7389R74&?GC,DZZ
M+#ET0J;>;1H!WDPY3+3CJ(:8]8BOZ6J-R:MEB7(Z"B<$E,@#72ZRAJW%8DQB
M['8\3 _?2<UF"V T7?;I? DP+99T,;6R^+2,X:E190-Y:$S7>M_?U/W8U^K=
MF&ZQA3Y9.A/7B^-1ULAZSP"/WJ7'[ .VL1V'Y2,% 4T9YP,01<#^T*LR1F7F
M.,T8RE!H!!(J\R!CIDN_V046Q;NZ:VSIF.X,O/0-R3"D!+,\X_#ZM#MG2UP2
M,YX>BN)R%<LKQ6K@_7;J:".M R4MOND9F=-4MF0KC&YF,J$.M-*9J"#0;\>R
M*B<K/J?[G?.@SZ9F?.?VQZ.2LU>V7HA%AS\8!? +$^<HKD.1Q= =;+U5K=:*
MW=^5),5OE7CJ16(RG@_I2F)E6W5"T^EM#EOW70YH$?/=5*X8)5])RF:]YB#*
M["4\-5<V4NG/$M>:K8J9U$4L=T\2DXQS:#B(\.F*HS;JIA<;T=%79;!U@"(6
MMZ#H9C6N)(^I!67@XSPT[W$^PL'X-N6@H:)Q!&@/(67@AN$N'_0#WRVZ>T"J
M/7DVYENL&Z.HY"UPV#)5TXV,:Z*")42'I^<#F\8+TQ.9':7JC"<-@YB72B)
MEQ5G.XNL3D>RO>_W0\,Q50NV%;ST9<AA/=A'#PYVA"7>2D@:,[5I=PL4'>BA
M.S_(0PB7AK&QZ.(10:2&P%K4,A$K@[%%H9W/'7"*;K::P$Z6L5%,I>W>(<Z^
M2PQT26K),5ZE8A!<%&/.@L48' >+5"6J32TV@"*SN"$Q:$V)<BFQU3SIS6:=
MR83C;[IO<T]O6XL!C][.*"C&D4R%K@LE",J#MYFY(\%9AUHC+IU0PD=]=$JH
M411F6&OV-JG#%'&9V:KI<YI*($:NZX[:P>9](]CN@!23> >8&ENL=1DYP#EE
M!01(O B7-2A"+@9Q"TOM1WECZ.1P,BA)+5R1>WL0=PL/F*7E;+JA-ZE?;.5P
M?B=W<TAO[\F787>ZQ8Q2+')<!\L!V&!LVH>::G+8%8DIG:3&E9(V J',!YAS
MY"M%6ZR:'N@UL=DH?3T+\4I?V -H(JQ%6U=]-B;VVM:5EED)49.*WB5N1K.'
M1TCWX(U2!\#]:V[[7OWP,?J=OL$'#A_AW^&3?>#.W^P?#@"X\T?^W\[#'%CV
M[D]E",,+GNB0%X)]%R=7G*/,C\X6 ,X=+= U?\2%&<VJXEMA-*OLJ'C$'8^)
M8-G3TWA3AET=.3W3%5QMN=9IN \.X=$$&_018C:"H!$(HS@Q&,,X- &QLR<L
MW)[T3FS)*"\Z#V>?9>M^"VS/([T3VV7F;MW(",[KNBP[WC,(F@UP<';5B,#&
M5PV0(785/APC5V'=W\,9-!T0T/0<_POPN%,_@AU9[I$M3 (CS\]8MF.407&.
MPQUJ[ZQ3.W,KVR*R.+R'9T8\]M@R3KMWUAH$3?I0?P1"^%UI[4ZD%^)LW7F:
M[REGZT)ZNHUS_.^:DKOD<:&NLKN8E0O6WL$AW'Y:[CQG"S<OXJRYP(D@HIU^
M>TX$.5ZTIXW-L>_)C6XH1T,_K^RNB2Y@&"!BF%8?LJZ"^@9XE8D/G*MP<-._
M"C'Z&P0Q!G"WSL[QOROCN%T?^YT=W>Y8%>0T I^&D7/'JIS7ZJZ9Y+%3[(W,
M'FV[:;S0R3.3DWWX:O#\TV<N1'C7'6QV1K2UK3/ .<)S!?<L8/S?,7??W!7^
M>^;M#L?A?'OF[?8G!OT?G;-#Z>V7X;DU?8=E^VV+\=;F&]$U*;/@^!PK:P/8
M@7WDG_(NPD*W/W3)VIP[:,=(DL#=&$>] $F<%X<^'PO<UN+V9(5;!/8%_,[=
MG434#?)TT.GPFE/U56?=X*DSA+OMX.C@6T%*%^C^:$C6G17XOS"PS$X,-SL:
M5V"?Y(S0/GT'(BM/0!B\VCB\;[K.[2RZ<ZNI'12'QP9,O#&"DY)[QR8@>A5K
M9)O=54>+X.3!_,&SN:XH78#@)(B<3]$'3\/?H!"/!3\IVUG>27\;7?_J0_WY
MB^+\1A!Z-7CU8>-[GAG)SMV<+#J_<E['HZS8QYE_W.3X]M=/>=') 7ARURDI
M<"/[9%8&=G[R[-HX6<0GP:O[R-6WM9=V]DDG#H)X[T;;[K?.#D]VJ^]DDMEY
M9Y0GW>ADT34Y%Z]/'Q/=UO^1'O*KA#@TH@O6C./ NJO.-G$09]]2;^/ V/AW
M*)NP&GU;#U?][[R.>_@65\*%K?YH/6P.AZ-]:^#@#-^IS\BL'STIV95K?"N^
M[<Y=?CN3%XG_)F?*%4"RO8O\9>J&]R3MZ)K9T=':R.\B?2&B>Y2^$/%1UG(7
M9^-]LX/Q[ICM='*?YO@NN<S/0,?QX[R".[=<&+GLYJX9V%)F1'F'%.QHTYPA
MC""WOT%]%XWNCMNRLK,D<[N *67EA3C=UN#.;%BC/AJOZ+;V/<\LNLDXO3^#
M=$HYOHZ"\*'H0@UW9[#!'1KN+MBPC-SB#-\%NOQ<N^.2.X3H.PSZ B(=3?&%
M#N(;&]MO%W3KC.WTD;L\BD%G;G-V1^.^7=7=4Q-&Z ;-@?Y\TK/EWXQX8Y^Y
M8Z?'A7=/=R3@F:/;2>A\RN/BNZ:L#H%)+#HSVIX!P>.I/T=_^\J[9M(MI@Z^
MN(5]SN;O6/Q-).ZB_D'AY/@GCJZK>6+\F).'O[K?V=MIXESC_]TH_@*F<!P1
M_X_;PIUZ_?^+,0BW,P;AWV\,A]+;NXMO^)X[>I=S7H</C.*XDPNYGKL+ZI/F
M:-KNWBC/L,911G07(?^\=II]!+"^:;-C+/4MYD9W*>0Y#8A[H]CLYEE<)M^B
M#K[U<U!/;X^Z.9[3Z2%;.7GH_N1Q_X>]W_,:W3V?8WL'SR>ZX KX7U#8A71R
M8>1U*!6FQ)G+.^ISQRY?:.#?_NL[G7RGD^]T\IU.OM/)=SKY3B?_5W5R^6W_
MXP8[LJXYM3]U[9FO?^C$Y,1%_\[KB,F_E\=%7W_+B2ON<^*E%]W[DHNN.''Q
M%1==<L5%7W_'B8>=N.C$)2<NON2BBTZ<NRZ[SWTOO?<E][K\XJ/Z:^YWXN*+
M+[[DQ(F++[OW)?>^K&MVKTLON??%EYVXZ#[W_;XK[O^ *Q^H_O+W/UAYWDTW
M/^A][W\X(M:_\-[+'_%#_=7U'SCUR([\H1W!$?/SV%]T\:7WONR2>]WGOEWU
MZ(H3%UURR<7WZIA?>O&]+CNJ[9K?Z](K[O_P>S\ 6HU^_K)31OK6]WSN^\;"
M?_F-5U_YB'[VW(]__C[W?> CO_\_FD]][U__T]<_>.*[+^E(KKCDBA/7GOC*
MOW[\ 3_%78%-/W[E_;[P9_%[X_Q][!-?5CQ9_9!TZA\?<^F5N[=^E/RMUS_R
MO[_EN4^\Y;FW_/!/7;3S?P?]$?BA+WOIX[3[O?HSQ"<><L-53WC-3TH?H$_]
M_',>]HS@7Y^S^_R'7O^<9[WH"]=Z3QPC7WCEV[S+GOW*5][\LK^X_+./_HN/
M/OI#>_NC?W?]"_['C8_+C,]\SZ=_+GO!/S]E^-\^]=4/OUOKW?B8=T0/^N+^
MRN>MWS!_W ?4$]QW/>/';]A<>O.[GXY^]/K'7/TG;WI2^?E'OV_X@J=QO_GW
MOWK3!Q\O7/?F:RY][RO_YM?8[WOZ+3<_^4<^^X)//OZG]Q_YR=4;WEM4[[GI
MC1^://\W?^C&%UQY@_^*RQYP\E5O>].;_NHI@T\\<?N*3X1O^<S-O_"EJY_Y
MG[]PV1NJI[^=IB=_][6/O-);QS_V]V^_]D%R,?^-WM^B+WWVFU\Y^,,7/O6]
MY,.Y[WGQC__Q=1?_KO9@_/ZG/R9>_KCOQ^;/>J[P _<]$9W^N6?$T65?_K<7
M]FY\Q9.N^_R]1M>5^I>>^/;RZM-?/_'"K[*WO,-XS5>_]*FWO>+RZU_XD7>+
M%_WA_T ^>>D-3WKU+WWI"Z^YZ7WFS?]T^4M_\O-?H._G/>&*]_SJTX+GIJ-+
M?OA>)?;)G_GN3[S[7[[ZMN<_\6MO?-)OO?9K;Z>_*__T#=SOW?2ZCXP^^:S7
M_<J5U#/>^%-_&5[UKC_^_.0/'[>'C9^0'_5*[>>N_X3YT=?XP6->OKKN42_[
M,=6K_N:?'R=B#VV^]_D_4+[SC]+GMQ^XN?C<G__=6]</NNJ%G_TYUORE6W[X
M1:'WY5N__V>8]/=?1WV4?M0_?OW$W_UD_K/_*K_G<=<7S__C__CD%WW!1OCW
MU:__\I?SWS[]]@<][M,_^NE?_BOJ 9<^^!>"\/V7;3[^AK]O'_K,&Y_S$P;_
MA7>^[JOB_+?^,7C&)7_UTZ>__RVW_)'Q._>EE0]_7KW\]=?=*C[A#WXN?<*G
M/_C[[O;6![_Q^Q_R@4>N'_RV*__@K_[I^Q[_M8)[XY.>?ND3'OSS?_GE7_T/
MT=/.7/N7S__LQU[WDW]QYL7_(C_O]5]ZQ7-^YXE?/]%\F'S%.V_]ER_^\[MN
MNL']W?N^I2E?\A[UCSZT>>M-[B?EWS+4'WKMZY[VA.NP__+^'TEN>O?IU8U?
M>NJ[?GW[R)^__HD_]M'+'O2P1P3![[[B7;=>^XX?^DOV=[2WO>^+O_ZVW_\2
M^9&//_V-[[_%_I>__?'W_:=;7O0/GWW4?WV[=O,+GK#=6]>_Z[DO>^!GKAA]
M\D\O?V5\W6\G;WOX3UB/AE[\Z+>\]:/)QT[_[!]]Y3G?^X%/?ZD0T<]\Y.LG
M[O>4,_,KWUC\VCL&3V8_^ZS[P^6?O^E#W]-[_4/&3W[TEW_!=*][U:W>=_W)
M4Q[BOY^[N7G34SYPY;L6[UV^Z2NO_Y''8R]Y^4O^1V=$7_G:7SSY&O9>_V'W
MX:_,G_IK?Q#_P9.N>?5GOK3ZXOTO_[?R65]\X1._]NJ_?;-!O$:XZB4?N1[A
M[.HS3?.*:U_[M\AVLXY_\=E_^>G[O]RC+KO_B\U?GS_K+:3Q\$=>N7C89>]X
M3OW96]^G7/D\P'OM[W\I3FYZT0?^]$]>^YZGO?]-O_:^']S??)_W?Y__P(]N
M7_^$]%7R=[\3?^F7U"?^[O6/^I<?N>'+7QX_\GKRI;?<##H]^"7:K_ST8R+T
M82<_]C<?*S[ZEI_]VM<>\ZAK1U]^]U]?^?+RE2_<H=_S7=>C]_WLHS_XI3]\
M[^??\'O/^^V'WO+_I=L/O>EW9Z^]]PUO/''_RU_Y;Y>]]#W%__.ZGW_H^ITW
MWR_X[F=>\9C/W?S;G_G)3__]HT]NHW^[5_B73^Y77WO5[__9#9\&_NLO_?$_
M_^._O?QG_^YKS_S-+SR+/?'>&U<_\HS?WC_N*_87C6=;M]R*?NR3C_GI*__L
M]T^YG_KS3SXD_<@3'_/R*S3T\9<]X0KK@:][_"=?^B_^.T\\Z,,/_?S-%[V>
M__AG\,\]Z,_7KWU1>^U-^Z?_R<]>_ZG_]KH__?B7_^9)TU]]QK_NW=]^-783
M_P\/_?CC7_^'KWM <=TK7ZS_XG_XS4_]ZE=:\96G7_/G__  [N2MU]WK%4_[
M;^_ZAYEPV9N?4'WNYO*K__18Z-4?\8:7GW67]_2?V=M[KU">^\#//%4B?_$'
M'?MISW[X2]_WU(NJ>W_^J:?^]"$W/')QZE=>]J,/?,KE7_W>:_N7O^-^/_6
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M<?<#HK[[]67H?RO#_J.!=:L<CY(QK L)6PB6'@LJKD'6$?2JE]F[DNJ/\PF
MQ/0CYG:"FM83U4OO6EG';?<7)1>_51"_)#&SFZ38=?&J%I(O[VLBT9!U9O_U
M=$6J?A5F9UCT!VXXBHY4=<J7BTQ6W].FUY=(_$3U07I0K_K$NJ?)XM7$.W."
M'E7";AA>G0JU4Y$M;E@4-C.<U^2WM+0OAY@<U'UY"#R1$$ *H!@#;IXOTC1A
MVLT>!I@?*=/,'VG:S\^',]ICK_U(\FYK8>6F_HM4= >Z#.#Q?18AW":-G,AO
M*JLQ%3//,JYWQ9+O_46XUJ#T_9THU];BBO.E1HK;4ZRL_<(KO99.)S7*@<6=
MTP7+PN1:@4&=U9BRX&_=''-E!$U\$.&@A>'+MWI*OI7HU,($BT<E%J(A"%&#
MGQ?+NQBC%8^+/Y@G4([0_^5].>30;OV\#BH%0)"6&4B6<E$!9NYFDN&6P]6;
M%!^V'R%HT:S75D_=UBJ%<>J/5B(S5LG9]\.GJJ*3[I!FM37]4U9K,Y*4CZYU
M,7;$0GQ5Z(0 !"O1<Z'L ]$ENQ\'!&3_=CM!KE][ 5I0H LG#7CGTU%>_G\Q
M/*C!_0U0R'I5 0DG6(J]722RQ)W%BJ7_)Z'6-Q YCZ$G^<H<.=Y]]EPV8YB;
M9!(K%C1+"546CV<J]L6>($G=4%WL0HR3H->$T2JSH4_>#*]?R/6P+)!K\06Y
MCSY$U=[U[3=IP=6B<=BMD&6ZF;6;,3<^;MB?V#?.;/!$&8)_!&4 &^8P, WZ
M;L(21S,/W_]3UN]'M@A]X&/OTB\; AF;CWIN36+'))X43E:YA)TUDU1"'=++
MQWAQW=QX8RTZ&]JL" UU<)_6=7B(<%<,==',LVCY#N18>#QR"W+!F3+*+I&Z
MX52E9A5HBN'(Q&2TNGK*)%FT.M;.F(3#[-;#*,O7MMJX_RF&:5]I'&\9<C2-
M.>JLM-57G2[JR9&W-2,$45:N8BS:ZED;Z8-!FEK$13^S@'+R&,92D/#?A1VF
MHW\U6(>P*/>--?OKIG;(UQR[V_OS[DZ3C3J?9_06!U#UK3\W#:FS6,X5>^UZ
M);4L>8?A<?14G5\U"87,V ASE/$M#*W@%I_<#E0XEOUY4HGY&01")T"NWU)2
MTT")E+E)D/[,T',[)/0S4%J:I\E7V&YHYXHBW0^;3_WTM)A1SV"=R\=-EA5R
M0TUDAF</RK,MZ-3+J+O BT ASFU;KJ.BW97-0#SH-2/\P,JLQFNH 0\."47W
M)HY273CV]5 II"/N-L1<:00Y<Q!_L7J6AACSK^</S=6/9R;&VKX.[S4<*$S0
M)J8UF]O!R:;F6Z100U[.3\41_ 0T_L>9(U#J5I?HT-!=C T?N:"G2,7'JL*/
M=/_!A=F=9A!RA^*"!P$$#0]O#6PDL'3MDK1RQOUP.F]Q>;)AII 7<>&$%I5@
ML >A1'/]KA@S+3/;=FE,+/E.*-"?,>\SJW#DE<8B+XV![,HY"6JWVF9:><@\
MI3V<XQ>@#&XI#,!(:AK2#5^/K6?69';;R]JQU<C7/G &&F3]4[A.G6AN2F%+
MZI&EICG;9+ (57:$'G>Y#FA<$ _#.+J_X8OF1%N46 PVNFIPSJO^$U%=:-V/
MA"@.QF1(1FQ*(NH%ZV5H&'P,7]@@6K "+KXQD^V4GM']F>E)/"D>FS_%'. @
M2.QC_4S=0#"\O4_PTMWHQ8$-L+[S9_<8_!]'WMN*T@!/Z%K$GWJ2_&.W,<7C
M$MGM0XO,OX%(A?4YY.CA86\  =EP:@$?&-IV5N1?8Q1)S"!5!32+$ANQ.!:!
M[;"P+/&"58/J\P$*Q^:&DQ3;1&4E1HKO"PO?)O<_CUC8\4+'$\I39> .RF*N
MQN'5H20U@.D+*4<L?DQ9 OFB@K#77L-K+9MB/#P*!POA+!F<%[D-7"5_65]7
M*+W<*KI(-(AHK[PDN7^X8X" 9YO4I9X8+2;P"RVCMOPHJP\]562J,QVMY_ZY
M"!6U"D*"]>60 BR8M3V*; B')R]DCEO@"$TE;0<DHXCF@@_'0IU\^?G1S.Z6
M7Y "C=WGLTM^=$)OR005<!;%8X1. "(!GRB]9)F =47M6\>MLXP+MDR1(Z%/
MJW1F ]8#R/VRO6OH O4<)<\LN\G0&9H(?!5*>:M\^9N(P@S1>8 \!HVLX1KJ
M1A6>U=V%-.+$X_5Y#@Z"6N[-TG6;+^;'J4IU.NMJ$!Y#PT"P#C&WRXOGX=0M
M[#"YNX.#KW=I"VVW"I>PQZVE57O0DE8Y4_LE9P*9<GDLY,<8IIH'IIH;@_,M
MO;C>GV/R*]BQGT.'+3&LGU4YONZZ(('S +NI"9+PCD9@PCG^''6&>G\8!@W]
MVUSW #@OZMF,P^")MD)E%<//9D4:6?<F"M<CC-KGC[I1QZS@,R5^?=]?1KS2
M_[/KX]>7Q:^[;P 2:=5]AODHO#<  UC@H^-7CR21L>D<I(;0-T#L\%AP1=>L
M_@KZ8<B[*JB<ZL+HAVQ[_3< U+S!A#PF\\6P^AI&*GM\?P$2BE;]P:2H.9L&
M);[[O$.$2-AXU4J(L6%8M;(N?&PDE#Z5^)\$F7&W$33G\DZ>O9FCC'KFX[FQ
M7;W;L]/%P>9'$J1&!DNQMN/)5MLWP*7X0C'XU<LU8*#37L11)Y'=W:$B[=B_
M0/ACT]*?M9TW@&: G^#0@<.ZDK.5T=%JO[@._;J[QZ=MEI:-:=5^7)^ ?)%'
MC>_Y%;5&4=\BIV7*NY:]U:8>LZ=O\K3TUX]6( 05J#5[L]7+LM5,<EEUSX&^
M8&YQNC+?_P,A5K$RBK]+,GVG"'$85C#,L9?4^*Y7OJ,-@]/@5%>(AC6YC]$(
M(VKN-HA>A%H$<KD)?5D,8TW\EFGCTR<CY6;_E-]Y>RFTR(:K7K?Z]0?2(*T2
M-TJV92>BENSCRDZN)8%TGUQ$D8WKG3]C+-BN9M;(QGPK,DI4M!Z##/<ZPN:@
M)'X>K=7EL2-%?41D/E[V*]NB'"V7X(0;JX,F3AJTC='._IQ,I_2YFG9)F(R^
MPZ<NG ^Q*WX )Y$F"M.(EE:R'/,#743:#N&RI7;%J (M!S5U%*D/3*0>1N<(
M75SSNIJ>EM?!P]'C,XX&A6_=9AK01"!$LX$5.MZ3!"D'/?^IFH?VV3#9F)>#
MXZL@%9#/V(/' JUGM/B\T-BQ2]!F0EELN(>ZNK>4D9(WB9W=W^;Q9XLSB/J*
MJ)?-&(-Q 7IK@.Z0AM,>D2!O>+LM:D5U])GUA6Z^24HRJ4%Y9EJ3$GT3<7EY
M5'+ZAB8;;Y+F@OJ\PITL$57SC&B^).1JS#@]G4V [@I)M/ :3B]GFR1@Q9:^
M!JJB@6K!1M>9.#=ZU\$O*:EP%Y;9+($U N_M)+^+X?.#?"&&9S\!BF?@1U#K
M0=Y8/F@UGQ29O/-A>5&3O'5G%K<A4BL6I!*2UQO]'?#]ZILQE9\7<11G(DDB
M&HSQLV60@]FA<(3 0:@]6KM3:-#X +J]1CVD&-*U)4JF1V'D%!E1$\0Y?+@?
M,YF>C=96ST25D#O7QF12XOO#=5):_U,OJ8:'7T54S7T&7):<2T5Q66YSKX[L
MW7>]O2H7^KBN;^'F=I2EI?W6>V#/PT$>"Y M2':DN(*OW/7GN L"\2I:ZGU:
M[J(R7WI=^]B?<T(3@0LM+&GGVPU/>093*7*=G=\J+P(>B[Z_3\X[Y!Q_WJ_X
M^+&-G\ZK* /+LJO!U!YHX/SB;(B._I1KYQJ$M^7CI'IH@<&R-;C+7?N('4]S
M(8OWED#(FHEY#\Y*].9F'D]%>I%")^9 L+<$H_^G05@:7[01D7_43+8"RQO@
MXVO<POC?L%:R\1]Y<E:-VIJ_,4GT5FK.F6.,*M<XYYS+L=;*I2@],S7/E]_5
MJ99Q;\RA=9TAH=B9^Y!V@JKE;@.)F\AI?..S=^/\EL^;ETM0!RUA V8]XWY+
M*1IE6@T$Q[[0?GD]HA*Q2L4<_*7EKU_YL:4(SS^Z4YBZY[!>38H,'SF$P\CK
M8D^>S\6\#N%^%NY85SG+_+!H?W!-5B402YX7V6AL0@R$LPJ6!LO1)IP<D: Y
MMER$X?&$[E;'WRA5/ILQ+<%98?UX9$\>2#!-T:RVY +MD NNA']:]3^Z+CJ+
M+1;9J<PZJ=(DVRLG"W51*;9/^2P%;#?!4_=@K<'Q'<;;>!&HQ>\, EY]@Z?=
M-I^10TL]^!W+-AOCZ=\&GNR_.SSC']*20^BK9A'5,+>'",W*<_%(EB6] >XN
MN0TPG;F@O;MQ$L)?74FY/(K*6WZSF!94N['0%98D["#P9,)F(K;?"_*V.1Z(
M_IJ;@AN> ="@_M'+.OUA(?\)XV4]^673/V^NT9YRQ,]1/F^-_SC[>/5NW;S.
M"4)259]-/>5<91L3A;:$GJSJ$F/\:Y!+)L*I'_?'/=CK1JT9[-MPB0H*L_-1
M2$,*\=8*.4BM'P?(YMVZ+T&^@'5G<(&2Y"(BW1 U?+AZ&27KR]NDOL9LO.LM
MHA];&%__9;*.(SO?USU,IA+7#!9O,ID'*GWQMG+!"3] 8O].B/LHN>?[%%Y'
M#V.4(U>Z3$=V'A5TZA=K/_YW?_;TE?HA* "IP_DI?CUGI>1?SK5=\)B%3\"'
M_10A)-!%N(>S9DD*A]KI+S,03&0*$\$?^'QUH#UT9HI"_"'9ZC?#"!>65 B1
M%:_G[K\L"?V#;8YPA@L?&$49V?)+^;][W!VJ*WXOF,YF_(67F3K8'-\EYKJ2
MU[GN>5^V,K,D"72\]*IW4UIV$I0*^H^M?F,?I!CXZ7.?Y]O_F[-^2>1TW_;@
M3/FBL;UI_"NNO\]%E*L5%$:]E/;^=GN'];=6/UJ$R!4(7D!HK/4;9SAB,.E^
MN@@W/=*_.?!9_;\?2-ZOW6I%U9I^+\KD)'HR<S&U>?>.T8G4_/W]GG])ZO<#
MTZZ/PV"1?'*U?C#PXE<IUZ]_ 2Z='.#9%CY^ X2)02H=UC/VN_D-XU;<@PPT
MJ2,9"MT#%&$.9V5N33T#.0/DUJH4Z[5A,B(V7<.9HX\%<$]Q%@2K<M@Z51@"
M(R163S)O +HSG&V?Z>S-6/?[_7'Z\D3%E6##W*5CUX-870>#?N_.TS5#/%>/
MN@Q5J96Y<?M\-VU"62IDUN-/T%D'\9PR^?KCMH?C-5PKH.-L*TQI6?C@:DC(
M,?P-8':<#JY]R#XN<A.B6QGBRYY56X6D$)#%GBK&?]=S77E&-58:C(P4>88Z
M0OZT:,D;!#,')MBV,[HU!;#N<K2M(Q*8)!W,7Y, ,,/42H0/?..;W2K\0VX-
M\Z_^E&8X?#G%>QJ;=BCR<'J?81J@J;B.8ZC/GVA"WJ2 G IP=EU!:+E];T9Z
M3?K%O_><$,6XF&<T%V?VV-=7PWJ#Y$#-GMO7($OZ+!!4_9(=_OFHF%<?KYW&
MK?(YQP#XKJYZ5 OXK:_ JWRI H.0(WQ>@%M5:[26UG"+7A42?!Q@\T"Q;$3)
M7"-Y*F,.K*@PA/0DX'B+H+M0:"+C%MF67F6\+'[66^-9!IO2)>\S^L@RGDTS
M!S7Q^;?R-&)\JRB:(M5R/'X6"_WC=6>-!WK0 K(QG][L)>F??+ %:>D7UB6J
M%]U1PW@$3/%.MWNZ]CE)=/=^A@BEBYR41;^.COGYM5["G/(J\Q*L=51PW9)F
M5;NT:2?9/5>%"0_ZZ3$BB%')@HM@"%Y2*@B?7<KV099U9S%G(.EO"YW=<S!\
MP=X:!R==69H!]IU0Q5=.&0(?H6O:^#'2-+ST%[NY:Y-0_F]#W^7 Q-?OVB*U
MO';JS,^PMW,JDKB"<:>/S_;SY2]KU-.+G[2_1:%G>5)PTS((R(;Z-XT:.V=G
MLUDRA@[$^ @\#I'D[2V9N0,1Y9-[MH/8OY02(DBC13VYJ5QZ0O_XI7EHK1*N
M&)-__EFU.X*AP,*"%<%=TW%[36H93_(=I8WE<)_=-/W786IUOK-2A*BB',')
M4T,_MV/<,_6?BF));4I,K'>+/\R,DD?G*:OY9.P9%>I3T]/DHW\$$RP+HT&4
M,Z1L/H[FXWY+B+>,(D.K,/"V<C@5=BR[6P]0H9_5D'<ZBFX72G83KQ!MZD%Y
M'U3'^6.187J>="X-3U_'3L/Z\V^RH#WA0HRB7I.I/QC-,ZL/03O.%6WJ,&!)
MDU[YC;R1*VN(6'X]?[#X)8.+MF7(R!B$R2Q /)%4 6'?$..5'+HD</4&&/AD
M2%\3#"H5<.AUV]4P?$A)E%UF)_"DGM=[ ZB(: P\C5HICY07E049-?DEI&=C
M'1IH%#5HDN$M_)"HKY:4X<=\CMK[LJ@J0\Z^S@2LE^6F#]'RNE4S[&A;]VC]
MD?$QOLM6JJ)"%(SK#K_Z!C",ZGC_ =XXZ!T\:="'I2",S=OAOTT:W8Z>#1H.
M!)(&#MKMC>O8 OSS1G1E&CU?GU\1G;*T J/[2L:GY(]MI,$AC7%!(V%N$0VN
M9_(8_>ANO_3'NUY<FZ5MRNPLBHN3P2#+05(.#VHY^(2?55VM#)H3GO ?UQK)
MZN<^5<2@.9245"2@>&F;),F0*GDPR\'M]C@11VQ8"9A_7(,6EBMN3U+,-&-
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M41;[7BZ%?EIW"T["17#'I5K"J!AX1/A$9*:_4=[B^857K2\2B,1)-=C?83+
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M<4C2Y)4AMOC_9V-5WP#_]BDM,N/I^>5@U_%Q>#[G1=[<J7*C\Z5DLZJ=#\4
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M9.*W8'D SH1JAJ_Z<2_;B+;!UMF<#T5FYC&;6)]=R$D7 9\%*,_>'>'A:51
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M9<W9I)FG#G+7$3GDSMT5O$19D8H#F95I?9?&[>%M%H'62M 1!>6A0:0%INW
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MR"@N9U7@O0U=,;0GT377I^Z0/SC0R0]?/[//NC$+%VIQB>C%>DH$3IQOH 9
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MM,.W_,%5SAYQ4#Y[R*L#=3MH(0M%'?#\*1."4#=W@.@JW-+%DT@!,@!-@#J
M$<"-/P0!UP"BA_!?16@BX'!K'0@*[:1A ;/$DT_C&R, </R?-;ZY#@ "0 '0
M *=#%E*G[ZV_]4+6'N7XAXZG+=!0>Q34\5 DOGSRL+4<R.#FU^&0.&A/R/V3
M#<[_8 ,-)Q04[HC$4R\<]M0)Y?BM6_AN6R"^%[1MD* _:Q".<G\6'%%_%M0L
M[)'?"^HV*)?O!04'>_GO!;QE_Q0M:VEG\X<AOBH(T%:2E<-?B [S5HR,5G"T
MQ0WX.\"WI(1P_!M-UO[O[6015KI@1Y0BL[8]"O!#DK6W8OP571MICSJD:[K9
MWT"\^$8F=8%8HN (>7.4^7<_T;311'[SDX/\'U>Y0R- K%&_$J^+GRB_HNM8
MVG^E:R(L;QA\)Y_#3PLG?5L(?G#QXP5UM/EF,;*#"FV\3K)P% KN8 ]WM/F#
MY?2WF@,5?J"?^4;7AMK8_EAQZEL%7K?OY //(5K^J@-1S1<A_)0E^'8]]"K6
MPSJR/WMP_?>O7,?.'!8/9OW7^7GI>YGA4.J'P_+);WP$AUQLY[Z:^=OP?T4A
MVCS,*P-XK:WQ-?;X\_$_F+Y24N+BOU,$#L^&^/,WBM#AF?M/RJ',G<,\?B;M
M_S(1S1U4_^?K#FU!\M6BAWH!"&]\/?ZH8_ANIZ]EFH,<D=!W[0\3H3&^*/[=
M=']//] .VAVT_\<&W].?@0'@B+8_<##" WX+.-K1"OF7>6F)XO^FYH$S_^!(
M@+]X'$#VNV=^54/[N^,==N$XTAYJ"4'JV:L=3!V"GW"(#^OPF?/XX\1A047^
M!]DG;!!PM--/I.-P!-0&^CTJ*N@<,&D<TO#E,^9H%%P)X@A!F*,@5H?:NSM]
M"_.D7QL?4 YJ5!QL&/]?Z#\1&F'_QV+Q@_%_IH"0-I"?*,?-[5&ZYC8_T<@L
M(7@^B!M*!:FL"U+[%J!(OI%_:GS2%H[PD+&'VGRSU-FOG5?^1CZPKA7$VAQ]
M&*%.ND 0J%\TU_M&_KGY*0L;.;@]'/&#<<F_,L@J?:\X4$,=[GAP/8F".^&7
M(23D1\.1VN,-^3?J:8O#4/<W^BG$04#["_EP!EW]RG?@SM?? _ZDDQ]F";Y&
MGF.4AZ6# 3U^6#Y]J,+L'P9[@C^D\-EW  #B-SR]!7 10+ _L+\,."UC!;>
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MP:2_VNLUE#V6-D?8&"K%75U-W9NN.2'U:8$O3AX\F]_ 8 J=NM5AZKL;8K1
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MR(/ZGV+L0\6-E?<!O93.N#8[,,UL5=/S&H?@QCP)XZ1GS67U!;>TBM/008)
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MJ4OU?\R2W>EGY?Q6]8XWW_<#)=X C<TBMF(Q:)QP'/^7CC<!^P"I$(PZ[L.
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MBQVL'81:$FQZT,^:RXCHU&U5<_M"_O&_5)5T^#WZ/=Y:_J.LY/6_9IG_SFD
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M=+&ZI$#2N"AO:06AB=1[LDW$,'L[2!1,\*/*=1Q>RY9ZEWYIF)*NV(#;<HU
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M$ZL2A6B;REY4;J6LM,TNN0GY?324=O"#GKJON!9N[+XS>&9+4@HXE55Z3X
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M0O/.3CIEL$:H-MRB\)"K&1?*"\S$6!&6AL!35!"DS>'B*^AQ;D?=8+,S/6E
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M*NZD1USE:C#3&6Z6DD39<':5.5,MMGSS>@NZ#)D.M]NK9I4FEN_E+K#.FO,
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M<^^Y]Y[[_[[O>5B09,^LF?G-FC5K]MH[>?;IR.D4X)*RO)(\  D)&<D;R1L
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M""2#OFFAXIV39ZO^V_HD_4%3G5O=.:>QONLAG6M=O_0MS-^G_QL*RM[YL2*
MT]86T>.$>$?_2^D;)_-1R@\.S_F[,>+].X?__)W])^?<YN?S8\1*.OUC0UDZ
MZ_[W]YW' O-;1,_] B#?_/;ZJX_J1YR^T61G1RC\/[P_;\@."!+G1^C^WG[A
MG<F=R?]3@1_M9V$ N+@[G248\IF^%=C=Q0;Z#^O2&L;]W<VS9/XED0#_D'$
MZ1^9^<T-[1^)=SX$=*@3R!H(U7=2/5LZ2+_AH)WW(0XN(UX8YX22["^V,>P@
M8'?7WUCH8 C(#O2C*LKIG"EIG/,0-)ZE.PRL '0!0BQA0)MS[[U=OY=Y[&_"
M9YRS'B5G.YK_'\:/X@YQ^NMD\4OP?^>H0>V OW'0+9U@NI9VO_'PK8$(/: 7
M3 FJJ*NF^KU 87YG_R:,90^&^$@Y@>R^1XK@V^ 5O[//HFL#M+5T/Z]06!Y
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MA$*(=#J!&"CV:2N2),)+-*3S]E<840!(R*AHZ!B86-@X2/_8B01 1OG>>0F
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ML#R[U."P!CMS>EFZ<G)S<'$"Q"2]7"VM'8$P&BL@XH)7G&[C>3,=#<A&G,Z
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M2O\M(X9:>OP71@OZPS3_I]GS-]5_;M_3'NCR]RK%]Z-*_2+USXV<G:H\+2%
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M5S+7K@-MC-:L%6"V=[9E+6[S'@YC6*7IUN&ZYTL4(]\-RD^H%"YCA:B+G^V
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MLEKW*(<OC?)>"3A@WD&F!"0Z^=6N%N[S*<.*P]T)QIE;96KI.A3YW/#3P\W
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M4 EZ\NK9_9P^G6(&PSANU1OL/M;FIP#KA?SNCP=:=O?$<6R.FA5*@K:>M_E
M75Z$-90I;4E6:S>@WH)K::7ZZ6D\,S#H.60<9@S^7'E=B,Y7ZJD;8767E<DF
MQ?ADJ(:X^P)WQJ.^\%%Y8E6Z(+%G7UDEE$\!S_"[3@'X3[WT7B@\/"HLN+IY
M#;R:^7&>]/4#UA^18/<XM&X3ECL%=%'C=T_<T!MGVSYP3(,];\MTT,:Y@]''
M-NR&K-RAW?0P@7#1T.D!85[%%Y#G@F!5X=UTD&]OCSD'3%2R>G#7O5*G;5,7
MBMXZ]7[4KC0O)T5>E'S5+Z&76_@MU.QYI!0>_?W(Z)1T.]QNY44E]>/4UOV[
MBCA<KER;5$BH8+Q5.[UEYP ,".9.;L;\+H<VAVJ^:8+T'>_%6^Q^@P.]X \'
M Q5UBN7:>4J356F7BN/>+7TZ.3GJ)_D2TYR!75)4\^936MI8<1O.!\^<6KT/
MI23ZA;T0&6M^24+I ]?+VDHCS^(.^GMA%G)Y8^-X"^FL+A^=AMAG;HR.ZJPQ
MIK"HZ ^_JS0;8)A!<6F6H8* U@<_7F4-S.NNYG55""O;:B:<>?S ;'E2Y,[6
MUV.U$_G;'ZQ";PX\?:]?M9RC(T*B&,2R!;I,7"8/Z/["GTGVOFK>O\8_2G@C
M]ROSV@T_7<&&HW$SZ[1Z8D]!'8-W>F)IP^'D"9M-*?\?<6\95%D3M E>&F@:
M:+2A<=?&W=W=K7%W:=RA<7=W=R[NWK@[%[BXN[MOO_-]NS.S\\[&3,1N;)R(
MBCA_JI[*DY7Y9%95GKQK>QN>SB +0.L\$,!QI]T=#'';B!$5!BQ>L4+@\6Y4
M 96[FU\TE:;#9Y_LC[>IKY8:AK+?K?X8L,F,M-76=DU=/MI XO3T?  T/FBF
M%#=?*VI?K%FD5GHV=S[7 [(J<\^LM#;VBOHU^6D]2CSN[I;$%K6G7FZ;N#K^
M>OBR&K#TV@>@[$JI_V8H^I+Z@  6DXO+92>8BJ+G?%-7/ ]3._TJ=E7$@JBC
MX/JW[@KH74BW9<::IJE:]L7'T/IU=>Q:$?AL9^XAU02T6CD'U?G.QW*_G:4M
MISF^]2LN*B=,$<#;!P'YB+HX1KVXZ^.4E7C8"WY] !["QB*\](;]QJ1^/WD:
M)R=:><RI3PJ.5P(K-.7BHVA5W3*?[IX]/).!W1?VGG</%'K)%S=1.0EO;PDE
MIIZ'M@]41CLQ8=Z>XB%'/;B/Y8:IOC;*4W2SE#D?@,NEL(<[/=MYKTF\P[S.
M[M]+'P"]"C9\"">8:GF73OX30'OEQ$MGVWISI]BLM^M[R/$M6[71[G#RF$_Q
MKL7%O.,#P8M9G7B4FT]!GY+*UPJ"5S>\$DB9J^K4,G[1^QEZ5M$37W7%J^R=
MHR<+83L=IM#M;M[W$VOY_/45\:I.UM/YQG?/]7>SXDXF+MZHV/?PSL+"R^3P
M96V>YH*J/+[V@+'4])K/6'(W&V^2)/?OB3FL578A8YWV4^P\#0Y7?=".(&.;
M11O2(<J7,[7*'XFPK.!7X< 2*MIXU@:8\48ZRURV)S(BF-Q"_65SO,X,JWLS
M(Z 6=1UK,M>0BFH?@@DK3A;A1EE^"TA%^[QN#. 826>RO/3+,=O0,TM.]X&E
M4]\&#7ENM8+,!/)'-M0$$^ML2TQH6OWPQ$%'DR!/SC%\A&-G_"RHW>D"DL^X
MR>F_Y%'4NU1&']V0.Q>YS'[54W86M0_X!F<&"78X80F-$I1HD*[X*WIZ8V1D
M2DA_&?6[&V/'I)?X(IAJ)^UK;]"UVHSM8'3U[O[Z6)'=MG58=?#3*'4%M_Q&
M+D (>.>M8>TGU2C%CACK3:0)PRBB?VMQ5^%.6<V#7VF+>6M>([@7'D//X) O
MI-2T4[F 4;@_EYZ(EFG>,;U($T@U9X[W%38U28*+!HPP$?O6H^+A-S>-2K[&
M)E)PA9M]"UGGRCDB%B1 >#-A@!;TU\+EK6OY8O(';[PL;_#OSHWRA(14^.2A
M7XW^7RGOITX+3; JT$X+=-=I=_.W\;#36KP^\7AM#E1I'_@ 0''$A*GKUGOL
M 3%GY#JDC65$Z<*?<]7 +ZU*E-!2U@I$=HM4]EMC7['QE*B/(1'Q-$1*I[5H
MGAR@PN/EF-<6+_:KDO_:8P,,@=R\X"$99&,OXOS0(0?2JT(C9J:O2]44YBX\
MI77(._1UVZX-P&;D0FJMV_7F+(<!M"O)KU=UYB86QG%2@UV<F%LAK*>_:!TE
MIOV_4,](JJL**D/;(,C<.B?6-5E:EO\T]L^'3748,4BG8)/8M5BH-@KPVU1U
M></1>SR12NC;SQ^3C;EP7J>P)S\O$+-;U%KUL7!)WID]UDU_*$M_NI]4^]YM
M;(X#9"H:!K6^UFV9V-Z%;9>'I9$/:/WX:N2[95GE3I\_]'U.)3R<%\K>"T?2
M[=GN3;D^P_;J^T;/B<ZU#HC9SCHQ\LS$YPNJC:K_9R:<2;E#[U'PB?<R<+SQ
MT_$E"9,L3)5*&^1L?[_V\UN_%$O!+8Z*;% +U/K#V4IUA+NE)$J$;E/J4*\$
MY2>[XO?(C%&IV<BLK@OQ7XY;!O'93<A\Y!MJD[U-F=D/0MLBM=]B1]-=)Z1_
MP-2E/7(L-,48T7.SXZ+7LV7O&0-)M5RBIQBJZ]0C[3Z+_\01+*Y Z"MJ6AR2
M="B!PCHB@2[<]^ MS<*/,FL.K:);9FJBO<$!+&OXX68A(LX^D;%).=J)&?P:
M(E;9S1N<+Z.**@5:R75$G;3MJ=(B0*L:LPQ629GKL/>%_82(BWLO8Z3Y75M4
M&])A[)._-E/AIXN7TJ"T<>\_9US9VC0%/5O'A6+OC+MP5I)=P#@;HC37&C^\
M7)Z%P.FH#26DS/P!$+&%/\@ R^B4"=":4<.53/#"0L5"FQK@:YLS=>KB7H\(
M6*1.EANCU]+*DC54L:VONGIKVV@-U)5['&-;MH4KBY*)&.H%,]?EUL:\*2;0
M&%3:>YE4$R)-Z[1)$B:YY,^(&G1K5]Z_U-LYW1^'*'%M@['.)I+S"8X6&!L:
MZ;TJK=$1XI&OMY=%O"OXA7L?L,XUH/[U='QIEY:"6XA821_10AMM2.;4IO'/
M<S_:U]MQ\F=TB,>\RD86,,SB+D0K:;]#_M>?%7%$,L4$DC\<=/1)5?&C$)9V
M%E<._BAFG[^?&^CWCEPA);MQZWU^"\:51[D;(78L9:*I_HG!]4>J_JM#2?G*
MI4X8_AG?AHDB+(2J9C!9A>/07AL^LOD><B@MASMYZ]6D9^>3=XI6;YPNP6"U
MIO%C$;%V3%.E*-]S!G4G4780HGGSQ/(@LQLZ*"/,)UHF,2-MC%AJB9"=JG]K
MF<R9R0%/NLP[=O?JI%7GE;+A8G\1\QR/8/1=VS-^YM4OB+A=*H9&W*7,Z;<B
M)Y!XO?>\[\_<XF31K65&G- RK(98UKFK$CIB$D,2>:U.Z3PU GH2Z:&;F/M3
MS-+S\9?S"VV_'AY6'L:;%WM<ST1(@5U\H^LIZ(X*3,1<[E#0B!J=R+!C#OD9
MR/;HEZ@E4H0SP%MD@&I*[KCH)RS=P;RH7@S\RU'^=+:+:0RO)F9^'3$7UB*_
MK7#_CO9#L</^LW&TYU [I#9*%>O%N=85]-&]P'M.Q9GP&Z^O7LDL\_-U%?5_
MY7-4/W>1,$\ZD1JN</;(-V.3JE043<FC5</;: >FZ#%SB>U$ N435XW;B<V%
MJ *W]_!M25.?M15W^K^!D4@6H-_/K,/S-X0-:U;-JPQJM2OH5!<U/0ZWC3)H
M[!4'Q'QP/&#3T)5U*.EB ^"O</HRZI>/V)BL;"9M<CO/:+LN!U',BAI^GCF#
MEG$A=<#:Y=1T+(U$"1\ M93ZXG!F^635L)(U9^KS;'>UFEH*0&!]6.;G04*+
MS< E;25BZ=YH$:?#<]_B\5*'%1?NLXHYW5+[1JM%S8V2JL:.H^QLN%+CDK)@
MJE!R"^.:*1RR<#%\6B\[1".P9Y\?_+)=RR+8ZL<Y6QNXPMF;-"H]N2D\7U.S
MW%WKK4Z8A\ZXML-W)!H&"Q=6 =7=3F!/UF(=SWC&<MYN[2+FUI]Y)- FT(+_
MCHIU:T"J3ED%2"9IB)4ST#C("S;%S+-^?XSRTK1E^XT07-%49-H]8AL_QH*@
MCRUN5TUVIX+] ;"B>#Q6BV2B)+3]\LP)/LM8@3FW>2N=63.9>V]:MK3TD [8
M=?&=MT'PRZ?6N?T:0'JK-U(5;WLQ\5/M6O-"5?:<-0/6U)+-C8RS1%2)];Q
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M5D0K32ZPCGW"J8U">#,YZ@*!EX%Y"2-FSV?JF!L&"8(J(_@MQHY?#+Q5B)X
MJ^S]3P?O92*9ZS>$O]P0D8H>F2L&B<^PJ+79M?G+AUCNE3X 7EH']8[2AHPK
MA42T>91RC85Y/X2<J\<TI9R!5IJ@[@1-4&/F"&F\G"1IPGB6I([^Y]_3#-@
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M>#J4S<^BR0H2OX_H.M&'IT\+=>OX,>'2OK$>7M_AM@_[T0[.?)>[7QF5&^Z
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M?TS!0*2L*_-!15 4K)$HM8?O]C;U@I8-G\_J39]\6KQ0VCY;JR7K?D5B:_@
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MI6N]14ICA/P106XBRI5'C?%AV([,6OZW)F0#WW3%@[UZ%D4!CR]7_)N\EZA
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MU0?@X1+=M*H3@VR2BW-MNC55$_DQ=%J4%:;;J!/#KY- WGOT5G/BR:%=__[
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MUSKO"YN<ME$<10*&-J9"CF^24#%J.",D43=<?^&7W_>5%O%!;:U^PZX/B!^
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MG,=Y;YP1H6WF,30*N43#Y'63/&ZHF8JX^^E^OA_N^_T;OC]\Z5F2-]2-S+$
M7O?"SG5K)<TN/-6B*_)MV_H7,KRJTN+I\(A4E$LV$$M-LZ8N:'>!02F#X]-B
M.X2T=ZJO<6#BTPWJ\7$ K62^8,[)6K9Z\_.NE<ZE%I.2CQ8BAYH/4GQS3%"5
M5BD0Z2.+VO0LW6#>-QX*IQCT9Z-2FIP?_-RBFIP[Q.:L%/#.5YVK?*S](9A%
MX/JY7O;C+'/Y1(V["#WHL.D1%7YC!XG(>>A.]W[4 _"FP=:6CAJL(3;U4<R:
M+]TA)]G^)_[_%SP%3^/IOM:]D\ 'M:(R$'4P/C7FS&Q:WA($J]FA%RE>]SJ3
MNGZ-G9K "/ZM+A;WR@6O4#"IEAY*ZVRUS)-/0\G#H?T*\I6ZJ2_]/$&7U?UP
M I/[5R3/3F0F_812YL.AL\[V:GQ<(0\L5I+2I"#W1YV@B,"3]_!FIQ=Q_;C3
MM1A,O57LS>5VV,$KM"PX^LY=B:RK_1_/1D%*B:.#B34"5$ROSI/%> =D[XA$
MML>*WW$-A[4)TS*Q,5OO!2(.=W-26[OH4*Z0/KAEZ#AB:4FR\DO:%@')UC/Q
MDN6&F90FA29@ZD5%9)'S@P$<.)GZ1#^4F;&[5S0GAJ_HH;M)TN9?V_\B^$M9
MFX&C@O)RW8 P!B,D&US2>0)P0RG:74 D_ED/,\K/?QH](=T:1VDA;$BFT(C+
M/D^,K*J30 /E!^^QPLEO%^M'(MJC52Y"[O(\\8H\^N-!2S0BO,\V0?SP-950
M0>B8BIOQ-@N\/9_[G7*$& /OX"09N1>L3'K-[+4(@\J'>YR<',_N'\H9A\'V
M;<C1N+>3P+CS[\ KYFI,6;$GL%8S=N<,TC9K,G%LXY0V ?.<@E=O*O+YQ2P3
MZ6!!.4;&QIEXMZ;DRSZ5.W8[-JAMZ,O1X:T%S]_T65=$.)KL<B=\M8%>Z/P_
M6)=T80''A[Z:-U\D6RCF!"TU=,]B,]M[#3&+0%>I9%VQ4][W"MKF>T%/SO8H
M<>T(#*W2X<CF;_D^BTD#'=TVTGI<(4W>-1^;JZ.U%2(]5A0 Y8H$VB S1SC%
M7&,ILZW>T>:@;F2HS)6U_(+RU,Q-"*5GF5[P6,WN/)0SFY;-@R/+^J:'60RL
MEAJL3-TK'04>$D*#5^<3&XEX5-M:U+DW>T")E.!9<E5?')D>>ZQZ7%)1:""J
MM?]\@-/P^1A+F;DV+J(<#X5R_(,8N-67'=S1'XP'[2Y)2 [[#;/#+J2\'Q=(
M=-7M1=OZ5A%1=>8JUF/I9;$Y(YA*2>RQRLE=X(8F0MH;>-Q;V.;@KGO6OB#[
MLEV37N\1HUK3_?LY@8!GD+"F8O! M7O)USZ*+1J^_6QC5NMLT2NW@3R/[1<<
M.P%[C"MFWK:S*W-JH!S\KC_AS?&Z!E3 H)%X!FT:UA?(10P O@$99\32@HB&
M2(-,:XBRK)2NYT;#7"?6:N9BPX@[0I?TH5)Q2,BN,B1R?;XWC'0+]]^SU3F<
M!LC]R]]02P,$%     @ <X9X6@<ICLK';@$ FKP! !(   !I;6<Q,S(X,# R
M.#E?-BYJ<&?LNP=8%-VV)EP(@J*"*$@&)4@&"4V&%I LM.0,DFF:G'.+2$Z2
ME2B2<\Y)R3GG*%ERSM ][3EGSG?O-V?&;\+]_SO/,P7UL*MZ]]I[O6OMM=Y5
MNT!.(G\ #V4DI"4 -#0TP 7U R 7;QV*NT!- $!.#F $ . .@($F -Q"M1X
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MIF*X[[=7!@G]>8J>'#Q?>M%J2K01U+4O?O2]X"8.7%>M> <)F-WWN=X:_ 8
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MWH.W%X?2R\L51,RH$6B&\CZ/M"Z2)6_5Y1LV^LA4T/HRI?X@!+<S_N>S>($
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M7_\U9LH3<RV>L/@+])=R] 9 O'?]+]4\%8Z$-X"!F-S;E11<O@'(<7^>&9_
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M&8FF!@3-)4B]*N02L*FR57A3$%G(;LFM6A3]O,K5Z7\!RO"_"IWPA:.J_S)
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M5/6J9LC_^C-N\87-OE/\"TXA1IW^2E_A)GOX VS9>L<#/O%8H)E&PFF)/U7
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MP>,ZS!>BJVP7$NC:_K;H1!0A;?JL4&PQPP=,W$\K#J?SXINM3IX;(C<99_<
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MM )[VPT\\(Z"QNP?D2D##LHF:UZ.6'^([OT_3(C$S(/=TW%7!?-:-ZK$\QY
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M<:T]U"LD2AT>$"^YXY+([UU\+Z? Z.57'\]+IPC>:S/S[^;"L,QY"=<8CXJ
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M@K"!ST8U\P##+T0XAX?KN%+W*<:HJ15S/H;GTDT*,"(3R_?3?Q6"5QV?C%;
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MM=Z6":+@06ZVZU()#6D4Q,-*:T1!AB6-MNG3T+:AMBG9P.YBJ[97@5-];DV
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M<U&7A/(US-CS3!4Z"*%6S="!OX2 *;C-8@WMBQ$B.G$K!8ME)Q_PZ".))N0
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M$#5]#X>)3U#KMWKCD$,G8BEM:LVR,7V51'.Y%^^DINQ9TJEX52^ N# ,Z#S
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MZR@WX-1\%:<TY@Y6<!14[#0_N^?D/(>J]?%8OCGWNWJ)9:UTU%_1O\06!?H
MD>="[QE-5?8L)FSV2D!'D5HW;T]X 4'#IV&=6-M%02[-X4/(]48Q"_!O[]=.
M[G"!W9V;,0RAK=(_%JF(@=.Q9AGX3SH,[_D;G7/63P2)N=8XQXFW7Q34YF!$
MW^=^Q'65DP^WFJH +JEOP.;F$XK<]G"JEQ-68TK-4Z^7Q6;-3+-WZ">7\B,J
MB&D)AF38GU'%!R#3L!8MZ \.7-,+Z,#SN&V1$T[XC/R0<!^;IVWDKRZ7+O!X
M$>>^ N?T46ZU^40 Y8QY[$U:)[9>Y[57;A$'494$_:4=>U1IP2K=Q&NLD+C&
M7/7//!O+2V=GS=93>1+A/DO63.L7P%4)+F9PLE\*^-LW\G P]3WM[QV#&486
MS:9H5Y<:%D)V5LR,::4</"P&&EDDE(BL1&R1LF1SO33?\?<Z ZVE;L?\ GPH
MJW9:V#4@@8K<]UPIZVG4X?,Y@!76=FE=\2;T@8+Z\YE-&JF8?#-_]3B1+7\O
MA'?$N6R0-OH"B! ^L@Z;%T0/=$CVO<SLMI_<5ROB<1-0GO$24%[&^(-8D1(-
MIGA6QV3A#E].7M\[QZ/S4QT>95&2\;J) -4B&GYV"VS]PUC7&N:'#7&WNZ<-
M4:A.XM'/Z*W_\DR99#@,V,6!BRVPD!^(P8KG,9IN-G8\&($?GP2^:1!=H5)\
M9]!,-V$WU<B4Z?C[ ZN%(RN,2;](Z9T1=")45U/ZYQ+/I$ZG]0F/']^EX+6X
MC!0$I?<PO*%"&6B=MA;R+HFG>9L(@_N.U[*ZAMSE]<R[8-GD!\^6=[MM-I*!
M4[*PDR5&/.?4H=;>^V8R3&JD2'.4PH/YI2=UC%.2 ^V)LP,'5*20CL.2*67R
MQ98HQ&X,-^DE@YE%FDVY$.A#L2GJ=5PRQU?\%1Z%H?E@*KYY.)G+B-89KJ2Z
M6OQ&\+#&&5;XXJ,R&P#=["P;CF>(%8^FYB(_&89JH=B@13,G0=:LOE-?I^3<
M6N0PE36OW_Z^G*8AW9S"+>C!)J0</ZE3=K39!./@8G^1*4U403 SR"+:<;NP
MO:I)W7CBM1^-%31V$JQMI/U<U)T>PSPK&YD=?X/FB93M?"%T=W!^ 655YH.1
M:D-,A<+DQ!Z(%VQK_;P:^^Y\=5G-,KO:2_[H7TYAK+60.(N;PNY#4UDPXJ>K
MR36OAU7>1MS^KC)*6+M[PS;0%V/D)VP*/@WQOQW2?MUB2 KQ'%SHHPFKRZNA
M/.M0V[S&O#&CX$U#M1IVLM?V&T2=@1D,N53.&Y.*7%O\;VA]Y?0#=>O#..5S
M9U=<==1X912N=7&A*)^/=<(98:HOERCI.KR/PS,KC2:]G6/  L,DW&Z:4@GJ
M S'[:]6^?(3KK/SMC0R%"U#;CM-#;\X E!:(5#WKIR]E<XV#.-C)C>N.]/3!
M^Y=K+%N')=;MW,H8J9"L29P;4H<-&V[9,L?OZ%'-1"RM;%MI_NE9AH$M,X=O
M;3IUKGUIJL0ESM!8X7LY;X=T2B(^&3,:E\V8]WU3&K&P4!)Z9K_\IIT'&;:6
MUC!^8 ZB]6/?2&7 0KQ03;(^RYA77\LL.%[,]8QI\7[.^.U60\+K#["[(/P5
MZL,*<RR:=J/MW/D(U@)XGLF^_$2'VQIX-GX+"\>H=#FX[3N<)EP&M6M$W,QZ
M/$K9F]0>('X_<8+-^ \H<"D-X@)X 6\3M8%XK6Z^Z<P_V2:)>^6VVE/WLH\Z
MD7!UZ[<V%-*F[;R%Q''RP&D>O0"?DX'H'Y:(-G@LMF^:I!>3IU YD2,3VY:;
MAV;V8+8V<&B_R(! ER:5[X]G(#+@B ?S*19F!2<6S S-'(G*_GT;_\KV7KJ2
M' 6MYE[W8]?4ZQCMW1:4#L/&[QCS;#/)].KJ'=KOK_0#RJ=Y>7FK^8= 2#+T
MSMJ.L4>B[ M7OA'B;P0>EW&UM#+_P/OH>&-'"YEVQ2%5!/L%0X!37YO;&':T
M+]M >6J8J3#W1WU30Q$#0T_L"6<*8[$YJ(8](IC$A+Q*CBI$8BXM;B6GMT+-
MLS_4E3YH)-JOJA_&K38"<U@J)44,R2<_"7=_/7E=AU_CF6G6*[YK:_8($5"Q
M^7GZ!;#\#AN"GVLYS+T''&J9FOE(OWQ#J,E:1IBK,:!E98AAQ]JK(L>6X'0#
M+[,%>*H_O"Z'C%ODDYGWRO46=#-WZ? F+[TE'R!_B)U&:N"Y'.HGHW,<,S?)
M?PDAD]E\RLM>FDE\7(Z7Y@V(3AP?)BFQGQ?SM499?Y 7$F3DJY1V^C*TD)"4
MJWTN!Y!RG$T96[$AN4BP'F/'@9CQK9SN"X#V965]!<',;S%-JA-FMY\\<8/>
M4\+(\ &Z+H1!\ZU+'_$.9X/2?H3WXF39?EW"4UT9(6JH02;"[K1\-.B[3KCQ
MC7]0D6)^JWQ=-B6J"5S8";'UPVQ4@!GW&#JJ\SY1-NPQ;*2U5W&Q2/@^6G@\
M+,[!N6^I:'W=$;VQ/_]@QHKOR]Z.<S_T]Y829[0JM#O:CW4=3X#6G@J#$4_)
M*E9E7ZT]>S37<P& ==M='[&$OE$&1=<P,%;EJ2X-15HQGAG4,$X:-S.=&8Y+
M'C C3/H#&C/[>O0[W0+%B.\K<4ZK0H]3,DQA"MC?6?9X!MII!]G))+G97U[]
MF&O<RQH9']K?D*QM@F,G!=]&RG6R'J:QP(1+K2NG]G_:E)@GO:@)G.'N,_CU
M0TV)95WG\3#)R+CQ.VQTI]LZ"!#_C.-'%39Y57&H*0@)6C'K(&*X?!C(GNR)
MW-OF8(L97ISD+,O;8'T5 5'DA IW(ZP_[/3^O'JV,<4S*W+C^Q<!%6*6(:X\
M>H+MT[V([%$_;JAY&\9,(,B"2?AV.^@T)_C6(L%L7)0/!6:(Q4]BC$EK5&*/
M%IS*-W$#.B;K.CVGZ<11PG2]ZY;ZC%SENZ^U3C.!2U=J(<Q8:W4,J*LTI'SK
M]-X'B1FV) DY+_*"5UI.O45BI CHSECR]BY.%-40S2%9YIZW7E_\/H \$Z'S
MK8_,[)GMP O&0=:GTQ7[423%@$<JYQ?=6G1SHF0-<[1^["!CHU+#@WY=)N:=
M [NPD?QBUI5M%'@],W@Y7ZR;(O>AT2XA@W[[;/ZI0>7_4-7?I2K3TPL %VZ6
M=NY]*:_368>+SN%XU6(=?-,EO Q3JH(B.>BPILAQ/55?TX._ORRVE [OJ<J%
M3V5;GP*E5*4NPZ!ELS'0UJCP.6"<^!EW74&@92GF#^8(\_F/LP'\\6&D#U((
MOU?V;XD!_ 5&_O>;,J;&>+::14<W<PUDK!^8M;OS8'HX-Z:?DKEZ&=JFM36$
M\0$EU.U^)..57HVNO^\COF,HMVL8F\W+?A6]5X+EM_[<2=[C2Z?FF&R\2?P!
MO=0J>Z>P=,8>SS,F9*M][UQO^?VN&MSCR<C^]Z6O;SF\V87#&.>EFC@9JS!^
M.1G9HUL)/\&YZUMWI:C3DHT=9 C4GXE(N7H;UVPE$\>C+.]I2UE]#SX=?$"N
M*K;\XNV-(Y)9-Y-4CDL]?0&0;7+K#A^:(!L-?R72#O#L!N72]_0;%VQ$50()
M>(;F$-3Y6EBRN9NM8C1'6!=+X\BM7HM8T<A:Q;KC_#MH7UP:VS-,V(#3>1IG
M\-NEZZ\.8$,R:=(SD;4*;E^/2P;#@/USN1]X2;3$P'EI^XZ*:MK#QI226^63
M1KJ33V:_JT5P]*5V<Z5J5KE<RM .8S@Y3B5SL_F6;'5-,8FM1%_YC)))! \X
M4(_D.XY_)#^=X@*@_J65 [5[/%;"P@K6DDZ/R>(I>*&4';$4$=:#C486#C'#
MY"8J.<0T;M4W1>I+U3[/)W5WUB ZY RN]^8C!+4?TVY8L8R);P6K)8\.\O'8
M_[QG2G.76WKI5MW"!T4V#%/XH?1;0;+3F2??&S\)%;KNMD$JEE_>(M"X73>H
ML6B;(3&MI\1^/A4HSE]ZA8M4(K8D^MC&N4S8@#"+\'S1[_71D$1':?L"\RR,
M?@)&6>AHYC37-1'TN$E,0TJI).=AEEVOD@6%\[;<B],J>H(O5-$4S4SA:A//
MPU89*\W!H3V]&I).-H?R4VDX7NS3?)@T1BJTA+<E^.!)\_7;'^:[7D22V[RX
MJL2L3T)TN#/:]"@,:,>4A+NA= C!LA+AG1P#YU\_/ARCI;E_%X@ED#XEM$C-
M0?>>'K3.4VMQ/!$$=<PS5 7+F8\_Y1'H8^4)_>'_2')!R;?N5M.M,."@%J>
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M$?VNAE-THE'R5'N@*2<R+%S[T5V63T.O.*6NETS(<-LL?I1AGU)?6K@VC\V
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M#]F"KOCQD=PZ%A 7C,_;<C[_AQF'U@G*/]U-!7Q?;,6%PMBWEH-D1RD@FJC
MF%/*ZFWC1;VEU,5J#=9$>"C38'E,083,FL0F^P/T2#K2(JY(J1D=T9RWW>AM
MR:/)X\+IZ_JB@*3N$?4KBFN 3W#HK!Q'_Z><4&7489%#:<M&8[-3BV>,//CG
M3_>@TT<* VS2= %#."VK5]> FG<<5WSB>-N#K2_YN%>MN-<SUB1<8W$$XQ)W
MRKTHJ;IX@QM?<$88S3P8>3S,7*V7I2O+\7SOL"AA?L+^D+%<A^M)]2C);?6U
M>7CD]XSE5E]$.40$19]5!/9&JILO'QE,08\&K)KG'S.AOR:HKS&N91.5&(,C
M5=M1F%E!"7XCSSRF](,0G8UPID4-[SX*C\G;S7;MXEA0YI-(:$_B 2P^WW+L
M>>OTAX^# <?LL1EH09 ORYE/PH0!]%+(E;&B[0^,Q])$%Y&P>%SGO6@[95"!
M]9PX\4 IO3;Y N:*&>2;'W+ 6V_R>G5G)]$;_2L#<.#E2F?W@2*D9::N1-&F
MJ*6,>Y*Z]9PLB$A7;0M@.U\,=D0*AP,M?'BJ(D^C#EWRS(9=T'!1Y],[]TNX
M%DE^C]+'6QXC([O+- 7%FS,%F2H%$--+,TM%<\<<B=2F?+K2:TP5SCY/T7T%
M:U#BW0 >..I=JD1$?L1#05=>D]A/ U?KQ&P@_Z&L]#\>"FQRN"H?A$5LFN2L
MC]YH'KA0C/:A0'C:R"'/#]*LEEIA%!3)=.@(KQ+"[/RV#Z!*8[VJE*>=\\]B
MTX!@;:NO 7CF>?^_KJQ8Q3T3N"X7> VP$ W<5FES@:?<S"7Q]!IP!1FX!N0P
M'W1!7J#K7$- !8_X<MMHMKK^'4151#%@@][=8,*T&Y2EW_)A$TAX#>!DZMC;
MZ#BAJ\R$?UCIL9U]<PU80FS3957=X,6&&]EG\SLN\"K^ ?&F]##CX_+AF6S*
MM ;368__;2+/H2P1-M;8]NJ#\C4@FP2U^W>,Y^L+_4XS,8238;X9#"ZJ_D_S
M@G3W<*"*CF7YP8KI?_E&! #VKX"5$FW2/?NA(T*P08Z>2Z@*<?GC5(.OW^B%
MK2 ']HY'OSNA9AG8IWN%#B*3M]MAUQ+YAN&#=XZ55(J;DR'9@<M[,"!$MJJX
M<C &<-P*#9DG/VF$&1=65#G(IA;T^% Y,*1W&5G]4B)X:?!&5^$':4I"PXTZ
MNAY:W?CJ<RS/LG/_6>29[9EM:C.DBG_XV"/.UOM0[*L5[,/"#3FSP!C,>YJ#
MTGL;92.*K'P]Z@[29F8!)LM.9J763XNDB6K8VSR,8"O$)[X-CL-*JM,-*Y1R
ME^FML:KMO^]_@^H_>A6D7;HZZZL,<-/#\J&FLL@/X32.;+UIG[WWN'\K<AZO
MN]UO_[W/POT1D"S[7J3O"9^E(6<"-W>Y RW-+, R2QG@WBZ/"2R"*(\?G Q;
M7KYL@(6X2=.+YC*\(6:!\5N3971RW*Y^#.*"*.#CNK.NPC]HTN+]!.=U,LO'
MZO=I*AX)GI++X^0D^&5^&CQ.?OQ^K=+_.QUE1 #K#HAEAF>&^4AW1L*7ZW='
MO81C%L@:*O,+#LC;)KPASK=HPGD)5CWIUB1YE3 5Z&X-M&0P+4S6(+)\]%L
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M/INF66M]RFOT:#B-"2:ET,$@;;;#L;9N\B1.G8_$Y]8.O]/3YHT(Z7)YNFO
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MXB\)Z<=.TL<#:U8T:IW%WFA7?_%\?$#$Z0M>B#N.T^W/W7'3%ABW;[07&*N
M)PN0,"'Q;XFZ#29T%YCE!CVLA!8*0:^26[RR)R%U#+]Z2-?WY0S>2:XM,)8]
M[J9K@+\WZ4M2H@Y+D)YZE!L<!& #L)6<O+P=4(:X8C$SG#6=</+BB=H4\75*
M(0 M!/<:7=(5UUPRS.5<"@UGJJ9).N,.ES^=E6QGDPT+=QO31W(GV]V(503,
M\J\0I+Y_#=#-?I>?KCB^U0B'93VO22,]/Q9"^EGSOU^$3-QZW!\\,*IHL)U-
M(EL9F;_7N'<;5C"W^S)GL6;9)+^T:.HVP:LS?<D,YUSCG9GJ>9/^+B6"MW<#
M@MX_^O"_PF^E\Q%?K,I^J5N5SBVL&&M 19<W>9*EOA/8&%*]5Y#7T;?+I@B@
M!(!E9Q"\#:C,2++QK_E).]5E#T\)A.D:O&P=_6UY"D[KI20GA&8C[+KSH$^+
M0AXY\.$+#77+4F0X)WS+M9^)&/]V@(U5FQRP93$L)!I46TV:<M.Z(<<Y>WJ]
MH)H\^XNPZFM :?+N-(_U!3T11[B]C@+=H9/ D8#QX.^9.P=&WO74?4PD%W1
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M'@FY94+8R9^%.#G*=!R#:"+VA.DP[ZX!2E/=_FD7-#0?I6T.&?U"\#B>'P_
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M_ Y,J.168#J^%,,!DK8(?13\O!]HKO[VNCPK.8ZLO428.@3$^-I=BRX66,9
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MFZP4M=C@"F7^SX(*-'/.@>1 5S$#+YI&_NI5WH,/*>C(68.?+7T^K*]RW6Z
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M<0)J06;<:Q5%>]/;FI];-ESV[\_X!4#=7[Z4@*=ZJOU^(A[T!+8MA@27%Y(
M81+0I+]+ NCJ^,W_J:H%8_BKZ'957X?Q2,]$*'3/\3.U1=O;?.TMH/MA7[.B
M6]+DX]_-@,,*U0Z2IT!H76@B"9@1/B2/9J9Q_]V8].W>(P$WCE!']TNW&@E4
M4'-L5YD4^:$7A.ZBAXZ<#W)'9[UDCSZ^5%(&U\K*<O3V5/\SO-9A?S!+KU0
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MBQ< +\X? &T%H VX\/^R_#?(_]LQ+M"^ %BN7WQPN>K2A;N BRP7+K%<H T
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MT',E]P\Y%)U- W "];#YQ>Q0598R!-B[&F+?KQ& 9\=&MLY>B8OS1_5R+^[
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MY=,Q^+7=6YE[7H_3E^5QO+3X\/D2<5(G>UN=TKZ3WX()"R18[&7JV%QO/>^
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MQ[SM(\BFOA6D3A,P.\G&RQF@)^!N23=WWCT.[2TAVX1HC$$&+]+'P*V-3=A
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M(]S5BAW9G:U(-:O>]SD3%M:F87^6\W,T"VDC7V!SMV[+M_ B21(*O/LM16A
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MQ+#FU[<W0P+N&W@$$!A[B+_N 0N*LNZ<\M)JR1N)XI)?SG^>PIM\<CO)-YF
M>9TSA8XWOJ^=%.ZH_1%@>5Y-/^9+ATZ*)S.6(:8_%@>Z9KSN#E3,]"7.VH&V
M]/C-HU42;?E8,BHHU^.&R2\'O$_"Y=1Z3?_D7'-#P)2+/028XRQN\2S@*R+P
ML*\!61B?=2)7.C7XS>WG7I\R5J$"OT*O>^>BVBA7=";RQG2?X[<L:,QDQ$*
MJ)VX,ECCXI6DJI)?!5"*F$(L')=?@A.#2-W.Y4%\R[/?0Q_,K$+"[K5D1+D7
MSS:@(N:?#?])SW7CTM*_."Q@GHM>.*&_O)-R12$8U6]+U//L.!/!3_OG\\(]
MTDG;^",SDA<^^[N-V =T"'6(63\XKYJNN!ZBP?OCH8>?;9)>E$Y;A_9DX4>#
MI>"J72,+^OW-EH_G8J*'?%D\7O_'IP:1:(MD!D@W8WYNF2SSH"%]&.GD7!43
MA#[)%5BY?D<W96$P)]4D=Q$B"A[A.0SIQ6CV7JI!(?&XP3WIKC<[!K<M%9#:
M;6)L6<1A&2D:[8 =HX#TN[E08/'7'#MC9C&/$ZT\P'GP%<7 &&GOLG.9[IH5
M-5]4K^C=?E+_@RQ7!+6XSYF@J?.CX>"&@UN ;M#^Z84&MXHARGI;*]+\(;7'
M,B"5/\C]F,+\\M;E\C5Q^UVJ7E'4!'Z$G]&/B_]AJ!9.V!;LMKIY2ZCP.%,/
M,?.Z<U-,]BPV)_F*@E&CNO.]R>::3N*9(^7N\UB7B?@\E#$JV\>DO&M!0<6P
M>-/_\M8V?!M.9 JTQ>;CPBKJ*N/6WWX2OR?P%'_2FTSI345;^'*\J_&)OW;?
M)B7\!3/Y\+)KY3B EP9^&'A%,>VW]N<RNI1@>PF48+V(\5[YD_LE[F?M%870
MN?+QND37"NDM;K4P5OR$\8_Y_XM]1,I*(40.=,1A6OD\V/6]$Q+BA]P%>Q9X
MT&U&%M@%T2S86-C,+Q:G_WJ7\>X8<&ND@3! B_^7 $Q,' S2I(7)D;Q6LP?.
M>/^&:>)UP@-H*AP<_4)P2=0NJG2;(]FZ3 <0]9DT.XC:3!_4[DLG?X.VN?VG
M$M*/Q.78&86]9SD[S]#F1F5>$*"",$> 9),:HV%:)6HXKU_A%<M=]'OE\KE7
M"E;Z/%<49CTF!4#$>]:VBP3(TRE$<.LQ4*FUN1.:A+/MIF?;U5S@>43R695B
MVEUQCIT]-^X)I<<3FTLOTO\ZH&M:"%!7W=W>QV<*R#S?^NV3R548-I*7"*>#
M^NX]N89LH^TGXX_4)"]R[R9=45!-_3&-Q]XFZF%D%A9VX'/'3["!1/][6DSW
MYD.R]\>?<_D4 Z/+%4M+",HQVJF"-@T%6DCM1Y6+$ 4W54-?M&)EY6I:9>4+
MV?WVW%=ZYF^\O2OBC1)EBZ6G'(R9V6VSE#-+1<V,6K=,K5):VPY'E;JN*.Z&
M\I#XW%KS;Y$8.]OO?>N(599"XCLB3O7^<INS>Y<LXKDYX>[!LR62F[F>Z.2O
MX^1(D:Q_B"YPR1.8W)R :15!P,0T%>W\5S,->WK&!IE%'N,-C8$_QCP>:M_X
MA'$WC32[G35=F+HWFVL*#B@?K?-QK=S5-S5.2 67+N2N)1L&3@SV&G6^*;7+
MNYO(2*-#-;6&;Z@Y+</EN"KN:OT(9Q8J5P&,^&+UFL27<FPC+SEAJGCWHP <
M/05)O"O#2%P@0X,3WQA5,/JSFS9),</.C5_\+KM%-'\8G?&/2T:8.+ZOFJ4#
MUQ&93T]6KWY*3!*V_$'FQ(T(FT4=^ !NS::5F4,:?WV^*&%WC%Q_VST::\&?
MXOOXYD\F4!)[7$KI9FQ/$UB,.;O:M*4&"'B&V#SJ%06(#.Z( BQ!#EQ(L;!N
M$<=,&.AN$2K<L-.NL ;M* (T]1XP!D8 @+DJ*A.;*:D/%C .GN(]5Q1T[=Q0
M["[V5U_H#;Q97+7$JF)C8*@POBJB>@F,;4B0L[2T<FUD]>V\D88UIM6OS63/
MJ=H2.&T!I2!<5 /RD@IVLD(3BB$_)!OS$1 0"/LNU\$]<][+V<&927&F1DA_
M[FL,OU6.R(B+H<5@&V0R@GVF0DQ^:6<B#3"8P]FV^& AWJ;:'-%Z.%*V6N-?
MR^SC7_,%;-ZRH]TNEL>3*L-<V.S!@2ZZ951H55N74]PV1P2=7+CAE+HZ[KOJ
M59+B<,CN"[AYH 4O: 9S/7QF1D&LGK-N>P>*P24!<]GF@^8>5@P-#KH@$GQ5
M'?Z\%M_7NII/M6?#.;$=N_<*3T3AVC@-?YSN?7GXK2ERK1^ J<OJFH"^P;2&
MB:(.UI.5/:OXM>^HE2\%,,,M>T-W0IP97"55Q1=,+B:! Q._.MY-C"MCAYY+
M[5=6D3(NLO]IEU&(@QMWKS#EI&;U=#B?GVZD9E6,! DLEV]KXCKND,PZLX)W
M-.CQ8U%D403 3W!O)X]SO.& QB!X(%FDI#58\A%V9K[*,9&*/]F//6V"[7-.
MI<OM$\*Y,GQ@A21\.:C1?$7Q=<_T@G$V%])Q^_+^3VP/S\,)#5:8Z@3ZW"U3
M2A(]HM2IP5$[(WDDN+*U]+0,N_/9IM=/.%LX4\VOLGI+8_OQ@J9!-T:/-I\N
M?Z)GO#JN(F>UO8*CO+!-Y5S-A!M8A=B47WZHY P/^*6SU?X ZF4;5__H1N_F
MM^&[9I&KBSM. =)UW7HZ#$_M?0?WZ",2;G'X@\WO]/II/57]_*[N;=,5Q9U0
MYMV65M)'$Y(S_MQHMCBWZNW,$9D=-S1BHYOA%/@M!+BNETQ !KY[EU8B*R<G
M8P\0[C U,7UQ_: N_RI67MI57OJ=^G\[>;WQT=6"H8#3Y:7:*%<TOY[O9 (P
M)0O)NQF6XBJN5>S>H/FZ(*P3YPB&6@EQTJF]N$ $_2@ QE>,V88VE'4]*CX+
M/5W,J[8V4)]I9R"+$H1J?=9X&6 RI.#JO5\>[K_ 6^C5#KK=EMZA^85NB,LO
MCEQBMOK^B)N;AY>'^X1^'TTPU"ZZTD>[XJ>)H1;PK+PO1VRFPHBI: BH(*;O
M@^ 4'-*7]7BF&&]:F-Q@A$ZF9I/@84&\_^8NQ$EOQFR,72M_70!,>Z5G QG"
MFN4J:YN6^YGD-.^JZ&;Y!6)RR5<4-B0]?'6OTE@9*?^ZBJ\H&':-<@9*W9;I
M\%NU(0_5[O]Z'YGM\SCGQM!+O0 .WBB8)BZ. 4%R>S9.5B^) =LA7=X[IJ?8
M"_F_7#:$V-UJ^Y:6+/*YF.'P;0)3,L.3N<(<@G)LZKIV"5_#SK/%5"2HN*QO
MP;=SH$]QYVVEED2K5$%T65S!A\[Q7M,.=,]$MR$RNFSX2 H"OF<J/'P&FPA\
M7U/UO%>3'G-K/;T.SD'B[^*1#E'P9-7W8B*Y:1-N0O;>V2GIOL6BT^;1EBD>
MGIZ4?\O(A#$*K=_WV/M9B@0AV,M37?737JZD(U0&&1,FXQH*I](F(?.[V0;:
M'M'==@1_YZA>W,^UFC.5H)_VHL8H;5BR<9*ZV.=4P2'E/A^,K41A<>6$$VL4
M3 J73P6I*((:=+>P1IQ&9%FF36 >%T/^"&4U,7YRSG7W7PAV,Y3O-1D2B5:+
M>/I.F;E5BPFI,I6*-/+-V5I$J P,&J4L#1IY-/YI7' T0@ CQ/Q=C)#:"2*E
MUR\8D, </A2;,?(66Y<,6*17(#V&2RHFE!4F1\@KX$&MTT?9W"+85#!7OI-Q
M#17$)T6=+3U[+/(VRZ5R'3,M?UZ1BHYUBXMQ:+*@! B<J'Z%6#49%+ED*47)
M#^DQ=F.U,PM<L# /YLB4(G/PSGO'5 /^X7&LN7GO+52#AT0R<(#V90F ^U^)
M8?U<YF("\ZYQ!/LL2E5^?V<B]UH=.?2$J524^P8:FHWJ/-R'1=](R\LP^Z1Z
MFP.56W;*2>7F[^4)S"D^*:9N7=2H%YML V6#@&^];49-&<NP>R3)TD6%Y0)\
M%"[D;"$'/;W]CYJHGW>_#ZQA<D?JX>/,['1-.<:I%.OEA&O'Y*K5D^K&*J85
M0#[+J;U_EX#$0M[)M*X'(Q#QTI9%&G]OF7>ZTZ9\ #<8E\7VS(1#9GK,*JCV
MV$Q01L5\!VY]LBFZ>O*6#%%#LHO<%K-=CB0N2=>8LIENG/2IV(ABMG'9=>H7
MP.J58#V$?XB/!L _KMQ1>UJJ5[&W0A/*M?<>-3SFXU.V>TF%'T64&J@EODT.
MJO:2'ZARS-P07-9)R\U)=Y(<>:_ +%\Q6R"LREP^G@+R11CY;\P0/>]*5IRV
M)?B82_"H,B 3NNQJ4]<?02=[7R.BPYT:4QU C+$9OY(-AH<GY*TYNXDRD/=W
M4TI<LMZR2T.P6A%5V0YWW#UEP!9:=)C@&KDZF1S:TXKC7N8>HTXUPQ'*<8SQ
M<S&)S[I,L48O$0G= I__C3<<[P09F7Z@C$V.C0$:I>0@1/7:G445-S;./ 9:
MFT(\ET8*]'-5?1#Z.0^!#*\3E+5ED&R"CE1=HEI:DDQ& $E)AV%-W$LRZ[DS
M,8HLQAMQ1>&ULA72>GF/GCJD?GBA:?C<@&B0V^$UU!IZ@''F,D,\I53\T>WA
M00LB$@DZE/>><FC1WNL)4RZ(%.DJ]M&.+>-R*8^.97Y"09T>.U'%SV"M958-
MK@MK8 ;7EQ:V:ND;I+TWW^K:)-'2E.+-N7CHI@/+\=]<E0,-?Y7N/.,Z,JNL
M.E.[HNCAO=/.3&HRS@ 3S+H-HBZ%9IP2V9RF,4]75^ZZ@7-J+;_&4B$ZIAH6
MLLOXPZ3Y(WB,:A]0?3"Y8;UX[[D'K>+,CUXO+R\F[Z>4#,6O.VE?\L>RV<>+
MZ3"YE'_NBRV-+C"AH"AS0:B>[7;EJJ:53R$!X%1A([\(A;<H?5E/:1  +"HN
MT,+W<[4&ZHK>P^&_N#(3C+9[9HJ>I8E]BT&*BIJ546D'($9$-5R34S#%1^^.
MMCG,.E?"P2P5'E4_\VDTN%S^;*8>!#A7[MC<QH_FEV.MO@4$QWEH3^I&'M^9
M?_L9;%X"8'L<UB,S5C2NQ>PVVP, MKFB$<Q#[*9EJLF&K;"RD0'$NZ7T#(\X
MF@^=;^S$H!(\K+?U_0*$#6BB$%'AN_*%VR+CX?RBW_I$!Y#B M5ODY0T_[Z\
MEPLX2\%7X)JGET&99\:K7K3<@"V'],RCQ QB25J2Y,/49K5D/7/"[2ZOB%#)
MJ<T9C"E^$G=%$8/.+(ID1WO=@RIU9\T@)4 _^<)$O<XD%;=V7Z[&4^%T4BM?
M_O7 E,+LJR&X\IT"4,Y\V"CGS4Z?&X-9EO0[3X8,]2G.>,M8B(9I2?16T"/]
MG:G"XYS:\0J0PNX$E%8<:=1@DNIF4K+C.UIILE5D!!@1'1"&/%XE)76ULQ$B
M<R^2UH[NNFB(3L!(51UU9)VBG3_+N<32F]&>H;UE"TN60?@8 0:]S:#/4=[Q
M2HIN4(=.#5J\%GHD/XS,CTNBPMJ,-BFEM[/]D$?]A3W<Y&<0[!WF,$44&X_6
MWN 8$L/$L5&QB?S5\EY<T*:N^*?8M.GM1\Y:)OEUON,GJH$;OBWZ![9:55'&
MG6^6Q92WP[O5W.WVU^/]1=5,(//5SES/H]"O&XJ;F7Y["*$JU,XTKFT[R59#
MW"!2D]ZX][9IB#_ILQHK#CT[VB0X:3-0R?T&4F2H6IE1.>M5&H(\\/ ?\9YD
M!_C-N[;HIU5#9K,TFDL@?T8_EWZ?P49>0YREJVK 6?UZ2-MFPH:QI?43$F=A
MGG!"C2R2N4!+94V&65#?5'PFITR@#!C@+&IL&!A;LBFT6C@!T:I0-Y3W)?_-
MP[QCAS<',A$>&?5,%D46 =EB])1'37%4V@I6:XMO=T55A"9;G!EP29%P.C)C
MD$;1ZEC4M:@E%@2XNU=Y861P>K>?8IKK(?:Y*.&6B4I)X:RY,5HY-H%WT4.T
M1DPK' SXCH/GYR;DUZ2'A)NO\56U^(HN&S&2997Y' !W\1S4-/W)S5L7L4#G
MIC?EQ1-\P!+<JN?HU5FK"G[98E&3[&([RFITF3036E:\ ]Y,Q7JBK[]]>ZXW
MDQ7D#R*ML<!1&41;Z&;Y;2OL=>5-$>@"[0TV?H5=1XL\7KHO(6Z*G7 /PS1A
M($*,E#6UVWOR[#5*AX%EF[JA69)F21GHHR]9UK\%S8^LI^U_&&1+[2S^L3:5
M(-/SH_>-[SX//XU\ 8BYY@OFUDOM!/='HJ:^Y1D2TV#_\@X(&S#-8-#Z)O'G
M1:::L'W6%46$IK,3?C:)8VFXUH6'C00OG$,-#PGX?<^3G@33.>D&\7V>/N3L
M-AP0&^!3+S72A>KL&^/7>U:8.EPL;6.56K2F;%CQR[4H4K?Y-":&;_+M;#7H
M]VF;4-_NRU>LK) *V^?!D@VVF-BNT4"'FVH2<(?;W_/#_O)J2/H(IX[H.Q'&
MWNX>HXK!= _ E<YYAY<!*AX+B>]GB^>N4=\TMST7,3>_TQ)2;"^NRTGCXKY_
M8$_YF;D-U:)#*1,&N,,A%@;H U27E?6QV]#?S+([?E7!J<.<C;LLB^YS8D]X
M];84M^CZ?/Y'?'/Q;SMP8<GBVKJHZ,C4AJ&F5#<)T,O>&-BM$L5!T-!+&%(V
MYJE_];?Q)V\BKR@R;I@)/ZW>+NO?ELJ*+@OO'L0X:!<[4OLB@/+,%L/-KZW!
MV!7PXKS-PM,@YR#*F:9W&:_[?=P"W'PXGZNC1S"#! -*PN->>=DB'0GW?W<'
M>]A_5H\90TJR]1Z7-$!062$<FE\YC/1E@8;)KH80^4D0!%FDYS(Y7C2@B7M"
MIKJB*!3];Y-3NHZ/';_UC!?(U"1^9[$Q"-X/9UWYTS?%DJR.C[]?\*^*!=\$
M\]3&S>Z[3ZI-"EMY'+XH."?U-?PR8+9&'A.C/GT+?A!GE*B3T@<HR1J2!I0T
M0LI9]?Q=8I>7:5X^0*/#.-W<7!R:&AN;$AZ&+5,9.D12/4P *1?$*IBO)RJ8
MO# U??WUVL;$8QH7/);:+(.;EO):  +)_STM!!H @H4 E^2Y#8SN*OU?T.&^
M96F\63C&_$=?3=>R('XYH>I+H06'::Q<N84U4X)C8)JA=Z&V,X7<?6?\2AB&
M<W7.L0D?%8Z1P^D&$7_CH5Y/)QJ4G>9S\]S!UHAR0+V?QS*J29AMH"HK=F&/
M+4IW3O6L+?*R'SLV;_.KHWYK8TFX<7>;;PA/PT08NOG1?"8+VAM96*NG,#C9
M(Q(,RAJO"FF8$X\FL'9+15Y*MRBU2Y)"5I.8;#[%>I*U<.JW+5O$[U.M&_N4
MS5D#7[C\]6 E_ FS]]_B384E:> &QS%M%- 8W;RC;[+IW++U47]T2/=4O@?G
M_6U0/U*.+JK7T ,PWC..M$E);BO>F8Y?Q;;6HZ>7FE1XZ6":>-XPK!D^, S&
MCU/*XZ<=P573_<0RZM&\%)(!8JW3RI+YQ2I+E 1?Q7(E?.?8*RU, Z+%]:8J
MC *<?ETG3+]WV.,4#_*\.4R1]PY07KI!!%?ZC)SJ?5J@G>IY^!LR&6_'V6:=
MW*J<=/^_RUGKG 7!:T=1RU0$T[5RL2522E?6W6;_"H[4A!=_<B.F"AR>F5+
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MR)M?-GY'LA26Y#%R_M-C[+].K9^5QCX97\2L.K6M'3HCA_C-2! F3I,>A+)
MQ[[;4K;?LX8JO2;,?"B#^IDV:W#@;</]AW0E;>;WO4I8+MDQT[R@S,JJ,ZHW
M%FN3P_>'N =?F==)%< [%4/O0Y.>1_79,J,O%$^ -82_<QUP'=22!_4+0Q7F
MJ+DI= B(\HM OS[C N3=_\?>FT8UE7;;PJFR% $1E4Y!22E**Z#2*5U*+*"
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MV#P6]G7Y0X9AQV@/2'[ESL]G4C(:5C?,#3ZB:HG_).B6B&F5-D :ZD?M,SV
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M_+T(!6M:C(-K<)J&V.,[<6Z?,X]]JE!5=RY,NEWV>E"-J6:M6VKA$&"GES'
MR:(]^>3:.8$>BX%$?7@F4)N;9P-/$;]-4(+_NJFC/^$@GP#>Y,2T;6 Z4+O=
M%X;'T52!3><-[?9/'(G2!X;FKXC[;7RF>?<Q-@/+5_A&@5KDHH ;W8EZ!SRI
M$\#T'Z8:@ISF0%X(8=Q33Y#9O(_5]QU_-P?Y(ETR$%Z^)#Z\S&_<M(P1?1&S
M^T6K:O_ZD;?-/JPH#&A10SJ4X=B_99&[6JI5II44]'!\8=PV-@-RP^O L%;C
M#O-EP-WL&&ZU(-58E.<\27@MY<_ABW)ZA8B.:&]&=B/#!/ESC WY;9W)Y0E+
M=D[B-,?BOI=_X?R-\ \YH9H%<4Q-(RJ$Q.SQ:ZHO*ZVI0OFSJ9!X!$>)BB(;
M= /C44Q,VZ0.4V^UDQ[?Y-N.W8%3,N=,@)*_@#[3+2+G&H?J/$Q['(EM!)UF
MCD*WWHI@JLSDO7Q84QJY,L M5K-LS,:_>,S'7?NUNE=(F*<B^5?;<RZ.'38*
MDMY)U[K,JI&^"5E6JL_Z76:)0X*[,;'.=J'6YUX?UF!4J@\R+!Y4G.P_Y\^S
M%O5ZI[XV?-:VPGGX+7>J_Z6UG7$9#=A9C;I,F>B&1&MYU_@_H4=I7 (HPD*-
M%?6Y<B3;)X%I>OS!?F/GP$*_*;F,S@V]LI3FH%!*AZ+!$+.AG^RATS$>7W74
M$)L8A#WTK.ZM;KZUZBRFIEF.]R/4BWSJN_R9AQQ=-)6!4?8-,*1W I)^K4:@
M@$4$525O7]$%%' D]- Z9L<BX<@ Q;=NN/EXQ<1Y?;B1BHK6/J%$7JF;W#E%
M.PT-]>N9^'8T;'PB3HLL5_]_#27^LB"+$H@:RX-D5+YZI$%/^2&\"?S,!KX*
MA9T*MQ$)0=ETKW<[ZLI_>*9=O5'0'JP2SYUW9EF(F)A"KA'ZN&A3E,'*<8$"
MNQ@26V'D&S%0RSSV9^X]09JQ",\.5\QU;*)= K=P3O"86B3V*H8=1TI8":O"
M2K@'RF9[[N'\ZJGLH:9K*Z_Q/#)X72#GD? 3>^C-DZ)W2TU';[S_E-2S)F/X
MME"^3_13MX.T=U)*A>&U=@LQ^ZP 3L"QC@KKLQ4.)V9SR+>5F1FJK&,7ZDI=
MG+*5%E])E<_;9$N=2[N<6V;AFEF^L,],\_RU4^;Z?13"#T";*<4+FTAA._4E
M]['IKJ /IY;KPI9\,:&=MN%ZTUB*E:_"1-XZ"OT8.'40+4'Z_9/XBJ3C<)T
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MK@=%=0V/7_$\,JQ[[R![+J$PP6Y0SRCE9-';,+\!&5NMCM,;5IR8Z;EV[3B
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MEOHY>@86*![+5W)IROFY?^89I?99MJT&.D+_#^@M3@02&^+IX'7 F$)\!-N
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MYS57H -XS\'6(X$HR4_ZLM_KT>8X"0FZ\,G@AL.)30Q:T5J]0K82(AYC]5*
ME;_6;6P=+!KW7^T)<?+:^BF K"H(/5[A+FXI(^]8)?:T7HR$:HB]X-^=RPE7
M.ME8\<PZY GM:+A81@:7'8>NFF;9M?QJ5+'76C3Z\O[*S-+(Y^?+3YI:*OIU
MN:+<( E8%HR$"!]Z+(I]CI)$$15I![X#UZ974RE>*Y8L>H*I/-Z&_3".(TE5
MW,)1KN:PVJ9$FF*H7,5C-#+N-W>+MWHOZ]RS]]#]W=!)6NLV47V//R11<K$3
M4MP_P% .ZP(;BF&3N!&@#%OG!46<3%3TFY(8(NP"U;'BN QXS-!36-DST;:1
MT!GDL'&>#,CA2#8#QL8Y$M6+04'&#:T_#I<&&;X*S+NI/4[<!O?J6D"J68H7
M@K<5U)NJX[5ID'J@HA%XNIPO]Y9P8'Y*)X,QFS2-VOZ2I2V"JS6O&]!+XJNP
M\JIXT6K-FI$'!@VR=T\&;) 2PR4"/,Q&?J/-\#UKWC5L22E-#'_R)EP%+7JK
MS+JL_EI,E7QX85*PNFLF,_]D4]:AQHEK*1G/+XR^<U$,RS)6OZUD;*$<FEX[
M<_?AC+63JT[:G> 3.4>/?!@S+WE$_(2">9[1;RJ&2X=$D;Q /V*=;PK??!IY
MRS"]RR-8,G'J&#N?W#F7N"XA NU"QZ1S)Y6'1]HAW6>Y<RLO?7?^U:Q9;9!S
M-&'YWK9S0H0!*F U!F!;2F[G[^ $M_ .$X:12$@5'UG;R!['H=H\#=FSC66@
MKS.YB:.5$<CTU_ZP"EPF)5SO;\UG))&C+5ZC4L(&/M<_MKA#-]*,>TU_;,"7
M,6H'GA"7/W,TN!&<D>5B!GW<IATEU?KC%#CA0>;XIJ]/2E)S7")@52R(^7J1
MN7I:X,UP[3B@<Z$^#2O661%=])%Q*%++.X5GXM8?K/P!.@&SR!'E34\"1 E'
M\,9L(G^/(S<0=&<""B"R8TH6[HL=Q)V3>.V@J!<WNAI+/!;&(U+"?&C 9<K.
M18F*>3G7W0'7S7H\^VM2.^LN2MB]LFW8O68I?L_^=8B>M^7^>>>N]CH"*>4%
MC?HF-U6UP2W+,^ C1<G1_FJPJ&JI2D1SU?3B;_..X<<JJXUU2@3U2!G#Q_FS
M V6&UTNJPV@!5C:N#Q,6L<M5<(^2 YW9%.XI-FGE.]Y)H,VD5:R/DR:YS?^S
MO.6*5.DD80 @8U:^J\&U+U$- VP8FCI.[+G??P--*A8W&I(T[]1UMH"EQ;A]
MY)5#5&=:6$CQ!<O(6=B> ]-$S-/H!+YT R2F\RB0+JZ;'S5-64Z8UDX ]N"5
MV/KO>PUBM?FV'!1#(J>CVCSXRH>2['% TE^N*2+9JQ^O%B$]+I'#'<X2.R]$
M^/JY#&MR-"E\69K9B"YE;*F#+DNYF)X :X<?=JS*O&' ]  ^8)B@$CANE^=S
M57,]T.1,APHC.Y\AVS_18?!D/OM&7.G,FX:H0 9]MRH\7'F7[N;JKWVU_UU@
M[6E!(T$9&BWX'E0KFX<'[+EI0!R'9+F^H,CB?\KI(B YI:0X_*E2T(UJ_P2.
MXE:S5IC&O&Z^N$U:]QOV&[),!;'#_H*F@)BH7%<_D[;EU+5.LGQ=J;N$F\&Y
M<D.'1YS, '/[#))#$_>>WU"9_%"CKZAMU^"?15.K<MFE":YE#KI5#EGYHFN5
M@$O^*<.4,;.,]S4, S'_"@LQUPK]_CE4G<%*'$^.,"!$U"K7E@2@GGR.H?BB
MQFFG.6T4,)0)C.4PZ+'X VS@'/MP4W;>[#QE=S%:>L%MN8G"E>AZ<N7S+ARF
M0W6<FUJTN.$S%5<6./[F9AGP$YU]EIA&WT&0P[O"0 3C1+I13T=>T,?%,+>S
M6Q78EY_4\*^P7WOJPPIO]&*COFH:*1E0W_K=V_#=R@D/<0403&'9IKH"I<'J
M\,/NT3LE5!>>B@^UTB@(@B',?EN\)A,[1NPD/HU8KN9I@+[<GT$T1Z-+FZ6=
M?'6>(H4_PS'PY*2R)A<:!A8>+[GU)30;A!3.C[C*:Z5BPQ^^T-9T-:?]R)[*
ME\W[LR>R[%T#MPF.\D^ ZL2W$_QAJ@0WFW0X,BEHGW6T+'89"YX'V)E >Y3@
M#A.Y;6D"J ,8&# "VHVM ]J/<#WH7ARY+$'A'!/S--+ 1*>G:J0B%G"JMHA3
MFST1MNCM[)8Y=$7OY-O/A2[LVTOFXUF&Y&+)Y%#KX./M>\>=BC&"HGRWVOB=
MZE?;GYD%YT=:5\YD&=EV90R7+- RZV^[)V-U(/$C/".\D2 7%0SL!PT8EO%!
MQONF45*@>QM]5QU&S/]VL<7;.8Y,['#NY,,$/W']G)(>IH22<TO=P!;QH&,>
MY((<B8?ILOD^V TUMJL;1X2* 0VJF,3;A&T!37WQS1&/^-X43!)!B6TR,U.6
M]*C:%TQBH'8NWOKL,#"I=T!9U!39QIC0F$T[YV"RY6RVE;Q1M!G3DA\/@Q8/
MC0/L*2*2"<X)$6(CD PZ:QHE :K X("_4ABG)F%)$\PV1 C*! WPEZ28)US*
M2KKV,F9,!';UOG1N8_/*DPC,8SF^-)4YLKPOA+FZ<\%T+ZQAG4 ,9M=[ T]]
MT)*Y=/_1^O-)Q^4MOP9ASPPID0=IYD/8,'"EKL7OW?SXF[SJ!?WL[-SXO*/U
MAD&3Z;87E/5K7'/:KSH?QUG?,_SDYUPA]RDA 5RPJYX34=..*K"S#TT.6@K=
M>_'8( =LM+ K0.X66Z\8*A,ES+B0*RWRBP\7?6AT<+#'9EU)/P)NY9E![Y"2
MT%[\17;$,H<E>?L/O-JP[GP-='P,IV-&X5@FA&E(V$V<JPMR=QY\D_HH/8%$
M<M.OPI8OW?!93=#"GY:XU5T^A:E)]3M*.;]._QX/]]9;.*#MQ%< QJ,<!+F0
M*#2(4A0B K![%C)>5A#>FLK5<^B_\T49O9;6',G$1[J]"NT1-GO7@HQ-2L^/
M3BK8]!J<?0Y/"!4!GS=ZW^04^T$*)#VP%AZJVI\U@D=8DK>(3]'+ #N/:T##
M SY *4CT ('*!;F<"N\JMPOG%G-,#]#P1]AT1G!&,1B_.,"H+N3(S-371GI)
M]>G%7O^\XA_MLQ;Q @6J$5(9R+&'W=R?!164RUA1:(2RQ5B3J0U:M2HL&*ZF
MAU/B38^RM_(F,72KH!)PA+HAVU)YP%2CQ=65)SGF30LW"C)P'\8;Z5=%,/*>
M1\N_"K3O8AZJ-/Z>VKV460EG($3:166?F70I<FJXS# L+\Y29*]U2^GVCXU:
MY]8,PX_580YU&0Z<B^Q*O9$98+@WX.D#CPI:[H.!3.FBV8JHI_XE'[X GEI"
MQ&7*K=U\  ;6G#"%W-*J,(_9HBE$^&LCP4,TIDA;GUBFHL0 WJH"IP](+>22
M8E<T'SVZLOY787+WA8'PQ!7-,)ZF[:&W>JJZ41+6MM?A\;F0Q/?BG>)'P:=L
MY$<*4DR5"5W(VKZ4L&CW%RQGCDH71@IT0.WF^XXT^WJSN]L4?XPY2^9<+YKR
MC34V\F$$SC=KELU/[8VG.3:T#%SAFQ7\F/KA@^XHL)UP$&ASPWNSZ...7'>P
M0;*M3P*G/9VSG!#]L)>=S@U@8Q+3TO\</7]^=&SA<X@'C@+M3FI8E-._<3WO
MX>AD-T.:5F>K9'>KS[;_T+.F8>U/+B :$BN$BXO"E\[I1L+*"]JC@F']ZK$@
M_@*/V.9"A#AJF3[6&D'MVPF*KR#91*"]^1GO,GU9<@6C >VJ\J '\B1SC=/K
M;5]\?-0>DEEI45)YYF@'C4I.MBY5_]C9],QM3WF5^6"6NHO=M6LE#QSF@H_[
MNG5/,UE[K<4D#UB$9_SY)<#A'(Y&<C[=;BT6+H6_0[8@MF?X;7SF7A;<AY-#
M&LO@XF$D4PCP4"\-[9P'ZN#L+%-XYB"-BP5=V0W,GZ_#TAZCJ:5+W(=#MM]P
MH3!ME3\HT\AC-7KH1 AIZ_#AX_A,=5BTN'/0SBD3&_L]92J<VC9D[>I*/CP#
M5G :5B88V+$Y1L1R'^<Y]SK84(+7Y63GL;6I]5-B():S;<1MF""[X'KB#$/<
M\EG\&^D&\$EA@(O.%#JT>N'SN%;U;QOUA0^GJ!@MO"@<:04N@R&72@EX#LCP
M9=@-79)C(]P&\":+GHC:A?+MDP.3HP*##)PX78W1%=;C!JDK>!/CBLB=.>%!
M10%R'\$+#TL%=TH"LK/=] N]MI2A>&BX;_VR FD1WDPI".X OGUCJ^WTISG+
M])(E>UPZAFT:PS+!,"U:6![! Q\T!*;8W;@)3'^=K=W&%-W^%MWYF4%]0U-K
M:<7H0@9]R?%TF?OXSL[8UYY:,D?D:[!R\56?2-5'+/:>M"^3!RT3G(/G3E4F
M+V86GK)U"I=*INAT_ :15"W.VF^T! "N7(G!;&7GPPL797S%5<N?F02HF9]N
M.UV!)-'9+I3;R%J5Y=T<$F.."E,(^1BU;,+LVPV., QQW9U5''$N\)94EZIA
ME]))4!XP%M&/*9JWQT50AT.GEN0Q*0FWM0KC@Z(ZW,S3DDHF ^2=6_.*/90C
M^/L/<%*6,1(4'R$B <FN,I6 ^T)['Q@5S@1 -+9Y-S<]"26)8B@.&DN6 ^TF
M[.>=R/$DF-(Y<9_ZR-$I'8;HT7#)%4W3J>&)E5V11A,<1TC,G!<N1%#;H).@
M*\N K]X'.@'LVWS5M]!>^-P&_W%+F0H]".KD &G-SH)& >PAMR?<@GJY1-#6
MM$V0)\@)>0]34U#%,\/41Q>,C )7).$Q+0YUA?X[<B>DB+<6Y.A&8=* '?P#
M?^*,J$#=@83.5%R;EW]@%".0(O=N#*\2TSYLBDS#[.MFQ-9GTI?&2[MNRGQZ
MY2\7\N*S[.=SC*>5ZSYWARO,2JWK#@ D@\3;<Z*#R4X/WU5=>R-=^BA+1>U:
M2:;*DU)\M'J*3IG8XSC#RIPAAV+5+NL]S<Q,_S4+9Z6B<&GOUQ.S:7/O)Z7M
M,0ZXT^;29[_[GWI@ALKX"OM@']0H1%R'"[6%2\EL@JI1TZ-]7UKZ>/5]@E4R
M@Z/"3PJA?(;+MR),TO&($'&G0 %B 8LFCAMU1<D:'VM7OZ<H4@*PX"%?V 1X
MX'&<D14)CE*W$%$GF\1")Z+8MX$K"X3M'%=JOD$[E\). @VH4R(TRM-E\FJ<
MZ9&APK4ZHL2Y=YX"DGO+FMZ^X)F8Y>&!,_XBRYHR_?&=%X^%'[B@Y]]?H6H8
M?-;?8!M+Y8!C_ZOCA(J]PX66NV7$UED.8M8!)\:LE#/ZJX.46Z] !!13H6\T
M DHN6W&'Y;"['0F%9 (=!L3'JP(9]#@\EHBGQZ+X+(T-D:+G0(,.=D.2]!D.
M]\XIRM./0L3&UM+/J#44,1V,7^,>$"***G@N0@0CA)T@1#SP07(DYKZ^.<C<
MD5L-TX[%D!0B3KZ";LX7\T+AZ?;/#2$"#WS9!?7T"!'SLCGOA(C7_RB@])77
M$U#,DH C1+P_P]/6AD_IA@D5(G2^@$)$(A;E1=]0)Y*QD!QR._"ERUZ(V#5%
MH%+6G5$!=+Z6Z2XA8NTV:5XQ&?6_+4MRN9D"W?2/[N/WS;&@@\V"!&"^DC!$
M 2_@#PH1<_LL^6<B>3N%B'XG017 ?@:>$2+>G*#\>4,5>M=+F3>ET)'0SZA-
M9#:1V41F$YE-9#:1V41F$YE-9#:1V41F$YE-9#:1V41F$YE-9#:1^3^.#.9/
MXN,ROE3$= 1?B@7)$OEJ1!F\*\> K]D'FJ$8A^&0\VMP9]QX<OP?4>P<(<);
MB/""UZXQC=DJR%M!L7,#B.,8+#2PUMI7)LA9)CCWC5-^FG]4-=N8IIQ9/M(Y
M5&6-;V9G7'@Z<_<!]E)]IJ.GO[S#B]_F!U/=SMVX6J'P\97:9*B*7-"-3O)\
M>[(JR7A)C,'WKPKD2H&H7]DS;])]HIF M&V1373U@FO34'5I:4,LWI7I>M?$
ME'J!O3[PSL8@X4^R99"54K)1TJ7CUJ^2C9+7A(A]P%_=[#SHU;92(:*2Q/1
M(,<H,JCY:R @1,33.@ ^UP_J!2N$B#,Y5"&"KU^@!*-1BR$"=:LK_1S):2&B
M<Q)@--SB:TSWY*%W3/C=^NS ,:]O+']'GUPRE,TC?2"G6XW4J59K5D\/_4;^
M."/G\%+W1._L(4,+BBE ?4V :?*V[.O?T/K!]+@0,<MM96UEK.[Q?GSO2I#8
M2><S<F;9RNEUG;3;D_)OG=6L[:TOU%S-]'E%/V$W8&U5"CX,80D1":<4@^Y?
M&GUWV?]HL'-JQ\QHGU?62(7UWN8#_@R.+L/^692Y-?D4+?1VY&'FC*CUSA/
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M'WGHEVN:RD#)@NK,J=EAS \!!B/C<1\JHJ0YB_HN7.Y9<MW'7O#KZ^XV@*:
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M72D,X =<$]US0'?E.L]UJ.Z7RT\YG35Y^CF1-4MI6G6-JQGVN^B6/KX;WU4
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MT^X9;5SMI]8UA[4I.O2/9>K':F4+G4AQ8@A"N22H?@:[,OP#[AM,K26P.'+
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MK4N[P659-<74>1SRCI -80QE1N,79EX ;C.4^]$RG3815/X<;-/B@Q"F1BG
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M03%IN#RE4YZ"Y0'PU\DZIU\*#HYYP/.)=BW6F-;?<U)O))\+V%%'6QJ?0TD
M)X\<F.8?(+>QJ>A&L3Y\ N3LCQYE\9*3QJ*H" 9_GY?4K0F4#@6=4M"<_?QO
M4_4'G2=HX%3TZ2@T%UROM2"IMI$6XD(26U"9*(@=Y;^6DK+[>Q-$X.ZB>C'R
M8<&2ABLNI?Q!*8:BM3E](HWDV/V:*)0\>.\FWTT&L+943G*3"39EC0W+B]*5
MA1SX'R5=?BVJUOQ[Y=$!]-27CX/",D'/.MK>FT,QOJMCR>KKCLK+;BWJ6JY&
M<N%V[[2"(L4FP@0"?8\3E7V_V*N+)>-.Z[.$D? ]KF-\)XSNCI@5(Z)/=-I4
MH>13++NFITEV0;(2*?:='YJ6E:-K KUY.J;/,4;J7[U4P6BL&[@D;P=_#?;!
MWFHI@(M?:LOY+,EJ[Y+F9"$S-HAW@U/4M]F@1(<M KV40)G31?L?<3'3L#/8
MC_<7]_:V%E<YJ'B'0+%#!\9TQF#IF3%LD.X@4Y=3MWV1RI05$A10C.Y9Y$*6
M]GI+,$:);V\[ (0WO0L:'X)1-I1A!ULR2X!I.:D-V9+A)^5C6EH)/AT-Y&8I
MZ):R6T +H:GYC92ZZOAO:_]T7A_PK9-V>+[\[*8<_>"2*:O1I^)+?8WMZS#;
M5@&'&&_=LHL"WD+O*RW.+Q?=#^L=?\K03)D,K)+>#1L&]$ZG](?MG5 G46][
MZ(Y ZN"3 U9Y5O9]2FXR9L]\?$R2) 9.V+N-JMP=<5I7_.!P2)H/M4(7.KI\
MSZ-BI9D_-1P_9FG$D^OCB>@&"/,2MC%@*XZ:\P#"__TD$")/2&C&<YEQ)38]
MK&#:CM7H*$<PE$FWB=Z*$W\\VB9-BQF$Y&3\039"E*WINF>]</MTGS  G7FS
M]^?QLTX.8CK)=US2*79DR%0$&FM16G3^;EYX-^QGIL?2$/0L2NO'^VS<2GLK
M%HS6# OBD7RL/'W)P&A!P\_&T(I%;*1/9WP_YB9)GLI"WY\U4A>YV_^2.$WY
MU)]\J>52F5<"3L7?2]^W\7=_(\B#0WQ+4C24W_R33=YTOI;@VGBZ:T>09AZ'
M\,,8_$J#+_ 6AMU3);9)1J&77A)OEZH8PQQ.%-XVKM_$F=F^]?CLEJ1(N:N4
M)\>JT5/LKS&S./!^28@BA. %F 8 9$G]1U,Y^27"#'0OB,YZR^"B1),6I9&+
ME.QJ>JYM&^!&NP8E>8L!")DFECS]L]Z?[@.IWV4,H"+KQG( &EX+9-BWTZGS
M@?XR)FLA7^#X(=B#\4#8638(CDX0W.@2I;^Z#\Y&WQU-L8<;GZ[_L)7;O89#
MOJ#Z9\_F)+UFZB$1P=.]&0&QNKF(DGFI-W[C/[O:AE[@)6PTA"H4(W(G1SB)
M6(ERY6F%?VY0F3*_<S7IR]5\/PRUKK,)#S[ 5-'Q$E9/::F9%^;*+[$06O]<
MS%^.;,#CR23?H,DA:N&5W4H'1RT5OA-2*21O'(X-TJA]NMK6_\K/W#[P<I]Z
MX2I^W8)JD4 (P*<7&W <OX#UWMUE$W.D!PC=!'ZB@YT8;! 1EFK,!\3Y4'+2
M=!>NU=&SRC,NONUD>/^5=BTY"9PV!X5[<1/S"\P>? A!-,FXSWF.[[[8,/A!
M2Q[% ;0EQ,-X>8!L!S#PS%_H^RGJ1F?VW*]-;YT\N@(0]LKH[P]GIK\'DB35
M$YA25!@/#!GK=<2C]T0]+;3VJZH8U'I>94ZB^5=<SN @<N?(0W$X0LE-]#:/
MK4?R8'C]4" !3ZU'WMPXD?S^BHZBJ0HN$Z_44.+M/95X95+!<APM>"_LNY:L
M &OD?0.39P?%LWI[8UG<)0=[),.C>U&Y;ZK'E^;L>OC,W:HP:-Q[Y/4&.<E,
MA_[F,DH YL@:)=0K;%D>.:P67V2H=^<D%N"SC0PI-E9SYE/-T].HBQ2;"]=\
ME\?P;%"#]I9%?]<Y^I>R-U6SKB_@PRZV'W 3>&T/+^AO6)?D?M58<S@;U,0&
M(=B@],4&='8\'Q)N"0C1P#-<)&.U5N!Y:9!!%J:;_Z,Z%;K93E/LO,J?U!D0
M$AU5R;S.R,E&V93!925L;+=_3]_I^>!JBJX(:ER=G7 )GP/BUZ5RHHZ?=#K0
M-ZC1FP^/E%"7@<9JIL\Q=@70.;H#1/2C?V6B2U'BC/UL%/>1!8!Q9'!EZ%R#
M4%82C?PH&\K73A!APC4Z&QO'/RO/1SO%>IT:'!FR:\KP\B (N -Z&!V:$17+
MX[/SFL\F=:C>:>?W)?BMX6^%*T(>)Y.S5,S<:)#Z4FO%X?JQPE5RB3B%=M)<
M9"6GL,HG+(^\.M0&4RE&>RCU^S\-;[OO%MLW7IV_[.9U!EGU%2<9WOMZW$E+
MI?6THDF-5:U3X;S;6#:?0/)%(3/\ #=^A@VBJ>80L1(HU[< NF8&D*(LDGX#
M[&C')MN;?\ZV/C**DU-5_-#I0;G\E<9 I]RZ29BY%W38E1!8TD?ERB#>"PJD
MGJ:0P0/PPQ2@-*0$F4L+8(HY]&)$#[U+*94<?T^)URR8H64OSZ "Z7.4W^XO
MI]VO&OG#R]J"@9Y5%S7/JJW1J;[[)8G:EL2A8.HBZ_0 85_]@FS-,F5N:VX#
M[085/W'[O7S7X)V4>^^7A8,ZGN3F7^2&B:41;5_=MA4)'"]ULB^_/"*PTU9Z
MKN2O2:(I!^JG)KD_[Y)\577/:WHPXG6\B]+3B0M/[U(5*14NB7(K2A&5SB\J
M[:]DSG#(_BQ61=C.#/2_#_0],-T">V"AM[G%!D5%L$$NY:3U(Z(-AZ=7TM2/
M%#@5#[)[$6B$<7'8ORSZB_1B8^OQY.BQ-U:H>IM7CV55GDG8Q#(Y\&4BASJ,
M+O#DE#OY 0DV:,:%!#ML[0?/?SK/!LEAN#DCAD_0ZXUG[I\4MH,IQIUUP3*M
MV:#'$38_=L?17[!!SN4)\ _*HRQY-NB?]C+.]Z\#G,^J'7J:?F+:<JX^S 9]
MBT>?AFR.H4YRQC&T+V@#G6,Q]'__@+4?)XG^3 1\V* [P_S'EB3LIMY#\+>[
M^EPLDC;Z^W'8RW3E_8N[?_]_.MQW<6HW%)!?W/IRY(HR2J$.="-F-CP9*<3J
MM]:WQIM&18.*58&()5XMKX[Q6KF&B2_T&2"'!O[U$_*%#7E74>U[['S ]03[
ML:WF88CCA^4N&YC51'!-_"_X55,6]XT0Q@4R-8<I%#JW),W2;0=N<&T^IWN#
M9T1AR=\V(CX22(I1%25=Z"0M(,Z,R08)?&G-6?HTK74WF*7X^!5=2G1GY&GU
M08HLP^7LEY@5KK!RGNE_--^3,R!3GM"]%:$EC9E:AX?$L!$7:[#'KPV?"/J4
M0^!UO(^*TV7[%R-7)N@<*JW=/YBL0:'=8'*)A_-%898_:1#;>3U?_)1#A6S-
M<@CL#(M?XIE?FY4$'PPJY<)3IZ\R=*DFM?^VGW=AY;OER//)/3X1/!ZEZ9$B
M8H 90X@RG6,LB)PFP?B,%9 6,+I"CI%\?.2H(!+:)^DW\KAF3:SXIHN&_'S6
MI_#!"QV-;2V$NH[K>QW)15&!%:ZCX7Y1"*/BA".C^&&8)!L4M)AZFP+M5N?<
MPMY8&NWO=9:")#]3+EZ0WLK\_;OPPUWX]A94$KX@/88>$UT6VD-L@5N@!-&I
M'9$P0A>!ITL2Y44O3X8L<<I1"QO$%)9:\G]^Y,3Z!&OT2NF5XN5>P@^$B$$9
MV(=,C1*FQ9$W)HIA03+^F>[9"'#U07B:$#P+\QNS(N7)KVM0E_\.)/"A8,99
MU4 0PY^AGD3@0#\?;!*!JQF: ZL#;^$HZ$>RO,<8EGS\)*%A<4M5KP_-H;+?
MJ[%G 'Y[: J=:?"!>8VA3B$\>-76-HX2HN"%5Z%PJJ**]GS=>KZQ.GVAIM)S
MP_L"EF0L-\4&7: NOHH+E:5\6N_BOS34:$16'MSP^ZZ?HS;P8;A-[PKM-21E
MHM.L,K'[C[7;=&F++(K!C/"\)UA "7E?/_T;+LG&'CL].MR6.R#9KF99,$GT
M>R;]IP_FRVY89$2GJ&;V;:+X@EI)3R2P@ R6%2W6XBKV;;M7:Z?@P%M4%7EY
M^O4:A>RX7)]"9X/,T+>P//&BK"$"_=;B1T/*?O8VVF_Q(:RA;_LA8>DE^F>"
MW[$Z#) I7;SKK=@)*-"R;E.XDA3J@8>T(J<H-D@09<.8NXL52'19T&<T3VQ7
M >66+8RH\=6L"N"1X6)()^!PI(NZ_V-+_<D?TOAQ&[ Z:'?. ^QI]!W"P_O;
M:?$BK'%O7OJE4LIH9M?I2>9/E)I3ZES "^IB7WOMUUW^5%V80/"NQVCJ?4UD
MCEW3&P9_LK9U*\,$^6VWF5\HL.NKPIH$YH]ZB3)NJ9[G>V IHG[GH+17<DRR
MJ;W;)2^,?Z%AOK5,2B5/'WFD>A(C[-=\&_.EH<BU@GJWJK&6?G;@<)>)Z*;
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M^,TC1OKV7A5#O2<NA!# GU)))_0>3B?BZ*VD(IN+D]K*L<>V-(].0>0)8L-
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MW*L#7B<..<B4WWEC%HUY653H]J6WQ)SDF(QYN>4Y4"J;')FI8XO?BPWG/8=
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M0TM""_BS7XB0GHO@>1<O8Q768+(**UW'<L*[=4LL9 K^=.-?%<^SOC"# "1
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MG4$WM]0M&W]]MX%.!LF'6LSU?3)4\O_:]\!N6^*[/ZZ53LTXW;TH3B3>3Z,
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M#]\5_?:_]/?[#=VC1$,,N["5N,=68>LO0!P.7/,39'*T#@CGG@5&6,5WR?+
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MDP#.-Q)]9&[%R0(U;?7H;80K7&2;R*"^FR*NO&EH#8)_9>*R:!? G1/M@.*
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M^)?H$+X742M!M[>B>TGU+*&W3J,WX/?A=CR,=!FGX@[T+MG9N2ZNPN"0C\N
M89F=*=GM4I9)XCRI2WFFZ>0@H<9ECL3?@>\<TP$8<]D G.-5QD&/A'.0S=D$
M!7PW<Z/> LX[!"BE<M+H%G(?.7356V^>8\/I2"#' T)35V2>%+9PRE1V YZT
M\%OU>.54+,(^#42SD()M+KQ!2 W($"-A>"ME6((NDH?\(A0;-S0E;,B,#;-
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MK-=3-%E/EDE\K:=20BK%3:3.A@F/WK<^3XRKD ":<U^YH?2T^HLXYD7-JA[
MS^DA5-UH[I"35D6ZRP-,+?A]Y2,WDGQC6&.XI0%1AGU,]H%)H'VY.7<WVU@$
MT-XT62UHA/T&1(!C./2#R.2J-(X= '@OZ.GOB5J1U-M:HV;CE!22*C!9&*R5
M9I)7F9_E/)-YT,)E:9A)G&OG)S<3#-U>QM[OP]L+&#5-9K!U*,RC5 9YSHHU
MSH3-N_N@!X^M8,MW<M^09)!C:J5U0*VA@AT;@PNDO]?7$5HD/@Z:OXSZJX.>
M3\;!]LZN5\4N<P.;I+FTX66:J(]T)KD(<7_? -FWOR+NZ[*<\<+<P.5AI^&P
MO)^3R-HX<Y1:%FVB?K?5L4/<F )L/=]MOJ,^]"L;D+)[^>QS(&F5L8T6V15.
MU)2ZI:_&)8<RM-/18](D,#KM#XYI77=QD;E7ZI#=8%Q>*1DH3P*-?TIQ-%33
MSD,PGU!$:U #"/Z( "[B(]>A<W%L!1!_F5O$$01.MHQ+-D+E.4( .4;?7ZMN
MH I(M<!?!GX4;$LHJHH)>LIRB!6.6>9B+5ER/ZJKG*^^R/8]X>SV@9E:K['Y
M7ANU.3N+Y_6/27-3>7O0KBS/>D0\5I@DB=8%=?BE!C(]5%4/C22)#^I+ &76
M@^@;_@#Q? 6U//@1<Z$I>%7'X8.:0@F/\J2\P_R<.9\$C=(V((9N!_DLU@LF
M8<$VZ")R_F*CR:45J5%+&Y 'Q,T-)Q_Y8AE_E@$5DQ'85Y3*=LJ]62;NW2CH
M<R'U,^MOEG@5XMK/!7GFF?1R/+^.\6FY(+=4?RLKFRDY+T#?@"0,-4>P7)BU
M]E9HXT$UM X=J0F7Q-YT/NN1:U$([OG>L,@Q3%DPK0AO[=7(!LH=TBZ_[W.!
M9WY==C4M_@A[1=S"^X0H$TCD:?$Z$>6D0O8)4./" $\1\Y$LP:?A(KRV=4RL
M+T]\!B'!D[O"D>[E:!G& 4,^YND^%DI-0YZ-=:Y%'!4N/M^K2LFH5PMY5X:\
M5\[/?L#0FIM'4E5JIH&'@A]CCFC4:T1BMW2^9U]UH2A%8(10UGY;.1H#T(O=
MG!LYPN*H\PW6,\ZE7N]<%6*]:D;N#?92L,P,0=?^%]>J^Y02L(?\L+>[AFA6
MW%=S,.]06J+\L6IP/M=1$9>'ZI\OW^)'F%+V#?1&:]V@+_<,?JPD23QUH[E>
M 9VANPE1Q17F;.ZU[Q:I]J0/=>F!X]\YXJ=6&KEO]$5T*+A$LI0Z.I2>7VN5
MA_H\%0BJ,$CAXH:'>I;RRUT-?W8N-(SMZ5Z6$?1255<_C]1V2%DW:)KH'R $
MNFL3@@Q&'D EK8S$(?_QV<+%8^MKL#^OT\2Q<].UOAN0@E1Z!.:K-^*GG;[,
M/^UM3 0O![NSD*7#$^++MV1%,'L#XFDQ[L>U)?^ILM)NO=F!3Z=M=N"+;D"6
M#X,6_ZH%?Y$?RMOD^)&LRL%R"_GEAR;'Z\;OP"BBY:E+B.B:X'"$73?FB+>;
M%L#+SYH9$P7@46C!;\B?H,='GE9Y?_GLK,;N(6^\S_M4L_=5-775I6SQ'I>6
M8)T&/&L/?G.!O)')/PODAS<7R)_>Q<LD:6"&:3MXNU&SMF HT^)P2UKEA^RS
M>1UO6AD=2F=KJ//#=M2B"A>70,-"9IAT,'Y.LK*L=6*H]IB2K=BI*-M%#? ^
M[B-N79S')]7TJ'H:9VRPQQV$QYRP/<J\LV9XLFC7$L,YX6*#?H6R;>Q+)9E6
M':FF?*-A6ZKSJ44.-I8D-_%\Q,T5QQS)%DKXR%1Q/X'R?N:M]QQM*9^3[Y!E
MD_+R=8%UOI1-OOAP_/C1.AN3Q5Q^;D[SAF%+MM@;>(X:20V[^'<V[R!ULY'@
M#:\=!KJ@-QL)#B)Z<HD<<2)=K:FC5A3EQ\Q]&=@E?M+-U4M>0GL@7S4V(?".
M&MHWZ.[5AX[M1RLKJU\VOSWXR$F[>:R'15VI!F^P8:@X4Z J_BYM_TP-B?@Z
MCRQN*$G5#/TR7_[5CWAW]K[Z1'\%=Z_*B"MRL%#\CN"C?:-I-ON]5ILL]S&E
M'5\:BN;9Q"4J24A3*;UWKO1[1%T.FMB7V^YMEB/[H__]^(#9>C=+Y\&)T_=@
MVEE-3A:7/JCF/\[&-1F7UV7N*S:T<P^/N$ G=,0\V]66%'^C8Z[ ($N1G (#
MH^#_=$!D_],!X;O9 ?$R OIKU\9A&9.P/V!3-F 5/Z"@ MC%4!..?@O=A+L+
MRZ_)P'GZ L_/)YM[B8E?%_7  ONQ/SWQ?-&,HPBOJYWTX\BX;$">XCM3.><)
M_[1B6&VV8E1NMF)TGL/]\D&PCF01LE=7%'DW20+T9/(JTY8W(!'HJ_IZ:-CV
M!,)0QUL:M@&>W45$AL^E16;G.7\T?N;K'Q2@KI']\[&%]%K2,^,U/$_> SC,
MBX#%8<&# )] ZU2TAC/>LH_G'ONB3Y2,SMU5<=3LSB,S+:1F@0VZ-VXR_%Y*
MVIDBJDEA.OCDX_OMBIG"NDPT<4M,8616/,&X GFZ2S F+E.^9N5.VK>B;1T6
ME2^SD0HWTWEWR4PYV+ G+Q:WV1P24=5$Y 6(8QOUL)5=7 GH9DN+H%\<@O--
M99T?V5'/.3LV(%EP)HVW8[/+KV,^M/(AVPFMP9*L1XAQ@LLK6795C_4/%QC&
MO9U>K;F)AT93;1>77$)#SX2:AUW[?BEC =&H=[;R;^]9B,L[]1M5J+R+"V(-
M(^?#$Y2O!;QT/3I -!$R;=NYR%1I3TI0:%=<*[#LB0TYK4F\%U^Z((;:JI,?
MDYOJ;V\3FRF\-?9SB54$TN0+_;@FMU)#0L=ZKUN[L*G>,V??YK2G\^U26ISB
M7XSCZ 8DFL]/?/'KQV"E7;Q]M'WDM4\.2WPG"Y\ 138@Y_!-9,Y>\,P&)'T(
M]E^1XPJ=\>1S[>YD/@H^H/"!3W\# L9C]F-[D,E8^A"-D_,O#%H,GF);<73
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M*T\0_#JC\['<>N2CU T1485M@O-AM2VY;0-%6&<L?ODF]M &Y/?O[V3!MN3
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MK6PL_)=<AKT 1K@=PO8HI&/I-0A.5=?B7%?B_X0.N[#E^2ZU@'DN#'NT8!3
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M%G#K0#*?@9=PDPUW<ZQ8JPV^P?4;$#G.62+Z-,NMBEZ'M04($?H"@:],B:C
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MZM5""((.S=9C\/L:\415O[OLT3.6B0,&>D.3@L-Y-2F"V+:N7S/2-=XH#7#
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M'_Z^4OT7QBNP;C$XYUQ#YS+9@8C-2C756/A8M:%+/H,L.G]N@&4]L/GE^FO
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M<IP-RN0Q@BR[(@Z"GCG,@!'Q_!?V+%FW??G>=\I,:+0;!- <9;ZR;HRMQ9I
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M:G*V>_ )UZLB4:#WN!*./H_-Z,H<XB\N:$3KX0J93!B$Y*"!"RS_03D@S.L
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MW^2"0KF@V19(/6KM ,.=^0\0/J>5A#]DIHJ\3.]%'OILJA-3@S2E@].0X?"
MNB7(\<[3H<VM$?OUHK9UL#Z:&)K&R67QCN-WJ]3R]$G_!VMO&M54UK6+QK(4
M!3$BG;11$9!>I(=(2BFA "$" M*F$)$F8D2@#!(2E;XO:16%%-)$VH 0.H$(
MH7D5$>D[!9*(2"?9"G%+NA/>,\8==[R?]X[OG/']V'\V(5E[[3GG\SQKK3DG
MJN%]%"J-RNHE-B%X\H$[G9$25!CY LAI"N\'?<XD,0POS_KD\8CYM3(G9/%0
M<6H7(VPJR"1DW*S"E:0Y_,0SR[9WFE2"R#"=%2ND@ZOP_H5346F:+F\*KQNK
M)1QNK_Z@B:-HO#5<E"FX8Q0Q:AGX_Y'>6B#&D>9/K;TN83OPRKJN2,F DL!Y
M]Q,+-ZZQZER5JWM.*F9!U*A!A(5R5(/>NA@3-FW!WY\OE*M[<3+@(R;R$%<#
ME.=#P?2=6U@37^"OUH4-"6^<,2A[M0#?6H:]U>_2\7PVA@X[Y&$??N+XB-;@
MF9JB,.V)93T;R4 /PY9^6LB#P>>O7$H*PA0KWYIRM8OMC$Q1^B6.KB<J*7O,
M*1HCL=EVKNK[U!9/%,D=='W4GX#]='@@#"CTIIY(/]FN?,RNM+CGB&CVQ512
M5(M+W(KM>9,CUBY_I7FALJC/\]=;F<AIA?/@XZ=8 [K)2V+219S/:$T$5 $)
M)'9;J@.Q*\I2S<W4YORN@0 2=I[69L)5D2>Q"S^V?7D47O9!_"_KIDRWO*^S
MCJ,Z:UQ))K(7"7H+((<B44DP5JVE-.XD?[QI9)U*WP_JT*'@63PLF#I])[*I
MD)VN12/,F).FOD3"&G@O+N6O/X\A.Q5]6KV.O]&[B0"O#,W"^.D&.]U0:!*
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MX2L@DWPE)G$*436V]#&P>GLV>)N0=+V1PTDRW)K<O&<T,AOSL&,MK-<PZ\0
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M;H0REN#H$8F0^+P=4)H]AS;O+/3'H']]_OZ5ZNN6Q%<9'BILTRR<2C9+Y$C
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MOQ,*G"?1M ;%>OA[P0 FXDB0^_ R<3]7@MYQSF@<9_9TQ<WIP_2JN7)98'B
M(?"AV\_65SH!>R+[54WAU7E ZO3*_,QTX'-OD<?#D7AJ/#ND$8P]42'JB)_,
MO51H[AJXSV3PI,N3K)#3Z)&RW&L$  HT4AOJ^:.\FP,AE81+/>%M8:\:+ML]
M36SX=#-MQ26N-%\SARXSFH7\=A"9V:E+F.Z<9:,<5+I9V+W0],/<OQY?3AF]
M+(#$]7'Z, OE+*F_FF]_7<WZ3)R2F1&#-4S-8N_,"#'KO>735>UA6_KX9C]7
M/W!=J"NL'^WTF4S:V1I_4^/YG)=$N#[ &? Z@K@J@,R8F]4NI<RI=X!:@()#
M@ZW:S:1)SX02^JR7V,G=ITY_\/6>G?WM459P2;I'XLR[05/TWJHVN5J'\^YD
M=[DDM'ZWJG,'VIQ2_N'VAMWPBS;;$UFV*HOH@!]LU6'7Y]RW5276>?(I6$7[
MFR6V1G8YSD\;TS_DU33-AC9P='G/"!\)(X@UY*@ LKG%$/V&$>$Z"B,UJ2EW
M;SY]\#;2QUGIQNO)G@*O$-NR$%;_QW2;"]C:4-6FMJ )HV\'LJ+4CK*[1?(6
M26SRC$6WK\8$-[ T1%XO,;+CRAOLE8G!+X8UNM^=,K0>&OE<B3KV<+K+)(>A
MU:+T^^/;55F/FYHL\3];R.%?(<Z_'M2:_MS)0PP!S2Z[W<<Q6X.. LCE<5WY
MU8MCM>7M+PKO*GPJ'*C[_>+AD]G'CB6<JK<Z7.JDV9=2\BWZ9VGF8[M8W_H_
M,OF'"$?"^RWE)^YR;9^_W"[2VCD*A%SC ?T,(FUCZB57'[0%9!GP.9%WG2K!
MRKKU+-G8K8TC*[[*G9.&R#C"=&IE<*=BW1BYYL]6P@'TS=17?WK]WM+P]<2C
M:T6_YF]!]^J;XM23O8U0TKX9\G'*-TA>$FY2P6?'_A5N%S%6>2G'3]8\.][T
M0VWP:WWW4/4?&RDYZ"M828N2A!+G#@]M2G>NZ*TJ9SNY/A\ST^Z"G((T%8W7
MK[YVZSJ^,L8?X+]!4.9[$-.^J*2\3FD6N5L 2>J$@C5TG@5M#@%B@.QN*!,%
MP>:)R_!]K*PZQB*\8MRM6EO:AS^^&&,T9#B<WWQU?!PCSBZ,@O\E.1U%[,>D
M"YD^(F@^94X7[ <L+E*H "%-SZ_EA8/QH.$ZS*ZNKJ%YU-!GM]7H@T6.3'IQ
ML,Q?GKZ%BJ,?YNWW5'X(:=[.JPJ+?N9SF_ 3-M=(H,G@IX1&%4QL[.<?R4Q!
M<5]/?M]CWJYD8] 3>*D^ZH"!MZNTE41FALFO]=)!S^CT5QJ<T+(#NH<E@S4N
M)2B([V^UCI>&?FS+ 0MJ?\EP=X$^0>K2QB.?+2S&]YI+K9AX>@]G/E_6MC[N
MY$#9[TX^>?(UQ49OQ?\GB>RMPW"?BB!SO>1-+5/MJXU 0$UN>8GJF_".-_I3
M@X;O*-F]X0><7AA^.6% NU5V+O[2T6R3M3,L,L/FGE ./R2*X16PM"YE5=90
MC[CE9)])/E]LHO'Q"ZCDY=X*W&T E;+F_.U\D1&UJ:V%Q=LJ+VTR>)E?(;6L
M6&=C^3F7\)]+ZX0B+L:M$&_(V!X+.4>1?^]$'"]SRV$Z%WI&&ESW7AXC.8OW
MW7SBF:,NPSS9.!I<3@AAI9N-T'WER]P.D]R*K++/E9D_N%GA6'IZ33M@?[>M
MG4'::%K)B8*LL. S!_,O@#1&AQ8M#+PU)RXQV/0XNF1YF[L=_8IQQL">>A6=
MJB#^NW=IF%=ARJ$SU6GWKAS[[C5K",]/)GQ\B\! .<:$9*$G5N'5QC/_<ZG0
M)X/$&NV?:5YKYOB!UD/=GAO<$T46(!38W3TG,5P;L?I8BQ>-&N,K8[_;UXU6
MZWQA)MA>:Z6.:^M<L3AG.'GR7O*'YH%7ZJ)1$T[.I4S1B&\7.L.??"S9=\ZT
MS3EG46TDS5_J?>F,K=IL_>=/K/#7X:8NJ3DK?^J'Q1TE:[R^?"=%/\UU-K0Q
MRVZ]0X8$#'(,\*/*<%XN/+H:=QZ,*@5M/":VJ+NQ^73>!W+:FE&AC7VF-?#'
M<_GXP79YY0[Z;.,87>80+R-8KXR2&5$4D]OG[O<_\!W7$G\6VV$_TS;\=$8(
M"V_ L5HU?9/1S&Z"0>/?1'T[H+4]!Q-;QY.M:^I%665;*>W)7N#S%[=M6(.B
M.(>$[?RZ[D]CU(:JB9Z%J)O8^*V0+5Y^4Y7CI@_)96KDTPTAZJ;7^&_2^/OV
M[!1( ;3X@\0^U'9CI[C[&BF!PAD20[=AD@S!FO*.D5K+48PTPUZUBIH',*[>
M1T=Y&+>:VI:8[?[4=Y8[)L3FH_BWL$9H-W$FD6&2AM? '0:K6*,T2=RO "PA
ME$).\OT%0-ROWC!:MV? :.+. _9UF,/+!?[S[P=(GSTILSH%CG7GKWVB/SU]
M[@3OW']W)5R2&\QLTA)+ W9+>^U/+DXIXSW*LYJA5[F0D46&5Q>5[SCG1&6%
M !WCXQ//^*6L:"A*O*LQ^$J0&VT,RXWH*+SC4F8B=RG%^6/%D8'<%Z7K@>_>
MLY9Z?5 T=U^-]N9W.*T*!Z98:C+E7G7P]^_U1AUCS0;(<IKHRM]];1'D2(V"
MN8#"6DCRC8"'5H<<&^BZ0O39+]*W(;Y"G#972UXJKR9.SRG7\0='BK_BM*JL
MVL00QAB=Q>E/;^?\OJD%XL2GE(-_MC$_SO^_VK &I[>S%QM"9A&O""_YC[@8
M_)1\W QRO8'CM)*W*OD^F$HQZ?MP[M='/L51U7P=; %#]9$_]L/3P/3?4[*L
M%_>+KMRDC:PC%IXBE*X30C:4\)-Y;28T0Z!?. Q"MQ)SXY?W6+3;&%X:6]4-
MI1,.8GV9-//F1 KB\-SJUV63!R#R[/@71F9O&%*7_"=I7:QLP#A?'<.YPN]'
M4?)J.)[X4<]/\1P#[AU +9:AEXF2:7?X!XREP?9QHQD.NSW>M=LS:\)]AR-U
M##R'#<763V_/?;LP%AKX(312+UNEHY%AD70MV1+S4S&ZB=GE'F>@G7V2/]S[
M$5MAGWAR,=L5F+)%5/C?_!'C[2O7.^&6[CD%5[4-(LGG:-B=3GOZB&N01NII
M49P\O9VG8$SK,_O@C5-25%/36KWL.?4:&[)<Z?FZ$.YV7&*\[V*-Z2M;N_YA
M!%0 "1Y*HE)@ZQN<(R"IW\WR$.MM/AV:3FRX?0^^F[5!IR;VQ_$5<7!60B)@
MT%T_$Z0,92W-&LE=U_[8$K6ACAZTN=@F;N@92>GMC"_[7.#XB(?@1N_4'V90
M.?<(*T8E[M_$.<KX?@*E*)/C@7^SS7[!.<V-9GV)I5,S"?O:'<BK<ZJ@+9,J
M_MG3.)8^#P,)'A,4!WN/24,=Q(6&IKI1[=K:TN O#THEHBYJ-[2'(;;. B^Z
M+$^-=:IA$YU&X3H,)<?N+<,H';+A!]A%:E..5?%R4]:],V7MPXD9C)F@.>,_
M5QOU+U:7"B &O*/*2.0INK>RK<LN;64Q]5[G>,4](4;![]+J<</.;(/",J=O
M;UV>O5\9?%NZJ-%JR_^^0&7GL'!6*8-^J9>KW0+.E58R-<9)S@V7KS[.I*1A
MCNA>MC[EG<,HV?>L][R>SAB.P+#_ 3<[TS$;M',Z>HN<T+@Z*!K-,P<V5\]'
MNK6VV$\^J%5SUS*[.]MU].6ADV^O B8]2$GPA?6[QC,A6U]"(R0L;+2\0R2]
M5]PE;^:WO?@P[]T?%1VJ8+^GYC5-C+:GM\=*2\L5\Y]@A,P4AI?]5_^8?,G7
M$5?1U,BFM37JW^^'M#^?.>%4BWSSU?QI6MZ?NXRX('[ZRX_@IAF".RIJ^_%/
MEN!W.@N,$CY68@=V3L72D+P_^-KO_KRS1\KIMY^4-OAWO4D&BIM:@.'E0./F
MMREPA=]@/1L_23]DVJQE<B[ASO'2\*;@;>;W;IY"5]OW-)Q!*5AE4S>*BR&M
MWB$E7*, MQ.-] Z$./M,@]$]OC+C)XK$Q)T9:)E$C^8,K9X$^Z1:/_?F[.TC
M DAL,F%'*=QFVJPGLQ[W4_<*A2XU;2>[_QAL;91.W.>S2A7#RX$##.F\QPP'
MJ-"3.] 71R*#X2HE:!&[-@>#7D^EQ;:07Z9\K?Y:#PKD&+U+9&GQE3@<X8,.
M9^$G46 Z58[P(XW,%D!>7F?>"X>5S/_"VC@4B#-RWY].EUOTZ'3-?'MZV[$6
M)N$NE]CW)Q"AGD)R$RTS>YOK>>MB@4.-'+\.>_81*\.B"R_QRJ!Z\GA%0B]K
M["MW0+?O&E;S1IG\N+YAF*GW>8TKQYPU;^94C,4N9@G_ZZL.P0?&<IO_\=L0
M5U*+OR8,I)=G&0X$<WL!Y%<.KT,IUV;-GN-]_XV4#.\Q7__I?<>]2X2]E9H?
MO[[ING2K!^) N(1@74),9[+C@4FN1#C[(&BS0(A%2;2' BYT<_RK#4"$WA^+
MTZC&DOOF%(4RPXL= !#OMMLU6\JQMFK+JMY;QC(Z,(XC%*< =#A;/?>+ND;P
MKT*] '[HQ>DE =#/JVZ)AZ]*+_O!_^B=Z!TK>1(P'DP/&E"KL#:JETPX[E1B
MYQKB4EIY*2RVPO2L9? )[H8TF)JX&D:^[WIRJ?6,)_:&:<]XCV-1X/T*4:FR
MW+<Y(1,Y6A2[QQ6F+B[/F+)F?2:?LI _TGE"C8S9*=]09TD%8+TP,;XT=R^8
M6,N]P.K-CS4*M6$B8W$.C!?IL.YZ;]_WJ^8BB2A:D0G+KW&D':6]'06$IO\8
M6Z?$L_CW$T[*O'8*9\PWDH3@! ;#DMR$5)] M^4/S>^R'*)WF- (K#C\X$ZQ
M<[H;]PR18_S-I9T_U\J:9+]]\0G,$D XR+6VO KV.,>UB%A^]J,-VV'D-H*U
M,3\[Q$_[=\N=GE!P0,AW F _NXF?/D>*-[VAU@>D'V#&:X3I^B>6Q/5?JV?
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MQ3N25%8R1U?2;*'Z5V#\5-3\0?K2(__ A\Q%I,E+]>2^L6(K<;B#&Z"[I71
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MA+_T*",H/E_[!J>G.>Y68N*#'[K0_ V>M$G57ZIK-WL967?YM7OOV?$2I/[
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M_OYID=5CSH59")^:/<P?97O$1%_)9;'XTX-FEZ("^+-><^.W^#^5?7A__K@
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M>M7-6)XX=:,&8]D5"7<G7&V]SWS]]5KZ[+<2OBB1@^<&\#*T+25 +W8@&+Y
M3B7*<0." 0)3))4+8YKBSL8$EN$'"0T$6J@7 ]HG_E<?5!0]HUM# JGN3\#
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M>=SRR-SG.2DPUX_%\1[!J3-=@:%4I4@>^F7!Q ,&&"$,SG%67DVA, ]AZ):
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M@UG?+RY>1B6V[5'W/X>PP#>.Z0+"K!EM $ZZ-=!W8+TJR54IRYB>E(N:PG:
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MOI+>:@HCW%9%UK]&J<[H+S;,SE;S!\!8E7,3=T5K34]_E7<P6S7)A18JN9:
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MBNO@+\XK,N2!(M1:#0D7]E/7L?T14:NSO]1^_?R)W^U22;!'BB $ 5 0,N2
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MY(1!6)^3QM,>?,^;K<G <Z:(3W>;=U4TX?-O>*S%40!1](_AL[#<:CRTDC
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M@6  ZTNGA:R,7!OP R>L.+A)VI[*7^)DY._?A>SR2"H;7I_VKJ*QE1(9YOX
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M5'.2]9Z2,Y9Q9[1.G9/>F62O7L*##N 4D&I)%K+AC;89YYSY\PCWU&>+!?_
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M_.Z>Q?67HDLH]Z-N9MJV -6QR)(0E1G$F-! AHVX*I>70#)_#O&,$]A6KVS
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M\E=]0-A7#Y UM_@1'JME?/2943[\LCV#A:6;P$I5#D=SMT+['?Q4A_GQ5HM
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M=1UF_I!4P6J)>CK&EO]!^S5WL:41OPD%\H.*M9"%:J8XK6+55E;(W<E7F)K
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M*;QIN$IL15N?N_)I?SGB4B B%<-)%]Y%';G>[9-U! ..,^'U:&_WCJB.:_*
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MK]BNPUQ K7%L7.H!/(@!6$S$_(O6]ZIZ/_#.0H?IBX-)Y,.-N,^;V3K,+\[
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MC8=.;H,RJI3GQ1<0F9N47%STVS$Z3Q;+YF_I\SLRWG&(8VGH .@ZHN&7FOA
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MV+$-RFB/8L<^51_I9*>V)6_#&_WR S8.<)6U,XW-3\B&%OE%%([_B?YR@>G
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MN\QBE:/I]J^"JFK\14F/7KC%=;^]46GD4N+K/>"$:2S5?3OV85KD1[T"0%D
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M1MSZ97LGNZY2["W>Q]I/11^:+3Y@"X4#0BP4^7SB![)RAQH^CO5W $NIR\=
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MN=O?3>8^I"1<#DD]^V;P8O/(X%TF?8/1GM_PN;#H0YM]PQ?42@Y$4-M%A;0
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M'!2M-FPV_.-I/,=H=4HK5@(#<2^3FP>1B0GA!"2YPR%=C1#+4L'S$AB['DR
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M4 4*E4SR4\/_^Y[8_J\=H8N/(!(17[VO,$%C:!*UD6Y!U->K8+02";GP1P@
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MZ&XWB+0H$,*8H1:H +%J3>7$Z.U(P<X'H].&347H'U;I&VWGQR0-@$/S>):
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M23OM"K\Y/Z/LYNK[&;Y9GY$;:8?F$&5<) @G(KQ%PO$1/0'V!D41 /IUG9X
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M,.=SL"M0TY:( ]\FO !,C@!H'?#OD?X]TK]'^O_Y2+UED'P==",+%RZ.84Q
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M9OCL8A%QC1FM:Q(X8>U#UKRUR+AVR4OLE7 ZJ+@)XIQ#<?7;\KK!=]Z1YGX
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M_(39-B*7782*3H(L3CXGF6_+5%(\56E):Z /%<IQ(Z0B_#G51L=CK=;N8LU
M3+5T=D>D!Q[G>/00\E1/L!'&<0<'VR(M^ZU5W%%/TJA6S9_"?@[8LA<B9<WY
MZH>L$.TN&;KC.<7^+C.F]40\$^O '<R03*X_DW([? !QE3RZ9'0MXNL>WKW
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M^U.P<U-0#!L4K(9^!5M"V%8H&1E0TP9O40U?8LU.J^"Q"G'G"[$$A+9.;WR
M5$5IUS'=Q3)& 254249<SRO@GOL:]MP>'QT1,P-LWXTIW8\SZL:6J6"??!ZQ
M>5R7]VUI?SMFB#)TC$\4);IJ?M%5>7<2V"^+4W"(& A1A+;%(._!>#(GC"'A
M3V<M>L#9K+O5M!<>%_O+I;0L@'"4GQNY !Z6)))54NEE\U;!,HC4O()ZE.TJ
M>$Y9"#WM'*$5TJ<($R+<-3HH9NRL=A7377,4X5UY)Z_^D@\<H,]A.JMITO%<
M<$I]:C!=0K=CN<+;2):QLH93PNAQV??MH=V)=YK<G,YX74Y-O!JQNN_:%S?@
M_/[J(=95N PS*M&N8X$X):3ET^>. 0>":>J4-J%,K-F$J-6X!T';85HA*U0[
MC[4.<=:Z##1D>I,'.E5%K1%1B@[A:<I15LRU]R?DK:8ATD?"T5Z 4\?+F03%
M<N,GT%D)U0;:(<UI6C_EBIX A8-&.*W%6<:$4$*>@L[II[JQVYQ(R-JJ^#YZ
M;>A88AF:AAC>?8D>0;BN+723MZ5^B/8.:QZR]B;+JI?J@(9F!S%D+O)6N1%C
M& F$7A)S[B]AOE8U0O7\'O_AL1$X5*$G- .Y0@<@MG.@0NR?=J$(E\/[B ,R
MM6:/[MIGNBQ&^64LK@I[%J;)4C"R!$0D7$V?P_)%C%0%UJW^7 G9DDE;U^L"
M%XD=79NE8JI'%YJ,#^J ]*_O9ATA9K"CD"BM*?82(+)7LKN$I*:EBD[$E2L.
MI^<*:PQ;& /]2NM1Z=6&5JX-:H0DE+-F(UGJ_+^05?S(=Z )U90XY]MECY.L
MF*KYZ+9G5 ?F!BIQQ$['RP[1'$+:<5YJT'X'#8#D<\ 6<]8Z."905^$$X@1,
M.KK[*FO;,^# "(\CK.&.CN!EYBK%.>QN1(RSX9UG57U%<*JZ(7U"G@'6C&=1
MUI$DJ3_4(#@IGXJ$*V=<\F+;W*BZ'4]=!GL)[P1$7R>D@F.-VD3V,R=+W04]
M@0&F\VS8CG%@C71LY76PQ1^,[92E*( ",*93YMQ*LD1]JYA)S:5V#R!A[@39
M&-TF0 *T*YE?6NC6 C-FMX1M*.@]6DDWJ,_T#\U'W50T0^13>&.^I!C,@NH!
MQ.T<K_:ET,&E&C&!EZL#"U$CE1Q9R&@9.S $RL);K3M@8(^NILGU2JSL4*V"
M/)6U/EVKY(G .4A8XMZ2T.ZCJ_2$V7%".\JZA8):V*"-:O?8E+];P<S C%;"
M1"E@*DQH)!EC'71HT_B+# G=%MC;>5I/J!&*A1Q>#0_O#"8)_BDY F<THKLB
M;T35WRJ4_0R\P)ED8!M@R@2"\CK70F\N0HQFMD&_]P]936O5-,N$4DH?261G
MF'&"Y@BVX, 72S)'!E7\7 _*7NAG>Y(#]@R$?@3R[3:%EGX'UZ4<PQQU)P]
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MY3UH7S^77PQ[UJ,M/-6ER4W"N/@*4-+:O+&\)#?N?C_C"><R9]!YJ[$:6VF
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M':GE-@GX^>9C!K1+<T)ICIMQ%(6KVND..PQT^&\@E5Y:]KJ0THEMFLM'P\/
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M;QI.8;L+B$I4B,H@^Q/!R2:2A>/>A+IW'J_&-\#+!2M;_P$B?UVZW?RU8,Q
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M$2#[3:1LSCQPW+ 1_UZ\Q7A;O)4M. ;,T1#5+YPMQ@?TF2C;S8VA+L8;Z:L
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M?HN'?#OIF_ ?H.?FC>3KSG8$M:SB]$:2P1%MN:/^/$KF<SQA5^!O2PB%)9^
M<$H3M9^AX:536O$%J6'(1#Y?*LB@NX+S&N-'<?KYZD%:V)<#QX)IOTER""E2
MJILT?-1HB.7T%I(0X77H#)7OO-:8*W(UN./?2\PFJ5F<>9WBS6%L;RG3SI.:
M!3EZRNVQ(R!((W3&-@(&&J6_DJ$3+X-7*_S,T8#F7LG\B4%J$W>1)]\>1#7[
MY+PH 2&$08R2O^*WA)&Q)34JIF[MS,3[.)\;Q;S:*Y@MB:6FF4B.(JYA)W8)
M!* *?1&XC3IJ=BFD5.O7SNO L*:.UN^J_Q(5R"2\^&+P^6@#=>%D<+B6VTQV
MB,XKDHF=>\5.& W$EX"@2/03\]%)OBX+.1\![A@V8>N0M)87VN0XO9  :B[1
MTU:>?(OPUU/B99T<2S9U#S*W%))1'2(CXFYY3Q](TP3),XG>&[]&W=<Y.5">
M&-'[X*/GJ4&=GB]#@O_(Q1>,&O9R%-1*\[$X]+PF<.P24KD#I>7 VY!*+3F'
M<)Z"ULAU2&&NBMS7U:BTY#B.BC>+T:HARV[N<U$XRM0<K3__:;Q:<BUR=J>?
M[2-@Q5SRRUX-.0M?@RA2)Y87L;NT0K BKX%& 8&M4+5WEM^GY0$:X6Q.V] :
MA41U&WKZMG[.V/2=8OG82X,G' :^T,[M.=F]@>4YMQ:=KZ O9R>IY#D5N@J_
M1YZ"OA_;]GW3YG)UV45!J0 YR+^&0P US,8)IS.'ON0U%;D)!X.GAHU8/+A$
M>!HIU%^[@6>4:*D4S$]!^! "[0;HJ[JKN.0WS'Z'<EVY4)]>_?A-;41IP; R
M<B!\5>Z'YH58= ^=#O+4WF.3VC9&?V6CX)EK0[*ONGY*INP?UZ=_QU='")KC
M?>:)J:\I]/E=8NHO\&<@"K71?XZ$7JMFV8Y,*Z^+W=E=K;B=Z+L.#ZIE-$Y!
M=O/CSFL(X6D+MC#Q^4)4H0G4V1AHQPBWERUTE<W[!-Q!<QN9"\7>KNGN\!)N
M]'B*>!;(U=#FPR[&>R5(8<'IXNA:?T6S8.X;'U:&T 419]\%KK+$4!NVI"'2
MB>!5.$!M)#.JM80D4PC,1/Z&]9(FY97+4:W*]%K7*\4(2[<2J6NBKT9H/$FT
MCA)9A7A=)4N52V!G!7T=' J8B(V,X]P!'RP>O6S>3+4$-2W]5D\_>Q"7#V6*
MS"M&\IR=)(@P8R/!4(42,WP]O*Y#0NB?ZQ(*YGH:$48:'YM(<>3KU*J2;,3U
M .IR4U,,UJJ%=NP ]7B:NVB+QI\I]<X7I+ (@JP)10Y4HZ&:*GQ6SZ1\+IG*
M-I'"JSI$>S6-45!6@HK<_OA?#]EESN+^$(#*C1D"*VCB#W3GE_^VX?TN.>K/
MYZ:"NR;2%UT:@3'G,@,OH_%N3EBR@[.% BTUDZ\OV/.9-F+M1?G:[)_I2S%?
MWROS^D*^,2N\E[[UKD7W4;[^[R:2P.AK(LUF$&.XR+"5*\?OF$A770DYW#XW
MX<RHSY&2^J*1?B?PCU>C/O'ZFY>7<S>$Q#SL;XOZ?$6NY6_??WJ[B6[5(OU$
M:SOC$,E_F$A=$F25B8360I4\S$1ZHP2+N6"0Q%W+_$!LSVUD0Y^.]VEW$ KR
M)-[&?"9LH-JPP]5YV0FTA=ABXK_Y@" L9*$SJ4.\$.1I5BME6ST9&="SYT\?
MR-'0C]'>K'NC_9(4;#_N]+3;H\P_S@9$[49+[A0/L(6R0FMB9 02I>SE#'(I
M7!8_AVG/H;#=]%\ '1*@_QF$(@'JX>;@+?JPF0DX;*,QQ<]3?0N<5PUPTX<V
MMQ/CBZ(QD9H@_GGL%/A48[%3O $IO*J.@ZP'V9];R)UB:JMYUSW=P_<'R<<J
M_])8'<9OH&$3Z8")U)!K(K6\-OO#R_A8HKHEJ1ZJ><(9XCB#(*3F8U2>1O^0
M<!*.W"CJJS95Z?4$;J:)M."<)Y.*?0H.:LJX.N["D<L5E5SDY^C)>1.^:ZK=
ME$[LK :NI<BIXD3;^MKDDB_\E*\NPGFZ%X9%1$G[JL9O<.=C,ZL.<6,N9P.V
M"KP_CX3K/^W SAMBL9F\]5_#6P%CYKC=C8"I=B<WUGJG<>-IKUHU3*G0)IKJ
M*/)&G)/=(KQJ0Z^XH+OSM (2.Z73'MNK26JK,Y'2<4>\7O+/?4GMD^+<B7%L
M/H2=N[*-MC <I"BDD<[5Z&EC3IFF()Z\MP;=\*@DK#JGX!$[Q=&"/5E@]/FA
MS?].]N_W:[SM;E4TE^M^S7%9=<_S11CT3V7QQ]0F$C2=B'\@P+VWV_]WT3FK
MQ$1Z4FLB?9M@(N&Y>X_W2#[]F_5;QL#Z\(3LD4]=5V7WOO7V?MMB??Z6_U<V
MJ9T/_R4\23_?K^+^;V]KR\-RZC]7)_"O5;F[<,0M\#_WO\\SUH03^8BD?3(B
M9%=G@CM#2E&$"=(GW8P^/[\CP+K_YMN;W'N1(PY.O\DVGXCQ5EQV+GL<K0B]
MN#C\EQ,Q83?Q.^OY,9<^6W@'^F_&J&W1OUP:_YGZWD0JY:KVFDC:"[/N1)Y7
M,5,E\W!*K-A/P;''UH/SR&@X>*0IDSMAC%X_"Q5_(0@\ OC:Y!T/DDPD>_;[
MCQ'\=ND@D#2'RCWDES3412\?CDRYK\_VU-Y>*@C]ZP6X_]*L3\KC=K9C0:5!
M#]A9NSNKC2XQ8^=*.B?+?;J.=!6_Z*+IJH.]-.%NKZ.>?YD,A3RK[#Y[FGWC
M5I[^EN*BSDEFO>>.]__Q#9\3F-,7E38?I_NZ-DG2WZ!BECF9%P*?8IB!3SGK
MVA 0>W!T9<,S.,#A&'H>;(VSWO68O]#KVPL['@4Z(4\-A]87]?Y?#8W,CO_<
MA/^7([.6?TWY;A_NP.V#$!9>E!]_ZJ\54/Q['M=V\[M_)DV_05CO?=2KDK']
M@)!BI?*T24(V#'EEN(!L5<*7&K>_^]FBRU-_6KUNCX)CEWTE8%GY=RE[?DQK
M^N8;U:)Y:\JI3\.Y[8?:<% _DX^6WAQO(NT(HADT4S,Y;6?:Q6!;8YRS7C*>
MI<0_*AH[JIQ8\LQ$$M.X?RR^ LTSD:)IK[CX@I5(TI_+]\]P&]WIKOCW7CY\
M'7]F]3Y9MP,YKW_5+MX@5WWO=PGQWBE">%)AEF2!Z" 2<0[;$?/D%^!,P(7U
MG?.-M>7I G77I;B'[+(C=2BGJ"+&*]+\#TC_(P&95+R'6ETZMLU Q;:!EX9
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MCCQB$'7T$)]S)= P0CG]ESJ'5OON<<9U!0>KLO//N'@'/?L^>6EQY89 P_K
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MN8L^IX9\8+V.W(07K F;0?6XCDF$A)I(-/("VC5)D2Q L*$_UU'G3)R;2+,
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M'HXWTSUP-O;KF4O$!<WK=;\D<!>]\"'Z=!(:Z(IY>1S?@$Y2M"69?DU;$HE
M4*+/B-J(!F3Y97M;*G31R*?UIY<6[%C)_V,+,>N-7J"J;G,@1]TZ@ARGYSF0
M=_9G&R-#U*Y'Z)OB)W>&8ZR [RU.B>DK2SFQ5(X&:3>K7_^R)1G]0YM*:DT]
MU3;!N>>S5X)%T0?58/Q@_20EN[ U4O8'A=NQF^5(#KQ#M%_'GS;UNDG"%K@!
M3UGI>)8H06-\)31581'9P2QM=.QGZ'A!L+>.3X7G8CUDQ+DH/4-<.!GWW=LS
M)MYWO:K$,XP'MZ)50Z['KB>QTX^>G/'S_)V2LDF*JWC^L."A''<00WUJC9><
MKOJ)5JRF,"B<(-,UI9^D$&E@&2+,6_!50'$=0,V![")B#>P%>&@%Z8);L5#M
M&R&/6 7"X? ;S3K!3,"6LN8QW).49^@%!(US,534@=36SZ.J=WK_[F"JGVIZ
M!+I,;')W6P7YC]E-=%XDNTF=23BA;97?P>&6&B0A2/AJD+L>&%LANU1VX65D
M%A0[')*D(=74EGC!",EJ"8R,?Z?L#P9)6G(!^0&G.,[;E&,[@@/TT2RIQR6-
M!*R22.W2HL"=##W59IA%%2_@A)JH8"^IM6[@%$;?][*3&-:Q1GKUR%Q0>Q@S
M6$B/4-%YUP [Z*G9SH1K+0FJM *P4_39B1%1M#;\.&OP?F*'ZK;-8)&C#JH=
MD*E=\:.D+.WQ6(PMC><ZDKBPI(4U _ZDF^L0 ^X-R"#T7%*,+_J4E[^W2:4H
MY&>+H).GD6L[;K=6##_^ED%M..AOFZY^F##^5ZGM+T0TMXE!MS2,L?N,Q)S3
M&KI*KJ=FPN$ZOCV\W)*%[T?[M(W2,&21FE @M2/0_..3E*25CU#)N91)B@,+
MI,D802)1B330OA)STYVX<PN&,$AFV/F\I[L.F<5A2_OMR?WF4:#C;X7-D&U"
M?["E!#E!?X5H<G@&3_-!/ 948TY(8;7Y)'S0<G-,722F62XS LNW:(AJS'K7
M0\O?14LQ=M0C2VGP4NRR7F_W_)P0]P%6YEGU/=6H0H/D$&OB:0M6"UH\9HA>
MVAB/_NL9J)<PB9>^B4"["#):9R%CB[N22NY5: /P;R2Y A,3=YNDW/ZM;*/'
MN3])\<=Z]?L/N*3?>>"K@P@!PUE9J_R7C)91RK=_5LSZC8\[.9C:@6"2,MW\
MY_NM#EJ]NKG&IBEF);B(7B0<O7#/,UXR UT6J#AG1+0A8!!MUQ8_L#3> A&M
M'K;*>]QGUT#7OB==W&9==,"/W8:1-6O$O4<=6W.4;_@C%:3>Y%J$HDWF_?01
M!::6"]"=B.H;VF+NLTF*.V,M&1D#\ 5_Z!IEDY1"C\4@5$?-C%PP+ ^W7*>>
MAYEW*W,+]2E7[;REU3=_>9M6L>_W90$E6W9O^M+*PMC-4HQ+(>#3]H@,'Z\<
M3)"E6KR>VR:H'Y?S%Y$L;!9\"-NK"^,V(0^-A=R5\ JPZ1:'*7.]=>74;4Z[
M[*H?R$JZR?'=);[?]8Y=XV<VYGFLZ*E)3DF./:A<VE%WNBZI:#.R&&E.$05*
M&FQP![TFKIG?*]"/MQHSH09UBX^7?B=\'!5*W:,.E.Q"^46O_1#JZ\$S?H^?
M\V:63.6;/B[ZF>%MJ8*/W/UE:#[L@^[I*V-3AQT2.X;.<&R,W8[O9YA]D>8D
MY"A-56$ZBZJ;)--AR%(E6GH=_DP"2FYRG[/JJEKIF4J/N9;+DY3$9W':D->C
M,6LZH3AVP3.=W7:F:^*\!%5 WEC?)_5L>Y"PLDL4\)TJ?$6#6'4L_S9>,=5T
MGG/\2TLQEP+'6JYQ9^&[@<(<QNV %B$)?"LXQ')EDO(Y/;-_&;B.><H\["Q7
MQ<LX3Z1G!F2V5%Z_%RA,1:B\J<(<'NYLER&EA^\W"?4UIT^DN$\?='K\PPL*
M=..Q]_M!0/J &;^C[&PX?"I36&#ZBZ54#!$=ZKF2$^7,-N<)>5ZP#2K=ASD7
MP[Y5'">EC$'#TEKHMAS[ONB.MDK,W,2:=WP!J]#5H_(><A0.1@-R19ON1FW2
MC?7XM1N\A]3G_LQ'RZ+5A1HV"(GGR!S),69?ETR\"!UH9;K#3B^AI(P@TV',
M7FAV#\4<M+\J Y&\T21A(>'1,U;#W-J0%5-_4:KNBUF)QO!NJ%@_)F=4JP>O
M>CQIZ'E#L21,\=T:=Q:Q.4TR]GJ24AEWH%@X25D:I)YX-TGI)(FYL,G8ER87
M+V""#]DMZJD>-,$)YE2O)K/@E;6<&U)'QNM%'#XQ9TEC&LWQ+A(OG,%)#\>J
M"O 5Y(;\+O((O-RO: G,E5R?I+2$ZD-"1"O8/J;R6X=C5CXXI07NI*VR#,EZ
MYASX0TN]%H3?)#II];>N:*A]%W<!FOE#> [XF307IF$;.AP.+FF$.<[S!M7U
M ><9(2 NBK3(*HW])<Q;=C48%%7B!\$?-SB-;3'68*;\.5\VK@K-%KOTGN6.
M[V9E*TA)-:(E.3#=S(["-Z.T9KM3NI*1(U/JZMI3<]3LS^U107+UV3,&A9R6
M]SOLB(KS]7S^8WD++=N5UYR\5ZMHY7S98+F1C$>CEPDD&[%K H6Q-L4QWA+;
M2,N6>]Q^B2.7BEN#,DQJ.F\I)27>FX"@MY98RN]!1Q4J^C;++2Z-VU.J-LP0
MQL?,!%$:,H*(_3$;*7+VZ@<=\-[;^&8R,(]&[V&[P!]WPG-A7]TSFCR&BBF*
M4I(#Y/. G_6HK@#_P-*() M5UBV2AVJ#$=VKITIKZ*:#EBH_/O!B&ES,NW ;
M3#CRWKR54Z&3Y(X)[3D.T@@/9XQ1J6451*AG(7%T#^"M&V]ANG+X3>.J>Y>2
M-%_?Y^W$D)S@'>1->22EG>1<9*)BIRIRU]9>-*67Z+-[("O2E\1CZG/!4:1L
M:T#(W3[2I#@WWHN]A@4-Y'W;N87WP#,TS+P7+-@7,'4TV_"[OHD3)WB(]EF
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MP0O;(K6=ZH^VJ89$VJ%:A4S@@&_ N#?\S=/1=R4U.Y+OKKQL-<';!M?$FK_
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MSL8W ZLP[]N$U(_LB7!]=T"9$AP8VK/F;@^]+G%U;QEYL"C2DB])&', ]$_
M[1M#B)-HKXY,9+DIP#<=Q'\1-)!'$1/[%60'*F$7(-0D7D4/:]C2L4Q)8ZXY
MV'+9J6VC>5X#RI=N3=-=/RYQ%#O'2)Q% =>XMY/#:P,#&I]M2*&[S'"-.>I>
MT3JT9J8\6^((/_X#T4_-T(10&;5OFM0A:%B<F:%'SOE=FB;-FZ#W=1+FS"KK
M9D1@CIS,T@][1WU8N<QY0*#AVYB30/:-_C?,56C)ZRKA91]%GL"QJ8;N!*Y/
MD_:D#+*<<0?S2C"H#42I'8H,@0/\(? (#@KN/8)&M[/F<*-UY(Q5O3XG\!?7
MXX1:M<MPL?AOJDL7C^'G*]6^EUMN"R9[Z]MI3SZA"A T<,S6O$M@_+AKFA0C
M*0C[-(S6.=:/=(C76&[A]-COAR==OWLVQMS06;D-[98M[.>(5 \>\,_ UB!5
MRTL?'9TX48H_3([]H-@SU#Z>G(99:P+;%%EJ-$32)]'##[2[WK*BQ_IJC'LM
M9=W22,\$COQ$NO$?P* 79I0ZW[_#(9?L,^]_%XO,82S5/>+Z=I?MN*:2ZMTL
MF[LC*6&9-16**;<=I!-K+F/INWOPC[ERS8>H,L?+E_![\T:4WGY0%/(#[E@D
M<^W(T(\Y<D=D+7!)Y1J![O[84E5\6.+,_8:#"9]PBZ1BCZZDA-?-27;QD2M*
M'[6Y3-$&FPVSM!P56:O^H[+($*TA]T7KU(:5:,WN/RJ+G@Y\P$Z/]+%<;B0[
M<Q$=N0">*2RZ6-:$\TV?PL]8L\I$SXZ@@_((*"(NS*7\9G#"3X=BC]<>>?C]
ML:V"-RGB]*NJ>/^J+(-/Q!IEF_^K@L+*^+ )<4FT0T/-<,N<XNLJ%\&-N/.R
M9J71?X/J=9-W86PJX\Y4<K&X>O6/W]VY>OPHX;W2F:<:#56&"=.G4E,<W%M*
M0H59!'3P/=99"D4TDQ?^3XG5!#47GO]<O#&,ZR?GN/A2<UENOHJEYGT@2"?T
M,'\(V%BT\72V0;P,6JUD6&,![;T2F_%75!FRT)>_%$2W^Q?<JP0A"H*3*5[R
M.\+(9N=F#<>P3J, M#$^$LTYTRN8+8FCSKR))D),V\TG0 "F-):#RYB;;H=2
M3ETTY+$>#.KNTU4TXP5,T";A)52 'T9:J783P>%ZI)WL&E-4WB;VZ!6[F^D@
MH1($16+1X^P#XE6HF@=%:5\A,@_Z,Q_.8A#4?M*[1BMQYG+:BO<5W->J';FI
M$;<%0;WC]LBG+SYHZ?;-IQSH]JY+-H3N[DFH^S;%UNVRP5M3/!"[\FNRE Q6
M%+72*2"PD]7DE\OXIC9 )YP-/QI8JY1H+K-NOWTP=W2JI$(Q^L3D"X6!\_IY
M+P[W>"?YSFO!;)2$2DG3* KJ#'6,:E]!W\^/=O_X:,V99<<%50)T+_\<S@*8
M:39.A/%<IO,0%;T(!8/;I@_-"> $X6)REJK%FV>1Z*D4,T,Y3G<8(H":N:JG
M$2$/<U2NM89:H3&SZ<9P2T35E4%U9'_XJD(:P>!0RAF8P@V0$TE5O!3098B#
MR$J[E;EUI4P\'Z7S?)#Y($ >]M6&,8?+!/VUY\(*=E=R I-V86?!HR_J[]S9
MF1J5Y;)JXN^S4'X>%&2*A!S0R='ZF>Z[LX8%5-AUJ'1VD532R)>-S0=%K6(/
M2WECQ,GN5M4<%AG:BZ8= M481XNTLA>!M!W8SJ+:(:HSY*=3N\7XMW><KXO!
MUZ,>]V\<XAXG$IUX%7&59T^:R> V6K/34H6O,'/0DB+9@S1CC>4F\P/X>;%?
M:\F6MN+0G")-5:;HH);,$SO?0159$XC=0!QL(P)%NE<<J;^RG9/3#:Q#E8PE
MC%-Z2V+W3HR6._='W$LIV?Y3V>P_9MO_E\^?F@Q=_W,_R;56?4,S$QD&#0%L
M#+ZLFR:YOPH#3C/%\'4@_?,7R8; W3UFI\6B.QB7)O-?]4]T!/;N:II?F;NG
M2W@XZL+#PT<._);SF>,G@<]\]E@K!I!\UM E0(3#/+6=Y+VV:Q!TX]E)>=,D
M- %]-$TJ=3]EM8,$6?YTV.-?OJC\OW^Y<RH.M^-5930(U7^YJK'ES/$W$KO/
MR#Y>KDZ"K-S?,[\^D/>W3:?9BT,46)7%4;V4T'']6D+-,?RGYN60WIO^=)@Q
M37)%NKPP 6XO7HJ\DPO+8LK( M&_'"W_]W+_7NY_LIQP+SA1P1F"22@S^X;4
M&,$.1)',Y-J=_4\RD0;.\)37Q8I?/5(:"\.?_/I+P"KX6\='=E=2VU=>W;\U
MXX^"+U+HW\S;NAF?X)[HI7O7N?'[,/=2@79LZ7#HP^L1(''@]?/! STB<FK5
M_4X=:R$77O?U)2_;O7;&AE\^<S[?5O]IS?J[$V_66K6:U2[3I*X/L4[<CKD$
M>?=S^1,LR>)$7H9HY%J"@C-N3/[\_]U9-:'-X@TM]TNU, 7\MC_6-B,A0'OB
M X].JN-M047:1>=9&C@I%QGZ!Y< X7E4.];[W_:^!LUX-J^ A7Z#$MFB=%_:
M;_\^Z]]G_0_."@U''WW>>S.DH[FX-_M4V>;[^OD3X;;NNP=WW'NP>2'8)%4M
M+SU<]F;JU;G(*#P?OMUNG+SR<\''1PI8OOL?,'-(:_\8R"3VO#G$F 5=\F\R
MW+FLSTZ<L"H?*E9F>7MYK4$I!8TOWT9UC]NS0GJ"[TDD]8VQY8U<W:4W5-_R
MG;]L/4J U CNN)6%GQGP(_C<08S0<_\H9FE7=D^3AMSUB-E7L!AYGRV\2L!4
MJ>1?#Y?_^:M3+O\O+]G\O:YV8U#:DJ(OL*<CW*,%GYL]P8UY@RVE42I$:_/K
MM^=_^.[C?QJ*)V^LM1H4@EWCTZ0I:ZZ:X*C1[1S\KS'3I'-\]C2I+#6?X!^]
MT+YITNLUXHQKIYDG_[N_\/^T0/Q0V+\7_O?"_SL+W\&7^327^F"5U1Z".M7P
M.W"X]21$"5-D0I]I*^Z*;KV E_\2*8VG9"?GK] -J:35L;^S5S=NE"\1G0GC
M_"6'WO2?<[BG^_X/4$L#!!0    ( '.&>%JS2.+Q*S,! +59 0 2    :6UG
M,3,R.# P,C@Y7S@N:G!GS+AG5%/MVBT<*R)-0$"ZTCM(+X$\%N !I/<N(-(,
M"(@$"6 !(EU!0(I$Q!!:"+U)$9* @(!T"35!0'J"$I<2R&&?\XWSC7'V/F/L
M?=X_[\K/=:\[:U[WO.8UYV)\92R!+I@:F1B!3IP\ ;I]_ ,Q9D$W0"?^B]<_
M-OFO[G&"\1'$>>Z$YLG[ITZ(@4YRGCC%>8*!!XF"0"?._*\%H/_O.G'RU.DS
M9YG.,9]G.5[0> %T\L2I4R=/GSISYO3IX[LQQ_=!ISG/<%VY>NTLM[47DUCH
M1=4G+XO/B5^O[>:Q&:5(J'F'/64^S\MWB5] 4DI:1E9.74-32UM']\9-0R/C
MOTU,;>WL'1R=G%U\[OC>]?,/" Q_$/$P$A;UZ%E\0B+B>5)R9M:K[)S<UWGY
M[TK>HTK19>45=?4-C4W-+:UM/3@\H;?O4__ V/C$Y-3TUQDBB;S\;65U[?OZ
M!G7OQ\]]VB_@]Y]_X#H!.O6_H?]+7)S'N$Z>/GWJ--,_<)TX&?F/!9RGSURY
M>I;KFC635RBWF.J3<Q>OORRN[6865[.A\'B'C9[GE5 G25+_ >U_(OOW@#W]
M?T+VOX']_[B((-93)XX/[Q0G" (Z(G3=1<Z@:6&3$#_EQP)%*,JII9SBL@W(
MZ2,>3\_%!;HL17)R97M[\<D#P93*#Q_R&OCRR:NK41+Y42N1.0'NWU[F?<W:
M1E(&X^J5#P71'Y%T=4\.!NAW40G-E0'*\CU\ ]F*IXLQ0)-QI W:X&9#35U[
MYTOWY;K&E@\OQ6<[QHA\>=E:/.Y;9==W;K>*2[ 'X0;JVMNB'AX_S?R5W]1)
M003+C BVR3[OVFSI,-\8$KXOHK-<I%;2"_<NZ16RMLA6DB;S7.J##)6<?T#*
M)X^E^@BY6*=Z5Y7PW,G.!%L>\8?0?!F@D@< -P.4F$)B@!@@M8DXG.+1YZZ?
MP<B3<911.(0!6GW4^6"4 0HY/(47N-EY^4OG*3ALJAT"5:]Q#\HW3E0?LC5M
MREGT:DT/VA3VCKZ3,W\G#?7\D\1?ZZU&^R,3R+.Q6@#3<E<"DF!P:D(Z7]"L
MQ*LJ0#>MZVLCAL.*956Q&NV[:BJN9IB$";Z2$^U:EN3OYY=^)V.=.L?CJE "
M-M)"U$SXCY<+: 3&.#(YJ <.DA+\#.UHJMF9R97]G\>L/]1!9/K!,"P>UN8D
M5("G,T#\J7BOM62<UT(<DE1!IORLVICJ,>9S0$R13#3D,CBV8PH]P=O"MT(
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MY.Q0C_MKG))?^;?MV^"6UBL>^.@^F#<QK8BWL]NPS2!$]_O#\G939G;9O"A
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M E8GRGS\]N'ZIK!""_8<J.X8;NI=L<SRO#,,2\"F>(@#R(.;L%_=+KEI1]J
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M5*2>L!1(DA_+"7J>*^54/JSQ*DAW4D2/BVJ%X2V[_F#YTH$&H(67706'N&#
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MK.JY:N1$*;D.B1^^.%*#A9 AA+AD4;;.8RLO[P$DD*&V5LUUGN<9H*  Z-O
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MRTXQ7<T-ZL;MK=4K=J9PH&3<ZNHS,#_R0)+SD/MGEL5&J5K.ZFK@%_S$'($
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MG?D]M76WG)L(M V-M175_Z$)L2%#K(VRQ>N;NG:#3P>+Y>CQ83\G\<?N*H5
M&=\1F,X"8=HS'?K\\'7*R6^,#&1&T'59?/[,M_""IJ.G[FR..--UR@^.6B.\
MQK DGM.??:&&$1<L*(F5NF^K[<">>I-180HZ[-8S2DYFH1M..O[;(A,J'TNE
MQV]O.\<2'<AVQ/'^  Z?"QK6T'1.,)P P2SYS.WY1_BMW4_8[&JNRQYF>P1W
MT._RL\??3>+9#/LE>JKB[>OOMY]29_Q7@*/)7V2LCMONV8X;($CK ;^HKAES
M3*EU#6>,) X6CT@L?5PHAN3NS[IWJIGESB,AYR[\B1:_0O=,6<+CQXOBLU=0
M $?N=W#*H.J 2^ <5 UI3\F/Y)(;<$.L_W!T,IK>!0*)%/M0R;&R=:.G+S:H
M+GAY%LHAFG<SNA,(QU91PC'V$2<>"!=)=[M].+>HR.-Z'1736[YA:^X9]&MI
M7G-.[.GQ=\ZB42'[@H=]]N+[PJ1X XI[N P!<OF1=B'9SSU4,F,#LRR9>-4R
M3EJSO/"#HZ*WG"Q,#M_S:*M:B7J@,K0]!J5CW[:HM." &854N$I*$:UCP9:8
M221#**$16#F@:F$8;"?]:I/*A=8R<_XWR;!P$M:%^#<PDZ129[MW371U]YMI
M,T-31 =;#"*ASRIWHY"-5;/5V_!;NTT^ZI K!>(N%"\H1F%Q)UYY\E8?[<P]
MZ5'7/:DJK4/["W$-Y1XJN[:3O1_*G6S1.B76UJ&9$$23XU^6QA; ^]]'XK+H
M6<H>U9O8@M:^3(K'%@F HS'=C"2.\00M:9(@21;0HO(QB!;6^.;QW''ZU5RG
M,D[K%;=4?]>VEM8HQH0:X$1,D:^YPU."UL&-TKT&ADHTGXUBRB:OJD^U._BW
M#7*_"E=@\S<AO&F[K1V83?(>61\ O^UK/0:"\^,9)6:^!2X^L$Z5:JU6XPW3
M9BA!ON_7DN-CU6?J+@5*K@8Q9&"?S5_0>* ,O2)T\0$_NID9"?!WYPJ^$.Z(
ML+4B;K">P[=0XQ5.77>(>,*,D_:I,0YI <SB^Z]^<E\>--S2S 7P*AHIM+N4
M6?6#!-ES*?-98=4R)%WIA7!HWZ:*!0C0"3Z8T.()#F N2CB?7/][A?\W1[:)
MYGM/Z+-;^W<[H.$(W1;EH50RDJ.4D/)W)DUX]V!>G_XO>S<JA@RP L(28NGB
MR4(VF9(SGRKU<S^%V">5X;D?Z>> /?L8Z608ON+WQ',A?AIO(2K@GGV;:/B[
MRM2T!VO=/0P_4D0ES+&M!#=^UU#1?T@TC9"D&J\>Q&O3G,5'"E)U9U69S08$
M58C925KF;J%R!2[XLNF_?E+SOR15$+(J#G:F[E/[4$GAN /SUIM0MTW3A+1U
MK>!S^@/B*Q.AIY0L4MHA6K,EKK'GUHZZLQ EH)P2M83\ZP"Y#O$VKG)<[+34
M97\O"MGKTI0N^R]I=3M;[];W#[\C"R<<QA-)60H\W8)5E0X"A5;]%S1>&VPH
M=TN6:'.RBDL,7*_@WE1$9Y-T>T:HI(;.'%S2U%&%JC+DY=DIGMX_%,<ELIK+
MD_=5B>&>N'C\B+(G $G8V?B<XO3F;R#)DOPY@LG+,I7_B8O#PI@"7(^6W1RD
M%)G!;JY+\W\[./" )G%JGOP^U_^<\!(._N>$]^9LATW,^?_:,.6H :<F!PN=
M7OI'S3L/='9:N<Z-(YDO:.H1\3U_ Z)9_D_?2BTA^B'_>_L3+ OR%25[05/+
M)'1>BKNA>4&3L9+2LU=%$#IS6+N<)%%SN/ZXY_UX"JA9?C^H/,*5@H9M]S31
M#9X!3'#:LA$FN) E[6'">*I?=;7*+@O_[@Q43>W5A"\C1Q.LH%IAP7X!D\Q^
M4Y??O*I$*OT@K6?L_EH\-5LH=85L=RX#V>DC"4",W_(KW)/Q!R2MI?;A%9,*
MV:1"9J29]6]6MED/'-Z3^IX;G6%H#%W\)G+P/))E#2K/%=M/7.LGU-WSU-)[
M7D[\N_,]V!P>%601 J<3Y5PP7!YM3C>\H(G#G=5!MG8!7NG4^^<:%S3KTT+$
M>4BS_)F YS[KO^6 # *H[:B<+=3.RAY_\GE,F_XY7R"(6CI\^&M\$[(?L7 >
MUU9TSD6XH#E^G7&:CEN0@*PB<]/[RLZ*_;1%SW&3$9R?T&S@4>W;AJ</#?U@
M18P.\<J['@.[@\3=1,_K27H?M*$-5<(:\<]&S:<" *O5]KID%-QGY5:/#U)N
M4Y=4]"Y2T$GU@F;@S&)F['"@A_U+4P?QVOLO_[SQ=,@!AR,%.G0R>3*_AN9Z
MTY5:D$):WLFV5EN .1:E"#6AHB*,3Y4B1XL:6F*IS,1@C$TNU]YQ2<0#2C+)
M9F"%N6D8E01@[+0JO#^C:CRJWGLN?^I4*RC4..G9V-.JJ?<1B7T9RFR]O&PG
M5\/<";"BS)([SC*IEO#S(>U+N'/QB"=F+)'] .Y(^AUM>M+KY#\]7+LW([\7
ML:Q=T,2\%$IROMM)G.)]<13)3&)Y+Z=RVK!ZG_F56:/9ZE0VNOE6V=%P ,M&
MEFC!=W)P99\=AZW-2$/5TS2AV)VIRMBA6F#EQ+"B;3R3NZ=UMQLHFV4O2T9K
MFM]R=)HV>_WS5X+V1NX0(GB 'YAO6<!_S<9\J.4F+D:1)TXJ#Y&.?KJ)MK#:
M6JT4!\UK9A%V\#-V^\[WA>)"(BT@G!<T?9:65B3MQ L:1AURPR=[HB=F5'QU
M)?$/6%L.7+YI-7DNYMONOMQ2!K;]X4 I<<B;0_UQX.MR9;8T33M\?#X2OS]>
M)=OXT8#J-SMP0)'8+\+*4RR4J5YGU8/8M1HL'D8)YL+T"#E2RDW\P3-@&1?<
M?E-;YX'F],S)_8JR<#'<9Q^ ]^D-?[H?H,9!*KLPO@7;\]Y9J9WHM[_\_O2I
M_JDU)1@[_SI%ABH?Y$>7WLU%50P0VNZACQ1Q4B47J*66@W&/B0&)C6;,(+N=
M#X^0;TL?XD*YGRDM#*K",?\V\LJ^!AVZ:+X&M]8S$+YR:[>6 C>@O,>G"U(Z
MT)SS(=KW)A<(ZE%- #JGB(??BUN2S1I:2::ILE1[S.\2='A5:T_!1IYEA[?'
MP;"DQ^=\A/*(8B<KFO+"FI$N.8Y/ZGS('+L6_$2-C=$ZO\(T,&1G_7/[;TQ_
M3$:<E+E5Y9C*KEXC2%"[_ K+YU4%6V>9,1)WA+4THXR>VUG9>ER_^U\21^54
MJFV_3\@ADRHW?MU>=IR%)]SH0Y:14MFX/ZD:1+21C]>6B>X]OT<ZV/?&C[,Y
M492Q/3>K]U"1*KZW[$#@^[WV$#(J5369^<WX0+:V4)<V+R[)::?=O:92KNYJ
ML,-[>,=B[__#SIM&-95^_YZI<D F4>8Y3L@,*B"*D912B( 0F6<B(F/$B(($
M"4DI,PB4(J H1&2(#&$.( (!0J *%&36H$ 204;)$8A',G7JW\-=W;]:JV]W
MW[7ZS7T!+SB+??;SG+V_^_,EAZ<!VT9H3EG+T;^>S2GCEVHZW+^0AM/G_69R
M),B)^K<8I^69ZO5')S\?TI%8M*4:X3Z @4 5)X#_I#UB;@(,XCKQ(L#A, ;^
M/I3LF"N3#@N<<\!3A9"]O-.L]71+A70J8Z%P#IY,[^?,-):C[A:U7&_$K/M3
MN(B4:!5<?VRD63OZ-AJ]F=)-F5[GW'C/"YD;3A><!HG,#P)=&[8VQY9-[.7?
M^=&-,^ML!N\QH2EW*0_46.Y/F7$$":\/*($1<+W-OY@!O)A9N=N+WVOVDY&U
MWGL33&I"^<'8".B#GLL57F#<_:&*:BV+)W>?6*KU?9D 3E4$*[?##;ZWW]EQ
M@L;0L1>WETE_C'+-.[QWX>?2>)FWF0Z'*I;<.T%TB*S1UWO6.Z2PQ&S\9!1F
MEZQQA4T>+\GN":P[A77P9(8@990<GX=ZN$YI770M97A\OX+[*(0T.V4/0<GF
M:^H!TY1AJ"(6>^6#H_G3Y)JKXH3\R/@WG;Y?TZVXH8*/DBI/*>%XNMF5/==,
M6FBUFM6_'J-=*HJ<Z/4Q__7-C[5/$E]OTG"//P@^PW=@3S.0.[#&HUC\JW/L
MI]CC0LBNO6.61S$6@UUM:[5)6X/9#S0/ "=)W#,V<>7X*]7;2=563HUM8Z/T
M71G=+O8ZG=F.Z%,RI'8O8,=YMEA782!SEN9@0@OAW"W$SSV_2[E'"3%6Q,)3
M'-FSR:9(,4S";^.X YC;C-HT-#&_!ZH0 BC49.-9TB[V[%Q!<<C9I*83X.?5
M&^O2;1>,4W6NA#,JF.VGNITPG] 3=<<J+N3J@;T;Y,?.1+O<2UFZ@>$C\^\4
M]'*2]Y[2>^QVJ<<L\A3&O?JD U+)L>,27/WJLL%1I17EOWM(7J/44_/V)YXO
M.ZKT/NL9J\)VC"=JI1<9%2)#[N7"SL:.\: YG%%^_4N#!L$$O.G:C72-$GP&
M[JSM^6,&I/F3-4<.C@<=(V*XSZK&.W6Q(4+(_4RLW,1FQ XFH1]/#^G>7J P
M.N T^HV<&*"J]VY6L1"RAU.9+() 9_((S*UBL-CAML2SI#&SB;'HT+5TW\%
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MJ;*B'O5M-[0[U?P6\M#-]4_QG7_@O2A!,M/VG/-@-!<F&/0V[D6F:LJ,6![
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MN#XH^S)2!FQD?$VHA5G5SH3#Y7B(&A!*M2A/XMI"]V'\Q_HU5=]'&\NA<%(
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MX<HJES-# ZL".U_#S!0KWS\>ANN7_,G\^37];>03.^=WBTZ7>Q>:V%OLIY<
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M$U#Q>P7R&/Q<YO #2\T9K-)4.THTT1]81&SNQ^ OCL#B7V$J9YG(7@T+R:^
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M%K LK937;6K26FE%<Z>ZCN?Z!G7*N.PM?%Z6E^6X=#->\=GKLA>R$I2R]Q]
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MY>,-N23TD2T(D-;BO)+,#@BG]M,XEJ;]!-UR?1&[(:[:.&JEN<ZW?R,,CI0
M3":+8S4%=*\->M.O/"P9\:V1X)[9VE5GGX^!%_FZRP]LJ IHG^*,*6D9.-SY
M]AVZ<@"<R9B#/@=7@1/8<E-(2>AEDJPA%8;J-P%\PE[-NQ\<P?L:2/.<4T<3
MW;RK*9'>W5(U[YR1@IG<DJI\W4,DB0-D1X9R*SSET)QJ,;FR(T^M#O&&3W!+
MN%OP,>9V-R5L2CF&(!BG@R1W)\A+O1EB0RI0Y):Z[NAUO!"$K6C/[,:AO"DS
M1OV$N: Q8[7-CF"#PM*%NLB+ZDL_=(+N\@>RUJ *[ / #4;V!P.]X1^,W.HB
MN,&>-_TIL6P!C:8S=4/+!!)_AV*@(PISD9Y>3%[9\QWEW2<1,TB4,VHU4 82
M\9;BV&+8O;HL9R/UT8F+[.N,Z [R1&S$><98<6PP5,(-I=MRG^?)<&SUO$J.
M9^M9GK"^YLNG%%5^.AM2HO^N)BJNT NV4^W,&Z$W?(G<OTD@O9P &VCX80\9
M>BY9MFH;"C2X(903@_GZ3E:NQU5 T+H%QE3+QRR?Z,,,S:[E<LQK/QP5(]Y<
MK)S0<#H$D>\VY@K<98W3X,%W]"9ZL_Y7^>!J_]1,ZP0?6@TP8AC9#+-W>TRY
M8=I(LMR3@$1+__B(4W3/2<U;N=,S-Q VM*'IL(O>&2W3XT,]BINU\8=,%80^
MG8E(Y.$',86,!*'Z:0<+O<)*YKC[Z4WO:8F= EJ&6ESFQ.7^2LU]",2A1TU!
M"_Z>5S"I9\9O/3?VA"9O@ZIKEVR+(H8BY(!->L@-0"@ MR#- LBTXIBE]07<
MT=:ZX.B)N&6#SJ*:0@,"ZP1,FZ55'GQSR+GKV5O-GM3)9L3>1\:9)-72:QD>
M4:7NPCF2PY&E>P>9 NU,3&-#J U0\#Z_2W2J2][?:U4V_-&7P(,"-#UYV_B\
MJ"\+/U%QDU62CTE;]CDZ<\I@)MC+::C46OG:LW3IK]%.+77Y-_J8=SG2G*<&
M"L!96G>+*E@.9?(A0WY'ZC1WALP]W+>(N)V?'.Y)3I2KR#P]X42A8&"43[(+
MZL367K4>0C_EL]ZLES<KH:&3>EGZ7CK53%# =QLD&&P8JP.-O;U8L104UJ5M
MU*]6$*H .UG0_V?/AIN%LO5=Q;#WQ:M*6:'LH;5<4]G[")^4G/-3I\\6[K,M
M//$V_41@^=+/_8CQEVXNG[K:Q1WN(IR[:I*_"N4];J&W&\=\"= X_3[Z0*V
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MM6WQU]>%*H'GKQF+6D-UPHZX7Z1CN89-)WGZ"&7P<?/'1?%0_&' <AL$GI#
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M8=RS](9<?@9V29"1V18A7=>'AKZ:SW#N1[G3IMSZT>9Y3C"=\.E&5)8&L@+
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M*?"$;+'Z_/JNJ,[-A +8"K-&FH+%#DPH=L>WTI!]7/?EPU\H#,' :(K<$IW
M]1^>W1R>W6P&+&2-$&@VL$6Q*KWEH)+YU]#>*TER+=)<AE#Q4F:7UE<0 C3L
M.-JOT'>/!BIQ/<VZ2DG" ;.G/]#^.;F ZE\JE(K5J,?Z4,9#E$EAP-U)[*EW
M_2F.8.3-:T]"/GX63S0?EJ(ALX \F6UD2#.($2B-9P36YWM_)JNJKA; ]KN4
M5LO(:ZDD8"&'!7T50^*3'-")#3""(>%Z_/I94XYH!*(#LRU8Q.UJBY=-%*IW
M&55\LX+>$D"SF:1I@VV/5F%U8?Q@9Z7NI417V[<,6#"&$5O;93R-$,KBPL\%
M<WRF]GRC\3KW55A"_,]=4\I$'QZL>9@8>D.7MOW#][QI5\'0_C22J3!6/,"L
M3;[#&RX*<832A^>6_0C=%,RKZ[1U$+.*DMO=V6("%^GX0\D+LPF&,<ER>,5D
M(-:)46G'D%2NX*1?VN.C-;:.Q4;STI#HXO!%P_94:D ]>K# $C8W*(;,4#E2
M#>V(6.:=9L1X@4U7S6XH9[,HFI=X/9:]> ?1; II+,0#7U%.T/.;513.R6?@
M*DQ ADVB39K?#:-U.DH(94>A&*5MXX=LQ?E'6Q,7\%5P5:HQ@M^9A%?GKG%[
MGQ_GK#0^$H2*]XWB<5(1P=F/$O:3:#[@I<CA$K?'Z)AHU.DHSFT_:]8GL=$S
MXLH,DG5HN>'_^)#HFNT73Z^[?1BV="$4J4E9,)VPGK/H5&SNTL4V,ZBK,!U2
M7;4A_W1W$7T=%-@:6_]PN G>LH1)I1E1WN,TUA%BVS.I'G$2O#94+$2KSM\,
M%,9^'BA@EXJ]*R.>#8[M"Q$J9<(G\]C.'3MV:!]8T[[^SIWAN3MWYO_#:C>.
M:>5Q%G*BR:5C(590H?3FD4%9IU FX>D2];$!>25#@Y^5+"SQF/V=33<B&.ZH
M;_@%O;$8BM87XM1<CSCI&T:SN^K32 <P6IC"D,!/0/S;&^#3CCEYHVF6Y^%?
M;\27%I\Y6G#@:N7F@,* O_0,VD[F>^SI2^X[/WZ4.&#>GS L?YX>$8=L-\J6
MF&@-I+^]Y@C4_GE-L\*OZL_Q@QY=\2W=F;L=+<2S5L<=GF"#FK_)&)!E+^,.
MS09B2M_2M8JZ':OI[0Q9WAD2UT"5Z.(P62/?VCM5/44]XCA6(VL0G85<RT\3
M!NY<_?ER>P9[\S#[,"EZ(TMCBKYL*C\&V==$A)A!2;S-V3-H38**+^-H%X+J
M4_V9, 2';M"';TGST+IB5,*0,<A+MW/<V QF/\OUK4:D3&7__69$C+FW"GO/
M^=ILY+5,'L/#V*>B03[5O8=F3]W3/6T!EM3?E\[JC:,T&O\)<W6KL$R7+U6&
MBL*8<ZNP3?,T1T9[+B-A:S>&>/'Q:[6V]-)5V#GCO4)J('[E,9I,AYVA.G71
M=IZ), Q,E9-8E..#[A3:MC%L8G^JXPH>L\+$"5!;>JOG'R*B.C4@W,]<,%G8
M<4VZI\ X.EI#X^.11>?K3I&=D=][ +G_PW/[7ZJ96$BJ+AD_N7'!JH?E>Y#U
MY%RX?\VWY%_WW;^2<+;71?1;M8L?O^_JU82] 3F7]%NF-IH>S+:V>_NW5>B^
M%TMS=T+SSOL+^K(VG=\K0[$,3R?NC3KEU5;V++_P8.#"'_F&(=VHLD@EK0^!
M-<\E3:[\YCU0$[ L<$*KL=';/\MW=K$4&A,Q*.W>>:8)[4.N9SM/AT)4SL#I
M64%>(>C-C[W3; B,)JS"GD:YBM>-G_0(BY9N)EV9M7CV5,3E_!-C45\F"O1
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MDCX'.BL570K$2K/<#41(?J6KR0^!D:< <@)-GS!DG><)W9"(-Q%S8S*XY\B
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M#K\<S0N]A([E4'2.S?C(0<*1@.P(Z;19_N/<.(>^Y-5/_P-02P,$%     @
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MXQEP\ ?F%!Z810DS(2\MM]3,_BT:RW\U6 0)/[B3@#]U#Y@92M^7W])6YMM
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M1PK[;;QO#!9=T9\32['1='/16EE-*A)QJ]+3?&5>)7>NU+5Z\/5KI>(M\G^
M\!^]AA5L?AY#A]S# UD)3(C\D;-89'0&IM-Y7QL?.;+-*28DMRO[,ZKM'SFA
M<,\4I+_S_%RODQ2%)1:M2XKTG[,'!ALP;]8!?2*,TX%PKJS<X6K+9S/':_<
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M$)E:"2NS4Q\[\\;4&I.4GO)1E?F6:W&GT-S@1"TZE&*]!:-\'],%L$G^S2S
M4"Q-FGAXZ.AT56G6'J6(F%?LYW:V2_13*,X21BWMDM9WMP^HZ]_\7#GMA[]B
M.''G&;.=^T,I75=(R[%,R$G&U9LUIB$L\5$RZ[-']AR;V"S,NJ).?3'$^_J
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MS^R':@NL_0GS<OL<LH^[2GVE]JC :S%?DVY>O58ABU^5QJ8+>CX/4UZ*N.^
M%=G6=7G K&=\7Z )C/.OWM7@2S1=@BT"EEP4G:6N";=0& &=6J'\.D[0RQ4W
MM5$+)B^*S%-*K +CW#6#G9L>X$^6TG,9:H7184MJQ@@_V$ ;3A(82@MA]_UB
M0=#^,A2S76RS%5?*:9>*O-/<DF8?42G9843P__;5*-$S'IF&]X0NG!C*528<
MH6^:ZQ5LSH,F.UVF_$I4;E'F!+,69OVX"9V2'QL<%H?.\J_^/8W%^BG6UW^_
M->GMTM9J?T73'R[_XV;;YZ/?;DZ0"^/P;#AU?(I_<+<NR7I0GB.4M*$WX1&G
MEJK^W5':,<5XJOB=>TNCAH9=6ENXY,?G$G8AKQ_9V^LJ/+?OVMG#Q#,AKK#$
M+&136EZ(-['&F8TQ&<4!/M%XJH,,"ZC[L?MEO94OR':@POO11E9G[()CIVX
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M,'?EE!;UF>84_<E)Q4>SNWI&\L.?E -:%_5V7?O8HV]].O;H&+ [MFD8W!B
MQ;A:8@T+!72"?8Q.R:EBV62_)6.; F,JS!M]CWT@"Y;CJB>_>2X$P@Z^)?53
M$JC*!ZOQ/:0&,2Y]B:KK@C,*CF<Y'C@K<PZ?W;@>4N(4S^6]NC1A$EQ:2"T.
MR$<B .?^P@5QHO66)5$Y&L^/N[ &XVJ&)7;R#M;YA7N_\3[X8TKZQ9QMUDSS
MCRU%OVW%J+'*'VU\%K:?3<-/C:3V:UQ^Y<_M&I5E37#F9AQQ* 6VE0&XD7#I
M;X9"5I1948$/X'2_%C^I+YO^!+#Y5?;M@MVK)ANI)OT[+<U9R&58WJ]'?H=9
MN+ D^7L-\I(#+B5/XB_BC/5L4W5P!6)Q,FYN20,6V2T$XDOO\?H?@RFO>?[X
M[.#^X64&Y@T8%CNJ,C=HZ^%FH8-]TD.)4BF$6H\U"-#\I>J-+10_;.BN@[1!
MR\N:GWDN9UX.++.=K>.%6^56?F.5!*N 0Q+?.V"/6D.O4@Z&Q8A)@Q/J963%
MJ%FR(3#0Q<\O)'('5<VX.ZV4%<&^\O;+%6&O#[7WN^YS?3Y%OP;"R*G.)):$
M$., !_ J"1JC,;O0G^OJA9!LC5Z^,UWGTM+:GF*9\KZAX8O7KL.PG\#]R,;%
MD835$ZL[\ZLK8_WIQQF3SLT)_5">'YQK."X* WO$BJ86CO8&W9$FK#33B,K^
M'3?W\*O[:1M:)=E^^]WO9 ,4TB_QPEQ0R^84I>?$JQ@S(" !3Y2C6+;F/5R"
MC0L=#!NGF,_8HM]IU@?LL^<9V?NJY<SZOA<+#O03*3Z_]VJBVT3^XR6!32<8
M:RQA97VN@$6BC%YS=K I^O5# 9N[)>8P&\98:96QMJ6G7&!P=UZF@:SLK=^%
M[+L*>Y(?*//EWFDC0+N<[9P *?NLY=^7?&K*+*Y\K+DS0%P?4F8L]P_S&M1:
M\65J[XLG61:QG<^7M4BA*=!KU5*0T4R(,.(/$$K$IA8#1QJ*4%KKY%WNAT(7
M6#FRCQBJ>=\"$U*QSFG?_['UUE) XA^M4]-.-XM]PK2-9)O:;ZW2'[2"&*)I
M/*SQ5Z*.\$I;],:U*1PW6.\%]](IUZ8/')GX?>%%_/D1-<D7X2TYWR-V+CM.
MN&;)N 0T#7!AAY%GCDC0S[2?<09LJ6-,7!Z2'L"F6/,?!F2M#UEU +[ZP0$/
M0B+DAV6W'XS0E^I$-"RN^5ZYR9?@ZU[,*IYF],D4<XA$"5-C@+$>?!+R%$(:
M9:=R8!U'LRA&7Z:<%+LX'G(&GL=A;32]Z:<FB,XW-'HGL*4LD6PL%6G(CB)-
M8L6;VB."*BYJO"OT$!#Q=\XF7OH]"^.T3VB8#P[2^E N]E*UHU/S@<K'MRW*
M@N2H-VNF9[[22QDU#W1?O_G]C:+#_FS55@E3\+TC@87\5D#IZGO5]2X-O308
M++FF]V66ANC1,)CC\MO'_#V^S2VI)%?FILN/VO=&QX0"J[LSE<=,YR,&<!+T
MU]L, 9HG+M> P4FSFX8[)RRI<RK4\:5$%*]+"5_9:+ZS1LWC":KSWI/9\U?K
MIYQ*1J^</K2@BF4),N",N8S%$=Z1+@8B.B(B4?1^-&G)+V*0JU>'2U9>0O7&
MFH*YK!REL?'%&?@G-!\]>S]O>9[MUXKUP!<QQ1-.^&FT0:3OMZ4C0Y$K5@8_
M= (C'%K?32DI*]K9VS\1:;PI0OS6ZINBU3H4^(<6\FU"CW(R_J0R3C8]R>X4
M[KE8)QI^.B7$K\Y;N]GNU:2S@U$5V1%!72?-7FQ3G^QOFUC\X)9S]PWJZXUU
MTMD-Z8^-C,LU9ZWXM I;BK(M[FZ8?QMYR*.:*_#TG#+'L/+R-(%(-H_S-J=F
MEYBDVAKH#>7T., &7FL5H/3C:[*^9Q"'X@8II\(2^UPSG?C'+G=))O6LYGBX
M5IB (H@K, 7$%=:SIF_-!ET#VQ\_?+D3T(2[Q(2\EP!+F)#[.X/X@]1URUU3
M&K<GP[@5>0C3L69"WJR%4/7[4\7O4%@(>#$O[=O'-RQGNP1)D=+&K2H#D';\
M=+#1QA7-LU-=#Z]+MN=J?FRZ]5Q/&)U6R0X=2?_K,6RK SC1PPF>N :>6AEY
M/! 2J6_G2W<C\<4$A%-3;]O_'A?8;&%"Q#\D;*Z+N\3?,]D.1TIG3%6D$A\L
M*Z5I*!%<U[__]KB8J1#J$MMS:*CFY4HV?Y@E5R<I*6@9'1I@*[[OK]#OJI+.
MK6F*K'KI^3O>.I[H)#%\9$$S+HZHXEU2!MUV'[_RL2S*<@E4+5W7A=H9C-RT
MXZ BFNE8W!6?90B#1R,1#??S#B(MG_=5QPD Y'7.G%JUC9IWON_>Y3NMGZT-
MDZ^8G_\X;F^D$&@<)HDOQ'V1U@-K",[-<_T[<<[G$?P#9-@"-Q$[-':&=F/&
M+]B4SQO!Z\>ZCSSFM#SB'<#[V5KH:G=SG:\?HD@PV?NOMFFNR8/YVKHR(Z.,
MGP$#F%AG 8SWSCS@[7P>K4$<BR_D5T/R#6/!(/WFV0R[<?\+4^:^1C;*(5<,
M6G@2#GU-NSNM7)M2KK37/1W_??H>RC0!P\Z$>(VX#1:<31C$0)@0C_0$!->X
M1 N&=R,4!P7"$N$!7/3D6_<UA'2$'NR-E:YG*[(<J%7/9F5Q&RN2!6DU$7)4
M%=1#!K\$5E>8GIHX,(G-U56S# R/J+/B+#JSXIY%*C/B=*K3',X-ELXTV>VO
MV'I=90"G=-G;IZN:J/:Z-88'ACIGNKYU4'6.=Q*6'R/'$JRRM(-&UP+Y;(V.
MO*M+C8G(RX;I]O)L29U.@Y7IRVK?!!_GCPTZ)Q:PT!L4&%S@HE5C%^A&428H
M5Z(UW4IMYAW6<C<O)60;YUFTIOK#C_LW?S$9X5K+H52N/3#9ZVB,.D^+I,SU
M8U*0S=))$C.U3 CQ&OI"V[3:EXL?I@P:-![CL&5_[BXY#]4*,)9U+B[JS\"/
M09[I<=^=XOGKE<5$U#S^I(X+Q;G/B9,"[0,U:&9@""DBTHU@?K/2UIO?W&;I
M%7'F0HP9/G=AEG6K+,%TQH]VF#B-*Z!(W7\E'P)K"NL)!,:HD<V@'RGE?H(3
MQ3*^(X*\W]8>3TS#DBK=V_ M1G\+W?+4#LV=[;0SY7E!$+?-*0XU.(9XL/&0
M"3G &UT*!IP77CU%<$M@GU08)M<DH![<J''=>V76]LZ>]Z^*>$+M;3<^"CR0
MRSPHR'=-]A[XBQXY<%^>^[62X##E-U9PI2D7?.HYTS#^465=TZ$I5H[T.[<F
M=CCHHYY[6H&C=D;R\-M/0D&E51$23,@5/+$:H0T.$:)DP1&7P^MH!1 =G'_]
M ,.!/CWM.NXQ"T_E-PU^]N=:Q F?-@WK9QW)([DAA=8%LDM+QDI2S;P;L):V
M?I"APNC#G0&?M3Y?VP,S!J+XL\W>QBW<4MB/@(&W@K_8+2WI#[<T^JB'24UW
M>"-&)U@%2\_ZY@.KF]\.;Z,E)O>Q\4L\H"K 3_+/E&H)#"(6)A>H3M&4(VO6
M.B,_3K0.;XAZOV"XVY"_4+7\ K+Z;/W-/]A_XFC4_ZFQI0B(DZQ3D>YX#O1E
M(#V!)EV#(A'ZQ<1FX*D:O;.YR"<Z\JNZ8ECUAJ 2[U^_0K.LLH;#T.U//[;Q
M^^\$CY>\EPBD.XGS$H)5"\1JHK.,KZ>*',3=1BBS)_9,!C=63CA,#%V/DPLJ
MSS3U5/;-F47]/6-)WK'(5J&].Y:%2DDCGM/I6SU/HGDH\_=\^HA RGW<I>UP
MBUCSC FBIM_[D!MLDN'EP :WT?IG>&R:F06[@LA4*DH/FDHO8VC0;H"FP"]J
M\(2.*.D, O:C0'V\N<:9FW:[ Z 57#0]1W K^@'S;(W_VVY).D?'.LQZLM2J
M:9W_TJ=F*\._3(8:Z%DZ@12+_H++,WYPY (_T7DH/6'((.)5O=J/N3_!I++U
M"\6[[IBS-TMM/E\K5^5KZ]!^.C64'>]K2\[Q;,VH!0=6, MRIL=I2C%$ \"J
M@R5!393;F/*K+UW$&R$ZK8;EO9H9%^MN837CMWWAQA-B1U-GM# =^3&U^-U;
MO&W)_3P"XR1C!,DK3B]2*TQ%*(.!*] G=K#XGWF'-EVP%0YS82*)G7Z][] T
M7#JY;Y?Q88&%'^^%#U)L-%2H_2.^MY3;*9WO9:-=U^6G<78=2C">*H\0WKN
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M5X([FN9H<+>P4C7KL<=I5F=>GZ":)]-L9I$K54BN+DD@Q8G"G\Y@ 4U[G:X
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M#5I0+II^XD(N1JQX-$'[W],BR@96.KZW3,%=R,;: 2S>;^W =WKQZZO].!&
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M ?K"(H^>2ML&8+IU0;M\?M/:$X*=2 Z*XK*W085NP(LT5*IYSF&FHVIW0H%
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MW1[OF*JX$F=2%*GO9[:VZ^%5#'H%!>D5OKIW#HJ*YY*W$S^29.)=TTA2[1L
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M$LT]W/I'_]K?=ON/<V?>'M\E?_/XZ]]OS!R1+%I[ G4*E45OV-+T4*=>Y^"
MU@&:^3&A"1[%9Z?1]EB2T>'51_BFVZ''P^:7T5*8KEH,=XU]@X !EMQ?A,=A
M9/!?H FAPTI*<]JIT[N0YNQ!M@8FE#*&XZ4M6H.)F'254K5BWOUFS'-V*EJ1
M8ZH%'P737IFF:>\ :*T JLL[,;>$0TDOW?;1E'#8LJ<V@9FPN>\8P,K4BS2H
M'9CBA%ON_.YTAU.8<<^6[U[J=W^XJ\TGQSX@*+PG?L<UYI>[>&]&5WR^%*=>
MVBHGG!>CUKX+.-GEF7L Z>*12?;EG.B=2CEQR=MUV],SX4*#LWI\J>#=YYN^
MVC7R'492]Y %?A5;E?9^NLN;3G\,#%>J.?3^>OFP \E;NDXE:A*\H'S@I_O'
M>.16-EZ?I:T+#+-2XP,B74&]2NXZ8J'#G;<E3ASNY,.]!$7G.V)#HG=D.I_O
M&A@9]'C5GCJE?->.=AE;=K+65?YH[LX[=ZJ\*UR:#.Q.W@]QJ=%Q5\B>?1LW
MK6[G4'4T-CG/9?\=7QQO;K!$HVGWD(NYP:F2/;=B[OB'NK@H9F7SI;JK].Z'
MJGTP]G7+<MZ9N;OV^-;=#Z_^UR%T%4F)HY0^5VA &@L8P"Q/5'MWYPLHL")9
MY,H0N*\CGK]\1)IM]J)*9M*_%/*P0OT?U#4OGFMP&NG+@]>DA?A\TAQQNT@8
M"?P422^M(_3".3CA0=RF=<2<)JA"OUC][\>O$<0!-"^C"R,X6+:.>#2$J2<<
M6T?<ULD@+?B(@Z3C-?AJOZVR*!O%/&*K='+#_SQ.OHG!*485X(,O;'SAX*8I
M6<;8>U#\TUE5O2+.H-@>=C8;@>$4D:1@/T!QX28TP62_(#/),A'UI*X6H(^I
M25&<^0A).P_5M)LFA-3A8P-?1DJ_]]*,^Q['JN^X-W:FN2WGGBW^WK=([)Z*
M:WA_79GS^GO?/?DZ)):#P5X R/>W,=PV[]5]3.*NR[;DO<^]<C4( W=PNVTM
M$EM= ISV566?SG;V-Y91V5QG5>NH=IP?Z6@VSYW9$_?L>_>9<@/'TW=?MO\9
MI?;2P.(6)-IR1OUXR._;CFS:EKC-?I,VTWUTV0?4%UA $CS7\25>=#4?F4S;
MWM\NR3/5$KW3EAYUQV7:[( \./3?"+X0BQMEZ ].BZEB$]Z2*\JHPS.Z24KF
M0T-&*U3DK()-!L=5SJFJ5Z^%4%F\('(K(W5B2.<724RKQ;5'1-TF*%ZH1^QG
M-RY=I5\P[%U'J+*=:B)(4D1M*-)?3&]=F&T36T*>DQEMJ0W!E1.0PMS2'Q9N
M<T7/2G_V.CV0)N2@E/[:>C?1<X[;8.5XF:BX]PG722J]PG7^[A9^.#??\2#+
MX*RN[V.4<85+7-4I*KF'$^RHP. %IY/[ASDRWY2?NE5B-WBR-#,ZCS@^ULMQ
M6/-67_'A:5G=#3S]\52Y'\K]4<2I'"-M595IW<#D)_2NM+@<I]?S&G(U"\IV
M>/7SO\N46@V=YWW^_6;?EIP,SYMOKTG+/;!9?)3+V3XZCJVW: 5W$0>V8$*I
MR39;0"H3IS)3:C% U#H-V^<T49"P6O,P:]R#ES_YH5908EQ'4YMQ>VE1SRN.
MLG>]%<CI"TEX,N7;J;_ ND'3ATV'13M%0Q1UM/GE,AU8::WHGSR;BE&D1[(W
M$)# .B*+X, CY:JRM^%J"![\OI1UQ&\F[0=,<NKP22POLFFJ.57!;RQ<\,P'
M(GY81[@F]>*>[T\ 5=6]7\?$,H[IK7[/14JFNZ>>*?-5KO^5JVG$<.\.N@@9
M13DJ19[=9],K:_47DU\_/,/;_77L_+Z3U5[;+^O+#'S8^Y&)[IO+/7W?656=
MTUKE4J"XT0\5^!@E[Z>:G!+1^,0MWK KIBRYRZWZ:-WAO5UM0[.]O^[)U)0-
MWRG3O/';UOSYFZ\XV;'W>>5.69>EMTRG'GWJ<]TQV]/>ZTS-Q?+6@QL[B ^(
M0U.2.+EU1*<G^ACW)?;:E"9HG;^.8&'2Q&)ELQ'O<7*PII&4;B77$,2-2AQD
MW++^HJ%74CZWCMA64Q1@?[H?M[@056.^&/'#X:YS9$8=Z2@I+*F83"[5'(9#
M.%&7>KT ;*?I> ,'">NS-],L1>_&+;M,L]D-Y\;[NLERD,OHJW6$+'$GY-A[
M#*C,0>_]Z2W[*')J.SVK.Z$P<=?9=83PK]E'SV]/&WEK#3(8J?,UK4Y23/7H
MC7NK,@JLP%?H#Z<C3AL9%2A*9F=/8^4S3AGPZN/W+TA$W!(<O."EHVR>ZGN2
MJSY2<-F!?S]&W>*P^O4<-:YYC]%O5 _5]"SFV6?/L\/='LZ[(M-2#ZL[*@CN
M9EMO1P?^+HHF,,>^+;F:1B\=N#C6+)SXT8RCQ2RY;MJVY="FW[;,'/FR+>GZ
M(<D.TG%V(VF! 9"ZZ,V%"_PJR+'/"Y186D0*ST+?,-IP$$#.GNZ_8*,QMRJ#
MVP))<>DR80>NI#%H>@-FLU&$(T_Q>9YIPL#% @';Z7@4\>.+4F\@2V"S=I,0
MJK\PR65G8.1H.A"9AUP,!AF"/@A/N/*(X#N\?)BT6;^3K(%_ZXQD#D(7QR;'
MH#2?VSTLQT%?R=LLU];\%2VLUPWW%GQ49"HET\?L^8)V")IN%A>#1]8]C=-)
MJ0HL*K>W80:W5HTRN5'VDDYI!PZUGLHW"HC?&E$JX5A[L+>.B/IVJX=WT5"S
M\&G+A=#A[?-.\BYW)GU;S650QHZG]JE69U:7<G;T2GC(.GR(QK,T8F/@K9=U
M,A*.SVI\D?WP-BOO8TBZNG5JQ+[8"XR_/O_Q]O3O.T^_-IE4W%'?(@BL?$8=
M8D.ZQP?C3,<3>(M3%546]\*YR+%"0=80']P-C.3SQ'PE]X:;WNAS!O0JX>8$
M8)U&XG.V^VHY]CFV[IO ?K872)USBKP7^S=J(_$P1.<W+[( #P9-%KI731PE
M(0FN')2\V* 8D51IFPC6$+)B=AVQ9656[R64IU=9@3<W-?)B,(H"'N?QKAAV
M-\>RB$5">VYQB-^5HVX)"^?O^V$WD#_L;7S^%)]MXI1WS)+)C^#OPY]V.<#@
M@?*,GH=O0/6HK;=3%=QNL+ZU'#IUG[\PZ[CO?N&]0N"KT7E%(^:I=[IVM,@B
M)R,&-YQ[\5-&EUMM2OF>'VF""IGX,(.S#[\\NWQ);V^V9LGQ5EL,TZY(F=T6
M5MB[YWGTK<T]N#9JWO<"T;9/^DV81-SWG]2[2H><&?BC%S6C8QM+-P9O^DF=
M91\1=4&AZP@).0C#P<K"&*!B:>$:0!'L@<KYF+$/?4?S3H N-\#(KEI.DE9"
M-]&"#EI_;7H7N ,\WU0[1LLCF</-.4'1!=X3]^*%&74TS[46&I)@ @6)Q>8'
M@$P7R0:&)_9UX7(P32M]/=1DW_M>@FF??I'8G$$.QK"VQ'!T9]'?!K J3S,@
MED$-UAW\%3-;\'!616!0@$%MY#G+G ^Y_?7[6\./EU?0+UYL?MG=57O0?E]U
M$;6:UU&JU9,:DL((>5:;_JKM=I,/_V(_U2 D/\)[&?27]9.]]GY?_;LJ3Q_;
M$U%& :AJEQ(')PE7XP["_I+HB$];5^J_5]BKE2G-,J0#3[FS!BN=@-=6*N?D
M*H9^>ZVF<I(=]_S&34W)3==*A^;6E*')1U(DSGWL,ZV_*>5FHS\Q"NN(2#7J
MDMFB;F5'2R:[NVW_N.[:^Y*&OOU':W?Z25<&:5R_%71RSQJ*L_3II>!DPUJA
M2 E_@Y?:<+F"8 M- JHLBFJ-C1%2"QHXP#%5#K>T]!*I OGD+A02MO[G\_*0
MATOK=5E+GO9+*E3L,F+FU'H^KCE5_4&2Z5]TC3-[\5:GVP,5-:9T;#[LWW.0
M(&N>0S7X\FFA5QJKNCOPAL DU<=;=8]9_@5'CU-[E^OCO3N^NG$O1!LJ>B#3
MF$%1]OIO?V0V@?':*IFIX<FOSAH$E1MZ!0Y[OC/@EKM'EVSF[FEZ&E1%3P"C
M;]Y\T+!-Z3>'70B$^JZ\5XB_'#A;U\@@<B%*>+@;4# =KW9N;A^T487#(5<A
M&J_#(=Y(X,M&S^&V$H?8BFC<$[PJ[^7<3^H34EADFSYC$_!W+:^S(J*AKC I
M/"XJ<%.NA-#T!6R[=FL=<8Y^':MFHS%#0GYK_TC; Z/6GF%"D1N+G8-9-B;0
M/P],*68D+F7">FCG)WC6T6&:5EB@+(3C%1]:(KUHI,O-!.X<;JR-9,1\MKK\
M&+^XB-?EV3@M*F\]B)YJ(D5F,SY(2SL?0V:^\GAU)3K5)(;J'C>BJGPO:*_:
MTT:#LU5<T*3]L:@VE1JH=9.3/9@W/LS\VOCD>Y"A'4[>[0,-I>FA\FSXXL=\
M-?'KM%>\F+L1\4^#I@.O/RH3KBX_Z05D?7R.&6[V0E0;2)S6/K+IW#;[WW-E
MC4E' W>LW<&<)V>35.AAFGZFR%F;0VME: >A"W%8XP1;&G8&24QVP]\=\<'<
M)84Y.G!]0O1^L#D5)U(C'&T=K.%>P?:\T/@QASRC$FGA;*)Y9I>(4-E<-,#[
M]N&;9>:W#W/BW^H6]X):&TN=(M-#]HD6>F7ZT>YJZXA+ :<K7]LF^1_J5K/1
MR8D_)IO9Y=WEWN7)=.M^NC?O=%/ T<?:6ZN90UUO\1']Y5FUJ0RW[MVQW(Z'
MGLH80ZO7^WQT'LY[,7AAO(BS079UZL/W/1A6)A>I^LXG*S-.,MWS_8V-;!-;
M$DQ\X9S.#WMV/Z3=!:[_+Y]Y18YBH1T_80H[#;.01W!;1PQ<V4JO0_[OCT:&
MR6+7@*1_$<&'Q @HYI%%>3.>:Q?_]4XS+O+1*)S?0A7N>D*:];FW1ET.A%I"
M11_D M8159?W_7HCQ*TCWJJ;4X66I+'Y=80+7=H0ZJ;^K<K_F6:CB6\62?F$
M<-E9X@P5+5(D'!H2>[-UQ%40*N8IIZ76P4$)W)=X5T9UL6$ZP?*LU[R'9=$C
M%:M@>ZG-FSHB'__Z/4(43>>*#1WG+GWY-E:-Q-L+B?UT[N@,R4ZTHS,$O<%#
M-J-K.GX:/3%A\+7=NO3;LI+N[2^-0Z'I;[_# 5OC3U6]>9OC>*M:[>"IBR?O
MZYIFKCJ=^U3#ZO87-,G8>3K*=Y]OO!\S-N)6,/R7OVV)0\O'=_M:(@8K(VXY
MUIR9;36P=7BKZ ;3'])/8O[-*OK7$3*C8L+M%N>CV_^,R*?UH.!+=-(Z(F _
M=545#!7M0&/7$1]<,7T-&,0ZPO,'<E6&RX8=H<A>T6-:V/_KF<DK@^)05D92
M(?$4Q7^"O_R A7O_6T_K;8X:TQ%)M5:$E:J!$C]AI<B>;>&!>V_XM7XT$6\4
MVDU_@@<(&BQN/&VY;IA:.N0[=]$AZL6L3OC;>P_8TH9>*/@ %E94%=UVXB-A
M.Y0:"1R_"]+<S+[*()4=#$[=B.'4F=SVJ' _]=2VY4NMP=%'(5+=\^H];K==
MC/5-E-\]'"@P37OX.6A71;>_17'.\:-Q7T.+X /)W(,=%>H&QEI]F2)YX@ )
M)4)TUHW#BM!+OFN*8$J_I?XEJ*2MV-'4F.7;-KBCI7FPDNY7?)B^W^^@2=W9
M:X7GA^YURMZT73LLJ%RK,*-H0Y6\ @K8QSN!DB?@*HZ4X1D]2)YZ] I)(>Q%
MK>;8K%7S1'EK0\M@X\]4 [/>(V$W9]U-[SVNJ&YHN)+U?R@Q=)X.Z9FN[2KL
M04'9-N+J\ILZ/:RYCDTQYG/ 5+P[;?_]\&##(6 ^(]1/U=&FMZ!@3TW+E2&F
M!_EY>:]+8^46X9Y+3F,]DQ??'DPML5(*G[X78'4PO.UNQ$G^A4RE9RNZ[]][
M(%T.O4U1[QWO*SHU=&ZMPHE.3/A.3V$WXW+;)2Q[V.F!!O6@?K>I.%<U,P[3
M;ZQ*LBC*\-'ALZV Z=4F9ZM1YZ&H2B"GM,@(#JKS,[ZO:J,]:G[%13-'[]ON
M=_533V^S)6O<:H[*/F#JR%\X>UI)NB%2X:^Q0"E]_?OW1^?T_W5G_RT$K_5!
MH2:UF=1K;UHJ93W4GM77ONGT#WU=Q7E28Z.0LM7]S:21B2;2X8T[(ZC,'BDU
M5.OIX1DQ<G_*4+\O9@A8KO>I1(ZF:DZTH6&/+O@SU/;TA5ZM;]8!SWW*\T,7
MXV/4,CQK#W;E'SH5-^N1C;%J3^)3U0D>[0/QJ SM74,P[DH9/M06.)\3SU/?
MT5YX BA,VU'$_@-8*=O64S_;]J>JJKS/GYZ/_BQR'F@]&\$BBW9"2[RZ]E(#
M*(_7$=PSM<M9TP&8BTR$^_WGI,O"]IK793WZ57_LMV)CD[$IZ8-O%;=?>-6@
MX+ FNXY(C5Q'7!='H $'@MB5I3/X2-%A^W\MTER:\CFS-7+#&^@V9;C,O0"5
M=Q6J0WE7^ S&AW_\^KJPOM)S\-'<48K1^=G.-Y8NZ/8?W(6IRJ;I=]\-A)>/
MQK="]+20Q4IG!X^2P N30H=!S_-E!C\<MSX:\G7/%QT%]1?#A2?Q+"Z#\#L8
MREI'9);NA+!ZA:%E?9P<OV[O!%_SJ:S*&J>01Q$R1^<T"@JC;_Z1$?0$&^#;
M>)&Q_9:5K4:=\>@B"OR^.LU,**2KHB/C8_E(63RF<VK/[2MVZJI8H)DQ7]$!
MZ&54'1VA_3E"V]9NVPK U0J!LX/1^+J&7<6BT?_K6GRM++U8LKO%G5OS[8Z6
M@U=,)7=4H<ND<?IHS5P+*VT@/M1;-K7**N=_4/?>04UN7_]HC@T%$95>H])K
M+'0B.8J @(!T""4'$2$@34 "!*)(KT>J4L400H_2P4 $ BB((!"03A+I+4%*
MA!!^^+LS=^X[Y[QWOK^9.W?F_2/_[,SLY]EKK;W6Y_/LO=;R[RD6BYR3EKOJ
MMYAO0;022O\Y6?7$DFI@B/1Z:6B8?MD\5[;42,/+(O(:;Z& =*^ 325/NH>E
M.:/<ZJ H'.*9ZM1;@72BUV.4,'2(/F,T?!<:>6X4Q8^\Z>R*<4==>"3OWD37
MRRA>&N&S#DJH%UA;71N8>'\O_U$_9:.3$T()97J^I\_$5H8K?:8('P+X"$1;
M[[<P[H9X%=U&8WTGM4?'N7:2*(Y3"IMA.2X*FW\(L*6T'@+^92^,K-?LBQ_%
M8;4 #ACGM$<!S0PG )U@U'1\0V!OI[$$T9W<81_NY%B/*-_%'6OS7?/Z8#90
M)^_O\^3BK+"/^IMH=R-+1%94"<CE; (8+:(K2W:48:"(6U1HXE+WN',NW^T,
M0W.,H1R&+U=4T\P\(4FE%W2Y?YG@J3 A6[(X''W9,DOPX8V LE+6>G/:5^&H
MN\-EDW+%6,'AIZGI>8< #?!)NAO%K;U?\#.=G]R=K+)Q$K%CN_TJITOH+,W>
MLZ?URD]( U1XS&O>$QYHIE >Y/?XW>3U7CE]!;AXN3=#9^<Y@SS+R69":XAH
ME6/T=H2+#()#V3IO2NL.;4MX<H(H5K5ZIY'^V.Y@GX"1?(E-(WT5YKGH-:=;
MB+37KJ!=KO_,GY!(%!,AHD9/JT[!:,;=;TGZ]ATLF;(%$4CMSH6<TK\->I1O
MMO@\P 0:35C_F-O) "E7@S?CX]$Y/[8L10UNF5,5(K(CRT-!'K.%N;JZI!W+
MF^5)>::NIOFLKZH,):[$(_56(J7I;!^M9RX@K;@BPA4\/U-P<?F\QG^B'B!F
MB*4ENN5*'W!VM?=J//0M(J9_K2N.3_;Y^7@/G>$[G:%)B"34\:\)TO@-2,K
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MQ;XPF_(\_.9!-E(>'3X $U8!/9OF>$$%1FUS  66PD\,MUYV<&+$'R&;KQQ
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MUMP[Z=[U$G(B!IIG.\AZ>OG;=LYK<,Z1'II?C>N&7ZK[MBW_.KE 2\Y^^9B
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M6,N7HK%_72M1BBH7&)?)5^_,^=4GB'A!1;6_KCX$O*7O'V%"<C %QPJJW>!
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M-2$J-Q%GZXV.WJ=3]]9_^<XL#1W4W3[E>B>3&#2&VD;SE?F:C+,!Z0Y@2S4
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MJSM\"!!:$J\+1N-PP XQ(,,F32^7BKXXC\A1BM7T;*!' .L]:3N722XUD**
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M$E[G-!J_W_I"4^+XM[ 23\%@FT:UH +RC(]H2Z:EX!AJNOV#&/9(X^J<&.;
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M/]Y*P=S(0,,9E1,]I?:["BW69E7LB Y[DMN=X&& ";N16IJ;<4I3:R8+R=L
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M1Y%8K,]B6,I6X7/"M%4?8LD8],;O78RR O*1(23!#4>/=%O"APK]\<X^$Z6
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M<_&L6=.XH!?<4G:L.[#R7$E0@4]HL)%#D X76Y%S,CPLKF+-V^/KZ25<@VJ
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MRV2S&6O\<EA_RHSNR9:LT@)O>P62 _Q>4CZL-O."7)M,>K\$O9QT'Y]*#M^
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MO";;H\]:K??=WBIE;1#8<C>M@!7H=R<O(TM=,RP5Y1G$+O!5\!LB#P668T_
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ML$5%Y7U\">C ] IKSW7OSOA3/+S5D!KIZBCZ<!YG6L)+E?G5R]P:'7CT3CZ
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M!44'^JDQX/V;]B%G@EVRYH:JQ9;-F14N>A4&TWIIF8MX'?I_:!-<-_?]W7F
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M*YN/&T'L@(?P]N$9A+BFL20<#$/CY /=U>P=H>+N&)MVF*J)!6#(),2U'&3
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M-'=:4BJ7BSHHKCQ=Q#I7\_3!Y!\]5_VV 1JW&1R!%O\T"04>>X&U4@?(*>*
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M)<QE^-3<^\$N5HC0Z(GPR\^?O0,8;>$-&Z-NI;XY^NKZ]LWAO6ZHOW[F/B+
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M&)?B;V><&D-LG2BU\M IMVM0.)KKZ Q 610%K #O#5@T'69RC032AWSF:M@
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M[K[-ZFUQJ%8Y%*L3C$ODQN0:NA=NBMP;O:>SJ2_5H>(1UT/'Y9%6(:G0D/#
M8D95<'N'06IKHA2!12M&DF.)KT+)>&,N:A-(;!ADMVR() _FM-:P6> N-K[D
M$'>(N0G<-,=B9Q?EFV05^?@%?SW3;>I)JUQ.GG+%_R3Z%6_60]@LQH-= I)M
M;Y5BX$G0'SC4+%W;8Q;C%>)QIG<&;U'R&5.]-'A[P#KT$CWKP-M=C[P;-FM_
M6CYM^_KTL%A%\D*JCU=FP[]/._IJ\W8/=\2:(G^:;.69E "KQHF;<8ZLP4;L
MC5 2PO@Y:-<BW=*_2%:L&GQ0!=UD4F@1]_VH!18[K.7YKH.$$[7J[@)S^#1-
M\4D@8^9&5C(^AI<:WJ*KSTP:U#Y\^7O'EBG5J1LIU<)K4R^]?;1S2#Y8SS-V
MH:M:5=)5PQ9?(: JW$-GT<(R_^\SKPY[]C0Z.]\/L"S;MH&UM)^$--.PUK'\
ME-2=,HW2W/#LH^G])PW9O/E]MNAXZ<>&&)0NH)*GKS#H<*"H,/DJH3_\RMCS
MYUP]A]3#K[O3U%VNICQ_W99.F_:0;OPN\B&T$59+4I"!,L@Z'%L8!]IQ0S5P
MH8W9# H/IH@E'.J>J2I5DM0%\'R:R_OV^5D;YPY4UE2]F==7^/DV3W-3W%U[
MJ4.):)T<&-=9;Z:\_,:X&&^ %'2AU=_@NL@K%(6HGRG2EZNK"%%\\<O%UTAX
MTP7#_M)-FE*UYQ%&KJSW+L6W/Q@.]Q:3F@JWM;C@G^<.T>NWYDHY#57>^-/)
M3VPCBM]7.R8Z1V*<*\^<3W[;7KC!_?%R3I)]3::#=#K$;)$FMM"8P<@@=G8"
M:QE$H=Y(!DG._T=Y\;G<LV'[/2>=%_L;R?M>O?^C=?OIEL(OZ?;;U_YJLS;W
M4YS;FG2(/M.T3BXXUGI+_A"'1?/[.F>D!VDDQ(]2>:W-<XKX7_L8J\3675::
M8JQ HT%!.]>:=ZE*8-1ZHRP1PYU+Z )O*(0.EZ:./>Y'B#"5=KTA@3Y)4ILG
MR8V\,V.D=PO>785MLSJ(EMC[1QBZEUY%&^S62C5>]C_BDZD2)LTH)=%(5]P6
M]M7<*XY<Z[K6VP1?5_>Y>#Q8>#4I]#+FQ-&/>_A28VDW["6L%1K'W,)0%%M+
MB@A;1D HCQ1;15X#,GKLP,)0KL0O9KUOM3F]K1!;\WO7E);YTV>_9M[(O9\8
M&6BYJ_-EI-J"<RUW#MP=F%Q)WBI'-&%Q!1C'0ZI/<397I5KSR&1F\#%B,UK=
M=)*@B+LM:D9OKNQ0!%FN=>EP* [;R-C55Y5Z#:Z 63D1I-52^B+8,BLA0N*W
MXGGYG,1)P)DM%>GB*%Q+_.5*R1.KC9YBTZ1IUJ!S.2_$GV=PVW0(MEE.$"LV
M>6\*P$/-A]I?Y,0HM(1CV)V_2349><?<?LG('.8G?M')X,Q:B."?0'JCWZIZ
M\+O DMTR<HS4R+9:+[@O@ZC40342Q/XA_.3H$N9:7QS:+N8<>KJ? :>_JLUB
M:5B>U3B%;=RX+FMW#T0IG'9[/,O*+B?<.N\@PRJ#_^?C*0,Y* ]>I5Y'>Q;;
M3&3OW5J^O?Q*^]41KZOOC<\'#RS4VM# ,R)G8[OE1]YSH2VP37*Y+'"FK1)[
M2!XB[+FP0>*H#8D%'7"5:L@@*5:Z8+@7F/L"5\'3+02BA4E]<Y'0;=B\74!1
M?=E9[RFKS=U?^ZIH6X.\=X_%24NQ_))I8W>V2\],A(\/EGP."$Q%CN8RX)+'
M$>3!J\2A8X@C -I&0+@E6/E(7"OM7LK;+DC&Z?T"[/NA/F+]0M>UF%3B%FDJ
MV.[=G+2G+QTU\:%J10\QO".TTL54DZ/(GC]E$$S'P+70K6#M6P"/![4-4ABP
M!AZ6J0-Z6>T&-:ODJ>Z-,QE\O]!B03#LMBT7#J]B-V8.IJ8P=KWIVU%%LM8X
M558D+&L(SDI&!J,&6AMA%:W)S. V2N+(>C;C)]"H<; C^3LQ0:K85TG3  E\
MQ\[!DR:SB\G#JZ*G8WP\LEQLNGY?S#ERL?X-6_^.O6?<E]M['95O+>V0).=8
MN!?N:83O+YSK+0YPV(+^]/X;QLS9R*N4UIV['5UOD!TP\N72>+\2K5;K6F0
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MADD Z2&(4S :1VP.R"!![8UHG(?YRJZONU0AQ,?")'Y*C%9=>5I2"%WY,7'
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M28#7>TGP(PF &X#\1Z;>2( 3:<*W$F!M7BMBC(</SX@^2X!,&V@8]14.(Q)
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MD F3$,.BE$212DEF0L 398VB-HR='IP-?D<U,3",9^_,^C>KW)K*YOJTWF[
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M4K-010:T=VU)E#E'E- )25D292937 TW 66IT7]K'7X=''L#>RB>9L()8O
MB"AEDD@6.8+I(]9(D7 V6(U^" $/5Q'N$<Y@IS9Q3DA0EX1@6.V9 =:ANR)B
M49C1B-+A(MQ#N$47[\S0-F27Z)*E5DL9<48<5VC\T81DRH$M:!+\$,5B.$,E
MDB\*47R8T,0EK@RC2233B!&=,<!=9Q6>'@L?H(:E$<_2(1\V.80,V=6<5<.X
MI$9K6(<P4@2M1")BPPGCS(9)DE*E!HNJC^?__0Q!>!#=;HY/;;N;W/8-[$A8
ME.($>!QLW'L?RO9HE4=\M>V%17^\)..&Q7$, C\ACG$@THQG)*,"5#C.J*8Q
MUV:XA:P^&VG<'SL-:.^)&;?A1O\%,K<VN7Z /:?'L559FF;2J)2$3J:@@B<I
MR3"]F[HPXZ"6\U!]/]''3TL(#2 5F(DL94Q:(AW%8F&)(2I-P2 !E4+:5(7.
M#;9,PW>W8SD<)\2,^A3/H]Z]U"=%PYB#&IN$@H)D4@D182H) )FCD92@50TV
M,/?VG4(?_H!N^ .8"Q_[4'_+.X;,2!9+D$)A$H=8#SXD,N.H$MN0<Y9(,]SS
M&H?@'%J1P6C!&HE,0C1++9ZB&8%E JS%-(^%IC0"<WZHJ[+V]WR.2)88_LI#
MEX@8N#9-#5@&<815@2@GH$<"Q2@1@38P5")YTN>$P57]YYOMQ>S9IVFF<,I8
MXK=&$X7ED^.,* EZI\:T>0NR/8L'NS7ZO:?C/1+%Q%(EH53$<#!W(L<<&"D6
MM$$6)DQ$J0B??!7\QS^0\I&6-HVL]NHAGG(091&  :9[N9 :EPI#+1V<H/EJ
M+^'B?+[.X?P""E*69I81Q@SF<#)05915)!0\890[T%0&6\5PF2?3[1;F8<ZD
M>S768,)^NZ?2<4&MU(R"C(G1]Y!I(EBH"4BAE&?6THBNO&K^%SM>.&'+X2:1
M2"T,)RGN]D8:\5AS2Q3EH3013Y0>;.[-%VWT^G#5TW)D]D#0@J6&SSV9[7@N
MK0ZI2/$89TFB*!.@0FM.$D,3P7!BT\'5)QA\3.KJCM6]XHNC(:')@KZXV4?O
M!6K&:(!M35*=@;+%8T94EL:H;!EK=4RU'*S79S#QJ"ORM=C$&B,8T2D>'Q5F
M&1&IUJ# )'$66VI"/EC(O6-I>LUSW.Z;/2D_:41#+EP$+**=)9$*)9&)SHB+
M6<QC;CGC3SV"XW$.IWT<K0Z64X/N!L8!PW-/\014&262&"RSX'B8N6AP9L)W
MFKYT9R81$.Q3S"2*J-%,)I1H1160('<@@VU$N(P56!Q2)_RIRN"' ?HAP$B<
M&<9%"'H45K1AUA 1@=A.$I;P++*:#J\2Y."*,[+%EXXM<>F2F$E0JDB6 D5$
MVC@BJ3\;(3-*@4P7<K!+MPTMF'PTQ@V%Z6[B[H4>C8TUN 70UE;UGKL#UZO
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M1!O5[8-@NDW/26=E[0$.G@:5P-NS%NU@4'?* I6#6H-F\.^Q/Q-XP[\B3TZ
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M91G6];G7;J]5T.1OMMW4 B9'*#)SAC_N64.[ !G:=OOG:'_V-#JUQ"9XYK/
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M7%RQG"=?[L^BF)LWP++33VAO=&J.LM-@3>\7+;SN<=,YAAUL=?&Y[5;Z)%(
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M_@RABI2/83UXMS1.C_MB[6%V+HP]R+D/Z@@TE?N#*PV*4">@!K%"TFL0\$'
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MM#M3FV,)7CF2BD%[*AJY&V)1K%)&:4ME" [9/A4Z"M\D[#0F2S;+1BQ9KZ?
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MTW0M_23!C6H<!7YYNH7O*0#"PU-F&BR4VP<5N@$E4[=L3YZCT2?M.Z-! $^
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MC+Q#68465 &KO^,W_UC-OA9?T[CPA!5:0=/'T;?ZA\4@YT>/IU:3@<ZWCMC
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MW5%>JZ+E[$JAB*&.7^"[O'*SBVE3DMZND4K(M7T(<U1F&2T_0]U\XB#T_#F
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M#_$41A+YM&E..KUNK .\<".W8^U]L3Z+#9:F<C:/((&Z3Y@BJ1@"ZJPI2=)
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M@M/-BC&0M8G!N5SU""K$H3\_J=9WC(:$F@A%:F^UYHR7.O_X2U0!QQD^=23
MD$4,]VYK;'<4Z'K4*VGOZBB!08(3+./.N+V;B\X>SL'QABYUK^&L$Z,G7?*6
MC]]S)_#8\VIGF>\]VA=NUFR>RRK[,Y3S>=)50@?&%W$?89PCI5G@&+XT,C:
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MCN_,/9\S9KD1LVK2<0Y!YHULZJHE4?[X:PUY" ONJAK%JG=4AB.W2-F=_=.
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M#-T?H,A'M)4&;3YH\X_.S?,TG\1"/4/F0$J"9*)?2$>NO?:%6GP2PA/?VE0
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M&#G^.[)LT-KJ(<TOB^Q23CAI;KWRZQS%9<H-^!2^S'W"8P;^<[LZA<';,M>
MA1&E"%RRFDG;;LLPEJ][W@*T_0C,VZXZ!"SK\/"APAC_/M*F3+Y0#H2U)3<O
M1EW\7+HV2GT JG8,8R+T*4K #95T5Z#T.R>9?T._FG)5,)O;BQS5CRW&B9T<
M\:!IVG;Y%5JFS@IIHL(4470NH^ X>DJ.W)40+,LB(P7BCV/N;1"80./ !F*;
M 1;O\4-K+\B?M,2+>P. =H@W^E+,++:IGCAH5+O9A+[ _7GO7A]3N.VKYOI]
M>BY$[D"1Q;E$'5T3F;<FK,@?:3]D1UIPQ/8.>D!,I+B-.QJXS_Z_4*[DL^@#
M+YJ)C'04? ?SL?1^5?0S23F4Z2AZ^?))'T7CMN?+E&FADA9W%_XMH^Y<5DUY
M*:TO8N%2NEH4K(ROH+;!YY4F*9T1X^AY =JO5/D]:*4"]EQ9IU%[T:<+U'71
M",C89)$ VR4=0;0#>I9PV'SM(B1?2F\<5E"L8"E&LJXLV?OO%B3*XM"RQ1\]
MBRLZ@2\:&F]T=GA_M.'L'CTZ/#P5;G6L.?D69K4 884VX4C)/7AX>GHO.CLZ
M.GAT>'9?*A"O#(E#C59-28E*>+KLZNIJG,FBUA_&)!GB0J1>YT=<!5A*$1ZY
M.Z@BC;F2GFMTN91?R@3MX^FQ;'(X?XM^<2X=%]\:+B"EISY'1?W1X<$O(N5R
M"TV9/7:86Z,TS$]/2@#N1II[8E=E4$A:+[;?!26'!CPQN_T1I(3;/;JGH<YO
M\"B\<^P:C/6<]<.&YM-TAE9KTC=T%,&YI=,(U,1<_*MM+$J6;BD)_P Z)9)C
M;2_.6U6XY(II$Q3+0OU>D((H?3'JLP^B>L-N4OM[?.&S)W0\^I,ZN-'==#[E
M77?TZ.0T)(77)X27V7@!/95L=#IHT.Y =@Y]'-JTZ\8:L9JHS'0\+RY'J@D*
MO;[ST7)F>>W1/PGA%>B(+A17]*T-LU)YYJBFTO?Q_#.;<UDP"B];!Q/X[,EP
M +6,=VY[1&)@N[E#34K/K:HU;2U5/'(__G_2K0S_>J@J&L$=EB5;BJ[5W&[]
M]6P X:02N"1DA61%#.F;X8CCWEUHR14IRV5+OEK'$"2W*D#V$A!;@KJ1N\*P
MKN(4A_(^"9>DF'%NB#AF.Q(#*;)5X&@_0G/)Q Y*[3+(T:8A,RT27CERZ=G8
ML]7]UCU<%5DZ#7IK3DW2E$9W.[/%+EA9.MZ-<]K9M>BVNC:T^"&GH?^]X+0*
M[@1FR8R\4_H3]V1D_R"XHPR;95J:H9:%4$>A#_M/99,VQ-T)W>[$0CIT&ZNB
MJK>H;:8L##4#VXM7,:-"F-UEI(Q+H21!\P1+,YAC;N9_<OU&R5Z>*T3Q;H9>
M=FGQOC2?ZXUFYK?QQ3BZ=D&'<\:U8.^00C(EN;:NE 9VOM5RR7FG/[0M!7V5
M,DV7;GZ#/JW:A]2@07E&5DU!7O13>OA(#Y5JB1HZMIQMSY_G3Y^<^V9SSFZ=
MZ3.8#:D6SN>X;FPK9?]VUS9XI($EN9\T'T>%E*V2*TA&(6?0R+)KCT(*=M<^
MCED!BS*)WANSXJML_\@1DM,FX]^M@&UVM+.NJ^BHU7ANQ"K]P/6?I%&BP:8]
M:L6FXKNJ>+F2![-QSQ1)EE*W$!^_TV_4KM,8O:UL[Q&W>-QMQ]+/KTKN92_M
MZ2UIE+ <H34<H *6,$JICX292/XB7(O2Q*<C$X$D>(<)RSKR!K#Y +Y\U\"'
M60(%"V4C8[A!_BC+*:U_W*0I<7Y%5F_,5(LBLT+I*+2=5J)^?7I>68FBE2B,
MA#QB[H2C]F?X7"OT0L@DW$X("[G?B[D3=C;V_6/EBYD*M;*$QWC!&VE8_;/P
M]FICF9;@O_GY O_V(\67Q6X=J^@EW8'VZ^?^(WVGK)?GOE'6S\45PL C^V7N
MZK!7HS*M>Z:P< KH<?*5]!ARIU/2,G'I/0]<CED=2TLK=V,993Q&R ]W;5P"
MS$&NB;0HY%S_S#92]'-FFR"$&J<ER^_:?/GRM)19]C=:P58![>2DHH^$\N?
M:^J#VB%WO&J6D:B5$<<'1<]@J.C;O$W3.+9ZD6BF_J]U[VA#!Z%D0]ZQU8K8
MDY/N=!9N #?>+7#CZ0!N_/K C7?9!N4G?WKGA:<!E>,;T?M_DYK\S $/&?!.
M_U9[6NL)F00^@;4!8CGTR6CH>AF*RU$+P3>(;'DIT=SD.+>SM<7NV.:0FFW]
MX8Z<K#2$Y4%&_L&!D2Y /(R5*?<Z"IO+WR!$#[YK'Z8=$>H]-UG-/V9A.< ;
MJQ_ [PU%OR%6_AM.QB>0V)V1LY/QZ:.CT\.SP]/[CQX>G9W1V()"17AF-,S,
M38X>9#Q'UTP*U#"9SO>='@Y.-$>D^%WGJ;NRV=J0 @;&6K*$  T.U]:V:$^7
M0"_43<*A8T9[I$*SR\W@7_J[@D[P>S^]?%,!B,O/<,3YFUX$MB#[AJZ_63 ,
M>3G3S(I7WGJ2LZL?^]W2MF&&73/LFB^R:^CIS(&JV\9MF;J4/O$*F^R!0TU_
M>O5F$-!!0&]90+D-KP 0@OZ3B+SET8M?G]K"'HVO,()9L+T(Q:J!I>U06K)=
MJ6U%DC$(\2#$MRO$+C#(0$_2IO29-8? .0+&#3*E[\/^WHNW/^[=TU_"'&'X
MA)-=3B&K6+?_8C7V6GHLI#73S0^R/<CV+5L0TIK(=OR-$S*$$4VV'?D.M%LL
M4"_]BGC3]'8T9RW#^PD,;[7=UZX_1)SUV]ZTXVJ?2)$W^^8IDJ1Q(?*TM(T$
M WS!B/-ZMM&,1-+CF:G7C*9.^;_2$5>\ 0-L;8Q_::K#==#M^O<^IL_#!;Q9
M8 ZH2:O,L&F'3?O/656_XJ<2F:].1L^=8IR,5/AS%1GT6];=?Z/](=V6:"\V
MF51BMYQUV]JYU=)&-,6P+X9]<<O[@A1_!<2#-#,*(TJ@=J.=0;;;2H^559D6
MG L.=DR8.Y;<KD500*:U/R\7*LX<D8I4,DM+J^T'15KICX(5)6%'6+F;SV6O
M?*07-*7QJ +_OE&T-/6B2%P'1AS/FLNWIS=W4J?3LM0FQIL#<L31TC$2NQU<
MB_D<?9_H(9EMUBBZ8-B[P]Z]94/4=7YC+ 9#?'47M@Z8UL&"\.^:O2KM\27)
M%.[LA_T8US&"7[;MG#[/;_A!K >Q_CO%^MQVVO.0\Z4QMCV@ 0Z^UL:#VMH2
MQ*4HT(&T<W6+[1%IZUOBB!O/3=:,82SA4$V#AW/#RD',!S&_95X*$FZ-A&EF
M33&E(99NM*F Q;58Q6O;<X)DL9A*JT5RI8&7A<5#)E8>)-D>\UV#3 \R?>LI
MZ1!LF:^EB,5Y"6'D*JPYY.B14_S!5=QH'&Z)\ Y$;]/J??2,&^HZM/4KTO9S
M^>>%]M/E -K;9Z\N-(!V[?,!<(;'T1ZJ)LK'VW;--XWT^5'1O"YVL;[.E9O2
M$J0@@X!IR9%)Q>-O7L"PRFK3B+5OHETR-^/HU^[?*AN?"5$'QLD)AUW<VQ9F
M"50^XC4"HM=F$G7Q ?;$VF* EXI+X*)>Q':ES+V%H_"N:5O&)#*D'>KK]%+)
MTWN_6G#.5@S[;'CY1$[Z\2;30EQ;&Q%"DS<@WGZ7 <JQT[#C;WI/L0QT_+05
MK2ABDEAXCF'6MH[%QA+[167D&:%84-IAF5;,/R8#>"WF,KR_D20;7$FG[[(-
MUY"-DQH.(R/](=P^ZN\N12JBH&D<A<'6N$T'^.+7I^/H NGKWGU>KU=:/VR;
MCE=!]3'=C/B0S A9/N/H/+>_I(4T'\Q2:DQLG_N@J"0&2I O:W)7RF&W)(UW
M8J)JD9+-P^A#KLN7LB,X"::<2A$$($[<M0 81(Q9#B#X$NT$I<P1-B1=Q;>*
MMUXOBE*)<EB')"06I)2826?CF<'P1'V*QL 7 ZB-I93)$D1 %4 "3@YIY=9V
M\DHS->FJ#D"9(YJ&S*HO#(WLBJDB*CN?@N/6_VY19%+6G6HIS\GA ;U):A[(
M8DR+A,MHJF:ZP'UDX8W<XK4$&R41&6C+<(J86<J->E2W2A)*@Y2M(J%S7^Z,
M8?.3LG16MT?.HPQJ3SJ?) 7T<]"<O+,/HF_@$A94756=1U4R"3<ZZR!KN<Z'
MCH!N260+=G."2<,Q2#TU2.:G7/E$-_#V<(853:F; !UAU5V548CX0,$3J2T6
M7FN8%>0F;TJASF8N+=FU@(OYG^QU+33O<)#LZD'R)-L$_BA26@K#5-=X&-Q'
M0O%>IJ& .&^\CNAY#;V1609*GV#VA7]5LT*Q6Z7OX!#Y+&6U:K5; >81#^=>
M+=85[7[2;RRVI,2S8BU"!Y7KGQP>CBXNKX']<=3]?OEVMAYQWKBB2"ACVF8H
M*;/UCBVGA*\ND2:P?\54[K+8#V5;=ZMLZVPHVQK*MN[<^<(&DU9TJ[E._UZ1
M4+0YME1K;BIDX<%D;]>14EN? >S@I)&U^'U+'7_!ATUZ:9P+U+:G4.S-M+TA
M.8XM5*^8H,A:/.8#J7MI=U:FC/[V=B60XDLC 0EV#+B,GG[4PGW_2(6!!&<'
MK?>*"Y6;S*;:-$,==XW0*S3N@]N!>W ^SMRQY.A[+WEJJP5S !?3:5..HV?
M0]IY\SBQ#F&4\9?8HFSG-UWOGX45Y)N+:!_F%Y*9#V1FQ'GJ8Q2E5[D3.PQ;
MP,15KF5<]M.3-]<&"ULA/'7K>N!NM$:@0L1_2(2$>+DTRLS,6DPJ]A/+OV@8
M(("_CJ/G30G)&_4#3_7S)8:O7^_\28M[30QJPS'(%V]_'#$'%TD-<P XK&N
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M,!3GSD@1J&J5Y&?[4UF/8]UNV0I)OHZ9+Q,@"5:A!0)L@*@RSZ^?O?8C<R<
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M@?M.MLGF_?"7C2;L@(VP_)R'^=A!RZT,NS N0_B<+LXKJ$-=6(< 5P;,@:"
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M2I$BXFK1,7?2;$Y$9>N1%>\6Z'^3DR6D.KC<IY]G2.A(!1&LD-Q2(*R.K@=
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M]J#''C*) )YST>=M3.# (*Z04B+[VG*6AI^5CHO.Z%D^<G F(BB%_+IQK*<
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MPQO%/#W^YI'-Z@NI]52+UQI8/FG6Q>(^/KJ'?]Y[P.RMY)&1\ZO.$E_LHN'
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M @/?8.SU2A/X,(41WG$$TC'1D!LO(^R*0D2X;\E^5N),#?:NM<9.7A_U9V3
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M7)DT_1&)Y@&^;$*G\+@NTNGB7&$=J2!MT""1DT4..^[E\;L/Q.Y=[--P<Q,
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M=1UE/[YIPF.2,-=N$IZ"87EZ%OIU5*TC)Q>Y"8W"7;#\B<OQPU2!_U&Y4WP
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M\%$)G(RQ=:6_UE"C7B\9Y]2"Z;2_%!W+/E0222LI12S2*%5= P51]E;7IA1
MA3G/#)!U\GL7=/-9&C;(AA;:8?1/_X0.CD*[C S5<M1TKVGR-@YK3%':!(HV
M&1F$/V<E2ZFC^7M'H$+_;Z1;RBX15^2O$<1:I&1C=*2I+Y?^?TZ=\!M*-DFE
M: S>=''V#N1DD8F\]%EECP]Y8X9C4-$FU> R..N(T=)MG*AW 857B[SFKYH-
M^RU)FA=(V'_]O]_E!EHH3:N:<*6[Q>X(;Y39YM&]<W:O1,G>^+&Y[82-$ABU
M4EL.R%.6/S T97+@1N0W:_ R$,$<27$+ZNXS;,%Q !F3\G?NT8O5J_NO#=BO
M6D=QPR_8GBF#6KH1A7#>/&6<CPD%_9%? XH[2%8>58(WF\X3*YAVC=VU%KIH
M %A1PX+"\*=D3VIUZ:V"4#ZNWTOU,HI+5F^CLH2_Q HA1QJ_4J*L)"RZ+SO7
M9"B20GH_K1'9]S__/R9JX"[G^2M  [_%TW["A]V/0QN&N &@INF'&\E!%4WM
M(U#Q-:3$RO.Y6[_-;IA[(/P\#%0&T7@*C(-X.Z<_"%HT"UW@UQ/,'2/V,249
MDZ1GFHF,QBIN.#T!&=GX]3RBP5N%?3Z6":36/]=^[_.B5K@#_"'\XWWYQ$AC
M/+D'O/=Z(''7H144 Q![O=7RT)'R,&Y="P4O<A75],58=0?J4W 'JVF&!&RL
M#)AQM6$,:J]I4NUN%W.;'N*D\E&<Q*;7,]28CZBC<\"[#<PLEF0O582FB<LP
MUV\FVLN<R5SDH(OX]^Q 5E=#"=DKF21+)A%$%RM,9UJU,[ 4O+PL5LD(P<S0
MVF())N%-QSVPM$JNXZ,>W:6%MPIZF>ETS9Y&/&[0@0=S_6@2T&YJ#HFJ(S/1
M<B$(/F]?]3TN@*G8@DE9BZ1@E-:_/F1DEI:,&GLDBBQ)TP7NXQ';*Y&$!0[L
M Q%-$'__B+B_+:LN$5;;E$<ZKE>0O6MX\ 9_%EC,90OV?M?5-!.)^<2/44-;
MJD/SF^75K!Z]:DH(]Z=0K0F?O+&$>$(R%SPG'D;\)CU"O17XO7200R\F=Y%(
M.9^SRZ;? CF"E )G;O\4=VDS6=O5T.&6#'FT_Q:/FLGDF-<,>8$TB(Z3#%/J
M..F'$QYS(B\DAT#EB_TIL;+:45!6@<LG4:F$;?654/NIX^'J-[/1O^+735^:
M""7%(;V!F&I\:.4=DG0_&"^X%T1L3MX?"H-3:CBI0'QL2DW3NG_*F?,R]O%Y
MC7W\>1G[^(\9^_ATXY(/O0C9>1"'.D/)5]4DQDP>F5#H98A 2<)&56#6H+HD
MB$R0J4+W"(=+(5#OY#S#\14_74\TKU$1RB)A]OP=6 U$K#63P!&-97MUJNF"
MN=+< S@.F.46K?3("C9)4Y7P^**T'G15_C70,:FL+$K5"-%D2U[ 7)QX5.0I
MAE%-T]'"'FIT(2/.\"F8T=+:FA05*"<T?7EX=--;DVM9X5=4GP@%(7LKVQH3
MFPDECJ:3E'C;B)"OE#.L=(#5<F)Q*L?:+'W;2.3DOXK"K$K4D/94MWO2^? J
M%%:9.?6:( "WQ".Z!]VBX=#50HK9!IVW>-%(8M.5AB^]*7_Z=+M3VK++8CB[
MP0K1])*=+9+:H747JCB9Z!6S7:L(N,V5^0#TJ>EU=10J8R9SX7L6N15:K+(]
M%8GFG( F*)*$XIPHCBHW(_&3=<$K=<&SU=ZB2BA BL^XE1Y6P3PQI)^'.Z"E
MJF :09Q8'DM6$5E78#XQ*T;TL%TF!"4&Q8 BSM>\DVD3S]?JTA)],.LDTI68
MHJKSB\.E?*A0^<>KF0##7H#K+-I>*^36+8?42 HJ?HB'M:TZI8B>X" YQ$Y=
MK'30RB[YH063=4%N;^NZ35NM^3P3;GAJ7=.[ KU8YF#:;MK%''PJP ?V238(
MQMG]OQQE;E1/VOSUY:MLGV*TGIV*\^$DMIK1LC?L593]$;MF<I#>7G.)6 Y<
MUCK:>;LB3TA)(U<- "\<^5-&R%V5M90HI+YV+6PSU&1J-H-TW/US53CG&99V
M/7NV"V9=>DYEY#L+=&LB4#J5M$J%!*3;:LG3>JY)C87JYWZQ#DU03+5T,^">
M$G*<H<W>)2U6T.H[)2SM1:AFGZMDH^@Z4G+S2R5,!NCY5P>>?*)V>\*\15I#
M0G]6*R_7IKKQ]W1T?NOR%W"EB2H6'692F$I!^4E$G59\ ?V]+M5UL]]BI5C8
M(-2A1D)TWU'1Z<O__B,=')'!@8 !_9XH&!U1B'>%70%:_*$6&$07_LR O<MU
M,_0)1U:GO.NR:0JL2XN"&15Y6V@&#AWNR5_"/RM C,U&"'H[5_V;L!8%Q!IJ
M62_64_-'2R=:Z!.%L_"-4F7-""<*XL,_5"(YVY&2*AX+C=9UV:J4-357&+H(
M% M>U'?^=MWJQ;ZL_$%V2=_A8^)CT[(L7.^NH" *ZES9](W8)WS[QO^\XW[)
M+E%(2Y$0J$SE-68Y_.89"KLP%7*V%-W-UZ+CD-298O?"XS5JZHM0EC1N458>
MCDVM]%Q*EI=%KC,O,:CRW=%EF'R#9P3MII3] L)X1B5<JN#S^6YC@C\CVXD@
M")WBI;UQ#O!7$AF5/ZG?"ITV>^V4#M1PH5)I>5L)=AWGIOFS*!P0S^-=">Y&
MDUH7Z5G.(A&14S%H]$*GAI(GUS'SO(7 8Q2BNFX:4>00AS9CT")7/$=GMWB3
M"5B*+-<6;U!,I$_$[2(/IZWAS\B<:_FG2 M4!<+)$Z,Y$/;<86$!N4BV^4B;
M*JC%&ED5NLO'4^V%6<78B]4WV4-Q<![J0!6'$]I_JWP8[^QHF;\?'P^K#!/T
MHH5(W:3D>;-C]GZ0[#%Z.Y%H-FN1\N7[&\*9SS@:O+PCEKY,WI9N4)O\C;>H
M[L%B:G^R !;/+(1T1,5I1)$G?)B6C.(RF:,Y_VZYU%9C,R,E+N+N%XUPK<)-
M,1=GC7TL/WW[53[FT8DD9VK<LTO+7+!*E4'>IB*8B@A,W.--2;ASTP LX*W$
MD/:QT<>.\GC[?-=6;NN3L<UU4.*!VI)"6,UHB!GK4=#RA]N_R>*R6?/>%00V
M+5?<QNFF?8^-:-8>PV_T\J\((,1YH+VN9EK1A: DXB-KPK?%G5N';-:OF,]+
M=9W?YY:HF)<:*R3=PRWZB!5W&4%*,Q1X<!=TM7 O5C*8TI@;Q0@L((^/% 5-
MBDY-*4[A]%%#OWO7S.W<@E1R ):%+,E]HJ:,6_Z.N.E^09/69L]$1KK#($:N
ME<Y<T)A3U$REBU35;E%(G";9NILI:^U.35I(OV4U.'<@Z(I+%;Z3)V4V#<YQ
M5,^\L$3E9BG2S_C5^P/CG07HT%.B?I5]*A2?)]9L*7W>N;5F]-S><W==&@&X
M1 %/A(:F)(:,-I/J)FU/M7_(S:Q0T\<2BR/G'F]Y734PK?93;B@N:)C/"@WS
MU=,%#;.@83Z[(R0*9?XCU,+]*1%CJJFS1*+_-),3X ;EQ"1T0E* VEACJ4V5
MVJ V>[5S3_IK.G$<>@TZ[X](A*Y#ZC.@4_>_I=$8,_3B8Y?:[2H>?% Z#@Q:
MN7=5QR*P40"1Z:=1KYTZM23G["8T7>-<13RZY*NYDT17'(FAQ4X_U=E9J'$;
MI6P(H%ZUQ.;0,JY?N1!.,E=+X34I2M_KODCY3;*7>UTV-L#&3R0<?OX1&F"!
MAEH4%^FBN*6VY/\73;!R[PSO1IHFC1N"A*W8B'Y-[*3'%Q6E'S]M\5\1Z/TX
MHKY8E-:I.=4-EVJX>0OTBXP5QS P,(9$6$J8+R--)86$\,.6,8M!+C\5[F'T
MZSTV1P!UW'7E[>#"\!,"SQ%K"% 92"G<%?3$_+*7[38!EUF5AG).^3BIK\P'
MD4F8JNIEFD&*6PH"GTG(*21!VH*V(L6R3F3N&,6A&QTM#<IS8?*KP.B798\A
M4:SYR'OVVZ?>0BGZ %*F)'.;?0.)"BG(>AA@5.90 ;KHP?4A(\V B'Z;M(-9
M.LP!\:A]4!&-"R]$8K%>S8X(J*SAR(CX%/D@^!VXMA<O7XP@BMS%VGD?("*%
M-6VCWD =8_F4;T<SH>C@91!O02%^JK',^Y5^D>7FDIO6F?AOIPK1._\TM9N_
MP+E"L=G!/G)!*U8/C7%0I34=J9)<.>/;LJ2=Y>DHSNILH-6%,NG4-Q0Y^VFB
M?:[3)&U:2E)(%=^WW_F;ZHBK?J"X R<<"K;C>P$,:ZW0Z7#<T[&Q]8MYQ<&
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MO6-7M&-9RBIJZ)GM>=<F#+(Z1):V/TW'9-$B:2>:^4+A0A:*B7#OX::/=/)
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MS>=>PTRU=+YZZ>^(;I5]Q0M2E-- Y;5WK0W6X]M_4=/O,G@&_^_*AYWT0M]
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MH +E\\?9VYIR.;_*WC@/4JPLXRX+LJRICZ$UK>W$84=:X'2HT\T":U%O3H5
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M+((-J\K!H=P*'=(,>K+*QC[0Z&F:)@MJ^Z2P>NOX$>/%4)9+>JUA,&@!J"P
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MSY7OK#X^U1_Y05O_]H;E-E>-O3V\@AU6G[-8JM>"FJ'P%K-Y*],P<!_>[?@
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M_-^A(BB%%!EIHB!Q(N\!2D'LL>)5,CT!7;6A\P/) 588JC*-R]/G([WBUMR
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MOKBX8,4!O)E Q<$DM+QQJ<%DV[CBZI'7*TK;3A/[S4'@=! H@";LLFWRHC[
M'H/U["M2:  0G<QX05'$$F7._BJLZ(^6,=OPA^*!! L740+28$NZP%GLO,AO
MA#86SW7 4<B"+SC)0P@6&,7PR28C_8\R8:(Y),^NH!S(VC6L@.SW_Q>OY;U_
M09$0E[[0/YB;C!#C(=2)AS4RHMY <H94.%6>2A/L<*#C](N/Z5"FW!6)\TG2
M#M5S/U_HK7,ODXGUAN,B/&^2U$RQ1FG>BI*Y@GX%N^;!$4"I-/=.B602^5C+
M*[<M-W5=( 3>D-(HPVG@STWEK*]=ERH(1<L7*FK![4\&00FEI%FY()"72'T-
M?&I,H.UC]AHN: 0]!?G.;,-P7MJZ:;2LP;P/<76%![N43QO1H*(]@Z4]?<&Q
M)J?A[S#]01,]MS1$8-8H+$,VI9HSGQBW.#&"T4AX&\JO$L$$"4@I1,'4&')7
M=*8HI?; ;)XFK=-KSC%QPHC+&ZRJ=R#.M^[;O44+#UY.&#/%0EY*I5>B;',
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MC[UJ&"7HS O/3IAJ_ ;93]"3VHDP;Z[5/+T8APYOIJT5D:"IR7K#V&[K0R3
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M]]JU=.U'KSE;\VS-=^Z+(V9&],"6V-/@U.!O5U5].-O4!\/"I'W<?_HDOUN
M%+"@Y+F@?%(C,+"AY$19%E!8-(@S;X)Y$]SI)CAL'(%1&-V0AN.Z0;"0:)M=
MCKA/ 07BWZRT&@@K&9IID97/%.VS17\4MS[*=!-B[8AC9B8SGQ#,-GT0"N^T
M9;GJFP9AYQKM323C42K/9Z5M!.2-2CE3H5H;GX%H4H?*PNTH;7>[<ONN9*>T
M@S-YSZS$H:C%>%80:-OJ^"$!;2LBOXD_#\7@$+QB_2!4A5EI%N%U%-0> (VX
M+=VUXU'RJ"@7(PLB#L;;+!G"^B"H@"[RZ*]A5T_; =IO&8_-];=-E=J5](7U
M.VJBWF(6ZU8-B46HPI?K4(C'.<'3X#B\1^U5"<:<!A#RLDD[;MIYQ(R:+-C6
M@)HF9YQO.V!MRE=@:%9V)'27@AQL)%<\W>"+(" ?>-'_:!OHWCFV/P%D]!J5
MXD=-#UYY " +/0=V2G'6R1#S+M8]]D;]=R^;?,?MW$UOO)=6(V7LAQN?N&N%
ME!U/X@>PO*N-/X7P/R^^5X88<9@$?P9#CABL$7P,>T,XQ  ? I/49Q#L%&'8
M@&9J+%TPWH"](Z25AW8V=>@5YB(06?]3X<]FXZF?Q<O"O#F.<@>5;6_D<U\R
M 7I =*NN+>K.XS%*> \$L;&=,1\PPP-H6MY8(QH",08U--YNY1;8B$;L\'SQ
M^\:;>N4?(QJN(A@>NCB9\$]_$FX,9PS'[D<G'A@TW09+#G.EU=&DVHR#M\,!
M.;$7# !70I4JQ(+ICS/<*Q0 .&4'VFG8W:38/?:9"H%62[?)MVO#WQVN#?OS
MXIOO6SL@A4P#>\!@=#!O N@/HL]A^(.\P*C88*( C!RBL(F $.XM'"JHED7.
M(6)%Q#FL'(;EA\A]>3+S(X,#E8[9O#6OF2;X)M[SZ'+P;!S?9XD+$M^K/_1A
M!D>(*GDP@%45H'&C?)9"F21Z&=!Y7VTP%N)91C@S#0DY]X+"W9SQ4H?'1CR,
M7'CL1^%'_#EP#2,*]QD9-T/T/RF(_K</9HC^#-'_Y"*3C<NW,#CL#31?.Q_>
M5<X5@'QD=J(H]O3N=R2@R/B@O22*%PU,_3_AV>&-T#N3YIB,WYM$6@H"YL <
MT?'2N-C<$8GT2-09 (1NMZP+!$*F%QYE^X$A6!F&+9M5OX-!P!6?RR6+*9@?
M%OS!(2\!Z8_X0#T3)^*U>LT!.,OZH5X%!$26<PNJ6X@+;UT#Z@#\X3N&&LXI
MYH>88U$.@B/NFTL89L5,,BA%$DN8F1\,NI'I6$NH_)S2K2;: J(4([0M3.YJ
MIL=<5V':=:8"O3.^=Q*R24BZ#G^.69!'8F1]D#2-IH052OU/XG03UD_]M+6?
MF%WLJ3\RL#BB3%/^0N#^45@".,F:KJ^X6 !,7#6E-S+1_T]GUF=0= .7B<1@
M;,7RZ1'ZEM]>OWSS0@IRH */.A,BFR3B0N/CWY?$&!-G8>G-([^:]Z/,OC"Q
ME)R]R5S!"LZ.[?B[/E^\")1M,$V&G]T.%EF6!=0_@C(A0NGT6H%9Q]B2#+*U
M?7,-3]@F3'"V/ N+@T9VP*,3'Y5SR91.)&$*&AZA.W_&X_0<C[_),?C3#T_I
M/IF2CVB/3[P7@FDCLP^6L*F;*1O)+&K9T00)O D:!9 _XI]R(,?5A:%<UM\,
M,-I"7KG%=@'/90@1'^EHD42</#B*^D8UBFKA4"]16U"Z$]<U,>_2A!FM8<=B
M6.%B,M2!MT,S,+P2=DZ"*AX0$V (1//Y-(<@G!-RGTH^D=SS^, $,C/%U".R
MJS"P:_WE5TP(5?'<#GR/N2:., W?EU0[1\Z$LNL[]E948D"7\*_>>VG_:6I6
M&-6ML(F .B"+U&"X8^W?(A8^QQ605:_1U/!KNZ!",C!8S')6;;Q1\=CX$MET
M2JK$2CW,BJ",":SD0S1!IF,2J'L3G3,@<1$LP8W"89]C./&[#OFA6X.B:F7?
M3-XBW2\)W5'Y$=:V+]M-XB28IPI+<(UQS^N(Z\;HK? W @&VS'[YHPM;"4##
M!WT4*B&;>V(9Q6/DBH$A*HL/J6$<(I/7,CH]0N[*)S&XRZ =PR?MB:O7\8$I
MS@$)O0))+US C O;X_HY'79"=Y6GAW B39M8_4$:S$AUW:SDG%HV<G0737^9
MT!@%2AHAV*2/-VY57U8A*A]3X"G<M3^-C!=',D:@L"E;(8$)KQW>(%Z;56M2
MC<" SD^>.29^I,14:%.BW[9\+&999R=\$Z$WTVL) 4TXH VC7< !_#WO5INS
MW_.W.R"8$C;?U@9>&F0 VW7+$>?R2/BP0AHKW)G"GCB%ERKDZX._W Z&IJE)
M%KES.1W,R"Z)+LU^WKSK'YRD%OV>]0<ZD!*^1,[K7+<Z5& @6$-OD,ZY0M03
M]K09L!TDCOUMDL=L3+D.JUE"7,6OUOGE1*C.6L:B0VL3# @\05?S4P1;_<%[
MO,5+5%D0UD=Y3%;-?0-??F6^_'2%];.+[[Y]G"V^A(M\,6'Q7WQ%D?[4AN"F
MG1+:VUO$>_8_T^])=]$[-: =P],6/6/5,H-Y$%'#[VR!T3N0/.-ZIB])PE,3
ME7+2H<JZJD,;\Y'(_!\R42#5*6Q<51M):*W7+&0&?A\/8\A"P(.$ +QP>0%=
MAG;DTT1S35E"V6B*HSBCE$P2#U)S%1D#L"J[5O/:9)]=+,8+DI6L["RZF@JZ
M&I)YYI"6%*Y8Q%RPR ![H-_T;U:X8?(F*C (J9=]AV%IZR:R"J'?8.. Z IS
MZO"%LAW]\7'97?EQLTM'6 8#)[HA>0NO)&3^!I5!#7@\@'VPTL/K_<,Z>2?H
MR$YX\GOGMO^$4_S%."^D[&M#D&V)N2TB0X)"!!R,U6VUCL0%&:%1F.NY'R0!
MD[2KKP+&&.NRK5LU#G K,CZ2)?@.>7,(J5$NTL#!GBU0G8#V%;^\F-A4FV;"
MTKD#E\/IB173\*=[C\<9'SM2AD-^9A9E,L+N8T0<5MD])8M/'I@A21G&C:C7
M1&P*=:0WA>($"9V-JDX"G4@%UI='Y+"!W-CD?,3Q0@A:0]42,[H,U(,=RRT3
M?G,SN)6^S6Y*8)B=<ETSD0R3S?B;C"2_!O=B1-N04R6P5MJS:\VA6+2XIK!O
MO(9]U70N468X U=FX,J' JY<S,"5&;CRR1W06)13@GHSLD8"TI-SFE0 B]UT
M7B7.7T]EGD!80_; $%1$36)^;"03,8J?4%Q4QRZGB)SCEN;K!\=L:3&=<10;
MQF<QB[Y!R:7.&_]0#MB_01AJ]*C-%+7--%XMDOE#4<$0%?@XLVQ5@Z%"/C"J
M.VV/)(2ZW?(TA !>4P)T^^@8&(0"\AQ@IE4^@;T&$CWSDB-J_"EHCQ1C1M*S
M@:@&PI9AG9ELE5^C*GA%%G:^^#'F?6=6<&HE1*BE#<C0HFI<@'\[D@<">:Y6
M6^<:[)2M%8C!U!]M=2<U:A 114 6IO!I(IT\ P_F& DUB,RWKKCT%]\YOV^+
M>-[;:&2EPD7$@#X,SZ0%CXH7DGU_(!WZ.9$^L5&>;7(4)PCDJ=O\H!@$*$N2
MW,Q)EO^B1.6_#7X)FO>FK(27YNF%0/E((V<C/(_6):N@W>S93!,9MS<L]"I7
M) D=@*E^1YA6(@?'?33X_L;EUR5N;L,,/<'?',F&\$L]7[S0SD40L3!C)V)"
MPYN2W!M@H_7VVB^#7_*-J<VL6-")%%5XW%44"NG9>20'="1 I6#$PY45? H=
MF'%V+Z4L#8=HU*HA0];A4>+[Y.\I*H)T*WQ(@NH&VM2)E3I'-2.$+<#Z_(:$
M9YCV(E+XI2K[+R[?'!>O=_"*G^Y<XR^W>(Y8VQ9K]E]^T:6?6G5??.5_)5^Q
MTL=KM^\P<ED\?'!QD?D@"9!E72RXP"Y %*5"+P)] 4G:2 %!9#?-P#$=650X
M0\&'_#B^"$U8*SZ_\-BD;PYT9GD^)H)!\?MC(1>A$)?6K,Z/EF RN,C0@K4S
M>4J/5HA*+&&((_'2, J3K&W&-QWX2E75Y-K9=33+YX^\>D72P+A71RZ+[89=
MI A5+7Z%N9_%Q=<9O+E'(P:QZI3(6I_W?M@RJH-$]IRA0-I@9AIJ_M$Y/P&4
MGCK^9YK6";!L@N.$'?VZWT/RY:/6ONDPIFQZ #^"_CH+"HEH=$[4@8"(@/_&
M+IT.OM,LO]C+J1X2R-B0S/@4_A]2'I=?N4H+J I)X^L1O9"]@H_+>QFU?*I]
M>SP%L)1K%9-6?$L^FO?!.0&!0ZL_\7MASVH*&3N?D,<%I3_P?:1+4-1[Y(OF
MS<<:K'%P$\DHF:3.D&LL0L\::IF$,<XYVK*S#\_JRB>X;6M>,:JWVW\0^&[$
M9> ?\&R77\$O!(GFY+F,?".%V<&#DK^T)SWKD.-JPK4BP6 X#42\"#]'+SQ=
M&>[;@;LV/=!DR12Y:,7/Y'\+RP$1G//U. BA99SS@-,=F>%0D"A+)?Q=-E4-
M=1(MC- 6/(#@(A4S^I;0BU+4*%2N/:G1K^,+\6PP[%L?_<B_SY6.H09BNG+&
M"P+/!X@3@&@L_1GDU4+*$+.G3"<0 :&=E@MJ"WB)$(UVD@&B/VS-HF:W4,J0
M)05^'/%]01S-XJSMO-H--@A"8X#+H\M&>(JA.2HJ\1W:1;>UU<4O&M'*8T33
MTB0^:0L@@)W$ISM?_(BBS0JR"$#(!0I'KI/5LE_.3"A]2S$^*-0@UK7)5=/5
M&V-.+"^"]EBS.EWX>6SBR:\:.!U%PC@GN/,FC&LH'^.7BC5.A/LOMU,D(F&D
MS_]W6U>5 Y4Z16]>N6/X ^-)R@9D6JX"_(H#3F^;#5Y(R&]N*S+QGE"O/T%[
M[J]YJMW*%;XJVZMV\8HYV?W[!)3(,_\>_?J][NK5U6>Q5'\ 4=/"(@%(;66
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MP 61#7F[7Y?0OD4FV=E\$_(GH.&UM*J4\/IWD3>%D".)[!CDD5Q,#R&^""O
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M>CU;^(L $R*W11G4G1S:YXL7-QJXN+ \<F+^'GN*LL2=>5_9-Z'L@K]TI-"
M87]4TXMA682@!^Z5!?@3^CQX1F/(F<%5':@AO\9+]AT'AQ'*'DY,C+*P$174
MR,V@.TPWHQ^A !&WDL&)1(34/OW??:*1RT=,MI5 F9"8U67.K5R_I>H*]7X$
M'T?Q[!XZH;#MF,$@N*#KLF:J? /:,U,58?C&S/=HCH0_S=W*DHK/ OVX)9&
M5J#FDWB R_.G9]T&/A+<:^!"^>W[$R_OB_"FP]L_7_P:+&%I"+?Y;4A7'STS
MH2,SZ.->(80'6>0O_:)@"F*DR:V7(1AH./XX0?KIAZ>D4QN,"61J?SM_?1ZL
MJLT"M(W'*^/!F?J=KF5OBX@WD7>35@<OL(16/^(CTE-[/![%[P!92R9@NW#(
MV!L%7:&\R^V0:*TSECA&W/LCOO'649CM1_-&YXL?HUV,P.J^,J^$K@9Q+@+8
MPW69@,.GCJ[+&QRH^D^"VZ^AU-ZEM\FOCLEZ,74'#@XXQ_(F0Q!YFR42>&$0
MIVD@+%(('BR7667A\$.#-?[?;RR.YR?6O<.HBI" G.W""\N,&6>+JW)UM<Q7
M5T"ZXK9KGQCF6[E#,GIXM_ K@3:#(Y'1GX7B0E.N.,DF^(4_:P]@BOB88,>0
MDJ,#@P77*:]X>?R7=S65Q7'Y: :Q):79E5^1>H=P/FA^T^W5ETV^LRS-HRL<
MK,(Z\Q67.5I$0-=;+D^H:R?T7Q19,OZ.A&^-Q2XA,@F@77_EAJ"#B7IT[+Y#
M%=8>#;D.M4&X!?PZ?8LC6D,:% 0]4EFKJ/=8C/&7+NB7Y6TO?8CAWP>R>OG7
M@AWT,",* 1=:]_K(%.R :W/#Y0J1.G0O_!;$>_2Q#-;F,$V$$)G?HY1PRE:V
MZ%'ZJ7ZAS/2X1)UH@'UU5?&42U]12$?!$.F6U3C^AI!1>/4=T\CW/)I$D2@.
MQ6X9@AFR+G'G J""ZPF?#3 ([S39R6W5/7'.L@.P":L;(.G[,M+);%L]9RCN
MY< 4KA+N6<UQZRY/'$)AE@/.ND6]PJY6@=C37!AXY"'];=SG=L\,\OFT0#Y/
M9I#/#/+YY,)^PQ\GY' ](V/94\.YR)K#/B:DF3O0M2Q)H\3'2-=T[L# 7Q.D
M2U#3,N-ZD_C<B'S&EN0D/8MY9])Y1?^I.B#$[?>1$BT<"1HGS'G]B9?_F^&I
M8P6-,7T:/GM3FLCX18TPSU @,#*F,B?>27%E?)AGQ8.G(UP!D&$+ :EY4QQA
M1^_RF,5:)QA\4OQ\XQ7"2V7BT_/%4Q]U7\,,#J4SV[J",%3-IO 1:M<WE0Q
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M$3* &;" W'VZUWV0E2M<3-X$-D]CW<' I4+%JN6(F6**H=)4QB%1[?-D,6&
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MRPNTBK(>(IK0!_I^WV2$QT+A(C3%$@> ;T$;TZ-$A03TMDLYLROXAFRO$3X
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M/Z1Q:W-H2_ =X@:;KDC37786":FJO(2R:Q[9WB#WMK_(5.N\=<'OJ2<;FUG
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M*[YKI=:LG">F.UPV=A=CT$B4[['HPD%G"&>S= 0R0';)#HQ W"+?O&KWW6'
M/HM1E')0]#*O,"Z8+V279);"@D37D9? '7I%LZ-*T!35>;U@7ARG=(N+^>TN
M:PPP3;'2;S=9/.&1=(#31AN'FRI+V1'>E7*6 ^@Y0KC+W.5XDIJ'%E T(1 +
M2G4<2S90_ 4X2T9C25J%L66G=E(=R*:@/6[D]<-&R^BX3(1L4T[#5:W)'^SX
MOH:! O'F/D(< 1F(Z#B!"T/XZG=8^H3&@^O?K;'#,?D( QH^?)$&TE](KGD
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MK[7S&KL$VR,*B*?@35*"L+%P*1@(S0K)CC@)#(2AS&VZ.S^;TEK]F$T$F&U
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M]K !#,Q[H7Y-O_J;.K6&3_(Y]^6<#<<KMZ"_*Z#?M*!O07\[H-^LU[N=9I]
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MNE"MX5]9'\L'%LLMEM<:/8OE%LO+@>58"73[!3(^>Q' 6JZ:/U0QK] O%Q&
MHU"-!&]A_5.* (W#W8<J\ZNC5:P$>$T2P&9!6@&PE8@5U%<'C5Z9(E;.X2%8
M,?31Z"^A.Q< \7()L,PE\^ VX'?5MWL@A,N ]::%\-V$\%*E45H(?\T0OG7]
M_6+B15M!<,JKD7U1F@\I?V<1W")XT^986@3?:A4\S.49-%I]2GYOWQ/ELOD4
M2U6^'[MEI:,X\9(T$<4"_ZN@FV>E[N3E0JS=2K;SZ$)W_4<7NK-P7$8X+E5^
MI:U+\BKA>77WE69]VTKVD>"Q*-8B58JHC T<W-*P[RCVCY=]XC['^O[_A;^C
M< ;[.U??KJ])UU>ITK8[RPN%Z5(E6UJ8MC!=A.FMN[.7G67>1FZ)A8,UDS&?
M JE7NJTM4J^)U$_&!#\$U(;0>!APM_0NKGXKSJK:KG7[ _._SJJ=S,?3K?7@
MHMMUG=<?X?^Q8L6*E1*$R#3@3[_>[[[_[_@R()G2_M;;>M0Z8/941(['?2E,
M[A,8YQ/O,F1[1%A*<)Q<!R*JL*.CO8(@RLJT-)I+@UG =!!>L%9A+.VQ"9);
MLN7OIFR9,Q4$_\Z4*UM;V]HR)K&2;8<D6]M*-BO9K&2[O]YNO]EK-=Z[K5YK
MT"A'O=WS=.2;UM&)DX24[]I383GW57/D<<R=21J+)(G9ES3P'&\&4G(8QR&(
M2QF^^3!+Z8?Z5^KQR]P >QCQ0B1,QTJ8IY4P3T8/5L24Q">G4PP:]6:WWC=3
M#+XUVOUMRQF0$V@*G8OHRG/$RN9NYV*6J((+,KFK=Z]O[K=/A^R3%\XF/)KR
M)Y,U:T8BH3&E*J4UK*AY$:*F:T6-%356U#Q*U#1!U/2V+6J6' "M*7VRS&+I
M'^MO5O;\:!2LE3TO3O;TK.RQLL?*GC7J/M=[_4['C#O8>D&,96ETC[1ZFLT-
M2Y[68V,16N_NDS.VB?4.-[%N%;#(-K&V3:QM$^M7H3?O6A!LJ>HW6%7TM:BB
MJZ)@.]U!MU.JF@[<7ZUN9A% S?;]3:'2RTL1 /!-04MUT@A$+A;7Q"BF1SO9
M__P@%\? !L'N+%(/:HW_^=,?;CH'&T,6B]>O$:\UT@ZVC[2'0>S!O>PBXK@N
M[!3N=^86K'8.K)H- "L+4Q:FGARFFHWMPQ16%/!<CT>>+.ZR.C7UGB.(54-=
M?RC,8N/.86.K9-AHJ[7L*!2VM@^%>V$04R63,3N-/$=<@_T:3<(T%GLAYG;&
M8-V>5ACZG6<"_H)+(\JL >/69;-T! H>XXX3ID&"&M_8BZ96W]LY3&N53=_;
M;"J(1;3-(%JK!,K=6>H+UFCQ:J/]EK][W^BX\B>J"N6-85&IB),$O$ F:!S<
M"">E2GXG8[A"1!;"=A'"FA;"+(3].(1MO8+I8R#LLQ?P@'*R+83M+(0U00NS
M&/:",&P9^6P2U%28US)<:VY?-3N706P ;9WZ;2S#0]$[5#(Z@;T#[RIXH,O=
M<):081K%*9=QA_JM@WK64/R<1R,>B+AZ<N.+.1LZ9  WZ_4F>SM.82;Q1%6;
MN/:2R8Z=MDX]U_7%2PXI7XO8!KW:QHIX/F:)2Q5Z5P(L+?$:;J0>W*"W?0!>
M=M!1HX..O*Y .)V)():H? 8OA6V;JX/<-:-<D/-N1[G<6]G-HNP.HBQ6[3@\
M/K\_5>?)SLE>#PQM;C'M:C[A:AY2A#_[UZ>S(X#2..$(A_NADV*PX788PR)F
MN1'S?.]7BYB[Q.-V,3<$F!?\)@S"Z1R41_@VIO8:SD1,N450BZ!W(.C>\,@B
MZ"XQO5W,YT/0/>X[J2]-^",O^#["(KT63RV>KL;3_8//%D]W"0+L8CX?GNZ+
ML1=X%DXMG*X+IT?#3Q9.=PD![&(^'YP>\9'P+9):)%T'24_/#BR2[A+SV\5\
M/B0]C01F[UA+WP+JFH#:?N7<:4.B2H9P>QA@Q$[YI6"'R&3<H:#/?9YP]MGS
M!7L[#J,I3U3%'L\ 1 P(Q0=Q^,2%;XPR.XUW=T&369:Q/ 0H"]-NKAK>\\R6
M>>[/;V"*TV^-[C?<NF^-^O=O<3J%.^>/)*1K*3Y&H>]NIG+@X<7!%];HUF20
MVH_(S8T/E2+HSN5RKMI<L\!AN]9IM7Z2^^11 B]\U&L/?EH<GD$"]Q'AAO#B
MJ9?J&+Z\KX+#LPZ(+6R8+0F[8R5AB]J3+0F[RR5AGWC21.9+2)?D80R?\"0%
M:ZVL$O#\\)?CX<77LX-B*&]Q\-\:_4:[WX YK! \12E#@N?%2YE3(]4((]XC
M\7L*V(P&N*IGKI.>6!BQ1N>M^RY+0\J*2(+JZDQX $JPRD5J#%KMBGJ>;F3+
M)J  NZD_9PY/8U!YDXD7P_=4,Q+>/A(,]TK&UGOP]I&8<'^,<?KX($H;D!?0
MDR.1!G 7/1!P:!)&L#)N[=DUQH=APWW2Y <5Y-TL%-UY1*'H5JW7?_A=[6ZM
MV?R!<M%U:KRQ&RG&RR5C_77Z)NSJV=5[S.J5TAU<UEH4ST?/(%+PFY_?--^\
MAL5\4I?ET?#L\,OPC%W\>G V/#WX>G&X=UYAA\=[M749P!+]*P9QNX"O<@&M
M("S;CKR6!7Q2X?=I_N&9U[('5V;^2NEKFR6R] '3DWJ9:_T^?L_V>!3Z@IW7
MV"<15+]P;QH&%?:EMK^VLF%!QH+,"UW W@M:P"=%CF,^%1\L=KQ@TK<+:!=P
M,]AQX24^@ ?&EGI4\!WCK/8FGAC?+LIGHZSNC+)ZT'GH5BCBN4]#USSVS,\U
M\<QSA,WXU-&F.LP<A[X?7L-P&#8I"(,8SSS5>:=ZC7%PBA3LR7Y^#L?#.WHY
M?AK*3[$C( 87NEB/TAZ"KCH$!8AK=W]:_QAT,+CS%/2'SCQ;K5JC_? #S&:M
M]XA3SWJM_8C#TD>]JUFO#>Y]5REUM=4%AA]OPI>B[]>CHW36"[W1\35;T&!6
M;LJ8_JNWRJ/CE%I)M*3_*-(G57.'R'Z+Y;PM*[QL5M@'A6@KQ\<;\Z&58M-*
MS2J[X%HHM5]W1Q+F7A81OF8AN$G"?-EX64J+]<E/G$NQAUL^@RZI[O[B<#\*
MKY\JA/-NN'H":^F%,$-V)E)9=2!"3N5]RLT,(_9VEO4K$MF5H;QR:8:Z%>@[
MSRVOA1>^4/.6IFS>TMFZR'_99NS3EMPHDSA_)<+:8OKFS8DRF1 EQY.71>P6
M+5Z(@E+J5;48;$G5.LJLH^P.1]D7SYEPX;,]X?,@M,XQZQQ[1<XQZ1&[U9?[
M+Z/H_5\-1]@XNP!=9=QQPC1(X.'6+V;]8B^!#:Q?;&=W;MO2^Y7(9HOCUA=6
M(@QY6<1NT>*%*"6E7E6+P994K2_,^L+N\(7]+8S%;,(NHM1+$NL*LZZP5^4*
MXUX$PZBP3R&/7,Q(UC%AL17)+Y+X7PMI6_?6KN[<M@7R*Q&W%L:M=ZM$$/*R
MB-VBQ0O124J]JA:#+:E:[Y;U;MWAW;J8P$!B=E!CO^(0DS"P+B[KXGI%+B[M
MS[(R^$42^FLA8^O.VM6=*X4$?B7RU6*Y]6F5"$=>%K%;M'@ABDFI5]5BL"55
MZ].R/JT[([8"GDS@!4=B/+;N+.O.LNXL*WY?!J&_%C*V[JQ=W;EM"]]7(EHM
MC%M/5HD@Y&41NT6+%Z*3E'I5+09;4K6>+.O)NLN3!3IT).;LGS5V/A$R$POK
MVU;8Y^'>J75M6=>6=6U9>?PR"/VUD+%U;>WJSI5.&K\266MQW?JZ2H0I+XO8
M+5J\$"6EU*MJ,=B2JO5U65_7';ZNSQ$/OF,:A$R(L,XMZ]RRSBTK@%\&H;\6
M,K;.K5W=N>V+WU<B7"V06V]6B4#D91&[18L7HI64>E4M!EM2?4;)!O_RD2_H
MQS)-+W_[72_\@978](0?!N?/,EW7NV*.S^,8&>E25)6'!,<##X2QX@5JJ/^M
M>H$K;CY46Q_'OKBINN1#\$+8R=!/I\%'UXMG/I]_P&]O,U8'& C'IJTO^%7A
MAAXDW5@5@?MQ%L8>/3D2/D^\*_%Q%-[@BN L,R_.S9H,V&C>LX@;,X6>>@\;
M]:*1"[NC_L;-G&0*J9J0%_A> "-+>)1\X&D2?BQ^ 4LM/Y9[3UHJ'\-\/W#_
MFL_CCV_>9U2R%&YQ3PVR6-C>I]W%E\)V^7Z5UX2_EILX"GUW,ZMR>+Q_\"^]
M**4<(7NX8/@!F"D9C>*$20E8 !12J @QBH(")X.75P'^PU1=(M_4J(/V]).^
M'K;7Y[-8?(C%C$<\$7I1I*)%][U9-*^OO-@;>;Z7S#_H^Y?8T?)U@U9MT/[)
M!!HU38DT[U?<UJW5N_?==8<KL?^DGL3U+("5YF?G15F?:R]&\7 '9),^WEE3
M;>^7$WG76M=3D-_/[ZRR=/J8Q5A**AM<GLP#\,)"(GZ0^IY<O>1L$HGQSV_^
M$(E9&"7?4"N>@88-*_8M$I=>#%LMW&^S=.1[SC?N.*L18CQ>OD[T5E<X(4A.
MU*M3>'J$FKP"NO4W\(S&B V6#O-ALK-LF.R4ALF&>9_QSUXT96]/]X8GG]CA
M/C.5M[_^Q;O!]QVG4Q'!79[[\YO/WYJ#T9BWNMUJSVVTJ^U.;U0=C ;U:HNW
MVBW>;(]:]<X;1F.Z2<YPZ?:^U5N-CCL:=*J# ?S5[C<[U7YKU*AV1VZCY?3&
M'>&Z;UC I[!@KO ^#%/72\((QW;H;G-!FZU^Q@Z%Q?CK/5KNYH>6=X;GV\*R
M)V.VI6#VM >3U1\Q2]:SXG=.5+^P$PTKJZVLEK(:E@DD7PQR&7XB8 6;U/TV
MXCX/'/$MG@B1Q-N4*WO&L-@G.2Q,!X)A,1Y3AT3AB.E(1*S5H#"8-N.!BS^T
M+.Z7"_=;%O<M[EO<+S'NQPG\,X7UB[^%,P'@71KH/\]&AIA_0H.#Q\<$]GOA
M%-X_@0EY5X(=A7',QF'$DHE@<\&CF*%]YUI)L3.2HFTEA9445E+LAJ1P)CRX
M%"65%'LTN)AY 7P1.M\GH0]OB=G![ZF7S*V8V&DQL7;&P\OE4RLFK)C8$3'!
MX\FW<5G%! R.??;#:VLY[+9(Z%J18$6"%0EE$ E!F(CX6Q)^6R$;QE[  \?C
MVQ0)QSA&EH2L(!L^JY'YAI0P@7YCZ,6VRVI6E)BOZ)4A2:2$@;$V9V+'<B:*
M.I'-F=@]MGO>G F*7_OQ*+[MYB\\,L)OR^EPVP*)1V1[=)\VVV-;,[\(R=K_
M%/+(I7 251E(GBP6?,;P[1&//)@8NY@(&)%(0?F**T!A3NU'U)%-[Z:!Q0]X
MWYOE8:V-QJC?Z+?ZU7%3.-7VN#6H\G9]4!WTG'9CY+3<?J/]1&&M)S,O %EP
M 0_ZY,-&O&$B=F#9?WZ31*E83P1LB4Q_!-_H51^\!$;A/&#7U6HQ^(,4?9<1
MLR,S*IA#Y=WKIV;??PHVX5>"<>0"D%2XFR!IPRF,;8Z"RC2CF8K58S)6[VZ0
M(DSSX*HX'<6>Z_%HSM[BX__TAWZS6?^X)]]!OS4^OKLWPJY"/^$#2%V#T12&
M%A=\K&$Q:,,I!&WX80QCA*N<_, N-L 7A]3H?61"GMOA _!B=-N.E[AMX:=
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M'U*+S/TX-$9SQ?V4)]F;EMI6*>HY^')010)O#-(>%AB&[4W)I)IR5[#1W%#
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M"HXB5QYQ3B4R)% D=%0".ZR\N+>M;*W^@26HO%M@2KMCZ.F 4QB/"'T" .\
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MV&X.FH3<*/AI  D "<OLZ;3Z+SN:;S0R U0 5 !4Z!$JO+*7PPWWP0 F "8
M)O0($U['-/3#&6 "8 )@ F!"LQ#_:8?CZJ<WD[I>YS@VP 7 !<"%?<2%Q;$T
M  F=*AN9!\M&/HLJ^:=4B!YSSE1^^1.!9YOG<K5M#O^P(SOV^?IL74U2]3KZ
M>.'BM&)D4%%,*1QEVKT#YWH@O"W+J24U>Q ;#^%\."H\,88IE)+1B%-ED/&8
M(T<)E]IX*FVX>SY<BDD[[10B*07$A27(.<>0C0Y30X4CGMP['ZZI\IW.9_7,
MCHO\;QT/5S?/WCP7[N3M+]\Y&(ZS03G<FF*\G;/AP/8 XK< \:T$1'!>*&#]
M?:Q7-E 1O$0V/\I8[SQR'CLDM Q$81:EE:U@_:;. N5LU\> =L8& >H!Z@'J
M >J_ O58BXSF2B/+0T3<)8Z,I@KYJ VQ)BDM[KGU4I 8!!-(1B<13_F'YIJ@
MH'!B2C""E=L:U%-)!]Q(P'O >\![P/M>X?UC\?W&>CY>TC^M)+UCAG'4!1Y,
M1,D'@KC1!IFH'2)8:!TLU5JHNPRCN5'8,HQ2= YQ37,<091$-,9D4HXE5 QM
M,DR=ER@_^@[5$$$&$@N@FB=BP#K5=N <X!S@'."<1W(.EU30*%!(6&3^P![I
M0"EBDK(0O M)F+N<8Z+E)!F!!#&9<TB.A+23'GF7*<IZXPCFV^<<1H!N.DHW
M/1 9T W0S<&EM$P@."EI4,RXG<'?2J23+VC.HPX:<QKI7?"/0JI$#4'"4(VX
M]!89K27BCM# A?&4;*]Z00@>& PEC#936M_H+&L,X.L3"=9O+6MN:S@.^=I>
M%/ELLM5L*=(BON:[;GXW?KD!:W]*']KCIW0@9^M8>E\O+N.XMHV5Q\_E\3I;
M/B&([ .K;U1%.Y(>[R67MVK>S> ="FK8_RK-1@4%6-=[)0.L ZSK@!H"UH&2
M =9M'.L>SLD$Q[T-+J$H*$8<)XI,S(\4$\$:(J1DZ6Y.)LAHFW2,])$C'K%#
MQLE20DZ88J,3U_=R,D?A7_-Z=I$OI?XP.0JK@R7+E/63\7(N2+/#H(DK7]T(
M*]_'?\^'=;[ULSC]-/3Q79P.)^%]])./X^93FCE#+65XU$"2/M61#\%T@1]
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MHAPQZP3B5OD<D@>#=-0L2LZ,9*WTIT 8OP^&"%-$^MQM\J>=3NUX!HTF0.1
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M0J%VURF[A6H.:!FPPZ[8@:M$B64119(8XBE@9"QA*#)#O(PX*HS;&  "['"
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M/J1WTXF/,=2_3"<7A>6/QF$)6U].T]==@+;HG[-!%B'T:.^%37=%2D J!ZJ
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M-"3EWF='(X: <\3K20YV"49)N(!54-I0L0>.!F,#3;OD:-S1W[UT-8"7@)>
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M70(:("K" I1QC6<WS?*+; +DN.2.KTSU530@M*YKDV)4-#24\G>@)/K,2PC
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M,DCAWQGF*JUPDV22GVF?$RQ6@F:-<I\L]P+_-:X:,EP(F0_Z&LA?T/<;[*@
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MQYLJS!/9XF[^:4"@IUMW1%#(S/20:Y.2CE#0HI5>#5\!>Z+"@_6MZYH#-[@
MW*UK;N[6&U ;Q^9NK,0>&I/)):A3C/:58ZR)QJ@6O7N')I:\;TGKNG0N*TQ&
M I2C;!DSZD7#FPZG5YQ,H@4Q=#I)_-DTS^3K==M\TIVXU+&8%0\"^= A@/6$
M#6*%V56?7Z3TNN) <1+UBJ,$*8IO4!Z,>0P-3IE0X16C@-<XX)+FUD[N-H&9
M!@,QDB(\*DCS):TYRK04(HT]EB4\8&&4%XRG60BFI"CRV/43X>YE?M_)J)-G
M*%=_-^U_E=UV??[DKME[F[W.O-CR6UA_"O+.ZT%X6F5&P^9-/R*D4U R TE*
MXE>\&TH^.UUT25[+-0Y"(J:C-,M.M0:7E!702F1\(U6E&O6Y4(GW0\0\OU0Y
M9^>5+$<32S!]D1K%85?PEN*-XZ\H:QQ%V&*2ZWB.W2L:JF,LU"AQ/:N$.B1C
M96>G+3N3U+C7\D[U)%>A_:DZKRH9D64AD_O".I3;'OBM3E$SME>81C+XUH2?
M"IF&'DN3-&5AX!8L=7G)/)^[?NQ[/)/R/CC;;]2(\4W9XY(FN.Z)@U-3Z<E_
M_$-_^80.:PDZPK\]>?W;J_UBE]5V.12[''ROG',OR%/!"A<GPR6%8+D0$7,S
M+LH\240:!??Y7HIEJZ9*]_1B<)A&3IF7^]N!+^;CC]^90=_V(#%\8Z=7YNXT
MW4EV$.8QF<\'QK4:I73G$8<T04P&;RNY0>-A):ES#8! CY."PVCAK<=--Q<[
M9@%5X70%];0U;W*X#>3U_,GY02N*S]^\^%7KAT^-/VE8[H&+'H7G2I&Z&?-=
M+%G. Q<(7@0L+=*R**1PH_C.HV3N&Z$4/.4G"HY>2%UDU<ZX#O*')\]?OGGR
MU#I"QJXR/DSZ69M)/R9O_0!MJ>(*X^,B%R2-A 2MMZWR(8>E&^8*C2L"#JRF
MJ17(3LMWV8W%^UXO73-V^P 'ZYT.V'9 I<_W?N&^#8;V&TP4@W<3/]^;T4 X
MW)OVIZO!&!H*JLSCP'-U0V^G.Y=RHU(A-VH@^+"<*77 W(3=X@"EOBGMIX<F
M6I@6:PW6-N1#V778*1-4)440D%=]$VUJ_+':[JB*5W2IIHR+"=(.*7[42-L(
M$-UHQ.#GOE%+Z2 ;D\/8'9*4_:AVBM3P,T5\NXG0>XFV),#/T+V%J<#D* !]
M?'XH\N41VRSUW3 %$1@5!1C,HI LBX($/LHB"",_]MQ[415WC?OGC5B^;1O
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M[0JP(HY%#%**>7GBXX#E@&5E%C&_]'CBQTD2NZ$58%: 60%F!=BCPU8KP([
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MC[U>A_>DD*(("I9B:"/,N6!9*C*6RL 'WL<CR?>&YZ:9%T5Y)E@9Y#'H\%'
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M5\H$()P&+'2#F.72CYF7\RP,\]2/R[TV^7>)_3X80K@GP9$@1.<TI3.GK;V
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M T>.)"F83C28T)'TDC #(SLQD.QE+GHMN%-PI^!.P9W=09A.F6@(1RPDBCC
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M"(XX]@:.)AQI;9S12DM.?(^B(JI$1;HN?R\=IHN=?+R4H0S$2:Z0#MXBGE1
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MY#R+R!&&;>!,.G__K0Z'-'5Y)RS=E[C"MT!*@927PHX%4FZ'%.XH\Y@&A!,
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M\/LXYE_ _GU[/@6V^9_F]1MMXX.9Q8*S+IC%?4J]/70$Y4,W+!2H*U!7H*Y
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M8U!WL0:_\%V^KXV7?AC5?CRM%[/X_6(V \J]AVOX;CSU?[ZJ(C#*1;:DX6N
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M^=VEA6FWA6G9TW.T!B:J">8, \(*BA$7 )0Z,H:"9,I*@;EB\5@-3)MRM-G
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MG.;]+]1@CYF*\7G7M=ZI_=<MK!MUG3F)0)]ECZL:ZL/N5RXB6_#A61(5)Z<
MNP; A:C'336L:D\?EVK8W'-!\XF.F7M84KU9)=&<;//LRP?6G=3$O9[LSX#P
M#Y^&6U1Z,?G[;#]T0SD_012)"ZR%4Q$1KQSB02OD5'8,E$@J2F6YVO$CGG2O
MW-*/:-11_<OD-[#)I^'GV;2N'YUOH /*Q( I56)"IR"S!2!Z1[_^,MN+ 0@1
M$E4<*Z2#Y:#LE4?.1H*4LM0JQBQ1.^GHHP!$_44(\=RI!C%DHL#**4CZ2<)*
M"25U K<+4;M+U"+WA44[SJ(O@*C/6:U>0LB/>[(KH[L$D;N@<XKG\#+5\T%%
M^NL5=9\X"L&H]RJ(B#R/"G'"'')!1B2E4%1SKX7#!XE"S*?^SU_J>A'##XL9
M7&P;36BG831O+J,-:]WVZ"@T$0..>8D5/+X*^:%-A05G"LX4G.D4SNQ' 9R4
MTLR VB>:("[@-ZN30R8*XH.25A#5B5CT"ATZ%([&N$#,*0C[22)+"4MU KH+
M4;M+U"+WA44[SJ(O@*BEHKF_X>B?IK,4LW7][8^?+T:S$I;NA.[Y4@]B>[ 3
M'=(\V2E,%VX<;Q^P5;R, Q.T&^K^),+;$4>%8TR(RV 15R(AQX) WGF'L8]>
M&MJ%*NRE"EW,8OUV$AHUVGS#.L[QZ&BX4 .L=1="%;?*Q>TSY$K,O(!@":-U
M!>!>"GC= "TR*,6H1Y$% OBB'0 &P8@1+DR0 8=N-/C<"2W/'4(GP#F= *8B
M_#TD5HFE]3GL\U+QZ<2(6N2^L&C'6?0%$+4,(._U '+>'6$Y27U>PN:]T-XE
M;'YGM1ZE&D?ID;;4(\ZL1RY$A81E)ODHM74[U7I14NZ](2B&@!'GGB!'"$9)
MN(!54-I0T?U!YG+ F1PPW8G!(OV*8_="]KM"K+Z"45?H5\:=]P=-O.*$1<R0
MED0C[K!"AEJ)E.#$1.H<3SMS2)X939X[8JV&J@2L"[84;"G,UA](N6'<N6'4
MJN"0X3XA;K %[<\MPD)'9;S!+ATNB_DBQIW+,N[\=$2VX$/OZ%=\C_[X'CHD
M$2@WR&D%Z$.)0MIXB6B,(6I!F=F=@?C,OL<O #*C23WR_[#CQ35OXX\?UOZ$
MW/0GD+C#H<##,J?@"'CQG$TE)2%VOR%&-H=+2T+L=.R DA K";$G-B-4DM8&
M0I'71B..B49&R82"\-$KAP%G11?,B V5=Z"$&!M@PP?&=&*S;TF(%3#J&!AU
MA7[%*>T/FB3O+%=$(,P(0SRW"UII(J(B&IFTXS:1CJ')<R?$"#BP92I_ 9<"
M+H79^H,I^S-B4FIF%/@1QN9EOI%(I+'S2#H5#8Z>,F.ZD!&[6?W?E!$CSY(1
MDT-6,F*G([(%'WI'O^)\],?YX,KC$!)'PCE $AD5<L)1P!3"D@R:2"8/YGP<
M!GVV,V+D8"FQ3L2TNB+#I4>L$X_AN"FQ?\0:K+C*3D(5/U]$G_^83ZN/\'))
MD9V085!29"5%]L1V1:2:::,C<CB!5^L21LX*C;!.4FCA7;([>SZ>(ZC9JL!V
M4$VC -]/\TNEE:QDS@I&O43#MSBO_0$9X@/UC 1DF56(&Y.0(=(B+[@"@!&)
MTYUF@FZ"S',GU$J'68&< CF%V7J%-/OS:=0YAH.AR.21%1S3D(OS)'),!$&H
M\9[K+N33OA@4NI5F*XUG)R7)!39Z1[_BJ?3'4XF""^; /XD\@*?BF$4Z8HR(
MHY9;%R*AKA^>RML/'V;Q [@?I3&M/WBRF86#WW,6]=__&D8?*S^V-3P7H-0Y
M&H_J.8KCADT:KK_(8<_EE2POO%DCQ(:,L:_>A%%],;:7K],X?MZD@ 2"_/>B
MGH_2Y>H"F\\@8*'9_$USMRB?L7Z=;:/Q*-_6-;I<W>;R9 ?*DUT]LMN>TFUD
M9T/.E2&&<$&P9$9]M9FF_#/&"[C,\9HXHTF^/]30Z!:BO/KWK^UZ@T-^,"N,
M;,Y),/[JVC<^'P&V^>[]6:SL2B54HY5.J#YFI5"-Z@K$S2_&MLDSUM4</AY&
M*<59G/A8N3C_%..D>3DN8Q[510YZY.1C?G4Q"7$VOH3KJ*:MBFK2E?FM9$>S
MY7F6'_;3\_-I)LG4_YGU3//BZK#YF9U7G^#$<)7-&_#1>%G!BS<F.;M X.%:
MIH$MUC^O6]S-J_?03O*.ZWJJ]/074*DYU>O1'*["?P'=\G.L6E2K?@;XF]>;
MRG%-JLUM:'PHLJKI'/4.S5(_+&99GK(,@/B-/S:B,#^KJPAT"-T6AT%SV=FX
ML9/+ZD-^L'#):QF?5A>+F3\#6*GV7?477-(3&(5".D6)$ ASY1$/.B*M70Y"
M$.<\2=J(G?"U-AP+K2*R!D?$<W+5")V0<<01HZ7AU!S:*&S%9[6^X^?9M*X?
MG0ZE \K$@*F;TZ%=X+:JO;6,+UO8 GP6SR_&T\L86SP*HQF8R]-9W0)6PZ0@
M.KCZ;6PGP^K]!@Z=61 XN+5K>!?_M;#C_,4-D(VG=1;1]FSM!]J"G/QNP_55
M $P=5N_:E[K/[%&EQ"*GR-H\]D_2//;/>^!X9G4($4N]T^54F/U)F7W%H4NM
M.N@!5PF1J.->(T*S7TT50<;&A(+G1ECL/ \[9286WI%"4?"K-7"B#BF'BCF2
M,3%L7&+)RWYP%>&X^US5F-PKH-Y1G$VMX10<\\<RVZO]V0 3HTA,8$08QXB3
M")Z:]0X12Y/D0@8==C#V21FD^9%C+$#)ECOVQ_.SDUG'24=,R#1=S*J<8JCO
M2 )TX6('U:?1_*P'VHP2(JGV"3%%".)&"N2$H(AY9["(TF&U,V@=*^]!!UBD
MC QP#!B1)@A@< %6I'>"*^4.EKK:9-;?LTM7 \OFR*W]L!T!!"O\JA(!T2\I
M1: W-_9V@9F^:E16$X]HPPAI-,OETI/)"+18;6>7VV;:*EHQ:[)WV39<'3^:
M+(V^QOL:7\(+-7BYXTSM)E(RBS;-XZPU'V>K[%\/^-@J0XE+'EDN@8^]!:4+
M?R/.5/3!.VSL;EV.$M[(%,"X\Q3Q2"DR7MC<B!)-("(*K/J RD8,@*Z=9N&U
MH== ,W!N9L*&6^N5 [)TL/]7O>'9K.'Z.$B=!!/18%!^-@)2!P'&?F 2,:TE
ML(P%K/;/RC3]1&IXKP'J'N!TE6;3\QT/-RN_3\M*"&3;4HB-#UP+ U_S8?:Y
MXU6XBG]UZ?9[%XNK/MFZ^DOWX8@G2HUV 7DN&?@ F"(;I0),TB&"F10PW36K
M"/,I*(%TMORY,"R'*WC.Q7HGD[!&L>/"T;7JG^;-'X#A?P)^WY-R/4Y=*!]V
MW!P;=NEBJJW\*U MOS4">%V2+6=I_JVJ-C.O%_!HT;(=(U\BG./55@;P?YKL
MQ.?7B+UI\H4M'L/WP9>/%^>3[33L]5SV4(PFS>6N^BWAS[UI2% W;RZF]:CY
MYED<PR5_C&_<]',F4K[Q=<O(YWLFP@E]>+;DJABD"X_U)]0E)B-FB\NNLH*9
ML\[6#;9+ZB[SSTV6^;5=S*=OMM^ Y]Z^W#)BTV7;>!VO[?B3O:S?O/IVS;)[
M:RTR@VWPZ#5>.RQ+/5'YV:&?V)[:C U-T(#6IJ)8[<EAV@C*)5*$9(N6>F2X
MUD@%*ZR7AD1%_TE;W()# 2CF]SZ,O7KA*="WMW<W=^$2!^"+S<$Q6TQ X4\_
M3.#K\X[@*\.BZ=F>U#DTT-97@.^VF'QL>[K;S-%]K.&>&''46XI=\(@D'<$]
M# 99+0.B ?OHI4W.[\04DL_UWN >,B-S!1TXE]9J@CSS/H+MIYS=*>O^<1F>
M_B/./HY\W&_3_3I=TKDQW^KW^4%MOO_]M)[_.IW_5X0K63V[ U7($3SL>, ?
MCA_#10TJ.*<_RS5 F\,%7.;7-3\WD7^[]N^JE7]WT9C 64:/$VP@D0>BO$+$
M>Y$CK0EI+R(H36&DMI;[W6SD0UR"HW%3ZR/\-)TM7\J?.W@CP*%9@P[E7;.Y
MNG"9;6)CN G8I;1J@SZ_3,+"-PYM]4<#,YME5J7*ZJHR<A;;$&OWT36&)*C#
M$F'J".+1403JS"*+/1.2$^DDO:X/.0F>6@EPZHB#8UA"3D>.F!4N6@_&)B/=
MB]@W:A%0=1VEG4R[#:>C*VFS#3ZLK;EE'6N7KO9>,<S]FO4EZHB3=T,VF/>$
M?!'M@S;*..0\"8C+@)$E02*'*;7!&4;D3JJ*10F&HJ'(*RT1QSKOC/ >89/G
MX402,.N=+U)<D4.X(@*G0#1&5#@-CBT!Z-6<HF!X O!5TA%[".@MKLBV*T)U
M<45Z[XK\#LP*SRS+:^N*Y#Q8Z?18D^>/O]?;!9C[4'>GYN.J1!-,S"9(GS^3
MZX_F\']0FOGK,QR"4OPS7EY]OLW6KY/Q\-UP!:W9FI5O4T^VJINZ.MUFE?OR
MS2:SOUE'U7[SLAQ_HRDL?Z"Y2WBCFDSG<)IZT=SG?#2^>C<KM>ZF"C>2*X_'
M$R&-4=%(Y"V/B"L6D4D^(,>\%1J@@>X&2A\T_\*?Q; 8QW=I?SGAE6@VDOEV
M$JZ]THCJ6[ :/H[FE^]S3^I[N*+OQO#6JRJ"07*1I7:VB"\^6;&D45O&"@*0
M39A=J6T8O<^U+8WY#_]+T_%X^JFNO@9=L[3@Z@%8;CY>S%L5,&CX=SD#I9K'
MV?F@*4\#6ZW]0%8@]IO7CP>"1R2Q.Y9T7+5_-]W?^]JZFS3P=BE"OJ'\<32V
ME]/%\B/KGN0A_FKU>9\K32[J^+J.%W8&RGM%F+:#OCGNU;XYT!]']<B-QL#=
MKU??<<. Y_:TW R9^6HSB[R\Y3:-_.TMAY(G/<P,!:9/>Z'#ISV?'F))\=6_
MIZ7O$Q]&AO+$'Z<98G[,,]XQ"5[?NAMYG]I\Y'3X8PP#T2<Z+JG0ZCJM@#_S
MNTT%9:%;X;%"J].7QSTW>40Z/JX&]F$+058UY\_"EET@;Q'J(M2G*M35LI.D
M"'<1[B+<)R+<ZW&<1:J/P:DE:-%U-5)H553NZ7!=H5Z1V9<ILT<VDXKK4V2Z
MR/1)R?1Z'TZ1ZB+51:I/1*K7:T6*5)> QDM4(X561>4^K<IM-YQ7TU14;I'J
M(M4G(M5-JWSU0TD-%;$N8GTZ8OW]=-WX4N2ZR'61ZQ.1ZV:D;[6Q!;)(=8E[
MO"0U4FCU;"IW/8BW?64H<I_M=#P*U4K;=59I'%<I-YWM];'9]A;RMQH(L^X^
M@*(8BF+H(E\>5S'D)0Q58[(5Y5"40U$.13EL3GZ-L_-F>$DSO.OH#EW1$$5#
M% W1*PVQ.=FHZ(>N!H6::4R[42$/%$O^L0&@O3=V[9G"QQ^ICHZZ0>>X,O)N
M,:_G=I+O- \%VS,GF3U0<NY#^H. P3/M+SH^<FZ>>S+M)_V>@50'8K:]2O.8
MY&O._E#I?\2<;4D83WD8):A<VL[,UA)K1)4PA#$= A;71UDZPKG/:]ZUY1)Q
M)C&R7B24--$J4LZ%/=Q6@A__M1C-+W^9U//9HEG;_"ZO;7Y_9B?+?07K><IM
MC=6CMPM+<OMZX2+'/9+C AJ]H]^VTKL_X?[2':Y[,>B1%+8&IXB,\'D+O33(
M6$&08%$E1JVA+/8$/3JR"]CP CP%> KP%&;K#=[LGY$?N"5<,XF\# G4//7(
M2N\1)8(XG8B1?&?GBL6<,,  E%B>D1\]159Q@Y1@V$OF 63\TT'#1G3D&CBL
MVV(W*D5S1J(^]$J6^VVK'LH[UJP48>Z1,)\D<MPOZW%RJK%KT%R(>MR\Q:J:
M]7%YB\WM&32?Z)B)C"75F_44S<DVS[Y\8-W)<WSIQJIV[U%VW-9;$;LC1B>I
MZ8M9473VL\:D2#3>^D 0]N!]<'!#D*%,(*V)$(P01JRY[G@D3),(WJ&8=$0\
MJ(2<HP))H55TGA&'T],Y'ML;F!^=T*!<#)BB):YT"F)<,*-W].LOL[T8S' ^
M1A481XPP@SAU'&FK'*)*&BID]#[LY#&ZC!D=26904D#G%/3 28)."4EU M4+
M4;M+U"+WA44[SJ(O@*C/64)?0M%'"46W)4?=D:*35/3%FR@J^XFB"E^OJ/O$
M<0O!/*$I<<2)U;G^4B*CG4),>,U5Y)PPW>VXQ3\:37BP6#<1;*!$*=X_0#WU
M0YLF"SP5>"KPU"EXV@\>46/!E?!MUQ=GBB.C!$&.4HNM2@:KG0K-+H-'1X+>
MI8+_-/3 28)."7YU M4+4;M+U"+WA44[SJ(O@*BE_OKD@MY@-Z<X*G'O;JBB
M+W4HMD=<T2'-,Z["=.'&\?918\7I.#!!NZ']3R)^SH2P,0:)(B48<:($LE0I
MI*UAC*D0;2+=#H'\M%*J!PNAJX$DI@LAC%L%Y/:Q>B7,7M"PA->Z@G0O!<5N
MR-%JGIS!$3EI">(L6>14$D@[%0%\''<J] )C%@ E'8FQRQ)C/PDE<)*(4V)M
MG8#T0M3N$K7(?6'1CK/H"R!JF<W>Z]GLO#O"<I+ZO,31>Z&]2QS]SNYV190F
M!B-I.$><A82T=@X9C%TBA"LLW$X$0BM0\SP@2EF$8Z) QB2'%.9$1AZ3Q[3'
M,]Z-&6#,NA!$Z%>4NQ<:H2O$ZBM$=85^91)\?S"&,Q*]4!PEPW)%N0Q($P&0
M8W%4U')CH^\)QG0EQMV))&Q7=$$!G@(\A=DZCC?[)\%C&BSG-" 3G45<V(0<
M,0%AP3$3R@N".]ZDVI])\+1,@C\=82[(T3OZ%9>E/RZ+$THQRRGX&\Z ^\$4
M,M8X%$R*DI)HHMS%I8>Z+.YN7')?C$MO/WR8Q0_@>?P"X#.:U"/?^"<;<+7M
MJOSQP]H9D9O."!)WC1 >JN*,'!Y2GK/)I23@[GAT?U^& RJ0I"I^OHA-0\M\
MV@QO*BFY$S(>2DJNI.2>.ESJB>,<7%M&8O:)N4.&48<(TRQ$9256.VN7O\3V
M&,_.9T=TB%>Z\>TD_+C4C.^G>1K'ANE14G5%4Q3H>B$6<?%[^X,]0EIM(M9(
M"@_8$P)!SAJ.-#<$8\.-8;*/V%/R=AU4# 6%"@H59NLX^.S/VWELDS6$(VJ)
M0]P)@PR1'#DC9$A.BRAW?90OR-MU!"=*"J_(=0&1 B+%E>F?*Q,8H](FB33\
MAKA4!%GG#=+44Z((US@\JNKPN2#JAL1>R>9U&5TVLWGPNW7CN ?$P^CCO6Y1
MPI]=R)5=7=QM5]-^-)_J]6@.5^$?-B[NCV9<7';-JW:AX2:MUT3;G)#'AX*Q
MKVX9D_=,=/P"LMV+2#\L0 ]\J$"!5/-/<?PQ5N?PWEE=1:!#N#D1V85K'S27
MG96GG5RNUK!7^Z[P"T[_!.A"M0<<,08QJS@X,RX@8XE%U <2.&>!\IV^*6N4
MT(XSY$T^1A,"3E/2* 0IA5>":2E/=I-T%YBM:F\L9^=__^/O=4[8Q_.+\?0R
MPHL+$)99PXT@([CZ;6PGP^H]_-E\M$WL3R;@ (XOJRD V6.9]-4-%;'$)6=\
M1%X&C'@.PQIJ!?(,RX1C4'(W ONDC-7\R(8(D+OE';+7&\XE)W6<=$1'INEB
M5F4'O;[#A>["Q39E)6<6%+FM/BTC$LBV(8E61U8!#, JV=&L^IBMORI<84"7
M[J1W>)1UPU^Z#S^$.1\$U<C% !)OP5O)?@VRX+-X;*WC>&<_1Y?AIR/YF5N6
M4G>!.8?%Y%U2XNWM)79=N$2P;*?@[@#?SJ*??IC U^<Y0%=2U!0.3NJ8F;(U
M,C[9N@_*AVGK2;9)G%,"\10HTEK)7"8-W,=3-.%1!4HKY?/CTC;[(\X^CGS<
MKXO6K9F-VJG?9YIOOO_]M)[_.IW_5X0K63V&@\5*;BX]Z@('5G#\&"YJ4,$Y
M_5DUJK=J55VL-CBS,6GWF!L7C7[.TG8D>Y<Y3*/$*/G<' RV;F8KCC!)6 >&
M=73Q$!U@1V.F%L!^FLZ6+^7/[;>('Y$?.C1KT"'O@QW<&.S[4:]S$/<,T;'_
ML."/SBXS](FJM:L&U6TAL\:Q (9MF',"3F8C ?L/*?&U];BM2;6F-&T,#;$_
M;#5M3=NL7"\6,W\&Q.U#*"L2+30)"#N1:[Y KVJF"/)":":TA9=WAQ!+DSC3
M":ED-.+28J0]H#M6QKF0J 7[X&"^Q%Z/X>?9M*X?'[4:8,T'1/8F;@4&)#C3
M5;,[9= #YG(V<"J9 F[2#'&,%7*$2R2)TY@)PIW=<52)]10[X"830$5QG0#>
MC9=(4<EUT(ZY)'H;)V5<#9B\>0MQQ_AMMG]?3\:1[C.?#"YXA0WB+H)M"7\@
MJQ2&AR&M45H;2W>8SX%_(@08DTDFF1G6(2NE!O/4&BQ ]P?B>LM\%.,!4+O;
MS+=IGS1]KS<QX?W"]RM0;N.IV>N.,S\"9+Z KXQ5_-<"G'3XJGRH'T_K'$9M
MS])^H.WFR^]>15X'C0 T.8$CI@((^#\&_!]$2 !@]LDB$UE 2DD9O;6&JMUB
M[*<$YI(*>((HTJ?1_*P'NE:$Q)BP'%'"..(*0-LX:Q"3PB?I(I-RAUE=DH$$
M01%)+B#...CGE-=?>,$\I=X"^QZL8WZ367_/KEH-+)M+H.R'[>@RF.Y7 61$
MOR2"3$6G5>M7C<K*"@X>6]9H:31KTYHCT&)U=G"V5%U6<OFO65,&F_7KZOC1
M9*DXF\S.^!)>J,%['3<@EH^919OF<=:JX%O,B4^C\?@)DZO2<B8,0Y3EY"HC
M%EE0CXARAR7!5DFW$[G4R8-SQ!.2TCC0PLX@DXQ$SCN*A1<^'G 27=&HQT^B
M-"QY<5\CXQ.P\MK!7YH)2[__?]7-8\\3 *)?S$&&@,43V RSNCW)AS;H,IKX
M\2)G/N>?IILGSO%9."E<[/+S:01RL'YQ%;:=Q7%.=.63=Q\&(HW*>F7!?%:@
MTKT@R&G0ZT)E8T8*(L3.X!2IK9,)"R0D!3.=2H(T2R"5*5#-N(W&D4[!P'T,
M[8X# >CB:(&Y&A8=;*CA40L /_WPMK+>QXM6G0-KCAO<2)6MW @N^P,HU3'P
M>DY@V8L+^+5-:N5D5CYP'&>VF9!Q<3&;?@2D@$,GT_.Q==.TJ"\J=[F3OI-+
MM(APH6%3#F81R 'JKH&>[LM GIMMK24HAI@0%]0B+9T&]DZ8,(8C(>RZ#!C-
M1%)"(V8R,I&DD,8B@N])G0 [BCAUN.%!3R,#NE<R<(,(--P;ZZUP[R8;?_>W
MMXV%#@81H:LZEZ41E=]K9:C1]E]/IE76Y-E+A=N_SOUJ^$WU2]HPR]8"D!-W
MDRE82/YL%#^"3.V3G38BG19P$QOWX^+5:N6M/$I^,ID6(S"ZEH\F5Q__6U7]
M%?X+CK"MZUS5_0'@L1UMD)])GAKU[\T'E@_O?YI<P.?7B+U)X_@9A=$L-H\:
MOGR\.)^\":/Z8FPO7^=W=PJ]AV(T:9[/:J@1_/G?"V#+=+EZ4,V!*$["FPMP
MS9MO;O 0P/:-FW[.7)&?]'K\PN=[5HD3^O#<Q%7?1!?X^"?4):G*P+?!94U%
M^YJSSM93K);4'4T 5>#"YG8V?VT7\^F;[3?@N;<OMXS8C+)J_(K7=OS)7M9O
M7GV[9MF]C0B9P39X]!JO'9:EGJA3Z]!/;$_CPH8F:"!N4U&L&D"9-H)RB10!
M)XIK,-P,UQJI8(7UTI"HZ#_9_0CW<A*V379UF73=Q.Q-ZF_P\L95W:6N;G!X
M#;54R92K YE G%N,#!4"10P/*$J'Q>Z"4<R(",[D AWX 8]6@#GN")(N$.95
M$C&$'5/$G\6P&,=WZ5YU%F_'XVEK+[Y+URLI<HU%_1XNYSOXS)^OJ@CFQT7.
M/,\6RT(08,48WL[O>W__)*]>> *[9;O6S=U;@98+SQK('Z41?&;41H?@"^KI
M>!1LZQ/#?]KP#I@WTXMLWC=Q=3@T3>%Y?JI??V&AQI,JS+L$Z!$*<]77U;1U
M74.X?*DMA&V;4?F&\L<1&$?3Q?(C[=D(QD/\U>KS/I>U7M3Q=1TO;':I5H1I
M6^.:XU[M&Q3Y<52/''AM\\O7J^^X80)D>UHIAX*JKS8A<'G/+09^>\NQ9"CI
M X]\X&%TJ)3"5_\>^CU]N5\RU$QW_G[O&%JJ;YU9ND^ 'SG(]!C]IOI$^_,+
MK6Y<VBIO6]IZL';\U4T>D8Z/\UP?-BOWOZ*=53_N=/X\"Y=V@=I%QCLBXP6L
M.OQP"JV.LF'\@?-L\3"/LVV<P7L/:3Y1.'O$)/=#$/_V4<)=(']1"T4M=)$O
MCZX66%$+12UT7RT4L[?##Z?0JL1HG@&]OFXR/M-%;2>A_J:$9HIH=QJCFD3B
ME\#.+J!YL):2?[/G0;R@Y6?W'<$8[<R?-=T (7Z,X^E%S@/?A\\/3??N#PQ]
M,A7R4-+V=1+K44<O/S.?OIR9S,I:(KU%FHF .+8&&1P"$E3CJ)UTEN_.9!92
M8I'8_]_>MS:W<619?M]?@=".9[LCF'2^']+,1M"2O:-9M^6PY9V8^3*13['&
M(,"I B2Q?_W>S"J\"%"B2( LD-41;1% /3-OWG/NS?M -%+2MAIP"EMD3&1<
M,$4X,]?#D;KXHAAVAQ_]V(:]W%@&B&V4 6)?*QMV@L7=>I ]MS7<)STX0,P@
MG@/$/#V(4=XQ8VU"DN8$-!IS,AE-B"D;J,?.<[X=\<JQQ(81I'#2&98(<IAI
ME!)EE$6-89X>%6+8"59WJ\O_W-;PP^C!SAWZF!#SI&W[H;'YP]CV_R=.8FW'
MQ;2W 8ZJFEE=,F'ZT[#F*3.L/2OA.^[./A$UO7=QO/]F]].F6BR(1$.4**2H
M$)>"(4TP1TR0W*3<^,BW\IR=9-0'X1$6-@(]$P39?$Y4/F%NM,-TJ[S6 UOS
MBO>PH_@W[/8/R_GH[*(!< 8)'0#GJX!CL [)*X.2IR:7F[?(>"<12U2S@),1
MAEP''.Y%%%%[)()C #B,(J<=V/9$1TX8 %#<*B;ZP( CF!X YPDNY\&:'W;J
M']*:'QV!'_HI6_,/Y6O=5-3TE&9-':;SG'W>-][U1/94[CSDSX:;!:6%$01H
M64J9FRF'K/$*"4*=HF#>^^V^A7>I-/*@W$R?*"-[O>_R1<%\%K1M +0!T 9
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MP.$U=,Q$EZA7S4WK&);[?&QGT_IJ;1&O-0B>P="U72Y]K"Z7*_>FY]@<I\P
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MY5+(]3L(<A:X'.9$)VFU9]+>>R:?BE/I]W@YZ[8R3C;MB_XZE9;.RM=K 4L
M?]EAT::.YH3&;'LTV:@L>:1%/XTKZZIQEQYQ!%%,QCCL<0)#@I+L'@6K1%.A
MD'<,Q-A$*_!6K121@D[93^$3!^E7.?, RXAT!',7%$>2>JL?P^8^SV]Y"-^E
M/YIXEL?OH%F/8&,'4&$>"9&W.AGER!)B8<'Z9"Q6EN"X_S?\>2$'OTPG?E[7
M<6\YD,#ACC0'<I'T9-N8GB%;?9W>3."\5H7<'[4>PH=!G'<F=V\I.[XY#MOF
MRDG>8&Q-8D+&K6V5P8?Q31MX#T]K=!!61DX04%$)M,9I9$%-(J$ '8C"UINM
MQ/=OGM2G0FL6$=4#J>F=<J+&DF -1\+G8@S4 =HK;Y&-V@8O%8#Z5G:)DH)R
MF='>\ BR+P0RA"IDI2 J,HE)W"K#^5"0?T.&>N2"4 ]<C1"6'08) 5_3R,.:
MHY028\SVSO:]W_(PU&UW/'J?%?5 :FY!:K:U2K-#K>22<XL [*9S],!Q@'UU
M3+G*6@FW[(I13.S$Y[H3S0Q&NPU?6=3TR?@P*A6J5M%SK%7/O)2OJN-:[9_;
MZ+HU9?F_FM$/TYR*L;FO4$ZTKOL4JL;/FU*$*HZGGPX;17Y<8<?MV'41QT63
M#"MEE9X%'R;M/M&JG,M*\'(DS@CXQ <0Z/+S?]CT(>::%(VO*]<NC\P3)]-9
MS(1DFH,OKD94MU$\F[$7UG>A8'8$CX5\3H 8CW,!MIW!S/;RLIY^!C4]B^.K
M([!,6)!@I3.!6,PYT((GY(+'@'.<Q, Q8U1=A\4DJ3(R8*1IWH<%WIHK>&ND
M.)8L!*&M/6P,!E$G"M]<9+L/4OK%[=7UJH*_UO&B @V^*@&X[K[/H1?-X4R8
ME(3*%3!08M@C[B28,#ABD/)DDR- >^A6C:MOF?U5]#*\SH_+C*1LOY C-6#:
M$H_4'($%4RK9Y?RM!3@O@\6NU><#M&_S6L?CJXU\^@M;34I=GAQX-IO!Z^=:
M/?!C!9<X#NO&"&<43PQ%PG+N/!!YJPR(JXY)85!R7FTEGGK.B=,2K'26SPF6
M(4.C1$S8R+@+F(:M /W?8C,# 0#V]=HVYWLB^N1($D]+F8;%"@&YR!SR9*UH
MVS)(<0G7BYB2UA;X%$?G-BR*0H5E.:AEV;7U)-:UPE!+6>T(;U&;6;BK9DM@
MBYC7N8Y!*]M'(+O8YG#L9!$E M2SM0Y,3ZV1M"%&0K03=LO#I"2SQ&1Y#U1G
M:]X@4.0J)RPE+ D#E6X>1';QSNJ#?93=-VUAK9*<W^8+Y;J[8%SE"J>=-'D8
MF%S5+(=\%#,F?Y>CG*I497*816LQB.W!72[VHOY#;O-94FMW&65E_2R<F8NJ
M ;F8_*C>TM:+*E^Y2&^N*Y&9:&:>.?BWR0U."MU84M-%RO?)*&;C$)ZPZK(+
M@)2-1[$\Q&AF/Z\72VQFK?V7,Q>JB1_/PVJ-A;C($[Z>O=!TU=U:DQ%-$UHS
M9.$)M^S8ENML'YW?T<7\]/9B6L]*X0,8E&E)2(;GF5[$[__2O=A?1[F*:VNI
MQHQ7*SY>DB:R)9O':C[>J!97#EA9!)L&:"_$<S#X5K'QRWH<:I>)MIEDNII>
MN[.,]^_=S\LRX 63_@:"!_ #(C@#8?T;:$!?7<+Z.&N:*2S6MHK0VXD_O7ZM
M-D-H51'\4RXV?*VH=GFB65=U=):CJ1>L?['6EQ=JET3'QEH)[J1V\=P/L;4A
M#/:28X5HL@ BV :D$W'(^*"9$80IN46:4L!*PZ%(:)?K@+)<@8L1Y#S7VE+/
ML7^::4!+[QD_FBR@HO\7L74-X/VLNG=(V VB9)TS&KN(M !AX!%KY*@*R$1.
M0\ @'&+;Q/P&41I,S,<U,6]PQRVTU35-_=&.YVUETK*)G^E0IB[P:U473=W6
MDS_[_?6(23QZ\7;URWN@*OEY1C]/)Q_0SU6V$\Y:;O%Z@XC]2QR'(N!_-$#?
M7G1%<%K2TMX9%' V!B;3M3L/6Q'K6Q%+L.GZ3[3S9"=+9.I*R"XYZI%X W (
MFG)+D7*Y#"S5$1GA)"+1.6D\5=)MA3=Q1Y(00:*8<JBQDQ(Y)10RFAHEC'><
M;):A6@Q>6SLV]QO\;9\!3?HHS*J%,0%TO>ZVJ,IPC*^ZU@9V=&$_KY<C/CI9
MTAJ,;>' '"<)<8\-,H$+1&FN,2R]"YAOR1+!'DQWBPP<!&B8XS^XM"CH)$EB
M6"=N'DZ6R&F_:R]NECM?<N36_BVE/S=-X$M[55K<3#= )\UG\Y+ N!#$:KT.
M36OL_J4CU5W%\G^UDS:QNP Q!5J_ZR*=W(+MO.,J_SH?+\XG72+>>#R:S]K=
MTNWCV_3?U0DS,-7=O'137+S0TFCH*H$O2@M>MQ"V_+Z;8-PLQ['S9W2)Q=?<
M98L>#*4CQ9$L21^]$"D <>0F9PBFA$PN^IVBE"+1I(&+;E49#)@YHRB*,F<4
M*Z80<$^/),;2,$LP$?XZV?P]>IB"V=6;=@"7L2S/3,<7-=[DOHU=-3A85>7%
M<I&X96>@I4$.9#%U]*MU+L$Q,(ZYM/['V+6]"3'9[*K9/OODFC@6MUS33<32
M-0=CV"W0UBV4^P4<A[/7.>MT,& C)0]&#P=AU#@7N=?).<R84W8K2T+S8"0'
MV64^YLT- ".M.4< )!)SI<"(H \NN_PX9+?;FVC@+7)9G[8M6U;Z6]ITO<="
M&P38K)Q,K3NRO5JU]GVI#-S,:EN\FSD=L:L*7!R2N7H,/&4KR;O]FD,XS'+.
M?K9N*+MWW2>Z;#K85CS3WUYXKXM)V S* MC_];P:VQ#'E^>YU-J7"Z\=*+1:
M:N=9E(#CF5HS*Y$.+B*J610Y"X6YK79"1&.5P%8#],Z1+$$F9(,PR G&P49C
MWCKZ)/V/&V25'(/7Z*3(7(ENZ0CW8<0(H)$3)322,/F(@ZV.')<8@9P01@D.
MBFU9:-\B1D_(]W@]!/0HO-C]J,B7F(O,A8"48:"L0K;NK8HH499MBY@"<7W!
MC=FG:7_KU>RHQ[<J+\MW[OPM"F.M6N]]118VJ]_DNYP\@")B$FL=<4"82(DX
MI2 BDF%DF,H!&51'M=6=Q@8>"38.41=!>3F>:U[YK+P2\4I[2^US4$3D"!31
MNIRV!=S(%^1T%:;02UF-DDG+0,=AART"S*/(A.PL9UB)F*3 (FS9H=(3BYD#
MX<0 FE@ 7[,@L)83ZK7UP>.M#. G**OT*&3U[62T*C*PJ]C@K,T*Z:+H;I;&
MU6[?2I"7/03:']-T7G<E?O]7CB8">Z,LEM;;V47<\\T'^& _=IDG.;HO^R>[
M,PMK_&C]<@-Q62RUZB+XX5K#/MZ.N)G<D7['3-_"1K1C.*;,YX:)^'^[UC>_
MUO.FN6XE/E#I;<!,X05FR&.5RT>FA!SV'A'NN0\J&,^W'&;61N:#=D@"EL(Y
M+"!KI$>>24*XUHY9_B1+;Y>%6$C54>BHWM1A;KU_,,=YI^=A:S$3@:4+N8Y&
M, "_SG*D15!(T904CU8%LN4$818H(C$*!<IM=B*;7+F#(1F(-%1Q:91\DDZ0
MK/Y)&S?#CT+"_\C!\7YMT#<$L C9I@0_U?1SKQA.)! 4G,V)V80B2X5&QI/D
M->AQJ[:K0PE% M6@P6F <V*(H,:M0BQR>+:HJ#.J7^GGQ)H0<E$<D;*3@ M@
MU5;FR'XFDD\L!+L5>'+_MSQ4^OFQUM1I0U)VY4HWMXG2'W9D-OI:C;HV>P/C
M[D:E&P\0L*KTABQE=*^QZJ:$'AZ!7K;"!Z9=0E*([-8$OJR!12"*F=%2>NK]
M5OU%S(@(S@AD<G4CKJE FCF"@,<0YE42,80O:ZQN" ^JJ7JHF#)\'X%,F,2P
MTXH@HVW*\RN1XR 847LEO 7)V&Y$K(2. GN0(RH-(!\)<+:$2Z1$0R!4DO"5
M(BK[EHDC"5!8B_+JT_/-/L7QQ]@Y=6XN( ("W7H<<I!>NV4\!FOJI[SO?$TC
MMCRW;708P2#_"#]_N"&=*RWRR)J1G7WAOGT:L:+Q#V,C.L<3!@Z)<(XBY2YP
M9(!+YEJI-L:8)/%;Y#E*RKTW!($RQK @/4&.$(R2< &KH+2AXLL+\M^ZJ3IK
M9^JWQ40MC4FRTR.2+<:>(#7/P-![*[%(\V$$QV.8;4=I*S,\QTSFHLK(@*;6
MBJE(W7;=#V^BE"H@83G)!>_R)CF<[4B2@NE<ONXKZ'[\@B..0W"*I^_;=>]H
MH7MS::82:%EG+]FFTNW3BSX? 'B('NV>J  K&9&<R\"%"4ACSQ%EG"L6>'!Q
MRT>Q=S!YTTG>;R!XO\;:7W?,7,[KN&1^B*Y3/W8GSPSSCMHH@9_FRC<<YVV$
M)!VRVL'H.N83WZKIO'=->,"W)KNS/'K,@+_;#+D]+ZEZL^O;55<+'\U2E_4W
M?__[:UTPAG8Y0[N<?3S-6L3!T"[G";3+N3._OVN+';JI8.YO5P2M<B:CRW5U
M:?80@3U/@D.,:"F,I#&Q+0YQ%Z_AKDWYY9[.W^RLI+B\S]ES[^%&/XRG_L\7
MHP@ >IE]T_4\/O<F0=T8Y6JRT[2CQ&R8KZ5P+>K,KDJJ-%^(_^^1,5"7/(4T
M'8^GGYJ7?7K8/=3W>4@5^#6IOX<&!-V7__=/;:[K)F3E)VTQ:9,7Y??)AR-@
M.]-Y=TA[-X+Q*?YN<3Q,[]A>-O%E$R]M-F87XU+VT-OS7BP> 9YAB9D?JZ9J
MM<G+Q376#H0CPW+DRFTU/B7?K2-:]\8MI'W_A3/)J>%W//..IXE3(P]XQW_Z
M?E;O&M*."V@0)3"M_OQ0@\434+< 4_G?[@680ZE:/O*R927YBQMF8X.1 .L
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MW@.2WAM),=$I>&L08Q10D7F)K!8$<6)2M)*%J+8B:PZ)I-GC^?[3=&\ RM4
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M;0P//',7JCJ=-->VQF*ST':W#UMM8*[@KZ_$KVI\(O$>LE8&E?#ECH8#$ U
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M_;WLFW]^B=BK-(Z?4:CJ6*3\)4SC_&+R*E3-Y=A>O<R_;DGFJ0 1R^^Q\"3
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MN?NOZ&=9?&S^ ) WF54%_R9S^&>\-!M@>  91[_'=MH 5A8R^S9'8DS@X-_
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M]Z9J/(@$S/E[N,$/XZG_\P40<F\O,\6MY[&+!>^"Q6$-7""@ZC,4QX5CEW4
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MPUZ8CKC]W3)X?F_O',$O?$C9A#_^5@AI.PNLT)DO+MR0VT \FC_#[^YR%3_
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M_, +EKMSB7 !VU2U5GTHJ?%UGD29K(U5K&P^XMTAAOZYHY+C:R.@*AJ/M[7
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MCSH>$@I2NO"[F:D2F$?IHS=GH^I%BHR7.A--,FP9NI\)0RB62>=4]%EY0WM
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MQEP?P_O?P!CF401H? 2Z&W/$6 HG@82^+4Q(B\:RY7P<["*!0(UWJ/YT0X#
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MU/)@4!AA6*N)5$FA#43Q04IAX#!'55$<.!/F3YZ[% &&7>1'@QONMS!%PU)
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MK[]D-CET(:2QZ>R)QR^<^W)-D?)"XXJQQM*4Q][)S(]OZ7Z28$[4ML2Y2G[
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MLCJBN"UAU2<5FC7";K0^_L+:3!UV95AFYB$R;"2J&,9O0SAJ#W"7RW@,J^&
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M$?0"QW_</Y-X8[B:_91TA%%G,1N6N-T= Q3L%-'5\^$HP1JGI&,_8.0*\1B
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M[)@!SY4[J]YQXQSK?81V)-XVWD?PWK8VJ9-A9NDXMJ\[Y]W"%N^-M?C/CA?
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M3]A7>=@7?"L*5V4F>%C9:"",\!M4%'4R84B8802)9R P<^$V D @JIC(;O2
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M%6#@8Q.C_[<'IN&UQIRN:&H%&'=AD)9EIRJ("G<Q96,K0&E-5<7,W_LM):1
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M*,.BP?YH=;0"1'7BB59^=G8!UU7^:JPC4XEE:C=P*U9GGBEEX&%&Z]9;D9#
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MZI\(DMH]D/H'=!)HK'\ZJRTS$T*2!O77,OXPE/UXTBAK]FK669>FAK(N<N5
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MQ-/.)UVL?W&BR E*I9W:C##.^BD&.P&@',(@&\X]W>)EJ."OR:J?'7Q2@$G
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MQ@0UZ6X7:8 #PID.3QDQK=75"C(.-QEC_8N3P&4^X .CO.8:Q+W): .>R,S
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M%1(GI4D0LO\=(T$XD1R V4M'EW>.UJ&P-Y?XGSCQ5O@27./OO4U3+X=VHUJ
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M4)TC* S#@&@4RMNNU\=<LJS\:J1GH;JMT>(5S  A/37J=I8E;IQ'D1-LR.$
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M<\E\ 7&_*&.<3W#;=R7&F7W8VR44SRA%3M;X'<MO/18VY>%U9S^6>A&R<5'
M)Z)<;E&<JEYG:\3=1F1/H%H4T1^A*R..O)7U@$:&-!Q1WL=NP>#9U-GV-RC(
M0T1DY>CG&VG(NK'Q;08X(J(T;,@A<X7>4!COZ,Q*P: *<U3VM$;6%Q01A3LD
M<UL$6Z)Q4T[,\!O2(4RO+Q MSMB1V7)9TCQSIO!E J<H:YQ13>P49\%90#8B
M>Y(Y27T>")L^V318>#K_17#P:BET';<-]3%Z%M!-RIDFCKLI?![!K<)@!M94
MF$X'GETK#&&O+<X8DQ)(J+46$PZ+?(S211#@@M#;:!4GVP)8!\TMS"C7(%1E
M11&W-QR0<X]#E&9QA X[>!OG4??N*6MI]MJ1)ED#3O*O&DKRCV_W<9*MO36Z
MB[TH74:/R NO4[KQJ*/?0Q+O4)+MJ?\?UQPP9@3#<"]7*^SSKT3][^W=Y?/7
M%/TKIZ?J&_F/(D&;J#6DZ<NS50G;V[-$^C[=72G5Y5/&JT0TWN#((V(Q6C\B
M'^$W>G"38_T.K0D/$Z&9[9>K2]H+)>30*KA8EE?/Y$]8 ZHQ-3J9]O2DJZ[3
M\Z3"[9$J5ES1T/WVM#+7^\#;?"N<6/M[P_+R=^\[NHG)V9Z]1$1#2E*R6K\2
MF9UMGHA^$/DH%<M2[;ZG7V7.MFQ_!\V\_OE*8%'"D0M6QX=!LAS"YJ (4$AF
M80<H.H74J,UO:VWJW;N$[)6%W]9B-@:BKK/E1Z]*-93;%L[4%0E3^:TM;MJ,
MZ$)$*4H0N8)+V9W;]*1G:B6SOZ!XG7B[#?:]4'#&BMN>=LIHW9V$\,XJ;@OC
M\GV%4C_!S")5:-*'>[1@"48.9%BUO,%)FA%1'=+3YI_(2\2:I*BI$?A3Y/]Q
M';_]F&:[I("?_M6 GOSKV\.BBV/YJ34!(;':U:8]A2_#L#$^W^UUV+JTSI&+
MSQWVZ<\LU@DJG@!XK"UK/HGMZ["-5#:P3CO#<[F- NQ%7GTQ;*S4,_(W41S&
MZ_UEG.SBHNZG>+ICAS(NSB(OU!5G_*:G$V?W7'%V/UZ<":W;$;5-+**(7",>
MXSVY_.^7KR%>LX7@6[FE/2;9$@L6%Z/:$*U6)S>SD%\WN&<F_3W3*<OP!YF6
MUL82-34\HZZD)@=GB@.4E*]C0>[3/QY0XM,7L34WU=G@,0S34+_LJ9Y$!"VG
M>@<K#V?N8=EO9'IEO=>GG2=#H]-B*A3NL/>*0[+GI##4K2S>4],4H>6.<6ZT
M9J8C>H^FYOQ(IGMJ= 1%U".*T'MA"QM 4;.7:5X]($:U>"JSJ1BAD8I<MA4V
MMF<6:P-%8\>6JQ<B$@F*(J:1]P%"2K4KO\:1GR?4?46+'%X_ ,5@+KUT([Y>
M-1N9/J(2Y"U7Y6V$RESNZ=1K9-?.3DXF7![B9'?])+.P=YN:UIM*/:A0I2\*
M8<3U+!&TM&>Z183]R3ZX0KN8Z)VBLU#9'(@\$,7%5C)9Q"6#AX%),#4ET:?]
M1\+EI4([AF#>,$ (E@>F\=O"\)U4^L55 ;(B1[59._H>X?-6 =>^7\T^):[<
M=:WEX"QV$YL[2E.XES6AU?+*FBO( E\NB@_'GVK6\FN$EUXEM_1=OV8-(==G
M[,!++3:;-0SN1 A"$$&ZOF-MF2UVTSH+UE*ZC4N4AW-1KZ2^9*VP9J,:QGGP
MG\S9K1V9)W MFSOW*7SJVM*,Y[\V5X"TG. .2H/$]6S6^^QX'[9*A1]Z)9\K
MW^F[>%=JO=#M;O:\IW3Y9.QU\/:;-1Q'.1$VQ;Q 'SD+\-Q)G "PAI.^X5GJ
M4#GK! ?FK,]=I\^YU\(:8^\:[5XW:Q[4OGAV[&1G <H@M4O@'CQKH(:I7?>+
MF<,QYM55[D!MM,@>-+C,G7]M#^]9@S;MD\\Q;NAG ;O6.2DQ%9T%2 /.3:'W
M_Q1 05)A]<^(X>$(1NM80F,R$Z>&*#IBUL -?F,2OVZ>)4XR+:X7W#)%B4TP
M")G8@MU0G"D @RSO)7E!N<^4YX:/QFYK.(Z?1?U4+=US[ O<% @ZQU]#HMZF
MJ!#K'LLI_8*G@&E6?-4*/#R+TK;:3*63O-TH5,XQEBI2]"R*\FKSDP32LP1*
M*JL4\;MG45OX","X4<*3%/]U&[5N(/)Y%-_5%^Z<*.GS*(([4+'BQ6:?1QU:
M?5X2A8Q/4B76.5U*'9Y^PL*MKH U/!3^ .)Y79S'@\@-KS^ >%X7Q0$@=NOZ
M_70"S1YLF9^ZCM6]EU'91CY;KEIJ*O4(SM%+1,!BG]=.F"Z6 V(DI(KLJ)U&
MH+)158=.Z1U+%^<K@?7Y'85OZ)XL[D:<H'[D<. !H.X!S^_QD70?1G&#7/*;
MHKPCP\=Q@N2;.!=G0A\XC!L$XS<32\R& 4_P8D7.3D-4M\<"3_J1U (ED*@,
MI8**@NL/GS3EEK@[;BP@>:!4F<I$K6%HTWRE2/4\I:>)G$5 F#D *TWF+-SA
M#>-6J$3GXTAK#+E"LSH+WSW#P#%=9=8N?>:!ZVAZ9^&A90Z]B?R+XLP+9P28
M6/DTZAWRMP*]"*V]K&SK#'Y"#78*CP=1(+H-R^@C^<^WVCQ:^!(]>Q]PJIX+
M:^=4,ZVGSRLJJ&IMN3HHF=,BSS:,M93U37N-K4V>S.0!D1T12 L*=EL93N[]
M-:X?L\7%*CBM[,,F6>IV&^,EIS@;H?=BI-PZ=0_[VZ=\Q+I $5IAD45%U-I.
MA<@G'T5$.L>JZI"M=J>=:OG++U&Z0SY>8<3?Z?*VUICC(D\)AQ)%Q_]7CE-V
MCK$_R:58*K#4_0SOQ__U5FLD$5ZM[^WO->VBBK(>H+A"+(=%K>VO0J4#:%02
MYS2W1@#Y?91FV&=!^,E>6K22W]9TF4J44-46!;?12RK>A+QF (SM<9I>>DFR
M)W-[]Y) Q,>2#M:(H/D5\#K2801NTZGX8)EG-&I<BQFZ;4TKMRCKK]Q-L7*U
M0DM-1Q=HW1,"HX:P5^N&*CPT/0D9/?R?/,%I@'VA5J_;RW293.$^*O/3U,D%
MEBLB=NGMLI#!MU&ET_.6R<S AJD]R%^"+\-9;VD&=04H0N_P%A>&C'1)9+VZ
MF(UR -/WM\1/$0/QIU_^+"D'S&EF\]);)$!N(B5]_Y;U, QH^Z>XPI$P<<(M
M&:;=U_"<+[T=8;(0_QL%_&R:!*HDP__VRI0G KDS9AA[NF-I8:7Z+(VM2F^C
MAR2FQFS^W$5JY=!A3KUTHQ9J MVC^9M7/=1HP'S)&(V(>8$.,FJH4VA3!Z%=
M1'J\9/@P$2;%+S<TD>-MM'R/4))N\$Y;Q1HZKNFCNPLQG>2JX<-\@<@,T6]>
MF!>O,&$8OWL1O[3D^,&LB8J7*$%^O(XHPY%IEZ8^T?5(U-JF=D+5.GIZB-6/
MJH7=%S;-IYA^N'K_V>,LG*,$SR95[!GO1>.\@!&5&^DA-VM8!KS5</=6]TUD
MUF IGU:JC)/B1XVYU\;0?A"I1%'[96+6##3@F:.1*%U\Z)T%6(K'E*98TF"^
MLX!,[O$A5Y+.15"I'KF:* G>DV;-2UJ/\W79$-X#UUQ9:,1EI*-VSCK08*1.
M*7MOG#5>8R02_UUSUC"-%$B]E]:Y5N,9(96$JM6LPWD&RJ=QC^2S1G",Q%(^
MO<^UQ," ?2DQ,$P1)P8;'?%F-.0@<1:A=SI;=)@?QJQA&[!9M3AWUE&*QA7]
MOE?,K/$;O$>Y3CFSAF@DBTD]@68=^SKF/-5W39IUEOTQT(WRD)IU6OF1.W:X
MV]4I(V;AXZCK]#7K1.$C;_;C7-#FG3W<F)%DL._;O%..C\'U"#^[>2<G'WG6
M"/WVYIVA?/QUK783G"0W.9S\O>(L%772WH:AI'J%V>[BB*:*(;N2R+UB.S:1
M=C!I[TQ"<8M)T56Y(9N@R,.<D_.I/*CBB+-:Y0)+R1PWHDLPE,QM#H7#@"Z!
M</U!^)<(/1QYR9Z)2%I AE:=BT,RM?4M+?)-UM8<2MJ_",QV)7=E,[(=9^UO
M<SI JXT]:W>!T^&I+R,F>13F)I&#I3P]$G4[\LEEA?W0<G6#:,'TD+XSY43,
M[ZNFCZPRZJ>R9(F,Z]6*/B^\H=:"M%=OD4E73T"NB9%!P])R;VBP_A%X"(<T
M',:G,Y>#G8;-B;_4QXT%>G&K!Y+*&'W$LG(& TT\.<R(:,U)L]>P+N0SFGSN
M<!8X^BF+_>_TYDXFP#X@:M$*X8P(XK0J[#2.P76&!KWDAQW:,SPJ0WFG^A5@
M</'TPD%(< =P4F$VHC-\WNS& 2O6.C[O=IU'E/%:SGFY\IIC3I[69-1Y$&XB
M\ G0Y*MALW;^FFJ;:ZE^L_82FY!/!^F.L_8G,PHR7^.<Q)/, 8-B_1K[%64]
M3G/1@M@@HN'8H3 B*CI!R*'6F!<M>4'X=Y$D5$*PTBJ#Z.+UMY\CV6V+;V_O
M?$GB= #;\3K!(09XZCYC!%>LU=@M"N*X7:;.#Z?T3[V,TYY0.&HHZTM339AN
M_/*S4GMO:J!D[@<WM*<-T2@NO!0%S0:4'%U^-?%3<( ;G(=\R APR.2&K&B3
M*.@-A[QEMA&GX.<WAC/Y_H:B,B=Y([I6%"Q\/\F],#U\-'Z7R@:=6C3?X \4
M%'^2G[\EBG*TII:&XB,MD:P88FH*^*75^B?AT-YPV)"I68-T,D"3UWXZ OT<
MQ'/%UZ6#-H5AD="[; K"LU0W.J-O.;,Q\:HN6F?Q J9WVS02%G@V0 [<P/RK
MHM'7PO:>?896Y%:?"8^[Q)[%"ZR!'6WD8GP6;[0&P-9(LC?/X#>S#,N]J9_%
M6ZP)'BQ, 6?QP#J)?)0:'\[B2?78,UQE[9AUA@Y3($H,+E/DYG 8/Y5%9Y*D
M'.[JW;JWG'EGX##(9K+,$%/<^68&'[/Q39-)PP5?FWQ+>N^7J\*S*[V-^NQT
M$R<0O'!$M2R5^1R;3P.2UJ9K;&KEXE#.K>X!QRP^#VO_3)Q\^I!V43\X;4J+
MI0X>9I[L^.UGL'E\CLI1.T\MRE0Z0HD*912X'<L1R=)M0H!OC O^V5:L&LEK
MP\7SK)\6IMNQ1')/\E!0[-GKJ'_OL:')UW@]HI#>QAY(C_TB"'!!W6U$"Z.4
M^2RIBIZ>5$<_^G!O4O6<>%'J^>5,N7JS=C>;=7@+.QI[.%Q$!S.OB!)Q>VLD
MU/$8 IC3BWWK&\[EZ[BQK)&N-\EF_3T]QN0- (W(=IIZ/;K*/H:OTN0'_.\W
MBX<D7B?>]I :OW^!YK8# :LVEM, >)-@%"0(^YMT0<X3[%6^#6&(Z>&9BD'5
M[@L"Z.8>4]SFE=V@$31<S!PE5P2\]$!.)YKZ/@HNB9:WQF\H6;Q3?0^EZ?4;
M]1(4\Y)V7QCW(EUEA%O_I'_>S_IZ9$19: (YY.B=:RW202=T7?&#>UR>!?>)
MS]P*'?VS\$RY2OI\-G)[GQWS"8YM#0%W+B6ZAU^M1."="V)3'ZW35:^&A.*P
MLU1?VYVUV?94+'C7>[@Z@=.WIATW0"L<X8X5MV,V/<JV6Q6'O20XQB$.*$+5
MAVG#1X/E.-K$(4$HO?Y73K"Q9K"MYJ<RT7(:VK-H'N8B-56V&UF<;&^Q11/N
M-;2/<#&1NHB*Q(@A[V,O26A[-E)3'K^MNU/_1H2>EX<6;6%D0MLRJ1O7KB1N
M9X_W:2A3NLRS-/.B $=K$;_WVEF;<OV ^.#AX#8JP^"DB,O[V!67MVF:H^ J
M3PBJ16%.^F",OJ)W]HU8 NGTM6@7SLB>1,&UET1D<GQ#JZ(QM'4I-L'(A>EV
MMK=_?#_?YDRE90%05(PF:(.BM$KU)]]+VOTM,E^:)=AG*BE9#+8G"OR+=6%E
M"Y^]C]]QMJ%*".4Y(6N.& H*X;V)%A_<Q,DHXO6',_R.(Y-UG3G2&V\QN>OM
M+HSWB/KN+%]#O.8F1S<^/%S*B\6:F/[R1Z!)[F+;TN^6[#J>7G^@Q,=I?0T>
M<+KRQX%&<K$2!FB6#71";C_\Z'+UNT?3O/!S00T<X33S+Q \B@#A$!;5\/_+
MTXQ9>YYC@7[-9OW:393PB,CU+<49>D+)&_910>%C40F7-F"K)=3D)_Y9>]YW
M F5J\>;AD)IU5G&2>B&9OD\8@P4@5E@<M)"'.&$6UHS([-<\H[V>XP=F*A7Y
M\$W\J];@)).K2^@)B&^WX4RUMJ-RC=:U'9U.,\C^3OU=4?"//V0)8^#RPSC*
MT$=V'3*#T3_^D*)U,^EKU^9=V8)QE/T8X&UE\O;"*HBM8^D6VC5;SZ$=0Z+$
M5#T:B?_L(;'RPKI*DS:I ;/H_+!MW4/&$=TW2((F'&_I+HRC'X*6 4Q N\QB
MV4KESC>N.8)$:=>;$(K*=@@;$O6ND%I1FS!P;)602=^0D1,_?T4_5'RAX ?A
M<YZ"8Z9 H7] V!:+?;.OXW1K,[["?#P%##^#6WX]N[/C6&BSA,A6/07]?W*$
M%WJV;L?!T)</^N;Q*2#Y,S3^&&=+GP*:_P(.S0!K^Q3P_ 4*/.9-]E/ ]<M<
MX3K8^:< [:]00#O"WC\%+G]S!!?IH\ D-P P%J%1#PR30 +F-CCNS6(23,!=
MD:9_WI@$1W#7B\E?-2:!$9P6WGG-T".Z=!9O.X.?W%6\3@-RN7^E3NULH?>/
M./U^[T5>4:[C*4L(#.O](@J^Q&\HB5AB(Q-O1^3W_KB.WW[T]T'Q;$3^J%^+
MR#^^#9V6(%;[J*&,/).9)Y7G<SY^'%M$7L1$8UZNKG""?#)XNB332O%ZDST3
M#K\@/_E=AT2-4:P22"WZ.,L06B9/^:M_^!>Y/>R(GD>32I.;Z!&DCQT?*&OW
MQ.T1['UG-DSD*&++JC3,[D#S3Z6T,-)M0+[!JSVMD10%K#'Y\YG\MD?TFR&L
M8.:' ,%T&Y'EI&L:W(1>U_U]Y""VR"OG0Q:DR*U%H)]:-)C^29"<<>P.X8UD
MBU":7WFYJB<YB#9Q9_OK]KS!21&D>1VMR6<C]C-_"/ND/<0IT]#395+MJ[2Y
ME89++IT1;1%>+T,E(&AQC.)HP3Z[9=>GCR;MPP>%O^YCY9+VL/8@R%""O3#<
M+U8K1$W?R^01>2FYX;Z&^SO\'87[Y[C;ZA&M,;U/19G^AC#P._;YA.9M2C)F
MIZL_/)Y/](=UE4\& F/JQP#IA_7"FI QQ_V _8VDDHR/:!<GV7/,5%SSIVY_
M>.=\DDT8U*CA\PAK%60_1HE!^$C3E1"TXVZ <P)SJ$5(@P^/LK;,$UL#!J@A
MP'?M-X[ZL4ZU^XV;A.:$KS&!H+-09P2<J0.]L0#S1,^:K)R8+T_@SC&5P)38
M1^>$U*EY4&"===2K?"KF&VKRG1-\I^'($;9E1]W\[?/HQ*+3%H:G$ITF3.".
MQF%,S[L#3.9SPM -WIT8_!-$RISP.C_$@N]H((W]HXQC^'?3!_<*I7Z"V427
MJXN<;'K"3F2O7W@I3I>KAV:>;G&EOL\4SE!3. LR4]TC+[I#;RC\];=%1M8:
MD2XT,L&GB[WFEA]7=3$+9YID#2C)OVH8R3^^$;D7Y#Z1<&50!2<UL["9C8G2
M+57.(>6F,I:W=6_*1V=?%C#N1>[[7GB)PE!2JZO?R/Y>_TPF;C&9N(.9N*O2
M3E%P1:5NO*,<L:!1=^M#I05F5'^.B1"FYS%]H*'15>DSF9:B:J.)L4WO;*+N
M1S3?QG+UE.7!7K*]^2U=7*J+/0546AW1Q-@N0G,:+K9?)<!(8L*CLI1^QY'B
M0.TV,3R#ZRA0;OI>&YL+=NFE&Z+ZO&%R$[O8OY!;[FU45<]<^!E^8Z&KXM74
M'0!,OOY&&IPK<COUL;@TK;*C/36 H$[_1[63-R]D*A517#?T*H^2[6WTALH8
M;Y%^H#\ S/S/KA<K:.;4>4B*:'KVF8@>87M[)'CT09D!38ME$0F0E'D"?(3?
M4+",&D7%1&0-&L,YI]'/1+;R'!U*ZPUH"*0I;57&'8J!PDCA"/&\++9'4^]\
MXEHM U2U$3C6(-!T?V9S_DQ=K$&ZT5MSO5D$!A;(8!G(\RR6J9 )UQ,51BU/
MG526)CC0$81E">5A0SSM>0\F,]U1::_ T3Q,Q^F9YQRE>MK#K6]"A R3V^4+
MP"5G'&*1A0R(0;8P=&PYZE ^-&^WVM;MJ,/R,""&V,<=]8)UIQ@"F/SM&K9W
M1_U(!](_S'#ODC\H#7+[5CN%/N5;TF5/B,7KB(7!D*/#]^,\HJ?I0QP2F4@3
M\QKW!Q6]4&O-I[=XK1?L@4.8?F/7^GF>/^C@[M8>MHCZ16,H]@\AG5T4T%.$
M:1U$&UOEX1U>B5[I='K:*VQ*, YPF!,5LI&5^JNWE7NG*+O9\^,KRT0TTOY+
MG>+$[3^]*EWVJA2(JAMR-/;S_(L=<Z3M3^JX_$CO-MR)=K\]Z;3NR=F]S;?"
MB;6_!R;GKC_\,"?Z!5UERGAY$0NR7!TN2P<E\&+/'T"R(Z?\16 P'GU<3.2G
MJ+.C!+$5]7<P-[E]STZA6J/T^M7I"8\LI<>N3L]YDC55.$SU4S<Y$8X9N;N1
MW[_!'_0O:KM9KLAE 56M).ZUHP8R3 V+!,:;. YJ9Z;R=.3-6=;\M">\]R$_
MX5O?VW-_#;TTK52T9?)(HV._YG12Y&99'3J77AA2(_I!E2L;"GUBCQP5%AP'
M3989N&IU]C#;GX: H!P+F)*BK7DMMM3R,(U65XYMCRLV5(6XC1KFE01'/MZ%
MJ/[HB9;)]I(@?=D%Y%:Y" K3WA7Y6\0@QP[K%""WVVV9S.&:I7(P"$IO:)L*
M@X]0D%*6+O?V8<=+]#IQ%PC1D4T;OVC1!*WA3+]5QUZ/AF87>X%%Y:%9O5L_
M%0[UPC@B87OK)!3Y,:@]6I,&3@=[UL5B!L64"*R7<;"]);SQAH/<"Y]Q%E+E
M^) B9)E\2>)\UT@40F_MU_1=AJ4*N8[R;?E2)+),3O9[H" DPF^%,^JY=8\\
M^LST:_Q.'34:*4@& *0SFE-G)COMQ5+WB!'MJ9FBF=7<>H=3H2*IV=NY\*9C
MWC1KM\ A+XJ@_7#%[_/' C7H9=)1C(;:G5N!(^*70-!H?(;1& RCT7CT<Q0"
MP7/!(2BD\RX'FD@MCC_!"UZK)+I2XC@"J2S\ QBFCL1W*D-\>P^+ATW9VJ^.
MT"B*Y-4A<@X+.N*]4TL[FUDDV73P.,)$:F5EP!ML'?DS[@D4,E+*.)"Q/J5:
M?#5U_,<)8LV,W+"EK]&. J-2B=L/V9")G'2/=$YOR#%C)S"?'.TW !F_D\C:
M26\1CL;H3<J=:C<.R*B=A"<M! Z?(.#1%%<9\I!Q-$K2V-X\VIG&T<A*FP#V
MG6\<#<\T^/PC<=29 IR_N@..T/EG"ES^YC N+:^B26Y&#KVH2ER5)H'& 9N!
MC@O4)-@X=).<T+-J$F@=N@:-]KB:!#B'-/VC?+4F <\A!5_;P\NE;!A#$V'P
M6M%ZDE&*;)='ZPB%1J*.WK(J?"ZY7>WYE_H;%.0L'XMXGA?[\DMIG;41(UDC
MNU*W2O9*%Z\IR^(E($[<'@X)NE.WZ-3NT;?$Y:J<B21NE]?2VK1O(VH%V!8I
MJR[C-$N_QMDBI#]&F%@:T:K5=:Z$316K^XS\340.A[!D[3A*2SX1A^4J^QB>
M8R-7H')NPK;V-BHYQ ]BH\@36TY,M%V%[0W#^C7>DI^.5WFZ>\IW]'Q1HJOJ
M<@;UJHZ>ZA<4D=4-R95R$6R)SDC//FK0EX$_K*]A/J$776J8]$(E?XB:.A<-
M,497;5U\QZB"D+U_-/RDE'I@$R".Q@6:?"U?0XE.UJ1=3U5P! Z9<Z%!/-SP
M)M3/E3S^JM@RZ_( A@R0AA@9HDA7;G%J-=9Q5,8>1!*A#-F1;BH^$5\E'$=C
M+'](;B>0'>2FX@_EG<AQ4$:SR?0U3DZ8@7\H:PR\NCGJI7;4QA%>$MU\8[GQ
M</*;%^:H?*/<EF4'.H4(R(C?4?F<?G#'JQY>^D4+[CG-+3_&5(0NTA2Q2=YA
M[Q6';&XE\<&2II//$UIK@#0@1T9R^.>%EV)ACO-I?L.:X<8$&;)''W/CVX?H
M8E_]^2LF,C/Q-WM6'%;R3J'9V3YQ39G0GZG4U#]LC/,AU7Y>W+J.C"(-+J<A
MD$E?>AE:D\/VWUXS:88&$=R.<R3*/INQ:BPKE-0U]ECMTQL<>1'5GFXCHE3F
M;*]0(E+^5]*-9_0GK 'U\O2<,,&QKW4EZ>I+.E@CXCZ.T+[0^F[R*) 3(&AL
M_Q"XC79YEK(3^"<I!;(>]M*>$36\K[E74ZUU?@%1^OWMK51__\KT+$'K3YFH
M]Q-3N6*\/'V)WU 2T9]2R#QU>U!2X^?!4N-GVV0LWLBMG%ZF;N*$UEAK7MA?
M&W +:-+N;C%!;;*+$Z(C7<1T2V@=L?(^H%CN3X-9[D^VR2BN_?H'D[B]L^X6
MDUBCFA9<@S8<R ^*VN_0QFU:7+ 5UB#(2.HY?@RS>W$QTK.T. *5S"GD1%BY
MX3"BQUYBVU3;C49M-W$$"QG_F +#$091O]=-<7UJ0BFSQ#@.G;ZIL0F(R*KC
M.!BCC/Y<^<PS&,T%G*DTTP%F*M!0ZNE+<H-5$Q>STLT1Z*3ZDQWLICTN3Y:
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MV?DDV^D:'2W*7?Q&3@"RH7VD?)H1-+8N9V7ON,TFUB<ZX$"PS^^_H926[Y&
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MF)G/\#X)>.#N$1/F>)\$0'!WBU-G>)\$53 WCFF.$(T,XI/ .I];B/F4[9,
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MJ2?P.P#A*_X&!3E+DC3:;BR-?#$VOCUO_I"-BP(^!25SB]S\]3I;(^XV(A(
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M8H3&:7+95MC8GN='&R@:A;=<O1"12% 4,8V\#Q!2JEWY-8[\/$E0SWU$OQ^
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M'>7;LL;L'28*F5D+H2+7[S/.*'O2&M%O.,B]\'><;=B*4.[<X-US7-2D%F8
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M=[48_','>)VY4<*'M&13V,$=)X"Q'[TZV2^Z!&.]XTS!5(WH$@S5+C&%PF%
MI\ZY1T38V2<'=YE6X08%M%0)+?*1DV7:5TUISBDXYUJ1_:JJI5?.C[=,W!<Q
M;N\V%(M,"H4SQ]7T2+&",$0[NB,[.VRPEC/VT'$0L6<2'7PN6<ZVVP*G+OM
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MADO,(HHPN7:G1 9S:.%\"Y*4Q9HH3FMR7C*_ EI++#TH[BR7+/ND4JZJ*]O
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M#T875AM@^9[G[(GD$5')0=]4"I,S56J9L?F@\1&YNWP-\;I8\L+%1N'2?LS
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MP;/B]!L:-)83_\CGOLQB\>FD?W2:RJP_%G(T+DX.9'::*R,+J;(3+1)>R(F
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M^1A$11 5]X#^,BL-^@^ -6KRNCXRW>2K)TP$S"U@KC[=EE-:\EP4:RATP&'
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M[W;^&:I0,Q-<=\Q&*0J@%RR-4XL!T-ND35H#X^<N413=8ISL-0^2N6"[QXC
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MU:&'*WG>82/J:._HZ*A#'?;<?)Y\&>-77*M$L)]%UG_'9;K2_KD73-UGE>P
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M-CIM-$J#E]S(<?( _O@N+=?E+*=.@Y<U%4^"2WW[S(V#._K4?[S1<QW4Y)>
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MI'$B0$?#TK16-=I"/Y>R D5-/V(!5? >%L&Y*ICL!&-EC"JLK(&E(4Q@)JF
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MBE@-[@MH/]7#]0Y7P+]8/*%KGL^S#=_IBGT-.R5C>_XL[%1<[_]02P,$%
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MOF^[.'9%SK HQAJ*XL]4$2:#4H4LQSA%%7[_JG_2&X[V><;9:+_&+S0:-?O
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MBQ$3IN)Z>P +I]=)KI@'90GH,Y!Z)N<^YL/1/E^)/OMNM!\O4_\!4$L#!!0
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MGE/,8!\B2K'#"%0I]$;ASQOM"?,W@:TY5(A'H5L2,,\QT(G;_'LW,)N6"F,
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M5P,IC05U]04FCH_COD)FY 6X5\K5C,]=2(:C0[J'_>&[T6&XP?TG4$L#!!0
M   ( '.&>%JF#ZUW>P4  'I%   /    ;')M<BUE>#,R7S$N:'1M[5Q1;]LV
M$'Y>?P77HH4#6+)D.VDJ>04R)P6"+6V09,!>:>ED<:5(C:1BN[]^1\I*Z]0I
M@J;MG()YL"/QCG?\[N.1%$U-2E/QUT_(I 2:XS>9&&8XO#[Y.Q@-PW@R:"]1
M8+"6F,QDOB+:K#C\]K2F><[$/#FLEVE%U9R)A#9&_LJJ6BI#A4F?NDIS=MVI
M? B8R&&9!*.T8B(H@<U+DT3AX2$3:2TU,TR*1 &GAET#ZD\&J.UJJ;LZ"BE,
MH-D'2.*H-FO+@9%U$J6NK* 5XZODBE6@R5M8D M94=$)SJ0QLFIU#2Q-0#F;
MHTWKB35HJ^A,99)+E3R+W%^Z*)F!0-<T@Z16$"P4K5N+B[8=,\GS])9[7_+(
ME;T')2R*0@IPH"Q8;LJD8";(L!P<C"?+DLV8(6U8K!XB4W\/7*)/0<G0.JB=
M165Z<G%U^N9T>G1U^NYM!\M.>DI\T#HHSANE&TP.Q$AR"9GM\.15=$!D04P)
MY)*J&16@@W=+#BMRE!E;,HRBH8>P@[!WV<QT"YTF/;I'J,A);[9GD>H@C4?[
M49],2UIC2\C!R)9=V71.XL,^^4N@\SFY--2@#U.9P][_#N_=@'YK_%X\BP^B
M]/LV^/;XPJ'XZN%E9[H@Z>F[F:<WF)=M,,]\B7E] C0K.^L-3A"41LA02A8%
MR_#*EOU)%4.(R54)" PTAF6Z3TY%%I*>U7OQ;#F,XBR=RJJF8M5>YBG6GDNT
MA%HP6Q&LS;!BU;=-MUHST*YUNG$>.'.MZJM4D_="+CCD<T#YDIKD+LJL0V]C
MG!R$!P<OG[>AMY,=89+@91B/1\_3]81I0^[G9ULOWOL%@T:.A&@H)Q=@9X<$
MB?)&JHK$4? '*:1RT:A!,9D30-AR<@P95#.DT"CN(_N&X\TXM_7<A+FCSSK\
MI&@XQW#C%6?H^(*9TI4K^+=A"BKT36_F2TMG]"/>[^4WM6%IHW!2BC6<+)'2
M8@Y=?XA?C<:IY?_NDF*XPZ08MJ1@ F-?41<"6TJ9[?=,./375"DH4QA+=$C;
MJ/5M,>6<H!KR!2F%!36&4?>=5L$$%9F]CQ7F;D7ATA1*-;P-ND2BT3:);=(F
MO!5,0V>8M[8$U"YTTIE4F*L<7K;!.,99\8#3E6S6(FW;XR@*H^>=/&+.::TA
MT5!3] .ZN+DU2*OG5DYH7W7&KYG&%0!G9I5T^FLAE,IOQE!G;GR("RIK;FGC
M9EU; X_,6+I%E<GO4(W#>/AUFJ-P-/[1-L?[X?Z]C.(_ZC:BZ\6G(_56XB\P
M7,%, 7V?N,_ WM@">M>#7?_$=>RU'6,RRM?=#F_?=/)N-H12Z-WWG&,]I+/?
MJP<?(W$3<D85#IS#L<O0^Y_TGJU1>S1(/1";SR:8'@V/QK=$H_5U&R#K,::[
M$^[7Z+CD+'_T":<%KOT<Z &94B5Q<+X,R>\@@C/**BGZY"P\#K>!ZT> 7>&N
M1\.CX=%X6);_F7*YS^./DYT>#8^&1\/G\2Z/GRO0S#[:=$_;IB6#@IPL(6OL
M5CYYUSY;]RE]EXGJT?!H>#1\2N]2>N]<,9&QFO+/,_G>?5.Y3]^^BWHT/!H>
MC1^*AI]5^RW/G2"B1\.CX;<\O\F6YQG+2@J<3(%3(7W6WV6^>C0\&AX-_RRE
MR]\^=S\>1GHT/!H>#9^[;WZBXC8SW]P<+/";F8^ FAX-CX9'PR?Q+9N9'S.Y
M_:G*49;)1ABL[%Y[F_AMCWGMV&&_!Q#MAQROMB\!R3C5VK)Q#L'FV3GT=?M;
M0@H.RR!GJCVE:8^^-95(<Z9K3E>)+=WR(I%_&FT/^78N.;$ 1/Z%-XQ\?,](
MJ6[%E G.!")GJ%H?SMLLP(K;VVV[W/A-"P,JH7Q!5]J-XY.!?7/*ZR>3@7OG
MRG]02P$"% ,4    " !SAGA:]D98\N0& 0!%6@$ $@              @ $
M    :6UG,3,R.# P,C@Y7S N:G!G4$L! A0#%     @ <X9X6FZ0ZI$,;
M!;\  !(              ( !% <! &EM9S$S,C@P,#(X.5\Q+FIP9U!+ 0(4
M Q0    ( '.&>%J<F9U.#DP! '5V 0 3              "  5!S 0!I;6<Q
M,S(X,# R.#E?,3 N:G!G4$L! A0#%     @ <X9X6A1B!X= NP$ Q=X! !,
M             ( !C[\" &EM9S$S,C@P,#(X.5\Q,2YJ<&=02P$"% ,4
M" !SAGA:A-KY>YB5 0 IW $ $P              @ $ >P0 :6UG,3,R.# P
M,C@Y7S$R+FIP9U!+ 0(4 Q0    ( '.&>%H+BNJ-+CL!  AD 0 3
M      "  <D0!@!I;6<Q,S(X,# R.#E?,3,N:G!G4$L! A0#%     @ <X9X
M6C8!X<H@H $ 6LP! !,              ( !*$P' &EM9S$S,C@P,#(X.5\Q
M-"YJ<&=02P$"% ,4    " !SAGA:"ROB\8U;  !:K   $@
M@ %Y[ @ :6UG,3,R.# P,C@Y7S(N:G!G4$L! A0#%     @ <X9X6O[ZT)BM
MD@  <,,  !(              ( !-D@) &EM9S$S,C@P,#(X.5\S+FIP9U!+
M 0(4 Q0    ( '.&>%K_B6O!E'X  $70   2              "  1/;"0!I
M;6<Q,S(X,# R.#E?-"YJ<&=02P$"% ,4    " !SAGA:.M)F(8B)  !GVP
M$@              @ '760H :6UG,3,R.# P,C@Y7S4N:G!G4$L! A0#%
M  @ <X9X6@<ICLK';@$ FKP! !(              ( !C^,* &EM9S$S,C@P
M,#(X.5\V+FIP9U!+ 0(4 Q0    ( '.&>%I"EJHN"_<# )+@!  2
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M+3(P,C0Q,C,Q+GAS9%!+ 0(4 Q0    ( '.&>%H$,?^D!B<  )^_ 0 /
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IO)T8 &QR;7(M97@S,E\Q+FAT;5!+!08     %P 7 +$%  !DHQ@    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>lrmr-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lrmr="http://www.larimartx.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lrmr-20241231.xsd" xlink:type="simple"/>
    <context id="C_8057ddb3-0a97-4d84-a521-6c651151f255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_82b36523-042a-479d-8709-14a5821a01e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_84970a30-febb-4823-a176-2eef9f5b17ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_84d96472-3ce3-4f5b-8844-308604770292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:SixthSubleaseYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_86c1a03b-7f05-4056-8a4b-a412c8acdc0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-09</startDate>
            <endDate>2021-08-09</endDate>
        </period>
    </context>
    <context id="C_89155b9d-f3b6-4453-9d28-eeacaa55b7e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8940587e-a90e-40f9-958f-9b1b19869429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8b7bbdf5-c433-4df2-8d61-5681d6000126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lrmr:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8ee26ea1-7981-475b-8275-d3cd88ccd7f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:DomesticAndStateLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8fc81d4f-669b-4cb9-9f96-bcb205c5ce02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="C_9310a56d-595a-456c-875c-d9c91b4958c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_937c9270-0745-4d6a-8ddd-353d3408b686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lrmr:SkinCellsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lrmr:EndOfStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_937d6158-f010-48b2-b04e-91b91f550795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9450bf35-e5d7-4e90-b946-f5ecc5c1b78f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:CommercialExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9458ab78-dd2a-4327-a9fc-7944f851ac55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_980a36da-7606-4c17-93a9-29aef7c80f1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9835f758-39d0-41f7-805e-a62b5ba91b72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:SecondMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="C_990b03ea-4e3f-428b-9463-5722c03fe7ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_99e2e692-a200-4366-9fac-4c228a2bb15b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lrmr:ZafgenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9be6fbc0-da98-4a6c-9580-1b53447c931e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lrmr:ZafgenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9d2671b4-535d-41fb-ba97-cf95d740ca0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lrmr:MTSHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_9ea41f95-519b-41f4-8b6c-cb288ac9b104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a04137e2-f395-4ec2-a749-7530c63c5c1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a1d529ba-7ef3-4346-82a1-30f1da0afd55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a3be7c9e-9f11-490a-8fdf-1cfea83b9a27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_a4b86fbb-6763-470f-9324-890bb9b86ef7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a5da52b3-1c55-4f2f-830b-7fe2b20e9c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lrmr:EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a6372807-b669-4c9a-bca6-c7c693a758c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:NomlabofuspSupportExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a95a6572-ed88-48df-9e64-6ef309bf3fc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a9758b43-c974-4811-91f8-dd665c753866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_aae3cd8b-68ec-413d-a96c-c3611488b3a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:LabSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-16</instant>
        </period>
    </context>
    <context id="C_ab791d56-0959-4081-945b-058f0d6c6f82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:TechnicalOperationsExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ad1539c6-fc3e-4f7a-a9a5-26892c4889b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">lrmr:NoExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ad4e109b-2beb-4b4b-8ec0-7ff1c78ca2a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="C_af3f57a9-5b04-4e27-9565-2e843bcf12e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_afb7c02e-1d17-4fbb-ad2f-056d597aacc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="C_b039d28f-1551-4683-aa18-2d31487cc476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b144c1ed-8a46-4360-ac5f-f8187e2445a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1b8129e-de19-4748-9c09-33dfd9514f6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_b23e5525-f6f6-400b-a668-fca905202d1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="C_b632cd5c-05ae-4251-a104-e7cf0498b02b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b79ab662-a9df-4027-a87d-1c4f950bae65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b7ccda8d-34e0-4891-abca-16e72fec5b80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="C_b89973be-3872-4363-9f3c-168e09a8a5a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_be61e1b5-4f33-432f-86bc-37fe2c3476b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bf68a9db-6f62-4ef9-b2b4-384b78706dbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="C_bf6d1d52-1fbd-434c-aff5-8c53c22ca6a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="C_bfbc57ff-0284-43eb-9410-6bcf4e5de594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:DevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c18bcdd4-7898-4e7b-aeaa-04861be8d49c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c37bbde8-7943-40d4-8b87-262850af251a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_c3a77d44-ca39-48a6-af59-4ea835940adf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c441b869-7333-4da3-92e6-35ae34bd02de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_c66d62d9-1b72-4c63-9f95-2f1a72677604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c7bb7719-628e-435e-ba3a-d42b56b0336b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cb7fc05a-bbd9-4909-a0df-1a1e3440df1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cde123be-1e24-4090-8fdb-2c9fe1cf13f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="C_d0f2886e-1b6f-49ac-a8ea-a868a6076338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d18029d6-d247-44b7-8d04-1bedb1e05fca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lrmr:PatientAndCaregiverAwarenessEventsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lrmr:FriedreichsAtaxiaResearchAlliancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d571d28c-42d3-4ede-a9a7-3e4acee72b97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:LabSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-10</instant>
        </period>
    </context>
    <context id="C_d699938b-88e6-4ed6-bb3e-ded55260a3c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:NomlabofuspSupportExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d69bdfda-1561-4df9-9031-4aaa6b8277e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lrmr:SkinCellsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lrmr:BeginningOfStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d6ea5928-6ce4-4e0b-9b61-49f02098f481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d91923f9-f154-40c9-b314-889b9878641c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_da30be71-5046-4b9b-aa5d-981a3c109ee3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dd2a27c7-acca-4e22-922e-e6e22f9cea4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dd95e4fc-82fa-4a33-961e-756339a32f40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="C_e50d16e4-c0fa-4f34-9de4-4fa19f2af4a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e567f291-5928-46ca-9886-4b12d459c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e624cc91-edd0-44c1-b110-f5bd07d78925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e75c96fd-9bc2-4e22-9c5a-481e9d15e507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ec704a28-ca88-417d-afd5-2b5e09e3a38e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-08</instant>
        </period>
    </context>
    <context id="C_ec7837b7-c9c1-4c07-8288-455007933963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f10a217c-c7c4-4985-8b2d-21543f8fe157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f1ad33a8-3ac6-4e46-a123-734c2ff51101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f1f8400e-a7d9-400c-8bc4-a27496b8c9f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_f552a753-5013-41ab-8a68-b985b7c0bac4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f56605f3-2e21-4b59-b70a-99e345371439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f62796d0-82ee-42f2-a018-74063dd58aa3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_f69f438f-7f98-46a0-8c4d-079bbdf2a12a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="C_f87f0f4d-223e-43e5-99fb-70416e4efc02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fc129cfd-3960-440f-aa81-c3cce8de7bad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fd07840a-58bc-4339-8331-bc488a2c40c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_fe166586-acda-4afa-90ba-bbddb1cf7183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fe3e5c5a-5d3a-4ea1-8f76-28fa8c02f25f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lrmr:PerformedInUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fef8b8b7-1ffd-45a1-bbb3-aeb02925b1c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_00309e6d-c478-4991-a287-b2b26b553406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lrmr:FromPriorPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_00c4f173-1035-4879-939f-3e16d63fb716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:IndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_013cfd75-8e64-4593-92c4-eddcb6f5a973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0315db95-9995-4825-83b1-6bd13c7f5edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_03512384-f164-4169-8f61-63c0a2fa35f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_04060931-70f8-40a1-b038-ff2323e800fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_06eb49df-ea1f-4795-b693-6ce41c4e020b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0788b521-b323-45f2-8f3d-8796f828638d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="C_07cc377a-796d-498e-9d5b-1591bcb5477b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_0ca29918-24cb-4049-81da-b0b595cb7f08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:DevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0d03b972-e68a-4737-840c-600693a1015c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FirstSubleaseYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_1807f4b1-8435-4d6f-ad59-b534cb43cab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-05</startDate>
            <endDate>2018-11-05</endDate>
        </period>
    </context>
    <context id="C_19c7f11a-defa-4ab7-93a5-13259f5e0f82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1ac20b4d-9dce-48ff-b9c6-72648d8b3bf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lrmr:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="C_1b3789f9-d2e6-472a-a24f-4537eda96328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="C_1e6ff9a0-2992-49a2-9d8e-9424081411f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1ecaa432-f3ba-4716-8bf2-ed620241e567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2164a742-c82f-4feb-86b4-11d2743876a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-28</instant>
        </period>
    </context>
    <context id="C_23a1dcc4-104b-43ca-95d3-232e06671bb5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="C_255549a6-f23b-4838-819a-a321c153cd07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:DomesticAndStateLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2778adb7-0fa7-4567-85f3-1f083a2430b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-28</endDate>
        </period>
    </context>
    <context id="C_298722ae-af18-416d-b772-0febae7b0ff4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="C_2b1053b4-6091-48b6-907a-083f14aa104f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">lrmr:TechnicalOperationsExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2da25a67-0650-40c0-a834-10e03326ad04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2e43c4d6-c27e-4c64-957a-2c359c114241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_30f69550-77db-454a-9913-83a4c6b940ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">lrmr:TrackFAProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lrmr:FriedreichsAtaxiaResearchAlliancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_3122611a-d6b2-4e58-baae-c58bceaa1852">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lrmr:FromPriorPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_35ab60ab-d305-4f2f-afea-0206294790a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_374ec650-46e4-4848-b593-f01df79d1e1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:IndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-30</instant>
        </period>
    </context>
    <context id="C_37be18e2-22dc-4e2a-9beb-0936213f0ff9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lrmr:BuccalCellsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lrmr:EndOfStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_391eac21-af51-488c-920c-35a738ee141e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <instant>2025-03-20</instant>
        </period>
    </context>
    <context id="C_396ac9d3-7432-4c48-bc3e-b130ad436bcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3aec0197-d24a-4489-bac3-6d1692746976">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:LabSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-16</startDate>
            <endDate>2023-10-16</endDate>
        </period>
    </context>
    <context id="C_3ddcccac-7c80-4352-b875-b59deec51ca1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3e6edd92-c786-4088-97cc-096585e1d03d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_41039f45-bcfe-4b0a-a6c8-f525353e3235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_410cee1a-9246-4e71-a46a-d8f61f308f49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FinalSubleaseYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_41dc2a61-cb1b-4e3f-b8e4-3a5beacac631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:InducementStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_458d2390-7c95-42ed-9486-6626384ec15f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4652a096-8724-4cdf-a118-748dbb5359af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_476aa55d-daca-4a72-aade-622790de18ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_47c2670a-5ab5-47d8-879f-4c1d86ad4d5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lrmr:PerformedOutsideUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">lrmr:Ircsection174Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_49e828c3-8eec-482d-9de9-b54a375e1b3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4a89193c-4cbe-4c85-bcc3-a83c9bc990b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4b1f55d6-efd7-4b66-b757-9829759cb41d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeSubleaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">lrmr:FirstSubleaseYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_4c5e5e8c-5db3-4232-b8b8-f18e413251e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4ccaf2c5-63d9-4610-8683-46ecfe234808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4d107843-e44a-43f6-84f2-18bd5c829091">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4d9b0d0f-39b2-4d7c-ad5a-792b1d5080d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4e6a434c-62eb-44df-bb26-a28924999a6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4f4d089e-ca07-4b47-be34-6ef0f252b0ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lrmr:EquipmentFurnitureAndFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_55adc7a3-9555-42f6-8998-4ce928494a2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_57646aae-7316-49d9-a9e1-466cd58a59b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5bc874d9-7864-4d71-a931-3ccf2f2d90ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="C_5e95afea-eb7a-4026-b213-a7dc1020f814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5fd8fb15-cf4d-4748-b06e-8e9b5decf68b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-01</instant>
        </period>
    </context>
    <context id="C_651ed535-6eb6-4fb6-8481-d70f3753107b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_68ab6f05-562c-4261-83f4-2fd2834ae9b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lrmr:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lrmr:FirstMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-22</startDate>
            <endDate>2025-01-22</endDate>
        </period>
    </context>
    <context id="C_6be3737e-d05f-4180-bd52-32638a31f43d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">lrmr:WakeForestUniversityHealthSciencesAndIndianaUniversityResearchAndTechnologyCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-11</startDate>
            <endDate>2019-12-11</endDate>
        </period>
    </context>
    <context id="C_703f9a1d-ba57-4229-9130-75f431315872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">lrmr:FromExerciseOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-11</instant>
        </period>
    </context>
    <context id="C_7578c18b-7d63-416f-a8a0-8914d0247733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lrmr:USGovernmentSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_758e50cf-6269-441d-9861-9ff2dd1261da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_763a19f3-ed28-42b9-b147-b3bf06139429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_7652464d-494e-4455-9127-a6517e3601ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:AdditionalOfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-08</startDate>
            <endDate>2019-08-08</endDate>
        </period>
    </context>
    <context id="C_778a5e08-2c19-4fa4-9229-8be5d4f04ff2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lrmr:BuccalCellsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">lrmr:BeginningOfStudyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_791bdce5-955d-4624-ac03-8deed77c6490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7d857bb0-3425-42ce-bed1-6edca2b32acc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_7dab3a33-605b-4d11-95ef-1864d775ec57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis">lrmr:OfficeAndLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-05</instant>
        </period>
    </context>
    <context id="C_7ebc587a-1024-446d-8850-c2e50902fec2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lrmr:AtTheMarketEquityOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7f9933f3-6cd7-4632-83be-ff4608000844">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7fd9fac5-2ec4-4412-abb9-5816a42accd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374690</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Segment">
        <measure>lrmr:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_71c8a0af-ec2c-48d9-8f27-c3dbcbf31221">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_bd259818-bdf7-4a47-943a-9b295cab8d72">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_e23d758f-b0a2-4652-a1a1-981d6741ce69">0001374690</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      id="F_bbd44322-5ac7-4240-84a9-fa6345eb0ea1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      id="F_271b7562-2770-4053-8b6a-b815a279d5b4"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      id="F_8b10b1a7-f362-40fe-8916-abb51d917633"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      id="F_f1c56ae0-d4be-4ff1-8d60-2cb57f25fa2a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_a5da52b3-1c55-4f2f-830b-7fe2b20e9c74"
      id="F_e67f9759-bc4c-4465-933e-6db26d968aa7">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d10ed809-200f-4b30-80d3-8c8fcced056e">http://fasb.org/srt/2024#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_8e858e57-0756-416b-b74d-b48de20c666a">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="C_396ac9d3-7432-4c48-bc3e-b130ad436bcd"
      id="F_a5f65a1c-dbe3-418f-9eaf-369ca80d6c94">http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_bf68a9db-6f62-4ef9-b2b4-384b78706dbf"
      decimals="0"
      id="F_921994da-5811-4028-8f53-85e77eb89620"
      unitRef="U_USD">6284</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_ec704a28-ca88-417d-afd5-2b5e09e3a38e"
      id="F_87fbb33e-f754-46a6-98ea-b08d228c7b45">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373"
      id="F_d09b5249-139c-4022-bd74-7a580647cdf5">2023-08-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_7dab3a33-605b-4d11-95ef-1864d775ec57"
      id="F_f3be3bdd-793f-4d1a-9a7e-f230d03efd1b">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OpenTaxYear
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_3544ef17-f3b5-4927-ba28-69fcaa25789b">2020 2021 2022 2023 2024</us-gaap:OpenTaxYear>
    <dei:DocumentType
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_c5a932fd-64df-49a7-873a-37ad37e025a2">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_9305b424-504f-4532-84a0-3a1478d3b4c7">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_434d51a3-810d-4eb1-bd38-2f51d0e86748">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_8843fc46-2c54-4006-bca1-00c019dbcb6e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d1f997dc-f40c-478b-9968-a40d2879e46c">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_18a28b17-e254-436d-a61e-ca6b1fe58fab">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_5a862ad5-6f61-4168-8f3c-dab5e8a6fadf">001-36510</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_1e5405fa-599b-4351-9a14-865e49eff32a">LARIMAR THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_58c47b71-bece-41e6-aecf-9bde10bfacf0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_3bf9237a-8d5d-4bf9-8196-a603a093ec54">20-3857670</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_3a236478-be7b-4e29-9024-ba3956ebac98">Three Bala Plaza East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_e5f92384-f5d8-4d46-8ade-9286aa75de50">Suite 506</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_91ffa032-52b2-44de-8586-65e6e0ecb280">Bala Cynwyd</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_f239ea53-3dd9-416e-86a9-c24e19699e2d">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_7a6f48a8-0c74-47ca-b41c-a0abffdf72cd">19004</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d7966022-37be-4f9a-90f6-252102321ed2">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_9963f86d-46f2-4576-9e1a-62069157d493">511-9056</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_991402fb-5c2d-455d-bf1a-178c66018f17">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_afd9fc6a-b04f-4879-97bf-64821dbb76e5">LRMR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_b52ba00b-197b-4176-a261-32cd7cc26064">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_399a3e82-c6e8-4fe7-90a1-dec2389a8ac5">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_4161032c-6f1c-40ee-887c-ff2231f50ca9">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_990095d4-c6ce-44db-b87d-a70f9dc134a0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_7228c073-b839-4b94-a199-2aac8c026bb8">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_345a0002-a41a-4483-aa45-b943cfd4e52a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_4554cdfd-710e-4d8c-8629-75835bf9f8d9">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_a18f4584-a459-4433-8313-f21e53919281">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_f6b6758c-c65c-4303-86d3-50b42daaf3b9">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_4cd3e50c-04a4-4b46-8b4d-b5fba08b3b6e">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_94528d5f-e698-4c37-9f06-417aea3c582c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_af3f57a9-5b04-4e27-9565-2e843bcf12e8"
      decimals="0"
      id="F_086a3f71-828b-4a4f-bb31-23f553c123b5"
      unitRef="U_USD">313608353</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_391eac21-af51-488c-920c-35a738ee141e"
      decimals="INF"
      id="F_7e973786-7bcb-42d4-a28e-2de7efaf6ef5"
      unitRef="U_shares">64027892</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_c691e078-8c18-441f-a0ee-2c3d2e1753d8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Part III of this Annual Report on Form 10-K incorporates certain information by reference from the registrant&#x2019;s definitive proxy statement for the 2025 annual meeting of stockholders to be filed no later than 120 days after the end of the registrant&#x2019;s fiscal year ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_3919e60d-1333-4f10-a0e4-f191b61d1e14">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cyber Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have implemented and maintain various information security processes designed to manage cybersecurity risks relating to our critical computer networks, third party hosted services, communications systems, hardware and software, and our critical data, including intellectual property, confidential information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products (Information Systems and Data).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Director of Information Technology, assisted by our managed information technology service provider and other third party service providers, leads the Company&#x2019;s cybersecurity risk management processes. This group works to identify and assess risks from cybersecurity threats by monitoring and evaluating our threat environment and the Company&#x2019;s risk profile using various methods in certain contexts, including, manual tools, subscribing to reports and services that identify cybersecurity threats, analyzing threat intelligence reports and feeds, conducting scans of certain environments, and other tests.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We implement and maintain various technical, physical, and organizational measures, processes, standards and policies designed to manage risks from cybersecurity threats to our Information Systems and Data, as applicable depending on the environment, including incident detection and response, disaster recovery/business continuity policies, network security controls and data segmentation, access controls, physical security, asset management and tracking, systems monitoring, and employee training.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our assessment and management of risks from cybersecurity threats are part of the Company&#x2019;s overall risk management processes. Our Director of Information Technology works with management to prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material impact to our business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;third-party service providers&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to assist us to identify, assess, and manage risks from cybersecurity threats. These third-party service providers may include threat intelligence service providers, cybersecurity consultants, cybersecurity software providers, managed cybersecurity service providers, and dark web monitoring services.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also have established a process to conduct diligence on certain third parties before engaging with those third parties, such as those that support our GxP processes, which may include a security assessment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have not identified any cybersecurity incidents or threats that have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;materially affected&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; us or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition; however, like other companies in our industry, we and our third-party vendors may, from time to time, experience threats and security incidents relating to our and our third-party vendors&#x2019; information systems and infrastructure. For more information, please see our risk factors under Part 1 Item 1A. Risk Factors.&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors holds oversight responsibility over the Company&#x2019;s cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of the board of directors is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of the Company&#x2019;s processes for monitoring and controlling cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who has over 10 years of information technology management experience.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of Information Technology, along with management, is responsible for helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy and communicating key priorities to relevant personnel. Management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security-related reports.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have processes designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Vice President Legal and Compliance, Vice President Finance and Administration, Vice President - Controller, Chief Financial Officer and Director of Information Technology&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, the Company&#x2019;s incident response policy includes a process for reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives reports from members of the Company&#x2019;s management concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them, as applicable.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_ab61f33f-787c-4145-82da-0e82a501810d">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_14e744d5-cece-42ef-977d-d5c2a35de90d">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_6f26ee33-a564-4304-a0b5-c19339b8e585">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_fbd75ab1-d570-4397-8a4b-70ed267323da">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors holds oversight responsibility over the Company&#x2019;s cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of the board of directors is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of the Company&#x2019;s processes for monitoring and controlling cybersecurity risks.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who has over 10 years of information technology management experience.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of Information Technology, along with management, is responsible for helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy and communicating key priorities to relevant personnel. Management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security-related reports.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have processes designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Vice President Legal and Compliance, Vice President Finance and Administration, Vice President - Controller, Chief Financial Officer and Director of Information Technology&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, the Company&#x2019;s incident response policy includes a process for reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee receives reports from members of the Company&#x2019;s management concerning the Company&#x2019;s significant cybersecurity threats and risk and the processes the Company has implemented to address them, as applicable.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_6d4cc33b-c36b-4bfb-8eb8-57fadbdd81e4">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors holds oversight responsibility over the Company&#x2019;s cybersecurity risk management as part of its general oversight function. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of the board of directors is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of the Company&#x2019;s processes for monitoring and controlling cybersecurity risks.&lt;/span&gt;&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_e582ce18-5833-4dfc-be5c-63267606dc3c">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The audit committee of the board of directors is responsible for overseeing the Company&#x2019;s cybersecurity risk management processes, including oversight of the Company&#x2019;s processes for monitoring and controlling cybersecurity risks.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_21fc6cbf-c0ec-49ee-8803-860c55dc65fa">&lt;div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who has over 10 years of information technology management experience.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Director of Information Technology, along with management, is responsible for helping to integrate cybersecurity risk considerations into the Company&#x2019;s overall risk management strategy and communicating key priorities to relevant personnel. Management is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security-related reports.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_896bf020-3849-46ba-9431-a64f1a35abc8">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, who has over 10 years of information technology management experience.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_a7da98fe-37ec-4da7-8bcc-16a01d5fc9ec">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including our Director of Information Technology&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_bd75036f-b276-48f6-ab9c-86c2ff9de130">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have processes designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Vice President Legal and Compliance, Vice President Finance and Administration, Vice President - Controller, Chief Financial Officer and Director of Information Technology&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, the Company&#x2019;s incident response policy includes a process for reporting to the audit committee of the board of directors for certain cybersecurity incidents.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_f5ceded3-4130-49a6-9d12-137385593e3b">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_35c4cb76-ac39-4da3-941c-010c468717b4">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_791bdce5-955d-4624-ac03-8deed77c6490"
      id="F_7db3b5aa-1304-423e-86b0-c2ce1a0d4c73">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_791bdce5-955d-4624-ac03-8deed77c6490"
      id="F_877d2a6f-1893-4b93-833a-b57981a77d8e">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_791bdce5-955d-4624-ac03-8deed77c6490"
      id="F_f5d6938d-567e-45a1-84e0-c2b5fb659d1c">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_791bdce5-955d-4624-ac03-8deed77c6490"
      id="F_5af7aee8-c290-48ea-a8e8-5d291002aa62">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_96a22d8b-91ba-46ed-8d11-efdd9c1d0952">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorName
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d0830f69-9d78-4f43-889f-799f00891c68">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_a64bc75f-5ea5-4d9a-b3b7-bccaacc8766a">Philadelphia, Pennsylvania, USA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_985b56aa-e227-4004-ab11-f2c32f8790ec">238</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_29bfa366-7d14-457b-9b90-3a343a24b305">238</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_11b81838-f2ec-4f39-a409-97c41bc3d814">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Larimar Therapeutics, Inc. and its subsidiary (the &#x201c;Company&#x201d;) as of December 31, 2024 and 2023, and the related consolidated statements of operations and comprehensive loss, of changes in stockholders&#x2019; equity and of cash flows for the years then ended, including the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_3c301ca0-cabb-4b02-9e3f-f818d1e904d6"
      unitRef="U_USD">33218000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_47281a5f-7791-4a7d-9996-9a576aba5ea9"
      unitRef="U_USD">26749000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_6a081653-2f00-424b-adf6-c573cfb77c6b"
      unitRef="U_USD">150236000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_c87ee92a-fe18-4fad-ae16-e1b12a9f55c9"
      unitRef="U_USD">60041000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_ff6a9af7-cee7-424b-ad2f-56b37869b6fe"
      unitRef="U_USD">11850000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_6d148ce1-793a-4bb4-a1a2-9b616fe8ecf8"
      unitRef="U_USD">3385000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_965b21e9-fff2-4619-9303-122979313bd3"
      unitRef="U_USD">195304000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_00779eb0-05e0-46ad-9aef-30d5d1f7d6c3"
      unitRef="U_USD">90175000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_8e8905bf-82e0-466e-b15b-e074caef0008"
      unitRef="U_USD">881000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_163c1827-0d69-49a2-9db2-9119ff014fff"
      unitRef="U_USD">684000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_a033f9ee-0724-4833-ba91-9097ae5f74eb"
      unitRef="U_USD">2838000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_acdc26e3-773a-434c-b766-ad25439c96e8"
      unitRef="U_USD">3078000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_f4d3463f-b347-4793-a74b-a7099f5c5518"
      unitRef="U_USD">606000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_8ec565f8-8781-4f52-a7a6-bb632f66a57a"
      unitRef="U_USD">1339000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_63624bf7-2a10-407e-a798-ea378dfc7e57"
      unitRef="U_USD">596000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_676186df-55ab-4faa-8a9b-be7058667e74"
      unitRef="U_USD">659000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_91bd9daa-e3c7-436f-8c3d-30f5d884fe2f"
      unitRef="U_USD">200225000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_ead6db1d-fbf1-4239-be44-4dab558013a2"
      unitRef="U_USD">95935000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_4aac5e54-e47c-4426-91d2-58e750b07c5a"
      unitRef="U_USD">2424000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_4a73e1fb-2472-4ceb-849d-f0ef8cb0ac9f"
      unitRef="U_USD">1283000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_6b6f7729-a562-446b-b103-fd670bef8c6d"
      unitRef="U_USD">20872000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_b67bba8d-023c-4250-8939-067801d70e17"
      unitRef="U_USD">7386000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_7fb79ec3-d36f-4665-8873-8f5d1d709abb"
      unitRef="U_USD">1060000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_b998ae3b-af89-4def-a2e4-2a96e0ae984a"
      unitRef="U_USD">837000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_5f12d967-02bc-45e5-80ed-22a95fbfdb5c"
      unitRef="U_USD">24356000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_f6775aef-15ee-4f0d-9520-42126f710177"
      unitRef="U_USD">9506000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_48b6969e-a2ab-4133-810f-338e83399ae1"
      unitRef="U_USD">4057000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_ed18227a-d2b4-4658-acbb-4677d202a1d2"
      unitRef="U_USD">4709000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_2a6cb1ab-3e60-43f2-9d58-748dbdcb59d1"
      unitRef="U_USD">28413000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_b8af1a1c-25d5-4e6b-b2cb-938d78592c7e"
      unitRef="U_USD">14215000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_9349a457-b88b-4b6d-a25f-473c068db78b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_90dc5f58-624d-4718-87c7-d4357005d966"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_e54fdf24-29c1-477b-82e0-eab9e0bc010b"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_b950f0da-6ce8-4ebd-9998-4af0b7958b3c"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_feb54f7a-d6b1-4f26-b932-d6c19b0dc355"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_689c44d2-c96b-40f9-98f1-5f12a15abd5c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_42029bbf-5e92-4722-b876-c2b1e81afcd4"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_2859acc8-2287-42e2-9808-6ce26b0e20e3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_5b11371a-940a-4e4d-9945-9c3b330b756c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_311f4dcb-777f-4862-90d8-4560970aa1d6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_efc93f66-cda6-44fe-9bf9-e806a53d9b0a"
      unitRef="U_shares">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_d48e582d-7dfb-4699-8999-5e09f605d6fe"
      unitRef="U_shares">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_2624b7a6-bca7-41a8-a406-1c1ffa42146a"
      unitRef="U_shares">63815065</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_d3529f1b-27ab-448e-81de-0dde47671640"
      unitRef="U_shares">63815065</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_2095d81d-021b-45f6-a8e2-15728a39c2b8"
      unitRef="U_shares">43909069</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_3dcffadd-a46c-4c9e-9e7d-ac6eb7e3065d"
      unitRef="U_shares">43909069</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_c47aa97d-651e-44d2-917a-5ecb725e35d5"
      unitRef="U_USD">64000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_c7e1fe52-0c0c-4ae3-bf65-aa1927a4145b"
      unitRef="U_USD">43000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_4d4b7442-7a16-4a88-ba31-2ad1732b5439"
      unitRef="U_USD">440758000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_6bdb536b-4900-4890-b997-3af885c64213"
      unitRef="U_USD">270150000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_9f7b891a-d8cd-4b70-9ea5-bb9a695f90e0"
      unitRef="U_USD">-269158000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_8a4914f0-42c5-4e57-9282-4e0e87104d3d"
      unitRef="U_USD">-188554000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_9c62e8a9-cea3-4fb7-90fe-1456b7e822d5"
      unitRef="U_USD">148000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_764653ac-f859-4be1-aae2-3de1b2c34e26"
      unitRef="U_USD">81000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_77b49b3b-83de-4d12-a331-abbaf9c52603"
      unitRef="U_USD">171812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_a45b402f-2099-46af-9370-af2ad6b3077e"
      unitRef="U_USD">81720000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_9e931512-c9ca-4665-a8fd-d40970e2d67e"
      unitRef="U_USD">200225000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_9cb872b1-990b-4cf7-a130-ecb765132329"
      unitRef="U_USD">95935000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_d2a09208-2e86-47e5-8cca-2fd65719864c"
      unitRef="U_USD">73278000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_b29d16fb-1e97-4f1f-941a-fc9d7668412e"
      unitRef="U_USD">27670000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_70581d76-6ef6-49d6-996a-d10de1d9a329"
      unitRef="U_USD">17612000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_d5c7d88e-2ec5-4aff-aa85-a8273e6e1b5a"
      unitRef="U_USD">14088000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_061fcbaf-5487-4c2d-b425-61af5ca445ad"
      unitRef="U_USD">90890000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_c91a24cf-2863-4f7d-a8cf-edb2813d097d"
      unitRef="U_USD">41758000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_f9e4740f-4809-4f2c-8b07-239a0c13cb18"
      unitRef="U_USD">-90890000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_3386eb88-9037-4a48-8270-f24688f29d59"
      unitRef="U_USD">-41758000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_f3a7c346-349b-4697-860e-1545be29238b"
      unitRef="U_USD">10286000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_486fbadd-93c4-48ff-bac5-2786aa0135f3"
      unitRef="U_USD">4809000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_545851e1-9907-41fd-be62-0602b606972b"
      unitRef="U_USD">-80604000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_b1aa49fe-4ec6-4cea-a25e-0e582a309c4e"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="2"
      id="F_3540d1fd-9f06-435c-844b-33455b985d3f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="2"
      id="F_4e0485eb-cec3-4c0d-b5bf-fde588820442"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="2"
      id="F_b4b012bd-b96e-4cfc-8a27-a59ad00c0276"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="2"
      id="F_905ee4af-f837-480c-b6be-49e78de9d93d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="0"
      id="F_63d1d18c-bd61-47f4-bef6-51ba49f0f85f"
      unitRef="U_shares">61256084</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="0"
      id="F_d76bf5cc-f2e9-40e7-ab1e-0226be141ac9"
      unitRef="U_shares">61256084</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="0"
      id="F_6bd96eb7-0fce-4756-a5d7-515ef6307968"
      unitRef="U_shares">43901241</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="0"
      id="F_9490a0ff-8462-4852-8ce6-0b3d9155c2e7"
      unitRef="U_shares">43901241</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_fca5a8f3-2262-4053-a802-a0a8b14d4344"
      unitRef="U_USD">-80604000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_5d3020a8-bdc1-42c7-857e-9aeb5dc3032d"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_a0a24fb8-5712-416d-a380-d7766af6a011"
      unitRef="U_USD">67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_2cf6c1f1-72c8-4586-8155-8806a8bb2e1b"
      unitRef="U_USD">112000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_6e584dbe-ab49-4ce2-89e8-548fff912126"
      unitRef="U_USD">67000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_637502b5-fdb7-4b38-b8e1-3d6a6993e83b"
      unitRef="U_USD">112000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_3449a0b9-ee2f-46a0-89bc-1bb427bc72a7"
      unitRef="U_USD">-80537000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_d0cf3a58-21c1-4a11-baac-258261996886"
      unitRef="U_USD">-36837000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_c3a77d44-ca39-48a6-af59-4ea835940adf"
      decimals="INF"
      id="F_eeb898e3-2c48-48cd-8e37-f386b6bc9ce9"
      unitRef="U_shares">43909069</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c3a77d44-ca39-48a6-af59-4ea835940adf"
      decimals="-3"
      id="F_d69095b7-07a5-47c7-b4c5-ec70a23bfd27"
      unitRef="U_USD">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f10a217c-c7c4-4985-8b2d-21543f8fe157"
      decimals="-3"
      id="F_9f1c25ee-8171-4c87-ad43-49105ee06135"
      unitRef="U_USD">270150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ddcccac-7c80-4352-b875-b59deec51ca1"
      decimals="-3"
      id="F_020a4247-e1d2-42d1-a2d0-6f61e2a031ad"
      unitRef="U_USD">-188554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b89973be-3872-4363-9f3c-168e09a8a5a6"
      decimals="-3"
      id="F_f3b2862a-6581-45fa-b035-d66e4ce9844b"
      unitRef="U_USD">81000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_14129381-8c24-48c2-ba20-77d5e03b186b"
      unitRef="U_USD">81720000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9"
      decimals="INF"
      id="F_af44b008-868b-4f8f-8be7-cd97fb0d9e6c"
      unitRef="U_shares">19736842</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9"
      decimals="-3"
      id="F_65846680-6080-46da-8c48-26ed9aaf675e"
      unitRef="U_USD">20000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_41039f45-bcfe-4b0a-a6c8-f525353e3235"
      decimals="-3"
      id="F_5f17a4ad-4677-4932-aa3c-5f1056a043b6"
      unitRef="U_USD">161736000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_adf01f88-ad49-4cc7-af35-079fc0b1dcec"
      unitRef="U_USD">161756000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9"
      decimals="INF"
      id="F_5230e2e2-5c43-4760-b678-07cbf9d58bd2"
      unitRef="U_shares">153750</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9"
      decimals="-3"
      id="F_77b99fcc-1ab3-4cbd-99a7-5450b117400c"
      unitRef="U_USD">1000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="C_41039f45-bcfe-4b0a-a6c8-f525353e3235"
      decimals="-3"
      id="F_0324be2e-e40e-4559-901b-8cc565bbefa2"
      unitRef="U_USD">-1000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_8a0129b8-7cbe-488f-8f39-d75b0b987aa9"
      decimals="INF"
      id="F_1afb878e-400d-4f77-a0d2-8b739fda880d"
      unitRef="U_shares">15404</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_41039f45-bcfe-4b0a-a6c8-f525353e3235"
      decimals="-3"
      id="F_e7bdda64-8c16-414d-8c80-52167bca648c"
      unitRef="U_USD">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_f9208759-2003-4db5-beac-f6d900646c78"
      unitRef="U_USD">77000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_41039f45-bcfe-4b0a-a6c8-f525353e3235"
      decimals="-3"
      id="F_566dbabd-459d-4e9d-a301-50c2cf43b68e"
      unitRef="U_USD">8796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_7b93aed6-398b-43ec-b029-186f7e56584d"
      unitRef="U_USD">8796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_35ab60ab-d305-4f2f-afea-0206294790a2"
      decimals="-3"
      id="F_093ea44e-04f2-4534-8aef-16d81c5841b9"
      unitRef="U_USD">67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_c512a226-9795-4a48-bcd6-e628bcb87ae0"
      unitRef="U_USD">67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_19c7f11a-defa-4ab7-93a5-13259f5e0f82"
      decimals="-3"
      id="F_79e8ff57-4ce3-48ec-9b15-f1b9256e5569"
      unitRef="U_USD">-80604000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_a096d7bc-5f7c-4543-9c6c-594b63f2e265"
      unitRef="U_USD">-80604000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_2da25a67-0650-40c0-a834-10e03326ad04"
      decimals="INF"
      id="F_a57ad577-9c6b-49da-809c-e1204aa5015b"
      unitRef="U_shares">63815065</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2da25a67-0650-40c0-a834-10e03326ad04"
      decimals="-3"
      id="F_9be0c0cb-3a6b-4fa4-b19d-6a20deef7ecc"
      unitRef="U_USD">64000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb7fc05a-bbd9-4909-a0df-1a1e3440df1c"
      decimals="-3"
      id="F_e91dcae6-1b3a-4a56-aa22-9cb8e287212e"
      unitRef="U_USD">440758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e50d16e4-c0fa-4f34-9de4-4fa19f2af4a2"
      decimals="-3"
      id="F_e1ac7dd6-847f-410a-a43d-695f91c476a5"
      unitRef="U_USD">-269158000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4ccaf2c5-63d9-4610-8683-46ecfe234808"
      decimals="-3"
      id="F_bec4289b-e535-4685-9206-fdac1c7ade17"
      unitRef="U_USD">148000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_339cb994-ebea-430b-b129-64216bce706c"
      unitRef="U_USD">171812000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_fef8b8b7-1ffd-45a1-bbb3-aeb02925b1c1"
      decimals="INF"
      id="F_25c19937-ff98-4279-9c04-b214689c26ad"
      unitRef="U_shares">43269200</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_fef8b8b7-1ffd-45a1-bbb3-aeb02925b1c1"
      decimals="-3"
      id="F_7ad25dc6-a7ad-42bc-bc0b-586d1703e6a6"
      unitRef="U_USD">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_651ed535-6eb6-4fb6-8481-d70f3753107b"
      decimals="-3"
      id="F_085e6a78-a4de-4bf4-9827-ce891a9f785d"
      unitRef="U_USD">262496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_84970a30-febb-4823-a176-2eef9f5b17ed"
      decimals="-3"
      id="F_b2bd4d9e-fcd1-4989-9e8b-10588da28857"
      unitRef="U_USD">-151605000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9ea41f95-519b-41f4-8b6c-cb288ac9b104"
      decimals="-3"
      id="F_b46252e5-df05-480c-8d22-3623ddcbdf59"
      unitRef="U_USD">-31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e567f291-5928-46ca-9886-4b12d459c211"
      decimals="-3"
      id="F_9d10f769-e88a-48a6-8fc4-8b4e8d8042e2"
      unitRef="U_USD">110903000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d6ea5928-6ce4-4e0b-9b61-49f02098f481"
      decimals="-3"
      id="F_db4cadbf-e520-40f2-9e20-735da915663f"
      unitRef="U_USD">7615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_90fd5f90-b4de-4e85-b60a-bdc91624657b"
      unitRef="U_USD">7615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_dd2a27c7-acca-4e22-922e-e6e22f9cea4d"
      decimals="INF"
      id="F_db4fa724-f2f2-4526-9d10-2fa20cbedce5"
      unitRef="U_shares">11466</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d6ea5928-6ce4-4e0b-9b61-49f02098f481"
      decimals="-3"
      id="F_cfc7b489-c798-42dc-b3c6-f9cdcf3d7459"
      unitRef="U_USD">33000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_b8829f24-3ab5-4a7c-9bd9-8e83e643963b"
      unitRef="U_USD">33000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_dd2a27c7-acca-4e22-922e-e6e22f9cea4d"
      decimals="INF"
      id="F_dc918255-a502-40c7-a08f-0b2a3b7e4f66"
      unitRef="U_shares">628403</lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_d6ea5928-6ce4-4e0b-9b61-49f02098f481"
      decimals="-3"
      id="F_012ca6c2-c24a-454b-9e22-0416536d1f86"
      unitRef="U_USD">6000</lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_be32de8f-eb58-4682-95f6-2396175b151a"
      unitRef="U_USD">6000</lrmr:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_d0f2886e-1b6f-49ac-a8ea-a868a6076338"
      decimals="-3"
      id="F_70daee25-24be-44df-96f2-2e1a78171bd3"
      unitRef="U_USD">112000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_47f21a3e-e1f3-4fd0-9a13-e391c6e0e700"
      unitRef="U_USD">112000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_57646aae-7316-49d9-a9e1-466cd58a59b6"
      decimals="-3"
      id="F_5d9fb608-5e06-4136-bfd2-bd17aabb7d09"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_4a611ff1-932a-465f-ae40-7b2c1323ae81"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_c3a77d44-ca39-48a6-af59-4ea835940adf"
      decimals="INF"
      id="F_440f7506-b91e-467c-8aec-f11dd0fd79bc"
      unitRef="U_shares">43909069</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_c3a77d44-ca39-48a6-af59-4ea835940adf"
      decimals="-3"
      id="F_0b53199d-0ff9-48b0-a4cf-1b0ba327865b"
      unitRef="U_USD">43000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f10a217c-c7c4-4985-8b2d-21543f8fe157"
      decimals="-3"
      id="F_f5ffda59-74f3-463b-835c-d8acc3d38920"
      unitRef="U_USD">270150000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3ddcccac-7c80-4352-b875-b59deec51ca1"
      decimals="-3"
      id="F_00ced02e-5ac7-4c46-90df-d653bb5d59fa"
      unitRef="U_USD">-188554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b89973be-3872-4363-9f3c-168e09a8a5a6"
      decimals="-3"
      id="F_f8799b47-04af-4451-84d8-2337065e35fd"
      unitRef="U_USD">81000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_7c2ab780-644e-41ed-b83d-f8759d1998ec"
      unitRef="U_USD">81720000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_25bcc1ed-8906-4121-9230-4f4d96744279"
      unitRef="U_USD">-80604000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_8e9e211c-25ed-4a12-a656-43bf0571f35f"
      unitRef="U_USD">-36949000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_6fcc625a-17e8-45a4-b7b9-91255bdfd6f2"
      unitRef="U_USD">8796000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_b3976328-4c81-430b-a251-48b31e0394ad"
      unitRef="U_USD">7615000</us-gaap:ShareBasedCompensation>
    <lrmr:CashAndNonCashOperatingLeaseExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_4bf0ade9-f78f-4b71-b099-0e56782a2de9"
      unitRef="U_USD">-189000</lrmr:CashAndNonCashOperatingLeaseExpense>
    <lrmr:CashAndNonCashOperatingLeaseExpense
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_b456c7c5-6402-4a7c-92e4-7dc973a8135b"
      unitRef="U_USD">-82000</lrmr:CashAndNonCashOperatingLeaseExpense>
    <us-gaap:Depreciation
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_ee92bfe2-b1ad-4ea4-a795-217d760f2fc7"
      unitRef="U_USD">318000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_b26f0aa0-2550-4de8-92e6-c141b4e50b7d"
      unitRef="U_USD">311000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_f65f1be5-ee4c-4f80-a503-d5bc176c1789"
      unitRef="U_USD">5256000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_c6247cb9-f29c-4c07-8456-ef95468523d7"
      unitRef="U_USD">1843000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_32869129-0822-48b9-be64-52fddbc71bd5"
      unitRef="U_USD">8465000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_9e2057ba-ec5b-4c70-8e86-65ed110e4853"
      unitRef="U_USD">1065000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_26c1cc01-1e26-4063-8bb5-21299194611e"
      unitRef="U_USD">1141000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_ba90cf90-4055-4103-96bf-502a11c67ba7"
      unitRef="U_USD">-403000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_f249beae-c9a0-403e-9a57-364eaf59df83"
      unitRef="U_USD">13436000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_5c38b526-a526-42be-a603-413cac8c0498"
      unitRef="U_USD">-1022000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_c166a39b-335f-484b-aaa4-0cd56580671b"
      unitRef="U_USD">-63000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_5174d865-6a12-4f76-b697-e0df517449b0"
      unitRef="U_USD">21000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_f207342b-de63-4504-9eca-d8949f2ccf08"
      unitRef="U_USD">-70760000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_ce512d47-72f8-43fa-8145-9793fe799614"
      unitRef="U_USD">-33459000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_97400da7-6eae-4ca6-801d-d05e5d3ba7f2"
      unitRef="U_USD">515000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_4b4187d4-6ed8-4705-b4f2-0dbbbbc42581"
      unitRef="U_USD">164000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_f39daf72-a3cc-432d-a015-d1e8b2231d6d"
      unitRef="U_USD">227872000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_4a74991b-6a18-45de-81e5-2ec84efab595"
      unitRef="U_USD">101233000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_ddf88761-7dfa-461c-8f78-edfdeb041938"
      unitRef="U_USD">143000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_a98de15b-9ddc-49ca-b8be-9bee8a338f4e"
      unitRef="U_USD">134750000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_72e4b8ac-932d-4c0b-a503-ce7e80b6555e"
      unitRef="U_USD">-85387000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_98472223-76ee-42c1-8f37-56290f39cb3c"
      unitRef="U_USD">33353000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_461be0b4-d3c7-487e-8073-d104ad4aeba6"
      unitRef="U_USD">161806000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <lrmr:ProceedsFromStockOptionsAndWarrantExercises
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_5b8a57e2-5590-48a9-8a26-d43779d55b77"
      unitRef="U_USD">77000</lrmr:ProceedsFromStockOptionsAndWarrantExercises>
    <lrmr:ProceedsFromStockOptionsAndWarrantExercises
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_1840d36c-278b-4568-8ee2-e49bf957b5c4"
      unitRef="U_USD">30000</lrmr:ProceedsFromStockOptionsAndWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_c5ff26b6-2116-46fd-a4c9-50680a6f8b0c"
      unitRef="U_USD">161883000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_9644f828-a9ed-47e7-bb4a-e3a12fddf7a3"
      unitRef="U_USD">30000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_62ce7ec2-b0f8-4808-b462-95f828a2be27"
      unitRef="U_USD">5736000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_ffc1a51d-2860-4e36-be37-965d03bddcdf"
      unitRef="U_USD">-76000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_9a6a6b5d-ee14-4d04-9dc4-bfc0b5021e1d"
      unitRef="U_USD">28088000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e567f291-5928-46ca-9886-4b12d459c211"
      decimals="-3"
      id="F_6050f6e8-9548-479e-be49-6cad0cc2972e"
      unitRef="U_USD">28164000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_a443991a-6327-490b-aae2-ff86383f622a"
      unitRef="U_USD">33824000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_b354956a-376b-400d-8bc9-ad22beab26a5"
      unitRef="U_USD">28088000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_3dabeff0-1176-4cc7-ae0a-bf9f255043e7"
      unitRef="U_USD">465000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_a44033af-a05a-478b-9387-927c1716c414"
      unitRef="U_USD">790000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <lrmr:OfferingCostsIncludedInAccountsPayableAndAccruedExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_1505305f-2d42-4fb5-b7cb-dafcbe79dd38"
      unitRef="U_USD">50000</lrmr:OfferingCostsIncludedInAccountsPayableAndAccruedExpense>
    <lrmr:ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_d1b2285b-141b-4342-ae13-4e407440aea7"
      unitRef="U_USD">9000</lrmr:ProceedsFromExerciseOfStockOptionsIncludedInOtherCurrentAssets>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_e91d44fd-a721-4bf4-ab8f-288457a02f82">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Description of Business and Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Larimar Therapeutics, Inc., together with its subsidiary (the &#x201c;Company&#x201d; or &#x201c;Larimar&#x201d;), is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Larimar's lead product candidate, nomlabofusp (nomlabofusp is the International Nonproprietary Name and the United States Adopted Name for CTI-1601), is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin ("FXN"), an essential protein, to the mitochondria of patients with Friedreich&#x2019;s ataxia ("FA"). FA is a rare, progressive and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Larimar has completed two Phase 1 clinical trials and a Phase 2 dose exploration trial, and has an ongoing Phase 2 OLE trial in patients with FA and an ongoing run-in study in adolescent patients with FA.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2021, the Company reported positive top-line data from its Phase 1 FA program after completing dosing of the single ascending dose ("SAD") trial in December 2020 and of the multiple ascending dose ("MAD") trial in March 2021. Data from these trials demonstrated proof-of-concept by showing that daily subcutaneous injections of nomlabofusp for up to 13 days resulted in dose-dependent increases in FXN levels from baseline compared to placebo in all evaluated tissues (buccal cells, skin, and platelets). There were no serious adverse events associated with either the MAD or SAD trials.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2023, the Company reported preliminary unblinded top-line data from the 25 mg cohort of the Phase 2 four-week, placebo-controlled, dose exploration trial of nomlabofusp in FA patients. Data from the cohort indicated nomlabofusp was generally well tolerated and showed increases in FXN levels from baseline compared to placebo in all evaluated tissues (skin and buccal cells) at day 14.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2023, the FDA cleared initiation of a second cohort (50 mg) of the four-week, placebo-controlled, Phase 2 dose exploration trial of nomlabofusp in patients with FA and the initiation of the OLE trial with daily dosing of 25 mg.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2024, the Company reported positive top-line data and successful completion of the Phase 2 dose exploration study. Nomlabofusp was generally well tolerated throughout the four-week treatment periods, had a predictable pharmacokinetic profile and led to dose dependent increases in FXN levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo. Patients who completed treatment in the Phase 2 dose exploration study or who previously completed a prior clinical trial of nomlabofusp are eligible to screen and possibly participate in the OLE study.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In March 2024, Larimar dosed the first patient in the OLE trial, evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver. The OLE study will evaluate the safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues as well as other exploratory pharmacodynamic markers (lipid profiles and gene expression data) following long-term subcutaneous administration of nomlabofusp. In addition, following the completion of enrollment, as well as at least one participant completing one year of dosing, clinical assessments collected during the study will be compared to data from a matched control arm derived from participants in the Friedreich&#x2019;s Ataxia Clinical Outcome Measures Study ("FACOMS") database.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 30, 2024, Larimar announced that the FDA's Center for Drug Evaluation and Research ("CDER") had selected nomlabofusp as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics ("START") Pilot Program. The objective of the program is to accelerate the development of drugs for rare diseases that lead to significant disability or death by facilitating frequent advice and regular communication with the FDA staff to expedite the review process of biologics and drugs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2024, the Company received access to the Medicines and Healthcare Regulatory Agency ("MHRA&#x201d;) Innovative Licensing and Access Pathway (&#x201c;ILAP&#x201d;) for the treatment of adults and children with FA. The ILAP is facilitating patient access to novel treatments by accelerating time to market through opportunities for enhanced engagements with UK regulatory authorities and other stakeholders. Along with the receipt of the ILAP designation, nomlabofusp has already been granted orphan drug designations in the U.S. and the European Union (the &#x201c;EU&#x201d;), and access to the PRIME scheme in the EU.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, the Company reported positive initial data from the ongoing OLE study. This data included safety, FXN levels, clinical, pharmacokinetic data and dose escalation:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nomlabofusp was generally well tolerated for up to 260 days in subjects. The most common adverse events were injection site reactions, with most being mild, brief in duration, and self-limited. Two participants had serious adverse events (one seizure and one anaphylactic reaction) that resolved within 24 hours and withdrew from the study; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-term 25 mg tissue FXN levels showed positive mean change from baseline of 1.32 pg/&#x3bc;g in buccal cells and 9.28 pg/&#x3bc;g in skin cells at Day 90 and that 25 mg of nomlabofusp increased and maintained tissue FXN levels over time, increasing from a mean level of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of HV at baseline to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% in buccal cells and from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% in skin cells at Day 90;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Tissue FXN levels appear to reach steady-state levels by Day 30 in buccal cells;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Early clinical data showed trends toward improvement across a number of clinical outcomes for long-term 25 mg daily nomlabofusp including: (1) decreased values indicating early trends towards improvement in the Modified Friedreich Ataxia Rating Scale (mFARS) and the FARS-Activities of Daily Living ("ADL"), Modified Fatigue Impact Scale and 9 hole peg test at 90 days relative to baseline;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.537%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.491405046981553%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Key pharmacokinetic data showed rapid absorption after subcutaneous administration with exposure appearing to reach steady state in plasma by day 30 with no further accumulation, which is consistent with data from our Phase 1 and Phase 2 studies.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Also in December 2024, Larimar announced that it was increasing the dose in the OLE to 50 mg of nomlabofusp daily for then currently enrolled and all future OLE study participants. In March 2025, the Company announced that its Safety Monitoring Team has deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp and therefore, Larimar expects to see additional reactions. To reduce the risk of allergic reactions, including anaphylaxis, Larimar amended the OLE protocol to administer premedication for the first month of dosing. The OLE study is ongoing with seven sites activated and participants continuing to enroll. All  study participants are currently receiving the 50 mg dose of nomlabofusp. The Company plans to provide an update on OLE data on at least 30 to 40 study participants, some of whom have been receiving nomlabofusp for more than a year, in September 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2025, Larimar initiated dosing of adolescents (12-17 years old) in a PK run-in study for pediatric patients with FA. Study participants in the PK run-in study are randomized 2:1 to receive either nomlabofusp at a weight-base dose expected to match the PK of adults receiving the 50 mg dose, or placebo, daily for seven days. Following assessment of safety and PK data, participants will be eligible to screen for the OLE study. The data from this cohort is expected to be presented during the nomlabofusp program update in September 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2025, Larimar announced that FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as a reasonably likely surrogate endpoint (&#x201c;RLSE&#x201d;) and the acceptability of FXN&#x2019;s use as an RLSE would ultimately be a matter of review of the data in a future marketing application. FDA recommended focusing on assessments of skin FXN concentrations rather than buccal FXN concentrations due to more consistent sampling and less variability. FDA acknowledged that data the Company recently submitted appear to support a relationship between increased FXN concentrations in skin cells and relevant tissues such as the heart, dorsal root ganglion and skeletal muscle. FDA also acknowledged that the nonclinical studies Larimar submitted were performed at relevant human doses. FDA also suggested that Larimar consider exploring the relationship between increases in FXN in skin and changes in pharmacodynamic (PD) markers such as lipid profiles and/or clinical measures to provide additional support for the use of FXN as an RLSE. Larimar plans to continue discussions with FDA regarding the adequacy of the safety data set for a BLA submission seeking accelerated approval targeted for year-end 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, the Company has obtained feedback from both FDA and EMA on the global Phase 3 study protocol and is on track to initiate the study by mid-2025 with potential sites in the U.S., E.U., U.K, Canada, and Australia.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to pre-commercial companies in the biotechnology industry, including, but not limited to, development and commercialization by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations, failure to secure regulatory approval for its drug candidates or any other product candidates and the ability to secure additional capital to fund its operations. Product candidates under development will require extensive non-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;capabilities. Even if the Company's drug development efforts are successful, it is uncertain when, if ever, it will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with U. S. Generally Accepted Accounting Principles ("GAAP")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024, and 2023, respectively, and cash flow used in operations of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024 and 2023, respectively. In addition, as of December 31, 2024, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2024, the Company had approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,736,842&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock in an underwritten public offering at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 205, "Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into the second quarter of 2026.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <lrmr:MeanLevelHVAtBaselinePercentage
      contextRef="C_778a5e08-2c19-4fa4-9229-8be5d4f04ff2"
      decimals="2"
      id="F_004f83f6-73db-4bbe-b2c5-79b985f13f8f"
      unitRef="U_pure">0.15</lrmr:MeanLevelHVAtBaselinePercentage>
    <lrmr:MeanLevelHVAtBaselinePercentage
      contextRef="C_37be18e2-22dc-4e2a-9beb-0936213f0ff9"
      decimals="2"
      id="F_77be9fd8-71a2-4066-8f01-bf0a7c9c0d23"
      unitRef="U_pure">0.30</lrmr:MeanLevelHVAtBaselinePercentage>
    <lrmr:MeanLevelHVAtBaselinePercentage
      contextRef="C_d69bdfda-1561-4df9-9031-4aaa6b8277e8"
      decimals="2"
      id="F_45f17f02-c237-4ba3-8946-556e9644b1f3"
      unitRef="U_pure">0.16</lrmr:MeanLevelHVAtBaselinePercentage>
    <lrmr:MeanLevelHVAtBaselinePercentage
      contextRef="C_937c9270-0745-4d6a-8ddd-353d3408b686"
      decimals="2"
      id="F_160f54e2-7b52-4f10-b661-4dcf2f3e77d2"
      unitRef="U_pure">0.72</lrmr:MeanLevelHVAtBaselinePercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_37d8d48f-74b8-4361-a1e4-c9c870cba969">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The consolidated financial statements include the accounts of Larimar and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated. The accompanying consolidated financial statements have been prepared in conformity with U. S. Generally Accepted Accounting Principles ("GAAP")&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <lrmr:GoingConcernPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_558aa2df-8d8c-4175-9459-32539a0a55ab">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been presented on the basis that it will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since its inception, the Company has incurred significant recurring operating losses and negative cash flows from operations. The Company has incurred net losses of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024, and 2023, respectively, and cash flow used in operations of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2024 and 2023, respectively. In addition, as of December 31, 2024, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;269.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company expects to continue to generate operating losses for the foreseeable future. As of December 31, 2024, the Company had approximately &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;183.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of cash, cash equivalents and marketable securities available for use to fund its operations and capital requirements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has funded its operations to date primarily with proceeds from sales of common stock and proceeds from the sale of prefunded warrants for the purchase of common stock, the acquisition in 2020 of cash, cash equivalents and marketable securities upon the merger with Zafgen, Inc. ("Zafgen") and, prior to the 2020 merger with Zafgen, capital contributions from Chondrial Holdings, LLC.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,736,842&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock in an underwritten public offering at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 205, "Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern", the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects its cash, cash equivalents and marketable securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements into the second quarter of 2026.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has not yet commercialized any products and does not expect to generate revenue from the commercial sale of any products for several years, if at all. The Company expects that its research and development and general and administrative expenses will continue to increase and, as a result, that it will need additional capital to fund its future operating and capital requirements. Unless and until the Company can generate substantial revenue, management continuously evaluates different strategies to obtain the required funding for future operations. These strategies include seeking additional funding through a combination of public or private equity offerings, debt or royalty financings, collaborations and licensing arrangements, strategic partnerships with pharmaceutical and/or larger biotechnology companies, or other sources. The incurrence of indebtedness would result in increased payment obligations and the Company may be required to agree to certain restrictive covenants, such as limitations on its ability to incur additional debt, limitations on its ability to acquire, sell or license intellectual property rights, minimum required cash balances and other operating restrictions that could adversely impact the Company's ability to conduct its business. Any additional fundraising efforts may divert the Company's management from their day-to-day activities, which may adversely affect its ability to develop and commercialize its product candidates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There can be no assurance that the Company will be able to raise sufficient additional capital on acceptable terms, if at all. If such additional financing is not available on satisfactory terms, or is not available in sufficient amounts, or if the Company does not have sufficient authorized shares, the Company may be required to delay, limit, or eliminate the development of business opportunities and its ability to achieve its business objectives, its competitiveness, and its business, financial condition, and results of operations will be materially adversely affected. The Company could also be required to seek funds through arrangements with collaborative partners or otherwise at an earlier stage than otherwise would be desirable and it may be required to relinquish rights to some of its technologies or product candidates or otherwise agree to terms unfavorable to it, any of which may have a material&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adverse effect on the Company's business, operating results and prospects. In addition, geopolitical tensions, volatility of capital markets, and other adverse macroeconomic events, including those due to inflationary pressures, rising interest rates, bank instability and the ability of the U.S. government to manage federal debt limits as well as the potential impact of other health crises on the global financial markets may reduce the Company's ability to access capital, which could negatively affect its liquidity and ability to continue as a going concern.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If the Company is unable to obtain sufficient funding when needed and/or on acceptable terms, the Company may be required to significantly curtail, delay or discontinue one or more of its research and development programs, the manufacture of clinical and commercial supplies, product portfolio expansion, pre commercialization efforts and/or commercial operations, which could adversely affect its business prospects, or the Company may be unable to continue operations. If the timing of the Company's clinical assumptions are delayed or if there are other forecasted assumption changes that negatively impact its operating plan, the Company would reduce expenditures in order to further extend cash resources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</lrmr:GoingConcernPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-5"
      id="F_b41891ee-19d7-4981-87e3-6ba47c017a21"
      unitRef="U_USD">-80600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-5"
      id="F_dd503a94-1acb-4f4f-b3a4-ac20b02867d8"
      unitRef="U_USD">-36900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-5"
      id="F_f4520e5f-10a5-4681-a199-9c86716b6298"
      unitRef="U_USD">-70800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-5"
      id="F_ce77c4c9-a8f4-4b11-a7f5-8ed3dff16de3"
      unitRef="U_USD">-33500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-5"
      id="F_2cde0441-cf98-49de-b40c-f3cda5dfe906"
      unitRef="U_USD">-269200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-5"
      id="F_b03a925a-c8b8-4754-9baf-7dd24b6d9006"
      unitRef="U_USD">183500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1b3789f9-d2e6-472a-a24f-4537eda96328"
      decimals="INF"
      id="F_e28576e5-8e48-4987-84e2-579b8c41f436"
      unitRef="U_shares">19736842</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_afb7c02e-1d17-4fbb-ad2f-056d597aacc2"
      decimals="2"
      id="F_6210a19e-4587-4977-9103-3300d1f9e0fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_1b3789f9-d2e6-472a-a24f-4537eda96328"
      decimals="-5"
      id="F_15501c02-1472-4e6d-a8e6-f47a6d031838"
      unitRef="U_USD">161800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_898c9d36-2362-441f-9f12-af94ab8f1a88">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#x2019;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;income; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#x2019; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value would be recorded in net income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e67f9759-bc4c-4465-933e-6db26d968aa7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment, net&#xb8; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs associated with internal research and development and external research and development services, including drug manufacturing and scale- up, other drug development and testing costs, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and to scale up the manufacturing process, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company is managed on a consolidated basis and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segment related to the development of clinical and preclinical product candidates for the development of the Company&#x2019;s proprietary new therapies, primarily nomlabofusp, the Company's life science segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is the Company's &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d10ed809-200f-4b30-80d3-8c8fcced056e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("CEO").&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the Company and its reportable segment based on net loss, which is reported on the consolidated Statements of Operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. All long-lived assets are located in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and regulatory approval.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM uses consolidated financial information, including consolidated net loss, to evaluate performance, forecast future period financial results, allocate resources for the company by, among other things, comparing budgeted to actual results.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 and 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Technical operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nomlabofusp support&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s only element of other comprehensive gain (loss) was unrealized gain (loss) on marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#x2019;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Accordingly, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,135,390&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,888,502&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options to purchase common stock, outstanding as of December 31, 2024 and 2023 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07 requires disclosure of incremental segment information on an annual and interim basis. The amendments also require companies with a single reportable segment to provide all disclosures required by this amendment and all existing segment disclosures in ASC 280, Segment Reporting. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8e858e57-0756-416b-b74d-b48de20c666a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, effective December 31, 2024, in these consolidated financial statements. ASU 2023-07 only impacted the disclosures and did not impact the consolidated financial statements. See Note 2, Segment Information, for disclosures related to the adoption of ASU 2023-07.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &#x201c;Improvements to Income Tax Disclosures (Topic 740),&#x201d; which requires entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes as well as additional information about reconciling items if certain quantitative thresholds are met. This ASU will require all entities to disclose income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. All entities are required to apply the guidance prospectively, with the option to apply it retrospectively. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it will adopt this ASU on January 1, 2025, the adoption of which is not expected to have a material impact on the Company&#x2019;s consolidated results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#x201d;, which requires disaggregated disclosures in the notes of the financial statements of certain categories of expenses that are included in expense line items on the face of the income statement. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company will evaluate the impact adopting ASU 2024-03 will have on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_2136b73a-2f60-46e8-8603-2e9acecec519">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. This process involves reviewing open contracts and purchase orders, communicating with our personnel and outside vendors to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expense, the recording as prepaid expense of payments made in advance of the actual provision of goods or services, valuation of stock-based awards and valuation of leases. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_0384acff-cbec-4bd8-a83e-ebcdaa6ab519">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and marketable securities. Cash balances may be held in financial institutions which may exceed federally insured limits. The Company has not experienced realized losses related to its cash, cash equivalents or marketable securities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is highly dependent on third-party manufacturers to supply products for research and development activities in its programs, to scale and optimize their manufacturing processes and, ultimately, to provide commercial supply. The Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for drug substance and formulated drugs related to these programs. The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for the Company by a third-party manufacturer, and the frozen liquid form of drug product is made at another manufacturer. The Company is undertaking a program with a third manufacturer to begin to produce a lyophilized version of the drug product from the same drug substance, that, once available, the Company intends to use in certain of its future planned clinical trials. The Company&#x2019;s research and development programs could be adversely affected by a significant interruption in these manufacturing services or in the supply of drug substance and formulated drugs.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_903c991d-c6b0-44a2-8da4-d6f76f5a9e3f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company considers all highly liquid investments with maturities of three months or less at the date of purchase to be cash equivalents. Cash equivalents consisted of money market funds as of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_8cbb98ad-90be-46e7-b3b1-1d34f784b7b0">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Marketable &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;securities consist of debt investments with original maturities greater than ninety days. The Company classifies its marketable securities as available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. When the fair value is below the amortized cost the amount of the expected credit loss is estimated. The credit-related impairment amount, if any, would be recognized in net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;income; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the remaining impairment amount and unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#x2019; equity. Credit losses, if any, are recognized through the use of an allowance for credit losses account and subsequent improvements in expected credit losses are recognized as a reversal of the allowance account. If the Company has the intent to sell the security or if it is more likely than not that the Company would be required to sell the security prior to recovery of its amortized cost basis, the allowance for credit loss would be written off and the excess of the amortized cost basis of the asset over its fair value would be recorded in net income.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_3366c433-de0f-441c-8dff-1689becd10d4">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e67f9759-bc4c-4465-933e-6db26d968aa7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; or&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; estimated useful life for equipment, furniture and fixtures and office equipment. Leasehold improvements are amortized over the shorter of the asset life or the term of the lease agreement. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in loss from operations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_4f4d089e-ca07-4b47-be34-6ef0f252b0ad"
      id="F_d2769560-89b9-46ad-9155-f0153602274c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_a78ce45f-1d08-40a2-a8d5-a5815fef984f">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Long-lived assets consist of property and equipment, net&#xb8; and right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset to its carrying value. Any impairment loss, if indicated, is measured as the amount by which the carrying amount of the asset exceeds the estimated fair value of the asset.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_7c91d1c2-d252-4e4b-8675-117040b6aacf">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Costs associated with internal research and development and external research and development services, including drug manufacturing and scale- up, other drug development and testing costs, clinical studies and non-clinical studies, are expensed as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses, depreciation, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside vendors engaged to conduct discovery, non-clinical and clinical development activities and clinical trials as well as to manufacture clinical trial materials and to scale up the manufacturing process, and other costs. The Company recognizes external research and development costs based on an evaluation of the progress to completion of specific tasks using information provided to the Company by its key service providers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Upfront payments, milestone payments and annual maintenance fees under license agreements are currently expensed in the period in which they are incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_dbcc0fc4-1882-4179-9421-b37df38a7382">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Patent Costs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_f5098410-ae5b-4d29-86db-1f447bea3531">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company measures all stock-based awards granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is the vesting period of the respective award. Typically, the Company issues awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to May 28, 2020, the Company had been a private company and lacked company-specific historical and implied volatility information for its common stock. Prior to January 1, 2023, the Company estimated its expected common stock price volatility solely based on the historical volatility of publicly traded peer companies. Beginning on January 1, 2023, based on the availability of sufficient historical trading data of the Company's own common stock on the Nasdaq Global Market to calculate accurately its volatility, the Company began blending its volatility starting from June 2020 (following its merger with Zafgen in 2020) to the date of each stock-based award, and weighing the volatility of its peer group for the amount of time from May 31, 2020 backwards so that the blended volatility equals the expected term of the related stock-based award. The expected term of the Company&#x2019;s stock options has been determined utilizing the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield considers the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_f8fdd861-97a3-45bc-a894-afdcb6027d0c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are defined as components of an enterprise for which separate discrete information is available for evaluation by the chief operating decision maker, or decision making group, in deciding how to allocate resources in assessing performance. The Company is managed on a consolidated basis and has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; operating and reportable segment related to the development of clinical and preclinical product candidates for the development of the Company&#x2019;s proprietary new therapies, primarily nomlabofusp, the Company's life science segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is the Company's &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d10ed809-200f-4b30-80d3-8c8fcced056e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;chief executive officer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ("CEO").&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies of the life science segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the Company and its reportable segment based on net loss, which is reported on the consolidated Statements of Operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. All long-lived assets are located in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, the Company has not generated any product revenue. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as it advances product candidates through all stages of development and clinical trials and regulatory approval.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The CODM uses consolidated financial information, including consolidated net loss, to evaluate performance, forecast future period financial results, allocate resources for the company by, among other things, comparing budgeted to actual results.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 and 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Technical operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nomlabofusp support&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="INF"
      id="F_d28de841-8788-430c-80af-12a02621a9ee"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="INF"
      id="F_baa13b8d-c08c-47cd-bdd5-09adfb77d853"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_982048d3-5cc3-4dce-9537-5cec34526103">The CODM uses consolidated financial information, including consolidated net loss, to evaluate performance, forecast future period financial results, allocate resources for the company by, among other things, comparing budgeted to actual results.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_7f9b44a9-63af-44bc-8fc0-67b9cdc6e514">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below summarizes the significant expense categories regularly reviewed by the CODM for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 and 2023:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating expenses:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Technical operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nomlabofusp support&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other income, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,809&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingExpenses
      contextRef="C_ab791d56-0959-4081-945b-058f0d6c6f82"
      decimals="-3"
      id="F_c0d22609-becb-42e9-941f-ba06c85faee7"
      unitRef="U_USD">44805000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2b1053b4-6091-48b6-907a-083f14aa104f"
      decimals="-3"
      id="F_c52f45c7-9769-4002-9d94-cba58fbf77a4"
      unitRef="U_USD">6781000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_bfbc57ff-0284-43eb-9410-6bcf4e5de594"
      decimals="-3"
      id="F_0264fd14-6013-494a-b75f-99de8fdcd0f6"
      unitRef="U_USD">24361000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0ca29918-24cb-4049-81da-b0b595cb7f08"
      decimals="-3"
      id="F_664460db-ba0d-48c9-ba71-3d1f65d7c242"
      unitRef="U_USD">15733000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_a6372807-b669-4c9a-bca6-c7c693a758c3"
      decimals="-3"
      id="F_fc161b5b-2204-4b0c-b37f-14bea290c57e"
      unitRef="U_USD">4112000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_d699938b-88e6-4ed6-bb3e-ded55260a3c7"
      decimals="-3"
      id="F_e4412534-117d-4916-9215-4e6ef8837d06"
      unitRef="U_USD">5156000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_c18bcdd4-7898-4e7b-aeaa-04861be8d49c"
      decimals="-3"
      id="F_8ae54e79-e77d-41da-bd1e-14ce7a3a45ca"
      unitRef="U_USD">15944000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_4d9b0d0f-39b2-4d7c-ad5a-792b1d5080d1"
      decimals="-3"
      id="F_3f052631-7aa3-49ce-bffc-a8081876974d"
      unitRef="U_USD">14088000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_9450bf35-e5d7-4e90-b946-f5ecc5c1b78f"
      decimals="-3"
      id="F_117b33ac-d373-48f7-ab42-89cd04306794"
      unitRef="U_USD">1668000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_cc99e24e-ed69-41f5-bbda-7fa44c9b5ed3"
      unitRef="U_USD">90890000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_0af35313-32a7-496d-8862-c11d2d5189c4"
      unitRef="U_USD">41758000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_8cc86cfe-f832-4b35-980e-09cee4d10526"
      unitRef="U_USD">10286000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_93c0d6b9-3db5-4bbf-b0ba-965a9ae78926"
      unitRef="U_USD">4809000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_42c138f5-a5ce-4161-9706-a933939fb8c6"
      unitRef="U_USD">-80604000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_bb294e7f-0467-4c9f-8857-e737858c8941"
      unitRef="U_USD">-36949000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_9d16c0d6-eba2-4e4a-961a-2e97f99eb735">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.
&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <lrmr:LikelihoodPercentageMinimum
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="2"
      id="F_f9a9ee81-b5fe-48be-8fee-8bd72a2e987e"
      unitRef="U_pure">0.50</lrmr:LikelihoodPercentageMinimum>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_bc19524e-74fd-453f-a212-bdbd368d364c">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Comprehensive Gain (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Comprehensive gain (loss) includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s only element of other comprehensive gain (loss) was unrealized gain (loss) on marketable securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_5ad2e8e5-902b-4c98-8783-f9adc7c739e7">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Loss Per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Prior to August 11, 2023, basic shares outstanding includes the weighted average effect of the Company&#x2019;s prefunded warrants issued in June 2020, the exercise of which requires little or no consideration for the delivery of shares of common stock. These prefunded warrants were exercised on August 11, 2023 and the Company received cash proceeds of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Accordingly, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were issued upon the exercise of these warrants and are included in issued and outstanding common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares, including potentially dilutive common stock equivalents assuming the dilutive effect of outstanding stock options, outstanding restricted stock units, and unvested restricted common shares, as determined using the treasury stock method. For periods in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which the Company has reported net losses (all periods since inception), diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, since dilutive common stock equivalents are not assumed to have been issued if their effect is antidilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company excluded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,135,390&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,888,502&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options to purchase common stock, outstanding as of December 31, 2024 and 2023 respectively, from the computation of diluted net loss per share for the twelve months ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, because they had an anti-dilutive impact due to the net loss incurred for the periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_ec7837b7-c9c1-4c07-8288-455007933963"
      decimals="-5"
      id="F_f8b6df93-1666-44f7-8d3c-256b4ee80cfb"
      unitRef="U_USD">100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_703f9a1d-ba57-4229-9130-75f431315872"
      decimals="INF"
      id="F_67956c3e-f910-4082-af21-35556f8dfe21"
      unitRef="U_shares">628403</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_703f9a1d-ba57-4229-9130-75f431315872"
      decimals="INF"
      id="F_5a620aa9-23e4-4eff-bc8b-55ad45b3ac81"
      unitRef="U_shares">628403</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4652a096-8724-4cdf-a118-748dbb5359af"
      decimals="INF"
      id="F_2c2896b0-97d1-4240-920e-5934367998ce"
      unitRef="U_shares">7135390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c7bb7719-628e-435e-ba3a-d42b56b0336b"
      decimals="INF"
      id="F_c85b36c3-242e-4749-b50b-eb5e40b20444"
      unitRef="U_shares">4888502</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d58edcb6-0742-4b18-876a-b0e14c9a3abd">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by us as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. We have assessed the recently issued guidance that is not yet effective and believe the new guidance will not have a material impact on the consolidated results of operations, cash flows or financial position.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07 requires disclosure of incremental segment information on an annual and interim basis. The amendments also require companies with a single reportable segment to provide all disclosures required by this amendment and all existing segment disclosures in ASC 280, Segment Reporting. The amendments are effective for fiscal years beginning after December 15, 2023, and interim periods beginning after December 15, 2024. The Company &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;adopted&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8e858e57-0756-416b-b74d-b48de20c666a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ASU 2023-07&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, effective December 31, 2024, in these consolidated financial statements. ASU 2023-07 only impacted the disclosures and did not impact the consolidated financial statements. See Note 2, Segment Information, for disclosures related to the adoption of ASU 2023-07.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &#x201c;Improvements to Income Tax Disclosures (Topic 740),&#x201d; which requires entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes as well as additional information about reconciling items if certain quantitative thresholds are met. This ASU will require all entities to disclose income taxes paid, net of refunds, disaggregated by federal (national), state and foreign taxes for annual periods and to disaggregate the information by jurisdiction based on a quantitative threshold. All entities are required to apply the guidance prospectively, with the option to apply it retrospectively. The ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has determined it will adopt this ASU on January 1, 2025, the adoption of which is not expected to have a material impact on the Company&#x2019;s consolidated results of operations or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &#x201c;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&#x201d;, which requires disaggregated disclosures in the notes of the financial statements of certain categories of expenses that are included in expense line items on the face of the income statement. This ASU is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company will evaluate the impact adopting ASU 2024-03 will have on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      id="F_0c29843b-49ce-488c-a165-bc15442dd93f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_1442177e-e6a1-4b1f-99f5-93eea897e005">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Cash Equivalents/Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024 and December 31, 2023 are measured in accordance with the standards of ASC 820, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which establishes a three-level valuation hierarchy for measuring fair value and expands financial statement disclosures about fair value measurements. The valuation hierarchy is based on upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:11.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
      &lt;td style="width:88.46%;box-sizing:content-box;"&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level &#x2013; 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:1pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level &#x2013; 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:middle;padding-bottom:0in;"&gt;&lt;p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Level &#x2013; 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts payable and accrued liabilities. For accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of December 31, 2024 and 2023 were considered representative of their fair values due to their short term to maturity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s cash equivalents and marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds invested in government &lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds invested in government &lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accrued interest receivable related to the Company&#x2019;s investments was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively, and is included in prepaid expenses and other current assets on the consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies its money market funds and U.S. treasury bills, which are valued based on quoted market prices in active markets with no valuation adjustment, as Level 1 assets within the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company classifies its investments in U.S. government and agency securities, corporate commercial paper, and corporate bonds, if any, as Level 2 assets within the fair value hierarchy. The fair values of these investments are estimated by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024, the unrealized loss for available-for-sale investments were non-credit related, and the Company does not intend to sell the investments that were in an unrealized loss position, nor will it be required to sell those investments before recovery of their amortized cost basis, which may be maturity. As of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; allowances for credit losses for the Company&#x2019;s investments were recorded. During the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognize any impairment losses related to investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023, the Company's cash equivalents and marketable securities consisted of a U.S. government money market fund, U.S. Treasury Bills and U.S. government and agency securities, all held in our name in a separate custody account with U.S. Bank. The U.S. government money market fund has same-day liquidity access and the U.S. government and agency securities all have maturities of 360 days or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Marketable Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_79925af4-90e1-4ec0-8281-bcc618fdb146">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s cash equivalents and marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted&lt;br/&gt;Prices in&lt;br/&gt;Active&lt;br/&gt;Markets &lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs &lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs &lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds invested in government &lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,702&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds invested in government &lt;br/&gt;&#160;&#160;&#160;securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,701&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,035&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_990b03ea-4e3f-428b-9463-5722c03fe7ef"
      decimals="-3"
      id="F_8cd26507-6022-46d8-b264-6c9a34c12f54"
      unitRef="U_USD">26702000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_a4b86fbb-6763-470f-9324-890bb9b86ef7"
      decimals="-3"
      id="F_1ba52513-a379-4322-8173-7e68f8d40c09"
      unitRef="U_USD">26702000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_8e9c6b13-9862-4af4-9fc4-6b3be1eab6f3"
      unitRef="U_USD">26702000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_980a36da-7606-4c17-93a9-29aef7c80f1d"
      decimals="-3"
      id="F_475e5493-c6fe-49a1-97a4-428fa3f5621d"
      unitRef="U_USD">26702000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70"
      decimals="-3"
      id="F_04c0b08e-8de2-4232-8040-941ab2333ed3"
      unitRef="U_USD">2947000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_937d6158-f010-48b2-b04e-91b91f550795"
      decimals="-3"
      id="F_858d13af-6162-4ab8-a70d-31e841e3d0ff"
      unitRef="U_USD">2947000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733"
      decimals="-3"
      id="F_bb2cac64-35ce-4e43-876e-e44def27691b"
      unitRef="U_USD">147289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_1e6ff9a0-2992-49a2-9d8e-9424081411f5"
      decimals="-3"
      id="F_0a9360b9-04ea-4290-9590-45eadcc17dae"
      unitRef="U_USD">147289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_ebeaa54c-d9b2-431f-9c94-1d1576a7bb54"
      unitRef="U_USD">150236000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_980a36da-7606-4c17-93a9-29aef7c80f1d"
      decimals="-3"
      id="F_be748b30-f025-41cc-aeef-9c49d9fc6a43"
      unitRef="U_USD">2947000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_06eb49df-ea1f-4795-b693-6ce41c4e020b"
      decimals="-3"
      id="F_416d2a9b-aaa5-4c65-adc6-08f416cb2dd0"
      unitRef="U_USD">147289000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_bf8a30f3-45c5-4178-8d3d-f15bc3661be8"
      unitRef="U_USD">176938000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_980a36da-7606-4c17-93a9-29aef7c80f1d"
      decimals="-3"
      id="F_8c189753-41ad-44da-950b-8027b3038a46"
      unitRef="U_USD">29649000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_06eb49df-ea1f-4795-b693-6ce41c4e020b"
      decimals="-3"
      id="F_d526f8fc-c077-4285-b758-10fb36d55e32"
      unitRef="U_USD">147289000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_03512384-f164-4169-8f61-63c0a2fa35f3"
      decimals="-3"
      id="F_b2f7cb0b-4545-4c24-9d24-d56a593ef451"
      unitRef="U_USD">24701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b039d28f-1551-4683-aa18-2d31487cc476"
      decimals="-3"
      id="F_b284aee9-cf50-4ab7-b171-dca2e90b10bf"
      unitRef="U_USD">24701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_499da8ed-d9c9-4adb-84cc-de94bd141539"
      unitRef="U_USD">24701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_c66d62d9-1b72-4c63-9f95-2f1a72677604"
      decimals="-3"
      id="F_ef1752c7-77c3-41ee-a8f1-ace1e3427655"
      unitRef="U_USD">24701000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f552a753-5013-41ab-8a68-b985b7c0bac4"
      decimals="-3"
      id="F_5319573d-e9bf-4226-a230-9b6c1e489f13"
      unitRef="U_USD">17334000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_7f9933f3-6cd7-4632-83be-ff4608000844"
      decimals="-3"
      id="F_b2fcd62d-0bca-4800-a667-a9b9f27c5a38"
      unitRef="U_USD">17334000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f"
      decimals="-3"
      id="F_c58c606e-1317-4852-af8b-a93842b25577"
      unitRef="U_USD">35719000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_2e43c4d6-c27e-4c64-957a-2c359c114241"
      decimals="-3"
      id="F_36c7d8f4-b4a7-4725-9ec3-a8606180fc2c"
      unitRef="U_USD">35719000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_4e6a434c-62eb-44df-bb26-a28924999a6a"
      decimals="-3"
      id="F_9ff89584-15f0-4fae-ad68-9405e0b80e43"
      unitRef="U_USD">6988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_89155b9d-f3b6-4453-9d28-eeacaa55b7e1"
      decimals="-3"
      id="F_1ededc3c-8725-4bad-98d9-8e32f03a5ea9"
      unitRef="U_USD">6988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_7f4b3a6f-1ece-43ab-aaf2-d83da5189d98"
      unitRef="U_USD">60041000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c66d62d9-1b72-4c63-9f95-2f1a72677604"
      decimals="-3"
      id="F_2dfff828-d1b4-4a57-8d0f-2b91081a3075"
      unitRef="U_USD">17334000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_b79ab662-a9df-4027-a87d-1c4f950bae65"
      decimals="-3"
      id="F_6aa9e4c9-d417-4bd9-87d2-27170ee403bd"
      unitRef="U_USD">42707000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_6ed566b7-b01e-4a6b-9c41-d1b58d2b3870"
      unitRef="U_USD">84742000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c66d62d9-1b72-4c63-9f95-2f1a72677604"
      decimals="-3"
      id="F_71f98989-d561-4ba9-99a3-4c5a336a2794"
      unitRef="U_USD">42035000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b79ab662-a9df-4027-a87d-1c4f950bae65"
      decimals="-3"
      id="F_05f61845-1145-4092-afc5-6df5d0096a27"
      unitRef="U_USD">42707000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InterestReceivable
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-5"
      id="F_5ee7f69c-8ff2-4c70-9117-b5d8ac7aaf82"
      unitRef="U_USD">1100000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-5"
      id="F_ad051fe7-de83-4036-be26-1ba944b826fc"
      unitRef="U_USD">300000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_c9b2c16b-210d-4089-9a21-4841e49b6e18"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_3c5d3fd1-8436-4c57-958f-32ac6682e68a"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="INF"
      id="F_e32cba59-6780-40ef-8c54-17b4af8083e4"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="INF"
      id="F_4ecacdeb-5a82-4304-9aa3-59ca56a641b8"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_9869da07-2113-4b11-95c7-8a0957e46729">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s marketable securities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.184000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized &lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,143&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;147,289&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Treasury Bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. Government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Corporate bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,960&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70"
      decimals="-3"
      id="F_71b00013-8b7e-4076-99c4-74df8883d86c"
      unitRef="U_USD">2945000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70"
      decimals="-3"
      id="F_9d2f5e9e-f558-4b07-a437-d1325eca89f4"
      unitRef="U_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_a8b8a631-3642-49ac-8bb9-22ed426c5e70"
      decimals="-3"
      id="F_6c211a10-5cab-4105-9c16-c7433fe5ff91"
      unitRef="U_USD">2947000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733"
      decimals="-3"
      id="F_1bd2669b-309b-4715-ad28-1e52ec177f07"
      unitRef="U_USD">147143000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733"
      decimals="-3"
      id="F_a5df0051-1caa-4c74-b543-e1aac9c21c93"
      unitRef="U_USD">166000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733"
      decimals="-3"
      id="F_4d21c26a-f490-427a-ae7c-d1f4ba1d05cc"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_7578c18b-7d63-416f-a8a0-8914d0247733"
      decimals="-3"
      id="F_a62b9018-ddc9-40c0-9bc1-d8b652bd07ce"
      unitRef="U_USD">147289000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_92221ff6-07b8-431f-bda9-3140572bc072"
      unitRef="U_USD">150088000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_82a0b5e4-e5f3-49b3-a4c5-cbfce5a2bd86"
      unitRef="U_USD">168000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_2bd9d121-856a-4621-96b0-467dc9fd50c7"
      unitRef="U_USD">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_d4f75028-19c9-42b9-8b7f-16a81092ccbf"
      unitRef="U_USD">150236000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f552a753-5013-41ab-8a68-b985b7c0bac4"
      decimals="-3"
      id="F_e61a1c52-737b-4ba6-b6e4-4456be367094"
      unitRef="U_USD">17330000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f552a753-5013-41ab-8a68-b985b7c0bac4"
      decimals="-3"
      id="F_71ff369e-ad8f-4207-9251-3d1913f43839"
      unitRef="U_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_f552a753-5013-41ab-8a68-b985b7c0bac4"
      decimals="-3"
      id="F_db3abb9e-f4fa-4ff8-aaac-35c0dc0a6bc3"
      unitRef="U_USD">17334000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f"
      decimals="-3"
      id="F_8ea60e42-2d26-4e34-8d64-002fe1e32e73"
      unitRef="U_USD">35653000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f"
      decimals="-3"
      id="F_1966e177-66d7-4eed-9588-4e5536c1e07b"
      unitRef="U_USD">66000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_00c5e533-4b6c-4e8b-8c0d-3aae7884080f"
      decimals="-3"
      id="F_2b16d513-22f6-4c7f-92ef-23e6602a42eb"
      unitRef="U_USD">35719000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_4e6a434c-62eb-44df-bb26-a28924999a6a"
      decimals="-3"
      id="F_ada9cb82-39f0-4cee-918d-9dc73dc6d3c8"
      unitRef="U_USD">6977000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_4e6a434c-62eb-44df-bb26-a28924999a6a"
      decimals="-3"
      id="F_37bc2fc2-d9ef-44cd-8f0f-4fd6bee147e3"
      unitRef="U_USD">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_4e6a434c-62eb-44df-bb26-a28924999a6a"
      decimals="-3"
      id="F_d70d4c3b-e7ba-4591-b496-ce9ad87c77d2"
      unitRef="U_USD">6988000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_dc3cde69-7465-41a4-9794-60e54aee03ca"
      unitRef="U_USD">59960000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_eb79e914-3df2-4dc3-bf82-4d311c45b74d"
      unitRef="U_USD">81000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_4bf93dc9-898e-4215-90d8-1be91034ac3e"
      unitRef="U_USD">60041000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_a3475fc3-2b27-4aaa-b747-829bc71b86d8">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</lrmr:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_b497e4df-0748-4ad1-b493-b4d0f9090d36">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,780&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;332&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Prepaid insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total prepaid expenses and other assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</lrmr:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <lrmr:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_a8c064bd-6ce1-4aa5-a4e6-907cf93571b2"
      unitRef="U_USD">9780000</lrmr:PrepaidResearchAndDevelopmentExpenses>
    <lrmr:PrepaidResearchAndDevelopmentExpenses
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_0ecb86e8-f910-47fb-bd82-3d90c02f37db"
      unitRef="U_USD">1994000</lrmr:PrepaidResearchAndDevelopmentExpenses>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_d03afd8d-6783-49af-ac1d-f107cdc91871"
      unitRef="U_USD">1054000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_b9b757db-f5be-464c-ae13-7d1f03b61150"
      unitRef="U_USD">332000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_5ffb3323-86d2-4f0b-b37b-f3771c2d4cfc"
      unitRef="U_USD">499000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_746ad3d7-9f0c-4513-a775-a5c45dce36ca"
      unitRef="U_USD">682000</us-gaap:PrepaidInsurance>
    <lrmr:OtherPrepaidExpenseAndOtherCurrentAssets
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_c6d42783-48db-4c83-be56-fc9d75860ac8"
      unitRef="U_USD">517000</lrmr:OtherPrepaidExpenseAndOtherCurrentAssets>
    <lrmr:OtherPrepaidExpenseAndOtherCurrentAssets
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_06b3d483-55da-4e19-956e-6f7f13a4c169"
      unitRef="U_USD">377000</lrmr:OtherPrepaidExpenseAndOtherCurrentAssets>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_0ec95783-cd76-44f6-918d-6f3a221a791d"
      unitRef="U_USD">11850000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_f59c6b83-190c-48e1-b063-ef5c54738264"
      unitRef="U_USD">3385000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_a3130217-ea9e-47c0-b226-9d4e80da56ed">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fixed assets, net consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_a5f65a1c-dbe3-418f-9eaf-369ca80d6c94;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Total property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, respectively. In addition, for the years ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of depreciation related to sublet assets recorded as other expense.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_ed67ef58-4cbf-49c7-bae9-f6ff47043e06">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fixed assets, net consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.477%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.775%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.399%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:10.776%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_a5f65a1c-dbe3-418f-9eaf-369ca80d6c94;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;lease term&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Total property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Property, plant and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_7fd9fac5-2ec4-4412-abb9-5816a42accd8"
      id="F_1123c8ed-a6ae-45cf-9c82-25292ee04703">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7fd9fac5-2ec4-4412-abb9-5816a42accd8"
      decimals="-3"
      id="F_04d72b60-d272-4296-928a-cd006e0f78c7"
      unitRef="U_USD">117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fe166586-acda-4afa-90ba-bbddb1cf7183"
      decimals="-3"
      id="F_cef92b41-2452-4b71-a093-c1fda25ee34e"
      unitRef="U_USD">117000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_1ecaa432-f3ba-4716-8bf2-ed620241e567"
      id="F_e5b3f9bb-c2f0-4bef-a5ff-23594fe5e6fb">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1ecaa432-f3ba-4716-8bf2-ed620241e567"
      decimals="-3"
      id="F_71d464c2-47ba-42a9-a1a2-e18d911e6595"
      unitRef="U_USD">1707000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_55adc7a3-9555-42f6-8998-4ce928494a2a"
      decimals="-3"
      id="F_03f689d6-107e-4b87-a055-8e73f28ce9ae"
      unitRef="U_USD">1192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_d91923f9-f154-40c9-b314-889b9878641c"
      id="F_be996420-b383-497e-acdc-3af951adabec">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d91923f9-f154-40c9-b314-889b9878641c"
      decimals="-3"
      id="F_c6d1b647-8dca-4f7d-9303-96acbb87edac"
      unitRef="U_USD">555000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_49e828c3-8eec-482d-9de9-b54a375e1b3c"
      decimals="-3"
      id="F_c99e0a2c-6458-492b-a69c-901330f0de68"
      unitRef="U_USD">555000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_396ac9d3-7432-4c48-bc3e-b130ad436bcd"
      decimals="-3"
      id="F_d9fabbda-59df-4f8f-a182-59a264d3f05f"
      unitRef="U_USD">45000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_82b36523-042a-479d-8709-14a5821a01e3"
      decimals="-3"
      id="F_4b23c02d-0f82-46ce-9731-bc7aef4439b8"
      unitRef="U_USD">45000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_57920912-e1a8-4a76-a118-794e67d12ba7"
      unitRef="U_USD">2424000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_66b2ab22-35eb-456b-a349-b34d9f36a6f9"
      unitRef="U_USD">1909000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_288f1372-8f20-47b0-8a27-87775df88c0d"
      unitRef="U_USD">1543000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_bc3fc17b-4a36-4be4-aca1-5484f75d8639"
      unitRef="U_USD">1225000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_237c511c-2c1c-4613-b5df-0abcc6c574ac"
      unitRef="U_USD">881000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_0246b2c7-7384-4c9c-938a-2914669d8d86"
      unitRef="U_USD">684000</us-gaap:PropertyPlantAndEquipmentNet>
    <lrmr:DepreciationExpenseExcludingLeasedAssets
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-5"
      id="F_9b0a0661-c26b-42c1-bf54-a49c2ddf3f57"
      unitRef="U_USD">300000</lrmr:DepreciationExpenseExcludingLeasedAssets>
    <lrmr:DepreciationExpenseExcludingLeasedAssets
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-5"
      id="F_147068ac-e88f-4872-ad81-84fc07371351"
      unitRef="U_USD">200000</lrmr:DepreciationExpenseExcludingLeasedAssets>
    <lrmr:DepreciationExpensesRelatedToSubletAssets
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-5"
      id="F_2c87d94f-ae9c-4bb6-ae33-068da712fcc8"
      unitRef="U_USD">100000</lrmr:DepreciationExpensesRelatedToSubletAssets>
    <lrmr:DepreciationExpensesRelatedToSubletAssets
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-5"
      id="F_7f2e15e6-6b5b-43e4-aa6c-9666c97c12de"
      unitRef="U_USD">100000</lrmr:DepreciationExpensesRelatedToSubletAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_ed20d6f4-b8bf-444c-bc79-525426ad3241">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_c4352fe3-4788-4846-8e11-8d505da47a5b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <lrmr:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_01207b7c-b6c5-4eeb-91ed-5ea6193b7758"
      unitRef="U_USD">17057000</lrmr:AccruedResearchAndDevelopmentExpenseCurrent>
    <lrmr:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_96b542cb-5faf-48d3-80bc-340b2f5a2cde"
      unitRef="U_USD">4594000</lrmr:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_289a93be-9e47-4815-a8e6-76e15dcf8052"
      unitRef="U_USD">3254000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_a33d5ea6-4fd0-4a1b-85be-c82b382611b1"
      unitRef="U_USD">2365000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_cf941a40-a608-41d6-9227-0716cc4a9f52"
      unitRef="U_USD">561000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_20536ca5-3310-4a79-bcbe-5e76293e5c87"
      unitRef="U_USD">427000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_5258bd18-baed-4237-8207-28fefdafc74a"
      unitRef="U_USD">20872000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_cc8b51b7-7f6d-4d7a-ba16-e7621b62a752"
      unitRef="U_USD">7386000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_c3895246-711a-482c-9488-7da5ac691e72">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders&#x2019; Equity and Stock Options&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Common Stock and Prefunded warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On May 28, 2020, the Company entered into a securities purchase agreement with certain accredited investors (the &#x201c;Purchasers&#x201d;) for the sale by the Company in a private placement of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,105,359&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock and prefunded warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, for a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share of the common stock and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per prefunded warrant. The prefunded warrants were exercisable at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.01&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and were exercisable indefinitely. In August 2023, the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of prefunded warrants were exercised and the Company received cash proceeds of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_921994da-5811-4028-8f53-85e77eb89620;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six thousand two hundred and eighty-four dollars&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The private placement closed on June 1, 2020. The aggregate gross proceeds for the issuance and sale of the common stock and prefunded warrants were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, transaction costs totaled $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and resulted in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company&#x2019;s Registration Statement on Form S-3, filed with the SEC on June 26, 2020, registered the resale of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,105,359&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock sold and the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;628,403&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock underlying the prefunded warrants. MTS Health Partners served as placement agent to the Company in connection with the private placement. As partial compensation for these services, the Company issued MTS Health Partners &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,260&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s Amended and Restated Certificate of Incorporation, authorized the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;115,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value common stock, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,815,065&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were issued and outstanding, and up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; par value undesignated preferred stock, of which &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares were issued or outstanding. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of the holders of the preferred stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Common stockholders are entitled to receive dividends, as may be declared by the board of directors of the Company (the &#x201c;Board&#x201d;), if any. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; cash dividends have been declared or paid to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2024, the Company sold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,736,842&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of its common stock in an underwritten public offering price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;161.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2022 ATM Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2022, the Company entered into a sales agreement (the "2022 ATM Agreement") with a Guggenheim Securities, LLC in connection with the establishment of an &#x201c;at-the-market&#x201d; offering program under which the Company could sell up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of shares of common stock (the &#x201c;ATM Shares&#x201d;) from time to time.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In February 2024, in connection with the underwritten public offering described above, the Company terminated the 2022 ATM Agreement. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ATM Shares were ever sold pursuant to the 2022 ATM Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2024, the Company entered into a sales agreement (the "ATM Agreement") with Guggenheim Securities, LLC in connection with the establishment of an &#x201c;at-the-market&#x201d; offering program under which the Company could sell up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of shares of common stock (the &#x201c;ATM Shares&#x201d;) from time to time. To date, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; sales of common stock have been made under this ATM Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Board adopted the 2020 Equity Incentive Plan (the "2020 Plan") on July 16, 2020 and the stockholders of the Company approved the 2020 Plan on September 29, 2020. The 2020 Plan replaced the predecessor plans (the "Prior Plans") that the Company assumed following its merger with Zafgen in May 2020. Options outstanding under the Prior Plans will remain outstanding, unchanged, and subject to the terms of the Prior Plans and the respective award agreements, and no further awards will be made under the Prior Plans. However, if any award previously granted under the Prior Plans, expires, terminates, is canceled, or is forfeited for any reason after the approval of the 2020 Plan, the shares subject to that award will be added to the 2020 Plan share pool so that they can be utilized for new grants under the 2020 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2020 Plan provides for the grant of incentive stock options (&#x201c;ISOs&#x201d;), nonstatutory stock options (&#x201c;NSOs&#x201d;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based restricted stock units, and cash or other stock-based awards. ISOs may be granted only to the Company&#x2019;s employees, including the Company&#x2019;s officers, and the employees of the Company&#x2019;s affiliates. All other awards may be granted to the Company&#x2019;s employees, including the Company&#x2019;s officers, the Company&#x2019;s non-employee directors and consultants, and the employees and consultants of the Company&#x2019;s affiliates.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,700,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#x201c;Plan Limit&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The maximum aggregate number of shares that may be issued under the 2020 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; over the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; term of the 2020 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As permitted by the 2020 Plan, the Company added &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,552,603&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,756,363&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares available for grant to the 2020 Plan on January 1, 2025 and January 1, 2024, respectively, increasing the maximum number of shares of the Company&#x2019;s common stock that may be issued under the 2020 Plan as of January 1, 2025 to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,179,529&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the twelve months ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,242&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;224,437&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares issued under the Prior Plans were canceled and became available for grant under the 2020 Plan. In addition, as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;626,926&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock were available for grant under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Valuation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.22&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 (amounts in millions, except for share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.39%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.062000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.602%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.042%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,273,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,235,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited/Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,436,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,094,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,436,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;2024 Option Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the twelve months ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company granted options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,235,377&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock to employees and directors under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date. Of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,235,377&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options granted, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,140,377&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; were granted to employees and vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options were annual grants to the Company's directors and vest &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the grant date. The weighted-average grant date fair value of options granted under the 2020 Plan during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total unrecognized compensation expense related to unvested stock options granted under the 2020 Plan was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.63&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inducement Stock Option Grant&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; inducement awards granted in the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total unrecognized compensation expense related to unvested inducement options granted under the 2020 Plan was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.28&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs were granted under the 2020 Plan to the Company's employees in order to maintain retention of key employees. The value of an RSU award is based on the Company's stock price on the date of the grant. The shares underlying the RSUs are not issued until the RSUs vest.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Activity with respect to the Company's RSUs during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 was as follows (in millions, except share, contractual term, and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.39%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.062000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.602%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.042%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;615,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;699,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unvested and expected to vest as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;699,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Unit Grants&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the twelve months ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,372&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of RSUs to employees under the 2020 Plan. The RSUs vest annually over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and have a weighted-average grant date fair value during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total unrecognized compensation expense for RSUs was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;January 2025 Option, Restricted Stock Unit Grants and Performance-Based Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 22, 2025, the Company granted options to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,084,162&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common stock, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;347,360&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of restricted stock units and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;200,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Performance-based restricted stock units to employees under the 2020 Plan. The options have an exercise price equal to the closing stock price as of the grant date, and vest over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% vesting on the first anniversary of the grant and the remainder vesting in equal monthly installments thereafter. The shares of restricted stock will vest annually over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The performance-based restricted stock units were granted to the Company's named executive officers. The grants included two performance milestones. The fist milestone, which relates to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of each grant, will vest if the FDA accepts the filing of a biologic license application for accelerated approval of nomlabofusp by December 31, 2026. The second milestone, representing &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of each grant will vest if the FDA approves the Company nomlabofusp BLA within 12 months of the BLA acceptance (no later than December 31, 2027.) If the first milestone is not achieved by December 31, 2026, the full grant will be forfeited.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense was classified in the consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.527%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.777000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.838000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2778adb7-0fa7-4567-85f3-1f083a2430b1"
      decimals="INF"
      id="F_c84194b9-a986-4f0a-9477-6679c25acd22"
      unitRef="U_shares">6105359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_a3be7c9e-9f11-490a-8fdf-1cfea83b9a27"
      decimals="INF"
      id="F_b50c33a1-9492-48a6-84a8-0298222d9558"
      unitRef="U_shares">628403</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_a3be7c9e-9f11-490a-8fdf-1cfea83b9a27"
      decimals="INF"
      id="F_d4c16f9a-6064-4b7b-8316-34eced4f1ebc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.88</us-gaap:SharesIssuedPricePerShare>
    <lrmr:WarrantsIssuedPricePerShare
      contextRef="C_2164a742-c82f-4feb-86b4-11d2743876a0"
      decimals="INF"
      id="F_0d34ddd7-feab-4e67-a7dc-7dbb43888c7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.87</lrmr:WarrantsIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2164a742-c82f-4feb-86b4-11d2743876a0"
      decimals="INF"
      id="F_cef464ad-dd95-49d4-a1c3-d45161d556b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_bf68a9db-6f62-4ef9-b2b4-384b78706dbf"
      decimals="INF"
      id="F_a6fe126f-db20-47e8-b010-06b069e14830"
      unitRef="U_shares">628403</lrmr:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_f1f8400e-a7d9-400c-8bc4-a27496b8c9f5"
      decimals="-5"
      id="F_eafc1521-d8ef-4f75-84af-c9b6cbacd2f3"
      unitRef="U_USD">80000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lrmr:StockAndWarrantIssuanceTransactionCosts
      contextRef="C_f1f8400e-a7d9-400c-8bc4-a27496b8c9f5"
      decimals="-5"
      id="F_a527e7f9-3c2b-437b-aa6c-afe27a39cf4f"
      unitRef="U_USD">4600000</lrmr:StockAndWarrantIssuanceTransactionCosts>
    <lrmr:ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts
      contextRef="C_f1f8400e-a7d9-400c-8bc4-a27496b8c9f5"
      decimals="-5"
      id="F_7ffbb297-2d0e-424e-9042-607a6d4a5d6f"
      unitRef="U_USD">75400000</lrmr:ProceedsFromIssuanceCommonStockAndWarrantsNetOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2778adb7-0fa7-4567-85f3-1f083a2430b1"
      decimals="INF"
      id="F_45bdc95c-24cf-4e95-86a4-ce93e19d98ca"
      unitRef="U_shares">6105359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_a3be7c9e-9f11-490a-8fdf-1cfea83b9a27"
      decimals="INF"
      id="F_19cbcd8b-445c-4726-86e6-093247a5d849"
      unitRef="U_shares">628403</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9d2671b4-535d-41fb-ba97-cf95d740ca0f"
      decimals="INF"
      id="F_c2ead07d-ad70-4195-a059-47696639dd57"
      unitRef="U_shares">35260</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_f851ac56-92ca-4d72-8548-b249e91d796b"
      unitRef="U_shares">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_e7eed030-4a6c-4bec-a1a1-8e098c4cfe8a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_9f147832-77ed-4aa8-bc3a-f6ecf4b7e186"
      unitRef="U_shares">63815065</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_79fb49a4-4b5e-47c0-be22-42322b3d7a0e"
      unitRef="U_shares">63815065</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_88defbe5-280d-4fb3-8a29-6c6e141fb52d"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_30260502-27ef-424b-a005-d678ad790bd4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_366286cc-9dd8-43c3-b7d0-e0e003c3c111"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_4dc4fa8f-1243-4479-a1ec-6e8809a0bdda"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_7aef83da-0807-4f01-8951-3073233eb8bb">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_891b2147-6d50-4dab-99ec-5a61ac1165d4"
      unitRef="U_USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b1b8129e-de19-4748-9c09-33dfd9514f6c"
      decimals="INF"
      id="F_a9e0583d-e356-4973-a144-6348909c57fb"
      unitRef="U_shares">19736842</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_cde123be-1e24-4090-8fdb-2c9fe1cf13f3"
      decimals="2"
      id="F_edd943db-a437-4b7b-b3f5-35b063e2b74d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_b1b8129e-de19-4748-9c09-33dfd9514f6c"
      decimals="-5"
      id="F_4388ac5c-0ee0-42d5-b747-5b53aa7061d0"
      unitRef="U_USD">161800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <lrmr:AggregateGrossSalesProceedsUnderSalesAgreement
      contextRef="C_9458ab78-dd2a-4327-a9fc-7944f851ac55"
      decimals="-5"
      id="F_4f42c4c2-e2fc-4dd2-bf01-e7175f82f627"
      unitRef="U_USD">50000000</lrmr:AggregateGrossSalesProceedsUnderSalesAgreement>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7ebc587a-1024-446d-8850-c2e50902fec2"
      decimals="INF"
      id="F_962c65bd-9a41-4dee-93c5-06b1146946d4"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <lrmr:AggregateGrossSalesProceedsUnderSalesAgreement
      contextRef="C_23a1dcc4-104b-43ca-95d3-232e06671bb5"
      decimals="-6"
      id="F_2424f102-64ad-4723-af9f-e18798c7ab88"
      unitRef="U_USD">100000000</lrmr:AggregateGrossSalesProceedsUnderSalesAgreement>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_7ebc587a-1024-446d-8850-c2e50902fec2"
      decimals="INF"
      id="F_f3c64b9b-8c12-4d6e-a075-bc008a04254c"
      unitRef="U_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973"
      id="F_1110f9bb-6646-4ca8-8557-c5f68e6ad8b6">The maximum number of shares that may be issued in respect of any awards under the 2020 Plan is the sum of: (i) 1,700,000 shares plus (ii) an annual increase on January 1, 2021 and each anniversary of such date thereafter through January 1, 2030, equal to the lesser of (A) 4% of the shares issued and outstanding on the last day of the immediately preceding fiscal year, or (B) such smaller number of shares as determined by the Board (collectively, the &#x201c;Plan Limit&#x201d;).</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue
      contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973"
      decimals="INF"
      id="F_6f65977c-3419-4316-8f76-693c563b8416"
      unitRef="U_shares">1700000</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdNumberOfSharesAllowedToIssue>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock
      contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973"
      decimals="2"
      id="F_92a80cd5-489a-4375-b868-e9066d2d5d35"
      unitRef="U_pure">0.04</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesPercentageOfOutstandingStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_8057ddb3-0a97-4d84-a521-6c651151f255"
      decimals="INF"
      id="F_782bd396-6d90-4f05-8fd1-bdf2f3f92823"
      unitRef="U_shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration
      contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973"
      id="F_62ef3f82-65b7-4857-ad67-3678d80bda08">P10Y</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardDuration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_b7ccda8d-34e0-4891-abca-16e72fec5b80"
      decimals="INF"
      id="F_2b2c296a-99a5-4d3f-a78c-166cf5a7f478"
      unitRef="U_shares">2552603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_476aa55d-daca-4a72-aade-622790de18ed"
      decimals="INF"
      id="F_cfb5e2a0-fe00-4064-8ab3-d4918cd14c78"
      unitRef="U_shares">1756363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_298722ae-af18-416d-b772-0febae7b0ff4"
      decimals="INF"
      id="F_9eb4fdf6-0a21-47a8-849c-e565696f16b9"
      unitRef="U_shares">3179529</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_3122611a-d6b2-4e58-baae-c58bceaa1852"
      decimals="INF"
      id="F_b489d19d-d416-4f23-a4a3-5c637410fac6"
      unitRef="U_shares">1242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_00309e6d-c478-4991-a287-b2b26b553406"
      decimals="INF"
      id="F_286571c1-54ad-443e-949d-827e32f3a040"
      unitRef="U_shares">224437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_5e95afea-eb7a-4026-b213-a7dc1020f814"
      decimals="INF"
      id="F_46afff41-b1e4-4486-9725-4d0ef4aca4c5"
      unitRef="U_shares">626926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_eb074e22-97fc-459b-a752-3d22e1efa633">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents, on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of stock options granted to employees:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.64%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.08%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.22&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.23&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="4"
      id="F_5f69359a-2ced-4d51-acfe-46a19e14a7b1"
      unitRef="U_pure">0.0412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="4"
      id="F_f98dc8a3-14fc-405f-a5be-72355f374007"
      unitRef="U_pure">0.0372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_f89b1b69-fb24-41d4-bd3e-ee8a7dc92257">P6Y2M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      id="F_1ea0ee34-d666-4245-93cd-3abd8926877d">P6Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="2"
      id="F_24c33936-ef98-4272-a2e0-6fd60f3516b1"
      unitRef="U_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="2"
      id="F_c346944f-ffed-4e12-b3da-027b324dece0"
      unitRef="U_pure">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="4"
      id="F_81236a9e-0eb7-4e63-b34a-0b86e1622ac2"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="4"
      id="F_c0b8974e-78de-46d0-8f16-4fdfbfcc8f07"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_2810430e-0520-4561-8e33-d637a650473e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes the Company&#x2019;s stock option activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 (amounts in millions, except for share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.39%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.062000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.602%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.042%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercise&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,273,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,235,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited/Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,088&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,436,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,094,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,436,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(a)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_a95bc63d-ce0b-4aaa-a7ae-353bfe532694"
      unitRef="U_shares">4273502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="2"
      id="F_8f507a0b-45de-426d-9d78-ed9f32afe5cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      id="F_3a618ce6-e0ee-457f-b121-9f290c037eed">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="INF"
      id="F_45085b7e-1c7b-4d87-b71d-975f7e67a47d"
      unitRef="U_shares">2235377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="2"
      id="F_5df27407-8da4-487c-bae1-77a2a733a174"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="INF"
      id="F_32cc7d5e-c4e7-413b-bd6e-6657284c85b0"
      unitRef="U_shares">15404</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="2"
      id="F_0f77839e-6181-459e-a8fb-9e51cd76a517"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="INF"
      id="F_e0e70eef-46da-475f-b3d5-cbcb00cec692"
      unitRef="U_shares">57088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="2"
      id="F_e6d7732c-e3d1-468b-9910-31459d6d0d7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_02280e6c-8a2c-43ac-bde7-5a39fce68ab7"
      unitRef="U_shares">6436387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="2"
      id="F_c7413e03-8618-4b07-92a6-75419e2bb4f4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_3932a7db-94cf-490a-924a-058e79c90bfd">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-5"
      id="F_8df5d249-b87f-4217-89c6-2eede8523974"
      unitRef="U_USD">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_7f6aad12-c898-4018-976f-d5cec7b0dec5"
      unitRef="U_shares">3094992</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="2"
      id="F_fcba4715-0313-43d5-a69e-25e96f8b4af1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_66839798-9a69-4e16-80bc-6b7e90ec2399">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-5"
      id="F_47c0ddf4-5bb5-46e7-b5b2-4813f6d81636"
      unitRef="U_USD">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_e283898e-b0f9-4bf0-ba58-08f6585cbfa0"
      unitRef="U_shares">6436387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="2"
      id="F_1cd2c31d-a3a7-499f-916a-c547bfa5f42d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_2bb30d92-9e6c-402d-9766-b35d5129cc48">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-5"
      id="F_e5453b9f-e4d7-4b3a-8e00-1b2a4abde12b"
      unitRef="U_USD">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_8940587e-a90e-40f9-958f-9b1b19869429"
      decimals="INF"
      id="F_56b72155-047c-4d8e-88b5-991bbc1f895d"
      unitRef="U_shares">2235377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_8940587e-a90e-40f9-958f-9b1b19869429"
      decimals="INF"
      id="F_e7ff3e42-aa18-4627-92cc-883a8dde0681"
      unitRef="U_shares">2235377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_a95a6572-ed88-48df-9e64-6ef309bf3fc6"
      decimals="INF"
      id="F_55f2b4c8-12d7-4271-9aef-dc495a0bc4d0"
      unitRef="U_shares">2140377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a95a6572-ed88-48df-9e64-6ef309bf3fc6"
      id="F_9ee5f350-1340-41ed-bacb-1a2f6456d8dd">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_07cc377a-796d-498e-9d5b-1591bcb5477b"
      decimals="2"
      id="F_211628cf-3711-4965-b552-3cb905e6b077"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_e75c96fd-9bc2-4e22-9c5a-481e9d15e507"
      decimals="INF"
      id="F_a7921bfc-a461-4cad-b1bf-437ecdcb09ad"
      unitRef="U_shares">95000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_e75c96fd-9bc2-4e22-9c5a-481e9d15e507"
      id="F_f535e90f-3ae0-4d59-9d36-3886cb0a56dc">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973"
      decimals="2"
      id="F_4f2298bd-c463-4102-ae67-b18de591d027"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_fc129cfd-3960-440f-aa81-c3cce8de7bad"
      decimals="-5"
      id="F_2ca20bdc-1f8e-4dd9-a86d-2d0cec6afbcd"
      unitRef="U_USD">10700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_013cfd75-8e64-4593-92c4-eddcb6f5a973"
      id="F_1e4d17c7-1cc5-496f-8c5e-715968aa4c81">P2Y7M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_41dc2a61-cb1b-4e3f-b8e4-3a5beacac631"
      decimals="INF"
      id="F_edf52b06-02b1-4eb2-a97a-a0c356416b62"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_3e6edd92-c786-4088-97cc-096585e1d03d"
      decimals="-5"
      id="F_8cd8979b-bc1d-46d0-a1d6-b022adb9316c"
      unitRef="U_USD">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_41dc2a61-cb1b-4e3f-b8e4-3a5beacac631"
      id="F_150fd180-25b8-4d12-a842-d94fc3576b1a">P2Y3M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_56997e96-ca4e-473e-9fcd-b3ca58ac62cd">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Activity with respect to the Company's RSUs during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 was as follows (in millions, except share, contractual term, and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.39%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.502%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:8.062000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.602%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:9.042%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Aggregate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Remaining&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Intrinsic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Grant Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Contractual&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Value (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in millions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;615,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;245,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;153,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,619&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;699,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unvested and expected to vest as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;699,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_b144c1ed-8a46-4360-ac5f-f8187e2445a1"
      decimals="INF"
      id="F_6134f825-cff2-4088-8608-27591338dd05"
      unitRef="U_shares">615000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_b144c1ed-8a46-4360-ac5f-f8187e2445a1"
      decimals="2"
      id="F_f70a90fe-95c1-4c69-9a51-53e7f32a923e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_a04137e2-f395-4ec2-a749-7530c63c5c1c"
      id="F_d4a14836-c6df-432c-a6cc-2151b8f1964a">P1Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      decimals="INF"
      id="F_1e9cacd1-0c36-44a1-9235-8815531131a9"
      unitRef="U_shares">245372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      decimals="2"
      id="F_bcee7d34-3139-42b4-8a7b-2769256eccde"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      decimals="INF"
      id="F_53c12ff4-41a8-4c66-98b7-35c847e44138"
      unitRef="U_shares">153750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      decimals="2"
      id="F_e805475c-4088-4374-9751-b22a0a7f907a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      decimals="INF"
      id="F_355aeed6-e210-4175-a277-8a93337deaf1"
      unitRef="U_shares">7619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      decimals="2"
      id="F_584fb90e-b6a1-43fa-b7f5-8b7eaeeb4b7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02"
      decimals="INF"
      id="F_b7178190-6944-43df-88bb-900bf114705b"
      unitRef="U_shares">699003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02"
      decimals="2"
      id="F_431ec574-f93c-406d-8150-6a0e72a49aec"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      id="F_02da442d-9eba-45af-b19d-0540357c5108">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02"
      decimals="-5"
      id="F_b5773a42-70b9-4337-9a9b-d9fe621e9e68"
      unitRef="U_USD">2700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber
      contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02"
      decimals="INF"
      id="F_4c1b448e-31ea-454b-932b-1383de7a6075"
      unitRef="U_shares">699003</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestOutstandingNumber>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02"
      decimals="2"
      id="F_56a89e08-65ca-4dd1-ba94-849100949936"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.69</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageGrantDateFairValue>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      id="F_c0afa914-2a1b-4b59-9164-b956dfb85e65">P1Y2M12D</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestWeightedAverageRemainingContractualTerms>
    <lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue
      contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02"
      decimals="-5"
      id="F_d3326af6-8d33-4671-abc9-82c2171480dc"
      unitRef="U_USD">2700000</lrmr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedAndExpectedToVestAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_a9758b43-c974-4811-91f8-dd665c753866"
      decimals="INF"
      id="F_28c2c299-3a74-4dbd-9a1a-2cd1d443d24b"
      unitRef="U_shares">245372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_a9758b43-c974-4811-91f8-dd665c753866"
      id="F_01bfb9ce-c6d0-45ca-92a5-c306f0ed7636">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_a9758b43-c974-4811-91f8-dd665c753866"
      decimals="2"
      id="F_13bcd528-bed4-4a3e-82c2-a43ec0aab40a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f87f0f4d-223e-43e5-99fb-70416e4efc02"
      decimals="-5"
      id="F_38ac12a5-bb75-4fd2-8876-4335334fe9d5"
      unitRef="U_USD">2300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_f02f5dcb-ef8e-4d7f-bb25-6587ebc31b0f"
      id="F_03b02e60-fc3c-492a-bb74-01f08d308ebe">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_f69f438f-7f98-46a0-8c4d-079bbdf2a12a"
      decimals="INF"
      id="F_2e18581d-0b5a-4dcb-8371-c558358a0b5d"
      unitRef="U_shares">2084162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_1ac20b4d-9dce-48ff-b9c6-72648d8b3bf5"
      decimals="INF"
      id="F_bad42637-c583-4007-b146-61b803514baa"
      unitRef="U_shares">347360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_b23e5525-f6f6-400b-a668-fca905202d1b"
      decimals="INF"
      id="F_6dbdc709-4bec-4bdc-a770-de6a97889a2a"
      unitRef="U_shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f69f438f-7f98-46a0-8c4d-079bbdf2a12a"
      id="F_18d398eb-11da-4cfa-9e3d-7766ecaa9276">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_bf6d1d52-1fbd-434c-aff5-8c53c22ca6a0"
      decimals="2"
      id="F_5df335a4-2134-47ff-9ba9-365cf6be3666"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_8fc81d4f-669b-4cb9-9f96-bcb205c5ce02"
      id="F_06a43593-23d0-431a-a8c4-24b0610a76b5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_68ab6f05-562c-4261-83f4-2fd2834ae9b1"
      decimals="INF"
      id="F_e2e7ac7a-f67d-4c51-b84c-578d39651558"
      unitRef="U_pure">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_9835f758-39d0-41f7-805e-a62b5ba91b72"
      decimals="INF"
      id="F_f114aaa1-edef-452a-86b8-56f01330e113"
      unitRef="U_pure">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_92a276fe-8235-44a0-9255-e01e7e6b057d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense was classified in the consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.527%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.777000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:11.838000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,053&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f56605f3-2e21-4b59-b70a-99e345371439"
      decimals="-3"
      id="F_d7aa16ca-835d-40a9-90dd-5280e8b6ba4c"
      unitRef="U_USD">4053000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_04060931-70f8-40a1-b038-ff2323e800fc"
      decimals="-3"
      id="F_7cb39aaf-627d-42e1-832f-37ad2c0bc44d"
      unitRef="U_USD">3077000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b632cd5c-05ae-4251-a104-e7cf0498b02b"
      decimals="-3"
      id="F_3d5f2de6-dfe7-4653-8104-351a6079ce43"
      unitRef="U_USD">4743000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4c5e5e8c-5db3-4232-b8b8-f18e413251e5"
      decimals="-3"
      id="F_908dfc79-fc29-433a-9cb6-3f283d0f9591"
      unitRef="U_USD">4538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_d7859519-4ff9-437b-a9c7-512b72e7cc36"
      unitRef="U_USD">8796000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_8e82b435-a01a-49c6-823b-9f79b31e7cfc"
      unitRef="U_USD">7615000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_fd9b7802-7179-4332-acd7-4a803269f4fb">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Intellectual Property Licenses&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is party to an exclusive License Agreement (the &#x201c;WFUHS License&#x201d;), dated November 30, 2016, as amended, with Wake Forest University Health Sciences (&#x201c;WFUHS&#x201d;) and an exclusive License Agreement (the &#x201c;IU License&#x201d;), dated November 30, 2016, as amended, with Indiana University (&#x201c;IU&#x201d;). Such agreements provide for a transferable, worldwide license to certain patent rights regarding technology used by the Company with respect to the development of nomlabofusp. Both agreements continue from their effective date through the last to date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In partial consideration for the right and license granted under these agreements, the Company will pay each of WFUHS and IU a royalty of a low single digit percentage of net sales of licensed products depending on whether there is a valid patent covering such products. As additional consideration for these agreements, the Company is obligated to pay each of WFUHS and IU certain milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in the aggregate upon the achievement of certain developmental milestones, which commenced with the enrollment of the first patient in a Phase 1 clinical trial. The Company enrolled the first patient in its SAD trial on December 11, 2019 and paid WFUHS and IU less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Company will also pay each of WFUHS and IU sublicensing fees ranging from a high-single digit to a low double-digit percentage of sublicense consideration depending on the Company&#x2019;s achievement of certain regulatory milestones as of the time of receipt of the sublicense consideration. The Company is also obligated to reimburse WFUHS and IU for patent-related expenses. In the event that the Company disputes the validity of any of the licensed patents, the royalty rate would be tripled during such dispute. The Company is also obligated to pay to IU a minimum annual royalty of less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million per annum.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the event that the Company is required to pay IU consideration, then the Company may deduct &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of such IU consideration on a dollar-for-dollar basis from the consideration due to WFUHS. In the event that the Company is required to pay WFUHS consideration, then the Company may deduct &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of such WFUHS consideration on a dollar-for-dollar basis from the consideration due to IU.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In October 2022, the Company initiated dosing of a Phase 2 study. Pursuant to the terms of both the WFUHS License and the IU License, the company recognized milestone expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million within research and development expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Both agreements continue from their effective date through the last date of expiration of the licensed patents, unless earlier terminated by either party in accordance with their terms.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Bala Cynwyd Office Space&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 8, 2019, the Company entered into an operating lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space in Bala Cynwyd, Pennsylvania, effective as of December 15, 2019, for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three years and six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with an option to extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_87fbb33e-f754-46a6-98ea-b08d228c7b45;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional years. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property and the lease term commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;February 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 9, 2023, the Company executed a lease extension agreement on its original &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square footage of office space in Bala Cynwyd, Pennsylvania (which was set to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d09b5249-139c-4022-bd74-7a580647cdf5;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;August 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;) and agreed to lease an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,462&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space from the same landlord.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The lease extension on the original &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,642&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square footage commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the Company recorded a right of use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The new lease on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,462&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional square footage commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and the Company recorded a right of use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The right of use assets and lease liabilities with these leases are reflected in the financial statements for the year ended December 31, 2024 as are the right of use asset and lease liability of the Company's Boston office space and lab space discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Boston Office Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the Company's 2020 merger with Zafgen described in footnote 1, on May 28, 2020, the Company acquired a non-cancellable operating lease for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,705&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space (the &#x201c;Premises&#x201d;). The lease expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 30, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As part of the agreement, the Company was initially required to maintain a letter of credit, of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. In October of 2024, upon the agreement with the landlord that we had achieved certain clinical development milestones required in the lease, this letter of credit was reduced to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. During both periods presented, this cash deposit and is classified as restricted cash within the consolidated financial statements. In addition to the base rent, the Company is also responsible for its share of operating expenses, electricity and real estate taxes, which costs are not included in the determination of the leases&#x2019; right-of-use assets or lease liabilities. The right-of-use asset is being amortized to other income/(expense) over the remaining lease term as a result of the sublease described below.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 27, 2020, the Company entered into a sublease agreement (the &#x201c;Sublease&#x201d;) with Massachusetts Municipal Association, Inc. (the &#x201c;Subtenant&#x201d;), whereby the Company sublet the entire Premises to the Subtenant. The initial term of the Sublease commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 4, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and continues until &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 30, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In connection with the Sublease, the Company evaluated the need for impairment under ASC 360 "Impairment Testing: Long-Lived Assets Classified as Held and Used," and determined there was no impairment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Sublease provided for an initial annual base rent of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which increases annually up to a maximum annual base rent of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Subtenant also is responsible for paying to the Company future increases in operating costs (commencing on January 1, 2022), future increases in annual tax costs (commencing July 1, 2021) and all utility costs (commencing March 1, 2021) attributable to the Premises during the term of the Sublease. As part of the Sublease, the subtenant deposited a letter of credit in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to assure their performance under the sublease. If there are no uncured events of default under the sublease, the amount of this security deposit decreases over time to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million on the sixth anniversary of the Sublease. The Company records sublease income on this sublease on a straight-line basis as a component of other income/(expense).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Lab Space&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 5, 2018, the Company entered into an operating lease for office and lab space in Philadelphia, Pennsylvania, effective as of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and expiring on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; with an option to extend the lease for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f3be3bdd-793f-4d1a-9a7e-f230d03efd1b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; additional years. On August 4, 2020, the Company executed the first option to extend the lease for an additional year, expiring on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. On August 9, 2021, the Company executed the remaining option to extend the lease for an additional year, expiring on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In September 2023, the Company extended this lease for an additional year with the option to terminate with four months' notice. On March 28, 2024, the Company gave the requisite notice and vacated the property in May 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 16, 2023, the Company entered into an operating lease for alternate lab space in King of Prussia, Pennsylvania for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Due to required tenant improvements to be completed by the landlord, the Company did not take immediate possession of the leased property. The actual lease term commenced on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;May 10, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Upon commencement of the lease term, the Company recorded a right of use asset and lease liability of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which are reflected in these consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Lease Expense&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Expense arising from operating leases was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;twelve months ended December 31, 2024 and 2023, respectively. For operating leases, the weighted-average remaining lease term for leases at December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years, respectively. For operating leases, the weighted average discount rate for leases at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. The Company has not entered into any financing leases.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturities of lease liabilities due under these lease agreements as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is not currently a party to any litigation, nor is management aware of any pending or threatened litigation against the Company, that it believes would materially affect the Company&#x2019;s business, operating results, financial condition or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lrmr:MilestonePaymentAmount
      contextRef="C_c37bbde8-7943-40d4-8b87-262850af251a"
      decimals="-5"
      id="F_7af5f693-9c00-4648-948e-46c2821c2039"
      unitRef="U_USD">2600000</lrmr:MilestonePaymentAmount>
    <lrmr:MilestonePaymentAmount
      contextRef="C_374ec650-46e4-4848-b593-f01df79d1e1f"
      decimals="-5"
      id="F_98fd4cfb-2e95-49f0-9dc1-0eccbd337542"
      unitRef="U_USD">2600000</lrmr:MilestonePaymentAmount>
    <lrmr:PaymentForLicenseAgreements
      contextRef="C_6be3737e-d05f-4180-bd52-32638a31f43d"
      decimals="-5"
      id="F_ac167afc-43cb-4784-98a4-a46884160650"
      unitRef="U_USD">100000</lrmr:PaymentForLicenseAgreements>
    <lrmr:MinimumAnnualRoyaltyObligation
      contextRef="C_374ec650-46e4-4848-b593-f01df79d1e1f"
      decimals="-5"
      id="F_0384cd11-b968-4dc9-aaf0-3d490cb33316"
      unitRef="U_USD">100000</lrmr:MinimumAnnualRoyaltyObligation>
    <lrmr:LicenseAgreementConsiderationDeductionPercentage
      contextRef="C_00c4f173-1035-4879-939f-3e16d63fb716"
      decimals="2"
      id="F_269d407f-03a9-47b9-83d8-1d9b512e2541"
      unitRef="U_pure">0.20</lrmr:LicenseAgreementConsiderationDeductionPercentage>
    <lrmr:LicenseAgreementConsiderationDeductionPercentage
      contextRef="C_9310a56d-595a-456c-875c-d9c91b4958c9"
      decimals="2"
      id="F_7ab7b81d-4173-4fa7-9f9b-c8cd977d5418"
      unitRef="U_pure">0.60</lrmr:LicenseAgreementConsiderationDeductionPercentage>
    <lrmr:MilestoneExpenses
      contextRef="C_0788b521-b323-45f2-8f3d-8796f828638d"
      decimals="-5"
      id="F_1f5f431e-15bd-4f30-aa33-2d7c46b2c6df"
      unitRef="U_USD">300000</lrmr:MilestoneExpenses>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373"
      decimals="INF"
      id="F_641cbf68-dcb4-4578-b3bb-7d4ac98324c6"
      unitRef="U_sqft">4642</lrmr:AreaOfOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_ec704a28-ca88-417d-afd5-2b5e09e3a38e"
      id="F_23ba6c66-aa03-41e8-a711-0dc6359e0073">P3Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373"
      id="F_dfb67d46-7ca5-472b-80bd-8e567af2b22c">2020-02-15</lrmr:LeaseTermCommencementDate>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_771f241b-8e8a-4b15-8dd7-e9a0ccad0373"
      decimals="INF"
      id="F_88a46b2d-ebfc-41e6-9859-2b3c9f2a4253"
      unitRef="U_sqft">4642</lrmr:AreaOfOfficeSpace>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_5bc874d9-7864-4d71-a931-3ccf2f2d90ca"
      decimals="INF"
      id="F_e8aafb59-382e-4698-9bee-49649439d166"
      unitRef="U_sqft">3462</lrmr:AreaOfOfficeSpace>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_dd95e4fc-82fa-4a33-961e-756339a32f40"
      decimals="INF"
      id="F_34230ea0-519b-4861-a783-fe0ca7c08995"
      unitRef="U_sqft">4642</lrmr:AreaOfOfficeSpace>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_dd95e4fc-82fa-4a33-961e-756339a32f40"
      id="F_43ee9270-7bfd-44a1-ba2e-0418f6a8c36a">2023-09-01</lrmr:LeaseTermCommencementDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_5fd8fb15-cf4d-4748-b06e-8e9b5decf68b"
      decimals="-5"
      id="F_99b0c0f1-3215-4759-8257-cb3a8c9ea50b"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_5fd8fb15-cf4d-4748-b06e-8e9b5decf68b"
      decimals="-5"
      id="F_df5d642c-55b4-4324-a11a-bacf9a07a10e"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_5bc874d9-7864-4d71-a931-3ccf2f2d90ca"
      decimals="INF"
      id="F_e1bcb953-8a88-475c-a995-c900a9f356ec"
      unitRef="U_sqft">3462</lrmr:AreaOfOfficeSpace>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_5bc874d9-7864-4d71-a931-3ccf2f2d90ca"
      id="F_8d5a6e41-0896-44b8-abac-57321170ac99">2023-10-01</lrmr:LeaseTermCommencementDate>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_7652464d-494e-4455-9127-a6517e3601ea"
      decimals="-5"
      id="F_29a1da94-5c43-42ba-b7ca-ae8adc67f4d8"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_7652464d-494e-4455-9127-a6517e3601ea"
      decimals="-5"
      id="F_ae4512c7-c113-4a8f-9ea8-cd902221999c"
      unitRef="U_USD">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <lrmr:AreaOfOfficeSpace
      contextRef="C_f62796d0-82ee-42f2-a018-74063dd58aa3"
      decimals="INF"
      id="F_3d6e9b35-3e35-454f-bdc0-9141ed403327"
      unitRef="U_sqft">17705</lrmr:AreaOfOfficeSpace>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_f62796d0-82ee-42f2-a018-74063dd58aa3"
      id="F_ff57f01d-f30c-4b68-a0e0-cafafb149422">2029-10-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:RestrictedCash
      contextRef="C_c441b869-7333-4da3-92e6-35ae34bd02de"
      decimals="-5"
      id="F_95b974f3-e133-4f4e-a798-78ef7041ec7f"
      unitRef="U_USD">1300000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_763a19f3-ed28-42b9-b147-b3bf06139429"
      decimals="-5"
      id="F_0afb67fa-215c-4aab-a688-6adee118b5a9"
      unitRef="U_USD">600000</us-gaap:RestrictedCash>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_fd07840a-58bc-4339-8331-bc488a2c40c3"
      id="F_590c6407-2fa8-40ad-8f1b-9cd83951376f">2020-12-04</lrmr:LeaseTermCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_fd07840a-58bc-4339-8331-bc488a2c40c3"
      id="F_abb980be-8531-4e08-b27d-9e42dd0c4852">2029-10-30</us-gaap:LeaseExpirationDate1>
    <lrmr:SubleaseAnnualBaseRent
      contextRef="C_4b1f55d6-efd7-4b66-b757-9829759cb41d"
      decimals="-5"
      id="F_0dd824a2-7be4-428e-95b6-1ebb69c276be"
      unitRef="U_USD">800000</lrmr:SubleaseAnnualBaseRent>
    <lrmr:SubleaseAnnualBaseRent
      contextRef="C_410cee1a-9246-4e71-a46a-d8f61f308f49"
      decimals="-5"
      id="F_0887635b-6a1f-4c09-9d45-2246e46cbd04"
      unitRef="U_USD">1000000</lrmr:SubleaseAnnualBaseRent>
    <us-gaap:SecurityDepositLiability
      contextRef="C_0d03b972-e68a-4737-840c-600693a1015c"
      decimals="-5"
      id="F_cec55fda-549e-49ff-9650-fe665f2f8b98"
      unitRef="U_USD">800000</us-gaap:SecurityDepositLiability>
    <us-gaap:SecurityDepositLiability
      contextRef="C_84d96472-3ce3-4f5b-8844-308604770292"
      decimals="-5"
      id="F_bbab8d91-4fcc-448a-8011-b8fbb033b7aa"
      unitRef="U_USD">400000</us-gaap:SecurityDepositLiability>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_1807f4b1-8435-4d6f-ad59-b534cb43cab2"
      id="F_868bc3e6-541f-43a6-8dbe-283e5a07a3b0">2019-01-01</lrmr:LeaseTermCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_1807f4b1-8435-4d6f-ad59-b534cb43cab2"
      id="F_64741758-6cab-459c-b460-7f413210d734">2020-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_ad4e109b-2beb-4b4b-8ec0-7ff1c78ca2a2"
      id="F_36088e0d-0166-422a-9630-937394228e71">2021-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_86c1a03b-7f05-4056-8a4b-a412c8acdc0b"
      id="F_e636a3ec-0b0a-4cb2-9de4-43075ef6505d">2022-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_aae3cd8b-68ec-413d-a96c-c3611488b3a4"
      id="F_e715c503-c07c-41ff-b0cc-14c4cd7d9c4a">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <lrmr:LeaseTermCommencementDate
      contextRef="C_3aec0197-d24a-4489-bac3-6d1692746976"
      id="F_1506bd6e-8d94-4ba4-85d7-72ff74ea7d10">2024-05-10</lrmr:LeaseTermCommencementDate>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_d571d28c-42d3-4ede-a9a7-3e4acee72b97"
      decimals="-5"
      id="F_c730f1d1-dba3-4a12-a258-9c1fc8d7da7a"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_d571d28c-42d3-4ede-a9a7-3e4acee72b97"
      decimals="-5"
      id="F_1a9dd06e-5f3f-4452-9a6a-2135fcf3ddae"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-5"
      id="F_a5cd38bf-655f-4dec-8d16-2039866c2cc5"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-5"
      id="F_9f30b871-98af-4826-b4ec-e8c75ca03918"
      unitRef="U_USD">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      id="F_bb4f0213-046a-4bd4-93dd-961aeeef61ca">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      id="F_c05bdb22-4bd4-4fda-a7c0-90cf8737e2b7">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="3"
      id="F_1c17d653-1c09-459d-80c4-234473d4dbee"
      unitRef="U_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="3"
      id="F_3cb2ae6f-60e0-40ff-bf6b-a8baceb3cf4b"
      unitRef="U_pure">0.11</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d87f61fb-cd92-482d-a1db-31865962ef3e">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Maturities of lease liabilities due under these lease agreements as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 are as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.94%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:15.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-kerning:none;min-width:fit-content;"&gt;Year Ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Operating&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,473&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_904cc617-2b1e-4f09-bbe8-f40c59a48bf0"
      unitRef="U_USD">1543000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_018fdca9-3320-43c6-a851-419fea63de7b"
      unitRef="U_USD">1473000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_137a7645-15ba-4714-8fbc-51d1e5cf5243"
      unitRef="U_USD">1267000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_45fc5294-4568-4996-bd8e-36f9443e61bc"
      unitRef="U_USD">1189000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_0a35459f-5449-43ca-a797-93ef68ec5595"
      unitRef="U_USD">959000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_2391f712-852e-47c5-817c-c2d75c8ce6a2"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_0e5d4f82-6b7d-497e-9be8-a83cd3dcc318"
      unitRef="U_USD">6431000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_fb344c1f-b92a-45ab-be56-40cf1ce5ddb9"
      unitRef="U_USD">1314000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_2dd775e3-3907-4ab9-9f7a-3241988fb400"
      unitRef="U_USD">5117000</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_8aa8f4be-6282-4c8c-a63c-d235bf987e15">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the years ended December 31, 2024, and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; income tax benefits for the net operating losses incurred in each year due to its uncertainty of realizing a benefit from those items.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The domestic and foreign components of loss before income taxes are as follows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.987%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.596%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.797%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.193%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in state tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nondeductible permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation forfeitures - DTA Write Off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D - acquired in merger with Zafgen&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D - Section 174 Costs post 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals &amp;amp; reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed assets &amp;amp; intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets / (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Changes in the valuation allowance for deferred tax assets during the year ended December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; related primarily to the increase in net operating loss carryforwards and tax credit carryforwards and a decrease other deferred tax assets associated with a reduction in the Company&#x2019;s effective state rate. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Changes to the valuation allowance were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance as of the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had net operating loss carryforwards that expire for federal, foreign and state income tax purposes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;164.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The federal and state operating losses begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, while the foreign net loss carryforward can be carried forward indefinitely. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company had federal net operating loss carryforwards that were generated after December 31, 2017 of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;159.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that do not expire, however these &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;carryforwards are limited to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the taxable income in any one tax period.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company also had available tax credit carryforwards for federal and state income tax purposes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million which begin to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2039&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Utilization of the pre-Merger net operating loss carryforwards attributable to Zafgen, of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to ownership changes occurred during the tax year associated with the Merger. In addition to the limitation of the pre-Merger NOL&#x2019;s of Zafgen, the net capitalized R&amp;amp;D deferred tax assets in the amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&amp;amp;D is disposed within five years of the Merger, or May 28, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than 50% over a three-year period. The ownership changes will limit the amount of pre-merger Zafgen carryforwards that can be utilized annually to offset future taxable income with an annual limitation of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; thousand per year. The Company has reduced their NOL and R&amp;amp;D tax credit deferred tax assets associated with the pre-Merger Zafgen operations as a result of the 382 analysis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company believes that as a result of its merger with Zafgen, its ability to utilize NOLs acquired in the transaction and our other NOLs is expected to be severely limited by Section 382 of the Code. Additionally, the Company&#x2019;s July 2021, September 2022 and February 2024 equity transactions could also limit its ability to utilize NOLs in the future. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception. If the Company experienced a change of control, as defined by Section 382, at any time since inception, utilization of its net operating loss carryforwards or tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Additionally, our July 2021, September 2022 and February 2024 equity transactions could also limit our ability to utilize NOLs in the future. Any limitation may result in expiration of a portion of the net operating loss carryforwards or tax credit carryforwards before utilization. Further, until a study is completed, and any limitation is known, no amounts are being presented as an uncertain tax position.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Tax Cuts and Jobs Act ("TCJA") requires taxpayers to capitalize and amortize research and experimental expenditures under IRC Section 174 for tax years beginning after December 31, 2021. This rule became effective for the Company during the year ended December 31, 2022 and resulted in the capitalization of research and development costs &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The Company is amortizing these costs for tax purposes over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; if the research and development was performed in the U.S. and over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; if the research and development was performed outside the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company&#x2019;s net deferred tax asset balance before the valuation allowance was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, and was comprised principally of net operating loss carryforwards, capitalized research and development expenses and tax credit carryforwards. During the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023, gross deferred tax assets increased due to deferred tax assets acquired as a result of additional net operating loss carryforwards and research and development tax credits generated.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#x2019;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets as of December 31, 2024 and 2023. Management reevaluates the positive and negative evidence at each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recorded any amounts for unrecognized tax benefits as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. There are currently no pending income tax examinations. The Company&#x2019;s tax years are still open under statute from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_3544ef17-f3b5-4927-ba28-69fcaa25789b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to the present. Earlier years may be examined to the extent that tax credit or net operating loss carryforwards are used in future periods. The Company&#x2019;s policy is to record interest and penalties related to income taxes as part of its income tax provision.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="INF"
      id="F_72fc1778-1964-4a25-ac10-22fc4f2be3ab"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="INF"
      id="F_a21b7094-43d0-4a42-a467-69cdc1a8a89e"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d2e0dd42-cee0-4603-ad77-9d552ea0f656">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The domestic and foreign components of loss before income taxes are as follows.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.987%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.596%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.797%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;80,604&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,949&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_db1cd6c9-d452-4fe5-8600-81b54c0c763f"
      unitRef="U_USD">-80604000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_dc47eb51-8725-44c9-97bb-168999c1e525"
      unitRef="U_USD">-36948000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_328a72ab-91be-438a-b2a3-8d12d08feaa3"
      unitRef="U_USD">-1000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_8477ac70-26b8-4a49-a33a-67872fd5ecad"
      unitRef="U_USD">-80604000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_85521b31-a658-4360-8a9b-bff5d3bd2cd2"
      unitRef="U_USD">-36949000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d84a189d-ac8b-4270-a10e-eed06f2b7721">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.193%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.023%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:13.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in state tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nondeductible permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock compensation forfeitures - DTA Write Off&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in deferred tax asset valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="3"
      id="F_92b7e310-1fde-48fe-896f-8eb584017d06"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="3"
      id="F_c01d7eae-3b8e-43ca-aa26-c6259670a4d1"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="3"
      id="F_878fb1af-3a8a-4244-bee9-b4ccbf307cf1"
      unitRef="U_pure">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="3"
      id="F_f59c22ce-bf09-48f2-9705-51fc6e6b9739"
      unitRef="U_pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="3"
      id="F_8025b5d0-0323-472c-a021-98625686fac4"
      unitRef="U_pure">-0.013</lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate>
    <lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="3"
      id="F_c08fce39-204f-46f6-84bb-d638621ac64d"
      unitRef="U_pure">-0.017</lrmr:EffectiveIncomeTaxRateReconciliationChangeInStateTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="3"
      id="F_3588c994-7338-4b05-b12b-628c68bd0554"
      unitRef="U_pure">-0.145</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="3"
      id="F_fbe00552-b9e7-4b1b-a83a-cde8a69ee1fc"
      unitRef="U_pure">-0.082</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="3"
      id="F_ca87d510-b935-4305-92b7-b93953ad3357"
      unitRef="U_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="3"
      id="F_080a5876-58a7-4a5f-8388-36ddea385024"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <lrmr:EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="3"
      id="F_bebe5ee1-3160-4410-85f7-25a5cba0a3d6"
      unitRef="U_pure">-0.018</lrmr:EffectiveIncomeTaxRateReconciliationStockCompensationForfeituresPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="3"
      id="F_f2f23cfc-a9ed-4eab-a26e-ed3d346b627b"
      unitRef="U_pure">-0.387</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="3"
      id="F_02449dd8-2f0c-4ec5-8874-3d4084bcf2b5"
      unitRef="U_pure">-0.296</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="3"
      id="F_bdaa7389-22aa-4a98-b987-f54249f89bc6"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="3"
      id="F_a76996f2-b0c9-4ddc-81ea-b319294db60f"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_6cc877f4-8fa0-4b69-8b36-8e1b28f1f560">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:2%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:14.54%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D - acquired in merger with Zafgen&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Capitalized R&amp;amp;D - Section 174 Costs post 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,319&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other temporary differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals &amp;amp; reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Fixed assets &amp;amp; intangibles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,298&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;142,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;768&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets / (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_5cf12f94-aeaf-402b-bab1-eda36baa97e4"
      unitRef="U_USD">66678000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_6a912f6d-b708-40e7-8df9-ee5736df5c11"
      unitRef="U_USD">66678000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_33f36dc2-1a06-4f62-9dc8-6c54718664cc"
      unitRef="U_USD">22616000</lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_31d6c62b-7b36-4d18-9004-cb076d058691"
      unitRef="U_USD">9411000</lrmr:DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_7f954465-ea16-4251-b5ea-f840c32629a6"
      unitRef="U_USD">4879000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_ba9983e0-32d6-4278-95f3-35c0c717137d"
      unitRef="U_USD">3490000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_72432283-b1ad-452b-8b47-6ac2d870d414"
      unitRef="U_USD">50177000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_6ff8b0ca-5368-4680-8c04-a968d845e2e2"
      unitRef="U_USD">45195000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_c598b854-97e2-4168-bb0b-fd7b05b28d20"
      unitRef="U_USD">28022000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_4e3d355f-942c-4d7f-ab12-770c23c19d06"
      unitRef="U_USD">16319000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_0ff2bd06-c869-4d9c-ae5a-6130ff7f7bec"
      unitRef="U_USD">30000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_c8253081-458e-4071-ba21-8b0e2aeaa3aa"
      unitRef="U_USD">21000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_6b468a85-a671-47c5-9f81-d9b79bd2078c"
      unitRef="U_USD">19000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_a73f5378-a11f-48cf-867d-d240b6f1940a"
      unitRef="U_USD">19000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_5004763d-1952-4e9e-8582-5d08cbc7ce78"
      unitRef="U_USD">119000</lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets>
    <lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_0e2e5e21-a0d2-447e-a6de-47099b598877"
      unitRef="U_USD">107000</lrmr:DeferredTaxAssetsFixedAssetsAndIntangibleAssets>
    <lrmr:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_ee365fc6-e966-477c-98e1-5ea046b92270"
      unitRef="U_USD">1196000</lrmr:DeferredTaxAssetsOperatingLeaseLiabilities>
    <lrmr:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_19405c41-f979-4d91-b5d8-f916fd06c032"
      unitRef="U_USD">1298000</lrmr:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_14b82c90-7087-4d0a-bb4b-802303c5f3c8"
      unitRef="U_USD">173736000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_ddd3873c-8ad3-4312-aedf-f5a3dccae245"
      unitRef="U_USD">142538000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_dcc00162-0a47-425d-93b7-58a700ac5010"
      unitRef="U_USD">708000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_6b9504a9-c936-4c82-8d59-44d22672e9cd"
      unitRef="U_USD">768000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_d649b855-6cc2-48c7-a17b-102785582cdd"
      unitRef="U_USD">708000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_d66512a3-e0ee-47b2-a30b-97d7648db127"
      unitRef="U_USD">768000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_5b4ff837-cbff-4487-925c-2fb19c43e512"
      unitRef="U_USD">173028000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_f8de57bb-4d6a-415e-a99b-62d9cdf9cb72"
      unitRef="U_USD">141770000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_d29713e7-b649-420d-a030-39beded0c5e1">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Changes to the valuation allowance were as follows:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.993%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:12.883000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Years ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance as of the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Increases recorded to income tax provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance at end of year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;173,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:pre-wrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="padding-top:0.01in;white-space:nowrap;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_de4eaa9c-a0ce-4578-be3c-a8f9cf77dcf8"
      unitRef="U_USD">141770000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e567f291-5928-46ca-9886-4b12d459c211"
      decimals="-3"
      id="F_da49e685-b5fc-4091-88e5-c0abd9414102"
      unitRef="U_USD">130831000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      decimals="-3"
      id="F_553fc9fb-9a0f-457f-843a-fcaacff73a03"
      unitRef="U_USD">31258000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_758e50cf-6269-441d-9861-9ff2dd1261da"
      decimals="-3"
      id="F_1f05628b-5993-42b2-a449-7ec2f157b273"
      unitRef="U_USD">10939000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-3"
      id="F_5ca23c1b-1885-40fd-bfd6-d3db0d042007"
      unitRef="U_USD">173028000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-3"
      id="F_e5be1e4d-708c-47f6-9c5f-f35db9208b78"
      unitRef="U_USD">141770000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_be61e1b5-4f33-432f-86bc-37fe2c3476b7"
      decimals="-5"
      id="F_a1cbc8b4-f2d7-4ad9-bb91-7edc218f329b"
      unitRef="U_USD">198200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_a1d529ba-7ef3-4346-82a1-30f1da0afd55"
      decimals="-5"
      id="F_e8a378e3-c428-477d-a791-08978c683a7f"
      unitRef="U_USD">1200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_4d107843-e44a-43f6-84f2-18bd5c829091"
      decimals="-5"
      id="F_f9c7c4c5-b77d-4d93-a7f8-cf96498e75a0"
      unitRef="U_USD">164500000</us-gaap:OperatingLossCarryforwards>
    <lrmr:NetOperatingLossCarryForwardExpirationYearBegin
      contextRef="C_7d857bb0-3425-42ce-bed1-6edca2b32acc"
      id="F_4c2bb7e5-a698-4a9e-824f-5318ec77e1a3">2026</lrmr:NetOperatingLossCarryForwardExpirationYearBegin>
    <lrmr:NetOperatingLossCarryForwardExpirationYearBegin
      contextRef="C_4a89193c-4cbe-4c85-bcc3-a83c9bc990b0"
      id="F_852bc970-dbe6-4996-b7c8-df62a54bddd8">2030</lrmr:NetOperatingLossCarryForwardExpirationYearBegin>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_8b7bbdf5-c433-4df2-8d61-5681d6000126"
      decimals="-5"
      id="F_47a41144-8f03-4eaa-b983-aeedc20cf3ac"
      unitRef="U_USD">159500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="C_ad1539c6-fc3e-4f7a-a9a5-26892c4889b7"
      id="F_3a43241a-e2c0-453d-945d-99277ec87af5">carryforwards are limited to 80% of the taxable income in any one tax period.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <lrmr:OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod
      contextRef="C_ad1539c6-fc3e-4f7a-a9a5-26892c4889b7"
      decimals="INF"
      id="F_9354fcc9-3553-4010-a42c-120e84e5ebc3"
      unitRef="U_pure">0.80</lrmr:OperatingLossCarryforwardsMinimumPercentageOfTaxableIncomeInTaxPeriod>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_8ee26ea1-7981-475b-8275-d3cd88ccd7f7"
      decimals="-5"
      id="F_e2997382-cfa5-48b9-8c02-cc1c13d2167f"
      unitRef="U_USD">28000000</us-gaap:TaxCreditCarryforwardAmount>
    <lrmr:TaxCreditCarryForwardExpirationYearStart
      contextRef="C_255549a6-f23b-4838-819a-a321c153cd07"
      id="F_b3b18211-165c-47e9-b49c-60a024a54cf6">2039</lrmr:TaxCreditCarryForwardExpirationYearStart>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_99e2e692-a200-4366-9fac-4c228a2bb15b"
      decimals="-5"
      id="F_ae5e7a8c-53bf-4ed7-982f-67af6d97bd93"
      unitRef="U_USD">33500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_99e2e692-a200-4366-9fac-4c228a2bb15b"
      decimals="-5"
      id="F_0a1c7595-21cc-414c-a241-ff843cbf35bb"
      unitRef="U_USD">66900000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <lrmr:NetCapitalizedRDDeferredTaxAssetsRealizationDescription
      contextRef="C_9be6fbc0-da98-4a6c-9580-1b53447c931e"
      id="F_ec20827b-95a7-4931-8fdb-cc0097da5c3d">is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&amp;D is disposed within five years of the Merger, or May 28, 2025</lrmr:NetCapitalizedRDDeferredTaxAssetsRealizationDescription>
    <lrmr:NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership
      contextRef="C_9be6fbc0-da98-4a6c-9580-1b53447c931e"
      decimals="-3"
      id="F_b4d040bf-2c32-42fc-865b-cdf463af3ff2"
      unitRef="U_USD">35000</lrmr:NetOperatingLossCarryforwardsAnnualUtilizationLimitChangeInOwnership>
    <lrmr:CapitalizedResearchAndDevelopment
      contextRef="C_f1ad33a8-3ac6-4e46-a123-734c2ff51101"
      decimals="-5"
      id="F_6a7d62b1-8baa-45ee-acaf-28530285d893"
      unitRef="U_USD">69200000</lrmr:CapitalizedResearchAndDevelopment>
    <lrmr:CapitalizedResearchAndDevelopment
      contextRef="C_da30be71-5046-4b9b-aa5d-981a3c109ee3"
      decimals="-5"
      id="F_7022a54d-7194-4347-b1c7-4286dfd438fe"
      unitRef="U_USD">24500000</lrmr:CapitalizedResearchAndDevelopment>
    <lrmr:CapitalizedResearchAndDevelopment
      contextRef="C_458d2390-7c95-42ed-9486-6626384ec15f"
      decimals="-5"
      id="F_15730f7a-d93f-46d3-94c3-4b0d2fe61604"
      unitRef="U_USD">22200000</lrmr:CapitalizedResearchAndDevelopment>
    <lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod
      contextRef="C_fe3e5c5a-5d3a-4ea1-8f76-28fa8c02f25f"
      id="F_670afaf1-a787-4bb1-b71f-9bd782082514">P5Y</lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod>
    <lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod
      contextRef="C_47c2670a-5ab5-47d8-879f-4c1d86ad4d5f"
      id="F_57a7ff60-913c-426e-bcfe-213d6812f5af">P15Y</lrmr:CapitalizedResearchAndDevelopmentAmortizationPeriod>
    <lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="-5"
      id="F_a2da44a4-e6bc-42e5-a64e-c7d822fb63c1"
      unitRef="U_USD">173000000</lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance>
    <lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="-5"
      id="F_3bafb025-cbd1-41f5-a795-81665d863c35"
      unitRef="U_USD">141800000</lrmr:DeferredTaxAssetsNetOfLiabilitiesBeforeValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_e624cc91-edd0-44c1-b110-f5bd07d78925"
      decimals="INF"
      id="F_de79c642-9907-4169-b6c7-61f3595660a8"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_fc9e667d-5a41-44b1-84d4-b1f6538f2d9d"
      decimals="INF"
      id="F_30398e9b-f160-48c8-9359-8b86e5e59a1c"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_0315db95-9995-4825-83b1-6bd13c7f5edd"
      id="F_0a366905-834b-472b-8cdc-e9701dfd6fc1">&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Related Party&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2024, the Company entered into an agreement with the Friedreich&#x2019;s Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium that includes pharmaceutical, biotechnology, academic and clinical partners. The consortium will conduct a natural history study designed to establish disease-specific neuroimaging biomarkers to track disease progression in the brain and spinal cord and provide a basis for utilizing these biomarkers in clinical trials. As an industry partner, the Company will help fund the study and contribute to the study design, research activities, and analysis. The Company will have access to all study data for use in its regulatory filings, as appropriate. During the twelve months ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of costs related to the Track-FA program and will fund future costs going forward. One of the Company&#x2019;s Directors is also a director of FARA.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additionally, during the twelve months ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company sponsored patient and caregiver awareness events held by FARA for a cumulative $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_30f69550-77db-454a-9913-83a4c6b940ff"
      decimals="-5"
      id="F_a6dc26ce-d3be-43e4-82cb-f89dc83276f2"
      unitRef="U_USD">900000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="C_d18029d6-d247-44b7-8d04-1bedb1e05fca"
      decimals="-5"
      id="F_625dc98f-fa00-42a8-852a-bd45c8f67c65"
      unitRef="U_USD">100000</us-gaap:OperatingCostsAndExpenses>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
